
TTD - Therapeutic Targets Database Full Data Download File
Title - Drug to disease mapping with ICD identifiers
Version 8.1.01 (2021.11.08)
Provided by IDRB   Lab of Innovative Drug Reasearch and Bioinformatics
                   College of Pharmaceutical Sciences
                   Zhejiang University
                   https://idrblab.org/
Provided by BIDD   BioInformatic and Drug Design Group
                   Department of Pharmacy
                   National Unviersity of Singapore
                   http://bidd.nus.edu.sg/
Any question about data provided here, please contact with:
Dr. Zhou (zhou_ying@zju.edu.cn) and Dr. Zhang (zhangyintao@zju.edu.cn)

--------------------------------------------------------------------------------------------------------
Abbreviations:
TTDDRUID	TTD Drug ID
DRUGNAME	Drug Name
INDICATI	Indication	Disease entry	ICD-11	Clinical status
--------------------------------------------------------------------------------------------------------

TTDDRUID	D00ABE
DRUGNAME	ALD-301
INDICATI	Ischemia [ICD-11: 8B10-8B11] Phase 2
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D00ABO
DRUGNAME	KW-2449
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D00ABW
DRUGNAME	Opterone
INDICATI	Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 1
	
TTDDRUID	D00ACC
DRUGNAME	ND1251
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1
	
TTDDRUID	D00ACH
DRUGNAME	HMR-4004
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D00ACP
DRUGNAME	Anti-HER-2 mab-FcgR2- FcgR4 fusion proteins
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00ADV
DRUGNAME	THF carbapenems
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated
	
TTDDRUID	D00AEQ
DRUGNAME	Hydroxyprogesterone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D00AES
DRUGNAME	Dicopp
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D00AEV
DRUGNAME	Oxothiazolidine carboxylate
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D00AHT
DRUGNAME	PRAME antigen-specific cancer immunotherapeutic
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Metastatic melanoma [ICD-11: 2E2Z] Phase 1
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D00AHV
DRUGNAME	SKL-PD
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D00AIS
DRUGNAME	AP-11014
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00AIZ
DRUGNAME	SND-159
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D00AJI
DRUGNAME	PF-4480682
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2
	
TTDDRUID	D00AJS
DRUGNAME	AIK11
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D00AKL
DRUGNAME	Immunose FLU
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D00AKQ
DRUGNAME	O-desulfated heparin
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D00AKR
DRUGNAME	AMG 479
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D00AKV
DRUGNAME	F-351
INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 2
	
TTDDRUID	D00AKY
DRUGNAME	SK&F-S-106203
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D00ALE
DRUGNAME	H1N1 pandemic influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D00ALJ
DRUGNAME	Placental expanded stem cell therapy
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D00AMQ
DRUGNAME	Ethanol
INDICATI	Cystitis [ICD-11: GC00] Approved
INDICATI	Chronic pain [ICD-11: MG30] Approved
	
TTDDRUID	D00ANG
DRUGNAME	Erythropoietin-transfected autologous cell therapy
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1/2
	
TTDDRUID	D00AOJ
DRUGNAME	Docosanol
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Approved
	
TTDDRUID	D00AQP
DRUGNAME	Ribavirin + interferon alfa-2a
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D00AQV
DRUGNAME	COTI-4A
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Investigative
	
TTDDRUID	D00AQY
DRUGNAME	IDDB-41331
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D00ARN
DRUGNAME	Tyloxapol
INDICATI	Cystic fibrosis [ICD-11: CA25] Terminated
	
TTDDRUID	D00ARS
DRUGNAME	MER-3001
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D00ASJ
DRUGNAME	Typherix
INDICATI	Salmonella infection [ICD-11: 1A09] Approved
	
TTDDRUID	D00ASX
DRUGNAME	PJ-015
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D00AUC
DRUGNAME	(99M)-TC-CPI
INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 2
	
TTDDRUID	D00AUM
DRUGNAME	AQU-010
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D00AUX
DRUGNAME	MSDC-0602
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D00AUZ
DRUGNAME	Thiolated chitosan nanoparticle theophylline
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D00AVG
DRUGNAME	GX-110E
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D00AVH
DRUGNAME	VEN100
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D00AWA
DRUGNAME	WIN-63759
INDICATI	Emphysema [ICD-11: CA21] Terminated
	
TTDDRUID	D00AWT
DRUGNAME	Propericiazine
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Approved
	
TTDDRUID	D00AXG
DRUGNAME	SMT-14224
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D00AXJ
DRUGNAME	Miconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D00AXT
DRUGNAME	MDC-922
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00AXZ
DRUGNAME	CAP-22
INDICATI	Diabetic angiopathy [ICD-11: BD53.Y] Investigative
	
TTDDRUID	D00AYA
DRUGNAME	BMS-188797
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D00AYW
DRUGNAME	HMS5552
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D00BBB
DRUGNAME	MetPril
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D00BCG
DRUGNAME	Goserelin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D00BCP
DRUGNAME	Chlorpropamide
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D00BCS
DRUGNAME	INT-0015/2008
INDICATI	Panic disorder [ICD-11: 6B01] Investigative
	
TTDDRUID	D00BCZ
DRUGNAME	XGP-610
INDICATI	Reperfusion injury [ICD-11: ND56.Z] Investigative
	
TTDDRUID	D00BDC
DRUGNAME	Morniflumate
INDICATI	Otitis media [ICD-11: AA80-AB0Z] Approved
	
TTDDRUID	D00BHL
DRUGNAME	EC20
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
	
TTDDRUID	D00BIY
DRUGNAME	CGP-48369
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D00BJV
DRUGNAME	BMS-986207
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D00BKV
DRUGNAME	SB 418790
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D00BLL
DRUGNAME	Fesoterodine fumarate
INDICATI	Overactive bladder [ICD-11: GC50.0] Approved
	
TTDDRUID	D00BLS
DRUGNAME	AZD0284
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
	
TTDDRUID	D00BMF
DRUGNAME	MK-4827
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Ewing sarcoma [ICD-11: 2B52] Phase 1
	
TTDDRUID	D00BMM
DRUGNAME	Dismutase mimetics
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00BND
DRUGNAME	BF-1
INDICATI	Cluster headache [ICD-11: 8A81.0] Phase 1
INDICATI	Migraine [ICD-11: 8A80] Phase 1
	
TTDDRUID	D00BOY
DRUGNAME	CP-18770
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D00BPE
DRUGNAME	AVE-1642
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D00BPH
DRUGNAME	COVA322
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1/2a
	
TTDDRUID	D00BTW
DRUGNAME	UC-781
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D00BTZ
DRUGNAME	CT-003230
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D00BUO
DRUGNAME	MM-141
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D00BUR
DRUGNAME	ICA-17043
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Discontinued in Phase 2
	
TTDDRUID	D00BVB
DRUGNAME	Men Quad TT
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 3
	
TTDDRUID	D00BVF
DRUGNAME	IP-889
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 3
	
TTDDRUID	D00BVJ
DRUGNAME	NHS-IL 12
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00BVS
DRUGNAME	Tanezumab
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
INDICATI	Chronic low back pain [ICD-11: MG30.02] Phase 3
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 3
INDICATI	Cancer related pain [ICD-11: MG30] Phase 3
	
TTDDRUID	D00BWF
DRUGNAME	AGN-XX/YY
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D00BXK
DRUGNAME	Pyrazole derivative 39
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D00BXZ
DRUGNAME	M-402
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00BYM
DRUGNAME	Volasertib
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	D00BZJ
DRUGNAME	Trumenba
INDICATI	Meningitis [ICD-11: 1D01] Approved
	
TTDDRUID	D00BZO
DRUGNAME	HL-035
INDICATI	Syndrome X [ICD-11: 5C53.4] Investigative
	
TTDDRUID	D00BZS
DRUGNAME	Gimatecan
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D00BZZ
DRUGNAME	PF-4603629
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D00CBP
DRUGNAME	DTPw-HBV/Hib
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
	
TTDDRUID	D00CBY
DRUGNAME	CEL-021
INDICATI	Interstitial cystitis [ICD-11: GC00.3] Investigative
	
TTDDRUID	D00CCI
DRUGNAME	Benoxaprofen
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market
	
TTDDRUID	D00CED
DRUGNAME	HG-1097
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00CEE
DRUGNAME	Tetraxim
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D00CEG
DRUGNAME	D-43787
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D00CEI
DRUGNAME	CM-2501
INDICATI	Poison intoxication [ICD-11: NE6Z] Preclinical
	
TTDDRUID	D00CFB
DRUGNAME	Zeniplatin
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2
	
TTDDRUID	D00CFU
DRUGNAME	RO-4840700
INDICATI	Schizophrenia [ICD-11: 6A20] Investigative
	
TTDDRUID	D00CGH
DRUGNAME	RO-23-7553
INDICATI	Prostate disease [ICD-11: GA91] Phase 1
	
TTDDRUID	D00CGU
DRUGNAME	IMS
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1
	
TTDDRUID	D00CGX
DRUGNAME	DV-1179
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Discontinued in Phase 1
	
TTDDRUID	D00CIF
DRUGNAME	EMD-503982
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D00CIT
DRUGNAME	Regavirumab
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Discontinued in Preregistration
	
TTDDRUID	D00CLC
DRUGNAME	SLV-338
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D00CLM
DRUGNAME	NIP-004
INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 1
	
TTDDRUID	D00CMA
DRUGNAME	VVZ-172
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D00CMC
DRUGNAME	BP-9906
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00CMV
DRUGNAME	ABT-102
INDICATI	Chronic pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D00COH
DRUGNAME	Biaryl mannoside derivative 24
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D00COJ
DRUGNAME	Inclisiran
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3
	
TTDDRUID	D00CPQ
DRUGNAME	RemoSynch
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
	
TTDDRUID	D00CQI
DRUGNAME	Indatuximab ravtansine
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D00CQL
DRUGNAME	N-8295
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D00CQQ
DRUGNAME	TGFK09SD
INDICATI	Hypoactive sexual desire dysfunction [ICD-11: HA00] Phase 2
	
TTDDRUID	D00CQW
DRUGNAME	TNP-351
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D00CRQ
DRUGNAME	Phenylate derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D00CSA
DRUGNAME	LFF-269
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D00CSQ
DRUGNAME	Triclosan
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative
INDICATI	Infection of P. falciparum [ICD-11: 1F40] Investigative
	
TTDDRUID	D00CTS
DRUGNAME	Lubiprostone
INDICATI	Chronic idiopathic constipation [ICD-11: DC32] Approved
	
TTDDRUID	D00CTZ
DRUGNAME	MEDI9929
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D00CVJ
DRUGNAME	Neu-P11
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 2
	
TTDDRUID	D00CVT
DRUGNAME	TD-6301
INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 1
	
TTDDRUID	D00CZT
DRUGNAME	Solanezumab
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D00DAE
DRUGNAME	Carboxyamidotriazole orotate
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D00DAU
DRUGNAME	LCP-3301
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D00DBE
DRUGNAME	CI-1018
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D00DBH
DRUGNAME	NPS 1776
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2
	
TTDDRUID	D00DBO
DRUGNAME	Pipamperone
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 1/2
	
TTDDRUID	D00DBU
DRUGNAME	SA-IGIV
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Discontinued in Phase 2
	
TTDDRUID	D00DCY
DRUGNAME	OraTest
INDICATI	Oral cancer [ICD-11: 2B6E] Approved
	
TTDDRUID	D00DDR
DRUGNAME	G3139 + Thalidomide
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D00DEF
DRUGNAME	Lisdexamfetamine
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
	
TTDDRUID	D00DFP
DRUGNAME	KBP-5074
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1/2
	
TTDDRUID	D00DHM
DRUGNAME	SDZ-208911
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Investigative
	
TTDDRUID	D00DHT
DRUGNAME	Mammalian sterile 20-like kinase 1 gene eluting stent
INDICATI	Artery stenosis [ICD-11: BD52] Investigative
	
TTDDRUID	D00DIB
DRUGNAME	Anti-CD33
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D00DIM
DRUGNAME	Monohydroxyethylrutoside
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D00DJC
DRUGNAME	CJX-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00DKK
DRUGNAME	Isotretinoin
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D00DPJ
DRUGNAME	Amezinium
INDICATI	Hypotension [ICD-11: BA20-BA21] Approved
	
TTDDRUID	D00DPP
DRUGNAME	CYCLOPLATAM
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D00DQX
DRUGNAME	Motesanib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 3
	
TTDDRUID	D00DRA
DRUGNAME	KA-20X
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Investigative
	
TTDDRUID	D00DRL
DRUGNAME	MK-2461
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D00DSD
DRUGNAME	GLI-5021
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D00DSG
DRUGNAME	PF-05313261
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D00DSN
DRUGNAME	Sepcidin
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D00DSV
DRUGNAME	Polynoma-1
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D00DTP
DRUGNAME	ZP-006
INDICATI	Pharyngitis [ICD-11: CA02.Z] Investigative
	
TTDDRUID	D00DXC
DRUGNAME	Macrocycle derivative 13
INDICATI	Cell proliferative disorder [ICD-11: FB86] Patented
	
TTDDRUID	D00DXH
DRUGNAME	LYS-6KAKT1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00DYI
DRUGNAME	Benzothiazole analog 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D00DYK
DRUGNAME	Lunacalcipol
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D00DYN
DRUGNAME	Botulinum neurotoxin vaccine
INDICATI	Botulism [ICD-11: 1A11] Phase 1
	
TTDDRUID	D00DZN
DRUGNAME	Beclamide
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Approved
	
TTDDRUID	D00EBH
DRUGNAME	ICI-170809
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D00ECB
DRUGNAME	CD-349
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D00ECO
DRUGNAME	SIB-1553A
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
	
TTDDRUID	D00EEL
DRUGNAME	Gaboxadol
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D00EEP
DRUGNAME	E-3309
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Discontinued in Phase 1
	
TTDDRUID	D00EFD
DRUGNAME	C-21191
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D00EFO
DRUGNAME	Interferon alpha-2b
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D00EGN
DRUGNAME	ETX-9101
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D00EGU
DRUGNAME	PACAP38
INDICATI	Nerve injury [ICD-11: ND56.4] Phase 1
	
TTDDRUID	D00EGV
DRUGNAME	Monoamine derivative 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D00EHX
DRUGNAME	TT-301
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D00EIB
DRUGNAME	Ha-1a
INDICATI	Sepsis [ICD-11: 1G40-1G41] Approved
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Approved
	
TTDDRUID	D00EIL
DRUGNAME	CG-103065
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00EJP
DRUGNAME	GSK2339345
INDICATI	Cough [ICD-11: MD12] Phase 2
	
TTDDRUID	D00EKM
DRUGNAME	Virapt
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D00EMB
DRUGNAME	GSK-1247446A
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D00EML
DRUGNAME	Q-Vax
INDICATI	Coxiella infection [ICD-11: 1C33] Terminated
	
TTDDRUID	D00ENU
DRUGNAME	CAB-101
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D00ENY
DRUGNAME	L-Glutamic Acid
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D00EPS
DRUGNAME	PMID18163548C4
INDICATI	Reperfusion injury [ICD-11: ND56.Z] Clinical trial
INDICATI	Myocardial ischemia [ICD-11: BA6Z] Clinical trial
	
TTDDRUID	D00EPT
DRUGNAME	E7850
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D00EQD
DRUGNAME	PN-277
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D00EQL
DRUGNAME	Tazemetostat
INDICATI	Follicular lymphoma [ICD-11: 2A80] Approved
INDICATI	Malignant rhabdoid tumour [ICD-11: 2A00.1Y] Phase 2
INDICATI	Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 2
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
INDICATI	Synovial sarcoma [ICD-11: 2B5A] Phase 1
	
TTDDRUID	D00EQY
DRUGNAME	KTN3379
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00ERV
DRUGNAME	Gallopamil
INDICATI	Asthma [ICD-11: CA23] Phase 2
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D00ESH
DRUGNAME	DCVax-Liver
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1/2
	
TTDDRUID	D00ETS
DRUGNAME	Hexobarbital
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D00EUL
DRUGNAME	PMID28270021-Compound-WO2016054807Example82
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D00EVP
DRUGNAME	Simenepag isopropyl
INDICATI	Ocular hypertension [ICD-11: 9C61.01] Phase 2
	
TTDDRUID	D00EWR
DRUGNAME	Fidarestat
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
	
TTDDRUID	D00EXZ
DRUGNAME	PB-357
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00EYC
DRUGNAME	F-7TG
INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 1
	
TTDDRUID	D00EYF
DRUGNAME	PEGylated insulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D00EZE
DRUGNAME	Panamesine
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2
	
TTDDRUID	D00EZO
DRUGNAME	TC-2216
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 1
	
TTDDRUID	D00FAW
DRUGNAME	CL-508
INDICATI	Vomiting [ICD-11: MD90] Investigative
	
TTDDRUID	D00FBC
DRUGNAME	KHK-6188
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D00FBM
DRUGNAME	LP-2307
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D00FCW
DRUGNAME	ViaScint
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Preregistration
	
TTDDRUID	D00FDD
DRUGNAME	INT-0020
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 1
	
TTDDRUID	D00FEA
DRUGNAME	GRL-0036A
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D00FGO
DRUGNAME	Melphalan
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
INDICATI	Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10] Phase 3
	
TTDDRUID	D00FGR
DRUGNAME	Miltefosine
INDICATI	Leishmaniasis [ICD-11: 1F54] Approved
INDICATI	Visceral leishmaniasis [ICD-11: 1F54.0] Phase 2
	
TTDDRUID	D00FGV
DRUGNAME	Carbinoxamine
INDICATI	Vasomotor/allergic rhinitis [ICD-11: CA08] Approved
	
TTDDRUID	D00FGW
DRUGNAME	Anthrax transdermal vaccine
INDICATI	Anthrax [ICD-11: 1B97] Phase 1
	
TTDDRUID	D00FGY
DRUGNAME	PF-755616
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D00FHI
DRUGNAME	Zabiciprilat
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D00FHR
DRUGNAME	MGCD-0103
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D00FIO
DRUGNAME	Anti-CD20-CAR-transduced T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D00FIV
DRUGNAME	Leukotoxin
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D00FIX
DRUGNAME	Agalsidase beta
INDICATI	Fabry disease [ICD-11: 5C56.01] Approved
	
TTDDRUID	D00FJC
DRUGNAME	Nuvanil
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D00FJH
DRUGNAME	N-acylpiperidine ether derivative 4
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D00FJQ
DRUGNAME	Leucine + metformin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D00FJS
DRUGNAME	KRH-2731
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D00FMK
DRUGNAME	SDZ-LAV-694
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 1
	
TTDDRUID	D00FMQ
DRUGNAME	FX-300
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D00FMV
DRUGNAME	Putrescine
INDICATI	Burn and burn infection [ICD-11: ND90-NE2Z] Discontinued in Phase 2
	
TTDDRUID	D00FMW
DRUGNAME	TIM ETEC vaccine
INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2
	
TTDDRUID	D00FOR
DRUGNAME	NBI-80649
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D00FQP
DRUGNAME	LAGATIDE
INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 2
	
TTDDRUID	D00FRX
DRUGNAME	CTA-056
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D00FRY
DRUGNAME	BILD-1351
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Terminated
	
TTDDRUID	D00FSB
DRUGNAME	BIIB095
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D00FSS
DRUGNAME	SPD-452
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D00FSV
DRUGNAME	Phytonadione
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
INDICATI	Vitamin K deficiency [ICD-11: 5B59] Approved
	
TTDDRUID	D00FUD
DRUGNAME	HRA-081025
INDICATI	Contraception [ICD-11: QA21] Investigative
	
TTDDRUID	D00FWB
DRUGNAME	L-163017
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D00FXQ
DRUGNAME	IG-CN-023
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D00FYF
DRUGNAME	NVP-DPP728
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D00FYP
DRUGNAME	PG-36
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated
	
TTDDRUID	D00FZA
DRUGNAME	ALD-805
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00FZH
DRUGNAME	Nest mesenchymal stem cells
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D00FZZ
DRUGNAME	PEG-FGF-21
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D00GAM
DRUGNAME	Beclanorsen
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D00GAV
DRUGNAME	AR-2474
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D00GBG
DRUGNAME	Resp syncytial virus ig
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Approved
	
TTDDRUID	D00GBZ
DRUGNAME	CEQ-508
INDICATI	Familial adenomatous polyposis [ICD-11: 2B90.Y] Phase 1/2
	
TTDDRUID	D00GCA
DRUGNAME	MK-7288
INDICATI	Excessive daytime sleepiness [ICD-11: MG42] Phase 1
	
TTDDRUID	D00GDN
DRUGNAME	ML-03
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated
	
TTDDRUID	D00GEG
DRUGNAME	Ralfinamide
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
	
TTDDRUID	D00GES
DRUGNAME	JD-5037
INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D00GFU
DRUGNAME	BTma22
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D00GFV
DRUGNAME	Leridistim
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2
	
TTDDRUID	D00GHG
DRUGNAME	VAX-102
INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2
	
TTDDRUID	D00GIR
DRUGNAME	DAC-060
INDICATI	Keratosis [ICD-11: ED56] Phase 2
	
TTDDRUID	D00GJK
DRUGNAME	Depigoid birch pollen extract vaccine
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2
	
TTDDRUID	D00GKH
DRUGNAME	HG-1179
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00GLQ
DRUGNAME	2LM20-4
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D00GLW
DRUGNAME	OM-294-DP
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00GNI
DRUGNAME	REGN-727
INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Approved
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
	
TTDDRUID	D00GNJ
DRUGNAME	Linaclotide
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
	
TTDDRUID	D00GNK
DRUGNAME	LY293111
INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2
	
TTDDRUID	D00GNN
DRUGNAME	P53 mdm-2-binding domain peptides
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00GOH
DRUGNAME	HepeX-B
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2
	
TTDDRUID	D00GOS
DRUGNAME	Clocortolone
INDICATI	Rosacea [ICD-11: ED90.0] Approved
	
TTDDRUID	D00GOV
DRUGNAME	Nivolumab
INDICATI	Melanoma [ICD-11: 2C30] Approved
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 3
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 3
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3
INDICATI	Central nervous system lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1/2
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Application submitted
	
TTDDRUID	D00GPQ
DRUGNAME	PF-03084014
INDICATI	Desmoid tumour [ICD-11: 2F7C] Phase 3
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D00GPY
DRUGNAME	OMP-18R5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00GXL
DRUGNAME	PBT-2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
	
TTDDRUID	D00GZW
DRUGNAME	ONO-2506
INDICATI	Stroke [ICD-11: 8B20] Phase 2/3
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D00GZY
DRUGNAME	AT1001
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D00HAN
DRUGNAME	IM23
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D00HAP
DRUGNAME	Dapagliflozin/metformin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D00HBE
DRUGNAME	AZD0914
INDICATI	Neisseria gonorrhoeae infection [ICD-11: 1A7Z] Phase 3
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D00HBF
DRUGNAME	CAB-103
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00HBR
DRUGNAME	AIKO-150
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 1
	
TTDDRUID	D00HCQ
DRUGNAME	Capecitabine
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D00HDB
DRUGNAME	AC-105
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2
	
TTDDRUID	D00HDC
DRUGNAME	MCP-204
INDICATI	Bladder disease [ICD-11: DC11-DC1Z] Investigative
	
TTDDRUID	D00HDH
DRUGNAME	Molecule 22
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D00HDK
DRUGNAME	PGX-5188
INDICATI	Bipolar disorder [ICD-11: 6A60] Preclinical
	
TTDDRUID	D00HDU
DRUGNAME	Moexipril
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D00HDZ
DRUGNAME	Wharton's Jelly-Mesenchymal Stem Cells
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D00HEA
DRUGNAME	Transcobalamin (vitamin B12) receptor-targeting mabTCR23-saporin conjugate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00HEN
DRUGNAME	Rotavirus vaccine, Lanzhou Institute of Biological Products
INDICATI	Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Approved
	
TTDDRUID	D00HFD
DRUGNAME	E-6080
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D00HGB
DRUGNAME	Niflumic Acid
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D00HGF
DRUGNAME	ERYTHRITOL
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 2/3
	
TTDDRUID	D00HGY
DRUGNAME	Insulin B chain vaccine
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D00HHP
DRUGNAME	CP-111905
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D00HHS
DRUGNAME	Pseudoephedrine
INDICATI	Nasal congestion [ICD-11: MD11.9] Approved
	
TTDDRUID	D00HHU
DRUGNAME	AFO-18
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D00HIC
DRUGNAME	Pseudomonas aeruginosa vaccine
INDICATI	Pseudomonas infection [ICD-11: 1B92] Discontinued in Phase 1
	
TTDDRUID	D00HMQ
DRUGNAME	Ormaplatin
INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1
	
TTDDRUID	D00HMZ
DRUGNAME	TV1-Kidney-1
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D00HNB
DRUGNAME	Clodronate
INDICATI	Hypercalcaemia [ICD-11: 5B91.0] Approved
	
TTDDRUID	D00HNK
DRUGNAME	RHb1.1
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Terminated
	
TTDDRUID	D00HNQ
DRUGNAME	TDI-0051
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D00HPD
DRUGNAME	Moxetumomab pasudotox
INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D00HPK
DRUGNAME	Naftifine
INDICATI	Dermatomycosis [ICD-11: EA60] Approved
	
TTDDRUID	D00HPX
DRUGNAME	ON-04
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D00HQB
DRUGNAME	TX-MSD
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D00HQE
DRUGNAME	Ty800
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2
	
TTDDRUID	D00HSK
DRUGNAME	Algenpantucel-L
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
	
TTDDRUID	D00HTO
DRUGNAME	Apomine
INDICATI	Osteopetrosis [ICD-11: LD24.10] Phase 2
	
TTDDRUID	D00HTT
DRUGNAME	XE-9
INDICATI	Transplant rejection [ICD-11: NE84] Terminated
	
TTDDRUID	D00HTY
DRUGNAME	PGF2alpha
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial
	
TTDDRUID	D00HUZ
DRUGNAME	NDDP
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D00HWO
DRUGNAME	Cyclacillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D00HYD
DRUGNAME	CDT-fenofibrate
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1
	
TTDDRUID	D00HYF
DRUGNAME	H5N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D00HYK
DRUGNAME	AFN-1252
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 2
	
TTDDRUID	D00HZA
DRUGNAME	YPEG-Somatropin
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 1
	
TTDDRUID	D00HZO
DRUGNAME	GS-497C
INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
	
TTDDRUID	D00HZV
DRUGNAME	Trimipramine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
	
TTDDRUID	D00IAH
DRUGNAME	Hemiacidrin
INDICATI	Urolithiasis [ICD-11: GB7Z] Approved
	
TTDDRUID	D00IBN
DRUGNAME	Piroxicam
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D00ICD
DRUGNAME	SH-529
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D00ICM
DRUGNAME	Naltiazem hydrochloride
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D00ICY
DRUGNAME	FP-187
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D00IDP
DRUGNAME	Emdogain
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D00IDR
DRUGNAME	Phenylalanine hydroxylase
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D00IDV
DRUGNAME	CRTX-070
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative
	
TTDDRUID	D00IEB
DRUGNAME	DRL-21994
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative
	
TTDDRUID	D00IFH
DRUGNAME	INO-1400
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00IFQ
DRUGNAME	MVT-1075
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00IFR
DRUGNAME	AZD1208
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00IJM
DRUGNAME	EPI-A0001
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2
	
TTDDRUID	D00IJQ
DRUGNAME	Zatosetron maleate
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 3
	
TTDDRUID	D00IKH
DRUGNAME	Hexylcarbamoyl fluorouracil
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Withdrawn from market
	
TTDDRUID	D00IKI
DRUGNAME	PF-04895162
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
	
TTDDRUID	D00INM
DRUGNAME	Occlusin
INDICATI	Liver cancer [ICD-11: 2C12] Preclinical
	
TTDDRUID	D00IOS
DRUGNAME	CYT-017-IL17Qb
INDICATI	Multiple sclerosis [ICD-11: 8A40] Terminated
	
TTDDRUID	D00IPW
DRUGNAME	CGP-47969A
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D00IQH
DRUGNAME	RQ-00000007 (oral)
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D00IQV
DRUGNAME	Homspera
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D00IRU
DRUGNAME	E-5842
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D00ISN
DRUGNAME	MT-1303
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D00ITC
DRUGNAME	PRT4445
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Phase 3
	
TTDDRUID	D00ITG
DRUGNAME	Clinafloxacin
INDICATI	Pneumonia [ICD-11: CA40] Terminated
	
TTDDRUID	D00IUD
DRUGNAME	K-832
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D00IUG
DRUGNAME	Levobunolol
INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved
	
TTDDRUID	D00IVF
DRUGNAME	Murepavadin
INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 3
	
TTDDRUID	D00IVN
DRUGNAME	Navicixizumab
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1
	
TTDDRUID	D00IWE
DRUGNAME	RP-6000
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D00IWL
DRUGNAME	PolyHeme
INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Phase 3
	
TTDDRUID	D00IXM
DRUGNAME	DR-3001
INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 3
	
TTDDRUID	D00IXN
DRUGNAME	GS-6637
INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 1
	
TTDDRUID	D00IYB
DRUGNAME	Maraciclatide
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D00IYM
DRUGNAME	AEZS-127
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D00IZD
DRUGNAME	DVC1-0101
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2
	
TTDDRUID	D00IZW
DRUGNAME	BM-13.1188
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D00IZY
DRUGNAME	DCN01
INDICATI	Ocular infection [ICD-11: 1F00.1] Phase 2
	
TTDDRUID	D00JAU
DRUGNAME	Irbesartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D00JBM
DRUGNAME	UR-5908
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D00JCA
DRUGNAME	NewGam
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 3
	
TTDDRUID	D00JCB
DRUGNAME	CD19/CD22 CAR T cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D00JDJ
DRUGNAME	AX-024
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D00JDL
DRUGNAME	MGD006
INDICATI	Acute myeloid lymphoma [ICD-11: 2A80] Phase 1
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D00JDP
DRUGNAME	AMX-213
INDICATI	Cachexia [ICD-11: MG20] Investigative
	
TTDDRUID	D00JED
DRUGNAME	AN-2898
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D00JFE
DRUGNAME	ARN-810
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D00JFN
DRUGNAME	MDC-917
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00JGL
DRUGNAME	D-4476
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Preclinical
	
TTDDRUID	D00JIV
DRUGNAME	PF-4989216
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00JIX
DRUGNAME	IKH-25
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00JJG
DRUGNAME	RAP101
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D00JJW
DRUGNAME	RH 1
INDICATI	Discovery agent [ICD-11: N.A.] Phase 1
	
TTDDRUID	D00JJZ
DRUGNAME	LaViv
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
	
TTDDRUID	D00JKJ
DRUGNAME	HS-P1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative
	
TTDDRUID	D00JME
DRUGNAME	SMT-14400
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D00JMG
DRUGNAME	HRA-081035
INDICATI	Contraception [ICD-11: QA21] Investigative
	
TTDDRUID	D00JMY
DRUGNAME	AMP-224
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D00JNL
DRUGNAME	Tenilsetam
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D00JNT
DRUGNAME	HCV-086
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1
	
TTDDRUID	D00JQA
DRUGNAME	Benzimidazole derivative 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D00JQE
DRUGNAME	BAY-60-5521
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1
	
TTDDRUID	D00JQQ
DRUGNAME	RX-465
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Terminated
	
TTDDRUID	D00JRA
DRUGNAME	Asenapine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D00JRD
DRUGNAME	PGF2ALPHA-IE
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3
	
TTDDRUID	D00JRS
DRUGNAME	Lopinavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D00JSG
DRUGNAME	Fluoratec
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Terminated
	
TTDDRUID	D00JVC
DRUGNAME	ATB-429
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D00JVR
DRUGNAME	Azelastine
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved
	
TTDDRUID	D00JWL
DRUGNAME	LEX-028
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D00JWN
DRUGNAME	Allogeneic human dental pulp stem cells
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D00JXV
DRUGNAME	INCB-10820
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D00JZD
DRUGNAME	GSK2321138A
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D00JZS
DRUGNAME	Anti-FGFR1 mab program
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00JZX
DRUGNAME	EP-012637
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D00KCR
DRUGNAME	Enkastim-iv
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00KDQ
DRUGNAME	Anti-CEA CAR-T cells
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Peritoneal metastasis [ICD-11: 2D91] Phase 1
	
TTDDRUID	D00KEF
DRUGNAME	Org-2766
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3
	
TTDDRUID	D00KFB
DRUGNAME	Dextromethorphan Polistirex
INDICATI	Dry cough [ICD-11: MD12] Approved
	
TTDDRUID	D00KGB
DRUGNAME	Abagovomab
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2/3
	
TTDDRUID	D00KGI
DRUGNAME	IVN-201
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1
	
TTDDRUID	D00KHD
DRUGNAME	TAK-128
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
	
TTDDRUID	D00KHI
DRUGNAME	Anti-PSMA CAR-T cell therapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00KHM
DRUGNAME	Pimozide
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D00KIE
DRUGNAME	Ensaculin hydrochloride
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D00KIU
DRUGNAME	MKC-242844
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative
	
TTDDRUID	D00KJO
DRUGNAME	MUT-056399
INDICATI	Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Preclinical
	
TTDDRUID	D00KKD
DRUGNAME	PMID26651364-Compound-5
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D00KLH
DRUGNAME	KR-6346
INDICATI	Stomach ulcer [ICD-11: DA60.Z] Terminated
	
TTDDRUID	D00KLP
DRUGNAME	Immune globulin + albumin
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D00KMI
DRUGNAME	CEP-37309
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D00KML
DRUGNAME	SYN004
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00KMQ
DRUGNAME	OI362GT
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1
	
TTDDRUID	D00KNI
DRUGNAME	BI-853520
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00KOV
DRUGNAME	Monatepil maleate
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Preregistration
	
TTDDRUID	D00KQN
DRUGNAME	PEGylated pitrakinra
INDICATI	Asthma [ICD-11: CA23] Phase 2
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D00KQT
DRUGNAME	FR-129169
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D00KRE
DRUGNAME	Olsalazine
INDICATI	Ulcerative colitis [ICD-11: DD71] Approved
	
TTDDRUID	D00KRT
DRUGNAME	Indocyanine green
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved
	
TTDDRUID	D00KSU
DRUGNAME	MT-274
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D00KTN
DRUGNAME	PMID25666693-Compound-121
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D00KTV
DRUGNAME	Salirasib
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 1/2
	
TTDDRUID	D00KUD
DRUGNAME	ADL 10-0101
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D00KVE
DRUGNAME	Cutamesine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Preclinical
	
TTDDRUID	D00KVO
DRUGNAME	Albendazole
INDICATI	Worm infection [ICD-11: 1F90.Z] Approved
	
TTDDRUID	D00KVX
DRUGNAME	LP-261
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00KWA
DRUGNAME	Recainam
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D00KWF
DRUGNAME	PYN-9
INDICATI	Ileus [ICD-11: DA93.0] Preclinical
	
TTDDRUID	D00KXO
DRUGNAME	Ciraparantag
INDICATI	Harmful effects of drugs, medicaments or biological substances [ICD-11: NE60] Phase 2
	
TTDDRUID	D00KXQ
DRUGNAME	LF-13-0491c
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D00LAA
DRUGNAME	VA-118020
INDICATI	Respiratory disease [ICD-11: CB40] Investigative
	
TTDDRUID	D00LBD
DRUGNAME	Metazosin
INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3
	
TTDDRUID	D00LCT
DRUGNAME	Symakalim
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D00LDI
DRUGNAME	UPA-targeted oncolytic Sendai virus
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00LFB
DRUGNAME	Ritodrine
INDICATI	Premature labour [ICD-11: JB00] Approved
	
TTDDRUID	D00LGA
DRUGNAME	NN-8226
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D00LGR
DRUGNAME	TP-0903
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00LHF
DRUGNAME	GS-9219
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D00LHI
DRUGNAME	BAY 794980
INDICATI	Discovery agent [ICD-11: N.A.] Phase 2
	
TTDDRUID	D00LJF
DRUGNAME	INT0001/2004
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D00LLI
DRUGNAME	Candistat-G
INDICATI	Candidiasis [ICD-11: 1F23] Discontinued in Phase 2
	
TTDDRUID	D00LMA
DRUGNAME	Heteroaryl-carboxamide derivative 4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D00LMR
DRUGNAME	AP-006
INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Investigative
	
TTDDRUID	D00LMY
DRUGNAME	RO-5212651
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D00LNW
DRUGNAME	Selinexor
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
INDICATI	Liposarcoma [ICD-11: 2B59] Phase 3
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D00LOB
DRUGNAME	RWJ-671818
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D00LPZ
DRUGNAME	Vapill
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D00LRP
DRUGNAME	PRS-080
INDICATI	Anaemia [ICD-11: 3A90] Phase 1/2
	
TTDDRUID	D00LSD
DRUGNAME	SERX-1
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D00LSI
DRUGNAME	Vidofludimus
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D00LSQ
DRUGNAME	PMID26815044-Compound-126
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D00LSW
DRUGNAME	VA-111913
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Phase 2
	
TTDDRUID	D00LVA
DRUGNAME	Dianicline
INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Discontinued in Phase 3
	
TTDDRUID	D00LWD
DRUGNAME	AF-3473
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D00LWF
DRUGNAME	P-1075
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D00LWR
DRUGNAME	BVT-A
INDICATI	Acromegaly [ICD-11: 5A60.0] Preclinical
	
TTDDRUID	D00LWS
DRUGNAME	Ataprost
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3
	
TTDDRUID	D00LWX
DRUGNAME	Promegapoietin
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Terminated
	
TTDDRUID	D00LXB
DRUGNAME	Panaecin
INDICATI	Lung infection [ICD-11: CA4Z] Investigative
	
TTDDRUID	D00LXD
DRUGNAME	Omega interferon
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2
	
TTDDRUID	D00LYE
DRUGNAME	GC-003
INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative
	
TTDDRUID	D00LYW
DRUGNAME	BW-1003C87
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D00LZM
DRUGNAME	CP1
INDICATI	Cough [ICD-11: MD12] Investigative
	
TTDDRUID	D00LZO
DRUGNAME	CZC-19091
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D00LZY
DRUGNAME	AA-184
INDICATI	Kidney injury [ICD-11: NB92.0] Investigative
	
TTDDRUID	D00MAM
DRUGNAME	AMG-JAK2-01
INDICATI	Myeloproliferative syndrome [ICD-11: 2A22] Investigative
	
TTDDRUID	D00MAN
DRUGNAME	GRC-6211
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D00MBR
DRUGNAME	Iratumumab
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
	
TTDDRUID	D00MBY
DRUGNAME	AAD-2004
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D00MCA
DRUGNAME	BB-PTH 1-84
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D00MCY
DRUGNAME	REC2615
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D00MDP
DRUGNAME	Prinomastat
INDICATI	Lung cancer [ICD-11: 2C25.0] Approved
INDICATI	Brain cancer [ICD-11: 2A00] Discontinued in Phase 3
	
TTDDRUID	D00MET
DRUGNAME	Recombinant uteroglobin
INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative
	
TTDDRUID	D00MEV
DRUGNAME	Sch-45752
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D00MFA
DRUGNAME	Aspartame
INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative
	
TTDDRUID	D00MFY
DRUGNAME	GPI-3000
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D00MGO
DRUGNAME	PMID28270021-Compound-WO2016054807Example1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D00MHP
DRUGNAME	SR-2640
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D00MIF
DRUGNAME	JTP-4761
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D00MIN
DRUGNAME	Propylthiouracil
INDICATI	Hyperthyroidism [ICD-11: 5A02] Approved
	
TTDDRUID	D00MIX
DRUGNAME	CP-114271
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D00MJI
DRUGNAME	Emactuzumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00MLJ
DRUGNAME	Pyrazole derivative 61
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D00MLQ
DRUGNAME	Protosufloxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D00MLW
DRUGNAME	Triheptanoin
INDICATI	Long-chain fatty acid oxidation disorder [ICD-11: BC43.10] Approved
INDICATI	Genetic epileptic syndromes with variable age of onset [ICD-11: 8A61.4Y] Phase 3
	
TTDDRUID	D00MLX
DRUGNAME	Abacavir/dolutegravir/lamivudine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D00MMV
DRUGNAME	Enoticumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D00MNG
DRUGNAME	HIV gp41 vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D00MPX
DRUGNAME	JX-1395
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00MQS
DRUGNAME	PD-165167
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D00MRH
DRUGNAME	MDPTQ
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D00MSP
DRUGNAME	FR-149581
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D00MTG
DRUGNAME	SAR279356
INDICATI	Serious infection [ICD-11: 1H0Z] Phase 2
	
TTDDRUID	D00MUC
DRUGNAME	CD19 CAR-T cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D00MVK
DRUGNAME	Ro-48-8391
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D00MWE
DRUGNAME	UX-004
INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Investigative
	
TTDDRUID	D00MXN
DRUGNAME	MK-3207
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D00MYQ
DRUGNAME	Protriptyline
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D00MYT
DRUGNAME	Thiopental
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D00MYW
DRUGNAME	NS-018
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 1/2
	
TTDDRUID	D00MZC
DRUGNAME	LTX-100
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D00MZK
DRUGNAME	FK-788
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D00NAX
DRUGNAME	Promazine
INDICATI	Psychomotor agitation [ICD-11: MB23.M] Approved
	
TTDDRUID	D00NBF
DRUGNAME	GM06
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
	
TTDDRUID	D00NBJ
DRUGNAME	Remetinostat
INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 2
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
	
TTDDRUID	D00NBW
DRUGNAME	ONCOS-102
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00NEL
DRUGNAME	BI-754091
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00NGN
DRUGNAME	Sabeluzole
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 3
	
TTDDRUID	D00NIV
DRUGNAME	ATYR-1920
INDICATI	Genetic disease [ICD-11: 8E02] Investigative
	
TTDDRUID	D00NJE
DRUGNAME	SFc
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D00NJJ
DRUGNAME	Mezlocillin
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D00NJL
DRUGNAME	Clofoctol
INDICATI	Bronchitis [ICD-11: CA20] Approved
	
TTDDRUID	D00NKB
DRUGNAME	Triamterene
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
INDICATI	Edema [ICD-11: MG29] Approved
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D00NNC
DRUGNAME	Etidronic acid
INDICATI	Paget's disease [ICD-11: FB85] Approved
	
TTDDRUID	D00NNI
DRUGNAME	ASP-3652
INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2
	
TTDDRUID	D00NOL
DRUGNAME	MK-0536
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D00NOP
DRUGNAME	OBP-401
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D00NOY
DRUGNAME	BetaRx
INDICATI	Type-1 diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D00NPE
DRUGNAME	MMP-408
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D00NPO
DRUGNAME	ABT-199
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
	
TTDDRUID	D00NPP
DRUGNAME	Zanamivir
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D00NPT
DRUGNAME	Minodronate
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D00NSD
DRUGNAME	XL-820
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D00NSM
DRUGNAME	CM-GLP-1
INDICATI	Brain injury [ICD-11: NA07.Z] Discontinued in Phase 1/2
	
TTDDRUID	D00NTR
DRUGNAME	Histoplasmin
INDICATI	Histoplasma infection [ICD-11: 1F2A.Z] Approved
	
TTDDRUID	D00NTW
DRUGNAME	BIBR-363
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D00NUG
DRUGNAME	Olokizumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D00NUO
DRUGNAME	IDP-122
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Application submitted
	
TTDDRUID	D00NVM
DRUGNAME	SNS-595
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D00NVO
DRUGNAME	Flezelastine
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D00NVX
DRUGNAME	Forasartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D00NWT
DRUGNAME	GR-213487
INDICATI	Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2
	
TTDDRUID	D00NWV
DRUGNAME	Ypeginterferon alfa-2a
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
	
TTDDRUID	D00NXM
DRUGNAME	GSK-2251052
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 2
	
TTDDRUID	D00NXT
DRUGNAME	Xmab 5871
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
INDICATI	IgG4 related disease [ICD-11: 4A43.0] Phase 2
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1/2
	
TTDDRUID	D00NYJ
DRUGNAME	Varlitinib
INDICATI	Metastatic biliary tract neoplasms [ICD-11: 2C14-2C17] Phase 2/3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D00NYL
DRUGNAME	AAV2/8-CBA-hSMN1
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Investigative
	
TTDDRUID	D00NZL
DRUGNAME	LY2603618
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D00OAB
DRUGNAME	APX-007
INDICATI	Bone metastases [ICD-11: 2D50] Investigative
	
TTDDRUID	D00OAU
DRUGNAME	GW-328267
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1
	
TTDDRUID	D00OAY
DRUGNAME	Lenampicillin hci
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D00OCB
DRUGNAME	CCT-018159
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D00ODY
DRUGNAME	PMID25666693-Compound-95
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D00OEG
DRUGNAME	RhTPO
INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Discontinued in Phase 3
	
TTDDRUID	D00OFV
DRUGNAME	Asperlicin
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative
	
TTDDRUID	D00OGX
DRUGNAME	Anapsos
INDICATI	Atopic dermatitis [ICD-11: EA80] Approved
	
TTDDRUID	D00OHP
DRUGNAME	PRO-GR-300
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D00OJL
DRUGNAME	QBP1 mimetics
INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative
	
TTDDRUID	D00OKK
DRUGNAME	PC4708
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D00OLY
DRUGNAME	PMID25666693-Compound-149
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D00OMJ
DRUGNAME	SJ-BRV
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D00ONE
DRUGNAME	CWF-0710
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D00OON
DRUGNAME	CAB-AXL-ADC
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D00OOZ
DRUGNAME	E-7107
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00OPX
DRUGNAME	Fostamatinib disodium
INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 3
	
TTDDRUID	D00ORZ
DRUGNAME	BMS-824393
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D00OTH
DRUGNAME	P-979
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D00OTL
DRUGNAME	Vernakalant
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 3
	
TTDDRUID	D00OTM
DRUGNAME	LY3022855
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00OTQ
DRUGNAME	Proximab
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D00OTT
DRUGNAME	ISIS 1570
INDICATI	Lleum inflammation [ICD-11: 1A40.0] Approved
	
TTDDRUID	D00OVC
DRUGNAME	EVT-201
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2
	
TTDDRUID	D00OVE
DRUGNAME	PF-06650808
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00OVU
DRUGNAME	Suvorexant
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D00OWU
DRUGNAME	RBP-8000
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2
	
TTDDRUID	D00OXP
DRUGNAME	Bb21217
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D00OYC
DRUGNAME	Motolimid
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D00OYQ
DRUGNAME	Imisopasem manganese
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D00OZC
DRUGNAME	THX-TS01
INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 3
	
TTDDRUID	D00PBI
DRUGNAME	SUVN-501
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D00PBS
DRUGNAME	Allogeneic NK cells
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D00PBX
DRUGNAME	GDC-0199
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D00PDG
DRUGNAME	CORT-108297
INDICATI	Weight gain [ICD-11: MG43.6] Discontinued in Phase 1/2
	
TTDDRUID	D00PDQ
DRUGNAME	Kuzbanian
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00PEH
DRUGNAME	Eltrombopag
INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved
INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 3
	
TTDDRUID	D00PEN
DRUGNAME	MGD007
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 1
	
TTDDRUID	D00PFW
DRUGNAME	AZD4818
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D00PGA
DRUGNAME	ALS-AAV9
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D00PGF
DRUGNAME	RV-1088
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D00PHK
DRUGNAME	Carboxylic acid derivative 1
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Patented
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Patented
	
TTDDRUID	D00PIE
DRUGNAME	Banoxantrone
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Discontinued in Phase 1
	
TTDDRUID	D00PJJ
DRUGNAME	FK-614
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D00PJK
DRUGNAME	SRI-21009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00PJY
DRUGNAME	Prosorba
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D00PLV
DRUGNAME	Nitroprusside
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D00PLX
DRUGNAME	MystiLol
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D00PMA
DRUGNAME	CL-246738
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2
	
TTDDRUID	D00PMB
DRUGNAME	VGX-3100
INDICATI	Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Phase 3
INDICATI	Dysplasia [ICD-11: LB30-LD2F] Phase 3
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2
INDICATI	Vulvar squamous intraepithelial lesion [ICD-11: 2E66.1] Phase 2
INDICATI	Vulvar intraepithelial neoplasia [ICD-11: 2E67.10] Phase 2
	
TTDDRUID	D00PNU
DRUGNAME	TGN-1412
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 1
	
TTDDRUID	D00POS
DRUGNAME	DL-017
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D00PPV
DRUGNAME	Siderophore-conjugated monocarbams
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D00PQS
DRUGNAME	NE-2
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D00PRI
DRUGNAME	Edetate calcium disodium
INDICATI	Toxicity [ICD-11: N.A.] Approved
	
TTDDRUID	D00PSG
DRUGNAME	NOX-100
INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 2
	
TTDDRUID	D00PTZ
DRUGNAME	Dasiprotimut-T
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3
	
TTDDRUID	D00PUT
DRUGNAME	BT-016
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D00PXQ
DRUGNAME	Fananserin
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D00PYP
DRUGNAME	NBI-37582
INDICATI	Depression [ICD-11: 6A70-6A7Z] Terminated
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D00PZH
DRUGNAME	AC-187
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D00PZK
DRUGNAME	APD-405
INDICATI	Vomiting [ICD-11: MD90] Discontinued in Phase 2
	
TTDDRUID	D00QAQ
DRUGNAME	Terpenoid schweinfurthins
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00QAX
DRUGNAME	PF-708093
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical
	
TTDDRUID	D00QBV
DRUGNAME	DD7
INDICATI	Acute respiratory distress syndrome [ICD-11: CB00] Investigative
INDICATI	Myocardial reperfusion injury [ICD-11: NB31] Investigative
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D00QCB
DRUGNAME	SRI-62-834
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D00QCV
DRUGNAME	MG-401
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00QCX
DRUGNAME	SCP-123
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D00QDJ
DRUGNAME	Trametinib
INDICATI	Metastatic melanoma [ICD-11: 2E2Z] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D00QEP
DRUGNAME	Inotuzumab ozogamicin
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Approved
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
	
TTDDRUID	D00QET
DRUGNAME	Montelukast
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D00QEZ
DRUGNAME	PMID25666693-Compound-60
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D00QFV
DRUGNAME	GR-DD1
INDICATI	Liver cancer [ICD-11: 2C12] Investigative
	
TTDDRUID	D00QFY
DRUGNAME	YM533
INDICATI	Chronic renal failure [ICD-11: GB61.Z] Discontinued in Phase 3
	
TTDDRUID	D00QGB
DRUGNAME	O-2442
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Investigative
	
TTDDRUID	D00QGV
DRUGNAME	Human interferon alpha oral
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D00QHT
DRUGNAME	AK-295
INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Terminated
	
TTDDRUID	D00QIJ
DRUGNAME	Huntingtin gene antisense
INDICATI	Huntington disease [ICD-11: 8A01.10] Preclinical
	
TTDDRUID	D00QIK
DRUGNAME	PS-519
INDICATI	Ischemia-reperfusion injury [ICD-11: DB98.B] Terminated
	
TTDDRUID	D00QJL
DRUGNAME	Influvac TC
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D00QKI
DRUGNAME	SCH-527123
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00QKL
DRUGNAME	T2c-003
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 1/2
	
TTDDRUID	D00QKS
DRUGNAME	BMS-954561
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
	
TTDDRUID	D00QLG
DRUGNAME	Lovaxin M
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D00QNW
DRUGNAME	Laropiprant/niacin/ simvastatin combination
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 3
	
TTDDRUID	D00QOF
DRUGNAME	ORG-13011
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Application submitted
	
TTDDRUID	D00QOG
DRUGNAME	F-2833
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D00QOH
DRUGNAME	OCT-SG815
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D00QOJ
DRUGNAME	99mTc-RP-128
INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 2
	
TTDDRUID	D00QTA
DRUGNAME	A-058
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D00QTL
DRUGNAME	MDDR 184045
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D00QTU
DRUGNAME	TH-1320
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00QUJ
DRUGNAME	AM-3005
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D00QUZ
DRUGNAME	TTP-814
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1/2
	
TTDDRUID	D00QVT
DRUGNAME	ATN-161
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D00QVY
DRUGNAME	Resorcinol compound 23
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D00QWK
DRUGNAME	CLL1-specific gene-engineered T cells
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D00QWU
DRUGNAME	BMS-779788
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1
	
TTDDRUID	D00QXB
DRUGNAME	WT1 peptide vaccine
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D00QXV
DRUGNAME	BMS-181101
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
	
TTDDRUID	D00QZJ
DRUGNAME	Growth hormone
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Investigative
	
TTDDRUID	D00RAM
DRUGNAME	Bone Marrow-Derived Mesenchymal Stem Cells
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D00RCI
DRUGNAME	Teduglutide
INDICATI	Short bowel syndrome [ICD-11: KB89.1] Approved
	
TTDDRUID	D00RDI
DRUGNAME	OPN-401
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D00RDO
DRUGNAME	PMID26651364-Compound-116
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D00RFZ
DRUGNAME	PSI-6130
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated
	
TTDDRUID	D00RGF
DRUGNAME	GCC-4401
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D00RGX
DRUGNAME	RG7876
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00RIB
DRUGNAME	RG-201
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 1
	
TTDDRUID	D00RIK
DRUGNAME	B7/CD28 costimulatory proteins
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D00RJA
DRUGNAME	VX-148
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Patented
	
TTDDRUID	D00RJB
DRUGNAME	Rilopirox
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2
	
TTDDRUID	D00RJE
DRUGNAME	Pancopride
INDICATI	Nausea [ICD-11: MD90] Phase 3
	
TTDDRUID	D00RJJ
DRUGNAME	Ganirelix
INDICATI	Ovulation dysfunction [ICD-11: 5A80] Approved
	
TTDDRUID	D00RMC
DRUGNAME	BIBX-1382
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	D00RMD
DRUGNAME	FK-960
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D00RNB
DRUGNAME	IQB-9302
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D00ROR
DRUGNAME	CYNK-001 cells
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D00ROV
DRUGNAME	FK-041
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D00ROY
DRUGNAME	Adjustable basal insulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D00RPV
DRUGNAME	EPB-200
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D00RQQ
DRUGNAME	ASP-1120
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D00RQW
DRUGNAME	Biaryl mannoside derivative 8
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D00RRU
DRUGNAME	BIIB037
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D00RSK
DRUGNAME	GW-406381
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 3
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 3
	
TTDDRUID	D00RTC
DRUGNAME	Vicinium
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3
	
TTDDRUID	D00RTU
DRUGNAME	227Th-rituximab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00RWQ
DRUGNAME	CX157
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2
	
TTDDRUID	D00RWU
DRUGNAME	FT-301
INDICATI	Muscle wasting disease [ICD-11: 8E4A.3] Investigative
	
TTDDRUID	D00RWW
DRUGNAME	Fexinidazole
INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Phase 2/3
	
TTDDRUID	D00RXR
DRUGNAME	AC-253
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D00RYA
DRUGNAME	SB-1578
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00RYU
DRUGNAME	IPH-2102
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D00RZA
DRUGNAME	EPB-500
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D00SBD
DRUGNAME	Recoflavone
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
	
TTDDRUID	D00SBN
DRUGNAME	Perhexiline
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D00SBU
DRUGNAME	PF614
INDICATI	Chronic pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D00SBX
DRUGNAME	ZL006
INDICATI	Fear-related disorder [ICD-11: 6B0Z] Investigative
	
TTDDRUID	D00SEB
DRUGNAME	Enalapril
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D00SFN
DRUGNAME	TUCARESOL
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2
	
TTDDRUID	D00SFY
DRUGNAME	BI-44847
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D00SGD
DRUGNAME	Pentacel
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D00SHQ
DRUGNAME	Bromperidol
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D00SHS
DRUGNAME	Human hemoglobin
INDICATI	Blood transfusion [ICD-11: QB98] Phase 3
	
TTDDRUID	D00SIA
DRUGNAME	ARQ-171
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00SIR
DRUGNAME	CS-461
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D00SIZ
DRUGNAME	RG6180
INDICATI	Metastatic melanoma [ICD-11: 2E2Z] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00SJE
DRUGNAME	Secobarbital
INDICATI	Intractable insomnia [ICD-11: 7A00] Approved
	
TTDDRUID	D00SJN
DRUGNAME	HLL1-Fab-A3B3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00SJX
DRUGNAME	NK-110
INDICATI	Muscle wasting disease [ICD-11: 8E4A.3] Investigative
	
TTDDRUID	D00SKM
DRUGNAME	TT12
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1
INDICATI	Oropharyngeal cancer [ICD-11: 2B6A] Phase 1
	
TTDDRUID	D00SKS
DRUGNAME	GS-8374
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D00SLY
DRUGNAME	Umeclidinium
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D00SMC
DRUGNAME	PAN-22
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative
	
TTDDRUID	D00SML
DRUGNAME	NMHSS1-1
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative
	
TTDDRUID	D00SMU
DRUGNAME	Lenti-D
INDICATI	Adrenoleukodystrophy [ICD-11: 8A44.1] Phase 3
	
TTDDRUID	D00SNY
DRUGNAME	TDI-0057
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D00SOZ
DRUGNAME	DE-117
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3
	
TTDDRUID	D00SPK
DRUGNAME	E-4021
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2
	
TTDDRUID	D00SQN
DRUGNAME	HBI-8000
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Registered
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Registered
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
	
TTDDRUID	D00SRE
DRUGNAME	HPMPA prodrugs
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative
	
TTDDRUID	D00SSZ
DRUGNAME	OBP-801
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00STJ
DRUGNAME	Enocitabine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D00STL
DRUGNAME	Nilotinib
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved
	
TTDDRUID	D00STZ
DRUGNAME	Mam-05.200
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D00SUK
DRUGNAME	Tonapofylline
INDICATI	Acute and chronic heart failure [ICD-11: BD1Z] Phase 2
	
TTDDRUID	D00SVK
DRUGNAME	PMID25684022-Compound-WO2011137219 37(4-6)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D00SVP
DRUGNAME	PF-4455242
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1
	
TTDDRUID	D00SVU
DRUGNAME	Y-25130
INDICATI	Nausea and vomiting [ICD-11: MD90] Approved
	
TTDDRUID	D00SWN
DRUGNAME	MS-806
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D00SWQ
DRUGNAME	Mitoglitazone
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D00SYV
DRUGNAME	GSK2618960
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 1
	
TTDDRUID	D00TAP
DRUGNAME	Helivax
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Discontinued in Phase 1
	
TTDDRUID	D00TBD
DRUGNAME	PHA-665752
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00TBI
DRUGNAME	Imidazole derivative 7
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D00TBJ
DRUGNAME	PF-271836
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D00TBS
DRUGNAME	SPIRU-211
INDICATI	Constipation [ICD-11: DD91.1] Investigative
	
TTDDRUID	D00TCM
DRUGNAME	Yellow fever vaccine
INDICATI	Yellow fever virus infection [ICD-11: 1D47] Approved
	
TTDDRUID	D00TED
DRUGNAME	JNJ-54728518
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D00TEN
DRUGNAME	TV-1390
INDICATI	Multiple sclerosis [ICD-11: 8A40] Preclinical
	
TTDDRUID	D00TGR
DRUGNAME	Citric acid, magnesium oxide, sodium picosulfate
INDICATI	Crohn disease [ICD-11: DD70] Approved
	
TTDDRUID	D00THA
DRUGNAME	QLT-091001
INDICATI	Restless legs syndrome [ICD-11: 7A80] Phase 2
INDICATI	Leber congenital amaurosis [ICD-11: 9B70] Phase 1
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1
	
TTDDRUID	D00THG
DRUGNAME	DE-105
INDICATI	Corneal disease [ICD-11: 9A78.Z] Phase 2
	
TTDDRUID	D00THJ
DRUGNAME	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3
INDICATI	Skin disease [ICD-11: EA00-EM0Z] Patented
INDICATI	Muscular wasting [ICD-11: 8C7Y] Patented
	
TTDDRUID	D00TIG
DRUGNAME	RG3806
INDICATI	Acromegaly [ICD-11: 5A60.0] Preregistration
	
TTDDRUID	D00TJV
DRUGNAME	RP-3120
INDICATI	Respiratory tract inflammation [ICD-11: CA07] Investigative
	
TTDDRUID	D00TJX
DRUGNAME	Albinterferon alfa-2b
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
	
TTDDRUID	D00TKC
DRUGNAME	NCP-004
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D00TLD
DRUGNAME	RIG-200
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D00TLM
DRUGNAME	PRUVANSERIN
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2
	
TTDDRUID	D00TLN
DRUGNAME	Cyproheptadine
INDICATI	Rhinitis [ICD-11: FA20] Approved
	
TTDDRUID	D00TLP
DRUGNAME	Simeprevir
INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Approved
	
TTDDRUID	D00TMK
DRUGNAME	Dengvaxia
INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 2
	
TTDDRUID	D00TMQ
DRUGNAME	Azetidine-1-carboxamide derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D00TNC
DRUGNAME	S-8510
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D00TNZ
DRUGNAME	Enadenotucirev
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00TPC
DRUGNAME	MAT-401
INDICATI	Aspergillosis [ICD-11: 1F20] Investigative
	
TTDDRUID	D00TPI
DRUGNAME	Nalidixic Acid + Ampicillin
INDICATI	Typhoid fever [ICD-11: 1A07] Investigative
	
TTDDRUID	D00TPQ
DRUGNAME	VT-384
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D00TPW
DRUGNAME	FST-201
INDICATI	Otitis externa [ICD-11: AA00-AA13] Phase 3
	
TTDDRUID	D00TQN
DRUGNAME	JTK-003
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2
	
TTDDRUID	D00TRL
DRUGNAME	REV-598
INDICATI	Carcinoid syndrome [ICD-11: 5B10] Terminated
	
TTDDRUID	D00TRV
DRUGNAME	Besifloxacin
INDICATI	Ocular inflammation [ICD-11: 9C61.24] Approved
	
TTDDRUID	D00TTS
DRUGNAME	Human chorionic gonadotropin
INDICATI	Heart disease [ICD-11: BA41-BA42] Terminated
	
TTDDRUID	D00TUP
DRUGNAME	Vitreosolve
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 3
	
TTDDRUID	D00TUR
DRUGNAME	LY2495655
INDICATI	Disuse muscle atrophy [ICD-11: 8B61] Phase 2
	
TTDDRUID	D00TVI
DRUGNAME	SR-58894A
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated
	
TTDDRUID	D00TXL
DRUGNAME	AAV2-hFIX16
INDICATI	Factor IX deficiency [ICD-11: 3B11] Phase 1
	
TTDDRUID	D00TYI
DRUGNAME	TG-3030
INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Investigative
	
TTDDRUID	D00TYP
DRUGNAME	KIN-4064
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00TYR
DRUGNAME	Anti-tubulin agents
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00UAE
DRUGNAME	Bavituximab
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Asthma [ICD-11: CA23] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
	
TTDDRUID	D00UBK
DRUGNAME	L-159689
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D00UBX
DRUGNAME	TNX-355
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D00UCC
DRUGNAME	ABT-518
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D00UCW
DRUGNAME	CEREBROCRAST
INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 1
	
TTDDRUID	D00UDP
DRUGNAME	Terameprocol
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D00UEC
DRUGNAME	ASP3662
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D00UEG
DRUGNAME	LY288513
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D00UEQ
DRUGNAME	Etomoxir
INDICATI	Heart failure [ICD-11: BD10-BD13] Terminated
	
TTDDRUID	D00UET
DRUGNAME	SAR-407899
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
INDICATI	Microvascular angina [ICD-11: BA86] Phase 2
	
TTDDRUID	D00UFZ
DRUGNAME	AMG 745
INDICATI	Muscle atrophy [ICD-11: FB32.Y] Phase 2
	
TTDDRUID	D00UGC
DRUGNAME	HSC660
INDICATI	Alopecia [ICD-11: ED70] Phase 1/2
	
TTDDRUID	D00UGX
DRUGNAME	Cenplacel-L
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D00UGY
DRUGNAME	Natural killer cells
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D00UHK
DRUGNAME	KI-0905
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D00UJF
DRUGNAME	Dextran
INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved
	
TTDDRUID	D00UKN
DRUGNAME	Mesenchymal stromal cells
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D00ULY
DRUGNAME	KAI-9803/ BMS-875944
INDICATI	Reperfusion injury [ICD-11: ND56.Z] Phase 2
	
TTDDRUID	D00UMJ
DRUGNAME	NM-007-LENK
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D00UNK
DRUGNAME	Coltuximab ravtansine
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D00UOQ
DRUGNAME	PAT-SC1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2
	
TTDDRUID	D00UOR
DRUGNAME	Desirudin
INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved
	
TTDDRUID	D00UOZ
DRUGNAME	MEDI-491
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1
	
TTDDRUID	D00UPU
DRUGNAME	RPR-107836
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D00UQF
DRUGNAME	GW4064
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Preclinical
	
TTDDRUID	D00UQW
DRUGNAME	RG7741
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00URZ
DRUGNAME	LG-740
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D00USF
DRUGNAME	Trazodone
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D00USS
DRUGNAME	Cholera vaccine
INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Approved
	
TTDDRUID	D00USX
DRUGNAME	CEFMATILEN HYDROCHLORIDE HYDRATE
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3
	
TTDDRUID	D00UTD
DRUGNAME	Nedaplatin
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
	
TTDDRUID	D00UUL
DRUGNAME	N8-GP
INDICATI	Factor VIII deficiency [ICD-11: 3B10] Phase 3
	
TTDDRUID	D00UVA
DRUGNAME	Carfilzomib
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D00UVU
DRUGNAME	Lipoteichoic acid
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D00UWY
DRUGNAME	RT-001
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 1/2
	
TTDDRUID	D00UXT
DRUGNAME	Acetrizoate Sodium
INDICATI	Radiographic contrast medium [ICD-11: N.A.] Approved
	
TTDDRUID	D00UYB
DRUGNAME	Anti-DLL-4 mab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00UYE
DRUGNAME	Meperidine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D00UYR
DRUGNAME	IMC-1
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2
	
TTDDRUID	D00UZR
DRUGNAME	Palbociclib
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D00VAJ
DRUGNAME	ORBOFIBAN
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3
	
TTDDRUID	D00VBT
DRUGNAME	ZK 304709
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D00VCH
DRUGNAME	F-98214
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D00VCZ
DRUGNAME	HGT-2610
INDICATI	Leukodystrophy [ICD-11: 8A44] Investigative
	
TTDDRUID	D00VFE
DRUGNAME	Saralasin Acetate
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D00VFH
DRUGNAME	PXS-25
INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 1
	
TTDDRUID	D00VFM
DRUGNAME	RWJ-49968
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D00VGP
DRUGNAME	XGP-215
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00VJC
DRUGNAME	Peg. Adrenomedullin
INDICATI	Lung disease [ICD-11: CA60-CA8Z] Phase 1
	
TTDDRUID	D00VKK
DRUGNAME	VPI-2690B
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D00VLF
DRUGNAME	HCV/MF59
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2
	
TTDDRUID	D00VMA
DRUGNAME	Vatreptacog alfa (activated)
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Phase 3
	
TTDDRUID	D00VMY
DRUGNAME	P-3378
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00VNH
DRUGNAME	ZK-200775
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1
	
TTDDRUID	D00VOE
DRUGNAME	Myoblast cell transplantation
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1
	
TTDDRUID	D00VOF
DRUGNAME	TNF-PEG-20
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00VPT
DRUGNAME	SB222200
INDICATI	Schizoaffective disorder [ICD-11: 6A21] Preclinical
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D00VPU
DRUGNAME	SLV-323
INDICATI	Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 1
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Discontinued in Phase 1
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 1
	
TTDDRUID	D00VPV
DRUGNAME	TAK-013
INDICATI	Uterine fibroids [ICD-11: 2E86.0] Discontinued in Phase 2
	
TTDDRUID	D00VQI
DRUGNAME	SQ-30741
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D00VQT
DRUGNAME	99mTc-EC-DG
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D00VSQ
DRUGNAME	E-1455
INDICATI	Schizophrenia [ICD-11: 6A20] Investigative
	
TTDDRUID	D00VUG
DRUGNAME	FF21101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D00VUL
DRUGNAME	Phenazopyridine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D00VUN
DRUGNAME	TRX-818
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00VXZ
DRUGNAME	YT-1006
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D00VZF
DRUGNAME	Merbarone
INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2
	
TTDDRUID	D00VZZ
DRUGNAME	Allopregnanolone
INDICATI	Postpartum depression [ICD-11: 6E20.0] Approved
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
INDICATI	Status epilepticus seizure [ICD-11: 8A66.1Y] Phase 3
INDICATI	Essential tremor or related tremors [ICD-11: 8A04.1] Phase 2
	
TTDDRUID	D00WAM
DRUGNAME	Hydroflumethiazide
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D00WBN
DRUGNAME	ALV-003
INDICATI	Coeliac disease [ICD-11: DA95] Phase 2
	
TTDDRUID	D00WCT
DRUGNAME	EVP-1001-1
INDICATI	Heart disease [ICD-11: BA41-BA42] Phase 2
	
TTDDRUID	D00WCX
DRUGNAME	Bezafibrate
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved
	
TTDDRUID	D00WDM
DRUGNAME	BST-204
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00WDY
DRUGNAME	BMS-903452
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D00WEL
DRUGNAME	ABS-401
INDICATI	Amnesia [ICD-11: MB21.1] Terminated
	
TTDDRUID	D00WEP
DRUGNAME	BLX-155
INDICATI	Deep vein thrombosis [ICD-11: BD71] Investigative
	
TTDDRUID	D00WHC
DRUGNAME	MB-03966
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Investigative
	
TTDDRUID	D00WHL
DRUGNAME	Juvidex
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2
	
TTDDRUID	D00WJC
DRUGNAME	DCDS0780A
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D00WJE
DRUGNAME	SUN-1334H
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2
	
TTDDRUID	D00WKL
DRUGNAME	PSX-4206
INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Investigative
	
TTDDRUID	D00WME
DRUGNAME	Conatumumab
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D00WMJ
DRUGNAME	CMC-001
INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
	
TTDDRUID	D00WMK
DRUGNAME	Relvar/Breo
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D00WOT
DRUGNAME	CDP-850
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D00WOX
DRUGNAME	Human retinal pigment epithelial cell therapy
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1/2
	
TTDDRUID	D00WPT
DRUGNAME	ACV-1
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D00WPU
DRUGNAME	Sazetidine-A
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D00WUC
DRUGNAME	Histidase-PEG-20
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00WUF
DRUGNAME	Pregabalin
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D00WVI
DRUGNAME	AS-1907417
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D00WVW
DRUGNAME	YM443
INDICATI	Functional dyspepsia [ICD-11: DD90.3] Approved
	
TTDDRUID	D00WWU
DRUGNAME	SMP-028
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D00WYV
DRUGNAME	V-3526
INDICATI	Encephalitis virus infection [ICD-11: 1C83-1C84] Terminated
	
TTDDRUID	D00WZK
DRUGNAME	BC-3781 intravenous
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D00XBC
DRUGNAME	GSK-2239633
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D00XBH
DRUGNAME	MNLP-462a
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D00XCX
DRUGNAME	DIFLOMOTECAN
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D00XDN
DRUGNAME	Pyrazole derivative 40
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D00XEM
DRUGNAME	Beta-cyclodextrin conjugate derivative 3
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D00XEU
DRUGNAME	GSK-923295
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D00XEX
DRUGNAME	MN-201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00XFT
DRUGNAME	Pyrazole derivative 53
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D00XFY
DRUGNAME	ISIS 2922 + foscarnet 3' -azido-3'-deoxythymidine 2'-3'-dideoxycytidine
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D00XHD
DRUGNAME	Balofloxacin
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved
	
TTDDRUID	D00XIP
DRUGNAME	MVA-BN Brachyury
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00XKB
DRUGNAME	AZ-4217
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Clinical trial
	
TTDDRUID	D00XKE
DRUGNAME	PMID26651364-Compound-109
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D00XLE
DRUGNAME	PF-4764793
INDICATI	Respiratory disease [ICD-11: CB40] Phase 1
	
TTDDRUID	D00XMZ
DRUGNAME	Drug 1940029
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 1
	
TTDDRUID	D00XNC
DRUGNAME	CAT-2200
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D00XND
DRUGNAME	PMA-511R
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D00XNW
DRUGNAME	AL-54478
INDICATI	Ocular hypertension [ICD-11: 9C61.01] Phase 2
	
TTDDRUID	D00XPA
DRUGNAME	L-759274
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 3
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 3
	
TTDDRUID	D00XPC
DRUGNAME	Halobetasol Propionate
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D00XPZ
DRUGNAME	ELB-WE-007
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D00XQK
DRUGNAME	HRC-102
INDICATI	Reperfusion injury [ICD-11: ND56.Z] Terminated
	
TTDDRUID	D00XQO
DRUGNAME	MANOALIDE
INDICATI	Arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D00XRI
DRUGNAME	TJN-220
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D00XRK
DRUGNAME	BMS-182193
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D00XSP
DRUGNAME	S-35678
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D00XSQ
DRUGNAME	PGL-1001
INDICATI	Female infertility [ICD-11: GA31.Z] Investigative
	
TTDDRUID	D00XTS
DRUGNAME	CR-3834
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D00XUN
DRUGNAME	Etidronate Disodium
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D00XVE
DRUGNAME	BR6819
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D00XVL
DRUGNAME	ITI-214
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
INDICATI	Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1
INDICATI	Immune dysregulation [ICD-11: 4A01.2] Phase 1
	
TTDDRUID	D00XWB
DRUGNAME	F-15845
INDICATI	Angina pectoris [ICD-11: BA40] Phase 1
	
TTDDRUID	D00XWD
DRUGNAME	Tegaserod
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
INDICATI	Gastro-oesophageal reflux [ICD-11: DA22] Withdrawn from market
INDICATI	Dyspepsia [ICD-11: MD92] Withdrawn from market
	
TTDDRUID	D00XWF
DRUGNAME	RBX2660
INDICATI	C. difficile infection [ICD-11: 1A04] Phase 3
	
TTDDRUID	D00XXZ
DRUGNAME	N-acylpiperidine ether derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D00XZP
DRUGNAME	UR-7198
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D00XZY
DRUGNAME	ORC-Vax
INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Approved
	
TTDDRUID	D00YAH
DRUGNAME	E2730
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
	
TTDDRUID	D00YAS
DRUGNAME	Q-102
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D00YBW
DRUGNAME	OXY-111A
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2
	
TTDDRUID	D00YBZ
DRUGNAME	OC-10X
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
INDICATI	Proliferative diabetic retinopathy [ICD-11: 9B71.01] Phase 1
	
TTDDRUID	D00YCO
DRUGNAME	Pulvomycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D00YDN
DRUGNAME	CXR-1002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00YEO
DRUGNAME	NZ-1002
INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Terminated
	
TTDDRUID	D00YER
DRUGNAME	HM-78136B
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D00YEV
DRUGNAME	BAICALEIN
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D00YFP
DRUGNAME	RG7697
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D00YGA
DRUGNAME	SB-219994
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D00YJD
DRUGNAME	SEL-103
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D00YJI
DRUGNAME	EOS-013
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Investigative
	
TTDDRUID	D00YLF
DRUGNAME	Serpacwa
INDICATI	Poison intoxication [ICD-11: NE6Z] Approved
	
TTDDRUID	D00YLM
DRUGNAME	TRAXOPRODIL MESYLATE
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 2
	
TTDDRUID	D00YLW
DRUGNAME	Dolasetron
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D00YMM
DRUGNAME	SAR-215500
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D00YMN
DRUGNAME	AIKO-152
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Investigative
	
TTDDRUID	D00YNJ
DRUGNAME	XB-387
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative
	
TTDDRUID	D00YNK
DRUGNAME	MGN-7455
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative
	
TTDDRUID	D00YNY
DRUGNAME	VPC-94075
INDICATI	Vascular disease [ICD-11: BE2Z] Investigative
	
TTDDRUID	D00YOV
DRUGNAME	MT-110
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00YOW
DRUGNAME	LM-1376
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D00YPR
DRUGNAME	CP-547632
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D00YQI
DRUGNAME	TRC105
INDICATI	Hemangiosarcoma [ICD-11: 2B56.1] Phase 3
INDICATI	Angiosarcoma [ICD-11: 2B56] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 2
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 2
INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2
INDICATI	Gestational trophoblastic neoplasia [ICD-11: 2F33-2F76] Phase 2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
	
TTDDRUID	D00YQZ
DRUGNAME	L-702958
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Terminated
	
TTDDRUID	D00YRF
DRUGNAME	UCB-1277763
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D00YRS
DRUGNAME	PMID26815044-Compound-H
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D00YSJ
DRUGNAME	Tecadenoson
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 3
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Discontinued in Phase 3
	
TTDDRUID	D00YTQ
DRUGNAME	BMS-345541
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D00YTS
DRUGNAME	AVP-13546
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Investigative
	
TTDDRUID	D00YTX
DRUGNAME	OG-19
INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative
	
TTDDRUID	D00YUB
DRUGNAME	NT-3
INDICATI	Constipation [ICD-11: DD91.1] Discontinued in Phase 2
	
TTDDRUID	D00YUP
DRUGNAME	LT-3001
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 1
	
TTDDRUID	D00YUQ
DRUGNAME	CART-19 T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D00YVF
DRUGNAME	Exenatide
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
	
TTDDRUID	D00YWH
DRUGNAME	Anti-MRSA
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D00YWL
DRUGNAME	BMS-936557
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2
	
TTDDRUID	D00YWP
DRUGNAME	Nandrolone
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D00YXA
DRUGNAME	PMID25666693-Compound-2
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D00YXG
DRUGNAME	Anti-mesothelin CAR transduced PBL
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1/2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D00YXR
DRUGNAME	Foxy-5
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D00YXU
DRUGNAME	CCX-025
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
	
TTDDRUID	D00YZA
DRUGNAME	Thiotepa
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D00YZD
DRUGNAME	Dolutegravir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D00YZP
DRUGNAME	EBS-A42
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D00ZBQ
DRUGNAME	TL-1892
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00ZBZ
DRUGNAME	OGX-427 + Paclitaxel
INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D00ZCN
DRUGNAME	Caspofungin
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D00ZCT
DRUGNAME	Fostemsavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D00ZDO
DRUGNAME	SELA-070
INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 1
	
TTDDRUID	D00ZEG
DRUGNAME	Umespirone
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1
	
TTDDRUID	D00ZEN
DRUGNAME	Seasonal influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D00ZFC
DRUGNAME	WilVent
INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Investigative
	
TTDDRUID	D00ZFP
DRUGNAME	Estrone
INDICATI	Menopausal and postmenopausal disorder [ICD-11: GA30] Approved
	
TTDDRUID	D00ZFQ
DRUGNAME	H2N3 MO 2003/AA
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D00ZGA
DRUGNAME	Casopitant
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Withdrawn from market
	
TTDDRUID	D00ZGE
DRUGNAME	Oncopurge
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D00ZGF
DRUGNAME	DA-6886
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 1
	
TTDDRUID	D00ZGT
DRUGNAME	MMR vaccine
INDICATI	Rubella prophylaxis [ICD-11: 1F02] Phase 3
INDICATI	Mumps virus infection [ICD-11: 1D80] Phase 3
INDICATI	Measles [ICD-11: 1F03] Phase 3
	
TTDDRUID	D00ZHM
DRUGNAME	Autologous adipose-derived stem cells
INDICATI	Anal fistula [ICD-11: DB50.1] Phase 2
	
TTDDRUID	D00ZHR
DRUGNAME	Salmonella typhimurium A1-R
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D00ZKC
DRUGNAME	CS-92
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 2
	
TTDDRUID	D00ZLC
DRUGNAME	NeuroCell-PD
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D00ZMN
DRUGNAME	Fluorofenidone
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D00ZMU
DRUGNAME	P28 cell penetrating peptide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 1
	
TTDDRUID	D00ZNP
DRUGNAME	HMR-1426
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
	
TTDDRUID	D00ZNS
DRUGNAME	CDE-5110
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D00ZOF
DRUGNAME	Sodium lactate
INDICATI	Acidosis [ICD-11: 5C73] Approved
	
TTDDRUID	D00ZPR
DRUGNAME	Neucardin
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3
INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 2
	
TTDDRUID	D00ZPT
DRUGNAME	BI-11634
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D00ZRO
DRUGNAME	Cyclic compound 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D00ZRS
DRUGNAME	TARP peptide vaccines
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D00ZTD
DRUGNAME	OZ277
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D00ZUU
DRUGNAME	ONO-5334
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2
	
TTDDRUID	D00ZVM
DRUGNAME	BAY1129980
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D00ZVS
DRUGNAME	Condoliase
INDICATI	Herniation disk [ICD-11: ND51.2] Phase 3
	
TTDDRUID	D00ZWE
DRUGNAME	AT-007
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D00ZWG
DRUGNAME	NS-638
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D00ZXR
DRUGNAME	Heteroaryl-carboxamide derivative 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D00ZZB
DRUGNAME	Oxaborole
INDICATI	Leishmania infection [ICD-11: 1F54.0] Investigative
	
TTDDRUID	D00ZZH
DRUGNAME	BK-218
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D01AAH
DRUGNAME	CAR-T cells targeting CD22
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D01ACE
DRUGNAME	BF/PC-13
INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative
	
TTDDRUID	D01ADH
DRUGNAME	Evitar
INDICATI	Wound healing [ICD-11: EL8Y] Phase 2
	
TTDDRUID	D01ADL
DRUGNAME	Roledumab
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2/3
	
TTDDRUID	D01AEF
DRUGNAME	3F8
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01AET
DRUGNAME	MPC-150-IM
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3
	
TTDDRUID	D01AFG
DRUGNAME	RG7414
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2
	
TTDDRUID	D01AHI
DRUGNAME	Dance-501
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D01AHO
DRUGNAME	Abarelix
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D01AIM
DRUGNAME	HBsAG-HBIG complex
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
	
TTDDRUID	D01AIN
DRUGNAME	Fezakinumab
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D01AJM
DRUGNAME	YP-009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D01AJY
DRUGNAME	Baclofen
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 3
	
TTDDRUID	D01AKK
DRUGNAME	ALXN1101
INDICATI	Molybdenum cofactor deficiency [ICD-11: 5B5K.A] Phase 2/3
	
TTDDRUID	D01AKU
DRUGNAME	MCP-201
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D01ALJ
DRUGNAME	BV-6481
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D01ALP
DRUGNAME	MBC-31
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D01ANE
DRUGNAME	EB-1,2,3 mab
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D01AQT
DRUGNAME	Terconazole
INDICATI	Candidiasis [ICD-11: 1F23] Approved
	
TTDDRUID	D01ARG
DRUGNAME	DB-900
INDICATI	Type-2 diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D01ARU
DRUGNAME	DST-2970
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D01ASM
DRUGNAME	NPC-15199
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2
	
TTDDRUID	D01ATS
DRUGNAME	LEO-90110
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D01AUL
DRUGNAME	L-697639
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D01AVF
DRUGNAME	SAR-106881
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Investigative
	
TTDDRUID	D01AXB
DRUGNAME	Duloxetine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D01AXK
DRUGNAME	Antibodie derivative 10
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Patented
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Patented
	
TTDDRUID	D01AXT
DRUGNAME	NP-50301
INDICATI	Eye disorder [ICD-11: 9A01-9A0Z] Discontinued in Phase 2
	
TTDDRUID	D01AYF
DRUGNAME	ND-1.1
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D01AYJ
DRUGNAME	Terbinafine
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2
	
TTDDRUID	D01AYP
DRUGNAME	Bromo benzyl ether derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D01AYX
DRUGNAME	AZD3293
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3
	
TTDDRUID	D01AZG
DRUGNAME	Risperidone
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D01AZP
DRUGNAME	BNC-105
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
	
TTDDRUID	D01BAU
DRUGNAME	SPN-812
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	D01BBB
DRUGNAME	VM-1500
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2/3
	
TTDDRUID	D01BBR
DRUGNAME	Dezinamide
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 2
	
TTDDRUID	D01BDY
DRUGNAME	Axomadol
INDICATI	Back pain [ICD-11: ME84.Z] Phase 2
	
TTDDRUID	D01BEX
DRUGNAME	PRS-060
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D01BFA
DRUGNAME	BIK-381
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Investigative
	
TTDDRUID	D01BGU
DRUGNAME	UX-002
INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Investigative
	
TTDDRUID	D01BHC
DRUGNAME	BTA-929
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D01BIQ
DRUGNAME	Human embryonic stem cell-derived motor neuron progenitors
INDICATI	Neuromuscular disease [ICD-11: 8C6Y] Investigative
	
TTDDRUID	D01BJK
DRUGNAME	Mimovax
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D01BJO
DRUGNAME	GABA mimetics
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D01BJS
DRUGNAME	HL-028
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D01BOD
DRUGNAME	Pro-Islet
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D01BOE
DRUGNAME	44-Bu
INDICATI	Heart arrhythmia [ICD-11: BC65] Investigative
	
TTDDRUID	D01BPF
DRUGNAME	Avitriptan
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 3
	
TTDDRUID	D01BPP
DRUGNAME	EC0225
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01BQC
DRUGNAME	Cefonicid
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D01BQJ
DRUGNAME	TCV-295
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D01BQK
DRUGNAME	Carbamide peroxide
INDICATI	Ear disease [ICD-11: AA0Y-AC0Z] Approved
	
TTDDRUID	D01BRD
DRUGNAME	SGN-CD123A
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D01BRX
DRUGNAME	IMM-252
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D01BUS
DRUGNAME	CA9-ADC
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D01BUT
DRUGNAME	LXT-101
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D01BVI
DRUGNAME	V-101
INDICATI	Erythema [ICD-11: ME64.0] Phase 2
	
TTDDRUID	D01BWJ
DRUGNAME	Tyrophostins
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01BYB
DRUGNAME	Adenosine triphosphate
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
INDICATI	Heart disease [ICD-11: BA41-BA42] Phase 2
INDICATI	Bradycardia [ICD-11: MC81.1] Discontinued in Phase 2
	
TTDDRUID	D01BZP
DRUGNAME	Tuberculosis therapy, Ithemba
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D01BZR
DRUGNAME	IC-041
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D01CAH
DRUGNAME	Mesenchymal stem cells
INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D01CAJ
DRUGNAME	AZD-3342
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D01CBE
DRUGNAME	Ygalo
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D01CBG
DRUGNAME	SRP-5051
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D01CBK
DRUGNAME	OSE2101
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D01CBU
DRUGNAME	FG-020318
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01CBV
DRUGNAME	C-5997
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D01CDE
DRUGNAME	BIMU-1
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
	
TTDDRUID	D01CEG
DRUGNAME	P-1736
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D01CEQ
DRUGNAME	CER-227185
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 1/2
	
TTDDRUID	D01CFL
DRUGNAME	Benzothiazoline derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D01CFQ
DRUGNAME	LB-2.1
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D01CGV
DRUGNAME	LY-2599506
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D01CHD
DRUGNAME	RG6061
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01CHI
DRUGNAME	VR315
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D01CIB
DRUGNAME	SAR164653
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D01CIN
DRUGNAME	STF-62247
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Investigative
	
TTDDRUID	D01CJB
DRUGNAME	Novovac-M1
INDICATI	Melanoma [ICD-11: 2C30] Terminated
	
TTDDRUID	D01CJY
DRUGNAME	FR-146687
INDICATI	Prostate disease [ICD-11: GA91] Phase 2
	
TTDDRUID	D01CKY
DRUGNAME	Ecabet sodium
INDICATI	Ulcer [ICD-11: CA02-CB40] Approved
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 2
	
TTDDRUID	D01CLK
DRUGNAME	CHGN111
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Investigative
	
TTDDRUID	D01CNB
DRUGNAME	E6201
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D01CND
DRUGNAME	PMID26651364-Compound-114
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D01CNV
DRUGNAME	PL-611
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D01COH
DRUGNAME	ZP-010
INDICATI	Bronchitis [ICD-11: CA20] Investigative
	
TTDDRUID	D01CON
DRUGNAME	IGIV3I Grifols
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D01CQJ
DRUGNAME	KLS-HPV
INDICATI	Cervical cancer [ICD-11: 2C77.0] Investigative
	
TTDDRUID	D01CRB
DRUGNAME	L-Tyrosine
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D01CTR
DRUGNAME	Plasminogen
INDICATI	Congenital plasminogen activator inhibitor type 1 deficiency [ICD-11: 3B50.1] Phase 2/3
INDICATI	Hypoplasminogenemia [ICD-11: DA0D.3] Phase 2/3
	
TTDDRUID	D01CUC
DRUGNAME	BCMA CAR T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D01CUO
DRUGNAME	TTI-621
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1
INDICATI	Mycosis fungoides [ICD-11: 2B01] Phase 1
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01CXJ
DRUGNAME	PAC-113
INDICATI	Oral candidiasis [ICD-11: 1F23.0] Phase 2
	
TTDDRUID	D01CXW
DRUGNAME	MEDI0680
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01CYA
DRUGNAME	Bendamustine hydrochloride
INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved
	
TTDDRUID	D01CYK
DRUGNAME	ME1100
INDICATI	Bacterial pneumonia [ICD-11: CA40.0] Phase 1
	
TTDDRUID	D01CYT
DRUGNAME	ELND-002
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D01CYW
DRUGNAME	PK-236
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D01CZH
DRUGNAME	Chanllergen
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D01DAD
DRUGNAME	CJ-13610
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D01DAW
DRUGNAME	Bifeprunox
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 3
	
TTDDRUID	D01DBF
DRUGNAME	APIT
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01DBQ
DRUGNAME	Teniposide
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
	
TTDDRUID	D01DCJ
DRUGNAME	GRNOPC-1
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1
	
TTDDRUID	D01DDN
DRUGNAME	SCH-900271
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
	
TTDDRUID	D01DGN
DRUGNAME	Ethiodized oil
INDICATI	Lymphatic disease [ICD-11: BD9Z] Approved
	
TTDDRUID	D01DGZ
DRUGNAME	ABBV-2222
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D01DIM
DRUGNAME	CLL442
INDICATI	Cutaneous squamous cell carcinoma [ICD-11: 2C30] Phase 1/2
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2
	
TTDDRUID	D01DJA
DRUGNAME	TSK-204
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D01DJI
DRUGNAME	PHY-906
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
	
TTDDRUID	D01DLT
DRUGNAME	Encapsulated live cells converting ifosfamide
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D01DMT
DRUGNAME	Dendrogenin A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01DNH
DRUGNAME	PMID25666693-Compound-150
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D01DOY
DRUGNAME	GR-127607
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 1
	
TTDDRUID	D01DPC
DRUGNAME	Ribavirin + interferon alfa-2b
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D01DPD
DRUGNAME	KW-6055
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D01DQI
DRUGNAME	Parvovirus H-1
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative
	
TTDDRUID	D01DQR
DRUGNAME	AIR-Epinephrine
INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1
	
TTDDRUID	D01DRE
DRUGNAME	SOM-0002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01DRL
DRUGNAME	RGH-2721
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D01DSP
DRUGNAME	Cephapirin
INDICATI	Sepsis [ICD-11: 1G40-1G41] Approved
	
TTDDRUID	D01DTO
DRUGNAME	AOB102
INDICATI	Eczema [ICD-11: EA80-EA89] Phase 2
	
TTDDRUID	D01DTQ
DRUGNAME	PXS-2076
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D01DVR
DRUGNAME	NT-001
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D01DVX
DRUGNAME	DPC-333
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated
	
TTDDRUID	D01DXI
DRUGNAME	PF-06290510
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 2
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D01EAG
DRUGNAME	MDDR 287569
INDICATI	Urinary incontinence [ICD-11: MF50.2] Investigative
	
TTDDRUID	D01EBJ
DRUGNAME	4991W93
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2
	
TTDDRUID	D01ECN
DRUGNAME	MVA-BN DF
INDICATI	Flavivirus infection [ICD-11: 1C80] Preclinical
	
TTDDRUID	D01EDJ
DRUGNAME	CSE-1034
INDICATI	Nosocomial infection [ICD-11: PL10] Phase 3
	
TTDDRUID	D01EDO
DRUGNAME	GW-250495
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D01EDS
DRUGNAME	SL-65.1498
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D01EFO
DRUGNAME	CGP-53716
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D01EHI
DRUGNAME	Live attenuated H1N1 pandemic influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D01EJG
DRUGNAME	RG6100
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D01EJJ
DRUGNAME	JTE-051
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1
	
TTDDRUID	D01EKN
DRUGNAME	RAV-12
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01EKQ
DRUGNAME	Ferrous Citrate, Fe-59
INDICATI	Iron deficiency [ICD-11: 5B5K.0] Approved
	
TTDDRUID	D01ELU
DRUGNAME	VSN-16R
INDICATI	Muscle spasm [ICD-11: MB47.3] Phase 2
	
TTDDRUID	D01EMD
DRUGNAME	Ovarian dendritic cell-based vaccine
INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 1/2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	D01EPO
DRUGNAME	ABIO 09-01
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D01EPP
DRUGNAME	EL-715
INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated
	
TTDDRUID	D01EQG
DRUGNAME	Azapropazone
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market
	
TTDDRUID	D01ERE
DRUGNAME	ASP4345
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D01ESB
DRUGNAME	YM-992
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 2
	
TTDDRUID	D01ESC
DRUGNAME	BBT-009
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D01ESJ
DRUGNAME	Luzindole
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated
	
TTDDRUID	D01EUF
DRUGNAME	BMS 275291
INDICATI	Kaposi sarcoma [ICD-11: 2B57] Discontinued in Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 3
	
TTDDRUID	D01EUO
DRUGNAME	Ragweed extract
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 3
	
TTDDRUID	D01EVP
DRUGNAME	Resorcinol compound 17
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D01EWC
DRUGNAME	CR-2991
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D01EXG
DRUGNAME	AMG 224
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D01EXL
DRUGNAME	RNF43-721
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D01EXY
DRUGNAME	BN-AO-014
INDICATI	Atrophy [ICD-11: 9A2Y-9C40] Preclinical
	
TTDDRUID	D01EYI
DRUGNAME	Umbilical Cord Mesenchymal Stem Cells
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D01EYM
DRUGNAME	BB-2275
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D01EYR
DRUGNAME	ImmunoVEX-timelan
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
	
TTDDRUID	D01EZA
DRUGNAME	EC-8042
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01EZY
DRUGNAME	JTP-2724
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D01FBO
DRUGNAME	H5N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2
	
TTDDRUID	D01FBP
DRUGNAME	Vanutide cridificar
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D01FBS
DRUGNAME	ALF-5755
INDICATI	Liver failure [ICD-11: DB99.7] Phase 2
	
TTDDRUID	D01FCK
DRUGNAME	Teglicar
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D01FCY
DRUGNAME	Engineered hnCD16 iNK Cell
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D01FDL
DRUGNAME	Dabelotine
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3
	
TTDDRUID	D01FDN
DRUGNAME	NAL-GLU
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2/3
	
TTDDRUID	D01FEC
DRUGNAME	Rusalatide acetate
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Discontinued in Phase 2
	
TTDDRUID	D01FFA
DRUGNAME	(+-)-tetrahydropalmatine
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
INDICATI	Irritability [ICD-11: MB24] Approved
INDICATI	Analgesia [ICD-11: MB40.8] Approved
	
TTDDRUID	D01FFC
DRUGNAME	OPB-51602
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01FFG
DRUGNAME	Antistasin
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	D01FGR
DRUGNAME	Diphenhydramine
INDICATI	Meniere disease [ICD-11: AB31.0] Approved
	
TTDDRUID	D01FHL
DRUGNAME	AGN-150998
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
	
TTDDRUID	D01FJA
DRUGNAME	UC-2024
INDICATI	Premenstrual syndrome [ICD-11: GA34.40] Investigative
	
TTDDRUID	D01FJN
DRUGNAME	BAY-1006451
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D01FJT
DRUGNAME	Bucillamine
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D01FLN
DRUGNAME	LX-2932
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D01FME
DRUGNAME	HNK-20
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Terminated
	
TTDDRUID	D01FQR
DRUGNAME	Ocaperidone
INDICATI	Schizoaffective disorder [ICD-11: 6A21] Phase 2
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 1b
	
TTDDRUID	D01FQV
DRUGNAME	Dichloroacetate sodium
INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 1
	
TTDDRUID	D01FRK
DRUGNAME	LA-N8
INDICATI	Factor VIII deficiency [ICD-11: 3B10] Investigative
	
TTDDRUID	D01FRP
DRUGNAME	APC-0013
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01FSX
DRUGNAME	REGN5093
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D01FTK
DRUGNAME	PN-403
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D01FTU
DRUGNAME	EQ-317
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D01FUB
DRUGNAME	AZD8529
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2
	
TTDDRUID	D01FUC
DRUGNAME	Exatecan
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D01FUL
DRUGNAME	Balapiravir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D01FWE
DRUGNAME	Certiva
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D01FWR
DRUGNAME	MPL-containing Pollinex allergy desensitization vaccine
INDICATI	Melanoma [ICD-11: 2C30] Preregistration
	
TTDDRUID	D01FXD
DRUGNAME	SCH-351591
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D01FYA
DRUGNAME	PU-H71
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 1
	
TTDDRUID	D01FYX
DRUGNAME	Andes-1537
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01FZX
DRUGNAME	LEO 22811
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D01FZZ
DRUGNAME	GDC0310
INDICATI	Chronic pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D01GAG
DRUGNAME	PV-921
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01GAZ
DRUGNAME	123I-DRM-106
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D01GBV
DRUGNAME	CDD-190
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D01GBY
DRUGNAME	Desloratadine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D01GCT
DRUGNAME	AZM-090
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D01GCY
DRUGNAME	NNC-26-0762
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Terminated
	
TTDDRUID	D01GDB
DRUGNAME	Tat Oyi-Cys22
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D01GDH
DRUGNAME	XR-9051
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D01GDO
DRUGNAME	Cytoporins
INDICATI	Respiratory tract infection [ICD-11: CA45] Preclinical
	
TTDDRUID	D01GEB
DRUGNAME	ROXINDOLE
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2
	
TTDDRUID	D01GEK
DRUGNAME	PMID25666693-Compound-133
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D01GEO
DRUGNAME	Telomestatin
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D01GFU
DRUGNAME	ADCON(R)
INDICATI	Wound healing [ICD-11: EL8Y] Discontinued in Phase 3
	
TTDDRUID	D01GFX
DRUGNAME	OSI-906
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D01GGB
DRUGNAME	SL-301
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01GHV
DRUGNAME	RANBEZOLID HYDROCHLORIDE
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical
	
TTDDRUID	D01GIF
DRUGNAME	BM-113
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D01GIG
DRUGNAME	RepliVec
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01GIW
DRUGNAME	S3
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D01GNW
DRUGNAME	NGN-9076
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D01GOY
DRUGNAME	AV-GBM-1
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D01GPA
DRUGNAME	Gepon
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D01GQD
DRUGNAME	EZN-3042
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01GQO
DRUGNAME	Mesenchymal stem cell therapy, ischemic-tolerant stem cells
INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 1
	
TTDDRUID	D01GSA
DRUGNAME	C-0334578
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Investigative
	
TTDDRUID	D01GSE
DRUGNAME	E-10030
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
	
TTDDRUID	D01GTB
DRUGNAME	ZD-2767
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D01GTC
DRUGNAME	TAK-041
INDICATI	XY disorder of sex development due to androgen resistance [ICD-11: LD2A.4] Phase 1
	
TTDDRUID	D01GUS
DRUGNAME	Udenafil
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved
	
TTDDRUID	D01GVC
DRUGNAME	GP-3269
INDICATI	Convulsion [ICD-11: 8A68.Z] Phase 1
	
TTDDRUID	D01GVM
DRUGNAME	Lemuteporfin
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D01GXB
DRUGNAME	Combinations SAR245409 / MSC1936369B SAR245408/SAR256212
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01GXL
DRUGNAME	REP8839
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D01GYK
DRUGNAME	Succimer
INDICATI	Metal intoxication [ICD-11: NE60] Approved
	
TTDDRUID	D01GYT
DRUGNAME	Fosfomycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D01HAT
DRUGNAME	CD19.CAR-aNKT cells
INDICATI	B-cell small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D01HBE
DRUGNAME	RHIZOXIN
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D01HBG
DRUGNAME	Apadoline
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D01HDP
DRUGNAME	SLV 306
INDICATI	Acute decompensated heart failure [ICD-11: BD1Z] Phase 2
	
TTDDRUID	D01HED
DRUGNAME	PMID25666693-Compound-158
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D01HEN
DRUGNAME	HBDt.Fc
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01HFP
DRUGNAME	HL-160
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01HGI
DRUGNAME	TGSC01AA(4)
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D01HGT
DRUGNAME	Anti-CD22
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D01HHD
DRUGNAME	Fovepta
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 3
	
TTDDRUID	D01HHH
DRUGNAME	CHR-4125
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01HHJ
DRUGNAME	HTU-PA
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1/2
	
TTDDRUID	D01HJQ
DRUGNAME	Aminoazetidine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D01HKL
DRUGNAME	ABT-335
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Approved
	
TTDDRUID	D01HKZ
DRUGNAME	TSR-011
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D01HLF
DRUGNAME	ATI-0810
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01HLO
DRUGNAME	PF-05190457
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D01HNL
DRUGNAME	Allantoin
INDICATI	Vulnerary [ICD-11: ND56.Z] Approved
	
TTDDRUID	D01HOI
DRUGNAME	MT-503
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01HOL
DRUGNAME	Autologous idiotypic cancer vaccine
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D01HOT
DRUGNAME	X-072-NAB
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D01HPI
DRUGNAME	DLX-0110
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated
	
TTDDRUID	D01HPP
DRUGNAME	ECFCs
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D01HPY
DRUGNAME	Melphalan flufenamide
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
INDICATI	Plasma cell myeloma [ICD-11: 2A83.1] Phase 1/2
	
TTDDRUID	D01HQJ
DRUGNAME	Dialyzable leukocyte cells
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D01HQQ
DRUGNAME	Bone morphogenetic protein-4
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative
	
TTDDRUID	D01HQU
DRUGNAME	AK107
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01HRJ
DRUGNAME	JEBIK V
INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Approved
	
TTDDRUID	D01HRR
DRUGNAME	Domitroban
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Preregistration
	
TTDDRUID	D01HRU
DRUGNAME	SBR-759
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 3
	
TTDDRUID	D01HSA
DRUGNAME	HG-1154
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D01HTH
DRUGNAME	Aptiganel HCl
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Investigative
	
TTDDRUID	D01HTJ
DRUGNAME	FG-65155
INDICATI	Reperfusion injury [ICD-11: ND56.Z] Investigative
	
TTDDRUID	D01HTL
DRUGNAME	Vinorelbine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D01HTS
DRUGNAME	MIP-1231
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01HVC
DRUGNAME	MTD-102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01HVE
DRUGNAME	ICI-D-1542
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D01HVM
DRUGNAME	99mTc-DI-DD3B6/22-80B3
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D01HVR
DRUGNAME	SAV-001
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D01HVT
DRUGNAME	Ribociclib Succinate
INDICATI	Hormone receptor positive and HER2-negative advanced or metastatic breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D01HVZ
DRUGNAME	TD-8954
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D01HWK
DRUGNAME	AA-10044
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D01HXA
DRUGNAME	AUS-131
INDICATI	Hot flushes [ICD-11: GA30] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D01HXN
DRUGNAME	TRL-382
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D01HYQ
DRUGNAME	IONIS-GCCRRX
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D01HZQ
DRUGNAME	VP-102
INDICATI	Molluscum contagiosum infection [ICD-11: 1E76] Phase 3
INDICATI	Common wart [ICD-11: 1E80] Phase 2
	
TTDDRUID	D01IBO
DRUGNAME	BCX-1470
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Discontinued in Phase 1
	
TTDDRUID	D01ICI
DRUGNAME	Remdesivir
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Approved
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D01ICU
DRUGNAME	Conjugated estrogens b
INDICATI	Hormone replacement therapy [ICD-11: 8E01] Approved
	
TTDDRUID	D01ICY
DRUGNAME	AVE-0657
INDICATI	Cheyne-stokes respiration [ICD-11: MD11.Y] Phase 2
	
TTDDRUID	D01IDE
DRUGNAME	E-5324
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D01IDQ
DRUGNAME	IPH-1101
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 2
	
TTDDRUID	D01IDW
DRUGNAME	SKI-O-703
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D01IED
DRUGNAME	BVD-523
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D01IEM
DRUGNAME	Pneumovax 23
INDICATI	Otitis media [ICD-11: AA80-AB0Z] Approved
	
TTDDRUID	D01IGH
DRUGNAME	SERA5-targeted malaria vaccine
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	D01IGZ
DRUGNAME	Napabucasin
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1/2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1/2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D01IHR
DRUGNAME	AC-1202
INDICATI	Memory loss [ICD-11: MB21.1Z] Phase 2
	
TTDDRUID	D01IHV
DRUGNAME	AD-0027
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01IJJ
DRUGNAME	MV-NIS
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 1
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 1
	
TTDDRUID	D01IJL
DRUGNAME	FR-182877
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D01IJM
DRUGNAME	LY3164530
INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01IKM
DRUGNAME	HB-adipose-derived mesenchymal stem cells
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D01ILA
DRUGNAME	GNbAC-1
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D01ILJ
DRUGNAME	Celvapan
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D01ILP
DRUGNAME	CNT0-3157
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D01IMN
DRUGNAME	VLA15-101
INDICATI	Lyme disease [ICD-11: 1C1G] Phase 1
	
TTDDRUID	D01IPI
DRUGNAME	Gemopatrilat
INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2
	
TTDDRUID	D01IPT
DRUGNAME	AGS-v
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1
	
TTDDRUID	D01IRG
DRUGNAME	Bictegravir, emtricitabine and tenofovir alafenamide
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D01IRW
DRUGNAME	Bermoprofen
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Preregistration
	
TTDDRUID	D01ISE
DRUGNAME	Bimakalim
INDICATI	Angina pectoris [ICD-11: BA40] Phase 2
	
TTDDRUID	D01ITB
DRUGNAME	TV1001sr
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D01IUD
DRUGNAME	PRT-20
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative
	
TTDDRUID	D01IUS
DRUGNAME	Mapracorat
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 3
	
TTDDRUID	D01IVE
DRUGNAME	Lobeline
INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 2
	
TTDDRUID	D01IWJ
DRUGNAME	Fluticasone furoate/ fluticasone propionate
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D01IWS
DRUGNAME	Inulin
INDICATI	Measure kidney function [ICD-11: MG02] Approved
	
TTDDRUID	D01IXD
DRUGNAME	Finafloxacin
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D01IYQ
DRUGNAME	TAK-201
INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2
	
TTDDRUID	D01IZE
DRUGNAME	Recombinant botulinum toxin vaccine
INDICATI	Yersinia infection [ICD-11: 1B93] Phase 2
	
TTDDRUID	D01JCT
DRUGNAME	CD19-CAR T Cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial
	
TTDDRUID	D01JEI
DRUGNAME	F-50003
INDICATI	Parainfluenza virus infection [ICD-11: 1D9Y] Terminated
	
TTDDRUID	D01JEO
DRUGNAME	Brevenal
INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative
	
TTDDRUID	D01JEU
DRUGNAME	Memantine
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D01JFM
DRUGNAME	AC-170
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3
	
TTDDRUID	D01JFT
DRUGNAME	Dipivefrin
INDICATI	Chronic open-angle glaucoma [ICD-11: 9C61.0] Approved
	
TTDDRUID	D01JGE
DRUGNAME	Netupitant/palonosetron
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 3
	
TTDDRUID	D01JGG
DRUGNAME	Sodelglitazar
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D01JGV
DRUGNAME	Ajmalicine
INDICATI	Circulatory disorder [ICD-11: BE2Z] Approved
	
TTDDRUID	D01JHN
DRUGNAME	CR-3124
INDICATI	Substance use disorder [ICD-11: 6C4Z] Terminated
	
TTDDRUID	D01JIA
DRUGNAME	L-glutamine
INDICATI	Short bowel syndrome [ICD-11: KB89.1] Approved
	
TTDDRUID	D01JIO
DRUGNAME	ZK-91587
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D01JKV
DRUGNAME	MK-8266
INDICATI	Essential hypertension [ICD-11: BA00] Phase 1
	
TTDDRUID	D01JLH
DRUGNAME	RESP-3000
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D01JLO
DRUGNAME	Tat-NR2B9c
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3
INDICATI	Stroke [ICD-11: 8B20] Phase 3
	
TTDDRUID	D01JMC
DRUGNAME	Lorcaserin
INDICATI	Obesity [ICD-11: 5B81] Approved
INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Phase 1
	
TTDDRUID	D01JMX
DRUGNAME	INS-1
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2
	
TTDDRUID	D01JNE
DRUGNAME	Lexibulin
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D01JOA
DRUGNAME	D-1927
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D01JOJ
DRUGNAME	RX-77368
INDICATI	Dementia [ICD-11: 6D80-6D86] Discontinued in Phase 2
	
TTDDRUID	D01JPA
DRUGNAME	TRC102
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01JPJ
DRUGNAME	PTC-725
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D01JQJ
DRUGNAME	Iodinated glycerol
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D01JRF
DRUGNAME	SPD-453
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D01JSG
DRUGNAME	SBL-109
INDICATI	Escherichia coli infection [ICD-11: 1A03] Investigative
	
TTDDRUID	D01JSI
DRUGNAME	PF-06863135
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D01JSO
DRUGNAME	VM-505
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D01JTL
DRUGNAME	KM-023
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D01JTW
DRUGNAME	PEV3A
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D01JUF
DRUGNAME	Phentolamine
INDICATI	Dermal necrosis [ICD-11: MC85] Approved
	
TTDDRUID	D01JWH
DRUGNAME	SAN-134
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1
	
TTDDRUID	D01JYT
DRUGNAME	INT-0022
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1
	
TTDDRUID	D01KCE
DRUGNAME	BLB-750
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Registered
	
TTDDRUID	D01KDM
DRUGNAME	GTP-004
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 1
	
TTDDRUID	D01KER
DRUGNAME	ARX-8203
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D01KGP
DRUGNAME	IPL 550,260
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D01KHH
DRUGNAME	Cyclobenzaprine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D01KHW
DRUGNAME	CZEN-002
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2
	
TTDDRUID	D01KHX
DRUGNAME	Rilmakalim
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D01KIC
DRUGNAME	ORV-116E
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D01KIS
DRUGNAME	CGP-53437
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D01KIU
DRUGNAME	PRE-084
INDICATI	Aging skin [ICD-11: EE40] Terminated
	
TTDDRUID	D01KIY
DRUGNAME	EPI-0031
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D01KJM
DRUGNAME	KST-401
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01KJZ
DRUGNAME	Pyrazole derivative 4
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D01KKB
DRUGNAME	PW-2101
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Preregistration
	
TTDDRUID	D01KKE
DRUGNAME	GW876008
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2
	
TTDDRUID	D01KKI
DRUGNAME	SGN-CD33A
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D01KKM
DRUGNAME	House dust mite allergy vaccine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Terminated
	
TTDDRUID	D01KKQ
DRUGNAME	Raltitrexed
INDICATI	Rectal adenocarcinoma [ICD-11: 2B92] Approved
	
TTDDRUID	D01KMR
DRUGNAME	Neramexane
INDICATI	Cancer related pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D01KMW
DRUGNAME	BMS-830216
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D01KMY
DRUGNAME	MK-8342
INDICATI	Contraception [ICD-11: QA21] Phase 2
	
TTDDRUID	D01KNA
DRUGNAME	Diamyd
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D01KNO
DRUGNAME	CTA1-3M2e-DD
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D01KNY
DRUGNAME	LCB-2183
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D01KOA
DRUGNAME	Selpercatinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
INDICATI	Thyroid cancer [ICD-11: 2D10] Approved
INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 1/2
	
TTDDRUID	D01KPS
DRUGNAME	IP-112
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preregistration
	
TTDDRUID	D01KPV
DRUGNAME	Fexofenadine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D01KQA
DRUGNAME	Nalbuphine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
INDICATI	Prurigo nodularis [ICD-11: EC91.0] Phase 2/3
INDICATI	Uremic pruritus [ICD-11: EC90.10] Phase 2/3
	
TTDDRUID	D01KQW
DRUGNAME	ID-93/GLA-SE
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2
	
TTDDRUID	D01KRQ
DRUGNAME	EMC-0901
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D01KSL
DRUGNAME	REGN3048 + REGN3051 mabs
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1
	
TTDDRUID	D01KSO
DRUGNAME	Synthetic peptide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01KTG
DRUGNAME	HDM201
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Liposarcoma [ICD-11: 2B59] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01KTN
DRUGNAME	Cefcapene pivoxil
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D01KWB
DRUGNAME	AD-313
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated
	
TTDDRUID	D01KWJ
DRUGNAME	VX-150
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D01KWK
DRUGNAME	Hydroxychloroquine + azithromycin + ivermectin 
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D01KXE
DRUGNAME	Influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D01KYG
DRUGNAME	INA-115E
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative
	
TTDDRUID	D01KYP
DRUGNAME	APL-130277
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3
	
TTDDRUID	D01KZC
DRUGNAME	Minopafant
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2
	
TTDDRUID	D01KZV
DRUGNAME	MIQ-004
INDICATI	Brain cancer [ICD-11: 2A00] Investigative
	
TTDDRUID	D01LAC
DRUGNAME	MOFEGILINE
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3
	
TTDDRUID	D01LAP
DRUGNAME	ISIS 2922 + Ganciclovir
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D01LAX
DRUGNAME	Poloxafuse-R
INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative
	
TTDDRUID	D01LBD
DRUGNAME	Haw-AD-14
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D01LBI
DRUGNAME	LIV-1205
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01LCC
DRUGNAME	PF-4217903
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01LEO
DRUGNAME	LJJ-10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01LES
DRUGNAME	MEGF0444A
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
	
TTDDRUID	D01LFA
DRUGNAME	ARX-201
INDICATI	Growth failure [ICD-11: LD2F.1Y] Discontinued in Phase 2
	
TTDDRUID	D01LFC
DRUGNAME	Mutant ras vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01LFH
DRUGNAME	Curmucin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01LFN
DRUGNAME	S. mutans Replacement Therapy
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D01LFQ
DRUGNAME	DWP-438
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01LGQ
DRUGNAME	PMID25666693-Compound-103
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D01LMM
DRUGNAME	BLY719
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01LNG
DRUGNAME	Balicatib
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2
	
TTDDRUID	D01LNP
DRUGNAME	Samarium-153-DOTMP
INDICATI	Bone cancer [ICD-11: 2B5Z] Investigative
	
TTDDRUID	D01LOE
DRUGNAME	LY2963016
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 3
	
TTDDRUID	D01LPK
DRUGNAME	MGX-006
INDICATI	Vomiting [ICD-11: MD90] Discontinued in Preregistration
	
TTDDRUID	D01LPX
DRUGNAME	Linotroban
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D01LQC
DRUGNAME	P45
INDICATI	Alopecia [ICD-11: ED70] Discontinued in Phase 2
	
TTDDRUID	D01LQZ
DRUGNAME	TG-4023
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D01LRH
DRUGNAME	Sibopirdine
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D01LRM
DRUGNAME	SBC-014
INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 2
	
TTDDRUID	D01LSB
DRUGNAME	MEMP1972A
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D01LSY
DRUGNAME	Atovaquone + azithromycin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D01LUH
DRUGNAME	SP-30
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D01LUS
DRUGNAME	Mesoglycan
INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Approved
	
TTDDRUID	D01LVE
DRUGNAME	CPI-0610
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Myelodysplastic neoplasm [ICD-11: 2A60] Phase 1/2
INDICATI	Myeloproliferative neoplasm [ICD-11: 2A20] Phase 1/2
	
TTDDRUID	D01LVM
DRUGNAME	PMA-BB10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01LWE
DRUGNAME	EGFRvIII CAR T cells
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D01LWO
DRUGNAME	TM-601
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01LXD
DRUGNAME	Semagacestat
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D01LXG
DRUGNAME	KC-11425
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D01LXZ
DRUGNAME	DWJ-206
INDICATI	Stomach ulcer [ICD-11: DA60.Z] Investigative
	
TTDDRUID	D01LYX
DRUGNAME	Eptastigmine
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3
	
TTDDRUID	D01LZB
DRUGNAME	Anti-HM1.24
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D01LZC
DRUGNAME	SDZ-GLI-328
INDICATI	Genetic disease [ICD-11: 8E02] Terminated
	
TTDDRUID	D01MAU
DRUGNAME	AZD-1446
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D01MBM
DRUGNAME	LPO-1010DR
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative
	
TTDDRUID	D01MBV
DRUGNAME	SB-207266A
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
	
TTDDRUID	D01MCB
DRUGNAME	HTERT plasmid DNA cancer vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01MDH
DRUGNAME	Conjugated stigmines
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D01MDT
DRUGNAME	Tizanidine
INDICATI	Spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D01MDX
DRUGNAME	TRBC1
INDICATI	Anaplastic large cell lymphoma [ICD-11: 2A90.A] Phase 1/2
INDICATI	Angioimmunoblastic T-cell Lymphoma [ICD-11: 2A90.9] Phase 1/2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 1/2
	
TTDDRUID	D01MFA
DRUGNAME	Infusible platelet membrane
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Discontinued in Phase 2
	
TTDDRUID	D01MFG
DRUGNAME	Cholera EPVaccine
INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Investigative
	
TTDDRUID	D01MFK
DRUGNAME	DFU
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D01MGA
DRUGNAME	Alatrofloxacin mesylate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D01MGV
DRUGNAME	WC-3048
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 3
	
TTDDRUID	D01MHI
DRUGNAME	Coluracetam
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D01MHL
DRUGNAME	T-2307
INDICATI	Mycoses [ICD-11: 1F2Z] Phase 1
	
TTDDRUID	D01MHT
DRUGNAME	BBT-046
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01MIP
DRUGNAME	SU5614
INDICATI	Airway inflammation [ICD-11: CA05] Terminated
	
TTDDRUID	D01MJT
DRUGNAME	MGN-2677
INDICATI	Artery stenosis [ICD-11: BD52] Investigative
	
TTDDRUID	D01MKD
DRUGNAME	Phenylalanine derivative 1
INDICATI	Glioma [ICD-11: 2A00.0] Patented
	
TTDDRUID	D01MMB
DRUGNAME	Extrothyroxine
INDICATI	Hyperlipoproteinemia [ICD-11: 5C80] Approved
	
TTDDRUID	D01MMG
DRUGNAME	BBT-015
INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative
	
TTDDRUID	D01MML
DRUGNAME	MLN9708
INDICATI	Amyloidosis [ICD-11: 5D00] Approved
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
	
TTDDRUID	D01MND
DRUGNAME	EU-C-001
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D01MNK
DRUGNAME	BS-194
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01MNV
DRUGNAME	HER-2VAX
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1
	
TTDDRUID	D01MPE
DRUGNAME	S-2150
INDICATI	Angina pectoris [ICD-11: BA40] Phase 2
	
TTDDRUID	D01MPX
DRUGNAME	PC-190723
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D01MQH
DRUGNAME	Vepalimomab
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1/2
	
TTDDRUID	D01MQP
DRUGNAME	SECTA belomycin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D01MSB
DRUGNAME	Hydroxychloroquine + azithromycin + tocilizumab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D01MSJ
DRUGNAME	Veronate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3
	
TTDDRUID	D01MSP
DRUGNAME	PMID30107136-Compound-Example3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D01MSZ
DRUGNAME	RM-4865
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D01MTY
DRUGNAME	Mefloquine + azithromycin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D01MUR
DRUGNAME	Brinzolamide
INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved
	
TTDDRUID	D01MUW
DRUGNAME	Antineoplaston AS2-1
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D01MVK
DRUGNAME	CV-787
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2
	
TTDDRUID	D01MVO
DRUGNAME	ARG201
INDICATI	Diffuse systemic sclerosis [ICD-11: 4A42.1] Phase 2
INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2
	
TTDDRUID	D01MWF
DRUGNAME	GTx-878
INDICATI	Prostate hyperplasia [ICD-11: GA90] Investigative
	
TTDDRUID	D01MXG
DRUGNAME	GLP-1 receptor PAM
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D01MXK
DRUGNAME	2PX
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D01MXV
DRUGNAME	Etilefrine
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Withdrawn from market
	
TTDDRUID	D01MYJ
DRUGNAME	WT-4869
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D01MYN
DRUGNAME	LY-2523199
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D01MZJ
DRUGNAME	LR3001
INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 2
	
TTDDRUID	D01MZT
DRUGNAME	FGFR2-ADC
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D01NAM
DRUGNAME	ELB-139
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D01NAP
DRUGNAME	MM-151
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01NBX
DRUGNAME	RS-2135
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D01NCC
DRUGNAME	Factor-VIIa-XTEN
INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D01NCH
DRUGNAME	Lufironil
INDICATI	Liver cirrhosis [ICD-11: DB93.1] Phase 2
	
TTDDRUID	D01NCS
DRUGNAME	TOL-463
INDICATI	Bacterial vaginosis [ICD-11: MF3A] Phase 2
INDICATI	Vaginal disease [ICD-11: GA1Y] Phase 1
	
TTDDRUID	D01NDF
DRUGNAME	AVN 101
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D01NDN
DRUGNAME	SNG-8006
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D01NEC
DRUGNAME	GSK2141795
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D01NFK
DRUGNAME	FP-1069
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D01NGB
DRUGNAME	ADC-1001
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D01NGH
DRUGNAME	Multi-envelope HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D01NGT
DRUGNAME	RG-7185
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D01NIR
DRUGNAME	Radotinib
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3
	
TTDDRUID	D01NJE
DRUGNAME	ED45
INDICATI	Acute respiratory distress syndrome [ICD-11: CB00] Investigative
INDICATI	Myocardial reperfusion injury [ICD-11: NB31] Investigative
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D01NJI
DRUGNAME	Mepyramine maleate
INDICATI	Headache [ICD-11: 8A80-8A84] Approved
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D01NJT
DRUGNAME	Esreboxetine
INDICATI	Fibromyalgia [ICD-11: MG30.01] Discontinued in Phase 2
	
TTDDRUID	D01NJW
DRUGNAME	PMID26815044-Compound-31
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D01NKF
DRUGNAME	LY-1-100
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D01NKS
DRUGNAME	Mefloquine + azithromycin +  tocilizumab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D01NKW
DRUGNAME	P2B-001
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D01NLB
DRUGNAME	Ziconotide
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 1/2
	
TTDDRUID	D01NMN
DRUGNAME	ALORACETAM
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D01NNL
DRUGNAME	Phosphonate
INDICATI	leukaemia [ICD-11: 2A60-2B33] Terminated
	
TTDDRUID	D01NOI
DRUGNAME	IPH-1201
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D01NPK
DRUGNAME	PTH-CBD
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D01NQM
DRUGNAME	Lasmiditan
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D01NSM
DRUGNAME	TST-10088
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01NTH
DRUGNAME	Ruthenium-based complexes
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01NTO
DRUGNAME	Meningitis B
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved
	
TTDDRUID	D01NTQ
DRUGNAME	SAR127963
INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 1
	
TTDDRUID	D01NTR
DRUGNAME	NTF-1836
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D01NTX
DRUGNAME	Mifamurtide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D01NUG
DRUGNAME	GSK870086
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D01NUR
DRUGNAME	ASTX660
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01NWV
DRUGNAME	Granexin gel
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
INDICATI	Radiation syndrome [ICD-11: NF00] Phase 3
INDICATI	Keloidal surgical scar [ICD-11: EL50.0] Phase 2
	
TTDDRUID	D01NXF
DRUGNAME	Mydicar
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D01NXX
DRUGNAME	SAR-126119
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1
	
TTDDRUID	D01NYQ
DRUGNAME	Drug 2696274
INDICATI	Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 2
	
TTDDRUID	D01NZH
DRUGNAME	ABBV-323
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
	
TTDDRUID	D01NZT
DRUGNAME	Prohibitin-TP-01
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D01OBM
DRUGNAME	MEDl-559
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1/2
	
TTDDRUID	D01ODC
DRUGNAME	TA-106
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D01ODT
DRUGNAME	Sophorolipid isoforms
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01ODU
DRUGNAME	BAY-35-3377
INDICATI	Otitis media [ICD-11: AA80-AB0Z] Phase 3
	
TTDDRUID	D01OFY
DRUGNAME	LAS-31180
INDICATI	Heart failure [ICD-11: BD10-BD13] Terminated
	
TTDDRUID	D01OGL
DRUGNAME	Technetium Tc-99m Red Blood Cell Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D01OGV
DRUGNAME	POL-6014
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D01OHD
DRUGNAME	AMXT-1501
INDICATI	Head and neck cancer [ICD-11: 2D42] Investigative
	
TTDDRUID	D01OIL
DRUGNAME	Gadobenate Dimeglumine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D01OIR
DRUGNAME	AYX-1
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D01OKS
DRUGNAME	Axokine
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 3
	
TTDDRUID	D01OLO
DRUGNAME	AS602868
INDICATI	Multiple myeloma [ICD-11: 2A83] Discontinued in Phase 1
	
TTDDRUID	D01OML
DRUGNAME	IoGen
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 3
	
TTDDRUID	D01OMM
DRUGNAME	DeltaFLU-LAIV
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D01OMO
DRUGNAME	AdHSV-2
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D01OMY
DRUGNAME	BHT-3034
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Investigative
	
TTDDRUID	D01OOQ
DRUGNAME	FP-253-GDEPT
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D01OPV
DRUGNAME	Selenomethionine Se-75
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D01OQQ
DRUGNAME	PMID30107136-Compound-Example50
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D01ORM
DRUGNAME	Mitonafide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D01OSN
DRUGNAME	Riferminogene pecaplasmid
INDICATI	Critical limb ischemia [ICD-11: BD4Y] Discontinued in Phase 3
	
TTDDRUID	D01OUA
DRUGNAME	TJN-598
INDICATI	Glomerulonephritis [ICD-11: 5D00.Y] Terminated
	
TTDDRUID	D01OUE
DRUGNAME	Betazole
INDICATI	Gastric secretory disorder [ICD-11: DD90] Approved
	
TTDDRUID	D01OVV
DRUGNAME	OVI-117
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01OWB
DRUGNAME	Immune globulin
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Approved
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Approved
INDICATI	Nervous system paraneoplastic or autoimmune disorders [ICD-11: 8E4A.1] Phase 3
INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 1
	
TTDDRUID	D01OWJ
DRUGNAME	TG-1024
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D01OXH
DRUGNAME	ASP-7035
INDICATI	Nocturia [ICD-11: MF55] Phase 2
	
TTDDRUID	D01OXI
DRUGNAME	DTI-015
INDICATI	Liver cancer [ICD-11: 2C12] Approved
INDICATI	Brain cancer [ICD-11: 2A00] Approved
	
TTDDRUID	D01OYR
DRUGNAME	AZD-9343
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1
	
TTDDRUID	D01OYS
DRUGNAME	Cyclolignan picropodophyllin
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D01OYX
DRUGNAME	N-acetylcysteine + fuzhenghuayu
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D01PAR
DRUGNAME	Vitamin
INDICATI	Vitamin deficiency [ICD-11: 5B55-5B71] Approved
	
TTDDRUID	D01PBW
DRUGNAME	CB-839
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D01PBX
DRUGNAME	Biphenyl mannoside derivative 6
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D01PCB
DRUGNAME	VALERGEN-DS
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D01PCE
DRUGNAME	BCH-2687
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D01PFX
DRUGNAME	TDI-0065
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D01PGJ
DRUGNAME	PDM-08
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01PGR
DRUGNAME	SAR245409
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01PHK
DRUGNAME	PCL-016
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D01PIL
DRUGNAME	Remoxipride
INDICATI	Schizophrenia [ICD-11: 6A20] Withdrawn from market
	
TTDDRUID	D01PJR
DRUGNAME	Tocainide
INDICATI	Ventricular arrhythmias [ICD-11: BC71] Approved
	
TTDDRUID	D01PJZ
DRUGNAME	Cyclic peptidomimetic derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D01PKG
DRUGNAME	Fenofibrate/ simvastatin
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 3
	
TTDDRUID	D01PLH
DRUGNAME	7U85
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D01PLJ
DRUGNAME	PMID25666693-Compound-58
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D01PLN
DRUGNAME	Cefalotin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D01PLR
DRUGNAME	PF-04171327
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D01PNR
DRUGNAME	Gastrin 17C diphtheria toxoid conjugate
INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative
	
TTDDRUID	D01PQK
DRUGNAME	Ruxolitinib + simvastatin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D01PQM
DRUGNAME	Vaccinia immune globulin
INDICATI	Vaccination [ICD-11: N.A.] Approved
	
TTDDRUID	D01PRH
DRUGNAME	APX-009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01PSI
DRUGNAME	AM-3301
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2
	
TTDDRUID	D01PSY
DRUGNAME	SIG-005
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D01PTS
DRUGNAME	VG-101
INDICATI	Menopause symptom [ICD-11: GA30.0] Phase 1/2
	
TTDDRUID	D01PVV
DRUGNAME	KD3010
INDICATI	Obesity [ICD-11: 5B81] Phase 1
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1
	
TTDDRUID	D01PXH
DRUGNAME	NAM-NK cells + IL-2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D01PYH
DRUGNAME	PANFLUVAC
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D01PZD
DRUGNAME	Romiplostim
INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D01PZJ
DRUGNAME	BDNA-002
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D01QAR
DRUGNAME	LY-221068
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D01QCY
DRUGNAME	OBP-AI1
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D01QGX
DRUGNAME	Lurasidone hydrochloride
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D01QIA
DRUGNAME	BL-1872
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D01QIN
DRUGNAME	Atorvastatin
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D01QIV
DRUGNAME	Prostaview
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D01QIX
DRUGNAME	Drug 2696275
INDICATI	Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 2
	
TTDDRUID	D01QKD
DRUGNAME	ATL-1101
INDICATI	Psoriatic disorder [ICD-11: EA90] Preclinical
	
TTDDRUID	D01QKR
DRUGNAME	ALNESPIRONE
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D01QKZ
DRUGNAME	ABT-413
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01QLH
DRUGNAME	Amyl nitrite
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D01QLM
DRUGNAME	AAB-002
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 0
	
TTDDRUID	D01QLP
DRUGNAME	Tarextumab
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D01QMC
DRUGNAME	LAI338
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D01QMK
DRUGNAME	Denintuzumab mafodotin
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
	
TTDDRUID	D01QML
DRUGNAME	Carphenazine
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
INDICATI	Schizophrenia [ICD-11: 6A20] Withdrawn from market
	
TTDDRUID	D01QNJ
DRUGNAME	KD-501
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D01QNO
DRUGNAME	LM-13765
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D01QNR
DRUGNAME	PIM447
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 1
	
TTDDRUID	D01QQC
DRUGNAME	Hematopoietic stem cell gene therapy
INDICATI	Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 1/2
	
TTDDRUID	D01QQM
DRUGNAME	LAMIFIBAN
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3
	
TTDDRUID	D01QRF
DRUGNAME	IKS-04
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01QRG
DRUGNAME	RPR 200765A
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D01QSG
DRUGNAME	VTP-27999
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D01QSO
DRUGNAME	Buparlisib
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D01QTD
DRUGNAME	GT-038
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Investigative
	
TTDDRUID	D01QTJ
DRUGNAME	XEN901
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
	
TTDDRUID	D01QUF
DRUGNAME	GW-3600
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D01QUS
DRUGNAME	Calcipotriol
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
	
TTDDRUID	D01QWS
DRUGNAME	GM-CT-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01QWT
DRUGNAME	Ramucirumab
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3
	
TTDDRUID	D01QXS
DRUGNAME	RX-0201N
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01QXW
DRUGNAME	CSL-324
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D01QXY
DRUGNAME	B7-2/GM-CSF
INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 1
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01QYA
DRUGNAME	Diamine derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D01QYQ
DRUGNAME	ATL-844
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D01RAE
DRUGNAME	Sonepiprazole
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D01RAN
DRUGNAME	LA-419
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D01RBK
DRUGNAME	Nisin
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Terminated
	
TTDDRUID	D01RBP
DRUGNAME	RE-024
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 3
	
TTDDRUID	D01RBR
DRUGNAME	SGS742
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D01RCC
DRUGNAME	BMS-186318
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D01RCM
DRUGNAME	TAK-114
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1
	
TTDDRUID	D01RDR
DRUGNAME	AB569
INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 1
	
TTDDRUID	D01REE
DRUGNAME	DA-3031
INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 3
	
TTDDRUID	D01REJ
DRUGNAME	VBY- 891
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D01RFF
DRUGNAME	Etoxazole
INDICATI	Pest attack [ICD-11: N.A.] Investigative
	
TTDDRUID	D01RFI
DRUGNAME	Ro-24-0238
INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated
	
TTDDRUID	D01RHK
DRUGNAME	PMID26651364-Compound-5d
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D01RIT
DRUGNAME	Pyrazole derivative 20
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D01RKQ
DRUGNAME	SDZ-280-446
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D01RKY
DRUGNAME	VAG-624
INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1
	
TTDDRUID	D01RLA
DRUGNAME	CYC-4068
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01RLG
DRUGNAME	RTU-007
INDICATI	Diabetic cataract [ICD-11: 9B10.21] Approved
	
TTDDRUID	D01RLS
DRUGNAME	Allostrome
INDICATI	Arthropathy [ICD-11: FA11-FA38] Phase 1/2
	
TTDDRUID	D01RLU
DRUGNAME	EG-016
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 1/2
	
TTDDRUID	D01RNF
DRUGNAME	ZG-451
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01RNL
DRUGNAME	Lintuzumab
INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 2
	
TTDDRUID	D01RNV
DRUGNAME	AMT-011
INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Phase 3
	
TTDDRUID	D01RQN
DRUGNAME	DS-1971
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D01RQP
DRUGNAME	IGN002
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D01RQV
DRUGNAME	Eculizumab
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Approved
	
TTDDRUID	D01RRF
DRUGNAME	STA-5312
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01RSK
DRUGNAME	CDP-146
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D01RSW
DRUGNAME	Orazamide orotate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01RTO
DRUGNAME	Polyhydroxy benzamide derivative 4
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D01RUK
DRUGNAME	PMID25666693-Compound-104
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D01RVA
DRUGNAME	ADR-851
INDICATI	Nausea and vomiting [ICD-11: MD90] Phase 1
	
TTDDRUID	D01RVS
DRUGNAME	AZD5985
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D01RXW
DRUGNAME	Vaniprevir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D01RYJ
DRUGNAME	OP-02
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01SAD
DRUGNAME	TT-115
INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D01SAK
DRUGNAME	TL-14077
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D01SAT
DRUGNAME	Bevantolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D01SAV
DRUGNAME	Oshadi D
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01SAY
DRUGNAME	Sipuleucel-T
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D01SBC
DRUGNAME	TSRI-265
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01SBP
DRUGNAME	Co-152791
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D01SCR
DRUGNAME	NPB-001-056
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2
	
TTDDRUID	D01SEO
DRUGNAME	ICI-181037
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D01SFN
DRUGNAME	IC9-GD2-CD28-OX40
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
	
TTDDRUID	D01SGK
DRUGNAME	Opicapone
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D01SGM
DRUGNAME	FK-906
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D01SHJ
DRUGNAME	E7046
INDICATI	Rectal adenocarcinoma [ICD-11: 2B92] Phase 1
	
TTDDRUID	D01SHZ
DRUGNAME	Rucaparib
INDICATI	Ovarian cancer [ICD-11: 2C73] Approved
	
TTDDRUID	D01SIB
DRUGNAME	MK-6349
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D01SJC
DRUGNAME	Transdur-sufentanil
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D01SJS
DRUGNAME	AXL-1717
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01SJT
DRUGNAME	PF-562271
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01SKR
DRUGNAME	Lamivudine /maraviroc/zidovudine fixed-dose combination
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D01SKT
DRUGNAME	IONIS-SOD111RX
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
	
TTDDRUID	D01SNU
DRUGNAME	P-BCMA-ALL01
INDICATI	Multiple myeloma [ICD-11: 2A83] Preclinical
	
TTDDRUID	D01SNV
DRUGNAME	Recombinant human nerve growth factor
INDICATI	Neurotrophic keratitis [ICD-11: 9A74] Phase 2
	
TTDDRUID	D01SNZ
DRUGNAME	VTS-270
INDICATI	Niemann-pick disease [ICD-11: 5C56.0Y] Phase 3
	
TTDDRUID	D01SPD
DRUGNAME	BAY-85-3934
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2
	
TTDDRUID	D01SPI
DRUGNAME	CGRP
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D01SPJ
DRUGNAME	Litenimod
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D01SPW
DRUGNAME	VR647
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D01SQI
DRUGNAME	POT-4
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
	
TTDDRUID	D01SQP
DRUGNAME	HM-61713B
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01SRB
DRUGNAME	AAV2-hRPE65v2
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 3
	
TTDDRUID	D01SSK
DRUGNAME	MTRN-2696
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01SSL
DRUGNAME	AT-027
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01STB
DRUGNAME	Ramipril
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D01SUF
DRUGNAME	GP-1200
INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative
	
TTDDRUID	D01SUL
DRUGNAME	JNJ-10397049
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Investigative
	
TTDDRUID	D01SUO
DRUGNAME	EBC-46
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01SUY
DRUGNAME	BRU-83-92
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D01SVG
DRUGNAME	KA-10X
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01SVO
DRUGNAME	EIDD-1931
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D01SWJ
DRUGNAME	AVP-13748
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Investigative
	
TTDDRUID	D01SWK
DRUGNAME	Rafabegron
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D01SXE
DRUGNAME	F-18 T808
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D01SXG
DRUGNAME	ThermoStem
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D01SXH
DRUGNAME	CD20-CAR-T Cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D01SXY
DRUGNAME	NVB-302
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 1
INDICATI	C. difficile infection [ICD-11: 1A04] Phase 1
	
TTDDRUID	D01SYU
DRUGNAME	Turofexorate isopropyl
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1
	
TTDDRUID	D01SZA
DRUGNAME	MR-1817
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D01TAQ
DRUGNAME	NLP-44
INDICATI	Acne vulgaris [ICD-11: ED80] Investigative
	
TTDDRUID	D01TBJ
DRUGNAME	CMX-2043
INDICATI	Myocardial reperfusion injury [ICD-11: NB31] Phase 2
INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D01TBL
DRUGNAME	HRGP
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01TBN
DRUGNAME	Ezlopitant
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2
INDICATI	Vomiting [ICD-11: MD90] Discontinued in Phase 2
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D01TCM
DRUGNAME	CEE-03-320
INDICATI	Substance use disorder [ICD-11: 6C4Z] Terminated
	
TTDDRUID	D01TDY
DRUGNAME	Unacylated ghrelin
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D01TEA
DRUGNAME	DSC-127
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
	
TTDDRUID	D01TGH
DRUGNAME	PF-572778
INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Terminated
	
TTDDRUID	D01THN
DRUGNAME	JTT-654
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D01THX
DRUGNAME	Factor viii
INDICATI	Hemophilia [ICD-11: 3B10.0] Approved
	
TTDDRUID	D01TIN
DRUGNAME	R-1458
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D01TJM
DRUGNAME	CTCE-9908
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 1/2
	
TTDDRUID	D01TJV
DRUGNAME	K-103-PA
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D01TJY
DRUGNAME	GLPG-0187
INDICATI	Bone metastases [ICD-11: 2D50] Phase 1
	
TTDDRUID	D01TLV
DRUGNAME	EVT 401
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D01TMF
DRUGNAME	Latrodectus antivenin
INDICATI	Poison intoxication [ICD-11: NE6Z] Approved
	
TTDDRUID	D01TMK
DRUGNAME	GX-G6
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D01TMQ
DRUGNAME	Bupropion+naltrexone
INDICATI	Obesity [ICD-11: 5B81] Phase 3
	
TTDDRUID	D01TMW
DRUGNAME	Tradjeta
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D01TNK
DRUGNAME	CAR-T cells targeting EpCAM
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
	
TTDDRUID	D01TNW
DRUGNAME	Dapagliflozin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D01TPU
DRUGNAME	AWD-160-275
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D01TQR
DRUGNAME	Nonoxynol-9
INDICATI	Contraception [ICD-11: QA21] Approved
	
TTDDRUID	D01TRU
DRUGNAME	NFTA-105
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D01TSI
DRUGNAME	Ergotamine
INDICATI	Headache [ICD-11: 8A80-8A84] Approved
	
TTDDRUID	D01TVQ
DRUGNAME	Ibritumomab
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2
	
TTDDRUID	D01TVR
DRUGNAME	Tagatose
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3
	
TTDDRUID	D01TVT
DRUGNAME	FAS-115
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D01TWG
DRUGNAME	Rozanolixizumab
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 2
	
TTDDRUID	D01TYB
DRUGNAME	Basulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D01UAD
DRUGNAME	PTX-022
INDICATI	Flavivirus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D01UAM
DRUGNAME	Human and mouse gp100 DNA plasmid vaccines
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01UAU
DRUGNAME	CTP-543
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D01UBV
DRUGNAME	DXL-1215
INDICATI	Endometriosis [ICD-11: GA10] Investigative
	
TTDDRUID	D01UBX
DRUGNAME	Aclarubicin
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
	
TTDDRUID	D01UBY
DRUGNAME	JNJ-41443532
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D01UDR
DRUGNAME	Ro-25-0993
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D01UDS
DRUGNAME	CNV-2197944
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D01UFK
DRUGNAME	ATX-MS-1467
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D01UFN
DRUGNAME	Falecalcitrol
INDICATI	Hyperparathyroidism [ICD-11: 5A51] Approved
	
TTDDRUID	D01UFZ
DRUGNAME	REL-1017
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D01UGG
DRUGNAME	Sabarubicin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01UHA
DRUGNAME	MIS-416
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative
	
TTDDRUID	D01UHU
DRUGNAME	Pyriplatin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01UJK
DRUGNAME	AVE0897
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D01UJS
DRUGNAME	Rebelex
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative
	
TTDDRUID	D01UKK
DRUGNAME	PF-06760805
INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 2
	
TTDDRUID	D01ULX
DRUGNAME	CC-0651
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01UMT
DRUGNAME	Ro 31-7453
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01UNF
DRUGNAME	BAL-0019764
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Preclinical
	
TTDDRUID	D01UNS
DRUGNAME	Thalidomide + hormones
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D01UPT
DRUGNAME	FA-70
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D01UTL
DRUGNAME	Desipramine
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D01UUD
DRUGNAME	Pitolisant
INDICATI	Excessive daytime sleepiness [ICD-11: MG42] Approved
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D01UUF
DRUGNAME	Rh-GDNF
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D01UUW
DRUGNAME	Trecetilide fumarate
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Investigative
	
TTDDRUID	D01UXC
DRUGNAME	Atenolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D01UXJ
DRUGNAME	Resminostat
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
	
TTDDRUID	D01UXP
DRUGNAME	LASSBio-294
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D01UXW
DRUGNAME	Morphine-6-glucuronide
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D01UYA
DRUGNAME	MEDI1341
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D01UZH
DRUGNAME	IQP-0528
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D01VAA
DRUGNAME	ACR-125
INDICATI	Keratosis [ICD-11: ED56] Investigative
	
TTDDRUID	D01VAB
DRUGNAME	Alprenolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Withdrawn from market
	
TTDDRUID	D01VAP
DRUGNAME	YM-430
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D01VCB
DRUGNAME	ACH-2928
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1
	
TTDDRUID	D01VCE
DRUGNAME	Gadomelitol
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D01VCW
DRUGNAME	MEN-10690
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D01VDI
DRUGNAME	AVI-5126
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
	
TTDDRUID	D01VEJ
DRUGNAME	Elapegademase
INDICATI	Adenosine deaminase defciency [ICD-11: 4A01.1] Approved
INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Phase 3
	
TTDDRUID	D01VEV
DRUGNAME	Cannabinoids
INDICATI	Schizophrenia [ICD-11: 6A20] Investigative
	
TTDDRUID	D01VFQ
DRUGNAME	CGEN-855
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D01VHJ
DRUGNAME	Nitazoxanide
INDICATI	Diarrhea [ICD-11: DA90] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D01VJN
DRUGNAME	Olanzapine/fluoxetine combination
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D01VLT
DRUGNAME	ASP8232
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 1
	
TTDDRUID	D01VMA
DRUGNAME	ITX-4520
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D01VMO
DRUGNAME	Flutrimazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D01VMZ
DRUGNAME	ARI-3037MO
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 2
	
TTDDRUID	D01VNL
DRUGNAME	JM-1232(-)
INDICATI	Anaesthesia [ICD-11: 9A78.6] Investigative
	
TTDDRUID	D01VNQ
DRUGNAME	AEM-18
INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Investigative
	
TTDDRUID	D01VNT
DRUGNAME	COL-003
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Preregistration
	
TTDDRUID	D01VOJ
DRUGNAME	RTI-4229-982
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D01VPK
DRUGNAME	FK-453
INDICATI	Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2
	
TTDDRUID	D01VPR
DRUGNAME	BBR-3438
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 2
	
TTDDRUID	D01VQA
DRUGNAME	VAL BRO 03
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3
	
TTDDRUID	D01VQM
DRUGNAME	CHR-5154
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D01VRQ
DRUGNAME	BAY-1902607
INDICATI	Cough [ICD-11: MD12] Phase 2
	
TTDDRUID	D01VSK
DRUGNAME	TR-14531
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D01VSR
DRUGNAME	Hepatitis C immune globulin
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
	
TTDDRUID	D01VTT
DRUGNAME	P-coumaric acid derivative 6
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D01VUE
DRUGNAME	BMS-182874
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D01VVL
DRUGNAME	PF-04523655
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	D01VWB
DRUGNAME	IL-2/gene-modified lymphocytes
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	D01VWD
DRUGNAME	HTI-101
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D01VWR
DRUGNAME	S-15261
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D01VZQ
DRUGNAME	LG-723
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D01WBD
DRUGNAME	Mibampator
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D01WBT
DRUGNAME	DYN-15
INDICATI	Blindness [ICD-11: 9D90] Investigative
	
TTDDRUID	D01WCL
DRUGNAME	SLV 354
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D01WCW
DRUGNAME	KPPF-1
INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative
	
TTDDRUID	D01WFI
DRUGNAME	VG-FLU
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D01WHC
DRUGNAME	Leuvectin
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D01WJL
DRUGNAME	Aminosalicylic Acid
INDICATI	Pulmonary and extrapulmonary tuberculosis [ICD-11: 1B10.Z] Approved
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Approved
	
TTDDRUID	D01WJM
DRUGNAME	D-26344
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D01WKE
DRUGNAME	Semapimod
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D01WKZ
DRUGNAME	Citarinostat
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D01WLB
DRUGNAME	Lu-AA39959
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 2
	
TTDDRUID	D01WLC
DRUGNAME	Metolazone
INDICATI	Edema [ICD-11: MG29] Approved
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D01WLE
DRUGNAME	MC-1101
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 2/3
	
TTDDRUID	D01WMI
DRUGNAME	SP-1031C
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01WMJ
DRUGNAME	Copper
INDICATI	Contraception [ICD-11: QA21] Approved
	
TTDDRUID	D01WMO
DRUGNAME	Tularemia vaccine
INDICATI	Tularemia [ICD-11: 1B94] Phase 1
	
TTDDRUID	D01WMW
DRUGNAME	RG7232
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Investigative
	
TTDDRUID	D01WOD
DRUGNAME	PF-4064900
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D01WQL
DRUGNAME	MPC-9528
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01WQO
DRUGNAME	BIRT 2584
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D01WQQ
DRUGNAME	ABT-981
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
	
TTDDRUID	D01WSL
DRUGNAME	NPB-1
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D01WTV
DRUGNAME	HDL-200
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
	
TTDDRUID	D01WUA
DRUGNAME	Treprostinil
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Approved
	
TTDDRUID	D01WVJ
DRUGNAME	BIO-306
INDICATI	Migraine [ICD-11: 8A80] Preclinical
	
TTDDRUID	D01WWD
DRUGNAME	KPS-0373
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D01WWN
DRUGNAME	Pyrazole derivative 57
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D01WXU
DRUGNAME	ZK-205367
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2/3
	
TTDDRUID	D01WYO
DRUGNAME	Hydroxychloroquine + nitazoxanide
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D01WYT
DRUGNAME	ASP3550
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D01WYV
DRUGNAME	Angiostatin/paclitaxel/carboplatin
INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
	
TTDDRUID	D01WZG
DRUGNAME	Creatine ALS-08
INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 3
	
TTDDRUID	D01WZL
DRUGNAME	AVE-8112
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D01XAE
DRUGNAME	PRX-12239
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D01XAJ
DRUGNAME	CSL-425
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D01XAR
DRUGNAME	AP-521
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D01XBA
DRUGNAME	Raloxifene
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D01XCL
DRUGNAME	Veratrum Viride Root
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D01XDL
DRUGNAME	Idarubicin
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
	
TTDDRUID	D01XDO
DRUGNAME	VSSP
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D01XEC
DRUGNAME	Botulinum toxin recombinant vaccine
INDICATI	Botulism [ICD-11: 1A11] Preclinical
	
TTDDRUID	D01XEO
DRUGNAME	Debio-0824
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1b/2a
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 1
	
TTDDRUID	D01XEQ
DRUGNAME	R348
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated
	
TTDDRUID	D01XFZ
DRUGNAME	GPD-1116
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D01XGX
DRUGNAME	JTP-4819
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D01XHG
DRUGNAME	DENBUFYLLINE
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3
	
TTDDRUID	D01XHU
DRUGNAME	AN-207
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01XIF
DRUGNAME	Ivermectin + nitazoxanide
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D01XIK
DRUGNAME	Antimalarials
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D01XLM
DRUGNAME	Piperazine
INDICATI	Enterobiasis [ICD-11: 1F65] Approved
INDICATI	Ascariasis [ICD-11: 1F62] Approved
	
TTDDRUID	D01XMC
DRUGNAME	VTB-38543
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D01XMP
DRUGNAME	TG-D
INDICATI	Bone disease [ICD-11: FC0Z] Investigative
	
TTDDRUID	D01XMS
DRUGNAME	ENT-103
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D01XNB
DRUGNAME	Omeprazole
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Approved
	
TTDDRUID	D01XOD
DRUGNAME	Alpidem
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D01XPG
DRUGNAME	CAN-296
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D01XPY
DRUGNAME	L-citrulline
INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 3
	
TTDDRUID	D01XQQ
DRUGNAME	TT-30
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D01XRP
DRUGNAME	Simethicone
INDICATI	Dyspepsia [ICD-11: MD92] Approved
	
TTDDRUID	D01XTN
DRUGNAME	Epaxal
INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Approved
	
TTDDRUID	D01XUE
DRUGNAME	Tedatioxetine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 1
	
TTDDRUID	D01XUG
DRUGNAME	ASP6432
INDICATI	Lower urinary tract symptom [ICD-11: GB71] Discontinued in Phase 1
	
TTDDRUID	D01XVF
DRUGNAME	Sirukumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 3
INDICATI	Giant cell arteritis [ICD-11: 4A44.2] Phase 3
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D01XVK
DRUGNAME	Pyrazoline derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D01XVX
DRUGNAME	CC-220
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D01XWG
DRUGNAME	Daunorubicin
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
INDICATI	Kaposi sarcoma [ICD-11: 2B57] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01XXF
DRUGNAME	Modified SDF-1
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D01XYJ
DRUGNAME	Zidovudine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D01XZG
DRUGNAME	G1T28-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01YCF
DRUGNAME	4SCAR-GD2
INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D01YCX
DRUGNAME	YJRN-0904
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D01YDF
DRUGNAME	Pibutidine
INDICATI	Ulcerative colitis [ICD-11: DD71] Discontinued in Phase 3
	
TTDDRUID	D01YDH
DRUGNAME	GSK2981710
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D01YFR
DRUGNAME	DWJ-205
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D01YGD
DRUGNAME	ICO-25
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D01YGF
DRUGNAME	KF-15570
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D01YGY
DRUGNAME	UC-1011
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D01YHL
DRUGNAME	DasKloster 0039-01
INDICATI	Asbestosis [ICD-11: CA60.2] Investigative
	
TTDDRUID	D01YHO
DRUGNAME	WP-1122
INDICATI	Glioma [ICD-11: 2A00.0] Investigative
	
TTDDRUID	D01YIF
DRUGNAME	PAC1
INDICATI	Anaplastic astrocytoma [ICD-11: 2A00.0] Phase 1
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D01YIO
DRUGNAME	JNJ-10311795
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D01YJR
DRUGNAME	IVN-birch
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative
	
TTDDRUID	D01YKI
DRUGNAME	ANX-510
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
	
TTDDRUID	D01YKR
DRUGNAME	FCR001
INDICATI	Organ transplant rejection [ICD-11: NE84] Phase 2
	
TTDDRUID	D01YLA
DRUGNAME	NP-432
INDICATI	Respiratory tract infection [ICD-11: CA45] Investigative
	
TTDDRUID	D01YLF
DRUGNAME	PTI-701
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D01YLK
DRUGNAME	Meningitis ACYW conj.
INDICATI	Meningitis [ICD-11: 1D01] Phase 1
	
TTDDRUID	D01YOC
DRUGNAME	BMS-181100
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 3
	
TTDDRUID	D01YQH
DRUGNAME	GM-CSF
INDICATI	Neurological disorder [ICD-11: 6B60] Approved
	
TTDDRUID	D01YQN
DRUGNAME	Levamisole Pill + Budesonide+Formoterol inhaler
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D01YSH
DRUGNAME	DV-7021
INDICATI	Liver disease [ICD-11: DB90-BD99] Terminated
	
TTDDRUID	D01YSU
DRUGNAME	AG-PPC709
INDICATI	Respiratory disease [ICD-11: CB40] Investigative
	
TTDDRUID	D01YTX
DRUGNAME	CBLC-4H10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01YVT
DRUGNAME	Colesevelam
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
	
TTDDRUID	D01YVZ
DRUGNAME	GLYX-13
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3
	
TTDDRUID	D01YYP
DRUGNAME	Margetuximab
INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 2
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
	
TTDDRUID	D01YZF
DRUGNAME	CART-BCMA
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D01ZAQ
DRUGNAME	AZD5363
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01ZBF
DRUGNAME	E-1224
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2
	
TTDDRUID	D01ZCC
DRUGNAME	PMID26815044-Compound-118
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D01ZCL
DRUGNAME	ACT-N
INDICATI	Brain injury [ICD-11: NA07.Z] Preclinical
	
TTDDRUID	D01ZDQ
DRUGNAME	ACH-1095
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D01ZDR
DRUGNAME	FR-208419
INDICATI	Dyspepsia [ICD-11: MD92] Terminated
	
TTDDRUID	D01ZEC
DRUGNAME	Cefacetrile
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D01ZEY
DRUGNAME	MDL-201112
INDICATI	Colitis [ICD-11: 1A40.Z] Terminated
	
TTDDRUID	D01ZFK
DRUGNAME	Tuberculosis recombinant vaccine
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2
	
TTDDRUID	D01ZFM
DRUGNAME	LNK-3248
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D01ZGH
DRUGNAME	JTK-853
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1
	
TTDDRUID	D01ZGS
DRUGNAME	TGN-208
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D01ZHB
DRUGNAME	Revusiran
INDICATI	Amyloidosis [ICD-11: 5D00] Phase 3
	
TTDDRUID	D01ZHQ
DRUGNAME	MIM-A2
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D01ZII
DRUGNAME	Chlorpromazine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D01ZJB
DRUGNAME	Autologous bone marrow-derived mesenchymal stem cells
INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 1
	
TTDDRUID	D01ZJK
DRUGNAME	Ardeparin
INDICATI	Venous thrombosis [ICD-11: BA43] Approved
INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3
INDICATI	Venous thromboembolism [ICD-11: BD72] Phase 3
	
TTDDRUID	D01ZJM
DRUGNAME	R-1479
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1
	
TTDDRUID	D01ZJP
DRUGNAME	Lopinavir + ritonavir + hydoxychloroquine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D01ZKE
DRUGNAME	Biaryl mannoside derivative 21
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D01ZLI
DRUGNAME	CBR-2092
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D01ZLK
DRUGNAME	APX005M
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative
	
TTDDRUID	D01ZLL
DRUGNAME	Aom-0755
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D01ZLR
DRUGNAME	PF-05082566
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D01ZLU
DRUGNAME	TAS-120
INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 3
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D01ZMR
DRUGNAME	Calcineurin
INDICATI	T-cell mediated immune dysfunction [ICD-11: 4A01.1Y] Investigative
	
TTDDRUID	D01ZMS
DRUGNAME	PK1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D01ZNH
DRUGNAME	IDAZOXAN HYDROCHLORIDE
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 3
	
TTDDRUID	D01ZNQ
DRUGNAME	TMC-310911
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D01ZOB
DRUGNAME	Terguride
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
	
TTDDRUID	D01ZOG
DRUGNAME	Difluprednate
INDICATI	Ocular pain [ICD-11: MC18] Approved
	
TTDDRUID	D01ZPK
DRUGNAME	BA-207
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D01ZPT
DRUGNAME	ACTR087
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D01ZPY
DRUGNAME	FMP2.1/AS02A
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D01ZQE
DRUGNAME	Metenkefalin + tridecactide
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D01ZQN
DRUGNAME	ALD-306
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D01ZRI
DRUGNAME	Axitinib
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved
	
TTDDRUID	D01ZSO
DRUGNAME	Moclobemide
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
INDICATI	Skin imperfections [ICD-11: EK71] Patented
	
TTDDRUID	D01ZSP
DRUGNAME	AAB-003/PF-05236812
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D01ZUA
DRUGNAME	Coenzyme Q10
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2
INDICATI	Pancreatic tumour [ICD-11: 2C10] Phase 2
INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Phase 1
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D01ZUV
DRUGNAME	GDC-0425
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D01ZVK
DRUGNAME	SCD-211
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D01ZWC
DRUGNAME	RPH-104 + olokizumab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D01ZWF
DRUGNAME	BPI-711001
INDICATI	Hypoglycemia [ICD-11: 5A41] Investigative
	
TTDDRUID	D01ZXW
DRUGNAME	Lintitript
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2
	
TTDDRUID	D01ZYG
DRUGNAME	Alemtuzumab
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
	
TTDDRUID	D01ZZG
DRUGNAME	INV-311
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D02AAD
DRUGNAME	Biaryl mannoside derivative 31
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D02AAO
DRUGNAME	AZD-4877
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D02ABS
DRUGNAME	BMS-180560
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D02ADC
DRUGNAME	SDZ-MKS-492
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D02ADJ
DRUGNAME	Apolipoprotein E
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated
	
TTDDRUID	D02ADM
DRUGNAME	Silibinin
INDICATI	Hepatic failure [ICD-11: DB99.7] Phase 2/3
	
TTDDRUID	D02AEI
DRUGNAME	BM-13.1196
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D02AEW
DRUGNAME	Xenon Xe-127
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D02AIM
DRUGNAME	Metoprine
INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D02AIN
DRUGNAME	AZD5718
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
	
TTDDRUID	D02AIZ
DRUGNAME	BIL010t
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D02ALD
DRUGNAME	NOLOMIROLE HYDROCHLORIDE
INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 3
	
TTDDRUID	D02ALZ
DRUGNAME	ONO-3307
INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 2
	
TTDDRUID	D02AMG
DRUGNAME	HGS-1029
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02ANJ
DRUGNAME	NZ-107
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D02ANO
DRUGNAME	LY-2393910
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D02AOD
DRUGNAME	HF-0220
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D02AQL
DRUGNAME	AT-003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02AQM
DRUGNAME	VAR-10300
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D02AQY
DRUGNAME	Actarit
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D02ARR
DRUGNAME	Dehydrocholic acid
INDICATI	Constipation [ICD-11: DD91.1] Approved
	
TTDDRUID	D02AUB
DRUGNAME	Bimosiamose
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2a
INDICATI	Psoriatic disorder [ICD-11: EA90] Phase 2a
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2a
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D02AUI
DRUGNAME	Technetium Tc-99m Mebrofenin Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D02AUY
DRUGNAME	MERS-five-helix bundle
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D02AVC
DRUGNAME	BMS-820132
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D02AWB
DRUGNAME	MERS-CoV-SDNA vaccine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D02AWQ
DRUGNAME	AZD1419
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D02AXG
DRUGNAME	Testosterone undecanoate
INDICATI	Hypogonadism [ICD-11: 5A61.0] Approved
	
TTDDRUID	D02AXS
DRUGNAME	GSK406725
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D02AYL
DRUGNAME	Pretomanid
INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 3
	
TTDDRUID	D02BAA
DRUGNAME	Patient-derived CD19- and CD22 specific CAR
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D02BAE
DRUGNAME	Synthetic conjugated estrogen
INDICATI	Vaginal disease [ICD-11: GA1Y] Phase 3
	
TTDDRUID	D02BAW
DRUGNAME	MK-6325
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D02BBC
DRUGNAME	CL-329167
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D02BCY
DRUGNAME	CD19 CART
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D02BDL
DRUGNAME	Dibenzoylmethane
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02BGL
DRUGNAME	DHAC
INDICATI	Mesothelioma [ICD-11: 2C51.2] Discontinued in Phase 2
	
TTDDRUID	D02BGU
DRUGNAME	Pyrido/pyrrolo-fused pyrimidine derivative 1
INDICATI	Pain [ICD-11: MG30-MG3Z] Patented
	
TTDDRUID	D02BGZ
DRUGNAME	AXP-107-17
INDICATI	Radiation syndrome [ICD-11: NF00] Investigative
	
TTDDRUID	D02BHP
DRUGNAME	Nacolomab tafenatox
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Terminated
	
TTDDRUID	D02BHW
DRUGNAME	IM19 CAR-T
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D02BIY
DRUGNAME	DCVax-Direct
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D02BJN
DRUGNAME	Human liver progenitor cells
INDICATI	Liver cirrhosis [ICD-11: DB93.1] Investigative
	
TTDDRUID	D02BLD
DRUGNAME	Oprozomib
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D02BLO
DRUGNAME	Oxilan iohexol
INDICATI	Vascular disease [ICD-11: BE2Z] Approved
	
TTDDRUID	D02BMJ
DRUGNAME	ND-601
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D02BPX
DRUGNAME	NGM 282
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Primary biliary cirrhosis [ICD-11: DB96.1] Phase 2
	
TTDDRUID	D02BQE
DRUGNAME	E7820
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D02BRJ
DRUGNAME	Vabicaserin
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2
	
TTDDRUID	D02BTZ
DRUGNAME	Twinrix
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D02BVQ
DRUGNAME	TGC-9
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02BVW
DRUGNAME	FF-10501-01
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D02BWY
DRUGNAME	JNJ-64041757
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D02BYZ
DRUGNAME	ASP8273
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D02CAF
DRUGNAME	NOX-H94
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2
	
TTDDRUID	D02CBD
DRUGNAME	J-30
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02CCA
DRUGNAME	GSK-172981
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D02CEO
DRUGNAME	SND-226
INDICATI	Toxoplasmosis [ICD-11: 1F57] Investigative
	
TTDDRUID	D02CFP
DRUGNAME	Citicoline
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved
	
TTDDRUID	D02CFR
DRUGNAME	GW-559768X
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02CFV
DRUGNAME	Solubilized type 1 native bovine collagen
INDICATI	Scleroderma [ICD-11: 4A42] Phase 2
	
TTDDRUID	D02CGC
DRUGNAME	Sorbinil
INDICATI	Diabetic cataract [ICD-11: 9B10.21] Terminated
	
TTDDRUID	D02CGY
DRUGNAME	Bifemelane
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D02CII
DRUGNAME	Abaloparatide
INDICATI	Postmenopausal osteoporosis [ICD-11: FB83.11] Approved
	
TTDDRUID	D02CJA
DRUGNAME	CM-2236
INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Preclinical
	
TTDDRUID	D02CJX
DRUGNAME	Desoxycorticosterone Acetate
INDICATI	Discovery agent [ICD-11: N.A.] Approved
	
TTDDRUID	D02CKG
DRUGNAME	Diltiazem + niclosamide
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D02CKH
DRUGNAME	OPI-1002
INDICATI	Acute kidney injury [ICD-11: GB60] Phase 2
	
TTDDRUID	D02CKO
DRUGNAME	Anoro
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D02CKX
DRUGNAME	Carbimazole
INDICATI	Hyperthyroidism [ICD-11: 5A02] Approved
	
TTDDRUID	D02CLV
DRUGNAME	AdCh63 AMA1
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2
	
TTDDRUID	D02CND
DRUGNAME	KI-0901
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02CNR
DRUGNAME	Anecortave acetate
INDICATI	Macular degeneration [ICD-11: 9B78.3] Approved
	
TTDDRUID	D02COS
DRUGNAME	IdB-1016
INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 2
	
TTDDRUID	D02CPP
DRUGNAME	Vonoprazan
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Approved
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 3
	
TTDDRUID	D02CQL
DRUGNAME	Adyvia
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D02CRM
DRUGNAME	KI-0907
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D02CTS
DRUGNAME	Ospemifene
INDICATI	Dyspareunia [ICD-11: GA12] Approved
INDICATI	Postmenopausal vaginal atrophy [ICD-11: GA30.2] Phase 3
	
TTDDRUID	D02CTZ
DRUGNAME	LY433221
INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative
	
TTDDRUID	D02CUN
DRUGNAME	NM504
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 0
	
TTDDRUID	D02CVF
DRUGNAME	SynGEM
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D02CWZ
DRUGNAME	AMBAZONE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02CXA
DRUGNAME	LG-912
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D02CXZ
DRUGNAME	PMID26815044-Compound-123
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D02CYL
DRUGNAME	MOR-208
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2/3
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D02CYR
DRUGNAME	Chromic phosphate P 32
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D02CZF
DRUGNAME	Aderbasib
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D02CZK
DRUGNAME	Karenitecin
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
	
TTDDRUID	D02DBA
DRUGNAME	Helicobacter pylori vaccine
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Phase 1
	
TTDDRUID	D02DEH
DRUGNAME	GM-602
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
	
TTDDRUID	D02DES
DRUGNAME	Anakinra
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D02DEZ
DRUGNAME	GALE-301
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 1/2
	
TTDDRUID	D02DFJ
DRUGNAME	Biaryl mannoside derivative 10
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D02DGU
DRUGNAME	Tretinoin
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
INDICATI	Acute promyelocytic leukaemia [ICD-11: 2A60.0] Approved
	
TTDDRUID	D02DHU
DRUGNAME	SKF-81297
INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated
	
TTDDRUID	D02DJF
DRUGNAME	BAX-111
INDICATI	Pain [ICD-11: MG30-MG3Z] Preregistration
	
TTDDRUID	D02DJG
DRUGNAME	LY-2189102
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D02DJR
DRUGNAME	AMG 167
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1
	
TTDDRUID	D02DJS
DRUGNAME	Iodoxamate Meglumine
INDICATI	Bile duct disease [ICD-11: LB20] Approved
	
TTDDRUID	D02DKD
DRUGNAME	Benzquinamide
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D02DLP
DRUGNAME	VOFOPITANT HYDROCHLORIDE
INDICATI	Vomiting [ICD-11: MD90] Phase 2
	
TTDDRUID	D02DMQ
DRUGNAME	Eletriptan
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D02DMW
DRUGNAME	S-1360
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D02DNA
DRUGNAME	Cureskin
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Approved
	
TTDDRUID	D02DOK
DRUGNAME	SJ-8002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02DOZ
DRUGNAME	ALKS 3831
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D02DPA
DRUGNAME	Cimetidine
INDICATI	Acid-reflux disorder [ICD-11: DA22] Approved
	
TTDDRUID	D02DPP
DRUGNAME	MTHF
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 4
	
TTDDRUID	D02DPU
DRUGNAME	Aniracetam
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved
	
TTDDRUID	D02DSD
DRUGNAME	Sodium Chromate Cr-51
INDICATI	Hemorrhage [ICD-11: MG27] Approved
	
TTDDRUID	D02DSZ
DRUGNAME	Temocapril hydrochloride
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D02DTQ
DRUGNAME	PF-3893787
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D02DVB
DRUGNAME	AGN-191743
INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1
	
TTDDRUID	D02DVK
DRUGNAME	CV-9201
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D02DWK
DRUGNAME	2-hydroxyoleic acid
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1/2
	
TTDDRUID	D02DWM
DRUGNAME	Amphotericin B
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
INDICATI	Mycoses [ICD-11: 1F2Z] Investigative
	
TTDDRUID	D02DWN
DRUGNAME	AB-0440a
INDICATI	Bone disease [ICD-11: FC0Z] Investigative
	
TTDDRUID	D02DWX
DRUGNAME	Prostvac-VF
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D02DXC
DRUGNAME	SPN-803
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D02DXV
DRUGNAME	HAP aniline mustard
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02DYU
DRUGNAME	SC-75416
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D02DZI
DRUGNAME	MGN-8107
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D02DZK
DRUGNAME	LY3303560
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D02EAS
DRUGNAME	TBC 11251 (TBC)
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Withdrawn from market
	
TTDDRUID	D02ECG
DRUGNAME	Sodium pyruvate
INDICATI	Asthma [ICD-11: CA23] Phase 1/2
	
TTDDRUID	D02EEJ
DRUGNAME	SCY-635
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D02EEK
DRUGNAME	J 591 Lu-177
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D02EFJ
DRUGNAME	MDAB-16
INDICATI	Bone disease [ICD-11: FC0Z] Phase 2
	
TTDDRUID	D02EGY
DRUGNAME	Aromatic hydrazine carboxyimidoamide derivative 6
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D02EHE
DRUGNAME	BI-730357
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	D02EHV
DRUGNAME	Human neutral insulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D02EKI
DRUGNAME	Hydroxychloroquine + intravenous famotidine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D02EKO
DRUGNAME	PMID25666693-Compound-126
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D02ELN
DRUGNAME	HM-5016699
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02ELS
DRUGNAME	L-alanosine
INDICATI	Brain cancer [ICD-11: 2A00] Phase 2
	
TTDDRUID	D02EMR
DRUGNAME	Cilomilast
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 3
INDICATI	Bronchitis [ICD-11: CA20] Discontinued in Phase 3
INDICATI	Emphysema [ICD-11: CA21] Discontinued in Phase 3
	
TTDDRUID	D02ENG
DRUGNAME	BVT.2733
INDICATI	Lupus [ICD-11: 4A40] Phase 3
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 2
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D02EOH
DRUGNAME	SGT-53
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02EOR
DRUGNAME	ABBV-399
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02EOS
DRUGNAME	CVX-241
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02EPS
DRUGNAME	Oralair grasses
INDICATI	Grass pollen hypersensitivity [ICD-11: 4B07] Approved
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved
	
TTDDRUID	D02EPW
DRUGNAME	Hydroxychloroquine + azithromycin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D02EQX
DRUGNAME	Hydroxychloroquine + camostat mesylate
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D02ERH
DRUGNAME	EP-2060
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D02ESK
DRUGNAME	GSK-732461
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D02ESL
DRUGNAME	ON-01210.Na
INDICATI	Radiation syndrome [ICD-11: NF00] Phase 1
INDICATI	Acute radiation syndrome [ICD-11: NF00] Phase 1
	
TTDDRUID	D02ESX
DRUGNAME	Neomedi
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D02ETJ
DRUGNAME	SIL-43
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02ETP
DRUGNAME	SOM-0420
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D02ETU
DRUGNAME	PMID28270021-Compound-WO2014152663 701
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D02ETY
DRUGNAME	SAR97276
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D02EVF
DRUGNAME	Losartan/thioctic acid
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D02EVL
DRUGNAME	TDT-077
INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Investigative
	
TTDDRUID	D02EVT
DRUGNAME	SAR-152954
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Discontinued in Phase 1
	
TTDDRUID	D02EWF
DRUGNAME	RiVax
INDICATI	Ricin poisoning [ICD-11: NE61] Phase 1
	
TTDDRUID	D02EXB
DRUGNAME	Vero cell seasonal influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D02EXZ
DRUGNAME	Ferric maltol
INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 3
	
TTDDRUID	D02EYG
DRUGNAME	Linagliptin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D02EYZ
DRUGNAME	GSK2654909A
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1
	
TTDDRUID	D02EZM
DRUGNAME	Fospropofol disodium
INDICATI	Monitored anaesthesia care [ICD-11: N.A.] Approved
	
TTDDRUID	D02FAI
DRUGNAME	Pbi-shPDX-1 LP
INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative
	
TTDDRUID	D02FBG
DRUGNAME	UC-2029
INDICATI	Premenstrual syndrome [ICD-11: GA34.40] Investigative
	
TTDDRUID	D02FCQ
DRUGNAME	Protokylol Hydrochloride
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D02FCU
DRUGNAME	MIV-210
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D02FDJ
DRUGNAME	Ioforminol
INDICATI	Pulmonary embolism [ICD-11: BB00] Phase 2
	
TTDDRUID	D02FDZ
DRUGNAME	LCP-AtorFen
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2/3
	
TTDDRUID	D02FEA
DRUGNAME	FENDILINE
INDICATI	Coronary artery disease [ICD-11: BA80] Withdrawn from market
	
TTDDRUID	D02FEJ
DRUGNAME	ODC-0501
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 1/2
	
TTDDRUID	D02FEM
DRUGNAME	Natamycin
INDICATI	Conjunctivitis [ICD-11: 9A60] Approved
	
TTDDRUID	D02FEV
DRUGNAME	S-8921
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D02FGG
DRUGNAME	AFM-21
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02FHP
DRUGNAME	RX-01-423
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical
	
TTDDRUID	D02FIC
DRUGNAME	JB-004/A
INDICATI	Inner ear disease [ICD-11: AB30-AB37] Phase 2
	
TTDDRUID	D02FIJ
DRUGNAME	FK-224
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D02FLB
DRUGNAME	Sodium bicarbonate
INDICATI	Metabolic acidosis [ICD-11: 5C73] Approved
	
TTDDRUID	D02FNJ
DRUGNAME	AL-309
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D02FNU
DRUGNAME	Ipsapirone
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D02FPT
DRUGNAME	H5N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D02FTU
DRUGNAME	Recombinant follicle stimulating hormone
INDICATI	Female infertility [ICD-11: GA31.Z] Investigative
	
TTDDRUID	D02FTV
DRUGNAME	INGN-241
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D02FXK
DRUGNAME	Botulinum Toxin Type B
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D02FXU
DRUGNAME	Lapaquistat acetate
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 3
	
TTDDRUID	D02FYE
DRUGNAME	TT-223
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D02FYI
DRUGNAME	Tozaride
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D02GAC
DRUGNAME	Clomocycline
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D02GDK
DRUGNAME	Cx-601
INDICATI	Perianal fistula [ICD-11: DB50.1] Phase 3
	
TTDDRUID	D02GDN
DRUGNAME	Berirab
INDICATI	Rabies [ICD-11: 1C82] Approved
	
TTDDRUID	D02GEC
DRUGNAME	Omalizumab
INDICATI	Asthma [ICD-11: CA23] Approved
INDICATI	Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 2
	
TTDDRUID	D02GFZ
DRUGNAME	Heparin-EGF-like factor
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated
	
TTDDRUID	D02GGG
DRUGNAME	BLI-1100
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D02GIA
DRUGNAME	BL-7040
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
	
TTDDRUID	D02GIU
DRUGNAME	Cilastatin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D02GJE
DRUGNAME	CG-8840
INDICATI	Bladder cancer [ICD-11: 2C94] Terminated
	
TTDDRUID	D02GJZ
DRUGNAME	Ioflupane i-123
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D02GKJ
DRUGNAME	Monosialoganglioside
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved
	
TTDDRUID	D02GLD
DRUGNAME	MF-101
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 3
	
TTDDRUID	D02GMT
DRUGNAME	Org-7797
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2
	
TTDDRUID	D02GNH
DRUGNAME	Quinazoline derivative 9
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D02GNL
DRUGNAME	KMJ-372
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D02GOG
DRUGNAME	BY-963
INDICATI	Myocardial disease [ICD-11: BC43.20] Approved
	
TTDDRUID	D02GPG
DRUGNAME	JNJ-42165279
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
INDICATI	Social anxiety disorder [ICD-11: 6B04] Phase 2
	
TTDDRUID	D02GRR
DRUGNAME	Oleclumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02GSA
DRUGNAME	RBx10558
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D02GTN
DRUGNAME	ZY-15106
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D02GTT
DRUGNAME	AR-XYZ
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D02GTV
DRUGNAME	Menomune
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D02GTY
DRUGNAME	Tamibarotene
INDICATI	T-cell leukaemia [ICD-11: 2A90] Phase 3
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3
	
TTDDRUID	D02GUG
DRUGNAME	Ajmaline
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Approved
	
TTDDRUID	D02GVH
DRUGNAME	PIRODAVIR
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2
	
TTDDRUID	D02GWF
DRUGNAME	PACTIMIBE
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2/3
	
TTDDRUID	D02GWJ
DRUGNAME	MCT-125
INDICATI	Fatigue [ICD-11: MG22] Phase 2
	
TTDDRUID	D02GYD
DRUGNAME	CDP-845
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D02HBB
DRUGNAME	AEZS-108
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3
	
TTDDRUID	D02HBI
DRUGNAME	Bmab-100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02HBW
DRUGNAME	SCH-32615
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D02HCU
DRUGNAME	WEB-2347
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D02HDG
DRUGNAME	AQX-1125
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D02HDP
DRUGNAME	V-1810
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02HED
DRUGNAME	Perphenazine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D02HFD
DRUGNAME	Glutathione
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D02HFN
DRUGNAME	BFCR4350A
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D02HHM
DRUGNAME	SGN-CD19B
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D02HJR
DRUGNAME	SID-530
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D02HKC
DRUGNAME	MUC1-Poly-ICLC
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D02HKL
DRUGNAME	Suriclone
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Preregistration
	
TTDDRUID	D02HLL
DRUGNAME	RQ-00317076
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D02HNF
DRUGNAME	Radium-223 chloride
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D02HNG
DRUGNAME	MK-0752
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D02HPF
DRUGNAME	Biaryl mannoside derivative 9
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D02HPI
DRUGNAME	FGI-103-723
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative
	
TTDDRUID	D02HQR
DRUGNAME	Anti-HBs human mab
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D02HRD
DRUGNAME	KLS-0611
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 2
	
TTDDRUID	D02HSB
DRUGNAME	Cabazitaxel
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D02HTD
DRUGNAME	GS-9451
INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D02HUB
DRUGNAME	Nestorone
INDICATI	Endometriosis [ICD-11: GA10] Phase 3
	
TTDDRUID	D02HUU
DRUGNAME	FluPro
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D02HUW
DRUGNAME	SAR-548304
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1
	
TTDDRUID	D02HUY
DRUGNAME	Debio 0827
INDICATI	Chronic pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D02HVW
DRUGNAME	Zibotentan
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 3
	
TTDDRUID	D02HWP
DRUGNAME	CHLOROXINE
INDICATI	Erythema [ICD-11: ME64.0] Approved
	
TTDDRUID	D02HWR
DRUGNAME	PV-1019
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02HXS
DRUGNAME	Bufexamac
INDICATI	Dermatitis [ICD-11: EA80-EA89] Approved
	
TTDDRUID	D02HYK
DRUGNAME	Chondroitin
INDICATI	Cataract [ICD-11: 9B10] Approved
	
TTDDRUID	D02IAR
DRUGNAME	Nov-038
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D02IBS
DRUGNAME	INH-001
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D02IBU
DRUGNAME	Oritavancin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated
	
TTDDRUID	D02IBX
DRUGNAME	Pyrrolo[2,3-b]pyridine derivative 3
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D02ICI
DRUGNAME	VIT-45
INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved
	
TTDDRUID	D02IHW
DRUGNAME	Nepafenac
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
	
TTDDRUID	D02IIE
DRUGNAME	Penicillin V Potassium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D02IIL
DRUGNAME	KOSN1559
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02IIM
DRUGNAME	FCX-013
INDICATI	Scleroderma [ICD-11: 4A42] Phase 1
	
TTDDRUID	D02IIW
DRUGNAME	Faropenem
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved
	
TTDDRUID	D02IJA
DRUGNAME	Tau-binding PET tracer
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D02IJP
DRUGNAME	CLX-0900
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Terminated
	
TTDDRUID	D02IKD
DRUGNAME	HG-1245
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02IKF
DRUGNAME	M9831
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02IKQ
DRUGNAME	Hepatitis B DNA vaccine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	D02ILI
DRUGNAME	ZP-G-CSF
INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative
	
TTDDRUID	D02IND
DRUGNAME	CBI-006
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02INX
DRUGNAME	TD-1211
INDICATI	Opioid-induced constipation [ICD-11: DB32.1] Phase 2
	
TTDDRUID	D02INZ
DRUGNAME	BABIM
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D02IOC
DRUGNAME	CP154,526
INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative
	
TTDDRUID	D02IOH
DRUGNAME	Alphaprodine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D02IPI
DRUGNAME	CTA-002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D02IQY
DRUGNAME	Ergoloid mesylate
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D02IRD
DRUGNAME	Megesterol acetate
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D02IRL
DRUGNAME	IDX375
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2
	
TTDDRUID	D02ISP
DRUGNAME	SKI-2034R
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D02ITL
DRUGNAME	AV-201
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D02IUD
DRUGNAME	Sodium Fluoride F-18
INDICATI	Bone related disease [ICD-11: FB82-FB85] Approved
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D02IUO
DRUGNAME	CORT-113083
INDICATI	Weight gain [ICD-11: MG43.6] Investigative
	
TTDDRUID	D02IWC
DRUGNAME	AZD2624
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2
	
TTDDRUID	D02IYC
DRUGNAME	IMP-701
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02IZN
DRUGNAME	ON-123
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02JAY
DRUGNAME	Stannsoporfin
INDICATI	Neonatal hyperbilirubinemia [ICD-11: KA87] Phase 2
	
TTDDRUID	D02JBI
DRUGNAME	SAL-200
INDICATI	Bacteremia [ICD-11: 1A73] Phase 2
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1
	
TTDDRUID	D02JDL
DRUGNAME	Porfimer Sodium
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
	
TTDDRUID	D02JDN
DRUGNAME	IFN-alpha
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
	
TTDDRUID	D02JEW
DRUGNAME	GSK-2130579A
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D02JFF
DRUGNAME	ISIS 16518
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02JGD
DRUGNAME	SKL-10406
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
	
TTDDRUID	D02JHW
DRUGNAME	ANG-2864
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02JIB
DRUGNAME	Ro-25-2016
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D02JIF
DRUGNAME	EDP-19
INDICATI	Brain cancer [ICD-11: 2A00] Investigative
	
TTDDRUID	D02JIN
DRUGNAME	264W94
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D02JIS
DRUGNAME	Iobenguane I-123
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Approved
	
TTDDRUID	D02JKY
DRUGNAME	TD-9855
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
INDICATI	Orthostatic hypotension [ICD-11: BA21] Phase 1
	
TTDDRUID	D02JMI
DRUGNAME	SLV-310
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2
	
TTDDRUID	D02JMU
DRUGNAME	Tasquinimod
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D02JMZ
DRUGNAME	Recombinant human keratinocyte growth factor-2
INDICATI	Wound healing [ICD-11: EL8Y] Phase 1
	
TTDDRUID	D02JNC
DRUGNAME	BCMA CAR-T
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D02JND
DRUGNAME	ADC-3680
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D02JNM
DRUGNAME	Desonide
INDICATI	Atopic dermatitis [ICD-11: EA80] Approved
	
TTDDRUID	D02JNX
DRUGNAME	OxycoDex
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D02JNY
DRUGNAME	BIBN-140
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D02JOA
DRUGNAME	Phenylisoserine derivatives SK80
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
	
TTDDRUID	D02JOH
DRUGNAME	BMS-708163
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D02JOI
DRUGNAME	EPI-3905
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative
	
TTDDRUID	D02JQB
DRUGNAME	PMID25666693-Compound-140
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D02JRD
DRUGNAME	VT-310
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D02JRT
DRUGNAME	111In-imciromab pentetate
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved
	
TTDDRUID	D02JUM
DRUGNAME	METIAPRIL
INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2
	
TTDDRUID	D02JVX
DRUGNAME	Resorcinol compound 7
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D02JWA
DRUGNAME	Flomoxef sodium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D02JWN
DRUGNAME	STNM-01
INDICATI	Pyloric stenosis [ICD-11: DA40.0] Investigative
	
TTDDRUID	D02JXG
DRUGNAME	SB-265610
INDICATI	Asthma [ICD-11: CA23] Phase 2
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D02JYA
DRUGNAME	Raxibacumab
INDICATI	Anthrax [ICD-11: 1B97] Approved
	
TTDDRUID	D02JYT
DRUGNAME	GSK2654911A
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1
	
TTDDRUID	D02JYY
DRUGNAME	Indium In-111 Oxyquinoline
INDICATI	Diagnostic radiopharmaceutical [ICD-11: N.A.] Approved
	
TTDDRUID	D02JZJ
DRUGNAME	ETS-6218
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2
	
TTDDRUID	D02KAF
DRUGNAME	GT-2203
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D02KAU
DRUGNAME	PF-03882845
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Terminated
	
TTDDRUID	D02KAW
DRUGNAME	CDP-7657
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D02KBD
DRUGNAME	Mebutamate
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D02KBE
DRUGNAME	Ad-OC-hsvTK/valacyclovir
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D02KBO
DRUGNAME	Ciprokiren
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D02KCV
DRUGNAME	Iothalamate
INDICATI	Arthropathy [ICD-11: FA11-FA38] Approved
	
TTDDRUID	D02KEL
DRUGNAME	AVO113
INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D02KEW
DRUGNAME	Levamisole + isoprinosine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D02KEY
DRUGNAME	SPP-676
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D02KFP
DRUGNAME	Invert sugar
INDICATI	Nutritional deficiency [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D02KIE
DRUGNAME	Cimetropium bromide
INDICATI	Spasm [ICD-11: MB47.3] Approved
INDICATI	Gastric motility disorder [ICD-11: DA21] Approved
	
TTDDRUID	D02KII
DRUGNAME	Vaqta
INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Approved
	
TTDDRUID	D02KIU
DRUGNAME	Etonogestrel
INDICATI	Contraception [ICD-11: QA21] Approved
	
TTDDRUID	D02KJX
DRUGNAME	Betain anhydrous
INDICATI	Inborn homocystinuria [ICD-11: 5C50] Approved
	
TTDDRUID	D02KKA
DRUGNAME	MK-1775
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02KKQ
DRUGNAME	BAM-1110
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2
	
TTDDRUID	D02KLD
DRUGNAME	BVT-74316
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D02KLE
DRUGNAME	P-536
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D02KLW
DRUGNAME	DIZOCILPINE
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D02KMG
DRUGNAME	Milveterol
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D02KMO
DRUGNAME	Pinacidil
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D02KOF
DRUGNAME	Lomefloxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D02KOY
DRUGNAME	RotaTeq
INDICATI	Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Approved
	
TTDDRUID	D02KPJ
DRUGNAME	UCART19
INDICATI	Burkitt cell leukaemia [ICD-11: 2A85.6] Phase 1
	
TTDDRUID	D02KQE
DRUGNAME	ON-09300
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D02KRI
DRUGNAME	Epristeride
INDICATI	Hirsutism [ICD-11: ED72] Phase 3
	
TTDDRUID	D02KRS
DRUGNAME	Amantadine
INDICATI	Influenza A virus infection [ICD-11: 1E30] Approved
	
TTDDRUID	D02KSP
DRUGNAME	Tislelizumab
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Approved
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
	
TTDDRUID	D02KTA
DRUGNAME	DER-45-EV
INDICATI	Rosacea [ICD-11: ED90.0] Phase 2
	
TTDDRUID	D02KTG
DRUGNAME	CGEN-25068
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D02KUO
DRUGNAME	Cenegermin
INDICATI	Neurotrophic keratitis [ICD-11: 9A74] Approved
	
TTDDRUID	D02KVT
DRUGNAME	TUSC2/FUS1 gene therapy
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D02KXE
DRUGNAME	Aom-0811
INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Investigative
	
TTDDRUID	D02KXW
DRUGNAME	HE3286
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D02KYP
DRUGNAME	AC-101
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D02KZI
DRUGNAME	L-786392
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D02LAP
DRUGNAME	Oxymera
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D02LBK
DRUGNAME	ARRY-797
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
INDICATI	Dilated cardiomyopathy [ICD-11: BC43.0] Phase 2
	
TTDDRUID	D02LCI
DRUGNAME	TA-5493
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D02LCL
DRUGNAME	T-5224
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D02LCR
DRUGNAME	Tiapride
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D02LCT
DRUGNAME	ARTELINIC ACID
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D02LDN
DRUGNAME	Magnesium Sulfate
INDICATI	Acute pain [ICD-11: MG31] Approved
	
TTDDRUID	D02LDV
DRUGNAME	Thiamine Hydrochloride
INDICATI	Wernicke-Korsakoff Syndrome [ICD-11: 5B5A.1] Approved
INDICATI	Thiamine deficiency [ICD-11: 5B5A] Approved
	
TTDDRUID	D02LHR
DRUGNAME	INDORAMIN
INDICATI	Hypertension [ICD-11: BA00-BA04] Withdrawn from market
	
TTDDRUID	D02LIY
DRUGNAME	Euro-Celtique 2
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D02LJR
DRUGNAME	Methenamine
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D02LJW
DRUGNAME	Tirbanibulin
INDICATI	Actinic keratosis [ICD-11: EK90.0] Approved
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D02LMR
DRUGNAME	Adva-27a
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02LNU
DRUGNAME	CART22-65s cells and huCART19 Cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D02LOB
DRUGNAME	JIN-2013
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D02LPF
DRUGNAME	Altretamine
INDICATI	Ovarian cancer [ICD-11: 2C73] Approved
	
TTDDRUID	D02LPY
DRUGNAME	A-623
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2/3
	
TTDDRUID	D02LQA
DRUGNAME	TTH 03-001
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D02LRQ
DRUGNAME	Cycrimine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D02LSR
DRUGNAME	SNK-882
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D02LTL
DRUGNAME	Dermatan sulfate
INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved
	
TTDDRUID	D02LUP
DRUGNAME	RN-1005
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Terminated
	
TTDDRUID	D02LVZ
DRUGNAME	Darbepoetin alfa
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved
	
TTDDRUID	D02LWU
DRUGNAME	Pralatrexate
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Approved
	
TTDDRUID	D02LYH
DRUGNAME	PMI-004
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Preclinical
	
TTDDRUID	D02LZB
DRUGNAME	Demecolcine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D02MBM
DRUGNAME	Mosquirix malaria recombinant vaccine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Preregistration
INDICATI	Malaria [ICD-11: 1F40-1F45] Preregistration
	
TTDDRUID	D02MBN
DRUGNAME	SD-6010
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 3
	
TTDDRUID	D02MBO
DRUGNAME	EPICOAT cancer vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D02MFC
DRUGNAME	62Cu-ATSM
INDICATI	Hypoxia [ICD-11: MD11.1] Phase 1
	
TTDDRUID	D02MFK
DRUGNAME	Affinitak + Cisplatin
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative
	
TTDDRUID	D02MGH
DRUGNAME	Pneumococcal vaccine
INDICATI	Streptococcus infection [ICD-11: 1B53] Approved
	
TTDDRUID	D02MHD
DRUGNAME	NPC-16570
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D02MHE
DRUGNAME	CVS-1123
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 1
	
TTDDRUID	D02MLA
DRUGNAME	AXP-107-08
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D02MLN
DRUGNAME	ChAdOx1 nCoV-19 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D02MLO
DRUGNAME	WT1-targeted autologous dendritic cell vaccine
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D02MLW
DRUGNAME	Ibutilide
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Approved
	
TTDDRUID	D02MMF
DRUGNAME	FP-1097
INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 2
	
TTDDRUID	D02MMG
DRUGNAME	Pyrimidine derivative 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D02MMP
DRUGNAME	VX-500
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D02MNY
DRUGNAME	ON-01135
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D02MPT
DRUGNAME	MAGE-A3 immunotherapeutic
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D02MQL
DRUGNAME	RWJ-61907
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D02MRN
DRUGNAME	Golotimod
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2
	
TTDDRUID	D02MRX
DRUGNAME	ONO-4059
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D02MSG
DRUGNAME	AcVx-25
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D02MTK
DRUGNAME	AT-008
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D02MUA
DRUGNAME	PF-06439535
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02MVA
DRUGNAME	NI-0701
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D02MVG
DRUGNAME	AMG-548
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D02MXT
DRUGNAME	MK-2894
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D02MYI
DRUGNAME	CAR-T Cells targeting PSCA
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D02MZD
DRUGNAME	AMG 876
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D02MZY
DRUGNAME	Cefpiramide
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D02NBY
DRUGNAME	LACTIN-V
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 2/3
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D02NDC
DRUGNAME	GSK-2202083A
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D02NDP
DRUGNAME	PMID26651364-Compound-7a
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D02NDV
DRUGNAME	Levovist
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D02NEH
DRUGNAME	Ibutamoren
INDICATI	Fibromyalgia [ICD-11: MG30.01] Approved
	
TTDDRUID	D02NEZ
DRUGNAME	IMX-942
INDICATI	Mucositis [ICD-11: CA00] Preclinical
	
TTDDRUID	D02NFA
DRUGNAME	A-68828
INDICATI	Kidney disease [ICD-11: GC2Z] Terminated
	
TTDDRUID	D02NFE
DRUGNAME	Anti-CD19 CART Cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D02NGR
DRUGNAME	MK-499
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2
	
TTDDRUID	D02NHD
DRUGNAME	Ragaglitazar
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D02NHW
DRUGNAME	GSK-264220A
INDICATI	Coagulation defect [ICD-11: 3B10.0] Clinical trial
	
TTDDRUID	D02NHY
DRUGNAME	PLADD
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D02NIP
DRUGNAME	ITASETRON
INDICATI	Nausea [ICD-11: MD90] Phase 1
	
TTDDRUID	D02NJA
DRUGNAME	Fomepizole
INDICATI	Athylene glycol or methanol poisoning [ICD-11: NE61] Approved
	
TTDDRUID	D02NJE
DRUGNAME	PEK fusion protein vaccine
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1
	
TTDDRUID	D02NJK
DRUGNAME	MDR-03030
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D02NMG
DRUGNAME	SLV-332
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Preclinical
	
TTDDRUID	D02NMJ
DRUGNAME	Meningococcal B vaccine
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved
	
TTDDRUID	D02NMO
DRUGNAME	FR-79620
INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical
INDICATI	Obesity [ICD-11: 5B81] Preclinical
INDICATI	Eating disorder [ICD-11: 6B82] Preclinical
	
TTDDRUID	D02NMR
DRUGNAME	SFX-01
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Subarachnoid hemorrhage [ICD-11: 8B01] Phase 2
	
TTDDRUID	D02NNN
DRUGNAME	CBP-501
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02NNV
DRUGNAME	VX-745
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D02NNZ
DRUGNAME	1,2,4-triazole derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D02NOC
DRUGNAME	Cotara
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D02NSF
DRUGNAME	Oxymorphone
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D02NSS
DRUGNAME	CART-22 cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D02NTO
DRUGNAME	Tolnaftate
INDICATI	Dermatophytosis [ICD-11: 1F28.2] Approved
INDICATI	Jock itch [ICD-11: 1F28.3] Approved
	
TTDDRUID	D02NTS
DRUGNAME	JNJ-39393406
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2
INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 2
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
	
TTDDRUID	D02NUS
DRUGNAME	MB-314
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02NUT
DRUGNAME	KU-60019
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial
	
TTDDRUID	D02NVF
DRUGNAME	M-241247
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D02NXM
DRUGNAME	GSK2110183
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D02NXQ
DRUGNAME	NXL-105
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D02NXR
DRUGNAME	S-117957
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D02NYA
DRUGNAME	Anti-Ebola mAb
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1/2
	
TTDDRUID	D02NYK
DRUGNAME	Pifithrin-alpha
INDICATI	Toxicity [ICD-11: N.A.] Terminated
	
TTDDRUID	D02NZF
DRUGNAME	NZ-17000
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D02NZO
DRUGNAME	Amlodipine/ irbesartan fixed-dose combination
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3
	
TTDDRUID	D02OAH
DRUGNAME	PMID25666693-Compound-5
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D02OAV
DRUGNAME	Chloral hydrate
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
	
TTDDRUID	D02OBU
DRUGNAME	Valpentin
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D02OBW
DRUGNAME	Aminoazetidine derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D02OCD
DRUGNAME	NIBR-785
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D02OCF
DRUGNAME	AZD-8294
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated
	
TTDDRUID	D02OEP
DRUGNAME	CWF-07pre03
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D02OGQ
DRUGNAME	APD
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D02OHR
DRUGNAME	SC-57666
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D02OIP
DRUGNAME	OP-05
INDICATI	Liver cancer [ICD-11: 2C12] Investigative
	
TTDDRUID	D02OJC
DRUGNAME	Xaliproden
INDICATI	Juvenile idiopathic arthritis [ICD-11: FA24] Phase 3
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
INDICATI	Lateral sclerosis [ICD-11: 8B61] Discontinued in Phase 3
INDICATI	Peripheral sensory neuropathies [ICD-11: LD27.3] Discontinued in Phase 3
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 3
	
TTDDRUID	D02OJN
DRUGNAME	Ru-41740
INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Approved
	
TTDDRUID	D02OLJ
DRUGNAME	N-acylpiperidine ether derivative 7
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D02ONA
DRUGNAME	AUTO3
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
	
TTDDRUID	D02ONK
DRUGNAME	Y-20024
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D02ONR
DRUGNAME	RG7686
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
	
TTDDRUID	D02ONT
DRUGNAME	5-FP
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02OOB
DRUGNAME	PRX-12205
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D02ORJ
DRUGNAME	H1N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D02ORS
DRUGNAME	YKP-GI
INDICATI	Constipation [ICD-11: DD91.1] Phase 2
	
TTDDRUID	D02OTH
DRUGNAME	FR-115427
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D02OTK
DRUGNAME	CH-4051
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D02OYJ
DRUGNAME	rMERS-CoV-E vaccine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D02OZE
DRUGNAME	Digoxin
INDICATI	Heart failure [ICD-11: BD10-BD13] Approved
INDICATI	Arrhythmia [ICD-11: BC9Z] Approved
INDICATI	Congestive cardiac insufficiency [ICD-11: BD1Z] Approved
	
TTDDRUID	D02OZK
DRUGNAME	Obatoclax
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D02OZT
DRUGNAME	DCR-MYC
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
	
TTDDRUID	D02OZY
DRUGNAME	Metharbital
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D02PAH
DRUGNAME	Bendroflumethiazide
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D02PAJ
DRUGNAME	UR-9650
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D02PAW
DRUGNAME	TLC-388
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D02PCR
DRUGNAME	Spectinomycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D02PGP
DRUGNAME	PU3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02PHE
DRUGNAME	AZD9668
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
INDICATI	Bronchiectasis [ICD-11: CA24] Phase 2
	
TTDDRUID	D02PIH
DRUGNAME	HO-221
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1
	
TTDDRUID	D02PIN
DRUGNAME	GR-94839
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D02PIO
DRUGNAME	Benralizumab
INDICATI	Asthma [ICD-11: CA23] Approved
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D02PJA
DRUGNAME	Hydriodic acid iodine-125
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D02PKV
DRUGNAME	Human recombinant factor VIIa
INDICATI	Factor IX deficiency [ICD-11: 3B11] Investigative
	
TTDDRUID	D02PMO
DRUGNAME	Topotecan
INDICATI	Ovarian cancer [ICD-11: 2C73] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D02PMT
DRUGNAME	Nagrestipen
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Phase 1
	
TTDDRUID	D02PNH
DRUGNAME	COL-171
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Preclinical
	
TTDDRUID	D02PNP
DRUGNAME	AGN-214868
INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2
	
TTDDRUID	D02POH
DRUGNAME	TA-7906
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D02PPN
DRUGNAME	Methylphenidate
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 4
	
TTDDRUID	D02PQB
DRUGNAME	ATX-101
INDICATI	Obesity [ICD-11: 5B81] Phase 3
	
TTDDRUID	D02PSS
DRUGNAME	RG1577
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D02PSZ
DRUGNAME	A-74498
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D02PTD
DRUGNAME	IDC-7181
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical
	
TTDDRUID	D02PTI
DRUGNAME	AST-005
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D02PVS
DRUGNAME	KUR-213
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D02PWM
DRUGNAME	Dyphylline
INDICATI	Acute bronchial asthma [ICD-11: CA23] Approved
	
TTDDRUID	D02PXP
DRUGNAME	CIGB-370
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02PYB
DRUGNAME	SDZ-GPI-562
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D02PYM
DRUGNAME	QAK-423
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D02PYN
DRUGNAME	SR 16234
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D02QAO
DRUGNAME	IPP-203101
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D02QBJ
DRUGNAME	TIPLASININ
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D02QBT
DRUGNAME	AZETIRELIN
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D02QCD
DRUGNAME	DEXMETHYLPHENIDATE HYDROCHLORIDE
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
	
TTDDRUID	D02QCM
DRUGNAME	Calcitonin Human
INDICATI	Paget's disease [ICD-11: FB85] Approved
INDICATI	Postmenopausal osteoporosis [ICD-11: FB83.11] Phase 3
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D02QDQ
DRUGNAME	QAX-576
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D02QFW
DRUGNAME	NNZ-2566
INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 2
INDICATI	Rett syndrome [ICD-11: LD90.4] Phase 2
INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 2
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D02QGM
DRUGNAME	CGS-26529
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D02QHJ
DRUGNAME	Intratect
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D02QJE
DRUGNAME	PMID25666693-Compound-23
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D02QJH
DRUGNAME	Fluocinolone Acetonide
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D02QLH
DRUGNAME	PTL-43401
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02QLQ
DRUGNAME	SRD-174
INDICATI	Pruritus [ICD-11: EC90] Phase 2
	
TTDDRUID	D02QMQ
DRUGNAME	S-3578
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D02QND
DRUGNAME	GF-011802-00
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D02QOL
DRUGNAME	XMetD
INDICATI	Hypoglycemia [ICD-11: 5A41] Investigative
	
TTDDRUID	D02QPR
DRUGNAME	Manganese Chloride
INDICATI	Overactive bladder [ICD-11: GC50.0] Approved
	
TTDDRUID	D02QQB
DRUGNAME	A-216546
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D02QQE
DRUGNAME	NKTR 214
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D02QQT
DRUGNAME	Quattvaxem
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D02QQV
DRUGNAME	ACAM-1000
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 3
	
TTDDRUID	D02QUB
DRUGNAME	GM-CT-02
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Investigative
	
TTDDRUID	D02QWJ
DRUGNAME	EREMOMYCIN
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D02QWK
DRUGNAME	SHP647
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D02QXI
DRUGNAME	ST-04
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D02QYY
DRUGNAME	LY01005
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D02QZL
DRUGNAME	PNQX
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D02QZR
DRUGNAME	LY-545694
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D02RAI
DRUGNAME	ABX-PTH
INDICATI	Parathyroid disease [ICD-11: 5A50-5A5Z] Terminated
	
TTDDRUID	D02RAU
DRUGNAME	KRP-297
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Terminated
	
TTDDRUID	D02RBB
DRUGNAME	SUPERVAX
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D02RBQ
DRUGNAME	NG-2
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Investigative
	
TTDDRUID	D02RBR
DRUGNAME	Nitazoxanide + ivermectin + chloroquine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D02RCV
DRUGNAME	BVF-247
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D02RDC
DRUGNAME	NV.XOD.09
INDICATI	Brain cancer [ICD-11: 2A00] Investigative
	
TTDDRUID	D02RDE
DRUGNAME	JTV-605
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Terminated
	
TTDDRUID	D02RDX
DRUGNAME	XP-23829
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	D02RED
DRUGNAME	DCVax-Brain
INDICATI	Brain cancer [ICD-11: 2A00] Phase 3
	
TTDDRUID	D02REJ
DRUGNAME	JNJ-17216498
INDICATI	Narcolepsy [ICD-11: 7A20] Phase 2
	
TTDDRUID	D02REM
DRUGNAME	DPI-221
INDICATI	Urinary incontinence [ICD-11: MF50.2] Investigative
	
TTDDRUID	D02REO
DRUGNAME	TDI-0050
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D02RGZ
DRUGNAME	MKC-204
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D02RHC
DRUGNAME	ET190
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D02RHU
DRUGNAME	SF-111
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D02RHV
DRUGNAME	PROXODOLOL
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2
	
TTDDRUID	D02RIV
DRUGNAME	Hydroxystilbamidine Isethionate
INDICATI	Blastomycosis [ICD-11: 1F22] Approved
	
TTDDRUID	D02RJY
DRUGNAME	PHA-739358
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D02RKG
DRUGNAME	MORAb-004
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
	
TTDDRUID	D02RLS
DRUGNAME	R-1554
INDICATI	Overactive bladder [ICD-11: GC50.0] Terminated
	
TTDDRUID	D02RNJ
DRUGNAME	SK&F-104662
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D02RNR
DRUGNAME	LB-100
INDICATI	Astrocytoma [ICD-11: 2A00.0Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02RNS
DRUGNAME	Oglufanide
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
	
TTDDRUID	D02ROU
DRUGNAME	ASP-1707
INDICATI	Endometriosis [ICD-11: GA10] Phase 2
	
TTDDRUID	D02RPK
DRUGNAME	Z 360
INDICATI	Discovery agent [ICD-11: N.A.] Phase 2
	
TTDDRUID	D02RPO
DRUGNAME	BMS-986249
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02RPP
DRUGNAME	TPI ASM8
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D02RQT
DRUGNAME	Tenidap
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D02RQU
DRUGNAME	Pravastatin
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
	
TTDDRUID	D02RRX
DRUGNAME	SILTENZEPINE
INDICATI	Stomach disease [ICD-11: DA43-DA4Y] Phase 1
	
TTDDRUID	D02RSN
DRUGNAME	Levofloxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D02RSY
DRUGNAME	ADVM-022
INDICATI	Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 3
	
TTDDRUID	D02RUO
DRUGNAME	ONO-8815Ly
INDICATI	Miscarriage [ICD-11: JA00.0] Terminated
	
TTDDRUID	D02RUZ
DRUGNAME	A-922500
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative
	
TTDDRUID	D02RVC
DRUGNAME	PPI-383
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D02RVE
DRUGNAME	TA-7552
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2
	
TTDDRUID	D02RVN
DRUGNAME	Selurampanel
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
	
TTDDRUID	D02RXG
DRUGNAME	Nalfurafine hcl
INDICATI	Uremic pruritus [ICD-11: EC90.10] Approved
	
TTDDRUID	D02RXJ
DRUGNAME	Ribavirin + lopinavir + ritonavir + interferon beta-1b
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D02RYE
DRUGNAME	AMA-237
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D02RZC
DRUGNAME	ASC-JMX2
INDICATI	Prostate hyperplasia [ICD-11: GA90] Investigative
	
TTDDRUID	D02RZL
DRUGNAME	AZD4769
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D02SAC
DRUGNAME	Anti-CD123 CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D02SAK
DRUGNAME	2NTX-99
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D02SBQ
DRUGNAME	Urofollitropin
INDICATI	Female infertility [ICD-11: GA31.Z] Approved
	
TTDDRUID	D02SDC
DRUGNAME	Inactine
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 3
	
TTDDRUID	D02SDY
DRUGNAME	NaBen
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2/3
	
TTDDRUID	D02SES
DRUGNAME	Peptide analog 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D02SEU
DRUGNAME	PT-107
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D02SGL
DRUGNAME	PMID26815044-Compound-49
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D02SGT
DRUGNAME	OM-197-MP-AC
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02SHI
DRUGNAME	M8891
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02SJB
DRUGNAME	Imidazopyridazine derivative 8
INDICATI	Pain [ICD-11: MG30-MG3Z] Patented
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D02SJG
DRUGNAME	VT-362
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D02SJN
DRUGNAME	VBP
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D02SKA
DRUGNAME	FCE-22716
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D02SKQ
DRUGNAME	PMID29334795-Compound-28
INDICATI	Histamine H3-associated disorder [ICD-11: NE61] Patented
	
TTDDRUID	D02SLV
DRUGNAME	CB-1922
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D02SME
DRUGNAME	INO-4885
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D02SMV
DRUGNAME	Herpes simplex virus therapy
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Preclinical
	
TTDDRUID	D02SNE
DRUGNAME	NeuGene
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative
	
TTDDRUID	D02SNJ
DRUGNAME	SPD602
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2
	
TTDDRUID	D02SNQ
DRUGNAME	Pyrazole derivative 8
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D02SNY
DRUGNAME	WF-10
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2
	
TTDDRUID	D02SOL
DRUGNAME	GF-15
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02SPX
DRUGNAME	IDX899
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D02SRB
DRUGNAME	BPL-001
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D02SSR
DRUGNAME	Methylene blue + vitamin C + N-acetyl cysteine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D02SSV
DRUGNAME	ALN-RSV02
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D02STG
DRUGNAME	ONO-4232
INDICATI	Acute heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D02STN
DRUGNAME	ABIRATERONE
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D02SUB
DRUGNAME	SWT-06101
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 1
	
TTDDRUID	D02SUP
DRUGNAME	TT-114
INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D02SUR
DRUGNAME	L-697,661
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D02SVQ
DRUGNAME	HBI-3000
INDICATI	Heart arrhythmia [ICD-11: BC65] Phase 2
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 1
	
TTDDRUID	D02SWB
DRUGNAME	Grass pollen-derived peptides
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 1/2
	
TTDDRUID	D02SXZ
DRUGNAME	S-707106
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D02SYQ
DRUGNAME	Sm-14
INDICATI	Schistosomiasis [ICD-11: 1F86] Phase 1
	
TTDDRUID	D02SYV
DRUGNAME	Lenzilumab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1
	
TTDDRUID	D02SZF
DRUGNAME	18F-SMIBR-K5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02TAB
DRUGNAME	CJ-50300
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 3
	
TTDDRUID	D02TBI
DRUGNAME	Carbenicillin
INDICATI	Infection of the upper and lower urinary tract [ICD-11: GC08] Approved
	
TTDDRUID	D02TBU
DRUGNAME	CIGB-552
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02TDV
DRUGNAME	ZK-001
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1/2
	
TTDDRUID	D02TGD
DRUGNAME	Netoglitazone
INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 2
	
TTDDRUID	D02TGF
DRUGNAME	Apolipoprotein E-derived peptides
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D02TGN
DRUGNAME	XMT-1536
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02TGW
DRUGNAME	GE-20372A
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D02THB
DRUGNAME	SKF-96067
INDICATI	Peptic ulcer [ICD-11: DA61] Discontinued in Phase 3
	
TTDDRUID	D02TIK
DRUGNAME	HP-184
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D02TIY
DRUGNAME	Monoamine derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D02TJS
DRUGNAME	Dicumarol
INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
	
TTDDRUID	D02TJT
DRUGNAME	MK-8109
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
	
TTDDRUID	D02TKX
DRUGNAME	Sac-0601
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative
	
TTDDRUID	D02TLD
DRUGNAME	AMT-050
INDICATI	Cholesterol metabolism disorder [ICD-11: 5C8Z] Terminated
	
TTDDRUID	D02TLO
DRUGNAME	Ifosfamide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D02TMO
DRUGNAME	177Lu-AMBA
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D02TNS
DRUGNAME	TMC-353121
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Preclinical
	
TTDDRUID	D02TNW
DRUGNAME	VR179
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D02TOI
DRUGNAME	Tricyclic phytocannabinoid derivative 2
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
	
TTDDRUID	D02TOK
DRUGNAME	IL-2 mimetic peptides
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02TOS
DRUGNAME	AMSH
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D02TQE
DRUGNAME	TA-102
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D02TQO
DRUGNAME	Vitamin E
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D02TSJ
DRUGNAME	Promethazine + sumatriptan
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D02TTF
DRUGNAME	YM-90K
INDICATI	Convulsion [ICD-11: 8A68.Z] Discontinued in Phase 2
	
TTDDRUID	D02TTL
DRUGNAME	Debio 0932
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02TTP
DRUGNAME	TDI-0015
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D02TUL
DRUGNAME	PF-06651600
INDICATI	Alopecia [ICD-11: ED70] Phase 2/3
INDICATI	Asthma [ICD-11: CA23] Phase 2
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
	
TTDDRUID	D02TVU
DRUGNAME	HTERT vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02TWR
DRUGNAME	BIIB080
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 1/2
	
TTDDRUID	D02TXV
DRUGNAME	TRN-157
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D02TYL
DRUGNAME	HER-801
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2
	
TTDDRUID	D02TYV
DRUGNAME	DPS-102
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D02TZB
DRUGNAME	T2 18C3
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D02UAR
DRUGNAME	DiffGAM
INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 2
	
TTDDRUID	D02UBC
DRUGNAME	MEDI6383
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02UCW
DRUGNAME	PA-2794
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D02UDO
DRUGNAME	PMID26651364-Compound-9d
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D02UFG
DRUGNAME	Metaproterenol Sulfate
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D02UFQ
DRUGNAME	TAK-285
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02UGL
DRUGNAME	TR-Flu
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D02UIC
DRUGNAME	SSR-128428
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D02UIE
DRUGNAME	ZK-91296
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D02UJD
DRUGNAME	PD-143188
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2
	
TTDDRUID	D02UJG
DRUGNAME	ISIS-387898
INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative
	
TTDDRUID	D02UJQ
DRUGNAME	TM-400
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Investigative
	
TTDDRUID	D02UJS
DRUGNAME	PMID30107136-Compound-Example49
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D02UKX
DRUGNAME	CAP1-6D
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D02ULG
DRUGNAME	CP-4033
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02ULU
DRUGNAME	Semaglutide
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D02UMF
DRUGNAME	KT6-971
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2
	
TTDDRUID	D02UNP
DRUGNAME	IMA-901
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
	
TTDDRUID	D02UOE
DRUGNAME	Miltirone
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D02UOZ
DRUGNAME	NB-001
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
	
TTDDRUID	D02UPI
DRUGNAME	AGS-6MF
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02UQG
DRUGNAME	RDEA-436
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D02UQU
DRUGNAME	ABS-301
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D02URD
DRUGNAME	SAR425899
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D02URM
DRUGNAME	Rezafungin
INDICATI	Candidiasis [ICD-11: 1F23] Phase 3
	
TTDDRUID	D02URS
DRUGNAME	Potassium iodide
INDICATI	Thyrotoxicosis [ICD-11: 5A02] Approved
	
TTDDRUID	D02URX
DRUGNAME	KamRAB
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2/3
	
TTDDRUID	D02USE
DRUGNAME	Heterocyclic derivative 15
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D02USG
DRUGNAME	P-2745
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1
	
TTDDRUID	D02UVT
DRUGNAME	Dolutegravir + abacavir sulphate + lamivudine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D02UWX
DRUGNAME	OT-440
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D02UXK
DRUGNAME	MBX-3254
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D02UYB
DRUGNAME	Patisiran
INDICATI	Hereditary amyloidosis [ICD-11: 5D00.2] Approved
INDICATI	Amyloidosis [ICD-11: 5D00] Approved
INDICATI	Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3
INDICATI	Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3
	
TTDDRUID	D02UYM
DRUGNAME	SB414
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D02VBF
DRUGNAME	BI-D1870
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Preclinical
	
TTDDRUID	D02VBL
DRUGNAME	EMZ701
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D02VCJ
DRUGNAME	Metrizamide
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Approved
	
TTDDRUID	D02VCK
DRUGNAME	FLUPAROXAN
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 3
	
TTDDRUID	D02VER
DRUGNAME	Radavirsen
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D02VFB
DRUGNAME	Miproxifene
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D02VFC
DRUGNAME	Cefoxitin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D02VFK
DRUGNAME	PPRT-152
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated
	
TTDDRUID	D02VHE
DRUGNAME	A-72055
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D02VIF
DRUGNAME	OLT1177 gel
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D02VIP
DRUGNAME	SB-267268
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1
	
TTDDRUID	D02VIT
DRUGNAME	Arbidol
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D02VJP
DRUGNAME	Cobicistat
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D02VJY
DRUGNAME	Biricodar
INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2
	
TTDDRUID	D02VKC
DRUGNAME	NBQX
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 1
	
TTDDRUID	D02VLT
DRUGNAME	CholeraGarde cholera vaccine live attenuated
INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Phase 2
	
TTDDRUID	D02VLX
DRUGNAME	Beractant
INDICATI	Neonatal respiratory distress [ICD-11: CB04.2] Approved
	
TTDDRUID	D02VMC
DRUGNAME	RP-1000
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D02VMJ
DRUGNAME	TRICLABENDAZOLE
INDICATI	Helminth infection [ICD-11: 1F90.0] Approved
	
TTDDRUID	D02VNY
DRUGNAME	Pleodrug
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Investigative
	
TTDDRUID	D02VOJ
DRUGNAME	RWJ-51204
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical
	
TTDDRUID	D02VPS
DRUGNAME	Anti-FGFR2 humanized mab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02VPX
DRUGNAME	Calcidiol
INDICATI	Vitamin D deficiency [ICD-11: 5B57] Approved
	
TTDDRUID	D02VQU
DRUGNAME	STF-31
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02VRN
DRUGNAME	KT-1
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D02VSP
DRUGNAME	MK-7655
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D02VTB
DRUGNAME	BAY1193397
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D02VUL
DRUGNAME	AIKO-151
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Investigative
	
TTDDRUID	D02VUX
DRUGNAME	PF-217830
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2
INDICATI	Bipolar disorder [ICD-11: 6A60] Discontinued in Phase 2
	
TTDDRUID	D02VYE
DRUGNAME	Opdivo + Yervoy
INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 3
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 3
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D02VZP
DRUGNAME	Flesinoxan
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3
	
TTDDRUID	D02WAB
DRUGNAME	Diloxanide
INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved
	
TTDDRUID	D02WCI
DRUGNAME	Pirfenidone
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved
	
TTDDRUID	D02WDO
DRUGNAME	MGN-1333
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D02WEL
DRUGNAME	VG-106
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D02WEU
DRUGNAME	ApoCell
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	D02WFK
DRUGNAME	Cycloserine
INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
INDICATI	Obsessive compulsive disorder [ICD-11: 6B20] Phase 2
	
TTDDRUID	D02WFN
DRUGNAME	MK-7622
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D02WGD
DRUGNAME	LOR-220
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D02WGN
DRUGNAME	YM-114
INDICATI	Nausea [ICD-11: MD90] Discontinued in Phase 2
	
TTDDRUID	D02WGY
DRUGNAME	Eprotirome
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3
	
TTDDRUID	D02WHY
DRUGNAME	Rubidium chloride Rb82
INDICATI	Coronary artery disease [ICD-11: BA80] Approved
	
TTDDRUID	D02WII
DRUGNAME	TR-14035
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1
	
TTDDRUID	D02WIW
DRUGNAME	Dexbrompheniramine
INDICATI	Hay fever [ICD-11: CA08.00] Approved
	
TTDDRUID	D02WJB
DRUGNAME	PMID26815044-Compound-124
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D02WLS
DRUGNAME	Onyvax-105
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1
	
TTDDRUID	D02WMX
DRUGNAME	CR-6261
INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2
	
TTDDRUID	D02WQR
DRUGNAME	GSK-008A
INDICATI	Gynecological disease [ICD-11: GA6Z] Investigative
	
TTDDRUID	D02WQZ
DRUGNAME	Aprosulate sodium
INDICATI	Coagulation defect [ICD-11: 3B10.0] Discontinued in Phase 1
	
TTDDRUID	D02WRE
DRUGNAME	ATS-907
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D02WRV
DRUGNAME	OrthoDerm
INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Phase 2
	
TTDDRUID	D02WSB
DRUGNAME	CRS-207
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	D02WST
DRUGNAME	Unfractionated heparin
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3
	
TTDDRUID	D02WSY
DRUGNAME	CVX-060
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D02WUC
DRUGNAME	Fenquizone
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D02WUW
DRUGNAME	PLD-177
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Terminated
	
TTDDRUID	D02WVT
DRUGNAME	E-3810
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D02WWT
DRUGNAME	Aryl mannoside derivative 19
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D02XAC
DRUGNAME	MG-1102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02XAS
DRUGNAME	SGM-1019
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1
	
TTDDRUID	D02XBN
DRUGNAME	ZPL521
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1/2
	
TTDDRUID	D02XBW
DRUGNAME	Urea
INDICATI	Dermatological disease [ICD-11: DA24.Y] Approved
	
TTDDRUID	D02XBY
DRUGNAME	AGS-005
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Discontinued in Phase 1/2
	
TTDDRUID	D02XEI
DRUGNAME	DCVax-Ovarian
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
INDICATI	Brain cancer [ICD-11: 2A00] Phase 3
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D02XGC
DRUGNAME	PF-3864086
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D02XGF
DRUGNAME	H5N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Registered
	
TTDDRUID	D02XHD
DRUGNAME	KI-0805
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 3
	
TTDDRUID	D02XHV
DRUGNAME	FluBlok
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D02XIY
DRUGNAME	Octreotide
INDICATI	Acromegaly [ICD-11: 5A60.0] Approved
	
TTDDRUID	D02XJI
DRUGNAME	Emedastine
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved
	
TTDDRUID	D02XJJ
DRUGNAME	LM11A-31
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D02XJY
DRUGNAME	Midodrine
INDICATI	Orthostatic hypotension [ICD-11: BA21] Approved
	
TTDDRUID	D02XKK
DRUGNAME	FRM-0962
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D02XLI
DRUGNAME	LY-2979165
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1
	
TTDDRUID	D02XMD
DRUGNAME	BGS-649
INDICATI	Endometriosis [ICD-11: GA10] Phase 2
	
TTDDRUID	D02XMM
DRUGNAME	Midaglizole
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D02XNH
DRUGNAME	C-linked disaccharide biphenyl mannoside derivative 6
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D02XNJ
DRUGNAME	CogniXan
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D02XNT
DRUGNAME	BMS-A
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D02XNW
DRUGNAME	VX-680
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D02XOK
DRUGNAME	Levomilnacipran
INDICATI	Fibromyalgia [ICD-11: MG30.01] Approved
	
TTDDRUID	D02XOM
DRUGNAME	HX-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02XPI
DRUGNAME	Hydroxychloroquine + ivermectin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D02XSA
DRUGNAME	Stiripentol
INDICATI	Dravet syndrome [ICD-11: 8A61.11] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D02XSL
DRUGNAME	GlyT1 PET radiotracers
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D02XTN
DRUGNAME	RO5545965
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D02XTT
DRUGNAME	LV305
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D02XUC
DRUGNAME	VF001
INDICATI	Venous leg ulcer [ICD-11: BD74.3] Phase 2
	
TTDDRUID	D02XUE
DRUGNAME	TDI-0106
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D02XUN
DRUGNAME	Trivalent seasonal influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D02XUY
DRUGNAME	AZ-1297442
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D02XVC
DRUGNAME	Phenylate derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D02XXF
DRUGNAME	BMN044
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D02XXN
DRUGNAME	Evacetrapib
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
	
TTDDRUID	D02XXQ
DRUGNAME	MEDl-557
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1
	
TTDDRUID	D02XXT
DRUGNAME	Diphencyprone
INDICATI	Alopecia [ICD-11: ED70] Phase 2
	
TTDDRUID	D02XXW
DRUGNAME	Allogeneic/autologous adult mesenchymal stem cell therapy
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 1/2
	
TTDDRUID	D02XYA
DRUGNAME	Astuprotimut-R
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D02XYB
DRUGNAME	SARIPIDEM
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D02XYT
DRUGNAME	Furopyridine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D02XYW
DRUGNAME	CD19-directed CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D02YAD
DRUGNAME	Vivia-008
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02YAQ
DRUGNAME	GW-974
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D02YBD
DRUGNAME	CAL-401
INDICATI	Candidiasis [ICD-11: 1F23] Investigative
	
TTDDRUID	D02YBP
DRUGNAME	Mequitamium iodide
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D02YCH
DRUGNAME	Icodextrin
INDICATI	Kidney disease [ICD-11: GC2Z] Approved
	
TTDDRUID	D02YCL
DRUGNAME	SB-36131
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D02YEG
DRUGNAME	VBY-376
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D02YEO
DRUGNAME	NBTXR3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D02YEY
DRUGNAME	FPL-62064
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 3
	
TTDDRUID	D02YIP
DRUGNAME	AbGn-168
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D02YIW
DRUGNAME	5-(N,N-hexamethylene)-amiloride
INDICATI	Coronavirus infection [ICD-11: 1D92] Preclinical
	
TTDDRUID	D02YIZ
DRUGNAME	Erythromycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D02YKI
DRUGNAME	PF-04995274
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D02YNH
DRUGNAME	CP-809101
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D02YNI
DRUGNAME	OTX-015
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D02YOQ
DRUGNAME	NUCB-1000
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 1
	
TTDDRUID	D02YPG
DRUGNAME	Etomidate
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D02YPU
DRUGNAME	Pyridoxamine
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 3
INDICATI	Diabetic kidney disease [ICD-11: GB61.Z] Phase 3
	
TTDDRUID	D02YQB
DRUGNAME	MenQuadfi
INDICATI	Meningococcal infection [ICD-11: 1C1C] Approved
	
TTDDRUID	D02YQJ
DRUGNAME	B-5354a
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D02YRD
DRUGNAME	4SCAR19 and 4SCAR70
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D02YRX
DRUGNAME	C-0333158
INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative
	
TTDDRUID	D02YSO
DRUGNAME	GX-C4
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D02YVM
DRUGNAME	Zicronapine
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D02YWD
DRUGNAME	B27PD
INDICATI	Uveitis [ICD-11: 9A96.Z] Phase 1/2
	
TTDDRUID	D02YWE
DRUGNAME	EBP-1597
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D02YWM
DRUGNAME	BIO-500
INDICATI	Radiation syndrome [ICD-11: NF00] Investigative
	
TTDDRUID	D02YWV
DRUGNAME	GR-159897
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D02YWW
DRUGNAME	IDM-1
INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 3
	
TTDDRUID	D02YXQ
DRUGNAME	GT-2016
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D02YYF
DRUGNAME	Bretylium
INDICATI	Ventricular fibrillation [ICD-11: BC71.1] Approved
	
TTDDRUID	D02YYS
DRUGNAME	BDNA-001
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D02YZK
DRUGNAME	RO-5303253
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D02ZAN
DRUGNAME	SparVax recombinant protective antigen anthrax vaccine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2
INDICATI	Anthrax [ICD-11: 1B97] Phase 2
	
TTDDRUID	D02ZAT
DRUGNAME	VGV-S
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D02ZBW
DRUGNAME	LC-150444
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D02ZCE
DRUGNAME	AD-337
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 1
INDICATI	Myalgia [ICD-11: FB56.2] Phase 1
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 1
	
TTDDRUID	D02ZCM
DRUGNAME	Ad26.ENVA.01 HIV-1 recombinant vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D02ZEM
DRUGNAME	OBERADILOL MONOETHYL MALEATE
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D02ZGI
DRUGNAME	Secalciferol
INDICATI	Disorder of calcium metabolism [ICD-11: 5C64.5] Approved
	
TTDDRUID	D02ZHW
DRUGNAME	177Lu-DOTA-octreotate
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3
	
TTDDRUID	D02ZJI
DRUGNAME	Levalbuterol
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D02ZKB
DRUGNAME	WAY-126227
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D02ZKL
DRUGNAME	Reglixane
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D02ZKR
DRUGNAME	BCX-3408
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Gout [ICD-11: FA25] Phase 2
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D02ZLM
DRUGNAME	F-991
INDICATI	Allergic skin disorder [ICD-11: 4A82] Discontinued in Phase 2
	
TTDDRUID	D02ZMB
DRUGNAME	Urelumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D02ZMI
DRUGNAME	AA-29504
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D02ZNH
DRUGNAME	TT-310
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D02ZPM
DRUGNAME	Anpirtoline
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D02ZPN
DRUGNAME	NN-414
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D02ZQN
DRUGNAME	PMID28270021-Compound-WO2013009582Example16
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D02ZQS
DRUGNAME	GSK269962A
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Clinical trial
	
TTDDRUID	D02ZSU
DRUGNAME	NS-49
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2
	
TTDDRUID	D02ZTJ
DRUGNAME	Sulfasalazine
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
	
TTDDRUID	D02ZUG
DRUGNAME	Atogepant
INDICATI	Migraine [ICD-11: 8A80] Phase 2/3
	
TTDDRUID	D02ZUO
DRUGNAME	Forodesine
INDICATI	B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 1/2
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1/2
	
TTDDRUID	D02ZUT
DRUGNAME	TRP6-01
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D02ZVY
DRUGNAME	Diphenyl purine derivative 4
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D02ZWG
DRUGNAME	SR-80027A
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D02ZWJ
DRUGNAME	EP-94
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative
	
TTDDRUID	D02ZWO
DRUGNAME	DEF-201
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative
	
TTDDRUID	D02ZWR
DRUGNAME	IMO-2134
INDICATI	Allergy [ICD-11: 4A80-4A85] Preclinical
INDICATI	Asthma [ICD-11: CA23] Preclinical
	
TTDDRUID	D02ZXK
DRUGNAME	TJ003234
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D02ZXM
DRUGNAME	Thioguanine
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
	
TTDDRUID	D02ZYI
DRUGNAME	IPP-201007
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D02ZYV
DRUGNAME	Biaryl mannoside derivative 15
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D02ZZC
DRUGNAME	NN-8630
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2
	
TTDDRUID	D02ZZG
DRUGNAME	LEO 43204
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2
	
TTDDRUID	D02ZZU
DRUGNAME	DM-CHOC-PEN
INDICATI	Brain cancer [ICD-11: 2A00] Phase 2
INDICATI	Brain metastases [ICD-11: 2D50] Phase 2
	
TTDDRUID	D03AAV
DRUGNAME	ProLindaun
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03ABH
DRUGNAME	Deriglidole
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D03ACE
DRUGNAME	ASP5094
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D03ACT
DRUGNAME	PRS-211375 iv
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D03AEG
DRUGNAME	CBI-008
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03AFF
DRUGNAME	JNJ-64007957
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D03AFX
DRUGNAME	CM-2397
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D03AGK
DRUGNAME	PF-05251749
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D03AJF
DRUGNAME	SPN-810
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
	
TTDDRUID	D03AJU
DRUGNAME	Osilodrostat
INDICATI	Cushing disease [ICD-11: 5A70] Approved
	
TTDDRUID	D03AKH
DRUGNAME	CER-001
INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 2
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D03AKL
DRUGNAME	ATLIPROFEN METHYL ESTER
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D03ALS
DRUGNAME	VA-DIFTET
INDICATI	Clostridium infection [ICD-11: 1A04] Approved
	
TTDDRUID	D03AND
DRUGNAME	RAF265
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D03AOP
DRUGNAME	DS-8500
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D03APL
DRUGNAME	AS-1403
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1
	
TTDDRUID	D03APM
DRUGNAME	ABT-110
INDICATI	Chronic pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D03AQZ
DRUGNAME	GMB-Vax
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D03ATI
DRUGNAME	ITV-2
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D03AUN
DRUGNAME	RG1512
INDICATI	Acute coronary syndrome [ICD-11: BA41] Discontinued in Phase 2
	
TTDDRUID	D03AVA
DRUGNAME	SNG-8033
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D03AVS
DRUGNAME	SR13668
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03AXQ
DRUGNAME	Soluble FePPi
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2
	
TTDDRUID	D03AYQ
DRUGNAME	EB-1020
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	D03AZB
DRUGNAME	Neo-1528
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D03AZK
DRUGNAME	Sodium zirconium cyclosilicate
INDICATI	Hyperkalemia [ICD-11: 5C76] Approved
	
TTDDRUID	D03AZR
DRUGNAME	Berubicin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D03AZU
DRUGNAME	Org-31710
INDICATI	Contraception [ICD-11: QA21] Discontinued in Phase 1
	
TTDDRUID	D03AZY
DRUGNAME	PNU-177864
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D03BAC
DRUGNAME	Revacept
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2
	
TTDDRUID	D03BAY
DRUGNAME	N-acylpiperidine ether derivative 5
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D03BBU
DRUGNAME	Lucatumumab
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
	
TTDDRUID	D03BCE
DRUGNAME	FPT-038
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D03BCV
DRUGNAME	Macrocycle derivative 6
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D03BDE
DRUGNAME	QRX-401
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Discontinued in Phase 1
	
TTDDRUID	D03BDP
DRUGNAME	Triferic
INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved
	
TTDDRUID	D03BFS
DRUGNAME	SPN-809
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D03BFU
DRUGNAME	Pradaxa
INDICATI	Stroke [ICD-11: 8B20] Phase 3
	
TTDDRUID	D03BGG
DRUGNAME	ST-1141
INDICATI	Functional bowel disorder [ICD-11: DD91] Phase 1
	
TTDDRUID	D03BHM
DRUGNAME	R1507
INDICATI	Graves ophthalmopathy [ICD-11: 9C82.3] Phase 2
	
TTDDRUID	D03BHO
DRUGNAME	JTP-2942
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D03BHZ
DRUGNAME	AZD8186
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03BIH
DRUGNAME	DFN-15
INDICATI	Migraine [ICD-11: 8A80] Phase 3
	
TTDDRUID	D03BJX
DRUGNAME	Botulinum toxin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03BKN
DRUGNAME	MS201408-0005B
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03BKV
DRUGNAME	KML-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03BLF
DRUGNAME	Triamcinolone
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D03BLG
DRUGNAME	AGS-009
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D03BMR
DRUGNAME	PRX-1
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D03BND
DRUGNAME	GFC-001
INDICATI	Leishmania infection [ICD-11: 1F54.0] Investigative
	
TTDDRUID	D03BNF
DRUGNAME	IMGN632
INDICATI	Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Phase 1/2
	
TTDDRUID	D03BNU
DRUGNAME	XL-388
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D03BOZ
DRUGNAME	RS-130830
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2
	
TTDDRUID	D03BPU
DRUGNAME	Hematological disease agents
INDICATI	Hematologic disease [ICD-11: 3C0Z] Investigative
	
TTDDRUID	D03BQD
DRUGNAME	NMS-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03BQP
DRUGNAME	Rebamipide
INDICATI	Peptic ulcer [ICD-11: DA61] Phase 3
	
TTDDRUID	D03BRP
DRUGNAME	Aromatic hydrazine carboxyimidoamide derivative 5
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D03BSK
DRUGNAME	URC102
INDICATI	Gout [ICD-11: FA25] Phase 2
	
TTDDRUID	D03BTP
DRUGNAME	Fosfluridine tidoxil
INDICATI	Keratosis [ICD-11: ED56] Terminated
	
TTDDRUID	D03BVH
DRUGNAME	AWD-23-111
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D03BVW
DRUGNAME	V-419
INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 3
INDICATI	Poliovirus infection [ICD-11: 1C8Y] Application submitted
	
TTDDRUID	D03BWQ
DRUGNAME	ATN-658
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03BXU
DRUGNAME	LNK-754
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
	
TTDDRUID	D03BYM
DRUGNAME	BAY1895344
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03BZN
DRUGNAME	Sodium taurocholate
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1/2
	
TTDDRUID	D03BZS
DRUGNAME	MK-8655
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D03BZU
DRUGNAME	RG7802
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D03CAT
DRUGNAME	Cefteram pivoxil
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D03CBU
DRUGNAME	PHY-626
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03CCH
DRUGNAME	SK&F-95601
INDICATI	Peptic ulcer [ICD-11: DA61] Terminated
	
TTDDRUID	D03CCY
DRUGNAME	XEL 001HP
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D03CDK
DRUGNAME	ASP-7147
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
	
TTDDRUID	D03CEF
DRUGNAME	Desvenalfaxine succinate
INDICATI	Fibromyalgia [ICD-11: MG30.01] Approved
	
TTDDRUID	D03CFJ
DRUGNAME	NCX-701
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D03CFR
DRUGNAME	SEP-226332
INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Discontinued in Phase 1
	
TTDDRUID	D03CGQ
DRUGNAME	AG-013958
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 1/2
	
TTDDRUID	D03CGS
DRUGNAME	CHF-3098
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Withdrawn from market
	
TTDDRUID	D03CHE
DRUGNAME	PF-251802
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D03CHM
DRUGNAME	MSC1936369B
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D03CHT
DRUGNAME	Fudosteine
INDICATI	Expectorant [ICD-11: MD10] Approved
INDICATI	Bronchitis [ICD-11: CA20] Approved
	
TTDDRUID	D03CIN
DRUGNAME	PTX-007011
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D03CJL
DRUGNAME	Droperidol
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D03CKP
DRUGNAME	DasKloster 0182-01
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Investigative
	
TTDDRUID	D03CKX
DRUGNAME	Cromafiban
INDICATI	Coronary artery disease [ICD-11: BA80] Discontinued in Phase 2
	
TTDDRUID	D03CLP
DRUGNAME	Dendritic cell vaccine
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D03CMR
DRUGNAME	TER-16998
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D03CMZ
DRUGNAME	CAR-T cells targeting EGFRviii
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D03CNS
DRUGNAME	Cyclothiazide
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D03CNT
DRUGNAME	L-698532
INDICATI	Neurological disorder [ICD-11: 6B60] Terminated
	
TTDDRUID	D03CNV
DRUGNAME	VMD-30283
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2
	
TTDDRUID	D03CPM
DRUGNAME	SLV-334
INDICATI	Brain injury [ICD-11: NA07.Z] Phase 2
	
TTDDRUID	D03CQE
DRUGNAME	Gatifloxacin
INDICATI	Respiratory tract infection [ICD-11: CA45] Approved
	
TTDDRUID	D03CQN
DRUGNAME	Chk1-A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03CTH
DRUGNAME	Biphenyl mannoside derivative 10
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D03CUF
DRUGNAME	Furazolidone
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
	
TTDDRUID	D03CUS
DRUGNAME	CS-207
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D03CVT
DRUGNAME	ONC1-13B
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D03CVV
DRUGNAME	Anisperimus
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2
	
TTDDRUID	D03CWO
DRUGNAME	ENDG-3020
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D03CWX
DRUGNAME	MEM-1414
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 1
	
TTDDRUID	D03CYF
DRUGNAME	RVX-408
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D03CZE
DRUGNAME	VPZ-758
INDICATI	Raynaud disease [ICD-11: BD42.0] Investigative
	
TTDDRUID	D03CZX
DRUGNAME	PMA-201
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D03DAP
DRUGNAME	Flecainide
INDICATI	Tachyarrhythmias [ICD-11: BC71] Approved
INDICATI	Paroxysmal atrial fibrillation [ICD-11: BC81.30] Phase 1
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D03DAY
DRUGNAME	ITV-1
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D03DBW
DRUGNAME	Pretubulysin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03DDR
DRUGNAME	Quinine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D03DEI
DRUGNAME	Sulfinpyrazone
INDICATI	Gout [ICD-11: FA25] Approved
	
TTDDRUID	D03DFY
DRUGNAME	NP-7557
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D03DHM
DRUGNAME	CCX507
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1
	
TTDDRUID	D03DHQ
DRUGNAME	CX-516
INDICATI	Pervasive developmental disorder [ICD-11: 6A00-6A0Z] Phase 2/3
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2/3
	
TTDDRUID	D03DIG
DRUGNAME	Codeine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
INDICATI	Cough [ICD-11: MD12] Phase 1
	
TTDDRUID	D03DII
DRUGNAME	Pollen allergen immunotherapy
INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Investigative
	
TTDDRUID	D03DJL
DRUGNAME	Indacaterol
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
INDICATI	Asthma [ICD-11: CA23] Phase 4
	
TTDDRUID	D03DJT
DRUGNAME	Bococizumab
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D03DKR
DRUGNAME	GALAMUSTINE HYDROCHLORIDE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03DKV
DRUGNAME	RGB-286638
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D03DMB
DRUGNAME	GSK2894512
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D03DNI
DRUGNAME	Hepatitis C virus E2 protein vaccines
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated
	
TTDDRUID	D03DOC
DRUGNAME	DCC-2909
INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative
	
TTDDRUID	D03DOW
DRUGNAME	SWT-05141
INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative
	
TTDDRUID	D03DPZ
DRUGNAME	INK128
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D03DQK
DRUGNAME	PEG-Hb/HS
INDICATI	Shock [ICD-11: MG40] Investigative
	
TTDDRUID	D03DRR
DRUGNAME	Noberastine
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D03DRW
DRUGNAME	UTIBAPRIL
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D03DSB
DRUGNAME	Trospectomycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Preregistration
	
TTDDRUID	D03DSR
DRUGNAME	Ambroxol
INDICATI	Bronchitis [ICD-11: CA20] Approved
	
TTDDRUID	D03DSX
DRUGNAME	SSR411298
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D03DTQ
DRUGNAME	PMX-700
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative
	
TTDDRUID	D03DTU
DRUGNAME	BCL-5
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D03DTW
DRUGNAME	EHT-107
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03DUH
DRUGNAME	ACAM-FLU-A
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D03DUI
DRUGNAME	GBR 830
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D03DUY
DRUGNAME	BMS-833923
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1b
	
TTDDRUID	D03DVD
DRUGNAME	Norovirus virus-like particle vaccine
INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1/2
	
TTDDRUID	D03DVJ
DRUGNAME	Propylhexedrine
INDICATI	Obesity [ICD-11: 5B81] Approved
	
TTDDRUID	D03DVV
DRUGNAME	NC-1006
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D03DWZ
DRUGNAME	SNP-002
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D03DXN
DRUGNAME	Polyestradiol Phosphate
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D03DXS
DRUGNAME	Odapipam
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1
	
TTDDRUID	D03DYB
DRUGNAME	AZD-0275
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated
	
TTDDRUID	D03DYT
DRUGNAME	K252a
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03DZK
DRUGNAME	WSBI-19711A
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D03EBK
DRUGNAME	HIV-specific STAR fusions
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D03EBV
DRUGNAME	JNS-001
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
	
TTDDRUID	D03EDD
DRUGNAME	VN/107-1
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D03EDQ
DRUGNAME	Vismodegib
INDICATI	Basal cell carcinoma [ICD-11: 2C32] Approved
INDICATI	Primitive neuroectodermal tumour medulloblastoma [ICD-11: 2A00.11] Phase 2
	
TTDDRUID	D03EEA
DRUGNAME	PMID25666693-Compound-70
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D03EEH
DRUGNAME	Gadodiamide
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Approved
	
TTDDRUID	D03EER
DRUGNAME	Thyrotropin
INDICATI	Hypothyroidism [ICD-11: 5A00] Approved
	
TTDDRUID	D03EFD
DRUGNAME	KT-95
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated
	
TTDDRUID	D03EHN
DRUGNAME	Avdoralimab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D03EHR
DRUGNAME	Lecimibide
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Terminated
	
TTDDRUID	D03EIA
DRUGNAME	Anti-CD19-CAR T
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D03EIC
DRUGNAME	ZD-7349
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1
	
TTDDRUID	D03EIG
DRUGNAME	C3BS-GQR-1
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D03EIK
DRUGNAME	NV.RYM.09
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D03ELL
DRUGNAME	Amisulpride
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D03END
DRUGNAME	Insecticide
INDICATI	Pest attack [ICD-11: N.A.] Investigative
	
TTDDRUID	D03EOF
DRUGNAME	Meplazumab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D03EOT
DRUGNAME	Borocaptate sodium B 10
INDICATI	Brain cancer [ICD-11: 2A00] Approved
	
TTDDRUID	D03EOZ
DRUGNAME	IMG-7289
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 1/2
	
TTDDRUID	D03ERR
DRUGNAME	H1N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D03ESO
DRUGNAME	GW-3333
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Preclinical
	
TTDDRUID	D03ESU
DRUGNAME	Anti-SEB mabs
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D03ESW
DRUGNAME	Cetefloxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D03EWD
DRUGNAME	CTAP101
INDICATI	Kidney disease [ICD-11: GC2Z] Preregistration
	
TTDDRUID	D03EXK
DRUGNAME	Povidone-iodine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D03EZB
DRUGNAME	AR-H047108
INDICATI	Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 2
	
TTDDRUID	D03EZE
DRUGNAME	GSK2126458
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D03EZQ
DRUGNAME	AN-1006
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D03EZR
DRUGNAME	CMD-003
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D03FAP
DRUGNAME	A-75729
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D03FBV
DRUGNAME	PF-04950615
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3
	
TTDDRUID	D03FCF
DRUGNAME	Novolimus
INDICATI	Artery stenosis [ICD-11: BD52] Approved
	
TTDDRUID	D03FDN
DRUGNAME	PMID26161824-Compound-69
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D03FDT
DRUGNAME	Phenolphthalein
INDICATI	Constipation [ICD-11: DD91.1] Withdrawn from market
	
TTDDRUID	D03FEO
DRUGNAME	Ipecac
INDICATI	Poison intoxication [ICD-11: NE6Z] Approved
	
TTDDRUID	D03FEP
DRUGNAME	Nanofibers
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D03FFA
DRUGNAME	HB-AS02V
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
	
TTDDRUID	D03FFL
DRUGNAME	Chitosan-thiomer
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 2
	
TTDDRUID	D03FFY
DRUGNAME	AZD3355
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2
	
TTDDRUID	D03FGI
DRUGNAME	Anti-LAG3 mAb
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D03FIE
DRUGNAME	AEZS-126
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03FIL
DRUGNAME	Insulin Zinc Susp Recombinant Human
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D03FIS
DRUGNAME	EDP-23
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03FKQ
DRUGNAME	Ultrase
INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Approved
	
TTDDRUID	D03FLC
DRUGNAME	Lamotrigine
INDICATI	Bipolar disorder [ICD-11: 6A60] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D03FLT
DRUGNAME	CP-331684
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D03FNJ
DRUGNAME	Pipobroman
INDICATI	Refractory chronic myeloid leukaemia [ICD-11: 2A20] Approved
	
TTDDRUID	D03FON
DRUGNAME	Comvac5
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D03FOP
DRUGNAME	AMG 319
INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 1
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D03FOT
DRUGNAME	AMD-AAV7
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D03FPA
DRUGNAME	APP-018
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D03FQY
DRUGNAME	PMID26815044-Compound-121
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D03FSF
DRUGNAME	PMID25666693-Compound-73
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D03FUG
DRUGNAME	Pegylated carboxyhemoglobin
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 2
	
TTDDRUID	D03FUO
DRUGNAME	GDC-0834
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D03FVI
DRUGNAME	97-139
INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Discontinued in Phase 2
	
TTDDRUID	D03FVR
DRUGNAME	GSK-1827771
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D03FVS
DRUGNAME	Salvicine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D03FXM
DRUGNAME	Protamine
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
	
TTDDRUID	D03GAI
DRUGNAME	IR-103
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3
	
TTDDRUID	D03GAN
DRUGNAME	A-558693
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D03GAX
DRUGNAME	TAK-802
INDICATI	Urinary dysfunction [ICD-11: GC2Z] Discontinued in Phase 2
	
TTDDRUID	D03GAY
DRUGNAME	H-409/22
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2
	
TTDDRUID	D03GCJ
DRUGNAME	Carteolol
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D03GCR
DRUGNAME	MK-8742
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
	
TTDDRUID	D03GET
DRUGNAME	Menadione
INDICATI	Vitamin K deficiency [ICD-11: 5B59] Approved
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D03GFC
DRUGNAME	AZD-7545
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D03GFZ
DRUGNAME	Thieno[3,2-c]pyridine-7-carboxamide derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D03GGN
DRUGNAME	RO-09-4889
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03GHR
DRUGNAME	C-myb
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D03GHV
DRUGNAME	PR1 peptide antigen vaccine
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	D03GII
DRUGNAME	SR-26831
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D03GIV
DRUGNAME	SNP-001
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative
	
TTDDRUID	D03GKP
DRUGNAME	FD-891
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D03GLK
DRUGNAME	Imidazole derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D03GLL
DRUGNAME	TSS-HIG
INDICATI	Endotoxic shock [ICD-11: 1G41] Investigative
	
TTDDRUID	D03GLM
DRUGNAME	BMS-210285
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D03GNI
DRUGNAME	ISOQUINE
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	D03GNR
DRUGNAME	ANA-975
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1
	
TTDDRUID	D03GOI
DRUGNAME	Liraglutide
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D03GOO
DRUGNAME	Fumaric acid
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
INDICATI	Pustular palmoplantar psoriasis [ICD-11: EA90] Phase 3
	
TTDDRUID	D03GOP
DRUGNAME	Imvamune smallpox vaccine
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
INDICATI	Smallpox [ICD-11: 1E70] Phase 3
INDICATI	Monkeypox virus infection [ICD-11: 1E71] Phase 3
	
TTDDRUID	D03GPK
DRUGNAME	DA-9801
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
	
TTDDRUID	D03GQC
DRUGNAME	PD-117596
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D03GQH
DRUGNAME	B-581
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D03GRD
DRUGNAME	AX-200
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D03GSN
DRUGNAME	KVD001
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	D03GTO
DRUGNAME	C-Met/PD-L1 CAR-T Cell
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
	
TTDDRUID	D03GVC
DRUGNAME	Methyclothiazide
INDICATI	Edema [ICD-11: MG29] Approved
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D03GVG
DRUGNAME	NP-2
INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2
	
TTDDRUID	D03GWV
DRUGNAME	ZP-002
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D03GWY
DRUGNAME	Ciglitazone
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Preclinical
	
TTDDRUID	D03GXU
DRUGNAME	WIN-901
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D03GYK
DRUGNAME	Laropiprant+niacin
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 3
	
TTDDRUID	D03HAA
DRUGNAME	PMID30107136-Compound-Example45
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D03HAW
DRUGNAME	HemaMax
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D03HCZ
DRUGNAME	Propoxyphene Hydrochloride
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D03HDL
DRUGNAME	MK 8719
INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1
	
TTDDRUID	D03HDP
DRUGNAME	ACEA-1416
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D03HDV
DRUGNAME	DWP-431
INDICATI	Bone development disorder [ICD-11: FB86] Phase 3
	
TTDDRUID	D03HFG
DRUGNAME	Fluvoxamine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D03HGP
DRUGNAME	CTP-conjugated WT1 peptide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03HGW
DRUGNAME	AV-370
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03HHD
DRUGNAME	Pyrazoline derivative 4
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D03HHG
DRUGNAME	PMID26651364-Compound-121
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D03HHJ
DRUGNAME	GSK3174998
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03HIG
DRUGNAME	AVX-470
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1
	
TTDDRUID	D03HJK
DRUGNAME	Zithromax
INDICATI	Syphilis infection [ICD-11: 1A6Z] Approved
	
TTDDRUID	D03HJZ
DRUGNAME	AZ-11657312
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D03HKA
DRUGNAME	ZFP TF
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D03HKR
DRUGNAME	CDX-0158
INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03HLK
DRUGNAME	PRT-060096
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D03HML
DRUGNAME	CD56-specific gene-engineered T cells
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D03HMM
DRUGNAME	ABS-201
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Investigative
	
TTDDRUID	D03HOP
DRUGNAME	HG-1220
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03HOT
DRUGNAME	BC-19
INDICATI	Brain disease [ICD-11: 8C70-8E61] Investigative
	
TTDDRUID	D03HQE
DRUGNAME	CRT0066101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03HQR
DRUGNAME	SUN-44
INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Investigative
	
TTDDRUID	D03HSA
DRUGNAME	Actimab-A
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D03HSF
DRUGNAME	Ro-23-7777
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D03HSN
DRUGNAME	CNTO-1959
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D03HSQ
DRUGNAME	GBR-401
INDICATI	B-cell lymphoma [ICD-11: 2A86] Investigative
	
TTDDRUID	D03HSS
DRUGNAME	LG-1041
INDICATI	Hunter syndrome [ICD-11: 5C56.31] Investigative
	
TTDDRUID	D03HTI
DRUGNAME	HMR-3787
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D03HTZ
DRUGNAME	LD201t1
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D03HUX
DRUGNAME	PCM-075
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03HVN
DRUGNAME	P-1
INDICATI	Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 3
	
TTDDRUID	D03HVV
DRUGNAME	Efaproxyn
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 3
	
TTDDRUID	D03HXO
DRUGNAME	NPS-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03HYQ
DRUGNAME	Ranolazine
INDICATI	Chronic/stable angina [ICD-11: BA40.1] Approved
INDICATI	Paroxysmal atrial fibrillation [ICD-11: BC81.30] Phase 2
	
TTDDRUID	D03HYX
DRUGNAME	Mometasone
INDICATI	Skin allergy [ICD-11: 4A82] Approved
	
TTDDRUID	D03IBI
DRUGNAME	Levotofisopam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D03ICO
DRUGNAME	AR-709
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D03ICS
DRUGNAME	NPT-500
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D03IDK
DRUGNAME	CEP-18050
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative
	
TTDDRUID	D03IDU
DRUGNAME	Hydrogen peroxide
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D03IEB
DRUGNAME	Penecure
INDICATI	Onychomycosis [ICD-11: EE12.1] Investigative
	
TTDDRUID	D03IGB
DRUGNAME	BVT.28949
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
	
TTDDRUID	D03IGH
DRUGNAME	Darunavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D03IHA
DRUGNAME	GT 1061
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D03IHD
DRUGNAME	Anti-CD22-CAR-transduced T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D03IIP
DRUGNAME	EP-3533
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Terminated
	
TTDDRUID	D03IJO
DRUGNAME	GS-9820
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	D03IJZ
DRUGNAME	Recombinant botulinum toxin
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D03IKT
DRUGNAME	Paramethasone
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 3
	
TTDDRUID	D03IKZ
DRUGNAME	HBP-347
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 3
	
TTDDRUID	D03ILU
DRUGNAME	D17.4
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Investigative
	
TTDDRUID	D03IMU
DRUGNAME	TNFR1 NAM
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D03INC
DRUGNAME	Triplelastat
INDICATI	Kidney transplant rejection [ICD-11: NE84] Investigative
	
TTDDRUID	D03ING
DRUGNAME	Anrukinzumab
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D03INQ
DRUGNAME	Laevo-Bambuterol
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D03IOM
DRUGNAME	CART-19
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2/3
	
TTDDRUID	D03IQD
DRUGNAME	PF-06480605
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
	
TTDDRUID	D03IQH
DRUGNAME	EDG-006
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D03IQK
DRUGNAME	BC-821
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D03IQP
DRUGNAME	Alpha-Helical lipopeptides LLS
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D03IRG
DRUGNAME	PNK-007
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D03ISE
DRUGNAME	PAFENOLOL
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D03ISJ
DRUGNAME	BMS-863233
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D03ITZ
DRUGNAME	Aryl mannoside derivative 4
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D03IUD
DRUGNAME	Ceftolozane sulfate
INDICATI	Respiratory tract infection [ICD-11: CA45] Phase 4
	
TTDDRUID	D03IUY
DRUGNAME	Estropipate
INDICATI	Hypogonadism [ICD-11: 5A61.0] Approved
	
TTDDRUID	D03IWT
DRUGNAME	NT-13317
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D03IXK
DRUGNAME	ME-344
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D03JAA
DRUGNAME	Glycodiazine
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D03JAF
DRUGNAME	Nrti
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D03JBI
DRUGNAME	PPI-03306
INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Investigative
	
TTDDRUID	D03JCA
DRUGNAME	MB-11055
INDICATI	Fatty liver disease [ICD-11: DB92.Z] Phase 2
	
TTDDRUID	D03JCT
DRUGNAME	M-110101
INDICATI	Seborrhea [ICD-11: ED91.2] Investigative
	
TTDDRUID	D03JDA
DRUGNAME	Nu-3
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1/2
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D03JFJ
DRUGNAME	PMID26651364-Compound-108
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D03JHJ
DRUGNAME	FK-352
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D03JIH
DRUGNAME	SSR-125180
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D03JJY
DRUGNAME	GANTACURIUM CHLORIDE
INDICATI	Anaesthesia [ICD-11: 9A78.6] Phase 1/2
	
TTDDRUID	D03JLR
DRUGNAME	PLX51107
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03JMF
DRUGNAME	IKI-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03JMN
DRUGNAME	AD-177
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated
	
TTDDRUID	D03JNS
DRUGNAME	Peanut allergy vaccine
INDICATI	Peanut hypersensitivity [ICD-11: 4A83] Phase 1
	
TTDDRUID	D03JOA
DRUGNAME	Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D03JPH
DRUGNAME	Isoxicam
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Withdrawn from market
	
TTDDRUID	D03JQR
DRUGNAME	RG-7273
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1
	
TTDDRUID	D03JRA
DRUGNAME	Beta-lactam
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Investigative
	
TTDDRUID	D03JRG
DRUGNAME	VU0364739
INDICATI	Coagulation defect [ICD-11: 3B10.0] Clinical trial
	
TTDDRUID	D03JRJ
DRUGNAME	NTE-122
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D03JRL
DRUGNAME	TDI-0102
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D03JRO
DRUGNAME	ADCI
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 1
	
TTDDRUID	D03JSJ
DRUGNAME	Mupirocin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D03JSO
DRUGNAME	ASP-2535
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
	
TTDDRUID	D03JSS
DRUGNAME	Tidembersat
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 1
	
TTDDRUID	D03JTG
DRUGNAME	Fruquintinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D03JTL
DRUGNAME	APVO414
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D03JUF
DRUGNAME	KRL-104
INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 1
	
TTDDRUID	D03JUM
DRUGNAME	Pentaxim
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D03JUN
DRUGNAME	Anti-IL31
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D03JWU
DRUGNAME	REC-01
INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 1
	
TTDDRUID	D03JXN
DRUGNAME	Recombinant anti-IgE Fabs
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D03JXR
DRUGNAME	NOSO-74
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D03JYD
DRUGNAME	Tnk-6123
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D03JZC
DRUGNAME	PF-06263507
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03JZD
DRUGNAME	Neurosolve
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Preclinical
	
TTDDRUID	D03KAC
DRUGNAME	XL147
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D03KAV
DRUGNAME	Biphenyl mannoside derivative 12
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D03KAY
DRUGNAME	Darunavir + ritonavir + oseltamivir + hydroxychloroquine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D03KDO
DRUGNAME	Prochymal
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
INDICATI	Acute radiation syndrome [ICD-11: NF00] Phase 3
INDICATI	Heart disease [ICD-11: BA41-BA42] Phase 3
	
TTDDRUID	D03KEK
DRUGNAME	Artemisinin SP
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D03KFJ
DRUGNAME	TB-102
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative
	
TTDDRUID	D03KGH
DRUGNAME	Upamostat
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D03KHN
DRUGNAME	CLR-1404
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D03KHO
DRUGNAME	PF-05175157
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D03KHQ
DRUGNAME	DNA-Ad
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2
	
TTDDRUID	D03KHX
DRUGNAME	MC-D11
INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1/2
	
TTDDRUID	D03KIA
DRUGNAME	Cerivastatin
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D03KIK
DRUGNAME	AP-300
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D03KIZ
DRUGNAME	RG7596
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2
	
TTDDRUID	D03KJP
DRUGNAME	Meningococcal CYW vaccine
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Terminated
	
TTDDRUID	D03KJS
DRUGNAME	Antalarmin
INDICATI	Depression [ICD-11: 6A70-6A7Z] Terminated
	
TTDDRUID	D03KJU
DRUGNAME	NV-04
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D03KJV
DRUGNAME	Ultramorph
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D03KLF
DRUGNAME	MDX-1203
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03KLU
DRUGNAME	CT-406
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D03KNZ
DRUGNAME	Monoamine derivative 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D03KOU
DRUGNAME	XPro-1595
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D03KOZ
DRUGNAME	Epalrestat
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Approved
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D03KPZ
DRUGNAME	Ciprofloxacin+dexamethasone
INDICATI	Otitis externa [ICD-11: AA00-AA13] Approved
INDICATI	Acute otitis media [ICD-11: AB00] Approved
	
TTDDRUID	D03KQF
DRUGNAME	Maprotiline
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
	
TTDDRUID	D03KRF
DRUGNAME	Superoxide dismutase mimetics
INDICATI	Retinopathy [ICD-11: 9B71] Investigative
	
TTDDRUID	D03KST
DRUGNAME	KT2-962
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D03KTD
DRUGNAME	Chromomycin a3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D03KTE
DRUGNAME	LGD2941
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1
	
TTDDRUID	D03KTK
DRUGNAME	TAK-937
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1
	
TTDDRUID	D03KTU
DRUGNAME	BMS-561388
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D03KUB
DRUGNAME	Deslorelin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D03KVW
DRUGNAME	MDX-1411
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03KVY
DRUGNAME	BCT303
INDICATI	Hypothyroidism [ICD-11: 5A00] Phase 2
	
TTDDRUID	D03KWN
DRUGNAME	AZD-6703
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D03KWU
DRUGNAME	VRP-S vaccine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D03KXY
DRUGNAME	Doxifluridine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D03KYG
DRUGNAME	Perindopril
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D03KYI
DRUGNAME	IMD-1622
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D03KZM
DRUGNAME	Tolvaptan
INDICATI	Hyponatraemia [ICD-11: 5C72] Approved
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3
	
TTDDRUID	D03LAB
DRUGNAME	TBC-3711
INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 2
	
TTDDRUID	D03LAI
DRUGNAME	MSB0010445
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D03LAL
DRUGNAME	RBBX-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03LAV
DRUGNAME	MEDI0700
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D03LBD
DRUGNAME	G-115
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D03LCX
DRUGNAME	CCX-662
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03LFA
DRUGNAME	Allogeneic CART-19
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D03LFR
DRUGNAME	SB-756050
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D03LGG
DRUGNAME	Zucapsacin
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
	
TTDDRUID	D03LGX
DRUGNAME	NI-105
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D03LGY
DRUGNAME	Divalproex sodium
INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved
	
TTDDRUID	D03LIE
DRUGNAME	PAV-059
INDICATI	Encephalitis virus infection [ICD-11: 1C83-1C84] Investigative
	
TTDDRUID	D03LJR
DRUGNAME	Sirolimus
INDICATI	Organ transplant rejection [ICD-11: NE84] Approved
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
INDICATI	Dutch elm disease [ICD-11: 8D64] Phase 1/2
	
TTDDRUID	D03LKU
DRUGNAME	Spheramine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D03LKV
DRUGNAME	BMN045
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D03LLL
DRUGNAME	PRX-12255
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D03LMK
DRUGNAME	IB-07A085
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D03LNM
DRUGNAME	TK-112690
INDICATI	Mucositis [ICD-11: CA00] Investigative
	
TTDDRUID	D03LNN
DRUGNAME	IDX136
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Preclinical
	
TTDDRUID	D03LNV
DRUGNAME	Argotom-VAX
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D03LQC
DRUGNAME	APD-209
INDICATI	Cachexia [ICD-11: MG20] Phase 2
	
TTDDRUID	D03LQQ
DRUGNAME	Alinidine
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3
	
TTDDRUID	D03LRU
DRUGNAME	Alvespimycin hydrochloride
INDICATI	Refractory hematologic malignancy [ICD-11: 2A85.5] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D03LSO
DRUGNAME	SPD-418
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 1
	
TTDDRUID	D03LTA
DRUGNAME	Haemophilus influenzae B vaccine
INDICATI	Haemophilus influenza [ICD-11: 1G40] Approved
	
TTDDRUID	D03LTO
DRUGNAME	Tigatuzumab
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D03LUF
DRUGNAME	CD137 CAR-T Cell
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D03LUN
DRUGNAME	Laronidase
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Approved
	
TTDDRUID	D03LWG
DRUGNAME	BGJ398
INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D03LWO
DRUGNAME	Desirudin Recombinant
INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
	
TTDDRUID	D03LXH
DRUGNAME	GAI-122
INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative
	
TTDDRUID	D03LXJ
DRUGNAME	KB-2683
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D03LZK
DRUGNAME	APS-3010
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03MAD
DRUGNAME	CP-800569
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D03MBU
DRUGNAME	SC-006
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03MCV
DRUGNAME	RB-006
INDICATI	Vascular disease [ICD-11: BE2Z] Discontinued in Phase 3
INDICATI	Coronary artery disease [ICD-11: BA80] Discontinued in Phase 3
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3
	
TTDDRUID	D03MDV
DRUGNAME	PAT-CSL1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03MDW
DRUGNAME	DS-7309
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D03MDY
DRUGNAME	PLX9486
INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03MER
DRUGNAME	Endogenous human peptide LL-37
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D03MEU
DRUGNAME	Pathogen-specific aAPCs vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D03MFQ
DRUGNAME	CHF-5074
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D03MFV
DRUGNAME	MNLP-18
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Preclinical
	
TTDDRUID	D03MGL
DRUGNAME	Tafamidis meglumine
INDICATI	Hereditary amyloidosis [ICD-11: 5D00.2] Approved
INDICATI	Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3
	
TTDDRUID	D03MGV
DRUGNAME	ASP-5034
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D03MIN
DRUGNAME	M-0004
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 1
	
TTDDRUID	D03MIP
DRUGNAME	SPI-256
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D03MIR
DRUGNAME	Doxazosin
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D03MKE
DRUGNAME	Resorcinol compound 15
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D03MLR
DRUGNAME	ADE-LAM
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D03MNN
DRUGNAME	SKI-758
INDICATI	Ischemia [ICD-11: 8B10-8B11] Approved
	
TTDDRUID	D03MNS
DRUGNAME	ADL-7445
INDICATI	Constipation [ICD-11: DD91.1] Discontinued in Phase 1
	
TTDDRUID	D03MSF
DRUGNAME	Nerenone
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D03MSN
DRUGNAME	HD-101
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D03MSV
DRUGNAME	PB-1023
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D03MTN
DRUGNAME	Mepolizumab
INDICATI	Severe asthma [ICD-11: CA23] Approved
INDICATI	Asthma [ICD-11: CA23] Phase 2/3
	
TTDDRUID	D03MTY
DRUGNAME	LA22-radioimmunoconjugates
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03MUM
DRUGNAME	EDONENTAN HYDRATE
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2
	
TTDDRUID	D03MUT
DRUGNAME	Calfactant
INDICATI	Acute lung injury [ICD-11: NB32.3] Approved
	
TTDDRUID	D03MWM
DRUGNAME	Oncolysin B
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Discontinued in Phase 2
	
TTDDRUID	D03MWZ
DRUGNAME	Syntropin
INDICATI	Dwarfism [ICD-11: 5B11] Phase 1
	
TTDDRUID	D03MXK
DRUGNAME	AT-406
INDICATI	Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D03MYO
DRUGNAME	MGL-3196
INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 1
	
TTDDRUID	D03MYX
DRUGNAME	AM0010
INDICATI	Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 3
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D03MZJ
DRUGNAME	BUCINDOLOL
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2/3
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D03MZQ
DRUGNAME	Sevelamer hydrochloride
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Approved
	
TTDDRUID	D03MZU
DRUGNAME	AHCQ
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D03NAW
DRUGNAME	Dulaglutide
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D03NCL
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D03NDI
DRUGNAME	KCO-912
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D03NGH
DRUGNAME	Ramoplanin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
	
TTDDRUID	D03NHS
DRUGNAME	PCO371
INDICATI	Hypoparathyroidism [ICD-11: 5A50] Phase 1
	
TTDDRUID	D03NHW
DRUGNAME	Ofloxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D03NHZ
DRUGNAME	Engineered toxin bodies
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03NIW
DRUGNAME	B244
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D03NJN
DRUGNAME	PAT-SM5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03NJY
DRUGNAME	SF1126
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
	
TTDDRUID	D03NLJ
DRUGNAME	FGI-106
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D03NLQ
DRUGNAME	ABT-957
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D03NLV
DRUGNAME	KDT-501
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D03NMM
DRUGNAME	AM-643
INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative
	
TTDDRUID	D03NMQ
DRUGNAME	131I-CLR-1404
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D03NOS
DRUGNAME	Rimiterol
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D03NPH
DRUGNAME	Quazepam
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D03NPI
DRUGNAME	Idecabtagene vicleucel
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
	
TTDDRUID	D03NPZ
DRUGNAME	NNC-22-0031
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D03NTF
DRUGNAME	CWP-231
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03NTJ
DRUGNAME	Prolixin decanoate
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D03NVS
DRUGNAME	NC-003
INDICATI	Myalgia [ICD-11: FB56.2] Phase 2
	
TTDDRUID	D03NWC
DRUGNAME	SNG-8023
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D03NXS
DRUGNAME	GKT-04
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative
	
TTDDRUID	D03NZM
DRUGNAME	T-588
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2
	
TTDDRUID	D03NZV
DRUGNAME	SC-236
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D03OBV
DRUGNAME	AS-1405
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D03OCG
DRUGNAME	FGF-21
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1/2
	
TTDDRUID	D03ODX
DRUGNAME	IC-84
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D03OFA
DRUGNAME	Ro-09-1428
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D03OFF
DRUGNAME	Pioglitazone
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D03OFN
DRUGNAME	NK-314
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03OGQ
DRUGNAME	AZD-7009
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2
	
TTDDRUID	D03OIO
DRUGNAME	Anti-Mesothelin CAR-T cells
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03OIW
DRUGNAME	Kinetin
INDICATI	Skin photodamage [ICD-11: EJ40] Approved
	
TTDDRUID	D03OKG
DRUGNAME	FK-739
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D03OKS
DRUGNAME	DC-IL-12 DNA therapeutic
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D03OLA
DRUGNAME	L-745631
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D03OMK
DRUGNAME	DM-107
INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative
	
TTDDRUID	D03ONE
DRUGNAME	BL-6010
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D03ONX
DRUGNAME	CL-H02
INDICATI	Headache [ICD-11: 8A80-8A84] Investigative
	
TTDDRUID	D03ONZ
DRUGNAME	MCS-18
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D03OPE
DRUGNAME	CL-284027
INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D03OPS
DRUGNAME	HR2P-M2 peptide
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D03OQI
DRUGNAME	Tozadenant
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D03OSE
DRUGNAME	GVAX
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D03OSG
DRUGNAME	MBX-8025
INDICATI	Obesity [ICD-11: 5B81] Phase 2/3
INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2
INDICATI	Primary biliary cholangitis [ICD-11: DB96.1] Phase 2
	
TTDDRUID	D03OSO
DRUGNAME	HT-61
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative
	
TTDDRUID	D03OTH
DRUGNAME	Belagenpumatucel-L
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D03OTX
DRUGNAME	PSP-D-GITRL
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03OVA
DRUGNAME	8-chloro-adenosine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D03OVN
DRUGNAME	ReN-003
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2
INDICATI	Retinopathy [ICD-11: 9B71] Investigative
	
TTDDRUID	D03OYY
DRUGNAME	MAR-531
INDICATI	Hypoglycemia [ICD-11: 5A41] Investigative
	
TTDDRUID	D03PBT
DRUGNAME	DuP-983
INDICATI	Pruritus [ICD-11: EC90] Terminated
	
TTDDRUID	D03PBW
DRUGNAME	PG-760564
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D03PCJ
DRUGNAME	MPI-461359
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D03PCP
DRUGNAME	NCT-400
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D03PDY
DRUGNAME	SB-332235
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D03PEF
DRUGNAME	Hedgehog labelled stem cells
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D03PGE
DRUGNAME	PG-2
INDICATI	Fatigue [ICD-11: MG22] Approved
	
TTDDRUID	D03PGS
DRUGNAME	IONIS-TTRRX
INDICATI	Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3
	
TTDDRUID	D03PHU
DRUGNAME	Tetrazolast meglumine
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D03PIA
DRUGNAME	CB-183315
INDICATI	Malignant carcinoid syndrome [ICD-11: 5B10] Phase 3
	
TTDDRUID	D03PIR
DRUGNAME	Ceftezole
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D03PJP
DRUGNAME	Trenonacog alfa
INDICATI	Discovery agent [ICD-11: N.A.] Discontinued in Phase 3
	
TTDDRUID	D03PKI
DRUGNAME	Geldanamycin
INDICATI	Peripheral nerve damage [ICD-11: ND56.4] Discontinued in Phase 2
INDICATI	Kidney cancer [ICD-11: 2C90.0] Discontinued in Phase 2
	
TTDDRUID	D03PKJ
DRUGNAME	MK-6186
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D03PLQ
DRUGNAME	Benzothiazole analog 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D03PLR
DRUGNAME	RemuneX
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 3
	
TTDDRUID	D03PMB
DRUGNAME	PTI-601
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D03POY
DRUGNAME	ISIS-AR
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D03PQW
DRUGNAME	BAY 79-4620
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03PRC
DRUGNAME	K562/GM-CSF
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D03PRM
DRUGNAME	NST-141
INDICATI	Pruritus [ICD-11: EC90] Phase 2
	
TTDDRUID	D03PRV
DRUGNAME	BGC-20-1259
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D03PSA
DRUGNAME	1,2,4-oxadiazole derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D03PSP
DRUGNAME	Panobacumab
INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2
INDICATI	Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 2
INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 1/2
	
TTDDRUID	D03PTH
DRUGNAME	Pyrantel
INDICATI	Worm infection [ICD-11: 1F90.Z] Approved
	
TTDDRUID	D03PTZ
DRUGNAME	BTS-73947
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1
	
TTDDRUID	D03PUA
DRUGNAME	Siltuximab
INDICATI	Idiopathic multicentric Castlemans disease [ICD-11: 2A81.Y] approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D03PUG
DRUGNAME	Revax-TBE
INDICATI	Flavivirus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D03PVQ
DRUGNAME	EDP-420
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D03PVY
DRUGNAME	GlycoPEGylated erythropoietin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D03PWD
DRUGNAME	GMI-1271
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D03PXT
DRUGNAME	Altastaph
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 2
	
TTDDRUID	D03PYA
DRUGNAME	Cyclohexyl carbamate derivative 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D03PYD
DRUGNAME	K-604
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2
	
TTDDRUID	D03PZY
DRUGNAME	PHER-O2
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D03PZZ
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 7
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D03QAO
DRUGNAME	AZD-9742
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Phase 1
	
TTDDRUID	D03QAQ
DRUGNAME	SN429
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D03QAS
DRUGNAME	E-758
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03QAW
DRUGNAME	PMID25666693-Compound-61
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D03QBL
DRUGNAME	Autologous idiotypic cancer vaccine
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D03QBS
DRUGNAME	Furazolidinone
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D03QBT
DRUGNAME	Golnerminogene pradenovac
INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 3
	
TTDDRUID	D03QBY
DRUGNAME	Anavip
INDICATI	Poison intoxication [ICD-11: NE6Z] Phase 3
	
TTDDRUID	D03QCW
DRUGNAME	Interferon alfa-n1
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved
	
TTDDRUID	D03QEB
DRUGNAME	VGX-1027
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D03QEC
DRUGNAME	ASP4131
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative
	
TTDDRUID	D03QFN
DRUGNAME	Patrome
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D03QFO
DRUGNAME	SOR-N43
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D03QFY
DRUGNAME	PPLs
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D03QGB
DRUGNAME	JNJ-5207852
INDICATI	Narcolepsy [ICD-11: 7A20] Investigative
	
TTDDRUID	D03QGM
DRUGNAME	Sulpiride
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D03QHC
DRUGNAME	KAF156
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D03QHM
DRUGNAME	JNJ-64041809
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D03QHR
DRUGNAME	GFC-036
INDICATI	Leishmania infection [ICD-11: 1F54.0] Investigative
	
TTDDRUID	D03QIE
DRUGNAME	Bicifadine
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
INDICATI	Chronic low back pain [ICD-11: MG30.02] Phase 3
	
TTDDRUID	D03QIP
DRUGNAME	fluciclovine F-18
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D03QJA
DRUGNAME	GSK-812397
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D03QJL
DRUGNAME	Ibudilast
INDICATI	Castleman's disease [ICD-11: 4B2Y] Approved
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
INDICATI	Methamphetamine dependence [ICD-11: 6C46.2] Phase 2
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D03QJN
DRUGNAME	DPC 423
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D03QKW
DRUGNAME	KUC-7483
INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 1
	
TTDDRUID	D03QLG
DRUGNAME	CEP1347
INDICATI	Asthma [ICD-11: CA23] Phase 2/3
	
TTDDRUID	D03QMY
DRUGNAME	IDM-2101
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D03QNA
DRUGNAME	CIGB-845
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D03QNW
DRUGNAME	Hextend
INDICATI	Blood transfusion [ICD-11: QB98] Approved
	
TTDDRUID	D03QQP
DRUGNAME	BDNA-003
INDICATI	Chlamydia infection [ICD-11: 1A81] Investigative
	
TTDDRUID	D03QRS
DRUGNAME	Triptorelin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 4
	
TTDDRUID	D03QSC
DRUGNAME	NT-KC-005
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D03QSR
DRUGNAME	TP-20
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D03QSS
DRUGNAME	AMX0035
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
	
TTDDRUID	D03QTB
DRUGNAME	NSD-551
INDICATI	Brain cancer [ICD-11: 2A00] Terminated
	
TTDDRUID	D03QTM
DRUGNAME	Oncophage vitespen
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
	
TTDDRUID	D03QTP
DRUGNAME	CGP-52411
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D03QUJ
DRUGNAME	PYM-60001
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D03QVY
DRUGNAME	EZN-4482
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03QWG
DRUGNAME	Ad-IFN-alpha
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
	
TTDDRUID	D03QWO
DRUGNAME	Dexefaroxan
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2
	
TTDDRUID	D03QWT
DRUGNAME	Doripenem
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 3
	
TTDDRUID	D03QWZ
DRUGNAME	PP-099
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
	
TTDDRUID	D03QXD
DRUGNAME	RXP-470
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D03QZB
DRUGNAME	F-1394
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D03QZJ
DRUGNAME	CC-122
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D03RCB
DRUGNAME	FGI-101-1A6
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D03RCJ
DRUGNAME	Sodium Succinate
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D03RCP
DRUGNAME	NM-135
INDICATI	Dermatitis [ICD-11: EA80-EA89] Discontinued in Phase 2
	
TTDDRUID	D03RCV
DRUGNAME	D2A21
INDICATI	Burn and burn infection [ICD-11: ND90-NE2Z] Phase 3
	
TTDDRUID	D03RDQ
DRUGNAME	Gavilimomab
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 2/3
	
TTDDRUID	D03RDS
DRUGNAME	Labetuzumab govitecan
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D03REC
DRUGNAME	KP-736
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D03RFK
DRUGNAME	GTP-200
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D03RGO
DRUGNAME	CP-331
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D03RHZ
DRUGNAME	MDL-27192
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 2
	
TTDDRUID	D03RIO
DRUGNAME	GSK598809
INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Phase 2
	
TTDDRUID	D03RIX
DRUGNAME	Sirukumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D03RJZ
DRUGNAME	Oxeglitazar
INDICATI	Gout [ICD-11: FA25] Phase 1
	
TTDDRUID	D03RKC
DRUGNAME	EG-Vac
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03RLC
DRUGNAME	MOR-6292
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D03RLP
DRUGNAME	GT160-246
INDICATI	Diarrhea [ICD-11: ME05.1] Phase 3
	
TTDDRUID	D03RMN
DRUGNAME	1069C
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03RNX
DRUGNAME	EPC-K1
INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 2
	
TTDDRUID	D03ROA
DRUGNAME	Tr-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03ROX
DRUGNAME	Betaxolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D03RQW
DRUGNAME	Rostaporfin
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03RSI
DRUGNAME	IMMLG-5521
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D03RSQ
DRUGNAME	Vivia-007
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03RTC
DRUGNAME	BMS-812204
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D03RTK
DRUGNAME	Trabectedin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
	
TTDDRUID	D03RTR
DRUGNAME	INP-02
INDICATI	HIV-associated dementia [ICD-11: 6D85.3] Investigative
	
TTDDRUID	D03RTS
DRUGNAME	Celecoxib
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D03RUL
DRUGNAME	AP5280
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2
	
TTDDRUID	D03RVC
DRUGNAME	YH-4808
INDICATI	Duodenal ulcer [ICD-11: DA63] Phase 2
	
TTDDRUID	D03RXE
DRUGNAME	Biphenyl mannoside derivative 3
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D03RXS
DRUGNAME	TAK-831
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D03RYJ
DRUGNAME	REL-1015
INDICATI	Chronic pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D03RYN
DRUGNAME	Cytolin
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical
	
TTDDRUID	D03RYS
DRUGNAME	VNA-932
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1
	
TTDDRUID	D03RZM
DRUGNAME	Steroid hormone conjugates
INDICATI	Cachexia [ICD-11: MG20] Terminated
	
TTDDRUID	D03RZU
DRUGNAME	CNS-5788
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D03RZV
DRUGNAME	Tolazoline
INDICATI	Pulmonary hypertension [ICD-11: BB01] Approved
	
TTDDRUID	D03SCP
DRUGNAME	PNT-200
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03SDH
DRUGNAME	Siratiazem
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D03SFN
DRUGNAME	Elzasonan hydrochloride
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
	
TTDDRUID	D03SFU
DRUGNAME	TERTATOLOL
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D03SGF
DRUGNAME	WBZ-7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03SGR
DRUGNAME	Efalizumab
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
INDICATI	Renal transplantation [ICD-11: NE84] Phase 2
	
TTDDRUID	D03SHD
DRUGNAME	Myo-inositol
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D03SHI
DRUGNAME	Ro-5287373
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03SHM
DRUGNAME	PMID25666693-Compound-88
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D03SHP
DRUGNAME	GSK2849466
INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 1
	
TTDDRUID	D03SIA
DRUGNAME	OBI-1
INDICATI	Factor VIII deficiency [ICD-11: 3B10] Phase 3
	
TTDDRUID	D03SKC
DRUGNAME	KRP-104
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D03SKD
DRUGNAME	Oxycodone
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
INDICATI	Back pain [ICD-11: ME84.Z] Phase 3
	
TTDDRUID	D03SKF
DRUGNAME	SC-124a
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 3
	
TTDDRUID	D03SKL
DRUGNAME	BAY 86-9766
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D03SKR
DRUGNAME	Clonidine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 3
	
TTDDRUID	D03SLK
DRUGNAME	SAR292833
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D03SLO
DRUGNAME	OSU-2S
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03SMB
DRUGNAME	2-18F-FE-5-Br-glyburide
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D03SNE
DRUGNAME	PMID27828716-Compound-BIO-acetoxime
INDICATI	Malignant glioma [ICD-11: 2A00.0] Patented
	
TTDDRUID	D03SQT
DRUGNAME	Q203
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Phase 1
	
TTDDRUID	D03SRY
DRUGNAME	Estramustine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D03SSE
DRUGNAME	Mechlorethamine
INDICATI	T-cell lymphoma [ICD-11: 2A90] Approved
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 3
	
TTDDRUID	D03SSG
DRUGNAME	PA-10040
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D03SSH
DRUGNAME	AI-1008
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Investigative
	
TTDDRUID	D03STA
DRUGNAME	Darotropium
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D03STV
DRUGNAME	GSK-2197870A
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D03SUQ
DRUGNAME	Apilimod dimesylate
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D03SVG
DRUGNAME	GSK-2189242A
INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2
	
TTDDRUID	D03SVX
DRUGNAME	Aliskiren
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D03SVZ
DRUGNAME	Yersinia pestis vaccine
INDICATI	Yersinia infection [ICD-11: 1B93] Terminated
	
TTDDRUID	D03SWH
DRUGNAME	PNU-142633
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2
	
TTDDRUID	D03SXE
DRUGNAME	Betamethasone Valerate
INDICATI	Dermatological disease [ICD-11: DA24.Y] Approved
	
TTDDRUID	D03SXI
DRUGNAME	INCAGN1949
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D03SXQ
DRUGNAME	MDX-1140
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03SXS
DRUGNAME	LY-2875358
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D03SYC
DRUGNAME	LY-GSK-3i
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03SZK
DRUGNAME	VXM-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03SZR
DRUGNAME	M-carboxycinnamic acid bishydroxamide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D03TAP
DRUGNAME	MCT-275
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D03TAT
DRUGNAME	Weight regulating human endocrine peptide
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D03TAY
DRUGNAME	VGX-3400
INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D03TBD
DRUGNAME	BMS-986148
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03TBJ
DRUGNAME	GRT-6005
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 3
	
TTDDRUID	D03TDB
DRUGNAME	TMB-358
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D03TDE
DRUGNAME	AC-4402
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D03TDK
DRUGNAME	Sulfonamide derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D03TDW
DRUGNAME	Thiopilocarpine
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
	
TTDDRUID	D03TFJ
DRUGNAME	Benzimidazole
INDICATI	Cytomegalovirus Disease [ICD-11: 1D82] Investigative
	
TTDDRUID	D03TGB
DRUGNAME	MOD-1002
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D03TGJ
DRUGNAME	Sorivudine
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D03TIJ
DRUGNAME	Titanocene dichloride
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D03TIS
DRUGNAME	Brentuximab vedotin
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Approved
	
TTDDRUID	D03TJN
DRUGNAME	KOS-1803
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D03TKI
DRUGNAME	FM-201
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D03TME
DRUGNAME	Crotalidae fab
INDICATI	Venom poisoning [ICD-11: NE61] Approved
	
TTDDRUID	D03TNA
DRUGNAME	ABT-724
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2
	
TTDDRUID	D03TNG
DRUGNAME	GCAN 101
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D03TOH
DRUGNAME	AC-0523
INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative
	
TTDDRUID	D03TPI
DRUGNAME	TV-1102
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D03TPR
DRUGNAME	Dextrothyroxine Sodium
INDICATI	High blood cholesterol level [ICD-11: 5C80.00] Approved
	
TTDDRUID	D03TQB
DRUGNAME	AU105
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
	
TTDDRUID	D03TRO
DRUGNAME	GRN-529
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D03TSR
DRUGNAME	Grass pollen immunotherapy
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3
	
TTDDRUID	D03TTQ
DRUGNAME	TRYPAN BLUE
INDICATI	Ophthalmic surgery injury [ICD-11: PK97] Approved
	
TTDDRUID	D03TTT
DRUGNAME	AR-00341677
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03TVE
DRUGNAME	FGF21-PKE Adnectin
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D03TVW
DRUGNAME	Stepronin
INDICATI	Bronchitis [ICD-11: CA20] Approved
	
TTDDRUID	D03TVY
DRUGNAME	OTI-030
INDICATI	Knee injuries [ICD-11: NC9Z] Phase 2
	
TTDDRUID	D03TWD
DRUGNAME	PMID30107136-Compound-Example4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D03TXW
DRUGNAME	CSP-9222
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03TXY
DRUGNAME	PMID28216367-compound-6d
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D03TYI
DRUGNAME	Aminophylline
INDICATI	Bronchial asthma [ICD-11: CA23] Approved
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D03TYJ
DRUGNAME	ATHX-105
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D03TYT
DRUGNAME	PF-03800130
INDICATI	Bipolar disorder [ICD-11: 6A60] Investigative
	
TTDDRUID	D03TYY
DRUGNAME	Nicotine-Q
INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 2
	
TTDDRUID	D03TZG
DRUGNAME	MGN-9103
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Investigative
	
TTDDRUID	D03UAO
DRUGNAME	MG-1105
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D03UBI
DRUGNAME	VALERGEN-DP
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D03UBW
DRUGNAME	Ficlatuzumab
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D03UDF
DRUGNAME	LOXO-195
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03UDW
DRUGNAME	AI-850
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03UEO
DRUGNAME	Clazakizumab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D03UFM
DRUGNAME	BMS-200980
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Preregistration
	
TTDDRUID	D03UFQ
DRUGNAME	Malaria vaccine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D03UHV
DRUGNAME	ONO-4578
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03UIB
DRUGNAME	TOK-8801
INDICATI	Arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D03UID
DRUGNAME	RJR-2403
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D03UIF
DRUGNAME	SA-6541
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D03UIW
DRUGNAME	Brontictuzumab
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D03UKI
DRUGNAME	Autologous dendritic cell vaccines
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03UKJ
DRUGNAME	Pazopanib + Tyverb/Tykerb
INDICATI	Inflammatory breast cancer [ICD-11: 2C62] Phase 2
	
TTDDRUID	D03UMA
DRUGNAME	CNT0-0007
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 1
	
TTDDRUID	D03UNN
DRUGNAME	L-689560
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated
	
TTDDRUID	D03UNT
DRUGNAME	Anti-CD19-CAR vector-transduced T cells
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial
INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Clinical trial
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Clinical trial
INDICATI	Follicular lymphoma [ICD-11: 2A80] Clinical trial
INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Clinical trial
INDICATI	Prolymphocytic leukaemia [ICD-11: 2A82.1] Clinical trial
	
TTDDRUID	D03UOG
DRUGNAME	P2B-004
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03UOT
DRUGNAME	Hydroquinone
INDICATI	Melasma [ICD-11: ED60.1] Approved
	
TTDDRUID	D03UQM
DRUGNAME	Retapamulin
INDICATI	Impetigo [ICD-11: 1B72] Approved
	
TTDDRUID	D03URV
DRUGNAME	HL-1172
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03USI
DRUGNAME	SL-87.0495
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D03UUL
DRUGNAME	APN01
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D03UVL
DRUGNAME	SSR-240612
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D03UVS
DRUGNAME	Gemcitabine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D03UVX
DRUGNAME	NOPPI
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03UWE
DRUGNAME	CAT-1904
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D03UXT
DRUGNAME	Recombinant house dust mite allergy desensitization injection
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D03UYI
DRUGNAME	TAK-427
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2
	
TTDDRUID	D03UZC
DRUGNAME	DS-1150b
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D03UZP
DRUGNAME	RG7888
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 2
	
TTDDRUID	D03VAR
DRUGNAME	Trecovirsen sodium
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D03VCF
DRUGNAME	Urtoxazumab
INDICATI	Escherichia coli infection [ICD-11: 1A03] Discontinued in Phase 2
	
TTDDRUID	D03VCJ
DRUGNAME	NP-01
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D03VDA
DRUGNAME	PTL-303
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D03VDC
DRUGNAME	Talc
INDICATI	Pleural disease [ICD-11: CB27] Approved
	
TTDDRUID	D03VDX
DRUGNAME	CPD-0905
INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative
	
TTDDRUID	D03VEZ
DRUGNAME	AD-439
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D03VFL
DRUGNAME	TOCOTRIENOL
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved
	
TTDDRUID	D03VFV
DRUGNAME	IL1aQb
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D03VGD
DRUGNAME	PACIS
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D03VGW
DRUGNAME	GCR-1087
INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D03VHI
DRUGNAME	HMR-3562
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D03VLG
DRUGNAME	DCB-WH1
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
	
TTDDRUID	D03VLH
DRUGNAME	ColoAd1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D03VLO
DRUGNAME	CD1-TB
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D03VLS
DRUGNAME	Lu-AA37096
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D03VMW
DRUGNAME	HepaGam B
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D03VNB
DRUGNAME	NI-0801
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D03VNJ
DRUGNAME	Carperitide
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D03VNX
DRUGNAME	Pro-urokinase
INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved
	
TTDDRUID	D03VPC
DRUGNAME	Cilostazol
INDICATI	Intermittent claudication [ICD-11: BD40.00] Approved
	
TTDDRUID	D03VPJ
DRUGNAME	AN0128
INDICATI	Psoriatic disorder [ICD-11: EA90] Phase 2
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D03VPM
DRUGNAME	DPV-001
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D03VRX
DRUGNAME	Albumin Iodinated Serum
INDICATI	Imaging [ICD-11: QA0B] Approved
	
TTDDRUID	D03VTN
DRUGNAME	TRIMOPROSTIL
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 3
	
TTDDRUID	D03VUV
DRUGNAME	Adarotene ester derivative back-up compounds
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03VWB
DRUGNAME	MP-157
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D03VXG
DRUGNAME	Insulin Lyspro recombinant
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D03VXJ
DRUGNAME	Hydrochloric acid
INDICATI	Alkalosis [ICD-11: 5C74] Approved
	
TTDDRUID	D03VXP
DRUGNAME	PMID25666693-Compound-145
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D03VXQ
DRUGNAME	Oxetane 3,3-dicarboxamide compound 1
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Patented
	
TTDDRUID	D03VYZ
DRUGNAME	MRX-4
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D03VZH
DRUGNAME	Ethchlorvynol
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D03WAJ
DRUGNAME	Heptabarbital
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D03WAT
DRUGNAME	PRC-4016
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 2
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D03WAU
DRUGNAME	Anamorelin
INDICATI	Carbohydrate metabolism disorder [ICD-11: 5C51.Z] Phase 3
	
TTDDRUID	D03WAX
DRUGNAME	KST-301
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03WCJ
DRUGNAME	4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D03WCT
DRUGNAME	LAS-189913
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D03WDN
DRUGNAME	BI-638683
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03WEX
DRUGNAME	Vortioxetine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 3
	
TTDDRUID	D03WFI
DRUGNAME	Heteroaryl-carboxamide derivative 9
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D03WGM
DRUGNAME	SOM-0888
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D03WHC
DRUGNAME	Nnrti
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D03WJB
DRUGNAME	Biphenyl mannoside derivative 25
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D03WLI
DRUGNAME	Technetium Tc-99m Pentetate Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D03WMK
DRUGNAME	AC-162352
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D03WMT
DRUGNAME	ML-721
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03WMY
DRUGNAME	NPC-17731
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D03WMZ
DRUGNAME	MEDI5884
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
	
TTDDRUID	D03WNG
DRUGNAME	CORT-125134
INDICATI	Cushing disease [ICD-11: 5A70] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Clinical trial
	
TTDDRUID	D03WNN
DRUGNAME	RG-7010
INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 1
	
TTDDRUID	D03WOG
DRUGNAME	Evinacumab
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
INDICATI	Elevated C-reactive protein [ICD-11: MA14.15] Phase 2
INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2
	
TTDDRUID	D03WOQ
DRUGNAME	LY3127804
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03WOW
DRUGNAME	QS-21
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D03WPA
DRUGNAME	Trovafloxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D03WPI
DRUGNAME	NC-190
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D03WPP
DRUGNAME	Necitumumab
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
	
TTDDRUID	D03WQS
DRUGNAME	BMS-582664
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
	
TTDDRUID	D03WRJ
DRUGNAME	Lisofylline
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D03WRN
DRUGNAME	AVT-02 UE
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Discontinued in Phase 2
	
TTDDRUID	D03WSE
DRUGNAME	XomaZyme-Mel
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2
	
TTDDRUID	D03WTE
DRUGNAME	BT-301
INDICATI	Periodontal disease [ICD-11: DA0C] Investigative
	
TTDDRUID	D03WTX
DRUGNAME	SBC-105
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D03WUH
DRUGNAME	YM-099
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D03WUU
DRUGNAME	Multivalent (HIVIS 07) DNA vaccine Derma Vax/ZetaJet
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical
	
TTDDRUID	D03WVP
DRUGNAME	IBU-PC
INDICATI	Inflammation associated with osteoarthritis [ICD-11: FA00-FA05] Preclinical
INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical
	
TTDDRUID	D03WWG
DRUGNAME	Elcatonin
INDICATI	Disorder of calcium metabolism [ICD-11: 5C64.5] Approved
	
TTDDRUID	D03WWW
DRUGNAME	Hepcidin
INDICATI	Hemochromatosis [ICD-11: 5C64.1Y] Phase 1
	
TTDDRUID	D03WXL
DRUGNAME	Staphguard
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative
	
TTDDRUID	D03WXM
DRUGNAME	C-linked disaccharide biphenyl mannoside derivative 4
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D03WYV
DRUGNAME	TAK-225
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D03WZJ
DRUGNAME	A33-Ac-225
INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative
	
TTDDRUID	D03XAO
DRUGNAME	NVX-108
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D03XBB
DRUGNAME	DX-2400
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03XBT
DRUGNAME	Prostatix
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D03XCR
DRUGNAME	Simotaxel
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03XDD
DRUGNAME	OG-45
INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative
	
TTDDRUID	D03XDX
DRUGNAME	Tarazepide
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 2
	
TTDDRUID	D03XES
DRUGNAME	Eptazocine hbr
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D03XET
DRUGNAME	POD-003
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D03XEV
DRUGNAME	NDC-1187
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03XEY
DRUGNAME	Epstein-barr virus-specific immunotherapy
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 2
	
TTDDRUID	D03XFH
DRUGNAME	ACTR-BCMA
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D03XHD
DRUGNAME	A-11259
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D03XHS
DRUGNAME	ACT-178882
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D03XIH
DRUGNAME	ABS-103
INDICATI	Bipolar disorder [ICD-11: 6A60] Terminated
	
TTDDRUID	D03XJP
DRUGNAME	Y-175L
INDICATI	Lupus [ICD-11: 4A40] Investigative
	
TTDDRUID	D03XLO
DRUGNAME	PEV-8
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D03XLX
DRUGNAME	CP-778875
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2
	
TTDDRUID	D03XOC
DRUGNAME	Trilostane
INDICATI	Cushing disease [ICD-11: 5A70] Approved
	
TTDDRUID	D03XRA
DRUGNAME	GSK2661380
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03XRZ
DRUGNAME	PF-05094037
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D03XSJ
DRUGNAME	Buclizine
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D03XST
DRUGNAME	MC-207252
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Terminated
	
TTDDRUID	D03XSX
DRUGNAME	CEL-2000
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D03XTC
DRUGNAME	Esmolol
INDICATI	Acute supraventricular tachycardia [ICD-11: BC81] Approved
	
TTDDRUID	D03XTY
DRUGNAME	APR-246
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2
INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D03XUQ
DRUGNAME	ABS-212
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D03XYW
DRUGNAME	Fenoprofen
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D03XZP
DRUGNAME	IL-12 gene therapy
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D03XZT
DRUGNAME	Cyclic compound 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D03YAA
DRUGNAME	PMID27215781-Compound-28
INDICATI	Endometriosis [ICD-11: GA10] Patented
	
TTDDRUID	D03YAS
DRUGNAME	ONO-AE1-437
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D03YBJ
DRUGNAME	DS-8895
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03YBQ
DRUGNAME	DNL151
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D03YCT
DRUGNAME	TVX-004
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D03YEG
DRUGNAME	REGN-910
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03YEM
DRUGNAME	CD19/CD22 CAR T-Cells
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D03YET
DRUGNAME	Coal tar
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
	
TTDDRUID	D03YFL
DRUGNAME	PMID25666693-Compound-71
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D03YGL
DRUGNAME	RHIgM22
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D03YGP
DRUGNAME	CC-8490
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
	
TTDDRUID	D03YGR
DRUGNAME	Cinacalcet
INDICATI	Hyperparathyroidism [ICD-11: 5A51] Approved
INDICATI	Kidney disease [ICD-11: GC2Z] Phase 3
	
TTDDRUID	D03YGX
DRUGNAME	SP-D
INDICATI	Lung inflammation [ICD-11: CA40.Z] Investigative
	
TTDDRUID	D03YIT
DRUGNAME	CL-186659
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D03YIU
DRUGNAME	Danoprevir + ritonavir + interferon
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D03YIX
DRUGNAME	Pneumostem
INDICATI	Respiratory distress syndrome [ICD-11: CB00] Phase 2
INDICATI	Bronchopulmonary dysplasia [ICD-11: KB29.0] Phase 1/2
	
TTDDRUID	D03YJC
DRUGNAME	SKL-NP
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D03YJW
DRUGNAME	Fus-1 tumor suppressor gene therapy
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D03YJZ
DRUGNAME	SDZ-89-104
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Terminated
	
TTDDRUID	D03YKE
DRUGNAME	FG-4592
INDICATI	Kidney disease [ICD-11: GC2Z] Phase 3
INDICATI	Anaemia [ICD-11: 3A90] Phase 3
	
TTDDRUID	D03YKO
DRUGNAME	VT-346
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D03YKQ
DRUGNAME	AD-452
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D03YLN
DRUGNAME	CP-67015
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D03YLZ
DRUGNAME	Thiamphenicol
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D03YMD
DRUGNAME	RP-805
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D03YOS
DRUGNAME	Phenoxodiol
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	D03YPL
DRUGNAME	RP-70676
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Terminated
	
TTDDRUID	D03YPR
DRUGNAME	HL-1983
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D03YSJ
DRUGNAME	NBI-29
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D03YSL
DRUGNAME	CAT-1000
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D03YSQ
DRUGNAME	SAR-405838
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03YVO
DRUGNAME	Methylnaltrexone bromide
INDICATI	Opioid-induced constipation [ICD-11: DB32.1] Approved
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D03YVR
DRUGNAME	Oxamflatin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D03YXI
DRUGNAME	PIKAMILONE
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D03YZJ
DRUGNAME	ALO-02
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D03ZAE
DRUGNAME	Peg-G-CSF
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D03ZBL
DRUGNAME	MMS-255
INDICATI	Multiple sclerosis [ICD-11: 8A40] Terminated
	
TTDDRUID	D03ZBM
DRUGNAME	NPC-567
INDICATI	Rhinitis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D03ZBN
DRUGNAME	Olprinone
INDICATI	Heart failure [ICD-11: BD10-BD13] Approved
	
TTDDRUID	D03ZBT
DRUGNAME	Crizotinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
	
TTDDRUID	D03ZCG
DRUGNAME	CMV vaccine
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Discontinued in Phase 1
	
TTDDRUID	D03ZCH
DRUGNAME	4SCAR19 and 4SCAR20
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D03ZDX
DRUGNAME	SM-88
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2/3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D03ZFG
DRUGNAME	Cerulenin
INDICATI	Weight loss [ICD-11: MG43.5] Approved
	
TTDDRUID	D03ZFN
DRUGNAME	Tromethamine
INDICATI	Acidosis [ICD-11: 5C73] Approved
	
TTDDRUID	D03ZGV
DRUGNAME	Co-60549
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D03ZHE
DRUGNAME	MDX-070
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2
	
TTDDRUID	D03ZHN
DRUGNAME	SL-65.1708
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1
	
TTDDRUID	D03ZIK
DRUGNAME	MT-001
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D03ZIP
DRUGNAME	LOAd703
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D03ZIS
DRUGNAME	PERFOSFAMIDE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D03ZJK
DRUGNAME	NNZ-3006
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D03ZKE
DRUGNAME	CS-003
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D03ZKM
DRUGNAME	UX-001
INDICATI	Hereditary inclusion body myositis [ICD-11: 4A41.2] Phase 3
INDICATI	Myopathy [ICD-11: 8C7Y] Phase 2
	
TTDDRUID	D03ZLN
DRUGNAME	SEL-403
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D03ZLR
DRUGNAME	Apimostinel
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D03ZME
DRUGNAME	Darinaparsin
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 2
INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2
	
TTDDRUID	D03ZMK
DRUGNAME	NTP-6009
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D03ZMY
DRUGNAME	AM-220
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D03ZNK
DRUGNAME	Tc99-labeled 14F7 humanized mab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D03ZOZ
DRUGNAME	PMID25666693-Compound-97
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D03ZPX
DRUGNAME	PRX-07034
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D03ZPY
DRUGNAME	SQ-33351
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D03ZSA
DRUGNAME	BMS-986016
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D03ZTE
DRUGNAME	Chenodiol
INDICATI	Cholelithiasis [ICD-11: DC11] Approved
	
TTDDRUID	D03ZVD
DRUGNAME	KW-4490
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D03ZVW
DRUGNAME	Vapiprost
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D03ZWR
DRUGNAME	APC-300
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D03ZXZ
DRUGNAME	XL-228
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D03ZYQ
DRUGNAME	Olokizumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] phase 3
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D03ZYZ
DRUGNAME	Prophylactic dengue fever vaccine
INDICATI	Flavivirus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D03ZZC
DRUGNAME	Vascugel
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 1/2
	
TTDDRUID	D03ZZH
DRUGNAME	SLV-313
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
	
TTDDRUID	D03ZZK
DRUGNAME	Fluocinonide
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D03ZZM
DRUGNAME	DMT310
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D03ZZX
DRUGNAME	123I-MNI-420
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 1
	
TTDDRUID	D04AAN
DRUGNAME	Mesoridazine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D04AAR
DRUGNAME	XB-513
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Terminated
	
TTDDRUID	D04AAW
DRUGNAME	Cidofovir
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Approved
	
TTDDRUID	D04ABS
DRUGNAME	CPH-102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D04ACD
DRUGNAME	[111In]B3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04ACK
DRUGNAME	Anti-CD30 CAR T cells
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D04ACW
DRUGNAME	Alogliptin/metformin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D04AEQ
DRUGNAME	V81444
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2
INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04AGG
DRUGNAME	Favipiravir
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D04AGM
DRUGNAME	PRTT-100
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D04AHQ
DRUGNAME	LY3009120
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04AHY
DRUGNAME	HT-2157
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1/2
	
TTDDRUID	D04AIB
DRUGNAME	AZD1772//RDX5791
INDICATI	Chronic kidney disease [ICD-11: GB61] Phase 2
	
TTDDRUID	D04AIT
DRUGNAME	B-Lactams
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D04AIV
DRUGNAME	Eteplirsen
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Approved
	
TTDDRUID	D04AKG
DRUGNAME	SER-287
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1
	
TTDDRUID	D04ALI
DRUGNAME	FHT-CT4
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D04AMD
DRUGNAME	ZD-6126
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D04APR
DRUGNAME	Tirilazad mesylate
INDICATI	Subarachnoid hemorrhage [ICD-11: 8B01] Approved
INDICATI	Cataract [ICD-11: 9B10] Approved
	
TTDDRUID	D04APY
DRUGNAME	KC-11404
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D04AQH
DRUGNAME	Sermorelin
INDICATI	Pediatric growth disorder [ICD-11: FB86] Approved
	
TTDDRUID	D04ARO
DRUGNAME	PEV-4
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D04ASA
DRUGNAME	X-083-NAB
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D04ASH
DRUGNAME	Leuprorelin acetate
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D04ASP
DRUGNAME	Influenza virus DNA vaccine
INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D04ATE
DRUGNAME	AT-009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04ATM
DRUGNAME	Trimegestone
INDICATI	Hormone replacement therapy [ICD-11: 8E01] Approved
	
TTDDRUID	D04ATY
DRUGNAME	Bulleyaconitine A
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D04AUA
DRUGNAME	MIV-170
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D04AYH
DRUGNAME	ADE-CRAN
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D04AYZ
DRUGNAME	CSL-654
INDICATI	Factor IX deficiency [ICD-11: 3B11] Phase 3
	
TTDDRUID	D04AZM
DRUGNAME	ARQ 736
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04AZT
DRUGNAME	MEDI1814
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D04BBA
DRUGNAME	Thiazole carboxamide derivative 24
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D04BBT
DRUGNAME	Heterocyclic derivative 12
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D04BCB
DRUGNAME	Lobeglitazone
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D04BCW
DRUGNAME	Ketobemidone
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D04BEN
DRUGNAME	Amrubicin
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D04BFC
DRUGNAME	CC-292
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
	
TTDDRUID	D04BFI
DRUGNAME	LGD-4665
INDICATI	Immune thrombocytopenic purpura [ICD-11: 3B64.13] Phase 2
	
TTDDRUID	D04BFU
DRUGNAME	LIDORESTAT
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D04BFX
DRUGNAME	IPL-423
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D04BHS
DRUGNAME	Recombinant batroxobin
INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Phase 2
	
TTDDRUID	D04BHY
DRUGNAME	KP-27
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04BIG
DRUGNAME	SR-90067
INDICATI	Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 2
	
TTDDRUID	D04BIY
DRUGNAME	NKTR-140
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D04BKO
DRUGNAME	Etripamil
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
INDICATI	Paroxysmal supraventricular tachycardia [ICD-11: BC81.Z] Phase 2
	
TTDDRUID	D04BKZ
DRUGNAME	Mangafodipir Trisodium
INDICATI	Magnetic resonance imaging of liver [ICD-11: ME21] Approved
	
TTDDRUID	D04BLE
DRUGNAME	A-3309
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 3
	
TTDDRUID	D04BMR
DRUGNAME	AL-59640
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative
	
TTDDRUID	D04BNA
DRUGNAME	RF1V
INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Phase 2
	
TTDDRUID	D04BNB
DRUGNAME	Lenzilumab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D04BNP
DRUGNAME	Temazepam
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D04BOK
DRUGNAME	DiabeCell
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D04BOT
DRUGNAME	Dalotuzumab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D04BPS
DRUGNAME	Naveglitazar
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D04BQR
DRUGNAME	Acecainide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D04BQV
DRUGNAME	Isofagomine tartrate
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2
	
TTDDRUID	D04BRF
DRUGNAME	TA-101
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D04BRW
DRUGNAME	Five membered heterocyclic benzamide derivative 2
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D04BSV
DRUGNAME	L-377202
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D04BSZ
DRUGNAME	PD-0204318
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D04BUH
DRUGNAME	Cizolirtine
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D04BVL
DRUGNAME	IM19
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D04BVN
DRUGNAME	PDGF-BB
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
	
TTDDRUID	D04BXA
DRUGNAME	Pyrazole derivative 32
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D04BXH
DRUGNAME	COTI-001
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative
	
TTDDRUID	D04BXJ
DRUGNAME	ED-1812
INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical
	
TTDDRUID	D04BXX
DRUGNAME	AN-019
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2
	
TTDDRUID	D04CBI
DRUGNAME	Oestradiol valerate and dienogest
INDICATI	Endometriosis [ICD-11: GA10] Approved
INDICATI	Contraception [ICD-11: QA21] Approved
	
TTDDRUID	D04CCK
DRUGNAME	MT-119
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04CCX
DRUGNAME	PMID30107136-Compound-Example14
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D04CDO
DRUGNAME	TAS-102
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
	
TTDDRUID	D04CEY
DRUGNAME	PYM-50018
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Preclinical
	
TTDDRUID	D04CFL
DRUGNAME	SB 242784
INDICATI	Arterial calcification [ICD-11: BD52.Y] Preclinical
	
TTDDRUID	D04CFW
DRUGNAME	Bacampicillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D04CJE
DRUGNAME	ATF-936
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1
	
TTDDRUID	D04CJL
DRUGNAME	Ferric citrate
INDICATI	Chronic kidney disease [ICD-11: GB61] Approved
	
TTDDRUID	D04CJN
DRUGNAME	CTP-298
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D04CKB
DRUGNAME	IkT-001
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D04CKC
DRUGNAME	GPC3-CART cells
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
	
TTDDRUID	D04CKG
DRUGNAME	SPI-2012
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D04CKR
DRUGNAME	CAL-103-R
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D04CLH
DRUGNAME	PMID26048809-compound2
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D04CLM
DRUGNAME	YM-758
INDICATI	Angina pectoris [ICD-11: BA40] Phase 2
	
TTDDRUID	D04CNX
DRUGNAME	Ro-25-1132
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D04CON
DRUGNAME	SL-89.0591
INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2
	
TTDDRUID	D04CQK
DRUGNAME	MK-8521
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D04CQV
DRUGNAME	Cis-urocanic acid
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D04CRL
DRUGNAME	Glatiramer Acetate
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
	
TTDDRUID	D04CRN
DRUGNAME	Atomoxetine
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
	
TTDDRUID	D04CSZ
DRUGNAME	Menthol
INDICATI	Throat irritation [ICD-11: CA0Y] Approved
	
TTDDRUID	D04CTD
DRUGNAME	SNDX-6352
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04CTP
DRUGNAME	EP-200
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04CUZ
DRUGNAME	SRG
INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative
	
TTDDRUID	D04CWI
DRUGNAME	Galidesivir
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D04CWS
DRUGNAME	Anti-M1 prime
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D04CXX
DRUGNAME	GNKG-168
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	D04CYD
DRUGNAME	ONT-10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04DAL
DRUGNAME	LAS-41001
INDICATI	Rosacea [ICD-11: ED90.0] Discontinued in Preregistration
	
TTDDRUID	D04DBA
DRUGNAME	BAG956
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Investigative
	
TTDDRUID	D04DDW
DRUGNAME	MK-49
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D04DFJ
DRUGNAME	Pulmonary insulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D04DFR
DRUGNAME	FX005
INDICATI	Melanoma [ICD-11: 2C30] Phase 2/3
	
TTDDRUID	D04DGE
DRUGNAME	SB-247853
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D04DHZ
DRUGNAME	CART-EGFR
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D04DJN
DRUGNAME	Dihydrotestosterone
INDICATI	Prostate hyperplasia [ICD-11: GA90] Phase 4
	
TTDDRUID	D04DJS
DRUGNAME	ICI 118,551
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D04DKH
DRUGNAME	NAFTOPIDIL
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D04DKL
DRUGNAME	ALT-836
INDICATI	Adult respiratory distress syndrome [ICD-11: CB00] Phase 2
	
TTDDRUID	D04DLW
DRUGNAME	NA-1 neuroprotectant
INDICATI	Stroke [ICD-11: 8B20] Phase 2
	
TTDDRUID	D04DMO
DRUGNAME	FR-194738
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Terminated
	
TTDDRUID	D04DMQ
DRUGNAME	Fabesetron
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2
	
TTDDRUID	D04DMZ
DRUGNAME	AVXS-101
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 3
	
TTDDRUID	D04DNB
DRUGNAME	Xentuzumab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D04DNL
DRUGNAME	ALN-FLU01
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Preclinical
	
TTDDRUID	D04DQO
DRUGNAME	ABBV-257
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D04DQP
DRUGNAME	ADRIAC-36
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04DQT
DRUGNAME	Ribavirin + interferon beta-1a
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D04DQZ
DRUGNAME	AZD-2327
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D04DSD
DRUGNAME	TEI-5178
INDICATI	Nephritis [ICD-11: GB40] Phase 1
	
TTDDRUID	D04DTH
DRUGNAME	Emapalumab
INDICATI	Primary haemophagocytic lymphohistiocytosis [ICD-11: 4A01.23] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D04DUF
DRUGNAME	Phenylsulfonyl derivative 2
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Patented
	
TTDDRUID	D04DUG
DRUGNAME	AAV-GUS
INDICATI	Genetic disease [ICD-11: 8E02] Terminated
	
TTDDRUID	D04DUH
DRUGNAME	PMI-005
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
	
TTDDRUID	D04DUJ
DRUGNAME	S-2474
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D04DVA
DRUGNAME	HAp-IFN
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D04DVF
DRUGNAME	CHF-1522
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D04DXA
DRUGNAME	Tofogliflozin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D04DXN
DRUGNAME	Benzoyl peroxide
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D04DYA
DRUGNAME	SMTP-0
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04DYC
DRUGNAME	PF-06463922
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D04DYZ
DRUGNAME	ABT-839
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Terminated
	
TTDDRUID	D04DZD
DRUGNAME	Bidisomide
INDICATI	Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 3
	
TTDDRUID	D04DZE
DRUGNAME	BRL 26830A
INDICATI	Obesity [ICD-11: 5B81] Terminated
	
TTDDRUID	D04EAT
DRUGNAME	MCS-110
INDICATI	Bone metastases [ICD-11: 2D50] Phase 2
INDICATI	Tenosynovial giant cell tumour [ICD-11: 2F7B] Phase 2
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D04EAZ
DRUGNAME	M102.4
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D04EDM
DRUGNAME	PMID25684022-Compound-US20120277229 41(1.3)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D04EET
DRUGNAME	West Nile virus vaccine
INDICATI	West nile virus infection [ICD-11: 1D46] Terminated
	
TTDDRUID	D04EFB
DRUGNAME	OP-03
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D04EFG
DRUGNAME	DD-3
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D04EFK
DRUGNAME	DDP-225
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
INDICATI	Chronic functional vomiting [ICD-11: DD90.4] Discontinued in Phase 2
	
TTDDRUID	D04EGR
DRUGNAME	1-MNA
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2/3
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D04EGX
DRUGNAME	Cabergoline
INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Approved
	
TTDDRUID	D04EHF
DRUGNAME	DAV-132
INDICATI	Toxicity [ICD-11: N.A.] Investigative
	
TTDDRUID	D04EIF
DRUGNAME	LOXORIBINE
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2
	
TTDDRUID	D04EIL
DRUGNAME	YM-344031
INDICATI	Asthma [ICD-11: CA23] Preclinical
	
TTDDRUID	D04EIX
DRUGNAME	AA-102
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical
	
TTDDRUID	D04EJG
DRUGNAME	SHR-1314
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1/2
	
TTDDRUID	D04ELD
DRUGNAME	Glassia
INDICATI	Emphysema [ICD-11: CA21] Approved
	
TTDDRUID	D04ELS
DRUGNAME	ISCAR
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D04EMB
DRUGNAME	IW-1973
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D04ENF
DRUGNAME	Gene therapy, retinopathy,
INDICATI	Retinopathy [ICD-11: 9B71] Investigative
	
TTDDRUID	D04ENK
DRUGNAME	TCV-309
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2
	
TTDDRUID	D04EOH
DRUGNAME	APC-003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04EON
DRUGNAME	BAL-101553
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D04EPP
DRUGNAME	RTL-342m
INDICATI	Optic neuritis [ICD-11: 9C40.1] Investigative
	
TTDDRUID	D04EPS
DRUGNAME	ON-24160
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04EQF
DRUGNAME	MT-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04EQX
DRUGNAME	BIIB-098
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
	
TTDDRUID	D04ERQ
DRUGNAME	CXD-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04ESH
DRUGNAME	PMID30107136-Compound-Example8
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D04ETV
DRUGNAME	Nemonaxacin
INDICATI	Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Phase 3
	
TTDDRUID	D04EVE
DRUGNAME	VR876
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
	
TTDDRUID	D04EXW
DRUGNAME	A-Fizz
INDICATI	Anal fistula [ICD-11: DB50.1] Investigative
	
TTDDRUID	D04EXX
DRUGNAME	KBF-611
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D04EYC
DRUGNAME	Metaraminol
INDICATI	Hypotension [ICD-11: BA20-BA21] Approved
	
TTDDRUID	D04EYG
DRUGNAME	Ranibizumab
INDICATI	Hereditary hemorrhagic telangiectasia [ICD-11: LA90.00] Approved
	
TTDDRUID	D04EZI
DRUGNAME	Peru-15 pCTB
INDICATI	Diarrhea [ICD-11: ME05.1] Phase 1
	
TTDDRUID	D04EZR
DRUGNAME	SIG-003
INDICATI	Respiratory disease [ICD-11: CB40] Investigative
	
TTDDRUID	D04FAC
DRUGNAME	SHEF-1
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D04FAI
DRUGNAME	SCIO-323
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Preclinical
	
TTDDRUID	D04FBR
DRUGNAME	Mycophenolate mofetil
INDICATI	Organ transplant rejection [ICD-11: NE84] Approved
INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 3
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D04FDN
DRUGNAME	Palifosfamide
INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2
	
TTDDRUID	D04FFM
DRUGNAME	ADXS-HPV
INDICATI	Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Phase 2
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2
	
TTDDRUID	D04FFY
DRUGNAME	AMG-8563
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D04FGX
DRUGNAME	EP-302
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04FHB
DRUGNAME	R547
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D04FHY
DRUGNAME	BL-7020
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D04FIO
DRUGNAME	Aom-0871
INDICATI	Transplant rejection [ICD-11: NE84] Investigative
	
TTDDRUID	D04FIP
DRUGNAME	Cyclodextrin
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 4
	
TTDDRUID	D04FKX
DRUGNAME	D-3263
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04FMB
DRUGNAME	XK-469
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04FNQ
DRUGNAME	BIM23A760
INDICATI	Acromegaly [ICD-11: 5A60.0] Phase 2
INDICATI	Carcinoid syndrome [ICD-11: 5B10] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 3
	
TTDDRUID	D04FNR
DRUGNAME	Mitumomab
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D04FOP
DRUGNAME	Ravulizumab
INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D04FPN
DRUGNAME	CD19 CAR-T lymphocytes
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
	
TTDDRUID	D04FQD
DRUGNAME	PH-80
INDICATI	Premenstrual syndrome [ICD-11: GA34.40] Phase 3
	
TTDDRUID	D04FRB
DRUGNAME	CGP-13774
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D04FRL
DRUGNAME	PMID25666693-Compound-44
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D04FRU
DRUGNAME	LLG783
INDICATI	Intermittent claudication [ICD-11: BD40.00] Phase 2
INDICATI	Vascular systems peripheral arterial disorder [ICD-11: BD5Z] Phase 2
	
TTDDRUID	D04FSD
DRUGNAME	TgAAG76
INDICATI	Blindness [ICD-11: 9D90] Phase 1/2
	
TTDDRUID	D04FTB
DRUGNAME	AR-H049020
INDICATI	Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 1
	
TTDDRUID	D04FVD
DRUGNAME	TGBA01AD
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2
	
TTDDRUID	D04FVU
DRUGNAME	Palonosetron
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D04FWP
DRUGNAME	AMG 157
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D04FXE
DRUGNAME	KW-3433
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D04FXS
DRUGNAME	Didox
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D04FXY
DRUGNAME	SMT-19969
INDICATI	C. difficile infection [ICD-11: 1A04] Phase 3
	
TTDDRUID	D04FYI
DRUGNAME	H pylori vaccine
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Terminated
	
TTDDRUID	D04FYL
DRUGNAME	Contusugene ladenovec
INDICATI	Oral cancer [ICD-11: 2B6E] Phase 3
INDICATI	Liver metastasis [ICD-11: 2D80] Phase 1
	
TTDDRUID	D04FYM
DRUGNAME	Genital herpes therapy
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1
	
TTDDRUID	D04FYU
DRUGNAME	DMP-444
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 3
	
TTDDRUID	D04FYZ
DRUGNAME	Plevitrexed (R)-isomer
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
	
TTDDRUID	D04GAG
DRUGNAME	GBR 1342
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D04GBP
DRUGNAME	QR-010
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1/2
	
TTDDRUID	D04GBW
DRUGNAME	IC31 seasonal influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D04GCC
DRUGNAME	N-acylpiperidine ether derivative 6
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D04GCH
DRUGNAME	Bmab-200
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04GCV
DRUGNAME	APS-2010
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D04GDI
DRUGNAME	NP93-31
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D04GEI
DRUGNAME	TAK-448
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D04GFO
DRUGNAME	MC-2001
INDICATI	leukaemia [ICD-11: 2A60-2B33] Preclinical
	
TTDDRUID	D04GGA
DRUGNAME	StaphStop
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative
	
TTDDRUID	D04GGG
DRUGNAME	CD123/CLL1 CAR-T Cells
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2/3
	
TTDDRUID	D04GGJ
DRUGNAME	WST-057
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 1
	
TTDDRUID	D04GGQ
DRUGNAME	MPC-0767
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04GIJ
DRUGNAME	Piperazine urea derivative 4
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D04GIO
DRUGNAME	Anti-CD19 and Anti-CD20 CAR-T Cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D04GJN
DRUGNAME	Megestrol
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D04GJX
DRUGNAME	ZD-9720
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D04GKL
DRUGNAME	RAXOFELAST
INDICATI	Ischemia [ICD-11: 8B10-8B11] Phase 2
	
TTDDRUID	D04GKO
DRUGNAME	Cilazapril
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D04GKP
DRUGNAME	AS-902330
INDICATI	Arthropathy [ICD-11: FA11-FA38] Phase 2
	
TTDDRUID	D04GLJ
DRUGNAME	OCFENTANIL
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D04GMY
DRUGNAME	TD-5108
INDICATI	Gastroparesis [ICD-11: DA41.00] Phase 2
	
TTDDRUID	D04GNG
DRUGNAME	CC-90011
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04GNX
DRUGNAME	SHP615
INDICATI	Seizure disorder [ICD-11: 8A6Z] Phase 2
	
TTDDRUID	D04GPZ
DRUGNAME	Hyaluronidase (ovine)
INDICATI	Resorption of radiopaque agents [ICD-11: N.A.] Approved
	
TTDDRUID	D04GRB
DRUGNAME	THRX-198321
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D04GSA
DRUGNAME	DAU-6285
INDICATI	Vomiting [ICD-11: MD90] Terminated
	
TTDDRUID	D04GSL
DRUGNAME	ImmuCyst
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Approved
	
TTDDRUID	D04GSV
DRUGNAME	TRICIRIBINE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D04GSY
DRUGNAME	Buserelin acetate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D04GTA
DRUGNAME	Pegsunercept
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D04GTW
DRUGNAME	ReSX-i
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D04GVN
DRUGNAME	PF-807925
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D04GWO
DRUGNAME	Otilimab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D04GWY
DRUGNAME	Telinavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D04GXS
DRUGNAME	BL-1893
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D04GYO
DRUGNAME	Oxiconazole
INDICATI	Tinea pedis [ICD-11: 1F28.2] Approved
	
TTDDRUID	D04GZA
DRUGNAME	Gentian violet
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D04GZS
DRUGNAME	Tempol
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2
	
TTDDRUID	D04HAA
DRUGNAME	WL-276
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04HAF
DRUGNAME	LY-2624803
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2
	
TTDDRUID	D04HBH
DRUGNAME	AM-3701
INDICATI	Bone metastases [ICD-11: 2D50] Investigative
	
TTDDRUID	D04HBJ
DRUGNAME	IGFBP 2 variants
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04HBL
DRUGNAME	PMID30107136-Compound-Example59
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D04HCS
DRUGNAME	PMID25666693-Compound-93
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D04HDZ
DRUGNAME	GRN163
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D04HER
DRUGNAME	SOM-0999
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D04HEW
DRUGNAME	PMID26815044-Compound-32
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D04HHW
DRUGNAME	FK-011
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D04HIS
DRUGNAME	Varilrix
INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Approved
	
TTDDRUID	D04HIZ
DRUGNAME	BO-653
INDICATI	Artery stenosis [ICD-11: BD52] Discontinued in Phase 2
	
TTDDRUID	D04HJE
DRUGNAME	AZ-01, PEGylated interferon-beta
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D04HLE
DRUGNAME	Vitaxin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D04HMD
DRUGNAME	Glyphosate
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D04HMK
DRUGNAME	Hi8 melanoma vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D04HMM
DRUGNAME	XP-20925
INDICATI	Migraine [ICD-11: 8A80] Preclinical
	
TTDDRUID	D04HOT
DRUGNAME	LFG-316
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
	
TTDDRUID	D04HQA
DRUGNAME	FIT-06
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D04HQC
DRUGNAME	SB-9200
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D04HQJ
DRUGNAME	AB-103
INDICATI	Necrotizing soft tissue infection [ICD-11: 1B71] Phase 3
	
TTDDRUID	D04HQT
DRUGNAME	proglumide
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D04HSH
DRUGNAME	IMGN289
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04HTL
DRUGNAME	ABX-0402
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D04HUC
DRUGNAME	mRNA-046
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04HVB
DRUGNAME	Panomifene
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D04HWK
DRUGNAME	IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
	
TTDDRUID	D04HXB
DRUGNAME	Meningitec
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D04HXP
DRUGNAME	PN-2XXX
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative
	
TTDDRUID	D04HXS
DRUGNAME	REC-15/3079
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2
	
TTDDRUID	D04HYR
DRUGNAME	XN-05
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04HZX
DRUGNAME	CCX-832
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1
	
TTDDRUID	D04IAJ
DRUGNAME	MVA62B
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D04IBA
DRUGNAME	Ellipravin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D04IBG
DRUGNAME	Infanrix-DTaP-IPV-Hep B
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D04IBI
DRUGNAME	ABX-301
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D04ICN
DRUGNAME	DuP-630
INDICATI	Dermatitis [ICD-11: EA80-EA89] Terminated
	
TTDDRUID	D04IDT
DRUGNAME	Helicobacter vaccine
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Terminated
	
TTDDRUID	D04IEM
DRUGNAME	Nartograstim
INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Approved
	
TTDDRUID	D04IFD
DRUGNAME	GR-ARA1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04IFU
DRUGNAME	GSK835726
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2
	
TTDDRUID	D04IHB
DRUGNAME	RUTI
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2
	
TTDDRUID	D04IIU
DRUGNAME	INDISULAM
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
	
TTDDRUID	D04IJZ
DRUGNAME	Microplasmin
INDICATI	Eye disorder [ICD-11: 9A01-9A0Z] Phase 3
	
TTDDRUID	D04IKF
DRUGNAME	18F-LMI-1195
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D04IME
DRUGNAME	SCH-48461
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D04INP
DRUGNAME	Pixykine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D04IPX
DRUGNAME	WEHI-0103122
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04IQH
DRUGNAME	PF-655
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	D04ITO
DRUGNAME	Rifaximin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D04ITR
DRUGNAME	PMID26868298-compound-N3
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D04IUB
DRUGNAME	NT0202
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
	
TTDDRUID	D04IUQ
DRUGNAME	SonoRx
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved
	
TTDDRUID	D04IUY
DRUGNAME	APC-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04IWZ
DRUGNAME	PT2.0
INDICATI	Clostridium infection [ICD-11: 1A04] Investigative
	
TTDDRUID	D04IXD
DRUGNAME	IPH-2101
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D04IXJ
DRUGNAME	Bimetopyrole
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D04IXL
DRUGNAME	HCV vaccine
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D04JAB
DRUGNAME	Tcelna
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D04JAQ
DRUGNAME	FH-AAV8
INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Investigative
	
TTDDRUID	D04JAT
DRUGNAME	PF-4427429
INDICATI	Migraine [ICD-11: 8A80] Phase 1
	
TTDDRUID	D04JCD
DRUGNAME	Six-membered heterocyclic benzamide derivative 6
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D04JCN
DRUGNAME	Pergolide
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D04JCT
DRUGNAME	AA-204
INDICATI	Kidney disease [ICD-11: GC2Z] Investigative
	
TTDDRUID	D04JEE
DRUGNAME	Propranolol
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D04JFB
DRUGNAME	RX-20001
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D04JFG
DRUGNAME	BMS-986253
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D04JFT
DRUGNAME	KW-5139
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D04JGA
DRUGNAME	BMS-191095
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1
	
TTDDRUID	D04JHH
DRUGNAME	CAR-T cells targeting CD19
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D04JHN
DRUGNAME	Hydromorphone
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
INDICATI	Chronic pain [ICD-11: MG30] Phase 3
	
TTDDRUID	D04JIE
DRUGNAME	SER-201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04JIM
DRUGNAME	UCB-35440
INDICATI	Rhinitis [ICD-11: FA20] Phase 2
	
TTDDRUID	D04JIS
DRUGNAME	OG-Cx-833
INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative
	
TTDDRUID	D04JJE
DRUGNAME	RP-66153
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D04JKE
DRUGNAME	Promostem
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D04JKG
DRUGNAME	TherAtoH
INDICATI	Hearing disorder [ICD-11: AB50-AB57] Investigative
	
TTDDRUID	D04JLW
DRUGNAME	AWD-72-011
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D04JMG
DRUGNAME	CEQ-626
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D04JMI
DRUGNAME	Plasma derived human butyrylcholinesterase
INDICATI	Neurotoxicity [ICD-11: NE61] Phase 1
	
TTDDRUID	D04JMQ
DRUGNAME	Flurithromycin ethylsuccinate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D04JNC
DRUGNAME	ZL-N-91
INDICATI	Lung inflammation [ICD-11: CA40.Z] Investigative
	
TTDDRUID	D04JNI
DRUGNAME	GSK2245840
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D04JNZ
DRUGNAME	PROSTRATIN
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D04JOE
DRUGNAME	Placulumab
INDICATI	Sciatica [ICD-11: ME84.3] Phase 1/2
	
TTDDRUID	D04JPJ
DRUGNAME	Lomustine
INDICATI	Brain cancer [ICD-11: 2A00] Approved
	
TTDDRUID	D04JPQ
DRUGNAME	PSN-101
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D04JQR
DRUGNAME	LY-367385
INDICATI	Neurological disorder [ICD-11: 6B60] Terminated
	
TTDDRUID	D04JRK
DRUGNAME	P-1104
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D04JSE
DRUGNAME	MK-7725
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D04JSI
DRUGNAME	CAR-T cells targeting CD133
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical
	
TTDDRUID	D04JTD
DRUGNAME	PX-12
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D04JTX
DRUGNAME	BI-224436
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D04JTY
DRUGNAME	Thiolactomycin
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
INDICATI	Urinary tract infection [ICD-11: GC08] Investigative
	
TTDDRUID	D04JVU
DRUGNAME	Long-acting IFN-alpha
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D04JVX
DRUGNAME	AKP-320
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D04JYK
DRUGNAME	GC-1107
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 3
	
TTDDRUID	D04JZD
DRUGNAME	Polyvalent crotalid antivenin ovine fab
INDICATI	Poison intoxication [ICD-11: NE6Z] Approved
	
TTDDRUID	D04JZH
DRUGNAME	PF-01247324
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D04JZP
DRUGNAME	Mazapertine succinate
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2
	
TTDDRUID	D04KAQ
DRUGNAME	Pivampicillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D04KBL
DRUGNAME	Bevacizumab
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Approved
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
INDICATI	Brain metastases [ICD-11: 2D50] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Application submitted
	
TTDDRUID	D04KBU
DRUGNAME	AIR-001
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D04KCT
DRUGNAME	Org-21465
INDICATI	Anaesthesia [ICD-11: 9A78.6] Discontinued in Phase 1
	
TTDDRUID	D04KEL
DRUGNAME	EV-086
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D04KFR
DRUGNAME	NVP-SAA164
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D04KGB
DRUGNAME	Anti-IFN-alpha human mabs
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D04KHH
DRUGNAME	CEFCANEL DALOXATE HYDROCHLORIDE
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3
	
TTDDRUID	D04KHY
DRUGNAME	Spiroglumide
INDICATI	Stomach disease [ICD-11: DA43-DA4Y] Phase 2
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1
	
TTDDRUID	D04KIH
DRUGNAME	Ac-YVAD-FMK
INDICATI	Photocontact dermatitis [ICD-11: EK20] Patented
INDICATI	Irritant contact dermatitis [ICD-11: EK02] Patented
INDICATI	Allergic contact dermatitis [ICD-11: EK00] Patented
	
TTDDRUID	D04KJO
DRUGNAME	Formoterol
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D04KJT
DRUGNAME	ABT-333
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D04KKE
DRUGNAME	Diaziquone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D04KKX
DRUGNAME	QX-30002222
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D04KMO
DRUGNAME	CGP-35348
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D04KMP
DRUGNAME	SUVN-G3031
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3
	
TTDDRUID	D04KMQ
DRUGNAME	GSK3117391
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D04KNL
DRUGNAME	PG-545
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 1
	
TTDDRUID	D04KQF
DRUGNAME	Tubacin
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D04KRV
DRUGNAME	Iofolastat I-124
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D04KTI
DRUGNAME	LY3127804
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D04KTZ
DRUGNAME	Cloxacillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D04KUJ
DRUGNAME	Purine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D04KUK
DRUGNAME	Medium chain triglycerides
INDICATI	Lymphatic disease [ICD-11: BD9Z] Approved
	
TTDDRUID	D04KVA
DRUGNAME	BVI-007
INDICATI	Thrombotic stroke [ICD-11: 8B20] Phase 1
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1
	
TTDDRUID	D04KVQ
DRUGNAME	BAY-86-9596
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04KWH
DRUGNAME	Des-Arg(9)-[Leu(8)]-BK
INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative
	
TTDDRUID	D04KWO
DRUGNAME	MEDl-551
INDICATI	Scleroderma [ICD-11: 4A42] Phase 1
	
TTDDRUID	D04KWY
DRUGNAME	RTI-336
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 1
	
TTDDRUID	D04KXF
DRUGNAME	CEFTRAZONAL BOPENTIL
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D04KYB
DRUGNAME	ASCJ-9
INDICATI	Alopecia [ICD-11: ED70] Phase 2
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D04KYY
DRUGNAME	Allopurinol
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Approved
	
TTDDRUID	D04KZH
DRUGNAME	FluBiovax
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D04KZN
DRUGNAME	CTP-354
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1
	
TTDDRUID	D04KZS
DRUGNAME	PRO-045
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2
	
TTDDRUID	D04KZY
DRUGNAME	Gilteritinib
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
	
TTDDRUID	D04LAQ
DRUGNAME	Candoxatrilat
INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 1
	
TTDDRUID	D04LBC
DRUGNAME	Iclaprim
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
INDICATI	Pneumonia [ICD-11: CA40] Phase 2
INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Application submitted
	
TTDDRUID	D04LBJ
DRUGNAME	ASOBAMAST
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D04LCQ
DRUGNAME	Tafluprost
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D04LCX
DRUGNAME	Vax-SPIRAL
INDICATI	Leptospira infection [ICD-11: 1B91] Approved
	
TTDDRUID	D04LDH
DRUGNAME	BZ6
INDICATI	Ataxia-telangiectasia [ICD-11: 4A01.31] Investigative
	
TTDDRUID	D04LDK
DRUGNAME	TZP-202
INDICATI	Dyspepsia [ICD-11: MD92] Preclinical
	
TTDDRUID	D04LEH
DRUGNAME	LTX-03
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D04LEK
DRUGNAME	GSK729327
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
	
TTDDRUID	D04LFG
DRUGNAME	CGP-25454A
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated
	
TTDDRUID	D04LFR
DRUGNAME	SAR404460
INDICATI	Pre-sarcopenia [ICD-11: FB32.Y] Phase 1
	
TTDDRUID	D04LGK
DRUGNAME	VRT-750018
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D04LHG
DRUGNAME	SP-SAP
INDICATI	Cancer related pain [ICD-11: MG30] Investigative
	
TTDDRUID	D04LHJ
DRUGNAME	Methscopolamine Bromide
INDICATI	Nausea and vomiting [ICD-11: MD90] Approved
	
TTDDRUID	D04LIH
DRUGNAME	AVI-6002
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D04LIR
DRUGNAME	PD-159913
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D04LJB
DRUGNAME	NP-213
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2
	
TTDDRUID	D04LKS
DRUGNAME	Ruxolitinib
INDICATI	High-risk myelofibrosis [ICD-11: 2A20.2] Approved
INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Approved
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1/2
INDICATI	Vitiligo [ICD-11: ED63.0] Phase 1/2
	
TTDDRUID	D04LMJ
DRUGNAME	MMB-4
INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative
	
TTDDRUID	D04LMZ
DRUGNAME	X-22
INDICATI	Smoking dependence [ICD-11: 6C4A.2] Phase 2
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 2
	
TTDDRUID	D04LOR
DRUGNAME	BMS-919373
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2
	
TTDDRUID	D04LPZ
DRUGNAME	SAB-301
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1
	
TTDDRUID	D04LQN
DRUGNAME	ELAD
INDICATI	Acute liver failure [ICD-11: DB91] Phase 3
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2/3
	
TTDDRUID	D04LRQ
DRUGNAME	TDI-0059
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D04LRU
DRUGNAME	AHR-16462B
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D04LSD
DRUGNAME	ABT-239
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
	
TTDDRUID	D04LSH
DRUGNAME	SAR101099
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 1
	
TTDDRUID	D04LTF
DRUGNAME	TLN-4601
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D04LTO
DRUGNAME	Steamchol
INDICATI	Gallstone [ICD-11: DC11.3] Investigative
	
TTDDRUID	D04LTQ
DRUGNAME	Buproprion+zonisamide
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D04LUG
DRUGNAME	BSP-C801
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D04LVK
DRUGNAME	Ceritinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
	
TTDDRUID	D04LWT
DRUGNAME	GSK1440115
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D04LXB
DRUGNAME	Captisol-enabled Melphalan
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D04LYD
DRUGNAME	Azosemide
INDICATI	Edema [ICD-11: MG29] Approved
	
TTDDRUID	D04LZF
DRUGNAME	NVX-208
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 1/2
	
TTDDRUID	D04MBK
DRUGNAME	AGS-67E
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Malignant lymphatic [ICD-11: 2A82] Phase 1
	
TTDDRUID	D04MBQ
DRUGNAME	iPSC-derived RPE (autologous)
INDICATI	Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1
	
TTDDRUID	D04MBS
DRUGNAME	BMS-182657
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D04MCY
DRUGNAME	BMS 650032
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D04MDJ
DRUGNAME	Cefdaloxime pentexil tosilate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D04MDO
DRUGNAME	HuL2G7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04MEB
DRUGNAME	Antituberculosis agents
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D04MEM
DRUGNAME	ORMD-1001
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D04MFQ
DRUGNAME	Myotubularin
INDICATI	Myotonic dystrophy [ICD-11: 8C71.0] Investigative
	
TTDDRUID	D04MFW
DRUGNAME	DL-3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D04MFY
DRUGNAME	AJ-3941
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D04MGD
DRUGNAME	Elpetrigine
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1
	
TTDDRUID	D04MGI
DRUGNAME	PF-821385
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical
	
TTDDRUID	D04MGU
DRUGNAME	Technetium (99m Tc) bicisate
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Approved
	
TTDDRUID	D04MGW
DRUGNAME	BI-836858
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D04MHP
DRUGNAME	AZP-2006
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D04MHV
DRUGNAME	Heterocyclic derivative 17
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D04MKJ
DRUGNAME	Renzapride
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 3
	
TTDDRUID	D04MLE
DRUGNAME	GKA-23
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D04MLR
DRUGNAME	CD123-specific gene-engineered T cells
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D04MMJ
DRUGNAME	ADX-2 series
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D04MNL
DRUGNAME	SERM-3339
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2
	
TTDDRUID	D04MOF
DRUGNAME	Milveterol+Fluticasone
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D04MOZ
DRUGNAME	NB3178
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D04MPB
DRUGNAME	Bevirimat
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D04MPV
DRUGNAME	Pyrazole derivative 15
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D04MRA
DRUGNAME	BAY-73-7977
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D04MRG
DRUGNAME	Stevioside
INDICATI	Sweetener [ICD-11: N.A.] Approved
	
TTDDRUID	D04MRQ
DRUGNAME	Irsogladine
INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Approved
	
TTDDRUID	D04MRX
DRUGNAME	Chondroitinase
INDICATI	Intervertebral disc displacement [ICD-11: FB1Y] Investigative
	
TTDDRUID	D04MSM
DRUGNAME	Carbamazepine
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
INDICATI	Type-1 diabetes [ICD-11: 5A10] NDA filed
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
	
TTDDRUID	D04MUQ
DRUGNAME	RiVax + TVax
INDICATI	Ricin poisoning [ICD-11: NE61] Phase 1
	
TTDDRUID	D04MWJ
DRUGNAME	Methacholine Chloride
INDICATI	bronchial hyperreactivity [ICD-11: CB40] Approved
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D04MXN
DRUGNAME	CEP-32496
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D04MXO
DRUGNAME	BCX-5191
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D04MXV
DRUGNAME	VGV-L
INDICATI	Lyme disease [ICD-11: 1C1G] Investigative
	
TTDDRUID	D04MYC
DRUGNAME	NSC-625487
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D04MYG
DRUGNAME	Fenbunafide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04MYO
DRUGNAME	ABN-912
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D04MYS
DRUGNAME	LL-4218
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D04MZP
DRUGNAME	NI-0101
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D04MZR
DRUGNAME	Bucelipase alfa
INDICATI	Exocrine pancreatic insufficiency [ICD-11: DC35.1] Phase 3
	
TTDDRUID	D04NAQ
DRUGNAME	Emricasan
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Phase 2
INDICATI	Liver cirrhosis [ICD-11: DB93.1] Phase 2
	
TTDDRUID	D04NBY
DRUGNAME	SPVF-2801-10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04NCC
DRUGNAME	PMID28350212-Compound-18
INDICATI	Alzheimer disease [ICD-11: 8A20] Patented
	
TTDDRUID	D04NCJ
DRUGNAME	BMY-21950
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D04NCK
DRUGNAME	Streptokinase
INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 4
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 3
	
TTDDRUID	D04NDK
DRUGNAME	Oral human gammaglobulin
INDICATI	Juvenile idiopathic arthritis [ICD-11: FA24] Phase 2
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2
	
TTDDRUID	D04NDM
DRUGNAME	Paromomycin
INDICATI	Intestinal amebiasis [ICD-11: 1A36] Approved
	
TTDDRUID	D04NFB
DRUGNAME	DMP-963
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D04NHQ
DRUGNAME	HSV529
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1
	
TTDDRUID	D04NIZ
DRUGNAME	AMG 747
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D04NJP
DRUGNAME	TRF-1101
INDICATI	Sickle-cell anaemia [ICD-11: 3A51] Phase 2
	
TTDDRUID	D04NJS
DRUGNAME	SAR351034
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 1
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D04NKJ
DRUGNAME	Alferon LDO
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 2
	
TTDDRUID	D04NMF
DRUGNAME	DISC-PRO
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Discontinued in Phase 1
	
TTDDRUID	D04NMJ
DRUGNAME	PMID25553724-Compound-US2012830453910
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented
	
TTDDRUID	D04NNJ
DRUGNAME	ZANOTERONE
INDICATI	Prostate hyperplasia [ICD-11: GA90] Phase 3
	
TTDDRUID	D04NNK
DRUGNAME	Recombinant therapeutic proteins
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04NOE
DRUGNAME	OTSGC-A24
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
	
TTDDRUID	D04NPP
DRUGNAME	SLX-2101
INDICATI	Raynaud disease [ICD-11: BD42.0] Discontinued in Phase 2
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2
	
TTDDRUID	D04NPR
DRUGNAME	Lu AF35700
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D04NPX
DRUGNAME	ZD-1611
INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 1
	
TTDDRUID	D04NQI
DRUGNAME	Amodiaquine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D04NQZ
DRUGNAME	V502
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 1
	
TTDDRUID	D04NRB
DRUGNAME	Cetilistat
INDICATI	Obesity [ICD-11: 5B81] Phase 3
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
	
TTDDRUID	D04NRP
DRUGNAME	ALS-2135
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D04NRV
DRUGNAME	IMM-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D04NSW
DRUGNAME	S-12340
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D04NTJ
DRUGNAME	Glisoxepide
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D04NVG
DRUGNAME	Angiotensin (1-7)
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D04NVK
DRUGNAME	ShRNA molecule silencing DNAPK radiosensitizer
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D04NWP
DRUGNAME	DRAFLAZINE
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2
	
TTDDRUID	D04NWU
DRUGNAME	ONO-4053
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D04NXG
DRUGNAME	PMID26651364-Compound-128
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D04NXL
DRUGNAME	Indibulin
INDICATI	Advanced sarcoma [ICD-11: 2A60-2C35] Phase 2
	
TTDDRUID	D04NXQ
DRUGNAME	Pefloxacin
INDICATI	Gonococcal urethritis [ICD-11: 1A70.0Y] Approved
	
TTDDRUID	D04NXR
DRUGNAME	RO-16-8714
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D04NYX
DRUGNAME	AP-15012
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04OBB
DRUGNAME	Pheniramine
INDICATI	Hay fever [ICD-11: CA08.00] Approved
	
TTDDRUID	D04OBS
DRUGNAME	ZP-013
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D04OCC
DRUGNAME	Org-9616
INDICATI	Anaesthesia [ICD-11: 9A78.6] Discontinued in Phase 2
	
TTDDRUID	D04OCO
DRUGNAME	AC-163954
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D04ODH
DRUGNAME	Gonadorelin
INDICATI	Hypothalamic hypogonadism [ICD-11: 5A61.2] Approved
	
TTDDRUID	D04ODO
DRUGNAME	GSK-256073
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D04ODQ
DRUGNAME	447C88
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1
	
TTDDRUID	D04OFR
DRUGNAME	MEDI8897
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2/3
	
TTDDRUID	D04OFY
DRUGNAME	ABBV-321
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04OGH
DRUGNAME	SEL-068
INDICATI	Smoking dependence [ICD-11: 6C4A.2] Phase 1
	
TTDDRUID	D04OGP
DRUGNAME	HL-10
INDICATI	Respiratory distress syndrome [ICD-11: CB00] Phase 3
	
TTDDRUID	D04OGS
DRUGNAME	LIV-2008
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04OGZ
DRUGNAME	D-699126
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04OIF
DRUGNAME	TAK-259
INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 1
	
TTDDRUID	D04OIG
DRUGNAME	DSLIM
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04OJM
DRUGNAME	Human interleukin-2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D04OKJ
DRUGNAME	Garenoxacin
INDICATI	Endocarditis [ICD-11: BB40-BA42] Terminated
	
TTDDRUID	D04OLK
DRUGNAME	AST-1306
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04OMR
DRUGNAME	PF-04840082
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1
	
TTDDRUID	D04ONP
DRUGNAME	ALBIFYLLINE
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1
	
TTDDRUID	D04OOC
DRUGNAME	FCE-20696
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Terminated
	
TTDDRUID	D04OPS
DRUGNAME	MDT-011
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D04OQU
DRUGNAME	ASP2408
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D04ORP
DRUGNAME	GMK
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D04OSA
DRUGNAME	AZD-3839
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D04OSE
DRUGNAME	Nifedipine
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D04OTH
DRUGNAME	SomaKit-TOC; gallium (68Ga) edotreotide
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
	
TTDDRUID	D04OTY
DRUGNAME	BFH-772
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D04OUP
DRUGNAME	NNI-AD
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D04OXD
DRUGNAME	Netivudine
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 3
	
TTDDRUID	D04OXG
DRUGNAME	PMZ-2123
INDICATI	Cerebral oedema in diabetic ketoacidosis [ICD-11: 8D60.1] Phase 1
	
TTDDRUID	D04OXU
DRUGNAME	E-2078
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D04OYW
DRUGNAME	ST-06
INDICATI	Injury [ICD-11: NA00-ND5Z] Investigative
	
TTDDRUID	D04OZL
DRUGNAME	Hu3S193
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 2
	
TTDDRUID	D04OZR
DRUGNAME	TTH 02-001
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D04PAF
DRUGNAME	ANA-04
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D04PAN
DRUGNAME	Perflubron
INDICATI	Contrast imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D04PAU
DRUGNAME	GSK2245035
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D04PBH
DRUGNAME	CONTIGOSIDE B
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2/3
	
TTDDRUID	D04PBS
DRUGNAME	MC-3001
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Preclinical
	
TTDDRUID	D04PCT
DRUGNAME	PMID30107136-Compound-Example12
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D04PDI
DRUGNAME	CD19-targeted CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Clinical trial
	
TTDDRUID	D04PEI
DRUGNAME	BMS-509744
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D04PEO
DRUGNAME	IRT-101
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D04PER
DRUGNAME	XEN-402
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
INDICATI	Vasodilatation of extremities [ICD-11: EG00] Phase 2
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D04PFD
DRUGNAME	TriMixDC
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D04PGB
DRUGNAME	Gpi-1046
INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated
	
TTDDRUID	D04PGO
DRUGNAME	MDL-28133A
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D04PHC
DRUGNAME	Epinephrine
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D04PIH
DRUGNAME	Novaferon
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D04PIU
DRUGNAME	CART-BCMA cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D04PKQ
DRUGNAME	Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Patented
	
TTDDRUID	D04PKR
DRUGNAME	Aviptadil
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D04PKX
DRUGNAME	PMID26651364-Compound-125
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D04PLC
DRUGNAME	FOV1101
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Discontinued in Phase 2
	
TTDDRUID	D04PLI
DRUGNAME	SR46349B
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
INDICATI	Primary insomnia [ICD-11: 7A00] Phase 3
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 3
	
TTDDRUID	D04PMM
DRUGNAME	AZD1386
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2
INDICATI	Esophagus sensitivity [ICD-11: DA2Y-DA2Z] Discontinued in Phase 2
	
TTDDRUID	D04PMS
DRUGNAME	HER2 antigen-specific cancer immunotherapeutic
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D04PPE
DRUGNAME	VE-04051645
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04PPK
DRUGNAME	CER-522
INDICATI	Aortic valve stenosis [ICD-11: BB70] Phase 1
	
TTDDRUID	D04PSL
DRUGNAME	FINROZOLE
INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2
	
TTDDRUID	D04PUI
DRUGNAME	BT-062
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D04PUO
DRUGNAME	OPNT001
INDICATI	Eating disorder [ICD-11: 6B82] Phase 2
	
TTDDRUID	D04PVE
DRUGNAME	PDA-002
INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 2
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 2
	
TTDDRUID	D04PVN
DRUGNAME	SPI-376
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D04PWT
DRUGNAME	DP-b99
INDICATI	Stroke [ICD-11: 8B20] Phase 3
	
TTDDRUID	D04PXS
DRUGNAME	Amitifadine
INDICATI	Obesity [ICD-11: 5B81] Phase 3
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2
	
TTDDRUID	D04QCY
DRUGNAME	Antineoplaston-A3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D04QFV
DRUGNAME	SNX-024
INDICATI	Obesity [ICD-11: 5B81] Terminated
	
TTDDRUID	D04QFX
DRUGNAME	1-TDC
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D04QFY
DRUGNAME	GTx-027
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04QHT
DRUGNAME	EDP-20
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04QIE
DRUGNAME	Pemafibrate
INDICATI	Hyperlipidemia [ICD-11: 5C80.Z] Approved
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 3
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
	
TTDDRUID	D04QIL
DRUGNAME	IMP-111
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04QJD
DRUGNAME	Valaciclovir
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D04QKU
DRUGNAME	RG-7090
INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 2
	
TTDDRUID	D04QLL
DRUGNAME	hESC-derived RPE (MA09-hRPE)
INDICATI	Myopic macular degeneration [ICD-11: 9B75.Y] Phase 1/2
INDICATI	Dry age-related macular degeneration [ICD-11: 9B75] Phase 1/2
INDICATI	Stargardt disease [ICD-11: 9B70] Phase 1
	
TTDDRUID	D04QLR
DRUGNAME	Dyclonine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D04QNO
DRUGNAME	Symbicort
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D04QPA
DRUGNAME	AST-OPC1
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1/2
	
TTDDRUID	D04QPD
DRUGNAME	FV-100
INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Phase 3
	
TTDDRUID	D04QQZ
DRUGNAME	AT132
INDICATI	X-linked myotubular myopathy [ICD-11: 8C72] Phase 1/2
	
TTDDRUID	D04QRG
DRUGNAME	Antineoplaston A-10
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D04QRX
DRUGNAME	Thiazole carboxamide derivative 27
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D04QSH
DRUGNAME	DW-167
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2/3
	
TTDDRUID	D04QSJ
DRUGNAME	R0-93877
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
INDICATI	Constipation [ICD-11: DD91.1] Approved
	
TTDDRUID	D04QST
DRUGNAME	Riboflavin
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D04QUG
DRUGNAME	A-101
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D04QUX
DRUGNAME	PF-446687
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 2
	
TTDDRUID	D04QVK
DRUGNAME	1,2,4-tri-substituted imidazoline derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D04QVN
DRUGNAME	FPL-64170
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D04QVZ
DRUGNAME	DAS181
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D04QWE
DRUGNAME	Levallorphan
INDICATI	Narcotic depression [ICD-11: 6A7Z] Approved
	
TTDDRUID	D04QWQ
DRUGNAME	VX-509
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2/3
	
TTDDRUID	D04QWV
DRUGNAME	APX-008
INDICATI	Bone metastases [ICD-11: 2D50] Investigative
	
TTDDRUID	D04QXF
DRUGNAME	Anti-CD3 monoclonal antibody
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D04QXG
DRUGNAME	SR 120819A
INDICATI	Eating disorder [ICD-11: 6B82] Terminated
	
TTDDRUID	D04QXK
DRUGNAME	KY-62
INDICATI	Leishmania infection [ICD-11: 1F54.0] Terminated
	
TTDDRUID	D04QXW
DRUGNAME	ARC-069
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D04QYS
DRUGNAME	SNA-120
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Pruritus [ICD-11: EC90] Phase 2
	
TTDDRUID	D04QZD
DRUGNAME	Eslicarbazepine
INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved
	
TTDDRUID	D04QZI
DRUGNAME	Retosiban
INDICATI	Preterm labour [ICD-11: JB00] Phase 3
	
TTDDRUID	D04RAT
DRUGNAME	BIIR-777
INDICATI	Neurological disorder [ICD-11: 6B60] Preclinical
	
TTDDRUID	D04RBY
DRUGNAME	EX-201
INDICATI	Mucositis [ICD-11: CA00] Investigative
	
TTDDRUID	D04RCG
DRUGNAME	MEN-10627
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D04RCT
DRUGNAME	CHF-3381
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D04RCZ
DRUGNAME	Immunosuppressant synthetic peptide
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Approved
	
TTDDRUID	D04RDT
DRUGNAME	CEP-431
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D04RDW
DRUGNAME	CAR-T cells targeting Lewis-Y
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04REV
DRUGNAME	CDX-1307
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
	
TTDDRUID	D04RFE
DRUGNAME	AnervaX.DB
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D04RFX
DRUGNAME	LFn-p24
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D04RGA
DRUGNAME	Dinoprost Tromethamine
INDICATI	Abortion [ICD-11: JA00] Approved
	
TTDDRUID	D04RHJ
DRUGNAME	RG7116
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04RJM
DRUGNAME	DW-941
INDICATI	Coronavirus infection [ICD-11: 1D92] Investigative
	
TTDDRUID	D04RKH
DRUGNAME	APH-0911
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04RKW
DRUGNAME	7-methylxanthine
INDICATI	Myopia [ICD-11: 9D00.0] Phase 2
	
TTDDRUID	D04RLB
DRUGNAME	HPIV-1 vaccine
INDICATI	Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1
	
TTDDRUID	D04RLX
DRUGNAME	Tariquidar
INDICATI	Adrenocortical carcinoma [ICD-11: 2D11.Z] Discontinued in Phase 2
	
TTDDRUID	D04RLY
DRUGNAME	Vindesine
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
	
TTDDRUID	D04RMM
DRUGNAME	Clazakizumab
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D04RMP
DRUGNAME	Co-111732
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D04RNG
DRUGNAME	CAR-T cells recognizing EpCAM
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D04RNN
DRUGNAME	SUN-101
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D04RRZ
DRUGNAME	MEDI4736
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D04RSI
DRUGNAME	FAS1
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical
	
TTDDRUID	D04RSR
DRUGNAME	Crolibulin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D04RSZ
DRUGNAME	GI-13000
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D04RUA
DRUGNAME	WRR-276
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D04RUP
DRUGNAME	SDZ-NKT-343
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1
	
TTDDRUID	D04RWV
DRUGNAME	INS1009
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1
	
TTDDRUID	D04RXX
DRUGNAME	N-acylpiperidine ether derivative 2
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D04RYU
DRUGNAME	Digitalin
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D04RZD
DRUGNAME	Interferon Alfa-2b, Recombinant
INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved
	
TTDDRUID	D04RZE
DRUGNAME	FluLaval
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
INDICATI	Influenza A virus infection [ICD-11: 1E30] Approved
	
TTDDRUID	D04RZZ
DRUGNAME	A-5021
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2
	
TTDDRUID	D04SBH
DRUGNAME	Zamifenacin
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 3
	
TTDDRUID	D04SBI
DRUGNAME	H.P. Acthar Gel
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
	
TTDDRUID	D04SBW
DRUGNAME	Hexavalent conjugate vaccine
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Phase 1
	
TTDDRUID	D04SBX
DRUGNAME	Temafloxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market
	
TTDDRUID	D04SDN
DRUGNAME	RWJ-3981
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D04SEJ
DRUGNAME	IW-9179
INDICATI	Dyspepsia [ICD-11: MD92] Phase 2
	
TTDDRUID	D04SFH
DRUGNAME	Medrysone
INDICATI	Eye inflammation [ICD-11: 9A02] Approved
	
TTDDRUID	D04SHH
DRUGNAME	TC-6499-12
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
	
TTDDRUID	D04SHO
DRUGNAME	NMI-1182
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D04SIO
DRUGNAME	NGD-91-1
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D04SIU
DRUGNAME	MCD-386
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D04SJT
DRUGNAME	MB-11040
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D04SKM
DRUGNAME	CART-10 cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D04SLF
DRUGNAME	Bevacizumab + Trastuzumab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D04SNL
DRUGNAME	Grippol Plus
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D04SOA
DRUGNAME	H1N1 pandemic influenza A vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D04SOS
DRUGNAME	BMS-181168
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D04SOU
DRUGNAME	MK-4074
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D04SPJ
DRUGNAME	AZD7624
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D04SPK
DRUGNAME	Seratrodast
INDICATI	Allergic asthma [ICD-11: CA23.0] Discontinued in Phase 3
	
TTDDRUID	D04SQJ
DRUGNAME	EW-A-401
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 1
	
TTDDRUID	D04SQO
DRUGNAME	DEBIO 1562
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
	
TTDDRUID	D04SRO
DRUGNAME	GRT-3983Y
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
	
TTDDRUID	D04STQ
DRUGNAME	CBH-11
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated
	
TTDDRUID	D04SUU
DRUGNAME	Thymosin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D04SUX
DRUGNAME	Recombinant birch pollen allergen
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D04SVB
DRUGNAME	FR-133605
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D04SWF
DRUGNAME	FP-1302
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D04SWT
DRUGNAME	Anti-CD47 mab
INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative
	
TTDDRUID	D04SXL
DRUGNAME	APG-115
INDICATI	Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04SZA
DRUGNAME	P-3914
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D04SZG
DRUGNAME	COTI-219
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Investigative
	
TTDDRUID	D04TBC
DRUGNAME	OZ-439
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D04TBW
DRUGNAME	C-Rx
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D04TCQ
DRUGNAME	J-775Y
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D04TDQ
DRUGNAME	Noscapine (narcotine)
INDICATI	Cough [ICD-11: MD12] Approved
	
TTDDRUID	D04TEF
DRUGNAME	Alpha-1 antitrypsin
INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 2
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 1/2
	
TTDDRUID	D04TFE
DRUGNAME	CreaVax-HCC
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
	
TTDDRUID	D04TFL
DRUGNAME	SGX203
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D04TGF
DRUGNAME	AZD-2927
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2
	
TTDDRUID	D04TGU
DRUGNAME	MK-3901
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D04THK
DRUGNAME	AL0-212
INDICATI	Critical limb ischemia [ICD-11: BD4Y] Investigative
	
TTDDRUID	D04THU
DRUGNAME	KP-624
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Investigative
	
TTDDRUID	D04TIJ
DRUGNAME	Namitecan
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04TIL
DRUGNAME	ANA773
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2a
	
TTDDRUID	D04TIT
DRUGNAME	Nowarta110
INDICATI	Plantar wart [ICD-11: 1E80.1] Phase 1/2
	
TTDDRUID	D04TIU
DRUGNAME	PMID25666693-Compound-154
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D04TJL
DRUGNAME	LAS-41004
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D04TJP
DRUGNAME	Totrombopag
INDICATI	Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 1
	
TTDDRUID	D04TKP
DRUGNAME	L-748415
INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated
	
TTDDRUID	D04TKU
DRUGNAME	H1N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D04TLJ
DRUGNAME	Soblidotin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D04TLQ
DRUGNAME	Cyclic peptidomimetic derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D04TNT
DRUGNAME	ABT-639
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D04TPF
DRUGNAME	TDI-0054
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D04TPQ
DRUGNAME	Aganepag isopropyl
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
	
TTDDRUID	D04TPS
DRUGNAME	A-887755
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D04TPU
DRUGNAME	RO-5323441
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D04TQO
DRUGNAME	Tenapanor
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
INDICATI	Kidney disease [ICD-11: GC2Z] Phase 2
INDICATI	Constipation [ICD-11: DD91.1] Phase 2
	
TTDDRUID	D04TQT
DRUGNAME	Barusiban
INDICATI	Androgen deficiency [ICD-11: 5A81.1] Phase 2
	
TTDDRUID	D04TSO
DRUGNAME	UNBS-1450
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04TSV
DRUGNAME	CI-992
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D04TUN
DRUGNAME	HTI-1066
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04TXB
DRUGNAME	Ceplene/Peg-Intron/Rebetol
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D04TYP
DRUGNAME	RG7600
INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 1
	
TTDDRUID	D04TZA
DRUGNAME	PF-04957325
INDICATI	Itching [ICD-11: 1F28-1G07] Investigative
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D04TZK
DRUGNAME	LNK-3186
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D04TZT
DRUGNAME	SDZ-280-636
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D04UAL
DRUGNAME	Clovoxamine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
	
TTDDRUID	D04UAZ
DRUGNAME	CTA-091
INDICATI	Hyperparathyroidism [ICD-11: 5A51] Investigative
	
TTDDRUID	D04UBI
DRUGNAME	AB928
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04UFI
DRUGNAME	ImMucin
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D04UFY
DRUGNAME	UX-003
INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Phase 3
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 3
	
TTDDRUID	D04UHW
DRUGNAME	PMID25684022-Compound-WO2008079988
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D04UHX
DRUGNAME	HumaRAD-HN
INDICATI	Head and neck cancer [ICD-11: 2D42] Discontinued in Phase 1
	
TTDDRUID	D04UKC
DRUGNAME	Riociguat
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Approved
	
TTDDRUID	D04UKJ
DRUGNAME	NP-61
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1
	
TTDDRUID	D04UKP
DRUGNAME	Tenatumomab
INDICATI	Glioma [ICD-11: 2A00.0] Phase 3
	
TTDDRUID	D04UME
DRUGNAME	BI-144807
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D04UNO
DRUGNAME	KUL-7211
INDICATI	Neurogenic bladder dysfunction [ICD-11: GC01.4] Phase 1
	
TTDDRUID	D04UNY
DRUGNAME	Anti-GD2 T-cells (1RG-CART)
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
	
TTDDRUID	D04UOJ
DRUGNAME	PYN-7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D04UPJ
DRUGNAME	DasKloster 0247-01
INDICATI	Pulmonary hypertension [ICD-11: BB01] Investigative
	
TTDDRUID	D04UPM
DRUGNAME	KBAB-401
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D04UPW
DRUGNAME	RWJ-68023
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 1
	
TTDDRUID	D04UQF
DRUGNAME	Influvac tC cell culture-derived influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D04UQS
DRUGNAME	NXD-9062
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D04URO
DRUGNAME	Streptokinase
INDICATI	Pulmonary embolism [ICD-11: BB00] Approved
	
TTDDRUID	D04URZ
DRUGNAME	AVX-003
INDICATI	Glomerulonephritis [ICD-11: 5D00.Y] Investigative
	
TTDDRUID	D04USC
DRUGNAME	Ergotidine
INDICATI	Respiratory allergy [ICD-11: 4A80] Approved
	
TTDDRUID	D04USK
DRUGNAME	H5N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Preclinical
	
TTDDRUID	D04UTH
DRUGNAME	Long-acting erythropoietin conjugate
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1
	
TTDDRUID	D04UTT
DRUGNAME	Olodaterol
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D04UUD
DRUGNAME	CC-401
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D04UUH
DRUGNAME	Lithium Carbonate
INDICATI	Manic depression disorder [ICD-11: 6A71] Approved
	
TTDDRUID	D04UWG
DRUGNAME	Autologous T-cell therapy
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D04UWU
DRUGNAME	Oraxol
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D04UXX
DRUGNAME	PD-158771
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D04UYT
DRUGNAME	CBLB-612
INDICATI	Radiation syndrome [ICD-11: NF00] Investigative
	
TTDDRUID	D04UYY
DRUGNAME	AD5-10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04UZN
DRUGNAME	Pyrimethamine/sulfadoxine
INDICATI	Pneumocystis pneumonia [ICD-11: CA40.20] Approved
	
TTDDRUID	D04UZT
DRUGNAME	Quinestrol
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D04VAR
DRUGNAME	GSK-2136773
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative
	
TTDDRUID	D04VBF
DRUGNAME	JNJ-38518168
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	D04VCF
DRUGNAME	ADR58
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D04VCN
DRUGNAME	Bovactant
INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Approved
	
TTDDRUID	D04VCQ
DRUGNAME	CART33 cells
INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 1/2
	
TTDDRUID	D04VCS
DRUGNAME	Neocartilage
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D04VDY
DRUGNAME	L-741671
INDICATI	Vomiting [ICD-11: MD90] Terminated
	
TTDDRUID	D04VEJ
DRUGNAME	Lymecycline
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D04VFJ
DRUGNAME	Toremifene
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D04VFW
DRUGNAME	SAR-116242
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D04VGR
DRUGNAME	PMID27998201-Compound-9
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Patented
	
TTDDRUID	D04VGS
DRUGNAME	Selenium sulfide
INDICATI	Erythema [ICD-11: ME64.0] Approved
	
TTDDRUID	D04VGY
DRUGNAME	CYT-007-TNFQb
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1/2
	
TTDDRUID	D04VHB
DRUGNAME	RSV recombinant vaccine
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D04VHK
DRUGNAME	CLR-3001
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D04VHL
DRUGNAME	MystiTears
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative
	
TTDDRUID	D04VHQ
DRUGNAME	AVI-7012
INDICATI	Junin virus infection [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D04VHZ
DRUGNAME	Interferon-alpha 2b
INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D04VIP
DRUGNAME	4030W92
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D04VIS
DRUGNAME	Andrographolide
INDICATI	Bacillary dysentery [ICD-11: 1A02] Approved
	
TTDDRUID	D04VJH
DRUGNAME	ACREOZAST
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D04VJQ
DRUGNAME	BVS857
INDICATI	Insulin-resistant disorder [ICD-11: 5A44] Phase 1
	
TTDDRUID	D04VKO
DRUGNAME	ATON-004
INDICATI	Heavy metal poisoning [ICD-11: NE60] Discontinued in Phase 2
	
TTDDRUID	D04VKS
DRUGNAME	Acrisorcin
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D04VLR
DRUGNAME	PA-161
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical
	
TTDDRUID	D04VMG
DRUGNAME	ELEMENE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04VMM
DRUGNAME	Encapsulated cancer cells
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D04VMT
DRUGNAME	Sotalol
INDICATI	Sinus rhythm disorder [ICD-11: BC9Y] Approved
	
TTDDRUID	D04VOE
DRUGNAME	AS-1402
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D04VOZ
DRUGNAME	TKM-ApoB
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 4
	
TTDDRUID	D04VPA
DRUGNAME	Moricizine
INDICATI	Arrhythmia [ICD-11: BC9Z] Approved
INDICATI	Heart arrhythmia [ICD-11: BC65] Withdrawn from market
	
TTDDRUID	D04VPP
DRUGNAME	ATI-1150
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04VQH
DRUGNAME	XEN-D0501
INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2
	
TTDDRUID	D04VRB
DRUGNAME	NeuVax
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D04VRN
DRUGNAME	MMR
INDICATI	Rubella prophylaxis [ICD-11: 1F02] Phase 3
INDICATI	Mumps virus infection [ICD-11: 1D80] Phase 3
INDICATI	Measles [ICD-11: 1F03] Phase 3
	
TTDDRUID	D04VSI
DRUGNAME	Arbidol
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 4
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D04VSM
DRUGNAME	CS-8958
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D04VTV
DRUGNAME	SYN-114
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1
	
TTDDRUID	D04VUM
DRUGNAME	CGEN-928
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D04VUY
DRUGNAME	RG-7166
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1
	
TTDDRUID	D04VVD
DRUGNAME	TeloB-Vax
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D04VVL
DRUGNAME	Malaria next generation vaccine
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D04VWJ
DRUGNAME	ARRY-520
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D04VWO
DRUGNAME	Recombinant soluble CD6
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D04VXN
DRUGNAME	Moxalactam Disodium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D04VXS
DRUGNAME	ENT-102
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D04VZS
DRUGNAME	CTS-21166
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D04WBT
DRUGNAME	Act1
INDICATI	Wound healing [ICD-11: EL8Y] Phase 3
	
TTDDRUID	D04WBY
DRUGNAME	Menotropins
INDICATI	Female infertility [ICD-11: GA31.Z] Approved
	
TTDDRUID	D04WCA
DRUGNAME	AVP-7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04WCI
DRUGNAME	PAMAPIMOD
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D04WCJ
DRUGNAME	DV-100
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D04WCO
DRUGNAME	EPB-415
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D04WDA
DRUGNAME	CSL-412
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D04WDX
DRUGNAME	PJ34
INDICATI	Coronavirus infection [ICD-11: 1D92] Preclinical
	
TTDDRUID	D04WFD
DRUGNAME	Nortriptyline
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D04WFL
DRUGNAME	Trastuzumab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Application submitted
INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Application submitted
	
TTDDRUID	D04WFV
DRUGNAME	Hepatitis B immune globulin
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D04WHM
DRUGNAME	G0-203-2c
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D04WHX
DRUGNAME	FP-21399
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D04WIE
DRUGNAME	Sirna-027
INDICATI	Exudative age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1/2
INDICATI	Neovascular age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1
	
TTDDRUID	D04WIF
DRUGNAME	ISIS-GCGR
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical
	
TTDDRUID	D04WIG
DRUGNAME	CY-1747
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D04WJO
DRUGNAME	Talaporfin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D04WLX
DRUGNAME	AIK-21
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D04WMR
DRUGNAME	Tepoxalin
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D04WNA
DRUGNAME	ART-237
INDICATI	Arthropathy [ICD-11: FA11-FA38] Investigative
	
TTDDRUID	D04WOM
DRUGNAME	Seractide Acetate
INDICATI	Essential hypertension [ICD-11: BA00] Approved
	
TTDDRUID	D04WQJ
DRUGNAME	AMG-181
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
	
TTDDRUID	D04WQT
DRUGNAME	RG7201
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D04WSK
DRUGNAME	99mTc-ImmuRAID-LL1
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D04WSL
DRUGNAME	Cardiotoxin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04WTN
DRUGNAME	Oxabact
INDICATI	Hyperoxaluria [ICD-11: 5C51.2] Phase 3
	
TTDDRUID	D04WUA
DRUGNAME	CP-101,606
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Investigative
	
TTDDRUID	D04WVI
DRUGNAME	M-17 E. Coli
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 3
	
TTDDRUID	D04WVL
DRUGNAME	SF-1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1/2
	
TTDDRUID	D04WVY
DRUGNAME	SPI-026
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
	
TTDDRUID	D04WWG
DRUGNAME	S-1389
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D04WXG
DRUGNAME	DVC-LVS
INDICATI	Tularemia [ICD-11: 1B94] Phase 2
	
TTDDRUID	D04WYX
DRUGNAME	Netarsudil
INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
	
TTDDRUID	D04WZK
DRUGNAME	AZD-2858
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D04WZL
DRUGNAME	CART-meso cells
INDICATI	Pancreatic cancer [ICD-11: 2C10] Clinical trial
	
TTDDRUID	D04XAB
DRUGNAME	Autologous cancer vaccine
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D04XBU
DRUGNAME	ATL-104
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D04XCK
DRUGNAME	OMP-313M32
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04XCO
DRUGNAME	AZD-8848
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D04XDT
DRUGNAME	Delafloxacin Meglumine
INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Approved
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Approved
	
TTDDRUID	D04XEG
DRUGNAME	Fenoterol
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D04XEO
DRUGNAME	ChelASE
INDICATI	Retina disorder [ICD-11: 9B70-9B7Z] Discontinued in Phase 1
	
TTDDRUID	D04XEQ
DRUGNAME	Imetelstat
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2/3
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 2
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
	
TTDDRUID	D04XGT
DRUGNAME	Benznidazole
INDICATI	Chagas disease [ICD-11: IF53] Approved
INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Approved
	
TTDDRUID	D04XGU
DRUGNAME	Crestor/TriLipix
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Approved
	
TTDDRUID	D04XIA
DRUGNAME	Meningococcus B vaccine
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Terminated
	
TTDDRUID	D04XIO
DRUGNAME	Dutogliptin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D04XIV
DRUGNAME	Mesenchymal precursor cell
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D04XJE
DRUGNAME	REM-001
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D04XJG
DRUGNAME	BKR-013
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D04XJM
DRUGNAME	R1295
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D04XJV
DRUGNAME	GRC-9332
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative
	
TTDDRUID	D04XJX
DRUGNAME	GP-1001
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D04XLU
DRUGNAME	Dendritic cell vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical
	
TTDDRUID	D04XMJ
DRUGNAME	LY525327
INDICATI	Migraine [ICD-11: 8A80] Terminated
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated
	
TTDDRUID	D04XML
DRUGNAME	TRI-002
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D04XMN
DRUGNAME	NK-109
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D04XNQ
DRUGNAME	BioScavenger
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04XOX
DRUGNAME	Malate synthase
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D04XPD
DRUGNAME	DV-0100
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D04XPW
DRUGNAME	Cocaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D04XQW
DRUGNAME	Dornase alfa
INDICATI	Cystic fibrosis [ICD-11: CA25] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D04XSP
DRUGNAME	Alpha-fetoprotein cancer vaccine
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
	
TTDDRUID	D04XTK
DRUGNAME	SRM003
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D04XUJ
DRUGNAME	CBT-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2
	
TTDDRUID	D04XVE
DRUGNAME	QAX-028
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D04XVJ
DRUGNAME	LEO-29102
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D04XVN
DRUGNAME	Trametinib
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D04XVU
DRUGNAME	GKT-137831
INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 2
	
TTDDRUID	D04XWX
DRUGNAME	PS-178990
INDICATI	Muscle atrophy [ICD-11: FB32.Y] Phase 1
	
TTDDRUID	D04XZE
DRUGNAME	NS-7
INDICATI	Nerve injury [ICD-11: ND56.4] Phase 2
	
TTDDRUID	D04YAJ
DRUGNAME	SELODENOSON
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 2
	
TTDDRUID	D04YAK
DRUGNAME	MPC-2130
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04YCE
DRUGNAME	Pidotimod
INDICATI	Urinary tract infection [ICD-11: GC08] Withdrawn from market
	
TTDDRUID	D04YCQ
DRUGNAME	GEN-003
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 2
	
TTDDRUID	D04YEW
DRUGNAME	Tarafenacin
INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2
	
TTDDRUID	D04YEY
DRUGNAME	PS-388023
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Terminated
	
TTDDRUID	D04YFA
DRUGNAME	VAX-161
INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D04YGT
DRUGNAME	VAL-001
INDICATI	Acne vulgaris [ICD-11: ED80] Investigative
	
TTDDRUID	D04YHG
DRUGNAME	ErepoXen
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 3
	
TTDDRUID	D04YHJ
DRUGNAME	Meninge B
INDICATI	Meningitis [ICD-11: 1D01] Phase 1
	
TTDDRUID	D04YHR
DRUGNAME	Samarium Sm-153 Lexidronam Pentasodium
INDICATI	Cancer related pain [ICD-11: MG30] Approved
	
TTDDRUID	D04YHW
DRUGNAME	R-1487
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D04YIA
DRUGNAME	CNVN-202
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D04YJN
DRUGNAME	R411
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D04YJO
DRUGNAME	CGS-19480A
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D04YKM
DRUGNAME	Microfibrillar collagen hemostat
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
	
TTDDRUID	D04YKO
DRUGNAME	Piperidine derivative 2
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D04YKQ
DRUGNAME	NaQuinate
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D04YKY
DRUGNAME	NT-502
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D04YLQ
DRUGNAME	AMG 334
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D04YLU
DRUGNAME	AZ-599
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D04YMH
DRUGNAME	Lumiracoxib
INDICATI	Knee osteoarthritis [ICD-11: FA01] Approved
	
TTDDRUID	D04YNI
DRUGNAME	WY-48989
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D04YPN
DRUGNAME	Treosulfan
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D04YPZ
DRUGNAME	Decapeptide allergy vaccine
INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2
	
TTDDRUID	D04YRD
DRUGNAME	DTX101
INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1/2
	
TTDDRUID	D04YSC
DRUGNAME	CD19 CAR T cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2/3
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2/3
	
TTDDRUID	D04YSK
DRUGNAME	Pagibaximab
INDICATI	Enterococcus faecium infection [ICD-11: 1D01.0Y] Phase 2/3
	
TTDDRUID	D04YSQ
DRUGNAME	HepaXen
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D04YSY
DRUGNAME	Recombinant NOV
INDICATI	Corneal disease [ICD-11: 9A78.Z] Investigative
	
TTDDRUID	D04YTT
DRUGNAME	DAV-148
INDICATI	Enterobacteriaceae infection [ICD-11: MG50.C] Investigative
	
TTDDRUID	D04YTX
DRUGNAME	HPy-HP 097
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Investigative
	
TTDDRUID	D04YWM
DRUGNAME	Atacicept
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
INDICATI	Lupus [ICD-11: 4A40] Phase 2
	
TTDDRUID	D04YWS
DRUGNAME	RAGE-Fc fusion protein
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D04YXL
DRUGNAME	PEGylated IFN beta 1-a
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D04YZL
DRUGNAME	Sodium chloride
INDICATI	Skin burns [ICD-11: ME65.0] Approved
	
TTDDRUID	D04YZS
DRUGNAME	KIT-302
INDICATI	Pain [ICD-11: MG30-MG3Z] Application submitted
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Application submitted
INDICATI	Hypertension [ICD-11: BA00-BA04] Application submitted
	
TTDDRUID	D04ZAH
DRUGNAME	Piperacillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D04ZBA
DRUGNAME	NVLS/FX-18A
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D04ZBT
DRUGNAME	Icatibant
INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Approved
	
TTDDRUID	D04ZBU
DRUGNAME	JTT-302
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2
	
TTDDRUID	D04ZCL
DRUGNAME	VZ-564
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D04ZCZ
DRUGNAME	GINKOLIDE B
INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated
	
TTDDRUID	D04ZEP
DRUGNAME	A-849531
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D04ZFO
DRUGNAME	WVE-120102
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 1/2
	
TTDDRUID	D04ZHJ
DRUGNAME	TNF alpha kinoid
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D04ZIJ
DRUGNAME	Pepstatin
INDICATI	Malaria [ICD-11: 1F40-1F45] Terminated
	
TTDDRUID	D04ZIO
DRUGNAME	NBI-640756
INDICATI	Essential tremor or related tremors [ICD-11: 8A04.1] Phase 1
	
TTDDRUID	D04ZIZ
DRUGNAME	DMUC-5754A
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 1
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
	
TTDDRUID	D04ZJG
DRUGNAME	PI-88
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D04ZJP
DRUGNAME	HSR-113
INDICATI	Nausea and vomiting [ICD-11: MD90] Discontinued in Phase 1
	
TTDDRUID	D04ZJQ
DRUGNAME	VN/13-1RA
INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative
	
TTDDRUID	D04ZKY
DRUGNAME	SEP-363856
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
	
TTDDRUID	D04ZLC
DRUGNAME	N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D04ZLG
DRUGNAME	IDEC-151
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D04ZLJ
DRUGNAME	LOSOXANTRONE
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D04ZND
DRUGNAME	PGL-2001
INDICATI	Endometriosis [ICD-11: GA10] Phase 2
	
TTDDRUID	D04ZNG
DRUGNAME	LF-08-0133
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D04ZNL
DRUGNAME	RG-7234
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D04ZOZ
DRUGNAME	MS-322
INDICATI	Spasm [ICD-11: MB47.3] Discontinued in Phase 2
	
TTDDRUID	D04ZQB
DRUGNAME	KPT-9274
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D04ZQO
DRUGNAME	TG-2349
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D04ZSL
DRUGNAME	SB-313-xTZ
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D04ZSZ
DRUGNAME	DS-AH-14
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D04ZTA
DRUGNAME	ANA-5
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D04ZTY
DRUGNAME	Voglibose
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D04ZUU
DRUGNAME	AKT-10081
INDICATI	Clostridium infection [ICD-11: 1A04] Investigative
	
TTDDRUID	D04ZVO
DRUGNAME	ZS-9
INDICATI	Hyperkalemia [ICD-11: 5C76] Investigative
	
TTDDRUID	D04ZWD
DRUGNAME	EZN-4150
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D04ZWH
DRUGNAME	UK-279,276
INDICATI	Stroke [ICD-11: 8B20] Discontinued in Phase 2
	
TTDDRUID	D04ZWQ
DRUGNAME	Org-25435
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
	
TTDDRUID	D04ZXP
DRUGNAME	Dicycloplatin
INDICATI	Prostate cancer [ICD-11: 2C82.0] Registered
	
TTDDRUID	D04ZYP
DRUGNAME	Cat-SPIRE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D04ZZD
DRUGNAME	AVP-6
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D04ZZM
DRUGNAME	Resorcinol compound 21
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D04ZZQ
DRUGNAME	VAS-2870
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D04ZZT
DRUGNAME	AGS-004
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D04ZZX
DRUGNAME	Mi-TUMEX
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05AAD
DRUGNAME	Isatoribine
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D05AAM
DRUGNAME	BINOSPIRONE MESYLATE
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D05AAQ
DRUGNAME	BCP-1081
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D05AAW
DRUGNAME	VR-776
INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Discontinued in Phase 1
	
TTDDRUID	D05ACQ
DRUGNAME	Gallium maltolate
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D05ADE
DRUGNAME	RAD-100
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D05ADP
DRUGNAME	R-roscovitine
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D05AEE
DRUGNAME	RG7935
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D05AFC
DRUGNAME	Dalfopristin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D05AFP
DRUGNAME	CY-301
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D05AFR
DRUGNAME	Rolitetracycline
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D05AFX
DRUGNAME	Nefopam
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D05AHC
DRUGNAME	NOV-205
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D05AHE
DRUGNAME	Methylergonovine
INDICATI	Spontaneous abortion [ICD-11: JA00.0] Approved
	
TTDDRUID	D05AHK
DRUGNAME	INGN-234
INDICATI	Oral cancer [ICD-11: 2B6E] Discontinued in Phase 2
	
TTDDRUID	D05AHQ
DRUGNAME	Epiroprim
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D05AJT
DRUGNAME	XL019
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 1
	
TTDDRUID	D05AKH
DRUGNAME	OnabotulinumtoxinA
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D05ALG
DRUGNAME	RWJ-49815
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
INDICATI	Obesity [ICD-11: 5B81] Investigative
INDICATI	Eating disorder [ICD-11: 6B82] Investigative
	
TTDDRUID	D05ALP
DRUGNAME	REG1
INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 3
	
TTDDRUID	D05AON
DRUGNAME	LSI-518P
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D05APM
DRUGNAME	ANG-2684
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D05APW
DRUGNAME	ABT-116
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D05AQB
DRUGNAME	FAS-89B
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D05AQP
DRUGNAME	ASP-0306
INDICATI	Urinary dysfunction [ICD-11: GC2Z] Discontinued in Phase 1
	
TTDDRUID	D05AQT
DRUGNAME	PMID28270021-Compound-WO2014078408Example1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D05ARP
DRUGNAME	Ganciclovir
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D05ASV
DRUGNAME	VTX-1463
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1
	
TTDDRUID	D05ATD
DRUGNAME	AVX-502
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2
	
TTDDRUID	D05ATI
DRUGNAME	Sodium lauryl sulfate
INDICATI	Constipation [ICD-11: DD91.1] Approved
	
TTDDRUID	D05ATQ
DRUGNAME	MVA HER-2 AutoVac
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D05AVB
DRUGNAME	DW-1029M
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D05AVL
DRUGNAME	JNJ-61178104
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
	
TTDDRUID	D05AWP
DRUGNAME	Moxidectin 
INDICATI	River blindness [ICD-11: 1F6A.0] Approved
INDICATI	Onchocerciasis [ICD-11: 1F6A] Approved
	
TTDDRUID	D05AXS
DRUGNAME	CRx-189
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated
	
TTDDRUID	D05AZE
DRUGNAME	Biphenyl mannoside derivative 30
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D05BAJ
DRUGNAME	PDR001
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
INDICATI	Esophageal squamous cell carcinoma [ICD-11: 2E60.1] Phase 2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05BBB
DRUGNAME	Saratin
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2
	
TTDDRUID	D05BBQ
DRUGNAME	RP-66364
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D05BCA
DRUGNAME	MX-4509
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1
	
TTDDRUID	D05BCF
DRUGNAME	Clavulanate+Amoxicillin
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D05BCU
DRUGNAME	RQ-00000004
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 3
	
TTDDRUID	D05BDY
DRUGNAME	PXT-3003
INDICATI	Charcot marie tooth disease [ICD-11: 8C21.Z] Phase 3
	
TTDDRUID	D05BGY
DRUGNAME	PM184
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D05BHF
DRUGNAME	Masilukast
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D05BII
DRUGNAME	Ancrod
INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Phase 3
	
TTDDRUID	D05BIJ
DRUGNAME	RWJ-140998
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D05BIN
DRUGNAME	F-14512
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D05BIT
DRUGNAME	Maxy-10
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D05BJD
DRUGNAME	Motexafin gadolinium
INDICATI	Brain cancer [ICD-11: 2A00] Approved
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D05BKS
DRUGNAME	Nimotuzumab
INDICATI	Head and neck cancer [ICD-11: 2D42] Approved
	
TTDDRUID	D05BKY
DRUGNAME	NK-1005
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D05BLG
DRUGNAME	MC-116
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D05BLN
DRUGNAME	MGCD516
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D05BLQ
DRUGNAME	Neuromed 2
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D05BMC
DRUGNAME	GW-42004
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2
	
TTDDRUID	D05BMG
DRUGNAME	Amphetamine
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
	
TTDDRUID	D05BNS
DRUGNAME	Oral-Vimo-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05BPC
DRUGNAME	Tiprelestat
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
	
TTDDRUID	D05BPD
DRUGNAME	Emepepimut-S
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D05BPO
DRUGNAME	PF-06801591
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D05BQK
DRUGNAME	Butalbital
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
INDICATI	Headache [ICD-11: 8A80-8A84] Approved
	
TTDDRUID	D05BRZ
DRUGNAME	PG-140
INDICATI	Transplant rejection [ICD-11: NE84] Investigative
	
TTDDRUID	D05BSG
DRUGNAME	Enkastim-ev
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05BTL
DRUGNAME	PMID26651364-Compound-126c
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D05BTM
DRUGNAME	Maxacalcitol
INDICATI	Disorder of calcium metabolism [ICD-11: 5C64.5] Approved
	
TTDDRUID	D05BTR
DRUGNAME	Tallimustine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D05BUD
DRUGNAME	Mannoside derivative 10
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D05BWH
DRUGNAME	PRX-3140
INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D05BWX
DRUGNAME	CB-2431
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 2
	
TTDDRUID	D05BWY
DRUGNAME	CLR-300
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D05BXO
DRUGNAME	Brasofensine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D05BXY
DRUGNAME	Talimogene Laherparepvec
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D05BYA
DRUGNAME	NVP-AUY922
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D05BYJ
DRUGNAME	PF-06413367
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D05BYO
DRUGNAME	ISIS-SOD1
INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 1
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1
	
TTDDRUID	D05BYP
DRUGNAME	Lupron 3-month depot
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Phase 2
	
TTDDRUID	D05CBJ
DRUGNAME	PA-799
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05CBP
DRUGNAME	PMID26651364-Compound-9a
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D05CDF
DRUGNAME	Doramapimod
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
	
TTDDRUID	D05CDG
DRUGNAME	R-1164
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1
	
TTDDRUID	D05CEK
DRUGNAME	CV 6209
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D05CEO
DRUGNAME	Brodalumab
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D05CEU
DRUGNAME	Flunarizine
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D05CFG
DRUGNAME	PR104
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D05CFH
DRUGNAME	AGN-199981
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D05CFQ
DRUGNAME	AMG-191
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D05CFV
DRUGNAME	Dapirolizumab pegol
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D05CGH
DRUGNAME	Evatak
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05CGO
DRUGNAME	XP-28
INDICATI	Muscle fatigue [ICD-11: FB32.5] Phase 3
	
TTDDRUID	D05CGX
DRUGNAME	SPK-FIX
INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1/2
	
TTDDRUID	D05CHI
DRUGNAME	Rifabutin
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Approved
INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Approved
	
TTDDRUID	D05CHN
DRUGNAME	Irofulven/Taxotere
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05CHR
DRUGNAME	LBY-135
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D05CJN
DRUGNAME	HG-1336
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D05CJU
DRUGNAME	DLX-105
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
	
TTDDRUID	D05CKF
DRUGNAME	AJD-101
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D05CKR
DRUGNAME	Nabumetone
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D05CMT
DRUGNAME	COMBO Stent
INDICATI	Coronary artery disease [ICD-11: BA80] Clinical trial
	
TTDDRUID	D05CMY
DRUGNAME	Peginterferon lambda-1a
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D05CMZ
DRUGNAME	ONO-2952
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
	
TTDDRUID	D05COE
DRUGNAME	PMID30107136-Compound-Example52
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D05COG
DRUGNAME	DU-1777
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D05CPD
DRUGNAME	BIOO-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05CPS
DRUGNAME	Dendritic cell vaccine
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
	
TTDDRUID	D05CPV
DRUGNAME	Dronedarone
INDICATI	Angina pectoris [ICD-11: BA40] Approved
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Withdrawn from market
	
TTDDRUID	D05CQS
DRUGNAME	NB1011
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D05CRG
DRUGNAME	L-054852
INDICATI	Acromegaly [ICD-11: 5A60.0] Investigative
	
TTDDRUID	D05CRY
DRUGNAME	ADCT-502
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05CSS
DRUGNAME	CAR-T cells targeting MucI
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D05CTQ
DRUGNAME	CD138 CAR T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D05CTS
DRUGNAME	C-202
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D05CTY
DRUGNAME	NV.TLM.10
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Investigative
	
TTDDRUID	D05CVC
DRUGNAME	90Y-cG250
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05CVH
DRUGNAME	Hu neutral insulin
INDICATI	Type-1 diabetes [ICD-11: 5A10] Approved
	
TTDDRUID	D05CYX
DRUGNAME	DAV-121
INDICATI	Toxicity [ICD-11: N.A.] Investigative
	
TTDDRUID	D05DAX
DRUGNAME	TT-120
INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D05DBT
DRUGNAME	EG-HPV
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Investigative
	
TTDDRUID	D05DBY
DRUGNAME	Imagabalin
INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 3
	
TTDDRUID	D05DBZ
DRUGNAME	AGS-8M4
INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2
	
TTDDRUID	D05DCL
DRUGNAME	ZYT-1
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 1
	
TTDDRUID	D05DCX
DRUGNAME	Genetically modified allogeneic sertoli cells
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D05DDN
DRUGNAME	HCV-796
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2
	
TTDDRUID	D05DDZ
DRUGNAME	MV-6401
INDICATI	Artery stenosis [ICD-11: BD52] Preclinical
	
TTDDRUID	D05DFV
DRUGNAME	PRO-044
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D05DKT
DRUGNAME	CART19 cell
INDICATI	B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1
	
TTDDRUID	D05DNA
DRUGNAME	FR-183998
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D05DNH
DRUGNAME	A-79296
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Terminated
	
TTDDRUID	D05DON
DRUGNAME	MILACAINIDE TARTRATE
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2
	
TTDDRUID	D05DOY
DRUGNAME	ING-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05DPE
DRUGNAME	BR-05001
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D05DPU
DRUGNAME	SP-102
INDICATI	Sciatica/lumbar radicular pain [ICD-11: ME84.3] Phase 3
	
TTDDRUID	D05DQF
DRUGNAME	Indole N -acetamide
INDICATI	Hepatovirus infection [ICD-11: 1E51] Investigative
	
TTDDRUID	D05DQR
DRUGNAME	HDV-interferon
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D05DRG
DRUGNAME	PDC-31
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Investigative
	
TTDDRUID	D05DSK
DRUGNAME	E2101
INDICATI	Spasm [ICD-11: MB47.3] Discontinued in Phase 1
INDICATI	Cervical dystonia [ICD-11: 8A02.0Y] Discontinued in Phase 1
	
TTDDRUID	D05DSS
DRUGNAME	GI-13020
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	D05DVP
DRUGNAME	Zafirlukast
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D05DXT
DRUGNAME	XEN-D0103
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 1
	
TTDDRUID	D05DZA
DRUGNAME	PUR-0110
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2
	
TTDDRUID	D05DZJ
DRUGNAME	TDI-0055
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D05DZK
DRUGNAME	Interferon alpha 2a
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
	
TTDDRUID	D05DZR
DRUGNAME	Elotuzumab
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
	
TTDDRUID	D05EAJ
DRUGNAME	ETV-003
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Investigative
	
TTDDRUID	D05EAM
DRUGNAME	Pentamidine
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Withdrawn from market
	
TTDDRUID	D05EBY
DRUGNAME	PCSK9 Adnectin
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D05ECA
DRUGNAME	LJM716
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D05ECK
DRUGNAME	SKF-110679
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2
	
TTDDRUID	D05ECQ
DRUGNAME	RX-10001
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D05EEJ
DRUGNAME	ETRX-101
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 2
	
TTDDRUID	D05EFR
DRUGNAME	SprayGel
INDICATI	Abdominal surgical procedure [ICD-11: N.A.] Approved
INDICATI	Pelvic inflammatory disease [ICD-11: GA05] Approved
INDICATI	Gastric disease [ICD-11: DA40-DA7Z] Approved
	
TTDDRUID	D05EHJ
DRUGNAME	IMOVAX
INDICATI	Poliovirus infection [ICD-11: 1C8Y] Approved
	
TTDDRUID	D05EHS
DRUGNAME	MyoDys
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1
	
TTDDRUID	D05EIT
DRUGNAME	CVT-E002
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D05EJG
DRUGNAME	L-Tryptophan
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D05EKM
DRUGNAME	FR-121196
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D05EKO
DRUGNAME	OvaSave
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D05ELM
DRUGNAME	AC-150
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2
	
TTDDRUID	D05ELO
DRUGNAME	Insulin, porcine
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D05ELV
DRUGNAME	Zinc Chloride
INDICATI	Common cold [ICD-11: CA00] Approved
	
TTDDRUID	D05ELY
DRUGNAME	Influenza A virus vaccine H9N2
INDICATI	Influenza A virus H9N2 infection [ICD-11: 1E30] Phase 2
	
TTDDRUID	D05ELZ
DRUGNAME	IC9/CAR.19/IL15-transduced CB-NK cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D05EMG
DRUGNAME	Butylscopolamine
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Approved
	
TTDDRUID	D05EMV
DRUGNAME	GR148672X
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial
	
TTDDRUID	D05EMW
DRUGNAME	Long-acting polysialic acid-interferon alpha 2b conjugate
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D05ENG
DRUGNAME	AVX701
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Rectosigmoid junction cancer [ICD-11: 2B91.Z] Phase 1/2
	
TTDDRUID	D05ENJ
DRUGNAME	Fasitibant chloride
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
	
TTDDRUID	D05EOT
DRUGNAME	CM-PK
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D05EPE
DRUGNAME	VRC-SRSDNA015-00-VP
INDICATI	Coronavirus infection [ICD-11: 1D92] Phase 1
	
TTDDRUID	D05EPM
DRUGNAME	Ethotoin
INDICATI	Complex partial seizure [ICD-11: 8A68.0] Approved
	
TTDDRUID	D05EPU
DRUGNAME	ZD7114
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D05EPV
DRUGNAME	Ozoralizumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D05EPY
DRUGNAME	L-693612
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D05ERA
DRUGNAME	PXL-01
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2
	
TTDDRUID	D05ERT
DRUGNAME	GV-196771
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2
	
TTDDRUID	D05ETC
DRUGNAME	SN-32793
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D05EUH
DRUGNAME	H5N1 influenza virus vaccine
INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1/2
	
TTDDRUID	D05EUI
DRUGNAME	DeltaFLU
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D05EUR
DRUGNAME	LJN452
INDICATI	Primary biliary cholangitis [ICD-11: DB96.1] Phase 2
	
TTDDRUID	D05EUS
DRUGNAME	Human microbio modulator
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05EVF
DRUGNAME	Iodine-123-iodophenylpentadecanoic acid
INDICATI	Coronary artery disease [ICD-11: BA80] Approved
	
TTDDRUID	D05EVI
DRUGNAME	U-78875
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D05EXN
DRUGNAME	CC-223
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D05EYG
DRUGNAME	L-745337
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D05FBZ
DRUGNAME	CPHPC
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2
	
TTDDRUID	D05FCR
DRUGNAME	GT0918
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D05FFR
DRUGNAME	MGBG
INDICATI	Head and neck cancer [ICD-11: 2D42] Terminated
	
TTDDRUID	D05FGG
DRUGNAME	Azilsartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D05FGN
DRUGNAME	DFV890
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D05FGP
DRUGNAME	DWP-418
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05FHZ
DRUGNAME	MGD009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05FIJ
DRUGNAME	GSK2816126
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05FKU
DRUGNAME	ETC-1922159
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05FOB
DRUGNAME	GenFusAb
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D05FOF
DRUGNAME	CHS-0214
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 3
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D05FPZ
DRUGNAME	M7824
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D05FQD
DRUGNAME	Metaiodobenzylguanidine I-131
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
INDICATI	Pheochromocytoma [ICD-11: 5A75] Application submitted
	
TTDDRUID	D05FQF
DRUGNAME	FLUNOPROST
INDICATI	Nasal congestion [ICD-11: MD11.9] Investigative
	
TTDDRUID	D05FRM
DRUGNAME	ApoVax104-HPV
INDICATI	Cervical cancer [ICD-11: 2C77.0] Investigative
	
TTDDRUID	D05FRP
DRUGNAME	Rindopepimut
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 3
INDICATI	Brain cancer [ICD-11: 2A00] Phase 3
	
TTDDRUID	D05FSK
DRUGNAME	MSL-143438
INDICATI	Yersinia infection [ICD-11: 1B93] Investigative
	
TTDDRUID	D05FTJ
DRUGNAME	Mefenamic acid
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Approved
	
TTDDRUID	D05FTY
DRUGNAME	ES-1005
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D05FUP
DRUGNAME	CAR-T cells targeting Mesothelin
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
	
TTDDRUID	D05FUU
DRUGNAME	Pratosartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3
	
TTDDRUID	D05FVK
DRUGNAME	RPI-78M
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D05FVX
DRUGNAME	CDP-484
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1/2
	
TTDDRUID	D05FWF
DRUGNAME	Fostrap
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 1
	
TTDDRUID	D05FWH
DRUGNAME	SCH-900776
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D05FYA
DRUGNAME	Thioperamide
INDICATI	Cognitive impairment [ICD-11: 6D71] Terminated
	
TTDDRUID	D05FZM
DRUGNAME	CD19-UCART
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Clinical trial
	
TTDDRUID	D05GBH
DRUGNAME	F4co vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D05GBR
DRUGNAME	MVA CSP
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D05GBZ
DRUGNAME	ABS-205
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated
	
TTDDRUID	D05GDS
DRUGNAME	N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D05GEF
DRUGNAME	KRN-5500
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 2
	
TTDDRUID	D05GGD
DRUGNAME	SYNVISC-ONE
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 4
	
TTDDRUID	D05GGP
DRUGNAME	HEGF
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved
	
TTDDRUID	D05GIO
DRUGNAME	ICT-037
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05GJJ
DRUGNAME	JR-051
INDICATI	Fabry disease [ICD-11: 5C56.01] Investigative
	
TTDDRUID	D05GJP
DRUGNAME	LBVH-0101
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
	
TTDDRUID	D05GJW
DRUGNAME	Cladribine
INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
INDICATI	Relapsing-remitting multiple sclerosis [ICD-11: 8A40.0] Phase 3
	
TTDDRUID	D05GKD
DRUGNAME	Tramadol
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D05GKN
DRUGNAME	SBC-106
INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Investigative
	
TTDDRUID	D05GKZ
DRUGNAME	Follistatin
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D05GLT
DRUGNAME	Norisoboldine
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D05GMG
DRUGNAME	NNI-351
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D05GMT
DRUGNAME	Pyridinone carboxamide derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D05GNW
DRUGNAME	AZD-9164
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D05GOA
DRUGNAME	Vivia-1615
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05GOM
DRUGNAME	S-20928
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated
	
TTDDRUID	D05GPB
DRUGNAME	Eptacog alfa
INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 1
	
TTDDRUID	D05GPN
DRUGNAME	Recombinant human CFH protein
INDICATI	Kidney disease [ICD-11: GC2Z] Investigative
	
TTDDRUID	D05GPO
DRUGNAME	Olopatadine
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved
INDICATI	Ocular allergy [ICD-11: 4A81] Phase 3
	
TTDDRUID	D05GQD
DRUGNAME	CSA-13
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical
	
TTDDRUID	D05GQH
DRUGNAME	ADX-88178
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D05GQL
DRUGNAME	KNI-102
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D05GQV
DRUGNAME	RTA-801
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D05GRY
DRUGNAME	Nesiritide
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D05GSI
DRUGNAME	LA-480
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05GUK
DRUGNAME	INTOPLICINE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05GVO
DRUGNAME	PAT-NM-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05GVQ
DRUGNAME	Muromonab-cd3
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Approved
	
TTDDRUID	D05GVV
DRUGNAME	Pyrimidine derivative 5
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented
INDICATI	Fibrosis [ICD-11: GA14-GC01] Patented
INDICATI	Blood vessel proliferative disorder [ICD-11: BE2Z] Patented
	
TTDDRUID	D05GXC
DRUGNAME	Peginterferon lambda alfa-1a
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D05GYL
DRUGNAME	UR-63325
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D05GYU
DRUGNAME	EP-201
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D05GZB
DRUGNAME	Dupixent
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3
	
TTDDRUID	D05GZD
DRUGNAME	Rilapladib
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1
	
TTDDRUID	D05HAD
DRUGNAME	DP-4088
INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 1
	
TTDDRUID	D05HAJ
DRUGNAME	Follitropin alfa/lutropin alfa
INDICATI	Infertility [ICD-11: GB04] Approved
	
TTDDRUID	D05HBZ
DRUGNAME	E 7974
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D05HCO
DRUGNAME	1954U89
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D05HDX
DRUGNAME	GW-501516
INDICATI	Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 4
	
TTDDRUID	D05HEJ
DRUGNAME	Beta 1-6 glucan-conjugated trastuzumab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D05HFN
DRUGNAME	99mTc-tetrofosmin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D05HFU
DRUGNAME	TGX-6B4
INDICATI	Thrombosis [ICD-11: DB61-GB90] Preclinical
	
TTDDRUID	D05HFY
DRUGNAME	Acenocoumarol
INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved
	
TTDDRUID	D05HGL
DRUGNAME	GW-695634
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D05HHP
DRUGNAME	Astenose
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D05HHZ
DRUGNAME	NX-002
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D05HID
DRUGNAME	rAAV1.tMCK.human-alpha-sarcoglycan
INDICATI	Discovery agent [ICD-11: N.A.] Phase 1
	
TTDDRUID	D05HIJ
DRUGNAME	SAR260301
INDICATI	Pten-deficient tumour [ICD-11: 2C50-2F93] Discontinued in Phase 1
	
TTDDRUID	D05HIP
DRUGNAME	Comvac4-HB
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D05HIX
DRUGNAME	MK-6406
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D05HJO
DRUGNAME	PD-2024
INDICATI	Insulin-resistant disorder [ICD-11: 5A44] Investigative
	
TTDDRUID	D05HJR
DRUGNAME	Oncoprex
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05HKB
DRUGNAME	RS 86
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D05HKC
DRUGNAME	PMID26651364-Compound-123
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D05HKG
DRUGNAME	Pegylated interferon lambda
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D05HLC
DRUGNAME	NVC-727
INDICATI	Conjunctivitis [ICD-11: 9A60] Investigative
	
TTDDRUID	D05HPI
DRUGNAME	Daptomycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D05HRW
DRUGNAME	SKL-NP2
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D05HSC
DRUGNAME	Tubocurarine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
INDICATI	Smoking dependence [ICD-11: 6C4A.2] Approved
	
TTDDRUID	D05HSI
DRUGNAME	T-0632
INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Discontinued in Phase 1
	
TTDDRUID	D05HTS
DRUGNAME	PLX8394
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
	
TTDDRUID	D05HUG
DRUGNAME	OMS-403
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2
INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Phase 2
	
TTDDRUID	D05HUQ
DRUGNAME	BIOVANCE
INDICATI	Wound healing [ICD-11: EL8Y] Phase 4
	
TTDDRUID	D05HUZ
DRUGNAME	TTI-314
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D05HVY
DRUGNAME	GSK-644784
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2
	
TTDDRUID	D05HWN
DRUGNAME	BIIB-021
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D05HWX
DRUGNAME	99mTc-depreotide
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D05HXX
DRUGNAME	Tranexamic Acid
INDICATI	Excessive bleeding [ICD-11: GA30.02] Approved
	
TTDDRUID	D05HYC
DRUGNAME	F-50077
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Discontinued in Phase 2
	
TTDDRUID	D05HYL
DRUGNAME	YM-022
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated
	
TTDDRUID	D05HYT
DRUGNAME	IPAZILIDE FUMARATE
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 2
	
TTDDRUID	D05HZI
DRUGNAME	MDL 101,731
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 2
	
TTDDRUID	D05HZJ
DRUGNAME	GPC-3298306
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
	
TTDDRUID	D05IAN
DRUGNAME	G3139 + Irinotecan
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Investigative
	
TTDDRUID	D05IBA
DRUGNAME	Shanvac-B
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D05IBP
DRUGNAME	DFD-09
INDICATI	Rosacea [ICD-11: ED90.0] Application submitted
	
TTDDRUID	D05IBV
DRUGNAME	AR-12432
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D05ICS
DRUGNAME	ProSavin
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2
	
TTDDRUID	D05ICT
DRUGNAME	ABBV-744
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D05IEN
DRUGNAME	Epstein Barr-based gene therapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05IHU
DRUGNAME	Tetrahydrozoline
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Approved
	
TTDDRUID	D05IHZ
DRUGNAME	VP-20621
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D05IIB
DRUGNAME	NoroVAXX
INDICATI	Norovirus infection [ICD-11: 1A23] Investigative
	
TTDDRUID	D05IIN
DRUGNAME	SSR125543
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
INDICATI	Congenital adrenal hyperplasia [ICD-11: 5A71.01] Phase 2
	
TTDDRUID	D05IIP
DRUGNAME	L-651582
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D05IJM
DRUGNAME	Recruitin
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D05ILN
DRUGNAME	Agalsidase alfa
INDICATI	Fabry disease [ICD-11: 5C56.01] Approved
	
TTDDRUID	D05ILZ
DRUGNAME	NN8209
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D05INV
DRUGNAME	PEGPH20
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Gallbladder disease [ICD-11: DC11.3] Phase 1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
	
TTDDRUID	D05IPF
DRUGNAME	Kombiglyze XR/Komboglyze FDC
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D05IPO
DRUGNAME	BTS-79018
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D05IQI
DRUGNAME	LX9211
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D05IQX
DRUGNAME	Belimumab
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Approved
	
TTDDRUID	D05IRT
DRUGNAME	P276-00
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2
	
TTDDRUID	D05IRV
DRUGNAME	Elesclomol
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	D05ISO
DRUGNAME	Bemarituzumab
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
	
TTDDRUID	D05ISV
DRUGNAME	Live attenuated human parainfluenza virus type 2 vaccine
INDICATI	Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1
	
TTDDRUID	D05ITS
DRUGNAME	ALN-VEG01
INDICATI	Macular degeneration [ICD-11: 9B78.3] Terminated
	
TTDDRUID	D05IUQ
DRUGNAME	Anti-PECAM-1 mab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05IVZ
DRUGNAME	RU-33965
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D05IWE
DRUGNAME	Alloferon
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D05IYA
DRUGNAME	MEDI3902
INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2
INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 1
	
TTDDRUID	D05IZC
DRUGNAME	RGI-1001
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D05IZG
DRUGNAME	BAY-Z-4305
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D05JAA
DRUGNAME	ARRY-382
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D05JAC
DRUGNAME	Linagliptin
INDICATI	Type 2 diabetes [ICD-11: 5A11] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D05JAS
DRUGNAME	Biphenyl mannoside derivative 5
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D05JBC
DRUGNAME	N-(2-aminoethyl)-1-aziridine-ethanamine
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
	
TTDDRUID	D05JBP
DRUGNAME	IPI-194
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05JCG
DRUGNAME	CBF-BS2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D05JDR
DRUGNAME	Ceftibuten
INDICATI	Chronic bronchitis [ICD-11: CA20.1] Approved
	
TTDDRUID	D05JEG
DRUGNAME	BMN-701
INDICATI	Pompe disease [ICD-11: 5C51.3] Phase 3
INDICATI	Type 2 glycogen storage disease [ICD-11: 5C51.3] Phase 3
	
TTDDRUID	D05JEL
DRUGNAME	Onzeald
INDICATI	Brain metastases [ICD-11: 2D50] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D05JET
DRUGNAME	Remacemide
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D05JFA
DRUGNAME	INTERCEPT
INDICATI	Blood transfusion [ICD-11: QB98] Phase 3
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2
	
TTDDRUID	D05JFY
DRUGNAME	Hydralazine hydrochloride/ isosorbide dinitrate
INDICATI	Heart failure [ICD-11: BD10-BD13] Approved
	
TTDDRUID	D05JGR
DRUGNAME	TBDT
INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative
	
TTDDRUID	D05JHB
DRUGNAME	ArtemiC
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D05JHJ
DRUGNAME	LB-10522
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D05JLG
DRUGNAME	ACS-6
INDICATI	Respiratory distress syndrome [ICD-11: CB00] Investigative
	
TTDDRUID	D05JMP
DRUGNAME	IDR-803
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05JMW
DRUGNAME	RGA-1512
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D05JNI
DRUGNAME	Framycetin
INDICATI	Alcoholic cirrhosis of liver [ICD-11: DB94] Approved
INDICATI	Acute liver failure [ICD-11: DB91] Approved
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D05JPJ
DRUGNAME	ELND-004
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D05JQD
DRUGNAME	M-6040
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D05JQF
DRUGNAME	Tipredane
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D05JRG
DRUGNAME	Antithrombin alfa
INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved
	
TTDDRUID	D05JSU
DRUGNAME	Edivoxetine
INDICATI	Pediatric attention deficit hyperactivity disorder [ICD-11: 6A05] Phase 3
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3
	
TTDDRUID	D05JTJ
DRUGNAME	IC-50
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D05JXF
DRUGNAME	YD-501
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D05JXM
DRUGNAME	PF-3932295
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D05JXR
DRUGNAME	SC-52012
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D05KAC
DRUGNAME	PG-102
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D05KBP
DRUGNAME	INO-8875
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2
	
TTDDRUID	D05KBU
DRUGNAME	Gabapentin enacarbil
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
	
TTDDRUID	D05KCJ
DRUGNAME	ANZ-521
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2
	
TTDDRUID	D05KED
DRUGNAME	Rocilinostat
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	D05KEZ
DRUGNAME	Ethyl chloride
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D05KFA
DRUGNAME	BL-1832
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 3
	
TTDDRUID	D05KFH
DRUGNAME	CD171 specific CAR T cells expressing EGFRt
INDICATI	Ganglioneuroblastoma [ICD-11: 2A00.11] Phase 1
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
	
TTDDRUID	D05KGG
DRUGNAME	IMA101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05KHN
DRUGNAME	ICI-169369
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D05KHP
DRUGNAME	ABC-3
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D05KIV
DRUGNAME	Ecopipam hydrochloride
INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 2
	
TTDDRUID	D05KKC
DRUGNAME	CHML
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D05KKF
DRUGNAME	NC-2500
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Investigative
	
TTDDRUID	D05KKP
DRUGNAME	PF-06252616
INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 2
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D05KKV
DRUGNAME	Dicaffeoylquinic acids
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D05KLQ
DRUGNAME	HIV vaccines
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D05KME
DRUGNAME	ORADUR-ADHD
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1
	
TTDDRUID	D05KNG
DRUGNAME	ALB-109564(a)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05KOA
DRUGNAME	Prophylactic DNA vaccine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Terminated
	
TTDDRUID	D05KON
DRUGNAME	Felbamate
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D05KOP
DRUGNAME	Ii-Key hybrid peptide vaccine
INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D05KOY
DRUGNAME	Stem cell therapy, spinal cord injury
INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative
	
TTDDRUID	D05KQE
DRUGNAME	MK-287
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2
	
TTDDRUID	D05KRC
DRUGNAME	Emopamil
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D05KRH
DRUGNAME	CNDO-113
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05KRS
DRUGNAME	CT-340
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D05KSY
DRUGNAME	LIM-0746
INDICATI	Cholesterol metabolism disorder [ICD-11: 5C8Z] Investigative
	
TTDDRUID	D05KTK
DRUGNAME	CJC-1004
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D05KTV
DRUGNAME	NGD-93-1
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D05KUP
DRUGNAME	ERB-257
INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 1
	
TTDDRUID	D05KVC
DRUGNAME	Paliroden
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D05KWY
DRUGNAME	ZD-9063P
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D05KXJ
DRUGNAME	GSK233705
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D05KZK
DRUGNAME	SMT-D002
INDICATI	Seborrhea [ICD-11: ED91.2] Approved
	
TTDDRUID	D05KZM
DRUGNAME	Dimesna
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 3
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 3
	
TTDDRUID	D05KZV
DRUGNAME	VR-461
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D05LBH
DRUGNAME	PMID28621580-Compound-WO2013112959C68
INDICATI	Fibrosis [ICD-11: GA14-GC01] Patented
	
TTDDRUID	D05LBN
DRUGNAME	TAK-981
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D05LBU
DRUGNAME	Ticlopidine
INDICATI	Stroke [ICD-11: 8B20] Approved
	
TTDDRUID	D05LCN
DRUGNAME	BMP-7 bone morphogenetic protein
INDICATI	Kidney disease [ICD-11: GC2Z] Phase 4
	
TTDDRUID	D05LCX
DRUGNAME	A-70276
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated
	
TTDDRUID	D05LDK
DRUGNAME	IPX203
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D05LDQ
DRUGNAME	BAY 94-9027
INDICATI	Stroke [ICD-11: 8B20] Phase 3
INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 3
	
TTDDRUID	D05LEO
DRUGNAME	Fluorouracil
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Tumour [ICD-11: 2A00-2F9Z] Investigative
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative
	
TTDDRUID	D05LGX
DRUGNAME	Fipamezole
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D05LIH
DRUGNAME	Anti-CD19 CAR-T cells
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2
INDICATI	B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
	
TTDDRUID	D05LKP
DRUGNAME	Sulfadiazine
INDICATI	Rheumatic fever [ICD-11: 1B40-1B42] Approved
	
TTDDRUID	D05LKZ
DRUGNAME	HPP-607
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05LLH
DRUGNAME	Penciclovir
INDICATI	Recurrent herpes labialis [ICD-11: 1F00.01] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D05LLJ
DRUGNAME	MK-4815
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D05LMC
DRUGNAME	AMG 595
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D05LOB
DRUGNAME	FP-1201
INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 3
	
TTDDRUID	D05LOV
DRUGNAME	ADV-1002401
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D05LOY
DRUGNAME	ACH-702
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D05LPP
DRUGNAME	ABH001
INDICATI	Liver cancer [ICD-11: 2C12] Phase 3
	
TTDDRUID	D05LPW
DRUGNAME	DA-1229
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D05LQX
DRUGNAME	BOL-303259-X
INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
	
TTDDRUID	D05LRD
DRUGNAME	BMS-933043
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Phase 1
	
TTDDRUID	D05LST
DRUGNAME	Myrcludex B
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D05LSY
DRUGNAME	AKP-020
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D05LTJ
DRUGNAME	ISIS 325568
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D05LTY
DRUGNAME	Enbrel
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D05LUT
DRUGNAME	Molecule 23
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D05LVL
DRUGNAME	AVR-147
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D05LXC
DRUGNAME	QA-241
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D05LXH
DRUGNAME	Beta-interferon
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D05LYC
DRUGNAME	KR-62436
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D05LYX
DRUGNAME	Glibenclamide
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
INDICATI	Stroke [ICD-11: 8B20] Phase 3
	
TTDDRUID	D05LZG
DRUGNAME	R-type pyocins
INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative
	
TTDDRUID	D05MBE
DRUGNAME	NK-102
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D05MBZ
DRUGNAME	Tamsulosin
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved
	
TTDDRUID	D05MCS
DRUGNAME	GSK2190915
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D05MDJ
DRUGNAME	ORG-34517
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2
	
TTDDRUID	D05MDQ
DRUGNAME	CG-701338
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05MEL
DRUGNAME	PV-705
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2
	
TTDDRUID	D05MEP
DRUGNAME	AE-O
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D05MEY
DRUGNAME	Epitinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05MFA
DRUGNAME	Valacyclovir Hydrochloride
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Approved
	
TTDDRUID	D05MFG
DRUGNAME	Spirapril
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D05MFO
DRUGNAME	MDL-11939
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3
	
TTDDRUID	D05MGQ
DRUGNAME	MDX-1342
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D05MHI
DRUGNAME	AC-607
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 2
	
TTDDRUID	D05MIL
DRUGNAME	Iopentol
INDICATI	Urinary tract disease [ICD-11: GC2Z] Approved
	
TTDDRUID	D05MIQ
DRUGNAME	O-SPC/rBRU vaccine
INDICATI	Shigella infection [ICD-11: 1A02] Phase 1
	
TTDDRUID	D05MJS
DRUGNAME	PRO22
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D05MKA
DRUGNAME	Lixisenatide
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D05MKG
DRUGNAME	Nalmefene prodrug
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Investigative
	
TTDDRUID	D05MLX
DRUGNAME	ONYX-411
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D05MNV
DRUGNAME	Fosclin
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3
	
TTDDRUID	D05MNW
DRUGNAME	Virginiamycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D05MOZ
DRUGNAME	G-202
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Adenocarcinoma [ICD-11: 2D40] Phase 2
	
TTDDRUID	D05MPX
DRUGNAME	Bornaprine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D05MQK
DRUGNAME	Tadalafil
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved
	
TTDDRUID	D05MQO
DRUGNAME	BEA-005
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated
	
TTDDRUID	D05MRY
DRUGNAME	Six-membered heterocyclic benzamide derivative 7
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D05MSG
DRUGNAME	BMS-694153
INDICATI	Migraine [ICD-11: 8A80] Investigative
	
TTDDRUID	D05MSL
DRUGNAME	DC-756
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D05MSM
DRUGNAME	CK-37
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05MUA
DRUGNAME	NOX 2149
INDICATI	Stress [ICD-11: 6B40-6B45] Investigative
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D05MVA
DRUGNAME	RGD-891
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D05MVX
DRUGNAME	ATA520
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D05MWY
DRUGNAME	RF-1051
INDICATI	Genetic disease [ICD-11: 8E02] Discontinued in Phase 2
	
TTDDRUID	D05MXK
DRUGNAME	GW-473178
INDICATI	Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 1
	
TTDDRUID	D05MXL
DRUGNAME	CHDI-003940246
INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative
	
TTDDRUID	D05MZI
DRUGNAME	nusinersen
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Approved
	
TTDDRUID	D05NBD
DRUGNAME	MONTIRELIN TETRAHYDRATE
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Preregistration
	
TTDDRUID	D05NCT
DRUGNAME	DPC-1528
INDICATI	Acne vulgaris [ICD-11: ED80] Investigative
	
TTDDRUID	D05NDN
DRUGNAME	Alovudine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D05NDR
DRUGNAME	Sifalimumab
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D05NDY
DRUGNAME	OAP-189
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D05NEK
DRUGNAME	N-acetylcysteine
INDICATI	Cystic fibrosis [ICD-11: CA25] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D05NFR
DRUGNAME	TPX-0005
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D05NHA
DRUGNAME	Resorcinol compound 20
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D05NHT
DRUGNAME	BP-C1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D05NIO
DRUGNAME	NP-17
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D05NIR
DRUGNAME	ALX-0061
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D05NJG
DRUGNAME	PH sensitive micelles
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05NJI
DRUGNAME	STX 64
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D05NJL
DRUGNAME	ALSE-100
INDICATI	Bone disease [ICD-11: FC0Z] Investigative
	
TTDDRUID	D05NLD
DRUGNAME	ARRY-300
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05NLR
DRUGNAME	Adva-33c
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05NMJ
DRUGNAME	Biphasic porcine insulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D05NMU
DRUGNAME	DasKloster 0274-01
INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative
	
TTDDRUID	D05NOS
DRUGNAME	Triflupromazine
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Approved
	
TTDDRUID	D05NQR
DRUGNAME	LyphoDerm
INDICATI	Wound healing [ICD-11: EL8Y] Terminated
	
TTDDRUID	D05NRI
DRUGNAME	Ceronapril
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D05NRX
DRUGNAME	VG-102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05NSF
DRUGNAME	4SC-207
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05NTQ
DRUGNAME	PRO-015
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Investigative
	
TTDDRUID	D05NTY
DRUGNAME	NPC-18166
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D05NUH
DRUGNAME	Hm61713
INDICATI	Lung cancer [ICD-11: 2C25.0] Approved
	
TTDDRUID	D05NUN
DRUGNAME	Pyrazole derivative 36
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D05NUP
DRUGNAME	SBS-1000
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D05NUT
DRUGNAME	ALS-00T2-0501
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1
	
TTDDRUID	D05NWJ
DRUGNAME	SLV-337
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D05NWM
DRUGNAME	Pyraclostrobin
INDICATI	Plant grey mould disease [ICD-11: N.A.] Investigative
	
TTDDRUID	D05NYF
DRUGNAME	HuMax-TF
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D05NYK
DRUGNAME	BEL-0222
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1/2
	
TTDDRUID	D05NYO
DRUGNAME	Imab-027
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D05NZV
DRUGNAME	BRL 35135
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D05OAI
DRUGNAME	CART-19/22
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D05OAJ
DRUGNAME	AW-814141
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D05OBK
DRUGNAME	DwLIP-GCGRrx
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D05ODE
DRUGNAME	CC-90001
INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 1
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 1
	
TTDDRUID	D05ODU
DRUGNAME	Belerofon
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D05OEG
DRUGNAME	E-2001
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1
	
TTDDRUID	D05OEU
DRUGNAME	Technetium Tc-99m Succimer Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D05OFO
DRUGNAME	TC-2696
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D05OFX
DRUGNAME	Lacosamide
INDICATI	Convulsion [ICD-11: 8A68.Z] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 3
	
TTDDRUID	D05OHY
DRUGNAME	CAR-T cells targeting EphA2
INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D05OIS
DRUGNAME	Benzyl alcohol
INDICATI	Head and body lice [ICD-11: 1G00.0] Approved
	
TTDDRUID	D05OIU
DRUGNAME	PMID27998201-Compound-5
INDICATI	Cirrhosis [ICD-11: DB93] Patented
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Patented
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Patented
INDICATI	Multiple sclerosis [ICD-11: 8A40] Patented
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Patented
	
TTDDRUID	D05OMO
DRUGNAME	PMID26651364-Compound-11b
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D05OMT
DRUGNAME	MK-8033
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05ONA
DRUGNAME	Cyt-1010
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D05OQJ
DRUGNAME	Methyprylon
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D05OQX
DRUGNAME	NCX-4016
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2
INDICATI	Claudication [ICD-11: FA11] Discontinued in Phase 2
INDICATI	Nephropathy [ICD-11: GC2Z] Discontinued in Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D05ORA
DRUGNAME	MOR-103
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1/2
	
TTDDRUID	D05ORI
DRUGNAME	AGI-350
INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Investigative
	
TTDDRUID	D05ORO
DRUGNAME	Anti-N3pG-Abeta antibody
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D05OSR
DRUGNAME	Human immune globulin
INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Approved
	
TTDDRUID	D05OTD
DRUGNAME	Heterocyclic derivative 4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D05OTL
DRUGNAME	NW-3509
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D05OTZ
DRUGNAME	SMP-986
INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2
	
TTDDRUID	D05OVC
DRUGNAME	Atipamezole
INDICATI	Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 2
	
TTDDRUID	D05OVR
DRUGNAME	ALP-242
INDICATI	Cystic fibrosis [ICD-11: CA25] Terminated
	
TTDDRUID	D05OWB
DRUGNAME	mab-216
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D05OXZ
DRUGNAME	BIWA 4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05OZG
DRUGNAME	BTSCAN
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D05OZQ
DRUGNAME	Efpeglenatide
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D05PCM
DRUGNAME	PF-04965842
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3
INDICATI	Lupus [ICD-11: 4A40] Phase 2
	
TTDDRUID	D05PDJ
DRUGNAME	SAGE-217b
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D05PFE
DRUGNAME	HC-15
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05PFS
DRUGNAME	LTI-291
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D05PGG
DRUGNAME	Prostvac
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D05PGM
DRUGNAME	AdV-tK
INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Phase 2
	
TTDDRUID	D05PGU
DRUGNAME	Clostridium difficile toxoid vaccine
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 3
	
TTDDRUID	D05PHH
DRUGNAME	Gabexate
INDICATI	Pancreatitis [ICD-11: DC31-DC34] Approved
	
TTDDRUID	D05PIX
DRUGNAME	CG-400549
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D05PIZ
DRUGNAME	Levomethadyl Acetate
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Approved
	
TTDDRUID	D05PJJ
DRUGNAME	NOX 2137a/b
INDICATI	Stress [ICD-11: 6B40-6B45] Investigative
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D05PKF
DRUGNAME	SOM-0720
INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D05PLH
DRUGNAME	Carisoprodol
INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Approved
	
TTDDRUID	D05PMU
DRUGNAME	Dicaffeoyltartaric acids
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D05PQF
DRUGNAME	ONO-4127
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1
	
TTDDRUID	D05PQW
DRUGNAME	AZD-5180
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D05PRV
DRUGNAME	PerCvax
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2
	
TTDDRUID	D05PTG
DRUGNAME	EPD-clofarabine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D05PTH
DRUGNAME	MK-8175A
INDICATI	Contraception [ICD-11: QA21] Phase 2
	
TTDDRUID	D05PTL
DRUGNAME	NMB-T-BMX-OS01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05PTT
DRUGNAME	ROSMARINIC ACID
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D05PUD
DRUGNAME	Aldesleukin
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D05PVW
DRUGNAME	CX-2007
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative
	
TTDDRUID	D05PWA
DRUGNAME	PNT-600
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05PWU
DRUGNAME	PRo antigen cancer vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D05PWX
DRUGNAME	Sulfatinib
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05PWZ
DRUGNAME	Ecromeximab
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2
	
TTDDRUID	D05PXA
DRUGNAME	BTX1503
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D05PXL
DRUGNAME	PL-3394
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D05PYB
DRUGNAME	Elstree-BN
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1/2
	
TTDDRUID	D05PZB
DRUGNAME	AT9283
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D05PZI
DRUGNAME	MB-CART20.1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D05PZN
DRUGNAME	TRO-19622
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 2
	
TTDDRUID	D05PZZ
DRUGNAME	DDP-200
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2
	
TTDDRUID	D05QAA
DRUGNAME	PNU-248686A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05QBF
DRUGNAME	Devazepide
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative
	
TTDDRUID	D05QBH
DRUGNAME	LAS-41003
INDICATI	Eczema [ICD-11: EA80-EA89] Phase 2
	
TTDDRUID	D05QCE
DRUGNAME	KM-01221
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D05QDC
DRUGNAME	Acitretin
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
	
TTDDRUID	D05QFA
DRUGNAME	R-71762
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D05QFO
DRUGNAME	RLY-106
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D05QGH
DRUGNAME	DXL-625
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative
	
TTDDRUID	D05QHL
DRUGNAME	Sivelestat sodium hydrate
INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 4
INDICATI	Community-acquired pneumonia [ICD-11: CA40.Z] Phase 2
	
TTDDRUID	D05QHO
DRUGNAME	ACE-527
INDICATI	Escherichia coli infection [ICD-11: 1A03] Phase 2
	
TTDDRUID	D05QHU
DRUGNAME	CRS-3123
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 1
	
TTDDRUID	D05QIK
DRUGNAME	CM4620
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D05QIM
DRUGNAME	TA-NIC
INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Approved
	
TTDDRUID	D05QIS
DRUGNAME	VX-944
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D05QIU
DRUGNAME	Embeconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 1
	
TTDDRUID	D05QIZ
DRUGNAME	GTx-822
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D05QJT
DRUGNAME	GW274150
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D05QKI
DRUGNAME	LixiLan
INDICATI	Type-2 diabetes [ICD-11: 5A11] Application submitted
	
TTDDRUID	D05QKO
DRUGNAME	NBI-5788
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D05QKZ
DRUGNAME	Adipose-derived regenerative cell therapy
INDICATI	Chronic myocardial ischemia [ICD-11: BA6Z] Phase 3
	
TTDDRUID	D05QLQ
DRUGNAME	HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D05QMG
DRUGNAME	FR167653
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D05QMJ
DRUGNAME	RWJ-56423
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D05QML
DRUGNAME	PQ-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05QMQ
DRUGNAME	MLN-0905
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative
	
TTDDRUID	D05QNO
DRUGNAME	Decamethonium
INDICATI	Muscle spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D05QOL
DRUGNAME	Polatuzumab vedotin
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2
	
TTDDRUID	D05QPC
DRUGNAME	[L/D]-aminopterin
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D05QPW
DRUGNAME	Choline salicylate
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D05QTO
DRUGNAME	LF-801
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D05QUL
DRUGNAME	T89
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
INDICATI	Angina pectoris [ICD-11: BA40] Phase 3
	
TTDDRUID	D05QXT
DRUGNAME	BAY-38-1315
INDICATI	Arteriosclerosis [ICD-11: BD40] Preclinical
	
TTDDRUID	D05QXW
DRUGNAME	TZ-111
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D05RBF
DRUGNAME	PMID25666693-Compound-99
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D05RBH
DRUGNAME	N9-GP
INDICATI	Factor IX deficiency [ICD-11: 3B11] Phase 1
	
TTDDRUID	D05RBL
DRUGNAME	CL-184005
INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated
	
TTDDRUID	D05RBO
DRUGNAME	OPM-3023
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2
	
TTDDRUID	D05RCZ
DRUGNAME	HSV2 DNA vaccine
INDICATI	Genital herpes [ICD-11: 1A94] Phase 1
	
TTDDRUID	D05RDE
DRUGNAME	TJN-505
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D05REB
DRUGNAME	ZT-1
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D05REH
DRUGNAME	Flosulide
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D05REL
DRUGNAME	GR-82334
INDICATI	Vomiting [ICD-11: MD90] Terminated
	
TTDDRUID	D05RFC
DRUGNAME	Tumor vascular thrombogen
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05RFI
DRUGNAME	QBI-206
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05RFO
DRUGNAME	A-928605
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05RGV
DRUGNAME	MK-1496
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05RHI
DRUGNAME	Trifluridine
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D05RIM
DRUGNAME	SPN-808
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1
	
TTDDRUID	D05RIY
DRUGNAME	Perflubutane lipid microsphere-encapsulated
INDICATI	Heart disease [ICD-11: BA41-BA42] Approved
	
TTDDRUID	D05RJG
DRUGNAME	Schiff base compound 1
INDICATI	Alzheimer disease [ICD-11: 8A20] Patented
	
TTDDRUID	D05RJP
DRUGNAME	Oblimersen
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D05RKV
DRUGNAME	Sch-036
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D05RLR
DRUGNAME	1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole
INDICATI	Conjunctival fibrosis [ICD-11: 9A61.3] Investigative
	
TTDDRUID	D05RMW
DRUGNAME	ZD-3638
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D05ROI
DRUGNAME	Dabrafenib
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D05RPN
DRUGNAME	BMS-488516
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D05RPT
DRUGNAME	MER-2101
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D05RQW
DRUGNAME	Guglipid
INDICATI	Lipoprotein disorder [ICD-11: 5C80-5C8Z] Approved
	
TTDDRUID	D05RQX
DRUGNAME	Cefaclidine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Preregistration
	
TTDDRUID	D05RQY
DRUGNAME	MM-093
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D05RRA
DRUGNAME	HQK-1004
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D05RRU
DRUGNAME	IL-2/CD40L-expressing leukemia vaccine
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
	
TTDDRUID	D05RSC
DRUGNAME	Sofinicline
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	D05RSS
DRUGNAME	PF-03772304
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05RTB
DRUGNAME	Anti-Staphylococcus enterotoxin B hyperimmune globulin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D05RTF
DRUGNAME	AME-527
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1/2
	
TTDDRUID	D05RTV
DRUGNAME	Superoxide dismutase
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
	
TTDDRUID	D05RTX
DRUGNAME	RO-1752
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D05RUH
DRUGNAME	FMX101
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3
	
TTDDRUID	D05RUJ
DRUGNAME	G-1128
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Discontinued in Phase 2
	
TTDDRUID	D05RUM
DRUGNAME	Melperone
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Withdrawn from market
	
TTDDRUID	D05RVA
DRUGNAME	CFG920
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D05RWL
DRUGNAME	NSD-788
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1
	
TTDDRUID	D05RWN
DRUGNAME	Lanthanum polystyrene sulfonate
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Investigative
	
TTDDRUID	D05RXI
DRUGNAME	Hydrocortamate
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D05RXW
DRUGNAME	LAS-41002
INDICATI	Eczema [ICD-11: EA80-EA89] Phase 2
	
TTDDRUID	D05RZE
DRUGNAME	LY-2623091
INDICATI	Chronic kidney disease [ICD-11: GB61] Phase 2
	
TTDDRUID	D05RZI
DRUGNAME	AA-193
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2
	
TTDDRUID	D05RZJ
DRUGNAME	Recombinant human CC10
INDICATI	Endometriosis [ICD-11: GA10] Investigative
	
TTDDRUID	D05RZW
DRUGNAME	YM-934
INDICATI	Angina pectoris [ICD-11: BA40] Phase 2
	
TTDDRUID	D05SBI
DRUGNAME	TBC-395
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D05SBO
DRUGNAME	LY2835219
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D05SBR
DRUGNAME	Piclidenoson
INDICATI	Keratoconjunctivitis sicca [ICD-11: 9A79] Phase 3
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D05SCQ
DRUGNAME	TDI-0079
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D05SEW
DRUGNAME	OB-24
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05SFD
DRUGNAME	DMP-961
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D05SGI
DRUGNAME	BGB-3113
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D05SHK
DRUGNAME	Nadolol
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D05SHQ
DRUGNAME	ASP-2002
INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative
	
TTDDRUID	D05SJD
DRUGNAME	DasKloster 0501-01
INDICATI	Scleroderma [ICD-11: 4A42] Investigative
	
TTDDRUID	D05SJK
DRUGNAME	Bone marrow stem cell therapy
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 1
	
TTDDRUID	D05SJW
DRUGNAME	Gallamine Triethiodide
INDICATI	Stabilize muscle contraction [ICD-11: FB3Z] Approved
	
TTDDRUID	D05SJY
DRUGNAME	WS-CoQ10
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D05SLM
DRUGNAME	LY-2590443
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D05SMP
DRUGNAME	PMID25666693-Compound-116
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D05SMV
DRUGNAME	P2B-002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05SNX
DRUGNAME	APT070
INDICATI	Reperfusion injury [ICD-11: ND56.Z] Phase 3
	
TTDDRUID	D05SOF
DRUGNAME	SPM-3672
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D05SOH
DRUGNAME	CTAP-201
INDICATI	Hyperparathyroidism [ICD-11: 5A51] Phase 1
	
TTDDRUID	D05SOW
DRUGNAME	SX-MTR1
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D05SPL
DRUGNAME	Monofer
INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved
	
TTDDRUID	D05SQU
DRUGNAME	BIM-64152
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D05SSC
DRUGNAME	Dalcetrapib
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 3
INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 3
	
TTDDRUID	D05SSJ
DRUGNAME	Dotarizine
INDICATI	Migraine [ICD-11: 8A80] Terminated
	
TTDDRUID	D05STL
DRUGNAME	ARRY-502
INDICATI	Allergic asthma [ICD-11: CA23.0] Phase 2
	
TTDDRUID	D05STQ
DRUGNAME	Pazufloxacin
INDICATI	Conjunctivitis [ICD-11: 9A60] Phase 3
	
TTDDRUID	D05SUA
DRUGNAME	A-798
INDICATI	Obesity [ICD-11: 5B81] Terminated
	
TTDDRUID	D05SVN
DRUGNAME	PdB-W433F
INDICATI	Streptococcus infection [ICD-11: 1B53] Investigative
	
TTDDRUID	D05SVQ
DRUGNAME	C-AFG
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated
	
TTDDRUID	D05SWL
DRUGNAME	PMID25666693-Compound-28
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D05SXB
DRUGNAME	SMT-D004
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D05SXC
DRUGNAME	SCR-44001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D05SXL
DRUGNAME	PLR-8
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D05SXT
DRUGNAME	INP-03
INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative
	
TTDDRUID	D05SYO
DRUGNAME	KR-33889
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D05TBI
DRUGNAME	DG-770
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D05TBQ
DRUGNAME	SAR408701
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D05TCC
DRUGNAME	TMX-202
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D05TDJ
DRUGNAME	TS01
INDICATI	Stroke [ICD-11: 8B20] Phase 1
	
TTDDRUID	D05TDS
DRUGNAME	Nu-2
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D05TFW
DRUGNAME	H1N1 HA flu vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D05TGV
DRUGNAME	PEG-Infergen
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2
	
TTDDRUID	D05TIB
DRUGNAME	Trospium
INDICATI	Spasm [ICD-11: MB47.3] Approved
INDICATI	Overactive bladder [ICD-11: GC50.0] Approved
	
TTDDRUID	D05TJR
DRUGNAME	Fluvirin
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D05TKB
DRUGNAME	GS-9256
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D05TKO
DRUGNAME	Retagliptin
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D05TKW
DRUGNAME	alpha-ketothiazole analogue 36
INDICATI	Alzheimer disease [ICD-11: 8A20] Clinical trial
	
TTDDRUID	D05TLM
DRUGNAME	E-5065
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D05TLP
DRUGNAME	Carabersat
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 2
	
TTDDRUID	D05TLQ
DRUGNAME	ETR-001
INDICATI	Kidney disease [ICD-11: GC2Z] Investigative
	
TTDDRUID	D05TLR
DRUGNAME	Tetramune
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market
	
TTDDRUID	D05TMA
DRUGNAME	MAGE-A4 TCR
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05TMQ
DRUGNAME	Aprobarbital
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D05TMW
DRUGNAME	Methotrexate
INDICATI	Choriocarcinoma [ICD-11: 2C75.0] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D05TNY
DRUGNAME	Generalized glucocorticoid
INDICATI	Adrenal adenoma [ICD-11: 2F37.Y] Investigative
	
TTDDRUID	D05TOJ
DRUGNAME	Peretinoin
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
	
TTDDRUID	D05TPA
DRUGNAME	SP-1062C-O
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative
	
TTDDRUID	D05TPI
DRUGNAME	EPICATECHIN
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 1/2
	
TTDDRUID	D05TQG
DRUGNAME	Pyrazole derivative 30
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D05TRI
DRUGNAME	GeNOsyl
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
	
TTDDRUID	D05TRJ
DRUGNAME	SB-728-HSPC
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D05TSG
DRUGNAME	ANB-020
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D05TSJ
DRUGNAME	LY2784544
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Myeloproliferative neoplasm [ICD-11: 2A20] Phase 2
	
TTDDRUID	D05TUL
DRUGNAME	MB-11316
INDICATI	Injury [ICD-11: NA00-ND5Z] Phase 2
	
TTDDRUID	D05TUQ
DRUGNAME	MAT-302
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D05TUZ
DRUGNAME	Tasonermin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D05TVI
DRUGNAME	TD-9594
INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative
	
TTDDRUID	D05TVW
DRUGNAME	DCVax-Head/Neck
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2
	
TTDDRUID	D05TWD
DRUGNAME	Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 1/2
	
TTDDRUID	D05TXS
DRUGNAME	BMN-168
INDICATI	Phenylketonuria [ICD-11: 5C50.0] Investigative
	
TTDDRUID	D05TZJ
DRUGNAME	Ankinara
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D05UAA
DRUGNAME	SX-HIV1
INDICATI	Retrovirus infection [ICD-11: 1D9Y] Investigative
	
TTDDRUID	D05UAO
DRUGNAME	J591-Ac-225
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D05UAV
DRUGNAME	Bis(olanzapine) pamoate monohydrate
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 3
	
TTDDRUID	D05UBX
DRUGNAME	Cefmetazole
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D05UCM
DRUGNAME	Sulfonatoporphyrin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D05UCW
DRUGNAME	MEDI-2338
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D05UDU
DRUGNAME	YK-3237
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05UEF
DRUGNAME	RR-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05UEI
DRUGNAME	99mTc-besilesomab
INDICATI	Bone metastases [ICD-11: 2D50] Approved
	
TTDDRUID	D05UFG
DRUGNAME	BIBW 2992
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
	
TTDDRUID	D05UFJ
DRUGNAME	Minnelide 001
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
	
TTDDRUID	D05UFN
DRUGNAME	PN-202
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative
	
TTDDRUID	D05UFP
DRUGNAME	PEG-SN38
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D05UGH
DRUGNAME	LEO 124249
INDICATI	Asthma [ICD-11: CA23] Phase 2
INDICATI	Eczema [ICD-11: EA80-EA89] Phase 2
	
TTDDRUID	D05UGJ
DRUGNAME	XL844
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D05UGL
DRUGNAME	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1
INDICATI	Skin disease [ICD-11: EA00-EM0Z] Patented
INDICATI	Muscular wasting [ICD-11: 8C7Y] Patented
	
TTDDRUID	D05UHF
DRUGNAME	Galsulfase
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Approved
	
TTDDRUID	D05UHJ
DRUGNAME	SM-10888
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D05UIL
DRUGNAME	TV-4710
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Discontinued in Phase 2
	
TTDDRUID	D05UJF
DRUGNAME	PBSVax
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D05UJS
DRUGNAME	ADVAX
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D05UJU
DRUGNAME	MV-2101
INDICATI	Vascular disease [ICD-11: BE2Z] Preclinical
	
TTDDRUID	D05UKK
DRUGNAME	FK-888
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2
	
TTDDRUID	D05ULR
DRUGNAME	Sildenafil
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D05UMD
DRUGNAME	R-87366
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D05UMO
DRUGNAME	BAY-793
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D05UOU
DRUGNAME	CD19-CAR-T2 Cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D05UPB
DRUGNAME	CI-972
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D05UQD
DRUGNAME	Omapatrilat
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D05UQF
DRUGNAME	NCX-226
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Investigative
	
TTDDRUID	D05URO
DRUGNAME	Quinvaxem
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D05URT
DRUGNAME	MX-7091
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D05USL
DRUGNAME	KU-55933
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05USQ
DRUGNAME	Nintedanib
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D05UTF
DRUGNAME	SB-41947
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05UTV
DRUGNAME	Albuterpenoids
INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Phase 2
	
TTDDRUID	D05UTW
DRUGNAME	ErythroMax
INDICATI	Hypoxia [ICD-11: MD11.1] Phase 1
	
TTDDRUID	D05UVD
DRUGNAME	Timolol
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D05UVL
DRUGNAME	SND-121
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D05UXF
DRUGNAME	Emapunil
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D05UXU
DRUGNAME	INM-176
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D05UYQ
DRUGNAME	Camicinal
INDICATI	Delayed gastric emptying [ICD-11: DA41.00] Phase 2
INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 2
	
TTDDRUID	D05UYW
DRUGNAME	Dorzolamide
INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved
	
TTDDRUID	D05UZO
DRUGNAME	MIVOBULIN ISETHIONATE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D05VAA
DRUGNAME	Isbufylline
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D05VAE
DRUGNAME	Posiphen R-phenserine
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D05VEP
DRUGNAME	DX-2802
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D05VEU
DRUGNAME	Coagulin-B
INDICATI	Hemophilia [ICD-11: 3B10.0] Discontinued in Phase 1/2
	
TTDDRUID	D05VFO
DRUGNAME	Rh-erythropoietin-alfa
INDICATI	Postoperative inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D05VFQ
DRUGNAME	TriTAb
INDICATI	Poison intoxication [ICD-11: NE6Z] Discontinued in Phase 2
	
TTDDRUID	D05VFZ
DRUGNAME	ABP-710
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 1
	
TTDDRUID	D05VGL
DRUGNAME	Tavaborole
INDICATI	Onychomycosis [ICD-11: EE12.1] Approved
	
TTDDRUID	D05VGS
DRUGNAME	ALB-127158(a)
INDICATI	Obesity [ICD-11: 5B81] Terminated
	
TTDDRUID	D05VHB
DRUGNAME	EMP-123
INDICATI	Peanut hypersensitivity [ICD-11: 4A83] Phase 1
	
TTDDRUID	D05VIL
DRUGNAME	Nalmefene
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Approved
	
TTDDRUID	D05VIN
DRUGNAME	Imidazole derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D05VIX
DRUGNAME	Gemfibrozil
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved
	
TTDDRUID	D05VKS
DRUGNAME	VT-122
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D05VLB
DRUGNAME	PEGylated recombinant IFN-alpha2b
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05VLN
DRUGNAME	Isomazole
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D05VLS
DRUGNAME	Rofecoxib
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
	
TTDDRUID	D05VNG
DRUGNAME	BB-1101
INDICATI	Multiple sclerosis [ICD-11: 8A40] Terminated
	
TTDDRUID	D05VNP
DRUGNAME	TESTOSTERONE BUCICLATE
INDICATI	Contraception [ICD-11: QA21] Phase 1
	
TTDDRUID	D05VNS
DRUGNAME	CD19 and CD22 CAR-T Cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D05VNX
DRUGNAME	IPC-003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05VOP
DRUGNAME	RAP-160
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Preclinical
	
TTDDRUID	D05VQD
DRUGNAME	BMS-183729
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D05VQI
DRUGNAME	Cyclandelate
INDICATI	Dementia [ICD-11: 6D80-6D86] Approved
	
TTDDRUID	D05VSH
DRUGNAME	REGN3767
INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05VTE
DRUGNAME	CAI orotate
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2
	
TTDDRUID	D05VTN
DRUGNAME	CCX-354
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D05VUX
DRUGNAME	BHV-0223
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1
	
TTDDRUID	D05VVT
DRUGNAME	PEG-PLA-TNP-470
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05VVX
DRUGNAME	PTC299
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D05VWK
DRUGNAME	AXP-107-16
INDICATI	Gynecological disease [ICD-11: GA6Z] Investigative
	
TTDDRUID	D05VWX
DRUGNAME	CGEN-25008
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05VXF
DRUGNAME	YSCMA
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D05VXQ
DRUGNAME	SRSC-355
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated
	
TTDDRUID	D05VYJ
DRUGNAME	SUN-09
INDICATI	Hypertonia [ICD-11: KB08.1] Discontinued in Phase 3
	
TTDDRUID	D05VYY
DRUGNAME	Rapamycin
INDICATI	Lymphangioleiomyomatosis [ICD-11: CB07] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D05VZE
DRUGNAME	Marimastat
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 3
	
TTDDRUID	D05VZJ
DRUGNAME	J-104132
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2
	
TTDDRUID	D05WCI
DRUGNAME	ABT-384
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D05WDD
DRUGNAME	Group B streptococcal vaccine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D05WDG
DRUGNAME	Natroba
INDICATI	Sarcoptes scabiei infection [ICD-11: 1G04] Phase 3
	
TTDDRUID	D05WDM
DRUGNAME	Ro5203280
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D05WEP
DRUGNAME	Befloxatone
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 3
	
TTDDRUID	D05WET
DRUGNAME	Anti-CD38 CAR-T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D05WFF
DRUGNAME	GNI-102
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 1
	
TTDDRUID	D05WJF
DRUGNAME	Defibrotide
INDICATI	Hepatic veno-occlusive disease [ICD-11: DB98.6] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D05WJQ
DRUGNAME	Saredutant
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 3
	
TTDDRUID	D05WKQ
DRUGNAME	LAI287
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D05WKT
DRUGNAME	PK-44
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D05WLE
DRUGNAME	INO-1800
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	D05WOS
DRUGNAME	BMS-986226
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05WPQ
DRUGNAME	BW A4C
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D05WQT
DRUGNAME	Flanvotumab
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D05WRB
DRUGNAME	Galactofucan sulphate fraction
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D05WSD
DRUGNAME	NaAPR1M-74
INDICATI	Hookworm infection [ICD-11: 1F68] Investigative
	
TTDDRUID	D05WSP
DRUGNAME	UK-396082
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D05WTS
DRUGNAME	Galavit
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Approved
	
TTDDRUID	D05WTT
DRUGNAME	Remune
INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Phase 3
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Application submitted
	
TTDDRUID	D05WTZ
DRUGNAME	Galarubicin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D05WUN
DRUGNAME	OTI-020
INDICATI	Myocardial disease [ICD-11: BC43.20] Phase 3
	
TTDDRUID	D05WUQ
DRUGNAME	Omtriptolide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05WUZ
DRUGNAME	TT-113
INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D05WVO
DRUGNAME	EDP-17
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05WVU
DRUGNAME	131i-chtnt
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D05WWJ
DRUGNAME	ALX-5407
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D05WWX
DRUGNAME	Biphenyl mannoside derivative 14
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D05WYW
DRUGNAME	L-373890
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D05XAH
DRUGNAME	Aromatic hydrazine carboxyimidoamide derivative 4
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D05XCZ
DRUGNAME	VPC-51299
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D05XDZ
DRUGNAME	LMT-X
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D05XEA
DRUGNAME	RP5063
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D05XFQ
DRUGNAME	VLN-244
INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative
	
TTDDRUID	D05XGH
DRUGNAME	PMID26651364-Compound-6e
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D05XGO
DRUGNAME	Cariprazine
INDICATI	Bipolar disorder [ICD-11: 6A60] Approved
	
TTDDRUID	D05XIA
DRUGNAME	SF-22
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Preclinical
	
TTDDRUID	D05XJW
DRUGNAME	Resiniferatoxin
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
INDICATI	Cancer related pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D05XKN
DRUGNAME	APG-101.10
INDICATI	Gout [ICD-11: FA25] Investigative
	
TTDDRUID	D05XKW
DRUGNAME	VM-501
INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 3
	
TTDDRUID	D05XLO
DRUGNAME	INCB13739
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2a
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D05XMY
DRUGNAME	Acteoside
INDICATI	Nephritis [ICD-11: GB40] Terminated
	
TTDDRUID	D05XNF
DRUGNAME	IM21 CART
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D05XPZ
DRUGNAME	JWCAR029
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D05XQE
DRUGNAME	Plaunotol
INDICATI	Ulcer [ICD-11: CA02-CB40] Approved
	
TTDDRUID	D05XRZ
DRUGNAME	HI-6
INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative
	
TTDDRUID	D05XSJ
DRUGNAME	Asfotase alfa
INDICATI	Genetic disease [ICD-11: 8E02] Approved
	
TTDDRUID	D05XTO
DRUGNAME	ABT-100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D05XTQ
DRUGNAME	DELTIBANT
INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 2
	
TTDDRUID	D05XUY
DRUGNAME	JM216
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D05XXF
DRUGNAME	ORMD-0901
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D05XXQ
DRUGNAME	MLR-1326
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D05XYC
DRUGNAME	LY-231617
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D05XYH
DRUGNAME	MIC-31
INDICATI	Gastrointestinal ulcer [ICD-11: DA60.Z] Investigative
	
TTDDRUID	D05XZQ
DRUGNAME	HepaStem
INDICATI	Liver failure [ICD-11: DB99.7] Phase 2
	
TTDDRUID	D05YAD
DRUGNAME	PMID25656651-Compound-11c
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Patented
	
TTDDRUID	D05YAG
DRUGNAME	Recombinant human endostatin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D05YAS
DRUGNAME	Tolafentrine
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D05YBZ
DRUGNAME	Tolonium chloride
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D05YEI
DRUGNAME	SUN-K0706
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D05YEL
DRUGNAME	CH-3697
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D05YES
DRUGNAME	StaphVAX
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 3
	
TTDDRUID	D05YFE
DRUGNAME	Diphyllin
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D05YFL
DRUGNAME	AFTVac
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D05YHW
DRUGNAME	Vapaliximab
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D05YIX
DRUGNAME	LymphoScan
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 3
	
TTDDRUID	D05YLL
DRUGNAME	FL-386
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D05YLN
DRUGNAME	SAR256212
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D05YLO
DRUGNAME	Her-2-Bi-armed ATC
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D05YLP
DRUGNAME	SP-333
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
	
TTDDRUID	D05YMT
DRUGNAME	Tricomin
INDICATI	Alopecia [ICD-11: ED70] Approved
	
TTDDRUID	D05YOT
DRUGNAME	PPRT-321
INDICATI	Prostate hyperplasia [ICD-11: GA90] Terminated
	
TTDDRUID	D05YQL
DRUGNAME	BM-ca
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D05YQT
DRUGNAME	LBR-101
INDICATI	Migraine [ICD-11: 8A80] Phase 1
	
TTDDRUID	D05YRG
DRUGNAME	TDI-0025
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D05YRP
DRUGNAME	C4.4a-ADC
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05YRV
DRUGNAME	ETX-6107
INDICATI	Arteriosclerosis [ICD-11: BD40] Preclinical
	
TTDDRUID	D05YTG
DRUGNAME	SLx-4090
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 2
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D05YTN
DRUGNAME	Saracatinib
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D05YUI
DRUGNAME	Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy
INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Phase 1/2
	
TTDDRUID	D05YUK
DRUGNAME	FOROPAFANT
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3
	
TTDDRUID	D05YWJ
DRUGNAME	IFX-1
INDICATI	Hidradenitis suppurativa [ICD-11: ED92.0] Phase 2
	
TTDDRUID	D05YWN
DRUGNAME	GS-168
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Investigative
	
TTDDRUID	D05YYB
DRUGNAME	ACE-06X
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D05YYK
DRUGNAME	AP-401
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D05YYP
DRUGNAME	RG-7599
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D05ZAI
DRUGNAME	Grippol TC
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D05ZBV
DRUGNAME	RTX-240
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D05ZCQ
DRUGNAME	DAP-81
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D05ZCZ
DRUGNAME	Beifutai
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D05ZDA
DRUGNAME	JZAD-IV-22
INDICATI	Narcolepsy [ICD-11: 7A20] Investigative
	
TTDDRUID	D05ZDD
DRUGNAME	Recombinant human cartilage-derived retinoic acid-sensitive protein depot
INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Phase 2/3
	
TTDDRUID	D05ZDJ
DRUGNAME	THR-18
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D05ZEW
DRUGNAME	INO-3510
INDICATI	Influenza A virus H1N1/H5N1 infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D05ZGQ
DRUGNAME	Dexchlorpheniramine Maleate
INDICATI	Rhinitis [ICD-11: FA20] Approved
	
TTDDRUID	D05ZGW
DRUGNAME	DPI-201-106
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D05ZHA
DRUGNAME	Alilusem
INDICATI	Diuretic vasodilator [ICD-11: BA00] Phase 3
	
TTDDRUID	D05ZHZ
DRUGNAME	PMID26651364-Compound-5e
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D05ZIF
DRUGNAME	DFN-02
INDICATI	Migraine [ICD-11: 8A80] Phase 3
	
TTDDRUID	D05ZIK
DRUGNAME	Mirtazapine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D05ZIS
DRUGNAME	SM-04690
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
	
TTDDRUID	D05ZIT
DRUGNAME	EC-400
INDICATI	Macular degeneration [ICD-11: 9B78.3] Investigative
	
TTDDRUID	D05ZJG
DRUGNAME	Anisodine
INDICATI	Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] Approved
	
TTDDRUID	D05ZLH
DRUGNAME	IMP-731
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D05ZLY
DRUGNAME	AST-008
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D05ZNA
DRUGNAME	ESBA-903
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D05ZPL
DRUGNAME	Polidocanol
INDICATI	Reticular veins [ICD-11: EF20] Approved
INDICATI	Spider veins [ICD-11: EF20] Approved
	
TTDDRUID	D05ZQC
DRUGNAME	PRISOTINOL
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D05ZQV
DRUGNAME	NK-611
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D05ZSB
DRUGNAME	Ovine corticotropin-releasing hormone
INDICATI	Cushing disease [ICD-11: 5A70] Approved
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D05ZSX
DRUGNAME	NN-8828
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D05ZTH
DRUGNAME	Iloprost
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Approved
	
TTDDRUID	D05ZTJ
DRUGNAME	Anileridine Hydrochloride
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D05ZVU
DRUGNAME	ANG-3062
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D05ZWG
DRUGNAME	Senktide
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
	
TTDDRUID	D05ZWR
DRUGNAME	PMID25666693-Compound-90
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D05ZXS
DRUGNAME	MAXY-G34
INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 2
	
TTDDRUID	D05ZXZ
DRUGNAME	BAY 57-1293
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 2
	
TTDDRUID	D05ZYM
DRUGNAME	N-Acetyl-D-glucosamine
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Approved
	
TTDDRUID	D06AAG
DRUGNAME	Anthrax Immune Globulin (AIG)
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2
	
TTDDRUID	D06AAP
DRUGNAME	Ipodate
INDICATI	Graves disease [ICD-11: 5A02.0] Approved
	
TTDDRUID	D06ABF
DRUGNAME	Loratadine
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2
	
TTDDRUID	D06ABM
DRUGNAME	CAB-175
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D06ACI
DRUGNAME	BZYX
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D06ACW
DRUGNAME	Adenosine monophosphate
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D06AEB
DRUGNAME	Iodoquinol
INDICATI	Amoebiasis [ICD-11: 1A36] Approved
	
TTDDRUID	D06AEO
DRUGNAME	Cyproterone
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D06AES
DRUGNAME	BB-16000
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06AGD
DRUGNAME	MK-0963
INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 1
	
TTDDRUID	D06AGH
DRUGNAME	Trametinib + dabrafenib
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D06AHQ
DRUGNAME	Ro-31-8830
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D06AJL
DRUGNAME	Antacids
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Approved
	
TTDDRUID	D06AKC
DRUGNAME	IVVS-1001
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D06AKJ
DRUGNAME	FR-111142
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D06ALB
DRUGNAME	BCH-2763
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D06ALD
DRUGNAME	Empagliflozin
INDICATI	Type-1 diabetes [ICD-11: 5A10] Approved
	
TTDDRUID	D06ALE
DRUGNAME	IFX-1
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D06ALK
DRUGNAME	Xmab-2513
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D06ANS
DRUGNAME	CVBT-141H
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2
INDICATI	Coronary heart disease [ICD-11: BA80.Z] Phase 2
	
TTDDRUID	D06ANT
DRUGNAME	Grass pollen extract sublingual vaccine
INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Approved
	
TTDDRUID	D06APK
DRUGNAME	Rinfabate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3
	
TTDDRUID	D06APO
DRUGNAME	PDC-748
INDICATI	Cough [ICD-11: MD12] Phase 2
	
TTDDRUID	D06AQI
DRUGNAME	NN344
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D06AQJ
DRUGNAME	TRK-530
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D06AQP
DRUGNAME	EC-0531
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06ARI
DRUGNAME	NM-001
INDICATI	Respiratory tract infection [ICD-11: CA45] Investigative
	
TTDDRUID	D06ARV
DRUGNAME	Anti-IL-23
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 3
	
TTDDRUID	D06AVN
DRUGNAME	CS-891B
INDICATI	Alopecia [ICD-11: ED70] Discontinued in Phase 2
	
TTDDRUID	D06AWA
DRUGNAME	SCIB-1
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
	
TTDDRUID	D06AWD
DRUGNAME	Anti-D human immunoglobulin
INDICATI	Acquired haemolytic anemia [ICD-11: 3A4Z] Approved
	
TTDDRUID	D06AWE
DRUGNAME	Buprenorphine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Phase 3
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D06AZH
DRUGNAME	B-220
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D06BBF
DRUGNAME	BLV-0801
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06BBO
DRUGNAME	Polymerized vaccine
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3
	
TTDDRUID	D06BBV
DRUGNAME	XZK-monascus
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D06BBZ
DRUGNAME	ZM-224832
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D06BCB
DRUGNAME	Vinpocetine
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Approved
	
TTDDRUID	D06BDE
DRUGNAME	Remdesivir
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D06BDP
DRUGNAME	OtiVax
INDICATI	Otitis media [ICD-11: AA80-AB0Z] Terminated
	
TTDDRUID	D06BEP
DRUGNAME	Chlordiazepoxide
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D06BEX
DRUGNAME	Gene therapy, congestive heart failure
INDICATI	Congestive heart failure [ICD-11: BD10] Investigative
	
TTDDRUID	D06BFH
DRUGNAME	5-fluoro-1H-indole-2-carboxylic acid
INDICATI	Glioma [ICD-11: 2A00.0] Investigative
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D06BFP
DRUGNAME	CGS-17867A
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Terminated
	
TTDDRUID	D06BGK
DRUGNAME	FiloVax
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative
	
TTDDRUID	D06BGO
DRUGNAME	Telcyta canfosfamide
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 3
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
	
TTDDRUID	D06BGS
DRUGNAME	AIDSVAX
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D06BGZ
DRUGNAME	LY3200882
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06BHB
DRUGNAME	Trastuzumab deruxtecan
INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D06BHG
DRUGNAME	Safotibant
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	D06BHI
DRUGNAME	BMS-986089
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2
	
TTDDRUID	D06BHK
DRUGNAME	ORG-9453
INDICATI	Paralysis [ICD-11: 8B60] Investigative
	
TTDDRUID	D06BHQ
DRUGNAME	YM-17K
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D06BIE
DRUGNAME	PanBlok
INDICATI	Pandemic influenza infection [ICD-11: 1E30] Phase 2
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2
	
TTDDRUID	D06BJP
DRUGNAME	NXB-4221
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D06BKF
DRUGNAME	PEGylated recombinant EPO
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D06BKH
DRUGNAME	GR-MD-02
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1
	
TTDDRUID	D06BKK
DRUGNAME	NN9748
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D06BLQ
DRUGNAME	Sofalcone
INDICATI	Ulcer [ICD-11: CA02-CB40] Approved
	
TTDDRUID	D06BMO
DRUGNAME	BI 1026706
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
	
TTDDRUID	D06BPF
DRUGNAME	R-102557
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D06BPG
DRUGNAME	Nomifensine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Withdrawn from market
	
TTDDRUID	D06BQU
DRUGNAME	Salicin
INDICATI	Analgesia [ICD-11: MB40.8] Approved
	
TTDDRUID	D06BSE
DRUGNAME	EDI1200
INDICATI	Ectodermal dysplasia [ICD-11: LD27.0] Phase 2
	
TTDDRUID	D06BSG
DRUGNAME	Thieno[3,2-c]pyridine-7-carboxamide derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D06BSV
DRUGNAME	PMID30107136-Compound-Example46
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D06BTD
DRUGNAME	4Ab-028
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative
	
TTDDRUID	D06BTF
DRUGNAME	Almorexant
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Terminated
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated
	
TTDDRUID	D06BUA
DRUGNAME	Nexopamil
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D06BUI
DRUGNAME	PN-355
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D06BUS
DRUGNAME	ST-7
INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative
	
TTDDRUID	D06BVT
DRUGNAME	Affitope AD-02
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
	
TTDDRUID	D06BYG
DRUGNAME	Clostridium butyricum MIYAIRI 588
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D06BYS
DRUGNAME	Imepitoin
INDICATI	Convulsion [ICD-11: 8A68.Z] Discontinued in Phase 1
	
TTDDRUID	D06BYV
DRUGNAME	Phensuximide
INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved
	
TTDDRUID	D06CAC
DRUGNAME	Anidulafungin
INDICATI	Candidiasis [ICD-11: 1F23] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D06CAS
DRUGNAME	Cerliponase Alfa
INDICATI	Tripeptidyl peptidase 1 deficiency [ICD-11: 5C50] Approved
INDICATI	Neuronal ceroid lipofuscinosis [ICD-11: 5C56.1] Approved
	
TTDDRUID	D06CAV
DRUGNAME	KiroVAX-004
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D06CCR
DRUGNAME	Fialuridine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D06CDN
DRUGNAME	AG-TMB711
INDICATI	Gastric motility disorder [ICD-11: DA21] Approved
	
TTDDRUID	D06CDO
DRUGNAME	Chlorphentermine Hydrochloride
INDICATI	Appetite suppressant [ICD-11: MG43] Approved
	
TTDDRUID	D06CDP
DRUGNAME	MT-176
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D06CEA
DRUGNAME	Purine derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D06CFJ
DRUGNAME	DC-480
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D06CFT
DRUGNAME	PP-4001
INDICATI	Cystitis [ICD-11: GC00] Phase 2
	
TTDDRUID	D06CFZ
DRUGNAME	ARM-AK-105
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D06CGB
DRUGNAME	Desogestrel
INDICATI	Contraception [ICD-11: QA21] Approved
	
TTDDRUID	D06CIE
DRUGNAME	Amifostine
INDICATI	Mucositis [ICD-11: CA00] Approved
	
TTDDRUID	D06CIJ
DRUGNAME	ISIS-CRP
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D06CIR
DRUGNAME	Thymosin beta-4
INDICATI	Neurotrophic keratitis [ICD-11: 9A74] Phase 3
INDICATI	Alopecia [ICD-11: ED70] Phase 2
	
TTDDRUID	D06CJN
DRUGNAME	INCAGN1876
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D06CKX
DRUGNAME	SB-649868
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2
	
TTDDRUID	D06CML
DRUGNAME	VLF-02
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D06CMW
DRUGNAME	MVA-BN polytope HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2
	
TTDDRUID	D06CNP
DRUGNAME	Abiraterone acetate
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D06CSK
DRUGNAME	BCT-194
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D06CSR
DRUGNAME	INP-1750
INDICATI	Diarrhea [ICD-11: ME05.1] Investigative
	
TTDDRUID	D06CTD
DRUGNAME	IN-N01
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D06CTE
DRUGNAME	Imiquimod
INDICATI	Skin cancer [ICD-11: 2C30-2C37] Approved
	
TTDDRUID	D06CTM
DRUGNAME	Ferumoxytol
INDICATI	Chronic kidney disease [ICD-11: GB61] Approved
	
TTDDRUID	D06CVN
DRUGNAME	EC0489
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06CVO
DRUGNAME	OrM3
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2b
	
TTDDRUID	D06CVT
DRUGNAME	Tianeptine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
	
TTDDRUID	D06CWH
DRUGNAME	Betamethasone Benzoate
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D06CWM
DRUGNAME	AZD-7507
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06CWV
DRUGNAME	W-205GBA2ED
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D06CWZ
DRUGNAME	CAR-CLD18 T cell
INDICATI	Adenocarcinoma [ICD-11: 2D40] Clinical trial
INDICATI	Pancreatic cancer [ICD-11: 2C10] Clinical trial
	
TTDDRUID	D06CXL
DRUGNAME	Anakinra
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D06CYI
DRUGNAME	Nitric Oxide
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D06CZJ
DRUGNAME	Idursulfase
INDICATI	Infertility [ICD-11: GB04] Approved
INDICATI	Hunter syndrome [ICD-11: 5C56.31] Approved
	
TTDDRUID	D06CZS
DRUGNAME	V85546
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D06DBJ
DRUGNAME	REGN-846
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1/2
	
TTDDRUID	D06DCL
DRUGNAME	LY335979
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 3
	
TTDDRUID	D06DET
DRUGNAME	AE-3763
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D06DFU
DRUGNAME	TP-023
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical
	
TTDDRUID	D06DHB
DRUGNAME	E7016
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D06DKD
DRUGNAME	QBI-139
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06DKU
DRUGNAME	Amiodarone
INDICATI	Ventricular tachycardia [ICD-11: BC71] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D06DLI
DRUGNAME	MCI-186
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Approved
	
TTDDRUID	D06DLN
DRUGNAME	SHP621
INDICATI	Eosinophilic esophagitis [ICD-11: DA24.1] Phase 2
	
TTDDRUID	D06DLO
DRUGNAME	Ro-24-7341
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D06DLQ
DRUGNAME	CGP-37849
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1
	
TTDDRUID	D06DMQ
DRUGNAME	VX-970
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06DMV
DRUGNAME	ER-21018
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative
	
TTDDRUID	D06DOJ
DRUGNAME	Seribantumab
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D06DPJ
DRUGNAME	HITOPK-032
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D06DPQ
DRUGNAME	AIM-101
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D06DPS
DRUGNAME	PD-170292
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D06DQF
DRUGNAME	RO-5095932
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D06DRU
DRUGNAME	ELP-10
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D06DSQ
DRUGNAME	DPIV/CD26
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D06DUO
DRUGNAME	SSR-182289
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2
	
TTDDRUID	D06DUS
DRUGNAME	PVX-410
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06DWQ
DRUGNAME	TOPIXANTRONE HYDROCHLORIDE
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 2
	
TTDDRUID	D06DZI
DRUGNAME	GR-127935
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated
	
TTDDRUID	D06DZZ
DRUGNAME	NVX-188
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06EBJ
DRUGNAME	CX-02
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06EBU
DRUGNAME	ALTU-242
INDICATI	Gout [ICD-11: FA25] Investigative
	
TTDDRUID	D06ECI
DRUGNAME	TD-101
INDICATI	Flavivirus infection [ICD-11: 1C80] Phase 2
INDICATI	Pachyonychia [ICD-11: EE10.3] Phase 1
	
TTDDRUID	D06ECJ
DRUGNAME	Verapamil
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D06ECM
DRUGNAME	HBN-2
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D06EDP
DRUGNAME	DSP-0565
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
	
TTDDRUID	D06EDT
DRUGNAME	ZOPOLRESTAT
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D06EEL
DRUGNAME	Miokamycin
INDICATI	Bronchitis [ICD-11: CA20] Approved
	
TTDDRUID	D06EEM
DRUGNAME	JD-3000
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D06EFW
DRUGNAME	RG7304
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06EGV
DRUGNAME	LY2801653
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Biliary tract cancer [ICD-11: 2C17] Phase 2
	
TTDDRUID	D06EHW
DRUGNAME	IAI-100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06EHX
DRUGNAME	TAK-935
INDICATI	Dravet syndrome [ICD-11: 8A61.11] Phase 2
INDICATI	LennoxGastaut syndrome [ICD-11: 8A62.1] Phase 2
INDICATI	Tuberous sclerosis [ICD-11: LD2D.2] Phase 2
INDICATI	Glutamate excitotoxity [ICD-11: 5C73] Phase 1
	
TTDDRUID	D06EIC
DRUGNAME	ASP-015K
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D06EIJ
DRUGNAME	RFT-5.dgA
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D06EIM
DRUGNAME	IPN-200
INDICATI	Flavivirus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D06EIO
DRUGNAME	Trimelamol
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D06EIY
DRUGNAME	Lm-Malaria
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D06EMM
DRUGNAME	CERC-301
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D06EMQ
DRUGNAME	AM-112
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D06EMT
DRUGNAME	Chlormerodrin
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D06EMW
DRUGNAME	AZD8566
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D06ENH
DRUGNAME	Prostacyclin analog
INDICATI	Pulmonary hypertension [ICD-11: BB01] Investigative
	
TTDDRUID	D06ENM
DRUGNAME	Oliceridine
INDICATI	Acute pain [ICD-11: MG31] Approved
INDICATI	Thyroid disease [ICD-11: 5A00-5A06] Clinical trial
	
TTDDRUID	D06ENR
DRUGNAME	HG-1096
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D06EPF
DRUGNAME	Plicamycin
INDICATI	Testicular cancer [ICD-11: 2C80] Approved
INDICATI	Hypercalcaemia [ICD-11: 5B91.0] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Withdrawn from market
INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D06EPO
DRUGNAME	PF-4136309
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D06EPP
DRUGNAME	CNB-001
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D06EQN
DRUGNAME	XR-510
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D06EQP
DRUGNAME	Aceprometazine
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Approved
	
TTDDRUID	D06ERY
DRUGNAME	BMS-394136
INDICATI	Arrhythmia [ICD-11: BC9Z] Phase 1
	
TTDDRUID	D06ESU
DRUGNAME	AM-461
INDICATI	Respiratory disease [ICD-11: CB40] Phase 1
	
TTDDRUID	D06ETI
DRUGNAME	ABT-263
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 3
INDICATI	Relapsed or refractory chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D06EUC
DRUGNAME	PMX-10098
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D06EVZ
DRUGNAME	Anti-GD2 CART
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2
	
TTDDRUID	D06EWO
DRUGNAME	Gemtuzumab ozogamicin
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
	
TTDDRUID	D06EWT
DRUGNAME	CLR1404-I-124
INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1/2
	
TTDDRUID	D06EWW
DRUGNAME	Sacrovir
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D06EXA
DRUGNAME	SALVINORIN A
INDICATI	Cerebral vasospasm [ICD-11: BA85.Z] Phase 1
	
TTDDRUID	D06EXI
DRUGNAME	FGLL
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D06EYQ
DRUGNAME	TDI-0094
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D06EZI
DRUGNAME	Capreomycin Sulfate
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Approved
	
TTDDRUID	D06FAA
DRUGNAME	Metelimumab
INDICATI	Scleroderma [ICD-11: 4A42] Phase 1/2
	
TTDDRUID	D06FBB
DRUGNAME	Azithromycin/chloroquine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3
	
TTDDRUID	D06FCR
DRUGNAME	CL-277082
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D06FDR
DRUGNAME	Didanosine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D06FEA
DRUGNAME	Dinoprostone
INDICATI	Medical abortion [ICD-11: JA00.1Z] Approved
	
TTDDRUID	D06FEQ
DRUGNAME	WIT-301
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D06FER
DRUGNAME	BMX-010
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	D06FES
DRUGNAME	Doxepin
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D06FGJ
DRUGNAME	Protexia
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D06FGM
DRUGNAME	Snake venom antisera
INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative
	
TTDDRUID	D06FHQ
DRUGNAME	BMS-936561
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D06FIT
DRUGNAME	SB-728-T
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D06FJO
DRUGNAME	Benzydamine
INDICATI	Chemotherapy or radiotherapy-induced mucositis [ICD-11: DA42-DA60] Discontinued in Phase 2
	
TTDDRUID	D06FKC
DRUGNAME	Eltoprazine
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Dyskinesia [ICD-11: MB47.4] Phase 2
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D06FLP
DRUGNAME	AMG 811
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
INDICATI	Discoid lupus erythematosus [ICD-11: EB51.0] Phase 1
	
TTDDRUID	D06FMO
DRUGNAME	ABP 501
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Application submitted
	
TTDDRUID	D06FMY
DRUGNAME	CGP-70726
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D06FOA
DRUGNAME	Bone morphogenetic protein-2
INDICATI	Bone injury [ICD-11: ND56.Y] Investigative
	
TTDDRUID	D06FOF
DRUGNAME	Imidazole derivative 5
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D06FOL
DRUGNAME	CALDARET HYDRATE
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D06FOU
DRUGNAME	Trifarotene
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D06FPF
DRUGNAME	Valortim
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D06FPQ
DRUGNAME	Frovatriptan
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D06FQS
DRUGNAME	TGOF02N
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D06FQU
DRUGNAME	INCB53914
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D06FRB
DRUGNAME	ACH-0137171
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D06FSC
DRUGNAME	NP-118809
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D06FSD
DRUGNAME	NN-9161
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1/2
	
TTDDRUID	D06FSV
DRUGNAME	Onco-D
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06FTM
DRUGNAME	RG7221
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
	
TTDDRUID	D06FTW
DRUGNAME	RP135
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D06FTY
DRUGNAME	CT-400
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06FUE
DRUGNAME	CDX-3379
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06FUM
DRUGNAME	PMID26815044-Compound-114
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D06FUQ
DRUGNAME	MIQ-003
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D06FVX
DRUGNAME	Nedocromil sodium
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved
	
TTDDRUID	D06FWC
DRUGNAME	Fludiazepam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D06FWG
DRUGNAME	Oncomer
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D06FYE
DRUGNAME	Atorvastatin + aspirin + ramipril
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D06FZH
DRUGNAME	MazF gene therapy
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D06FZX
DRUGNAME	Antazoline
INDICATI	Nasal congestion [ICD-11: MD11.9] Approved
	
TTDDRUID	D06GAM
DRUGNAME	Fleroxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D06GAP
DRUGNAME	SAR252067
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
	
TTDDRUID	D06GAQ
DRUGNAME	Atu-111
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D06GBQ
DRUGNAME	Enfuvirtide
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D06GCK
DRUGNAME	Eupatilin
INDICATI	Pancreatitis [ICD-11: DC31-DC34] Approved
INDICATI	Chronic diarrhoea [ICD-11: 1A36.0Z] Approved
	
TTDDRUID	D06GCO
DRUGNAME	Gonadoreline-6-d-trp acetate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D06GCP
DRUGNAME	PSD-506
INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2
	
TTDDRUID	D06GDH
DRUGNAME	DA-5018
INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Discontinued in Phase 2
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2
	
TTDDRUID	D06GDR
DRUGNAME	VAP-1 monoclonal antibody
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2a
	
TTDDRUID	D06GDY
DRUGNAME	Paroxetine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D06GFG
DRUGNAME	KD-3020
INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Preclinical
	
TTDDRUID	D06GGL
DRUGNAME	MSB11022
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
	
TTDDRUID	D06GGT
DRUGNAME	MCL-1-specific antisense oligonucleotide + nilotinib (AMN107)
INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Investigative
	
TTDDRUID	D06GIP
DRUGNAME	Thymol
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D06GJT
DRUGNAME	Alizapride
INDICATI	Vomiting [ICD-11: MD90] Approved
	
TTDDRUID	D06GKE
DRUGNAME	GZ402665
INDICATI	Niemann-pick disease [ICD-11: 5C56.0Y] Phase 2/3
	
TTDDRUID	D06GKN
DRUGNAME	Alosetron
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
	
TTDDRUID	D06GKR
DRUGNAME	Deferoxamine
INDICATI	Acute iron or aluminum toxicity [ICD-11: FB83.20] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D06GMG
DRUGNAME	Etoposide
INDICATI	Testicular cancer [ICD-11: 2C80] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D06GMJ
DRUGNAME	GSK945237
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D06GMM
DRUGNAME	FT-026
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D06GNF
DRUGNAME	TS-022
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D06GOF
DRUGNAME	IDP-123
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3
	
TTDDRUID	D06GOT
DRUGNAME	Pyrrolo[2,3-b]pyridine derivative 2
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D06GRK
DRUGNAME	ARC029
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D06GSA
DRUGNAME	CMV DNA vaccine
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Preclinical
	
TTDDRUID	D06GSE
DRUGNAME	GPI-1337
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated
	
TTDDRUID	D06GUA
DRUGNAME	GSK2269557
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D06GUG
DRUGNAME	BTT-1023
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D06GWF
DRUGNAME	Valganciclovir
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D06GYJ
DRUGNAME	PD-01
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 4
	
TTDDRUID	D06GYY
DRUGNAME	Ifenprodil
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D06GZW
DRUGNAME	PEGylated leptin
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D06HBJ
DRUGNAME	BAY2306001
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2
	
TTDDRUID	D06HBQ
DRUGNAME	Gliquidone
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D06HBT
DRUGNAME	LT-1951
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1/2
	
TTDDRUID	D06HCC
DRUGNAME	LANEPITANT
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D06HCD
DRUGNAME	SM-6586
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D06HCF
DRUGNAME	SPD-557
INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 2
	
TTDDRUID	D06HCP
DRUGNAME	MELARSOPROL
INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Approved
	
TTDDRUID	D06HFI
DRUGNAME	L-ornithine phenylacetate
INDICATI	Acute liver failure [ICD-11: DB91] Phase 2
	
TTDDRUID	D06HGM
DRUGNAME	LPO-1010CA
INDICATI	Cataract [ICD-11: 9B10] Investigative
	
TTDDRUID	D06HGO
DRUGNAME	MDY-1001
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative
	
TTDDRUID	D06HGY
DRUGNAME	RTA-403 analog
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D06HIO
DRUGNAME	Istaroxime
INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2
	
TTDDRUID	D06HKB
DRUGNAME	Lodenosine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D06HLY
DRUGNAME	Pilocarpine
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D06HMN
DRUGNAME	BAY1251152
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D06HMO
DRUGNAME	CVBT-141B topical
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
	
TTDDRUID	D06HNO
DRUGNAME	MEDI4920
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 1
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D06HPA
DRUGNAME	Argidene
INDICATI	Dermatological disease [ICD-11: DA24.Y] Discontinued in Preregistration
	
TTDDRUID	D06HPP
DRUGNAME	AGT-182
INDICATI	Hunter syndrome [ICD-11: 5C56.31] Phase 1
	
TTDDRUID	D06HQG
DRUGNAME	SPM-5185
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D06HQM
DRUGNAME	Apo805K1
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D06HRD
DRUGNAME	EUR-1100
INDICATI	Eosinophilic esophagitis [ICD-11: DA24.1] Phase 1/2
	
TTDDRUID	D06HRY
DRUGNAME	SNAP-5089
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D06HUF
DRUGNAME	AM-365
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 2
	
TTDDRUID	D06HUH
DRUGNAME	Recombinant human butyrylcholinesterase
INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative
	
TTDDRUID	D06HUS
DRUGNAME	PF-06755347
INDICATI	Chronic inflammatory demyelinating polyneuropathy [ICD-11: 8C01.3] Phase 1
	
TTDDRUID	D06HWG
DRUGNAME	Inflexal V
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D06HWU
DRUGNAME	CHR-4487
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D06HXC
DRUGNAME	NPY-1 antagonist
INDICATI	Eating disorder [ICD-11: 6B82] Investigative
	
TTDDRUID	D06HYC
DRUGNAME	VLI-01B
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06HYF
DRUGNAME	M2698
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06HYG
DRUGNAME	Barucainide
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D06HZA
DRUGNAME	GSK2586184
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
INDICATI	Arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D06HZY
DRUGNAME	Fructose
INDICATI	Vomiting [ICD-11: MD90] Approved
	
TTDDRUID	D06IAA
DRUGNAME	LK-410
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D06IAQ
DRUGNAME	Ambenonium
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Approved
	
TTDDRUID	D06IAR
DRUGNAME	Adenosine
INDICATI	Paroxysmal supraventricular tachycardia [ICD-11: BC81.Z] Approved
	
TTDDRUID	D06IBG
DRUGNAME	MK-3415A
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 3
	
TTDDRUID	D06ICE
DRUGNAME	Radiolabeled anti-PSMA huJ591 minibodies
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D06ICW
DRUGNAME	MDI-P
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D06IDT
DRUGNAME	Demecarium bromide
INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved
	
TTDDRUID	D06IEX
DRUGNAME	Cardiotrophin-1
INDICATI	Acute liver failure [ICD-11: DB91] Phase 1
	
TTDDRUID	D06IFR
DRUGNAME	PF-3654764
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D06IGC
DRUGNAME	ACT-0932
INDICATI	Glioma [ICD-11: 2A00.0] Investigative
	
TTDDRUID	D06IGE
DRUGNAME	Factor IX-XTEN
INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D06IGU
DRUGNAME	Troleandomycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D06IGW
DRUGNAME	Coronary artery disease gene therapy
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1
	
TTDDRUID	D06IHW
DRUGNAME	SCF-I2
INDICATI	Discovery agent [ICD-11: N.A.] Preclinical
	
TTDDRUID	D06IIB
DRUGNAME	Halcinonide
INDICATI	Skin disease [ICD-11: EA00-EM0Z] Approved
	
TTDDRUID	D06IJG
DRUGNAME	Silyman DD
INDICATI	Liver disease [ICD-11: DB90-BD99] Approved
	
TTDDRUID	D06ILL
DRUGNAME	BMS-986158
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D06IME
DRUGNAME	CCX-140
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D06IPN
DRUGNAME	Sunscreens
INDICATI	Skin cancer [ICD-11: 2C30-2C37] Approved
	
TTDDRUID	D06IPV
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D06IPZ
DRUGNAME	MK-3281
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D06IQE
DRUGNAME	H1N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 3
	
TTDDRUID	D06IVH
DRUGNAME	Org-20781
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D06IVN
DRUGNAME	PolongaTab
INDICATI	Poison intoxication [ICD-11: NE6Z] Discontinued in Preregistration
	
TTDDRUID	D06IXT
DRUGNAME	Propyphenazone
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D06IYV
DRUGNAME	TAK-810
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1
	
TTDDRUID	D06IZM
DRUGNAME	Erythrityl Tetranitrate
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D06IZQ
DRUGNAME	JKB-121
INDICATI	Fatty liver disease [ICD-11: DB92.Z] Phase 1/2
	
TTDDRUID	D06IZS
DRUGNAME	XEL-004FP
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D06JAL
DRUGNAME	8H9
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
	
TTDDRUID	D06JBA
DRUGNAME	HGS-TR2J
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D06JBV
DRUGNAME	SGN LIV1A
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D06JCO
DRUGNAME	Palomid-529
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D06JDK
DRUGNAME	Perflexane-lipid microsphere
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D06JDV
DRUGNAME	K-312
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D06JED
DRUGNAME	Subcuvia
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D06JGH
DRUGNAME	Pyridoxal Phosphate
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D06JHN
DRUGNAME	VG-WNV
INDICATI	West nile virus infection [ICD-11: 1D46] Investigative
	
TTDDRUID	D06JHV
DRUGNAME	Flumatinib
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2
	
TTDDRUID	D06JHW
DRUGNAME	PMID25666693-Compound-37
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D06JKO
DRUGNAME	Dust mite allergen extract
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D06JKV
DRUGNAME	[111In]SRVII23
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D06JLG
DRUGNAME	AVX-601
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 1
	
TTDDRUID	D06JLQ
DRUGNAME	KIN-100
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D06JLX
DRUGNAME	Measles vaccine
INDICATI	Measles [ICD-11: 1F03] Approved
	
TTDDRUID	D06JNC
DRUGNAME	CRD-007
INDICATI	Aortic aneurysm [ICD-11: BD50] Phase 2
	
TTDDRUID	D06JPB
DRUGNAME	Ergocalciferol
INDICATI	Hypoparathyroidism [ICD-11: 5A50] Approved
	
TTDDRUID	D06JPY
DRUGNAME	AZD2995
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D06JQM
DRUGNAME	SPP-800
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D06JQS
DRUGNAME	HuM195/rGel
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D06JRD
DRUGNAME	Metamizole
INDICATI	Pain [ICD-11: MG30-MG3Z] Withdrawn from market
INDICATI	Fever [ICD-11: MG26] Withdrawn from market
	
TTDDRUID	D06JTW
DRUGNAME	FM-VP4
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D06JTZ
DRUGNAME	Contepo
INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 2
	
TTDDRUID	D06JUE
DRUGNAME	NN8555
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D06JUR
DRUGNAME	Rogletimide
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D06JVU
DRUGNAME	A-68552
INDICATI	Obesity [ICD-11: 5B81] Terminated
	
TTDDRUID	D06JVV
DRUGNAME	ALD-151
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Discontinued in Phase 1
	
TTDDRUID	D06JWO
DRUGNAME	KT-362
INDICATI	Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 1
	
TTDDRUID	D06KCF
DRUGNAME	Mavrilimumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D06KCM
DRUGNAME	CUV-3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06KCU
DRUGNAME	MLN1202
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 2
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Terminated
	
TTDDRUID	D06KDP
DRUGNAME	Ganglioside gm1
INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Withdrawn from market
	
TTDDRUID	D06KEJ
DRUGNAME	PV903
INDICATI	Infertility [ICD-11: GB04] Discontinued in Phase 1
	
TTDDRUID	D06KFR
DRUGNAME	RP-73163
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D06KGC
DRUGNAME	AEZS-120
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D06KGI
DRUGNAME	TG-0054
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
	
TTDDRUID	D06KGV
DRUGNAME	HUMAN CORTICOTROPIN-RELEASING HORMONE
INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved
	
TTDDRUID	D06KIJ
DRUGNAME	AG-858
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D06KJG
DRUGNAME	CLX-0301
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D06KJQ
DRUGNAME	BI 201335
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
	
TTDDRUID	D06KKL
DRUGNAME	PulmoXen
INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative
	
TTDDRUID	D06KKO
DRUGNAME	PMID26815044-Compound-50
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D06KKS
DRUGNAME	Cefradine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D06KLJ
DRUGNAME	STAMP
INDICATI	Dental caries [ICD-11: DA08.0] Phase 3
	
TTDDRUID	D06KNE
DRUGNAME	INCB15050
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D06KNJ
DRUGNAME	PB-127
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
	
TTDDRUID	D06KNK
DRUGNAME	TDZD-8
INDICATI	Malignant glioma [ICD-11: 2A00.0] Patented
	
TTDDRUID	D06KOL
DRUGNAME	Napitane mesilate
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D06KOM
DRUGNAME	DN24-02
INDICATI	Urogenital cancer [ICD-11: 2C95-2C9Z] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D06KOR
DRUGNAME	SWT-05104
INDICATI	Vitiligo [ICD-11: ED63.0] Investigative
	
TTDDRUID	D06KPR
DRUGNAME	CER-002
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 1
	
TTDDRUID	D06KPV
DRUGNAME	CreaVax-RCC
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved
	
TTDDRUID	D06KPW
DRUGNAME	U-103017
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D06KQG
DRUGNAME	HER-2-targeting CAR T Cells
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D06KQN
DRUGNAME	TPI-926
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 2
	
TTDDRUID	D06KRZ
DRUGNAME	MC-4232
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D06KSA
DRUGNAME	TK-115339
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D06KSV
DRUGNAME	Omigapil
INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 2
INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 1
	
TTDDRUID	D06KTF
DRUGNAME	HL-029
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D06KTJ
DRUGNAME	TAK-659
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D06KUY
DRUGNAME	ACH-2684
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D06KVU
DRUGNAME	ABP 215
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Application submitted
	
TTDDRUID	D06KWU
DRUGNAME	DWP-09031
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D06KXS
DRUGNAME	PT-112
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06KYN
DRUGNAME	Arbutamine
INDICATI	Coronary artery disease [ICD-11: BA80] Approved
	
TTDDRUID	D06KYU
DRUGNAME	Rycals
INDICATI	Heart failure [ICD-11: BD10-BD13] Preclinical
	
TTDDRUID	D06KZL
DRUGNAME	AG140699
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D06LAN
DRUGNAME	BlockAide/CR
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D06LAX
DRUGNAME	PGI-02749
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D06LBO
DRUGNAME	Croconazole
INDICATI	Dermatological disease [ICD-11: DA24.Y] Approved
	
TTDDRUID	D06LBV
DRUGNAME	E-4767
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D06LBZ
DRUGNAME	MVA-BN JEV
INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Preclinical
	
TTDDRUID	D06LCB
DRUGNAME	Thiazole carboxamide derivative 9
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D06LCS
DRUGNAME	Legionella pneumophila vaccine
INDICATI	Legionella infection [ICD-11: 1C19] Terminated
	
TTDDRUID	D06LCW
DRUGNAME	KIN-4044
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative
	
TTDDRUID	D06LDC
DRUGNAME	Palonidipine hydrochloride
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Preregistration
	
TTDDRUID	D06LDT
DRUGNAME	Segesterone acetate; ethinyl estradiol
INDICATI	Contraception [ICD-11: QA21] Approved
	
TTDDRUID	D06LEA
DRUGNAME	MER-102
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D06LEC
DRUGNAME	LPD-608
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D06LEG
DRUGNAME	Influenza A virus H5N1 vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D06LEJ
DRUGNAME	Lu-AA44608
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 1
	
TTDDRUID	D06LFE
DRUGNAME	Indomethacin
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D06LFV
DRUGNAME	NM-702
INDICATI	Angina pectoris [ICD-11: BA40] Phase 3
	
TTDDRUID	D06LGC
DRUGNAME	ZD-2486
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D06LGZ
DRUGNAME	ET-007
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Investigative
	
TTDDRUID	D06LHE
DRUGNAME	Inactivated H7N7 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2
	
TTDDRUID	D06LHG
DRUGNAME	FENBUFEN
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D06LHI
DRUGNAME	GCH-01
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D06LHK
DRUGNAME	2X-111
INDICATI	Brain metastases [ICD-11: 2D50] Phase 1
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D06LHU
DRUGNAME	Iodamide
INDICATI	Contrast medium for intravenous urography [ICD-11: GC2Z] Approved
INDICATI	Brain disease [ICD-11: 8C70-8E61] Withdrawn from market
	
TTDDRUID	D06LIQ
DRUGNAME	Cyclohexyl carbamate derivative 8
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D06LJG
DRUGNAME	BURKE-104
INDICATI	Verruca vulgaris [ICD-11: 1E80] Investigative
	
TTDDRUID	D06LKA
DRUGNAME	L2-05
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D06LKM
DRUGNAME	PNU-282987
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D06LKP
DRUGNAME	OTI-050
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D06LLS
DRUGNAME	PMID25684022-Compound-WO2009153313
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D06LMS
DRUGNAME	P-coumaric acid derivative 4
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D06LNW
DRUGNAME	Fidaxomicin
INDICATI	Clostridium difficile associated diarrhea [ICD-11: 1A04] Approved
	
TTDDRUID	D06LOQ
DRUGNAME	ARZOXIFENE
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D06LPT
DRUGNAME	STI-003
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 2
	
TTDDRUID	D06LQF
DRUGNAME	131-I-MIP-1095
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D06LQY
DRUGNAME	BI-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D06LRG
DRUGNAME	TRV027
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D06LRQ
DRUGNAME	TKP-1001
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D06LSZ
DRUGNAME	PMID25684022-Compound-US20120277229 40(1.2)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D06LUH
DRUGNAME	ABX-201
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D06LUI
DRUGNAME	Ad-IL-12 DNA therapeutic
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D06LUZ
DRUGNAME	GS-5885
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D06LVJ
DRUGNAME	Mam-06.301
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D06LXP
DRUGNAME	POL-7080
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D06LYG
DRUGNAME	Prilocaine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D06LYI
DRUGNAME	BPX-501
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1/2
INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Phase 1/2
INDICATI	Hematopoietic stem cell transplantation [ICD-11: QB63] Phase 1/2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D06LYS
DRUGNAME	Prednimustine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D06LYZ
DRUGNAME	A-841720
INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical
	
TTDDRUID	D06MAJ
DRUGNAME	Mizolastine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D06MBR
DRUGNAME	ACI-636
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D06MCH
DRUGNAME	TG-6002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06MDT
DRUGNAME	INV-155
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D06MEC
DRUGNAME	THA-901
INDICATI	Cancer related pain [ICD-11: MG30] Investigative
	
TTDDRUID	D06MGW
DRUGNAME	OrniFlu
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D06MHZ
DRUGNAME	NLG919
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06MIQ
DRUGNAME	MRE-0094
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
	
TTDDRUID	D06MIU
DRUGNAME	Mycoprex
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D06MIW
DRUGNAME	Pyrazole derivative 37
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D06MJP
DRUGNAME	TNFQb therapeutic vaccines
INDICATI	Crohn disease [ICD-11: DD70] Terminated
	
TTDDRUID	D06MKG
DRUGNAME	MBP(75-95)
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D06MLA
DRUGNAME	GET 73
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
	
TTDDRUID	D06MLZ
DRUGNAME	WAY-123223
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D06MMU
DRUGNAME	LM-CD45
INDICATI	Transplant rejection [ICD-11: NE84] Phase 1
	
TTDDRUID	D06MMW
DRUGNAME	ADCON-T/N
INDICATI	Wound healing [ICD-11: EL8Y] Approved
	
TTDDRUID	D06MNC
DRUGNAME	PRS-050
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06MNF
DRUGNAME	Pardoprunox
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D06MOB
DRUGNAME	WSB-102
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D06MOY
DRUGNAME	DM-99
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D06MPF
DRUGNAME	Sch-40120
INDICATI	Pruritus [ICD-11: EC90] Terminated
	
TTDDRUID	D06MPH
DRUGNAME	Pyrazole derivative 28
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D06MPJ
DRUGNAME	BD-NP
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D06MQM
DRUGNAME	Lumefantrine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D06MQW
DRUGNAME	GP-1002
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D06MRR
DRUGNAME	WilGraf
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D06MRS
DRUGNAME	NSD-761
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D06MRT
DRUGNAME	Acitazanolast
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D06MRY
DRUGNAME	Enteric-coated mycophenolate sodium
INDICATI	Transplant rejection [ICD-11: NE84] Approved
	
TTDDRUID	D06MTH
DRUGNAME	KIN-4050
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D06MTM
DRUGNAME	S-16276-1
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D06MUB
DRUGNAME	SMOi2-17
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06MUI
DRUGNAME	A-81988
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D06MUZ
DRUGNAME	SDZ-87-469
INDICATI	Coronary artery disease [ICD-11: BA80] Terminated
	
TTDDRUID	D06MWK
DRUGNAME	Aimpila
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D06MWU
DRUGNAME	LUF-5833
INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative
	
TTDDRUID	D06MXB
DRUGNAME	IB-09C190
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative
	
TTDDRUID	D06MXY
DRUGNAME	BL-1827
INDICATI	Cancer related pain [ICD-11: MG30] Discontinued in Phase 1
	
TTDDRUID	D06MYP
DRUGNAME	SK-MS10
INDICATI	Gastritis [ICD-11: DA42] Phase 2
	
TTDDRUID	D06NAG
DRUGNAME	Anti-CD137
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D06NBK
DRUGNAME	Sodium Iodide I-131 Capsules
INDICATI	Thyroid disease [ICD-11: 5A00-5A06] Approved
	
TTDDRUID	D06NDP
DRUGNAME	CIGB-128
INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 1
	
TTDDRUID	D06NEU
DRUGNAME	CJ-23423
INDICATI	Arthralgia [ICD-11: ME82] Discontinued in Phase 2
	
TTDDRUID	D06NHK
DRUGNAME	Sitagliptin + atorvastatin
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3
	
TTDDRUID	D06NIT
DRUGNAME	PF-4181366
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D06NJB
DRUGNAME	AM-802
INDICATI	Lung inflammation [ICD-11: CA40.Z] Investigative
	
TTDDRUID	D06NKA
DRUGNAME	IRC-083927
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06NLP
DRUGNAME	WTC-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06NMP
DRUGNAME	CGP-29030A
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D06NMY
DRUGNAME	MDC-1231
INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative
	
TTDDRUID	D06NMZ
DRUGNAME	NVP-ADW742
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D06NND
DRUGNAME	FPA144
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
	
TTDDRUID	D06NNQ
DRUGNAME	VRC-HIVADV014-00-VP
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D06NNU
DRUGNAME	NSC-631570
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D06NOF
DRUGNAME	ATI-9242
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D06NOR
DRUGNAME	IVL745
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D06NOU
DRUGNAME	D-9120
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated
	
TTDDRUID	D06NPB
DRUGNAME	GLPG-0259
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D06NQA
DRUGNAME	Plasmid IL-12 immunotherapy
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1
	
TTDDRUID	D06NQH
DRUGNAME	RG7155
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D06NQJ
DRUGNAME	Triproamylin acetate
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D06NSA
DRUGNAME	Thiamylal
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D06NSL
DRUGNAME	PIC-060
INDICATI	Dermatitis [ICD-11: EA80-EA89] Terminated
	
TTDDRUID	D06NSS
DRUGNAME	Cromoglicate
INDICATI	Asthma [ICD-11: CA23] Approved
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Terminated
	
TTDDRUID	D06NVJ
DRUGNAME	Nicotinamide
INDICATI	Inflammatory skin condition [ICD-11: EF20.Y] Approved
	
TTDDRUID	D06NVN
DRUGNAME	BMS-599793
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D06NXG
DRUGNAME	PF-04236921
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D06NXY
DRUGNAME	Ethinyl Estradiol
INDICATI	Female hypogonadism [ICD-11: GA30.6] Approved
	
TTDDRUID	D06NYA
DRUGNAME	2-Methoxyestradiol
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
	
TTDDRUID	D06OAV
DRUGNAME	Aminohippurate sodium
INDICATI	Kidney disease [ICD-11: GC2Z] Approved
	
TTDDRUID	D06ODM
DRUGNAME	Talsaclidine fumarate
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
	
TTDDRUID	D06OES
DRUGNAME	CART-38 cells
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D06OFD
DRUGNAME	BAY-85-8102
INDICATI	Brain disease [ICD-11: 8C70-8E61] Phase 1
	
TTDDRUID	D06OFJ
DRUGNAME	NPI-3304
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D06OFS
DRUGNAME	Rilmenidine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D06OFZ
DRUGNAME	LEISH-F1
INDICATI	Leishmania infection [ICD-11: 1F54.0] Phase 2
	
TTDDRUID	D06OIG
DRUGNAME	Hib-MenCY-TT vaccine
INDICATI	Meningitis [ICD-11: 1D01] Phase 3
	
TTDDRUID	D06OIV
DRUGNAME	Tolbutamide
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D06OMH
DRUGNAME	Safflower seed-derived apolipoprotein A1
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D06OMK
DRUGNAME	Tacrolimus
INDICATI	Organ transplant rejection [ICD-11: NE84] Approved
INDICATI	Ocular allergy [ICD-11: 4A81] Phase 3
	
TTDDRUID	D06OMW
DRUGNAME	Rasagiline
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
INDICATI	Skin cancer [ICD-11: 2C30-2C37] Patented
INDICATI	Skin imperfections [ICD-11: EK71] Patented
	
TTDDRUID	D06ONB
DRUGNAME	AZ505
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D06OQI
DRUGNAME	Tilarginine acetate
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 3
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D06ORI
DRUGNAME	Ketamine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D06ORU
DRUGNAME	Butacaine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D06OSM
DRUGNAME	Tandospirone
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D06OUL
DRUGNAME	Ceforanide
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D06OUT
DRUGNAME	ANG-4011
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D06OUW
DRUGNAME	PBI-220
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative
	
TTDDRUID	D06OVF
DRUGNAME	Santalum
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D06OVM
DRUGNAME	KM-3413
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06OVY
DRUGNAME	Cefixime
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D06OWF
DRUGNAME	TBI-301
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D06OZJ
DRUGNAME	RWJ-67657
INDICATI	Arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D06OZW
DRUGNAME	Artemisone
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2/3
	
TTDDRUID	D06PAW
DRUGNAME	Z-4105
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D06PAZ
DRUGNAME	Encainide
INDICATI	Heart arrhythmia [ICD-11: BC65] Withdrawn from market
	
TTDDRUID	D06PBH
DRUGNAME	NN8640
INDICATI	Growth failure [ICD-11: LD2F.1Y] Phase 3
	
TTDDRUID	D06PDQ
DRUGNAME	AOP-200704
INDICATI	Heart arrhythmia [ICD-11: BC65] Phase 2
	
TTDDRUID	D06PDT
DRUGNAME	TARP peptide-pulsed autologous dendritic cell vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D06PEB
DRUGNAME	Cinalukast
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D06PEW
DRUGNAME	IT-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D06PFK
DRUGNAME	TDT-044
INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative
	
TTDDRUID	D06PFT
DRUGNAME	Rhumab Beta7
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
	
TTDDRUID	D06PGZ
DRUGNAME	Setrobuvir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D06PHH
DRUGNAME	Rimacalib
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D06PHO
DRUGNAME	E-3030
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1
	
TTDDRUID	D06PHS
DRUGNAME	EVT302
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D06PJK
DRUGNAME	Euro-Celtique 3
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D06PKL
DRUGNAME	BPL-003
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D06PKS
DRUGNAME	ONO-4007
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2
	
TTDDRUID	D06PLP
DRUGNAME	Resten-MP
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
	
TTDDRUID	D06PNN
DRUGNAME	Biaryl mannoside derivative 26
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D06PPL
DRUGNAME	BIX-01294
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical
	
TTDDRUID	D06PQR
DRUGNAME	OPC-8490
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2
	
TTDDRUID	D06PQT
DRUGNAME	Vitamin B1
INDICATI	Vitamin B1 deficiency [ICD-11: 5B5A] Approved
	
TTDDRUID	D06PSS
DRUGNAME	Nateglinide
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D06PSU
DRUGNAME	BAY1143572
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06PTA
DRUGNAME	Levosalbutamol/ipratropium
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4
	
TTDDRUID	D06PTG
DRUGNAME	ARX788
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D06PTT
DRUGNAME	MS-424
INDICATI	Ischemia [ICD-11: 8B10-8B11] Discontinued in Phase 2
	
TTDDRUID	D06PTW
DRUGNAME	Thiazole carboxamide derivative 12
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D06PVA
DRUGNAME	Volociximab
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D06PVN
DRUGNAME	R-65
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D06PXT
DRUGNAME	CF602
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical
	
TTDDRUID	D06PYP
DRUGNAME	JTS-653
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2
	
TTDDRUID	D06PZC
DRUGNAME	SAM-6
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D06PZO
DRUGNAME	ASC-101
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D06QAJ
DRUGNAME	PS948115
INDICATI	Respiratory failure [ICD-11: CB41] Discontinued in Phase 1
	
TTDDRUID	D06QAK
DRUGNAME	BMN-111
INDICATI	Achondroplasia [ICD-11: LD24.00] Phase 3
	
TTDDRUID	D06QBV
DRUGNAME	BI 894999
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06QBX
DRUGNAME	VDA-1102
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2
	
TTDDRUID	D06QBY
DRUGNAME	INT131
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D06QCC
DRUGNAME	Cefmenoxime
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D06QCE
DRUGNAME	MTKi-328
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06QDR
DRUGNAME	Choline alfoscerate
INDICATI	Amnesia [ICD-11: MB21.1] Approved
	
TTDDRUID	D06QEL
DRUGNAME	FARANOXI
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D06QEW
DRUGNAME	CLT-003
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Investigative
	
TTDDRUID	D06QGH
DRUGNAME	Dukoral
INDICATI	Escherichia coli infection [ICD-11: 1A03] Approved
	
TTDDRUID	D06QHT
DRUGNAME	Risotilide
INDICATI	Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 2
	
TTDDRUID	D06QIP
DRUGNAME	AP-022
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D06QIW
DRUGNAME	EPO peptide mimetics
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D06QJE
DRUGNAME	F-992
INDICATI	Urinary incontinence [ICD-11: MF50.2] Terminated
	
TTDDRUID	D06QJG
DRUGNAME	PG-1014491
INDICATI	Bone disease [ICD-11: FC0Z] Investigative
	
TTDDRUID	D06QKV
DRUGNAME	Brodimoprim
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D06QMA
DRUGNAME	MK-5286
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D06QMV
DRUGNAME	DWP-450
INDICATI	Glabellar frown line [ICD-11: NA0Z] Application submitted
	
TTDDRUID	D06QOA
DRUGNAME	PSI-938
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D06QOC
DRUGNAME	GX-301
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D06QOD
DRUGNAME	CT-120
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D06QOF
DRUGNAME	R7128
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2
	
TTDDRUID	D06QOJ
DRUGNAME	RS-8359
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D06QOK
DRUGNAME	DW-2282
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D06QOM
DRUGNAME	TP-101
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D06QPI
DRUGNAME	NY-ESO-1 tumour vaccine
INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 1
	
TTDDRUID	D06QQH
DRUGNAME	T-1210
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2
	
TTDDRUID	D06QRW
DRUGNAME	Lazabemide
INDICATI	Skin imperfections [ICD-11: EK71] Patented
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3
	
TTDDRUID	D06QRY
DRUGNAME	IDN-5390
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06QSN
DRUGNAME	Itolizumab
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D06QUY
DRUGNAME	CO-18
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D06QWM
DRUGNAME	OI338GT
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D06QXI
DRUGNAME	NRX-4204
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D06QYJ
DRUGNAME	Anticancer glycosaminoglycans
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D06QYR
DRUGNAME	PF-4800567
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Preclinical
	
TTDDRUID	D06QZL
DRUGNAME	Lerisetron
INDICATI	Vomiting [ICD-11: MD90] Phase 3
INDICATI	Testicular germ cell tumour [ICD-11: 2C80.2] Phase 3
INDICATI	Nausea [ICD-11: MD90] Phase 3
	
TTDDRUID	D06RBJ
DRUGNAME	DIPROTEVERINE HYDROCHLORIDE
INDICATI	Angina pectoris [ICD-11: BA40] Phase 3
	
TTDDRUID	D06RCB
DRUGNAME	Diethylcarbamazine
INDICATI	Lymphatic filariasis [ICD-11: 1F66.3] Approved
	
TTDDRUID	D06RCE
DRUGNAME	HER2-specific T cells
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D06RCS
DRUGNAME	Besonprodil
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1
	
TTDDRUID	D06REJ
DRUGNAME	MX-7065
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D06REO
DRUGNAME	Befunolol hci
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D06RFG
DRUGNAME	Estradiol valerate/dienogest
INDICATI	Discovery agent [ICD-11: N.A.] Approved
	
TTDDRUID	D06RGG
DRUGNAME	Levothyroxine
INDICATI	Hypothyroidism [ICD-11: 5A00] Approved
	
TTDDRUID	D06RGW
DRUGNAME	PMID25684022-Compound-WO2004087707
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D06RHC
DRUGNAME	DS-1040
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 1
	
TTDDRUID	D06RIM
DRUGNAME	LIM-0705
INDICATI	Insulin-resistant disorder [ICD-11: 5A44] Phase 2
	
TTDDRUID	D06RNK
DRUGNAME	Hi8 HBV vaccine
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2
	
TTDDRUID	D06RQD
DRUGNAME	Anti-GD2 mab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06RQU
DRUGNAME	HC-Toxin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D06RRD
DRUGNAME	Fibrates
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Investigative
	
TTDDRUID	D06RSE
DRUGNAME	V935
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06RUD
DRUGNAME	FT-011
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D06RUK
DRUGNAME	Combotox
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D06RUL
DRUGNAME	Bitolterol
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
INDICATI	Asthma [ICD-11: CA23] Withdrawn from market
	
TTDDRUID	D06RVQ
DRUGNAME	Xenon
INDICATI	Brain injury [ICD-11: NA07.Z] Phase 3
	
TTDDRUID	D06RVY
DRUGNAME	SIR-1076
INDICATI	Retinopathy [ICD-11: 9B71] Preclinical
	
TTDDRUID	D06RWM
DRUGNAME	Carmeseal
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D06RYG
DRUGNAME	PRAME-SLP
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D06RYU
DRUGNAME	RLP-035
INDICATI	Escherichia coli infection [ICD-11: 1A03] Investigative
	
TTDDRUID	D06RYY
DRUGNAME	ZD-9379
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1
	
TTDDRUID	D06RZQ
DRUGNAME	HG-1091
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D06SAT
DRUGNAME	HZ-166
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D06SBB
DRUGNAME	Basiliximab
INDICATI	Organ transplant rejection [ICD-11: NE84] Approved
	
TTDDRUID	D06SBD
DRUGNAME	DS-2248
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06SBK
DRUGNAME	Atocalcitol
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D06SBL
DRUGNAME	MM-121
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D06SBS
DRUGNAME	SSR-504734
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D06SCK
DRUGNAME	MB-311
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06SCP
DRUGNAME	VISION 5
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
	
TTDDRUID	D06SCQ
DRUGNAME	QBM076
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D06SCY
DRUGNAME	BM-32
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D06SDP
DRUGNAME	Melanotetan II
INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical
INDICATI	Obesity [ICD-11: 5B81] Preclinical
INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Preclinical
	
TTDDRUID	D06SDQ
DRUGNAME	UCB0599
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D06SEA
DRUGNAME	CX-7000
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06SEL
DRUGNAME	NNRTIs
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D06SEY
DRUGNAME	Etilevodopa
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 3
	
TTDDRUID	D06SFX
DRUGNAME	Soybean Oil
INDICATI	Bupicavaine toxicity [ICD-11: NE6Z] Approved
	
TTDDRUID	D06SHZ
DRUGNAME	SHP616
INDICATI	Neuromyelitis optica [ICD-11: 8A43] Phase 1
	
TTDDRUID	D06SIG
DRUGNAME	AR177
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D06SJO
DRUGNAME	GSK-2282512A
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D06SJZ
DRUGNAME	XB-947
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06SMP
DRUGNAME	SMT-15000
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D06SMU
DRUGNAME	SMT-D003
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D06SNS
DRUGNAME	Mirostipen
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D06SNV
DRUGNAME	MORAb-28
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06SRB
DRUGNAME	Brain-derived neurotrophic factor peptidomimetics
INDICATI	Rett syndrome [ICD-11: LD90.4] Investigative
	
TTDDRUID	D06SRX
DRUGNAME	MDA-19
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D06SSR
DRUGNAME	AVP-26452
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1
	
TTDDRUID	D06STK
DRUGNAME	Purine derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D06STX
DRUGNAME	Thiadiazolyl carboxamide derivative 1
INDICATI	Alzheimer disease [ICD-11: 8A20] Patented
	
TTDDRUID	D06SUS
DRUGNAME	AZD-3043
INDICATI	Anaesthesia [ICD-11: 9A78.6] Phase 1
	
TTDDRUID	D06SVC
DRUGNAME	M-0011
INDICATI	Alpha-mannosidosis [ICD-11: 5C56.21] Phase 3
	
TTDDRUID	D06SVW
DRUGNAME	Insulin recombinant
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D06SWS
DRUGNAME	NN-1952
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D06SWT
DRUGNAME	Aryl mannoside derivative 5
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D06SYA
DRUGNAME	MT-061
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D06SYN
DRUGNAME	Ioflubenzamide (131I)
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D06SZU
DRUGNAME	WVE-210201
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2/3
	
TTDDRUID	D06TAL
DRUGNAME	Tazofelone
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
	
TTDDRUID	D06TAR
DRUGNAME	DM-512
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D06TEO
DRUGNAME	UCL-1390
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
INDICATI	Eating disorder [ICD-11: 6B82] Terminated
	
TTDDRUID	D06TFE
DRUGNAME	Technetium Tc-99m Depreotide
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D06TFI
DRUGNAME	LY2157299
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2/3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D06TGE
DRUGNAME	Taranabant
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 3
	
TTDDRUID	D06TGS
DRUGNAME	Cx-603
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Preclinical
	
TTDDRUID	D06THG
DRUGNAME	DS-1205
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D06THT
DRUGNAME	INGN-402
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D06TJJ
DRUGNAME	FLUORESCEIN
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Approved
	
TTDDRUID	D06TJQ
DRUGNAME	CRLX301
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D06TKE
DRUGNAME	ZD-7288
INDICATI	Angina pectoris [ICD-11: BA40] Phase 2
	
TTDDRUID	D06TKI
DRUGNAME	CHR-3996
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06TKR
DRUGNAME	CART 19
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Preclinical
	
TTDDRUID	D06TLK
DRUGNAME	EPB-600
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D06TME
DRUGNAME	MEDI-546
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D06TMH
DRUGNAME	HG-1164
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06TNG
DRUGNAME	Polythiazide
INDICATI	Edema [ICD-11: MG29] Approved
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D06TNL
DRUGNAME	Ethacrynic acid
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D06TNO
DRUGNAME	CD19 CAR T-cells
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D06TOE
DRUGNAME	Micafungin
INDICATI	Candidiasis [ICD-11: 1F23] Approved
	
TTDDRUID	D06TQD
DRUGNAME	CMPD-167
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D06TQR
DRUGNAME	PF-06372865
INDICATI	Chronic pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D06TQZ
DRUGNAME	Meticillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D06TTS
DRUGNAME	LZ-8
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D06TTT
DRUGNAME	Recombinant Tat protein vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D06TVC
DRUGNAME	Tienoxolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D06TVG
DRUGNAME	Inaperisone
INDICATI	Pollakiuria [ICD-11: MF50.1] Discontinued in Preregistration
	
TTDDRUID	D06TVU
DRUGNAME	Q-101
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D06TWA
DRUGNAME	TB-403
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D06TWE
DRUGNAME	CLX-0921
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D06TWS
DRUGNAME	CAR-T cells targeting CD2
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
	
TTDDRUID	D06TZT
DRUGNAME	RIPISARTAN
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D06TZZ
DRUGNAME	CAT 1004
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D06UAD
DRUGNAME	HR2P peptide
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D06UBF
DRUGNAME	V180
INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 1
	
TTDDRUID	D06UCV
DRUGNAME	Z-335
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D06UDG
DRUGNAME	Valsartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D06UDO
DRUGNAME	Phenindamine
INDICATI	Common cold [ICD-11: CA00] Approved
	
TTDDRUID	D06UDV
DRUGNAME	AZD2516
INDICATI	Chronic neuropathic pain [ICD-11: MG30.5] Discontinued in Phase 2
	
TTDDRUID	D06UEC
DRUGNAME	ADXS-HER2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D06UEP
DRUGNAME	GKT-136901
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D06UFH
DRUGNAME	CZ-112
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D06UIS
DRUGNAME	LY-2828360
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D06UJD
DRUGNAME	H-102
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative
	
TTDDRUID	D06UJO
DRUGNAME	Rhenex
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D06UKG
DRUGNAME	LY-377604
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D06ULU
DRUGNAME	Sucralfate
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D06UND
DRUGNAME	FP-85A
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1
	
TTDDRUID	D06UNI
DRUGNAME	RBx-10017609
INDICATI	Respiratory disease [ICD-11: CB40] Phase 2
	
TTDDRUID	D06UNR
DRUGNAME	Unithiol
INDICATI	Metal intoxication [ICD-11: NE60] Approved
	
TTDDRUID	D06UNW
DRUGNAME	IVN-mite
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D06UNY
DRUGNAME	SB204
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3
	
TTDDRUID	D06UOL
DRUGNAME	PIROTIODECANE
INDICATI	Ophthalmic graves disease [ICD-11: 5A02.0] Investigative
	
TTDDRUID	D06UOU
DRUGNAME	MGA271
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1
	
TTDDRUID	D06UPS
DRUGNAME	Rozrolimupab
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 2
	
TTDDRUID	D06UPW
DRUGNAME	WSS-45
INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative
	
TTDDRUID	D06URI
DRUGNAME	ATL101
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D06URK
DRUGNAME	CKD-533
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D06URS
DRUGNAME	Arcitumomab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D06URX
DRUGNAME	CAR-T Cells targeting MUCI
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D06USG
DRUGNAME	CS-560
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 3
	
TTDDRUID	D06UTH
DRUGNAME	RDEA-684
INDICATI	Gout [ICD-11: FA25] Phase 2
	
TTDDRUID	D06UTM
DRUGNAME	Anti-CD19-CAR T cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D06UUE
DRUGNAME	AZ-AAV9
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D06UUU
DRUGNAME	BLX-1017
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D06UVD
DRUGNAME	Bleomycin
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Approved
	
TTDDRUID	D06UVO
DRUGNAME	DuP-654
INDICATI	Pruritus [ICD-11: EC90] Discontinued in Phase 2
	
TTDDRUID	D06UVZ
DRUGNAME	DPD-207
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D06UWD
DRUGNAME	Clobutinol
INDICATI	Cough [ICD-11: MD12] Withdrawn from market
	
TTDDRUID	D06UWF
DRUGNAME	SOR-C13
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D06UXL
DRUGNAME	GI-248573
INDICATI	Bladder disease [ICD-11: DC11-DC1Z] Terminated
	
TTDDRUID	D06UYI
DRUGNAME	AM103
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2
	
TTDDRUID	D06UZS
DRUGNAME	VDA-1124
INDICATI	Aortic aneurysm [ICD-11: BD50] Investigative
	
TTDDRUID	D06VAQ
DRUGNAME	EUK-189
INDICATI	Skin burns [ICD-11: ME65.0] Phase 1
	
TTDDRUID	D06VCC
DRUGNAME	REGN-421
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06VCJ
DRUGNAME	Fusion toxin protein
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06VCN
DRUGNAME	Denagliptin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2/3
	
TTDDRUID	D06VFF
DRUGNAME	EGFR antisense DNA
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2
	
TTDDRUID	D06VFI
DRUGNAME	PRTT-200
INDICATI	Fibromyalgia [ICD-11: MG30.01] Investigative
	
TTDDRUID	D06VFO
DRUGNAME	Anisodamine
INDICATI	Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] Approved
	
TTDDRUID	D06VFP
DRUGNAME	SOTB07
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D06VHG
DRUGNAME	NSI-189
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D06VIZ
DRUGNAME	NVX-144
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06VJK
DRUGNAME	Verpasep caltespen
INDICATI	Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Discontinued in Phase 3
	
TTDDRUID	D06VLI
DRUGNAME	HPPH photodynamic therapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D06VMJ
DRUGNAME	Melogliptin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D06VMV
DRUGNAME	BHF-177
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D06VNK
DRUGNAME	Succinic acid
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D06VOM
DRUGNAME	NEBO-174
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1
	
TTDDRUID	D06VPE
DRUGNAME	Lu-AA38466
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1
	
TTDDRUID	D06VPT
DRUGNAME	TDI-0028
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D06VRI
DRUGNAME	Leflunomide
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D06VRS
DRUGNAME	CRB-15
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D06VSD
DRUGNAME	Captopril
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D06VTI
DRUGNAME	Macrocycle derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D06VTL
DRUGNAME	ZO-Y49
INDICATI	Gynecological disease [ICD-11: GA6Z] Investigative
	
TTDDRUID	D06VVH
DRUGNAME	GSK-2115160A
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D06VWA
DRUGNAME	FR-901469
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D06VWL
DRUGNAME	VA-106483
INDICATI	Nocturia [ICD-11: MF55] Phase 2
	
TTDDRUID	D06VXE
DRUGNAME	ALS-2160
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D06VXY
DRUGNAME	SB-237376
INDICATI	Arrhythmia [ICD-11: BC9Z] Terminated
	
TTDDRUID	D06VYE
DRUGNAME	Belotecan hydrocholoride
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Approved
	
TTDDRUID	D06VYF
DRUGNAME	PMID25666693-Compound-3
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D06VYK
DRUGNAME	Azithromycin
INDICATI	Bronchitis [ICD-11: CA20] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D06VZN
DRUGNAME	SPK-843
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 3
	
TTDDRUID	D06WAA
DRUGNAME	CKBP-004
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06WAM
DRUGNAME	Oradoxel
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06WAN
DRUGNAME	Benzimidazole and imidazopyridine derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D06WBA
DRUGNAME	SQ-28603
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D06WBE
DRUGNAME	ERTIPROTAFIB
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D06WCR
DRUGNAME	JAIVAC-1
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	D06WCW
DRUGNAME	UCB-1350883
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06WDT
DRUGNAME	PF-04094667
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D06WEB
DRUGNAME	LAF-389
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D06WEK
DRUGNAME	Ammonium chloride
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D06WGK
DRUGNAME	Q-LAIV
INDICATI	Seasonal influenza infection [ICD-11: 1E30] Approved
	
TTDDRUID	D06WGO
DRUGNAME	Resorcinol compound 8
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D06WGQ
DRUGNAME	Anthrax DNA vaccine
INDICATI	Anthrax [ICD-11: 1B97] Discontinued in Phase 1
	
TTDDRUID	D06WHL
DRUGNAME	NS-257
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D06WHN
DRUGNAME	KDT-500
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D06WHY
DRUGNAME	AZD-5438
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06WJC
DRUGNAME	GC-24
INDICATI	Hyperthyroidism [ICD-11: 5A02] Investigative
	
TTDDRUID	D06WJI
DRUGNAME	OPC-28326
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2
	
TTDDRUID	D06WKA
DRUGNAME	MD-1100
INDICATI	Constipation [ICD-11: DD91.1] Approved
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
	
TTDDRUID	D06WLG
DRUGNAME	P53 fusion protein
INDICATI	Liver cancer [ICD-11: 2C12] Investigative
	
TTDDRUID	D06WLY
DRUGNAME	PN-951
INDICATI	Hematologic disease [ICD-11: 3C0Z] Investigative
	
TTDDRUID	D06WNQ
DRUGNAME	TKM-PLK1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D06WOF
DRUGNAME	Rova-T
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1
	
TTDDRUID	D06WOJ
DRUGNAME	JTH-601
INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2
	
TTDDRUID	D06WPM
DRUGNAME	Coprexa
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 3
	
TTDDRUID	D06WQT
DRUGNAME	Nolatrexed
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D06WRF
DRUGNAME	KD019
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Polycystic kidney disease [ICD-11: GB8Y] Phase 2
INDICATI	Brain metastases [ICD-11: 2D50] Phase 2
INDICATI	Meningioma metastases [ICD-11: 2D51] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D06WRJ
DRUGNAME	Icotinib hydrochloride
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Registered
	
TTDDRUID	D06WRY
DRUGNAME	NFTC-103
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D06WSG
DRUGNAME	AP-005
INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative
	
TTDDRUID	D06WSQ
DRUGNAME	AWD-140-190
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 1
	
TTDDRUID	D06WTI
DRUGNAME	NRP290
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D06WTQ
DRUGNAME	TD-0714
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D06WTZ
DRUGNAME	Lovastatin
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
	
TTDDRUID	D06WUK
DRUGNAME	Carlumab
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Phase 2
	
TTDDRUID	D06WXJ
DRUGNAME	Thiazole carboxamide derivative 14
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D06WXS
DRUGNAME	APX-002
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D06WYG
DRUGNAME	99mTc-MIP-1407
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Investigative
	
TTDDRUID	D06WZQ
DRUGNAME	LPO-1010UV
INDICATI	Uveitis [ICD-11: 9A96.Z] Investigative
	
TTDDRUID	D06XAA
DRUGNAME	RG7667
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 2
	
TTDDRUID	D06XAE
DRUGNAME	Drotaverine
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
	
TTDDRUID	D06XAK
DRUGNAME	H-216/44
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated
	
TTDDRUID	D06XAT
DRUGNAME	BCT-100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D06XBG
DRUGNAME	MIP-1267
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06XBN
DRUGNAME	ACT-GRO-777
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D06XCD
DRUGNAME	PMID27998201-Compound-12
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Bone cancer [ICD-11: 2B5Z] Patented
	
TTDDRUID	D06XCF
DRUGNAME	EQ-917
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D06XCP
DRUGNAME	AZD5991
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D06XDI
DRUGNAME	QAW-039
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D06XDJ
DRUGNAME	Clemizole
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D06XDS
DRUGNAME	GSK-1070806
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D06XEL
DRUGNAME	DG051
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2
	
TTDDRUID	D06XES
DRUGNAME	Melphalan
INDICATI	Ovarian cancer [ICD-11: 2C73] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D06XFV
DRUGNAME	Neo-Kidney Augment
INDICATI	Chronic kidney disease [ICD-11: GB61] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D06XGB
DRUGNAME	Tissue Repair Cells (TRCs)
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2
	
TTDDRUID	D06XGC
DRUGNAME	BMS-986202
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Preclinical
	
TTDDRUID	D06XGW
DRUGNAME	Acetylcysteine
INDICATI	Liver disease [ICD-11: DB90-BD99] Approved
	
TTDDRUID	D06XHC
DRUGNAME	Amcinonide
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D06XIT
DRUGNAME	ABT-414
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
	
TTDDRUID	D06XIX
DRUGNAME	RHuA1AT
INDICATI	Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Investigative
	
TTDDRUID	D06XIZ
DRUGNAME	HM-2002
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D06XJP
DRUGNAME	APT-222
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D06XJQ
DRUGNAME	SIRS-T
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D06XKM
DRUGNAME	Privigen
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1
	
TTDDRUID	D06XLC
DRUGNAME	BMS-739562
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06XME
DRUGNAME	TT-105
INDICATI	Deep vein thrombosis [ICD-11: BD71] Investigative
	
TTDDRUID	D06XMF
DRUGNAME	KT&G-101
INDICATI	Atrophy [ICD-11: 9A2Y-9C40] Phase 3
	
TTDDRUID	D06XMU
DRUGNAME	Testosterone
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
INDICATI	Hormone deficiency [ICD-11: 5A61.1] Phase 2
INDICATI	Male hormonal deficiency [ICD-11: 5A81] Investigative
	
TTDDRUID	D06XMW
DRUGNAME	DPK-060
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D06XNW
DRUGNAME	NKP-3752
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06XOI
DRUGNAME	BMY-41802
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D06XOT
DRUGNAME	F18-flutemetamol
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D06XPL
DRUGNAME	TOCA-511
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2/3
	
TTDDRUID	D06XPX
DRUGNAME	CERE-135
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D06XRA
DRUGNAME	LU AA24493
INDICATI	Stroke [ICD-11: 8B20] Discontinued in Phase 2
	
TTDDRUID	D06XRQ
DRUGNAME	AA-861
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D06XSB
DRUGNAME	GW-870086-X
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D06XSG
DRUGNAME	AZD8075
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D06XTA
DRUGNAME	PMID27998201-Compound-17
INDICATI	Hair loss [ICD-11: ED70] Patented
	
TTDDRUID	D06XVF
DRUGNAME	CBT-1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Application submitted
	
TTDDRUID	D06XVN
DRUGNAME	Farletuzumab
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D06XVR
DRUGNAME	BAN2401
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D06XVX
DRUGNAME	RP-5000
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D06XWB
DRUGNAME	Huperzine A
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D06XWD
DRUGNAME	CAR-T Cells targeting HER2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D06XWQ
DRUGNAME	Benzothiazine-carboxamide compound 2
INDICATI	Skin inflammation [ICD-11: EF20.Y] Patented
	
TTDDRUID	D06XXA
DRUGNAME	AMA-1-Dico
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D06XXD
DRUGNAME	IG-AI-025
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D06XXH
DRUGNAME	Dacomitinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
	
TTDDRUID	D06XYL
DRUGNAME	DP-6001
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D06XZM
DRUGNAME	GBL-100
INDICATI	Dermatological disease [ICD-11: DA24.Y] Discontinued in Phase 1
	
TTDDRUID	D06XZR
DRUGNAME	Pizotyline
INDICATI	Headache [ICD-11: 8A80-8A84] Approved
	
TTDDRUID	D06XZW
DRUGNAME	Troglitazone
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D06YAG
DRUGNAME	ABX-102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06YAI
DRUGNAME	SOM-0004
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D06YAK
DRUGNAME	MG-3
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D06YCR
DRUGNAME	Marburg virus DNA vaccine
INDICATI	Marburg virus infection [ICD-11: 1D60.1] Phase 1
	
TTDDRUID	D06YEE
DRUGNAME	Prodigiosin
INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative
	
TTDDRUID	D06YEG
DRUGNAME	Indirab
INDICATI	Rabies [ICD-11: 1C82] Approved
	
TTDDRUID	D06YEK
DRUGNAME	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4
INDICATI	Skin disease [ICD-11: EA00-EM0Z] Patented
INDICATI	Muscular wasting [ICD-11: 8C7Y] Patented
	
TTDDRUID	D06YFA
DRUGNAME	Bromocriptine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D06YFO
DRUGNAME	AD-121
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1/2
	
TTDDRUID	D06YFT
DRUGNAME	1-methyl-L-tryptophan
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D06YGP
DRUGNAME	BN-OD-026
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D06YHL
DRUGNAME	Cefamandole
INDICATI	Microorganisms infection [ICD-11: 1A00-1A09] Approved
	
TTDDRUID	D06YKN
DRUGNAME	Resorcinol compound 22
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D06YMT
DRUGNAME	PLX-ORI3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06YNK
DRUGNAME	TRM-88
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D06YOD
DRUGNAME	ZD-7717
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D06YPQ
DRUGNAME	SPI-452
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D06YPU
DRUGNAME	Dexibuprofen
INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Approved
	
TTDDRUID	D06YRR
DRUGNAME	GSK2254233A
INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2
INDICATI	Haemophilus influenza [ICD-11: 1G40] Phase 2
	
TTDDRUID	D06YSK
DRUGNAME	HuMax-Her2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06YSP
DRUGNAME	AT13387
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D06YTE
DRUGNAME	NOX-D14
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D06YUM
DRUGNAME	AZD6423
INDICATI	Suicidal ideation [ICD-11: MB26.A] Phase 1
	
TTDDRUID	D06YUR
DRUGNAME	Oxindole derivative
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D06YWA
DRUGNAME	BVA-101
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D06YWH
DRUGNAME	YM155
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D06YXD
DRUGNAME	Taprostene
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3
	
TTDDRUID	D06YYD
DRUGNAME	Dexlansoprazole
INDICATI	Non-erosive gastro-esophageal reflux disease [ICD-11: DA22.0] Approved
INDICATI	Erosive esophagitis [ICD-11: DA25.0] Approved
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
INDICATI	NSAID-associated gastric ulcer [ICD-11: DA60] Phase 3
	
TTDDRUID	D06YYY
DRUGNAME	KAR-1880
INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative
	
TTDDRUID	D06ZAK
DRUGNAME	CA-50040
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative
	
TTDDRUID	D06ZAM
DRUGNAME	MF268
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D06ZAS
DRUGNAME	Technetium Tc-99m Ferpentetate Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D06ZAY
DRUGNAME	Haloprogin
INDICATI	Dermatophytosis [ICD-11: 1F28.2] Approved
INDICATI	Candidiasis [ICD-11: 1F23] Approved
	
TTDDRUID	D06ZCH
DRUGNAME	SA-ANP
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D06ZCP
DRUGNAME	Ischemic tolerant allogeneic mesenchymal stem cell therapy
INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 2
	
TTDDRUID	D06ZEC
DRUGNAME	Glucagon
INDICATI	Hypoglycemia [ICD-11: 5A41] Phase 1
	
TTDDRUID	D06ZEE
DRUGNAME	Atovaquone
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D06ZEO
DRUGNAME	Vericiguat
INDICATI	Heart failure [ICD-11: BD10-BD13] Approved
	
TTDDRUID	D06ZFV
DRUGNAME	QPI-1007
INDICATI	Ischemic optic neuropathy [ICD-11: 9C40.4] Phase 3
INDICATI	Non-arteritic anterior ischemic optic neuropathy [ICD-11: 9C40.40] Phase 3
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2/3
	
TTDDRUID	D06ZHN
DRUGNAME	Lactermin
INDICATI	Oral mucositis [ICD-11: DA01.11] Phase 1
	
TTDDRUID	D06ZHZ
DRUGNAME	FX-125L
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2
	
TTDDRUID	D06ZII
DRUGNAME	Eszopiclone
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D06ZIL
DRUGNAME	CTA-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D06ZIS
DRUGNAME	SIG-990
INDICATI	Rosacea [ICD-11: ED90.0] Investigative
	
TTDDRUID	D06ZIT
DRUGNAME	Pegloticase
INDICATI	Gout [ICD-11: FA25] Approved
	
TTDDRUID	D06ZJD
DRUGNAME	Melapuldencel-T
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D06ZKG
DRUGNAME	SC-56525
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D06ZME
DRUGNAME	RTL-551
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D06ZNU
DRUGNAME	Pyrrolo[2,3-d]pyrimidine derivative 16
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Patented
	
TTDDRUID	D06ZPS
DRUGNAME	Oxyphenbutazone
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D06ZPX
DRUGNAME	BTL-TML-001
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
INDICATI	Herpes simplex labialis [ICD-11: 1F00.01] Phase 2
	
TTDDRUID	D06ZQK
DRUGNAME	Nucleozin analog 3061 (FA-2)
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D06ZQL
DRUGNAME	NP-2 gene therapy
INDICATI	Cancer related pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D06ZUK
DRUGNAME	Imipramine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D06ZUP
DRUGNAME	Dirithromycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D06ZVC
DRUGNAME	WAY-181187
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D06ZVG
DRUGNAME	AST-120
INDICATI	Poison intoxication [ICD-11: NE6Z] Approved
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative
	
TTDDRUID	D06ZVO
DRUGNAME	PX-478
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06ZVZ
DRUGNAME	Duvelisib
INDICATI	Follicular lymphoma [ICD-11: 2A80] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D06ZWG
DRUGNAME	AVE-5997EF
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D06ZWL
DRUGNAME	Amdoxovir
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D06ZXF
DRUGNAME	U3-1565
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D06ZXH
DRUGNAME	PHN-131
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2/3
	
TTDDRUID	D06ZXT
DRUGNAME	N-6547
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D06ZYC
DRUGNAME	MLN0415
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D06ZYM
DRUGNAME	Cholestyramine
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
	
TTDDRUID	D06ZZL
DRUGNAME	MEDI-500
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Terminated
	
TTDDRUID	D07AAN
DRUGNAME	Sodium Iodide I-123
INDICATI	Thyroid disease [ICD-11: 5A00-5A06] Approved
	
TTDDRUID	D07ABV
DRUGNAME	Posaconazole
INDICATI	Aspergillosis [ICD-11: 1F20] Approved
	
TTDDRUID	D07ACL
DRUGNAME	PNT-2258
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
	
TTDDRUID	D07ACP
DRUGNAME	CWF-0902
INDICATI	Migraine [ICD-11: 8A80] Investigative
	
TTDDRUID	D07ACT
DRUGNAME	Ceftriaxone
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07ACZ
DRUGNAME	CLR457
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D07ADU
DRUGNAME	AEM-28
INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1/2
	
TTDDRUID	D07AEO
DRUGNAME	Isotretinoin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D07AGR
DRUGNAME	SB-206284A
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D07AHC
DRUGNAME	LITOXETINE
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 3
	
TTDDRUID	D07AHW
DRUGNAME	Vitamin C
INDICATI	Vitamin C deficiency [ICD-11: 5B56] Approved
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 2
	
TTDDRUID	D07AIE
DRUGNAME	BAL-2299
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D07AJC
DRUGNAME	HIV MAG pDNA vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D07AJO
DRUGNAME	Bicyclic heteroaryl benzamide derivative 9
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D07AKD
DRUGNAME	TOL-101
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1/2
	
TTDDRUID	D07ALX
DRUGNAME	Sirolimus
INDICATI	Lymphangioleiomyomatosis [ICD-11: CB07] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D07ANO
DRUGNAME	Synthetic neutrophil inhibitor peptide
INDICATI	Rhinitis [ICD-11: FA20] Phase 1
	
TTDDRUID	D07AOL
DRUGNAME	PEITC
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D07AOO
DRUGNAME	Rilotumumab
INDICATI	Grade IV malignant glioma [ICD-11: 2A00.0] Discontinued in Phase 2
	
TTDDRUID	D07AOY
DRUGNAME	Avarofloxacin
INDICATI	Bacterial pneumonia [ICD-11: CA40.0] Discontinued in Phase 2
	
TTDDRUID	D07APS
DRUGNAME	TRC093
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07APX
DRUGNAME	Neuromed 5
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D07ARN
DRUGNAME	SAR-125844
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D07ATG
DRUGNAME	GSK2190914
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D07AUI
DRUGNAME	Influenza A virus vaccine H5N1
INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 2
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D07AUS
DRUGNAME	KRL-901
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 1
	
TTDDRUID	D07AVU
DRUGNAME	PMID28621580-Compound-WO2015089220C70
INDICATI	Retinopathy [ICD-11: 9B71] Patented
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Patented
	
TTDDRUID	D07AVV
DRUGNAME	Ac-YVAD-cmk
INDICATI	Photocontact dermatitis [ICD-11: EK20] Patented
INDICATI	Irritant contact dermatitis [ICD-11: EK02] Patented
INDICATI	Allergic contact dermatitis [ICD-11: EK00] Patented
	
TTDDRUID	D07AWM
DRUGNAME	Segard
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 3
	
TTDDRUID	D07AYI
DRUGNAME	CWP232291
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D07AYN
DRUGNAME	Chikungunya virus vaccine
INDICATI	Chikungunya virus infection [ICD-11: 1D40] Phase 2
	
TTDDRUID	D07BAE
DRUGNAME	SUN-0597
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative
	
TTDDRUID	D07BAJ
DRUGNAME	Clade D HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D07BBD
DRUGNAME	Zona pellucida contraceptive vaccine
INDICATI	Contraception [ICD-11: QA21] Terminated
	
TTDDRUID	D07BCO
DRUGNAME	WAY-100635
INDICATI	Eating disorder [ICD-11: 6B82] Terminated
	
TTDDRUID	D07BCT
DRUGNAME	Tobramycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07BCU
DRUGNAME	Eflornithine + sulindac
INDICATI	Familial adenomatous polyposis [ICD-11: 2B90.Y] Phase 3
INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 3
	
TTDDRUID	D07BDW
DRUGNAME	OC-108
INDICATI	Hemorrhoids [ICD-11: DB60] Approved
	
TTDDRUID	D07BDY
DRUGNAME	Tisocalcitate
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D07BEE
DRUGNAME	AnergiX.RA
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D07BFP
DRUGNAME	PMID27215781-Compound-37
INDICATI	Prostate cancer [ICD-11: 2C82.0] Patented
	
TTDDRUID	D07BGC
DRUGNAME	GDC-0084
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D07BIK
DRUGNAME	VEL-0230
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D07BKL
DRUGNAME	KW-2170
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D07BKR
DRUGNAME	ARQ 621
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D07BLC
DRUGNAME	AMT-090
INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative
	
TTDDRUID	D07BNG
DRUGNAME	RHIgM12B7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07BNL
DRUGNAME	NV.AT.08
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D07BPO
DRUGNAME	Ingavirin
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D07BPS
DRUGNAME	Suprofen
INDICATI	Miosis [ICD-11: LA11.62] Approved
	
TTDDRUID	D07BQE
DRUGNAME	Alteplase
INDICATI	Pulmonary embolism [ICD-11: BB00] Approved
	
TTDDRUID	D07BRZ
DRUGNAME	LY-517717
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2
	
TTDDRUID	D07BSE
DRUGNAME	Hyaluronate sodium
INDICATI	Joint lubricant [ICD-11: FA30-FA38] Approved
INDICATI	Enthesopathy [ICD-11: FB53-FB55] Phase 3
INDICATI	Pancytopenia [ICD-11: 3A70.Z] Investigative
	
TTDDRUID	D07BSQ
DRUGNAME	Progesterone
INDICATI	Premature labour [ICD-11: JB00] Approved
INDICATI	Contraception [ICD-11: QA21] Phase 3
	
TTDDRUID	D07BUH
DRUGNAME	F-627
INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 2
	
TTDDRUID	D07BUO
DRUGNAME	AZD-3783
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D07BVI
DRUGNAME	Ipilimumab
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D07BWU
DRUGNAME	PMX-10072
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D07BXC
DRUGNAME	IZONSTERIDE
INDICATI	Hirsutism [ICD-11: ED72] Phase 1/2
	
TTDDRUID	D07BXE
DRUGNAME	Daniquidone
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D07BXQ
DRUGNAME	VR632
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D07BYK
DRUGNAME	Penciclovir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D07BZW
DRUGNAME	PMID25666693-Compound-85
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D07CAQ
DRUGNAME	SAFINGOL
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D07CBH
DRUGNAME	SKL13865
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1
	
TTDDRUID	D07CBY
DRUGNAME	Cyclin A2
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D07CCV
DRUGNAME	MK-0431C
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
	
TTDDRUID	D07CEI
DRUGNAME	Zinc Sulfate
INDICATI	Zinc deficiency [ICD-11: 5B5K.2] Approved
	
TTDDRUID	D07CGH
DRUGNAME	1D09C3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D07CGI
DRUGNAME	M-M-R II
INDICATI	Measles [ICD-11: 1F03] Approved
	
TTDDRUID	D07CIB
DRUGNAME	CI-1013
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1
	
TTDDRUID	D07CIN
DRUGNAME	(-)-Phenserine
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D07CIX
DRUGNAME	FM-101
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D07CJN
DRUGNAME	ST-101
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D07CLV
DRUGNAME	GDC-0152
INDICATI	Obesity [ICD-11: 5B81] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D07CMM
DRUGNAME	Interferon alfa-n3
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D07CMN
DRUGNAME	PD-200390
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2
	
TTDDRUID	D07CNF
DRUGNAME	G-CSF
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D07CNL
DRUGNAME	Anisotropine Methylbromide
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D07CNY
DRUGNAME	Instiladrin
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
	
TTDDRUID	D07CPL
DRUGNAME	Bicyclic heteroaryl benzamide derivative 6
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D07CPM
DRUGNAME	GP2013
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D07CPU
DRUGNAME	Rosoxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07CQJ
DRUGNAME	F-50040
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 1
	
TTDDRUID	D07CQW
DRUGNAME	Lomab B
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D07CTM
DRUGNAME	Carbol-fuchsin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07CUR
DRUGNAME	Bb2121
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D07CUU
DRUGNAME	SC-02
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D07CWD
DRUGNAME	Hydroxyurea
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved
	
TTDDRUID	D07CWH
DRUGNAME	INCB40093
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D07CXM
DRUGNAME	AVI-7288
INDICATI	Marburg virus infection [ICD-11: 1D60.1] Phase 1
	
TTDDRUID	D07DAU
DRUGNAME	Tafluposide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07DBE
DRUGNAME	Amolimogene
INDICATI	Dysplasia [ICD-11: LB30-LD2F] Phase 2/3
	
TTDDRUID	D07DBS
DRUGNAME	RP-64477
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D07DCG
DRUGNAME	Ivosidenib
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 3
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D07DCX
DRUGNAME	CDP-855
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D07DDK
DRUGNAME	HG-1177
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07DFC
DRUGNAME	Aromatic hydrazine carboxyimidoamide derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D07DGA
DRUGNAME	Imatinib and nilotinib derivative 2
INDICATI	Cas mediated disorder [ICD-11: N.A.] Patented
	
TTDDRUID	D07DGM
DRUGNAME	BQ-518
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D07DGR
DRUGNAME	SEL-113
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D07DIM
DRUGNAME	Herbimycin A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D07DIS
DRUGNAME	MG-1110
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07DIX
DRUGNAME	ALO-1567
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1
	
TTDDRUID	D07DJP
DRUGNAME	Avigen Parkinson
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2
	
TTDDRUID	D07DJQ
DRUGNAME	Emetine
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Approved
	
TTDDRUID	D07DLA
DRUGNAME	ISF-402
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D07DMY
DRUGNAME	MK-3475
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D07DNV
DRUGNAME	ARN-2966
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D07DPC
DRUGNAME	IMGN-853
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07DPI
DRUGNAME	Aspirin/ esomeprazole fixed-dose combination
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D07DPM
DRUGNAME	HP-011-101
INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 2
	
TTDDRUID	D07DQZ
DRUGNAME	CN-16
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D07DRO
DRUGNAME	SF-106
INDICATI	Retinopathy [ICD-11: 9B71] Investigative
	
TTDDRUID	D07DSK
DRUGNAME	BSI-302
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07DSN
DRUGNAME	BIIB 033
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D07DSQ
DRUGNAME	Vapreotide acetate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D07DTC
DRUGNAME	L-97-1 intravenous
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D07DTM
DRUGNAME	Cetraxal Otic
INDICATI	Otitis externa [ICD-11: AA00-AA13] Phase 3
	
TTDDRUID	D07DTV
DRUGNAME	AT7519
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07DTZ
DRUGNAME	VK0612
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D07DUU
DRUGNAME	Alglucosidase alfa
INDICATI	Pompe disease [ICD-11: 5C51.3] Approved
	
TTDDRUID	D07DVK
DRUGNAME	Beclomethasone
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D07DWB
DRUGNAME	Revascor
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
	
TTDDRUID	D07DWC
DRUGNAME	SDX-7320
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07DWF
DRUGNAME	ARQ 092
INDICATI	Proteus syndrome [ICD-11: LD2C] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07DZS
DRUGNAME	1,3-bis(1,3-benzothiazol-2-ylthio)acetone
INDICATI	Glioma [ICD-11: 2A00.0] Investigative
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D07DZT
DRUGNAME	H2TFPC-SGlc
INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative
	
TTDDRUID	D07EAV
DRUGNAME	PMID25666693-Compound-41
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D07EBF
DRUGNAME	CK-2017357
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3
INDICATI	Muscle fatigue [ICD-11: FB32.5] Phase 2
	
TTDDRUID	D07EBU
DRUGNAME	AMG-221
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Discontinued in Phase 1
	
TTDDRUID	D07EDB
DRUGNAME	Ozanimod
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D07EEN
DRUGNAME	Lixivaptan
INDICATI	Hyponatraemia [ICD-11: 5C72] Phase 3
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2
	
TTDDRUID	D07EFA
DRUGNAME	AST-915
INDICATI	Movement disorder [ICD-11: 8A07-8A0Z] Discontinued in Phase 1/2
	
TTDDRUID	D07EFB
DRUGNAME	LFn-p24-B-C
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D07EFM
DRUGNAME	Arecoline
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D07EGF
DRUGNAME	PMID25666693-Compound-56
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D07EGS
DRUGNAME	CGS-23425
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D07EGW
DRUGNAME	AE-0047
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Preregistration
	
TTDDRUID	D07EHB
DRUGNAME	Latrunculin B
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1
	
TTDDRUID	D07EHV
DRUGNAME	LGH-447
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D07EIJ
DRUGNAME	EPI-12323
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D07EIQ
DRUGNAME	Fluvoxamine
INDICATI	Obsessive compulsive disorder [ICD-11: 6B20] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D07EJY
DRUGNAME	AR-12286
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
	
TTDDRUID	D07EKK
DRUGNAME	PTC596
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1
	
TTDDRUID	D07ELC
DRUGNAME	ABI-2088
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07ELT
DRUGNAME	NOX-700
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D07ENB
DRUGNAME	NPI-32101
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D07ENH
DRUGNAME	IVV-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07EPV
DRUGNAME	Teneligliptin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D07EQJ
DRUGNAME	RG-7594
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D07ESC
DRUGNAME	Apremilast
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
	
TTDDRUID	D07ESH
DRUGNAME	PF-1913539
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 3
	
TTDDRUID	D07EUO
DRUGNAME	Naltrexone
INDICATI	Chronic alcoholism [ICD-11: 6C40.2Z] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D07EUY
DRUGNAME	H5N1 influenza vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D07EXH
DRUGNAME	Phloroglucinol
INDICATI	Urinary tract disease [ICD-11: GC2Z] Approved
	
TTDDRUID	D07EXV
DRUGNAME	XEMILOFIBAN
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 3
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3
	
TTDDRUID	D07FBM
DRUGNAME	ASP1941
INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 3
	
TTDDRUID	D07FCA
DRUGNAME	BAMLET
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D07FDM
DRUGNAME	FR-901379
INDICATI	Pneumocystis pneumonia [ICD-11: CA40.20] Terminated
	
TTDDRUID	D07FDV
DRUGNAME	Melaxin
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2
	
TTDDRUID	D07FEC
DRUGNAME	Plecanatide
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
INDICATI	Chronic idiopathic constipation [ICD-11: DC32] Approved
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
	
TTDDRUID	D07FGA
DRUGNAME	ZYC101a
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2/3
	
TTDDRUID	D07FGK
DRUGNAME	SAR-3419
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D07FGU
DRUGNAME	SAR440067
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D07FGV
DRUGNAME	LLL-2011
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 3
	
TTDDRUID	D07FHI
DRUGNAME	Chlamydia vaccine
INDICATI	Chlamydia infection [ICD-11: 1A81] Terminated
	
TTDDRUID	D07FHW
DRUGNAME	PF-915275
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D07FHZ
DRUGNAME	Ro 20-1724
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D07FIC
DRUGNAME	CYT-6091
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07FIF
DRUGNAME	APH-0701
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D07FIY
DRUGNAME	PMID25666693-Compound-50
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D07FJM
DRUGNAME	BRECANAVIR
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D07FKQ
DRUGNAME	Siponimod
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D07FKX
DRUGNAME	HMPL-011
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D07FMW
DRUGNAME	PMID25684022-Compound-US20130053382 38(5-7)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D07FND
DRUGNAME	Nabi-HB
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D07FNG
DRUGNAME	AM336
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D07FPJ
DRUGNAME	MK-4214
INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 3
	
TTDDRUID	D07FPR
DRUGNAME	R4996
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 1
	
TTDDRUID	D07FPY
DRUGNAME	SB-639
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07FQL
DRUGNAME	Diannexin
INDICATI	Myocardial reperfusion injury [ICD-11: NB31] Phase 2
	
TTDDRUID	D07FQS
DRUGNAME	ZP-011
INDICATI	Sinusitis [ICD-11: CA0A.Z] Investigative
	
TTDDRUID	D07FRV
DRUGNAME	Ramipril
INDICATI	Acute heart failure [ICD-11: BD10-BD13] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D07FTD
DRUGNAME	Sodium Monofluorophosphate
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D07FUH
DRUGNAME	LPCN-1087
INDICATI	Cough [ICD-11: MD12] Investigative
	
TTDDRUID	D07FUJ
DRUGNAME	Fluorescein Sodium
INDICATI	Diagnostic fluorescein angiography or angioscopy of vasculature [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D07FUO
DRUGNAME	TA-264
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D07FUP
DRUGNAME	Dupilumab
INDICATI	Atopic dermatitis [ICD-11: EA80] Approved
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D07FWF
DRUGNAME	PMID25666693-Compound-117
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D07FWH
DRUGNAME	RU-59863
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D07FXF
DRUGNAME	CP-613
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D07FYK
DRUGNAME	HuMax-VEGF
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07FZC
DRUGNAME	Recombinant vaccine
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D07FZF
DRUGNAME	XMT-1522
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D07GAA
DRUGNAME	ACP-001
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2
	
TTDDRUID	D07GAN
DRUGNAME	Biaryl mannoside derivative 12
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D07GCK
DRUGNAME	ARC-100
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D07GDN
DRUGNAME	Torcetrapib
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2
	
TTDDRUID	D07GDR
DRUGNAME	AMG 282
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D07GET
DRUGNAME	ALTU-236
INDICATI	Genetic disease [ICD-11: 8E02] Investigative
	
TTDDRUID	D07GFF
DRUGNAME	PKI166
INDICATI	Esophageal cancer [ICD-11: 2B70] Discontinued in Phase 2
	
TTDDRUID	D07GFZ
DRUGNAME	VVZ-138
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D07GGQ
DRUGNAME	ND-801
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D07GGT
DRUGNAME	ANT-429
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07GHA
DRUGNAME	PLX2853
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D07GHV
DRUGNAME	PF-05180999
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D07GIB
DRUGNAME	AZD5672
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D07GJH
DRUGNAME	PMID26161824-Compound-68
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D07GJZ
DRUGNAME	CQA 206-291
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D07GKS
DRUGNAME	MAGE-101
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D07GLB
DRUGNAME	PEV-7
INDICATI	Candidiasis [ICD-11: 1F23] Phase 1
	
TTDDRUID	D07GLF
DRUGNAME	Nemifitide
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D07GLX
DRUGNAME	CNS-1531
INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Terminated
	
TTDDRUID	D07GMF
DRUGNAME	MVA-85A
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2
	
TTDDRUID	D07GNL
DRUGNAME	GSK-523338
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D07GNO
DRUGNAME	KRN-330
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
	
TTDDRUID	D07GNP
DRUGNAME	Iopromide
INDICATI	X-rays imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D07GNR
DRUGNAME	Vivaglobin
INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Approved
	
TTDDRUID	D07GOY
DRUGNAME	CD59 gene therapy
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D07GQA
DRUGNAME	ZD-7155
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D07GRH
DRUGNAME	Ciclopirox
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D07GTF
DRUGNAME	Aipusheng
INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Approved
	
TTDDRUID	D07GTW
DRUGNAME	Fosdenopterin
INDICATI	Molybdenum cofactor deficiency [ICD-11: 5B5K.A] Approved
INDICATI	Encephalopathy [ICD-11: 8E47] Phase 2
	
TTDDRUID	D07GVE
DRUGNAME	EDP-14
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D07GVM
DRUGNAME	JNJ-42491293
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Phase 1
	
TTDDRUID	D07GWZ
DRUGNAME	NT-501 CNTF
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	D07GXR
DRUGNAME	Ubrogepant
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D07GYP
DRUGNAME	TYT-1
INDICATI	West nile virus infection [ICD-11: 1D46] Investigative
	
TTDDRUID	D07GZG
DRUGNAME	Endomorphins
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D07GZL
DRUGNAME	R-701
INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 1
	
TTDDRUID	D07GZZ
DRUGNAME	Grass allergy vaccine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Terminated
	
TTDDRUID	D07HAD
DRUGNAME	Telbermin
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Discontinued in Phase 2
	
TTDDRUID	D07HAR
DRUGNAME	OMS-302
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D07HBI
DRUGNAME	ZD-2138
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D07HBX
DRUGNAME	Salicyclic acid
INDICATI	Seborrhoeic dermatitis [ICD-11: EA81] Approved
	
TTDDRUID	D07HCH
DRUGNAME	LY2812176
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D07HGR
DRUGNAME	Lisinopril
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D07HJS
DRUGNAME	Anti-BCMA CAR-T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D07HJT
DRUGNAME	Amidine compound 3
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D07HKV
DRUGNAME	IMGN-388
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07HLS
DRUGNAME	Anacetrapib
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 3
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D07HLZ
DRUGNAME	GZ404477
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D07HOA
DRUGNAME	Heterocyclic derivative 9
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D07HOB
DRUGNAME	Irinotecan
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
	
TTDDRUID	D07HOF
DRUGNAME	Picibanil
INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Phase 4
	
TTDDRUID	D07HOH
DRUGNAME	MM-398
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
	
TTDDRUID	D07HOP
DRUGNAME	Alkyl mannoside derivative 9
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D07HOT
DRUGNAME	ALXN1007
INDICATI	Phospholipid syndrome [ICD-11: 4A45] Phase 2
	
TTDDRUID	D07HPH
DRUGNAME	MEDI5083
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07HPJ
DRUGNAME	AEW-541
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D07HQC
DRUGNAME	Modafinil
INDICATI	Narcolepsy [ICD-11: 7A20] Approved
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 4
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D07HRU
DRUGNAME	KRN633
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D07HSR
DRUGNAME	GSK2798745
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D07HTX
DRUGNAME	GL-331
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2
	
TTDDRUID	D07HUW
DRUGNAME	Oregovomab
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Epithelial ovarian cancer [ICD-11: 2B5D] Phase 2
	
TTDDRUID	D07HVY
DRUGNAME	Efavirenz
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D07HYR
DRUGNAME	GCC-1290K
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D07HZG
DRUGNAME	PF-00734200
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D07HZP
DRUGNAME	CNTO888
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07HZY
DRUGNAME	Xylose
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved
	
TTDDRUID	D07IBY
DRUGNAME	STA-9584
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07IEC
DRUGNAME	GSK2340273A
INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 2
	
TTDDRUID	D07IEF
DRUGNAME	Bisacodyl
INDICATI	Constipation [ICD-11: DD91.1] Approved
	
TTDDRUID	D07IEM
DRUGNAME	AMG-8562
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D07IEU
DRUGNAME	MLN2480
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D07IGC
DRUGNAME	DSP-8658
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D07IGE
DRUGNAME	Glyfoline
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D07IGQ
DRUGNAME	C-Immune
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D07IHT
DRUGNAME	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 1
INDICATI	Osteoporosis [ICD-11: FB83.0] Patented
	
TTDDRUID	D07IIX
DRUGNAME	AMELTOLIDE
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 1
	
TTDDRUID	D07ILQ
DRUGNAME	Guanfacine extended release
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
	
TTDDRUID	D07IMX
DRUGNAME	BMS-844421
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1
	
TTDDRUID	D07IND
DRUGNAME	SRD-285
INDICATI	Wound healing [ICD-11: EL8Y] Preclinical
	
TTDDRUID	D07INL
DRUGNAME	SCY-078
INDICATI	Invasive candidiasis [ICD-11: 1F23] Phase 3
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2
	
TTDDRUID	D07INU
DRUGNAME	LDN-22684
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D07INV
DRUGNAME	Ethoxzolamide
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
INDICATI	Duodenal ulcer [ICD-11: DA63] Withdrawn from market
	
TTDDRUID	D07IOT
DRUGNAME	TPI 287
INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
INDICATI	Brain metastases [ICD-11: 2D50] Phase 1
INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1
	
TTDDRUID	D07IPB
DRUGNAME	Valrubicin
INDICATI	Bladder cancer [ICD-11: 2C94] Approved
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D07IQE
DRUGNAME	Heterocyclic derivative 10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D07IQS
DRUGNAME	Atazanavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D07IRF
DRUGNAME	Prasugrel
INDICATI	Acute coronary syndrome [ICD-11: BA41] Approved
	
TTDDRUID	D07IRG
DRUGNAME	Calcium polycarbophil
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
	
TTDDRUID	D07ISD
DRUGNAME	AFPep
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D07ISE
DRUGNAME	Interferon alpha
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2
	
TTDDRUID	D07ISO
DRUGNAME	VariZIG
INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Approved
	
TTDDRUID	D07ISX
DRUGNAME	Thalidomide
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D07ITH
DRUGNAME	4SCAR19 cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D07IVS
DRUGNAME	Gerilimzumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D07IXD
DRUGNAME	P-0654
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D07IYC
DRUGNAME	TDI-0067
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D07IYO
DRUGNAME	Triazavirin
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D07IZF
DRUGNAME	Sch-57790
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D07IZG
DRUGNAME	GSK4112
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical
	
TTDDRUID	D07IZP
DRUGNAME	ND-401
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D07IZS
DRUGNAME	ITE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07JAG
DRUGNAME	Upadacitinib
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
	
TTDDRUID	D07JAI
DRUGNAME	NSC-639829
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07JBE
DRUGNAME	CG-200745
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07JCU
DRUGNAME	PRS-040
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D07JDR
DRUGNAME	LRN-672
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D07JEW
DRUGNAME	Human coagulation factor X
INDICATI	Renal cell carcinoma [ICD-11: 2C90] BLA submitted
	
TTDDRUID	D07JFE
DRUGNAME	CVT-427
INDICATI	Migraine [ICD-11: 8A80] Phase 1
	
TTDDRUID	D07JFU
DRUGNAME	CGEN-712
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative
	
TTDDRUID	D07JGH
DRUGNAME	UR-13756
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D07JGT
DRUGNAME	Nalidixic Acid
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D07JHH
DRUGNAME	Meclocycline
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07JHJ
DRUGNAME	IGANIDIPINE HYDROCHLORIDE
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 1
	
TTDDRUID	D07JHK
DRUGNAME	AMG 151
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D07JHV
DRUGNAME	Carimune NF
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D07JIN
DRUGNAME	FMX103
INDICATI	Rosacea [ICD-11: ED90.0] Phase 3
	
TTDDRUID	D07JJC
DRUGNAME	DPC-684
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D07JJS
DRUGNAME	Sulfamethizole
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D07JKA
DRUGNAME	SEN-1500
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D07JKY
DRUGNAME	KP-496
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D07JLM
DRUGNAME	Alagebrium chloride
INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 2/3
	
TTDDRUID	D07JMX
DRUGNAME	XEN-600
INDICATI	Iron overload disease [ICD-11: 5C64.10] Investigative
	
TTDDRUID	D07JNJ
DRUGNAME	PMID25666693-Compound-17
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D07JOS
DRUGNAME	NS-004
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D07JOW
DRUGNAME	XTL-Pseudomonas-mab
INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative
	
TTDDRUID	D07JPC
DRUGNAME	Arbekacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07JPK
DRUGNAME	ETX-1153b
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Preclinical
	
TTDDRUID	D07JPL
DRUGNAME	RT-401
INDICATI	Rhinitis [ICD-11: FA20] Investigative
	
TTDDRUID	D07JQO
DRUGNAME	SB 249417
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1
	
TTDDRUID	D07JRF
DRUGNAME	Influenza A virus H1N1 vaccine
INDICATI	Familial chylomicronemia syndrome [ICD-11: 5C80] Phase 3
	
TTDDRUID	D07JRL
DRUGNAME	Epithalon
INDICATI	Ocular inflammation [ICD-11: 9C61.24] Phase 1/2
	
TTDDRUID	D07JSI
DRUGNAME	Salicylihalamide A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D07JSK
DRUGNAME	Sulotroban
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D07JSX
DRUGNAME	IL-2 pDNA
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D07JTD
DRUGNAME	NSC-645809
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D07JTH
DRUGNAME	MM-Q01
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved
	
TTDDRUID	D07JUL
DRUGNAME	JR-032
INDICATI	Hunter syndrome [ICD-11: 5C56.31] Investigative
	
TTDDRUID	D07JVL
DRUGNAME	Diazepam
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D07JVO
DRUGNAME	Fosbretabulin
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D07JVS
DRUGNAME	Cephalosporin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07JVT
DRUGNAME	GWN323
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07JVU
DRUGNAME	Ciclosporin
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D07JWO
DRUGNAME	IL-21
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D07JWT
DRUGNAME	Perazine
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Approved
	
TTDDRUID	D07JXN
DRUGNAME	SPP-600
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D07JXR
DRUGNAME	IMD-4852
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D07JZF
DRUGNAME	Netilmicin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07JZT
DRUGNAME	LA-EP2006
INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 3
	
TTDDRUID	D07KAB
DRUGNAME	AST-VAC1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D07KAK
DRUGNAME	OSH-101
INDICATI	Alopecia [ICD-11: ED70] Phase 2
	
TTDDRUID	D07KAQ
DRUGNAME	L19-IL-2 fusion protein
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
	
TTDDRUID	D07KBM
DRUGNAME	AZD4573
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D07KCA
DRUGNAME	Aryl mannoside derivative 22
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D07KDE
DRUGNAME	Fusafungine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market
	
TTDDRUID	D07KDI
DRUGNAME	AR-42
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
	
TTDDRUID	D07KEH
DRUGNAME	AKB-6548
INDICATI	Anaemia [ICD-11: 3A90] Phase 3
	
TTDDRUID	D07KFB
DRUGNAME	Varespladib methyl
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D07KFG
DRUGNAME	Human prothrombin complex concentrate
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
	
TTDDRUID	D07KGR
DRUGNAME	VI-1121
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D07KGV
DRUGNAME	Anti-HCV agent
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D07KGW
DRUGNAME	PF-3392455
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D07KHH
DRUGNAME	LAS-34273
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D07KHR
DRUGNAME	PSMA-VRP
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D07KIB
DRUGNAME	4-fluoroselegiline
INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative
	
TTDDRUID	D07KIE
DRUGNAME	LYC-30937
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
	
TTDDRUID	D07KIJ
DRUGNAME	INCB3344
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D07KJH
DRUGNAME	LYMErix
INDICATI	Lyme disease [ICD-11: 1C1G] Approved
	
TTDDRUID	D07KKQ
DRUGNAME	Hepatitis A vaccine
INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Approved
	
TTDDRUID	D07KKZ
DRUGNAME	Ga 68 dotatate
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Approved
	
TTDDRUID	D07KMA
DRUGNAME	T-oligos
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07KMI
DRUGNAME	ACI-518
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D07KOR
DRUGNAME	INOC-002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D07KSG
DRUGNAME	Tamoxifen
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D07KTA
DRUGNAME	Ab-01
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2
	
TTDDRUID	D07KTP
DRUGNAME	SCH79687
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D07KUN
DRUGNAME	RAD-1901
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D07KVD
DRUGNAME	ARGX-109
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D07KVL
DRUGNAME	PMID28270021-Compound-WO2010077680 811
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D07KVV
DRUGNAME	Selinexor
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D07KWN
DRUGNAME	Isosteviol
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D07KYK
DRUGNAME	NK-111
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative
	
TTDDRUID	D07KYT
DRUGNAME	AC220
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	D07KYU
DRUGNAME	Benactyzine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Withdrawn from market
	
TTDDRUID	D07KYZ
DRUGNAME	GABA-B receptor PAM
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D07LAP
DRUGNAME	BMS-184476
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D07LBP
DRUGNAME	RabiCide
INDICATI	Rabies [ICD-11: 1C82] Investigative
	
TTDDRUID	D07LBQ
DRUGNAME	GSK2398852
INDICATI	Amyloidosis [ICD-11: 5D00] Phase 1
	
TTDDRUID	D07LCA
DRUGNAME	AMG0714
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D07LCF
DRUGNAME	Naloxegol
INDICATI	Opioid-induced constipation [ICD-11: DB32.1] Approved
	
TTDDRUID	D07LCP
DRUGNAME	Ad5Ag85A
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1
	
TTDDRUID	D07LCY
DRUGNAME	RVSVIN HIV-1 gag vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D07LEW
DRUGNAME	BIBS-39
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D07LFJ
DRUGNAME	BU-32
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07LGU
DRUGNAME	MMPT
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07LJR
DRUGNAME	CDR-267F018
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D07LLI
DRUGNAME	Mucin type glycoproteins
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D07LMO
DRUGNAME	Drug 2862277
INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 2
	
TTDDRUID	D07LPT
DRUGNAME	EP-7041
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D07LRB
DRUGNAME	Factor VIII-XTEN
INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D07LRT
DRUGNAME	A-425619
INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical
	
TTDDRUID	D07LSU
DRUGNAME	CDRI-S002-333
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D07LSV
DRUGNAME	Recombinant galectin-3
INDICATI	Corneal abrasion [ICD-11: NA06.4] Investigative
	
TTDDRUID	D07LUA
DRUGNAME	PfSPZ-GA1
INDICATI	Plasmodium falciparum malaria [ICD-11: 1F40] Phase 2
	
TTDDRUID	D07LUJ
DRUGNAME	URSOLIC ACID
INDICATI	Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 2
	
TTDDRUID	D07LWK
DRUGNAME	AVE0118
INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Phase 1
	
TTDDRUID	D07LWL
DRUGNAME	WIN-34B
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
	
TTDDRUID	D07LWT
DRUGNAME	FE-202767
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 2
	
TTDDRUID	D07LYC
DRUGNAME	SCYX-7158
INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Phase 1
	
TTDDRUID	D07LZH
DRUGNAME	ERB-041
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
	
TTDDRUID	D07MBQ
DRUGNAME	CNTO-736
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D07MCK
DRUGNAME	Salicylamide
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D07MDY
DRUGNAME	Elsulfavirine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D07MED
DRUGNAME	RG7716
INDICATI	Neovascular age-related macular degeneration [ICD-11: 9B78.3Z] Phase 3
INDICATI	Choroidal neovascularization [ICD-11: 9B76] Phase 2
	
TTDDRUID	D07MEH
DRUGNAME	Meglitinides
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 4
	
TTDDRUID	D07MEL
DRUGNAME	Amiprilose
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Preregistration
	
TTDDRUID	D07MEX
DRUGNAME	CLR-1401
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D07MFY
DRUGNAME	STX-200
INDICATI	Acute lung injury [ICD-11: NB32.3] Investigative
	
TTDDRUID	D07MGA
DRUGNAME	Hesperetin
INDICATI	High blood cholesterol level [ICD-11: 5C80.00] Approved
	
TTDDRUID	D07MGC
DRUGNAME	Talacotuzumab
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D07MHM
DRUGNAME	PP-405
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07MKL
DRUGNAME	ABT-229
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D07MLA
DRUGNAME	CIGB-200
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D07MLP
DRUGNAME	APN-601
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D07MMC
DRUGNAME	STP-702
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D07MME
DRUGNAME	Dexamethasone palmitate
INDICATI	Choroidal neovascularization [ICD-11: 9B76] Phase 1/2
	
TTDDRUID	D07MNI
DRUGNAME	PMID25666693-Compound-127
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D07MNT
DRUGNAME	P52-/p36- GAP vaccine
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2
	
TTDDRUID	D07MOK
DRUGNAME	KANAb-071
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D07MON
DRUGNAME	ONAPRISTONE
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D07MOX
DRUGNAME	Norepinephrine
INDICATI	Sepsis [ICD-11: 1G40-1G41] Approved
	
TTDDRUID	D07MPI
DRUGNAME	MEDI-0639
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07MPJ
DRUGNAME	A-75925
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2
	
TTDDRUID	D07MPL
DRUGNAME	SNX-5422
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1
	
TTDDRUID	D07MQC
DRUGNAME	PS-1145
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D07MQY
DRUGNAME	HIV-LAMP-vax
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D07MSB
DRUGNAME	Thiazole carboxamide derivative 11
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D07MSL
DRUGNAME	TL-1836
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07MTL
DRUGNAME	SRSC-371
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D07MTT
DRUGNAME	HP-831-064
INDICATI	Wound healing [ICD-11: EL8Y] Phase 1
	
TTDDRUID	D07MUN
DRUGNAME	Vitamin B6
INDICATI	Vitamin B6 deficiency [ICD-11: 5B5D] Approved
	
TTDDRUID	D07MUS
DRUGNAME	CPA-7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07MUT
DRUGNAME	TDI-0032
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D07MVE
DRUGNAME	PD-151832
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1/2
	
TTDDRUID	D07MVK
DRUGNAME	Halofantrine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D07MWY
DRUGNAME	XR-1853
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D07MXA
DRUGNAME	C75
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D07MXF
DRUGNAME	Zabofloxacin
INDICATI	Pneumonia [ICD-11: CA40] Phase 3
	
TTDDRUID	D07MZC
DRUGNAME	Vasoflux
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2
	
TTDDRUID	D07NAA
DRUGNAME	Sulfonylated piperazine derivative 4
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D07NAJ
DRUGNAME	Chloroprocaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D07NBA
DRUGNAME	Veltuzumab
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 1/2
	
TTDDRUID	D07NCC
DRUGNAME	VTT-201
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D07NCN
DRUGNAME	Doxofylline
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D07NCV
DRUGNAME	BXT-51072
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D07NDK
DRUGNAME	WAY-644
INDICATI	Aortic aneurysm [ICD-11: BD50] Investigative
	
TTDDRUID	D07NEE
DRUGNAME	AEZS-131
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07NEI
DRUGNAME	PMID30280939-Compound-US20179642901
INDICATI	Malaria [ICD-11: 1F40-1F45] Patented
	
TTDDRUID	D07NFT
DRUGNAME	P-2281
INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative
	
TTDDRUID	D07NFW
DRUGNAME	BMS-196085
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D07NGJ
DRUGNAME	S-23906-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D07NGZ
DRUGNAME	Insulin-glargine
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
INDICATI	Type-2 diabetes [ICD-11: 5A11] Application submitted
	
TTDDRUID	D07NHZ
DRUGNAME	CD19 CAR T cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D07NJI
DRUGNAME	Treximet
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D07NJN
DRUGNAME	Siltuximab
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D07NKJ
DRUGNAME	AT-001
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D07NKZ
DRUGNAME	VVP-808
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D07NLI
DRUGNAME	Vismed
INDICATI	Eye disorder [ICD-11: 9A01-9A0Z] Phase 4
	
TTDDRUID	D07NOI
DRUGNAME	BAY-57-9352
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
	
TTDDRUID	D07NPH
DRUGNAME	Colostrinin
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D07NPS
DRUGNAME	Zarnestra
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2
INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D07NPX
DRUGNAME	Triiodothyronine
INDICATI	Euthyroid goiter [ICD-11: 5A01.1] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D07NSU
DRUGNAME	Glucosamine
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
	
TTDDRUID	D07NTC
DRUGNAME	WCK-771
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D07NTN
DRUGNAME	CERM-11956
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1
	
TTDDRUID	D07NUH
DRUGNAME	IDX-15971
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D07NUL
DRUGNAME	PF-06650833
INDICATI	Lupus [ICD-11: 4A40] Phase 1
	
TTDDRUID	D07NUO
DRUGNAME	JNJ-39588146
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D07NUZ
DRUGNAME	Phospho-aspirins
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07NVF
DRUGNAME	WAS gene therapy
INDICATI	Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 1/2
	
TTDDRUID	D07NVI
DRUGNAME	CPI-613
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
INDICATI	Recurrent adult burkitt lymphoma [ICD-11: 2A85.6] Phase 2
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 1
INDICATI	T-cell lymphoma [ICD-11: 2A90] Phase 1
	
TTDDRUID	D07NVU
DRUGNAME	Midostaurin
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Approved
INDICATI	Chronic myelomonocytic leukaemia [ICD-11: 2A40] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D07NWC
DRUGNAME	SC-241
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D07NWZ
DRUGNAME	CL-301
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D07NYF
DRUGNAME	MLN-2201
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1
	
TTDDRUID	D07NZC
DRUGNAME	AMG 581
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1
	
TTDDRUID	D07OAD
DRUGNAME	GO-203-2c
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D07OAO
DRUGNAME	IONIS-HTTRX
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 3
	
TTDDRUID	D07OBJ
DRUGNAME	PHX-1766
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D07OBK
DRUGNAME	SL-201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07OCC
DRUGNAME	JSM-10292
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D07OCM
DRUGNAME	Dendritic cell-based immunotherapy
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D07OCV
DRUGNAME	HT-0712
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D07ODC
DRUGNAME	VBY- 036
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D07OED
DRUGNAME	BL-5040
INDICATI	Cachexia [ICD-11: MG20] Investigative
	
TTDDRUID	D07OEY
DRUGNAME	ZK-118182
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D07OFM
DRUGNAME	GSK525762
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D07OGR
DRUGNAME	YM-26734
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D07OGZ
DRUGNAME	Darexaban maleate
INDICATI	Acute coronary syndrome [ICD-11: BA41] Discontinued in Phase 3
	
TTDDRUID	D07OHO
DRUGNAME	Ampiroxicam
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D07OHT
DRUGNAME	ABT-450
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D07OIO
DRUGNAME	AZD-2461
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07OIX
DRUGNAME	Iodipamide
INDICATI	Gallbladder disease [ICD-11: DC11.3] Approved
	
TTDDRUID	D07OIZ
DRUGNAME	R-84
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07OJZ
DRUGNAME	Capmatinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D07OLO
DRUGNAME	Milacemide
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D07OMK
DRUGNAME	RO-48-6791
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D07ONP
DRUGNAME	Phenacemide
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D07OQJ
DRUGNAME	GM-CAIX
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Investigative
	
TTDDRUID	D07ORE
DRUGNAME	TVGV-1 vaccine
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2
	
TTDDRUID	D07ORO
DRUGNAME	Solamargine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D07OSS
DRUGNAME	9cUAB-30
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07OTU
DRUGNAME	NRX-1050
INDICATI	Bipolar disorder [ICD-11: 6A60] Investigative
	
TTDDRUID	D07OTW
DRUGNAME	WT2725
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D07OUE
DRUGNAME	AUX-202
INDICATI	Bone metastases [ICD-11: 2D50] Terminated
	
TTDDRUID	D07OVM
DRUGNAME	Benzothiazine-carboxamide compound 4
INDICATI	Skin inflammation [ICD-11: EF20.Y] Patented
	
TTDDRUID	D07OXW
DRUGNAME	FVh1 DNA-based influenza vaccine
INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D07OYT
DRUGNAME	NPB-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07OZO
DRUGNAME	BMP-4
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative
	
TTDDRUID	D07OZR
DRUGNAME	TKI258
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D07PAG
DRUGNAME	U-97456
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D07PAO
DRUGNAME	Sulphadoxine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D07PAY
DRUGNAME	B-956
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D07PBZ
DRUGNAME	Epoetin alfa
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved
	
TTDDRUID	D07PCI
DRUGNAME	Carboprost Tromethamine
INDICATI	Abortion [ICD-11: JA00] Approved
	
TTDDRUID	D07PCZ
DRUGNAME	AR20.5
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D07PFG
DRUGNAME	HL-009
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D07PFU
DRUGNAME	JNJ-63733657
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D07PHS
DRUGNAME	CXCL8
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D07PIA
DRUGNAME	AG-1350
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D07PIH
DRUGNAME	Pyrazole derivative 60
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D07PJR
DRUGNAME	Cyclic compound 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D07PJS
DRUGNAME	JNJ-68284528
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D07PLK
DRUGNAME	WIN-64821
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D07PMG
DRUGNAME	Afeletecan
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D07PMH
DRUGNAME	VH-0445 based conjugated therapeutics
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D07PML
DRUGNAME	Ublituximab + umbralisib
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2/3
	
TTDDRUID	D07PMP
DRUGNAME	PKI-402
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07PMU
DRUGNAME	111In-OC-125 F(ab1/2)-DTPA
INDICATI	Ovarian cancer [ICD-11: 2C73] Terminated
	
TTDDRUID	D07PNC
DRUGNAME	Organon
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D07PND
DRUGNAME	Diphenyl purine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D07PNQ
DRUGNAME	CD200Fc
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D07PNT
DRUGNAME	XL999
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07PNX
DRUGNAME	PMID26815044-Compound-115
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D07POC
DRUGNAME	Erlotinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 2
	
TTDDRUID	D07POS
DRUGNAME	Alkyl mannoside derivative 12
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D07POY
DRUGNAME	Peptagon
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D07PQJ
DRUGNAME	ARQ-087
INDICATI	Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10] Phase 3
INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07PRA
DRUGNAME	UX-005
INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Investigative
	
TTDDRUID	D07PRC
DRUGNAME	BAL-30072
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D07PRH
DRUGNAME	DE-098
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D07PSJ
DRUGNAME	Resorcinol compound 24
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D07PSL
DRUGNAME	PLX7486
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07PSP
DRUGNAME	U-75875
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D07PSX
DRUGNAME	ABBV-084
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D07PTH
DRUGNAME	13-cis-retinoic acid
INDICATI	Glioma [ICD-11: 2A00.0] Phase 3
INDICATI	Infertility [ICD-11: GB04] Phase 2
INDICATI	Azoospermia [ICD-11: GB04.0] Phase 2
	
TTDDRUID	D07PUS
DRUGNAME	DSM1
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D07PVB
DRUGNAME	Squalamine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	D07PVT
DRUGNAME	NVC-638
INDICATI	Conjunctivitis [ICD-11: 9A60] Investigative
	
TTDDRUID	D07PVX
DRUGNAME	Aryl mannoside derivative 21
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D07PWY
DRUGNAME	Anti-RON receptor mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07PXQ
DRUGNAME	ASP-2151
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 3
	
TTDDRUID	D07QAA
DRUGNAME	BRL-46470
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D07QAF
DRUGNAME	BI 207127
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D07QAH
DRUGNAME	Biaryl mannoside derivative 17
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D07QAK
DRUGNAME	Xanomeline tartrate
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D07QAR
DRUGNAME	Dalbavancin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07QBJ
DRUGNAME	HJP-272
INDICATI	Premature labour [ICD-11: JB00] Investigative
	
TTDDRUID	D07QCA
DRUGNAME	GDNF-producing adult stem cell therapy
INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 2
	
TTDDRUID	D07QCE
DRUGNAME	Azathioprine
INDICATI	Organ transplant rejection [ICD-11: NE84] Approved
	
TTDDRUID	D07QDT
DRUGNAME	MA-0211
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1
	
TTDDRUID	D07QFM
DRUGNAME	TP10
INDICATI	Myocardial ischemia [ICD-11: BA6Z] Phase 2
	
TTDDRUID	D07QFP
DRUGNAME	Teriflunomide
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	D07QFU
DRUGNAME	T-607
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D07QHF
DRUGNAME	SAR-260093
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D07QIQ
DRUGNAME	Anti-BCMA-CAR-transduced T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D07QIT
DRUGNAME	GPX-150D
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2
	
TTDDRUID	D07QJK
DRUGNAME	Plitidepsin
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
INDICATI	Angioimmunoblastic T-cell Lymphoma [ICD-11: 2A90.9] Phase 2
	
TTDDRUID	D07QKK
DRUGNAME	CHLORIDE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D07QKM
DRUGNAME	HL-1225
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D07QKN
DRUGNAME	Terpin hydrate
INDICATI	Cough [ICD-11: MD12] Approved
	
TTDDRUID	D07QLD
DRUGNAME	Pyrazole derivative 7
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D07QLG
DRUGNAME	Oxilofrine
INDICATI	Orthostatic hypotension [ICD-11: BA21] Approved
	
TTDDRUID	D07QNH
DRUGNAME	SAIT301
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D07QPM
DRUGNAME	Potassium Citrate
INDICATI	Kidney stone [ICD-11: GB70.0Z] Approved
	
TTDDRUID	D07QQD
DRUGNAME	Aescin
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D07QQP
DRUGNAME	INS-37217
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D07QSA
DRUGNAME	CP-83101
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D07QTB
DRUGNAME	AF-243
INDICATI	Deafness [ICD-11: AB52] Investigative
	
TTDDRUID	D07QTG
DRUGNAME	JNJ-479655
INDICATI	Alzheimer disease [ICD-11: 8A20] Clinical trial
	
TTDDRUID	D07QVY
DRUGNAME	DBT-066
INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative
	
TTDDRUID	D07QWW
DRUGNAME	NBI-34041
INDICATI	Eating disorder [ICD-11: 6B82] Phase 1
	
TTDDRUID	D07QWZ
DRUGNAME	AZT-P-DDI
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D07QXG
DRUGNAME	EF-27
INDICATI	Radiation syndrome [ICD-11: NF00] Terminated
	
TTDDRUID	D07QXM
DRUGNAME	AVI-4020
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1
	
TTDDRUID	D07QXU
DRUGNAME	NS 2359
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
	
TTDDRUID	D07QYQ
DRUGNAME	Chloroquine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
INDICATI	Malaria [ICD-11: 1F40-1F45] Withdrawn from market
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D07QZO
DRUGNAME	MPS-AAV8
INDICATI	Maroteaux-lamy syndrome [ICD-11: 5C56.33] Investigative
	
TTDDRUID	D07RAA
DRUGNAME	PMID26651364-Compound-119
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D07RDQ
DRUGNAME	LMB-100
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
	
TTDDRUID	D07RDU
DRUGNAME	IDP-107
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D07RGW
DRUGNAME	Mephenytoin
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D07RHF
DRUGNAME	GDC 695
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 3
	
TTDDRUID	D07RHP
DRUGNAME	INCB50465
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2
INDICATI	Marginal zone lymphoma [ICD-11: 2A85.0] Phase 2
	
TTDDRUID	D07RIE
DRUGNAME	BC-PN-02
INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Investigative
	
TTDDRUID	D07RIJ
DRUGNAME	Autologous melanoma cell vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07RJD
DRUGNAME	Resorcinol compound 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D07RKN
DRUGNAME	GGTI-2418
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07RKO
DRUGNAME	MRX-6
INDICATI	Contact dermatitis [ICD-11: EK0Z] Phase 2
	
TTDDRUID	D07RME
DRUGNAME	GX-401
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D07RMX
DRUGNAME	ZK-thiazolidinone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D07RPB
DRUGNAME	HT-90B
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D07RPC
DRUGNAME	RAP-103
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D07RPK
DRUGNAME	NIP-151
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D07RPR
DRUGNAME	Bropirimine
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 3
	
TTDDRUID	D07RPT
DRUGNAME	Lentiviral RNAi therapy
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D07RQA
DRUGNAME	Alkyl mannoside derivative 8
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D07RQR
DRUGNAME	SYN-120
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D07RRC
DRUGNAME	BioHib
INDICATI	Haemophilus influenza [ICD-11: 1G40] Approved
	
TTDDRUID	D07RSI
DRUGNAME	Lipobean
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Approved
	
TTDDRUID	D07RST
DRUGNAME	Ibuprofenamine
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
	
TTDDRUID	D07RUC
DRUGNAME	E-6087
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1
	
TTDDRUID	D07RUD
DRUGNAME	Progesterone
INDICATI	Amenorrhea [ICD-11: GA20.0] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D07RUH
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 14
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D07RUR
DRUGNAME	HB-1345
INDICATI	Acne vulgaris [ICD-11: ED80] Investigative
	
TTDDRUID	D07RUV
DRUGNAME	Terflavoxate
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2
	
TTDDRUID	D07RVP
DRUGNAME	GR-63799X
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D07RWY
DRUGNAME	LMI1195
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D07RXM
DRUGNAME	HM-90822
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07RXX
DRUGNAME	HG-1051
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D07RYI
DRUGNAME	Etelcalcetide
INDICATI	Secondary hyperparathyroidism [ICD-11: 5A51.1] Approved
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
	
TTDDRUID	D07RYM
DRUGNAME	PMID25666693-Compound-131
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D07RYX
DRUGNAME	Antide
INDICATI	Prostate hyperplasia [ICD-11: GA90] Discontinued in Phase 2
	
TTDDRUID	D07RZW
DRUGNAME	AZD9150
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D07SBP
DRUGNAME	AZD4831
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D07SBX
DRUGNAME	Anti-HCV peptides
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D07SCN
DRUGNAME	KC-11458
INDICATI	Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2
	
TTDDRUID	D07SDE
DRUGNAME	Pranidipine
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D07SDQ
DRUGNAME	Curcumin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D07SDT
DRUGNAME	HPP-376
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D07SEB
DRUGNAME	BM-17.0505
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D07SEZ
DRUGNAME	HG-1072
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07SGB
DRUGNAME	ABT-299
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1
	
TTDDRUID	D07SHZ
DRUGNAME	COTI-58
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Investigative
	
TTDDRUID	D07SJT
DRUGNAME	Pantothenic acid
INDICATI	Vitamin deficiency [ICD-11: 5B55-5B71] Approved
	
TTDDRUID	D07SKJ
DRUGNAME	LY3015014
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D07SKN
DRUGNAME	PF-885706
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 2
	
TTDDRUID	D07SLJ
DRUGNAME	JCAR024
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D07SMH
DRUGNAME	MK-5172
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D07SNG
DRUGNAME	DF-098
INDICATI	Haemophilus influenza [ICD-11: 1G40] Approved
	
TTDDRUID	D07SNN
DRUGNAME	STxB-E7
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Investigative
	
TTDDRUID	D07SNO
DRUGNAME	Dabrafenib + trametinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D07SOJ
DRUGNAME	Adenovirus/Semliki Forest virus hybrid vector delivered IL-12 immunotherapy
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D07SOO
DRUGNAME	Methoxyflurane
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D07SPG
DRUGNAME	ARGX-110
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D07SQT
DRUGNAME	Ferroportin mab
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1
	
TTDDRUID	D07SRN
DRUGNAME	Debio-1036
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D07STB
DRUGNAME	EG-1962
INDICATI	Subarachnoid hemorrhage [ICD-11: 8B01] Phase 3
INDICATI	Aneurysmal subarachnoid hemorrhage [ICD-11: 8B01.0] Phase 3
	
TTDDRUID	D07SUG
DRUGNAME	Busulfan
INDICATI	Myeloproliferative syndrome [ICD-11: 2A22] Approved
	
TTDDRUID	D07SWU
DRUGNAME	TM30338
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
	
TTDDRUID	D07SXG
DRUGNAME	PRT-061103
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D07SXO
DRUGNAME	AG-041R
INDICATI	Ulcerative colitis [ICD-11: DD71] Terminated
	
TTDDRUID	D07SYJ
DRUGNAME	Sulfameter
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07SYN
DRUGNAME	FX-007
INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical
	
TTDDRUID	D07SYO
DRUGNAME	Stromal stem cell therapy
INDICATI	Liver failure [ICD-11: DB99.7] Phase 1
	
TTDDRUID	D07SYY
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D07SYZ
DRUGNAME	RX-0201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D07SZJ
DRUGNAME	A-75169
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated
	
TTDDRUID	D07TAS
DRUGNAME	CI-959
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D07TBD
DRUGNAME	DT-2228
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D07TBJ
DRUGNAME	NuThrax
INDICATI	Anthrax [ICD-11: 1B97] Phase 2
	
TTDDRUID	D07TCS
DRUGNAME	CDP-6038
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D07TCV
DRUGNAME	Anti-CD19 anti-CD20 Bispecific CAR-T
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D07TDT
DRUGNAME	L-733560
INDICATI	Aspergillosis [ICD-11: 1F20] Terminated
	
TTDDRUID	D07TDV
DRUGNAME	Bendavia
INDICATI	Mitochondrial myopathy [ICD-11: 8C73] Phase 3
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 2
	
TTDDRUID	D07TEE
DRUGNAME	Gene therapy, mucopolysaccharidosis type I
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Investigative
	
TTDDRUID	D07TEP
DRUGNAME	SCH 420814
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D07TFL
DRUGNAME	Blosozumab
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D07TGN
DRUGNAME	Deslanoside
INDICATI	Heart failure [ICD-11: BD10-BD13] Approved
INDICATI	Arrhythmia [ICD-11: BC9Z] Approved
INDICATI	Congestive cardiac insufficiency [ICD-11: BD1Z] Approved
	
TTDDRUID	D07TGY
DRUGNAME	Indeloxazine
INDICATI	Dementia [ICD-11: 6D80-6D86] Approved
	
TTDDRUID	D07THJ
DRUGNAME	IPH-3102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D07TIX
DRUGNAME	TDI-0018
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D07TJM
DRUGNAME	PMID30784880-compound-6-5
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
	
TTDDRUID	D07TJT
DRUGNAME	Imilecleucel-T
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D07TKZ
DRUGNAME	BIOD-123
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D07TMJ
DRUGNAME	EGFRt/19-28z/4-1BBL CAR T cells
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	D07TMR
DRUGNAME	ISIS 23722
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D07TNU
DRUGNAME	DACTIMICIN
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D07TOK
DRUGNAME	Larotrectinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D07TPL
DRUGNAME	Ro-40-0655
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative
	
TTDDRUID	D07TQN
DRUGNAME	Asimadoline
INDICATI	Diarrhea-predominant irritable bowel syndrome [ICD-11: DD91.01] Phase 3
INDICATI	Pruritus [ICD-11: EC90] Phase 2
	
TTDDRUID	D07TQU
DRUGNAME	FibroStem
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Investigative
	
TTDDRUID	D07TQV
DRUGNAME	Lamivudine
INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Approved
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved
	
TTDDRUID	D07TRF
DRUGNAME	F18-florbetaben
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D07TRP
DRUGNAME	APTO-253
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07TRV
DRUGNAME	Anthrax vaccine
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Discontinued in Phase 1
	
TTDDRUID	D07TSS
DRUGNAME	MSC-100-IV
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
	
TTDDRUID	D07TSV
DRUGNAME	Atorvastatin
INDICATI	Hyperlipidemia [ICD-11: 5C80.Z] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D07TTI
DRUGNAME	AZD-8309
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D07TUD
DRUGNAME	PF-2391677
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1
	
TTDDRUID	D07TUT
DRUGNAME	ND-07
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D07TWK
DRUGNAME	TCN-P
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D07TWN
DRUGNAME	Tafenoquine
INDICATI	Plasmodium vivax malaria [ICD-11: 1F41] Approved
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D07TWZ
DRUGNAME	TDI-0053
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D07TXJ
DRUGNAME	Dextofisopam
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
	
TTDDRUID	D07TYE
DRUGNAME	GS-9857
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D07TYJ
DRUGNAME	PRO-98498
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D07TYM
DRUGNAME	Autologous T-lymphocyte cell therapy
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D07TYV
DRUGNAME	BAY1862864
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D07TZT
DRUGNAME	A-007
INDICATI	Skin cancer [ICD-11: 2C30-2C37] Phase 2
	
TTDDRUID	D07UAJ
DRUGNAME	CMB-401
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D07UAS
DRUGNAME	PEG arginine deiminase
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D07UBB
DRUGNAME	ITI-003
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D07UBG
DRUGNAME	Olmesartan medoxomil
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D07UBK
DRUGNAME	AS-1892802
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D07UBZ
DRUGNAME	Thiazoline derivative 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D07UDI
DRUGNAME	HO/04/08
INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative
	
TTDDRUID	D07UDO
DRUGNAME	DNX-3000
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07UDW
DRUGNAME	COG-112
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07UEJ
DRUGNAME	Empagli ozin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D07UFS
DRUGNAME	SPI-5557
INDICATI	Deafness [ICD-11: AB52] Investigative
	
TTDDRUID	D07UGA
DRUGNAME	Sphingosine-1-phosphate
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 1
	
TTDDRUID	D07UGI
DRUGNAME	PPS14 PCMV
INDICATI	Streptococcus infection [ICD-11: 1B53] Investigative
	
TTDDRUID	D07UHS
DRUGNAME	Fingolimod
INDICATI	Primary progressive multiple sclerosis [ICD-11: 8A40.1] Approved
	
TTDDRUID	D07UHX
DRUGNAME	9-AMINOCAMPTOTHECIN
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2
	
TTDDRUID	D07UHY
DRUGNAME	NIK-616
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated
	
TTDDRUID	D07UIS
DRUGNAME	CORT125281
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D07UJA
DRUGNAME	DRL-17822
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2
	
TTDDRUID	D07UKF
DRUGNAME	VBY-129
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D07UKJ
DRUGNAME	Enavatuzumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07UKT
DRUGNAME	ALRN-6924
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07ULK
DRUGNAME	OX-23
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D07ULS
DRUGNAME	DDG-39
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Terminated
	
TTDDRUID	D07UNH
DRUGNAME	Pyridine and pyrimidine derivative 1
INDICATI	Fibrosis [ICD-11: GA14-GC01] Patented
INDICATI	Pain [ICD-11: MG30-MG3Z] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D07UOS
DRUGNAME	MK-434
INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 1
	
TTDDRUID	D07UQQ
DRUGNAME	ACE-536
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
	
TTDDRUID	D07UQR
DRUGNAME	Keyhole limpet hemocyanin
INDICATI	Bladder cancer [ICD-11: 2C94] Discontinued in Phase 3
	
TTDDRUID	D07URD
DRUGNAME	PRX-102
INDICATI	Fabry disease [ICD-11: 5C56.01] Phase 1/2
	
TTDDRUID	D07URH
DRUGNAME	AP-004
INDICATI	Proctitis [ICD-11: DB33.Z] Investigative
	
TTDDRUID	D07USR
DRUGNAME	SAVX-1
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D07USV
DRUGNAME	MM-302
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D07UTC
DRUGNAME	QNL-111
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D07UUB
DRUGNAME	4SC-203
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07UWJ
DRUGNAME	Bromhexine
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Approved
	
TTDDRUID	D07UWV
DRUGNAME	Argatroban
INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved
	
TTDDRUID	D07UXF
DRUGNAME	AR19
INDICATI	Mental disease [ICD-11: 6E8Z] Phase 3
	
TTDDRUID	D07UXJ
DRUGNAME	Aom-0785
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D07UXP
DRUGNAME	Cinoxacin
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D07UYO
DRUGNAME	Linezolid
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07UZX
DRUGNAME	Nerve growth factor conjugated RAP peptide
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D07UZY
DRUGNAME	Lpathomab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07VAI
DRUGNAME	ALZ-801
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D07VAQ
DRUGNAME	MG-1109
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D07VBA
DRUGNAME	Estradiol Valerate
INDICATI	Hormone replacement therapy [ICD-11: 8E01] Approved
	
TTDDRUID	D07VDF
DRUGNAME	CXCR4 gene disrupted T cells
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D07VDZ
DRUGNAME	Topiramate
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
INDICATI	Seizure disorder [ICD-11: 8A6Z] Investigative
	
TTDDRUID	D07VFD
DRUGNAME	Mirogabalin
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Registered
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 3
INDICATI	Cancer related pain [ICD-11: MG30] Phase 3
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
	
TTDDRUID	D07VFQ
DRUGNAME	Six-membered heterocyclic benzamide derivative 3
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D07VHR
DRUGNAME	Phenylbutazone
INDICATI	Chronic pain [ICD-11: MG30] Approved
	
TTDDRUID	D07VHS
DRUGNAME	Isavuconazole
INDICATI	Invasive aspergillosis [ICD-11: 1F20.0] Phase 3
INDICATI	Invasive candidiasis [ICD-11: 1F23] Phase 3
INDICATI	Candidemia [ICD-11: 1F23.3Y] Phase 3
	
TTDDRUID	D07VHU
DRUGNAME	NIS793
INDICATI	Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D07VHX
DRUGNAME	Augmab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07VIB
DRUGNAME	Tecarfarin
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3
	
TTDDRUID	D07VIK
DRUGNAME	Arsenic trioxide
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
	
TTDDRUID	D07VJI
DRUGNAME	Hookworm vaccine
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D07VJK
DRUGNAME	IDN-6384
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07VKT
DRUGNAME	Ch14.18 mab
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 3
	
TTDDRUID	D07VLY
DRUGNAME	Doxorubicin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Tumour [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07VMC
DRUGNAME	LY-243062
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D07VNH
DRUGNAME	Acebilustat
INDICATI	Chronic blistering skin disorder [ICD-11: ME63.3] Phase 1
	
TTDDRUID	D07VOF
DRUGNAME	THA-904
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D07VPG
DRUGNAME	BW-773U82
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D07VQW
DRUGNAME	Sant7
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D07VRO
DRUGNAME	Benzalkonium chloride
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07VRP
DRUGNAME	EG-Mirotin
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative
	
TTDDRUID	D07VSA
DRUGNAME	KRX-0403
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D07VTD
DRUGNAME	HBV-MF59
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 2
	
TTDDRUID	D07VUD
DRUGNAME	ZD-3980
INDICATI	Prostate hyperplasia [ICD-11: GA90] Terminated
	
TTDDRUID	D07VWP
DRUGNAME	S-9947
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D07VXT
DRUGNAME	INCB8696
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1
	
TTDDRUID	D07VYO
DRUGNAME	Recombinant human alkaline phosphatase
INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative
	
TTDDRUID	D07VYP
DRUGNAME	FT-2102
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D07VZV
DRUGNAME	N-0861
INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3
	
TTDDRUID	D07WAF
DRUGNAME	Anti-Fas mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07WCB
DRUGNAME	Colchicine
INDICATI	Acute gout flare [ICD-11: FA25.0] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D07WCT
DRUGNAME	SAR-100842
INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 2
INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2
	
TTDDRUID	D07WDS
DRUGNAME	NNC-14-0189
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D07WDW
DRUGNAME	VR496
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D07WEN
DRUGNAME	Venglustat
INDICATI	Fabry disease [ICD-11: 5C56.01] Phase 2
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Phase 1
	
TTDDRUID	D07WEP
DRUGNAME	Diazoxide
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D07WEV
DRUGNAME	PMID26868298-compound-5705213
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D07WFK
DRUGNAME	Acetohexamide
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D07WFQ
DRUGNAME	VBP 926
INDICATI	Paronychia [ICD-11: 1F23.13] Phase 2
	
TTDDRUID	D07WGE
DRUGNAME	C-KAD
INDICATI	Cataract [ICD-11: 9B10] Phase 2
	
TTDDRUID	D07WGN
DRUGNAME	DP9
INDICATI	Myocardial ischemia [ICD-11: BA6Z] Phase 2
	
TTDDRUID	D07WGW
DRUGNAME	WJ-9708011
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D07WHN
DRUGNAME	FASORACETAM
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3
	
TTDDRUID	D07WHS
DRUGNAME	CL-316,243
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D07WJE
DRUGNAME	NVC-422
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2/3
	
TTDDRUID	D07WJU
DRUGNAME	SUVN-911
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
	
TTDDRUID	D07WLI
DRUGNAME	99mTc-fanolesomab
INDICATI	Appendicitis [ICD-11: DB10] Approved
	
TTDDRUID	D07WMD
DRUGNAME	MK-5478
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D07WMH
DRUGNAME	GT102-279
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Discontinued in Phase 2
	
TTDDRUID	D07WNG
DRUGNAME	Atrimer
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D07WON
DRUGNAME	Bronchostat
INDICATI	Bronchitis [ICD-11: CA20] Approved
	
TTDDRUID	D07WPE
DRUGNAME	Epothilon
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
	
TTDDRUID	D07WPQ
DRUGNAME	Oxycodone hydrochloride
INDICATI	Chronic pain [ICD-11: MG30] Application submitted
	
TTDDRUID	D07WQT
DRUGNAME	Ivermectin
INDICATI	Onchocerciasis [ICD-11: 1F6A] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D07WRW
DRUGNAME	LADIRUBICIN
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D07WSR
DRUGNAME	TS-032
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
	
TTDDRUID	D07WTG
DRUGNAME	Recombinant acidic fibroblast growth factor
INDICATI	Skin burns [ICD-11: ME65.0] Phase 3
	
TTDDRUID	D07WTH
DRUGNAME	UltraCD40L
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D07WUJ
DRUGNAME	H5N1 influenza vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D07WXE
DRUGNAME	L-alanyl-l-glutamine
INDICATI	Mucositis [ICD-11: CA00] Approved
	
TTDDRUID	D07WXH
DRUGNAME	Pandemrix
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D07WXI
DRUGNAME	Maribavir
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 3
	
TTDDRUID	D07WXQ
DRUGNAME	CKD-404
INDICATI	Growth failure [ICD-11: LD2F.1Y] Investigative
	
TTDDRUID	D07WYI
DRUGNAME	SPI-1620
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D07WYO
DRUGNAME	JI-3292
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D07WZH
DRUGNAME	Cephaloglycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07XAX
DRUGNAME	AEP-924
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated
	
TTDDRUID	D07XBA
DRUGNAME	PMID25684022-Compound-US20130053382 36(3-5)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D07XBE
DRUGNAME	Lentinan
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D07XBI
DRUGNAME	AVR118
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D07XBZ
DRUGNAME	ARC-200
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07XCF
DRUGNAME	Benfluorex
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Withdrawn from market
	
TTDDRUID	D07XCG
DRUGNAME	Apligraf
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved
	
TTDDRUID	D07XCQ
DRUGNAME	MDX-1414
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07XDQ
DRUGNAME	Figopitant
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D07XDS
DRUGNAME	Tomopenem
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D07XEV
DRUGNAME	WPP-201
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1
	
TTDDRUID	D07XGH
DRUGNAME	Pristinamycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D07XGR
DRUGNAME	Fenofibrate
INDICATI	High cholesterol level [ICD-11: 5C80.0] Approved
	
TTDDRUID	D07XGT
DRUGNAME	AM-577
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D07XHJ
DRUGNAME	TAN-950A
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D07XHO
DRUGNAME	Nafamostat
INDICATI	Pancreatitis [ICD-11: DC31-DC34] Approved
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2
	
TTDDRUID	D07XJJ
DRUGNAME	M118
INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 2
	
TTDDRUID	D07XJM
DRUGNAME	Dicyclomine
INDICATI	Functional bowel syndrome [ICD-11: DD91.0] Approved
	
TTDDRUID	D07XLA
DRUGNAME	GM04-001
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D07XMG
DRUGNAME	IFN-alpha 2B-XL
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2
	
TTDDRUID	D07XOV
DRUGNAME	EFT508
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D07XPE
DRUGNAME	Phenformin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Withdrawn from market
	
TTDDRUID	D07XPT
DRUGNAME	Ronacaleret
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2
	
TTDDRUID	D07XQS
DRUGNAME	ONC201
INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Phase 2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07XRU
DRUGNAME	Telmisartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D07XSD
DRUGNAME	SUN-13333
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D07XSN
DRUGNAME	Cytarabine
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
	
TTDDRUID	D07XVL
DRUGNAME	PMID25666693-Compound-119
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D07XVN
DRUGNAME	Dexrazoxane
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Chemoprotection [ICD-11: N.A.] Approved
INDICATI	Respiratory tract disease [ICD-11: CB7Z] Investigative
	
TTDDRUID	D07XVR
DRUGNAME	Sodium nitroprusside
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D07XXT
DRUGNAME	DEDN-6526A
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D07XYT
DRUGNAME	Medusa IL-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D07XYV
DRUGNAME	Bambuterol
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D07XZR
DRUGNAME	PMID25666693-Compound-134
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D07YAC
DRUGNAME	Anticalin
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D07YAR
DRUGNAME	NX-1207
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D07YCR
DRUGNAME	S-16020-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D07YDE
DRUGNAME	Nitroglycerin
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D07YDO
DRUGNAME	GTx-186
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07YEK
DRUGNAME	NV-52
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1
	
TTDDRUID	D07YGH
DRUGNAME	GSK239512
INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D07YGK
DRUGNAME	Vilaprisan
INDICATI	Endometriosis [ICD-11: GA10] Phase 2
	
TTDDRUID	D07YGQ
DRUGNAME	Anti-MUC1 AR20.5
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D07YHM
DRUGNAME	LY-2456302
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D07YHT
DRUGNAME	ENRASENTAN
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2
	
TTDDRUID	D07YHY
DRUGNAME	CR-2093
INDICATI	Intestine cancer [ICD-11: 2C0Z] Discontinued in Phase 1
	
TTDDRUID	D07YIX
DRUGNAME	NmVac4
INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 1
	
TTDDRUID	D07YJK
DRUGNAME	ShRNA apolipoprotein B100 gene siliencer
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D07YKJ
DRUGNAME	EVT-103
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1
	
TTDDRUID	D07YKQ
DRUGNAME	EPX-100
INDICATI	Dravet syndrome [ICD-11: 8A61.11] Phase 1
	
TTDDRUID	D07YLK
DRUGNAME	LE-300
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D07YLO
DRUGNAME	SDF-1
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D07YLV
DRUGNAME	Ciclesonide
INDICATI	Asthma [ICD-11: CA23] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D07YMP
DRUGNAME	TAB001
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07YNC
DRUGNAME	NCI-4650
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
	
TTDDRUID	D07YNH
DRUGNAME	SAN-61
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D07YNM
DRUGNAME	NN8765
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D07YOP
DRUGNAME	JBD-401
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07YPA
DRUGNAME	CGEN-920
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D07YPB
DRUGNAME	Hu-CART meso cells
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Peritoneal mesothelioma [ICD-11: 2C51.2] Phase 1
INDICATI	Pleural mesothelioma [ICD-11: 2C26.0] Phase 1
	
TTDDRUID	D07YPP
DRUGNAME	BreMel/TNF alpha
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D07YPV
DRUGNAME	AbelaDrug200
INDICATI	Head injury [ICD-11: NA00-NA0Z] Phase 1/2
	
TTDDRUID	D07YPW
DRUGNAME	Shigamabs
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
INDICATI	Haemolytic uraemic syndrome [ICD-11: 3A21.2] Phase 2
	
TTDDRUID	D07YRJ
DRUGNAME	AERAS-405
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D07YRV
DRUGNAME	AER-002
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D07YRW
DRUGNAME	ASP7991
INDICATI	Hyperparathyroidism [ICD-11: 5A51] Phase 2
	
TTDDRUID	D07YUH
DRUGNAME	HybriCell
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D07YUY
DRUGNAME	MDL-29311
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D07YVK
DRUGNAME	Sumanirole
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D07YVM
DRUGNAME	CLX-090700
INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical
	
TTDDRUID	D07YWY
DRUGNAME	Nafronyl
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved
	
TTDDRUID	D07YXD
DRUGNAME	HL-024
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07YZK
DRUGNAME	CAMI-103
INDICATI	Heart failure [ICD-11: BD10-BD13] Investigative
	
TTDDRUID	D07YZQ
DRUGNAME	Melanoma DNA vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D07ZAH
DRUGNAME	ACH-1625
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D07ZAK
DRUGNAME	RGX 501
INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 1/2
	
TTDDRUID	D07ZAO
DRUGNAME	OVI-123
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
	
TTDDRUID	D07ZBE
DRUGNAME	Iobitridol
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D07ZBO
DRUGNAME	ADepVac
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D07ZCK
DRUGNAME	ZK-93423
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 3
	
TTDDRUID	D07ZCU
DRUGNAME	BKT-120
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07ZDG
DRUGNAME	EDN-OL1
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D07ZES
DRUGNAME	T2CA
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative
	
TTDDRUID	D07ZGF
DRUGNAME	Biothrax
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Approved
	
TTDDRUID	D07ZHM
DRUGNAME	ATX-S10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07ZHV
DRUGNAME	CB1954
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D07ZJC
DRUGNAME	INOC-005
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D07ZKE
DRUGNAME	PMID25684022-Compound-US20120277229 45(1.5)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D07ZKK
DRUGNAME	131I-81C6
INDICATI	Brain cancer [ICD-11: 2A00] Terminated
	
TTDDRUID	D07ZMG
DRUGNAME	Thiazole carboxamide derivative 29
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D07ZMQ
DRUGNAME	HD-003
INDICATI	Kidney disease [ICD-11: GC2Z] Phase 2
	
TTDDRUID	D07ZNF
DRUGNAME	IMC-EB10
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D07ZNI
DRUGNAME	STX-140
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D07ZQS
DRUGNAME	Macrocycle derivative 9
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D07ZRI
DRUGNAME	Technetium Tc-99m Oxidronate Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D07ZSU
DRUGNAME	Freeze-dried bee venom
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
	
TTDDRUID	D07ZTB
DRUGNAME	HG-1068
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D07ZTD
DRUGNAME	MB-07811
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D07ZTO
DRUGNAME	Bethanechol
INDICATI	Urinary retention [ICD-11: MF50.3] Approved
	
TTDDRUID	D07ZUW
DRUGNAME	Nanoemulsion
INDICATI	Molluscum contagiosum infection [ICD-11: 1E76] Phase 2/3
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
	
TTDDRUID	D07ZUX
DRUGNAME	CR-3465
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1
	
TTDDRUID	D07ZUZ
DRUGNAME	CK-2127107
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 2
INDICATI	Muscle atrophy [ICD-11: FB32.Y] Phase 1
	
TTDDRUID	D07ZVO
DRUGNAME	PT1.2
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1
	
TTDDRUID	D07ZXE
DRUGNAME	Wetimicin
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D07ZZI
DRUGNAME	SLV-341
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D07ZZS
DRUGNAME	AGS-22ME
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D07ZZX
DRUGNAME	MDX-1110
INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
	
TTDDRUID	D08AAB
DRUGNAME	VLX600
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08AAV
DRUGNAME	AZD-3514
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D08ABQ
DRUGNAME	Acalabrutinib
INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D08ABX
DRUGNAME	CAR-T cells targeting CD34
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical
	
TTDDRUID	D08ADK
DRUGNAME	Glycoferon
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D08ADX
DRUGNAME	Clevudine
INDICATI	Hepatitis B [ICD-11: 1E51] phase 4
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D08AFD
DRUGNAME	NP-252
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D08AHH
DRUGNAME	LHW090
INDICATI	Kidney failure [ICD-11: GB6Z] Phase 2
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D08AJF
DRUGNAME	PI-0824
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D08ALK
DRUGNAME	Cisatracurium
INDICATI	Muscle spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D08ALQ
DRUGNAME	RPR-101821
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D08AMJ
DRUGNAME	TK-DLI
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Preregistration
	
TTDDRUID	D08AMQ
DRUGNAME	SB-234551
INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 1
	
TTDDRUID	D08ANE
DRUGNAME	Opdivo nivolumab +Yervoy ipilimumab
INDICATI	Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 2
	
TTDDRUID	D08ANF
DRUGNAME	Cerebral EDV
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D08ANJ
DRUGNAME	AP-30663
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 1/2
	
TTDDRUID	D08ANZ
DRUGNAME	Pembrolizumab
INDICATI	Melanoma [ICD-11: 2C30] Approved
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Cutaneous squamous cell carcinoma [ICD-11: 2C30] Phase 2
INDICATI	Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Application submitted
	
TTDDRUID	D08AOV
DRUGNAME	INO-1002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08AOZ
DRUGNAME	BMS-986142
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D08APZ
DRUGNAME	NT-100
INDICATI	Implantation failure [ICD-11: QB50] Phase 2
	
TTDDRUID	D08AWI
DRUGNAME	PRX-00023
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
	
TTDDRUID	D08AXM
DRUGNAME	VALERGENT-BT
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D08BBL
DRUGNAME	Iomab-B
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Phase 3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	D08BBU
DRUGNAME	GW-42003
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2
	
TTDDRUID	D08BCU
DRUGNAME	U-90042
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D08BDT
DRUGNAME	Halopredone acetate
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D08BEA
DRUGNAME	Ipamorelin
INDICATI	Postoperative ileus [ICD-11: DA91-DB30] Phase 1/2
	
TTDDRUID	D08BED
DRUGNAME	CERE-140
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D08BEO
DRUGNAME	Talampanel
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D08BIH
DRUGNAME	N-acylpyrrolidine ether derivative 2
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D08BIJ
DRUGNAME	IL-1 Monoclonal Antibody
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D08BIN
DRUGNAME	Munumbicins
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D08BKH
DRUGNAME	18-Methoxycoronaridine
INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Investigative
	
TTDDRUID	D08BKM
DRUGNAME	Porcine isophane insulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D08BLZ
DRUGNAME	Aryl mannoside derivative 23
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D08BMC
DRUGNAME	Olea europaea-containing vaccine
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3
	
TTDDRUID	D08BMO
DRUGNAME	Resveratrol
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D08BMV
DRUGNAME	PEG-hGH
INDICATI	Dwarfism [ICD-11: 5B11] Phase 2
	
TTDDRUID	D08BNB
DRUGNAME	Biaryl mannoside derivative 5
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D08BNJ
DRUGNAME	DTP-HepB-Polio-Hib
INDICATI	Pertussis [ICD-11: 1C12.Z] Phase 3
INDICATI	Tetanus [ICD-11: 1C13] Phase 3
INDICATI	Diphtheria [ICD-11: 1C17] Phase 3
	
TTDDRUID	D08BPD
DRUGNAME	EC-70124
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08BPS
DRUGNAME	JCAR017
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
INDICATI	Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Phase 1
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial
	
TTDDRUID	D08BQJ
DRUGNAME	Brain dendritic cell-based vaccine
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D08BTB
DRUGNAME	protirelin
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Approved
	
TTDDRUID	D08BTX
DRUGNAME	X-387
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08BVM
DRUGNAME	TTP-355
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D08BXT
DRUGNAME	Spermidine
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D08BYJ
DRUGNAME	WIN-902A
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D08BZZ
DRUGNAME	Omburtamab I-131
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2/3
INDICATI	Small round cell desmoplastic tumour [ICD-11: 2A20.5] Phase 1/2
	
TTDDRUID	D08CCC
DRUGNAME	AFP-Scan
INDICATI	Liver cancer [ICD-11: 2C12] Discontinued in Phase 2
	
TTDDRUID	D08CCE
DRUGNAME	Guaimesal
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D08CCF
DRUGNAME	IPX-159
INDICATI	Restless legs syndrome [ICD-11: 7A80] Discontinued in Phase 2
	
TTDDRUID	D08CDE
DRUGNAME	Celgosivir
INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 1/2
	
TTDDRUID	D08CDI
DRUGNAME	Lapatinib
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D08CEA
DRUGNAME	122-0551 foam
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
	
TTDDRUID	D08CEU
DRUGNAME	Recombinant Factor X
INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D08CGE
DRUGNAME	Integrin alpha 5/beta 1
INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative
	
TTDDRUID	D08CGG
DRUGNAME	VRC-EBOADV018-00-VP
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D08CGU
DRUGNAME	Bevacizumab + Rituximab
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3
	
TTDDRUID	D08CJM
DRUGNAME	Peptide YY 3-36
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D08CKJ
DRUGNAME	Fonsartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D08CLA
DRUGNAME	PMID25666693-Compound-123
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D08CLN
DRUGNAME	Suritozole
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D08CMF
DRUGNAME	Angeloxin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08CNP
DRUGNAME	AC430
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D08COR
DRUGNAME	ARC-520
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D08COU
DRUGNAME	FSH patch
INDICATI	Infertility [ICD-11: GB04] Phase 1
	
TTDDRUID	D08CPL
DRUGNAME	MIST-B03
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D08CPT
DRUGNAME	AC 137-164594
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
	
TTDDRUID	D08CQE
DRUGNAME	AVE-9940
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D08CQY
DRUGNAME	Brilacidin
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2
INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 2
	
TTDDRUID	D08CRO
DRUGNAME	PNH-192
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08CSE
DRUGNAME	IP-880
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
	
TTDDRUID	D08CSZ
DRUGNAME	HMR-3004
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D08CTT
DRUGNAME	Dimethindene
INDICATI	Respiratory allergy [ICD-11: 4A80] Approved
	
TTDDRUID	D08CUE
DRUGNAME	BI-661051
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08CVC
DRUGNAME	Tocofersolan
INDICATI	Vitamin E deficiency [ICD-11: 5B58] Phase 3
	
TTDDRUID	D08CVQ
DRUGNAME	Mipomersen
INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Approved
	
TTDDRUID	D08CWX
DRUGNAME	BVX-20-CD20
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative
	
TTDDRUID	D08CZE
DRUGNAME	Dihydropyrone
INDICATI	Hepatovirus infection [ICD-11: 1E51] Investigative
	
TTDDRUID	D08CZY
DRUGNAME	PMID28270021-Compound-WO2016054807Example71
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D08DBE
DRUGNAME	R-343
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D08DCP
DRUGNAME	BI-847325
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08DFF
DRUGNAME	AM-001
INDICATI	Dermatological disease [ICD-11: DA24.Y] Phase 2
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2
	
TTDDRUID	D08DFU
DRUGNAME	CMX-157
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D08DFX
DRUGNAME	Canagliflozin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 3
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D08DGC
DRUGNAME	CPL-7075
INDICATI	Diffuse systemic sclerosis [ICD-11: 4A42.1] Phase 3
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2
	
TTDDRUID	D08DGG
DRUGNAME	SnPP Protoporphyrin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D08DGW
DRUGNAME	CXL
INDICATI	Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Phase 2
	
TTDDRUID	D08DHN
DRUGNAME	VX-787
INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 3
	
TTDDRUID	D08DHR
DRUGNAME	EDP-22
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D08DIU
DRUGNAME	LN-144
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D08DJE
DRUGNAME	K-133W
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Investigative
	
TTDDRUID	D08DJH
DRUGNAME	Juvenile chondrocyte grafts
INDICATI	Contraception [ICD-11: QA21] Phase 2
	
TTDDRUID	D08DJP
DRUGNAME	AE-298p
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08DJV
DRUGNAME	TAK-195
INDICATI	Poliovirus infection [ICD-11: 1C8Y] Phase 1
	
TTDDRUID	D08DKA
DRUGNAME	Levcromakalim
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Preregistration
	
TTDDRUID	D08DMH
DRUGNAME	BAY2402234
INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 1
	
TTDDRUID	D08DMY
DRUGNAME	Bria-IMT
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D08DNA
DRUGNAME	PA-517
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D08DOE
DRUGNAME	ML-04
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D08DOQ
DRUGNAME	IGN301
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D08DPN
DRUGNAME	GSK-625433
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D08DPV
DRUGNAME	PRO-052
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative
	
TTDDRUID	D08DRU
DRUGNAME	Influenza A virus H5N1 cell culture-based vaccine
INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D08DSC
DRUGNAME	BST-1005
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D08DSF
DRUGNAME	MEDI-557
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1
	
TTDDRUID	D08DTD
DRUGNAME	Biostrophin
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1
	
TTDDRUID	D08DTR
DRUGNAME	RHPIV1 84/del/170/942A
INDICATI	Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1
	
TTDDRUID	D08DUF
DRUGNAME	GL-0817
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Oral cavity squamous cell carcinoma [ICD-11: 2B6E.0] Phase 2
	
TTDDRUID	D08DUY
DRUGNAME	T-1249
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D08DVE
DRUGNAME	BI-660848
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D08DWC
DRUGNAME	MSC2015103B
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08DWH
DRUGNAME	Idrapril
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D08DWM
DRUGNAME	Gp100:209-217(210M) peptide vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D08DZO
DRUGNAME	Malaria DNA vaccine
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2
	
TTDDRUID	D08DZZ
DRUGNAME	HE2100
INDICATI	Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 1
	
TTDDRUID	D08EAI
DRUGNAME	AS-101
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D08EAR
DRUGNAME	HE2200
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D08EBN
DRUGNAME	Nitazoxanide
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
	
TTDDRUID	D08ECB
DRUGNAME	LAS-101057
INDICATI	Asthma [ICD-11: CA23] Preclinical
	
TTDDRUID	D08ECW
DRUGNAME	Racotumomab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D08EDE
DRUGNAME	MIRNA-Rx07
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08EEM
DRUGNAME	PV-701
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08EEO
DRUGNAME	Demobesin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D08EES
DRUGNAME	XR-5000
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D08EEU
DRUGNAME	Englitazone sodium
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D08EGT
DRUGNAME	PMID25684022-Compound-WO2008005457
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D08EHL
DRUGNAME	Macrocycle derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D08EIK
DRUGNAME	LY3016859
INDICATI	Chronic kidney disease [ICD-11: GB61] Phase 1/2
	
TTDDRUID	D08EIX
DRUGNAME	T-686
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D08ELL
DRUGNAME	TBE-80E
INDICATI	Encephalitis virus infection [ICD-11: 1C83-1C84] Investigative
	
TTDDRUID	D08ELM
DRUGNAME	RWJ-58259
INDICATI	Artery stenosis [ICD-11: BD52] Terminated
	
TTDDRUID	D08ENB
DRUGNAME	GSK1995057
INDICATI	Adult respiratory distress syndrome [ICD-11: CB00] Phase 1
	
TTDDRUID	D08ENJ
DRUGNAME	Anti-CGEN-153 mab
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D08ENK
DRUGNAME	Insulin Susp Isophane Recombinant Human
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D08EOD
DRUGNAME	Methsuximide
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Approved
	
TTDDRUID	D08EOW
DRUGNAME	RG7112
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D08EPK
DRUGNAME	UBP-551
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D08EQD
DRUGNAME	FGF401
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D08EQQ
DRUGNAME	LPD-1050
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D08ESA
DRUGNAME	CI-966
INDICATI	Convulsion [ICD-11: 8A68.Z] Phase 1
	
TTDDRUID	D08EUS
DRUGNAME	CGC-11047
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D08EVF
DRUGNAME	Anti-Notch-1 mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08EVM
DRUGNAME	FR-128998
INDICATI	Thrombocytopenia [ICD-11: 3B64] Terminated
	
TTDDRUID	D08EVN
DRUGNAME	Tyropanoate sodium
INDICATI	Gallbladder disease [ICD-11: DC11.3] Approved
	
TTDDRUID	D08EWE
DRUGNAME	Plitidepsin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D08EWM
DRUGNAME	UCB-0942
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
INDICATI	Seizure disorder [ICD-11: 8A6Z] Phase 2
	
TTDDRUID	D08EYQ
DRUGNAME	ORE-1001
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1/2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D08FAC
DRUGNAME	CaCP-29
INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 2
	
TTDDRUID	D08FAT
DRUGNAME	RP-170
INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D08FDD
DRUGNAME	HL-4130
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D08FDX
DRUGNAME	MGCD265
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08FGX
DRUGNAME	PALOSURAN
INDICATI	Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2
	
TTDDRUID	D08FHP
DRUGNAME	BFKB8488A
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D08FHV
DRUGNAME	NY-008
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D08FHZ
DRUGNAME	ATL-313
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1/2
	
TTDDRUID	D08FIB
DRUGNAME	LY3316531
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D08FIX
DRUGNAME	OTSSP167
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Myeloproliferative neoplasm [ICD-11: 2A20] Phase 1
	
TTDDRUID	D08FJG
DRUGNAME	EHT/AGN-0002
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D08FJL
DRUGNAME	Carbetocin
INDICATI	Postpartum haemorrhage [ICD-11: JA43] Approved
	
TTDDRUID	D08FKD
DRUGNAME	Autologous renal cell carcinoma vaccine
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D08FKH
DRUGNAME	KLH-2109
INDICATI	Endometriosis [ICD-11: GA10] Phase 2
	
TTDDRUID	D08FKL
DRUGNAME	ACHN-975
INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 1
	
TTDDRUID	D08FKX
DRUGNAME	SDZ-MAR-327
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D08FMK
DRUGNAME	LY2944876
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D08FMR
DRUGNAME	ARC-1905
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
	
TTDDRUID	D08FNJ
DRUGNAME	RO-14
INDICATI	Phlebothrombosis [ICD-11: GB90.3] Phase 1
	
TTDDRUID	D08FOX
DRUGNAME	Piroximone
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Discontinued in Phase 3
	
TTDDRUID	D08FPM
DRUGNAME	Dhaq diacetate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D08FSD
DRUGNAME	SER-100
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D08FSR
DRUGNAME	QLT-091382
INDICATI	Sebaceous gland disease [ICD-11: EM0Z] Investigative
	
TTDDRUID	D08FTG
DRUGNAME	Phenindione
INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
INDICATI	Pulmonary embolism [ICD-11: BB00] Approved
	
TTDDRUID	D08FTP
DRUGNAME	99mTc-MIP-1404
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D08FUR
DRUGNAME	IMU-838
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D08FVH
DRUGNAME	4SCAR19/22 T cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D08FWJ
DRUGNAME	GSK3377794
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Synovial sarcoma [ICD-11: 2B5A] Phase 2
	
TTDDRUID	D08FWK
DRUGNAME	Oxypurinol
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2/3
	
TTDDRUID	D08FWO
DRUGNAME	Lixte-1.2
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D08FWW
DRUGNAME	Gammaplex
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D08FXE
DRUGNAME	MD-920
INDICATI	Wound healing [ICD-11: EL8Y] Phase 1
	
TTDDRUID	D08FXZ
DRUGNAME	RP-525
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08FYH
DRUGNAME	PF-04776548
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D08FZT
DRUGNAME	Corus 1030
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D08GAH
DRUGNAME	EV-075
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative
	
TTDDRUID	D08GBB
DRUGNAME	Valopicitabine dihydrochloride
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2
	
TTDDRUID	D08GBT
DRUGNAME	SAR-131675
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08GEX
DRUGNAME	TriGem
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2
	
TTDDRUID	D08GFN
DRUGNAME	MVA-BN Breast
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D08GHB
DRUGNAME	Fluvastatin
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
	
TTDDRUID	D08GHI
DRUGNAME	18F-AV-45 dimer
INDICATI	Cerebral amyloid angiopathy [ICD-11: 5D00.0] Investigative
	
TTDDRUID	D08GHX
DRUGNAME	TA-104
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D08GIH
DRUGNAME	NGR-hTNF
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 3
	
TTDDRUID	D08GIM
DRUGNAME	Elisidepsin
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D08GJH
DRUGNAME	Blonanserin
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D08GJO
DRUGNAME	Benorilate
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D08GKD
DRUGNAME	AZD-2315
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D08GKU
DRUGNAME	BriaVax
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D08GLH
DRUGNAME	DBP-118
INDICATI	Vomiting [ICD-11: MD90] Investigative
	
TTDDRUID	D08GLX
DRUGNAME	MDT-2004
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D08GNA
DRUGNAME	SKF-106610
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D08GNX
DRUGNAME	FPL-14294
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D08GNY
DRUGNAME	Lactococcus lactis anti-IL-27
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D08GOD
DRUGNAME	Tradipitant
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D08GOI
DRUGNAME	FT596
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D08GQK
DRUGNAME	WS-75624B
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D08GRF
DRUGNAME	LG-1550
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D08GRY
DRUGNAME	DUP 697
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1
	
TTDDRUID	D08GSC
DRUGNAME	KPE-02001003
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D08GSF
DRUGNAME	Proflavine
INDICATI	Sepsis [ICD-11: 1G40-1G41] Approved
	
TTDDRUID	D08GSM
DRUGNAME	AG-014
INDICATI	Coeliac disease [ICD-11: DA95] Investigative
	
TTDDRUID	D08GSX
DRUGNAME	MOR-104
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D08GUX
DRUGNAME	TD-4001
INDICATI	Bladder disease [ICD-11: DC11-DC1Z] Investigative
	
TTDDRUID	D08GUZ
DRUGNAME	Somatrem
INDICATI	Hormone deficiency [ICD-11: 5A61.1] Approved
	
TTDDRUID	D08GVB
DRUGNAME	AMR-001
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D08GYO
DRUGNAME	Procarbazine
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Approved
	
TTDDRUID	D08GZE
DRUGNAME	AbGn-107
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
	
TTDDRUID	D08GZJ
DRUGNAME	MK-2918
INDICATI	Migraine [ICD-11: 8A80] Investigative
	
TTDDRUID	D08GZX
DRUGNAME	PF-613322
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D08HDD
DRUGNAME	RP-58802B
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D08HDY
DRUGNAME	Pivmecillinam
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D08HES
DRUGNAME	MC-02331
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated
	
TTDDRUID	D08HFA
DRUGNAME	Y-27152
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D08HFW
DRUGNAME	TAK-901
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D08HGR
DRUGNAME	LLL-3348
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D08HGY
DRUGNAME	Naronapride
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2
	
TTDDRUID	D08HHT
DRUGNAME	Procervix
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2
	
TTDDRUID	D08HIH
DRUGNAME	ERB-196
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1
	
TTDDRUID	D08HJI
DRUGNAME	WT2527
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08HJT
DRUGNAME	Peplomycin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D08HKK
DRUGNAME	CD10-CART
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D08HKT
DRUGNAME	BEMORADAN
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D08HMK
DRUGNAME	ETC-276
INDICATI	Ischemia [ICD-11: 8B10-8B11] Discontinued in Phase 1
	
TTDDRUID	D08HNA
DRUGNAME	SMT-D001
INDICATI	Hypersalivation [ICD-11: DA04.6] Investigative
	
TTDDRUID	D08HOM
DRUGNAME	ABT-348
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2
	
TTDDRUID	D08HPZ
DRUGNAME	Tocilizumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
INDICATI	Juvenile idiopathic arthritis [ICD-11: FA24] Phase 3
	
TTDDRUID	D08HQI
DRUGNAME	ISIS-EIF4E
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D08HQK
DRUGNAME	Tetracaine
INDICATI	Spinal anesthesia [ICD-11: MB40.3] Approved
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D08HQT
DRUGNAME	ZK-005
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D08HRD
DRUGNAME	Plasmodium vivax vaccine
INDICATI	Plasmodium vivax malaria [ICD-11: 1F41] Phase 1/2
	
TTDDRUID	D08HRJ
DRUGNAME	Cyclizine
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D08HSS
DRUGNAME	LY3300054
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08HTF
DRUGNAME	JNJ-1930942
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D08HUB
DRUGNAME	ANG-2004
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D08HUC
DRUGNAME	Isoetharine
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D08HVD
DRUGNAME	NRLU-10
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1
	
TTDDRUID	D08HVE
DRUGNAME	Dimethyl Sulfoxide
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D08HVG
DRUGNAME	BAL-8557
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 3
	
TTDDRUID	D08HVR
DRUGNAME	Levodopa
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D08HWV
DRUGNAME	BGB-A317
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08HXB
DRUGNAME	Lopinavir + ritonavir + interferon beta
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D08HXG
DRUGNAME	PMX-60056
INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 2
	
TTDDRUID	D08HZC
DRUGNAME	Penicillamine
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D08HZL
DRUGNAME	Trimeprazine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D08HZN
DRUGNAME	ABC-4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08IAQ
DRUGNAME	ARC-AAT
INDICATI	Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Phase 1
	
TTDDRUID	D08IBS
DRUGNAME	Adenine
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D08ICT
DRUGNAME	PMID25666693-Compound-13
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D08ICX
DRUGNAME	Tofacitinib
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D08IDB
DRUGNAME	HuA33
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D08IDQ
DRUGNAME	BILA-2157BS
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D08IFG
DRUGNAME	Interferon-alpha dimers
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08IFL
DRUGNAME	Meclofenamic acid
INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Approved
INDICATI	Joint pain [ICD-11: ME82] Approved
	
TTDDRUID	D08IHF
DRUGNAME	A-74932
INDICATI	Lung cancer [ICD-11: 2C25.0] Terminated
	
TTDDRUID	D08IID
DRUGNAME	TNO155
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08IKV
DRUGNAME	58-1066
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08IMD
DRUGNAME	AZD-6495
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D08IMP
DRUGNAME	AAV-hAADC gene therapy
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D08INO
DRUGNAME	WX-UK1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2
	
TTDDRUID	D08IRG
DRUGNAME	BIIB 015
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08IRR
DRUGNAME	Org-10490
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D08IST
DRUGNAME	SB-509
INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Phase 2
	
TTDDRUID	D08IUW
DRUGNAME	VLI-03B
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative
	
TTDDRUID	D08IVF
DRUGNAME	BP1001
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D08IWD
DRUGNAME	Finasteride
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved
	
TTDDRUID	D08IXA
DRUGNAME	BQ788
INDICATI	Acute kidney injury [ICD-11: GB60] Phase 3
INDICATI	Encephalopathy [ICD-11: 8E47] Phase 3
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 3
INDICATI	Neuromyelitis optica [ICD-11: 8A43] Phase 3
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D08IYF
DRUGNAME	GSK-692342
INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 2
	
TTDDRUID	D08JAC
DRUGNAME	Fenretinide
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 3
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08JAH
DRUGNAME	TPM-001
INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Investigative
	
TTDDRUID	D08JAN
DRUGNAME	Cipatinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08JAP
DRUGNAME	Robalzotan
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D08JBL
DRUGNAME	PF-03446962
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D08JCA
DRUGNAME	Silver sulfadiazine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D08JCL
DRUGNAME	ONO-3805
INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 3
	
TTDDRUID	D08JEA
DRUGNAME	AKB-4924
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative
	
TTDDRUID	D08JGB
DRUGNAME	Otlertuzumab
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2
	
TTDDRUID	D08JGE
DRUGNAME	SonoLysis Prolyse
INDICATI	Cerebral ischemia [ICD-11: 8B11] Phase 2
	
TTDDRUID	D08JHG
DRUGNAME	ChimeriVax-Dengue
INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 2
	
TTDDRUID	D08JHY
DRUGNAME	AVM0703
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D08JHZ
DRUGNAME	BLD-2660
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D08JIP
DRUGNAME	Rintatolimod
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D08JIV
DRUGNAME	Amlodipine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D08JKK
DRUGNAME	RWJ-63556
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D08JLC
DRUGNAME	J-607Y
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D08JLH
DRUGNAME	Spartalizumab
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D08JLV
DRUGNAME	TH-337
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08JMI
DRUGNAME	ALN-VSP
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1
	
TTDDRUID	D08JML
DRUGNAME	Microxine
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D08JMO
DRUGNAME	Iron proteinsuccinylate
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved
	
TTDDRUID	D08JNE
DRUGNAME	RG1578
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D08JNG
DRUGNAME	Malonic acid
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D08JNI
DRUGNAME	MEDI5872
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D08JOE
DRUGNAME	ANA971
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1
	
TTDDRUID	D08JOY
DRUGNAME	Avrina
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 1/2
	
TTDDRUID	D08JPU
DRUGNAME	G6976
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08JRT
DRUGNAME	RhApo2L/TRAIL
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2
	
TTDDRUID	D08JSA
DRUGNAME	SB208
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2
INDICATI	Tinea pedis [ICD-11: 1F28.2] Phase 2
	
TTDDRUID	D08JSE
DRUGNAME	JNJ-42041935
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D08JSQ
DRUGNAME	DS-3032
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D08JTI
DRUGNAME	Anti-CD19/22-CAR vector-transduced T cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1/2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
INDICATI	Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2
	
TTDDRUID	D08JTN
DRUGNAME	AFM-20
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08JTU
DRUGNAME	R-944
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D08JUO
DRUGNAME	CR-4056
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D08JVS
DRUGNAME	NU-206
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 1
	
TTDDRUID	D08JWC
DRUGNAME	GS-9620
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D08JWJ
DRUGNAME	PF-1228305
INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 3
	
TTDDRUID	D08JWM
DRUGNAME	In-111-DAC imaging agent
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08JWY
DRUGNAME	PMID30107136-Compound-Example43
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D08JXR
DRUGNAME	HG-1202
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08JXW
DRUGNAME	INS-117548
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1
	
TTDDRUID	D08JYV
DRUGNAME	PSMA subunit vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D08JYW
DRUGNAME	CZ-ON002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08JZS
DRUGNAME	Mepyramine
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D08KAD
DRUGNAME	CYT-004-MelQbG10
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D08KBB
DRUGNAME	DT-310
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08KBK
DRUGNAME	Tedizolid
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Approved
	
TTDDRUID	D08KCA
DRUGNAME	Leupeptin
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D08KCJ
DRUGNAME	ABY-025
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
	
TTDDRUID	D08KCK
DRUGNAME	ART621
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1/2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1/2
	
TTDDRUID	D08KDK
DRUGNAME	T-2007
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
	
TTDDRUID	D08KDL
DRUGNAME	TES-23-NCS
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D08KDP
DRUGNAME	AS-8112
INDICATI	Vomiting [ICD-11: MD90] Terminated
	
TTDDRUID	D08KDU
DRUGNAME	PT-201
INDICATI	Urinary dysfunction [ICD-11: GC2Z] Phase 1
	
TTDDRUID	D08KEC
DRUGNAME	AG-NPN803
INDICATI	Nephritis [ICD-11: GB40] Investigative
	
TTDDRUID	D08KGY
DRUGNAME	PRX-302
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D08KHD
DRUGNAME	Leonurine
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative
	
TTDDRUID	D08KIB
DRUGNAME	SAR-114137
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D08KMU
DRUGNAME	Gca-186
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Clinical trial
	
TTDDRUID	D08KNG
DRUGNAME	VAN-10-4-eluting stent
INDICATI	Artery stenosis [ICD-11: BD52] Phase 1
	
TTDDRUID	D08KNK
DRUGNAME	MPL-containing Pollinex allergy desensitization vaccine
INDICATI	Allergy [ICD-11: 4A80-4A85] Preregistration
	
TTDDRUID	D08KOD
DRUGNAME	ISIS 15770
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08KPA
DRUGNAME	BZL-101
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D08KQK
DRUGNAME	PMID31244113-compound-2c
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D08KSU
DRUGNAME	AP12009
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
	
TTDDRUID	D08KSV
DRUGNAME	RG6146
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08KTO
DRUGNAME	AD04
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 1
	
TTDDRUID	D08KTQ
DRUGNAME	CJC-1295
INDICATI	Cachexia [ICD-11: MG20] Phase 2
	
TTDDRUID	D08KVK
DRUGNAME	CYT-009-GhrQb
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1/2
	
TTDDRUID	D08KVZ
DRUGNAME	Sibutramine
INDICATI	Obesity [ICD-11: 5B81] Approved
	
TTDDRUID	D08KWQ
DRUGNAME	Sn-117m-DTPA
INDICATI	Bone metastases [ICD-11: 2D50] Discontinued in Phase 2
	
TTDDRUID	D08KWV
DRUGNAME	NXT-1021
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D08KXC
DRUGNAME	SGX201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D08KXE
DRUGNAME	RP-67580
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D08KXO
DRUGNAME	CCP-020
INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Phase 3
	
TTDDRUID	D08KXX
DRUGNAME	JBD-411
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D08KYN
DRUGNAME	INNO-105
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08KYQ
DRUGNAME	Sulopenem
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 3
	
TTDDRUID	D08KZJ
DRUGNAME	CAY 10471
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D08KZM
DRUGNAME	CC49 humanized radioimmunoconjugates
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08KZR
DRUGNAME	BXL-746
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D08LAE
DRUGNAME	LGD-4033
INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Phase 1
	
TTDDRUID	D08LDB
DRUGNAME	GSK1265744
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D08LDG
DRUGNAME	Org-31433
INDICATI	Dementia [ICD-11: 6D80-6D86] Terminated
	
TTDDRUID	D08LDS
DRUGNAME	LUBELUZOLE
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Preregistration
	
TTDDRUID	D08LDV
DRUGNAME	PA-1050040
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D08LEY
DRUGNAME	Lanadelumab
INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Approved
	
TTDDRUID	D08LFX
DRUGNAME	MB-300
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D08LFZ
DRUGNAME	Diflunisal
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D08LHE
DRUGNAME	Prinoxodan
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Terminated
	
TTDDRUID	D08LIF
DRUGNAME	Propiram fumarate
INDICATI	Cancer related pain [ICD-11: MG30] Discontinued in Phase 3
	
TTDDRUID	D08LIU
DRUGNAME	Amooranin
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D08LJP
DRUGNAME	Rasburicase
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Approved
	
TTDDRUID	D08LJY
DRUGNAME	MB-312
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08LLB
DRUGNAME	Human CD19 targeted T Cells
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
	
TTDDRUID	D08LLM
DRUGNAME	NS-8
INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 1
	
TTDDRUID	D08LLR
DRUGNAME	UK-51656
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D08LMS
DRUGNAME	CG201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D08LQD
DRUGNAME	RESEQUINIL
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2
	
TTDDRUID	D08LQS
DRUGNAME	ETBX-021
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D08LRU
DRUGNAME	Disorazol Z-LHRH conjugates
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D08LRV
DRUGNAME	BGP-15
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D08LSA
DRUGNAME	SCY-524
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D08LTU
DRUGNAME	Minocycline
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
INDICATI	Rosacea [ICD-11: ED90.0] Phase 2
	
TTDDRUID	D08LUT
DRUGNAME	ABT-702
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D08LVF
DRUGNAME	Nitecapone
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D08LXJ
DRUGNAME	Heterologous liver cell therapy
INDICATI	Urea cycle disorder [ICD-11: 5C50.A] Phase 2
	
TTDDRUID	D08LYB
DRUGNAME	SB 239063
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D08LYZ
DRUGNAME	VesiGel
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
	
TTDDRUID	D08LZI
DRUGNAME	NS-220
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D08LZZ
DRUGNAME	DPO-1
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D08MAR
DRUGNAME	CP-230821
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D08MCC
DRUGNAME	NRX-101
INDICATI	Suicidal ideation [ICD-11: MB26.A] Phase 2
	
TTDDRUID	D08MCI
DRUGNAME	L1Q-001
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D08MCL
DRUGNAME	Recombinant human biglycan
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative
	
TTDDRUID	D08MCO
DRUGNAME	SPD-703
INDICATI	Otitis media [ICD-11: AA80-AB0Z] Terminated
	
TTDDRUID	D08MCS
DRUGNAME	ADS-5102
INDICATI	Dyskinesia [ICD-11: MB47.4] Phase 3
	
TTDDRUID	D08MCT
DRUGNAME	BMS-192548
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D08MDV
DRUGNAME	CT-3501
INDICATI	Coronary artery disease [ICD-11: BA80] Terminated
	
TTDDRUID	D08MDX
DRUGNAME	ED-001
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated
	
TTDDRUID	D08MEF
DRUGNAME	BAY-86-4884
INDICATI	Liver disease [ICD-11: DB90-BD99] Approved
	
TTDDRUID	D08MGU
DRUGNAME	SLIT TR-03
INDICATI	Lung cancer [ICD-11: 2C25.0] Preclinical
	
TTDDRUID	D08MHD
DRUGNAME	E-2609
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D08MHM
DRUGNAME	PF-3758309
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08MID
DRUGNAME	T-115
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08MIG
DRUGNAME	RPA-102
INDICATI	Anthrax [ICD-11: 1B97] Phase 2
	
TTDDRUID	D08MJO
DRUGNAME	CDP323
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D08MJX
DRUGNAME	R-56865
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D08MKR
DRUGNAME	DT388IL-3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D08MLG
DRUGNAME	CNI-H0294
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D08MLH
DRUGNAME	TUG-469
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D08MMP
DRUGNAME	ENDG-8010
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative
	
TTDDRUID	D08MOL
DRUGNAME	Anti-CMV mabs
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative
	
TTDDRUID	D08MPA
DRUGNAME	AMA-76
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
	
TTDDRUID	D08MRN
DRUGNAME	Hexylcaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D08MTA
DRUGNAME	Tetanolic acid
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D08MTG
DRUGNAME	Abafungin
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 3
	
TTDDRUID	D08MTN
DRUGNAME	Glucose analogue
INDICATI	Infection of P. falciparum [ICD-11: 1F40] Investigative
	
TTDDRUID	D08MUX
DRUGNAME	S33005
INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative
	
TTDDRUID	D08MVK
DRUGNAME	GCC-AP0341
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D08MVV
DRUGNAME	PRX-111
INDICATI	Female infertility [ICD-11: GA31.Z] Investigative
	
TTDDRUID	D08MVY
DRUGNAME	R-116712
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D08MXB
DRUGNAME	NCX-125
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D08MXP
DRUGNAME	LEE011
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D08MYF
DRUGNAME	Bio-Hep-B
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D08MYL
DRUGNAME	NIM-811
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D08MYO
DRUGNAME	LAG-078
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated
	
TTDDRUID	D08MYW
DRUGNAME	Human M-SAA3 peptide
INDICATI	Gastrointestinal infection [ICD-11: 1A40.Z] Investigative
	
TTDDRUID	D08NAB
DRUGNAME	Chymotrypsin
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D08NAD
DRUGNAME	Batabulin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3
	
TTDDRUID	D08NAI
DRUGNAME	SAR438584
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 3
	
TTDDRUID	D08NCO
DRUGNAME	Vanadate
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Application submitted
	
TTDDRUID	D08NDA
DRUGNAME	ISIS-HBV
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D08NDE
DRUGNAME	BLZ-945
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08NEM
DRUGNAME	BVRS-GamVac vaccine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1/2
	
TTDDRUID	D08NES
DRUGNAME	S-3536
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 1
	
TTDDRUID	D08NGV
DRUGNAME	PMID25553724-Compound-US2012820715110
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented
	
TTDDRUID	D08NHF
DRUGNAME	SR-11335
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D08NIN
DRUGNAME	NN-9926
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D08NJE
DRUGNAME	CR-845
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2/3
INDICATI	Chronic pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D08NJQ
DRUGNAME	TJ-8117
INDICATI	Nephritis [ICD-11: GB40] Discontinued in Phase 2
	
TTDDRUID	D08NLC
DRUGNAME	Cu64-CNND1-B
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D08NLN
DRUGNAME	Biolimus a9
INDICATI	Artery stenosis [ICD-11: BD52] Approved
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 3
	
TTDDRUID	D08NLQ
DRUGNAME	Licarbazepine
INDICATI	Bipolar disorder [ICD-11: 6A60] Discontinued in Phase 3
	
TTDDRUID	D08NMV
DRUGNAME	Ixekizumab
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3
	
TTDDRUID	D08NNR
DRUGNAME	Testosterone glucoside
INDICATI	Hypogonadism [ICD-11: 5A61.0] Discontinued in Phase 2
	
TTDDRUID	D08NNW
DRUGNAME	Boric acid
INDICATI	Otitis media [ICD-11: AA80-AB0Z] Approved
	
TTDDRUID	D08NPB
DRUGNAME	TO-195
INDICATI	Nephritis [ICD-11: GB40] Terminated
	
TTDDRUID	D08NPG
DRUGNAME	MBX-2044
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D08NQG
DRUGNAME	VB2-011
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D08NQZ
DRUGNAME	Tetracycline
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D08NRG
DRUGNAME	HYP-10
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D08NTD
DRUGNAME	Trappsol Cyclo
INDICATI	Niemann-pick disease [ICD-11: 5C56.0Y] Investigative
	
TTDDRUID	D08NTW
DRUGNAME	Antineoplaston A10 + antineoplaston AS2-2
INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D08NUS
DRUGNAME	XEL-005OP
INDICATI	Urinary tract disease [ICD-11: GC2Z] Investigative
	
TTDDRUID	D08NWC
DRUGNAME	Peginterferon alfa-2b
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved
	
TTDDRUID	D08NWF
DRUGNAME	crisaborole
INDICATI	Atopic dermatitis [ICD-11: EA80] Approved
	
TTDDRUID	D08NWY
DRUGNAME	ALS-2158
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D08NXP
DRUGNAME	ABBV-951
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D08NXW
DRUGNAME	GLP-1
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
	
TTDDRUID	D08NYL
DRUGNAME	AGN211745
INDICATI	Choroidal neovascularization [ICD-11: 9B76] Discontinued in Phase 2
	
TTDDRUID	D08NYO
DRUGNAME	PDGF gene therapy
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Investigative
	
TTDDRUID	D08NYZ
DRUGNAME	ASM-024
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D08NZG
DRUGNAME	Ifabotuzumab
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D08OAS
DRUGNAME	Flavimun
INDICATI	Yellow fever virus infection [ICD-11: 1D47] Discontinued in Preregistration
	
TTDDRUID	D08ODH
DRUGNAME	Atiratecan
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2
	
TTDDRUID	D08ODP
DRUGNAME	CSC-700008
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D08OES
DRUGNAME	NiCord
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 3
INDICATI	Sickle-cell anaemia [ICD-11: 3A51] Phase 1/2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1/2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
	
TTDDRUID	D08OGB
DRUGNAME	YourDex
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D08OHK
DRUGNAME	AKP-501
INDICATI	Female infertility [ICD-11: GA31.Z] Phase 1
	
TTDDRUID	D08OIT
DRUGNAME	Viroprev
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D08OJB
DRUGNAME	Benzoic acid linked peptide analog 4
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D08OJE
DRUGNAME	Femoxetine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 3
	
TTDDRUID	D08OJF
DRUGNAME	ICA-105665
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
	
TTDDRUID	D08OJU
DRUGNAME	SOU-001
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2
	
TTDDRUID	D08OKJ
DRUGNAME	Iron Dextran
INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved
	
TTDDRUID	D08OKW
DRUGNAME	Metalfullerene
INDICATI	Alopecia [ICD-11: ED70] Investigative
	
TTDDRUID	D08OLB
DRUGNAME	CH-5015765
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08OLR
DRUGNAME	ART-144
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D08OLU
DRUGNAME	AVP-5
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative
	
TTDDRUID	D08OMM
DRUGNAME	BL-1040
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2
	
TTDDRUID	D08ONJ
DRUGNAME	MPC-3100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08OOJ
DRUGNAME	CB-5083
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08OPS
DRUGNAME	ATYR 1940
INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 1/2
	
TTDDRUID	D08OPW
DRUGNAME	ARRY-575
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08OPX
DRUGNAME	4SC-205
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D08OQQ
DRUGNAME	Lavoltidine
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2
	
TTDDRUID	D08ORO
DRUGNAME	OPC-21268
INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2
	
TTDDRUID	D08ORV
DRUGNAME	AZD-4992
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1
	
TTDDRUID	D08OTE
DRUGNAME	RO-4995819
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D08OUL
DRUGNAME	EGT-0001474
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D08OUU
DRUGNAME	Genevx
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D08OUV
DRUGNAME	CHF-4227
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1
	
TTDDRUID	D08OVG
DRUGNAME	CKD-516
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08OVR
DRUGNAME	AMG 357
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D08OWA
DRUGNAME	NVC-704
INDICATI	Conjunctivitis [ICD-11: 9A60] Investigative
	
TTDDRUID	D08OWW
DRUGNAME	SLP-0906
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D08OXC
DRUGNAME	INDUS-82030
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D08OXD
DRUGNAME	Mannoside derivative 8
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D08OXU
DRUGNAME	IMO-3100
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D08OYF
DRUGNAME	Ad/PSA
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D08PAV
DRUGNAME	CDP-860
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D08PBB
DRUGNAME	L-694,458
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D08PBQ
DRUGNAME	Pancreas algenpantucel-L
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
	
TTDDRUID	D08PCE
DRUGNAME	Oxantel pamoate
INDICATI	Trichuris trichiura infection [ICD-11: 1F6G] Approved
	
TTDDRUID	D08PCH
DRUGNAME	Javelin
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D08PCR
DRUGNAME	CM3.1-AC100
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D08PFA
DRUGNAME	Rivoglitazone
INDICATI	Ocular inflammation [ICD-11: 9C61.24] Phase 3
	
TTDDRUID	D08PGC
DRUGNAME	Andolast
INDICATI	Rhinitis [ICD-11: FA20] Phase 3
	
TTDDRUID	D08PHD
DRUGNAME	DR-5001
INDICATI	Adenovirus infection [ICD-11: 1A20] Phase 3
	
TTDDRUID	D08PIE
DRUGNAME	Brigatinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
INDICATI	Anaplastic large cell lymphoma [ICD-11: 2A90.A] Approved
	
TTDDRUID	D08PIJ
DRUGNAME	JTV-506
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D08PIK
DRUGNAME	11C-GSK-215083
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1
	
TTDDRUID	D08PIQ
DRUGNAME	Methylprednisolone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative
	
TTDDRUID	D08PKF
DRUGNAME	AMI-HS
INDICATI	Liver disease [ICD-11: DB90-BD99] Discontinued in Phase 1
	
TTDDRUID	D08PKG
DRUGNAME	LY2541546
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D08PKI
DRUGNAME	EV-077
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D08PLK
DRUGNAME	Fremanezumab
INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Approved
	
TTDDRUID	D08PMB
DRUGNAME	Imeglimin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D08PMW
DRUGNAME	BMS-223131
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 2
	
TTDDRUID	D08PNQ
DRUGNAME	Trombodipine
INDICATI	Platelet aggregation disorder [ICD-11: 3B62] Discontinued in Phase 2
	
TTDDRUID	D08PNW
DRUGNAME	JPH-101
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Investigative
	
TTDDRUID	D08POF
DRUGNAME	ALX-0081
INDICATI	Thrombotic thrombocytopenic purpura [ICD-11: 3B64.14] Phase 3
INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 2
	
TTDDRUID	D08POH
DRUGNAME	Invaplex 50
INDICATI	Shigella infection [ICD-11: 1A02] Phase 1/2
	
TTDDRUID	D08PRP
DRUGNAME	IMGX003
INDICATI	Coeliac disease [ICD-11: DA95] Phase 2
	
TTDDRUID	D08PSC
DRUGNAME	BI 860585
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08PSI
DRUGNAME	H5N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D08PSU
DRUGNAME	Lmw heparin
INDICATI	Hematologic disease [ICD-11: 3C0Z] Approved
INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
	
TTDDRUID	D08PSV
DRUGNAME	CIGB-428
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Investigative
	
TTDDRUID	D08PUW
DRUGNAME	BAICALIN
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D08PVL
DRUGNAME	Ibulocydine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08PXL
DRUGNAME	MK-8457
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D08PXM
DRUGNAME	MDX-214
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 1/2
	
TTDDRUID	D08PXR
DRUGNAME	ABT-761
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D08PYC
DRUGNAME	AL-38583
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2
	
TTDDRUID	D08PYO
DRUGNAME	KW-2478
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D08PYQ
DRUGNAME	EDL-2000
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D08PZF
DRUGNAME	Liposomal disintergrin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08QAC
DRUGNAME	Ferumoxides
INDICATI	Liver cancer [ICD-11: 2C12] Approved
INDICATI	Liver disease [ICD-11: DB90-BD99] Approved
	
TTDDRUID	D08QAN
DRUGNAME	BVRS-GamVac-Combi vaccine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1/2
	
TTDDRUID	D08QCJ
DRUGNAME	Thiabendazole
INDICATI	Helminth infection [ICD-11: 1F90.0] Approved
INDICATI	Dutch elm disease [ICD-11: 8D64] Approved
	
TTDDRUID	D08QDB
DRUGNAME	KSI-4088
INDICATI	Nematode infection [ICD-11: 1F60-1F69] Investigative
	
TTDDRUID	D08QDF
DRUGNAME	Systebryl
INDICATI	Amyloidosis [ICD-11: 5D00] Phase 1
	
TTDDRUID	D08QED
DRUGNAME	TAK-850
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
	
TTDDRUID	D08QEF
DRUGNAME	CEP-37250
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08QGD
DRUGNAME	Ammonium lactate
INDICATI	Dermatological disease [ICD-11: DA24.Y] Approved
	
TTDDRUID	D08QGE
DRUGNAME	SI-614
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3
	
TTDDRUID	D08QGT
DRUGNAME	GDC0941
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D08QHJ
DRUGNAME	UPAR-lock
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08QHS
DRUGNAME	DG041
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2
	
TTDDRUID	D08QHX
DRUGNAME	PRX00933
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D08QIP
DRUGNAME	Pranlukast
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D08QJD
DRUGNAME	IGN-311
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D08QJS
DRUGNAME	Carbazochrome salicylate
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
	
TTDDRUID	D08QKJ
DRUGNAME	Stanozolol
INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Approved
	
TTDDRUID	D08QKY
DRUGNAME	IXS-312
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D08QLL
DRUGNAME	AG-NDT802
INDICATI	Cough [ICD-11: MD12] Investigative
	
TTDDRUID	D08QLM
DRUGNAME	Merimepodib
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2b
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D08QME
DRUGNAME	Ethambutol
INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Approved
	
TTDDRUID	D08QMX
DRUGNAME	Estradiol
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D08QPJ
DRUGNAME	MBI-2401
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D08QRE
DRUGNAME	MB-11319
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D08QRO
DRUGNAME	BL-6020
INDICATI	Cachexia [ICD-11: MG20] Investigative
	
TTDDRUID	D08QRT
DRUGNAME	99mTc-siboroxime
INDICATI	Diagnostic imaging [ICD-11: N.A.] Investigative
	
TTDDRUID	D08QTK
DRUGNAME	Anti-EGFL7
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D08QTP
DRUGNAME	BMS-433771
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Terminated
	
TTDDRUID	D08QUC
DRUGNAME	OT-121
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D08QUV
DRUGNAME	Amineptine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Withdrawn from market
	
TTDDRUID	D08QVM
DRUGNAME	NU-400
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D08QWQ
DRUGNAME	bimatoprost (free acid form)
INDICATI	Alzheimer disease [ICD-11: 8A20] Clinical trial
	
TTDDRUID	D08QXE
DRUGNAME	HP-161
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08QYJ
DRUGNAME	SORETOLIDE
INDICATI	Convulsion [ICD-11: 8A68.Z] Terminated
	
TTDDRUID	D08QYL
DRUGNAME	ISV-102
INDICATI	Ocular infection [ICD-11: 1F00.1] Investigative
	
TTDDRUID	D08QYS
DRUGNAME	Heat shock protein vaccine
INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 2
	
TTDDRUID	D08QYW
DRUGNAME	CAR-T Cells targeting EpCAM
INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 1/2
INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1/2
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D08QZH
DRUGNAME	Anti-HER2 CAR-T
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D08RAK
DRUGNAME	Japanese cedar pollen allergy sublingual immunotherapy
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D08RBC
DRUGNAME	Escitalopram
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
	
TTDDRUID	D08RBS
DRUGNAME	WX-037
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08RBV
DRUGNAME	Autologous dendritic cell vaccine, St Anna Children's Hospital
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D08RBW
DRUGNAME	LY900014
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D08RCI
DRUGNAME	CRTX-072
INDICATI	Cough [ICD-11: MD12] Investigative
	
TTDDRUID	D08RCV
DRUGNAME	Pyrido[2,3-d]pyrimidine derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D08RDB
DRUGNAME	Polyamine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D08RDC
DRUGNAME	R-765
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D08RDD
DRUGNAME	PF-06823859
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Dermatomycosis [ICD-11: EA60] Phase 2
INDICATI	Lupus [ICD-11: 4A40] Phase 1
	
TTDDRUID	D08RDG
DRUGNAME	PBI-4419
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D08RET
DRUGNAME	PMID30107136-Compound-Example47
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D08RFA
DRUGNAME	TAK-816
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Application submitted
	
TTDDRUID	D08RFZ
DRUGNAME	RSV mAb
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2/3
	
TTDDRUID	D08RGA
DRUGNAME	AZD6370
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D08RGH
DRUGNAME	ChAdOx1 MERS001 vaccine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1
	
TTDDRUID	D08RHR
DRUGNAME	Optaflu
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D08RHU
DRUGNAME	Cissampeline
INDICATI	Skeletal muscle relaxant [ICD-11: NE60] Approved
	
TTDDRUID	D08RIB
DRUGNAME	Edetate disodium
INDICATI	Heart arrhythmia [ICD-11: BC65] Approved
	
TTDDRUID	D08RID
DRUGNAME	MK-8616
INDICATI	Poison intoxication [ICD-11: NE6Z] Approved
	
TTDDRUID	D08RIL
DRUGNAME	GKT-03
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D08RJM
DRUGNAME	SD-101
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
INDICATI	Skin disease [ICD-11: EA00-EM0Z] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2
INDICATI	Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 1/2
	
TTDDRUID	D08RJY
DRUGNAME	Anti-EGFRvIII CAR transduced PBL
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1/2
INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1/2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
	
TTDDRUID	D08RKZ
DRUGNAME	IN0-3106
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1
	
TTDDRUID	D08RMH
DRUGNAME	APC-2059
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
	
TTDDRUID	D08RMJ
DRUGNAME	GSK461364
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08ROP
DRUGNAME	Leflunomide
INDICATI	Arthritis [ICD-11: FA20] Approved
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
	
TTDDRUID	D08ROQ
DRUGNAME	S-25585
INDICATI	Eating disorder [ICD-11: 6B82] Investigative
	
TTDDRUID	D08RPV
DRUGNAME	IDM-4
INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1/2
	
TTDDRUID	D08RQE
DRUGNAME	DepoVax
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Investigative
	
TTDDRUID	D08RSL
DRUGNAME	Genz-644470
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 2
	
TTDDRUID	D08RUN
DRUGNAME	2-Bromopalmitate
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D08RUW
DRUGNAME	PD-176931
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical
	
TTDDRUID	D08RUX
DRUGNAME	Z-321
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1
	
TTDDRUID	D08RWO
DRUGNAME	CAB-ROR2-ADC
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D08RXW
DRUGNAME	MT-062
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D08RYN
DRUGNAME	RQ-00202730
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D08RZV
DRUGNAME	HSR-609
INDICATI	Rhinitis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D08SAO
DRUGNAME	ZN-1014
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D08SAX
DRUGNAME	DB-772d
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D08SCL
DRUGNAME	MK-3697
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2
	
TTDDRUID	D08SCQ
DRUGNAME	Poractant alfa
INDICATI	Respiratory distress syndrome [ICD-11: CB00] Approved
	
TTDDRUID	D08SDI
DRUGNAME	House dust mite allergy vaccine
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1
	
TTDDRUID	D08SEI
DRUGNAME	Levocabastine
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved
	
TTDDRUID	D08SGE
DRUGNAME	M7583
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D08SHE
DRUGNAME	SEP-228432
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1
	
TTDDRUID	D08SHI
DRUGNAME	SG-1311
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative
	
TTDDRUID	D08SHM
DRUGNAME	NB-007
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D08SIC
DRUGNAME	BDB001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D08SIF
DRUGNAME	Milatuzumab
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D08SIR
DRUGNAME	CL-314698
INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D08SIT
DRUGNAME	NKP-1339
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08SJT
DRUGNAME	Sarilumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D08SJY
DRUGNAME	MRX34
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1
	
TTDDRUID	D08SJZ
DRUGNAME	Ibandronate
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D08SKH
DRUGNAME	Methoxsalen
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
	
TTDDRUID	D08SMN
DRUGNAME	POP-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08SNL
DRUGNAME	JTC-801
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D08SNT
DRUGNAME	Heteroaryl-carboxamide derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D08SNX
DRUGNAME	V-11294A
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D08SOF
DRUGNAME	Terfenadine
INDICATI	Allergy [ICD-11: 4A80-4A85] Withdrawn from market
	
TTDDRUID	D08SPH
DRUGNAME	Eculizumab
INDICATI	Neuromyelitis optica [ICD-11: 8A43] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D08SPP
DRUGNAME	TG-44
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Investigative
	
TTDDRUID	D08SSO
DRUGNAME	CNSB-006
INDICATI	Arthralgia [ICD-11: ME82] Investigative
	
TTDDRUID	D08SSP
DRUGNAME	Lersivirine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D08STA
DRUGNAME	CAL-203
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D08SUQ
DRUGNAME	ES-285
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D08SVH
DRUGNAME	Tacalcitol
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
	
TTDDRUID	D08SXS
DRUGNAME	Polyflu
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D08SXV
DRUGNAME	DWP-422
INDICATI	Arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D08SZO
DRUGNAME	F-12458
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08SZP
DRUGNAME	TA-103
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08TAB
DRUGNAME	XL-499
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D08TBK
DRUGNAME	Opdivo + Yervoynivolumab + ipilimumab
INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 3
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	D08TCU
DRUGNAME	GT-4001
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D08TDK
DRUGNAME	ANA-011
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08TEJ
DRUGNAME	Clascoterone
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D08TGG
DRUGNAME	Insulin transdermal
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1
	
TTDDRUID	D08TIA
DRUGNAME	IC-200214
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D08TJM
DRUGNAME	Binodenoson
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3
	
TTDDRUID	D08TKV
DRUGNAME	SKF-97426
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D08TLI
DRUGNAME	E-4716
INDICATI	Respiratory disease [ICD-11: CB40] Phase 2
	
TTDDRUID	D08TNG
DRUGNAME	RG7775
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D08TPH
DRUGNAME	TC-5653
INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Investigative
	
TTDDRUID	D08TPS
DRUGNAME	Epidermal growth factor
INDICATI	Vulnerary [ICD-11: ND56.Z] Approved
INDICATI	Wound healing [ICD-11: EL8Y] Phase 2
	
TTDDRUID	D08TQK
DRUGNAME	NM-9405
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D08TQP
DRUGNAME	INX-189
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D08TRG
DRUGNAME	AZD-3241
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D08TRM
DRUGNAME	ChAdOx1 MERS002 vaccine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1
	
TTDDRUID	D08TRX
DRUGNAME	CST-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08TVI
DRUGNAME	HPP-854
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D08TXL
DRUGNAME	A-796260
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D08TYK
DRUGNAME	GLS-5300 vaccine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1/2
	
TTDDRUID	D08TZZ
DRUGNAME	Oleuropein
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D08UAT
DRUGNAME	DPS-151
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D08UDB
DRUGNAME	GSK-2263167
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D08UDE
DRUGNAME	Peptide-conjugated phosphorodiamidate morpholino oligomers
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D08UDF
DRUGNAME	PIBAXIZINE
INDICATI	Spasm [ICD-11: MB47.3] Discontinued in Phase 2
	
TTDDRUID	D08UDG
DRUGNAME	MEDI4276
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08UDZ
DRUGNAME	MK-6105
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D08UEC
DRUGNAME	PMID25666693-Compound-135
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D08UEJ
DRUGNAME	Ajinomoto 2
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D08UGB
DRUGNAME	VRX806
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D08UGJ
DRUGNAME	Vincamine
INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Approved
	
TTDDRUID	D08UGS
DRUGNAME	JNJ 63723283
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D08UGX
DRUGNAME	LIAROZOLE
INDICATI	Dermatological disease [ICD-11: DA24.Y] Phase 2/3
	
TTDDRUID	D08UHC
DRUGNAME	PMA-104R
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08UHN
DRUGNAME	Irtemazole
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2
	
TTDDRUID	D08UHV
DRUGNAME	AMG 780
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08UJH
DRUGNAME	Toca 511 + Toca FC combination
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D08ULI
DRUGNAME	Org-4094
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D08UMH
DRUGNAME	Methylphenobarbital
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D08UMZ
DRUGNAME	STD-07
INDICATI	Constipation [ICD-11: DD91.1] Phase 1/2
	
TTDDRUID	D08UNC
DRUGNAME	GPC3 targeting CAR-T cells
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
INDICATI	Lung squamous cell carcinoma [ICD-11: 2C25.2] Phase 1
	
TTDDRUID	D08UNQ
DRUGNAME	NSD-644
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1
	
TTDDRUID	D08UOY
DRUGNAME	Vadimezan
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D08UQC
DRUGNAME	Oshadi R
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D08UQS
DRUGNAME	MEM-1003
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 2a
INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 2
	
TTDDRUID	D08USJ
DRUGNAME	Neostigmine
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Approved
	
TTDDRUID	D08USU
DRUGNAME	Ticarcillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D08UUD
DRUGNAME	R-1663
INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 1
	
TTDDRUID	D08UUK
DRUGNAME	Rostafuroxin
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D08UUL
DRUGNAME	LY2606368
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
INDICATI	Squamous cell anal carcinoma [ICD-11: 2C00.3] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08UVN
DRUGNAME	Anti-CEA CAR-T cells
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D08UVZ
DRUGNAME	E004
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D08UXQ
DRUGNAME	FHT-1106
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative
	
TTDDRUID	D08UYM
DRUGNAME	ONO-2333Ms
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D08UZA
DRUGNAME	Chitosan/IL-12
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D08UZD
DRUGNAME	Viraplex
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D08UZL
DRUGNAME	TMPyP4
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D08UZP
DRUGNAME	MPL-containing Pollinex allergy desensitization vaccine
INDICATI	Angina pectoris [ICD-11: BA40] Phase 3
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D08VAR
DRUGNAME	APH-0812
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D08VBV
DRUGNAME	TAP311
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 1
	
TTDDRUID	D08VDJ
DRUGNAME	IDN-13389
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08VDM
DRUGNAME	AZD4694
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D08VDV
DRUGNAME	PMID30107136-Compound-Example15
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D08VFX
DRUGNAME	Full-length Factor VIII molecule
INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D08VGS
DRUGNAME	Recombinant protein subunit vaccine  (seasonal influenza)
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Terminated
	
TTDDRUID	D08VGT
DRUGNAME	BMY-30129
INDICATI	Pruritus [ICD-11: EC90] Discontinued in Phase 2
	
TTDDRUID	D08VHG
DRUGNAME	RPL-554
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D08VIS
DRUGNAME	AKB-9778
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	D08VJC
DRUGNAME	PSMA ADC
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D08VJI
DRUGNAME	F-14413
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D08VKQ
DRUGNAME	INGN-007
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D08VKZ
DRUGNAME	Edaglitazone
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D08VLN
DRUGNAME	CAT-2000
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative
	
TTDDRUID	D08VMO
DRUGNAME	JTT-811
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D08VMW
DRUGNAME	MP-529
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08VRM
DRUGNAME	RO-0534
INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative
	
TTDDRUID	D08VRO
DRUGNAME	Ketanserin
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D08VRQ
DRUGNAME	EVIRNA
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08VRX
DRUGNAME	GHRP-2
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved
	
TTDDRUID	D08VSI
DRUGNAME	Revolade/Promacta
INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Approved
INDICATI	Chronic liver disease [ICD-11: DB99.0] Phase 3
INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 2
	
TTDDRUID	D08VSQ
DRUGNAME	BMS-816336
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 1
	
TTDDRUID	D08VTA
DRUGNAME	EXP-6803
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D08VTV
DRUGNAME	PMID28350212-Compound-7
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Patented
	
TTDDRUID	D08VUJ
DRUGNAME	ABT-202
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1
	
TTDDRUID	D08VVI
DRUGNAME	AR-54
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08VVR
DRUGNAME	TY-51924
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
	
TTDDRUID	D08VWF
DRUGNAME	GSK-932121A
INDICATI	Malaria [ICD-11: 1F40-1F45] Preclinical
	
TTDDRUID	D08VWJ
DRUGNAME	TD-1770
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D08VWK
DRUGNAME	Vaxchora
INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Phase 3
	
TTDDRUID	D08VWL
DRUGNAME	BRL-42715
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D08VWM
DRUGNAME	QUAN-0806
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative
	
TTDDRUID	D08VWO
DRUGNAME	LFF571
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2
	
TTDDRUID	D08VXD
DRUGNAME	CGF166
INDICATI	Deafness [ICD-11: AB52] Phase 1/2
	
TTDDRUID	D08VXL
DRUGNAME	Molsidomine
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D08VXO
DRUGNAME	Brompheniramine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D08VYC
DRUGNAME	Phosphate
INDICATI	Constipation [ICD-11: DD91.1] Approved
	
TTDDRUID	D08VYV
DRUGNAME	Metoclopramide
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D08VZH
DRUGNAME	ESS
INDICATI	Burn and burn infection [ICD-11: ND90-NE2Z] Phase 2
	
TTDDRUID	D08WAN
DRUGNAME	Lu-AF11167
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 1
	
TTDDRUID	D08WBF
DRUGNAME	BB-3644
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D08WBJ
DRUGNAME	KOS-2187
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 1
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 1
	
TTDDRUID	D08WCU
DRUGNAME	BMS-180448
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D08WCY
DRUGNAME	Seysara
INDICATI	Acne vulgaris [ICD-11: ED80] Application submitted
	
TTDDRUID	D08WDH
DRUGNAME	HXTC-901
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative
	
TTDDRUID	D08WDP
DRUGNAME	AM-3840
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D08WDT
DRUGNAME	VDA, HIV-1
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D08WFH
DRUGNAME	DNA-HIV-C/NYVAC-HIV-C
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D08WGI
DRUGNAME	AK-2
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D08WGZ
DRUGNAME	TS-033
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D08WHX
DRUGNAME	AGS-348
INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Phase 1
	
TTDDRUID	D08WII
DRUGNAME	Anti-MUC1 CAR T Cells
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D08WLY
DRUGNAME	ME-401
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D08WNO
DRUGNAME	GGF
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 1b
	
TTDDRUID	D08WOE
DRUGNAME	MC-3002
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Preclinical
	
TTDDRUID	D08WOJ
DRUGNAME	OBE-101
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D08WOW
DRUGNAME	LY3039478
INDICATI	T-cell acute lymphoblastic leukaemia [ICD-11: 2A90.5] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D08WQH
DRUGNAME	BI 1361849
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D08WQU
DRUGNAME	AEB1102
INDICATI	Arginase 1 deficiency [ICD-11: 5C50.A2] Phase 2
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D08WSG
DRUGNAME	AZD-8683
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D08WSW
DRUGNAME	BRL-32872A
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2
	
TTDDRUID	D08WSY
DRUGNAME	Denosumab
INDICATI	Postmenopausal osteoporosis [ICD-11: FB83.11] Approved
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D08WTE
DRUGNAME	Vorsetuzumab mafodotin
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Discontinued in Phase 1
	
TTDDRUID	D08WTW
DRUGNAME	Pyrazole derivative 12
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D08WUF
DRUGNAME	Influenza DNA vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D08WUK
DRUGNAME	MVA-MERS-S_DF-1 vaccine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1b
	
TTDDRUID	D08WVA
DRUGNAME	UK-224671
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1
	
TTDDRUID	D08WWN
DRUGNAME	RG7853
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
	
TTDDRUID	D08WYH
DRUGNAME	LY-2228820
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D08WYK
DRUGNAME	OJP-2028
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D08WYM
DRUGNAME	Nafarelin
INDICATI	Endometriosis [ICD-11: GA10] Approved
	
TTDDRUID	D08WYO
DRUGNAME	6F4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08WZC
DRUGNAME	PMID26651364-Compound-48
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D08WZQ
DRUGNAME	MRG-201
INDICATI	Keloid [ICD-11: EE60] Phase 2
INDICATI	Scleroderma [ICD-11: 4A42] Phase 1
	
TTDDRUID	D08XAC
DRUGNAME	Nystatin
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D08XBF
DRUGNAME	AMEP
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D08XDL
DRUGNAME	KHK2455
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08XDO
DRUGNAME	Glial progenitor cell therapy
INDICATI	Brain injury [ICD-11: NA07.Z] Phase 1/2
	
TTDDRUID	D08XFA
DRUGNAME	IL-2 XL
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
	
TTDDRUID	D08XFJ
DRUGNAME	NN-1218
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
INDICATI	Type-1 diabetes [ICD-11: 5A10] Application submitted
INDICATI	Type-2 diabetes [ICD-11: 5A11] Application submitted
	
TTDDRUID	D08XFR
DRUGNAME	AEZS-115
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08XFV
DRUGNAME	Flurazepam
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D08XHN
DRUGNAME	AL-59412C
INDICATI	Ocular hypertension [ICD-11: 9C61.01] Phase 2
	
TTDDRUID	D08XIF
DRUGNAME	GSK-0862
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D08XKL
DRUGNAME	SPI-014
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D08XLV
DRUGNAME	Sharon-5000
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative
	
TTDDRUID	D08XMM
DRUGNAME	NicVAX
INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Phase 3
	
TTDDRUID	D08XOF
DRUGNAME	P-13
INDICATI	Otitis media [ICD-11: AA80-AB0Z] Investigative
	
TTDDRUID	D08XOT
DRUGNAME	LY467711
INDICATI	Migraine [ICD-11: 8A80] Terminated
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated
	
TTDDRUID	D08XOY
DRUGNAME	ABT-126
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D08XPI
DRUGNAME	CMV-specific STAR fusions
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative
	
TTDDRUID	D08XPN
DRUGNAME	mab 1-7F9
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D08XPW
DRUGNAME	CYTISINE
INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 3
	
TTDDRUID	D08XQA
DRUGNAME	RSD-921
INDICATI	Anaesthesia [ICD-11: 9A78.6] Discontinued in Phase 2
	
TTDDRUID	D08XQV
DRUGNAME	USL311
INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D08XRD
DRUGNAME	SF-108
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D08XRX
DRUGNAME	ANGX-3227
INDICATI	Sickle-cell anaemia [ICD-11: 3A51] Discontinued in Phase 2
	
TTDDRUID	D08XUP
DRUGNAME	GE-37468A
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D08XVR
DRUGNAME	Baminercept
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D08XVU
DRUGNAME	MVA-BN anthrax
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative
	
TTDDRUID	D08XWZ
DRUGNAME	ALX-0646
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 1
	
TTDDRUID	D08XYX
DRUGNAME	Aprotinin
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
	
TTDDRUID	D08XZQ
DRUGNAME	PF-4287881
INDICATI	Respiratory tract infection [ICD-11: CA45] Phase 1
	
TTDDRUID	D08YAD
DRUGNAME	Disarmin
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D08YAL
DRUGNAME	PMID25666693-Compound-111
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D08YCS
DRUGNAME	TQ-1017
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D08YFD
DRUGNAME	PF-05212372
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D08YGD
DRUGNAME	Haempatch
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative
	
TTDDRUID	D08YGY
DRUGNAME	MK-6302
INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 1
	
TTDDRUID	D08YHB
DRUGNAME	BIIB 023
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D08YHE
DRUGNAME	NKR-2 CAR-T Cells
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D08YHS
DRUGNAME	Linopirdine
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3
	
TTDDRUID	D08YIN
DRUGNAME	Dalfampridine
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
	
TTDDRUID	D08YJN
DRUGNAME	BRT-FC-83C
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D08YKD
DRUGNAME	CLT-011
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D08YLC
DRUGNAME	ONO-01210
INDICATI	Acute radiation syndrome [ICD-11: NF00] Phase 1
	
TTDDRUID	D08YNC
DRUGNAME	MU-1140-S
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D08YNI
DRUGNAME	Somatoprim
INDICATI	Acromegaly [ICD-11: 5A60.0] Phase 2
	
TTDDRUID	D08YOM
DRUGNAME	Sulopenem etzadroxil
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D08YPQ
DRUGNAME	Thiazole carboxamide derivative 7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D08YPZ
DRUGNAME	Ammoniated mercury
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
	
TTDDRUID	D08YQG
DRUGNAME	Entelon
INDICATI	Lymphatic disease [ICD-11: BD9Z] Investigative
	
TTDDRUID	D08YRD
DRUGNAME	A-717
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D08YRM
DRUGNAME	Long-acting interferon beta conjugate
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D08YRO
DRUGNAME	Ad VEGF-C
INDICATI	Lymphatic disease [ICD-11: BD9Z] Investigative
	
TTDDRUID	D08YSY
DRUGNAME	VGX-200
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08YTF
DRUGNAME	RG6013
INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 3
	
TTDDRUID	D08YTQ
DRUGNAME	M2e influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D08YVP
DRUGNAME	Vericigiuat
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D08YVT
DRUGNAME	SCH-211803
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1
	
TTDDRUID	D08YWK
DRUGNAME	FX-006
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D08YWN
DRUGNAME	HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D08YWY
DRUGNAME	SCH-900117
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D08YXS
DRUGNAME	CAP-3.2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08YYY
DRUGNAME	Ocinaplon
INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Discontinued in Phase 3
	
TTDDRUID	D08ZAC
DRUGNAME	ICAR30 T cells
INDICATI	Anaplastic large cell lymphoma [ICD-11: 2A90.A] Phase 1
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1
	
TTDDRUID	D08ZAX
DRUGNAME	RS-93522
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D08ZBB
DRUGNAME	PMID25666693-Compound-84
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D08ZBT
DRUGNAME	SDZ-WAG-994
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D08ZBU
DRUGNAME	Cyanocobalamin Co-60
INDICATI	Vitamin B12 deficiency [ICD-11: 5B5F] Approved
	
TTDDRUID	D08ZCC
DRUGNAME	MTC-896
INDICATI	Seborrhea [ICD-11: ED91.2] Phase 2
	
TTDDRUID	D08ZCI
DRUGNAME	ALN-AT3SC
INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 1
INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1
	
TTDDRUID	D08ZCW
DRUGNAME	ZD-8321
INDICATI	Acute lung injury [ICD-11: NB32.3] Discontinued in Phase 2
	
TTDDRUID	D08ZDI
DRUGNAME	Anti-Factor D
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 1/2
	
TTDDRUID	D08ZDM
DRUGNAME	Nh-125
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08ZEB
DRUGNAME	Chlorzoxazone
INDICATI	Acute pain [ICD-11: MG31] Approved
	
TTDDRUID	D08ZEM
DRUGNAME	Quinazoline derivative 11
INDICATI	Cirrhosis [ICD-11: DB93] Patented
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Patented
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Patented
INDICATI	Multiple sclerosis [ICD-11: 8A40] Patented
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Patented
	
TTDDRUID	D08ZFC
DRUGNAME	IGN-312
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D08ZFJ
DRUGNAME	Colestilan
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D08ZGG
DRUGNAME	P-218
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D08ZHL
DRUGNAME	FGF-1
INDICATI	Coronary heart disease [ICD-11: BA80.Z] Phase 2
	
TTDDRUID	D08ZHQ
DRUGNAME	C4X-301
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D08ZIH
DRUGNAME	CGX-1160
INDICATI	Acute or chronic pain [ICD-11: MG30-MG31] Terminated
	
TTDDRUID	D08ZJJ
DRUGNAME	H1N1 pandemic influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D08ZJX
DRUGNAME	LY3076226
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08ZKJ
DRUGNAME	Ontazolast
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D08ZKN
DRUGNAME	PG-530742
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 2
	
TTDDRUID	D08ZLL
DRUGNAME	Quick-acting insulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D08ZOY
DRUGNAME	Tecogalan sodium
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08ZPO
DRUGNAME	H-1152
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
	
TTDDRUID	D08ZQI
DRUGNAME	FPA-008
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1/2
INDICATI	Pigmented villonodular synovitis [ICD-11: FA27.1] Phase 1
INDICATI	Tenosynovial giant cell tumour [ICD-11: 2F7B] Phase 1
	
TTDDRUID	D08ZRR
DRUGNAME	KW-5092
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D08ZRW
DRUGNAME	Cantide + Cisplatin
INDICATI	Tumour [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D08ZSQ
DRUGNAME	Parke-Davis 1
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D08ZTH
DRUGNAME	SLP-1002
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D08ZUC
DRUGNAME	TRK-950
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D08ZUG
DRUGNAME	RBT-05
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D08ZVY
DRUGNAME	Technetium Tc-99m Lidofenin Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D08ZXG
DRUGNAME	INT-2500
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D08ZXH
DRUGNAME	AX-208
INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated
	
TTDDRUID	D08ZXM
DRUGNAME	REG2
INDICATI	Venous thrombosis [ICD-11: BA43] Phase 1
	
TTDDRUID	D08ZXQ
DRUGNAME	Neublastin
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D08ZYZ
DRUGNAME	Chikungunya vaccine
INDICATI	Chikungunya virus infection [ICD-11: 1D40] Phase 2
	
TTDDRUID	D08ZZO
DRUGNAME	NS-696
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D08ZZP
DRUGNAME	EchoGen
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2
	
TTDDRUID	D09AAK
DRUGNAME	Ripretinib
INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Approved
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Phase 1
	
TTDDRUID	D09AAM
DRUGNAME	ICI-164384
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D09ACC
DRUGNAME	CNTO-0007
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1
	
TTDDRUID	D09ADN
DRUGNAME	VOXERGOLIDE HYDROCHLORIDE
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1
	
TTDDRUID	D09ADS
DRUGNAME	Immuncell-LC
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Approved
	
TTDDRUID	D09ADT
DRUGNAME	ABT-418
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
	
TTDDRUID	D09AFE
DRUGNAME	AG-NDP803
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D09AFI
DRUGNAME	INCB039110
INDICATI	Malignant neoplasm [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D09AFJ
DRUGNAME	SR-121787
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D09AFV
DRUGNAME	GLG-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09AGG
DRUGNAME	GSK2890457
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D09AGZ
DRUGNAME	CEE-04-421
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D09AHK
DRUGNAME	ZYN002-CBD
INDICATI	Seizure disorder [ICD-11: 8A6Z] Phase 2
	
TTDDRUID	D09AHZ
DRUGNAME	Celivarone
INDICATI	Ventricular arrhythmias [ICD-11: BC71] Phase 2/3
	
TTDDRUID	D09AIH
DRUGNAME	PCUR-101
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D09AIT
DRUGNAME	BHT-3201
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D09AJU
DRUGNAME	TS-111
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1
	
TTDDRUID	D09ALE
DRUGNAME	Enadoline
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D09ALM
DRUGNAME	BIIB061
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D09ALR
DRUGNAME	MM36
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D09AMZ
DRUGNAME	Enprofylline
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D09ANC
DRUGNAME	MC-02,479
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D09ANG
DRUGNAME	Misoprostol
INDICATI	Medical abortion [ICD-11: JA00.1Z] Approved
	
TTDDRUID	D09AOO
DRUGNAME	ANAVEX 2-73
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
INDICATI	Infantile spasm [ICD-11: 8A62.0] Phase 1
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
INDICATI	Rett syndrome [ICD-11: LD90.4] Phase 1
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
	
TTDDRUID	D09APA
DRUGNAME	Plasma derived factor VIII PEGylated liposomal
INDICATI	Factor VIII deficiency [ICD-11: 3B10] Phase 3
	
TTDDRUID	D09APB
DRUGNAME	IDX-189
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D09ATR
DRUGNAME	PF-06804103
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09AUP
DRUGNAME	GW-215864
INDICATI	Rhinitis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D09AVX
DRUGNAME	WIB-901H
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D09AVZ
DRUGNAME	E1/E4-deleted adenoviral vector
INDICATI	Ornithine transcarbamylase deficiency [ICD-11: 5C50.AY] Investigative
	
TTDDRUID	D09AWJ
DRUGNAME	H5N1 influenza vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D09AWM
DRUGNAME	ODSH
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D09AXQ
DRUGNAME	CD22-CART
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D09AYA
DRUGNAME	IB-08C175
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Investigative
	
TTDDRUID	D09AYM
DRUGNAME	MABp1
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	Hidradenitis suppurativa [ICD-11: ED92.0] Phase 2
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Pyoderma gangrenosum [ICD-11: EB21] Phase 2
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D09AYQ
DRUGNAME	PIRITREXIM
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
	
TTDDRUID	D09AYS
DRUGNAME	Antineoplaston-A5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D09BAP
DRUGNAME	KUR-212
INDICATI	Wound healing [ICD-11: EL8Y] Phase 2
	
TTDDRUID	D09BBA
DRUGNAME	TAK-071
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D09BBW
DRUGNAME	Sodium stibogluconate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D09BCC
DRUGNAME	ImmuDyn
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D09BCJ
DRUGNAME	PMID30124346-Compound-34TABLE4
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Patented
	
TTDDRUID	D09BCL
DRUGNAME	DCB-AD1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D09BDE
DRUGNAME	PAC-14028
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D09BDH
DRUGNAME	Rabeximod
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D09BDK
DRUGNAME	SNG-163
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09BEG
DRUGNAME	CNS-5161
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D09BEJ
DRUGNAME	AQST-305
INDICATI	Malignant carcinoid syndrome [ICD-11: 5B10] Phase 1
	
TTDDRUID	D09BEO
DRUGNAME	DBP-192
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D09BGB
DRUGNAME	Aryl mannoside derivative 1
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D09BHA
DRUGNAME	LY-353433
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated
	
TTDDRUID	D09BHB
DRUGNAME	Tolmetin
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D09BHF
DRUGNAME	WF-2421
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D09BID
DRUGNAME	PRO-206
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated
	
TTDDRUID	D09BIW
DRUGNAME	99mTc-sestamibi
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D09BIX
DRUGNAME	Nexagon
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
	
TTDDRUID	D09BJH
DRUGNAME	Retroviral MGMT-transduced hematopoietic cells
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1
	
TTDDRUID	D09BKE
DRUGNAME	NS398
INDICATI	Endometriosis [ICD-11: GA10] Terminated
	
TTDDRUID	D09BKY
DRUGNAME	Bevacizumab + Erlotinib
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
INDICATI	Hypopharyngeal squamous cell carcinoma [ICD-11: 2B6D.0] Phase 1/2
	
TTDDRUID	D09BLW
DRUGNAME	TgAAV-CFTR
INDICATI	Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2
	
TTDDRUID	D09BNP
DRUGNAME	Heterocyclic derivative 11
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D09BNR
DRUGNAME	Gazyva
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D09BNZ
DRUGNAME	LDE225
INDICATI	Skin cancer [ICD-11: 2C30-2C37] Phase 2
INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 2
	
TTDDRUID	D09BOH
DRUGNAME	Verubulin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Brain metastases [ICD-11: 2D50] Phase 2
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D09BPN
DRUGNAME	Anatibant
INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 2
	
TTDDRUID	D09BPT
DRUGNAME	Anti-CD9 mab
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Investigative
	
TTDDRUID	D09BQO
DRUGNAME	ATD transdermal gel
INDICATI	Contraception [ICD-11: QA21] Phase 1
	
TTDDRUID	D09BRE
DRUGNAME	U-78517F
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D09BSI
DRUGNAME	TDI-0039
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D09BTK
DRUGNAME	NCX-1000
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D09BVL
DRUGNAME	NS-1619
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D09BWC
DRUGNAME	E-4080
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D09BWG
DRUGNAME	CAR-T cells targeting CD19
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D09BXF
DRUGNAME	CLS003
INDICATI	Plantar wart [ICD-11: 1E80.1] Phase 2
	
TTDDRUID	D09BXJ
DRUGNAME	PF-5177624
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09BZJ
DRUGNAME	MEHD-7945A
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D09BZS
DRUGNAME	CK-101
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D09BZY
DRUGNAME	Nibentan
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 1
	
TTDDRUID	D09CAC
DRUGNAME	U-96988
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D09CBI
DRUGNAME	Anti-Her-2 mab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09CCZ
DRUGNAME	Triciribine prodrug
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D09CEJ
DRUGNAME	CYT003
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D09CEY
DRUGNAME	SKL-PSY
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1
	
TTDDRUID	D09CFM
DRUGNAME	DANOFLOXACIN
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D09CGE
DRUGNAME	Florbetapir F-18
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D09CHX
DRUGNAME	AMR-SIX-1
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D09CIB
DRUGNAME	BC-22
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D09CIF
DRUGNAME	TH-9402
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 2
	
TTDDRUID	D09CIQ
DRUGNAME	Cadralazine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D09CJO
DRUGNAME	CXB-029
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D09CKF
DRUGNAME	Licostinel
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1
	
TTDDRUID	D09CKG
DRUGNAME	MVA-MERS-S vaccine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1
	
TTDDRUID	D09CKT
DRUGNAME	LY433222
INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative
	
TTDDRUID	D09CLC
DRUGNAME	C188-9
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09CLG
DRUGNAME	VRC-SRSDNA015-00-VP vaccine
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 1
	
TTDDRUID	D09CLH
DRUGNAME	Samarium SM-153 lexidronam
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D09CLX
DRUGNAME	MDT-006
INDICATI	Constipation [ICD-11: DD91.1] Investigative
	
TTDDRUID	D09CMK
DRUGNAME	R-salbutamol sulphate
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2
	
TTDDRUID	D09CNO
DRUGNAME	Grass pollen allergy vaccine
INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 2/3
	
TTDDRUID	D09CNR
DRUGNAME	KLS-Npk
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D09CNV
DRUGNAME	EDG-005
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D09COD
DRUGNAME	Romurtide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D09CPR
DRUGNAME	Penicillin V
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D09CQB
DRUGNAME	GPs-0193
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D09CRQ
DRUGNAME	RPK-739
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D09CTF
DRUGNAME	Human recombinant factor VIII
INDICATI	Factor VIII deficiency [ICD-11: 3B10] Investigative
	
TTDDRUID	D09CTH
DRUGNAME	RP-701
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09CTY
DRUGNAME	OPHD-002
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated
	
TTDDRUID	D09CUR
DRUGNAME	Trans-sodium crocetinate
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 3
INDICATI	Brain metastases [ICD-11: 2D50] Phase 1
	
TTDDRUID	D09CXE
DRUGNAME	Norovirus bivalent vaccine
INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1/2
	
TTDDRUID	D09CYK
DRUGNAME	ENDG-3010
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D09CZA
DRUGNAME	Travoprost
INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved
	
TTDDRUID	D09CZS
DRUGNAME	DRF-1042
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09DAJ
DRUGNAME	FG-6874
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D09DAQ
DRUGNAME	ISIS 353512
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D09DBR
DRUGNAME	Micronomicin sulfate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D09DBY
DRUGNAME	Rilonacept
INDICATI	Arthritis [ICD-11: FA20] Approved
INDICATI	Acute gout flare [ICD-11: FA25.0] Phase 3
	
TTDDRUID	D09DDQ
DRUGNAME	FUB-130
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D09DER
DRUGNAME	QR-336
INDICATI	Radiation syndrome [ICD-11: NF00] Preclinical
	
TTDDRUID	D09DEU
DRUGNAME	HMPL-342
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D09DFB
DRUGNAME	EFEGATRAN SULFATE HYDRATE
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
	
TTDDRUID	D09DGE
DRUGNAME	LD-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09DHL
DRUGNAME	TDI-0090
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D09DHT
DRUGNAME	phorbol 12-myristate 13-acetate
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 2
	
TTDDRUID	D09DHY
DRUGNAME	Colchicine
INDICATI	Acute gouty arthritis [ICD-11: FA25.0] Approved
	
TTDDRUID	D09DIB
DRUGNAME	RG-4929
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2
	
TTDDRUID	D09DIG
DRUGNAME	Ablukast
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3
	
TTDDRUID	D09DIQ
DRUGNAME	CART22 cells expressing anti-CD22 scFv TCRz:41BB
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D09DJC
DRUGNAME	IRX4204
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D09DJO
DRUGNAME	Pafuramidine
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3
	
TTDDRUID	D09DJS
DRUGNAME	INV-400
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D09DJU
DRUGNAME	SU-14813
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D09DKY
DRUGNAME	AEZS-123
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Preclinical
	
TTDDRUID	D09DLN
DRUGNAME	L-739749
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D09DLP
DRUGNAME	Tramiprosate
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D09DND
DRUGNAME	Anti-GD2-CAR engineered T cells
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 1
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 1
	
TTDDRUID	D09DRG
DRUGNAME	NE-100
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D09DRM
DRUGNAME	NT-1635
INDICATI	Sarcopenia [ICD-11: FB32.Y] Investigative
	
TTDDRUID	D09DSK
DRUGNAME	JWH-051
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D09DTY
DRUGNAME	DABO-1047
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D09DUQ
DRUGNAME	AN-2718
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 1
	
TTDDRUID	D09DWL
DRUGNAME	Zaleplon
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D09DXX
DRUGNAME	PF-06282999
INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 1
	
TTDDRUID	D09DYB
DRUGNAME	CHDI-00316226
INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative
	
TTDDRUID	D09DYT
DRUGNAME	EP-5001
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D09EBJ
DRUGNAME	MC-02306
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D09EBL
DRUGNAME	Antegren
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
	
TTDDRUID	D09EBS
DRUGNAME	Oxymetazoline
INDICATI	Eye inflammation [ICD-11: 9A02] Approved
INDICATI	Nasal congestion [ICD-11: MD11.9] Approved
	
TTDDRUID	D09EDA
DRUGNAME	PRM-151
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 2
INDICATI	Thrombocythemia [ICD-11: 3B63] Phase 2
	
TTDDRUID	D09EDW
DRUGNAME	Deligoparin sodium
INDICATI	Ulcerative colitis [ICD-11: DD71] Discontinued in Phase 3
	
TTDDRUID	D09EED
DRUGNAME	SYM-009
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D09EEV
DRUGNAME	Declopramide
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
	
TTDDRUID	D09EFC
DRUGNAME	CAP-232
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2a
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D09EFW
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 13
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D09EGZ
DRUGNAME	Chloroquine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D09EHO
DRUGNAME	ABT-751
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D09EIQ
DRUGNAME	Biaryl mannoside derivative 18
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D09EIX
DRUGNAME	PMID26936077-Compound-13
INDICATI	Type-2 diabetes [ICD-11: 5A11] Patented
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Patented
INDICATI	Gastric ulcer [ICD-11: DA60] Patented
	
TTDDRUID	D09EJC
DRUGNAME	IRX-03
INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative
	
TTDDRUID	D09ELC
DRUGNAME	AVI-7537
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D09ELP
DRUGNAME	Clevidipine butyrate
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D09ELW
DRUGNAME	Enalkiren
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2
	
TTDDRUID	D09EMS
DRUGNAME	CO-8
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D09ENA
DRUGNAME	Org-30035
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D09ENF
DRUGNAME	PNT-300
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09ENR
DRUGNAME	Itarnafloxin
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D09ENZ
DRUGNAME	EPZ-004777
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D09EOZ
DRUGNAME	CX-99
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09EPU
DRUGNAME	18F-BAY-85-8050
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09EPX
DRUGNAME	MitoLinoleic
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative
	
TTDDRUID	D09EQA
DRUGNAME	SpirH
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D09EQZ
DRUGNAME	XN-0502
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09ESW
DRUGNAME	Anipamil
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 3
	
TTDDRUID	D09ETH
DRUGNAME	E-7050
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
	
TTDDRUID	D09EVP
DRUGNAME	NNZ-4921
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D09EVZ
DRUGNAME	BMS-488043
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D09EWK
DRUGNAME	PRO-053
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2
	
TTDDRUID	D09EXD
DRUGNAME	Rituximab
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D09EXQ
DRUGNAME	PMID26651364-Compound-8a
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D09EYJ
DRUGNAME	IPS cell program
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D09EYN
DRUGNAME	RSV F protein vaccine
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 3
	
TTDDRUID	D09EZU
DRUGNAME	Myrrhanol A
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D09FAZ
DRUGNAME	Azacitidine
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Approved
	
TTDDRUID	D09FDN
DRUGNAME	IMA201
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D09FEN
DRUGNAME	PRO-515
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D09FFI
DRUGNAME	SARS-CoV vaccine
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 1
	
TTDDRUID	D09FFS
DRUGNAME	FT-071
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D09FGM
DRUGNAME	ZP-10719
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Investigative
	
TTDDRUID	D09FGV
DRUGNAME	Recombinant S protein SARS vaccine
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 1
	
TTDDRUID	D09FGX
DRUGNAME	ELACRIDAR
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D09FHM
DRUGNAME	Fluzone QIV
INDICATI	Ovarian cancer [ICD-11: 2C73] Approved
INDICATI	Influenza [ICD-11: 1E30-1E32] Approved
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D09FHY
DRUGNAME	HIV multiantigen vaccine
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D09FJB
DRUGNAME	Tolazamide
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D09FJH
DRUGNAME	CFC-240
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D09FKY
DRUGNAME	GED-0301
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
	
TTDDRUID	D09FNI
DRUGNAME	Nonocog beta pegol
INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 3
	
TTDDRUID	D09FOP
DRUGNAME	MCP-202
INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 1
	
TTDDRUID	D09FQB
DRUGNAME	UR-12460
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D09FQP
DRUGNAME	PMID25684022-Compound-US20120277229 39(1.1)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D09FQS
DRUGNAME	FG-3622
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical
	
TTDDRUID	D09FQW
DRUGNAME	THVD-201
INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 3
	
TTDDRUID	D09FSG
DRUGNAME	Golimumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2/3
	
TTDDRUID	D09FTC
DRUGNAME	BacTRL-Spike vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D09FTJ
DRUGNAME	TTP-054
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D09FWK
DRUGNAME	E-003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09FYW
DRUGNAME	PF-06743649
INDICATI	Gout [ICD-11: FA25] Phase 1
	
TTDDRUID	D09FZI
DRUGNAME	TALTOBULIN
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D09FZM
DRUGNAME	BreMel/rGel
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D09GAG
DRUGNAME	DC-159a
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D09GBM
DRUGNAME	GD-AAV8
INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Investigative
	
TTDDRUID	D09GDD
DRUGNAME	Regorafenib
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Approved
	
TTDDRUID	D09GDY
DRUGNAME	GNI-103
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2
	
TTDDRUID	D09GEK
DRUGNAME	ASP3026
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
	
TTDDRUID	D09GFL
DRUGNAME	Trihexyphenidyl
INDICATI	Dystonia [ICD-11: 8A02] Approved
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D09GGJ
DRUGNAME	CVT-124
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 3
	
TTDDRUID	D09GGO
DRUGNAME	A-252444.0
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D09GHB
DRUGNAME	RO-4987655
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D09GHO
DRUGNAME	LY-334370
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D09GIA
DRUGNAME	SAR391786
INDICATI	Muscle atrophy [ICD-11: FB32.Y] Phase 2
	
TTDDRUID	D09GIP
DRUGNAME	QRS-5-005
INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated
	
TTDDRUID	D09GJQ
DRUGNAME	Tricyclic phytocannabinoid derivative 1
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
	
TTDDRUID	D09GLS
DRUGNAME	GSK1614235
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D09GMC
DRUGNAME	GX-101
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative
	
TTDDRUID	D09GME
DRUGNAME	Covid-19 aAPC vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D09GMH
DRUGNAME	Hepatitis B virus vaccine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D09GOS
DRUGNAME	Clotrimazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D09GPB
DRUGNAME	AZD2066
INDICATI	Chronic neuropathic pain [ICD-11: MG30.5] Discontinued in Phase 2
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D09GPI
DRUGNAME	FRM-6308
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1b
	
TTDDRUID	D09GQS
DRUGNAME	JD-0100
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D09GRB
DRUGNAME	NNC-90-0270
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D09GRH
DRUGNAME	O-Vax
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	D09GRX
DRUGNAME	Tucatinib
INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2/3
	
TTDDRUID	D09GSV
DRUGNAME	FBT-A05
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
	
TTDDRUID	D09GUI
DRUGNAME	PTL-68001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D09GUJ
DRUGNAME	Omadacycline
INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Approved
INDICATI	Bacterial pneumonia [ICD-11: CA40.0] Approved
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
	
TTDDRUID	D09GVB
DRUGNAME	OL-135
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D09GVI
DRUGNAME	VSF-173
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2
	
TTDDRUID	D09GWA
DRUGNAME	SARS-CoV-2 rS vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D09GXF
DRUGNAME	RB-105
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D09GYJ
DRUGNAME	BNT162a1 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D09GYT
DRUGNAME	Methoxamine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D09HAL
DRUGNAME	JTT-651
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D09HCE
DRUGNAME	Long-acting FSH conjugate
INDICATI	Female infertility [ICD-11: GA31.Z] Investigative
	
TTDDRUID	D09HCR
DRUGNAME	FM-401
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D09HDR
DRUGNAME	Deserpidine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D09HDV
DRUGNAME	AD-529
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Preclinical
	
TTDDRUID	D09HEV
DRUGNAME	GS-9005
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2
	
TTDDRUID	D09HFJ
DRUGNAME	NM-3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09HFL
DRUGNAME	GSK2398852 + GSK2315698
INDICATI	Amyloidosis [ICD-11: 5D00] Phase 2
	
TTDDRUID	D09HFS
DRUGNAME	AFP464
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D09HIC
DRUGNAME	BF-388
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D09HJS
DRUGNAME	BIZELESIN
INDICATI	Skin disease [ICD-11: EA00-EM0Z] Phase 1
	
TTDDRUID	D09HKX
DRUGNAME	Cefoselis
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D09HNR
DRUGNAME	Telithromycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D09HNV
DRUGNAME	Intedanib
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D09HOJ
DRUGNAME	NPB-01
INDICATI	Pemphigoid [ICD-11: EB41] Phase 3
	
TTDDRUID	D09HOW
DRUGNAME	S-364735
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D09HRH
DRUGNAME	Anti-CD133-CAR vector-transduced T cells
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D09HRS
DRUGNAME	GHB-16L2
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2
	
TTDDRUID	D09HTB
DRUGNAME	SAR153191
INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Phase 3
	
TTDDRUID	D09HTE
DRUGNAME	HA20
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D09HTS
DRUGNAME	Lanatoside a
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D09HUF
DRUGNAME	UR-60427
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D09HUU
DRUGNAME	EC1456
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09HVD
DRUGNAME	Ramucirumab
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Approved
	
TTDDRUID	D09HVH
DRUGNAME	NMS-E973
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09HVL
DRUGNAME	Bivalirudin
INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved
	
TTDDRUID	D09HVY
DRUGNAME	Cystatin C
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D09HYG
DRUGNAME	NP16
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative
	
TTDDRUID	D09HYI
DRUGNAME	M-2001
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D09IAN
DRUGNAME	Anti-CD19 Chimeric Antigen Receptor T Cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Clinical trial
	
TTDDRUID	D09ICC
DRUGNAME	SB220025
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D09ICH
DRUGNAME	CD7.CAR/28zeta CAR T cells
INDICATI	B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 1
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D09IEE
DRUGNAME	Prednicarbate
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D09IFW
DRUGNAME	Cruentaren
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical
	
TTDDRUID	D09IGF
DRUGNAME	MG-28
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09IGR
DRUGNAME	AZX-100
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D09IIX
DRUGNAME	HMAG-1 targeting GRSA
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D09IJP
DRUGNAME	A-71378
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D09IKZ
DRUGNAME	AS-1949490
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D09IMN
DRUGNAME	SAR153192
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09IMS
DRUGNAME	Mequitazine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
INDICATI	Respiratory disease [ICD-11: CB40] Phase 2
	
TTDDRUID	D09IMY
DRUGNAME	SLP-0905
INDICATI	Enterococcus faecium infection [ICD-11: 1D01.0Y] Investigative
	
TTDDRUID	D09INA
DRUGNAME	HD-148
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09INF
DRUGNAME	Laquinamod
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
	
TTDDRUID	D09INX
DRUGNAME	DSP-3905
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D09IOA
DRUGNAME	EM-3106B
INDICATI	Insulinoma [ICD-11: 2C10.1] Investigative
	
TTDDRUID	D09IOF
DRUGNAME	Troplasminogen alfa
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
	
TTDDRUID	D09IOI
DRUGNAME	Amoxapine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
	
TTDDRUID	D09IPV
DRUGNAME	Danazol
INDICATI	Menorrhagia [ICD-11: GA20.50] Approved
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D09IRN
DRUGNAME	LU AE58054
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D09IRQ
DRUGNAME	Ataluren
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 3
INDICATI	Dravet syndrome [ICD-11: 8A61.11] Phase 2
INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 2
INDICATI	Aniridia [ICD-11: LA11.3] Phase 1
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Application submitted
	
TTDDRUID	D09ISJ
DRUGNAME	SOM-0856
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D09ISS
DRUGNAME	CZEN-001
INDICATI	Pruritus [ICD-11: EC90] Phase 1
	
TTDDRUID	D09ITH
DRUGNAME	Botulism immune globulin
INDICATI	Clostridium infection [ICD-11: 1A04] Approved
	
TTDDRUID	D09IUG
DRUGNAME	F-3796
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D09IUR
DRUGNAME	Midismase
INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Phase 2
	
TTDDRUID	D09IVP
DRUGNAME	Anti-folate receptor 1 humanized mab
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D09IYH
DRUGNAME	Pyrazole derivative 58
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D09IYM
DRUGNAME	AT13148
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09IZX
DRUGNAME	GW-275919
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D09JBP
DRUGNAME	Paramethadione
INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved
INDICATI	Fetal trimethadione syndrome [ICD-11: LD2F.0Y] Approved
	
TTDDRUID	D09JCH
DRUGNAME	CDNA vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D09JDV
DRUGNAME	PMID26651364-Compound-5a
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D09JDX
DRUGNAME	RCD-2
INDICATI	Fecal incontinence [ICD-11: ME07] Preclinical
	
TTDDRUID	D09JEJ
DRUGNAME	CX-4945
INDICATI	Coronavirus infection [ICD-11: 1D92] Phase 2
INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09JES
DRUGNAME	Sampatrilat
INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 2
	
TTDDRUID	D09JET
DRUGNAME	NGD 96-3
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Investigative
	
TTDDRUID	D09JFY
DRUGNAME	Dutasteride + tamsulosin
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D09JGH
DRUGNAME	EC-145
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D09JGK
DRUGNAME	TAK-960
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09JJG
DRUGNAME	MCT-465
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09JJU
DRUGNAME	EchiTAb
INDICATI	Poison intoxication [ICD-11: NE6Z] Approved
	
TTDDRUID	D09JKN
DRUGNAME	P-BCMA-101
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D09JKS
DRUGNAME	GRASPA
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D09JLI
DRUGNAME	Vicriviroc
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D09JLP
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 10
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D09JMW
DRUGNAME	IHV001
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D09JNP
DRUGNAME	MVax
INDICATI	Ovarian cancer [ICD-11: 2C73] Approved
	
TTDDRUID	D09JPT
DRUGNAME	CB-183872
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D09JSM
DRUGNAME	IMC-3C5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09JTE
DRUGNAME	BIOO-6
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09JUG
DRUGNAME	Zileuton
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D09JUL
DRUGNAME	Naltrexone prodrug
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Investigative
	
TTDDRUID	D09JVK
DRUGNAME	LY3090106
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2/3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D09JVV
DRUGNAME	Physostigmine
INDICATI	Xerostomia [ICD-11: DA02.1] Discontinued in Phase 2
	
TTDDRUID	D09JXH
DRUGNAME	LUM001
INDICATI	Primary biliary cirrhosis [ICD-11: DB96.1] Phase 2
INDICATI	Primary biliary cholangitis [ICD-11: DB96.1] Phase 2
INDICATI	Primary sclerosing cholangitis [ICD-11: DB96.2] Phase 2
INDICATI	Progressive familial intrahepatic cholestasis [ICD-11: 5C58.03] Phase 2
INDICATI	Structural developmental anomalies of liver [ICD-11: LB20.0] Phase 2
	
TTDDRUID	D09JXL
DRUGNAME	SEGLITIDE
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D09JXM
DRUGNAME	Phenylpropanolamine
INDICATI	Obesity [ICD-11: 5B81] Withdrawn from market
	
TTDDRUID	D09JYF
DRUGNAME	Epocarbazolin-A
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D09JYL
DRUGNAME	Hu5F9-G4
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D09JYY
DRUGNAME	F-1013
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09KAK
DRUGNAME	NOX-F37
INDICATI	Acute and chronic heart failure [ICD-11: BD1Z] Preclinical
	
TTDDRUID	D09KDN
DRUGNAME	Cefazolin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D09KDV
DRUGNAME	Dihydroxyacetone
INDICATI	Sunburn [ICD-11: EJ40] Approved
	
TTDDRUID	D09KEB
DRUGNAME	PRT-060318
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D09KEW
DRUGNAME	KPL-716
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
INDICATI	Nodular prurigo [ICD-11: EC91.0] Phase 1
	
TTDDRUID	D09KGQ
DRUGNAME	Menadiol sodium diphosphate
INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
	
TTDDRUID	D09KGZ
DRUGNAME	QG-AGC1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D09KHE
DRUGNAME	EN3488
INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 3
	
TTDDRUID	D09KIG
DRUGNAME	ETX201
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
	
TTDDRUID	D09KIP
DRUGNAME	Chondrogel
INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D09KKD
DRUGNAME	AZD-3118
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D09KKH
DRUGNAME	Mepartricin
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D09KLO
DRUGNAME	AZD-5106
INDICATI	Urinary incontinence [ICD-11: MF50.2] Terminated
	
TTDDRUID	D09KLR
DRUGNAME	Alendronate
INDICATI	Paget's disease [ICD-11: FB85] Approved
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D09KLX
DRUGNAME	Cartistem-adipo
INDICATI	Arthropathy [ICD-11: FA11-FA38] Investigative
	
TTDDRUID	D09KMA
DRUGNAME	Zofroxia
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D09KNG
DRUGNAME	RSV-604
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2
	
TTDDRUID	D09KRE
DRUGNAME	Bezlotoxumab
INDICATI	C. difficile infection [ICD-11: 1A04] Approved
	
TTDDRUID	D09KRU
DRUGNAME	BI-831266
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09KRV
DRUGNAME	Adhexil
INDICATI	Injury [ICD-11: NA00-ND5Z] Phase 3
	
TTDDRUID	D09KRX
DRUGNAME	AVR-168
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D09KSW
DRUGNAME	3-CLA
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09KTE
DRUGNAME	BCL-004
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Investigative
	
TTDDRUID	D09KTI
DRUGNAME	GS-5816
INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D09KTS
DRUGNAME	Ibrutinib
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Approved
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D09KUE
DRUGNAME	NSC-88915
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09KWN
DRUGNAME	Anti-MUC1 CAR-T cells
INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1/2
	
TTDDRUID	D09KWX
DRUGNAME	Hl-con1
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
	
TTDDRUID	D09KXA
DRUGNAME	PD-131112
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D09KYB
DRUGNAME	Pyrimidine derivative 7
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented
INDICATI	Fibrosis [ICD-11: GA14-GC01] Patented
INDICATI	Blood vessel proliferative disorder [ICD-11: BE2Z] Patented
	
TTDDRUID	D09KYR
DRUGNAME	RP-49356
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D09KYZ
DRUGNAME	V-24343
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D09LBS
DRUGNAME	Sennoside b
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D09LDR
DRUGNAME	Oxazepam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D09LEB
DRUGNAME	RG7641
INDICATI	Kidney disease [ICD-11: GC2Z] Discontinued in Phase 1
	
TTDDRUID	D09LEN
DRUGNAME	Pneumococcal 13-valent conjugate vaccine
INDICATI	Streptococcus infection [ICD-11: 1B53] Approved
	
TTDDRUID	D09LEP
DRUGNAME	Pyrethroids
INDICATI	Pest attack [ICD-11: N.A.] Phase 2
	
TTDDRUID	D09LGV
DRUGNAME	MT-204
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D09LHG
DRUGNAME	YY-162
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
	
TTDDRUID	D09LIE
DRUGNAME	ASIbcl vaccine
INDICATI	B-cell lymphoma [ICD-11: 2A86] Terminated
	
TTDDRUID	D09LIZ
DRUGNAME	KI-0502
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D09LKR
DRUGNAME	TS-011
INDICATI	Stroke [ICD-11: 8B20] Phase 1
	
TTDDRUID	D09LKU
DRUGNAME	NOX-E36
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D09LLS
DRUGNAME	Havrix
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Approved
	
TTDDRUID	D09LMQ
DRUGNAME	Vaginal ring
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Investigative
	
TTDDRUID	D09LMX
DRUGNAME	Revatropate
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D09LNI
DRUGNAME	Fluconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D09LOZ
DRUGNAME	TTAC-0001
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D09LPI
DRUGNAME	BCG65-E7
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Discontinued in Phase 3
INDICATI	Anal intraepithelial neoplasia [ICD-11: 2E92.5] Discontinued in Phase 3
	
TTDDRUID	D09LPK
DRUGNAME	4E2Rcat
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D09LPN
DRUGNAME	Lepirudin
INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved
	
TTDDRUID	D09LPV
DRUGNAME	N6022
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D09LQK
DRUGNAME	BQ-123
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
	
TTDDRUID	D09LQP
DRUGNAME	RG-14893
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D09LSX
DRUGNAME	KU-0058948
INDICATI	Ovarian cancer [ICD-11: 2C73] Approved
	
TTDDRUID	D09LSY
DRUGNAME	EDP-322
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D09LTC
DRUGNAME	Non GC-C
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative
	
TTDDRUID	D09LTO
DRUGNAME	A-76341
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D09LVD
DRUGNAME	ISIS-APOARx
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1
	
TTDDRUID	D09LVK
DRUGNAME	TDI-0026
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D09LWP
DRUGNAME	PMID26651364-Compound-105
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D09LWS
DRUGNAME	Ezetimibe
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
	
TTDDRUID	D09LWZ
DRUGNAME	Mannoside derivative 7
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D09LZA
DRUGNAME	CS-4771
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1
	
TTDDRUID	D09LZN
DRUGNAME	ACER-001
INDICATI	Maple-syrup-urine disease [ICD-11: 5C50.D0] Investigative
	
TTDDRUID	D09LZT
DRUGNAME	Levomepromazine
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Approved
INDICATI	Bipolar disorder [ICD-11: 6A60] Approved
	
TTDDRUID	D09MAB
DRUGNAME	Anti-CD5 humanized mab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09MAS
DRUGNAME	FR-901483
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Discontinued in Phase 1
	
TTDDRUID	D09MCG
DRUGNAME	Amantidine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
	
TTDDRUID	D09MED
DRUGNAME	Toca 511/Toca FC
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 3
INDICATI	Glioma [ICD-11: 2A00.0] Phase 3
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09MEV
DRUGNAME	JES-9501
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D09MFV
DRUGNAME	KC-7F2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09MGR
DRUGNAME	Etoricoxib
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D09MHC
DRUGNAME	CJC-1134-PC
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D09MHN
DRUGNAME	Ixmyelocel-T
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
INDICATI	Dilated cardiomyopathy [ICD-11: BC43.0] Phase 3
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D09MHU
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 6
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D09MIN
DRUGNAME	LCL161
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D09MJH
DRUGNAME	SEA-CD40
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09MJJ
DRUGNAME	RP4010
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D09MJO
DRUGNAME	HL-004
INDICATI	Arteriosclerosis [ICD-11: BD40] Preclinical
	
TTDDRUID	D09MKH
DRUGNAME	TRI-102
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
	
TTDDRUID	D09MKL
DRUGNAME	TD-1607
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 1
	
TTDDRUID	D09MKQ
DRUGNAME	AMG 317
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D09MOD
DRUGNAME	NNC-252504
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D09MON
DRUGNAME	A-75998
INDICATI	Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 1
	
TTDDRUID	D09MPD
DRUGNAME	ALX-0651
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D09MPN
DRUGNAME	TDI-0087
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D09MPO
DRUGNAME	HLD100
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	D09MPU
DRUGNAME	Astromycin sulfate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D09MPX
DRUGNAME	SPF66
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	D09MQQ
DRUGNAME	CDD-0199-J
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
	
TTDDRUID	D09MQU
DRUGNAME	OGX-225
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D09MQY
DRUGNAME	CKD-403
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09MRD
DRUGNAME	MGN-4220
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D09MRL
DRUGNAME	Pidilizumab
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
	
TTDDRUID	D09MRY
DRUGNAME	ACU-0101979
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D09MSE
DRUGNAME	JNJ-38224342
INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 1
	
TTDDRUID	D09MTC
DRUGNAME	ADL-5945
INDICATI	Constipation [ICD-11: DD91.1] Discontinued in Phase 2
	
TTDDRUID	D09MUS
DRUGNAME	JBD-201
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D09MVZ
DRUGNAME	mab17-1a
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
	
TTDDRUID	D09MWJ
DRUGNAME	Alfuzosin
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved
	
TTDDRUID	D09MXE
DRUGNAME	TCK-1
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D09MXS
DRUGNAME	Sorbitol
INDICATI	Constipation [ICD-11: DD91.1] Approved
	
TTDDRUID	D09NAF
DRUGNAME	AV 133
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D09NAW
DRUGNAME	PF-05105679
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D09NBH
DRUGNAME	ICT-121
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D09NBM
DRUGNAME	SB-435495
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D09NCH
DRUGNAME	AM-230
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D09NCU
DRUGNAME	GS-6624
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D09NDM
DRUGNAME	IN-001
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 3
	
TTDDRUID	D09NEE
DRUGNAME	BVT-115959
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D09NEL
DRUGNAME	CWF-0804
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D09NFN
DRUGNAME	Pentetate calcium trisodium
INDICATI	Acute radiation syndrome [ICD-11: NF00] Approved
	
TTDDRUID	D09NFW
DRUGNAME	Dendritic cell vaccine
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D09NHD
DRUGNAME	Peptide P21S10
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D09NHS
DRUGNAME	PfCS-102
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2
	
TTDDRUID	D09NIA
DRUGNAME	Chlorthalidone
INDICATI	Edema [ICD-11: MG29] Approved
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D09NIB
DRUGNAME	Epipodophyllotoxin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D09NIY
DRUGNAME	Trolamine Polypeptide Oleate Condensate
INDICATI	Impacted cerumen [ICD-11: AA42] Approved
	
TTDDRUID	D09NKX
DRUGNAME	ANA-246
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated
	
TTDDRUID	D09NLC
DRUGNAME	Guar gum
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
	
TTDDRUID	D09NLK
DRUGNAME	Minokine
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D09NMD
DRUGNAME	Lasofoxifene
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1
	
TTDDRUID	D09NNA
DRUGNAME	Dromostanolone
INDICATI	Mammary tumour [ICD-11: 2C60-2C6Z] Approved
	
TTDDRUID	D09NNH
DRUGNAME	Dihydroergocristine
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
	
TTDDRUID	D09NQD
DRUGNAME	CIGB-55
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D09NQX
DRUGNAME	HBV-002
INDICATI	West nile virus infection [ICD-11: 1D46] Phase 1
	
TTDDRUID	D09NST
DRUGNAME	Afimoxifene
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Ductal carcinoma [ICD-11: 2E65.2] Phase 2
	
TTDDRUID	D09NTC
DRUGNAME	CC-486
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
	
TTDDRUID	D09NTG
DRUGNAME	Taurocholic Acid
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1/2
	
TTDDRUID	D09NTM
DRUGNAME	VR506
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D09NUH
DRUGNAME	4SCAR-FRa
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
	
TTDDRUID	D09NVR
DRUGNAME	PRN2246
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D09NVU
DRUGNAME	ZP-1848
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1
	
TTDDRUID	D09NWW
DRUGNAME	AMG-247
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D09NXZ
DRUGNAME	HL-038
INDICATI	Angina pectoris [ICD-11: BA40] Investigative
	
TTDDRUID	D09NYB
DRUGNAME	CASTANOSPERMINE
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D09NYS
DRUGNAME	Methylene blue
INDICATI	Acquired methemoglobinemia [ICD-11: 3A93] Approved
	
TTDDRUID	D09NYU
DRUGNAME	Polaprezinc
INDICATI	Ulcer [ICD-11: CA02-CB40] Approved
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Approved
	
TTDDRUID	D09OAQ
DRUGNAME	TNP-470
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D09OBB
DRUGNAME	Dextromethorphan
INDICATI	Cough [ICD-11: MD12] Approved
	
TTDDRUID	D09OBF
DRUGNAME	CMUS-100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09OCK
DRUGNAME	UK-371800
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 1
	
TTDDRUID	D09ODU
DRUGNAME	XL475
INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical
	
TTDDRUID	D09OHH
DRUGNAME	OS-440
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	Muscle spasm [ICD-11: MB47.3] Application submitted
	
TTDDRUID	D09OHP
DRUGNAME	Indeglitazar
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D09OHR
DRUGNAME	SY-1365
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09OHW
DRUGNAME	Dendritic cell therapy
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D09OJI
DRUGNAME	D-0502
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D09OJQ
DRUGNAME	Methadone
INDICATI	Dry cough [ICD-11: MD12] Approved
	
TTDDRUID	D09OKV
DRUGNAME	Amprenavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D09OKZ
DRUGNAME	CA4P
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D09OLR
DRUGNAME	Debio-1141
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D09OLZ
DRUGNAME	Cetrorelix
INDICATI	Ovarian stimulation [ICD-11: LB45.1] Approved
	
TTDDRUID	D09OMK
DRUGNAME	Tarvacin Anti-Viral
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1
	
TTDDRUID	D09ONL
DRUGNAME	SAR439794
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1
	
TTDDRUID	D09OOC
DRUGNAME	Gp100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D09OOQ
DRUGNAME	TGFK08AA
INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 2
	
TTDDRUID	D09OOV
DRUGNAME	Polymyxin B Sulfate
INDICATI	Pseudomonas infection [ICD-11: 1B92] Approved
	
TTDDRUID	D09OPH
DRUGNAME	NPB-3
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative
	
TTDDRUID	D09OPS
DRUGNAME	SN-28049
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09OQV
DRUGNAME	N-0923
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D09ORU
DRUGNAME	ZELANDOPAM HYDROCHLORIDE
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D09OSC
DRUGNAME	Anti-EGFRvIII CAR T cells
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D09OSM
DRUGNAME	TGFTX-1
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D09OTF
DRUGNAME	ACEA-1031
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D09OTG
DRUGNAME	MS-377
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D09OTU
DRUGNAME	SSR-180575
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D09OTX
DRUGNAME	RG7800
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 1/2
	
TTDDRUID	D09OUT
DRUGNAME	NN-818
INDICATI	Brain injury [ICD-11: NA07.Z] Preclinical
	
TTDDRUID	D09OWC
DRUGNAME	SKLB-010
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D09OWI
DRUGNAME	HDV-insulin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2/3
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D09OWK
DRUGNAME	AGN-2979
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2
	
TTDDRUID	D09OXR
DRUGNAME	Diffistat-G
INDICATI	Clostridium infection [ICD-11: 1A04] Discontinued in Phase 2
	
TTDDRUID	D09OZC
DRUGNAME	Lucanthone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D09PAU
DRUGNAME	M87o
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D09PCL
DRUGNAME	JNJ-64565111
INDICATI	Obesity [ICD-11: 5B81] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D09PDK
DRUGNAME	F-9TG
INDICATI	Factor IX deficiency [ICD-11: 3B11] Investigative
	
TTDDRUID	D09PEQ
DRUGNAME	Gentamicine sulfate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D09PEV
DRUGNAME	Itazigrel
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D09PFR
DRUGNAME	LAMB3-transduced autologous epidermal stem cells
INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Phase 1
	
TTDDRUID	D09PGG
DRUGNAME	MVI-816
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D09PGH
DRUGNAME	PA-508
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D09PGL
DRUGNAME	Capromab
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D09PGM
DRUGNAME	BY-1949
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D09PGT
DRUGNAME	T2c-002
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D09PHB
DRUGNAME	Mefenamic
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D09PIH
DRUGNAME	NK-1007
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D09PJB
DRUGNAME	ARG301
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D09PJX
DRUGNAME	Tetrabenazine
INDICATI	Hyperkinetic movement disorder [ICD-11: 6B60.8] Approved
INDICATI	Huntington disease [ICD-11: 8A01.10] Approved
	
TTDDRUID	D09PKU
DRUGNAME	ERBULOZOLE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D09PKZ
DRUGNAME	NM-9308
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D09PLF
DRUGNAME	Org-30029
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D09PLI
DRUGNAME	Efalith
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D09PLZ
DRUGNAME	NI-1201
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D09PMV
DRUGNAME	Interferon Alfa-2a, Recombinant
INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Approved
	
TTDDRUID	D09PNS
DRUGNAME	UGP-281
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D09PNV
DRUGNAME	KSG-504
INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Investigative
	
TTDDRUID	D09PNY
DRUGNAME	Tropicamide
INDICATI	Mydriasis [ICD-11: LA11.62] Approved
	
TTDDRUID	D09POH
DRUGNAME	AEG-33773
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
	
TTDDRUID	D09PON
DRUGNAME	MRLP-098
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D09POQ
DRUGNAME	OM-174
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09PPF
DRUGNAME	CNS-1067
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D09PPG
DRUGNAME	Metformin arginine-hemisuccinimide
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D09PPU
DRUGNAME	CA-170
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09PQP
DRUGNAME	SGN-70
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D09PQZ
DRUGNAME	Acalabrutinib
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Approved
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
	
TTDDRUID	D09PRN
DRUGNAME	TROVIRDINE HYDROCHLORIDE
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D09PRY
DRUGNAME	CB-28
INDICATI	Aging skin [ICD-11: EE40] Terminated
	
TTDDRUID	D09PSB
DRUGNAME	DPC-082
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D09PSY
DRUGNAME	ANS-6637
INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 1
	
TTDDRUID	D09PSZ
DRUGNAME	Deferitrin
INDICATI	Iron overload disease [ICD-11: 5C64.10] Phase 1/2
	
TTDDRUID	D09PTA
DRUGNAME	HP-290
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2
	
TTDDRUID	D09PTD
DRUGNAME	BMS-986168
INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1
	
TTDDRUID	D09PTL
DRUGNAME	SRI-3072
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Terminated
	
TTDDRUID	D09PTP
DRUGNAME	CEP-28122
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09PTY
DRUGNAME	V-212
INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Phase 3
INDICATI	Zoster [ICD-11: 1E91] Phase 3
	
TTDDRUID	D09PUL
DRUGNAME	L-Alanine
INDICATI	Glioma [ICD-11: 2A00.0] Approved
INDICATI	Dietary shortage [ICD-11: 5B5K] Approved
	
TTDDRUID	D09PVO
DRUGNAME	Aramchol
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2/3
	
TTDDRUID	D09PWS
DRUGNAME	KI-0902
INDICATI	Gastrointestinal ulcer [ICD-11: DA60.Z] Investigative
	
TTDDRUID	D09PYD
DRUGNAME	CGS-25462
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D09PYV
DRUGNAME	AZ-40140
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D09PYZ
DRUGNAME	MK-3328
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D09PZO
DRUGNAME	Idoxuridine
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Approved
	
TTDDRUID	D09PZV
DRUGNAME	ITV-4
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D09PZZ
DRUGNAME	Lypressin
INDICATI	Amnesia [ICD-11: MB21.1] Approved
	
TTDDRUID	D09QAD
DRUGNAME	CGS-15873A
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2
	
TTDDRUID	D09QBG
DRUGNAME	Cangrelor
INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved
	
TTDDRUID	D09QDP
DRUGNAME	Clorgyline
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
INDICATI	Skin imperfections [ICD-11: EK71] Patented
	
TTDDRUID	D09QEI
DRUGNAME	Pentoxifylline
INDICATI	Intermittent claudication [ICD-11: BD40.00] Approved
	
TTDDRUID	D09QHP
DRUGNAME	PS-873266
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D09QHU
DRUGNAME	SD-560
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Investigative
	
TTDDRUID	D09QIJ
DRUGNAME	PF-3491165
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D09QKI
DRUGNAME	PPL-100
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D09QLR
DRUGNAME	Dibenzothiazepines
INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Investigative
	
TTDDRUID	D09QMX
DRUGNAME	Q-301
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D09QOF
DRUGNAME	EM-2487
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D09QOR
DRUGNAME	Eniluracil
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D09QPD
DRUGNAME	HPP-515
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D09QPE
DRUGNAME	AP-1189
INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative
	
TTDDRUID	D09QQE
DRUGNAME	Crodox
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D09QQS
DRUGNAME	Diazepinone derivative 1
INDICATI	Reflux disease [ICD-11: DA22] Patented
INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented
	
TTDDRUID	D09QRG
DRUGNAME	BXT-25
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D09QRI
DRUGNAME	NX-001
INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 1
	
TTDDRUID	D09QRO
DRUGNAME	CGS-13080
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D09QRS
DRUGNAME	Chondrocelect
INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Approved
	
TTDDRUID	D09QSC
DRUGNAME	PSMA protein vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D09QTS
DRUGNAME	LC-01
INDICATI	Ocular inflammation [ICD-11: 9C61.24] Investigative
	
TTDDRUID	D09QUE
DRUGNAME	MVA-BN HIV Polytope
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2
	
TTDDRUID	D09QUQ
DRUGNAME	Levobupivacaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D09QVI
DRUGNAME	LQB-118
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09QVR
DRUGNAME	BMS-986218
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D09QVT
DRUGNAME	Streptococcus vaccines
INDICATI	Streptococcus infection [ICD-11: 1B53] Terminated
	
TTDDRUID	D09QVU
DRUGNAME	APH-0703
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D09QVV
DRUGNAME	Vincristine
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
	
TTDDRUID	D09QWD
DRUGNAME	CEP-37251
INDICATI	Bone metastases [ICD-11: 2D50] Phase 1
	
TTDDRUID	D09QWK
DRUGNAME	AMG-327
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D09QWN
DRUGNAME	CB4211
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1
	
TTDDRUID	D09QXC
DRUGNAME	PMID25666693-Compound-79
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D09QYD
DRUGNAME	ILS920
INDICATI	Stroke [ICD-11: 8B20] Phase 1
	
TTDDRUID	D09QZB
DRUGNAME	Resorcinol compound 32
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D09QZI
DRUGNAME	Norgestimate
INDICATI	Contraception [ICD-11: QA21] Approved
	
TTDDRUID	D09QZK
DRUGNAME	RIG-I adjuvant
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09QZS
DRUGNAME	Olaratumab
INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Approved
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D09RAB
DRUGNAME	PRO-300
INDICATI	Mucositis [ICD-11: CA00] Investigative
	
TTDDRUID	D09RBQ
DRUGNAME	Zutectra
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D09RDT
DRUGNAME	GT-3021
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Discontinued in Phase 1
	
TTDDRUID	D09RED
DRUGNAME	Prostat
INDICATI	Prostate hyperplasia [ICD-11: GA90] Approved
	
TTDDRUID	D09RGS
DRUGNAME	Anti-CD97 mab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D09RGW
DRUGNAME	AZD-3778
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D09RHQ
DRUGNAME	Ropivacaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D09RHS
DRUGNAME	Arilvax
INDICATI	Yellow fever virus infection [ICD-11: 1D47] Approved
	
TTDDRUID	D09RII
DRUGNAME	Voxelotor
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Approved
	
TTDDRUID	D09RJA
DRUGNAME	RELVARTM or BREOTM ELLIPTATM
INDICATI	Asthma [ICD-11: CA23] NDA filed
	
TTDDRUID	D09RJN
DRUGNAME	S-17092-1
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial
	
TTDDRUID	D09RKU
DRUGNAME	SCH-1518291
INDICATI	Schizophrenia [ICD-11: 6A20] Investigative
	
TTDDRUID	D09RLQ
DRUGNAME	CDX-1127
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D09RMS
DRUGNAME	AMT-070
INDICATI	Liver cirrhosis [ICD-11: DB93.1] Terminated
	
TTDDRUID	D09RMU
DRUGNAME	GPI-0100
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D09RMZ
DRUGNAME	HibTITER
INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2
	
TTDDRUID	D09RND
DRUGNAME	EZN-4176
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D09RNI
DRUGNAME	ESN-YY
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D09RNP
DRUGNAME	GSK 679769
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Discontinued in Phase 2
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
INDICATI	Incontinence [ICD-11: MF50.2] Discontinued in Phase 2
	
TTDDRUID	D09RON
DRUGNAME	LY-2300559
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2
	
TTDDRUID	D09RPB
DRUGNAME	DFD-06
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
	
TTDDRUID	D09RPP
DRUGNAME	CAR-GPC3 T cell
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Clinical trial
	
TTDDRUID	D09RPU
DRUGNAME	4'-GALACTOSYLLACTOSE
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D09RRG
DRUGNAME	BK-4SP
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D09RSN
DRUGNAME	MediPhage MRPA
INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative
	
TTDDRUID	D09RSY
DRUGNAME	Onyvax-P
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D09RTF
DRUGNAME	VT-1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D09RTK
DRUGNAME	Tapet
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09RUJ
DRUGNAME	SX-GLP1
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D09RUO
DRUGNAME	SGN-CD352A
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D09RUW
DRUGNAME	Iomeprol
INDICATI	Brain disease [ICD-11: 8C70-8E61] Approved
	
TTDDRUID	D09RVI
DRUGNAME	Tegobuvir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D09RXG
DRUGNAME	EA-230
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 2
	
TTDDRUID	D09RYU
DRUGNAME	Tractinostat
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09RZB
DRUGNAME	BBI-11008
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D09RZH
DRUGNAME	AdRTVP-1
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D09RZM
DRUGNAME	E-1101
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D09SAH
DRUGNAME	PZ01 CAR-T cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D09SAU
DRUGNAME	IMM-160
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative
	
TTDDRUID	D09SAV
DRUGNAME	Dendritic cell PEG fusion cancer vaccine
INDICATI	Kidney cancer [ICD-11: 2C90.0] Discontinued in Phase 1/2
	
TTDDRUID	D09SBE
DRUGNAME	Anti-CD7 CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D09SBY
DRUGNAME	Hebervis
INDICATI	Oral mucositis [ICD-11: DA01.11] Investigative
	
TTDDRUID	D09SCI
DRUGNAME	SKF-104351
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D09SCP
DRUGNAME	ADXS-PSA
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D09SFH
DRUGNAME	R-82150
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D09SFV
DRUGNAME	LY294002
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
	
TTDDRUID	D09SFX
DRUGNAME	AGEN1884
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09SGL
DRUGNAME	BTP-114
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09SGV
DRUGNAME	Daclatasvir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved
	
TTDDRUID	D09SHC
DRUGNAME	ALT-804
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09SHH
DRUGNAME	BAX-817
INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 3
	
TTDDRUID	D09SHL
DRUGNAME	S. epidermidis vaccine
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 1
	
TTDDRUID	D09SHX
DRUGNAME	GM-CSF cancer vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D09SIK
DRUGNAME	Azaribine
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
	
TTDDRUID	D09SIR
DRUGNAME	Lonidamine
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Discontinued in Phase 3
	
TTDDRUID	D09SJE
DRUGNAME	KB002/003
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D09SLI
DRUGNAME	Aryl mannoside derivative 13
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D09SLU
DRUGNAME	LG-101280
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D09SMA
DRUGNAME	PMID25666693-Compound-128
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D09SMG
DRUGNAME	Hepatyrix
INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Approved
	
TTDDRUID	D09SOA
DRUGNAME	Clonixin
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Approved
	
TTDDRUID	D09SOD
DRUGNAME	RAP-102
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D09SQM
DRUGNAME	VAY736
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2
INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D09SRR
DRUGNAME	Unoprostone
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D09SRZ
DRUGNAME	Recombinant factor IX-Fc
INDICATI	Haemophilia B [ICD-11: 3B11.0] Approved
	
TTDDRUID	D09SSC
DRUGNAME	Nipradilol
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D09SSY
DRUGNAME	Foscarnet + Cidofovir
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative
	
TTDDRUID	D09SVB
DRUGNAME	SEB-Humab
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative
	
TTDDRUID	D09SWM
DRUGNAME	Epostane
INDICATI	Abortion [ICD-11: JA00] Investigative
	
TTDDRUID	D09SXJ
DRUGNAME	NC-0604
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09SXR
DRUGNAME	KRH-102053
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09SYB
DRUGNAME	J5dLPS/OMP
INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 1
	
TTDDRUID	D09SZY
DRUGNAME	IQ-DAA
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 1
	
TTDDRUID	D09TAB
DRUGNAME	Pexidartinib
INDICATI	Tenosynovial giant cell tumour [ICD-11: 2F7B] Approved
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
INDICATI	Pigmented villonodular synovitis [ICD-11: FA27.1] Phase 3
INDICATI	Neurofibromatosis type 1 [ICD-11: LD2D.10] Phase 1/2
	
TTDDRUID	D09TBD
DRUGNAME	Sulfisoxazole
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D09TBM
DRUGNAME	PRX-12261
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D09TCY
DRUGNAME	CDX-1401
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D09TDG
DRUGNAME	NFTB-104
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D09TDK
DRUGNAME	DPN-205-734
INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D09TEI
DRUGNAME	ReN-1869
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D09TFB
DRUGNAME	TOFIMILAST
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D09TFL
DRUGNAME	PCI-27483
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D09TGC
DRUGNAME	MK-1903
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2
	
TTDDRUID	D09TGD
DRUGNAME	KUR-112
INDICATI	Bone disease [ICD-11: FC0Z] Phase 1
	
TTDDRUID	D09TGO
DRUGNAME	Autologous ET1402L1-CART cells
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1
INDICATI	Metastatic liver cancer [ICD-11: 2C12] Phase 1
	
TTDDRUID	D09TGT
DRUGNAME	Atu-027
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09TGX
DRUGNAME	Valspodar
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 3
	
TTDDRUID	D09TGZ
DRUGNAME	Examorelin
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Discontinued in Phase 2
	
TTDDRUID	D09THN
DRUGNAME	IMGN901
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D09TIW
DRUGNAME	SLP-0904
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D09TJJ
DRUGNAME	Pamrevlumab
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D09TJV
DRUGNAME	PGC-lysostaphin
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative
	
TTDDRUID	D09TKY
DRUGNAME	Biaryl mannoside derivative 7
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D09TLE
DRUGNAME	Tefinostat
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09TLJ
DRUGNAME	ATOFLUDING
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D09TLT
DRUGNAME	BZF961
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2
	
TTDDRUID	D09TMV
DRUGNAME	AZD-4619
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1
	
TTDDRUID	D09TNR
DRUGNAME	Ki-23057
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09TOK
DRUGNAME	PF-4531083
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D09TOL
DRUGNAME	RG-7816
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 1
	
TTDDRUID	D09TOS
DRUGNAME	ST-669
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D09TPF
DRUGNAME	Molindone
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D09TPW
DRUGNAME	PF-04475270
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D09TQI
DRUGNAME	VT-401
INDICATI	Muscular dystrophy [ICD-11: 8C70] Investigative
	
TTDDRUID	D09TQY
DRUGNAME	Dusigitumab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D09TRM
DRUGNAME	D-5410
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D09TSD
DRUGNAME	I-vation
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 2
	
TTDDRUID	D09TSX
DRUGNAME	CEL-011
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D09TUW
DRUGNAME	Hepatitis C vaccine
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D09TVH
DRUGNAME	TCH-013
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D09TXA
DRUGNAME	HelicoVax
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Investigative
	
TTDDRUID	D09TXG
DRUGNAME	CEMADOTIN HYDROCHLORIDE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D09TXO
DRUGNAME	humanin
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
	
TTDDRUID	D09TXU
DRUGNAME	DT-831j
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D09TYS
DRUGNAME	Loviride
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D09TYX
DRUGNAME	GC-501
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D09UAI
DRUGNAME	TB-402
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2
INDICATI	Venous thromboembolism [ICD-11: BD72] Phase 2
	
TTDDRUID	D09UCO
DRUGNAME	BMS-986046
INDICATI	Heart failure [ICD-11: BD10-BD13] Preclinical
	
TTDDRUID	D09UCU
DRUGNAME	APT3111
INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Investigative
	
TTDDRUID	D09UCV
DRUGNAME	SRW-LAMP-vax
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D09UDL
DRUGNAME	LTX-315
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09UFV
DRUGNAME	AZD-5423
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D09UFZ
DRUGNAME	CD38 CAR T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D09UGG
DRUGNAME	Zemab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09UGP
DRUGNAME	RPR-106541
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D09UHY
DRUGNAME	SMK-01/03
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D09UIM
DRUGNAME	LXR-0151
INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 1
	
TTDDRUID	D09UJB
DRUGNAME	PMID28350212-Compound-19
INDICATI	Alzheimer disease [ICD-11: 8A20] Patented
	
TTDDRUID	D09UKH
DRUGNAME	XL550
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D09UMN
DRUGNAME	LEQ-506
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09UMP
DRUGNAME	MN-305
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2
	
TTDDRUID	D09UMR
DRUGNAME	UV1 + GM-CSF vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D09UQS
DRUGNAME	LPG-1030I
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D09URP
DRUGNAME	DABIS MALEATE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09URT
DRUGNAME	OCO-1112
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D09USN
DRUGNAME	IC-485
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D09UTQ
DRUGNAME	GC-7101
INDICATI	Stomach ulcer [ICD-11: DA60.Z] Investigative
	
TTDDRUID	D09UVK
DRUGNAME	MK-8835A
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D09UVX
DRUGNAME	PRX-12247
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D09UXE
DRUGNAME	Fosmidomycin
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D09UXI
DRUGNAME	MGN-5804
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D09UXP
DRUGNAME	AZD-1744
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D09UXU
DRUGNAME	T1-1081
INDICATI	Macular degeneration [ICD-11: 9B78.3] Investigative
	
TTDDRUID	D09UZB
DRUGNAME	Glucopyranoside derivatives
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D09UZL
DRUGNAME	TAK-063
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D09UZO
DRUGNAME	Mercaptopurine
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
INDICATI	Crohn disease [ICD-11: DD70] Phase 4
	
TTDDRUID	D09VAB
DRUGNAME	BPR1K-0224
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09VAD
DRUGNAME	Angiopoietin 2 mAb
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09VAS
DRUGNAME	M281
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
	
TTDDRUID	D09VAZ
DRUGNAME	TRIENTINE
INDICATI	Inborn error of metabolism [ICD-11: 5C50-5C59] Approved
	
TTDDRUID	D09VBC
DRUGNAME	Carbetapentane
INDICATI	Cough [ICD-11: MD12] Approved
	
TTDDRUID	D09VBE
DRUGNAME	Elinogrel
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1
	
TTDDRUID	D09VBN
DRUGNAME	CTX110
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D09VCC
DRUGNAME	PL-6983
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D09VFA
DRUGNAME	Live attenuated cholera vaccine
INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Phase 2
	
TTDDRUID	D09VFU
DRUGNAME	MST-400
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09VFX
DRUGNAME	SAR342434
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D09VGC
DRUGNAME	Milnacipran
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D09VHA
DRUGNAME	BDF-9148
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Terminated
	
TTDDRUID	D09VHS
DRUGNAME	EM-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09VIX
DRUGNAME	VRC01LS
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D09VKP
DRUGNAME	C-Cure
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2/3
INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 2/3
	
TTDDRUID	D09VLQ
DRUGNAME	VP-50406
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2
	
TTDDRUID	D09VMI
DRUGNAME	Cediranib
INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 3
	
TTDDRUID	D09VOK
DRUGNAME	Trientine Hydrochloride
INDICATI	Wilson disease [ICD-11: 5C64.00] Approved
	
TTDDRUID	D09VOS
DRUGNAME	ETI-204
INDICATI	Anthrax [ICD-11: 1B97] Approved
	
TTDDRUID	D09VQO
DRUGNAME	CLR-901
INDICATI	Neurological disorder [ICD-11: 6B60] Terminated
	
TTDDRUID	D09VQW
DRUGNAME	MCTP-39
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D09VRO
DRUGNAME	Cyclohexyl carbamate derivative 6
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D09VRZ
DRUGNAME	AZM-131
INDICATI	Obesity [ICD-11: 5B81] Terminated
	
TTDDRUID	D09VSV
DRUGNAME	PH80-PMD
INDICATI	Migraine [ICD-11: 8A80] Phase 3
	
TTDDRUID	D09VTB
DRUGNAME	IDX-320
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2
	
TTDDRUID	D09VWI
DRUGNAME	BRX-005
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2
	
TTDDRUID	D09VXM
DRUGNAME	Crofelemer
INDICATI	HIV-associated diarrhoea [ICD-11: 1A2Z] Approved
	
TTDDRUID	D09VYF
DRUGNAME	RDEN1delta30
INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 2
	
TTDDRUID	D09VYS
DRUGNAME	BXL-1H5
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D09VYT
DRUGNAME	CD19-targeted CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Clinical trial
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Clinical trial
	
TTDDRUID	D09VZR
DRUGNAME	SGI-1252
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09WAY
DRUGNAME	OPN-501
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D09WBQ
DRUGNAME	DSM2
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D09WCC
DRUGNAME	MP-0270
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D09WCE
DRUGNAME	IS-159
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2
	
TTDDRUID	D09WCM
DRUGNAME	Spinosad
INDICATI	Head and body lice [ICD-11: 1G00.0] Approved
	
TTDDRUID	D09WCN
DRUGNAME	Intetumumab
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D09WDK
DRUGNAME	Tbo-Filgrastim
INDICATI	Neutropenia [ICD-11: 4B00.0] Approved
	
TTDDRUID	D09WEJ
DRUGNAME	Bromopride
INDICATI	Dyspepsia [ICD-11: MD92] Approved
	
TTDDRUID	D09WFI
DRUGNAME	Tetramethylpyrazine
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2
	
TTDDRUID	D09WFL
DRUGNAME	MP-12
INDICATI	Rift valley fever [ICD-11: 1D44] Phase 2
	
TTDDRUID	D09WGH
DRUGNAME	Ropidoxuridine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1
	
TTDDRUID	D09WGU
DRUGNAME	PEG-VM-501
INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative
	
TTDDRUID	D09WHM
DRUGNAME	DU-29894
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1
	
TTDDRUID	D09WIM
DRUGNAME	AviFluCide-I
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D09WIR
DRUGNAME	CC-90009
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D09WJT
DRUGNAME	Toleragens
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D09WKB
DRUGNAME	Anisindione
INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
	
TTDDRUID	D09WKH
DRUGNAME	Zosyn/Tazocin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D09WKM
DRUGNAME	BI-836826
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D09WKT
DRUGNAME	ARD-412
INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Investigative
	
TTDDRUID	D09WMV
DRUGNAME	BMS-753951
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D09WND
DRUGNAME	TETRAPLATIN TETRANITRATE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D09WNK
DRUGNAME	Fenfluramine
INDICATI	Dravet syndrome [ICD-11: 8A61.11] Phase 3
INDICATI	LennoxGastaut syndrome [ICD-11: 8A62.1] Phase 3
INDICATI	Obesity [ICD-11: 5B81] Withdrawn from market
	
TTDDRUID	D09WNQ
DRUGNAME	NCTX
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09WOI
DRUGNAME	NZ-39000
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D09WOY
DRUGNAME	SB-559457
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative
	
TTDDRUID	D09WPI
DRUGNAME	GOVX-B11
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D09WPN
DRUGNAME	AP22408
INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated
	
TTDDRUID	D09WRG
DRUGNAME	CEP-41750
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D09WRI
DRUGNAME	ELINAFIDE MESILATE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D09WSR
DRUGNAME	PCA062
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09WTQ
DRUGNAME	RC-8800
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D09WUY
DRUGNAME	TP-104
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D09WVR
DRUGNAME	FX-107
INDICATI	Dengue fever [ICD-11: 1D2Z] Preclinical
	
TTDDRUID	D09WWB
DRUGNAME	MenABCWY
INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 2
	
TTDDRUID	D09WXY
DRUGNAME	CDX-014
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D09WYC
DRUGNAME	Y-26611
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D09WYE
DRUGNAME	NST-001
INDICATI	Tinnitus [ICD-11: MC41] Phase 1
	
TTDDRUID	D09WYL
DRUGNAME	GSK-557296
INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Phase 2
	
TTDDRUID	D09WYX
DRUGNAME	Deflazacort
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Approved
	
TTDDRUID	D09WZG
DRUGNAME	Anascorp
INDICATI	Poison intoxication [ICD-11: NE6Z] Phase 3
	
TTDDRUID	D09WZU
DRUGNAME	BCI-838
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1
	
TTDDRUID	D09WZV
DRUGNAME	GMA-161
INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Approved (orphan drug)
	
TTDDRUID	D09XCX
DRUGNAME	PIRINIXIC ACID
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Preclinical
	
TTDDRUID	D09XDR
DRUGNAME	Granulosin
INDICATI	Chronic granulomatous disease [ICD-11: 4A00.0Y] Investigative
	
TTDDRUID	D09XEM
DRUGNAME	NGN-9080
INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative
	
TTDDRUID	D09XGB
DRUGNAME	VER 50589
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D09XGK
DRUGNAME	Testetrol
INDICATI	Hypogonadism [ICD-11: 5A61.0] Investigative
	
TTDDRUID	D09XHI
DRUGNAME	AZD-6538
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1
	
TTDDRUID	D09XHQ
DRUGNAME	TA-CD
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2
	
TTDDRUID	D09XHU
DRUGNAME	HER-2 Protein AutoVac
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D09XIZ
DRUGNAME	JNJ-26481585
INDICATI	Advanced stage follicular lymphoma [ICD-11: 2A80] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D09XJF
DRUGNAME	EPI 589
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D09XKO
DRUGNAME	KD-101
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1
	
TTDDRUID	D09XKT
DRUGNAME	KI-1003
INDICATI	Eating disorder [ICD-11: 6B82] Investigative
	
TTDDRUID	D09XKW
DRUGNAME	Castor oil
INDICATI	Constipation [ICD-11: DD91.1] Approved
	
TTDDRUID	D09XLS
DRUGNAME	FR139317
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1
	
TTDDRUID	D09XMP
DRUGNAME	SC-114
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D09XMX
DRUGNAME	SaxaDapa FDC
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
	
TTDDRUID	D09XNZ
DRUGNAME	CT-2408R
INDICATI	Shock [ICD-11: MG40] Terminated
	
TTDDRUID	D09XOF
DRUGNAME	NY-ESO-1 vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09XOR
DRUGNAME	Palladium Pd 103
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D09XPD
DRUGNAME	GivaRex
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09XPJ
DRUGNAME	Micacocidin A
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D09XQF
DRUGNAME	Isoniazid
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Approved
	
TTDDRUID	D09XQU
DRUGNAME	Tirapazamine
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
	
TTDDRUID	D09XRD
DRUGNAME	Comvax
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D09XRQ
DRUGNAME	HCBE-11
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09XSH
DRUGNAME	Cytoreg
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09XTN
DRUGNAME	Emicizumab
INDICATI	Factor VIII deficiency [ICD-11: 3B10] Approved
	
TTDDRUID	D09XUB
DRUGNAME	Viramidine
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
	
TTDDRUID	D09XUH
DRUGNAME	GASTRAZOLE
INDICATI	Duodenal ulcer [ICD-11: DA63] Phase 3
	
TTDDRUID	D09XUI
DRUGNAME	1,5-diphenylpyrrolidin-2-one derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D09XUY
DRUGNAME	Icofungipen
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2
	
TTDDRUID	D09XVQ
DRUGNAME	PT-14
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2
	
TTDDRUID	D09XVS
DRUGNAME	Tc-99m tilmanocept
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D09XWD
DRUGNAME	Teprenone
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D09XWT
DRUGNAME	AZP-03
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D09XXH
DRUGNAME	VCH-286
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D09XXW
DRUGNAME	Co-2-1068
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D09XYU
DRUGNAME	XR-12890
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D09XZB
DRUGNAME	Gefitinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
INDICATI	Urethral cancer [ICD-11: 2C93] Phase 2
	
TTDDRUID	D09XZL
DRUGNAME	LX-7101
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2
	
TTDDRUID	D09YAS
DRUGNAME	CYT-013-IL1bQb
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D09YBF
DRUGNAME	Gamma-tocotrienol
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D09YBZ
DRUGNAME	CO-12
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D09YDM
DRUGNAME	Camptothecin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D09YDO
DRUGNAME	Quinotolast
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D09YDQ
DRUGNAME	STX-107
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 2
	
TTDDRUID	D09YEY
DRUGNAME	Botulinum toxin type F
INDICATI	Dystonia [ICD-11: 8A02] Approved
	
TTDDRUID	D09YGK
DRUGNAME	Ultragrivak
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D09YGZ
DRUGNAME	OCT-002
INDICATI	Acute hyperammonaemia [ICD-11: 5C50.A] Phase 2
	
TTDDRUID	D09YHI
DRUGNAME	SX5
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative
	
TTDDRUID	D09YHJ
DRUGNAME	Ivermectin
INDICATI	Intestinal strongyloidiasis due to nematode parasite [ICD-11: 1F6B] Approved
	
TTDDRUID	D09YHL
DRUGNAME	MKG-02
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D09YJK
DRUGNAME	BMS-766
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D09YKI
DRUGNAME	Polyhydroxy benzamide derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D09YNJ
DRUGNAME	IQP-0410
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D09YPJ
DRUGNAME	SM08502
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09YRA
DRUGNAME	SSTarbaclofen
INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 2
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 2
	
TTDDRUID	D09YTH
DRUGNAME	CPU-228
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Investigative
	
TTDDRUID	D09YTY
DRUGNAME	Osutidine
INDICATI	Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 3
	
TTDDRUID	D09YUH
DRUGNAME	Anti-HIV peptides
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D09YUK
DRUGNAME	SS1(dsFv)-PE38
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D09YUQ
DRUGNAME	SR-11237
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D09YUS
DRUGNAME	KRG-3332
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated
	
TTDDRUID	D09YVQ
DRUGNAME	Chondrogen
INDICATI	Arthritis [ICD-11: FA20] Phase 1/2
	
TTDDRUID	D09YVX
DRUGNAME	Etofenamate
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D09YXN
DRUGNAME	CAR-T cells targeting Mesothelin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09YXS
DRUGNAME	GX-E2
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D09YXT
DRUGNAME	LY3321367
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D09YYQ
DRUGNAME	Aponidin
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D09ZAV
DRUGNAME	RG-8803
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Terminated
	
TTDDRUID	D09ZBJ
DRUGNAME	RAGE-immunoglobulin fusion protein
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Investigative
	
TTDDRUID	D09ZCA
DRUGNAME	Biphenyl mannoside derivative 24
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D09ZCH
DRUGNAME	HRC-201
INDICATI	Liver cancer [ICD-11: 2C12] Terminated
	
TTDDRUID	D09ZDY
DRUGNAME	CAR138 T Cells
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D09ZFF
DRUGNAME	HRC-101
INDICATI	Blood transfusion [ICD-11: QB98] Terminated
	
TTDDRUID	D09ZFJ
DRUGNAME	AMG 529
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D09ZGK
DRUGNAME	BCMA-CART
INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial
	
TTDDRUID	D09ZHZ
DRUGNAME	Mecobalamin
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved
	
TTDDRUID	D09ZIO
DRUGNAME	Eptifibatide
INDICATI	Acute cardiac ischemic events [ICD-11: BA40.Z] Approved
	
TTDDRUID	D09ZIS
DRUGNAME	Zonisamide
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D09ZJQ
DRUGNAME	Seocalcitol
INDICATI	Rickets [ICD-11: 5B57] Phase 3
	
TTDDRUID	D09ZKB
DRUGNAME	Ad35-GRIN/ENV
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D09ZKS
DRUGNAME	HP-228
INDICATI	Postoperative pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D09ZKU
DRUGNAME	DISBA-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D09ZLZ
DRUGNAME	RAD-140
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D09ZMV
DRUGNAME	Votucalis
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D09ZNL
DRUGNAME	ChronSeal
INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 1/2
	
TTDDRUID	D09ZNQ
DRUGNAME	Recombinant L-asparaginase
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Investigative
	
TTDDRUID	D09ZNS
DRUGNAME	Paramyxovirus therapy
INDICATI	Paramyxovirus infection [ICD-11: 1C8E.Y] Investigative
	
TTDDRUID	D09ZOQ
DRUGNAME	Incruse Ellipta
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D09ZPN
DRUGNAME	MK-6892
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D09ZPX
DRUGNAME	HSR-6071
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D09ZQN
DRUGNAME	Dienestrol
INDICATI	Atrophic vaginitis [ICD-11: GA30.2] Approved
	
TTDDRUID	D09ZQX
DRUGNAME	SL65.0155
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2
	
TTDDRUID	D09ZRB
DRUGNAME	PUR0200
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D09ZSC
DRUGNAME	Everolimus
INDICATI	Advanced/metastatic breast cancer [ICD-11: 2C60] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D09ZSO
DRUGNAME	Alefacept
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D09ZSY
DRUGNAME	CI-1012
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2
	
TTDDRUID	D09ZUM
DRUGNAME	CR-4892
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D09ZVC
DRUGNAME	Begacestat
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D09ZVJ
DRUGNAME	R-954
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D09ZVR
DRUGNAME	MDL-43291
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D09ZWH
DRUGNAME	LX2931
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Hereditary acantholytic dermatoses [ICD-11: EC20.2] Phase 2
	
TTDDRUID	D09ZWI
DRUGNAME	KUR-521
INDICATI	Back pain [ICD-11: ME84.Z] Investigative
	
TTDDRUID	D09ZWU
DRUGNAME	PMID25666693-Compound-40
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D09ZXO
DRUGNAME	Cilengitide
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D09ZXR
DRUGNAME	Eluxadoline
INDICATI	Diarrhea-predominant irritable bowel syndrome [ICD-11: DD91.01] Approved
	
TTDDRUID	D09ZYW
DRUGNAME	P53
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D09ZZB
DRUGNAME	EV71 vaccine
INDICATI	Enterovirus infection [ICD-11: 1D91] Phase 1
	
TTDDRUID	D09ZZF
DRUGNAME	IPH-41XX
INDICATI	Mycoses [ICD-11: 1F2Z] Investigative
	
TTDDRUID	D09ZZW
DRUGNAME	VX-759
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0A0BK
DRUGNAME	Cal-1
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0A0CC
DRUGNAME	Viperfav
INDICATI	Poison intoxication [ICD-11: NE6Z] Terminated
	
TTDDRUID	D0A0CY
DRUGNAME	CNDO-109
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D0A0EI
DRUGNAME	MP-0210
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0A0FB
DRUGNAME	ZYOG1
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0A0FG
DRUGNAME	NICANARTINE
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D0A0FI
DRUGNAME	FHT-401
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0A0FL
DRUGNAME	Bupivacaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0A0GU
DRUGNAME	E-52862
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0A0JH
DRUGNAME	Nafcillin
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0A0JM
DRUGNAME	Carotegrast
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0A0MJ
DRUGNAME	Nerve growth factor
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0A0MS
DRUGNAME	BI 655066
INDICATI	Chronic plaque psoriasis [ICD-11: EA90.0] Phase 3
INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Phase 2
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2
	
TTDDRUID	D0A0MT
DRUGNAME	KRL-103
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2
	
TTDDRUID	D0A0MU
DRUGNAME	FOZIVUDINE TIDOXIL
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D0A0NZ
DRUGNAME	LP-02
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
	
TTDDRUID	D0A0OO
DRUGNAME	Amprenavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0A0QH
DRUGNAME	Stapuldencel-T
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0A0RM
DRUGNAME	PMID26815044-Compound-51
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0A0SI
DRUGNAME	BAY 85-8501
INDICATI	Bronchiectasis [ICD-11: CA24] Phase 2
	
TTDDRUID	D0A0SK
DRUGNAME	HPH-116
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0A0SP
DRUGNAME	Pyrvinium
INDICATI	Worm infection [ICD-11: 1F90.Z] Approved
	
TTDDRUID	D0A0TF
DRUGNAME	Tc-99m ethylenedicysteine glucosamine
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0A0TI
DRUGNAME	TgAAC-09
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0A0TS
DRUGNAME	VesiculoVax
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D0A0TT
DRUGNAME	IONIS-AGT-LRX
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0A0UU
DRUGNAME	RG7828
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0A0YI
DRUGNAME	PMID25666693-Compound-34
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0A0YQ
DRUGNAME	CX-8998
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
INDICATI	Essential tremor or related tremors [ICD-11: 8A04.1] Phase 2
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0A0YZ
DRUGNAME	PYZD-4409
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D0A0ZW
DRUGNAME	ARN-6039
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0A0ZX
DRUGNAME	Glutathionarsenoxide
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D0A0ZY
DRUGNAME	ALD-901
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0A1AQ
DRUGNAME	Rosiglitazone + metformin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A1AS
DRUGNAME	Palivizumab
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Approved
	
TTDDRUID	D0A1CB
DRUGNAME	Cefepime
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0A1DG
DRUGNAME	KO-947
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A1DH
DRUGNAME	Nitrendipine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0A1DT
DRUGNAME	ICI-245991
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0A1FB
DRUGNAME	RPA gene based adenovirus 4 vector vaccine
INDICATI	Anthrax [ICD-11: 1B97] Phase 1
	
TTDDRUID	D0A1FG
DRUGNAME	MTL-005
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0A1GJ
DRUGNAME	CY-9652
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0A1GR
DRUGNAME	CALAA-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A1IL
DRUGNAME	VAL-083
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3
INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Phase 3
INDICATI	Grade IV malignant glioma [ICD-11: 2A00.0] Phase 1/2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0A1KP
DRUGNAME	SWT-05105
INDICATI	Vitiligo [ICD-11: ED63.0] Investigative
	
TTDDRUID	D0A1KR
DRUGNAME	JTK-652
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1
	
TTDDRUID	D0A1KU
DRUGNAME	PF-3274167
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Discontinued in Phase 1
	
TTDDRUID	D0A1LS
DRUGNAME	Genz-644282
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A1MK
DRUGNAME	HL-027
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0A1MX
DRUGNAME	Bapineuzumab
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0A1NU
DRUGNAME	ABT-279
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0A1PS
DRUGNAME	PRT-105
INDICATI	Poison intoxication [ICD-11: NE6Z] Phase 1
	
TTDDRUID	D0A1PX
DRUGNAME	Flurbiprofen
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0A1QC
DRUGNAME	Heparan sulfate
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative
	
TTDDRUID	D0A1RP
DRUGNAME	18F-fluorothymidine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0A1UL
DRUGNAME	RQ-00203078
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0A1VL
DRUGNAME	AR-R-1589
INDICATI	Eating disorder [ICD-11: 6B82] Preclinical
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0A1VS
DRUGNAME	Safflower Oil
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D0A1WN
DRUGNAME	PF-03715455
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0A1WS
DRUGNAME	ABBV-176
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A1XS
DRUGNAME	Colfosceril palmitate
INDICATI	Respiratory distress syndrome [ICD-11: CB00] Approved
	
TTDDRUID	D0A1XU
DRUGNAME	EVP-6308
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0A1YF
DRUGNAME	ABBV-3067
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1
	
TTDDRUID	D0A2AJ
DRUGNAME	Arglabin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0A2BK
DRUGNAME	KM-391
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Investigative
	
TTDDRUID	D0A2BO
DRUGNAME	S-110
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0A2BS
DRUGNAME	SelG2
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 2
	
TTDDRUID	D0A2CP
DRUGNAME	Emtricitabine/tenofovir alafenamide
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0A2GM
DRUGNAME	Heparin Calcium
INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0A2HR
DRUGNAME	Silver nitrate
INDICATI	Chlamydia infection [ICD-11: 1A81] Approved
	
TTDDRUID	D0A2HS
DRUGNAME	T-3.5
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0A2IH
DRUGNAME	KU-1257
INDICATI	Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 3
	
TTDDRUID	D0A2IK
DRUGNAME	NPS-846
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0A2KH
DRUGNAME	TRK-170
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
	
TTDDRUID	D0A2KL
DRUGNAME	OXS-1550
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	B-lineage leukaemia [ICD-11: 2A82.1] Phase 1/2
INDICATI	B-lineage lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0A2MA
DRUGNAME	FR-104
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0A2NA
DRUGNAME	PMID27998201-Compound-11
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0A2NH
DRUGNAME	IDEC-131
INDICATI	Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 1
	
TTDDRUID	D0A2OW
DRUGNAME	Otenzepad
INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2
	
TTDDRUID	D0A2PA
DRUGNAME	IMF-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A2PY
DRUGNAME	Pyrazole derivative 35
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0A2RA
DRUGNAME	TAK-491
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3
	
TTDDRUID	D0A2RF
DRUGNAME	KI-0906
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0A2RG
DRUGNAME	Conjugated estrogens a
INDICATI	Hormone replacement therapy [ICD-11: 8E01] Approved
	
TTDDRUID	D0A2RI
DRUGNAME	PMID26815044-Compound-127
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0A2RX
DRUGNAME	19-28z T CELLS
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0A2TJ
DRUGNAME	PBOX-15
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0A2UV
DRUGNAME	Ustekinumab
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2/3
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0A2VZ
DRUGNAME	D-3252
INDICATI	Coronavirus infection [ICD-11: 1D92] Phase 1
	
TTDDRUID	D0A2XD
DRUGNAME	TAK-065
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1
	
TTDDRUID	D0A2XV
DRUGNAME	HL-162
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D0A2XY
DRUGNAME	AGB101
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D0A2ZX
DRUGNAME	Metronidazole
INDICATI	Amoebiasis [ICD-11: 1A36] Approved
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
INDICATI	Perianal crohn disease [ICD-11: DD70.4] Phase 3
	
TTDDRUID	D0A3AB
DRUGNAME	NCY-118
INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated
	
TTDDRUID	D0A3AJ
DRUGNAME	4SC-301
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0A3CF
DRUGNAME	MK-1248
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A3CH
DRUGNAME	GRN-1201
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1
	
TTDDRUID	D0A3CL
DRUGNAME	AZD1979
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D0A3CW
DRUGNAME	Oleylphosphocholine
INDICATI	Leishmania infection [ICD-11: 1F54.0] Investigative
	
TTDDRUID	D0A3EA
DRUGNAME	Mu5B3
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0A3ES
DRUGNAME	OX-51
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0A3EX
DRUGNAME	GRC-15300
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0A3FQ
DRUGNAME	Rabies vaccine
INDICATI	Rabies [ICD-11: 1C82] Phase 3
	
TTDDRUID	D0A3FZ
DRUGNAME	Rilimogene galvacirepvec
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0A3HB
DRUGNAME	Propofol
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0A3HF
DRUGNAME	VE-16084
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0A3JJ
DRUGNAME	Pentacea
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0A3MJ
DRUGNAME	XEN007
INDICATI	Migraine [ICD-11: 8A80] Phase 1
	
TTDDRUID	D0A3MV
DRUGNAME	AR-A014418
INDICATI	Ovarian cancer [ICD-11: 2C73] Patented
	
TTDDRUID	D0A3NN
DRUGNAME	Aroplatin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0A3OA
DRUGNAME	TGX-003
INDICATI	Bone disease [ICD-11: FC0Z] Investigative
	
TTDDRUID	D0A3OE
DRUGNAME	Anti-C-met CAR-T cells
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
	
TTDDRUID	D0A3OF
DRUGNAME	GMC-283
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0A3OS
DRUGNAME	FLUINHIBIT
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0A3PF
DRUGNAME	TVX-001
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0A3PP
DRUGNAME	Biphenyl mannoside derivative 4
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0A3RP
DRUGNAME	Fedratinib
INDICATI	Polycythemia vera [ICD-11: 2A20.4] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0A3SQ
DRUGNAME	3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile
INDICATI	Glioma [ICD-11: 2A00.0] Investigative
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0A3SX
DRUGNAME	PTHr pepducins
INDICATI	Endocrine disease [ICD-11: 5B3Z] Investigative
	
TTDDRUID	D0A3VX
DRUGNAME	Glucocorticoid mimetics
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0A3WJ
DRUGNAME	Relatlimab
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2/3
INDICATI	Melanoma [ICD-11: 2C30] Phase 2/3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D0A3WZ
DRUGNAME	KBRV-201
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D0A3XA
DRUGNAME	CNS-1169
INDICATI	Schizophrenia [ICD-11: 6A20] Investigative
	
TTDDRUID	D0A3XC
DRUGNAME	PMID25666693-Compound-25
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0A3ZU
DRUGNAME	Pomalidomide
INDICATI	Systemic sclerosis [ICD-11: 4A42] Approved
	
TTDDRUID	D0A4BR
DRUGNAME	Aurothioglucose
INDICATI	Arthritis [ICD-11: FA20] Withdrawn from market
	
TTDDRUID	D0A4DP
DRUGNAME	LCS 16
INDICATI	Contraception [ICD-11: QA21] Phase 3
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0A4FE
DRUGNAME	OS-320
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
INDICATI	Dyskinesia [ICD-11: MB47.4] Phase 3
	
TTDDRUID	D0A4GQ
DRUGNAME	Tisotumab vedotin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D0A4HD
DRUGNAME	Allotrap-2702
INDICATI	Transplant rejection [ICD-11: NE84] Discontinued in Phase 2
	
TTDDRUID	D0A4IJ
DRUGNAME	Abacavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0A4JB
DRUGNAME	JDP-202
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0A4JI
DRUGNAME	NanoDisks
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D0A4JK
DRUGNAME	Butabarbital
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0A4KP
DRUGNAME	Tuberculosis therapeutics
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0A4MI
DRUGNAME	KPC-34
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0A4OT
DRUGNAME	TAMOLARIZINE HYDROCHLORIDE
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D0A4PJ
DRUGNAME	KTE-C19 CAR-T cell therapy
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2
	
TTDDRUID	D0A4RF
DRUGNAME	PMID17935984C1
INDICATI	Pain [ICD-11: MG30-MG3Z] Clinical trial
	
TTDDRUID	D0A4SU
DRUGNAME	WinRho SDF
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Approved
	
TTDDRUID	D0A4TU
DRUGNAME	MEDI-545
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D0A4UC
DRUGNAME	GS-6615
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 3
INDICATI	Long QT syndrome [ICD-11: BC65.0] Phase 3
	
TTDDRUID	D0A4UW
DRUGNAME	BAY-86-7548
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A4VI
DRUGNAME	AZD-2914
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated
	
TTDDRUID	D0A4VJ
DRUGNAME	CYT-500
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0A4VW
DRUGNAME	TP-110
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0A4WL
DRUGNAME	Creaferon
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Investigative
	
TTDDRUID	D0A4XJ
DRUGNAME	SU5402
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0A4XN
DRUGNAME	PRS-639058
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated
	
TTDDRUID	D0A4YE
DRUGNAME	Sulfaphenazole
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0A4YK
DRUGNAME	PBI-05204
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0A4ZZ
DRUGNAME	OHR/AVR118
INDICATI	Cachexia [ICD-11: MG20] Phase 2
	
TTDDRUID	D0A5BJ
DRUGNAME	EndoAngio-GT
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0A5BT
DRUGNAME	Camostat mesylate
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0A5CH
DRUGNAME	Integrin alpha-V/beta-3 receptor mab
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0A5CL
DRUGNAME	ABI-200
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0A5CM
DRUGNAME	Trolamine salicylate
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0A5CU
DRUGNAME	Ro-24-1882
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0A5CZ
DRUGNAME	DW-403
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0A5DJ
DRUGNAME	Pancrecarb
INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] NDA filed
	
TTDDRUID	D0A5EF
DRUGNAME	GW-427353
INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 2
	
TTDDRUID	D0A5EN
DRUGNAME	AMG-714
INDICATI	Coeliac disease [ICD-11: DA95] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D0A5FD
DRUGNAME	AR30
INDICATI	Mental disease [ICD-11: 6E8Z] Phase 2
	
TTDDRUID	D0A5FM
DRUGNAME	Nitric Oxide
INDICATI	Respiratory failure [ICD-11: CB41] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Tinea pedis [ICD-11: 1F28.2] Discontinued in Phase 2
	
TTDDRUID	D0A5HC
DRUGNAME	RV-568
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0A5IL
DRUGNAME	18F-NST-ML-10
INDICATI	Stroke [ICD-11: 8B20] Phase 2
	
TTDDRUID	D0A5JP
DRUGNAME	Iopanoic acid
INDICATI	Vascular disease [ICD-11: BE2Z] Approved
	
TTDDRUID	D0A5KF
DRUGNAME	IPN-120
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0A5KO
DRUGNAME	TD-3633
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D0A5KS
DRUGNAME	Hemoxin
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0A5LH
DRUGNAME	Penicillin G Procaine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0A5MC
DRUGNAME	MLN8054
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A5MD
DRUGNAME	PHA-568487
INDICATI	Cognitive impairment [ICD-11: 6D71] Preclinical
	
TTDDRUID	D0A5MI
DRUGNAME	LANIQUIDAR
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0A5NL
DRUGNAME	HS-HIV
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0A5NN
DRUGNAME	ECO-0501
INDICATI	Enterococcus faecium infection [ICD-11: 1D01.0Y] Investigative
	
TTDDRUID	D0A5OG
DRUGNAME	ReN-002
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0A5OT
DRUGNAME	Aromatic ethylene derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0A5PM
DRUGNAME	PPRT-550
INDICATI	Premenstrual syndrome [ICD-11: GA34.40] Terminated
	
TTDDRUID	D0A5RD
DRUGNAME	Radafaxine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D0A5SA
DRUGNAME	TAK-272
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0A5SE
DRUGNAME	Febuxostat
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Approved
	
TTDDRUID	D0A5SJ
DRUGNAME	B-cell lymphoma vaccine
INDICATI	Follicular lymphoma [ICD-11: 2A80] Preregistration
	
TTDDRUID	D0A5SR
DRUGNAME	Lenapenem hydrochloride hydrate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D0A5TM
DRUGNAME	SGB-1534
INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2
	
TTDDRUID	D0A5TS
DRUGNAME	EVT-101
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2
	
TTDDRUID	D0A5WQ
DRUGNAME	MRF-008
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0A5XN
DRUGNAME	Sprodiamide
INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 1/2
	
TTDDRUID	D0A5ZJ
DRUGNAME	DW-1350
INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated
	
TTDDRUID	D0A5ZL
DRUGNAME	Anti-LINGO
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0A6AP
DRUGNAME	Indigotindisulfonate
INDICATI	Bladder disease [ICD-11: DC11-DC1Z] Approved
	
TTDDRUID	D0A6CC
DRUGNAME	Depatuxizumab
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A6CQ
DRUGNAME	Levobetaxolol
INDICATI	Chronic open-angle glaucoma [ICD-11: 9C61.0] Approved
	
TTDDRUID	D0A6DK
DRUGNAME	Ruthenium (II) phosphine/picolinate complexes
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0A6DY
DRUGNAME	ATM AVI
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D0A6KA
DRUGNAME	CLL immunotherapeutic vaccine
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
	
TTDDRUID	D0A6KR
DRUGNAME	Balsalazide
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Approved
	
TTDDRUID	D0A6LT
DRUGNAME	PEG-bHb-CO
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2/3
INDICATI	Cerebral ischemia [ICD-11: 8B11] Phase 2
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 2
	
TTDDRUID	D0A6MN
DRUGNAME	SB773812
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0A6MS
DRUGNAME	Parke-Davis 9
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0A6NP
DRUGNAME	A35566-A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0A6NU
DRUGNAME	Haloperidol
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0A6OF
DRUGNAME	BMS-181321
INDICATI	Diagnostic imaging [ICD-11: N.A.] Investigative
	
TTDDRUID	D0A6OJ
DRUGNAME	TP-102
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0A6OO
DRUGNAME	PSI 7851
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0A6OS
DRUGNAME	TAK-379
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0A6PD
DRUGNAME	Oralgen Tree Pollen
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0A6PL
DRUGNAME	S-14506
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0A6QR
DRUGNAME	TMCB
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0A6RI
DRUGNAME	Meganucleases
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D0A6RX
DRUGNAME	Anti-hTfR IgG3-Av
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0A6SD
DRUGNAME	CLS008
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Application submitted
	
TTDDRUID	D0A6UQ
DRUGNAME	ETX-1153a
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Preclinical
	
TTDDRUID	D0A6VA
DRUGNAME	PVP-ILH
INDICATI	Conjunctivitis [ICD-11: 9A60] Phase 2
	
TTDDRUID	D0A6VD
DRUGNAME	VS-4718
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A6VE
DRUGNAME	FIDUXOSIN HYDROCHLORIDE
INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2
	
TTDDRUID	D0A6VM
DRUGNAME	VCL-HB01
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 2
	
TTDDRUID	D0A6WA
DRUGNAME	GAM-501
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
	
TTDDRUID	D0A6WQ
DRUGNAME	AG-4070
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0A6XC
DRUGNAME	CD19-targeted CART cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D0A6YN
DRUGNAME	SUN-C5174
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2
	
TTDDRUID	D0A7AG
DRUGNAME	CP51-2705
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0A7CH
DRUGNAME	WIP-901
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D0A7CO
DRUGNAME	Heparin
INDICATI	Venous thrombosis [ICD-11: BA43] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0A7CZ
DRUGNAME	PTX-007
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0A7GA
DRUGNAME	AMT-2003
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2/3
	
TTDDRUID	D0A7GE
DRUGNAME	Avanz
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0A7GH
DRUGNAME	ATI-2341
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Investigative
	
TTDDRUID	D0A7GI
DRUGNAME	BPZE-1
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Phase 1
	
TTDDRUID	D0A7GX
DRUGNAME	Echovist
INDICATI	Gynecological disease [ICD-11: GA6Z] Approved
	
TTDDRUID	D0A7HY
DRUGNAME	TAT-120
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative
	
TTDDRUID	D0A7JH
DRUGNAME	WY-50295-tromethamine
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0A7KI
DRUGNAME	Abaperidone
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0A7LL
DRUGNAME	PSMA ADC therapeutic
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0A7MY
DRUGNAME	TECFIDERA
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
	
TTDDRUID	D0A7NB
DRUGNAME	Siplizumab
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0A7NI
DRUGNAME	LIM-5310
INDICATI	Toxicity [ICD-11: N.A.] Investigative
	
TTDDRUID	D0A7NZ
DRUGNAME	CNTO-6785
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0A7PW
DRUGNAME	CP-903397
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0A7QN
DRUGNAME	Moxisylyte
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved
	
TTDDRUID	D0A7UK
DRUGNAME	PDS-0103
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D0A7UT
DRUGNAME	PF-04605412
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0A7VF
DRUGNAME	CP-79328
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0A7WO
DRUGNAME	NT-501
INDICATI	Ocular inflammation [ICD-11: 9C61.24] Phase 2/3
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 2/3
INDICATI	Macular telangiectasia type 2 [ICD-11: 9B75.3] Phase 2
	
TTDDRUID	D0A7WT
DRUGNAME	Dornase alpha
INDICATI	Cystic fibrosis [ICD-11: CA25] Approved
	
TTDDRUID	D0A7XQ
DRUGNAME	ON-044580
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0A7ZK
DRUGNAME	Lemborexant
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0A8AL
DRUGNAME	PFK-015
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0A8AU
DRUGNAME	MSB2311
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A8BK
DRUGNAME	MEN-10979
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0A8CJ
DRUGNAME	Tiopronin
INDICATI	Cystinuria [ICD-11: 5C60.2] Approved
INDICATI	Cystine urolithiasis [ICD-11: GB70-GB7Z] Approved
	
TTDDRUID	D0A8EG
DRUGNAME	TAK-591
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D0A8ES
DRUGNAME	EC-0845
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0A8FB
DRUGNAME	Trimethobenzamide
INDICATI	Nausea and vomiting [ICD-11: MD90] Approved
	
TTDDRUID	D0A8FD
DRUGNAME	S-18327
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1
	
TTDDRUID	D0A8GM
DRUGNAME	Ublituximab
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Nodal marginal zone lymphoma [ICD-11: 2A85.0] Phase 1/2
	
TTDDRUID	D0A8GW
DRUGNAME	PMID26651364-Compound-9e
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0A8HL
DRUGNAME	DMP-811
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0A8HN
DRUGNAME	Iboctadekin
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0A8IE
DRUGNAME	AM-831
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
	
TTDDRUID	D0A8IM
DRUGNAME	CF-238
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0A8IQ
DRUGNAME	ATX-MS2
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0A8JB
DRUGNAME	VAX-125
INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0A8JM
DRUGNAME	RDP58
INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2
	
TTDDRUID	D0A8KQ
DRUGNAME	GSK2256294
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0A8KX
DRUGNAME	M-518101
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
	
TTDDRUID	D0A8LP
DRUGNAME	AG2034
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A8LU
DRUGNAME	PMID25666693-Compound-113
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0A8LZ
DRUGNAME	BCG vaccine
INDICATI	Bladder cancer [ICD-11: 2C94] Approved
	
TTDDRUID	D0A8MH
DRUGNAME	M-516102
INDICATI	Pruritus [ICD-11: EC90] Phase 2
	
TTDDRUID	D0A8NN
DRUGNAME	CT-637
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0A8NW
DRUGNAME	PC-1005
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0A8PC
DRUGNAME	Influenza cell culture vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0A8QM
DRUGNAME	Lu-AA34893
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0A8RP
DRUGNAME	INDOPY-1
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0A8RV
DRUGNAME	Biaryl mannoside derivative 4
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0A8RX
DRUGNAME	Schizophyllan
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0A8TA
DRUGNAME	Volanesorsen
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Approved
INDICATI	Hyperlipoproteinemia [ICD-11: 5C80] Phase 3
INDICATI	Familial chylomicronemia syndrome [ICD-11: 5C80] Phase 1
	
TTDDRUID	D0A8UJ
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 9
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0A8UP
DRUGNAME	PMID15026062C41
INDICATI	Pancreatitis [ICD-11: DC31-DC34] Clinical trial
	
TTDDRUID	D0A8WR
DRUGNAME	LUpartumab amadotin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A8XN
DRUGNAME	Labetalol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0A8XY
DRUGNAME	Altropane
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
	
TTDDRUID	D0A8ZD
DRUGNAME	SR-33805
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1
	
TTDDRUID	D0A9BI
DRUGNAME	Hi-8 PrimeBoost therapeutic melanoma vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0A9BO
DRUGNAME	PG-120
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0A9BU
DRUGNAME	CB-24
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A9CV
DRUGNAME	INX-3280
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0A9CY
DRUGNAME	Pentisomide
INDICATI	Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 2
	
TTDDRUID	D0A9GE
DRUGNAME	FATE-NK100
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0A9GI
DRUGNAME	ILV-095
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0A9HT
DRUGNAME	Avastin
INDICATI	Brain metastases [ICD-11: 2D50] Phase 2
	
TTDDRUID	D0A9IY
DRUGNAME	PF-4447943
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 1
	
TTDDRUID	D0A9JA
DRUGNAME	Anti-CD44 mab
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative
	
TTDDRUID	D0A9JW
DRUGNAME	GPG
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2
	
TTDDRUID	D0A9KF
DRUGNAME	Calcium carbimide
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
	
TTDDRUID	D0A9KI
DRUGNAME	SB-242235
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D0A9ML
DRUGNAME	SelG1
INDICATI	Vaso-occlusive crisis [ICD-11: BE2Y] Phase 2
	
TTDDRUID	D0A9NN
DRUGNAME	Indinavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0A9OR
DRUGNAME	SLV319
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
	
TTDDRUID	D0A9OV
DRUGNAME	TAK165
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0A9PD
DRUGNAME	Lu AF20513
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0A9PN
DRUGNAME	GDC-0853
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
INDICATI	Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
	
TTDDRUID	D0A9PR
DRUGNAME	JNJ-61187191
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1
	
TTDDRUID	D0A9PW
DRUGNAME	AMT-060
INDICATI	Factor IX deficiency [ICD-11: 3B11] Phase 1/2
	
TTDDRUID	D0A9SA
DRUGNAME	Canfosfamide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0A9TA
DRUGNAME	MTL-007
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0A9TR
DRUGNAME	XT-101
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0A9VO
DRUGNAME	GYKI-52466
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0A9WW
DRUGNAME	FE-999040
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0A9YA
DRUGNAME	Dutasteride
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0A9YZ
DRUGNAME	APT-102
INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Investigative
	
TTDDRUID	D0A9ZA
DRUGNAME	NasoVac
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0A9ZX
DRUGNAME	Pentamycin
INDICATI	Vulvovaginitis [ICD-11: GA02.0] Approved
	
TTDDRUID	D0AA0L
DRUGNAME	Pancuronium
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0AA2D
DRUGNAME	Bifonazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D0AA2X
DRUGNAME	PNT-500
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0AA5K
DRUGNAME	ACT-101
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 1
	
TTDDRUID	D0AA6Z
DRUGNAME	Rambazole
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0AA8R
DRUGNAME	Sotirimod
INDICATI	Keratosis [ICD-11: ED56] Phase 2
	
TTDDRUID	D0AB2G
DRUGNAME	HL-022
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0AB4Q
DRUGNAME	Ispronicline
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2
	
TTDDRUID	D0AB7G
DRUGNAME	MCI-826
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0AC0A
DRUGNAME	SB-612111
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0AC6O
DRUGNAME	OBP-AI2
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0AC7C
DRUGNAME	IPS-01003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0AC8L
DRUGNAME	Proxinium
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1
	
TTDDRUID	D0AC8W
DRUGNAME	RC-3095
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0AC9S
DRUGNAME	CART-19/BCMA
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0AD0B
DRUGNAME	HIV vaccine Ad4-Clade C
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0AD3V
DRUGNAME	PF-06647020
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0AD4D
DRUGNAME	CXL-1020
INDICATI	Acute decompensated heart failure [ICD-11: BD1Z] Phase 2
	
TTDDRUID	D0AD4H
DRUGNAME	Cethrin
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1/2
	
TTDDRUID	D0AD4Z
DRUGNAME	Fasinumab
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
INDICATI	Chronic low back pain [ICD-11: MG30.02] Phase 3
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 3
	
TTDDRUID	D0AD5C
DRUGNAME	Acarbose
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
	
TTDDRUID	D0AD5S
DRUGNAME	SRP-4053
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D0AD6P
DRUGNAME	Danoprevir + ritonavir
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0AD6Z
DRUGNAME	mab 224G11
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0AD8L
DRUGNAME	Vivia-577
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0AD9Y
DRUGNAME	Kifunensine
INDICATI	Muscular dystrophy [ICD-11: 8C70] Terminated
	
TTDDRUID	D0AE1X
DRUGNAME	GS-9411
INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Phase 1
	
TTDDRUID	D0AE3U
DRUGNAME	SAR-113945
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
	
TTDDRUID	D0AE3X
DRUGNAME	Brimonidine
INDICATI	Ocular hypertension [ICD-11: 9C61.01] Approved
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3
	
TTDDRUID	D0AE5K
DRUGNAME	Oxyntomodulin
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0AE6Q
DRUGNAME	MBG453
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0AE8D
DRUGNAME	Benzothiazole analog 4
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0AF4F
DRUGNAME	HO-4073
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0AF5P
DRUGNAME	RVT-505
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D0AF6O
DRUGNAME	Lorlatinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
	
TTDDRUID	D0AF7D
DRUGNAME	APL-180
INDICATI	Heart disease [ICD-11: BA41-BA42] Discontinued in Phase 2
	
TTDDRUID	D0AF7N
DRUGNAME	Fibrimage
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3
	
TTDDRUID	D0AF8E
DRUGNAME	BXCL101
INDICATI	Neurofibromatosis type 2 [ICD-11: LD2D.11] Phase 1/2
	
TTDDRUID	D0AF8R
DRUGNAME	P-216CM
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0AG2A
DRUGNAME	Pyrrolo[2,3-d]pyrimidine derivative 4
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0AG4J
DRUGNAME	IRX-01
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0AG6K
DRUGNAME	MT201
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0AG7M
DRUGNAME	Benzoic acid linked peptide analog 6
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0AG7N
DRUGNAME	MEDI-575
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0AG8C
DRUGNAME	GC376
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0AG8L
DRUGNAME	BMS-986231
INDICATI	Acute decompensated heart failure [ICD-11: BD1Z] Phase 2
INDICATI	Acute heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D0AH2V
DRUGNAME	RM-6427
INDICATI	Cryptosporidium infection [ICD-11: 1A32] Investigative
	
TTDDRUID	D0AH6V
DRUGNAME	BN-2629
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0AI3G
DRUGNAME	HG-1224
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0AI7H
DRUGNAME	Anti-MUC1 CAR T Cells
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D0AI8V
DRUGNAME	DSP-1200
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1
	
TTDDRUID	D0AJ1V
DRUGNAME	Silvestrol
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0AJ3K
DRUGNAME	Gemcitabine
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0AJ3O
DRUGNAME	PMID27240464-compound-3f
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0AJ5E
DRUGNAME	Rifaximin DR
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
	
TTDDRUID	D0AJ5L
DRUGNAME	Oxatomide
INDICATI	Hay fever [ICD-11: CA08.00] Approved
	
TTDDRUID	D0AJ9V
DRUGNAME	ZW25
INDICATI	Biliary tract cancer [ICD-11: 2C17] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Oesophagogastric junction cancer [ICD-11: 2B71.Z] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D0AK0Z
DRUGNAME	ICT-69
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0AK2V
DRUGNAME	AEH-10p
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0AK2Y
DRUGNAME	PMID26651364-Compound-7b
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0AK4H
DRUGNAME	AMG-429
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0AK5G
DRUGNAME	RPAF-AH
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 3
	
TTDDRUID	D0AK5R
DRUGNAME	Floctafenine
INDICATI	Arthritis [ICD-11: FA20] Withdrawn from market
	
TTDDRUID	D0AK6L
DRUGNAME	Amidine compound 4
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D0AK8E
DRUGNAME	K-101
INDICATI	Onychomycosis [ICD-11: EE12.1] Investigative
	
TTDDRUID	D0AL0S
DRUGNAME	GSK-1362885
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0AL2K
DRUGNAME	Irbesartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0AL3O
DRUGNAME	VX-366
INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Discontinued in Phase 2
	
TTDDRUID	D0AL8T
DRUGNAME	Darbufelone
INDICATI	Asthma [ICD-11: CA23] Phase 2/3
	
TTDDRUID	D0ALN1
DRUGNAME	CWHM-12
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Preclinical
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Preclinical
	
TTDDRUID	D0AM0A
DRUGNAME	Aryl mannoside derivative 15
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0AM1D
DRUGNAME	Diaryl piperazine derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0AM1S
DRUGNAME	CCD-3693
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D0AM2D
DRUGNAME	Heterocyclic derivative 8
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0AM4P
DRUGNAME	Interferon gamma-n1
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D0AM4W
DRUGNAME	Oseltamivir + hydroxychloroquine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0AM6F
DRUGNAME	ETX-1153c
INDICATI	Clostridium infection [ICD-11: 1A04] Preclinical
	
TTDDRUID	D0AM8W
DRUGNAME	Zanapezil
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 3
	
TTDDRUID	D0AN1Y
DRUGNAME	L-670596
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0AN3N
DRUGNAME	SGT-001
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2
	
TTDDRUID	D0AN7B
DRUGNAME	Melatonin
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0AN9V
DRUGNAME	ADC-03
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0AO0K
DRUGNAME	CNT0-5
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D0AO5F
DRUGNAME	JOT101
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2
	
TTDDRUID	D0AO5H
DRUGNAME	Trimethoprim
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D0AO6B
DRUGNAME	Piperacetazine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0AO8L
DRUGNAME	NY-ESO-1 T-cell receptor therapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0AO9Q
DRUGNAME	SYNT001
INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 1/2
	
TTDDRUID	D0AO9S
DRUGNAME	Enflurane
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0AP4O
DRUGNAME	Gem 92
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0AP7A
DRUGNAME	BMS-986258
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0AP9E
DRUGNAME	Trilaciclib
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Approved
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0AP9T
DRUGNAME	Cefotetan
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0AQ3H
DRUGNAME	PF-610355
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D0AQ3U
DRUGNAME	PMID25666693-Compound-153
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0AQ8F
DRUGNAME	ETV-005
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0AR0B
DRUGNAME	ACAM-2000
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D0AR3J
DRUGNAME	Acocantherin
INDICATI	Heart failure [ICD-11: BD10-BD13] Approved
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Approved
	
TTDDRUID	D0AR5N
DRUGNAME	BMS-824383
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0AR7L
DRUGNAME	SAR-389644
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1
	
TTDDRUID	D0AR8G
DRUGNAME	Habeo
INDICATI	Scleroderma [ICD-11: 4A42] Phase 3
	
TTDDRUID	D0AS0V
DRUGNAME	5,8-Dihydroxy-1,4-naphthoquinone
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0AS1Y
DRUGNAME	Li-Key peptide vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Preclinical
	
TTDDRUID	D0AT5Y
DRUGNAME	Radiolabeled VEGF
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0AT8C
DRUGNAME	Pegfilgrastim
INDICATI	Malignant solid tumour [ICD-11: 2C10-2F32] Approved
	
TTDDRUID	D0AU2T
DRUGNAME	REGN1979
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	D0AU4G
DRUGNAME	3-amino-5-benzyl-substituted indazole derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0AV0O
DRUGNAME	OPC-51803
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1
	
TTDDRUID	D0AV3G
DRUGNAME	Domperidone
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved
	
TTDDRUID	D0AW4T
DRUGNAME	CART-123 cells
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0AW5T
DRUGNAME	PX-866
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0AW7H
DRUGNAME	StromaCel
INDICATI	Heart disease [ICD-11: BA41-BA42] Investigative
	
TTDDRUID	D0AW8E
DRUGNAME	Tezosentan
INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Phase 3
	
TTDDRUID	D0AW9T
DRUGNAME	ATryn antithrombin
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
	
TTDDRUID	D0AX0V
DRUGNAME	SOM-1033
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0AX1N
DRUGNAME	OGX-427
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0AX3M
DRUGNAME	KW-2581
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0AX4E
DRUGNAME	Bertosamil
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D0AX4H
DRUGNAME	GSK3179106
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1
	
TTDDRUID	D0AX9N
DRUGNAME	Biphenyl derivative 4
INDICATI	Histamine H3-associated disorder [ICD-11: NE61] Patented
	
TTDDRUID	D0AX9S
DRUGNAME	GW-409544
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1
	
TTDDRUID	D0AY0H
DRUGNAME	PMID26651364-Compound-10c
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0AY0U
DRUGNAME	Kadcyla
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0AY1I
DRUGNAME	GSK-2315698
INDICATI	Amyloidosis [ICD-11: 5D00] Phase 1
	
TTDDRUID	D0AY6U
DRUGNAME	MT-003
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0AY7K
DRUGNAME	Celiprolol hcl
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0AY7O
DRUGNAME	Polyinosinic:polycytidylic acid
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0AY8A
DRUGNAME	CA-4948
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0AY8D
DRUGNAME	NBXT-001+Nobilis inhalation device
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0AY9Q
DRUGNAME	Hexyl aminolevulinate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
	
TTDDRUID	D0AY9R
DRUGNAME	Linear DNA vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0AZ0T
DRUGNAME	NP-003
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0AZ1N
DRUGNAME	BSK01
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0AZ3C
DRUGNAME	Imatinib
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
INDICATI	Intestinal cancer [ICD-11: 2C0Z] Phase 3
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2
INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Investigative
	
TTDDRUID	D0AZ3Y
DRUGNAME	CTCE-0214
INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Phase 1
	
TTDDRUID	D0AZ4S
DRUGNAME	VT1021
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0AZ5O
DRUGNAME	LHD-4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0AZ5V
DRUGNAME	L-698544
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0AZ6M
DRUGNAME	Linezolid
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0AZ7F
DRUGNAME	NLX-E201
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative
	
TTDDRUID	D0AZ8Y
DRUGNAME	Biciromab
INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved
	
TTDDRUID	D0B0AX
DRUGNAME	HIF-1alpha
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 4
	
TTDDRUID	D0B0BE
DRUGNAME	PR-5-I
INDICATI	Fertility problem [ICD-11: 5A61] Preregistration
	
TTDDRUID	D0B0CP
DRUGNAME	Chlorprothixene
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Approved
	
TTDDRUID	D0B0EB
DRUGNAME	LY-929
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1
	
TTDDRUID	D0B0EO
DRUGNAME	CPG23STEM
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0B0EZ
DRUGNAME	DWJ-424
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0B0FK
DRUGNAME	NasoVAX vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0B0FU
DRUGNAME	Apramycin
INDICATI	Gram-negative bacterial infection [ICD-11: 1B74-1G40] Phase 1
	
TTDDRUID	D0B0GC
DRUGNAME	E-0722
INDICATI	Diabetic cataract [ICD-11: 9B10.21] Terminated
	
TTDDRUID	D0B0HK
DRUGNAME	G3139 + G-CSF
INDICATI	Acute leukaemia [ICD-11: 2A60] Investigative
	
TTDDRUID	D0B0LG
DRUGNAME	Apomab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0B0MA
DRUGNAME	F-2692
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D0B0MQ
DRUGNAME	KP-303
INDICATI	Bipolar disorder [ICD-11: 6A60] Investigative
	
TTDDRUID	D0B0NH
DRUGNAME	IK-5001
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2
	
TTDDRUID	D0B0NQ
DRUGNAME	LY293558
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0B0OA
DRUGNAME	LEO-27847
INDICATI	Kidney disease [ICD-11: GC2Z] Phase 1
	
TTDDRUID	D0B0QX
DRUGNAME	MSC-204
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0B0RZ
DRUGNAME	GRL-0667
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
	
TTDDRUID	D0B0SH
DRUGNAME	Oxtriphylline
INDICATI	Cough [ICD-11: MD12] Approved
	
TTDDRUID	D0B0TO
DRUGNAME	L-768277
INDICATI	Hyperthermia [ICD-11: MG26] Terminated
	
TTDDRUID	D0B0TW
DRUGNAME	SSJ-183
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0B0UF
DRUGNAME	IBI-308
INDICATI	Bronchioalveolar carcinoma [ICD-11: 2C25.0] Phase 3
	
TTDDRUID	D0B0UN
DRUGNAME	R7232
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 1
	
TTDDRUID	D0B0VD
DRUGNAME	MORAb-022
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0B0WJ
DRUGNAME	PMID25666693-Compound-51
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0B0WW
DRUGNAME	Physostigmine/scopolamine
INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Terminated
	
TTDDRUID	D0B0ZR
DRUGNAME	AF-05
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1
	
TTDDRUID	D0B1CJ
DRUGNAME	Amphiregulin targeting human mabs
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D0B1CU
DRUGNAME	CD19 CAR T-cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	Recurrent adult burkitt lymphoma [ICD-11: 2A85.6] Phase 1
	
TTDDRUID	D0B1DA
DRUGNAME	SAND-5
INDICATI	Glomerulonephritis [ICD-11: 5D00.Y] Preclinical
	
TTDDRUID	D0B1EM
DRUGNAME	Nateplase
INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved
	
TTDDRUID	D0B1EQ
DRUGNAME	Taspoglutide
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D0B1ET
DRUGNAME	Streptococcal B conjugated vaccine
INDICATI	Streptococcal B infection [ICD-11: 1G40] Phase 2
	
TTDDRUID	D0B1EV
DRUGNAME	Cyclopentolate
INDICATI	Examination of eyes or vision [ICD-11: QA00.6] Approved
	
TTDDRUID	D0B1FE
DRUGNAME	SPI-1005
INDICATI	Reperfusion injury [ICD-11: ND56.Z] Approved
	
TTDDRUID	D0B1GE
DRUGNAME	KB103
INDICATI	Dystrophic epidermolysis bullosa [ICD-11: EC32] Phase 2
	
TTDDRUID	D0B1GX
DRUGNAME	Iferanserin-Ventrus
INDICATI	Hemorrhoids [ICD-11: DB60] Discontinued in Phase 3
	
TTDDRUID	D0B1HT
DRUGNAME	Biaryl mannoside derivative 20
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0B1IC
DRUGNAME	CR8020
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
INDICATI	Influenza A virus infection [ICD-11: 1E30] Investigative
	
TTDDRUID	D0B1IP
DRUGNAME	Etretinate
INDICATI	Keratosis [ICD-11: ED56] Approved
	
TTDDRUID	D0B1IV
DRUGNAME	Vancomycin
INDICATI	Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Approved
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative
	
TTDDRUID	D0B1JE
DRUGNAME	TVX-005
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0B1KA
DRUGNAME	Radretumab
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2
	
TTDDRUID	D0B1KK
DRUGNAME	AZD0837
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
INDICATI	Nonvalvular atrial fibrillation [ICD-11: BC81.3Y] Discontinued in Phase 2
	
TTDDRUID	D0B1MJ
DRUGNAME	Dexniguldipine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0B1NA
DRUGNAME	PVAC
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0B1OH
DRUGNAME	ASB17061
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D0B1PC
DRUGNAME	OXECLOSPORIN
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1
	
TTDDRUID	D0B1PD
DRUGNAME	NPC-16377
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D0B1PE
DRUGNAME	Ro 5-4864
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0B1PH
DRUGNAME	Oxymethalone
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0B1PU
DRUGNAME	CGEN-856
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0B1RM
DRUGNAME	LP-226A1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0B1RX
DRUGNAME	ZYI-1
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2
	
TTDDRUID	D0B1RY
DRUGNAME	Aom-0977
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0B1SA
DRUGNAME	IDC-G103
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D0B1SG
DRUGNAME	BMS-813160
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0B1TI
DRUGNAME	MPSK3169A
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1
	
TTDDRUID	D0B1TL
DRUGNAME	Her2-targeted autologous T-cell therapy
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0B1TN
DRUGNAME	VLIM-88
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative
	
TTDDRUID	D0B1TT
DRUGNAME	AdCh63-MSP1
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2
	
TTDDRUID	D0B1TX
DRUGNAME	PVAXrcPSAv53l
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0B1UO
DRUGNAME	LV-SMENP dendritic cells vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D0B1VQ
DRUGNAME	GR-133347
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0B1VZ
DRUGNAME	ALG-1001
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	D0B1WU
DRUGNAME	C-101
INDICATI	Muscular dystrophy [ICD-11: 8C70] Discontinued in Phase 3
	
TTDDRUID	D0B2AH
DRUGNAME	DMP-695/696
INDICATI	Depression [ICD-11: 6A70-6A7Z] Investigative
	
TTDDRUID	D0B2BQ
DRUGNAME	Icopezil maleate
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D0B2BY
DRUGNAME	TAK-661
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2
	
TTDDRUID	D0B2CQ
DRUGNAME	GR-131663
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0B2DP
DRUGNAME	Triclofos Sodium
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0B2GI
DRUGNAME	Glimepiride
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0B2GM
DRUGNAME	Thiazole carboxamide derivative 20
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0B2HC
DRUGNAME	GSK-2302032A
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0B2HE
DRUGNAME	RypVax
INDICATI	Yersinia infection [ICD-11: 1B93] Discontinued in Phase 2
	
TTDDRUID	D0B2HF
DRUGNAME	OI287GT
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1
	
TTDDRUID	D0B2IB
DRUGNAME	KBPA-103
INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative
	
TTDDRUID	D0B2IR
DRUGNAME	Nemolizumab
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3
	
TTDDRUID	D0B2JL
DRUGNAME	JWB-1-84-1
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0B2JZ
DRUGNAME	K11777
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0B2LC
DRUGNAME	HP3070
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D0B2LF
DRUGNAME	R-253
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0B2NF
DRUGNAME	AEB701
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0B2NV
DRUGNAME	PMID29334795-Compound-22
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Alzheimer disease [ICD-11: 8A20] Patented
	
TTDDRUID	D0B2OC
DRUGNAME	R-sibutramine metabolite
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 2
	
TTDDRUID	D0B2OL
DRUGNAME	AA-2379
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2
	
TTDDRUID	D0B2OT
DRUGNAME	Isoflurophate
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D0B2RZ
DRUGNAME	ADX-71943
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Preclinical
	
TTDDRUID	D0B2SW
DRUGNAME	ASP-3291
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
	
TTDDRUID	D0B2UZ
DRUGNAME	Prochlorperazine
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D0B2VS
DRUGNAME	Benzyl phenyl ether derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0B2WJ
DRUGNAME	Flufenamic Acid
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Approved
	
TTDDRUID	D0B2WK
DRUGNAME	Ifetroban sodium
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2
	
TTDDRUID	D0B2WQ
DRUGNAME	Lomeguatrib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0B2WU
DRUGNAME	CAR-T cells targeting BCMA
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0B2XS
DRUGNAME	Autologous myoblast cell therapy
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
	
TTDDRUID	D0B2ZM
DRUGNAME	GB-2542
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0B2ZZ
DRUGNAME	Esomeprazole magnesium + Aspirin
INDICATI	Peptic ulcer [ICD-11: DA61] Phase 3
	
TTDDRUID	D0B3CC
DRUGNAME	AlloStim
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
	
TTDDRUID	D0B3CT
DRUGNAME	BE-13793C
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0B3CU
DRUGNAME	C-linked disaccharide biphenyl mannoside derivative 5
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0B3CY
DRUGNAME	L-692429
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Discontinued in Phase 1
	
TTDDRUID	D0B3DE
DRUGNAME	AVN-628
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D0B3DV
DRUGNAME	KTE-C19
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0B3DX
DRUGNAME	Norelin
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2
	
TTDDRUID	D0B3FV
DRUGNAME	NVP-LAQ824
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 3
INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0B3GF
DRUGNAME	JNJ-26854165
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0B3HD
DRUGNAME	Caffeine
INDICATI	Orthostatic hypotension [ICD-11: BA21] Approved
	
TTDDRUID	D0B3HF
DRUGNAME	SCRI-huCAR19v1
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0B3HP
DRUGNAME	SGC-1061
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0B3IC
DRUGNAME	Dopropidil
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D0B3ID
DRUGNAME	Medi-NK
INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
	
TTDDRUID	D0B3IZ
DRUGNAME	AMPSL
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0B3KI
DRUGNAME	YD-101
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0B3LP
DRUGNAME	Ro-16-6028
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3
	
TTDDRUID	D0B3MV
DRUGNAME	SSR-69071
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated
	
TTDDRUID	D0B3MX
DRUGNAME	NBI-6024
INDICATI	Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 2
	
TTDDRUID	D0B3QM
DRUGNAME	Metyrosine
INDICATI	Pheochromocytoma [ICD-11: 5A75] Approved
	
TTDDRUID	D0B3RL
DRUGNAME	R-IFN-1a
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0B3SV
DRUGNAME	Meningococcal vaccine group B quadrivalent recombinant vaccine
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 3
	
TTDDRUID	D0B3TA
DRUGNAME	TD-1414
INDICATI	Impetigo [ICD-11: 1B72] Phase 2
	
TTDDRUID	D0B3UJ
DRUGNAME	Paliperidone
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0B3UU
DRUGNAME	Antiviral BMS-1
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0B3VR
DRUGNAME	H5N1 avian influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0B3XG
DRUGNAME	Recombinant von Willebrand factor/recombinant Factor VIII complex
INDICATI	Von willebrand disease [ICD-11: 3B12] Phase 3
	
TTDDRUID	D0B3YK
DRUGNAME	AZD8601
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D0B3ZC
DRUGNAME	Claudiximab
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 2
	
TTDDRUID	D0B3ZF
DRUGNAME	ORM-12741
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0B4AB
DRUGNAME	ACEA-2085
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0B4AH
DRUGNAME	RECALL-VAX
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0B4CD
DRUGNAME	GSK-2018682
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1
	
TTDDRUID	D0B4CO
DRUGNAME	NNC-14-0185
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D0B4DC
DRUGNAME	Butenafine
INDICATI	Dermatologic infection [ICD-11: 1F28] Approved
	
TTDDRUID	D0B4DK
DRUGNAME	ChronVac-B
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D0B4DL
DRUGNAME	CRS-100
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1
	
TTDDRUID	D0B4EG
DRUGNAME	MBX-500
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0B4ES
DRUGNAME	Atamestane + Toremifene
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0B4EV
DRUGNAME	IPENOXAZONE
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
	
TTDDRUID	D0B4GZ
DRUGNAME	E6014
INDICATI	Oral mucositis [ICD-11: DA01.11] Discontinued in Phase 3
	
TTDDRUID	D0B4IF
DRUGNAME	Ketoconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D0B4JL
DRUGNAME	SERAZAPINE HYDROCHLORIDE
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D0B4JQ
DRUGNAME	Tripelennamine
INDICATI	Hypersensitivity [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D0B4KH
DRUGNAME	Technetium TC 99M medronate
INDICATI	Bone disease [ICD-11: FC0Z] Approved
	
TTDDRUID	D0B4KU
DRUGNAME	PF-06273340
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0B4MB
DRUGNAME	PRT-300
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative
	
TTDDRUID	D0B4ME
DRUGNAME	CX-1942
INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Investigative
	
TTDDRUID	D0B4MH
DRUGNAME	Cytorex-EBV
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0B4MK
DRUGNAME	ISIS-STAT3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0B4NI
DRUGNAME	PMID25666693-Compound-77
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0B4OF
DRUGNAME	123I-iometopane
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D0B4OK
DRUGNAME	Sym015
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0B4RU
DRUGNAME	Pregnenolone
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 4
	
TTDDRUID	D0B4TN
DRUGNAME	Biperiden
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0B4TT
DRUGNAME	GSK1004723
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1
	
TTDDRUID	D0B4VH
DRUGNAME	CDR-134F194
INDICATI	Diabetic complication [ICD-11: 5A2Y] IND submitted
	
TTDDRUID	D0B4XU
DRUGNAME	TGP-580
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Discontinued in Phase 2
	
TTDDRUID	D0B4XX
DRUGNAME	QR-333
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
	
TTDDRUID	D0B4ZQ
DRUGNAME	SL-90.0571
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 1
	
TTDDRUID	D0B5CN
DRUGNAME	Rh-MBL
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0B5EB
DRUGNAME	Ponezumab
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0B5FZ
DRUGNAME	Cefozopran
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved
	
TTDDRUID	D0B5GC
DRUGNAME	Flavonols
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0B5GS
DRUGNAME	Vancomycin hydrochloride
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 3
	
TTDDRUID	D0B5HA
DRUGNAME	ISIS-5320
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0B5HF
DRUGNAME	BI-135585
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0B5HS
DRUGNAME	NLG8189
INDICATI	Melanoma [ICD-11: 2C30] Phase 2/3
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
	
TTDDRUID	D0B5KE
DRUGNAME	EB-1053
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2
	
TTDDRUID	D0B5LF
DRUGNAME	Ximelegatran
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0B5MP
DRUGNAME	Aciclovir
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 3
	
TTDDRUID	D0B5PK
DRUGNAME	TEN010
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0B5PU
DRUGNAME	BMS-193884
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2
	
TTDDRUID	D0B5PV
DRUGNAME	CART-EGFRvIII T cells
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
INDICATI	Glioma [ICD-11: 2A00.0] Clinical trial
	
TTDDRUID	D0B5QK
DRUGNAME	Activated adult marrow stromal cells
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0B5RO
DRUGNAME	REN-1654
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D0B5RU
DRUGNAME	CS1-CAR T Therapy
INDICATI	Plasma cell myeloma [ICD-11: 2A83.1] Phase 1
	
TTDDRUID	D0B5RZ
DRUGNAME	GS-6620
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0B5SC
DRUGNAME	Silvestrol
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0B5TM
DRUGNAME	AMP-110
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0B5TO
DRUGNAME	Onyvax-CR
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1/2
	
TTDDRUID	D0B5UH
DRUGNAME	ALX-0761
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0B5VA
DRUGNAME	SAN-300
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0B5VV
DRUGNAME	IDegLira
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0B6BE
DRUGNAME	OT-417
INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative
	
TTDDRUID	D0B6BQ
DRUGNAME	ZD-6003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0B6BW
DRUGNAME	ZIO-102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0B6CC
DRUGNAME	Trimethaphan
INDICATI	Aneurysm [ICD-11: BD51.Z] Approved
INDICATI	Hypertensive emergency [ICD-11: BA03] Approved
	
TTDDRUID	D0B6DV
DRUGNAME	CT-10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0B6EA
DRUGNAME	NV-1020
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1/2
	
TTDDRUID	D0B6ER
DRUGNAME	Ro-31-6930
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D0B6EU
DRUGNAME	AS-35
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0B6GJ
DRUGNAME	TT-62
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2
	
TTDDRUID	D0B6GW
DRUGNAME	Diphtheria-tetanus vaccine
INDICATI	Clostridium infection [ICD-11: 1A04] Approved
	
TTDDRUID	D0B6HE
DRUGNAME	SKI-2852
INDICATI	Metabolic syndrome x [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D0B6HS
DRUGNAME	HRT
INDICATI	Estrogen deficiency [ICD-11: FB83.0Y] Discontinued in Phase 1
	
TTDDRUID	D0B6IZ
DRUGNAME	R1678
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D0B6JV
DRUGNAME	SB-201993
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0B6LP
DRUGNAME	Neo-Urinary Conduit
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
	
TTDDRUID	D0B6LT
DRUGNAME	OPNT002
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
	
TTDDRUID	D0B6NT
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 11
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0B6OG
DRUGNAME	BBT-007
INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative
	
TTDDRUID	D0B6PZ
DRUGNAME	FORMESTANE
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Withdrawn from market
	
TTDDRUID	D0B6QO
DRUGNAME	NPI-1999
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0B6QZ
DRUGNAME	AVE-2268
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0B6RA
DRUGNAME	LY404039
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D0B6SO
DRUGNAME	BRL-44154
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D0B6TW
DRUGNAME	Leucovorin Calcium
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0B6VN
DRUGNAME	TZI-41078
INDICATI	Arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0B6VQ
DRUGNAME	D-20450
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0B6WN
DRUGNAME	AVE0675
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0B6WP
DRUGNAME	Improved influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0B6WV
DRUGNAME	TNFmab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0B6XE
DRUGNAME	ASP9226
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1
	
TTDDRUID	D0B6YB
DRUGNAME	LE-SN38
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D0B6YR
DRUGNAME	HuMax-CD32b
INDICATI	B-cell lymphoma [ICD-11: 2A86] Investigative
	
TTDDRUID	D0B6ZI
DRUGNAME	H5N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0B7AB
DRUGNAME	R-TPR-013
INDICATI	Female infertility [ICD-11: GA31.Z] Phase 3
	
TTDDRUID	D0B7AF
DRUGNAME	KLS-Bfr
INDICATI	Osteonecrosis [ICD-11: FB81] Investigative
	
TTDDRUID	D0B7AH
DRUGNAME	INT-777
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D0B7BX
DRUGNAME	E-6276
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0B7CH
DRUGNAME	Phenylbutyrate
INDICATI	Urea cycle disorder [ICD-11: 5C50.A] Phase 2
	
TTDDRUID	D0B7CZ
DRUGNAME	Teloxantrone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0B7DW
DRUGNAME	Hyqvia + Kiovia
INDICATI	Nervous system paraneoplastic or autoimmune disorders [ICD-11: 8E4A.1] Phase 3
	
TTDDRUID	D0B7EB
DRUGNAME	Etoposide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0B7EF
DRUGNAME	MNT-03-01
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D0B7GE
DRUGNAME	OB-28
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0B7HH
DRUGNAME	HTERT-VISA-BikDD nanoparticles
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0B7HJ
DRUGNAME	U-54494A
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D0B7HX
DRUGNAME	Levosemotiadil
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2
	
TTDDRUID	D0B7JZ
DRUGNAME	CuraVac MG
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Investigative
	
TTDDRUID	D0B7KF
DRUGNAME	RG-7152
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D0B7LK
DRUGNAME	CY-1503
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2/3
	
TTDDRUID	D0B7LU
DRUGNAME	CX-5461
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0B7LZ
DRUGNAME	NDD-094
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0B7MO
DRUGNAME	PF-06886992
INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 3
	
TTDDRUID	D0B7MU
DRUGNAME	SYNSORB-Cd
INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 3
	
TTDDRUID	D0B7ND
DRUGNAME	UR-8225
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0B7NG
DRUGNAME	Chlorpheniramine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0B7OD
DRUGNAME	Amfepramone
INDICATI	Obesity [ICD-11: 5B81] Approved
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0B7OM
DRUGNAME	F-15441
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0B7OY
DRUGNAME	CT 327
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	D0B7PY
DRUGNAME	Prostate cancer vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1
	
TTDDRUID	D0B7QP
DRUGNAME	TM30339
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2
	
TTDDRUID	D0B7QU
DRUGNAME	AIM-102
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0B7SP
DRUGNAME	GSK163090
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
INDICATI	Episode [ICD-11: N.A.] Discontinued in Phase 2
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D0B7TH
DRUGNAME	99mTc-biciromab
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D0B7TM
DRUGNAME	BI-137882
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0B7UD
DRUGNAME	TP-103
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0B7VC
DRUGNAME	Menactra
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved
	
TTDDRUID	D0B7VH
DRUGNAME	Remoxy ER
INDICATI	Chronic pain [ICD-11: MG30] Application submitted
	
TTDDRUID	D0B7VK
DRUGNAME	Tifacogin
INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 3
	
TTDDRUID	D0B7XF
DRUGNAME	Lymphozene
INDICATI	B-cell lymphoma [ICD-11: 2A86] Investigative
	
TTDDRUID	D0B7YT
DRUGNAME	Scopolamine
INDICATI	Addictive disorder [ICD-11: 6C50-6C5Z] Approved
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D0B8AT
DRUGNAME	PB28
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0B8BY
DRUGNAME	INdoximod + temozolomide
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
	
TTDDRUID	D0B8BZ
DRUGNAME	CD19CART
INDICATI	B-cell lymphoma [ICD-11: 2A86] Clinical trial
INDICATI	leukaemia [ICD-11: 2A60-2B33] Clinical trial
	
TTDDRUID	D0B8CK
DRUGNAME	PF-05335810
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Discontinued in Phase 1
	
TTDDRUID	D0B8ES
DRUGNAME	AA-123
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0B8IN
DRUGNAME	PSP-D-CD40L
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0B8IZ
DRUGNAME	Analog insulin-PH20
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2
	
TTDDRUID	D0B8JG
DRUGNAME	ATI-0409
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0B8JQ
DRUGNAME	KRP-101
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D0B8KE
DRUGNAME	MDX-1204
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0B8LN
DRUGNAME	Iotrolan
INDICATI	Radiocontrast agent [ICD-11: N.A.] Approved
	
TTDDRUID	D0B8MB
DRUGNAME	[99MTC]-CBPAO
INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 1
	
TTDDRUID	D0B8MS
DRUGNAME	MEDI-547
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0B8MZ
DRUGNAME	Careram
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0B8NH
DRUGNAME	Nanogam
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D0B8NW
DRUGNAME	ICA-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0B8OB
DRUGNAME	PMID25684022-Compound-WO2011137219 36(3-5)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0B8QA
DRUGNAME	RP-66055
INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Terminated
	
TTDDRUID	D0B8QB
DRUGNAME	Magnesium
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Approved
	
TTDDRUID	D0B8RJ
DRUGNAME	AP vaccine
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D0B8RU
DRUGNAME	Aryl mannoside derivative 14
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0B8SC
DRUGNAME	BOF-4272
INDICATI	Gout [ICD-11: FA25] Discontinued in Phase 2
	
TTDDRUID	D0B8SV
DRUGNAME	NADH
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0B8SY
DRUGNAME	Calcium Gluceptate
INDICATI	Mild hypocalcemia [ICD-11: 5B5K.1] Approved
	
TTDDRUID	D0B8TK
DRUGNAME	LX-6171
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 2
	
TTDDRUID	D0B8UD
DRUGNAME	TNX-1800 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Preclinical
	
TTDDRUID	D0B8UJ
DRUGNAME	Nelarabine
INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved
	
TTDDRUID	D0B8UW
DRUGNAME	AUTO2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0B8WN
DRUGNAME	Ranitidine
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D0B8WS
DRUGNAME	Zostavax
INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Approved
	
TTDDRUID	D0B8WU
DRUGNAME	JTZ-951
INDICATI	Anaemia [ICD-11: 3A90] Phase 3
	
TTDDRUID	D0B8XK
DRUGNAME	SC-01
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0B8YZ
DRUGNAME	ELTANOLONE
INDICATI	Premenstrual syndrome [ICD-11: GA34.40] Discontinued in Phase 3
	
TTDDRUID	D0B8ZJ
DRUGNAME	OMP-336B11
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0B8ZP
DRUGNAME	PD-144418
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0B8ZR
DRUGNAME	NTO-1151
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2
	
TTDDRUID	D0B9AO
DRUGNAME	Saprisartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0B9AQ
DRUGNAME	WYE-130600
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0B9CA
DRUGNAME	Tuvirumab
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Terminated
	
TTDDRUID	D0B9DI
DRUGNAME	Lu-AE04621
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0B9DM
DRUGNAME	S-555739
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D0B9EH
DRUGNAME	Dermolastin
INDICATI	Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 2
	
TTDDRUID	D0B9EJ
DRUGNAME	Mitomycin A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0B9EN
DRUGNAME	Aleglitazar
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 3
	
TTDDRUID	D0B9FW
DRUGNAME	Idarucizumab
INDICATI	Reversal of the anticoagulant effects of dabigatran [ICD-11: N.A] Approved
	
TTDDRUID	D0B9GM
DRUGNAME	Oxibendazole
INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D0B9HH
DRUGNAME	MN-8001
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0B9IV
DRUGNAME	XEL-002LG
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0B9JO
DRUGNAME	Telavancin
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Approved
	
TTDDRUID	D0B9LM
DRUGNAME	PMID26651364-Compound-8b
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0B9MR
DRUGNAME	GSK-2256098
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1
	
TTDDRUID	D0B9NA
DRUGNAME	ICI-192605
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D0B9NU
DRUGNAME	Avian H5N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0B9OG
DRUGNAME	Adipiplon
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2
	
TTDDRUID	D0B9RD
DRUGNAME	ALK-001
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2
INDICATI	Stargardt disease [ICD-11: 9B70] Phase 2
	
TTDDRUID	D0B9RF
DRUGNAME	DW-953
INDICATI	Dyspepsia [ICD-11: MD92] Investigative
	
TTDDRUID	D0B9RG
DRUGNAME	Cabotegravir LA + rilpivirine LA combination
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0B9SR
DRUGNAME	SB-273005
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1
	
TTDDRUID	D0B9TX
DRUGNAME	Darodipine
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0B9UB
DRUGNAME	PB-200a
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D0B9XD
DRUGNAME	SP-1000
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D0B9XM
DRUGNAME	Nano-steroid
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0B9XW
DRUGNAME	Betalutin
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
	
TTDDRUID	D0BA0O
DRUGNAME	Syn-1002
INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical
	
TTDDRUID	D0BA1Y
DRUGNAME	SYL-045001
INDICATI	Ocular inflammation [ICD-11: 9C61.24] Phase 2
	
TTDDRUID	D0BA5E
DRUGNAME	ZYDPLA 1
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0BA5K
DRUGNAME	Apaxifylline
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D0BA6T
DRUGNAME	Methyldopa
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0BA7K
DRUGNAME	Recombinant human relaxin
INDICATI	Scleroderma [ICD-11: 4A42] Phase 2
	
TTDDRUID	D0BA8H
DRUGNAME	HemoTech
INDICATI	Hematologic disease [ICD-11: 3C0Z] Investigative
	
TTDDRUID	D0BA8M
DRUGNAME	LY-295501
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0BA9U
DRUGNAME	Levonorgestrel
INDICATI	Contraception [ICD-11: QA21] Approved
	
TTDDRUID	D0BB1T
DRUGNAME	Semparatide
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2
	
TTDDRUID	D0BB1X
DRUGNAME	KRP-105
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated
	
TTDDRUID	D0BB2F
DRUGNAME	Pyrazole derivative 26
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0BB2V
DRUGNAME	ABBV-838
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0BB9M
DRUGNAME	NE-0080
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Discontinued in Phase 2
	
TTDDRUID	D0BC0F
DRUGNAME	OSE-300
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D0BC2E
DRUGNAME	Hydroxyflutamide
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D0BC4Q
DRUGNAME	Lifibrol
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2
	
TTDDRUID	D0BC6M
DRUGNAME	ASG-5ME
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0BD0Q
DRUGNAME	Proglumetacin
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
	
TTDDRUID	D0BD5J
DRUGNAME	GSK2838497A
INDICATI	Haemophilus influenza [ICD-11: 1G40] Phase 2
	
TTDDRUID	D0BD6A
DRUGNAME	GT-1282
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0BD8D
DRUGNAME	Cisapride
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Approved
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative
	
TTDDRUID	D0BD9K
DRUGNAME	Gilotrif
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3
INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0BE0Z
DRUGNAME	Contezolid acefosamil
INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 2
	
TTDDRUID	D0BE1A
DRUGNAME	R-209130
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0BE6M
DRUGNAME	Anti-Mesothelin CAR-T cells
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1/2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D0BE8H
DRUGNAME	INCB62079
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1/2
	
TTDDRUID	D0BF0X
DRUGNAME	Interferon beta-1a
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0BF4Z
DRUGNAME	GSK2981278
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	D0BF8G
DRUGNAME	Pamidronate
INDICATI	Hypercalcaemia [ICD-11: 5B91.0] Approved
	
TTDDRUID	D0BF8Y
DRUGNAME	Pelareorep
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0BF9K
DRUGNAME	ABX-IL8
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0BG2L
DRUGNAME	ABC-7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0BG3B
DRUGNAME	VX-135
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0BG4W
DRUGNAME	Cupric Sulfate
INDICATI	Pest attack [ICD-11: N.A.] Approved
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
INDICATI	Herbicide [ICD-11: N.A.] Approved
	
TTDDRUID	D0BH2M
DRUGNAME	4SCAR19 and 4SCAR123
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0BH7Z
DRUGNAME	Girentuximab I-124
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D0BH8C
DRUGNAME	MGVWN-1
INDICATI	West nile virus infection [ICD-11: 1D46] Discontinued in Phase 1/2
	
TTDDRUID	D0BH9I
DRUGNAME	INN-108
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1/2
	
TTDDRUID	D0BI0F
DRUGNAME	Imidazole derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0BI1C
DRUGNAME	Live attenuated influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0BI3K
DRUGNAME	Omburtamab I-124
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D0BI3N
DRUGNAME	Cerdulatinib
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
INDICATI	Vitiligo [ICD-11: ED63.0] Phase 1
	
TTDDRUID	D0BI7J
DRUGNAME	FP-045
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D0BJ0Q
DRUGNAME	DDD-64558
INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative
	
TTDDRUID	D0BJ2W
DRUGNAME	DAS-431
INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 2
	
TTDDRUID	D0BJ3B
DRUGNAME	Soluble CD83
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0BJ5O
DRUGNAME	ASP-4178
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0BJ7G
DRUGNAME	WSB-961
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0BJ7W
DRUGNAME	GLPG-0492
INDICATI	Cachexia [ICD-11: MG20] Preclinical
	
TTDDRUID	D0BJ8Q
DRUGNAME	INO-8000
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0BK1N
DRUGNAME	Thioguanine
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0BK3Z
DRUGNAME	ProstaRex
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0BK4X
DRUGNAME	Cinryze
INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Approved
	
TTDDRUID	D0BK7D
DRUGNAME	Autologous dendritic cell-tumor cell fusion vaccine
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1
	
TTDDRUID	D0BL0G
DRUGNAME	TAK-233
INDICATI	Pheumatoid arthritis [ICD-11: FA2Z] Phase 1
	
TTDDRUID	D0BL3X
DRUGNAME	PMID25553724-Compound-US2011799419010
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented
	
TTDDRUID	D0BL6E
DRUGNAME	KUR-113
INDICATI	Bone injury [ICD-11: ND56.Y] Phase 2
	
TTDDRUID	D0BL6W
DRUGNAME	THA-902
INDICATI	Fibromyalgia [ICD-11: MG30.01] Investigative
	
TTDDRUID	D0BM3R
DRUGNAME	LY-307853
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D0BM4T
DRUGNAME	CaPre
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2
	
TTDDRUID	D0BM5G
DRUGNAME	Tazarotene
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
	
TTDDRUID	D0BM6S
DRUGNAME	IPI-493
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 1
	
TTDDRUID	D0BM7M
DRUGNAME	AZD8931
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0BM8Z
DRUGNAME	SOM-0633
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D0BN4Y
DRUGNAME	Ebalzotan
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D0BN7W
DRUGNAME	Roclatan
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3
	
TTDDRUID	D0BN9R
DRUGNAME	GelVac H5N1 influenza virus vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0BN9X
DRUGNAME	Tirofiban
INDICATI	Acute coronary syndrome [ICD-11: BA41] Approved
	
TTDDRUID	D0BO0K
DRUGNAME	INCSHR1210
INDICATI	Bronchioalveolar carcinoma [ICD-11: 2C25.0] Phase 3
INDICATI	Esophageal squamous cell carcinoma [ICD-11: 2E60.1] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0BO1H
DRUGNAME	PMID28270021-Compound-WO2016054807Example80
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0BO6I
DRUGNAME	EHT-899
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D0BO7P
DRUGNAME	Bictegravir + emtricitabine  +  tenofovir alafenamide
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0BO7U
DRUGNAME	BMX-001
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D0BOM7
DRUGNAME	XmAb22841
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0BP4Y
DRUGNAME	Technetium Tc-99m Sodium Pertechnetate Generator
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0BP6I
DRUGNAME	PM-102
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative
	
TTDDRUID	D0BP7C
DRUGNAME	J-104135
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0BP7W
DRUGNAME	VBY-106
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0BP9C
DRUGNAME	Etravirine
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0BQ0C
DRUGNAME	CD19 CAR-T cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0BQ5X
DRUGNAME	Diphtheria, tetanus, pertussis, HBV, Haemophilus influenzae vaccine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 3
	
TTDDRUID	D0BQ8A
DRUGNAME	PMID25553724-Compound-US2011796857710
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented
	
TTDDRUID	D0BQ8M
DRUGNAME	CY-208243
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0BQ8Y
DRUGNAME	Allyl isothiocyanate
INDICATI	Acute or chronic pain [ICD-11: MG30-MG31] Approved
	
TTDDRUID	D0BR0D
DRUGNAME	MGB-101
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0BR1S
DRUGNAME	ProscaVax
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0BR5W
DRUGNAME	Alpha-Helical lipopeptides IIS
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0BR6D
DRUGNAME	PMID27998201-Compound-10
INDICATI	Osteoporosis [ICD-11: FB83.0] Patented
	
TTDDRUID	D0BR7M
DRUGNAME	Breceptin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0BR8N
DRUGNAME	BVA-201
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0BR8X
DRUGNAME	PUL-042
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0BR9C
DRUGNAME	Biphenyl mannoside derivative 2
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0BS2S
DRUGNAME	TPU-002
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0BS3E
DRUGNAME	Biphenyl mannoside derivative 21
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0BS5E
DRUGNAME	AMO-02
INDICATI	Myotonic dystrophy [ICD-11: 8C71.0] Phase 2/3
	
TTDDRUID	D0BS6B
DRUGNAME	TP-801
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0BS6F
DRUGNAME	JNJ-64400141
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1/2
	
TTDDRUID	D0BS7T
DRUGNAME	VALERGEN-BT
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0BT0Z
DRUGNAME	PF-05241328
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0BT2P
DRUGNAME	MBP(82-98)
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 3
	
TTDDRUID	D0BT4P
DRUGNAME	TDI-0060
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0BT6B
DRUGNAME	CLT-009
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative
	
TTDDRUID	D0BT6G
DRUGNAME	Plovamer acetate
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0BT6H
DRUGNAME	IW-2143
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0BT7R
DRUGNAME	ASP-4901
INDICATI	Genitourinary disease [ICD-11: GA0Z-GC8Z] Phase 2
	
TTDDRUID	D0BU0J
DRUGNAME	Azanidazole
INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved
	
TTDDRUID	D0BU5G
DRUGNAME	BiovaxlD
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Preregistration
	
TTDDRUID	D0BU5Z
DRUGNAME	Argyrin B
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0BU8L
DRUGNAME	Celmoleukin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0BV0U
DRUGNAME	Lintuzumab Ac-226
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D0BV3B
DRUGNAME	SCH-602539
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0BV3J
DRUGNAME	Macimorelin
INDICATI	Somatotropin deficiency [ICD-11: 5A61.0] Approved
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved
	
TTDDRUID	D0BW1O
DRUGNAME	Zanamivir
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
	
TTDDRUID	D0BW2N
DRUGNAME	GZ402674
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0BW3P
DRUGNAME	Aerovant
INDICATI	Asthma [ICD-11: CA23] Phase 2a
	
TTDDRUID	D0BW4W
DRUGNAME	Sutezolid
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2
	
TTDDRUID	D0BW6F
DRUGNAME	GS-9876
INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0BW9R
DRUGNAME	BMS-181184
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D0BX0V
DRUGNAME	Sel-K1
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0BX1S
DRUGNAME	CD-832
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D0BX5L
DRUGNAME	LZM009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0BX7G
DRUGNAME	Anti-PrP mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0BY0Y
DRUGNAME	227Th-trastuzumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0BY6W
DRUGNAME	PSMA VRP therapeutic vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0BZ1D
DRUGNAME	CGX1321
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0BZ1L
DRUGNAME	PS386113
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D0BZ1Q
DRUGNAME	CRx-401
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0BZ7V
DRUGNAME	Matuzumab
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
	
TTDDRUID	D0BZ7W
DRUGNAME	Tolterodine
INDICATI	Overactive bladder [ICD-11: GC50.0] Approved
	
TTDDRUID	D0C0AA
DRUGNAME	DTS-108
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C0AC
DRUGNAME	GIT27-NO
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C0BE
DRUGNAME	ST-148
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0C0CE
DRUGNAME	Activated recombinant FVII-albumin fusion protein
INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 2/3
	
TTDDRUID	D0C0CF
DRUGNAME	CRD-103
INDICATI	Bipolar disorder [ICD-11: 6A60] Investigative
	
TTDDRUID	D0C0DY
DRUGNAME	Influenza A virus H7N9 vaccine
INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0C0EO
DRUGNAME	CP-105696
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1
	
TTDDRUID	D0C0EV
DRUGNAME	ChimeriVax-West Nile
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2
INDICATI	West nile virus infection [ICD-11: 1D46] Discontinued in Phase 2
	
TTDDRUID	D0C0EX
DRUGNAME	SDZ-MTH-958
INDICATI	Artery stenosis [ICD-11: BD52] Terminated
	
TTDDRUID	D0C0FA
DRUGNAME	FRAX-120
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C0FG
DRUGNAME	NRT-300
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0C0FO
DRUGNAME	Plant-based oncology candidate
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0C0HF
DRUGNAME	GM-MD-01
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Investigative
	
TTDDRUID	D0C0JT
DRUGNAME	Nimesulide
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Terminated
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Terminated
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Terminated
	
TTDDRUID	D0C0KI
DRUGNAME	Aminoazetidine derivative 7
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0C0KP
DRUGNAME	AllerB
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2b
	
TTDDRUID	D0C0LO
DRUGNAME	IMGN529
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Metastatic non-hodgkin's lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0C0ME
DRUGNAME	RO-26-2853
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0C0MN
DRUGNAME	Irbesartan/ trichlormethiazide fixed-dose combination
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3
	
TTDDRUID	D0C0NH
DRUGNAME	Avastin+/-Tarceva
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D0C0OB
DRUGNAME	LOU064
INDICATI	Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 2
	
TTDDRUID	D0C0ON
DRUGNAME	Human embryonic stem cell-derived osteoblasts
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D0C0QK
DRUGNAME	LIM-0744
INDICATI	Toxicity [ICD-11: N.A.] Investigative
	
TTDDRUID	D0C0QT
DRUGNAME	PPI-461
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0C0SK
DRUGNAME	Pyrimethamine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0C0SX
DRUGNAME	SCH-900353
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C0SZ
DRUGNAME	PRT6207
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C0TJ
DRUGNAME	PBI-230
INDICATI	Intoxication [ICD-11: 6C40-6C4B] Investigative
	
TTDDRUID	D0C0TU
DRUGNAME	SI-613
INDICATI	Knee osteoarthritis [ICD-11: FA01] Phase 2
	
TTDDRUID	D0C0TV
DRUGNAME	Autologous stem cell-based cancer immunotherapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C0WI
DRUGNAME	PNB-05
INDICATI	Obsessive compulsive disorder [ICD-11: 6B20] Investigative
	
TTDDRUID	D0C0YG
DRUGNAME	Youerjian
INDICATI	Hantavirus infection [ICD-11: 1D62] Approved
	
TTDDRUID	D0C0ZC
DRUGNAME	AZ-628
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C0ZN
DRUGNAME	VXA-A1.1
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0C1AY
DRUGNAME	GW-796406
INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 1
	
TTDDRUID	D0C1BG
DRUGNAME	Lactitol
INDICATI	Liver disease [ICD-11: DB90-BD99] Approved
	
TTDDRUID	D0C1BL
DRUGNAME	mab 37.1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C1CU
DRUGNAME	SUN-9221
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D0C1EO
DRUGNAME	Melanoma vaccine (ALVAC)
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2
	
TTDDRUID	D0C1GE
DRUGNAME	Fusolin
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D0C1IG
DRUGNAME	CUDC427
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C1IW
DRUGNAME	Ergonovine
INDICATI	Postpartum haemorrhage [ICD-11: JA43] Approved
	
TTDDRUID	D0C1JP
DRUGNAME	AEG35156
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0C1JV
DRUGNAME	QGC-001
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0C1LF
DRUGNAME	VLD-01
INDICATI	Diabetic cataract [ICD-11: 9B10.21] Investigative
	
TTDDRUID	D0C1MB
DRUGNAME	FR-180102
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Terminated
	
TTDDRUID	D0C1MZ
DRUGNAME	PMID25666693-Compound-10
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0C1NZ
DRUGNAME	REGN 3048
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1
	
TTDDRUID	D0C1OJ
DRUGNAME	Debio-0930
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D0C1PY
DRUGNAME	Potassium Acetate
INDICATI	Kidney stone [ICD-11: GB70.0Z] Approved
	
TTDDRUID	D0C1QB
DRUGNAME	LOSIGAMONE
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 3
	
TTDDRUID	D0C1QS
DRUGNAME	Iprodione
INDICATI	Plant grey mould disease [ICD-11: N.A.] Approved
	
TTDDRUID	D0C1QZ
DRUGNAME	Choline C-11
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D0C1RN
DRUGNAME	Japanese cedar peptide allergy desensitization agent
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0C1SF
DRUGNAME	Griseofulvin
INDICATI	Ringworm infection [ICD-11: 1F28] Approved
	
TTDDRUID	D0C1SI
DRUGNAME	MK-386
INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 2
	
TTDDRUID	D0C1TJ
DRUGNAME	HN-10200
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Discontinued in Phase 2
	
TTDDRUID	D0C1TO
DRUGNAME	EQ-818-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C1TR
DRUGNAME	ASP9853
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C1TT
DRUGNAME	SPI-017
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0C1UF
DRUGNAME	MDX-1100
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D0C1UP
DRUGNAME	SX-ARPC
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0C1WH
DRUGNAME	Letrozole
INDICATI	Hormonally-responsive breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0C1WL
DRUGNAME	C-2507
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0C1WP
DRUGNAME	SCH-1595241
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C1WR
DRUGNAME	AMG 232
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0C1XS
DRUGNAME	ZIMELIDINE
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Withdrawn from market
INDICATI	Depression [ICD-11: 6A70-6A7Z] Withdrawn from market
	
TTDDRUID	D0C1ZO
DRUGNAME	[N-methyl-3H(3)]AZ-10419369
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 1
	
TTDDRUID	D0C2AR
DRUGNAME	Gadocoletic acid
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
	
TTDDRUID	D0C2BP
DRUGNAME	AG-270
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C2CH
DRUGNAME	OGT-719
INDICATI	Liver cancer [ICD-11: 2C12] Discontinued in Phase 2
	
TTDDRUID	D0C2CP
DRUGNAME	Conjugated-trastuzumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C2EP
DRUGNAME	Remikiren
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0C2FJ
DRUGNAME	CL-275838
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2
	
TTDDRUID	D0C2GN
DRUGNAME	SLP-1001
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0C2HF
DRUGNAME	GR-253035
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1
	
TTDDRUID	D0C2HG
DRUGNAME	BYK-324677
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0C2HI
DRUGNAME	PegCNTF
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D0C2HR
DRUGNAME	ORG-9273
INDICATI	Paralysis [ICD-11: 8B60] Discontinued in Phase 2
	
TTDDRUID	D0C2IA
DRUGNAME	DPC-168
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1
	
TTDDRUID	D0C2II
DRUGNAME	Methazolamide
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D0C2IR
DRUGNAME	MP-AA-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C2KF
DRUGNAME	JNJ-26489112
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
	
TTDDRUID	D0C2KV
DRUGNAME	RGLP-1
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0C2MS
DRUGNAME	NP-07
INDICATI	Bipolar disorder [ICD-11: 6A60] Investigative
	
TTDDRUID	D0C2NT
DRUGNAME	NP-G2-044
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C2OR
DRUGNAME	MIM-D3
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0C2PH
DRUGNAME	CCT301-59 (targeting ROR2)
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
	
TTDDRUID	D0C2QF
DRUGNAME	LY-25582
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0C2QJ
DRUGNAME	GR-270773
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2
	
TTDDRUID	D0C2UH
DRUGNAME	V932
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C2WV
DRUGNAME	DPT-HBV
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0C2XI
DRUGNAME	Claritin/Singulair
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 3
	
TTDDRUID	D0C2YB
DRUGNAME	Cefoperazone
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0C2YZ
DRUGNAME	67Cu-SARTATE
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1/2
	
TTDDRUID	D0C2ZI
DRUGNAME	PSN-842
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0C2ZL
DRUGNAME	Ataciguat
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D0C3AA
DRUGNAME	CKD-712
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C3AD
DRUGNAME	GW-788388
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C3AN
DRUGNAME	SSR-146977
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1
	
TTDDRUID	D0C3BA
DRUGNAME	YM-358
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0C3BS
DRUGNAME	DU-176b
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Approved
	
TTDDRUID	D0C3CF
DRUGNAME	SDZ-NVI-085
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1
	
TTDDRUID	D0C3CZ
DRUGNAME	Aldoxorubicin
INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 3
INDICATI	Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 2
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0C3DA
DRUGNAME	CaroRx
INDICATI	Dental caries [ICD-11: DA08.0] Phase 2
	
TTDDRUID	D0C3DH
DRUGNAME	RAAV vaccine
INDICATI	Melanoma [ICD-11: 2C30] Terminated
	
TTDDRUID	D0C3ET
DRUGNAME	ASB-16165
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D0C3FK
DRUGNAME	TA-CD vaccine
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2
	
TTDDRUID	D0C3FN
DRUGNAME	AX-13057
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C3GW
DRUGNAME	TG-1022
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0C3GZ
DRUGNAME	STS-T4
INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative
	
TTDDRUID	D0C3HS
DRUGNAME	CDP-1050
INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 1
	
TTDDRUID	D0C3JB
DRUGNAME	MB-102
INDICATI	Acute kidney injury [ICD-11: GB60] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0C3LL
DRUGNAME	HER1-VSSP vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0C3LM
DRUGNAME	RAS-111
INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated
	
TTDDRUID	D0C3LP
DRUGNAME	Prezatide copper acetate
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved
	
TTDDRUID	D0C3LQ
DRUGNAME	Ulocuplumab
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D0C3MW
DRUGNAME	MBO7133
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1/2
	
TTDDRUID	D0C3RF
DRUGNAME	REP-9AC
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Preclinical
	
TTDDRUID	D0C3RK
DRUGNAME	N-(phenylpyrazolyl)benzamide derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0C3RP
DRUGNAME	TDI-0074
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0C3SW
DRUGNAME	Lesinurad
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Approved
	
TTDDRUID	D0C3TE
DRUGNAME	TEI-9874
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D0C3TI
DRUGNAME	Resimmune
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
	
TTDDRUID	D0C3UC
DRUGNAME	Ladostigil
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0C3VQ
DRUGNAME	Zadaxin/lamivudine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D0C3WS
DRUGNAME	EC-301
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative
	
TTDDRUID	D0C3XD
DRUGNAME	BIO-11006
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0C3XN
DRUGNAME	AG-1321002
INDICATI	Fever [ICD-11: MG26] Approved
	
TTDDRUID	D0C3YN
DRUGNAME	Heparin low molecular weight
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3
	
TTDDRUID	D0C3YQ
DRUGNAME	Mesna
INDICATI	Urinary dysfunction [ICD-11: GC2Z] Approved
	
TTDDRUID	D0C3ZR
DRUGNAME	TG100-115
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2
INDICATI	Angioedema [ICD-11: 4A00.15] Phase 1/2
	
TTDDRUID	D0C3ZZ
DRUGNAME	BNC375
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
	
TTDDRUID	D0C4AM
DRUGNAME	Pramlintide
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved
	
TTDDRUID	D0C4AY
DRUGNAME	REGN 3051
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1
	
TTDDRUID	D0C4BD
DRUGNAME	KH-901
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C4BI
DRUGNAME	EX-1314
INDICATI	Cachexia [ICD-11: MG20] Investigative
	
TTDDRUID	D0C4BL
DRUGNAME	Coxsackievirus A21
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0C4CJ
DRUGNAME	SF-105
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0C4DH
DRUGNAME	Glecaprevir; pibrentasvir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved
	
TTDDRUID	D0C4DZ
DRUGNAME	ThermoProfen
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D0C4EQ
DRUGNAME	ATYR-0030
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0C4FA
DRUGNAME	BAX-855
INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 3
	
TTDDRUID	D0C4FS
DRUGNAME	DT-200
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1
	
TTDDRUID	D0C4FT
DRUGNAME	HEXESTROL
INDICATI	Irregularities [ICD-11: N.A.] Withdrawn from market
	
TTDDRUID	D0C4GN
DRUGNAME	CD33-CAR-T Cell
INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0C4GX
DRUGNAME	GBL-310
INDICATI	Keratosis [ICD-11: ED56] Phase 2
	
TTDDRUID	D0C4HG
DRUGNAME	Levosimendan
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 4
INDICATI	Cardiac output syndrome [ICD-11: BC43] Phase 3
INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 2
	
TTDDRUID	D0C4HZ
DRUGNAME	PLR-9
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0C4JI
DRUGNAME	DK-0141
INDICATI	Acute lung injury [ICD-11: NB32.3] Investigative
	
TTDDRUID	D0C4JV
DRUGNAME	ISC-4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C4JX
DRUGNAME	QX-314
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0C4KE
DRUGNAME	MIM-3Aa
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D0C4KT
DRUGNAME	XOMA 052
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0C4LF
DRUGNAME	ARRY-162
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D0C4NF
DRUGNAME	FMP-825
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0C4NY
DRUGNAME	Promestriene
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D0C4PB
DRUGNAME	LY3381916
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C4QN
DRUGNAME	ROTIGAPTIDE
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 2
	
TTDDRUID	D0C4RB
DRUGNAME	Taxol
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D0C4SH
DRUGNAME	ZK-209614
INDICATI	Conjunctivitis [ICD-11: 9A60] Investigative
	
TTDDRUID	D0C4TB
DRUGNAME	Pyrazole derivative 22
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0C4UU
DRUGNAME	TDI-0099
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0C4VN
DRUGNAME	GM3 ganglioside vaccine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0C4WC
DRUGNAME	Disitertide
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
	
TTDDRUID	D0C4WY
DRUGNAME	SP-08
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0C4YA
DRUGNAME	AG-331
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0C4YC
DRUGNAME	Mesalazine
INDICATI	Ulcerative colitis [ICD-11: DD71] Approved
	
TTDDRUID	D0C4YF
DRUGNAME	TAN-1518A
INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0C4YQ
DRUGNAME	GSK315234
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0C5CE
DRUGNAME	Nabiximols
INDICATI	Cancer related pain [ICD-11: MG30] Phase 3
INDICATI	Muscle spasm [ICD-11: MB47.3] Phase 3
	
TTDDRUID	D0C5DM
DRUGNAME	SC-52150
INDICATI	Vomiting [ICD-11: MD90] Terminated
	
TTDDRUID	D0C5EG
DRUGNAME	A-366
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0C5FA
DRUGNAME	Duvortuxizumab
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D0C5FQ
DRUGNAME	BHT-3009
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0C5HV
DRUGNAME	R zileuton
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0C5IZ
DRUGNAME	H1N1 vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0C5JH
DRUGNAME	Rimantadine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
	
TTDDRUID	D0C5JQ
DRUGNAME	JNJ-40346527
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 2
	
TTDDRUID	D0C5KG
DRUGNAME	ORG-33628
INDICATI	Contraception [ICD-11: QA21] Discontinued in Phase 2
	
TTDDRUID	D0C5LI
DRUGNAME	SL-91.0893
INDICATI	Prostate hyperplasia [ICD-11: GA90] Terminated
	
TTDDRUID	D0C5LJ
DRUGNAME	ADC-1013
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C5MT
DRUGNAME	Rintatolimod
INDICATI	Chronic fatigue syndrome [ICD-11: 8E49] phase 3
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D0C5ND
DRUGNAME	RO-17
INDICATI	Ulcer [ICD-11: CA02-CB40] Investigative
	
TTDDRUID	D0C5NP
DRUGNAME	AGG-523
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
	
TTDDRUID	D0C5NT
DRUGNAME	PMID25666693-Compound-114
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0C5OF
DRUGNAME	Ro-44-3949
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0C5OK
DRUGNAME	Drug 2838232
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0C5PA
DRUGNAME	Sibenadet
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 3
	
TTDDRUID	D0C5SO
DRUGNAME	RS-PPCC
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0C5UE
DRUGNAME	Ipoxyn
INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative
	
TTDDRUID	D0C5VP
DRUGNAME	AB-1003
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Investigative
	
TTDDRUID	D0C5VQ
DRUGNAME	PRX-321
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0C5WE
DRUGNAME	AGT-2000
INDICATI	Brain cancer [ICD-11: 2A00] Investigative
	
TTDDRUID	D0C5WK
DRUGNAME	LY-392098
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D0C5WR
DRUGNAME	Cobalt chelate complex CTC-96 dermatological
INDICATI	Conjunctivitis [ICD-11: 9A60] Phase 2
	
TTDDRUID	D0C5XC
DRUGNAME	Clemastine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0C5XF
DRUGNAME	GSK-1344386B
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0C5YK
DRUGNAME	NMI-102
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0C5YQ
DRUGNAME	SDZ-62-826
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0C6BJ
DRUGNAME	VII-7-B
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D0C6DT
DRUGNAME	Esomeprazole
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D0C6DU
DRUGNAME	TVX-003
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0C6DX
DRUGNAME	CardiALLO
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D0C6EA
DRUGNAME	XZK
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D0C6FL
DRUGNAME	SPD-704
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Terminated
	
TTDDRUID	D0C6GK
DRUGNAME	EPZ-5676
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1
	
TTDDRUID	D0C6HM
DRUGNAME	Cebaracetam
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D0C6ID
DRUGNAME	Citatuzumab bogatox
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C6IQ
DRUGNAME	Stamulumab
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2
	
TTDDRUID	D0C6KK
DRUGNAME	RT002
INDICATI	Glabellar frown line [ICD-11: NA0Z] Phase 3
	
TTDDRUID	D0C6KS
DRUGNAME	KiroVAX-002
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D0C6MS
DRUGNAME	PF-04991532
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0C6ND
DRUGNAME	AIR-insulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
	
TTDDRUID	D0C6NM
DRUGNAME	Latanoprost
INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D0C6NV
DRUGNAME	RUT58-60
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2
	
TTDDRUID	D0C6OQ
DRUGNAME	Alclofenac
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0C6PL
DRUGNAME	Sm-p80-VR1020
INDICATI	Schistosomiasis [ICD-11: 1F86] Investigative
	
TTDDRUID	D0C6PS
DRUGNAME	Muromonab
INDICATI	Organ transplant rejection [ICD-11: NE84] Approved
	
TTDDRUID	D0C6QG
DRUGNAME	Manganese Chloride Tetrahydrate
INDICATI	Overactive bladder [ICD-11: GC50.0] Approved
	
TTDDRUID	D0C6QQ
DRUGNAME	Besipirdine
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3
	
TTDDRUID	D0C6RD
DRUGNAME	Ypeginterferon alfa-2b
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D0C6RM
DRUGNAME	BAY1436032
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C6RR
DRUGNAME	ACTR087 + rituximab
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D0C6TL
DRUGNAME	Leptin
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0C6VK
DRUGNAME	Lm Prostate
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0C6VO
DRUGNAME	StrataGraft
INDICATI	Burn and burn infection [ICD-11: ND90-NE2Z] Phase 1/2
	
TTDDRUID	D0C6VV
DRUGNAME	Prolarix
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0C6VX
DRUGNAME	PMID25684022-Compound-WO2010127754
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0C6XD
DRUGNAME	BCL-005
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0C6XR
DRUGNAME	Trimegestone/ethinyl estradiol
INDICATI	Contraception [ICD-11: QA21] Phase 3
	
TTDDRUID	D0C6YH
DRUGNAME	ARC-2022
INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Phase 1/2
	
TTDDRUID	D0C6YQ
DRUGNAME	BCL201
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1
	
TTDDRUID	D0C6ZS
DRUGNAME	CpG-10101
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0C6ZX
DRUGNAME	KW-3357
INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 3
	
TTDDRUID	D0C7AA
DRUGNAME	Ozagrel
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 4
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0C7CS
DRUGNAME	ALN-HPN
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0C7CV
DRUGNAME	Atu-134
INDICATI	Lung injury [ICD-11: NB32.3Z] Investigative
	
TTDDRUID	D0C7DY
DRUGNAME	S. pneumococcal next-generation vaccine
INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 2
	
TTDDRUID	D0C7ET
DRUGNAME	Tetrodotoxin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0C7FN
DRUGNAME	BMY-40062
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0C7GJ
DRUGNAME	Long-acting factor VIII
INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D0C7JF
DRUGNAME	Testolactone
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0C7JH
DRUGNAME	TP-9201
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D0C7JT
DRUGNAME	YM-976
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D0C7KB
DRUGNAME	Nova-EPO
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0C7KK
DRUGNAME	Zenarestat
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Terminated
	
TTDDRUID	D0C7LA
DRUGNAME	MAR--99
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0C7LD
DRUGNAME	Pemfexy
INDICATI	Mesothelioma [ICD-11: 2C51.2] Application submitted
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Application submitted
	
TTDDRUID	D0C7LF
DRUGNAME	DACOPAFANT
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1
	
TTDDRUID	D0C7NU
DRUGNAME	(S)-8-Hydroxy palmitic acid
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C7OQ
DRUGNAME	BIWB-1
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2
	
TTDDRUID	D0C7OT
DRUGNAME	CN54gp140-hsp70 conjugate vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0C7QW
DRUGNAME	XMetS
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0C7RV
DRUGNAME	SR12813
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0C7TO
DRUGNAME	Tr-3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C7UR
DRUGNAME	AGI-1096
INDICATI	Transplant rejection [ICD-11: NE84] Discontinued in Phase 1
	
TTDDRUID	D0C7WO
DRUGNAME	1192U90
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0C7WP
DRUGNAME	SB-431542
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Preclinical
	
TTDDRUID	D0C7XM
DRUGNAME	P2045
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D0C7YE
DRUGNAME	NKR-2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0C7YH
DRUGNAME	PMX-900
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C7ZB
DRUGNAME	GSK3196165
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0C8AL
DRUGNAME	Fluoropeptide vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0C8AP
DRUGNAME	AG-348
INDICATI	Pyruvate kinase deficiency [ICD-11: 5C53.00] Phase 2
	
TTDDRUID	D0C8DC
DRUGNAME	Ki-1769
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0C8DD
DRUGNAME	Losmapimod
INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 3
	
TTDDRUID	D0C8EB
DRUGNAME	PMID26651364-Compound-45
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0C8ES
DRUGNAME	CBL0102
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
	
TTDDRUID	D0C8EU
DRUGNAME	Temozolomide
INDICATI	Grade IV astrocytoma [ICD-11: 2A00.0] Approved
	
TTDDRUID	D0C8FX
DRUGNAME	Pyrithione Zinc
INDICATI	Seborrhoeic dermatitis [ICD-11: EA81] Approved
	
TTDDRUID	D0C8HR
DRUGNAME	Halometasone
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0C8IF
DRUGNAME	LY3154207
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0C8JW
DRUGNAME	Muscular dystrophy gene therapy
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1
	
TTDDRUID	D0C8KF
DRUGNAME	Resiquimod
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1/2
	
TTDDRUID	D0C8KP
DRUGNAME	Santalum album
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D0C8KY
DRUGNAME	SYN-1001
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0C8LG
DRUGNAME	CLT-010
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C8MG
DRUGNAME	SELA-212
INDICATI	Gout [ICD-11: FA25] Phase 2
	
TTDDRUID	D0C8NG
DRUGNAME	BI 655064
INDICATI	Lupus [ICD-11: 4A40] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 1
	
TTDDRUID	D0C8NK
DRUGNAME	TG-21
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0C8PE
DRUGNAME	JNJ-37822681
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0C8PI
DRUGNAME	Zoniporide hydrochloride
INDICATI	Angina pectoris [ICD-11: BA40] Phase 3
	
TTDDRUID	D0C8PQ
DRUGNAME	CVS-3083
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0C8PW
DRUGNAME	Albunex
INDICATI	Female infertility [ICD-11: GA31.Z] Approved
	
TTDDRUID	D0C8QA
DRUGNAME	KITE-585
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0C8QS
DRUGNAME	Ragwitek
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0C8RH
DRUGNAME	Cericlamine
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3
	
TTDDRUID	D0C8RW
DRUGNAME	Rec-antihemophilic factor
INDICATI	Hemophilia [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0C8TD
DRUGNAME	Thrombin-JMI
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
	
TTDDRUID	D0C8UN
DRUGNAME	KT-3799
INDICATI	Carbacephem [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0C8VF
DRUGNAME	Galcanezumab
INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Approved
	
TTDDRUID	D0C8XT
DRUGNAME	DLO6001
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0C8ZD
DRUGNAME	A-71623
INDICATI	Obesity [ICD-11: 5B81] Terminated
	
TTDDRUID	D0C8ZZ
DRUGNAME	PMID25666693-Compound-12
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0C9AQ
DRUGNAME	MBI 1121
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0C9AV
DRUGNAME	Mical (1)
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	D0C9DA
DRUGNAME	Calaspargase pegol
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Approved
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3
	
TTDDRUID	D0C9DB
DRUGNAME	424C79
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0C9EE
DRUGNAME	PAZELLIPTINE TRIHYDROCHLORIDE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0C9EN
DRUGNAME	AZD5312
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0C9ET
DRUGNAME	Aflibercept
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Approved
	
TTDDRUID	D0C9FF
DRUGNAME	DNK-333
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2
	
TTDDRUID	D0C9FN
DRUGNAME	PMID25666693-Compound-87
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0C9HE
DRUGNAME	Campyvax
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0C9IS
DRUGNAME	P-9808
INDICATI	Porphyria [ICD-11: 5C58.1] Phase 2
	
TTDDRUID	D0C9IW
DRUGNAME	Factor viia
INDICATI	Hemophilia [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0C9JI
DRUGNAME	Zn-DPA-B
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0C9JJ
DRUGNAME	AR-12
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0C9JL
DRUGNAME	Y-23684
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3
	
TTDDRUID	D0C9KQ
DRUGNAME	Genimune
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D0C9KW
DRUGNAME	AVN-457
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D0C9KX
DRUGNAME	TSD-0014
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0C9KY
DRUGNAME	Pyridobenzimidazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D0C9LE
DRUGNAME	YPL-1101
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0C9LQ
DRUGNAME	LentiGlobin
INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 3
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 1
	
TTDDRUID	D0C9MA
DRUGNAME	ACH-4471
INDICATI	Anaemia [ICD-11: 3A90] Phase 2
INDICATI	Glomerulonephritis [ICD-11: 5D00.Y] Phase 1
	
TTDDRUID	D0C9MJ
DRUGNAME	Anti-MUC1 CAR-T cells
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2
INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D0C9NJ
DRUGNAME	STA-5326
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D0C9PZ
DRUGNAME	PT2385
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Von hippel-lindau disease [ICD-11: 5A75] Phase 2
INDICATI	Brain cancer [ICD-11: 2A00] Investigative
	
TTDDRUID	D0C9QM
DRUGNAME	TH-1011
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0C9RF
DRUGNAME	CGEN-25007
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0C9RM
DRUGNAME	Nano-PGE1
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Investigative
	
TTDDRUID	D0C9RV
DRUGNAME	SRSS-016
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0C9RZ
DRUGNAME	BU-4601A
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0C9SW
DRUGNAME	Somatropin intranasal rhGH
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2
	
TTDDRUID	D0C9SY
DRUGNAME	Vardenafil
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved
	
TTDDRUID	D0C9TH
DRUGNAME	ALD-451
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
	
TTDDRUID	D0C9TP
DRUGNAME	CaspaCIDe donor lymphocyte infusion
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 2
	
TTDDRUID	D0C9WN
DRUGNAME	MKC-1106-PP
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0C9XA
DRUGNAME	GSK683699
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
	
TTDDRUID	D0C9XJ
DRUGNAME	Epirubicin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0CA0P
DRUGNAME	Certolizumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0CA2S
DRUGNAME	HYDAMTIQ
INDICATI	Brain ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0CA3J
DRUGNAME	GSK568859
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D0CA3M
DRUGNAME	Anti-meso-CAR T cells
INDICATI	Mesothelin Positive tumour [ICD-11: 2C51-2F10] Phase 1
	
TTDDRUID	D0CA6J
DRUGNAME	Tioconazole
INDICATI	Onychomycosis [ICD-11: EE12.1] Approved
	
TTDDRUID	D0CA7B
DRUGNAME	BDM-I
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D0CB2B
DRUGNAME	Serlopitant
INDICATI	Prurigo nodularis [ICD-11: EC91.0] Phase 3
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D0CB6N
DRUGNAME	AVI-6003
INDICATI	Marburg virus infection [ICD-11: 1D60.1] Phase 1
	
TTDDRUID	D0CB7L
DRUGNAME	Hepatitis B Hyperimmune
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D0CB8W
DRUGNAME	DE-081
INDICATI	Conjunctivitis [ICD-11: 9A60] Discontinued in Phase 2
INDICATI	Ocular allergy [ICD-11: 4A81] Terminated
	
TTDDRUID	D0CC1Y
DRUGNAME	VML-262
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0CC3O
DRUGNAME	APG-232
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0CC8L
DRUGNAME	CRILVASTATIN
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D0CD7Q
DRUGNAME	Beta-cyclodextrin conjugate derivative 4
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0CE0O
DRUGNAME	Alisporivir
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3
	
TTDDRUID	D0CE0Y
DRUGNAME	Anti-CD19-CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D0CE1R
DRUGNAME	Antibodie derivative 7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D0CE5S
DRUGNAME	PD-4074
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0CE6C
DRUGNAME	LMI070
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 3
	
TTDDRUID	D0CE6T
DRUGNAME	Elisartan potassium
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D0CE8J
DRUGNAME	Genaconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 1
	
TTDDRUID	D0CE9S
DRUGNAME	S(377588)-Fc vaccine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0CF0Y
DRUGNAME	Rolapitant
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Approved
	
TTDDRUID	D0CF2Q
DRUGNAME	Levamisole
INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved
INDICATI	Colon cancer [ICD-11: 2B90.Z] Withdrawn from market
	
TTDDRUID	D0CF3H
DRUGNAME	HG-1070
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0CF3M
DRUGNAME	Sifuvirtide
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0CF8T
DRUGNAME	Z-521
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 3
	
TTDDRUID	D0CF8Y
DRUGNAME	Pyrazoline derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0CG0K
DRUGNAME	ATI-502
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	Vitiligo [ICD-11: ED63.0] Phase 2
	
TTDDRUID	D0CG0N
DRUGNAME	PRO-140
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0CG1A
DRUGNAME	EBV-CTL
INDICATI	Post-transplant lymphoproliferative disorder [ICD-11: 2B32] Phase 2
	
TTDDRUID	D0CG8N
DRUGNAME	Tri-substituted urea derivative 2
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0CG8S
DRUGNAME	oxazine 89
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Clinical trial
	
TTDDRUID	D0CG9E
DRUGNAME	SL-11093
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0CH1U
DRUGNAME	Interleukin-3
INDICATI	Aplastic anemia [ICD-11: 3A70] Approved
	
TTDDRUID	D0CH3F
DRUGNAME	Resorcinol compound 16
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0CH4A
DRUGNAME	SBC-102
INDICATI	Enzyme deficiency [ICD-11: 5C51-5C57] Approved
	
TTDDRUID	D0CH4T
DRUGNAME	Lu-02-750
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0CH6B
DRUGNAME	ALZT-OP1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0CH6Z
DRUGNAME	BBR 3576
INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated
	
TTDDRUID	D0CH7C
DRUGNAME	Basmisanil
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
INDICATI	Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 2
INDICATI	Immune dysregulation [ICD-11: 4A01.2] Phase 2
	
TTDDRUID	D0CH8E
DRUGNAME	Macrocyclic peptide analog 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0CH9G
DRUGNAME	Pepvax
INDICATI	Cytomegalovirus Disease [ICD-11: 1D82] Phase 2
	
TTDDRUID	D0CI2U
DRUGNAME	Benzoic acid linked peptide analog 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0CI4B
DRUGNAME	MP-100
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D0CI4E
DRUGNAME	Pertuzumab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0CI5O
DRUGNAME	SPD-474
INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated
	
TTDDRUID	D0CI9T
DRUGNAME	Ceftobiprole
INDICATI	Community-acquired pneumonia [ICD-11: CA40.Z] Phase 3
INDICATI	Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Phase 3
	
TTDDRUID	D0CI9W
DRUGNAME	GSK-334429
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D0CJ3R
DRUGNAME	MS201408-0005C
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0CJ7Z
DRUGNAME	Abicipar pegol
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	D0CK2C
DRUGNAME	ZP-10395
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0CK3G
DRUGNAME	Ethinamate
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0CK5J
DRUGNAME	SF-116
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D0CK7F
DRUGNAME	AOB103
INDICATI	Rosacea [ICD-11: ED90.0] Phase 2
	
TTDDRUID	D0CK8H
DRUGNAME	Indazole derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0CL5D
DRUGNAME	Ragweed allergy vaccine
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D0CL9S
DRUGNAME	Telbivudine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0CM3Z
DRUGNAME	ATON-009
INDICATI	Metal intoxication [ICD-11: NE60] Phase 1
	
TTDDRUID	D0CM5P
DRUGNAME	Quinazoline derivative 10
INDICATI	Cirrhosis [ICD-11: DB93] Patented
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Patented
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Patented
INDICATI	Multiple sclerosis [ICD-11: 8A40] Patented
	
TTDDRUID	D0CN6Q
DRUGNAME	PMID26651364-Compound-5c
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0CN7A
DRUGNAME	PMID26651364-Compound-7c
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0CN7I
DRUGNAME	IMC-CS4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0CN8U
DRUGNAME	PF-06763809
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
	
TTDDRUID	D0CN9D
DRUGNAME	Anetumab ravtansine
INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 2
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D0CN9Q
DRUGNAME	CP-724714
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
	
TTDDRUID	D0CO2M
DRUGNAME	S-9788
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0CO2W
DRUGNAME	AMG 301
INDICATI	Migraine [ICD-11: 8A80] Phase 2
INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Investigative
	
TTDDRUID	D0CO3N
DRUGNAME	esuberaprost
INDICATI	Gout [ICD-11: FA25] Phase 3
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3
	
TTDDRUID	D0CO3O
DRUGNAME	RAP-701
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D0CO5F
DRUGNAME	ALLOD-2
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
INDICATI	Chronic low back pain [ICD-11: MG30.02] Phase 2
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D0CO6D
DRUGNAME	AMG 333
INDICATI	Migraine [ICD-11: 8A80] Phase 1
	
TTDDRUID	D0CO9B
DRUGNAME	Ad-p53
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D0CP3Z
DRUGNAME	ALS-012117
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0CP4E
DRUGNAME	Clonazepam
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
INDICATI	Seizure disorder [ICD-11: 8A6Z] Phase 2
	
TTDDRUID	D0CP6B
DRUGNAME	3-(phenoxymethyl) benzylamine derivative 5
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0CP8N
DRUGNAME	Silmitasertib
INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] phase 1/2
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0CQ0Z
DRUGNAME	Penfluridol
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0CQ1M
DRUGNAME	Heterocyclic-carboxamide derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0CQ1X
DRUGNAME	HTERT RNA vaccine
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0CQ2O
DRUGNAME	Interferon beta-1b
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
	
TTDDRUID	D0CQ2P
DRUGNAME	SPL-7013
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0CQ5A
DRUGNAME	SKL20540
INDICATI	Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1
INDICATI	Immune dysregulation [ICD-11: 4A01.2] Phase 1
	
TTDDRUID	D0CQ8D
DRUGNAME	AMR-103
INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated
	
TTDDRUID	D0CR0H
DRUGNAME	PMID25666693-Compound-138
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0CR1I
DRUGNAME	TJ-9
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0CR4Z
DRUGNAME	IPI-940
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0CR6E
DRUGNAME	SSYA10-001
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0CR7L
DRUGNAME	GSK3326595
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0CR8H
DRUGNAME	SYM-004
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 3
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0CR8J
DRUGNAME	Biphenyl mannoside derivative 26
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0CR9I
DRUGNAME	CX-5011
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0CR9L
DRUGNAME	Daromun
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D0CS0D
DRUGNAME	WAY-121898
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0CS2C
DRUGNAME	AZD9056
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0CS2F
DRUGNAME	Loperamide
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
	
TTDDRUID	D0CS2L
DRUGNAME	DG-1-66
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D0CS3A
DRUGNAME	CART-19
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D0CS6N
DRUGNAME	Benzodiazepine
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D0CT1S
DRUGNAME	BB IND-6989
INDICATI	Salmonella infection [ICD-11: 1A09] Phase 1
	
TTDDRUID	D0CT3I
DRUGNAME	AgaDerm
INDICATI	Dermatomycosis [ICD-11: EA60] Investigative
	
TTDDRUID	D0CT4D
DRUGNAME	Brivaracetam
INDICATI	Complex partial seizure [ICD-11: 8A68.0] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D0CT5O
DRUGNAME	ALX-101
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D0CT5Z
DRUGNAME	SLP-0907
INDICATI	Escherichia coli infection [ICD-11: 1A03] Investigative
	
TTDDRUID	D0CT7M
DRUGNAME	A-6
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
	
TTDDRUID	D0CT9C
DRUGNAME	Cyclophosphamide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0CT9Y
DRUGNAME	Clomifene
INDICATI	Female infertility [ICD-11: GA31.Z] Approved
	
TTDDRUID	D0CU1O
DRUGNAME	Dolutegravir + rilpivirine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Application submitted
	
TTDDRUID	D0CU1T
DRUGNAME	SB2
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Application submitted
INDICATI	Crohn disease [ICD-11: DD70] Application submitted
INDICATI	Psoriatic arthritis [ICD-11: FA21] Application submitted
INDICATI	Ulcerative colitis [ICD-11: DD71] Application submitted
	
TTDDRUID	D0CU2Q
DRUGNAME	DHES0815A
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0CV7Q
DRUGNAME	ASO-1
INDICATI	Fatty liver disease [ICD-11: DB92.Z] Investigative
	
TTDDRUID	D0CV7T
DRUGNAME	Patamostat
INDICATI	Hypotension [ICD-11: BA20-BA21] Terminated
	
TTDDRUID	D0CV7Z
DRUGNAME	Epothilone B
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D0CW1J
DRUGNAME	Pyrrole derivative 5
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0CW1P
DRUGNAME	Betamethasone
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0CW2B
DRUGNAME	ETX-101
INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 3
	
TTDDRUID	D0CW2N
DRUGNAME	Reolysinpelareorep
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0CW3B
DRUGNAME	M-101
INDICATI	Blood transfusion [ICD-11: QB98] Investigative
	
TTDDRUID	D0CW3U
DRUGNAME	Kanjinti
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Application submitted
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Application submitted
	
TTDDRUID	D0CW6S
DRUGNAME	Monoxanes
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0CW8S
DRUGNAME	ABX-1431
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 1
	
TTDDRUID	D0CX1F
DRUGNAME	Sulfonylated piperazine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0CX2J
DRUGNAME	R-1315
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0CX4C
DRUGNAME	PMID25666693-Compound-76
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0CY1B
DRUGNAME	CYC116
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0CY2Q
DRUGNAME	CrohnsVax
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
	
TTDDRUID	D0CY2Z
DRUGNAME	HuMax-HepC
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated
	
TTDDRUID	D0CY3A
DRUGNAME	Idraparinux
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3
	
TTDDRUID	D0CY3F
DRUGNAME	Aom-0925
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0CY3U
DRUGNAME	Five membered heterocyclic benzamide derivative 3
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0CY4V
DRUGNAME	Cetamolol
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D0CY9O
DRUGNAME	ON-128
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0CZ0D
DRUGNAME	EF-12
INDICATI	Coronary artery disease [ICD-11: BA80] Discontinued in Phase 3
	
TTDDRUID	D0CZ1A
DRUGNAME	IRISQUINONE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0CZ1Q
DRUGNAME	Desoximetasone
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0CZ5Z
DRUGNAME	SPD-465
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
	
TTDDRUID	D0D0BE
DRUGNAME	Ornidazole
INDICATI	Amoebiasis [ICD-11: 1A36] Approved
	
TTDDRUID	D0D0BM
DRUGNAME	Corticotropin-zinc Hydroxide
INDICATI	Ulcerative colitis [ICD-11: DD71] Approved
	
TTDDRUID	D0D0DH
DRUGNAME	TLPLDC
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	D0D0FB
DRUGNAME	TV1001
INDICATI	Diabetic angiopathy [ICD-11: BD53.Y] Phase 2
	
TTDDRUID	D0D0GH
DRUGNAME	NsG-0202
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0D0GV
DRUGNAME	Fenhexamid
INDICATI	Plant grey mould disease [ICD-11: N.A.] Approved
	
TTDDRUID	D0D0HB
DRUGNAME	DCVax
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
	
TTDDRUID	D0D0IF
DRUGNAME	ScFv23/rGel
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0D0JY
DRUGNAME	WNVax
INDICATI	West nile virus infection [ICD-11: 1D46] Investigative
	
TTDDRUID	D0D0KZ
DRUGNAME	AV4025
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0D0LD
DRUGNAME	L-873724
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0D0LH
DRUGNAME	NU-100
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
	
TTDDRUID	D0D0ML
DRUGNAME	Heterocyclic derivative 6
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0D0NA
DRUGNAME	KDT-600
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0D0OC
DRUGNAME	G-series prophage vaccine
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0D0OR
DRUGNAME	V520/V526 combination vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0D0OT
DRUGNAME	GS-4977
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D0D0PB
DRUGNAME	AIC-292
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0D0QA
DRUGNAME	AZD6482
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0D0QQ
DRUGNAME	Velac Gel
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3
	
TTDDRUID	D0D0RJ
DRUGNAME	LED-209
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0D0RW
DRUGNAME	KMB-17
INDICATI	Enterovirus infection [ICD-11: 1D91] Phase 3
	
TTDDRUID	D0D0SH
DRUGNAME	GMDP
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0D0TQ
DRUGNAME	AKN-028
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative
	
TTDDRUID	D0D0US
DRUGNAME	OB-14
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D0D0WH
DRUGNAME	Anti-CD73 mAb
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0D0WP
DRUGNAME	V-0096
INDICATI	Urticaria [ICD-11: EB00-EB05] Discontinued in Phase 2
	
TTDDRUID	D0D0XF
DRUGNAME	AG-702
INDICATI	Genital herpes [ICD-11: 1A94] Discontinued in Phase 1/2
	
TTDDRUID	D0D0XX
DRUGNAME	LY-290154
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0D0XY
DRUGNAME	ImmuneFx
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D0YK
DRUGNAME	GI-3000
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative
	
TTDDRUID	D0D0YM
DRUGNAME	Amosulalol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0D0ZD
DRUGNAME	Miglitol
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0D1AL
DRUGNAME	Haloperidol
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0D1BC
DRUGNAME	Melanocortin-4 Receptor antagonist
INDICATI	Anorexia nervosa cachexia [ICD-11: 6B80] Investigative
	
TTDDRUID	D0D1BR
DRUGNAME	GS-7340
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0D1CL
DRUGNAME	MB07133
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
	
TTDDRUID	D0D1CS
DRUGNAME	Boceprevir
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0D1DI
DRUGNAME	Arformoterol
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
INDICATI	Asthma [ICD-11: CA23] Phase 4
	
TTDDRUID	D0D1EI
DRUGNAME	Diphenyl purine derivative 5
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0D1EV
DRUGNAME	NSC-364432
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0D1FC
DRUGNAME	LY-362884
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D0D1GF
DRUGNAME	XL880
INDICATI	Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0D1GV
DRUGNAME	CNS-1237
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0D1HA
DRUGNAME	Cefotaxime
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0D1HH
DRUGNAME	Carvedilol
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0D1HI
DRUGNAME	Autologous T Cells Expressing MET scFv CAR
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 0
	
TTDDRUID	D0D1HR
DRUGNAME	TrkB NAM
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0D1HS
DRUGNAME	Ki23819
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0D1HW
DRUGNAME	Anagrelide
INDICATI	Thrombocythemia [ICD-11: 3B63] Approved
INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 2
	
TTDDRUID	D0D1IR
DRUGNAME	HG-1438
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D1JP
DRUGNAME	WR-279396
INDICATI	Leishmania infection [ICD-11: 1F54.0] Phase 3
	
TTDDRUID	D0D1LG
DRUGNAME	AZD-5099
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D0D1LS
DRUGNAME	5-Fluoro-2-deoxycytidine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0D1MA
DRUGNAME	Oxyphenonium
INDICATI	Visceral spasms [ICD-11: MD81.4] Approved
	
TTDDRUID	D0D1OG
DRUGNAME	Sapanisertib
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0D1PQ
DRUGNAME	EDP-21
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0D1RF
DRUGNAME	ABX-0401
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Preclinical
	
TTDDRUID	D0D1RM
DRUGNAME	Botulinum Toxin Type A
INDICATI	Blepharospasm [ICD-11: 9A05.Z] Approved
	
TTDDRUID	D0D1SG
DRUGNAME	Prednisolone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
	
TTDDRUID	D0D1TB
DRUGNAME	CPC-410
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D1TS
DRUGNAME	Isoquinoline derivative 2
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
	
TTDDRUID	D0D1TX
DRUGNAME	Recombinant human pro-urokinase
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D0D1UD
DRUGNAME	STI-001
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0D1UQ
DRUGNAME	Neu-120
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2
	
TTDDRUID	D0D1VJ
DRUGNAME	SDZ-210-086
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1
	
TTDDRUID	D0D1XG
DRUGNAME	CI-976
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D0D1XW
DRUGNAME	PEG-Interferon lambda (IL-29)
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1
	
TTDDRUID	D0D1YY
DRUGNAME	IGN-2098
INDICATI	Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 2
	
TTDDRUID	D0D1ZF
DRUGNAME	Mavacamten
INDICATI	Obstructive hypertrophic cardiomyopathy [ICD-11: BC43.12] Phase 3
	
TTDDRUID	D0D1ZS
DRUGNAME	CLP-1001
INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 2
	
TTDDRUID	D0D2AR
DRUGNAME	SOM-0003
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0D2CF
DRUGNAME	PMID25666693-Compound-115
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0D2CY
DRUGNAME	DEX-M74
INDICATI	Myopathy [ICD-11: 8C7Y] Phase 1/2
	
TTDDRUID	D0D2FZ
DRUGNAME	Ragweed allergy vaccine sublingual
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Approved
	
TTDDRUID	D0D2GW
DRUGNAME	EHC18
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1
	
TTDDRUID	D0D2GZ
DRUGNAME	AL-408
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0D2IU
DRUGNAME	Engerix B
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0D2JD
DRUGNAME	TH-0318
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D0D2JW
DRUGNAME	Polyhydroxy benzamide derivative 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0D2KU
DRUGNAME	JQ1
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0D2LE
DRUGNAME	Meso-CART
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0D2LF
DRUGNAME	YM-116
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0D2PD
DRUGNAME	ABBV-744
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0D2PQ
DRUGNAME	CT-2412
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0D2QE
DRUGNAME	PMID26651364-Compound-117b
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0D2RN
DRUGNAME	Aminopterin
INDICATI	leukaemia [ICD-11: 2A60-2B33] Withdrawn from market
	
TTDDRUID	D0D2RR
DRUGNAME	TgBSSL
INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Investigative
	
TTDDRUID	D0D2RZ
DRUGNAME	SDZ-267-489
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0D2SG
DRUGNAME	99mTc-ciprofloxacin
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Discontinued in Phase 2
	
TTDDRUID	D0D2SX
DRUGNAME	INNO-101
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2
	
TTDDRUID	D0D2TN
DRUGNAME	Rimexolone
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0D2TT
DRUGNAME	TV-1106
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 3
	
TTDDRUID	D0D2TZ
DRUGNAME	CMS-024-02
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0D2UA
DRUGNAME	2-NAP
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative
	
TTDDRUID	D0D2UU
DRUGNAME	XEL-003FL
INDICATI	Onychomycosis [ICD-11: EE12.1] Investigative
	
TTDDRUID	D0D2VS
DRUGNAME	Exemestane
INDICATI	Hormonally-responsive breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0D2WX
DRUGNAME	1614235 + 2330672
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0D2XA
DRUGNAME	REIC gene therapy
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0D2XQ
DRUGNAME	ASN007
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0D2YZ
DRUGNAME	BMTP-11
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0D2ZI
DRUGNAME	SOM-1000
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D0D3AI
DRUGNAME	L-NAME
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0D3BO
DRUGNAME	SOLPECAINOL HYDROCHLORIDE
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2
	
TTDDRUID	D0D3CJ
DRUGNAME	BYK-191023
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0D3DU
DRUGNAME	Methotrexate Sodium
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0D3FP
DRUGNAME	Drug 2881078
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D0D3HF
DRUGNAME	TBI-304
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0D3HM
DRUGNAME	RG7212
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0D3HV
DRUGNAME	PLR-21
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Terminated
	
TTDDRUID	D0D3JQ
DRUGNAME	Flovagatran
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D0D3KG
DRUGNAME	RG-7236
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1
	
TTDDRUID	D0D3KS
DRUGNAME	Orochol
INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Approved
	
TTDDRUID	D0D3KY
DRUGNAME	SC-106
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0D3LZ
DRUGNAME	20D75
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0D3PB
DRUGNAME	BAY 60-4552
INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2
	
TTDDRUID	D0D3PX
DRUGNAME	SCH 727965
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Discontinued in Phase 3
	
TTDDRUID	D0D3QJ
DRUGNAME	CRTX-067
INDICATI	Cough [ICD-11: MD12] Investigative
	
TTDDRUID	D0D3QN
DRUGNAME	CD11301
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
	
TTDDRUID	D0D3RS
DRUGNAME	Biaryl compound 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0D3RY
DRUGNAME	Merozoite surface protein 3 long synthetic peptide vaccine
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D0D3SW
DRUGNAME	ABX-103
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D3TO
DRUGNAME	PYN-22
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0D3TQ
DRUGNAME	GSK2330811
INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D0D3TU
DRUGNAME	DWJ-207
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0D3TX
DRUGNAME	EVP-6124
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0D3UI
DRUGNAME	ZY01
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D0D3UQ
DRUGNAME	Streptococcus mutans vaccine
INDICATI	Dental caries [ICD-11: DA08.0] Phase 1
	
TTDDRUID	D0D3VT
DRUGNAME	Dihydrexidine
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1/2
	
TTDDRUID	D0D3XM
DRUGNAME	TAK-137
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Phase 1
	
TTDDRUID	D0D3ZP
DRUGNAME	NBI-42902
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1
	
TTDDRUID	D0D4AQ
DRUGNAME	PCI-45292
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Preclinical
	
TTDDRUID	D0D4CX
DRUGNAME	Pegamotecan
INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 2
	
TTDDRUID	D0D4CY
DRUGNAME	Sulfapyridine
INDICATI	Dermatitis herpetiformis [ICD-11: EB44] Approved
	
TTDDRUID	D0D4DY
DRUGNAME	Tetracel
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Discontinued in Preregistration
	
TTDDRUID	D0D4HM
DRUGNAME	Alglucerase
INDICATI	Enzyme deficiency [ICD-11: 5C51-5C57] Approved
	
TTDDRUID	D0D4HN
DRUGNAME	Podofilox
INDICATI	External genital and perianal wart [ICD-11: 1A95] Approved
INDICATI	Condyloma [ICD-11: 1A95] Approved
INDICATI	Verruca vulgaris [ICD-11: 1E80] Approved
	
TTDDRUID	D0D4HO
DRUGNAME	GC021109
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0D4IH
DRUGNAME	Oxitropium bromide
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0D4IL
DRUGNAME	AMT-021
INDICATI	Acute intermittent hepatic porphyria [ICD-11: 5C58.11] Investigative
	
TTDDRUID	D0D4JI
DRUGNAME	SR-31747
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0D4JO
DRUGNAME	Artesunate
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0D4LP
DRUGNAME	JVRS-100
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D0D4LS
DRUGNAME	PUR003
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 1/2
	
TTDDRUID	D0D4NJ
DRUGNAME	CYT-005-allQbG10
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D0D4NX
DRUGNAME	PMID25666693-Compound-108
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0D4OL
DRUGNAME	SC-002
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0D4OS
DRUGNAME	VM-202
INDICATI	Angina pectoris [ICD-11: BA40] Phase 3
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 3
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 3
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
	
TTDDRUID	D0D4PB
DRUGNAME	Dextropropoxyphene
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0D4QL
DRUGNAME	Benzimidazole 5-carboxamide
INDICATI	Hepatovirus infection [ICD-11: 1E51] Investigative
	
TTDDRUID	D0D4RF
DRUGNAME	Sapacitabine
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 3
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0D4TC
DRUGNAME	Sym021
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0D4UO
DRUGNAME	DPK-DTSM-02
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D4UT
DRUGNAME	GSK2849330
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0D4VH
DRUGNAME	BM-212
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0D4VN
DRUGNAME	HPV-16 E7 vaccine
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2
	
TTDDRUID	D0D4VV
DRUGNAME	LY2874455
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0D4WA
DRUGNAME	PHY-777
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D4XF
DRUGNAME	Daniplestim
INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated
	
TTDDRUID	D0D4YZ
DRUGNAME	PSI-7977
INDICATI	HCV 1-6 infection [ICD-11: 1E51] Approved
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0D4ZE
DRUGNAME	JP-8019
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D4ZM
DRUGNAME	ISRAPAFANT
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D0D4ZN
DRUGNAME	CAR-T cells targeting BCMA
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0D4ZW
DRUGNAME	EGS-21
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D0D5AV
DRUGNAME	HPV 16/18 vaccine
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 3
	
TTDDRUID	D0D5BJ
DRUGNAME	BPX-201
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0D5CJ
DRUGNAME	SDZ-LAP-977
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0D5CQ
DRUGNAME	NVP-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0D5CY
DRUGNAME	Pradefovir
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2
	
TTDDRUID	D0D5DE
DRUGNAME	ALPRENOXIME HYDROCHLORIDE
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2
	
TTDDRUID	D0D5EJ
DRUGNAME	Insulin oral sublingual
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0D5EW
DRUGNAME	HKI-9924129
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0D5FB
DRUGNAME	EPO-derived peptide
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative
	
TTDDRUID	D0D5FQ
DRUGNAME	Agatolimod
INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 2
	
TTDDRUID	D0D5FR
DRUGNAME	Organosphosphates
INDICATI	Candidiasis [ICD-11: 1F23] Phase 2
INDICATI	Propagation of disease by mosquito [ICD-11: 1C80-1D48] Phase 2
	
TTDDRUID	D0D5FU
DRUGNAME	Baricitinib
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0D5GD
DRUGNAME	Flumazenil
INDICATI	Benzodiazepine overdose [ICD-11: PC91] Approved
	
TTDDRUID	D0D5GG
DRUGNAME	Pemoline
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
	
TTDDRUID	D0D5IJ
DRUGNAME	LN-030
INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated
	
TTDDRUID	D0D5IS
DRUGNAME	SYNSORB-Pk
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 3
	
TTDDRUID	D0D5KQ
DRUGNAME	PU24S
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D5LX
DRUGNAME	NKTT-120
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 1
	
TTDDRUID	D0D5MQ
DRUGNAME	Pyrazole derivative 27
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0D5MU
DRUGNAME	V10153
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
	
TTDDRUID	D0D5NI
DRUGNAME	GBP-1a
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0D5NV
DRUGNAME	GC-1109
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 2
	
TTDDRUID	D0D5NZ
DRUGNAME	H5N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0D5RH
DRUGNAME	TAK-442
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D0D5SQ
DRUGNAME	Candesartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0D5TN
DRUGNAME	TT-034
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2
	
TTDDRUID	D0D5VJ
DRUGNAME	UK-432097
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0D5XV
DRUGNAME	APX-E
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0D5YE
DRUGNAME	Imidazo quinoline derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0D5ZJ
DRUGNAME	Momelotinib
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 3
INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 2
INDICATI	Thrombocythemia [ICD-11: 3B63] Phase 2
	
TTDDRUID	D0D5ZR
DRUGNAME	TRO-40303
INDICATI	Lateral sclerosis [ICD-11: 8B61] Discontinued in Phase 2
	
TTDDRUID	D0D5ZU
DRUGNAME	QPI-1002
INDICATI	Renal transplantation [ICD-11: NE84] Phase 3
INDICATI	Renal artery disease [ICD-11: BD40.2] Phase 1/2
	
TTDDRUID	D0D5ZV
DRUGNAME	CMI-392
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D0D5ZX
DRUGNAME	RG-12915
INDICATI	Nausea [ICD-11: MD90] Discontinued in Phase 3
	
TTDDRUID	D0D6BT
DRUGNAME	Parathyroid hormone analog
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1
	
TTDDRUID	D0D6DB
DRUGNAME	Phytosel
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0D6EK
DRUGNAME	RDX-002
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Investigative
	
TTDDRUID	D0D6EW
DRUGNAME	Glypromate
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2
	
TTDDRUID	D0D6GT
DRUGNAME	Iota-carrageenan
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 4
	
TTDDRUID	D0D6HS
DRUGNAME	Mannoside derivative 12
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0D6LF
DRUGNAME	PD-156
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0D6MC
DRUGNAME	HC-030031
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0D6MV
DRUGNAME	PPI-668
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0D6NQ
DRUGNAME	HEV-239
INDICATI	Hepatitis E virus infection [ICD-11: 1E50.4] Approved
	
TTDDRUID	D0D6OM
DRUGNAME	Alkyl mannoside derivative 7
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0D6OO
DRUGNAME	NP-500
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
INDICATI	Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 1
	
TTDDRUID	D0D6PG
DRUGNAME	MBS-101
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0D6QH
DRUGNAME	Sci-DaPT-Vac
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D0D6QU
DRUGNAME	ADCON-L
INDICATI	Wound healing [ICD-11: EL8Y] Approved
	
TTDDRUID	D0D6SZ
DRUGNAME	TROXACITABINE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0D6VE
DRUGNAME	Pegvisomant
INDICATI	Acromegaly [ICD-11: 5A60.0] Approved
	
TTDDRUID	D0D6WF
DRUGNAME	NP-103
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0D6XD
DRUGNAME	MNX-200
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D6XH
DRUGNAME	LY-203725
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0D6XS
DRUGNAME	LD-02GIFRO
INDICATI	Gastroparesis [ICD-11: DA41.00] Phase 2
	
TTDDRUID	D0D6XT
DRUGNAME	H3B-6527
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
	
TTDDRUID	D0D6ZB
DRUGNAME	AX-9657
INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Investigative
	
TTDDRUID	D0D6ZK
DRUGNAME	15(S)-hydroxyeicosatetraenoic acid (ophthalmic, dry eye), Alcon
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Discontinued in Phase 3
	
TTDDRUID	D0D6ZL
DRUGNAME	HMPL-002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0D6ZW
DRUGNAME	BMS-986020
INDICATI	Scleroderma [ICD-11: 4A42] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0D7AJ
DRUGNAME	Pyrazoline derivative 11
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0D7AM
DRUGNAME	MS-1819
INDICATI	Exocrine pancreatic insufficiency [ICD-11: DC35.1] Phase 1/2
	
TTDDRUID	D0D7BX
DRUGNAME	Rivoceranib
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0D7CH
DRUGNAME	TAK-828
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
	
TTDDRUID	D0D7DH
DRUGNAME	Green soap
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D0D7DU
DRUGNAME	VLTS-589
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D0D7EK
DRUGNAME	TPI-1361-17
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0D7EL
DRUGNAME	CHR-3620
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0D7EN
DRUGNAME	Tiamenidine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0D7FV
DRUGNAME	CD19/CD22 Chimeric Antigen Receptor T Cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	Mediastinal large B-cell lymphoma [ICD-11: 2A60.32] Phase 1
	
TTDDRUID	D0D7GE
DRUGNAME	TAK-029
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D0D7GS
DRUGNAME	MultiStem
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 3
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 2
INDICATI	AIDS-related lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 2
	
TTDDRUID	D0D7KC
DRUGNAME	Alvimopan
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved
	
TTDDRUID	D0D7KR
DRUGNAME	CDD-0235-J
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0D7KU
DRUGNAME	SNA-001
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3
	
TTDDRUID	D0D7LA
DRUGNAME	Metformin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D0D7LP
DRUGNAME	RQ-00201894
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Investigative
	
TTDDRUID	D0D7MJ
DRUGNAME	CNSB-001
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D0D7MZ
DRUGNAME	UniGAM SD
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D0D7OE
DRUGNAME	RHAMLET
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D7QY
DRUGNAME	BPL-004
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0D7RE
DRUGNAME	BBI-8000
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D7TB
DRUGNAME	Opipramol
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0D7TD
DRUGNAME	Cethromycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
INDICATI	Pneumonia [ICD-11: CA40] Phase 3
	
TTDDRUID	D0D7UD
DRUGNAME	AS-013
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3
	
TTDDRUID	D0D7VO
DRUGNAME	GK1-399
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0D7WS
DRUGNAME	MTL-102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D7XM
DRUGNAME	NC-4016
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0D7XS
DRUGNAME	GPG-290
INDICATI	Angina pectoris [ICD-11: BA40] Investigative
	
TTDDRUID	D0D7XW
DRUGNAME	SINITRODIL
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D0D7YA
DRUGNAME	DSP-6952
INDICATI	Constipation [ICD-11: DD91.1] Phase 2
	
TTDDRUID	D0D7YF
DRUGNAME	NT-CC-017
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0D7YR
DRUGNAME	AMPE4L
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0D7YW
DRUGNAME	TC-5214
INDICATI	Palmar hyperhidrosis [ICD-11: EE00.00] Phase 2
	
TTDDRUID	D0D7ZU
DRUGNAME	Pyrazole derivative 23
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0D8CE
DRUGNAME	EVP-0334
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical
	
TTDDRUID	D0D8DA
DRUGNAME	KAG-308
INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative
	
TTDDRUID	D0D8DD
DRUGNAME	Sufentanil
INDICATI	Analgesia [ICD-11: MB40.8] Approved
	
TTDDRUID	D0D8EY
DRUGNAME	HLF 1-11
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2
INDICATI	Bacteremia [ICD-11: 1A73] Phase 1/2
INDICATI	Candidemia [ICD-11: 1F23.3Y] Phase 1/2
	
TTDDRUID	D0D8FN
DRUGNAME	LY-156735
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0D8GO
DRUGNAME	MLR-1045
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative
	
TTDDRUID	D0D8JB
DRUGNAME	PF-05212384
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0D8KI
DRUGNAME	Ad5-AC6
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Terminated
	
TTDDRUID	D0D8KQ
DRUGNAME	Jakafi
INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 3
	
TTDDRUID	D0D8KU
DRUGNAME	Ferritarg P
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0D8LK
DRUGNAME	Parvovirus B19 vaccine
INDICATI	Parvovirus infection [ICD-11: 1D93] Phase 2
	
TTDDRUID	D0D8LP
DRUGNAME	Phenylsulfonyl derivative 3
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Patented
	
TTDDRUID	D0D8MD
DRUGNAME	ZM-230487
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0D8MG
DRUGNAME	NOX-A12
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
	
TTDDRUID	D0D8MS
DRUGNAME	NSD-726
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0D8NG
DRUGNAME	Sc Veltuzumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 1
	
TTDDRUID	D0D8PF
DRUGNAME	Thiazole carboxamide derivative 16
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0D8QV
DRUGNAME	AXS-02
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
INDICATI	Chronic low back pain [ICD-11: MG30.02] Phase 3
INDICATI	Knee osteoarthritis [ICD-11: FA01] Phase 3
	
TTDDRUID	D0D8RC
DRUGNAME	Metformin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0D8RT
DRUGNAME	Quattro
INDICATI	Ragweed hypersensitivity allergic disease [ICD-11: 4A8Z] Phase 3
INDICATI	Grass pollen hypersensitivity [ICD-11: 4B07] Phase 3
	
TTDDRUID	D0D8SN
DRUGNAME	ALD-401
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2
	
TTDDRUID	D0D8SU
DRUGNAME	NMS-873
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0D8TE
DRUGNAME	FBS-0701
INDICATI	Iron overload disease [ICD-11: 5C64.10] Phase 2
	
TTDDRUID	D0D8UH
DRUGNAME	ABIO-08-01
INDICATI	Amnesia [ICD-11: MB21.1] Discontinued in Phase 2
	
TTDDRUID	D0D8UM
DRUGNAME	Afabicin
INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 2
	
TTDDRUID	D0D8VE
DRUGNAME	Halothane
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0D8VU
DRUGNAME	LGD-6972
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0D8XG
DRUGNAME	AeroLEF
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0D8ZB
DRUGNAME	Ioxithalamate
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0D8ZK
DRUGNAME	OBP-301
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1/2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D0D8ZU
DRUGNAME	AX-205
INDICATI	Motor neurone disease [ICD-11: 8B60] Terminated
	
TTDDRUID	D0D9AD
DRUGNAME	YM-750
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1
	
TTDDRUID	D0D9AH
DRUGNAME	VX-702
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2a
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2a
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D0D9AL
DRUGNAME	ATON-005
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1
	
TTDDRUID	D0D9BL
DRUGNAME	Anti-CD19 CAR-T cells
INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1/2
	
TTDDRUID	D0D9CO
DRUGNAME	SB-221420-A
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0D9FV
DRUGNAME	Orphenadrine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0D9FW
DRUGNAME	DP-VPA
INDICATI	Bipolar disorder [ICD-11: 6A60] Approved
	
TTDDRUID	D0D9HA
DRUGNAME	PF-04634817
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D0D9HW
DRUGNAME	Tenofovir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0D9HZ
DRUGNAME	PF-06438179
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0D9IQ
DRUGNAME	BGB-290
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D0D9JB
DRUGNAME	ALERT
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0D9JW
DRUGNAME	Ketorolac
INDICATI	Postoperative inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0D9KK
DRUGNAME	CD4-BFFI
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0D9KQ
DRUGNAME	E-6006
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D0D9KV
DRUGNAME	SKL-18287
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0D9LB
DRUGNAME	BIBV 308
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 1
	
TTDDRUID	D0D9LJ
DRUGNAME	Atiprimod
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0D9MV
DRUGNAME	Aryl mannoside derivative 17
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0D9NA
DRUGNAME	Almitrine
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0D9NP
DRUGNAME	Nix-0699
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Approved
	
TTDDRUID	D0D9NY
DRUGNAME	Bempedoic acid
INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Approved
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
	
TTDDRUID	D0D9OM
DRUGNAME	V1A F/U
INDICATI	Infertility [ICD-11: GB04] Investigative
	
TTDDRUID	D0D9VE
DRUGNAME	DCCR
INDICATI	Prader-Willi syndrome [ICD-11: LD90.3] Phase 3
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 2
	
TTDDRUID	D0D9YB
DRUGNAME	DPX E7
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 1/2
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
	
TTDDRUID	D0D9YU
DRUGNAME	PLATENSIMYCIN
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0D9ZB
DRUGNAME	TAK-583
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2/3
	
TTDDRUID	D0DA0C
DRUGNAME	Peniel-3000
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D0DA1U
DRUGNAME	C7R-GD2.CART cells
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
	
TTDDRUID	D0DA3D
DRUGNAME	MLR-1130
INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative
	
TTDDRUID	D0DA3T
DRUGNAME	Prostate dendritic cell-based vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0DA4B
DRUGNAME	JNJ-64407564
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0DA5M
DRUGNAME	C 82
INDICATI	Scleroderma [ICD-11: 4A42] Phase 1/2
	
TTDDRUID	D0DA6N
DRUGNAME	TEM-8-Fc
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0DA6X
DRUGNAME	JNJ-47910382
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0DBS7
DRUGNAME	GBR1302
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0DC0S
DRUGNAME	Octaplas LG
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0DC1I
DRUGNAME	RG-7356
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Discontinued in Phase 1
	
TTDDRUID	D0DC2P
DRUGNAME	PMID25684022-Compound-WO2012135799 42(1.4)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0DC4O
DRUGNAME	PMID25666693-Compound-74
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0DC6U
DRUGNAME	Dapivirine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0DC7I
DRUGNAME	PMID25656651-Compound-11b
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Patented
	
TTDDRUID	D0DC8J
DRUGNAME	CYT-609
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0DD0K
DRUGNAME	Losartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0DD0O
DRUGNAME	D-21805
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0DD4N
DRUGNAME	GEH-120714
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0DD4P
DRUGNAME	Cresemba
INDICATI	Invasive aspergillosis [ICD-11: 1F20.0] Phase 3
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0DD8T
DRUGNAME	VERU-111
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0DD9F
DRUGNAME	HumaSPECT
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0DD9T
DRUGNAME	HP-05
INDICATI	Fatigue [ICD-11: MG22] Investigative
	
TTDDRUID	D0DE0C
DRUGNAME	Diphenyl purine derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0DE4U
DRUGNAME	Erythropoietin beta
INDICATI	Erythropoietic porphyrias [ICD-11: 5C58.12] Approved
	
TTDDRUID	D0DE5I
DRUGNAME	PMID25666693-Compound-78
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0DE5K
DRUGNAME	PMID25666693-Compound-42
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0DF1R
DRUGNAME	Ulinastatin
INDICATI	Premature labour [ICD-11: JB00] Phase 3
	
TTDDRUID	D0DF6B
DRUGNAME	Azetidine-1-carboxamide derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0DF8Y
DRUGNAME	CTA-192
INDICATI	Hyperparathyroidism [ICD-11: 5A51] Investigative
	
TTDDRUID	D0DF9Z
DRUGNAME	Attapulgite
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
	
TTDDRUID	D0DG0P
DRUGNAME	Triflupromazine
INDICATI	Schizophrenia [ICD-11: 6A20] Withdrawn from market
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0DG0W
DRUGNAME	ALX-0625
INDICATI	Migraine [ICD-11: 8A80] Terminated
	
TTDDRUID	D0DG6C
DRUGNAME	Encapsulated transplanted islets
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	D0DG9F
DRUGNAME	PP-1420
INDICATI	Obesity [ICD-11: 5B81] Phase 1/2
	
TTDDRUID	D0DG9M
DRUGNAME	AZD-9139
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated
	
TTDDRUID	D0DH0Y
DRUGNAME	Aryl mannoside derivative 12
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0DH1H
DRUGNAME	CCT-241533
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0DH5X
DRUGNAME	Vibegron
INDICATI	Overactive bladder [ICD-11: GC50.0] Approved
	
TTDDRUID	D0DI0B
DRUGNAME	OX 19
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1
	
TTDDRUID	D0DI1B
DRUGNAME	TTP273
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0DI1R
DRUGNAME	PMID25666693-Compound-130
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0DI1T
DRUGNAME	Biaryl mannoside derivative 16
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0DI3E
DRUGNAME	DHP-218
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0DI6L
DRUGNAME	Sivextro
INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 3
	
TTDDRUID	D0DI6U
DRUGNAME	Alkyl mannoside derivative 10
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0DI8J
DRUGNAME	BMS-275183
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0DJ0S
DRUGNAME	NGM313
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0DJ1B
DRUGNAME	Naproxen
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
INDICATI	Endometriosis [ICD-11: GA10] Investigative
	
TTDDRUID	D0DJ2H
DRUGNAME	BION-1301
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0DJ4A
DRUGNAME	Preverex
INDICATI	Artery stenosis [ICD-11: BD52] Phase 2
	
TTDDRUID	D0DJ5T
DRUGNAME	Ecomustine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0DJ8D
DRUGNAME	GPI-16552
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0DJ8S
DRUGNAME	CART-Muc1 cells
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0DJ9D
DRUGNAME	Burosumab
INDICATI	X-linked hypophosphataemia [ICD-11: 5C63.22] Approved
	
TTDDRUID	D0DK2X
DRUGNAME	GSK-280
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0DK5R
DRUGNAME	Axicabtagene ciloleucel
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved
INDICATI	Large B-cell lymphoma [ICD-11: 2A81] Approved
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2/3
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2/3
INDICATI	Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Phase 2/3
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0DK5X
DRUGNAME	PF-06263276
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0DK8G
DRUGNAME	Technetium Tc-99m Etidronate Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0DK8V
DRUGNAME	Cetirizine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0DK8X
DRUGNAME	BMS-911543
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
	
TTDDRUID	D0DL2S
DRUGNAME	MILFASARTAN
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D0DL3R
DRUGNAME	PMID25553724-Compound-US2011801300410
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented
	
TTDDRUID	D0DL3W
DRUGNAME	APX-001
INDICATI	Candidemia [ICD-11: 1F23.3Y] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0DL7P
DRUGNAME	Diazepinone derivative 4
INDICATI	Reflux disease [ICD-11: DA22] Patented
INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented
	
TTDDRUID	D0DL8A
DRUGNAME	Clarithromycin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0DM2G
DRUGNAME	Bis-indolylmaleimide derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0DM4K
DRUGNAME	Heat-killed Mycobacterium vaccine
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0DM5A
DRUGNAME	SIM-6080
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D0DM6I
DRUGNAME	DAPITANT
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0DN0W
DRUGNAME	Niraparib Tosylate
INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Approved
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Approved
	
TTDDRUID	D0DN1I
DRUGNAME	JTT-551
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D0DN1V
DRUGNAME	Dapagliflozin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0DN3Q
DRUGNAME	Pyrazolo[1,5-a]pyridine derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0DN7Y
DRUGNAME	SER-214
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0DO0B
DRUGNAME	TT-111
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative
	
TTDDRUID	D0DO5J
DRUGNAME	MDAM (y-methylene-10-deazaaminopterin)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0DO5U
DRUGNAME	SK-7068
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0DO6K
DRUGNAME	Thiazole carboxamide derivative 23
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0DO8E
DRUGNAME	CAR-T cells targeting CLL1
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0DP0J
DRUGNAME	PR-924
INDICATI	T lymphoblastic leukaemia [ICD-11: 2B33.4] Phase 1
	
TTDDRUID	D0DP1O
DRUGNAME	CTD-02
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 1
	
TTDDRUID	D0DP3V
DRUGNAME	TG-C
INDICATI	Arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0DP5I
DRUGNAME	BMS-986205
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0DP6L
DRUGNAME	Isoflurane
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0DP7T
DRUGNAME	Human embryonic stem cell-derived vascular progenitors
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0DP8E
DRUGNAME	PMID30107136-Compound-Example57
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0DP8P
DRUGNAME	BW755C
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0DP8U
DRUGNAME	IKH-02
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0DP9O
DRUGNAME	Autologous chondrocyte implantation
INDICATI	Primary biliary cirrhosis [ICD-11: DB96.1] Phase 3
INDICATI	Cartilage disorder [ICD-11: FA34] Phase 3
	
TTDDRUID	D0DQ2D
DRUGNAME	RG7625
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 2
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2
INDICATI	Coeliac disease [ICD-11: DA95] Phase 1
	
TTDDRUID	D0DQ2N
DRUGNAME	SC-72393
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Investigative
	
TTDDRUID	D0DQ2T
DRUGNAME	Cu(II)ATSM
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1/2
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0DQ3H
DRUGNAME	Opicinumab
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0DQ5G
DRUGNAME	Pyrrolo[3,2-c]pyridine derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0DQ7T
DRUGNAME	Sporidin-G
INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 3
	
TTDDRUID	D0DQ7V
DRUGNAME	Lutetium Lu 177 dotatate
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Approved
	
TTDDRUID	D0DQ9N
DRUGNAME	Fibrovax
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0DR0P
DRUGNAME	ARQ 761
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0DR3I
DRUGNAME	S-33516
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0DR3T
DRUGNAME	Ad.hIL-12
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0DR4O
DRUGNAME	SRF231
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0DR4W
DRUGNAME	MyoCell SDF-1
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3
	
TTDDRUID	D0DR6N
DRUGNAME	CART-19 cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0DR6Q
DRUGNAME	Diphtheria, tetanus, acellular pertussis vaccine
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D0DS1L
DRUGNAME	AK-20
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative
	
TTDDRUID	D0DS2M
DRUGNAME	PrLL-37
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D0DS3J
DRUGNAME	18-MC
INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 1
	
TTDDRUID	D0DS4P
DRUGNAME	CGS-26393
INDICATI	Heart disease [ICD-11: BA41-BA42] Terminated
	
TTDDRUID	D0DS5U
DRUGNAME	Sodium polystyrene sulfonate
INDICATI	Mineral-electrolyte metabolism disorder [ICD-11: 5C64] Approved
	
TTDDRUID	D0DT1E
DRUGNAME	Rh-thrombin
INDICATI	Haemorrhage [ICD-11: MG27] Approved
	
TTDDRUID	D0DT1R
DRUGNAME	Triapine
INDICATI	Nerve injury [ICD-11: ND56.4] Phase 2
	
TTDDRUID	D0DT1Y
DRUGNAME	WTX-101
INDICATI	Wilson disease [ICD-11: 5C64.00] Phase 2
	
TTDDRUID	D0DT2P
DRUGNAME	Nafagrel
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0DT2S
DRUGNAME	TAK-202
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0DT5E
DRUGNAME	Cephalothin Sodium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0DT5H
DRUGNAME	AZD4785
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0DT7M
DRUGNAME	PMID25666693-Compound-124
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0DT8Y
DRUGNAME	MEDI5117
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0DU4T
DRUGNAME	IC9-CAR19 cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1
INDICATI	Immunoproliferative disorder [ICD-11: 2B32] Phase 1
	
TTDDRUID	D0DU6X
DRUGNAME	R-41D
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative
	
TTDDRUID	D0DU9I
DRUGNAME	RT-100
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 3
	
TTDDRUID	D0DV2Q
DRUGNAME	BMN-190
INDICATI	Neuronal ceroid lipofuscinosis [ICD-11: 5C56.1] Phase 2
	
TTDDRUID	D0DV3O
DRUGNAME	Epinastine
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved
	
TTDDRUID	D0DV3T
DRUGNAME	Epoetin zeta
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 3
	
TTDDRUID	D0DV4J
DRUGNAME	Beriplast-P
INDICATI	Wound healing [ICD-11: EL8Y] Approved
	
TTDDRUID	D0DV6D
DRUGNAME	Darolutamide
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D0DV8K
DRUGNAME	Dexamethasone
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D0DV8Z
DRUGNAME	Elezanumab
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2
	
TTDDRUID	D0DW3Z
DRUGNAME	PMID26815044-Compound-93
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0DW5P
DRUGNAME	Schiff base compound 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Patented
	
TTDDRUID	D0DW7A
DRUGNAME	PMID26651364-Compound-6b
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0DX0G
DRUGNAME	Tergenpumatucel-L + indoximod + chemotherapy
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0DX1F
DRUGNAME	Leber's congenital amaurosis gene therapy
INDICATI	Visual disturbance [ICD-11: 9D90] Phase 1/2
INDICATI	Leber congenital amaurosis [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	D0DX4J
DRUGNAME	P1446A-05
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0DX6L
DRUGNAME	SDZ-PSD-958
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Terminated
	
TTDDRUID	D0DX7J
DRUGNAME	Lucinactant
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D0DX9T
DRUGNAME	Skin tissue replacement therapy
INDICATI	Skin burns [ICD-11: ME65.0] Phase 1/2
	
TTDDRUID	D0DY1N
DRUGNAME	AMT-080
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative
	
TTDDRUID	D0DY4E
DRUGNAME	JNJ-17203212
INDICATI	Cough [ICD-11: MD12] Investigative
	
TTDDRUID	D0DY5R
DRUGNAME	Bicyclic heteroaryl benzamide derivative 8
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0DY7W
DRUGNAME	Nebracetam
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D0DY9I
DRUGNAME	MERS-CoVS-containing nanoparticle vaccine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0DY9K
DRUGNAME	BAX335
INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1/2
	
TTDDRUID	D0DZ3X
DRUGNAME	L-Proline
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D0DZ8U
DRUGNAME	Tranexamic acid
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0E0AS
DRUGNAME	(S)-oxybutynin
INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 2
	
TTDDRUID	D0E0AX
DRUGNAME	AP-611074
INDICATI	Condyloma [ICD-11: 1A95] Phase 1/2
	
TTDDRUID	D0E0BD
DRUGNAME	Glycerol phenylbutyrate
INDICATI	Hepatic encephalopathy [ICD-11: DB99.5] Approved
	
TTDDRUID	D0E0BE
DRUGNAME	Na-APR-1
INDICATI	Hookworm infection [ICD-11: 1F68] Phase 1
	
TTDDRUID	D0E0CT
DRUGNAME	Trimebutine
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
	
TTDDRUID	D0E0DL
DRUGNAME	ADX40-TB
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0E0DS
DRUGNAME	Box-5
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0E0FY
DRUGNAME	CTL-102-GDEPT
INDICATI	Head and neck cancer [ICD-11: 2D42] Discontinued in Phase 2
	
TTDDRUID	D0E0GC
DRUGNAME	LIM-0723
INDICATI	Toxicity [ICD-11: N.A.] Investigative
	
TTDDRUID	D0E0GW
DRUGNAME	BVT-3498
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Terminated
	
TTDDRUID	D0E0HE
DRUGNAME	Hexyl
INDICATI	Radiation syndrome [ICD-11: NF00] Phase 3
	
TTDDRUID	D0E0IG
DRUGNAME	TRX-385
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0E0IK
DRUGNAME	Adva-R46
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0E0JF
DRUGNAME	Pirazolac
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Preregistration
	
TTDDRUID	D0E0JO
DRUGNAME	GLPG-1837
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D0E0JV
DRUGNAME	CDRI-S007-867
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D0E0KQ
DRUGNAME	Pyronaridine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0E0LQ
DRUGNAME	Thiothixene
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0E0MU
DRUGNAME	AstraStim
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0E0NL
DRUGNAME	TRX-1
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0E0NM
DRUGNAME	DCC-2036
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 1/2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0E0OG
DRUGNAME	Lorazepam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0E0OI
DRUGNAME	Memex
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0E0QS
DRUGNAME	VM-301
INDICATI	Dermatitis [ICD-11: EA80-EA89] Discontinued in Phase 2
	
TTDDRUID	D0E0RP
DRUGNAME	CART20
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0E0RY
DRUGNAME	Melitracen
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
	
TTDDRUID	D0E0SA
DRUGNAME	PMID25666693-Compound-110
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0E0SH
DRUGNAME	CART-117 cells
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0E0ST
DRUGNAME	Tisokinase
INDICATI	Acute myocardial infarction [ICD-11: BA41] Approved
	
TTDDRUID	D0E0SW
DRUGNAME	Enoximone
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0E0UC
DRUGNAME	DSR-17759
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0E0UN
DRUGNAME	PC-22
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0E0WQ
DRUGNAME	Barbital
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0E0WU
DRUGNAME	TRIN-2755
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0E0XL
DRUGNAME	QMF149
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D0E0YW
DRUGNAME	DS-1062
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0E1AN
DRUGNAME	MINT-1526A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0E1AW
DRUGNAME	GC5101B
INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 3
	
TTDDRUID	D0E1AZ
DRUGNAME	ISU-201
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0E1DF
DRUGNAME	Afrezza
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved
	
TTDDRUID	D0E1FP
DRUGNAME	Interferon alpha 5
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 1/2
	
TTDDRUID	D0E1GC
DRUGNAME	PMID26651364-Compound-5g
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0E1HC
DRUGNAME	Tezacaftor and ivacaftor
INDICATI	Acute lung injury [ICD-11: NB32.3] Approved
	
TTDDRUID	D0E1HF
DRUGNAME	FFC-14A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0E1HY
DRUGNAME	GPCR39 pepducins
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0E1JP
DRUGNAME	Montelukast
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D0E1LB
DRUGNAME	MK-2578
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2
	
TTDDRUID	D0E1OJ
DRUGNAME	Xenon Xe-133
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D0E1RT
DRUGNAME	ASP7373
INDICATI	H5N1 influenza infection [ICD-11: 1E30] Phase 2
	
TTDDRUID	D0E1SQ
DRUGNAME	BIBW-22
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0E1ST
DRUGNAME	CAR-T cells targeting GD2
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D0E1SV
DRUGNAME	MIQ-001
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0E1SW
DRUGNAME	Acetazolamide
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D0E1UY
DRUGNAME	AC-501
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative
	
TTDDRUID	D0E1UZ
DRUGNAME	CL-283796
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D0E1VD
DRUGNAME	OM-89
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0E1VV
DRUGNAME	ELOMOTECAN HYDROCHLORIDE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0E1WH
DRUGNAME	LY-2608204
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0E1WI
DRUGNAME	Fentanyl
INDICATI	Analgesia [ICD-11: MB40.8] Approved
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
INDICATI	Cancer related pain [ICD-11: MG30] Phase 3
INDICATI	Chronic pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D0E1WY
DRUGNAME	EFIPLADIB
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0E1XL
DRUGNAME	Levetiracetam
INDICATI	Fibromyalgia [ICD-11: MG30.01] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D0E1YN
DRUGNAME	SB-2280
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0E1ZE
DRUGNAME	BBB-022
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0E1ZQ
DRUGNAME	SWA11-ZZ-PE38
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0E1ZR
DRUGNAME	VLD-517
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0E1ZV
DRUGNAME	Labetuzumab-SN-38
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0E2AF
DRUGNAME	PMID27998201-Compound-2
INDICATI	Alzheimer disease [ICD-11: 8A20] Patented
	
TTDDRUID	D0E2AJ
DRUGNAME	P-27A
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	D0E2CO
DRUGNAME	BMY-22089
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Terminated
	
TTDDRUID	D0E2CQ
DRUGNAME	RG7160
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Discontinued in Phase 2
	
TTDDRUID	D0E2CS
DRUGNAME	CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells
INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0E2CZ
DRUGNAME	FS-205-397
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0E2DL
DRUGNAME	CDCA1-derived epitope peptide vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0E2ED
DRUGNAME	IdioVax
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 2
	
TTDDRUID	D0E2EN
DRUGNAME	TDI-0048
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0E2EY
DRUGNAME	BLI-1005
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0E2FZ
DRUGNAME	ICA-69673
INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical
	
TTDDRUID	D0E2GH
DRUGNAME	MVAH5
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0E2HS
DRUGNAME	TAK-021
INDICATI	Enterovirus infection [ICD-11: 1D91] Phase 1
	
TTDDRUID	D0E2IN
DRUGNAME	LECOZOTAN HYDROCHLORIDE
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2/3
	
TTDDRUID	D0E2JN
DRUGNAME	KB-6806
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 2
	
TTDDRUID	D0E2KT
DRUGNAME	S-234462
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D0E2LA
DRUGNAME	TAS-103
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0E2LH
DRUGNAME	TT-173
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Phase 2
	
TTDDRUID	D0E2MI
DRUGNAME	ARH-1029
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Investigative
	
TTDDRUID	D0E2MJ
DRUGNAME	Otamixaban
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3
	
TTDDRUID	D0E2ML
DRUGNAME	IG-RD-001
INDICATI	Respiratory disease [ICD-11: CB40] Approved
	
TTDDRUID	D0E2NQ
DRUGNAME	Depression NCE
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1
	
TTDDRUID	D0E2OU
DRUGNAME	Quinupristin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0E2PX
DRUGNAME	E-4031
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2
	
TTDDRUID	D0E2QC
DRUGNAME	RK-023
INDICATI	Alopecia [ICD-11: ED70] Phase 2
	
TTDDRUID	D0E2QG
DRUGNAME	NC-6300
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 1
	
TTDDRUID	D0E2QN
DRUGNAME	AZD-1678
INDICATI	Asthma [ICD-11: CA23] Preclinical
	
TTDDRUID	D0E2RA
DRUGNAME	AV-7909
INDICATI	Anthrax [ICD-11: 1B97] Phase 2
	
TTDDRUID	D0E2TH
DRUGNAME	AVX101
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 1
	
TTDDRUID	D0E2VF
DRUGNAME	CD19 Redirected Autologous T Cells
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D0E2WE
DRUGNAME	Mapp-66
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0E2WF
DRUGNAME	ORG 34517/34850
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2
	
TTDDRUID	D0E2YL
DRUGNAME	UNI-rhIL-11
INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 3
	
TTDDRUID	D0E2YV
DRUGNAME	Glial cell line-derived neurotrophic factor protein
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Preclinical
	
TTDDRUID	D0E2YX
DRUGNAME	NRD-135S
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0E2ZA
DRUGNAME	PPC-5650
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0E2ZX
DRUGNAME	SGN-CD70A
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0E3BH
DRUGNAME	Ridogrel
INDICATI	Acute myocardial infarction [ICD-11: BA41] Approved
	
TTDDRUID	D0E3BJ
DRUGNAME	SLV-311
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 1
	
TTDDRUID	D0E3CX
DRUGNAME	NDX-1017
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0E3DS
DRUGNAME	Alkyl mannoside derivative 11
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0E3EA
DRUGNAME	AP-02-00
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative
	
TTDDRUID	D0E3EK
DRUGNAME	NP-619
INDICATI	Alopecia [ICD-11: ED70] Discontinued in Phase 2
	
TTDDRUID	D0E3EO
DRUGNAME	JTT-251
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0E3EY
DRUGNAME	Elsamitrucin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0E3FD
DRUGNAME	Bromazepam
INDICATI	Panic attacks [ICD-11: MB23.H] Approved
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0E3HY
DRUGNAME	IP10 C8
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D0E3JF
DRUGNAME	Cx-911
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0E3JL
DRUGNAME	SL-25.1188
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1
	
TTDDRUID	D0E3JP
DRUGNAME	Prednisone
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0E3LP
DRUGNAME	SEN-196
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
	
TTDDRUID	D0E3LW
DRUGNAME	NV-27
INDICATI	Artery stenosis [ICD-11: BD52] Terminated
	
TTDDRUID	D0E3MA
DRUGNAME	Polyacrylic acid
INDICATI	Contraception [ICD-11: QA21] Phase 2/3
	
TTDDRUID	D0E3NZ
DRUGNAME	L-696229
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D0E3OF
DRUGNAME	Warfarin
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Approved
INDICATI	Thrombosis [ICD-11: DB61-GB90] Application submitted
	
TTDDRUID	D0E3QU
DRUGNAME	Cytovaxine
INDICATI	Pseudomonas infection [ICD-11: 1B92] Terminated
	
TTDDRUID	D0E3RC
DRUGNAME	99mTc-sulesomab
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Approved
	
TTDDRUID	D0E3RW
DRUGNAME	Cefditoren
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0E3SA
DRUGNAME	Betafectin
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 3
	
TTDDRUID	D0E3SD
DRUGNAME	AZD-9272
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1
	
TTDDRUID	D0E3SF
DRUGNAME	MCB-3837
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0E3SH
DRUGNAME	Panobinostat
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
INDICATI	Primary myelofibrosis [ICD-11: 2A20.2] Phase 2
	
TTDDRUID	D0E3SX
DRUGNAME	SCH-1359113
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
	
TTDDRUID	D0E3UW
DRUGNAME	RG6046
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0E3VF
DRUGNAME	E coli vaccine
INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 1
	
TTDDRUID	D0E3WQ
DRUGNAME	Eterobarb
INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved
	
TTDDRUID	D0E3XG
DRUGNAME	Zolasartan
INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2
	
TTDDRUID	D0E3ZC
DRUGNAME	Oseltamivir
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0E3ZO
DRUGNAME	AIK33
INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative
	
TTDDRUID	D0E4DN
DRUGNAME	SC16LD6.5
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D0E4DO
DRUGNAME	PTX-111
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0E4DW
DRUGNAME	Phenytoin
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D0E4EP
DRUGNAME	Oncolysin M
INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1
	
TTDDRUID	D0E4EZ
DRUGNAME	R-1438
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0E4FG
DRUGNAME	Mozenavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D0E4FM
DRUGNAME	Y-700
INDICATI	Gout [ICD-11: FA25] Discontinued in Phase 2
	
TTDDRUID	D0E4GE
DRUGNAME	AZD-2551
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0E4GG
DRUGNAME	Resatorvid
INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 3
	
TTDDRUID	D0E4HZ
DRUGNAME	F-12682
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated
	
TTDDRUID	D0E4IB
DRUGNAME	PBF509
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D0E4JB
DRUGNAME	TP-834
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0E4JL
DRUGNAME	Rotigitine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0E4LS
DRUGNAME	LAG525
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0E4MB
DRUGNAME	GDC-9545
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0E4MT
DRUGNAME	Influenza A virus H3N2 vaccine
INDICATI	Influenza A virus H3N2 infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D0E4MX
DRUGNAME	Myomap
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D0E4PN
DRUGNAME	API-003
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0E4PQ
DRUGNAME	Inno-LC-01
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 3
	
TTDDRUID	D0E4RG
DRUGNAME	NCX-4215
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0E4RH
DRUGNAME	DDB-S
INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 2
	
TTDDRUID	D0E4SI
DRUGNAME	Rv-11
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0E4SX
DRUGNAME	VP20629
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 1
	
TTDDRUID	D0E4TD
DRUGNAME	Sharon-3000
INDICATI	Periodontitis [ICD-11: DA0C] Investigative
	
TTDDRUID	D0E4UB
DRUGNAME	AX-201
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0E4VQ
DRUGNAME	Beloranib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D0E4VT
DRUGNAME	MAHDL01
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Preclinical
	
TTDDRUID	D0E4WF
DRUGNAME	METHYLTHIOADENOSINE
INDICATI	Multiple sclerosis [ICD-11: 8A40] Terminated
	
TTDDRUID	D0E4WR
DRUGNAME	Azelaic Acid
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D0E4YR
DRUGNAME	IN0-3112
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1
	
TTDDRUID	D0E5BW
DRUGNAME	[131I]-Metuximab
INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
	
TTDDRUID	D0E5CX
DRUGNAME	Abloid
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0E5DB
DRUGNAME	Laromustine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0E5DP
DRUGNAME	Cixutumumab
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
	
TTDDRUID	D0E5FA
DRUGNAME	62Cu-PTSM
INDICATI	Occlusive coronary artery disease [ICD-11: BA80] Phase 2
	
TTDDRUID	D0E5FF
DRUGNAME	PT
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0E5GI
DRUGNAME	CJ-12255
INDICATI	Eczema [ICD-11: EA80-EA89] Phase 1
	
TTDDRUID	D0E5GO
DRUGNAME	PMID31955138-compound-16
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0E5GY
DRUGNAME	RO-319790
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0E5IP
DRUGNAME	WHI-P154
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Investigative
	
TTDDRUID	D0E5IT
DRUGNAME	PMA-411R
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0E5JC
DRUGNAME	MSX-122
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0E5MJ
DRUGNAME	INCB19602
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0E5MO
DRUGNAME	TrkA-XTEN
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0E5NY
DRUGNAME	AZD-2423
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0E5QY
DRUGNAME	MEN-B
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 2
	
TTDDRUID	D0E5RA
DRUGNAME	HGT-1111
INDICATI	Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 2
	
TTDDRUID	D0E5TH
DRUGNAME	BTL-TML-HSV
INDICATI	Oral herpes [ICD-11: 1F00.02] Phase 2
	
TTDDRUID	D0E5TI
DRUGNAME	Lyme disease vaccine
INDICATI	Lyme disease [ICD-11: 1C1G] Approved
	
TTDDRUID	D0E5UK
DRUGNAME	Fibrin Sealant
INDICATI	Wound healing [ICD-11: EL8Y] Approved
	
TTDDRUID	D0E5VO
DRUGNAME	Vinanterol/fluticasone furoate
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D0E5VP
DRUGNAME	KF-66490
INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative
	
TTDDRUID	D0E5WX
DRUGNAME	PF-04518600
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0E5XA
DRUGNAME	R763
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0E5YG
DRUGNAME	AZD1236
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D0E6AF
DRUGNAME	Radium-223-Dichloride
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D0E6AG
DRUGNAME	CPI-1205
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D0E6AH
DRUGNAME	Bryostatin-1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0E6AP
DRUGNAME	STX
INDICATI	Estrogen deficiency [ICD-11: FB83.0Y] Investigative
	
TTDDRUID	D0E6BB
DRUGNAME	Plazomicin
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
INDICATI	Prostate disease [ICD-11: GA91] Approved
INDICATI	Bronchitis [ICD-11: CA20] Approved
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
	
TTDDRUID	D0E6CH
DRUGNAME	Hydroxypropyl Cellulose
INDICATI	Insufficient tear production [ICD-11: 5B55.Y] Approved
	
TTDDRUID	D0E6DI
DRUGNAME	T487
INDICATI	Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D0E6EF
DRUGNAME	BMS-986192
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial
	
TTDDRUID	D0E6ES
DRUGNAME	S. flexneri type 2a-rEPA Asucc
INDICATI	Shigella infection [ICD-11: 1A02] Phase 3
	
TTDDRUID	D0E6FO
DRUGNAME	JTE-607
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2
	
TTDDRUID	D0E6FS
DRUGNAME	Rivaroxaban
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0E6GS
DRUGNAME	DasKloster 0249-01
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0E6HT
DRUGNAME	JNJ-63871860
INDICATI	Escherichia coli infection [ICD-11: 1A03] Phase 2
	
TTDDRUID	D0E6JF
DRUGNAME	CL-329753
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0E6JY
DRUGNAME	EDC/IL-4
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0E6KN
DRUGNAME	GSK2647544
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0E6LC
DRUGNAME	SPR-210
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D0E6LU
DRUGNAME	Resorcinol compound 10
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0E6ME
DRUGNAME	GED-0507-34-Levo
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
	
TTDDRUID	D0E6MW
DRUGNAME	BN-108
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0E6NH
DRUGNAME	MEDI-570
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D0E6NR
DRUGNAME	BAY-Y-3118
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0E6OA
DRUGNAME	TERIKALANT
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Terminated
	
TTDDRUID	D0E6OC
DRUGNAME	Tranilast
INDICATI	Ocular allergy [ICD-11: 4A81] Approved
	
TTDDRUID	D0E6OJ
DRUGNAME	Solumedrol
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0E6PF
DRUGNAME	Vacc-C5
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0E6QI
DRUGNAME	MEN-14295
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0E6QN
DRUGNAME	Staphylococcus aureus vaccine conjugate pentavalent
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Discontinued in Phase 1/2
	
TTDDRUID	D0E6RE
DRUGNAME	LB-102
INDICATI	Memory loss [ICD-11: MB21.1Z] Investigative
	
TTDDRUID	D0E6RX
DRUGNAME	ARD-1600
INDICATI	Smoking dependence [ICD-11: 6C4A.2] Phase 1
INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Phase 1
	
TTDDRUID	D0E6RZ
DRUGNAME	DAV-147
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0E6SB
DRUGNAME	HQK-1001
INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 2
	
TTDDRUID	D0E6SQ
DRUGNAME	ATL1102
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0E6SX
DRUGNAME	AZD-5069
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0E6UA
DRUGNAME	Deramciclane
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3
	
TTDDRUID	D0E6UD
DRUGNAME	FK-664
INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2
	
TTDDRUID	D0E6UU
DRUGNAME	AG-SCT101
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3
	
TTDDRUID	D0E6UZ
DRUGNAME	CUDC-907
INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1/2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0E6VF
DRUGNAME	VAX-128
INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D0E6VL
DRUGNAME	RWJ-22108
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D0E6VN
DRUGNAME	NDV-4
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative
	
TTDDRUID	D0E6VR
DRUGNAME	DS-1093
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1
	
TTDDRUID	D0E6XN
DRUGNAME	Cedar pollen allergen extract
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 3
	
TTDDRUID	D0E6XR
DRUGNAME	Dasatinib
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D0E6YQ
DRUGNAME	Tacrine
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D0E6ZI
DRUGNAME	BTM-0512
INDICATI	Vascular disease [ICD-11: BE2Z] Investigative
	
TTDDRUID	D0E6ZN
DRUGNAME	TKA-731
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0E7AD
DRUGNAME	Ibalizumab 
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0E7AK
DRUGNAME	VK-2809
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2
	
TTDDRUID	D0E7AS
DRUGNAME	SUN-N8075
INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Phase 1
	
TTDDRUID	D0E7BC
DRUGNAME	GM-CSF-expressing oncolytic adenovirus
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0E7BP
DRUGNAME	CP-663427
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0E7BS
DRUGNAME	PRX-12266
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0E7BY
DRUGNAME	StMN1 Lp
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0E7DH
DRUGNAME	Factor VIII gene therapy
INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 1
	
TTDDRUID	D0E7FC
DRUGNAME	STRO-001
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0E7FG
DRUGNAME	SMND-309
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0E7FM
DRUGNAME	GTx-758
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0E7FS
DRUGNAME	Adinazolam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0E7FT
DRUGNAME	PMID30124346-Compound-60TABLE5
INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented
INDICATI	Dyskinesia [ICD-11: MB47.4] Patented
	
TTDDRUID	D0E7GN
DRUGNAME	GFC-012
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0E7IM
DRUGNAME	OPB-31121
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
	
TTDDRUID	D0E7IZ
DRUGNAME	MTI-SAM3
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0E7MA
DRUGNAME	ATG002
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1/2
	
TTDDRUID	D0E7MV
DRUGNAME	Capreomycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2
	
TTDDRUID	D0E7OC
DRUGNAME	Serelsa
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 3
	
TTDDRUID	D0E7OL
DRUGNAME	C-0084
INDICATI	Glioma [ICD-11: 2A00.0] Discontinued in Phase 1
	
TTDDRUID	D0E7PQ
DRUGNAME	Vorinostat
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved
	
TTDDRUID	D0E7PZ
DRUGNAME	NOX-B11
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0E7QB
DRUGNAME	Mirikizumab
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
	
TTDDRUID	D0E7QN
DRUGNAME	Biapenem
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0E7RC
DRUGNAME	HER-2/HER-1 vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0E7RQ
DRUGNAME	SNN-0029
INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 1/2
	
TTDDRUID	D0E7RV
DRUGNAME	Aposense probe-cytotoxic agent conjugates
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0E7TR
DRUGNAME	TBI-302
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative
	
TTDDRUID	D0E7US
DRUGNAME	Flu (pre-) pandemic
INDICATI	Influenza A virus infection [ICD-11: 1E30] Approved
	
TTDDRUID	D0E7VY
DRUGNAME	BAY 98-7196
INDICATI	Endometriosis [ICD-11: GA10] Phase 2
	
TTDDRUID	D0E7WH
DRUGNAME	KPAX002
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Clinical trial
INDICATI	Parkinson disease [ICD-11: 8A00.0] Clinical trial
	
TTDDRUID	D0E7XM
DRUGNAME	BAY-2253651
INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Phase 2
	
TTDDRUID	D0E7XO
DRUGNAME	IMM-255
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0E7YQ
DRUGNAME	TABILAUTIDE
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2
	
TTDDRUID	D0E7ZN
DRUGNAME	PMID25553724-Compound-US2011000295210
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented
	
TTDDRUID	D0E7ZU
DRUGNAME	Deutetrabenazine
INDICATI	Tardive dyskinesia [ICD-11: 8A02.10] Approved
INDICATI	Huntington disease [ICD-11: 8A01.10] Approved
	
TTDDRUID	D0E8AE
DRUGNAME	Myolimus
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1
	
TTDDRUID	D0E8BD
DRUGNAME	NM-006-MENK
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0E8CI
DRUGNAME	Triprolidine
INDICATI	Hay fever [ICD-11: CA08.00] Approved
	
TTDDRUID	D0E8CZ
DRUGNAME	Amibegron
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 3
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 3
INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0E8DK
DRUGNAME	COL-1077
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0E8HA
DRUGNAME	T-817MA
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0E8HH
DRUGNAME	Fusion peptide EK1
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0E8IG
DRUGNAME	BA-016
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0E8IQ
DRUGNAME	DS-8201
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
	
TTDDRUID	D0E8IT
DRUGNAME	HBVax
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 4
	
TTDDRUID	D0E8IZ
DRUGNAME	Tonabersat
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
	
TTDDRUID	D0E8JL
DRUGNAME	ZT-386
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0E8JO
DRUGNAME	FO-152
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0E8KK
DRUGNAME	IkT-041
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0E8KO
DRUGNAME	Anti-CD3 activated vaccine-primed lymphocytes
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0E8LA
DRUGNAME	Saroglitazar
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Approved
	
TTDDRUID	D0E8LT
DRUGNAME	Prifinium
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
	
TTDDRUID	D0E8MW
DRUGNAME	D-1367
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D0E8NJ
DRUGNAME	ABP 798
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0E8NP
DRUGNAME	Birinapant
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0E8NW
DRUGNAME	KUR-115
INDICATI	Spinal disease [ICD-11: FA72] Investigative
	
TTDDRUID	D0E8PG
DRUGNAME	BGB-3112
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
	
TTDDRUID	D0E8PR
DRUGNAME	BAY1163877
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0E8QE
DRUGNAME	Vesigenurtacel-L
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
	
TTDDRUID	D0E8QK
DRUGNAME	JNJ-26070109
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Preclinical
	
TTDDRUID	D0E8SE
DRUGNAME	443C81
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0E8SV
DRUGNAME	RG7906
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Phase 2
	
TTDDRUID	D0E8TK
DRUGNAME	SPN-802
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1
	
TTDDRUID	D0E8UJ
DRUGNAME	BW-1370U87
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1
	
TTDDRUID	D0E8UO
DRUGNAME	Urokinase
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved
	
TTDDRUID	D0E8UP
DRUGNAME	PMID25666693-Compound-69
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0E8UV
DRUGNAME	Linetastine
INDICATI	Rhinitis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0E8VF
DRUGNAME	IMC-1C11
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0E8YH
DRUGNAME	NCX 1022
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D0E8YS
DRUGNAME	MOR-206
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0E8ZL
DRUGNAME	CD20-CART
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D0E8ZY
DRUGNAME	Vapitadine
INDICATI	Allergic skin disorder [ICD-11: 4A82] Phase 2
	
TTDDRUID	D0E9AF
DRUGNAME	ALN-TTRsc
INDICATI	Cardiomyopathy [ICD-11: BC43] Phase 3
	
TTDDRUID	D0E9AZ
DRUGNAME	Vax-TET
INDICATI	Clostridium infection [ICD-11: 1A04] Approved
	
TTDDRUID	D0E9BF
DRUGNAME	5-hydroxymethyl-2-furfural
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2
	
TTDDRUID	D0E9BQ
DRUGNAME	Anti-Neu5Gc mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0E9CC
DRUGNAME	Ombrabulin
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 3
	
TTDDRUID	D0E9CD
DRUGNAME	Isovanillin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0E9DP
DRUGNAME	AAV-IGF
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0E9EE
DRUGNAME	SR 144190
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
INDICATI	Acute or chronic pain [ICD-11: MG30-MG31] Discontinued in Phase 1
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1
	
TTDDRUID	D0E9GD
DRUGNAME	Biphenyl mannoside derivative 15
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0E9HQ
DRUGNAME	R7334
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
	
TTDDRUID	D0E9IT
DRUGNAME	N,N`-diacetyl-L-cystine
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2
	
TTDDRUID	D0E9JM
DRUGNAME	Potassium Chloride
INDICATI	Hypokalemia [ICD-11: 5C77] Approved
	
TTDDRUID	D0E9KA
DRUGNAME	Ingenol mebutate
INDICATI	Actinic keratosis [ICD-11: EK90.0] Approved
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D0E9KC
DRUGNAME	AFM-15
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0E9LH
DRUGNAME	CDRI-99/411
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0E9ME
DRUGNAME	MEDI7247
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0E9MI
DRUGNAME	FDY-5301
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
	
TTDDRUID	D0E9NJ
DRUGNAME	PARCETASAL
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0E9NU
DRUGNAME	KRN-23
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 3
INDICATI	X-linked hypophosphataemia [ICD-11: 5C63.22] Phase 3
	
TTDDRUID	D0E9OI
DRUGNAME	DWE-01
INDICATI	Ulcer [ICD-11: CA02-CB40] Investigative
	
TTDDRUID	D0E9PK
DRUGNAME	MOXONIDINE
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
	
TTDDRUID	D0E9PT
DRUGNAME	CK-2289
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Terminated
	
TTDDRUID	D0E9QZ
DRUGNAME	Copper catalyst-based agent
INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative
	
TTDDRUID	D0E9RP
DRUGNAME	WCK-2349
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Phase 2
	
TTDDRUID	D0E9SR
DRUGNAME	[3H]JNJ 7777120
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0E9SZ
DRUGNAME	SI-657
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0E9TP
DRUGNAME	Sulodexide
INDICATI	Tinnitus [ICD-11: MC41] Approved
	
TTDDRUID	D0E9UH
DRUGNAME	RP1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0E9UT
DRUGNAME	Lopinavir + ritonavir + interferon alpha
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Preclinical
	
TTDDRUID	D0E9VL
DRUGNAME	BDD-20617
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0E9WL
DRUGNAME	Loracarbef
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0E9WO
DRUGNAME	Febarbamate
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved
	
TTDDRUID	D0E9XG
DRUGNAME	YM-46A
INDICATI	Phlegmy cough [ICD-11: SA80-SA8Z] Discontinued in Phase 2
	
TTDDRUID	D0E9XP
DRUGNAME	Respiratory syncytial virus VLPvaccine
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1
	
TTDDRUID	D0E9XR
DRUGNAME	STP705
INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 2
INDICATI	Hypertrophic scars [ICD-11: EE60] Phase 1/2
	
TTDDRUID	D0E9YI
DRUGNAME	MGMTP140K gene-modified hematopoietic progenitor cells
INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative
	
TTDDRUID	D0EA7H
DRUGNAME	LF-7-0165c
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0EA9Y
DRUGNAME	Biaryl mannoside derivative 14
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0EB0Y
DRUGNAME	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0EB5N
DRUGNAME	Lefamulin
INDICATI	Community-acquired pneumonia [ICD-11: CA40.Z] Approved
INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 2
	
TTDDRUID	D0EC1Y
DRUGNAME	SIG-001
INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative
	
TTDDRUID	D0EC2K
DRUGNAME	SIPATRIGINE
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2
	
TTDDRUID	D0EC3H
DRUGNAME	Quinazoline derivative 12
INDICATI	Cirrhosis [ICD-11: DB93] Patented
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Patented
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Patented
INDICATI	Multiple sclerosis [ICD-11: 8A40] Patented
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Patented
	
TTDDRUID	D0EC3Z
DRUGNAME	PMID25666693-Compound-82
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0EC4Z
DRUGNAME	Six-membered heterocyclic benzamide derivative 4
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0EC5T
DRUGNAME	Neurox
INDICATI	Neuromuscular disease [ICD-11: 8C6Y] Approved
	
TTDDRUID	D0EC5X
DRUGNAME	Gemeprost
INDICATI	Cervical dilation [ICD-11: JB02.0] Withdrawn from market
	
TTDDRUID	D0EC6Q
DRUGNAME	Chlophedianol
INDICATI	Dry cough [ICD-11: MD12] Approved
INDICATI	Anaesthesia [ICD-11: 9A78.6] Withdrawn from market
	
TTDDRUID	D0ED3R
DRUGNAME	Clopidogrel
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0ED6E
DRUGNAME	CAM-2036
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0ED6O
DRUGNAME	CSTC1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0ED7U
DRUGNAME	Tiagabine
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0EE3Y
DRUGNAME	RSV-F
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D0EE6L
DRUGNAME	BP-897
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Discontinued in Phase 2
	
TTDDRUID	D0EE9G
DRUGNAME	TAK-214
INDICATI	Norovirus infection [ICD-11: 1A23] Phase 2
	
TTDDRUID	D0EF2H
DRUGNAME	FP-001
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0EF7V
DRUGNAME	Ro-31-4724
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0EF9B
DRUGNAME	DFD-11
INDICATI	Head and body lice [ICD-11: 1G00.0] Application submitted
	
TTDDRUID	D0EF9I
DRUGNAME	A-76895
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D0EF9Y
DRUGNAME	VSV-IFN-beta-NIS
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0EG1F
DRUGNAME	GR-199114X
INDICATI	Stomach ulcer [ICD-11: DA60.Z] Terminated
	
TTDDRUID	D0EG1I
DRUGNAME	Tofacitinib
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0EG5A
DRUGNAME	Retaspimycin
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2
	
TTDDRUID	D0EG5P
DRUGNAME	Matrix M
INDICATI	Vaccination [ICD-11: N.A.] Phase 1
	
TTDDRUID	D0EH0C
DRUGNAME	AV-965
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0EH1J
DRUGNAME	CD19.CAR-T cells
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
	
TTDDRUID	D0EH2O
DRUGNAME	BIMG80
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D0EH2Q
DRUGNAME	PF-05212366
INDICATI	Adolescent meningitis [ICD-11: 1D01.10] Phase 3
	
TTDDRUID	D0EH2T
DRUGNAME	PMID25666693-Compound-118
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0EH4P
DRUGNAME	PMID26815044-Compound-117
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0EH9A
DRUGNAME	Semprana
INDICATI	Migraine [ICD-11: 8A80] Application submitted
	
TTDDRUID	D0EH9Z
DRUGNAME	Heterocyclic derivative 14
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0EI1U
DRUGNAME	DCDT-2980S
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Discontinued in Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Discontinued in Phase 2
	
TTDDRUID	D0EI2V
DRUGNAME	SAR439459
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0EI4B
DRUGNAME	N-phenyl-pyridine-2-carboxamide derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0EI7H
DRUGNAME	ThromboMer
INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative
	
TTDDRUID	D0EJ0O
DRUGNAME	SC401
INDICATI	Hyperlipoproteinemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D0EJ3B
DRUGNAME	AMG 900
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0EJ6O
DRUGNAME	Ciprofibrate
INDICATI	Hyperlipoproteinemia [ICD-11: 5C80] Approved
	
TTDDRUID	D0EJ7U
DRUGNAME	CPP-115
INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 2
INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 1
INDICATI	Infantile spasm [ICD-11: 8A62.0] Phase 1
	
TTDDRUID	D0EJ8K
DRUGNAME	GSK-2392102A
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1
	
TTDDRUID	D0EK1C
DRUGNAME	PHE-377
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0EK1D
DRUGNAME	Arteflene
INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved
	
TTDDRUID	D0EK5H
DRUGNAME	JCV-specific TCR a chains-CD3zeta fusion protein
INDICATI	Progressive multifocal leukoencephalopathy [ICD-11: 8A45.02] Investigative
	
TTDDRUID	D0EK6D
DRUGNAME	FK-838
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D0EK9K
DRUGNAME	Sch-900875
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0EL0F
DRUGNAME	HBV-001-D1
INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 1
	
TTDDRUID	D0EL2L
DRUGNAME	VLCA- 04
INDICATI	Clostridium infection [ICD-11: 1A04] Investigative
	
TTDDRUID	D0EL2O
DRUGNAME	Egualen sodium
INDICATI	Ulcer [ICD-11: CA02-CB40] Approved
	
TTDDRUID	D0EL5Q
DRUGNAME	JTX-2011
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0EL6M
DRUGNAME	ImmuMax
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0EL9Z
DRUGNAME	AV0328
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2
	
TTDDRUID	D0EM1D
DRUGNAME	RO6867461
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	D0EM4S
DRUGNAME	JNJ-39439335
INDICATI	Musculoskeletal pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D0EM6S
DRUGNAME	Recombinant viral vector vaccine
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D0EN0F
DRUGNAME	TB-09
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0EN0G
DRUGNAME	Histamine Phosphate
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D0EN0W
DRUGNAME	Teprotumumab
INDICATI	Graves disease [ICD-11: 5A02.0] Approved
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 1
	
TTDDRUID	D0EN4G
DRUGNAME	R-102444
INDICATI	Pancreatitis [ICD-11: DC31-DC34] Terminated
	
TTDDRUID	D0EO2C
DRUGNAME	LY-2881835
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0EO3K
DRUGNAME	ETI-210
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative
	
TTDDRUID	D0EO5G
DRUGNAME	ALKS 6428
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 3
	
TTDDRUID	D0EO6G
DRUGNAME	Anti-CD19-CAR
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	Large cell lymphoma [ICD-11: 2A80.Z] Phase 1
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0EO6S
DRUGNAME	Glaspimod
INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Discontinued in Phase 2
	
TTDDRUID	D0EO8F
DRUGNAME	PMID30124346-Compound-LDT8
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Patented
	
TTDDRUID	D0EO8K
DRUGNAME	Valsartan
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0EP0C
DRUGNAME	Spironolactone
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0EP5O
DRUGNAME	NS-377
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0EP8X
DRUGNAME	Gamma Hydroxybutyric Acid
INDICATI	Narcolepsy [ICD-11: 7A20] Approved
	
TTDDRUID	D0EP9A
DRUGNAME	Dinutuximab
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3
	
TTDDRUID	D0EQ1J
DRUGNAME	S-111
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0EQ3O
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 4
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0EQ3V
DRUGNAME	Resorcinol compound 4
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0EQ5W
DRUGNAME	Sh-28-GST
INDICATI	Schistosomiasis [ICD-11: 1F86] Phase 3
	
TTDDRUID	D0EQ6D
DRUGNAME	JCARH125
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Clinical trial
INDICATI	Follicular lymphoma [ICD-11: 2A80] Clinical trial
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Clinical trial
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Clinical trial
	
TTDDRUID	D0EQ6V
DRUGNAME	Alhydrogel
INDICATI	Hookworm infection [ICD-11: 1F68] Phase 2
	
TTDDRUID	D0EQ9T
DRUGNAME	JNJ-39220675
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
	
TTDDRUID	D0ER5F
DRUGNAME	Ad5FGF-4
INDICATI	Angina pectoris [ICD-11: BA40] Phase 3
	
TTDDRUID	D0ER8I
DRUGNAME	Ushercell
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
	
TTDDRUID	D0ER9I
DRUGNAME	JNJ-40929837
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0ES1Q
DRUGNAME	Temsirolimus
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved
	
TTDDRUID	D0ES6N
DRUGNAME	SB-030
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D0ES7H
DRUGNAME	TV-Brain-1
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D0ES9J
DRUGNAME	BL-4040
INDICATI	Kidney injury [ICD-11: NB92.0] Investigative
	
TTDDRUID	D0ES9U
DRUGNAME	COR-003
INDICATI	Cushing disease [ICD-11: 5A70] Phase 3
	
TTDDRUID	D0ET2S
DRUGNAME	Epetirimod
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2
	
TTDDRUID	D0ET2T
DRUGNAME	GSK2586881
INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 2
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1
	
TTDDRUID	D0ET5E
DRUGNAME	Stem cell therapy, Dry AMD
INDICATI	Macular degeneration [ICD-11: 9B78.3] Investigative
	
TTDDRUID	D0ET6F
DRUGNAME	AT-004
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0ET9M
DRUGNAME	Biaryl mannoside derivative 30
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0ET9N
DRUGNAME	WC-3049
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 3
	
TTDDRUID	D0ET9U
DRUGNAME	Pyrazoline derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0EU0L
DRUGNAME	HIE-124
INDICATI	Anaesthesia [ICD-11: 9A78.6] Investigative
	
TTDDRUID	D0EU1R
DRUGNAME	GSK-2334470
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0EU9Z
DRUGNAME	InterveXin-PCP
INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Investigative
	
TTDDRUID	D0EV0H
DRUGNAME	PMID26911565-peptide-P9
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0EV1L
DRUGNAME	Elsiglutide
INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2
	
TTDDRUID	D0EV3G
DRUGNAME	PMID25666693-Compound-26
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0EV4B
DRUGNAME	CreaVax-PC
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0EV5O
DRUGNAME	NGP 555
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0EV6T
DRUGNAME	Tipranavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0EV6U
DRUGNAME	MFQ
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0EV8E
DRUGNAME	Econazole
INDICATI	Tinea versicolor [ICD-11: 1F2D.0] Approved
INDICATI	Cutaneous candidiasis [ICD-11: 1F23.14] Approved
INDICATI	Tinea corporis [ICD-11: 1F28.Y] Approved
INDICATI	Tinea cruris [ICD-11: 1F28.3] Approved
INDICATI	Tinea pedis [ICD-11: 1F28.2] Approved
	
TTDDRUID	D0EV9B
DRUGNAME	BTD-001
INDICATI	Narcolepsy [ICD-11: 7A20] Phase 2
	
TTDDRUID	D0EW2D
DRUGNAME	IMD-4482
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0EW3O
DRUGNAME	Cyclic peptidomimetic derivative 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0EW4L
DRUGNAME	Abatacept
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0EW4M
DRUGNAME	PNB-04
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0EW5Y
DRUGNAME	AlloDerm
INDICATI	Periodontal disease [ICD-11: DA0C] Approved
	
TTDDRUID	D0EW8Y
DRUGNAME	Thieno-phenanthridin-6-one
INDICATI	Brain ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0EW9U
DRUGNAME	[18F]DCFPyL
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0EX1C
DRUGNAME	RASV-Sp
INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 1
	
TTDDRUID	D0EY0A
DRUGNAME	AZD7687
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D0EY1E
DRUGNAME	Influsome-Vac
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0EY1Y
DRUGNAME	CRS-207 + GVAX
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
	
TTDDRUID	D0EY3X
DRUGNAME	KLS-40
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0EY5A
DRUGNAME	VLTS-587
INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 2
	
TTDDRUID	D0EY9S
DRUGNAME	1,2,4-oxadiazole derivative 4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0EZ0M
DRUGNAME	TTH 03-002
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0EZ5J
DRUGNAME	Daptacel
INDICATI	Pediatric immunological disease [ICD-11: GB4Z] Approved
	
TTDDRUID	D0EZ5Y
DRUGNAME	KiroVAX-001
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D0EZ9C
DRUGNAME	CTLA-4-XTEN
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0F0CS
DRUGNAME	ZARDAVERINE
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated
	
TTDDRUID	D0F0EP
DRUGNAME	Bemetizide
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0F0ET
DRUGNAME	T-270
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0F0FZ
DRUGNAME	UNBS-5162
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0F0ID
DRUGNAME	Polyoxidonium
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0F0JJ
DRUGNAME	E2012
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0F0JZ
DRUGNAME	CPG23CARD
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0F0LO
DRUGNAME	HG-1144
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F0MU
DRUGNAME	BLX-883
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1
	
TTDDRUID	D0F0NB
DRUGNAME	Insulin adjustable basal
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0F0NW
DRUGNAME	Dust mite peptide allergy desensitization
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D0F0OJ
DRUGNAME	JTK-656
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0F0OK
DRUGNAME	Sulfametopyrazine
INDICATI	Urinary tract infection [ICD-11: GC08] Withdrawn from market
	
TTDDRUID	D0F0PG
DRUGNAME	ZD-6804
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1
	
TTDDRUID	D0F0RR
DRUGNAME	GSK2592984A
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0F0TO
DRUGNAME	Sevoflurane
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0F0TW
DRUGNAME	SL-910102
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0F0UT
DRUGNAME	ACYLINE
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0F0VD
DRUGNAME	ACHP
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0F0VF
DRUGNAME	Benzoic acid linked peptide analog 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0F0VQ
DRUGNAME	SapC-DOPS
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F0VW
DRUGNAME	Anti-BCMA CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0F0VY
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 5
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0F0YL
DRUGNAME	SL-25.1039
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2
	
TTDDRUID	D0F0YM
DRUGNAME	MGN-4893
INDICATI	Polycythemia vera [ICD-11: 2A20.4] Investigative
	
TTDDRUID	D0F0YZ
DRUGNAME	Pentobarbital
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0F0ZE
DRUGNAME	Merimepodib
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Patented
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2
	
TTDDRUID	D0F0ZK
DRUGNAME	KB-003
INDICATI	Severe asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0F0ZY
DRUGNAME	Pazopanib HCl
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved
	
TTDDRUID	D0F1AX
DRUGNAME	CB-102930
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0F1CE
DRUGNAME	LCQ908
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
INDICATI	Familial chylomicronemia syndrome [ICD-11: 5C80] Phase 3
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 3
	
TTDDRUID	D0F1CN
DRUGNAME	SST-0001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F1DK
DRUGNAME	Pyridotriazolopyrimidine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0F1DY
DRUGNAME	Albiglutide
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D0F1EI
DRUGNAME	AZD-0303
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0F1EX
DRUGNAME	Alclometasone
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0F1FD
DRUGNAME	Complex heterocyclic compound 1
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D0F1GD
DRUGNAME	AuroVax
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D0F1GS
DRUGNAME	Calcium Acetate
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Approved
	
TTDDRUID	D0F1HT
DRUGNAME	MB-CART19.1
INDICATI	Precursor B-lymphoblastic neoplasm [ICD-11: 2A70] Phase 2
	
TTDDRUID	D0F1JB
DRUGNAME	Globorix
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Preregistration
	
TTDDRUID	D0F1JD
DRUGNAME	Apabetalone
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
INDICATI	Cardiac events [ICD-11: MC82] Phase 3
	
TTDDRUID	D0F1JY
DRUGNAME	LAS-186323
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0F1KP
DRUGNAME	PSN821
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D0F1LZ
DRUGNAME	Acetic Acid, Glacial
INDICATI	infection in the ear canal [ICD-11: AA0Y] Approved
	
TTDDRUID	D0F1MU
DRUGNAME	EML-336
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0F1OG
DRUGNAME	Soluble ErbB3 theragnostics
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F1OH
DRUGNAME	CD19CAT-41BBZ CAR T-cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0F1PH
DRUGNAME	Rimeporide
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D0F1UL
DRUGNAME	Dydrogesterone
INDICATI	Menstrual disorder [ICD-11: GA20.3] Approved
	
TTDDRUID	D0F1UW
DRUGNAME	C-Vaxin
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0F1UZ
DRUGNAME	Amitriptyline+ketamine
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Phase 2
	
TTDDRUID	D0F1VQ
DRUGNAME	ZIFROSILONE
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D0F1WD
DRUGNAME	C-10068
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D0F1WX
DRUGNAME	SSR240600
INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 2
	
TTDDRUID	D0F1ZB
DRUGNAME	LFA-102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0F1ZI
DRUGNAME	F-16-IL-2 fusion protein
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0F2AD
DRUGNAME	dioscin
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Preclinical
	
TTDDRUID	D0F2AK
DRUGNAME	Promegestone
INDICATI	Gynecological disease [ICD-11: GA6Z] Approved
	
TTDDRUID	D0F2BF
DRUGNAME	PMID28270021-Compound-WO2010077680 803
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0F2CH
DRUGNAME	Mutated growth hormone
INDICATI	Acromegaly [ICD-11: 5A60.0] Investigative
	
TTDDRUID	D0F2CQ
DRUGNAME	Fluoroglycoconjugates
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F2CW
DRUGNAME	Almitrine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0F2DD
DRUGNAME	KRH-102140
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0F2GK
DRUGNAME	RGI-3010
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0F2HA
DRUGNAME	ICI-D-8731
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D0F2IC
DRUGNAME	NTx-488
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2
	
TTDDRUID	D0F2IM
DRUGNAME	MEDI-573
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0F2JS
DRUGNAME	CHR-2797
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0F2JY
DRUGNAME	LY-2334737
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0F2KX
DRUGNAME	Granotapide
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D0F2KY
DRUGNAME	TetraMen-T
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 2
	
TTDDRUID	D0F2ML
DRUGNAME	MEDETOMIDINE
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0F2NF
DRUGNAME	GSK-958108
INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Phase 1
	
TTDDRUID	D0F2NG
DRUGNAME	HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0F2OG
DRUGNAME	AFM-19
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0F2PD
DRUGNAME	Arimoclomol
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2/3
INDICATI	Inclusion body myositis [ICD-11: 4A41.2] Phase 2/3
	
TTDDRUID	D0F2PO
DRUGNAME	Pindolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0F2PQ
DRUGNAME	BL-1050
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0F2PZ
DRUGNAME	SUN-E3001
INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated
	
TTDDRUID	D0F2QP
DRUGNAME	CRB-0022
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0F2QS
DRUGNAME	Mebiphon
INDICATI	Bone metastases [ICD-11: 2D50] Approved
	
TTDDRUID	D0F2RP
DRUGNAME	VEGF/rGel
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative
	
TTDDRUID	D0F2SA
DRUGNAME	BPKDi
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F2TY
DRUGNAME	EBV-related Hodgkin's disease vaccine
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Terminated
	
TTDDRUID	D0F2WN
DRUGNAME	NAHE-001
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2
	
TTDDRUID	D0F2WP
DRUGNAME	Relugolix
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
INDICATI	Endometriosis [ICD-11: GA10] Phase 3
	
TTDDRUID	D0F2XQ
DRUGNAME	Fludarabine
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Approved
	
TTDDRUID	D0F2XV
DRUGNAME	Aztreonam
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0F3BP
DRUGNAME	PAN-90716-DES
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D0F3BY
DRUGNAME	GW842470X
INDICATI	Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 2
	
TTDDRUID	D0F3EH
DRUGNAME	CS-712
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2
	
TTDDRUID	D0F3EO
DRUGNAME	HS-110
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0F3FB
DRUGNAME	S-9977
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D0F3FC
DRUGNAME	GSK-650394
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0F3FV
DRUGNAME	mRNA-1440
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0F3GA
DRUGNAME	Acyclic nucleoside phosphonates
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0F3GK
DRUGNAME	Peniel 1000
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D0F3GL
DRUGNAME	Vacc-4x
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0F3HA
DRUGNAME	Cyclohexyl carbamate derivative 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0F3HC
DRUGNAME	GS-9268
INDICATI	Non-cystic fibrosis bronchiectasis [ICD-11: CA24] Phase 3
	
TTDDRUID	D0F3HP
DRUGNAME	PMID25666693-Compound-101
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0F3II
DRUGNAME	COR100140
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical
	
TTDDRUID	D0F3IM
DRUGNAME	IMX-MSP4
INDICATI	Plasmodium vivax malaria [ICD-11: 1F41] Investigative
	
TTDDRUID	D0F3IP
DRUGNAME	Asasantin
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved
	
TTDDRUID	D0F3JA
DRUGNAME	HL-023
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F3JL
DRUGNAME	RSLV-132
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D0F3JT
DRUGNAME	Mecasermin
INDICATI	Growth failure [ICD-11: LD2F.1Y] Approved
	
TTDDRUID	D0F3KC
DRUGNAME	Indium-111
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3
	
TTDDRUID	D0F3LS
DRUGNAME	Insulin determir
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0F3MT
DRUGNAME	AVX901
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D0F3NF
DRUGNAME	TAS-116
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0F3NH
DRUGNAME	Balaglitazone
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D0F3ON
DRUGNAME	Adv-005
INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
	
TTDDRUID	D0F3PU
DRUGNAME	Iboctadekin + Doxil
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D0F3RQ
DRUGNAME	BAY 87-2243
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0F3SY
DRUGNAME	Tegafur
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0F3TI
DRUGNAME	PT-630
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D0F3VI
DRUGNAME	CEL-1000
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F3VW
DRUGNAME	Allergy immunotherapeutic vaccine
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1
	
TTDDRUID	D0F3WG
DRUGNAME	Disufenton sodium
INDICATI	Ischemia [ICD-11: 8B10-8B11] Phase 3
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D0F3ZG
DRUGNAME	RO-5458640
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0F470
DRUGNAME	FP-025
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0F4AP
DRUGNAME	Glycanics
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0F4CG
DRUGNAME	18F-AV-1451
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 4
	
TTDDRUID	D0F4CT
DRUGNAME	MRLP-164
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Investigative
	
TTDDRUID	D0F4DI
DRUGNAME	PMID25666693-Compound-30
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0F4DW
DRUGNAME	HG-1300
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F4FN
DRUGNAME	68Ga-DOTA-AE-105
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F4FV
DRUGNAME	DX-2300
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0F4GF
DRUGNAME	MK-8998
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0F4GJ
DRUGNAME	Trifenagrel
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0F4HB
DRUGNAME	Lucinactant
INDICATI	Respiratory distress syndrome [ICD-11: CB00] Approved
	
TTDDRUID	D0F4IC
DRUGNAME	AM-250
INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative
	
TTDDRUID	D0F4IF
DRUGNAME	N-phenyl-pyridine-2-carboxamide derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0F4IG
DRUGNAME	DS-4574
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0F4IM
DRUGNAME	Adcetris
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 3
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 3
INDICATI	T-cell leukaemia [ICD-11: 2A90] Phase 3
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D0F4JK
DRUGNAME	CE-224535
INDICATI	Arthralgia [ICD-11: ME82] Phase 2/3
	
TTDDRUID	D0F4LI
DRUGNAME	LASSBio-881
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0F4LP
DRUGNAME	hESC-derived CD15+ISL-1+cardiac progenitors
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D0F4MI
DRUGNAME	TAK-075
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D0F4MK
DRUGNAME	CyMVectin
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative
	
TTDDRUID	D0F4NB
DRUGNAME	PMID30124346-Compound-13TABLE4
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Patented
	
TTDDRUID	D0F4NH
DRUGNAME	VX-222
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0F4NN
DRUGNAME	CGTG-102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0F4NP
DRUGNAME	JNJ-17305600
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0F4NS
DRUGNAME	Mozavaptan
INDICATI	Hyponatraemia [ICD-11: 5C72] Approved
	
TTDDRUID	D0F4NW
DRUGNAME	RO-5428029
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0F4QJ
DRUGNAME	CR-5790
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D0F4QO
DRUGNAME	THE-320
INDICATI	Prostate hyperplasia [ICD-11: GA90] Approved
	
TTDDRUID	D0F4QV
DRUGNAME	GSK2696273
INDICATI	Chronic pain [ICD-11: MG30] Preregistration
INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Phase 2/3
	
TTDDRUID	D0F4RM
DRUGNAME	MD-2009
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0F4RX
DRUGNAME	OPC-14117
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 1
	
TTDDRUID	D0F4SI
DRUGNAME	N-9xxx
INDICATI	Vascular disease [ICD-11: BE2Z] Investigative
	
TTDDRUID	D0F4SN
DRUGNAME	KUR-111
INDICATI	Bone disease [ICD-11: FC0Z] Phase 2
	
TTDDRUID	D0F4SY
DRUGNAME	Pridopidine
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 3
	
TTDDRUID	D0F4TV
DRUGNAME	AWD-12-281
INDICATI	Rhinitis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0F4UI
DRUGNAME	CPD-VO
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F4UM
DRUGNAME	MG-4101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0F4VK
DRUGNAME	TB-101
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative
	
TTDDRUID	D0F4VW
DRUGNAME	SRX-246
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Phase 2
	
TTDDRUID	D0F4WS
DRUGNAME	BM-13.1180
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D0F4YX
DRUGNAME	PMID25666693-Compound-15
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0F4ZN
DRUGNAME	PAMAQUESIDE
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 3
	
TTDDRUID	D0F4ZY
DRUGNAME	Istradefylline
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 1
	
TTDDRUID	D0F5AB
DRUGNAME	Rad51
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F5AR
DRUGNAME	Cibinetide
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 1
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 1
	
TTDDRUID	D0F5BL
DRUGNAME	EXO-230
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 1/2
	
TTDDRUID	D0F5CO
DRUGNAME	Enloplatin
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Terminated
	
TTDDRUID	D0F5DK
DRUGNAME	TRAIL-R Atrimer
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F5DO
DRUGNAME	Arginine
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved
	
TTDDRUID	D0F5GF
DRUGNAME	AE-08
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0F5HB
DRUGNAME	Sotrastaurin acetate
INDICATI	Renal transplantation [ICD-11: NE84] Phase 2
	
TTDDRUID	D0F5IS
DRUGNAME	NGN-9079
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0F5IY
DRUGNAME	LIRIMILAST
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0F5JG
DRUGNAME	AK-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F5JH
DRUGNAME	CS-038
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0F5JR
DRUGNAME	ONO-1603
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D0F5JZ
DRUGNAME	PLX-4720
INDICATI	Cutaneous melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0F5KN
DRUGNAME	99mTc-MIP-1405
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0F5LB
DRUGNAME	Carbon monoxide
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D0F5MT
DRUGNAME	Fosamprenavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0F5NB
DRUGNAME	CD-581
INDICATI	Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 1
	
TTDDRUID	D0F5NG
DRUGNAME	KUR-114
INDICATI	Bone injury [ICD-11: ND56.Y] Investigative
	
TTDDRUID	D0F5NQ
DRUGNAME	PMID25666693-Compound-65
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0F5OR
DRUGNAME	Spiramycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0F5TD
DRUGNAME	PMID27841036-Compound-37
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D0F5TM
DRUGNAME	OPI-1100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F5TR
DRUGNAME	PMID25553724-Compound-US2012832440110
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented
	
TTDDRUID	D0F5TS
DRUGNAME	KM-3900
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F5UN
DRUGNAME	SLV320
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D0F5UO
DRUGNAME	KMS-88009
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0F5VD
DRUGNAME	Ezatiostat
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D0F5VX
DRUGNAME	MNX-100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 2
	
TTDDRUID	D0F5WX
DRUGNAME	GSK768974
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D0F5ZM
DRUGNAME	Imidazole salicylate
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0F5ZZ
DRUGNAME	Sharon-2000
INDICATI	Dental caries [ICD-11: DA08.0] Investigative
	
TTDDRUID	D0F6AB
DRUGNAME	AR-C-89855
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated
	
TTDDRUID	D0F6AJ
DRUGNAME	Hsp 6/11
INDICATI	Condyloma [ICD-11: 1A95] Investigative
	
TTDDRUID	D0F6CI
DRUGNAME	R-1437
INDICATI	Prostate hyperplasia [ICD-11: GA90] Terminated
	
TTDDRUID	D0F6CT
DRUGNAME	GI 181771
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
	
TTDDRUID	D0F6DF
DRUGNAME	AB-3D3
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D0F6EO
DRUGNAME	Amoxicillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0F6GR
DRUGNAME	Clentiazem
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D0F6GU
DRUGNAME	PF-2400013
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
	
TTDDRUID	D0F6GV
DRUGNAME	Perospirone
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Approved
	
TTDDRUID	D0F6HW
DRUGNAME	IPH-4201
INDICATI	Pancreatic cancer [ICD-11: 2C10] Terminated
	
TTDDRUID	D0F6IL
DRUGNAME	KNW-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F6JC
DRUGNAME	GSK1278863
INDICATI	Anaemia [ICD-11: 3A90] Phase 3
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 2
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1
	
TTDDRUID	D0F6JI
DRUGNAME	AR-D-111421
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0F6KM
DRUGNAME	ISIS-APOCIII
INDICATI	Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 1
INDICATI	Atherosclerosis [ICD-11: BD40] Phase 1
INDICATI	Hyperlipemia [ICD-11: 5C80] Phase 1
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D0F6OF
DRUGNAME	NMS-P626
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F6QN
DRUGNAME	SLP-0901
INDICATI	Escherichia coli infection [ICD-11: 1A03] Investigative
	
TTDDRUID	D0F6SS
DRUGNAME	Ganglioside vaccine
INDICATI	Metastatic sarcoma [ICD-11: 2D50-2E2Z] Phase 2
	
TTDDRUID	D0F6SY
DRUGNAME	StarGen
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	D0F6TD
DRUGNAME	SUN N4057
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
	
TTDDRUID	D0F6TN
DRUGNAME	Mannoside derivative 6
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0F6TV
DRUGNAME	Timcodar dimesilate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0F6WV
DRUGNAME	PD-157695
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0F6WW
DRUGNAME	LU-AA33810
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D0F6XR
DRUGNAME	DV-7028
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D0F6YK
DRUGNAME	Implitapide
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D0F6YM
DRUGNAME	VBP15
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0F6YW
DRUGNAME	Sagopilone
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0F6ZS
DRUGNAME	Ro-25-6833
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0F6ZT
DRUGNAME	GL-0810
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1
	
TTDDRUID	D0F7AJ
DRUGNAME	Ceftolozane/tazobactam
INDICATI	Discovery agent [ICD-11: N.A.] Approved
	
TTDDRUID	D0F7AT
DRUGNAME	Cryptenamine Acetates
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0F7BO
DRUGNAME	Alpha melanotropin
INDICATI	Lung injury [ICD-11: NB32.3Z] Investigative
	
TTDDRUID	D0F7CR
DRUGNAME	BMS-986178
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0F7CS
DRUGNAME	Rotenone
INDICATI	Piscicide [ICD-11: N.A.] Approved
	
TTDDRUID	D0F7EK
DRUGNAME	MX-6162
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D0F7FE
DRUGNAME	SY-300
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0F7FM
DRUGNAME	ASP2409
INDICATI	Organ transplant rejection [ICD-11: NE84] Phase 1
	
TTDDRUID	D0F7FX
DRUGNAME	AZD-9684
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D0F7FY
DRUGNAME	Antimicrobial oral vaccine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2
	
TTDDRUID	D0F7GX
DRUGNAME	ACE-011
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1
	
TTDDRUID	D0F7IG
DRUGNAME	PH10 nasal spray
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0F7LE
DRUGNAME	AZD-0902
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated
	
TTDDRUID	D0F7LI
DRUGNAME	PAN-301-1
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0F7NQ
DRUGNAME	Flumethasone Pivalate
INDICATI	Contact dermatitis [ICD-11: EK0Z] Approved
	
TTDDRUID	D0F7NT
DRUGNAME	349U85.HCL
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D0F7NZ
DRUGNAME	Guanidine Hydrochloride
INDICATI	Muscle fatigue [ICD-11: FB32.5] Approved
	
TTDDRUID	D0F7OY
DRUGNAME	Recombinant plague F1V vaccine
INDICATI	Yersinia infection [ICD-11: 1B93] Phase 2
	
TTDDRUID	D0F7PZ
DRUGNAME	PF-232798
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0F7QP
DRUGNAME	StarGen Stargardt's disease gene therapy
INDICATI	Stargardt disease [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	D0F7RU
DRUGNAME	Anti-TSLP mab
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0F7SW
DRUGNAME	MOL-2591
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0F7TR
DRUGNAME	Autologous skeletal myoblast therapy
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Phase 2/3
	
TTDDRUID	D0F7TV
DRUGNAME	Torbafylline
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Terminated
	
TTDDRUID	D0F7WQ
DRUGNAME	HE-2000
INDICATI	Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2
	
TTDDRUID	D0F7XN
DRUGNAME	M-216765
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0F7XT
DRUGNAME	Fluoxetine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0F7YW
DRUGNAME	MGN-1703
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0F7ZH
DRUGNAME	FXI-AS1
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D0F7ZJ
DRUGNAME	Iseganan
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0F7ZR
DRUGNAME	ARX-424
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0F8BF
DRUGNAME	Bicyclic heteroaryl benzamide derivative 2
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0F8BR
DRUGNAME	XGP-115
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0F8BS
DRUGNAME	YM-796
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D0F8CM
DRUGNAME	Pentosan Polysulfate
INDICATI	Painful bladder syndrome [ICD-11: MG30.50] Approved
INDICATI	Interstitial cystitis [ICD-11: GC00.3] Approved
	
TTDDRUID	D0F8CS
DRUGNAME	ISF-120
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0F8EM
DRUGNAME	Op-1
INDICATI	Tibial nonunions [ICD-11: FB80.8] Approved
	
TTDDRUID	D0F8EU
DRUGNAME	Oralex
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 2
	
TTDDRUID	D0F8GK
DRUGNAME	LY2886721
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0F8GT
DRUGNAME	AVI-6006
INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative
	
TTDDRUID	D0F8HN
DRUGNAME	DA-8031
INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Phase 2
	
TTDDRUID	D0F8HS
DRUGNAME	NLX-101
INDICATI	Rett syndrome [ICD-11: LD90.4] Phase 1
	
TTDDRUID	D0F8HU
DRUGNAME	VaxiFlu-S
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0F8HX
DRUGNAME	Lactoquinomycin
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Investigative
	
TTDDRUID	D0F8IO
DRUGNAME	Cephaloridine
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Withdrawn from market
	
TTDDRUID	D0F8JR
DRUGNAME	Cholecalciferol
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0F8KE
DRUGNAME	Imidazole benzamide derivative 1
INDICATI	Knee pain [ICD-11: ME82] Patented
	
TTDDRUID	D0F8KR
DRUGNAME	RTU-1096
INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative
	
TTDDRUID	D0F8NE
DRUGNAME	V-103
INDICATI	Contusion [ICD-11: ND56.0] Investigative
	
TTDDRUID	D0F8PG
DRUGNAME	PMID29334795-Compound-21
INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Patented
INDICATI	Corticobasal degeneration [ICD-11: 8A00.1Y] Patented
	
TTDDRUID	D0F8QM
DRUGNAME	FR-158999
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D0F8RA
DRUGNAME	Theophylline
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0F8RK
DRUGNAME	GED-aPC
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1
	
TTDDRUID	D0F8SK
DRUGNAME	Perfluoropropane gas-filled nanobubbles
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1/2
	
TTDDRUID	D0F8SW
DRUGNAME	SNS01-T
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
	
TTDDRUID	D0F8TB
DRUGNAME	TSR-033
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0F8TS
DRUGNAME	MPC-9055
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0F8UV
DRUGNAME	Nelipepimut S
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
	
TTDDRUID	D0F8VH
DRUGNAME	AA-166
INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Investigative
	
TTDDRUID	D0F8VM
DRUGNAME	Meningococcal vaccine groups A,C,Y,W-135 conjugate
INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 3
	
TTDDRUID	D0F8XI
DRUGNAME	DS-1442
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 1
	
TTDDRUID	D0F8XK
DRUGNAME	ISIS-GCCR
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical
	
TTDDRUID	D0F8ZD
DRUGNAME	OPN-302
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0F8ZG
DRUGNAME	GX-G3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0F9AO
DRUGNAME	BHV-5000
INDICATI	Rett syndrome [ICD-11: LD90.4] Phase 1
	
TTDDRUID	D0F9BX
DRUGNAME	GW-660511
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0F9BY
DRUGNAME	Anidulafungin
INDICATI	Convulsion [ICD-11: 8A68.Z] Approved
	
TTDDRUID	D0F9FR
DRUGNAME	Oxazolidinones
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 2
	
TTDDRUID	D0F9GE
DRUGNAME	Dipyridamole
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0F9GL
DRUGNAME	PMID25553724-Compound-US2011806744710
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented
	
TTDDRUID	D0F9HK
DRUGNAME	Strontium-89
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0F9IE
DRUGNAME	MK-5890
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0F9IK
DRUGNAME	SMRX-11
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0F9IS
DRUGNAME	FR-900482
INDICATI	leukaemia [ICD-11: 2A60-2B33] Terminated
	
TTDDRUID	D0F9IX
DRUGNAME	Samatasvir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0F9KI
DRUGNAME	LAS-30538
INDICATI	Hyperinsulinemia [ICD-11: 5A4Y] Terminated
	
TTDDRUID	D0F9NA
DRUGNAME	MRC-375
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0F9ND
DRUGNAME	MGAWN-1
INDICATI	West nile virus infection [ICD-11: 1D46] Discontinued in Phase 2
	
TTDDRUID	D0F9NN
DRUGNAME	AP-501
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0F9QH
DRUGNAME	Abituzumab
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D0F9QP
DRUGNAME	GW-559090
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2
	
TTDDRUID	D0F9SG
DRUGNAME	Dexfenfluramine
INDICATI	Obesity [ICD-11: 5B81] Withdrawn from market
	
TTDDRUID	D0F9TL
DRUGNAME	BT-063
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0F9VF
DRUGNAME	Propofol
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0F9VH
DRUGNAME	Tesetaxel
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
	
TTDDRUID	D0F9WF
DRUGNAME	SINOMENINE
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0F9XG
DRUGNAME	MEDI2070
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D0F9YJ
DRUGNAME	Pfs48
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0F9ZO
DRUGNAME	Spironolactone
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0FA0A
DRUGNAME	Apristor
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0FA2L
DRUGNAME	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3
INDICATI	Osteoporosis [ICD-11: FB83.0] Patented
	
TTDDRUID	D0FA2N
DRUGNAME	HE-3177
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0FA2O
DRUGNAME	Trioxsalen
INDICATI	Vitiligo [ICD-11: ED63.0] Approved
	
TTDDRUID	D0FA3O
DRUGNAME	Hydrocortisone
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0FA4C
DRUGNAME	JDP-201
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0FA4Q
DRUGNAME	IL1R1 NAM
INDICATI	Gout [ICD-11: FA25] Investigative
	
TTDDRUID	D0FA5Z
DRUGNAME	LX-1033
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
	
TTDDRUID	D0FA6S
DRUGNAME	Altiratinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0FB1C
DRUGNAME	BPX-04
INDICATI	Rosacea [ICD-11: ED90.0] Phase 2
	
TTDDRUID	D0FB1S
DRUGNAME	GTx-230
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0FB4W
DRUGNAME	CYAD-101
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D0FB6T
DRUGNAME	SYN-987
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0FC1J
DRUGNAME	Nifurtimox
INDICATI	Chagas disease [ICD-11: IF53] Approved
INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Phase 4
	
TTDDRUID	D0FC2D
DRUGNAME	Dec-RVKR-CMK
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0FC4R
DRUGNAME	CVX 096
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0FC5T
DRUGNAME	DIAVERIDINE
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0FC7H
DRUGNAME	MUC-1 CD40L dendritic cell vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0FC7P
DRUGNAME	Hepatitis B vaccine 1018-ISS conjugate
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Preregistration
	
TTDDRUID	D0FC8O
DRUGNAME	DWP-05195
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D0FC8P
DRUGNAME	Pyrazole derivative 19
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0FD0B
DRUGNAME	PSN-9301
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D0FD0H
DRUGNAME	Aminocaproic Acid
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
INDICATI	Postoperative hemorrhage [ICD-11: NE81.0Z] Approved
	
TTDDRUID	D0FD2I
DRUGNAME	Discodermolide
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1
	
TTDDRUID	D0FD3D
DRUGNAME	Cripto-1 mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0FD6D
DRUGNAME	CEP-11981
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0FD6E
DRUGNAME	Aspoxicillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0FD7H
DRUGNAME	ALT-803
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0FE3P
DRUGNAME	MIV 150 + zinc acetate
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0FE7D
DRUGNAME	Emibetuzumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0FE7H
DRUGNAME	PMID10498202C1
INDICATI	Multiple sclerosis [ICD-11: 8A40] Clinical trial
	
TTDDRUID	D0FE8F
DRUGNAME	Folic acid
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D0FF0I
DRUGNAME	MOD-5014
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Phase 2
	
TTDDRUID	D0FF0N
DRUGNAME	TBI-1501
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
	
TTDDRUID	D0FF2G
DRUGNAME	Sym013
INDICATI	Epithelial ovarian cancer [ICD-11: 2B5D] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0FF2S
DRUGNAME	RP-G28
INDICATI	Lactose intolerance [ICD-11: 5C61.6] Phase 2
	
TTDDRUID	D0FF6S
DRUGNAME	A-803467
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0FF7A
DRUGNAME	Z-6568
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0FG2Z
DRUGNAME	NC-6004
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
	
TTDDRUID	D0FG6M
DRUGNAME	GW642444
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0FG6T
DRUGNAME	NRP-388
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0FH3X
DRUGNAME	A-437203
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2
	
TTDDRUID	D0FH5N
DRUGNAME	IW-6118
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2
	
TTDDRUID	D0FH7C
DRUGNAME	Gold sodium thiomalate
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0FH8R
DRUGNAME	DB-160
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0FH9O
DRUGNAME	SDX-7500
INDICATI	Weight loss [ICD-11: MG43.5] Investigative
	
TTDDRUID	D0FI1K
DRUGNAME	ARX-212
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0FI1L
DRUGNAME	CAD-1883
INDICATI	Ataxic disorder [ICD-11: 8A03] Phase 1/2
	
TTDDRUID	D0FI3Q
DRUGNAME	Biaryl mannoside derivative 13
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0FI5C
DRUGNAME	MEDI-528
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0FJ0W
DRUGNAME	BAY 1026153
INDICATI	Endometriosis [ICD-11: GA10] Phase 1
	
TTDDRUID	D0FJ1N
DRUGNAME	PMID30107136-Compound-Example42
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0FJ1W
DRUGNAME	DE-766
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D0FJ3P
DRUGNAME	GW-2592X
INDICATI	Osteoporosis [ICD-11: FB83.0] Preclinical
INDICATI	Bone disease [ICD-11: FC0Z] Investigative
	
TTDDRUID	D0FJ4A
DRUGNAME	Thiazole carboxamide derivative 18
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0FJ8A
DRUGNAME	Deferoxamine Mesylate
INDICATI	Acute iron or aluminum toxicity [ICD-11: FB83.20] Approved
	
TTDDRUID	D0FJ9I
DRUGNAME	Cotellic
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0FJ9W
DRUGNAME	KB-004
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D0FK4P
DRUGNAME	PMID30107136-Compound-Example48
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0FK6A
DRUGNAME	TDI-0068
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0FK6N
DRUGNAME	Peptide analog 5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0FK6O
DRUGNAME	MIN-202
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0FK9H
DRUGNAME	Ontuxizumab
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D0FL0R
DRUGNAME	ALS-L1023
INDICATI	Obesity [ICD-11: 5B81] Phase 3
	
TTDDRUID	D0FL1E
DRUGNAME	Resorcinol compound 33
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0FL2K
DRUGNAME	Cantrixil
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D0FL3H
DRUGNAME	PMID26651364-Compound-6a
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0FL4G
DRUGNAME	DAF-3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0FL5S
DRUGNAME	CART-20 cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0FL5V
DRUGNAME	Clobetasol
INDICATI	Rosacea [ICD-11: ED90.0] Approved
INDICATI	Oral lichen planus [ICD-11: EA91.4] Phase 2
	
TTDDRUID	D0FL6C
DRUGNAME	HL-130
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0FL6L
DRUGNAME	IMA202
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0FL6X
DRUGNAME	DS-8587
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D0FL8A
DRUGNAME	PMID28270021-Compound-WO2010077680 481
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0FM2P
DRUGNAME	Flunisolide
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0FM2W
DRUGNAME	Defibrotide
INDICATI	Hepatic veno-occlusive disease [ICD-11: DB98.6] Approved
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 3
	
TTDDRUID	D0FM4T
DRUGNAME	EC-0746
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0FM5M
DRUGNAME	IMO-2125
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0FM7Z
DRUGNAME	BL-1021
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0FM9V
DRUGNAME	PMID30107136-Compound-Example60
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0FN1P
DRUGNAME	Saviprazole
INDICATI	Peptic ulcer [ICD-11: DA61] Terminated
	
TTDDRUID	D0FN4K
DRUGNAME	XToll
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	D0FN4T
DRUGNAME	RM-1929
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
	
TTDDRUID	D0FN6D
DRUGNAME	NGD-97-1
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
	
TTDDRUID	D0FN7J
DRUGNAME	Methocarbamol
INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Approved
	
TTDDRUID	D0FN9X
DRUGNAME	CGEN-671
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0FO1P
DRUGNAME	HL-021
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0FP0D
DRUGNAME	AZD-6088
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D0FP0R
DRUGNAME	Apaziquone
INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 3
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3
	
TTDDRUID	D0FP4R
DRUGNAME	UR-13870
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0FP5B
DRUGNAME	MK-8962
INDICATI	Fertility problem [ICD-11: 5A61] Phase 3
	
TTDDRUID	D0FP6V
DRUGNAME	Alpha-Helical lipopeptides IIK
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0FP8S
DRUGNAME	Neugranin
INDICATI	Neutropenia [ICD-11: 4B00.0] Preregistration
	
TTDDRUID	D0FP9N
DRUGNAME	P11187
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0FQ2U
DRUGNAME	Talabostat
INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0FQ3D
DRUGNAME	Nicotinyl hydroxamic acid derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0FQ4M
DRUGNAME	Selenotifen
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0FQ6O
DRUGNAME	Etarotene
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 3
	
TTDDRUID	D0FR1Q
DRUGNAME	Sulfonylated piperazine derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0FR3J
DRUGNAME	CD19 specific CAR T cells
INDICATI	Acute leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0FR6I
DRUGNAME	Cyanocobalamin
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved
	
TTDDRUID	D0FR7E
DRUGNAME	CX1789
INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Phase 2
	
TTDDRUID	D0FR9L
DRUGNAME	Haem arginate
INDICATI	Porphyria [ICD-11: 5C58.1] Approved
	
TTDDRUID	D0FS0D
DRUGNAME	1,2,3-triazole derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0FS0F
DRUGNAME	CK-301
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0FS1B
DRUGNAME	Micro-dystrophin gene therapy
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1
	
TTDDRUID	D0FS3H
DRUGNAME	IDP-126
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0FS9K
DRUGNAME	MINAMESTANE
INDICATI	Bladder cancer [ICD-11: 2C94] Terminated
	
TTDDRUID	D0FS9V
DRUGNAME	PMID26651364-Compound-120
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0FT2Z
DRUGNAME	P1025
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D0FT3R
DRUGNAME	Tildrakizumab
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
	
TTDDRUID	D0FT4P
DRUGNAME	Aryl mannoside derivative 3
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0FT4R
DRUGNAME	Sivelestat
INDICATI	Pyoderma gangrenosum [ICD-11: EB21] Phase 3
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
INDICATI	Anterior uveitis [ICD-11: 9A96] Application submitted
INDICATI	Axial spondyloarthritis [ICD-11: FA92.0] Application submitted
	
TTDDRUID	D0FT5T
DRUGNAME	CYP2001
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 1
	
TTDDRUID	D0FT7Y
DRUGNAME	Ammonia
INDICATI	Coronary artery disease [ICD-11: BA80] Approved
	
TTDDRUID	D0FT8G
DRUGNAME	PX-12
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0FU0O
DRUGNAME	XmAb18087
INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1
	
TTDDRUID	D0FU1J
DRUGNAME	PTG-100
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1
	
TTDDRUID	D0FU5Y
DRUGNAME	SequestOx
INDICATI	Chronic pain [ICD-11: MG30] Application submitted
	
TTDDRUID	D0FU8R
DRUGNAME	Anifrolumab
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3
	
TTDDRUID	D0FV1R
DRUGNAME	Anti-heparanase mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0FV3K
DRUGNAME	AC0010
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D0FV3V
DRUGNAME	Mepenzolate
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D0FV8P
DRUGNAME	POL-6326
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0FW0B
DRUGNAME	ZP2929
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0FW2A
DRUGNAME	LEO 80185
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 4
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	D0FW2B
DRUGNAME	BAX-930
INDICATI	Thrombotic thrombocytopenic purpura [ICD-11: 3B64.14] Phase 1
	
TTDDRUID	D0FW2D
DRUGNAME	NX-101
INDICATI	Dermal neurofibromatoses [ICD-11: LD2D] Phase 2
	
TTDDRUID	D0FW3M
DRUGNAME	Heterocyclic derivative 18
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0FW8Z
DRUGNAME	Kybiqo
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0FX2Q
DRUGNAME	Rifamycin
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 3
	
TTDDRUID	D0FX3P
DRUGNAME	ISIS 104838
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
INDICATI	Crohn disease [ICD-11: DD70] Discontinued in Phase 2
	
TTDDRUID	D0FX3U
DRUGNAME	Bevacizumab
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D0FX4J
DRUGNAME	Telenzepine
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Preregistration
	
TTDDRUID	D0FX5D
DRUGNAME	Cx-602
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Preclinical
	
TTDDRUID	D0FX6P
DRUGNAME	Dextranomer
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0FX8A
DRUGNAME	Tenecteplase
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved
	
TTDDRUID	D0FX8N
DRUGNAME	CT1812
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0FY0D
DRUGNAME	HD-201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0FY1W
DRUGNAME	Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0FY2N
DRUGNAME	NPRx-30
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0FY3O
DRUGNAME	Rabies immune globulin
INDICATI	Rabies [ICD-11: 1C82] Approved
	
TTDDRUID	D0FY4J
DRUGNAME	BBI-6000
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0FY4L
DRUGNAME	SAR438335
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0FY4M
DRUGNAME	Echinocandin
INDICATI	Candidiasis [ICD-11: 1F23] Investigative
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D0FY5E
DRUGNAME	TAI-GPC3-CART cells
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
	
TTDDRUID	D0FY6Q
DRUGNAME	JTK-109
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1
	
TTDDRUID	D0FZ1W
DRUGNAME	BTA-798
INDICATI	Rhinovirus infection [ICD-11: CA07] Phase 2
	
TTDDRUID	D0FZ1Y
DRUGNAME	CART30
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1/2
	
TTDDRUID	D0FZ1Z
DRUGNAME	Doxorubicin-CEA conjugate
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D0FZ4X
DRUGNAME	MitoPBN
INDICATI	Mitochondrial disease [ICD-11: 5C53.Y] Investigative
	
TTDDRUID	D0FZ5R
DRUGNAME	Imidazolidine-2,4-dione derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0FZ7Q
DRUGNAME	NanoPac
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2
INDICATI	Skin metastasis [ICD-11: 2D50] Phase 2
	
TTDDRUID	D0FZ8U
DRUGNAME	Glysopep
INDICATI	Deep vein thrombosis [ICD-11: BD71] Investigative
	
TTDDRUID	D0FZ9N
DRUGNAME	TDI-0049
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0G0AI
DRUGNAME	Obizur
INDICATI	Haemophilia A [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0G0AQ
DRUGNAME	ADC-1012
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G0BJ
DRUGNAME	VE-821
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G0BL
DRUGNAME	AMG 337
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Clear cell sarcoma [ICD-11: 2A60-2C35] Phase 2
	
TTDDRUID	D0G0CX
DRUGNAME	MCC-257
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D0G0DZ
DRUGNAME	Prazosin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0G0ER
DRUGNAME	DWJ-208
INDICATI	Cancer related pain [ICD-11: MG30] Phase 1
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0G0FQ
DRUGNAME	IMA-950
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0G0GI
DRUGNAME	DMP-696
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0G0GP
DRUGNAME	Carbon dioxide intranasal
INDICATI	Trigeminal neuralgia [ICD-11: 8B82.0] Phase 2
	
TTDDRUID	D0G0IA
DRUGNAME	Preflucel
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0G0IZ
DRUGNAME	Labradimil
INDICATI	Brain cancer [ICD-11: 2A00] Discontinued in Phase 2
	
TTDDRUID	D0G0KZ
DRUGNAME	ZP-2571
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G0LH
DRUGNAME	S-312-d
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2
	
TTDDRUID	D0G0MB
DRUGNAME	MEDI7510
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D0G0MM
DRUGNAME	H1N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0G0PI
DRUGNAME	CD38 and BCMA CAR-T Cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0G0PU
DRUGNAME	RO-5212054
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0G0RT
DRUGNAME	Carmoterol
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0G0TS
DRUGNAME	Meclinertant
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2/3
	
TTDDRUID	D0G0TT
DRUGNAME	RG7410
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1
	
TTDDRUID	D0G0UZ
DRUGNAME	SBP-002
INDICATI	Melanoma [ICD-11: 2C30] Terminated
	
TTDDRUID	D0G0VV
DRUGNAME	Bafetinib
INDICATI	Bone disease [ICD-11: FC0Z] Phase 2
	
TTDDRUID	D0G0XN
DRUGNAME	UK-156406
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 1
	
TTDDRUID	D0G0YL
DRUGNAME	LT-NS001
INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Phase 2/3
	
TTDDRUID	D0G0YZ
DRUGNAME	UK-356202
INDICATI	Myocardial hypertrophy [ICD-11: BC45] Clinical trial
	
TTDDRUID	D0G0ZE
DRUGNAME	TTP-547
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0G1AA
DRUGNAME	AKP-001
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0G1AK
DRUGNAME	UR-12510
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0G1AQ
DRUGNAME	KALA-617
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0G1CB
DRUGNAME	PRO-105
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Investigative
	
TTDDRUID	D0G1EA
DRUGNAME	SLP vaccine
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
	
TTDDRUID	D0G1EC
DRUGNAME	Aspirin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D0G1EE
DRUGNAME	ATRINOSITOL
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0G1EH
DRUGNAME	AEOL-10150
INDICATI	Multiple sclerosis [ICD-11: 8A40] Preclinical
	
TTDDRUID	D0G1GP
DRUGNAME	ISIS 2922
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Withdrawn from market
	
TTDDRUID	D0G1HX
DRUGNAME	CLBS03
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D0G1IG
DRUGNAME	F-16-131I
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D0G1IV
DRUGNAME	Testogen TDS
INDICATI	Hypogonadism [ICD-11: 5A61.0] Phase 2
	
TTDDRUID	D0G1JO
DRUGNAME	Combidex
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0G1LP
DRUGNAME	ALT-802
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G1MZ
DRUGNAME	CY-1787
INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1
	
TTDDRUID	D0G1NW
DRUGNAME	PF-4308515
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D0G1OS
DRUGNAME	LT-0301
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G1OZ
DRUGNAME	Mephentermine
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D0G1QL
DRUGNAME	ET-008
INDICATI	Cervical cancer [ICD-11: 2C77.0] Investigative
	
TTDDRUID	D0G1RA
DRUGNAME	Rhodamine-123
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1
	
TTDDRUID	D0G1RH
DRUGNAME	NPS-2143
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2
	
TTDDRUID	D0G1RM
DRUGNAME	Interferon
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Investigative
	
TTDDRUID	D0G1RT
DRUGNAME	L-694247
INDICATI	Migraine [ICD-11: 8A80] Terminated
	
TTDDRUID	D0G1SM
DRUGNAME	AZD-9335
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Preclinical
	
TTDDRUID	D0G1SN
DRUGNAME	ED1
INDICATI	Acute respiratory distress syndrome [ICD-11: CB00] Investigative
INDICATI	Myocardial reperfusion injury [ICD-11: NB31] Investigative
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D0G1SY
DRUGNAME	INP-05
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0G1TX
DRUGNAME	BA-011
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0G1TY
DRUGNAME	CPG 52364
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D0G1VS
DRUGNAME	UK-78282
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0G1VX
DRUGNAME	BENZYL BENZOATE
INDICATI	Infestations of lice and scabies [ICD-11: 1G00.Z] Approved
	
TTDDRUID	D0G1WC
DRUGNAME	OC-L vaccine
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
	
TTDDRUID	D0G1WL
DRUGNAME	PITAVASTATIN CALCIUM
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Approved
	
TTDDRUID	D0G1WM
DRUGNAME	Influenza A virus H7N1 vaccine
INDICATI	Influenza A virus H7N1 infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D0G1WR
DRUGNAME	DasKloster 0014-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G1WV
DRUGNAME	Thiophanate-methyl
INDICATI	Plant grey mould disease [ICD-11: N.A.] Phase 3
	
TTDDRUID	D0G1YA
DRUGNAME	PF-05212377
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0G1YH
DRUGNAME	ND-201
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0G1YN
DRUGNAME	DPI-3290
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0G1YO
DRUGNAME	GSK1521498
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D0G1YR
DRUGNAME	TRI-1144
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0G1ZU
DRUGNAME	EGFR CART
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
	
TTDDRUID	D0G2AV
DRUGNAME	DRH-12
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0G2CG
DRUGNAME	AL3818
INDICATI	Alveolar soft part sarcoma [ICD-11: 2A60-2C35] Phase 3
INDICATI	Leiomyosarcoma [ICD-11: 2B58] Phase 3
INDICATI	Synovial sarcoma [ICD-11: 2B5A] Phase 3
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 1/2
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1/2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1/2
	
TTDDRUID	D0G2CL
DRUGNAME	AG-2024
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0G2CQ
DRUGNAME	WC-3027
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D0G2DR
DRUGNAME	ANT-G12
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0G2EP
DRUGNAME	Amidine compound 6
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D0G2FV
DRUGNAME	Ultra-rapid insulin
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0G2FY
DRUGNAME	Anti-CCR5 mabs
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0G2GR
DRUGNAME	OP-2507
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D0G2GT
DRUGNAME	SGS-111
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D0G2GZ
DRUGNAME	XGP-120
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0G2IC
DRUGNAME	(S)-FLURBIPROFEN
INDICATI	Myalgia [ICD-11: FB56.2] Preregistration
INDICATI	Scapulohumeral periarthritis [ICD-11: FB53] Preregistration
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Preregistration
	
TTDDRUID	D0G2JZ
DRUGNAME	Bisbenzimide (Hoechst 33258)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0G2KD
DRUGNAME	Iophendylate
INDICATI	Spinal cord injury [ICD-11: ND51.2] Approved
	
TTDDRUID	D0G2LT
DRUGNAME	RGH-1756
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0G2MH
DRUGNAME	Iodohippurate Sodium
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D0G2MR
DRUGNAME	ProstaVac
INDICATI	Prostate hyperplasia [ICD-11: GA90] Phase 3
	
TTDDRUID	D0G2MW
DRUGNAME	Icosapent
INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved
INDICATI	Hyperglyceridemia [ICD-11: 5C80.1] Approved
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 3
	
TTDDRUID	D0G2OZ
DRUGNAME	MORAb-202
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0G2QH
DRUGNAME	AEE-788
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0G2RE
DRUGNAME	BN 50730
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3
	
TTDDRUID	D0G2SZ
DRUGNAME	Piliel
INDICATI	Alopecia [ICD-11: ED70] Discontinued in Phase 3
	
TTDDRUID	D0G2TA
DRUGNAME	Rfsh/rhfsh
INDICATI	Infertility [ICD-11: GB04] Approved
	
TTDDRUID	D0G2UP
DRUGNAME	DF-152
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0G2UY
DRUGNAME	HBF-0259
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D0G2VT
DRUGNAME	SUN-11031
INDICATI	Anorexia nervosa cachexia [ICD-11: 6B80] Terminated
	
TTDDRUID	D0G2XE
DRUGNAME	PMX-53
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D0G2XN
DRUGNAME	S-12968
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 3
	
TTDDRUID	D0G2XR
DRUGNAME	TCD-717
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0G2ZG
DRUGNAME	clindamycin phosphate + benzoyl peroxide
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D0G2ZL
DRUGNAME	Managlinat dialanetil
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0G2ZX
DRUGNAME	Vernakalant IV
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 3
	
TTDDRUID	D0G3AQ
DRUGNAME	Prazepam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0G3AR
DRUGNAME	CX-717
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
	
TTDDRUID	D0G3AT
DRUGNAME	GC813
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0G3BK
DRUGNAME	ZP-2307
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D0G3BN
DRUGNAME	AE-37
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0G3CO
DRUGNAME	NHP-229
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Preclinical
	
TTDDRUID	D0G3DC
DRUGNAME	ASP-1001
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2/3
	
TTDDRUID	D0G3DD
DRUGNAME	CL-H01
INDICATI	Migraine [ICD-11: 8A80] Investigative
	
TTDDRUID	D0G3DL
DRUGNAME	Rifampin
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Approved
	
TTDDRUID	D0G3EC
DRUGNAME	Baquting
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
	
TTDDRUID	D0G3EU
DRUGNAME	AMG-139
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
	
TTDDRUID	D0G3GF
DRUGNAME	AdPEDR
INDICATI	Exudative age-related macular degeneration [ICD-11: 9B78.3Z] Phase 2
	
TTDDRUID	D0G3GR
DRUGNAME	E7/HSP70 DNA vaccine
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
	
TTDDRUID	D0G3KP
DRUGNAME	Carbon nanospheres
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0G3LM
DRUGNAME	Clomethiazole
INDICATI	Stroke [ICD-11: 8B20] Phase 3
	
TTDDRUID	D0G3MH
DRUGNAME	PNU-96391A
INDICATI	Substance use disorder [ICD-11: 6C4Z] Terminated
	
TTDDRUID	D0G3MN
DRUGNAME	GSK2636771
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0G3OF
DRUGNAME	V-073
INDICATI	Enterovirus infection [ICD-11: 1D91] Discontinued in Phase 2
	
TTDDRUID	D0G3OI
DRUGNAME	MK-8237
INDICATI	Allergic asthma [ICD-11: CA23.0] Phase 3
	
TTDDRUID	D0G3PI
DRUGNAME	Alitretinoin
INDICATI	Kaposi sarcoma [ICD-11: 2B57] Approved
	
TTDDRUID	D0G3PK
DRUGNAME	Fsn-0503
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G3QF
DRUGNAME	Epoxyeicosatrienoic acid mimetics
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0G3RW
DRUGNAME	Low toxic paclitaxel derivative
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G3SH
DRUGNAME	Ursodeoxycholic acid
INDICATI	Primary biliary cirrhosis [ICD-11: DB96.1] Approved
	
TTDDRUID	D0G3TJ
DRUGNAME	ASKP-1240
INDICATI	Transplant rejection [ICD-11: NE84] Phase 2
	
TTDDRUID	D0G3UG
DRUGNAME	HG-1429
INDICATI	Bone disease [ICD-11: FC0Z] Investigative
	
TTDDRUID	D0G3UV
DRUGNAME	PMID25666693-Compound-55
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0G3YC
DRUGNAME	Netupitant
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 3
	
TTDDRUID	D0G3ZN
DRUGNAME	PF-00614435
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G3ZX
DRUGNAME	Omri-Hep-B
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	D0G4AE
DRUGNAME	KNX-Monoclonal204
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0G4AJ
DRUGNAME	AGN-208397
INDICATI	Retina venous occlusion [ICD-11: 9B74.1] Phase 1/2
	
TTDDRUID	D0G4AL
DRUGNAME	PA101
INDICATI	Pruritus [ICD-11: EC90] Phase 2
	
TTDDRUID	D0G4BF
DRUGNAME	DTaP-HepB prophylactic vaccine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
	
TTDDRUID	D0G4BI
DRUGNAME	Efinaconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D0G4CF
DRUGNAME	CVT-6883
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0G4CY
DRUGNAME	PA101B
INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Phase 2
	
TTDDRUID	D0G4DE
DRUGNAME	BIA 3-202
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0G4DF
DRUGNAME	AP-1600
INDICATI	Ocular inflammation [ICD-11: 9C61.24] Investigative
	
TTDDRUID	D0G4ES
DRUGNAME	Tetrandrine
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 1
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 3
	
TTDDRUID	D0G4GA
DRUGNAME	TC-6987
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0G4GY
DRUGNAME	Anti-meso-CAR vector transduced T cells
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 1
INDICATI	Malignant mesothelioma [ICD-11: 2C26.0] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0G4ID
DRUGNAME	KUR-024
INDICATI	Bone injury [ICD-11: ND56.Y] Investigative
	
TTDDRUID	D0G4IW
DRUGNAME	CART-19
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1
INDICATI	Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1
	
TTDDRUID	D0G4JB
DRUGNAME	NS-13001
INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative
	
TTDDRUID	D0G4JC
DRUGNAME	ANB-019
INDICATI	Pustular palmoplantar psoriasis [ICD-11: EA90] Phase 2
	
TTDDRUID	D0G4JI
DRUGNAME	Pyruvic acid
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D0G4KD
DRUGNAME	HS-113
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G4KG
DRUGNAME	Khellin
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0G4MB
DRUGNAME	ABT-510
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0G4OD
DRUGNAME	Tigecycline
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Approved
	
TTDDRUID	D0G4OS
DRUGNAME	SII Rmab
INDICATI	Rabies [ICD-11: 1C82] Phase 1
	
TTDDRUID	D0G4OT
DRUGNAME	XL784
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 2
	
TTDDRUID	D0G4QL
DRUGNAME	UNI-rE-4
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0G4RI
DRUGNAME	PF-06664178
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0G4SO
DRUGNAME	SUVN-F90101
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0G4XE
DRUGNAME	Adult stem cell therapy
INDICATI	Stroke [ICD-11: 8B20] Phase 2
INDICATI	Chronic myocardial ischemia [ICD-11: BA6Z] Phase 2
	
TTDDRUID	D0G4YN
DRUGNAME	177 Lu PSMA-617 targeted radioligand therapy
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0G4YR
DRUGNAME	MT-3995
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D0G4YT
DRUGNAME	Liranaftate
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D0G4YZ
DRUGNAME	11C-PBR-28
INDICATI	Brain disease [ICD-11: 8C70-8E61] Phase 2
	
TTDDRUID	D0G5AG
DRUGNAME	Mizoribine
INDICATI	Transplant rejection [ICD-11: NE84] Approved
	
TTDDRUID	D0G5BI
DRUGNAME	Lamivudine /lopinavir/ritonavir fixed-dose combination
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0G5BK
DRUGNAME	Octafluoropropane perflutren lipid microsphere
INDICATI	Heart disease [ICD-11: BA41-BA42] Approved
	
TTDDRUID	D0G5BL
DRUGNAME	RG7880
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1
	
TTDDRUID	D0G5CF
DRUGNAME	Doxercalciferol
INDICATI	Chronic kidney disease [ICD-11: GB61] Approved
	
TTDDRUID	D0G5CV
DRUGNAME	Resorcinol compound 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0G5DK
DRUGNAME	ONO-1301
INDICATI	Angina pectoris [ICD-11: BA40] Preclinical
	
TTDDRUID	D0G5ET
DRUGNAME	Velaglucerase alfa
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Approved
	
TTDDRUID	D0G5FR
DRUGNAME	KST-213
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G5GB
DRUGNAME	MGAH22
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0G5GJ
DRUGNAME	R-68151
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0G5GY
DRUGNAME	Calcifediol
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D0G5HI
DRUGNAME	PF-06678552
INDICATI	Hyperkalemia [ICD-11: 5C76] Phase 1
	
TTDDRUID	D0G5JL
DRUGNAME	Famotidine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0G5JW
DRUGNAME	Erythropoietin
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0G5LY
DRUGNAME	SCP-1
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0G5ME
DRUGNAME	Telcagepant
INDICATI	Cluster headache [ICD-11: 8A81.0] Phase 2
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D0G5ML
DRUGNAME	Donitriptan
INDICATI	Migraine [ICD-11: 8A80] Preclinical
	
TTDDRUID	D0G5OE
DRUGNAME	[131I]-BC8
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D0G5OV
DRUGNAME	WAY-255348
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G5PF
DRUGNAME	AFQ056
INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 2/3
	
TTDDRUID	D0G5QB
DRUGNAME	Alfentanil
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0G5RQ
DRUGNAME	AGX-51
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G5RT
DRUGNAME	MC-113
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0G5SK
DRUGNAME	Anti-CD19 CAR T cells
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 0
	
TTDDRUID	D0G5SU
DRUGNAME	Paquinimod
INDICATI	Lupus [ICD-11: 4A40] Phase 2
	
TTDDRUID	D0G5TF
DRUGNAME	Methylene blue
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0G5TU
DRUGNAME	LESOPITRON DIHYDROCHLORIDE
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
	
TTDDRUID	D0G5UB
DRUGNAME	Amlexanox
INDICATI	Respiratory tract inflammation [ICD-11: CA07] Approved
	
TTDDRUID	D0G5UH
DRUGNAME	ER-21041
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0G5UW
DRUGNAME	Saruplase
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2
	
TTDDRUID	D0G5UZ
DRUGNAME	BVD-CNV
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0G5VT
DRUGNAME	Nazvax-PX
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0G5WV
DRUGNAME	KTE-C19 CAR
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
	
TTDDRUID	D0G5XV
DRUGNAME	Zanubrutinib
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0G5YR
DRUGNAME	SAR-566658
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0G5ZE
DRUGNAME	MDL-28170
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0G5ZL
DRUGNAME	U-93385
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D0G6AB
DRUGNAME	Monocrotaline
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0G6BU
DRUGNAME	4pox
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0G6CF
DRUGNAME	B-701
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 1
	
TTDDRUID	D0G6CH
DRUGNAME	MD-990
INDICATI	Respiratory disease [ICD-11: CB40] Investigative
	
TTDDRUID	D0G6DF
DRUGNAME	HMPL-004
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 3
	
TTDDRUID	D0G6DR
DRUGNAME	Viltolarsen
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Approved
	
TTDDRUID	D0G6EB
DRUGNAME	MDX-1097
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2
	
TTDDRUID	D0G6EI
DRUGNAME	CP-533536
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D0G6EO
DRUGNAME	Hemoximer
INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 3
	
TTDDRUID	D0G6ES
DRUGNAME	TAK-218
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2
	
TTDDRUID	D0G6GB
DRUGNAME	Veglin
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
INDICATI	Kaposi sarcoma [ICD-11: 2B57] Phase 1
	
TTDDRUID	D0G6HA
DRUGNAME	Taliglucerase alfa
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Approved
	
TTDDRUID	D0G6HI
DRUGNAME	Friulimicin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0G6IQ
DRUGNAME	PMID25666693-Compound-143
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0G6JE
DRUGNAME	SCH-C
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0G6JU
DRUGNAME	Ibrutinib
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0G6KH
DRUGNAME	NOX-S91
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G6LR
DRUGNAME	PTI-721
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1
	
TTDDRUID	D0G6NA
DRUGNAME	REN-850
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1
	
TTDDRUID	D0G6OL
DRUGNAME	MVI-118
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0G6PG
DRUGNAME	CPA-926
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0G6PL
DRUGNAME	LG-2293
INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated
	
TTDDRUID	D0G6QF
DRUGNAME	Vandetanib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0G6QV
DRUGNAME	Albaconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2
	
TTDDRUID	D0G6RB
DRUGNAME	Cintredekin besudotox
INDICATI	Brain cancer [ICD-11: 2A00] Phase 3
	
TTDDRUID	D0G6RK
DRUGNAME	ER-23006
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0G6RU
DRUGNAME	NE-1530
INDICATI	Bronchitis [ICD-11: CA20] Discontinued in Phase 1
	
TTDDRUID	D0G6SD
DRUGNAME	Delavirdine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0G6SE
DRUGNAME	ANGIOTENSIN II
INDICATI	Increase blood pressure [ICD-11: BA04] Approved
	
TTDDRUID	D0G6SZ
DRUGNAME	GW873140
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 3
	
TTDDRUID	D0G6TL
DRUGNAME	DiaPep-277
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D0G6TV
DRUGNAME	Recombinant human lubricin
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D0G6TX
DRUGNAME	PYC-38
INDICATI	Respiratory distress syndrome [ICD-11: CB00] Investigative
	
TTDDRUID	D0G6UP
DRUGNAME	YM-75466
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D0G6UQ
DRUGNAME	EP-42675
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0G6US
DRUGNAME	SLV-322
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D0G6VC
DRUGNAME	Cx-501
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2
	
TTDDRUID	D0G6VL
DRUGNAME	Sarpogrelate
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0G6WW
DRUGNAME	Morrhuate sodium
INDICATI	Hemorrhoids [ICD-11: DB60] Approved
	
TTDDRUID	D0G6XC
DRUGNAME	SW-33377
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0G6XU
DRUGNAME	Melatonin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D0G6ZG
DRUGNAME	Amediplase
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 3
	
TTDDRUID	D0G6ZS
DRUGNAME	DTwP-HepB prophylactic vaccine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
	
TTDDRUID	D0G6ZW
DRUGNAME	Panimun Bioral
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 3
	
TTDDRUID	D0G7BR
DRUGNAME	AMAP-102
INDICATI	Arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0G7DJ
DRUGNAME	Etidocaine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0G7DP
DRUGNAME	RP-316
INDICATI	Hemorrhagic shock [ICD-11: MG40.1] Terminated
	
TTDDRUID	D0G7FJ
DRUGNAME	Meloxicam
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0G7HO
DRUGNAME	NS-649
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0G7IF
DRUGNAME	VLX1570
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0G7IV
DRUGNAME	Premarin/Pravachol
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 3
	
TTDDRUID	D0G7IY
DRUGNAME	Cromolyn sodium
INDICATI	Atopic dermatitis [ICD-11: EA80] Approved
	
TTDDRUID	D0G7KE
DRUGNAME	JX-2011
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0G7KJ
DRUGNAME	Diflorasone
INDICATI	Rosacea [ICD-11: ED90.0] Approved
	
TTDDRUID	D0G7KY
DRUGNAME	Imidazopyridazine derivative 5
INDICATI	Pain [ICD-11: MG30-MG3Z] Patented
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D0G7LC
DRUGNAME	PENNVAX-6
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0G7LP
DRUGNAME	Pepticlere
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
	
TTDDRUID	D0G7LT
DRUGNAME	PD-AAV9
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0G7MM
DRUGNAME	TA-8995
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D0G7MV
DRUGNAME	INCB24360
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 3
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D0G7QH
DRUGNAME	NeisVac-C
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved
	
TTDDRUID	D0G7SM
DRUGNAME	AEA-35p
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0G7SP
DRUGNAME	SB-209247
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated
	
TTDDRUID	D0G7SR
DRUGNAME	Zinforo
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0G7UV
DRUGNAME	VI-0134
INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Investigative
	
TTDDRUID	D0G7UX
DRUGNAME	Cyclosporin A
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0G7WY
DRUGNAME	Epanova
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Approved
	
TTDDRUID	D0G7XA
DRUGNAME	NB-002
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2
	
TTDDRUID	D0G7XT
DRUGNAME	Modified PT1.2
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0G7XW
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0G7YF
DRUGNAME	VX-467
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0G7YG
DRUGNAME	ABX-MA1
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 1
	
TTDDRUID	D0G7YS
DRUGNAME	ONYX-015
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
	
TTDDRUID	D0G7YZ
DRUGNAME	BMS-189664
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Terminated
	
TTDDRUID	D0G7ZT
DRUGNAME	Anti-PSCA mab
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0G8BE
DRUGNAME	AMPPL
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0G8BM
DRUGNAME	Fedratinib
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Approved
	
TTDDRUID	D0G8BV
DRUGNAME	Guggulsterone
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
	
TTDDRUID	D0G8CU
DRUGNAME	COTI-2
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 1
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1
	
TTDDRUID	D0G8DV
DRUGNAME	Ad5CMV-NIS
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0G8EI
DRUGNAME	HL-1020
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0G8LH
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 8
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0G8LN
DRUGNAME	ISIS-SGLT2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0G8MW
DRUGNAME	BIOLUP
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative
	
TTDDRUID	D0G8MY
DRUGNAME	SIM-0710
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G8NJ
DRUGNAME	Rescinnamine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0G8NK
DRUGNAME	Axanum
INDICATI	Peptic ulcer [ICD-11: DA61] Phase 3
	
TTDDRUID	D0G8NN
DRUGNAME	Pramipexole
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0G8NP
DRUGNAME	CS-00028
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0G8OB
DRUGNAME	Alpha-arylamino hydroxamic acids
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative
	
TTDDRUID	D0G8OC
DRUGNAME	Dihydrotachysterol
INDICATI	Hypocalcemia [ICD-11: 5B5K.1] Approved
	
TTDDRUID	D0G8PA
DRUGNAME	MK-8228
INDICATI	Cytomegalovirus Disease [ICD-11: 1D82] Approved
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 3
	
TTDDRUID	D0G8QW
DRUGNAME	Delapril
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0G8SQ
DRUGNAME	Levacecarnine hci
INDICATI	Nutritional deficiency [ICD-11: 5B50-5B71] Approved
INDICATI	Cognitive impairment [ICD-11: 6D71] Approved
	
TTDDRUID	D0G8UG
DRUGNAME	Sulukast
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0G8UL
DRUGNAME	Alferminogene tadenovec
INDICATI	Heart disease [ICD-11: BA41-BA42] Phase 3
INDICATI	Angina pectoris [ICD-11: BA40] Phase 3
	
TTDDRUID	D0G8UY
DRUGNAME	PF-04958242
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0G8YJ
DRUGNAME	CD19-TriCAR-T
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0G8ZQ
DRUGNAME	G17DT
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
	
TTDDRUID	D0G9AP
DRUGNAME	E-2011
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0G9AW
DRUGNAME	GS-9973
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2
	
TTDDRUID	D0G9BH
DRUGNAME	PC-8608
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G9CJ
DRUGNAME	X-082-NAB
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative
	
TTDDRUID	D0G9EI
DRUGNAME	Anti-IL-5 Receptor mab
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0G9EX
DRUGNAME	C5aR pepducins
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0G9FF
DRUGNAME	Nucleozin
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0G9FL
DRUGNAME	CT-064
INDICATI	Osteoporosis [ICD-11: FB83.0] NDA filed
	
TTDDRUID	D0G9FP
DRUGNAME	Rofleponide
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2
	
TTDDRUID	D0G9IU
DRUGNAME	Rifapentine
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Approved
INDICATI	Macular degeneration [ICD-11: 9B78.3] Investigative
	
TTDDRUID	D0G9JL
DRUGNAME	MTC-220
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G9JQ
DRUGNAME	PB1046
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
INDICATI	Cardiomyopathy [ICD-11: BC43] Phase 1
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1
	
TTDDRUID	D0G9KS
DRUGNAME	Aryl mannoside derivative 2
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0G9LP
DRUGNAME	Neutralase
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Discontinued in Phase 3
	
TTDDRUID	D0G9MC
DRUGNAME	TLC178
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0G9ME
DRUGNAME	NAX-5055
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Investigative
	
TTDDRUID	D0G9MY
DRUGNAME	CD33-specific gene-engineered T cells
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0G9NN
DRUGNAME	PEV-6A
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0G9OC
DRUGNAME	BMS-PCSK9
INDICATI	Coronary artery disease [ICD-11: BA80] Preclinical
	
TTDDRUID	D0G9OH
DRUGNAME	VVZ-149
INDICATI	Arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0G9PD
DRUGNAME	IChorcumab
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0G9RW
DRUGNAME	TAN-1496
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0G9SD
DRUGNAME	EF-13
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Preregistration
	
TTDDRUID	D0G9SH
DRUGNAME	SA-5845
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 1
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Preclinical
	
TTDDRUID	D0G9UO
DRUGNAME	HTRA-1 mabs
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D0G9XG
DRUGNAME	NBM-HD-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0G9XP
DRUGNAME	LB80380
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2b
	
TTDDRUID	D0G9XS
DRUGNAME	ADS-0101
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0G9YH
DRUGNAME	Amsacrine
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
	
TTDDRUID	D0G9ZJ
DRUGNAME	RG7458
INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 1
	
TTDDRUID	D0G9ZU
DRUGNAME	ESBA-105
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 2
	
TTDDRUID	D0G9ZV
DRUGNAME	BMS-986177
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
	
TTDDRUID	D0G9ZW
DRUGNAME	Roquinimex
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D0G9ZY
DRUGNAME	76Br-16alpha,17alpha-dioxolane progestin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0GA0A
DRUGNAME	Interferon alfacon-1
INDICATI	Hepatitis C [ICD-11: 1E51] Approved
	
TTDDRUID	D0GA1Q
DRUGNAME	H-345/52
INDICATI	Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 2
	
TTDDRUID	D0GA3M
DRUGNAME	BE-16627B
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0GA5T
DRUGNAME	Indiplon
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
INDICATI	Fibromyalgia [ICD-11: MG30.01] Approved
	
TTDDRUID	D0GA7H
DRUGNAME	Grass peptide allergy desensitization agent
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D0GA8I
DRUGNAME	ATLCAR.CD30 cells
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1
INDICATI	Immunoproliferative disorder [ICD-11: 2B32] Phase 1
INDICATI	Lymphatic disease [ICD-11: BD9Z] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0GB2L
DRUGNAME	SNN-0031
INDICATI	Brain injury [ICD-11: NA07.Z] Phase 1/2
	
TTDDRUID	D0GB3A
DRUGNAME	ABT-080
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D0GB3Z
DRUGNAME	Dicoppcopper gluconate + disulfiram
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0GB5X
DRUGNAME	Lulizumab pegol
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D0GB6Y
DRUGNAME	PMID26651364-Compound-10a
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0GB7F
DRUGNAME	ARX-AHD
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0GC2M
DRUGNAME	Acamprosate
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
	
TTDDRUID	D0GC3U
DRUGNAME	CD19-directed CAR-T cells
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0GC5H
DRUGNAME	Ramatroban
INDICATI	Perennial allergic rhinitis [ICD-11: CA08.03] Phase 2/3
	
TTDDRUID	D0GC8F
DRUGNAME	MED-27
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D0GD4Q
DRUGNAME	Patidegib
INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 2
INDICATI	Basal cell nevus syndrome [ICD-11: 2C32] Phase 2
INDICATI	Chondrosarcoma [ICD-11: 2B50] Discontinued in Phase 2
	
TTDDRUID	D0GD6J
DRUGNAME	TDI-0029
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0GD9E
DRUGNAME	GAP T cells
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0GE2F
DRUGNAME	GSK-2485852
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated
	
TTDDRUID	D0GE5B
DRUGNAME	RG-2833
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 1
	
TTDDRUID	D0GE6F
DRUGNAME	Thiazole carboxamide derivative 17
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0GF2R
DRUGNAME	KN035
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Pleomorphic sarcoma [ICD-11: 2B54] Phase 2
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0GG5I
DRUGNAME	Recombinant RGD-hirudin
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2
	
TTDDRUID	D0GG7L
DRUGNAME	BMS-986104
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0GG8N
DRUGNAME	LTX-200
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D0GG9P
DRUGNAME	Balixafortide
INDICATI	Metastatic breast cancer [ICD-11: 2C6Y] Phase 3
	
TTDDRUID	D0GH1C
DRUGNAME	CVT-1
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Terminated
	
TTDDRUID	D0GH3Q
DRUGNAME	ITF2357
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3
INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 2
INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 2
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
	
TTDDRUID	D0GH4B
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 13
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0GH7L
DRUGNAME	PRN1008
INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 2
	
TTDDRUID	D0GH8X
DRUGNAME	Pleo zinc
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0GH9W
DRUGNAME	Heteroaryl-carboxamide derivative 6
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0GH9Z
DRUGNAME	GW-275175
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated
	
TTDDRUID	D0GI6O
DRUGNAME	Iodine-124-labeled F-16 scFv antibody
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0GJ1U
DRUGNAME	C326
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
	
TTDDRUID	D0GJ2G
DRUGNAME	Anti-CD22 CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0GJ7B
DRUGNAME	NELOTANSERIN
INDICATI	Lewy body dementia [ICD-11: 6D82] Phase 2
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Discontinued in Phase 2
	
TTDDRUID	D0GJ7N
DRUGNAME	Demcizumab
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0GJ8R
DRUGNAME	Colestipol
INDICATI	Primary hypercholesterolemia [ICD-11: 5C80.00] Approved
	
TTDDRUID	D0GK1M
DRUGNAME	PNT-400
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0GK4E
DRUGNAME	EMIVIRINE
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0GK9J
DRUGNAME	ACVR2B
INDICATI	Muscle wasting disease [ICD-11: 8E4A.3] Investigative
	
TTDDRUID	D0GL0J
DRUGNAME	TGFTX-2
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0GL0K
DRUGNAME	MRZ-8456
INDICATI	Movement disorder [ICD-11: 8A07-8A0Z] Phase 1
	
TTDDRUID	D0GL0Q
DRUGNAME	ICX-RHY
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2
	
TTDDRUID	D0GL7H
DRUGNAME	Talotrexin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0GL7U
DRUGNAME	Norethindrone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0GL9N
DRUGNAME	Ruconest
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0GM0N
DRUGNAME	ENDG-6010
INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative
	
TTDDRUID	D0GM4S
DRUGNAME	AG-1284
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0GM6E
DRUGNAME	Pegdinetanib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0GM6O
DRUGNAME	Biphenyl mannoside derivative 9
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0GM8E
DRUGNAME	Haemophilus recombinant vaccine
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0GM9E
DRUGNAME	RQ-00310941
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative
	
TTDDRUID	D0GMN2
DRUGNAME	JS004
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0GN7U
DRUGNAME	PMID25553724-Compound-US2011803494010
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented
	
TTDDRUID	D0GN9J
DRUGNAME	Org-6632
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0GNF7
DRUGNAME	OPS-2071
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D0GO0R
DRUGNAME	Padeliporfin di-potassium
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0GO4T
DRUGNAME	IPH4102
INDICATI	T-cell lymphoma [ICD-11: 2A90] Phase 2
	
TTDDRUID	D0GO7W
DRUGNAME	21-AMINOEPOTHILONE B
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0GO9G
DRUGNAME	PC-mab
INDICATI	Artery stenosis [ICD-11: BD52] Investigative
	
TTDDRUID	D0GP0H
DRUGNAME	VGX-100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0GP1O
DRUGNAME	Emixustat
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2/3
INDICATI	Proliferative diabetic retinopathy [ICD-11: 9B71.01] Phase 2
	
TTDDRUID	D0GP4R
DRUGNAME	Picumeterol
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0GP7L
DRUGNAME	PMID26651364-Compound-115
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0GP8N
DRUGNAME	MK-8808
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0GP8P
DRUGNAME	GSK961081
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0GP8Q
DRUGNAME	Risankizumab
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2
	
TTDDRUID	D0GP9Q
DRUGNAME	TG100801
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
	
TTDDRUID	D0GQ7K
DRUGNAME	Mefloquine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0GR0I
DRUGNAME	CD19-targeted allogeneic T-cell therapy
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
	
TTDDRUID	D0GR0T
DRUGNAME	Methadyl Acetate
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Approved
	
TTDDRUID	D0GR1Y
DRUGNAME	Minnelide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0GR2J
DRUGNAME	Idoxifene
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 3
	
TTDDRUID	D0GR3C
DRUGNAME	Biphenyl mannoside derivative 22
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0GR5X
DRUGNAME	Tolamba
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D0GR6I
DRUGNAME	Ganitumab
INDICATI	Ewing sarcoma [ICD-11: 2B52] Clinical trial
	
TTDDRUID	D0GR9H
DRUGNAME	CD22-specific CAR T-cells also expressing an EGFRt
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D0GS2W
DRUGNAME	W-198
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0GS7N
DRUGNAME	L-158809
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0GS9X
DRUGNAME	OMP-21M18
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0GT0Y
DRUGNAME	MN-246
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1
	
TTDDRUID	D0GT3R
DRUGNAME	Anti-CD19 CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0GT4N
DRUGNAME	BRL-55834
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D0GT5W
DRUGNAME	Elbasvir
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0GT8W
DRUGNAME	BMS-587101
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0GT9I
DRUGNAME	Mineral oil
INDICATI	Constipation [ICD-11: DD91.1] Approved
	
TTDDRUID	D0GU1S
DRUGNAME	JNJ-55920839
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D0GU4K
DRUGNAME	Aprepitant
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
INDICATI	Nausea [ICD-11: MD90] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0GU4Z
DRUGNAME	CLP-1004
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D0GU9J
DRUGNAME	Ad2/HIF-1alpha/VP16
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D0GV0H
DRUGNAME	DPS-201
INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative
	
TTDDRUID	D0GV0O
DRUGNAME	Nephesh-1000
INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
	
TTDDRUID	D0GV0Q
DRUGNAME	BMY-43748
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0GV5G
DRUGNAME	PMID25666693-Compound-66
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0GV8J
DRUGNAME	Talazoparib
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3
	
TTDDRUID	D0GV9F
DRUGNAME	Biaryl mannoside derivative 2
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0GW1P
DRUGNAME	Actacel
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Phase 3
	
TTDDRUID	D0GW2L
DRUGNAME	AN-5973
INDICATI	Enterobacteriaceae infection [ICD-11: MG50.C] Investigative
	
TTDDRUID	D0GW3R
DRUGNAME	PAV-612
INDICATI	Rabies [ICD-11: 1C82] Investigative
	
TTDDRUID	D0GW4K
DRUGNAME	Lopinavir + ritonavir + ribavirin + interferon beta-1b
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0GW5H
DRUGNAME	Polyhydroxy benzamide derivative 5
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0GW6K
DRUGNAME	ADX N05
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 3
INDICATI	Excessive daytime sleepiness [ICD-11: MG42] Phase 2
	
TTDDRUID	D0GW8L
DRUGNAME	Pyrrole derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0GW8X
DRUGNAME	GDC-0077
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0GX0I
DRUGNAME	EDI200
INDICATI	X-linked hypophosphataemia [ICD-11: 5C63.22] Phase 2
	
TTDDRUID	D0GX2W
DRUGNAME	Nafithromycin
INDICATI	Community-acquired pneumonia [ICD-11: CA40.Z] Phase 2
	
TTDDRUID	D0GX3L
DRUGNAME	Arbaclofen placarbil
INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 3
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
	
TTDDRUID	D0GX6V
DRUGNAME	Pyrazole derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0GX8F
DRUGNAME	BN-82002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0GY0O
DRUGNAME	BAY-X-7195
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0GY0U
DRUGNAME	MultiGeneAngio cell therapy
INDICATI	Vascular systems peripheral arterial disorder [ICD-11: BD5Z] Phase 1/2
	
TTDDRUID	D0GY1D
DRUGNAME	FP0011
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2
	
TTDDRUID	D0GY1Y
DRUGNAME	CS-8080
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1
	
TTDDRUID	D0GY3R
DRUGNAME	SERMs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0GY4H
DRUGNAME	Taberminogene vadenovec
INDICATI	Vascular restinosis [ICD-11: BE2Z] Phase 3
	
TTDDRUID	D0GY4V
DRUGNAME	TY-11345
INDICATI	Peptic ulcer [ICD-11: DA61] Discontinued in Phase 2
	
TTDDRUID	D0GY5T
DRUGNAME	Tuberculin
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Approved
	
TTDDRUID	D0GY5Z
DRUGNAME	Aspirin
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
	
TTDDRUID	D0GY8G
DRUGNAME	Thiazole carboxamide derivative 19
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0GZ3A
DRUGNAME	L19-TNF-alpha
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D0GZ3J
DRUGNAME	NAMI-A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0GZ4G
DRUGNAME	PMID25666693-Compound-4
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0GZ5F
DRUGNAME	CX-1001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0GZ5M
DRUGNAME	Avobenzone + Ecamsule + Octocrylene
INDICATI	Discovery agent [ICD-11: N.A.] Approved
	
TTDDRUID	D0GZ7B
DRUGNAME	AG490
INDICATI	Multiple myeloma [ICD-11: 2A83] Terminated
INDICATI	Renal transplantation [ICD-11: NE84] Terminated
	
TTDDRUID	D0GZ8Q
DRUGNAME	Toremifene
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0H0AU
DRUGNAME	VER-155008
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H0BF
DRUGNAME	Verdinexor
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0H0BG
DRUGNAME	Sulbactam sodium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0H0BQ
DRUGNAME	NM-IL-12
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
	
TTDDRUID	D0H0CH
DRUGNAME	PMID30107136-Compound-Example54
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0H0EM
DRUGNAME	Dofequidar fumarate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D0H0EP
DRUGNAME	EDP-18
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D0H0EQ
DRUGNAME	Ponatinib
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
	
TTDDRUID	D0H0FX
DRUGNAME	NCX-6560
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D0H0GY
DRUGNAME	HL-001
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0H0HB
DRUGNAME	FAV-201
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Terminated
	
TTDDRUID	D0H0HJ
DRUGNAME	Tranylcypromine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
INDICATI	Prostate cancer [ICD-11: 2C82.0] Patented
	
TTDDRUID	D0H0IA
DRUGNAME	WY-28342
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0H0KA
DRUGNAME	Macbecin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H0KB
DRUGNAME	Riluzole
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Approved
	
TTDDRUID	D0H0KH
DRUGNAME	GS-4059
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0H0KK
DRUGNAME	PD-155080
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0H0LK
DRUGNAME	IC9.GD2.CAR.IL-15 T-cells
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
	
TTDDRUID	D0H0MO
DRUGNAME	1,3,4-oxadiazole derivative 5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0H0ND
DRUGNAME	Simvastatin
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
	
TTDDRUID	D0H0SH
DRUGNAME	ATB-284
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative
	
TTDDRUID	D0H0SJ
DRUGNAME	Neocarzinostatin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0H0SL
DRUGNAME	Hemoglobin glutamer
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved
	
TTDDRUID	D0H0UB
DRUGNAME	Darotropium + 642444
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D0H0UC
DRUGNAME	Resorcinol compound 12
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0H0VB
DRUGNAME	BC-822
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H0VI
DRUGNAME	Neo-GAA
INDICATI	Pompe disease [ICD-11: 5C51.3] Phase 2/3
	
TTDDRUID	D0H0VS
DRUGNAME	SBC-104
INDICATI	Genetic disease [ICD-11: 8E02] Investigative
	
TTDDRUID	D0H0VW
DRUGNAME	Oncolysin S
INDICATI	Nervous system cancer [ICD-11: 2A00] Discontinued in Phase 2
	
TTDDRUID	D0H0WK
DRUGNAME	Gadofosveset
INDICATI	Imaging [ICD-11: QA0B] Approved
	
TTDDRUID	D0H0YD
DRUGNAME	Impoyz
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	D0H0YZ
DRUGNAME	GGF-2
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D0H0ZQ
DRUGNAME	Ad35.CS.01
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2
	
TTDDRUID	D0H0ZU
DRUGNAME	MP-435
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0H0ZV
DRUGNAME	MEDI7814
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0H1AR
DRUGNAME	Methacycline
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0H1AY
DRUGNAME	AQW-051
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0H1BZ
DRUGNAME	Biaryl mannoside derivative 19
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0H1EA
DRUGNAME	TH-302
INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0H1FL
DRUGNAME	PF-514273
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D0H1FN
DRUGNAME	AL-02
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3
	
TTDDRUID	D0H1FV
DRUGNAME	Selfotel
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 3
	
TTDDRUID	D0H1GF
DRUGNAME	Sch-34826
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D0H1GJ
DRUGNAME	Sulfamerazine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0H1IX
DRUGNAME	Pyrazole derivative 5
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0H1JN
DRUGNAME	NsG-0501
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative
	
TTDDRUID	D0H1JS
DRUGNAME	Piperazine urea derivative 3
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D0H1LO
DRUGNAME	Lanthanum carbonate
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Approved
	
TTDDRUID	D0H1MK
DRUGNAME	INN-202
INDICATI	Coeliac disease [ICD-11: DA95] Phase 2
	
TTDDRUID	D0H1MV
DRUGNAME	RLP-068
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D0H1NI
DRUGNAME	PINS
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0H1NL
DRUGNAME	TESAGLITAZAR
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D0H1OO
DRUGNAME	AFT-EPO
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0H1PK
DRUGNAME	MVA-BN
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 3
	
TTDDRUID	D0H1PN
DRUGNAME	ME-3277
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D0H1QY
DRUGNAME	Camphor
INDICATI	Acute or chronic pain [ICD-11: MG30-MG31] Approved
	
TTDDRUID	D0H1TA
DRUGNAME	EK-399
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0H1TG
DRUGNAME	ISIS-CRPRx
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
	
TTDDRUID	D0H1TL
DRUGNAME	ABT-874
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
INDICATI	Crohn disease [ICD-11: DD70] Discontinued in Phase 2
	
TTDDRUID	D0H1UB
DRUGNAME	PanCyte
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0H1UK
DRUGNAME	MK-8591
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0H1UW
DRUGNAME	LATIN T1D
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D0H1UY
DRUGNAME	RQ-00000010
INDICATI	Gastric motility disorder [ICD-11: DA21] Investigative
	
TTDDRUID	D0H1VG
DRUGNAME	DBET6
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0H1WC
DRUGNAME	LY3023414
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0H1WT
DRUGNAME	Anti-SARS-CoV-2 REGN-COV2 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0H1WY
DRUGNAME	Pegademase bovine
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D0H1XL
DRUGNAME	Fc-IFN alpha 2b
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H1YE
DRUGNAME	BE-22179
INDICATI	leukaemia [ICD-11: 2A60-2B33] Terminated
	
TTDDRUID	D0H1YQ
DRUGNAME	Xatral
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved
	
TTDDRUID	D0H1YZ
DRUGNAME	LymPro
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0H2AM
DRUGNAME	XR-3054
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0H2AP
DRUGNAME	EDG-004
INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 3
	
TTDDRUID	D0H2CF
DRUGNAME	Anti-MUC1 mab
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0H2CV
DRUGNAME	SDZ-SCV-106
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D0H2DN
DRUGNAME	DE-310
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0H2DQ
DRUGNAME	Probucol
INDICATI	Coronary artery disease [ICD-11: BA80] Approved
	
TTDDRUID	D0H2DS
DRUGNAME	PTH(7-34) liposomal cream
INDICATI	Alopecia [ICD-11: ED70] Phase 1
	
TTDDRUID	D0H2EM
DRUGNAME	HIV-1 vaccine
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0H2GT
DRUGNAME	Pyrrole derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0H2HZ
DRUGNAME	GSK2646264
INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 1
INDICATI	Urticaria [ICD-11: EB00-EB05] Phase 1
	
TTDDRUID	D0H2IO
DRUGNAME	P32/98
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 2
	
TTDDRUID	D0H2IQ
DRUGNAME	BL-7010
INDICATI	Coeliac disease [ICD-11: DA95] Phase 1/2
	
TTDDRUID	D0H2JP
DRUGNAME	Buprenorphine + naloxone
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Approved
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3
	
TTDDRUID	D0H2JQ
DRUGNAME	NB-506
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0H2JS
DRUGNAME	Tin-117m-labeled annexin
INDICATI	Heart disease [ICD-11: BA41-BA42] Investigative
	
TTDDRUID	D0H2KE
DRUGNAME	LN-040
INDICATI	leukaemia [ICD-11: 2A60-2B33] Terminated
	
TTDDRUID	D0H2KL
DRUGNAME	PMID29338548-Compound-13
INDICATI	Schizophrenia [ICD-11: 6A20] Patented
	
TTDDRUID	D0H2KV
DRUGNAME	ALS 2-0426
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0H2LC
DRUGNAME	Anti-CD30 CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0H2LE
DRUGNAME	Gene therapy, Huntington's disease
INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative
	
TTDDRUID	D0H2LJ
DRUGNAME	TDI-0105
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0H2MA
DRUGNAME	Brilliant Blue G Ophthalmic Solution
INDICATI	Staining [ICD-11: N.A.] Approved
	
TTDDRUID	D0H2MF
DRUGNAME	PF-02367982
INDICATI	Endometriosis [ICD-11: GA10] Investigative
	
TTDDRUID	D0H2MM
DRUGNAME	Influenza H3N2 vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0H2MO
DRUGNAME	Colforsin daropate hci
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0H2NH
DRUGNAME	BRIFENTANIL
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0H2NI
DRUGNAME	YM-543
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0H2QL
DRUGNAME	WRSs2
INDICATI	Shigella infection [ICD-11: 1A02] Phase 1
	
TTDDRUID	D0H2QO
DRUGNAME	Tetrahydrofolic acid
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D0H2RI
DRUGNAME	Fludeoxyglucose F 18
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0H2RJ
DRUGNAME	Clazosentan
INDICATI	Cerebral vasospasm [ICD-11: BA85.Z] Phase 3
INDICATI	Vasospasm [ICD-11: 9B74.0] Discontinued in Phase 3
	
TTDDRUID	D0H2SY
DRUGNAME	Oxybuprocaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0H2UB
DRUGNAME	Suramin
INDICATI	African trypanosomiasis [ICD-11: 1F51] Phase 1
	
TTDDRUID	D0H2UN
DRUGNAME	SC-108
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D0H2UU
DRUGNAME	Entecavir+lamivudine+adefovir
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D0H2VN
DRUGNAME	GRL-11097
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0H2YX
DRUGNAME	Unoprostone isopropyl ester
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D0H2YY
DRUGNAME	JX-929
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0H2ZN
DRUGNAME	ZP-005
INDICATI	Pharyngitis [ICD-11: CA02.Z] Investigative
	
TTDDRUID	D0H2ZQ
DRUGNAME	S-18326
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 1
	
TTDDRUID	D0H2ZW
DRUGNAME	Xipamide
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0H3AB
DRUGNAME	Incobotulinum toxin A
INDICATI	Cervical cancer [ICD-11: 2C77.0] Approved
	
TTDDRUID	D0H3CV
DRUGNAME	Ro-48-8724
INDICATI	Multidrug resistant infection [ICD-11: MG51] Terminated
	
TTDDRUID	D0H3FA
DRUGNAME	BB-101
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0H3FX
DRUGNAME	TGF alpha
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0H3GK
DRUGNAME	Autologous cell based gene therapy
INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 1
	
TTDDRUID	D0H3HB
DRUGNAME	EG-011
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1/2
	
TTDDRUID	D0H3HM
DRUGNAME	Aripiprazole
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
INDICATI	Erythropoietic porphyrias [ICD-11: 5C58.12] Approved
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3
INDICATI	Bipolar disorder [ICD-11: 6A60] Application submitted
	
TTDDRUID	D0H3HV
DRUGNAME	AP-1030
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1/2
	
TTDDRUID	D0H3ID
DRUGNAME	Pfizer 10
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 1
	
TTDDRUID	D0H3JC
DRUGNAME	Ragweed allergy immunotherapy vaccine
INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 1
	
TTDDRUID	D0H3JF
DRUGNAME	VTX-2337
INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2
	
TTDDRUID	D0H3JH
DRUGNAME	CGI-1316
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0H3JR
DRUGNAME	MKC-121
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1
	
TTDDRUID	D0H3KI
DRUGNAME	2-deoxyglucose
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0H3MG
DRUGNAME	Felypressin
INDICATI	Localisation [ICD-11: N.A.] Approved
	
TTDDRUID	D0H3ND
DRUGNAME	AGS62P1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0H3NN
DRUGNAME	Chondrocyte tissue grafts
INDICATI	Back pain [ICD-11: ME84.Z] Phase 3
	
TTDDRUID	D0H3OZ
DRUGNAME	BIM-46187
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H3PC
DRUGNAME	Technetium Tc-99m Polyphosphate Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0H3PV
DRUGNAME	Insulin + pramlintide
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0H3ST
DRUGNAME	AKCEA-ANGPTL3-LRX
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D0H3TD
DRUGNAME	Imipenem
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0H3UO
DRUGNAME	RGD-039
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D0H3UR
DRUGNAME	M3814
INDICATI	Locally advanced rectal cancer [ICD-11: 2B92] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0H3VK
DRUGNAME	BIIB 028
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0H3WI
DRUGNAME	Ribavirin
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved
	
TTDDRUID	D0H3WU
DRUGNAME	Omega-3-acid ethyl esters 90
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved
	
TTDDRUID	D0H3XB
DRUGNAME	TULOPAFANT
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Terminated
	
TTDDRUID	D0H3YC
DRUGNAME	EP-128504
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0H3ZG
DRUGNAME	Six-membered heterocyclic benzamide derivative 2
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0H3ZR
DRUGNAME	CytoGam
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Approved
	
TTDDRUID	D0H4BF
DRUGNAME	NS-11757
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D0H4CB
DRUGNAME	Hemoglobin raffimer
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2/3
	
TTDDRUID	D0H4CL
DRUGNAME	C-linked disaccharide biphenyl mannoside derivative 1
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0H4DR
DRUGNAME	BMS-852927
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1
	
TTDDRUID	D0H4DU
DRUGNAME	KD-7332
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0H4EM
DRUGNAME	Tuberculosis recombinant subunit vaccine
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2
	
TTDDRUID	D0H4GB
DRUGNAME	CB1 antagonist, Bayer
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0H4GE
DRUGNAME	MSI-469
INDICATI	Periodontal disease [ICD-11: DA0C] Terminated
	
TTDDRUID	D0H4GI
DRUGNAME	CEP-5214
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0H4GN
DRUGNAME	Desflurane
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0H4GT
DRUGNAME	131I-radretumab
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D0H4GU
DRUGNAME	EPX-200
INDICATI	Dravet syndrome [ICD-11: 8A61.11] Phase 2
	
TTDDRUID	D0H4IM
DRUGNAME	PH-284
INDICATI	Cachexia [ICD-11: MG20] Phase 2
	
TTDDRUID	D0H4IP
DRUGNAME	SL-052
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0H4IU
DRUGNAME	GPI-16072
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D0H4JM
DRUGNAME	Yohimbine
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved
	
TTDDRUID	D0H4JN
DRUGNAME	RTI-113
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Terminated
	
TTDDRUID	D0H4KF
DRUGNAME	EC-0565
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H4LI
DRUGNAME	H6N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0H4LK
DRUGNAME	Thiazoline derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0H4NN
DRUGNAME	NB3322
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0H4NQ
DRUGNAME	AWD-5239
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D0H4RV
DRUGNAME	NDC-1022
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H4SE
DRUGNAME	Benzothiazine-carboxamide compound 6
INDICATI	Skin inflammation [ICD-11: EF20.Y] Patented
	
TTDDRUID	D0H4TC
DRUGNAME	Davalintide
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
	
TTDDRUID	D0H4TP
DRUGNAME	GSK189254A
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D0H4TQ
DRUGNAME	Thyrotropin Alfa
INDICATI	Thyroid cancer [ICD-11: 2D10] Approved
	
TTDDRUID	D0H4TR
DRUGNAME	PMID25666693-Compound-80
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0H4TT
DRUGNAME	Sanglifehrin A
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0H4UJ
DRUGNAME	INOGATRAN
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2
	
TTDDRUID	D0H4UP
DRUGNAME	CAR-GPC3 T Cells
INDICATI	Lung squamous cell carcinoma [ICD-11: 2C25.2] Phase 1
	
TTDDRUID	D0H4XV
DRUGNAME	IM0-8400
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Discontinued in Phase 1/2
	
TTDDRUID	D0H4YD
DRUGNAME	AMG520
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3
	
TTDDRUID	D0H4YL
DRUGNAME	Afluria Quadrivalent
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0H4ZD
DRUGNAME	GPI-2A
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0H5BC
DRUGNAME	Tosagestin
INDICATI	Contraception [ICD-11: QA21] Phase 2
	
TTDDRUID	D0H5CD
DRUGNAME	GI-129471
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0H5CV
DRUGNAME	ZK-119010
INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0H5DM
DRUGNAME	Viaskin Milk
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D0H5DU
DRUGNAME	Oxyphencyclimine
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D0H5ER
DRUGNAME	MLN-591RL
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0H5ES
DRUGNAME	Rontalizumab
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D0H5FW
DRUGNAME	PUR-118
INDICATI	Respiratory disease [ICD-11: CB40] Phase 1
	
TTDDRUID	D0H5GU
DRUGNAME	GlucoStem
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0H5HJ
DRUGNAME	ALN-PCS
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Preclinical
	
TTDDRUID	D0H5HS
DRUGNAME	HS-1183
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H5HT
DRUGNAME	PCAP-1
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0H5HZ
DRUGNAME	Etamicastat
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D0H5IZ
DRUGNAME	Etirinotecan pegol
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D0H5JW
DRUGNAME	[3H](R)-(-)-baclofen
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
	
TTDDRUID	D0H5KA
DRUGNAME	VRC-HIVDNA016-00-VP
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0H5KG
DRUGNAME	AR-9273
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0H5KK
DRUGNAME	Garnocestim
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Discontinued in Phase 1
	
TTDDRUID	D0H5KO
DRUGNAME	KW-3635
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D0H5LC
DRUGNAME	CHPMPC
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1
	
TTDDRUID	D0H5LK
DRUGNAME	Dapoxetine
INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Phase 4
	
TTDDRUID	D0H5LY
DRUGNAME	STNM-04
INDICATI	Liver cirrhosis [ICD-11: DB93.1] Investigative
	
TTDDRUID	D0H5MB
DRUGNAME	Bopindolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0H5MS
DRUGNAME	CT84.66
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D0H5MW
DRUGNAME	PHN-021
INDICATI	Motion sickness [ICD-11: NF08.3] Phase 2
	
TTDDRUID	D0H5MX
DRUGNAME	TAFA-93
INDICATI	Transplant rejection [ICD-11: NE84] Discontinued in Phase 1
	
TTDDRUID	D0H5NF
DRUGNAME	IFN-beta-CTP
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0H5NX
DRUGNAME	TOP-53
INDICATI	Metastatic lung cancer [ICD-11: 2D70] Discontinued in Phase 1
	
TTDDRUID	D0H5OX
DRUGNAME	HAL-MPE1
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1
	
TTDDRUID	D0H5PD
DRUGNAME	CP-0597
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0H5PG
DRUGNAME	CGS-22652
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1
	
TTDDRUID	D0H5TU
DRUGNAME	RQ-00000008
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0H5WM
DRUGNAME	S-0509
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
	
TTDDRUID	D0H5XB
DRUGNAME	Asparaginase Erwinia chrysanthemi
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
	
TTDDRUID	D0H5ZS
DRUGNAME	C31510
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1
INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 1
	
TTDDRUID	D0H6AF
DRUGNAME	Thiazole carboxamide derivative 4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0H6AG
DRUGNAME	PMID23981898C11d 
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Clinical trial
	
TTDDRUID	D0H6AL
DRUGNAME	1,3,4-oxadiazole derivative 4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0H6AT
DRUGNAME	SYM-005
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H6BL
DRUGNAME	APL-001
INDICATI	Leukopenia [ICD-11: 4B00.0Z] Investigative
	
TTDDRUID	D0H6BS
DRUGNAME	Rydaptmidostaurin
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	D0H6CA
DRUGNAME	Lenercept
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3
	
TTDDRUID	D0H6CX
DRUGNAME	PMID25666693-Compound-72
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0H6EF
DRUGNAME	MVA-BN HIV Multiantigen
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0H6FY
DRUGNAME	Natural killer cell therapy
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0H6IG
DRUGNAME	EP-400
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H6LE
DRUGNAME	LP-20104
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H6PH
DRUGNAME	GSK-2231260A
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0H6PK
DRUGNAME	FKF02SC
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0H6PN
DRUGNAME	LORECLEZOLE
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 2
	
TTDDRUID	D0H6PX
DRUGNAME	TAK-603
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
	
TTDDRUID	D0H6QD
DRUGNAME	Eptinezumab
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0H6QU
DRUGNAME	Apomorphine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
INDICATI	Idiopathic parkinson disease [ICD-11: 8A00.0Z] Phase 3
INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Phase 2
	
TTDDRUID	D0H6SH
DRUGNAME	MT203
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	D0H6TP
DRUGNAME	Monobenzone
INDICATI	Vitiligo [ICD-11: ED63.0] Approved
	
TTDDRUID	D0H6UK
DRUGNAME	HOO-IFOS
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H6UL
DRUGNAME	ICON-1
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0H6VG
DRUGNAME	KF-15766
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D0H6VL
DRUGNAME	NCL-00016149
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H6VY
DRUGNAME	SM-101
INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Approved (orphan drug)
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Preclinical
	
TTDDRUID	D0H6VZ
DRUGNAME	REV-576
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0H6YK
DRUGNAME	MK-3614
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D0H6ZA
DRUGNAME	Pritumumab
INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0H7AC
DRUGNAME	PF-03814735
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0H7AM
DRUGNAME	MEDI1873
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0H7AR
DRUGNAME	MK-51
INDICATI	Dermatological disease [ICD-11: DA24.Y] Phase 1
	
TTDDRUID	D0H7AV
DRUGNAME	Pilsicainide
INDICATI	Heart arrhythmia [ICD-11: BC65] Approved
	
TTDDRUID	D0H7AZ
DRUGNAME	Aminocandin
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D0H7BF
DRUGNAME	H3B-8800
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1
	
TTDDRUID	D0H7DM
DRUGNAME	IMX-110
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0H7FW
DRUGNAME	YF-476
INDICATI	Stomach ulcer [ICD-11: DA60.Z] Phase 2
	
TTDDRUID	D0H7GH
DRUGNAME	ETH615
INDICATI	Dermatitis [ICD-11: EA80-EA89] Discontinued in Phase 2
	
TTDDRUID	D0H7GQ
DRUGNAME	NS 1209
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
	
TTDDRUID	D0H7HR
DRUGNAME	Apilimod
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Preclinical
	
TTDDRUID	D0H7JC
DRUGNAME	GL-2045
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0H7JE
DRUGNAME	RS-100302
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D0H7KF
DRUGNAME	Quetiapine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 3
	
TTDDRUID	D0H7KQ
DRUGNAME	ABBV-8E12
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 2
	
TTDDRUID	D0H7LN
DRUGNAME	Lx-TB-PstS1
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
	
TTDDRUID	D0H7MB
DRUGNAME	Nextomabs
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0H7OO
DRUGNAME	PDS-0102
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0H7PS
DRUGNAME	MCT-175
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0H7PW
DRUGNAME	PIPERINE
INDICATI	Vitiligo [ICD-11: ED63.0] Phase 1/2
	
TTDDRUID	D0H7QU
DRUGNAME	BMS 791325
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0H7SG
DRUGNAME	PV-327
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D0H7SO
DRUGNAME	Heteroaryl-carboxamide derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0H7TB
DRUGNAME	18F labeled ethanolamine derivative
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H7TD
DRUGNAME	CK-2018509
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0H7TS
DRUGNAME	Mesenchymal stem cell therapy
INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 2
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
	
TTDDRUID	D0H7UR
DRUGNAME	Mannoside derivative 11
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0H7WA
DRUGNAME	FCP-3P1
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2
	
TTDDRUID	D0H7XJ
DRUGNAME	ASP-9521
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0H7XL
DRUGNAME	OSI-027
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D0H7YU
DRUGNAME	AviFlu
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0H7ZB
DRUGNAME	SX-013
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D0H7ZN
DRUGNAME	VM-206
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0H8BD
DRUGNAME	PMA-101R
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0H8DS
DRUGNAME	Tumor infiltrating lymphocyte
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0H8FH
DRUGNAME	Indapamide
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0H8FY
DRUGNAME	Firategrast
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0H8GW
DRUGNAME	PS-938285
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0H8JM
DRUGNAME	VT-214
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0H8MH
DRUGNAME	HGH-CTP
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 3
	
TTDDRUID	D0H8MR
DRUGNAME	CAT-1902
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0H8OA
DRUGNAME	MK-5442
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D0H8OH
DRUGNAME	Palovarotene
INDICATI	Fibrodysplasia ossificans progressiva [ICD-11: FB31.1] Phase 3
INDICATI	Emphysema [ICD-11: CA21] Phase 2
	
TTDDRUID	D0H8PX
DRUGNAME	MORAb-066
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0H8QL
DRUGNAME	Mazindol
INDICATI	Obesity [ICD-11: 5B81] Approved
	
TTDDRUID	D0H8UT
DRUGNAME	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 0
	
TTDDRUID	D0H8VM
DRUGNAME	UAI-201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H8VY
DRUGNAME	BMS-201038
INDICATI	Familial hypercholesterolemia [ICD-11: 5C80.00] Approved
	
TTDDRUID	D0H8WF
DRUGNAME	Glucagon recombinant
INDICATI	Hypoglycemia [ICD-11: 5A41] Approved
	
TTDDRUID	D0H8WX
DRUGNAME	RSV/PIV-3 vaccine
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1
	
TTDDRUID	D0H8WZ
DRUGNAME	SR-43845
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
	
TTDDRUID	D0H8XB
DRUGNAME	Lancovutide
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0H8ZI
DRUGNAME	PDS-0101
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 1
	
TTDDRUID	D0H8ZY
DRUGNAME	HEPLISAV-B
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Application submitted
	
TTDDRUID	D0H9AJ
DRUGNAME	MDL-28170
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0H9DA
DRUGNAME	AZD6738
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0H9DE
DRUGNAME	CS-722
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2
	
TTDDRUID	D0H9FR
DRUGNAME	PRN1371
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0H9FX
DRUGNAME	HCV-371
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1
	
TTDDRUID	D0H9GH
DRUGNAME	31.1Chi
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H9GQ
DRUGNAME	DOV-216303
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
	
TTDDRUID	D0H9HO
DRUGNAME	ONO-5334
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0H9HT
DRUGNAME	TAK-701
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0H9KW
DRUGNAME	Filaminast
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D0H9MA
DRUGNAME	COR-1
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D0H9MR
DRUGNAME	MP-PN-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0H9OT
DRUGNAME	PfAMA-1
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	D0H9PT
DRUGNAME	RG3638
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
	
TTDDRUID	D0H9QC
DRUGNAME	S-474474
INDICATI	Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 3
	
TTDDRUID	D0H9QN
DRUGNAME	AZ-TAK1
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Investigative
	
TTDDRUID	D0H9QX
DRUGNAME	FM-TP4000
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D0H9RD
DRUGNAME	DZ-2640
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0H9RN
DRUGNAME	NU-172
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2
	
TTDDRUID	D0H9SD
DRUGNAME	PMID30280939-Compound-WO2013148426
INDICATI	Malaria [ICD-11: 1F40-1F45] Patented
	
TTDDRUID	D0H9SF
DRUGNAME	A-76202M
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Terminated
	
TTDDRUID	D0H9SX
DRUGNAME	Daporinad
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D0H9VP
DRUGNAME	MP-4-CO
INDICATI	Sickle-cell anaemia [ICD-11: 3A51] Phase 2
	
TTDDRUID	D0H9WO
DRUGNAME	Gantofiban
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2
	
TTDDRUID	D0H9WR
DRUGNAME	LX-1031
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
	
TTDDRUID	D0H9WY
DRUGNAME	PAZ-320
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0H9XR
DRUGNAME	SC-435
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D0H9YO
DRUGNAME	FLUASTERONE
INDICATI	Arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0H9ZQ
DRUGNAME	Dexpanthenol
INDICATI	Wound healing [ICD-11: EL8Y] Approved
	
TTDDRUID	D0HA2R
DRUGNAME	BBT-012
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0HA7E
DRUGNAME	TD-Pur
INDICATI	Diphtheria [ICD-11: 1C17] Approved
	
TTDDRUID	D0HB0V
DRUGNAME	JX-594
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D0HB2F
DRUGNAME	ABD-035
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0HB4E
DRUGNAME	INCB47986
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0HB5V
DRUGNAME	CN-2097
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0HC9K
DRUGNAME	PMID30107136-Compound-Example41
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0HD0G
DRUGNAME	SB3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Application submitted
	
TTDDRUID	D0HD6C
DRUGNAME	Tetra-hydro-1H-1,2,6-triazaazulene derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0HD7C
DRUGNAME	PPA-904
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0HD7S
DRUGNAME	Pyrrole derivative 6
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0HD8X
DRUGNAME	ISF35
INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
	
TTDDRUID	D0HD9K
DRUGNAME	Acebutolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0HE0Y
DRUGNAME	Amifampridine
INDICATI	LambertEaton myasthenic syndrome [ICD-11: 8C62] Approved
	
TTDDRUID	D0HE1P
DRUGNAME	BAY 60-6583
INDICATI	Myocardial ischemia [ICD-11: BA6Z] Preclinical
	
TTDDRUID	D0HE3B
DRUGNAME	Biphenyl mannoside derivative 18
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0HE7C
DRUGNAME	ORIC-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0HE7I
DRUGNAME	H1N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0HE7X
DRUGNAME	PMID25666693-Compound-11
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0HE8M
DRUGNAME	1,2,4-oxadiazole derivative 5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0HE9J
DRUGNAME	APN-201
INDICATI	Dermatitis [ICD-11: EA80-EA89] Phase 1/2
	
TTDDRUID	D0HF0W
DRUGNAME	Levopropoxyphene Napsylate Anhydrous
INDICATI	Cough [ICD-11: MD12] Approved
	
TTDDRUID	D0HF1A
DRUGNAME	Bicyclic heteroaryl benzamide derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0HF2D
DRUGNAME	PBF-1129
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0HF7V
DRUGNAME	Peptide analog 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0HFJ8
DRUGNAME	PfSPZ vaccine
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D0HG5M
DRUGNAME	Apratastat
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0HG9P
DRUGNAME	VentaProst
INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 2
	
TTDDRUID	D0HH0G
DRUGNAME	ABT-767
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0HH0U
DRUGNAME	S-488410
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2
	
TTDDRUID	D0HH2I
DRUGNAME	CV-9103
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0HH3W
DRUGNAME	VBY-825
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0HH4L
DRUGNAME	Thiazolidine derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0HH9P
DRUGNAME	NCE-401
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D0HI0L
DRUGNAME	HSV-1716
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0HI1K
DRUGNAME	GSK618334
INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Phase 1
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D0HI1T
DRUGNAME	SAR440181
INDICATI	Acute heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D0HI5D
DRUGNAME	Naxitamab
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Approved
INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 2
	
TTDDRUID	D0HI8X
DRUGNAME	Heterocyclic derivative 13
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0HJ1R
DRUGNAME	INCB54707
INDICATI	Hidradenitis suppurativa [ICD-11: ED92.0] Phase 2
	
TTDDRUID	D0HJ1Y
DRUGNAME	BW B70C
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0HJ5H
DRUGNAME	BGC-20-1531
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D0HJ5Y
DRUGNAME	ChronsVax
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
	
TTDDRUID	D0HJ7I
DRUGNAME	DA-727
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D0HJ9U
DRUGNAME	LAU-0901
INDICATI	Brain ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0HK3N
DRUGNAME	Belnacasan
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
	
TTDDRUID	D0HK3U
DRUGNAME	AM-156
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative
	
TTDDRUID	D0HK3X
DRUGNAME	ASF-1057
INDICATI	Erythema [ICD-11: ME64.0] Phase 3
	
TTDDRUID	D0HK7G
DRUGNAME	DBT-1339
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0HK7R
DRUGNAME	Midafotel
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3
	
TTDDRUID	D0HL1X
DRUGNAME	ISIS-PKK
INDICATI	Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3
	
TTDDRUID	D0HL5N
DRUGNAME	Trastuzumab duocarmazine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0HM1S
DRUGNAME	FP-0230
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0HM1V
DRUGNAME	KYMRIAH
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
	
TTDDRUID	D0HM2S
DRUGNAME	BTI-320
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0HM5J
DRUGNAME	Brensocatib
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Preclinical
	
TTDDRUID	D0HM5L
DRUGNAME	Breast cancer vaccine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0HM5Q
DRUGNAME	ND-AMB
INDICATI	Leishmania infection [ICD-11: 1F54.0] Investigative
	
TTDDRUID	D0HM6B
DRUGNAME	T-121
INDICATI	Complex regional pain syndrome [ICD-11: 8D8A.0] Phase 3
	
TTDDRUID	D0HM7G
DRUGNAME	SUVN-G1031
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D0HN6Q
DRUGNAME	RG-7348
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0HN6X
DRUGNAME	SKYFlu
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0HN7B
DRUGNAME	COR-001
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D0HN7I
DRUGNAME	Alacizumab pegol
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0HN8P
DRUGNAME	Leronlimab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0HO0I
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 12
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0HO1A
DRUGNAME	CD19 CAR Gene Transduced T Lymphocytes
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0HO2T
DRUGNAME	AZD7325
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0HO9M
DRUGNAME	AV-2
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D0HP3M
DRUGNAME	BILD-1263
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Terminated
	
TTDDRUID	D0HP8K
DRUGNAME	Thiazole carboxamide derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0HP8Q
DRUGNAME	SAR339375
INDICATI	Syndromic genetic deafness [ICD-11: LD2H] Phase 1
	
TTDDRUID	D0HQ1W
DRUGNAME	SKF-96365
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D0HQ3A
DRUGNAME	ELGODIPINE HYDROCHLORIDE
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3
	
TTDDRUID	D0HQ6N
DRUGNAME	Benztropine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0HR5B
DRUGNAME	Apabetalone
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0HR5H
DRUGNAME	Ambroxol
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0HR5Q
DRUGNAME	CIP-137401
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0HR7P
DRUGNAME	Amonafide
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0HR7X
DRUGNAME	Riboflavin; ultraviolet-A (UVA) irradiation
INDICATI	Keratoconus [ICD-11: 9A78.50] Application submitted
INDICATI	Corneal deformity [ICD-11: 9A78.5] Application submitted
	
TTDDRUID	D0HR7Z
DRUGNAME	PF-05280014
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0HR8Z
DRUGNAME	Miglustat
INDICATI	Type 1 gaucher disease [ICD-11: 5C56.0Y] Approved
	
TTDDRUID	D0HS1D
DRUGNAME	PMID25666693-Compound-20
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0HS2E
DRUGNAME	Rx-04
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0HS3X
DRUGNAME	BCH-2051
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0HS4F
DRUGNAME	Oxytocin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0HS5V
DRUGNAME	Brivanib
INDICATI	Liver cancer [ICD-11: 2C12] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0HS9Y
DRUGNAME	CTCE-0501
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0HT2X
DRUGNAME	CNT0-1959
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0HT4H
DRUGNAME	SOM-0009
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0HT4Y
DRUGNAME	CC-92480
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0HU0A
DRUGNAME	TK216
INDICATI	Ewing sarcoma [ICD-11: 2B52] Phase 1
	
TTDDRUID	D0HU0W
DRUGNAME	Temocillin disodium
INDICATI	Sepsis [ICD-11: 1G40-1G41] Approved
	
TTDDRUID	D0HU9H
DRUGNAME	Panitumumab
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
	
TTDDRUID	D0HV4B
DRUGNAME	ADCT-402
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Burkitt cell leukaemia [ICD-11: 2A85.6] Phase 1
	
TTDDRUID	D0HV6O
DRUGNAME	AP-23588
INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated
	
TTDDRUID	D0HV6R
DRUGNAME	Mycophenolate mofetil
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0HV6X
DRUGNAME	TRK-130
INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2
	
TTDDRUID	D0HV7A
DRUGNAME	Lintuzumab Ac-225
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0HV7K
DRUGNAME	Melacine
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D0HW1I
DRUGNAME	PAN-622-toxin conjugate
INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Investigative
	
TTDDRUID	D0HW1L
DRUGNAME	HPN536
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0HX0P
DRUGNAME	INP-06
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0HX1T
DRUGNAME	DA-697b
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0HY3D
DRUGNAME	SY-1425
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D0HY3P
DRUGNAME	SGN-10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0HY4Q
DRUGNAME	98mTc-CIM-ANT
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Investigative
	
TTDDRUID	D0HY5G
DRUGNAME	COVID-19 S-Trimer vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0HY9S
DRUGNAME	BOS172722
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0HZ1V
DRUGNAME	KDM-1001
INDICATI	Gastritis [ICD-11: DA42] Investigative
	
TTDDRUID	D0HZ2A
DRUGNAME	Recombinant factor VIIa PEGylated liposomal
INDICATI	Factor VII deficiency [ICD-11: 3B14] Phase 1/2
	
TTDDRUID	D0HZ2E
DRUGNAME	M100907
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 3
	
TTDDRUID	D0HZ4C
DRUGNAME	AvidinOx
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0HZ8B
DRUGNAME	Brilacidin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0I0AW
DRUGNAME	elbasvir + grazoprevir
INDICATI	HCV-1 and HCV-4 infection [ICD-11: 1E51] Approved
	
TTDDRUID	D0I0BJ
DRUGNAME	Recombinant interleukin-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I0DL
DRUGNAME	Alpha 1-PI
INDICATI	Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Approved
INDICATI	Cancer related pain [ICD-11: MG30] Withdrawn from market
	
TTDDRUID	D0I0DQ
DRUGNAME	Glisolamide
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0I0DS
DRUGNAME	Theobromine
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0I0EG
DRUGNAME	Captopril
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0I0FA
DRUGNAME	JCAR020
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D0I0GM
DRUGNAME	Daxalipram
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2
	
TTDDRUID	D0I0JE
DRUGNAME	1,3,4-thiadiazole derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0I0JG
DRUGNAME	[3H]fenobam
INDICATI	Allodynia [ICD-11: MB40.1] Phase 1
	
TTDDRUID	D0I0KP
DRUGNAME	ISC-hpNSC
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2
	
TTDDRUID	D0I0LP
DRUGNAME	Parvovirus B19 vaccine
INDICATI	Parvovirus infection [ICD-11: 1D93] Phase 1/2
	
TTDDRUID	D0I0NJ
DRUGNAME	CART-19 cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1
	
TTDDRUID	D0I0NP
DRUGNAME	SL125
INDICATI	Hyperaldosteronism [ICD-11: 5A72] Investigative
INDICATI	Myocardial fibrosis [ICD-11: BC43.20] Investigative
INDICATI	Congestive heart failure [ICD-11: BD10] Investigative
	
TTDDRUID	D0I0NU
DRUGNAME	NKP-2235
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0I0RB
DRUGNAME	Nadifloxacin
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D0I0RF
DRUGNAME	BVT-142
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D0I0RJ
DRUGNAME	Amiloride
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0I0SG
DRUGNAME	CLVax 1.0
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0I0SH
DRUGNAME	KY-021
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0I0SY
DRUGNAME	MEDI-542
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0I0TB
DRUGNAME	Emodin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0I0TD
DRUGNAME	AZM-134
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D0I0UE
DRUGNAME	Lexipafant
INDICATI	Nerve injury [ICD-11: ND56.4] Phase 2
INDICATI	Hepatovirus infection [ICD-11: 1E51] Investigative
	
TTDDRUID	D0I0UM
DRUGNAME	CTL019
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial
	
TTDDRUID	D0I0VI
DRUGNAME	Albumin Human
INDICATI	Hypoalbuminemia [ICD-11: 5C53.2] Approved
	
TTDDRUID	D0I0VJ
DRUGNAME	Pyrazole derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0I0VY
DRUGNAME	DA-7101
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Discontinued in Phase 3
	
TTDDRUID	D0I0XF
DRUGNAME	IMO-8400
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
INDICATI	Waldenstrom macroglobulinemia [ICD-11: 2A85.4] Phase 1/2
	
TTDDRUID	D0I0XX
DRUGNAME	P2B-003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I0YS
DRUGNAME	TTP-4000
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0I0ZO
DRUGNAME	Anti-CD45 mabs
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0I0ZP
DRUGNAME	Glyminox
INDICATI	Sexually transmitted infection [ICD-11: 1A9Z] Phase 3
	
TTDDRUID	D0I0ZY
DRUGNAME	ETN-001
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0I1BQ
DRUGNAME	IL-18BP
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Discontinued in Phase 1
	
TTDDRUID	D0I1BX
DRUGNAME	CGS-32359
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0I1CQ
DRUGNAME	BIIB067
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3
	
TTDDRUID	D0I1DH
DRUGNAME	Technetium Tc-99m Mertiatide Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0I1DW
DRUGNAME	Edotecarin
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
	
TTDDRUID	D0I1DZ
DRUGNAME	DE-110
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 2
	
TTDDRUID	D0I1EX
DRUGNAME	DTI-0009
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2
	
TTDDRUID	D0I1FQ
DRUGNAME	Raltegravir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0I1FT
DRUGNAME	Lexgenleucel-T
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0I1FU
DRUGNAME	GSK2830930A
INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2
	
TTDDRUID	D0I1HM
DRUGNAME	CM-182
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0I1JG
DRUGNAME	ES-1
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D0I1KL
DRUGNAME	ACT-2
INDICATI	Wound healing [ICD-11: EL8Y] Phase 3
	
TTDDRUID	D0I1LH
DRUGNAME	Aldosterone
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0I1ML
DRUGNAME	AZD1222 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0I1OS
DRUGNAME	E-2212
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0I1OX
DRUGNAME	SPL-2101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I1PF
DRUGNAME	LCAR-B4822M CAR-T Cell
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0I1PS
DRUGNAME	Dasatinib
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0I1PY
DRUGNAME	Insulin Susp Protamine Zinc Beef/Pork
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0I1QI
DRUGNAME	Ganetespib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D0I1QJ
DRUGNAME	KP-100
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	D0I1SK
DRUGNAME	Isosorbide Dinitrate
INDICATI	Anal fissure [ICD-11: DB50.0] Approved
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D0I1TM
DRUGNAME	FP-1102
INDICATI	Vascular disease [ICD-11: BE2Z] Investigative
	
TTDDRUID	D0I1VK
DRUGNAME	Heterocyclic-substituted 3-alkyl azetidine derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0I1XE
DRUGNAME	Diphenyl purine derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0I1XG
DRUGNAME	Salmon Calcitonin
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D0I1YQ
DRUGNAME	Pyrazolopyridines and imidazopyridine derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0I1ZB
DRUGNAME	ENDG-4010
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I1ZT
DRUGNAME	ETV-002
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0I1ZY
DRUGNAME	Tralokinumab
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3
INDICATI	Asthma [ICD-11: CA23] Phase 1/2
	
TTDDRUID	D0I2AD
DRUGNAME	SF-113
INDICATI	Retinopathy [ICD-11: 9B71] Investigative
	
TTDDRUID	D0I2AV
DRUGNAME	Tositumomab
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved
	
TTDDRUID	D0I2FI
DRUGNAME	dequalinium
INDICATI	Myelopathy [ICD-11: 8B42] Clinical trial
	
TTDDRUID	D0I2GS
DRUGNAME	Contezolid
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Phase 2
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2
	
TTDDRUID	D0I2GT
DRUGNAME	TMX-30X
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0I2HL
DRUGNAME	NLC-002
INDICATI	Obesity [ICD-11: 5B81] Terminated
	
TTDDRUID	D0I2HV
DRUGNAME	PF-05402536
INDICATI	Smoking dependence [ICD-11: 6C4A.2] Phase 1
	
TTDDRUID	D0I2IY
DRUGNAME	ABT-700
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0I2JY
DRUGNAME	R-1206
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0I2KE
DRUGNAME	MK-7684
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0I2KZ
DRUGNAME	PC-2000
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D0I2LX
DRUGNAME	RMG-40083
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0I2MA
DRUGNAME	IO-21
INDICATI	Ulcer [ICD-11: CA02-CB40] Discontinued in Phase 2
	
TTDDRUID	D0I2MD
DRUGNAME	RL-6A
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0I2MK
DRUGNAME	Metoprolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0I2MR
DRUGNAME	PMID26651364-Compound-9f
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0I2NF
DRUGNAME	Intragam P
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D0I2OO
DRUGNAME	PMID28270021-Compound-WO2013161919Example85-117
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0I2OP
DRUGNAME	Belaperidone
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0I2PS
DRUGNAME	CMET Avimer polypeptides
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I2RB
DRUGNAME	ONO-4641
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0I2RS
DRUGNAME	PMID26936077-Compound-34
INDICATI	Type-2 diabetes [ICD-11: 5A11] Patented
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Patented
INDICATI	Gastric ulcer [ICD-11: DA60] Patented
	
TTDDRUID	D0I2SD
DRUGNAME	Medroxyprogesterone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0I2TT
DRUGNAME	RMH-41
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0I2VK
DRUGNAME	Isocarboxazid
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0I2VR
DRUGNAME	Choline magnesium trisalicylate
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
	
TTDDRUID	D0I2VT
DRUGNAME	ND7001
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 1
	
TTDDRUID	D0I2VW
DRUGNAME	GSK2838232
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0I2WV
DRUGNAME	Levamlodipine
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 4
	
TTDDRUID	D0I2XM
DRUGNAME	L-796568
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D0I2YV
DRUGNAME	BIBB-515
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0I3AS
DRUGNAME	CD-2475/101
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0I3BB
DRUGNAME	KW-7158
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2
	
TTDDRUID	D0I3BS
DRUGNAME	KRL-401
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1
	
TTDDRUID	D0I3CP
DRUGNAME	SDX-7400
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I3CV
DRUGNAME	L-695256
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0I3EI
DRUGNAME	NK-1001
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Discontinued in Phase 2
	
TTDDRUID	D0I3GT
DRUGNAME	Live attenuated recombinant vaccine
INDICATI	Chikungunya virus infection [ICD-11: 1D40] Phase 2
	
TTDDRUID	D0I3GZ
DRUGNAME	TAK-003
INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 3
	
TTDDRUID	D0I3HI
DRUGNAME	KP-413
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1/2
	
TTDDRUID	D0I3IG
DRUGNAME	Alseroxylon
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0I3JZ
DRUGNAME	Peginesatide acetate
INDICATI	Anaemia [ICD-11: 3A90] Approved
	
TTDDRUID	D0I3KT
DRUGNAME	PMID26815044-Compound-64
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0I3LE
DRUGNAME	Insulin-aspart
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0I3LO
DRUGNAME	IPI-549
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Adrenocortical carcinoma [ICD-11: 2D11.Z] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0I3NA
DRUGNAME	Human-cl rhFVIII
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3
	
TTDDRUID	D0I3OS
DRUGNAME	Rebmab-100
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 2
	
TTDDRUID	D0I3OX
DRUGNAME	ESN-XX
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0I3PG
DRUGNAME	SDZ-CPI-975
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D0I3QJ
DRUGNAME	HX-100
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 1
	
TTDDRUID	D0I3QU
DRUGNAME	ISIS 18078
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I3QX
DRUGNAME	Camrelizumab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0I3RD
DRUGNAME	TAK-733
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0I3RN
DRUGNAME	PGL-2
INDICATI	Endometriosis [ICD-11: GA10] Phase 2
	
TTDDRUID	D0I3RO
DRUGNAME	Droxidopa
INDICATI	Neurogenic orthostatic hypotension [ICD-11: 8D87.0Y] Approved
	
TTDDRUID	D0I3TD
DRUGNAME	CRL-37212
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I3TJ
DRUGNAME	Fluvax
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0I3TS
DRUGNAME	GW-594884A
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0I3TU
DRUGNAME	MK-7246
INDICATI	Respiratory disease [ICD-11: CB40] Phase 1
	
TTDDRUID	D0I3VP
DRUGNAME	SULOFENUR
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0I3VS
DRUGNAME	Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0I3VT
DRUGNAME	CAD-106
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3
	
TTDDRUID	D0I3VV
DRUGNAME	Telomelysin
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
	
TTDDRUID	D0I3WC
DRUGNAME	RO-4929097
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0I3XA
DRUGNAME	Ciproxifan
INDICATI	Obesity [ICD-11: 5B81] Investigative
INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative
	
TTDDRUID	D0I3XG
DRUGNAME	Verteporfin
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
	
TTDDRUID	D0I3XR
DRUGNAME	Tefibazumab
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D0I3YX
DRUGNAME	Capadenoson
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2
	
TTDDRUID	D0I3ZW
DRUGNAME	PMID25666693-Compound-159
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0I4BK
DRUGNAME	XmAb14045
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0I4DQ
DRUGNAME	Alprostadil
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved
	
TTDDRUID	D0I4EI
DRUGNAME	NSL-105
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Preclinical
	
TTDDRUID	D0I4EL
DRUGNAME	Odulimomab
INDICATI	Transplant rejection [ICD-11: NE84] Approved
	
TTDDRUID	D0I4FL
DRUGNAME	N-1177-inh
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1
	
TTDDRUID	D0I4GI
DRUGNAME	RO-26-9228
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2
	
TTDDRUID	D0I4GT
DRUGNAME	Hexylcarbamoyl fluorouracil
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0I4HG
DRUGNAME	4SCAR19 and 4SCAR38
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0I4HS
DRUGNAME	PE0139
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0I4LB
DRUGNAME	SM-16
INDICATI	Fibrosis [ICD-11: GA14-GC01] Terminated
	
TTDDRUID	D0I4LM
DRUGNAME	ABIO-05/01
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 2
	
TTDDRUID	D0I4LQ
DRUGNAME	RHIIP
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0I4MW
DRUGNAME	DWJ-425
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0I4OJ
DRUGNAME	Protectaid
INDICATI	Contraception [ICD-11: QA21] Investigative
	
TTDDRUID	D0I4OX
DRUGNAME	SURADISTA
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0I4PB
DRUGNAME	MCT-485
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I4PL
DRUGNAME	DPC-543
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
	
TTDDRUID	D0I4PW
DRUGNAME	APD371
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D0I4QA
DRUGNAME	Drug 2849330
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0I4RX
DRUGNAME	TJ-127
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D0I4TH
DRUGNAME	GDC-0068
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0I4UY
DRUGNAME	GSK-1108167A
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0I4VX
DRUGNAME	DRP-049
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D0I4WH
DRUGNAME	NCX-434
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Investigative
	
TTDDRUID	D0I4XF
DRUGNAME	ALT 005
INDICATI	Ophthalmic infection [ICD-11: 1F00.1] Phase 3
	
TTDDRUID	D0I4YP
DRUGNAME	BIOO-5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I4ZN
DRUGNAME	GSK2879552
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0I4ZQ
DRUGNAME	Collagenase clostridium histolyticum
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Approved
	
TTDDRUID	D0I5BN
DRUGNAME	NV-196
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0I5CN
DRUGNAME	VRS-859
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0I5CO
DRUGNAME	NNI-PD
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0I5DP
DRUGNAME	AMG 176
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0I5DS
DRUGNAME	Meprednisone
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0I5ED
DRUGNAME	Placental growth factor
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0I5EU
DRUGNAME	RG7421+RG7204
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D0I5FP
DRUGNAME	RHAMM-R3 peptide vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0I5GC
DRUGNAME	Dry-powder peptide YY(3-36)
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0I5GS
DRUGNAME	CAR.CD30 cells
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1/2
INDICATI	Immunoproliferative disorder [ICD-11: 2B32] Phase 1/2
INDICATI	Lymphatic disease [ICD-11: BD9Z] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0I5HE
DRUGNAME	NPY5RA-972
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0I5HF
DRUGNAME	Apixaban
INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved
	
TTDDRUID	D0I5HV
DRUGNAME	Articaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0I5IM
DRUGNAME	LY-518674
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0I5IS
DRUGNAME	MBS-103
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0I5JM
DRUGNAME	LC-350189
INDICATI	Gout [ICD-11: FA25] Phase 1
	
TTDDRUID	D0I5KI
DRUGNAME	Dibenzo [c,f]-[2,7]naphthyridine derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0I5KX
DRUGNAME	Thymalfasin
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Approved
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
	
TTDDRUID	D0I5LM
DRUGNAME	R-1065
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D0I5ND
DRUGNAME	CNX-010
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0I5NN
DRUGNAME	Valtorim
INDICATI	Anthrax [ICD-11: 1B97] Phase 1
	
TTDDRUID	D0I5OM
DRUGNAME	Dextrin-2-sulphate
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3
	
TTDDRUID	D0I5OR
DRUGNAME	Tetrahydrouridine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0I5PM
DRUGNAME	DW-908e
INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1
	
TTDDRUID	D0I5PQ
DRUGNAME	Interferon alpha-1b
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0I5QL
DRUGNAME	CRD-5
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D0I5QV
DRUGNAME	VIR-201
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0I5QX
DRUGNAME	Etanercept
INDICATI	Arthritis [ICD-11: FA20] Approved
INDICATI	Sciatica [ICD-11: ME84.3] Phase 3
INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 2
	
TTDDRUID	D0I5RR
DRUGNAME	V-503
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 3
	
TTDDRUID	D0I5SD
DRUGNAME	Azetidine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0I5TC
DRUGNAME	Cyanocobalamin Co-57
INDICATI	Vitamin B12 deficiency [ICD-11: 5B5F] Approved
	
TTDDRUID	D0I5TL
DRUGNAME	ADX-48621
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2/3
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2
INDICATI	Dyskinesia [ICD-11: MB47.4] Phase 2
	
TTDDRUID	D0I5TT
DRUGNAME	EPI-2221
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I5US
DRUGNAME	UB-421
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0I5VA
DRUGNAME	CF502
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical
	
TTDDRUID	D0I5WB
DRUGNAME	Clomiphene Citrate
INDICATI	Female infertility [ICD-11: GA31.Z] Approved
	
TTDDRUID	D0I5WJ
DRUGNAME	Blisibimod
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3
	
TTDDRUID	D0I5WO
DRUGNAME	Lymphocyte immune globulin, anti-thymocyte globulin
INDICATI	Aplastic anemia [ICD-11: 3A70] Approved
	
TTDDRUID	D0I5XU
DRUGNAME	PF-3635659
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0I5ZM
DRUGNAME	Remogli ozin-etabonate
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0I5ZO
DRUGNAME	AS-1522489-00
INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative
	
TTDDRUID	D0I5ZX
DRUGNAME	Recombinant novel coronavirus vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0I6AU
DRUGNAME	BDD-10103
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0I6EK
DRUGNAME	P10s-Padre/Montanide ISA 51 vaccine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D0I6FA
DRUGNAME	Hemoglobin crosfumaril
INDICATI	Hypotension [ICD-11: BA20-BA21] Approved
	
TTDDRUID	D0I6FS
DRUGNAME	Rh-bmp-2/acs
INDICATI	Bone induction [ICD-11: FC0Z] Approved
	
TTDDRUID	D0I6GC
DRUGNAME	NOGGIN
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0I6HJ
DRUGNAME	INC-106
INDICATI	Artery stenosis [ICD-11: BD52] Investigative
	
TTDDRUID	D0I6IB
DRUGNAME	Tenoxicam
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0I6IP
DRUGNAME	Candicidin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0I6IQ
DRUGNAME	Neihulizumab
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2
	
TTDDRUID	D0I6JF
DRUGNAME	Sodium phosphate P 32
INDICATI	Bone metastases [ICD-11: 2D50] Approved
	
TTDDRUID	D0I6JG
DRUGNAME	Organon-3
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0I6KC
DRUGNAME	HydroVAX
INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative
	
TTDDRUID	D0I6LD
DRUGNAME	Monovalent oral polio vaccine 1
INDICATI	Poliovirus infection [ICD-11: 1C8Y] Approved
	
TTDDRUID	D0I6LH
DRUGNAME	Triptolide
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D0I6LN
DRUGNAME	INP103
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0I6LR
DRUGNAME	BL-6030
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0I6MR
DRUGNAME	NN1406
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0I6NH
DRUGNAME	Anti-PD-L1 mAb
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0I6OI
DRUGNAME	RG7601
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
	
TTDDRUID	D0I6PP
DRUGNAME	VaxiGrip QIV IM
INDICATI	Influenza [ICD-11: 1E30-1E32] Phase 3
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0I6QN
DRUGNAME	K-454
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I6RC
DRUGNAME	Benzyl phenyl ether derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0I6RI
DRUGNAME	GRNVAC1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0I6RV
DRUGNAME	HR1P peptide
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0I6UE
DRUGNAME	STI-002
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0I6UK
DRUGNAME	BO-0742
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I6UN
DRUGNAME	AbGn-150
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0I6UU
DRUGNAME	UK-74505
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2
	
TTDDRUID	D0I6VU
DRUGNAME	Enzastaurin
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 1
	
TTDDRUID	D0I6XJ
DRUGNAME	AMP-X-0001
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative
	
TTDDRUID	D0I6YM
DRUGNAME	Ferroquine
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D0I6ZO
DRUGNAME	AZD-5213
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0I7BD
DRUGNAME	CYT-006-AngQb
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0I7BU
DRUGNAME	GSK1482160
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0I7EU
DRUGNAME	SB-208651
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0I7EX
DRUGNAME	Org-34116
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0I7FH
DRUGNAME	PF-4859989
INDICATI	Schizophrenia [ICD-11: 6A20] Investigative
	
TTDDRUID	D0I7HB
DRUGNAME	NuroPro
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0I7HG
DRUGNAME	RBT-401
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I7IB
DRUGNAME	Sodium butyrate
INDICATI	Refractory sickle cell ulcers [ICD-11: 3A51] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0I7LB
DRUGNAME	ZD-4953
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0I7MF
DRUGNAME	SIM-0702
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I7MG
DRUGNAME	AG-707
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1
	
TTDDRUID	D0I7MK
DRUGNAME	DasKloster 0080-01
INDICATI	Lymphangioleiomyomatosis [ICD-11: CB07] Investigative
	
TTDDRUID	D0I7MT
DRUGNAME	Puerarin
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
	
TTDDRUID	D0I7MX
DRUGNAME	LB-30870
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
	
TTDDRUID	D0I7NG
DRUGNAME	LOR-2040
INDICATI	Metastatic renal cancer [ICD-11: 2D50] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0I7OE
DRUGNAME	CryptoGAM
INDICATI	Cryptosporidium infection [ICD-11: 1A32] Discontinued in Phase 2
	
TTDDRUID	D0I7OF
DRUGNAME	Hexamethylene amiloride
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
	
TTDDRUID	D0I7PO
DRUGNAME	Micardis telmisartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0I7PU
DRUGNAME	Lirilumab
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0I7RO
DRUGNAME	BPC-157
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
	
TTDDRUID	D0I7SZ
DRUGNAME	Quinapril
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0I7TN
DRUGNAME	3-DEAZAADENOSINE
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0I7UZ
DRUGNAME	Peptide analog 6
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0I7VI
DRUGNAME	EG-10
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0I7YR
DRUGNAME	AG-NCA805
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0I7ZH
DRUGNAME	EGFR806-specific CAR T cell
INDICATI	Atypical teratoid/rhabdoid tumour [ICD-11: 2A00.1Y] Phase 1
INDICATI	Choroid plexus carcinoma [ICD-11: 2A02.12] Phase 1
INDICATI	Ependymoma [ICD-11: 2A00.0Y] Phase 1
INDICATI	Germ cell tumour [ICD-11: 2C80.2] Phase 1
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 1
INDICATI	Pineoblastoma [ICD-11: 2A00.20] Phase 1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
	
TTDDRUID	D0I8BC
DRUGNAME	S-100
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0I8BH
DRUGNAME	Vx-001
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0I8CA
DRUGNAME	Isoxyl
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0I8CK
DRUGNAME	IPL-512602
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0I8DD
DRUGNAME	Dantrolene
INDICATI	Hyperthermia [ICD-11: MG26] Approved
	
TTDDRUID	D0I8DH
DRUGNAME	ONX-0801
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0I8DX
DRUGNAME	AMG 820
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0I8FI
DRUGNAME	Isoproterenol
INDICATI	Heart block [ICD-11: BC63] Approved
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0I8FO
DRUGNAME	ABI-0043
INDICATI	Respiratory tract infection [ICD-11: CA45] Preclinical
	
TTDDRUID	D0I8FS
DRUGNAME	BIIB092
INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0I8FV
DRUGNAME	SUN13834
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 2
	
TTDDRUID	D0I8GN
DRUGNAME	INK4a
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I8GU
DRUGNAME	LI 401
INDICATI	Gingivitis [ICD-11: DA0B] Discontinued in Phase 2
	
TTDDRUID	D0I8HJ
DRUGNAME	lormetazepam
INDICATI	Nasal polyp [ICD-11: CA0J] Clinical trial
	
TTDDRUID	D0I8KA
DRUGNAME	BLZ-100
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
INDICATI	Malignant primary brain tumour [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0I8LL
DRUGNAME	XGP-310
INDICATI	Migraine [ICD-11: 8A80] Investigative
	
TTDDRUID	D0I8LS
DRUGNAME	Rubratin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Preregistration
	
TTDDRUID	D0I8LU
DRUGNAME	Zuclopenthixol
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0I8NM
DRUGNAME	Gene therapy, IFN-alpha
INDICATI	Head and neck cancer [ICD-11: 2D42] Terminated
	
TTDDRUID	D0I8OE
DRUGNAME	PcTx1
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0I8OY
DRUGNAME	XLCART001
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
	
TTDDRUID	D0I8PA
DRUGNAME	MN-7105
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I8QC
DRUGNAME	Anti-GM-CSF human mabs
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0I8QF
DRUGNAME	PU-2049
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D0I8QJ
DRUGNAME	Ranpirnase
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2
	
TTDDRUID	D0I8QS
DRUGNAME	BN82451
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0I8QT
DRUGNAME	Pyridostigmine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
	
TTDDRUID	D0I8QY
DRUGNAME	P31-Protein
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I8RR
DRUGNAME	Streptozocin
INDICATI	Pancreatic cancer [ICD-11: 2C10] Approved
	
TTDDRUID	D0I8RY
DRUGNAME	SDZ-ICM-567
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0I8SA
DRUGNAME	BO-110
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I8SC
DRUGNAME	WSB-290
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0I8TF
DRUGNAME	EXO-226
INDICATI	Diabetic kidney disease [ICD-11: GB61.Z] Discontinued in Phase 3
	
TTDDRUID	D0I8TJ
DRUGNAME	CY-1788
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1
	
TTDDRUID	D0I8TV
DRUGNAME	DLX-0201
INDICATI	Vomiting [ICD-11: MD90] Preclinical
	
TTDDRUID	D0I8TW
DRUGNAME	IBC-VS01
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0I8YO
DRUGNAME	Hepatitis B vaccine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0I8YS
DRUGNAME	RO5520985
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D0I8ZB
DRUGNAME	Ruthenium complexes
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D0I8ZM
DRUGNAME	CR-3294
INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2
	
TTDDRUID	D0I9AC
DRUGNAME	SM04554
INDICATI	Alopecia [ICD-11: ED70] Phase 2/3
	
TTDDRUID	D0I9AR
DRUGNAME	BMS-185857
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0I9FQ
DRUGNAME	XGP-125
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0I9FU
DRUGNAME	Bicyclic heteroaryl benzamide derivative 4
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0I9GA
DRUGNAME	AbGn-100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0I9GR
DRUGNAME	Plevitrexed
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
	
TTDDRUID	D0I9HF
DRUGNAME	Hesperidin
INDICATI	Vascular purpura [ICD-11: 3B60] Approved
	
TTDDRUID	D0I9HG
DRUGNAME	Amsilarotene
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0I9IF
DRUGNAME	AVN-492
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D0I9IL
DRUGNAME	OTL38
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D0I9LH
DRUGNAME	PMI-001
INDICATI	Lupus [ICD-11: 4A40] Discontinued in Phase 3
	
TTDDRUID	D0I9LO
DRUGNAME	RWJ-416457
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical
	
TTDDRUID	D0I9MG
DRUGNAME	IMM-308
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2
	
TTDDRUID	D0I9NC
DRUGNAME	MDL-101002
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0I9QH
DRUGNAME	SR-58878
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Terminated
	
TTDDRUID	D0I9RB
DRUGNAME	SOM-0525
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0I9TV
DRUGNAME	DW-816
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D0I9UH
DRUGNAME	MOXIFETIN HYDROGEN MALEATE
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Terminated
	
TTDDRUID	D0I9UP
DRUGNAME	HBX-41108
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0I9VO
DRUGNAME	Epratuzumab
INDICATI	Graft rejection in heart transplantation [ICD-11: NE84] Phase 3
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3
	
TTDDRUID	D0I9VU
DRUGNAME	PMID28350212-Compound-20
INDICATI	Alzheimer disease [ICD-11: 8A20] Patented
	
TTDDRUID	D0I9WR
DRUGNAME	CNTO-3157
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0I9XH
DRUGNAME	Celastrol
INDICATI	Motor neurone disease [ICD-11: 8B60] Preclinical
	
TTDDRUID	D0I9YI
DRUGNAME	AZD-6942
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0I9YM
DRUGNAME	IMCnyeso
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2
	
TTDDRUID	D0I9ZQ
DRUGNAME	SB-104
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0I9ZV
DRUGNAME	Recombinant soluble PSMA protein vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0IA0N
DRUGNAME	NRL-1
INDICATI	Acute repetitive seizure [ICD-11: 8A67] Phase 3
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3
	
TTDDRUID	D0IA1G
DRUGNAME	PAT-001
INDICATI	Non-syndromic ichthyosis [ICD-11: EC20.0Y] Phase 2
INDICATI	Autosomal recessive congenital ichthyosis [ICD-11: EC20.02] Phase 1
	
TTDDRUID	D0IA5O
DRUGNAME	GSK-2241658A
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0IA7K
DRUGNAME	MF-5137
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Terminated
	
TTDDRUID	D0IA8W
DRUGNAME	BMS-986156
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0IA9E
DRUGNAME	BTRX-246040
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0IA9Y
DRUGNAME	Vazegepant
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0IB3Z
DRUGNAME	Thiazolidine derivative 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0IB8D
DRUGNAME	PMID26651364-Compound-117a
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0IC2O
DRUGNAME	Anti-miR-191 modified oligonucleotide
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative
	
TTDDRUID	D0IC3K
DRUGNAME	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0IC6D
DRUGNAME	KM-133
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D0IC7A
DRUGNAME	TZTX-001
INDICATI	Endometriosis [ICD-11: GA10] Phase 3
	
TTDDRUID	D0IC8P
DRUGNAME	HL-026
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0ID0R
DRUGNAME	LF-984
INDICATI	Fibrosis [ICD-11: GA14-GC01] Terminated
	
TTDDRUID	D0ID2I
DRUGNAME	Typhella typhoid vaccine
INDICATI	Typhoid fever [ICD-11: 1A07] Discontinued in Phase 2
INDICATI	Salmonella infection [ICD-11: 1A08] Discontinued in Phase 2
	
TTDDRUID	D0ID3W
DRUGNAME	GW-813893
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2
	
TTDDRUID	D0ID4Y
DRUGNAME	Gimsilumab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0ID4Z
DRUGNAME	Fomivirsen sodium
INDICATI	Cytomegalovirus retinitis [ICD-11: 9B72.00] Approved
	
TTDDRUID	D0ID9W
DRUGNAME	ATA188
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0IE1E
DRUGNAME	Nitrofurazone
INDICATI	Skin burns [ICD-11: ME65.0] Approved
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3
	
TTDDRUID	D0IE4H
DRUGNAME	TAZOMELINE
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1
	
TTDDRUID	D0IE9L
DRUGNAME	M4344
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0IF4J
DRUGNAME	PMID26651364-Compound-110
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0IG2Y
DRUGNAME	MVA p53 vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0IG4I
DRUGNAME	THIOCOLCHICOSIDE
INDICATI	Muscle spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D0IG6J
DRUGNAME	Piperazine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0IG7W
DRUGNAME	BMS-986224
INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 1
	
TTDDRUID	D0IH2I
DRUGNAME	13C-urea
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Approved
	
TTDDRUID	D0IH3I
DRUGNAME	PMID28460551-Compound-1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Patented
INDICATI	Pancreatic cancer [ICD-11: 2C10] Patented
INDICATI	Lung cancer [ICD-11: 2C25.0] Patented
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Patented
INDICATI	Colon cancer [ICD-11: 2B90.Z] Patented
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Patented
INDICATI	Prostate cancer [ICD-11: 2C82.0] Patented
	
TTDDRUID	D0IH6G
DRUGNAME	Resorcinol compound 26
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0IH8R
DRUGNAME	PMID30280939-Compound-WO2008009652
INDICATI	Malaria [ICD-11: 1F40-1F45] Patented
	
TTDDRUID	D0II5S
DRUGNAME	DMP-728
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D0II7M
DRUGNAME	Modified adenovirus delta24-RGD
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0II9K
DRUGNAME	Girisopam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0IJ0F
DRUGNAME	AG-013
INDICATI	Oral mucositis [ICD-11: DA01.11] Phase 2/3
	
TTDDRUID	D0IJ0Q
DRUGNAME	ML-436
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0IJ0U
DRUGNAME	TS-071
INDICATI	Type-2 diabetes [ICD-11: 5A11] NDA filed
	
TTDDRUID	D0IJ1D
DRUGNAME	HuM-195-Bi-213
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 1/2
	
TTDDRUID	D0IJ2H
DRUGNAME	FK-584
INDICATI	Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] Discontinued in Phase 2
	
TTDDRUID	D0IJ3R
DRUGNAME	TRK-710
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0IJ4G
DRUGNAME	VPM-2-001
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Investigative
	
TTDDRUID	D0IJ5I
DRUGNAME	Befiperide
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0IJ7O
DRUGNAME	Metastat
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 1
	
TTDDRUID	D0IK1I
DRUGNAME	PHN-031
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D0IK1S
DRUGNAME	PMID25666693-Compound-102
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0IK1U
DRUGNAME	SEA-0400
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0IK5F
DRUGNAME	BSI-201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0IK5R
DRUGNAME	ERY974
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0IL0C
DRUGNAME	SK-1306X
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0IL0H
DRUGNAME	MaC46/M87o
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0IL1B
DRUGNAME	MCD-386/glycopyrrolate
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0IL2B
DRUGNAME	VML-252
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Discontinued in Phase 2
	
TTDDRUID	D0IL3O
DRUGNAME	Strontium malonate
INDICATI	Metabolic bone disease [ICD-11: FB8Y] Phase 2
	
TTDDRUID	D0IL4C
DRUGNAME	TgDCC-E1A
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0IL7L
DRUGNAME	Prednisone
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
INDICATI	Eczema [ICD-11: EA80-EA89] Phase 1
	
TTDDRUID	D0IL7V
DRUGNAME	KRP-107
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0IL8R
DRUGNAME	A-93178
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D0IM1B
DRUGNAME	MOv18IgE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0IM6O
DRUGNAME	Talactoferrin
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
	
TTDDRUID	D0IM6T
DRUGNAME	Tisagenlecleucel
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Application submitted
	
TTDDRUID	D0IM7C
DRUGNAME	AE-9C90CB
INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative
	
TTDDRUID	D0IN2K
DRUGNAME	CD22 CAR-T
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0IN5E
DRUGNAME	PMID25666693-Compound-48
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0IN7I
DRUGNAME	Nemonapride
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0IN7R
DRUGNAME	MUC-1 CART cell immunotherapy
INDICATI	Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10] Phase 1/2
	
TTDDRUID	D0IN8Z
DRUGNAME	LY2928057
INDICATI	Anaemia [ICD-11: 3A90] Phase 2
	
TTDDRUID	D0IN9G
DRUGNAME	Liatermin
INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 1/2
	
TTDDRUID	D0IO2X
DRUGNAME	PMID25684022-Compound-WO2011137219 38(5-7)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0IO9Z
DRUGNAME	Tafinlar + Mekinist
INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0IP2J
DRUGNAME	ProQuad
INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Approved
	
TTDDRUID	D0IP5E
DRUGNAME	PMID25666693-Compound-9
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0IP6X
DRUGNAME	Osanetant
INDICATI	Schizoaffective disorder [ICD-11: 6A21] Discontinued in Phase 2b
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2b
INDICATI	Depression [ICD-11: 6A70-6A7Z] Terminated
	
TTDDRUID	D0IP7M
DRUGNAME	PAT-SM4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0IP9E
DRUGNAME	Hyqvia
INDICATI	Immunodeficiency [ICD-11: 4A00-4A85] Approved
	
TTDDRUID	D0IQ0Z
DRUGNAME	GSK1070916
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0IQ1V
DRUGNAME	CIGB-300
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 3
	
TTDDRUID	D0IQ2P
DRUGNAME	NexVax2
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
INDICATI	Coeliac disease [ICD-11: DA95] Phase 1
	
TTDDRUID	D0IQ3E
DRUGNAME	Muc1-specific gene-engineered T cells
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0IQ4V
DRUGNAME	Anti-GPC3 CAR T
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
	
TTDDRUID	D0IQ6O
DRUGNAME	S-1286
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0IQ6P
DRUGNAME	Cabozantinib
INDICATI	Thyroid cancer [ICD-11: 2D10] Approved
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D0IR2V
DRUGNAME	Prodarsan
INDICATI	Cockayne syndrome [ICD-11: LD2B] Phase 1/2
	
TTDDRUID	D0IR7H
DRUGNAME	PMID25666693-Compound-27
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0IR8B
DRUGNAME	Benzonaphthyridine derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0IR8J
DRUGNAME	INDUS-815C
INDICATI	Retinopathy [ICD-11: 9B71] Investigative
	
TTDDRUID	D0IS5V
DRUGNAME	TC-34
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0IS5Z
DRUGNAME	Anti-CEA designer T cell therapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0IT1V
DRUGNAME	Zika virus vaccine
INDICATI	Semliki forest virus infection [ICD-11: 1D9Y] Phase 1
	
TTDDRUID	D0IT2G
DRUGNAME	Dexamethasone
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0IT2X
DRUGNAME	Carprofen
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0IT4N
DRUGNAME	PMID25666693-Compound-94
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0IT6Q
DRUGNAME	Tandutinib
INDICATI	Anaplastic mixed oligoastrocytoma [ICD-11: 2A00.0Y] Discontinued in Phase 2
	
TTDDRUID	D0IT7F
DRUGNAME	Sitagliptin + metformin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0IU0W
DRUGNAME	Q-201
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0IU1H
DRUGNAME	PMID25666693-Compound-52
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0IV3M
DRUGNAME	Polyethylene glycol
INDICATI	Constipation [ICD-11: DD91.1] Approved
	
TTDDRUID	D0IV4C
DRUGNAME	WP-1066
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
	
TTDDRUID	D0IV4E
DRUGNAME	Bromhexine + hydroxychloroquine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0IV7F
DRUGNAME	IDP-115
INDICATI	Rosacea [ICD-11: ED90.0] Phase 2
	
TTDDRUID	D0IV7J
DRUGNAME	131I-COU-1
INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative
	
TTDDRUID	D0IV7Z
DRUGNAME	AZD-8418
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0IW0Y
DRUGNAME	MEN-10207
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0IW1Y
DRUGNAME	F-16915
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D0IW4E
DRUGNAME	GALE-301 + GALE-302
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	D0IW4R
DRUGNAME	TREFENTANIL HYDROCHLORIDE
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0IW6R
DRUGNAME	PD-L1 mAb + LY
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0IW8I
DRUGNAME	LipoNeu
INDICATI	Streptococcus infection [ICD-11: 1B53] Investigative
	
TTDDRUID	D0IW9Q
DRUGNAME	MDX-1147
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0IX1A
DRUGNAME	Pentolinium
INDICATI	Hypotension [ICD-11: BA20-BA21] Approved
	
TTDDRUID	D0IX1I
DRUGNAME	NBI-98854
INDICATI	Movement disorder [ICD-11: 8A07-8A0Z] Phase 3
INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 2
	
TTDDRUID	D0IX4B
DRUGNAME	AG-024322
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0IX6I
DRUGNAME	cortisone
INDICATI	Atopic dermatitis [ICD-11: EA80] Approved
	
TTDDRUID	D0IX7G
DRUGNAME	FR-76830
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D0IX9E
DRUGNAME	NIZ985
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0IX9O
DRUGNAME	Q-Derp1
INDICATI	Various major chronic disease [ICD-11: N.A.] Phase 1
	
TTDDRUID	D0IY0R
DRUGNAME	Viquidacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical
	
TTDDRUID	D0IY2B
DRUGNAME	Hairpin RNA
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D0IY2M
DRUGNAME	AF-11
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0IY3Z
DRUGNAME	Bivigam
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D0IZ1A
DRUGNAME	LY309887
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0IZ1D
DRUGNAME	Brofaromine
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D0IZ1I
DRUGNAME	SD-726
INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical
	
TTDDRUID	D0IZ7T
DRUGNAME	YM-17E
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1
	
TTDDRUID	D0IZ8X
DRUGNAME	BPN14770
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0J0AE
DRUGNAME	CP-945598
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 3
	
TTDDRUID	D0J0AH
DRUGNAME	GP-668
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1
	
TTDDRUID	D0J0AN
DRUGNAME	Polymer-tubulysin A prodrug conjugate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0J0BB
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 11
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0J0BI
DRUGNAME	NG-049
INDICATI	Dyspepsia [ICD-11: MD92] Investigative
	
TTDDRUID	D0J0BN
DRUGNAME	TAK-079
INDICATI	Pheumatoid arthritis [ICD-11: FA2Z] Phase 1
	
TTDDRUID	D0J0BU
DRUGNAME	BETRIXABAN
INDICATI	Venous thromboembolism [ICD-11: BD72] Approved
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3
	
TTDDRUID	D0J0EL
DRUGNAME	1,8-dihydroxy-anthraquinone
INDICATI	Laxative [ICD-11: FA34.1] Withdrawn from market
	
TTDDRUID	D0J0EM
DRUGNAME	Virexxa
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
	
TTDDRUID	D0J0FD
DRUGNAME	MACI
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3
INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Phase 3
	
TTDDRUID	D0J0GJ
DRUGNAME	P-1116
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0J0GR
DRUGNAME	Rocapuldencel-T
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
	
TTDDRUID	D0J0HE
DRUGNAME	MK-8150
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D0J0HV
DRUGNAME	VBY- 285
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0J0IJ
DRUGNAME	RG7636
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 1
	
TTDDRUID	D0J0JC
DRUGNAME	FRG-8701
INDICATI	Stomach ulcer [ICD-11: DA60.Z] Terminated
	
TTDDRUID	D0J0JT
DRUGNAME	CC-11006
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J0KD
DRUGNAME	Fibrinolysin
INDICATI	Wound healing [ICD-11: EL8Y] Approved
	
TTDDRUID	D0J0KT
DRUGNAME	RhuDex
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2a
	
TTDDRUID	D0J0KX
DRUGNAME	PF-275366
INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 2
	
TTDDRUID	D0J0LC
DRUGNAME	PMID26651364-Compound-4
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0J0LI
DRUGNAME	Chorionic Gonadotropin
INDICATI	Fertility problem [ICD-11: 5A61] Approved
	
TTDDRUID	D0J0MK
DRUGNAME	JTT-608
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D0J0OF
DRUGNAME	Choroid plexus cell-derived factors
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D0J0PR
DRUGNAME	PIBROZELESIN HYDROCHLORIDE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0J0RG
DRUGNAME	UK-66914
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 1
	
TTDDRUID	D0J0RV
DRUGNAME	Larotaxel
INDICATI	Bladder cancer [ICD-11: 2C94] Discontinued in Phase 3
INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 3
	
TTDDRUID	D0J0WG
DRUGNAME	PMID27998201-Compound-1
INDICATI	Coronavirus infection [ICD-11: 1D92] Patented
INDICATI	Henipavirus Encephalitis [ICD-11: 1D63] Patented
	
TTDDRUID	D0J0WX
DRUGNAME	(-)-3PPP, Maryland
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0J0XN
DRUGNAME	OpRegen
INDICATI	Dry age-related macular degeneration [ICD-11: 9B75] Phase 1/2
	
TTDDRUID	D0J0YH
DRUGNAME	BI-187004
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0J0ZM
DRUGNAME	RP-400C
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0J0ZS
DRUGNAME	Gabapentin
INDICATI	Complex partial seizure [ICD-11: 8A68.0] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0J0ZU
DRUGNAME	KIN-3031
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0J1AU
DRUGNAME	CODA-001
INDICATI	Cornea epithelial defect [ICD-11: 9A78] Phase 2
	
TTDDRUID	D0J1AV
DRUGNAME	LAS 100977
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0J1CF
DRUGNAME	Her2- and PSA-targeted TGX-D1
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0J1CL
DRUGNAME	EcoNail
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2
	
TTDDRUID	D0J1DE
DRUGNAME	Heterologous liver-derived stem cells
INDICATI	Ornithine transcarbamylase deficiency [ICD-11: 5C50.AY] Investigative
	
TTDDRUID	D0J1FB
DRUGNAME	GSK586529
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1
	
TTDDRUID	D0J1FL
DRUGNAME	AZD-2098
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0J1GA
DRUGNAME	GSK-1399686
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
	
TTDDRUID	D0J1GR
DRUGNAME	CP-868596
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 3
INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 3
INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0J1HB
DRUGNAME	PF-06840003
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0J1HG
DRUGNAME	HG-1338
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0J1IT
DRUGNAME	Norovirus vaccine
INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1/2
	
TTDDRUID	D0J1KG
DRUGNAME	PD-4048
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0J1KS
DRUGNAME	BMS-945429
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0J1MI
DRUGNAME	Mebendazole
INDICATI	Worm infection [ICD-11: 1F90.Z] Approved
	
TTDDRUID	D0J1ML
DRUGNAME	Mestranol
INDICATI	Contraception [ICD-11: QA21] Approved
	
TTDDRUID	D0J1MO
DRUGNAME	TRX-518
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0J1NQ
DRUGNAME	Pinaverium bromide
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 3
	
TTDDRUID	D0J1OG
DRUGNAME	Prolanta
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1
	
TTDDRUID	D0J1PW
DRUGNAME	Orthokine
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0J1QX
DRUGNAME	Carrimycin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0J1RH
DRUGNAME	CY-1748
INDICATI	Deep vein thrombosis [ICD-11: BD71] Terminated
	
TTDDRUID	D0J1RS
DRUGNAME	H5N1 pandemic influenza mab
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0J1TN
DRUGNAME	ETEC vaccine
INDICATI	Escherichia coli infection [ICD-11: 1A03] Phase 1
INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Phase 1
	
TTDDRUID	D0J1TS
DRUGNAME	AZD2207
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D0J1TU
DRUGNAME	Technetium Tc-99m Sestamibi Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0J1UA
DRUGNAME	Elosulfase alfa
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Approved
	
TTDDRUID	D0J1VY
DRUGNAME	Entacapone
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0J1WJ
DRUGNAME	ALS-769
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0J1WO
DRUGNAME	ISIS 113715
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0J1ZH
DRUGNAME	PH94B NS
INDICATI	Social anxiety disorder [ICD-11: 6B04] Phase 3
	
TTDDRUID	D0J2AJ
DRUGNAME	Nivolumab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0J2BH
DRUGNAME	TA-GW
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Discontinued in Phase 2
	
TTDDRUID	D0J2ES
DRUGNAME	BIO-300
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0J2GG
DRUGNAME	SR-3850
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0J2HH
DRUGNAME	Cyclohexyl carbamate derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0J2IB
DRUGNAME	ANG-3070
INDICATI	Scleroderma [ICD-11: 4A42] Investigative
	
TTDDRUID	D0J2IH
DRUGNAME	Avosentan
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 2
	
TTDDRUID	D0J2IN
DRUGNAME	CAR-T cells targeting GPC3
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
	
TTDDRUID	D0J2KV
DRUGNAME	Propafenone
INDICATI	Tachyarrhythmias [ICD-11: BC71] Approved
	
TTDDRUID	D0J2LG
DRUGNAME	DCVax-001
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0J2MJ
DRUGNAME	Selegiline Hydrochloride
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
INDICATI	Motor symptoms [ICD-11: 6A25.4] Investigative
	
TTDDRUID	D0J2NB
DRUGNAME	KRH-594
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D0J2NI
DRUGNAME	TDI-0010
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0J2NK
DRUGNAME	Oxytetracycline
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0J2NS
DRUGNAME	Anti-D
INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Investigative
	
TTDDRUID	D0J2NX
DRUGNAME	LE-DT
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0J2OC
DRUGNAME	MBX-700
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0J2RV
DRUGNAME	XL-888
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J2TN
DRUGNAME	Diphenoxylate
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
	
TTDDRUID	D0J2VB
DRUGNAME	Iboctadekin + rituximab
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D0J2VS
DRUGNAME	1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 2
INDICATI	Skin disease [ICD-11: EA00-EM0Z] Patented
INDICATI	Muscular wasting [ICD-11: 8C7Y] Patented
	
TTDDRUID	D0J2XP
DRUGNAME	BPI-713001
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0J2YR
DRUGNAME	PI-166
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1
	
TTDDRUID	D0J3AN
DRUGNAME	HL-076
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0J3AV
DRUGNAME	PEG-LPA-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0J3BU
DRUGNAME	Duteplase
INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved
	
TTDDRUID	D0J3BY
DRUGNAME	Pimagedine HCl
INDICATI	Diabetic kidney disease [ICD-11: GB61.Z] Phase 2/3
	
TTDDRUID	D0J3CC
DRUGNAME	Latranal
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0J3CT
DRUGNAME	FK-143
INDICATI	Prostate disease [ICD-11: GA91] Phase 2
	
TTDDRUID	D0J3DC
DRUGNAME	VLP norovirus bivalent vaccine
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D0J3DN
DRUGNAME	Anti-CD19-CAR PBL
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
INDICATI	Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Phase 1/2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
	
TTDDRUID	D0J3EA
DRUGNAME	Theliatinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0J3EN
DRUGNAME	AB122
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J3FK
DRUGNAME	DNX-2000
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0J3HE
DRUGNAME	ACAM529
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1
	
TTDDRUID	D0J3KY
DRUGNAME	ReN-001
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1
	
TTDDRUID	D0J3MY
DRUGNAME	NPI-3114
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0J3NJ
DRUGNAME	RP-69698
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0J3OV
DRUGNAME	PI-083
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0J3PS
DRUGNAME	ASP-0265
INDICATI	Endometriosis [ICD-11: GA10] Terminated
	
TTDDRUID	D0J3QN
DRUGNAME	CG-1255
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative
	
TTDDRUID	D0J3QU
DRUGNAME	ZD-7944
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0J3RY
DRUGNAME	Denileukin diftitox
INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0J3SU
DRUGNAME	isatin sulfonamide 34
INDICATI	Cystic fibrosis [ICD-11: CA25] Clinical trial
	
TTDDRUID	D0J3TI
DRUGNAME	Rosmantuzumab
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J3TP
DRUGNAME	ZD-0870
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 2
	
TTDDRUID	D0J3VV
DRUGNAME	IPH-3201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0J3YX
DRUGNAME	BAY 86-6150
INDICATI	Hemophilia [ICD-11: 3B10.0] Discontinued in Phase 2/3
	
TTDDRUID	D0J3ZA
DRUGNAME	KBSA-302
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative
	
TTDDRUID	D0J3ZT
DRUGNAME	PRT-201
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 3
	
TTDDRUID	D0J4BO
DRUGNAME	Norovirus monovalent vaccine
INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1/2
	
TTDDRUID	D0J4CA
DRUGNAME	PMID28270021-Compound-WO2010077680 103
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0J4CV
DRUGNAME	AAV-sFLT gene therapy
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 1
	
TTDDRUID	D0J4EG
DRUGNAME	L-648051
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0J4GO
DRUGNAME	Dichlorphenamide
INDICATI	Chronic glaucoma [ICD-11: 9C61.0Z] Approved
	
TTDDRUID	D0J4GQ
DRUGNAME	FR-152558
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0J4IT
DRUGNAME	Cat peptide allergy desensitization agent
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3
	
TTDDRUID	D0J4IX
DRUGNAME	Glaziovine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0J4JM
DRUGNAME	Reserpine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0J4KC
DRUGNAME	CETi-1
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2
	
TTDDRUID	D0J4LI
DRUGNAME	Thymoctonan
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2
	
TTDDRUID	D0J4LV
DRUGNAME	PMID30107136-Compound-Example53
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0J4MY
DRUGNAME	Tasidotin hydrochloride
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J4NR
DRUGNAME	MC-4001
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D0J4PB
DRUGNAME	GW 597599
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0J4PM
DRUGNAME	NNC-0151-0000-0000
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0J4QE
DRUGNAME	Diazepinone derivative 5
INDICATI	Reflux disease [ICD-11: DA22] Patented
INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented
	
TTDDRUID	D0J4TX
DRUGNAME	AVX-002
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0J4UO
DRUGNAME	Macrocycle derivative 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0J4WA
DRUGNAME	BAY1213790
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2
	
TTDDRUID	D0J4WW
DRUGNAME	NIP-520
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D0J4XV
DRUGNAME	AZD4635
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J4YH
DRUGNAME	P-coumaric acid derivative 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0J4YV
DRUGNAME	AP-214
INDICATI	Candidiasis [ICD-11: 1F23] Phase 2
	
TTDDRUID	D0J5AD
DRUGNAME	FI-6
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0J5CX
DRUGNAME	TAK-637
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 2
	
TTDDRUID	D0J5DC
DRUGNAME	Clofibrate
INDICATI	Dysbetalipoproteinemia [ICD-11: 5C80.2] Approved
	
TTDDRUID	D0J5DL
DRUGNAME	L-4-OXALYSINE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0J5ED
DRUGNAME	LTX-109
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D0J5EQ
DRUGNAME	Maclizumab
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0J5FU
DRUGNAME	MIV-701
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1
	
TTDDRUID	D0J5GT
DRUGNAME	ZANKIREN
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D0J5HG
DRUGNAME	ETS-6103
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0J5HR
DRUGNAME	LGK974
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J5HU
DRUGNAME	Ro-46-2005
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0J5KF
DRUGNAME	Granisetron
INDICATI	Nausea and vomiting [ICD-11: MD90] Approved
	
TTDDRUID	D0J5KZ
DRUGNAME	OBE-102
INDICATI	Weight loss [ICD-11: MG43.5] Investigative
	
TTDDRUID	D0J5NA
DRUGNAME	INO-3106
INDICATI	Aerodigestive tract cancer [ICD-11: 2C29.Z] Phase 1
INDICATI	Malignant neoplasm [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J5NB
DRUGNAME	Pyrazole derivative 25
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0J5OS
DRUGNAME	Vasonex
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D0J5QA
DRUGNAME	GRNCM-1
INDICATI	Heart disease [ICD-11: BA41-BA42] Investigative
	
TTDDRUID	D0J5QD
DRUGNAME	GL-4001
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0J5QW
DRUGNAME	ON-579
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0J5RN
DRUGNAME	Armodafinil
INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0J5SD
DRUGNAME	Gamma-secretase modulators
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0J5TN
DRUGNAME	CEP-751
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated
	
TTDDRUID	D0J5TS
DRUGNAME	Carzinophilin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0J5UC
DRUGNAME	SDZ-ISQ-844
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0J5UK
DRUGNAME	IRT-102
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0J5VR
DRUGNAME	Idelalisib
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved
	
TTDDRUID	D0J5WI
DRUGNAME	FK-518
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D0J5XM
DRUGNAME	Pyrido[2,3-d]pyrimidine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0J5XS
DRUGNAME	TV-1380
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2
	
TTDDRUID	D0J5XZ
DRUGNAME	VP004
INDICATI	Substance use disorder [ICD-11: 6C4Z] Discontinued in Phase 1
	
TTDDRUID	D0J5YC
DRUGNAME	Fosphenytoin
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D0J5YU
DRUGNAME	TSR-022
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J6AB
DRUGNAME	MK-5108
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J6AE
DRUGNAME	CYAD-01
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J6AJ
DRUGNAME	JTCR016
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2
	
TTDDRUID	D0J6AU
DRUGNAME	Odanacatib
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 3
	
TTDDRUID	D0J6BR
DRUGNAME	Pentastarch
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
	
TTDDRUID	D0J6DQ
DRUGNAME	Tremelimumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Malignant mesothelioma [ICD-11: 2C26.0] Phase 3
	
TTDDRUID	D0J6DS
DRUGNAME	Thiazolidine derivative 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0J6DU
DRUGNAME	VLP-based influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0J6EQ
DRUGNAME	M-512101
INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1
	
TTDDRUID	D0J6FE
DRUGNAME	AVI-4557
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0J6FF
DRUGNAME	PENNVAX-GP/MVA-CMDR HIV vaccine regime
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0J6GJ
DRUGNAME	SPI-1005
INDICATI	Meniere disease [ICD-11: AB31.0] Phase 2b
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0J6GO
DRUGNAME	NRP409
INDICATI	Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 3
	
TTDDRUID	D0J6II
DRUGNAME	Azimilide
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 3
	
TTDDRUID	D0J6JC
DRUGNAME	PTL-101
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Investigative
	
TTDDRUID	D0J6JZ
DRUGNAME	MINALRESTAT
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 3
	
TTDDRUID	D0J6KZ
DRUGNAME	S-777469
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D0J6LN
DRUGNAME	Etazolate
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 2
	
TTDDRUID	D0J6LP
DRUGNAME	Colchiceine amide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0J6LU
DRUGNAME	Cryopreserved human liver cells
INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 1
	
TTDDRUID	D0J6MS
DRUGNAME	BIBU-251
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0J6NG
DRUGNAME	OPA-6566
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2
	
TTDDRUID	D0J6NV
DRUGNAME	GI-5005
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0J6NW
DRUGNAME	Shigella vaccine
INDICATI	Shigella infection [ICD-11: 1A02] Phase 2
	
TTDDRUID	D0J6OV
DRUGNAME	(R)-PFI-2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical
	
TTDDRUID	D0J6PR
DRUGNAME	AC-100
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D0J6PY
DRUGNAME	Taxol/Paraplatin/Herceptin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0J6RV
DRUGNAME	BAY1161909
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J6TN
DRUGNAME	2085-P
INDICATI	Otitis media [ICD-11: AA80-AB0Z] Discontinued in Phase 3
	
TTDDRUID	D0J6UA
DRUGNAME	CTP-499
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D0J6UV
DRUGNAME	IBI-20089
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 1
	
TTDDRUID	D0J6VE
DRUGNAME	Ad-IFNg
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
	
TTDDRUID	D0J6VN
DRUGNAME	Indol-3-carbinol
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical
	
TTDDRUID	D0J6VU
DRUGNAME	CVS-995
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Terminated
	
TTDDRUID	D0J6VW
DRUGNAME	CUV-9900
INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative
	
TTDDRUID	D0J6WA
DRUGNAME	HS-10296
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D0J6WE
DRUGNAME	CD19-CAR-T Cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0J6WJ
DRUGNAME	Modified vitamin A
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D0J6WV
DRUGNAME	WRR605
INDICATI	Amoebiasis [ICD-11: 1A36] Investigative
	
TTDDRUID	D0J6WW
DRUGNAME	Proquazone
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
	
TTDDRUID	D0J6WX
DRUGNAME	Flutropium bromide
INDICATI	Cough [ICD-11: MD12] Approved
	
TTDDRUID	D0J6XC
DRUGNAME	tiratricol
INDICATI	Wound healing [ICD-11: EL8Y] Clinical trial
	
TTDDRUID	D0J6XO
DRUGNAME	A-331440
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0J6YZ
DRUGNAME	Very small embryonic-like stem cells
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D0J6ZA
DRUGNAME	SRD-441
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D0J7AI
DRUGNAME	BN-80245
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0J7CD
DRUGNAME	Poly IC-poly arginine
INDICATI	Keratosis [ICD-11: ED56] Investigative
	
TTDDRUID	D0J7CE
DRUGNAME	CDE-6960
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0J7CH
DRUGNAME	QGE-031
INDICATI	Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 3
INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 2
	
TTDDRUID	D0J7CP
DRUGNAME	OctreoScan
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0J7EH
DRUGNAME	ACCLAIM
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
INDICATI	Angina pectoris [ICD-11: BA40] Phase 2
	
TTDDRUID	D0J7EP
DRUGNAME	AVN 397
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
	
TTDDRUID	D0J7HV
DRUGNAME	HER2.taNK
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1
	
TTDDRUID	D0J7KR
DRUGNAME	Lenalidomide
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0J7LV
DRUGNAME	VLP vaccine
INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2
	
TTDDRUID	D0J7ML
DRUGNAME	D-20133
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J7MQ
DRUGNAME	MKC-1106-MT
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0J7OG
DRUGNAME	Midecamycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0J7OU
DRUGNAME	C-CAR088
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0J7QC
DRUGNAME	124I-8H9
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0J7QU
DRUGNAME	E-913
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0J7QX
DRUGNAME	AT-012
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0J7RK
DRUGNAME	Dobutamine
INDICATI	Heart failure [ICD-11: BD10-BD13] Approved
	
TTDDRUID	D0J7RP
DRUGNAME	RP-AAV8
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Investigative
	
TTDDRUID	D0J7TM
DRUGNAME	Benzylpenicilloyl Polylysine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0J7UI
DRUGNAME	ICI-198615
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0J7UL
DRUGNAME	ALX148
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J7VH
DRUGNAME	4SCAR19 and 4SCAR22
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0J7WO
DRUGNAME	BSF-78438
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0J7XL
DRUGNAME	Gramicidin D
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0J7XN
DRUGNAME	UR-5269
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0J8AE
DRUGNAME	OMN-54
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J8BZ
DRUGNAME	BIIB 2024
INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0J8DD
DRUGNAME	TAK-653
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2
	
TTDDRUID	D0J8EC
DRUGNAME	ACT-280778
INDICATI	Essential hypertension [ICD-11: BA00] Phase 2
	
TTDDRUID	D0J8ED
DRUGNAME	JP-1201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0J8GO
DRUGNAME	Aminoazetidine derivative 4
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0J8HJ
DRUGNAME	PMID26651364-Compound-127
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0J8IJ
DRUGNAME	Eliglustat tartrate
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Approved
	
TTDDRUID	D0J8JF
DRUGNAME	RG-4934
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D0J8JP
DRUGNAME	Pimavanserin
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0J8MA
DRUGNAME	KA2237
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D0J8NC
DRUGNAME	ASP-8370
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0J8OC
DRUGNAME	Scriptaid
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0J8OV
DRUGNAME	BNT162b1 SARS-CoV-2 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0J8PI
DRUGNAME	Edotreotide
INDICATI	Acromegaly [ICD-11: 5A60.0] Phase 2
	
TTDDRUID	D0J8PR
DRUGNAME	LY03003
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0J8RM
DRUGNAME	Posatirelin
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Discontinued in Phase 3
	
TTDDRUID	D0J8RR
DRUGNAME	Dextromethorphan+quinidine
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
	
TTDDRUID	D0J8RS
DRUGNAME	PD-146176
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0J8RV
DRUGNAME	SMT-A07
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0J8SE
DRUGNAME	DFD-07
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2/3
	
TTDDRUID	D0J8TH
DRUGNAME	CEB-925
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Terminated
	
TTDDRUID	D0J8UV
DRUGNAME	AC-260584
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0J8VV
DRUGNAME	PRO-055
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative
	
TTDDRUID	D0J8WE
DRUGNAME	CRYPTOPHYCIN 52
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0J8WJ
DRUGNAME	AKL-0707
INDICATI	Lipodystrophy [ICD-11: EF01] Discontinued in Phase 2
	
TTDDRUID	D0J8WO
DRUGNAME	TAK-428
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2
	
TTDDRUID	D0J8XO
DRUGNAME	BCH-150
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated
	
TTDDRUID	D0J8YA
DRUGNAME	PentaLyte
INDICATI	Blood transfusion [ICD-11: QB98] Phase 2
	
TTDDRUID	D0J8ZA
DRUGNAME	Quinethazone
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0J9AK
DRUGNAME	MK-944a
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D0J9CF
DRUGNAME	IDDBCP-150101
INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Preclinical
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0J9CG
DRUGNAME	NmVac
INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 1
	
TTDDRUID	D0J9CS
DRUGNAME	PMID25666693-Compound-59
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0J9DI
DRUGNAME	Heterocyclic derivative 5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0J9EI
DRUGNAME	Lopinavir + ritonavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0J9GR
DRUGNAME	OX-27
INDICATI	Cancer related pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D0J9HO
DRUGNAME	Single Tablet Regimen of sofosbuvir and ledipasvir
INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 3
	
TTDDRUID	D0J9HW
DRUGNAME	Olaparib
INDICATI	Ovarian cancer [ICD-11: 2C73] Approved
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0J9IH
DRUGNAME	PELITREXOL
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0J9JQ
DRUGNAME	XR-5082
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0J9KC
DRUGNAME	IGN-101
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2
	
TTDDRUID	D0J9NJ
DRUGNAME	CLX-0901
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0J9PD
DRUGNAME	STP-206
INDICATI	Necrotizing enterocolitis of newborn [ICD-11: KB88] Phase 2
INDICATI	Enterocolitis [ICD-11: 1A40.Z] Phase 1/2
	
TTDDRUID	D0J9PK
DRUGNAME	OXA-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0J9PS
DRUGNAME	MEDI1841
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0J9PT
DRUGNAME	BMS-820836
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0J9QS
DRUGNAME	BTRC4017A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0J9SB
DRUGNAME	Derlotuximan biotin
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D0J9TA
DRUGNAME	Sensor linked micelle
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0J9TO
DRUGNAME	HG-1076
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0J9UA
DRUGNAME	hESC-derived RPE (PF-05206388)
INDICATI	Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1
	
TTDDRUID	D0J9UB
DRUGNAME	RG7593
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Discontinued in Phase 2
	
TTDDRUID	D0J9UN
DRUGNAME	Uracil mustard
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
	
TTDDRUID	D0J9UY
DRUGNAME	V505
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2
	
TTDDRUID	D0J9VG
DRUGNAME	NSI-566
INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 2
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1
	
TTDDRUID	D0J9VK
DRUGNAME	CM-156
INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Investigative
	
TTDDRUID	D0J9VL
DRUGNAME	MC2-01 PAD cream
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
	
TTDDRUID	D0J9XZ
DRUGNAME	Torasemide
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0J9YS
DRUGNAME	DFRF4539A
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0J9ZR
DRUGNAME	Niclosamide
INDICATI	Cestodes infection [ICD-11: 1F70-1F76] Approved
	
TTDDRUID	D0JA1Z
DRUGNAME	TA-6666
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0JA3Y
DRUGNAME	MEDI-578
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0JA7V
DRUGNAME	PRX-105
INDICATI	Poison intoxication [ICD-11: NE6Z] Phase 1
	
TTDDRUID	D0JA8R
DRUGNAME	HLA-DQ2 peptide vaccine
INDICATI	Coeliac disease [ICD-11: DA95] Phase 1
	
TTDDRUID	D0JB0D
DRUGNAME	Influenza subunit vaccines
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0JB0N
DRUGNAME	BLV-0704
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0JB2J
DRUGNAME	Isatuximab
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
INDICATI	Plasma cell myeloma [ICD-11: 2A83.1] Phase 3
	
TTDDRUID	D0JB3H
DRUGNAME	Omaveloxolone
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Clinical trial
	
TTDDRUID	D0JB4V
DRUGNAME	XEN-403
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0JB4W
DRUGNAME	CHIR-29498
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0JB7Z
DRUGNAME	AIT-034
INDICATI	Dementia [ICD-11: 6D80-6D86] Discontinued in Phase 3
	
TTDDRUID	D0JB9C
DRUGNAME	PF-06688992
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0JC3U
DRUGNAME	Resorcinol compound 11
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0JC4J
DRUGNAME	SARMs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0JC7A
DRUGNAME	NP-50501
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0JC8G
DRUGNAME	PL2100
INDICATI	Stroke [ICD-11: 8B20] Terminated
	
TTDDRUID	D0JC8L
DRUGNAME	PMID25666693-Compound-31
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0JC9K
DRUGNAME	VI7734
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 1
	
TTDDRUID	D0JC9N
DRUGNAME	Adapalene
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D0JD1R
DRUGNAME	Zn-DPA-G
INDICATI	Glioma [ICD-11: 2A00.0] Investigative
	
TTDDRUID	D0JD4S
DRUGNAME	CU-906
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0JD4T
DRUGNAME	Anti-CD19 CAR transduced T cells
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0JD5W
DRUGNAME	PMID27998201-Compound-7
INDICATI	Abdominal aortic aneurysm [ICD-11: BD50.4] Patented
	
TTDDRUID	D0JD6Y
DRUGNAME	CD19 CAR T
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D0JE2E
DRUGNAME	Rosuvastatin
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
INDICATI	Elevated C-reactive protein [ICD-11: MA14.15] Phase 3
	
TTDDRUID	D0JE4D
DRUGNAME	Dornase Alfa
INDICATI	Cystic fibrosis [ICD-11: CA25] Approved
	
TTDDRUID	D0JE8O
DRUGNAME	BNT162b2 SARS-CoV-2 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0JF2I
DRUGNAME	BNT162c2 SARS-CoV-2 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0JF3M
DRUGNAME	P-144
INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 2
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D0JF6C
DRUGNAME	Eltanexor oral
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0JF6O
DRUGNAME	Eltenac
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D0JF9Z
DRUGNAME	CSL-362
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0JG2X
DRUGNAME	JCAR018
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0JG6T
DRUGNAME	XEN-401
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0JH5K
DRUGNAME	TVI-Kidney-1
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D0JH6W
DRUGNAME	DX-9065a
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D0JH9T
DRUGNAME	ACE-393
INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2
	
TTDDRUID	D0JI1J
DRUGNAME	GP-683
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0JI1S
DRUGNAME	RDEA-640
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0JI2E
DRUGNAME	Aleplasinin
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0JI4J
DRUGNAME	BMS-986179
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0JI4M
DRUGNAME	CAR-T cells targeting HER2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0JI5G
DRUGNAME	PCNU
INDICATI	Brain cancer [ICD-11: 2A00] Terminated
	
TTDDRUID	D0JI8B
DRUGNAME	Milataxel
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0JJ1B
DRUGNAME	Artilide
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 1
	
TTDDRUID	D0JJ7S
DRUGNAME	Valbenazine Tosylate
INDICATI	Tardive dyskinesia [ICD-11: 8A02.10] Approved
	
TTDDRUID	D0JK2N
DRUGNAME	PMID25666693-Compound-22
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0JK2R
DRUGNAME	RMJH-111b
INDICATI	Essential hypertension [ICD-11: BA00] Phase 1/2
	
TTDDRUID	D0JK3V
DRUGNAME	Imidazole derivative 4
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0JL0C
DRUGNAME	LEAF-4L6715
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D0JL1M
DRUGNAME	Thiethylperazine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0JL2K
DRUGNAME	Grepafloxacin
INDICATI	Chronic bronchitis [ICD-11: CA20.1] Approved
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market
	
TTDDRUID	D0JL3Y
DRUGNAME	HuGAL-F2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0JL4D
DRUGNAME	CBT-101 + CBT-501
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0JM0G
DRUGNAME	Non-Hodgkin's lymphoma vaccine
INDICATI	Haemophilus influenza [ICD-11: 1G40] Phase 2
	
TTDDRUID	D0JM7Z
DRUGNAME	ASP8062
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2
	
TTDDRUID	D0JN3M
DRUGNAME	ITAMELINE
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1
	
TTDDRUID	D0JN5H
DRUGNAME	Trunkamide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0JN5N
DRUGNAME	Laquinimod
INDICATI	Lupus [ICD-11: 4A40] Phase 3
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
INDICATI	Primary progressive multiple sclerosis [ICD-11: 8A40.1] Phase 2
	
TTDDRUID	D0JN6P
DRUGNAME	PEPIDH1M
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
	
TTDDRUID	D0JN8C
DRUGNAME	mRNA-1325
INDICATI	Semliki forest virus infection [ICD-11: 1D9Y] Phase 1/2
	
TTDDRUID	D0JN9Z
DRUGNAME	DB103
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0JO0I
DRUGNAME	VBY- 825
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0JO3U
DRUGNAME	Elliptinium acetate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0JO3X
DRUGNAME	AG-SDT102
INDICATI	Genitourinary disease [ICD-11: GA0Z-GC8Z] Investigative
	
TTDDRUID	D0JO4O
DRUGNAME	LEAF-4L7520
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D0JO7Y
DRUGNAME	Fulvestrant
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0JO8T
DRUGNAME	ACER-003
INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2
	
TTDDRUID	D0JO8Z
DRUGNAME	Fosfestrol
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0JO9M
DRUGNAME	Anti-hCD70 CAR transduced PBL
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
	
TTDDRUID	D0JP4A
DRUGNAME	OsteoCel
INDICATI	Injury [ICD-11: NA00-ND5Z] Approved
	
TTDDRUID	D0JP4H
DRUGNAME	Bethanidine
INDICATI	Heart arrhythmia [ICD-11: BC65] Withdrawn from market
	
TTDDRUID	D0JP8D
DRUGNAME	GSK249320
INDICATI	Stroke [ICD-11: 8B20] Phase 2
	
TTDDRUID	D0JQ2W
DRUGNAME	GBM-Lamp-Vax
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D0JQ4R
DRUGNAME	AA-10022
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0JQ4S
DRUGNAME	Xmab-7195
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0JQ7Y
DRUGNAME	Ximelagatran
INDICATI	Coagulation defect [ICD-11: 3B10.0] Withdrawn from market
	
TTDDRUID	D0JR0F
DRUGNAME	Thiazole carboxamide derivative 25
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0JR0P
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 4
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0JR9V
DRUGNAME	JBP-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0JR9Y
DRUGNAME	MAS825
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0JS0W
DRUGNAME	PF-05230907
INDICATI	Nontraumatic intracerebral hemorrhage [ICD-11: 8B00.4] Phase 1
	
TTDDRUID	D0JS2A
DRUGNAME	Somatotropin rdna
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved
	
TTDDRUID	D0JS2L
DRUGNAME	Anti-RSV mab
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D0JS4E
DRUGNAME	ICM-3
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Terminated
	
TTDDRUID	D0JS7E
DRUGNAME	LMS-611
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0JS8H
DRUGNAME	ME1111
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2
	
TTDDRUID	D0JS9U
DRUGNAME	GSK-2231395A
INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 1
	
TTDDRUID	D0JT0B
DRUGNAME	Amidine compound 5
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D0JT0U
DRUGNAME	CAR-T cells targeting CD33
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical
	
TTDDRUID	D0JT1P
DRUGNAME	Brain tumor vaccine
INDICATI	Brain cancer [ICD-11: 2A00] Discontinued in Phase 1
	
TTDDRUID	D0JT5I
DRUGNAME	PF-04457845
INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 2
	
TTDDRUID	D0JT6Q
DRUGNAME	IC14
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0JT8B
DRUGNAME	PMID25666693-Compound-147
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0JU3A
DRUGNAME	U-Strip Diabetes
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0JU5X
DRUGNAME	Bardoxolone methyl
INDICATI	Mixed connective tissue disease [ICD-11: 4A43.3] Phase 3
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 2
	
TTDDRUID	D0JV0O
DRUGNAME	GM608
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0JV4A
DRUGNAME	PA08140
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0JV4Q
DRUGNAME	Lanoconazole
INDICATI	Dermatological disease [ICD-11: DA24.Y] Approved
	
TTDDRUID	D0JV4R
DRUGNAME	TriCAR-T-CD19
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0JV8Q
DRUGNAME	XB-05
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0JV8Z
DRUGNAME	HIV recombinant proteins vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0JW0V
DRUGNAME	GCS-100
INDICATI	Chronic kidney disease [ICD-11: GB61] Phase 2
	
TTDDRUID	D0JW1S
DRUGNAME	Meglumine gadoterate
INDICATI	Blood brain barrier [ICD-11: 5C61.5] Approved
	
TTDDRUID	D0JW2O
DRUGNAME	Anti-HER3/EGFR DAF
INDICATI	Metastatic epithelial tumour [ICD-11: 2D60] Phase 1
	
TTDDRUID	D0JW2Y
DRUGNAME	Anti-Clostridium difficile mabs
INDICATI	Clostridium infection [ICD-11: 1A04] Investigative
	
TTDDRUID	D0JW6R
DRUGNAME	LAM-002
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0JW7D
DRUGNAME	Omiganan
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
INDICATI	Rosacea [ICD-11: ED90.0] Phase 3
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	External genital and perianal wart [ICD-11: 1A95] Phase 2
INDICATI	Vulvar intraepithelial neoplasia [ICD-11: 2E67.10] Phase 2
	
TTDDRUID	D0JW7T
DRUGNAME	Amide derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0JW9E
DRUGNAME	CAR-T cells targeting Mucl
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical
	
TTDDRUID	D0JX4I
DRUGNAME	PMID25666693-Compound-62
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0JX7M
DRUGNAME	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0JY0M
DRUGNAME	CD28 and CD137 CAR-T Cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0JY2K
DRUGNAME	NS-1643
INDICATI	Heart arrhythmia [ICD-11: BC65] Investigative
	
TTDDRUID	D0JY2X
DRUGNAME	Neu-2000
INDICATI	Cardiac arrest [ICD-11: MC82] Phase 1
	
TTDDRUID	D0JY3V
DRUGNAME	Racecadotril
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
	
TTDDRUID	D0JY4Y
DRUGNAME	E-3040
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D0JY5S
DRUGNAME	Methantheline
INDICATI	Gastritis [ICD-11: DA42] Approved
INDICATI	Pancreatitis [ICD-11: DC31-DC34] Approved
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D0JY6R
DRUGNAME	MTL-101
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0JY8T
DRUGNAME	Bazedoxifene
INDICATI	Osteopetrosis [ICD-11: LD24.10] Approved
	
TTDDRUID	D0JZ4C
DRUGNAME	Px563L
INDICATI	Anthrax [ICD-11: 1B97] Phase 1
	
TTDDRUID	D0JZ5Y
DRUGNAME	Gp75 DNA vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0JZ7P
DRUGNAME	Thymosin alpha-1
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0JZ8X
DRUGNAME	HGTV43
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0K0AT
DRUGNAME	SARALASIN
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0K0CK
DRUGNAME	AZ-17
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D0K0DB
DRUGNAME	RO-25-6981
INDICATI	Cancer related pain [ICD-11: MG30] Terminated
	
TTDDRUID	D0K0DV
DRUGNAME	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0K0DY
DRUGNAME	Zinc hyaluronate
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D0K0EK
DRUGNAME	Prasterone
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 4
	
TTDDRUID	D0K0FV
DRUGNAME	QR-334
INDICATI	Salivary gland dysfunction [ICD-11: 5B0Z] Discontinued in Phase 2
	
TTDDRUID	D0K0GF
DRUGNAME	SSR-181507
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0K0GN
DRUGNAME	LDI-200
INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 3
	
TTDDRUID	D0K0IM
DRUGNAME	MK-8666
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0K0IN
DRUGNAME	KBSA-301
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1
	
TTDDRUID	D0K0IS
DRUGNAME	Polyglutamate camptothecin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0K0IW
DRUGNAME	CRA-028129
INDICATI	Psoriatic disorder [ICD-11: EA90] Terminated
	
TTDDRUID	D0K0JQ
DRUGNAME	Dilmapimod
INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 2
	
TTDDRUID	D0K0KG
DRUGNAME	Heterodimeric IL-15
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0K0KH
DRUGNAME	Tropisetron
INDICATI	Fibromyalgia [ICD-11: MG30.01] Approved
	
TTDDRUID	D0K0KJ
DRUGNAME	LF-521
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0K0KP
DRUGNAME	GE-68
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D0K0KQ
DRUGNAME	BC-819
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
	
TTDDRUID	D0K0LA
DRUGNAME	LC34AD3
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0K0LG
DRUGNAME	CPG23NEUR
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0K0MB
DRUGNAME	LP-10218
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K0MI
DRUGNAME	Sulphur hexafluoride microbubble ultrasound agent
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0K0MW
DRUGNAME	Lofexidine
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Approved
INDICATI	Heroin and opiate withdrawal [ICD-11: 6C43] Approved
	
TTDDRUID	D0K0OB
DRUGNAME	AL-18
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D0K0OU
DRUGNAME	MBX-1684
INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative
	
TTDDRUID	D0K0OX
DRUGNAME	PMID30074795-compound-2
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0K0OZ
DRUGNAME	Famotidine
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D0K0SB
DRUGNAME	NKM
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0K0SW
DRUGNAME	VLST-002
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0K0TC
DRUGNAME	Sertraline
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0K0TZ
DRUGNAME	Multimeric-001
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0K0VH
DRUGNAME	S-5751
INDICATI	Rhinitis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0K0VO
DRUGNAME	Urapidil
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1/2
	
TTDDRUID	D0K0WA
DRUGNAME	CNTO-5825
INDICATI	Allergic asthma [ICD-11: CA23.0] Phase 1
	
TTDDRUID	D0K0XG
DRUGNAME	MF-8615
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0K0XW
DRUGNAME	C-9138
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1
	
TTDDRUID	D0K0YC
DRUGNAME	PD-0325901
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0K0ZB
DRUGNAME	Tresperimus
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 3
	
TTDDRUID	D0K0ZI
DRUGNAME	PMID25666693-Compound-141
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0K0ZK
DRUGNAME	ADX-63365
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0K1AF
DRUGNAME	A-74273
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0K1AI
DRUGNAME	Sch-58500
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0K1AK
DRUGNAME	LCAR-B38M CAR-T Cell
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D0K1AP
DRUGNAME	NSL-101
INDICATI	Facial pain [ICD-11: MB6Y] Phase 2
	
TTDDRUID	D0K1BR
DRUGNAME	NLP-61
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0K1CL
DRUGNAME	SDZ-224-015
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0K1DC
DRUGNAME	Romergoline
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D0K1EG
DRUGNAME	QAV-680
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D0K1EO
DRUGNAME	Picroliv
INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 2
	
TTDDRUID	D0K1HO
DRUGNAME	Acifran
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 3
	
TTDDRUID	D0K1LJ
DRUGNAME	Ad5-TRAIL
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0K1LO
DRUGNAME	R-873
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2
	
TTDDRUID	D0K1OA
DRUGNAME	D-4418
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Discontinued in Phase 1
	
TTDDRUID	D0K1OK
DRUGNAME	CCR5 mab
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0K1OM
DRUGNAME	Remdesivir + chloroquine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0K1OR
DRUGNAME	IB-06F259
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K1PR
DRUGNAME	B-428
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0K1QD
DRUGNAME	Sulfamylon
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0K1QO
DRUGNAME	CEFETECOL
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3
	
TTDDRUID	D0K1SR
DRUGNAME	PH-794428
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2
	
TTDDRUID	D0K1ST
DRUGNAME	Revefenacin
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0K1SZ
DRUGNAME	Norcisapride
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2
	
TTDDRUID	D0K1TM
DRUGNAME	AMP-423
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K1UD
DRUGNAME	MMV00/0053
INDICATI	Malaria [ICD-11: 1F40-1F45] Terminated
	
TTDDRUID	D0K1UF
DRUGNAME	Saliphenylhalamide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0K1UO
DRUGNAME	Resorcinol compound 30
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0K1VK
DRUGNAME	AZD8055
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2
	
TTDDRUID	D0K1VV
DRUGNAME	SR8278
INDICATI	Myocardial disease [ICD-11: BC43.20] Preclinical
	
TTDDRUID	D0K1XK
DRUGNAME	Hydralazine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0K1XV
DRUGNAME	RemUnity
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3
	
TTDDRUID	D0K1YQ
DRUGNAME	SP-10
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0K1ZD
DRUGNAME	Edobacomab
INDICATI	Endotoxic shock [ICD-11: 1G41] Discontinued in Preregistration
	
TTDDRUID	D0K2AA
DRUGNAME	Biaryl mannoside derivative 11
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0K2AR
DRUGNAME	Pyridocarbazole
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K2BQ
DRUGNAME	BRL-61063
INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2
	
TTDDRUID	D0K2CR
DRUGNAME	Nemorubicin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0K2CV
DRUGNAME	HOE-694
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D0K2EC
DRUGNAME	MEDI-77
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0K2ER
DRUGNAME	MK-886
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0K2FH
DRUGNAME	Serenoa repens extract
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved
	
TTDDRUID	D0K2GA
DRUGNAME	Silteplase
INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved
	
TTDDRUID	D0K2GV
DRUGNAME	HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0K2HA
DRUGNAME	PF-2413873
INDICATI	Endometriosis [ICD-11: GA10] Phase 1
	
TTDDRUID	D0K2HU
DRUGNAME	PF-06444752
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0K2ID
DRUGNAME	NKTR-181
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
INDICATI	Chronic low back pain [ICD-11: MG30.02] Phase 3
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D0K2KD
DRUGNAME	PB-6
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0K2KR
DRUGNAME	Eplerenone
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0K2KS
DRUGNAME	HuCNS-SC
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 2
	
TTDDRUID	D0K2LR
DRUGNAME	LG-611
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0K2MT
DRUGNAME	ADC-7828
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0K2NA
DRUGNAME	YM-57158
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1
	
TTDDRUID	D0K2OV
DRUGNAME	Oxytrex
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0K2PH
DRUGNAME	Elvucitabine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D0K2PS
DRUGNAME	Carmoxirole
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D0K2QG
DRUGNAME	DASANTAFIL
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2
	
TTDDRUID	D0K2RV
DRUGNAME	Timothy grass extract
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1
	
TTDDRUID	D0K2RY
DRUGNAME	Itriglumide
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0K2TB
DRUGNAME	Docarpamine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0K2UJ
DRUGNAME	MUT-11931
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0K2WK
DRUGNAME	Cicletanine
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
	
TTDDRUID	D0K2XB
DRUGNAME	GX-51
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K2XK
DRUGNAME	PMID26815044-Compound-I
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0K2ZF
DRUGNAME	PH-797804
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0K2ZG
DRUGNAME	5-LO (pain/neuro-inflammation), St Charles Pharmaceuticals
INDICATI	Nervous system inflammation [ICD-11: 1D0Y] Investigative
	
TTDDRUID	D0K3DA
DRUGNAME	PMID26651364-Compound-112
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0K3DQ
DRUGNAME	Cefotiam
INDICATI	Respiratory tract infection [ICD-11: CA45] Approved
	
TTDDRUID	D0K3FG
DRUGNAME	EDP-13
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K3FJ
DRUGNAME	Imidazole derivative 6
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0K3FX
DRUGNAME	NT-503
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 1/2
	
TTDDRUID	D0K3GB
DRUGNAME	99mTc-MIP-1340
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0K3GU
DRUGNAME	PF-3185043
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D0K3JQ
DRUGNAME	RPI-MN
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0K3JZ
DRUGNAME	PT-00311
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0K3KE
DRUGNAME	PMID25666693-Compound-155
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0K3KM
DRUGNAME	PMID25666693-Compound-148
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0K3LO
DRUGNAME	Romosozumab
INDICATI	Postmenopausal osteoporosis [ICD-11: FB83.11] Approved
	
TTDDRUID	D0K3LW
DRUGNAME	Malathion
INDICATI	Pediculus capitis infestation [ICD-11: 1G00.0] Approved
	
TTDDRUID	D0K3LX
DRUGNAME	RNAPc2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2
	
TTDDRUID	D0K3MC
DRUGNAME	Lofepramine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
	
TTDDRUID	D0K3MU
DRUGNAME	NRL-0301
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative
	
TTDDRUID	D0K3OK
DRUGNAME	Difelikefalin
INDICATI	Pruritus [ICD-11: EC90] Phase 3
	
TTDDRUID	D0K3QS
DRUGNAME	Everolimus
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved
INDICATI	Kidney cancer [ICD-11: 2C90.0] Phase 3
	
TTDDRUID	D0K3QW
DRUGNAME	REC-0436
INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative
	
TTDDRUID	D0K3RP
DRUGNAME	NRI-1013
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0K3SM
DRUGNAME	MALP-2S
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D0K3SV
DRUGNAME	PF-05236812
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1
	
TTDDRUID	D0K3UQ
DRUGNAME	Vercirnon
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
	
TTDDRUID	D0K3VA
DRUGNAME	Erdosteine
INDICATI	Bronchitis [ICD-11: CA20] Approved
	
TTDDRUID	D0K3WN
DRUGNAME	DNP-004089
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0K3WO
DRUGNAME	MK-08887A
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0K3XB
DRUGNAME	JCAR015
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
	
TTDDRUID	D0K3XP
DRUGNAME	Methoxy polyethylene glycol-epoetin beta
INDICATI	Kidney transplant rejection [ICD-11: NE84] Approved
	
TTDDRUID	D0K3XS
DRUGNAME	Custirsen
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0K3YG
DRUGNAME	ANX-201
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated
	
TTDDRUID	D0K3ZL
DRUGNAME	MA09-hRPE cells
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 1/2
INDICATI	Stargardt disease [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	D0K3ZR
DRUGNAME	Bisoprolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0K4CD
DRUGNAME	ASP-8477
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D0K4CH
DRUGNAME	IMGN-009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K4CQ
DRUGNAME	Indecainide
INDICATI	Dysrhythmias [ICD-11: BC9Z] Approved
	
TTDDRUID	D0K4DI
DRUGNAME	Anistreplase
INDICATI	Acute coronary syndrome [ICD-11: BA41] Approved
	
TTDDRUID	D0K4ED
DRUGNAME	Ro-23-9424
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0K4FP
DRUGNAME	AZD-8165
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0K4GG
DRUGNAME	STP-902
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D0K4GI
DRUGNAME	Affinitak + Gemcitabine
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative
	
TTDDRUID	D0K4GW
DRUGNAME	INL-002
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
	
TTDDRUID	D0K4HW
DRUGNAME	N-DESMETHYLCLOZAPINE
INDICATI	Schizoaffective disorder [ICD-11: 6A21] Phase 2
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0K4IS
DRUGNAME	PF-06293620
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0K4IV
DRUGNAME	TD-1439
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D0K4JI
DRUGNAME	JOT106
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0K4JQ
DRUGNAME	GSK2336805
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0K4JS
DRUGNAME	ATX-3105
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0K4MH
DRUGNAME	Tapentadol hydrochloride
INDICATI	Acute pain [ICD-11: MG31] Approved
	
TTDDRUID	D0K4MU
DRUGNAME	Crobenetine
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0K4MW
DRUGNAME	LP-30171
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K4NZ
DRUGNAME	Velneperit
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
	
TTDDRUID	D0K4OC
DRUGNAME	DI-VAL-L-DC
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0K4OF
DRUGNAME	PlaMavax
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D0K4OL
DRUGNAME	LOR-2501
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0K4OS
DRUGNAME	TS-121
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1
	
TTDDRUID	D0K4PN
DRUGNAME	AZD-1134
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0K4QT
DRUGNAME	BAY-Y-5959
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D0K4RK
DRUGNAME	Blinatumomab
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2/3
	
TTDDRUID	D0K4RU
DRUGNAME	AF-130
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D0K4SZ
DRUGNAME	PMID25666693-Compound-46
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0K4UT
DRUGNAME	DNA-2401
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0K4UV
DRUGNAME	KU-5039
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0K4UW
DRUGNAME	Imitrodast
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0K4VN
DRUGNAME	Molecule 21
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0K4VW
DRUGNAME	Cenersen
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0K4WT
DRUGNAME	S-1033
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2
	
TTDDRUID	D0K4WW
DRUGNAME	11A1
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0K4YE
DRUGNAME	PMID32198291-compound11r
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0K5BP
DRUGNAME	HSP-990
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0K5BY
DRUGNAME	MIM-3Ae
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D0K5CB
DRUGNAME	Salbutamol
INDICATI	Acute asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0K5CJ
DRUGNAME	DAVLB-HYDRAZIDE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0K5CX
DRUGNAME	Celacade
INDICATI	Chronic heart failure [ICD-11: BD1Z] Approved
	
TTDDRUID	D0K5EE
DRUGNAME	S-33084
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Preclinical
	
TTDDRUID	D0K5ER
DRUGNAME	Rosiglitazone XR
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0K5ET
DRUGNAME	M207
INDICATI	Migraine [ICD-11: 8A80] Phase 3
	
TTDDRUID	D0K5HD
DRUGNAME	LY-315902
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0K5HI
DRUGNAME	Talnetant
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
INDICATI	Schizoaffective disorder [ICD-11: 6A21] Discontinued in Phase 2
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2
	
TTDDRUID	D0K5HO
DRUGNAME	PMID32198291-compound13b
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0K5IP
DRUGNAME	Palonosetron + fosnetupitant
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Approved
	
TTDDRUID	D0K5IQ
DRUGNAME	DAA-1097
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0K5JE
DRUGNAME	HD-0701
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative
	
TTDDRUID	D0K5JG
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 5
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0K5KS
DRUGNAME	Adalimumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0K5LQ
DRUGNAME	Pemirolast
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved
	
TTDDRUID	D0K5LT
DRUGNAME	Adult stem cell therapy
INDICATI	Stroke [ICD-11: 8B20] Discontinued in Phase 2
	
TTDDRUID	D0K5MC
DRUGNAME	SNK-01
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D0K5NG
DRUGNAME	HLD200
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Application submitted
	
TTDDRUID	D0K5NN
DRUGNAME	GFP-bacterial methioninase/selenomethionine GDEPT
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K5OT
DRUGNAME	Penicillin G Sodium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0K5QY
DRUGNAME	AP-101
INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative
	
TTDDRUID	D0K5RX
DRUGNAME	KYS-05050
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K5SN
DRUGNAME	Dosmalfate
INDICATI	Stomach ulcer [ICD-11: DA60.Z] Approved
	
TTDDRUID	D0K5TE
DRUGNAME	BMS-955176
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0K5UK
DRUGNAME	HuMax-Wnt
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K5WM
DRUGNAME	CS-3030
INDICATI	Thrombosis [ICD-11: DB61-GB90] Preclinical
	
TTDDRUID	D0K5WS
DRUGNAME	Cholecalciferol
INDICATI	Vitamin D deficiency [ICD-11: 5B57] Approved
	
TTDDRUID	D0K6AL
DRUGNAME	PM1183
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
	
TTDDRUID	D0K6CG
DRUGNAME	DRA-161
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0K6CW
DRUGNAME	CEN-109
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0K6DG
DRUGNAME	ONO-8130
INDICATI	Pollakiuria [ICD-11: MF50.1] Terminated
	
TTDDRUID	D0K6ES
DRUGNAME	CRT-0004592
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K6GI
DRUGNAME	Benzimidazole derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0K6GZ
DRUGNAME	Sparfloxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0K6HE
DRUGNAME	PRO-001
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 2
	
TTDDRUID	D0K6HG
DRUGNAME	V116517
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
	
TTDDRUID	D0K6IM
DRUGNAME	PMID28270021-Compound-WO2010077680 495
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0K6JQ
DRUGNAME	INO-3401
INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D0K6JZ
DRUGNAME	DCLL9718S
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0K6KU
DRUGNAME	AFX-9901
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0K6LA
DRUGNAME	OPC-22575
INDICATI	Ulcerative colitis [ICD-11: DD71] Investigative
	
TTDDRUID	D0K6LX
DRUGNAME	MK-5823
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0K6MW
DRUGNAME	Teicoplanin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0K6NS
DRUGNAME	T-226293
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0K6NW
DRUGNAME	REC-02
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 1
	
TTDDRUID	D0K6PP
DRUGNAME	AG-NPP709
INDICATI	Bronchitis [ICD-11: CA20] Phase 3
	
TTDDRUID	D0K6QU
DRUGNAME	IT-141
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0K6SM
DRUGNAME	Ilepatril
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 2/3
INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2/3
INDICATI	Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2/3
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2/3
	
TTDDRUID	D0K6TN
DRUGNAME	Resorcinol compound 25
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0K6UG
DRUGNAME	RhH1.3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0K6UO
DRUGNAME	NK-101
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D0K6UQ
DRUGNAME	HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0K6UV
DRUGNAME	DNL201
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0K6VD
DRUGNAME	Juniper tar
INDICATI	Eczema [ICD-11: EA80-EA89] Approved
	
TTDDRUID	D0K6XI
DRUGNAME	Griffithsin
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
	
TTDDRUID	D0K6ZH
DRUGNAME	PSI-661
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated
	
TTDDRUID	D0K6ZI
DRUGNAME	H2N2 live attenuated influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0K7BF
DRUGNAME	NX-201
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Investigative
	
TTDDRUID	D0K7DV
DRUGNAME	Kevetrin
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0K7FT
DRUGNAME	AG-221
INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0K7FY
DRUGNAME	EGF816
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D0K7HU
DRUGNAME	Ciclesonide
INDICATI	Obstructive airway disease [ICD-11: CB40.Y] Approved
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0K7JC
DRUGNAME	ZP-001
INDICATI	Contracture [ICD-11: FA30-FA34] Investigative
	
TTDDRUID	D0K7KV
DRUGNAME	ORP-100
INDICATI	Respiratory disease [ICD-11: CB40] Investigative
	
TTDDRUID	D0K7LA
DRUGNAME	Low molecular weight dextran sulphate
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Phase 2
	
TTDDRUID	D0K7LI
DRUGNAME	Resorcinol compound 31
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0K7LU
DRUGNAME	Santonin
INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved
	
TTDDRUID	D0K7MY
DRUGNAME	ESI-014
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0K7NC
DRUGNAME	PMID30107136-Compound-Example16
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0K7NI
DRUGNAME	ABT-RTA-408
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0K7NJ
DRUGNAME	Recombinant coagulation factors
INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D0K7NQ
DRUGNAME	Colistin
INDICATI	Pseudomonas infection [ICD-11: 1B92] Approved
	
TTDDRUID	D0K7OO
DRUGNAME	SA-14-14-2
INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Approved
	
TTDDRUID	D0K7OW
DRUGNAME	GSK-1360707
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
	
TTDDRUID	D0K7PD
DRUGNAME	Cat hair allergen extract
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1
	
TTDDRUID	D0K7PQ
DRUGNAME	ST-570
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0K7QQ
DRUGNAME	TS-134
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0K7SX
DRUGNAME	Avelumab
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0K7TE
DRUGNAME	Biaryl mannoside derivative 27
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0K7TX
DRUGNAME	HOE-065
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1
	
TTDDRUID	D0K7UL
DRUGNAME	S-2678
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0K7VM
DRUGNAME	ARI-1778
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0K7WK
DRUGNAME	Ondansetron
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Approved
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
	
TTDDRUID	D0K7WQ
DRUGNAME	GS-441524
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0K7XA
DRUGNAME	Pyrazole derivative 21
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0K7XR
DRUGNAME	KSB-304
INDICATI	Ulcerative colitis [ICD-11: DD71] Terminated
	
TTDDRUID	D0K7ZH
DRUGNAME	PF-06649751
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0K8AA
DRUGNAME	Zinc salts
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0K8AL
DRUGNAME	OG-232
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K8BJ
DRUGNAME	MNK-010
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0K8BO
DRUGNAME	TX-RAD
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0K8CI
DRUGNAME	Otilonium bromide
INDICATI	Gastric motility disorder [ICD-11: DA21] Approved
	
TTDDRUID	D0K8CP
DRUGNAME	HO/02/10
INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative
	
TTDDRUID	D0K8DI
DRUGNAME	SQ-109
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2
	
TTDDRUID	D0K8FI
DRUGNAME	Pegmusirudin
INDICATI	Angina pectoris [ICD-11: BA40] Phase 2
	
TTDDRUID	D0K8GD
DRUGNAME	AR20
INDICATI	Mental disease [ICD-11: 6E8Z] Phase 3
	
TTDDRUID	D0K8HA
DRUGNAME	LL-6531
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0K8HF
DRUGNAME	PLD-147
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0K8IX
DRUGNAME	Thiazolidinedione
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D0K8JE
DRUGNAME	TT-123
INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D0K8KA
DRUGNAME	DOX-PSASP-BBN-RGD prodrugs
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0K8KJ
DRUGNAME	DuP-129
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Terminated
	
TTDDRUID	D0K8KX
DRUGNAME	Quercetin
INDICATI	Obesity [ICD-11: 5B81] Approved
	
TTDDRUID	D0K8LB
DRUGNAME	PI-88/Taxotere
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0K8MP
DRUGNAME	Permethrin
INDICATI	Sarcoptes scabiei infection [ICD-11: 1G04] Approved
	
TTDDRUID	D0K8MQ
DRUGNAME	FP-1096
INDICATI	Endometriosis [ICD-11: GA10] Discontinued in Phase 3
	
TTDDRUID	D0K8NR
DRUGNAME	AMG 386
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Preclinical
	
TTDDRUID	D0K8NW
DRUGNAME	Ritanserin
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3
	
TTDDRUID	D0K8PH
DRUGNAME	SUVN-504
INDICATI	Vomiting [ICD-11: MD90] Investigative
	
TTDDRUID	D0K8RK
DRUGNAME	Alisporivir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0K8SH
DRUGNAME	GX-137
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0K8TI
DRUGNAME	Ranirestat
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 3
	
TTDDRUID	D0K8TO
DRUGNAME	AP1903
INDICATI	Transplant rejection [ICD-11: NE84] Phase 1/2
	
TTDDRUID	D0K8UN
DRUGNAME	SCIB-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K8WE
DRUGNAME	Anti-CD33 CAR-T cells
INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 1/2
	
TTDDRUID	D0K8WJ
DRUGNAME	Sf-1019
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
	
TTDDRUID	D0K8XT
DRUGNAME	Thiazole carboxamide derivative 10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0K8YG
DRUGNAME	ISA-HPV-01
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2
	
TTDDRUID	D0K8YK
DRUGNAME	DVD-Ig
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K8YX
DRUGNAME	4SCAR19 and 4SCAR30
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0K9BV
DRUGNAME	TVB-2640
INDICATI	Astrocytoma [ICD-11: 2A00.0Y] Phase 2
INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 2
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0K9CZ
DRUGNAME	VPM-1-002
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2
	
TTDDRUID	D0K9DI
DRUGNAME	GSK-356278
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 1
	
TTDDRUID	D0K9ES
DRUGNAME	Suprofenac
INDICATI	Ocular inflammation [ICD-11: 9C61.24] Investigative
	
TTDDRUID	D0K9FA
DRUGNAME	Dolutegravir + lamivudine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0K9HF
DRUGNAME	BLX-301
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative
	
TTDDRUID	D0K9IB
DRUGNAME	Vonapanitase
INDICATI	Arterial thrombosis [ICD-11: DB61-DD30] Phase 3
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 3
	
TTDDRUID	D0K9IF
DRUGNAME	PF-06305591
INDICATI	Chronic pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D0K9JO
DRUGNAME	AskBio009
INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1/2
	
TTDDRUID	D0K9KN
DRUGNAME	JNJ-26113100
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D0K9KS
DRUGNAME	Draculin
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0K9MB
DRUGNAME	CX-1030
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0K9MC
DRUGNAME	CetuGEX
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0K9MN
DRUGNAME	ZP-EPO
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0K9MY
DRUGNAME	Saxagliptin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D0K9NJ
DRUGNAME	F18-ML-10
INDICATI	Brain cancer [ICD-11: 2A00] Phase 2
	
TTDDRUID	D0K9OL
DRUGNAME	SCH 50911
INDICATI	Absence seizure [ICD-11: 8A68.2] Terminated
	
TTDDRUID	D0K9OU
DRUGNAME	MBX400
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 1
	
TTDDRUID	D0K9PC
DRUGNAME	AG-881
INDICATI	Glioma [ICD-11: 2A00.0] Phase 3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0K9PG
DRUGNAME	NXD-30001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K9PS
DRUGNAME	CHF-5480
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0K9QH
DRUGNAME	Benzothiazine-carboxamide compound 3
INDICATI	Skin inflammation [ICD-11: EF20.Y] Patented
	
TTDDRUID	D0K9QQ
DRUGNAME	Pyrvinium pamoate
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0K9RR
DRUGNAME	LF-943
INDICATI	Ischemia [ICD-11: 8B10-8B11] Terminated
	
TTDDRUID	D0K9SS
DRUGNAME	GP2015
INDICATI	Ankylosing spondylitis [ICD-11: FA92.0] Application submitted
INDICATI	Juvenile idiopathic arthritis [ICD-11: FA24] Application submitted
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Application submitted
INDICATI	Psoriatic arthritis [ICD-11: FA21] Application submitted
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Application submitted
	
TTDDRUID	D0K9TC
DRUGNAME	Sameridine
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0K9UK
DRUGNAME	E-6700
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0K9UT
DRUGNAME	Epi-13
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0K9WL
DRUGNAME	Glucagon injection
INDICATI	Hypoglycemia [ICD-11: 5A41] Phase 2
	
TTDDRUID	D0K9WP
DRUGNAME	131I-TM-601
INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0K9XI
DRUGNAME	DHF-18
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0K9YJ
DRUGNAME	JNJ-3534
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0K9ZU
DRUGNAME	CD45RB
INDICATI	Glioma [ICD-11: 2A00.0] Investigative
	
TTDDRUID	D0KA4R
DRUGNAME	NNZ-2591
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0KA7I
DRUGNAME	PMID30107136-Compound-Example7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0KA9L
DRUGNAME	AME-133v
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D0KB0Y
DRUGNAME	Pegargiminase
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2/3
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Argininosuccinate synthase deficiency [ICD-11: 5C50.A3] Phase 1
	
TTDDRUID	D0KB2E
DRUGNAME	FR167356
INDICATI	Osteoporosis [ICD-11: FB83.0] Preclinical
	
TTDDRUID	D0KB2Z
DRUGNAME	PMID25666693-Compound-1
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0KB6S
DRUGNAME	MVA-mBN85B
INDICATI	Measles [ICD-11: 1F03] Phase 2
	
TTDDRUID	D0KC1H
DRUGNAME	Infliximab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0KC1N
DRUGNAME	Adalimumab
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0KC2S
DRUGNAME	CAR-T cells targeting mesothelin
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D0KC5X
DRUGNAME	S-18616
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0KC7H
DRUGNAME	NCX-1236
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0KC7K
DRUGNAME	EC-154
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0KC8X
DRUGNAME	Bicyclic heteroaryl benzamide derivative 5
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0KC9U
DRUGNAME	Stage IV melanoma vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0KC9V
DRUGNAME	AD10-1025
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D0KD1A
DRUGNAME	HF-0699
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0KD1U
DRUGNAME	Practolol
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Approved
	
TTDDRUID	D0KD4U
DRUGNAME	FK-355
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0KD4X
DRUGNAME	Rapacuronium bromide
INDICATI	Muscle spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D0KD5P
DRUGNAME	Nefiracetam
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0KD5X
DRUGNAME	Pyrazole derivative 31
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0KD7E
DRUGNAME	XEL-003FP
INDICATI	Onychomycosis [ICD-11: EE12.1] Investigative
	
TTDDRUID	D0KD9F
DRUGNAME	Equilin
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0KE0C
DRUGNAME	STP-805
INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative
	
TTDDRUID	D0KE1F
DRUGNAME	DFP-10917
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
	
TTDDRUID	D0KE1V
DRUGNAME	SDZ-249482
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0KE4C
DRUGNAME	HG-1071
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0KE4Q
DRUGNAME	DFD-29
INDICATI	Rosacea [ICD-11: ED90.0] Phase 2
	
TTDDRUID	D0KE4Z
DRUGNAME	ARL-67085
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0KE7K
DRUGNAME	URG-302
INDICATI	Overactive bladder [ICD-11: GC50.0] Preclinical
	
TTDDRUID	D0KE8Q
DRUGNAME	PMID26651364-Compound-46
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0KE9G
DRUGNAME	hESC-derived oligodendrocyte progenitors (AST-OPC1)
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 1/2
	
TTDDRUID	D0KF3A
DRUGNAME	PMID25666693-Compound-98
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0KF3O
DRUGNAME	CardioPET
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
	
TTDDRUID	D0KF6X
DRUGNAME	MLN3897
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0KF9Q
DRUGNAME	Rigosertib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
	
TTDDRUID	D0KF9T
DRUGNAME	Anti-CD19 CAR-T
INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0KG1U
DRUGNAME	BXCL702
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0KG3R
DRUGNAME	Rivaroxaban
INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved
	
TTDDRUID	D0KG3Y
DRUGNAME	Imatinib
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0KG4B
DRUGNAME	Cefbuperazone sodium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0KG4Q
DRUGNAME	Cemiplimab
INDICATI	Cutaneous squamous cell carcinoma [ICD-11: 2C30] Approved
	
TTDDRUID	D0KG5D
DRUGNAME	Mapatumumab
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0KG5U
DRUGNAME	PMID26651364-Compound-9b
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0KG9M
DRUGNAME	PMID27998201-Compound-22
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented
INDICATI	Pancreatitis [ICD-11: DC31-DC34] Patented
INDICATI	Alzheimer disease [ICD-11: 8A20] Patented
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Patented
	
TTDDRUID	D0KH8Q
DRUGNAME	Ruxolitinib
INDICATI	Myelofibrosis [ICD-11: 2A22] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0KI3U
DRUGNAME	NXB-5886
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0KI5R
DRUGNAME	Dabigatran etexilate
INDICATI	Venous thromboembolism [ICD-11: BD72] Phase 3
	
TTDDRUID	D0KI9N
DRUGNAME	Antimicrobial LL-37 cathelicidin
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0KJ0U
DRUGNAME	AZD-7928
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Preclinical
	
TTDDRUID	D0KJ2J
DRUGNAME	BAY 1082439
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0KJ4S
DRUGNAME	ADS-4101
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
	
TTDDRUID	D0KJ4U
DRUGNAME	ACEA-1011
INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Terminated
	
TTDDRUID	D0KK1I
DRUGNAME	MVA E2 vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0KK2E
DRUGNAME	Eribulin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0KK4N
DRUGNAME	ISA-P53-01
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
	
TTDDRUID	D0KK4U
DRUGNAME	CB-1267
INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated
	
TTDDRUID	D0KK9D
DRUGNAME	CA-011
INDICATI	Chronic pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D0KK9E
DRUGNAME	Exherin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0KK9V
DRUGNAME	GI-4000 + gemcitabine
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0KL3K
DRUGNAME	YM-440
INDICATI	Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 2
	
TTDDRUID	D0KL3U
DRUGNAME	AR9281
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0KL4E
DRUGNAME	SAR422459
INDICATI	Stargardt disease [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	D0KL4J
DRUGNAME	Rabeprazole
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0KL4T
DRUGNAME	Ensitiximab
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0KL5U
DRUGNAME	SYM-008
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0KL7C
DRUGNAME	Aviptadil
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
INDICATI	Acute lung injury [ICD-11: NB32.3] Investigative
	
TTDDRUID	D0KL7G
DRUGNAME	MCL-1-specific antisense oligonucleotide + midostaurin(PKC412)
INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Investigative
	
TTDDRUID	D0KL9X
DRUGNAME	Krypton, Kr-81m
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0KM0W
DRUGNAME	PMID25666693-Compound-137
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0KM1B
DRUGNAME	Follicle stimulating hormone
INDICATI	Infertility [ICD-11: GB04] Phase 2
	
TTDDRUID	D0KM1F
DRUGNAME	PT-00114
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D0KM3P
DRUGNAME	NOStentin
INDICATI	Artery stenosis [ICD-11: BD52] Discontinued in Phase 1
	
TTDDRUID	D0KM4T
DRUGNAME	UAI-101
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0KM7O
DRUGNAME	Otamixaban
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Preclinical
	
TTDDRUID	D0KN0I
DRUGNAME	Valetizumab
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0KN1U
DRUGNAME	Myo-inositol hexaphosphate
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2/3
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Investigative
	
TTDDRUID	D0KN2C
DRUGNAME	Insulin long-acting iv
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0KN2M
DRUGNAME	Cynarin
INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Approved
	
TTDDRUID	D0KN5B
DRUGNAME	CYT107
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0KN7H
DRUGNAME	Mitoflaxone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0KN7T
DRUGNAME	Thiazole carboxamide derivative 22
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0KN7Y
DRUGNAME	NPT088
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 1
	
TTDDRUID	D0KP0L
DRUGNAME	SE-ET-TP020d
INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative
	
TTDDRUID	D0KP0W
DRUGNAME	Valproic Acid
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0KP2R
DRUGNAME	ID-12
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0KP9A
DRUGNAME	Anti-PD-L1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0KQ0C
DRUGNAME	Danegaptide
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2
	
TTDDRUID	D0KQ2D
DRUGNAME	RVX-297
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0KQ7M
DRUGNAME	ARQ 531
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 2
	
TTDDRUID	D0KQ8H
DRUGNAME	PMID21925774-compound-5e
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
	
TTDDRUID	D0KQ8W
DRUGNAME	SurVaxM
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0KQ8X
DRUGNAME	Entresto
INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 3
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3
	
TTDDRUID	D0KR1N
DRUGNAME	PPI-2458
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0KR2J
DRUGNAME	Entecavir
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0KR3X
DRUGNAME	CGS-30440
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0KR5B
DRUGNAME	Hydrocortisone
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
INDICATI	Congenital adrenal hyperplasia [ICD-11: 5A71.01] Phase 2
	
TTDDRUID	D0KR5K
DRUGNAME	Capravirine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0KR6E
DRUGNAME	SER-207
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0KR9E
DRUGNAME	PMID26815044-Compound-122
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0KR9U
DRUGNAME	Picrotoxin
INDICATI	Respiratory distress syndrome [ICD-11: CB00] Approved
	
TTDDRUID	D0KS0I
DRUGNAME	WAY-256805
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0KS6F
DRUGNAME	IRX-2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D0KS6W
DRUGNAME	Phenyltoloxamine
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D0KT1Q
DRUGNAME	Pyrazole derivative 11
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0KT3X
DRUGNAME	Thrombin/fibrinogen matrix patch
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
	
TTDDRUID	D0KT4B
DRUGNAME	CLP-1002
INDICATI	Congestive heart failure [ICD-11: BD10] Investigative
	
TTDDRUID	D0KT8D
DRUGNAME	AC0058TA
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
	
TTDDRUID	D0KT8U
DRUGNAME	Semotiadil
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Preregistration
	
TTDDRUID	D0KU4M
DRUGNAME	MB07803
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0KU5J
DRUGNAME	Resorcinol compound 5
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0KV1I
DRUGNAME	GC-1113
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1
	
TTDDRUID	D0KV1Q
DRUGNAME	Trafermin
INDICATI	Periodontitis [ICD-11: DA0C] Phase 3
	
TTDDRUID	D0KV1Z
DRUGNAME	ImmunoVEX HSV2
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1
	
TTDDRUID	D0KV2E
DRUGNAME	Sonepcizumab
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
	
TTDDRUID	D0KV3M
DRUGNAME	Varlilumab
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D0KV4Z
DRUGNAME	CI-949
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0KV6C
DRUGNAME	RG3039
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 1
	
TTDDRUID	D0KW2A
DRUGNAME	BN50739
INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Terminated
	
TTDDRUID	D0KW2M
DRUGNAME	Relacatib
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0KW3Z
DRUGNAME	GORALATIDE
INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Phase 2
	
TTDDRUID	D0KW8U
DRUGNAME	PTS-508a
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0KW9T
DRUGNAME	RSIFN-co
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0KX1A
DRUGNAME	Aryl mannoside derivative 6
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0KX1E
DRUGNAME	CEP-2563
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0KX1Y
DRUGNAME	Erenumab
INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Approved
	
TTDDRUID	D0KX2W
DRUGNAME	1,2,4,5-tetra-substituted imidazole derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0KX3A
DRUGNAME	PF-4194471
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0KX6E
DRUGNAME	DI-Leu16-IL2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0KX7A
DRUGNAME	CR-4174
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0KX7I
DRUGNAME	Ensartinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D0KX8B
DRUGNAME	GNE Lipoplex
INDICATI	Myopathy [ICD-11: 8C7Y] Phase 1
	
TTDDRUID	D0KX8N
DRUGNAME	Diaryl morpholine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0KX9B
DRUGNAME	EP-101
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0KX9Z
DRUGNAME	S-12363
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0KY3W
DRUGNAME	INO-4800 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0KY4O
DRUGNAME	ASF-1075
INDICATI	Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0KY7S
DRUGNAME	ISIS-FXI
INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 2
	
TTDDRUID	D0KZ0V
DRUGNAME	CD19 CAR T Cells
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0KZ3Q
DRUGNAME	Omnitram
INDICATI	Chronic pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D0L0AU
DRUGNAME	DMPDDF
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0L0BX
DRUGNAME	ICARITIN
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0L0CL
DRUGNAME	CP-471358
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0L0CV
DRUGNAME	Diamine derivative 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0L0DA
DRUGNAME	PRX003
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0L0DO
DRUGNAME	ETR-002
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0L0DZ
DRUGNAME	XL-041
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1
	
TTDDRUID	D0L0GM
DRUGNAME	Vilanterol
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0L0HV
DRUGNAME	VX-916
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0L0JM
DRUGNAME	Igiv-hb
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0L0KI
DRUGNAME	NB-401
INDICATI	Respiratory tract infection [ICD-11: CA45] Investigative
	
TTDDRUID	D0L0LR
DRUGNAME	UCL-67022
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0L0MB
DRUGNAME	Acetophenazine
INDICATI	Bipolar disorder [ICD-11: 6A60] Approved
	
TTDDRUID	D0L0MK
DRUGNAME	Pachycarpine
INDICATI	Postpartum haemorrhage [ICD-11: JA43] Approved
	
TTDDRUID	D0L0MO
DRUGNAME	Satigrel
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Preregistration
	
TTDDRUID	D0L0NE
DRUGNAME	DPC-A78277
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0L0OU
DRUGNAME	CLT-005
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative
	
TTDDRUID	D0L0RO
DRUGNAME	AE37 peptide vaccine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0L0RX
DRUGNAME	ABX-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L0SI
DRUGNAME	Galectin 2
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0L0SW
DRUGNAME	Bentiromide
INDICATI	Pancreatic cancer [ICD-11: 2C10] Approved
	
TTDDRUID	D0L0UF
DRUGNAME	MEN-11467
INDICATI	Respiratory tract inflammation [ICD-11: CA07] Terminated
	
TTDDRUID	D0L0VV
DRUGNAME	GUT-70
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L0XV
DRUGNAME	NP-05
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D0L0ZC
DRUGNAME	GSK1059615
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1
INDICATI	Endometrial cancer [ICD-11: 2C76] Discontinued in Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1
	
TTDDRUID	D0L0ZF
DRUGNAME	VESNARINONE
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Approved
	
TTDDRUID	D0L1BS
DRUGNAME	PF-454583
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D0L1CO
DRUGNAME	MAGE-A10 TCR
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2
	
TTDDRUID	D0L1DP
DRUGNAME	ABT-089
INDICATI	Dementia [ICD-11: 6D80-6D86] Discontinued in Phase 2
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2
	
TTDDRUID	D0L1DR
DRUGNAME	Recombinant human iduronate-2-sulfatase
INDICATI	Hunter syndrome [ICD-11: 5C56.31] Phase 3
	
TTDDRUID	D0L1DU
DRUGNAME	HIF-1 alpha gene therapy
INDICATI	Occlusive arterial disease [ICD-11: BD4Z] Discontinued in Phase 2
	
TTDDRUID	D0L1EX
DRUGNAME	M2del11 HAavir H5N1
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0L1FN
DRUGNAME	Emfilermin
INDICATI	Infertility [ICD-11: GB04] Phase 1/2
	
TTDDRUID	D0L1GD
DRUGNAME	MK-8353
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0L1HK
DRUGNAME	TCN-032
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0L1IH
DRUGNAME	A-79175
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0L1JE
DRUGNAME	CJC-1131
INDICATI	Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 2
	
TTDDRUID	D0L1JW
DRUGNAME	Hydrastine
INDICATI	Haemostatic astringent [ICD-11: MG27] Approved
	
TTDDRUID	D0L1KX
DRUGNAME	CR-665
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0L1LJ
DRUGNAME	Bervastatin
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D0L1LV
DRUGNAME	TGFK07AD
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3
	
TTDDRUID	D0L1NF
DRUGNAME	D-420720
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0L1NU
DRUGNAME	PHA-666859
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Investigative
	
TTDDRUID	D0L1OC
DRUGNAME	Anti-LT alpha
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0L1OF
DRUGNAME	HE-33
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Investigative
	
TTDDRUID	D0L1OT
DRUGNAME	TroVax
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0L1OY
DRUGNAME	ALCURONIUM
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0L1PH
DRUGNAME	CB-5300
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0L1PO
DRUGNAME	Alkyl mannoside derivative 4
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0L1PP
DRUGNAME	PMID27998201-Compound-13
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Patented
	
TTDDRUID	D0L1PW
DRUGNAME	R112
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative
	
TTDDRUID	D0L1QF
DRUGNAME	Corifollitropin alfa
INDICATI	Infertility [ICD-11: GB04] Approved
	
TTDDRUID	D0L1SV
DRUGNAME	Cyclohexyl carbamate derivative 4
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0L1TB
DRUGNAME	NPS-4
INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative
	
TTDDRUID	D0L1UH
DRUGNAME	ASP-0777
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0L1VF
DRUGNAME	PH-10
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D0L1VI
DRUGNAME	AQ-13
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D0L1VP
DRUGNAME	NX-CP105
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1
	
TTDDRUID	D0L1VR
DRUGNAME	ALT-946
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D0L1VT
DRUGNAME	Cyprodine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0L1WV
DRUGNAME	Kawain
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0L1YM
DRUGNAME	McN3377
INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 1/2
	
TTDDRUID	D0L1YR
DRUGNAME	Ara-LAMP-vax
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0L1YS
DRUGNAME	NE-033
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D0L1ZK
DRUGNAME	MDCO-216
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1
INDICATI	Acute coronary syndrome [ICD-11: BA41] Preclinical
	
TTDDRUID	D0L1ZM
DRUGNAME	HF-0299
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0L2BC
DRUGNAME	MEDI-534
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D0L2BH
DRUGNAME	S-34109
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Terminated
	
TTDDRUID	D0L2BT
DRUGNAME	DMARDs
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0L2CI
DRUGNAME	Insulin degludec
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved
	
TTDDRUID	D0L2CN
DRUGNAME	Fibroblast growth factor-18
INDICATI	Cartilage lesions [ICD-11: NC93.3Z] Phase 2
	
TTDDRUID	D0L2FR
DRUGNAME	KU-135
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L2GX
DRUGNAME	RG7342
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0L2IQ
DRUGNAME	Fasidotril
INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2
	
TTDDRUID	D0L2JE
DRUGNAME	XmAb13676
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0L2JM
DRUGNAME	Levomequitazine
INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 3
	
TTDDRUID	D0L2KL
DRUGNAME	DNA/MVA HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0L2LG
DRUGNAME	WC-3018
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0L2LS
DRUGNAME	Fluoxymesterone
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0L2MA
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 12
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0L2MX
DRUGNAME	Benzthiazide
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D0L2NV
DRUGNAME	U-89854
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D0L2OS
DRUGNAME	REG-3
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D0L2OT
DRUGNAME	Lipovaxin-MM
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0L2PV
DRUGNAME	MOR-105
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0L2QC
DRUGNAME	OPT-88
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Terminated
	
TTDDRUID	D0L2QJ
DRUGNAME	UC-84
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0L2QZ
DRUGNAME	Biphenyl mannoside derivative 27
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0L2RV
DRUGNAME	PF-4325667
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D0L2TT
DRUGNAME	DasKloster 0028-01
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Investigative
	
TTDDRUID	D0L2UN
DRUGNAME	Auranofin
INDICATI	Inflammatory arthritis [ICD-11: FA2Z] Approved
	
TTDDRUID	D0L2UQ
DRUGNAME	Pracinostat
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D0L2VB
DRUGNAME	FE-203799
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative
	
TTDDRUID	D0L2VT
DRUGNAME	PV-10
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
INDICATI	Cutaneous melanoma [ICD-11: 2C30] Phase 3
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
INDICATI	Metastatic liver cancer [ICD-11: 2C12] Phase 1
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1
	
TTDDRUID	D0L2VV
DRUGNAME	Typhim Vi
INDICATI	Salmonella infection [ICD-11: 1A09] Approved
	
TTDDRUID	D0L2WJ
DRUGNAME	Ryzodeg
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved
	
TTDDRUID	D0L2WK
DRUGNAME	CAM2043
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1/2
	
TTDDRUID	D0L2WW
DRUGNAME	RGel-Adnectin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L2XO
DRUGNAME	BAY11-7082
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0L2XU
DRUGNAME	Solulin
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0L2YF
DRUGNAME	Pc4
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0L2YR
DRUGNAME	DT-1687
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0L2ZY
DRUGNAME	X-82
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0L3CQ
DRUGNAME	Dexpirronium
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0L3DC
DRUGNAME	HMR-1031
INDICATI	Arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0L3DK
DRUGNAME	Vildagliptin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D0L3EO
DRUGNAME	Cinitapride
INDICATI	Functional dyspepsia [ICD-11: DD90.3] Phase 3
	
TTDDRUID	D0L3EW
DRUGNAME	ICI-D-6888
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D0L3GG
DRUGNAME	GEM-132
INDICATI	Cytomegalovirus retinitis [ICD-11: 9B72.00] Terminated
	
TTDDRUID	D0L3GH
DRUGNAME	CTCE-0324
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Investigative
	
TTDDRUID	D0L3HG
DRUGNAME	I-432
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0L3HU
DRUGNAME	BAY 86-5044
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0L3IL
DRUGNAME	ASM8
INDICATI	Allergic asthma [ICD-11: CA23.0] Phase 2
	
TTDDRUID	D0L3JI
DRUGNAME	NGD 94-1
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0L3JL
DRUGNAME	Aryl mannoside derivative 8
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0L3KA
DRUGNAME	BP-100-1-01
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 2
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
	
TTDDRUID	D0L3KN
DRUGNAME	NeurArrest
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0L3LO
DRUGNAME	ET-006
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D0L3MP
DRUGNAME	VRX496
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Approved
INDICATI	Coronavirus infection [ICD-11: 1D92] Approved
	
TTDDRUID	D0L3MZ
DRUGNAME	Heptazyme
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2
	
TTDDRUID	D0L3OE
DRUGNAME	SRSS-021
INDICATI	Vomiting [ICD-11: MD90] Terminated
	
TTDDRUID	D0L3RO
DRUGNAME	TAS-119
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0L3RZ
DRUGNAME	SBC-103
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2
	
TTDDRUID	D0L3SP
DRUGNAME	MVA-BN Filo
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 3
	
TTDDRUID	D0L3TR
DRUGNAME	Estetrol
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D0L3UI
DRUGNAME	Rabies VRVg
INDICATI	Rabies [ICD-11: 1C82] Phase 3
	
TTDDRUID	D0L3VA
DRUGNAME	QAN-747
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D0L3VC
DRUGNAME	DG-8
INDICATI	Osteosarcoma [ICD-11: 2B51] Investigative
	
TTDDRUID	D0L3VT
DRUGNAME	Myoblast cell transplantation therapy
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 1
	
TTDDRUID	D0L3VU
DRUGNAME	Pumactant
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D0L3VY
DRUGNAME	Karomab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L3WJ
DRUGNAME	IRT-103
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0L3XE
DRUGNAME	Short ragweed pollen extracts
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D0L3XV
DRUGNAME	SMART anti-E/P selectin
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D0L3YX
DRUGNAME	T-62
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1
	
TTDDRUID	D0L4AL
DRUGNAME	NTx-265
INDICATI	Stroke [ICD-11: 8B20] Phase 2
	
TTDDRUID	D0L4BR
DRUGNAME	HuCD40L
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0L4BU
DRUGNAME	Sanaria PfSPZ Vaccine
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	D0L4CN
DRUGNAME	MTIG7192A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0L4CW
DRUGNAME	Growth hormone releasing factor peptides
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Investigative
	
TTDDRUID	D0L4EG
DRUGNAME	Mentat
INDICATI	Cognitive impairment [ICD-11: 6D71] Approved
	
TTDDRUID	D0L4ET
DRUGNAME	Hepatect CP
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0L4FS
DRUGNAME	Genistein
INDICATI	Menopause symptom [ICD-11: GA30.0] Phase 2/3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0L4GF
DRUGNAME	AG-3296
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0L4GH
DRUGNAME	HBN-3
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D0L4GX
DRUGNAME	JTT-252
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0L4HK
DRUGNAME	TVX-002
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0L4HL
DRUGNAME	RG7314
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 2
	
TTDDRUID	D0L4HY
DRUGNAME	Guanabenz
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D0L4JT
DRUGNAME	Sulfanilamide
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0L4LX
DRUGNAME	Atorvastatin/ ezetimibe
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3
	
TTDDRUID	D0L4PM
DRUGNAME	AVE-3247
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D0L4PY
DRUGNAME	KB-5492
INDICATI	Peptic ulcer [ICD-11: DA61] Discontinued in Phase 2
	
TTDDRUID	D0L4SB
DRUGNAME	Oncolysin CD6
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D0L4SD
DRUGNAME	Alpha-acetyldigoxin
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0L4SL
DRUGNAME	TA-270
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0L4UN
DRUGNAME	HIV-IG
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3
	
TTDDRUID	D0L4US
DRUGNAME	BMS-770767
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2
	
TTDDRUID	D0L4VD
DRUGNAME	RG6058
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 3
	
TTDDRUID	D0L4VI
DRUGNAME	L-cysteine
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial
	
TTDDRUID	D0L4VZ
DRUGNAME	SPP-1148
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D0L4WO
DRUGNAME	SGN-19A
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Preclinical
	
TTDDRUID	D0L4XW
DRUGNAME	Nimenrix
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved
	
TTDDRUID	D0L4YD
DRUGNAME	Solifenacin
INDICATI	Overactive bladder [ICD-11: GC50.0] Approved
	
TTDDRUID	D0L4ZK
DRUGNAME	RG-7351
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
	
TTDDRUID	D0L5AH
DRUGNAME	CELIKALIM
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0L5AK
DRUGNAME	TTI-1612
INDICATI	Interstitial cystitis [ICD-11: GC00.3] Investigative
	
TTDDRUID	D0L5AP
DRUGNAME	Gitalin
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0L5BK
DRUGNAME	KW-2149
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D0L5CZ
DRUGNAME	Rocuronium
INDICATI	Muscle spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D0L5DK
DRUGNAME	99mTc-CYT-379
INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 1
	
TTDDRUID	D0L5DZ
DRUGNAME	4SC-202
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0L5EA
DRUGNAME	REC-200
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0L5FB
DRUGNAME	TAK-329
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0L5FY
DRUGNAME	Metipranolol
INDICATI	Open-angle glaucoma [ICD-11: 9C61] Approved
	
TTDDRUID	D0L5GH
DRUGNAME	Olcegepant
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D0L5HM
DRUGNAME	CD19 CAR T cells
INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D0L5IA
DRUGNAME	PEGylated hyaluronidase (human recombinant)
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D0L5IL
DRUGNAME	Betamarc
INDICATI	Cachexia [ICD-11: MG20] Phase 2
	
TTDDRUID	D0L5JA
DRUGNAME	ETS-2101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0L5KF
DRUGNAME	RU-58841
INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1
	
TTDDRUID	D0L5KK
DRUGNAME	ROR1R-CAR-T Cell
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D0L5KU
DRUGNAME	Remimazolam
INDICATI	Procedural sedation [ICD-11: JB0C.3] Approved
INDICATI	Anaesthesia [ICD-11: 9A78.6] Phase 3
	
TTDDRUID	D0L5MF
DRUGNAME	PYRAZOLOACRIDINE
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D0L5NU
DRUGNAME	Human Factor XIII
INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Phase 1
	
TTDDRUID	D0L5OP
DRUGNAME	PMID26651364-Compound-6c
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0L5PO
DRUGNAME	Phenyl Aminosalicylate
INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Approved
	
TTDDRUID	D0L5QT
DRUGNAME	Pentetate zinc trisodium
INDICATI	Acute radiation syndrome [ICD-11: NF00] Approved
	
TTDDRUID	D0L5RW
DRUGNAME	Plerixafor
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved
	
TTDDRUID	D0L5UO
DRUGNAME	Darapladib
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 3
	
TTDDRUID	D0L5VS
DRUGNAME	KF-17837
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0L5VX
DRUGNAME	MNK-1411
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D0L5WA
DRUGNAME	SR-46559A
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D0L5WD
DRUGNAME	Ularitide
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3
INDICATI	Acute heart failure [ICD-11: BD10-BD13] Phase 3
	
TTDDRUID	D0L5WF
DRUGNAME	Somavaratan
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 3
	
TTDDRUID	D0L5WM
DRUGNAME	Amiodarone
INDICATI	Tachyarrhythmias [ICD-11: BC71] Approved
	
TTDDRUID	D0L5XG
DRUGNAME	PF-4191834
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0L5XI
DRUGNAME	AMG-517
INDICATI	Chronic pain [ICD-11: MG30] Discontinued in Phase 1
	
TTDDRUID	D0L5YF
DRUGNAME	ZD-4190
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0L5YV
DRUGNAME	Salmeterol
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0L5ZH
DRUGNAME	CC-90006
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0L6AF
DRUGNAME	AEZS-112
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0L6BH
DRUGNAME	NN9068
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0L6BI
DRUGNAME	Glucagon rdna
INDICATI	Hormone deficiency [ICD-11: 5A61.1] Approved
	
TTDDRUID	D0L6BU
DRUGNAME	CKD-10101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L6DA
DRUGNAME	Valdecoxib
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
	
TTDDRUID	D0L6DO
DRUGNAME	Fosfluconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D0L6FF
DRUGNAME	NanoDTPA
INDICATI	Iron overload disease [ICD-11: 5C64.10] Investigative
	
TTDDRUID	D0L6GO
DRUGNAME	Emtricitabine + tenofovir 
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0L6HF
DRUGNAME	MDX-1459
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L6HU
DRUGNAME	CAR-T Cells targeting CEA
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0L6IF
DRUGNAME	AGT-0031
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0L6IJ
DRUGNAME	HG-1143
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L6JE
DRUGNAME	Insulin-lispro
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0L6JX
DRUGNAME	CGP-50068
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1
	
TTDDRUID	D0L6KC
DRUGNAME	BILR-355
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0L6KK
DRUGNAME	TF2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D0L6LD
DRUGNAME	AZD-3199
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0L6NW
DRUGNAME	LY2605541
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 3
	
TTDDRUID	D0L6OA
DRUGNAME	BL-1020
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0L6OY
DRUGNAME	GSK-2590066A
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0L6PZ
DRUGNAME	PT-401
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0L6QI
DRUGNAME	Rokitamycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0L6RF
DRUGNAME	BAY1179470
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0L6RR
DRUGNAME	Transplant acceptance inducing cells
INDICATI	Transplant rejection [ICD-11: NE84] Phase 1/2
	
TTDDRUID	D0L6SS
DRUGNAME	BPX-101
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0L6UZ
DRUGNAME	L-374,087
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0L6VH
DRUGNAME	BF-389
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0L6WT
DRUGNAME	MD-921
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D0L6XO
DRUGNAME	AZD1390
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D0L6XQ
DRUGNAME	RWJ-676070
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 1
	
TTDDRUID	D0L7AS
DRUGNAME	NABILONE
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0L7BV
DRUGNAME	Gevotroline
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1
	
TTDDRUID	D0L7FB
DRUGNAME	T1-IR
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L7FM
DRUGNAME	Probenecid
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Approved
INDICATI	Gout [ICD-11: FA25] Approved
	
TTDDRUID	D0L7JE
DRUGNAME	OC104-26
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0L7JR
DRUGNAME	Lenogastrim
INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Approved
	
TTDDRUID	D0L7LC
DRUGNAME	Romidepsin
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 3
	
TTDDRUID	D0L7LH
DRUGNAME	Anti-IP10
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D0L7LT
DRUGNAME	DCVax-Pancreas
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D0L7MA
DRUGNAME	NP-1998
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 2
	
TTDDRUID	D0L7MK
DRUGNAME	TR-4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L7MO
DRUGNAME	F-80002-RR
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L7OJ
DRUGNAME	CAR-T Cells targeting Mesothelin
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0L7OY
DRUGNAME	D-7193
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2
	
TTDDRUID	D0L7PG
DRUGNAME	CKD-406
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0L7PK
DRUGNAME	V-0191
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D0L7QB
DRUGNAME	Alfaferone
INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved
	
TTDDRUID	D0L7QR
DRUGNAME	VL-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L7RJ
DRUGNAME	DP-109
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0L7SY
DRUGNAME	Delequamine hydrochloride
INDICATI	Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 3
	
TTDDRUID	D0L7TA
DRUGNAME	MIN-101
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D0L7TN
DRUGNAME	GSK3003891A
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D0L7UQ
DRUGNAME	Prothionamide
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Approved
	
TTDDRUID	D0L7UT
DRUGNAME	IMX-MSP3
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0L7VC
DRUGNAME	GI-6207
INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 2
	
TTDDRUID	D0L7VL
DRUGNAME	LIDOFLAZINE
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D0L7WS
DRUGNAME	RX-3117
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0L7YL
DRUGNAME	Rhuph20
INDICATI	Reproduction [ICD-11: JA00-JA02] Approved
	
TTDDRUID	D0L7ZX
DRUGNAME	BAY-17-1998
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0L8CJ
DRUGNAME	MV-9411
INDICATI	Keratosis [ICD-11: ED56] Discontinued in Phase 2
	
TTDDRUID	D0L8EO
DRUGNAME	Anti-TLR3 mabs
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0L8EQ
DRUGNAME	CB-182804
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D0L8GO
DRUGNAME	RK-28
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0L8HB
DRUGNAME	MEDI9197
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0L8IH
DRUGNAME	IMA-910
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
	
TTDDRUID	D0L8IO
DRUGNAME	AVN 322
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0L8KJ
DRUGNAME	Oglemilast
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0L8KK
DRUGNAME	ALB-137391(a)
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative
	
TTDDRUID	D0L8MO
DRUGNAME	ME-3407
INDICATI	Duodenal ulcer [ICD-11: DA63] Phase 2
	
TTDDRUID	D0L8OE
DRUGNAME	AC3056
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D0L8ON
DRUGNAME	Rx-101
INDICATI	Radiation syndrome [ICD-11: NF00] Investigative
	
TTDDRUID	D0L8OP
DRUGNAME	AVP-21D9
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 1
	
TTDDRUID	D0L8OZ
DRUGNAME	EG-013
INDICATI	Fetal growth restriction [ICD-11: KA20.1Z] Investigative
	
TTDDRUID	D0L8PG
DRUGNAME	SK-126
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0L8PH
DRUGNAME	Biferonex
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
	
TTDDRUID	D0L8PO
DRUGNAME	YC-12
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0L8PZ
DRUGNAME	ARQ 751
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0L8QQ
DRUGNAME	VELNACRINE
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3
	
TTDDRUID	D0L8RD
DRUGNAME	INT-0003/2005
INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Phase 1
	
TTDDRUID	D0L8RG
DRUGNAME	CI-986
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0L8SP
DRUGNAME	MTL-004
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L8TL
DRUGNAME	YP-008
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated
	
TTDDRUID	D0L8TN
DRUGNAME	BU-4514N
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0L8TP
DRUGNAME	Ektomun
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0L8UQ
DRUGNAME	FKB327
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0L8US
DRUGNAME	PG-11144
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L8VA
DRUGNAME	CSL-112
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D0L8WA
DRUGNAME	AVAC
INDICATI	Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 2
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0L8YH
DRUGNAME	AntiHer2-XTEN-Docetaxel
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0L8YY
DRUGNAME	SR-14136
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0L8ZX
DRUGNAME	OX-NLA
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 3
	
TTDDRUID	D0L9AJ
DRUGNAME	Seletracetam
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 3
	
TTDDRUID	D0L9BV
DRUGNAME	TDM-621
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Phase 1
	
TTDDRUID	D0L9BW
DRUGNAME	JNJ-1136
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0L9CD
DRUGNAME	AZD-2115
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0L9GG
DRUGNAME	Alprazolam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
	
TTDDRUID	D0L9GR
DRUGNAME	Very low dose (VLD) cyclobenzaprine
INDICATI	Fibromyalgia [ICD-11: MG30.01] Investigative
	
TTDDRUID	D0L9HG
DRUGNAME	Rotavirus vaccine I321
INDICATI	Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Phase 3
	
TTDDRUID	D0L9HX
DRUGNAME	Voclosporin
INDICATI	Lupus nephritis [ICD-11: 4A40.0Y] Approved
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
INDICATI	Kidney disease [ICD-11: GC2Z] Phase 2
	
TTDDRUID	D0L9HZ
DRUGNAME	EP1090
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0L9IA
DRUGNAME	Glufosfamide
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2
	
TTDDRUID	D0L9KH
DRUGNAME	APD-334
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
INDICATI	Pyoderma gangrenosum [ICD-11: EB21] Phase 2
	
TTDDRUID	D0L9MM
DRUGNAME	Split virion H1N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0L9NX
DRUGNAME	Satavaptan
INDICATI	Acute and chronic heart failure [ICD-11: BD1Z] Phase 3
	
TTDDRUID	D0L9PA
DRUGNAME	X-396
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0L9PL
DRUGNAME	UC-38
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0L9PX
DRUGNAME	F10
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0L9PY
DRUGNAME	CP-66948
INDICATI	Gastric ulcer [ICD-11: DA60] Discontinued in Phase 1
	
TTDDRUID	D0L9QM
DRUGNAME	MK-7145
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D0L9TD
DRUGNAME	HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0L9TQ
DRUGNAME	PRD_002214
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0L9UU
DRUGNAME	Gentamicin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0L9WF
DRUGNAME	ARH-1
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0L9XF
DRUGNAME	BBI503
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0L9XL
DRUGNAME	NPS-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0L9XS
DRUGNAME	Plasmin
INDICATI	Occlusive disease [ICD-11: BD4Z] Phase 2
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D0L9YS
DRUGNAME	Octopamine
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2a
	
TTDDRUID	D0L9YX
DRUGNAME	Dihydroxyaluminium
INDICATI	Skin inflammation [ICD-11: EF20.Y] Approved
	
TTDDRUID	D0L9ZF
DRUGNAME	OsteoStem
INDICATI	Bone injury [ICD-11: ND56.Y] Investigative
	
TTDDRUID	D0L9ZK
DRUGNAME	R-1068
INDICATI	Vomiting [ICD-11: MD90] Discontinued in Phase 1
	
TTDDRUID	D0L9ZR
DRUGNAME	Praziquantel
INDICATI	Flatworm infection [ICD-11: 1F70-1F86] Approved
	
TTDDRUID	D0LA0Q
DRUGNAME	PMID25666693-Compound-162
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0LA1R
DRUGNAME	AEB07
INDICATI	Transplant rejection [ICD-11: NE84] Phase 2
	
TTDDRUID	D0LA2R
DRUGNAME	Dihydroxyfumaric acid derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0LA5G
DRUGNAME	Evernimicin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3
	
TTDDRUID	D0LA6Z
DRUGNAME	Beraprost 314d
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3
	
TTDDRUID	D0LA9K
DRUGNAME	REGN4018
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	D0LB0X
DRUGNAME	KH064
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Clinical trial
	
TTDDRUID	D0LB2L
DRUGNAME	MS201408-0005A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0LB3Z
DRUGNAME	ABL 001
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 3
INDICATI	Promyelocytic leukaemia [ICD-11: 2A82.1] Phase 2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D0LB4T
DRUGNAME	AD-5075
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D0LB6D
DRUGNAME	RG7203
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0LB8B
DRUGNAME	Sialyl Lea-KLH conjugate vaccine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0LB8Z
DRUGNAME	TPIV200
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0LC0Q
DRUGNAME	Brincidofovir
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0LC2B
DRUGNAME	NSP-805
INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2
	
TTDDRUID	D0LC2G
DRUGNAME	Cyclohexyl carbamate derivative 7
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0LC3C
DRUGNAME	ARD-3150
INDICATI	Bronchiectasis [ICD-11: CA24] Phase 3
	
TTDDRUID	D0LC4L
DRUGNAME	KI-0806
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0LC5L
DRUGNAME	PF-06747143
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0LC6K
DRUGNAME	Fluticasone
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0LC8F
DRUGNAME	EDP-15
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D0LD5B
DRUGNAME	Ribavirin + lopinavir + ritonavir + interferon alfa-2a
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0LD8U
DRUGNAME	TG-3003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0LD9P
DRUGNAME	CST-104
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0LE3O
DRUGNAME	CEP-37248
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0LE4M
DRUGNAME	mab-338
INDICATI	Metapneumovirus infection [ICD-11: CA40.13] Investigative
	
TTDDRUID	D0LE5N
DRUGNAME	CTL119
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1
	
TTDDRUID	D0LE6F
DRUGNAME	CC-11050
INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2
	
TTDDRUID	D0LE6K
DRUGNAME	BL-Angiostatin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0LE7P
DRUGNAME	SDZ-GLC-756
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 1
	
TTDDRUID	D0LE8H
DRUGNAME	Chloromethylpyrrolindolines
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0LF0O
DRUGNAME	BMS-695735
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0LF1E
DRUGNAME	AQST-117
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3
	
TTDDRUID	D0LF1U
DRUGNAME	Flavopiridol
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Discontinued in Phase 3
	
TTDDRUID	D0LF3K
DRUGNAME	A/Anhui/05
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0LF5B
DRUGNAME	KN-38-7271
INDICATI	Ischemia [ICD-11: 8B10-8B11] Discontinued in Phase 2
	
TTDDRUID	D0LF5Q
DRUGNAME	ABT-267
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
	
TTDDRUID	D0LF6M
DRUGNAME	Chimeric Antigen Receptor Modified T cells Targeting CD19
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0LF8Z
DRUGNAME	Pentasa Sachet
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
	
TTDDRUID	D0LG1H
DRUGNAME	NPL-2003
INDICATI	Obsessive compulsive disorder [ICD-11: 6B20] Phase 2
	
TTDDRUID	D0LG1K
DRUGNAME	TAR-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0LG3Q
DRUGNAME	PLX-PAD cell therapy
INDICATI	Critical limb ischemia [ICD-11: BD4Y] Phase 3
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D0LG4V
DRUGNAME	SR-47063
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 1
	
TTDDRUID	D0LG6A
DRUGNAME	Budesonide
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0LG7X
DRUGNAME	RP6530
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1
	
TTDDRUID	D0LG8E
DRUGNAME	Ephedrine
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0LG8T
DRUGNAME	DS-3201
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0LH4J
DRUGNAME	Aliskiren/valsartan
INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 2
	
TTDDRUID	D0LH4P
DRUGNAME	CX-1846
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0LH9E
DRUGNAME	Imidazolidine-2,4-dione derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0LI1C
DRUGNAME	NITD609
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D0LI3A
DRUGNAME	GS-326
INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative
	
TTDDRUID	D0LI3H
DRUGNAME	BMS-633
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0LI5N
DRUGNAME	IONIS-PTP1BRX
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0LI7L
DRUGNAME	CC-0101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0LI9I
DRUGNAME	Sinopharms inactivated vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0LJ0L
DRUGNAME	Lu-AA47070
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1
	
TTDDRUID	D0LJ1B
DRUGNAME	Reparixin
INDICATI	Pancreatic islet transplantation failure [ICD-11: NE84] Phase 3
INDICATI	Graft rejection in heart transplantation [ICD-11: NE84] Phase 2
INDICATI	lung transplantation [ICD-11: PK80.20] Phase 2
INDICATI	Ischemia-reperfusion injury [ICD-11: DB98.B] Phase 2
	
TTDDRUID	D0LJ1Z
DRUGNAME	CZ-MD001
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0LJ2S
DRUGNAME	Anti-NY-ESO-1 CAR-T cells
INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 1/2
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
INDICATI	Synovial sarcoma [ICD-11: 2B5A] Phase 1/2
	
TTDDRUID	D0LJ4E
DRUGNAME	NIR178
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0LJ4J
DRUGNAME	DB104
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2
	
TTDDRUID	D0LJ5Q
DRUGNAME	GSK2340274A
INDICATI	Influenza A virus H1N1/H5N1 infection [ICD-11: 1E30] Phase 4
	
TTDDRUID	D0LJ6P
DRUGNAME	Etanidazole
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0LJ7R
DRUGNAME	M5
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0LJ8C
DRUGNAME	LCZ696
INDICATI	Heart failure [ICD-11: BD10-BD13] Approved
	
TTDDRUID	D0LK4X
DRUGNAME	Carebastine
INDICATI	Ocular allergy [ICD-11: 4A81] Phase 3
	
TTDDRUID	D0LK8E
DRUGNAME	PMID28270021-Compound-WO2016054807Example112
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0LK8O
DRUGNAME	Lifarizine
INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 2
	
TTDDRUID	D0LK8U
DRUGNAME	CG-1521
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0LK9L
DRUGNAME	Adsorbed COVID-19 (inactivated) vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0LK9N
DRUGNAME	Fradafiban
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0LL1N
DRUGNAME	ADCT-301
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0LL4Y
DRUGNAME	TAK-931
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0LL6K
DRUGNAME	TRX-585
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0LL7C
DRUGNAME	3C23K
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0LL9K
DRUGNAME	L-771688
INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2
	
TTDDRUID	D0LL9W
DRUGNAME	VBI-1901
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 1/2
	
TTDDRUID	D0LM0X
DRUGNAME	Ceramide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0LM3T
DRUGNAME	G3139 + Fludarabine
INDICATI	Acute leukaemia [ICD-11: 2A60] Investigative
	
TTDDRUID	D0LM4A
DRUGNAME	Varenicline
INDICATI	Smoking dependence [ICD-11: 6C4A.2] Approved
	
TTDDRUID	D0LM4U
DRUGNAME	ATR-01
INDICATI	Adrenocortical carcinoma [ICD-11: 2D11.Z] Phase 1
	
TTDDRUID	D0LM6D
DRUGNAME	1,3,4-oxadiazole derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0LM6O
DRUGNAME	Gam-COVID-Vac vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0LN1Z
DRUGNAME	Methylprednisolone
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0LN9P
DRUGNAME	TELUDIPINE HYDROCHLORIDE
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0LO2G
DRUGNAME	HSRx-888
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0LO3F
DRUGNAME	NG-348
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0LO5B
DRUGNAME	THZ1
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D0LO5N
DRUGNAME	SAR-103168
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0LP1L
DRUGNAME	CAR-T cells targeting BCMA
INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial
	
TTDDRUID	D0LP2P
DRUGNAME	Nu-3
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1/2
	
TTDDRUID	D0LP4Q
DRUGNAME	RBPI-21
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0LP4X
DRUGNAME	Aganirsen
INDICATI	Genitourinary tract cancer [ICD-11: 2C8Z] Investigative
	
TTDDRUID	D0LP7U
DRUGNAME	AMV564
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0LP7W
DRUGNAME	GSK-2210875
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D0LQ2Y
DRUGNAME	2CVV
INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative
	
TTDDRUID	D0LQ3L
DRUGNAME	GSK2982772
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1
	
TTDDRUID	D0LQ7V
DRUGNAME	HIVAX
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0LR0R
DRUGNAME	Methdilazine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0LR1M
DRUGNAME	LY-444711
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Discontinued in Phase 1
	
TTDDRUID	D0LR1W
DRUGNAME	Influenza virus vaccine quadrivalent
INDICATI	Seasonal influenza infection [ICD-11: 1E30] Phase 3
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0LR1Z
DRUGNAME	MK-2640
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0LR2Q
DRUGNAME	LXR-015-2
INDICATI	Ischemia [ICD-11: 8B10-8B11] Terminated
	
TTDDRUID	D0LR4B
DRUGNAME	Loxoprofen gel
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0LR4M
DRUGNAME	ETN-002
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0LS3U
DRUGNAME	KD-332
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Phase 2
	
TTDDRUID	D0LS4U
DRUGNAME	Etrabamine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated
	
TTDDRUID	D0LS6W
DRUGNAME	KI-0803
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0LS8H
DRUGNAME	MTX110
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D0LS9E
DRUGNAME	Durvalumab
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Approved
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Biliary tract cancer [ICD-11: 2C17] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
	
TTDDRUID	D0LT0U
DRUGNAME	ORG-25935
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2
	
TTDDRUID	D0LT2Z
DRUGNAME	Vaccimel
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0LT4D
DRUGNAME	NI-1401
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0LT5Y
DRUGNAME	Piperazine derivative 5
INDICATI	Atopic dermatitis [ICD-11: EA80] Patented
	
TTDDRUID	D0LT6Z
DRUGNAME	PMID25553724-Compound-US2012810604610
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented
	
TTDDRUID	D0LU1O
DRUGNAME	FAZ053
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0LU4N
DRUGNAME	EGFRvIII CAR
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D0LU5Q
DRUGNAME	TPM-1/Morphine
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0LU6N
DRUGNAME	SPD-473
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
	
TTDDRUID	D0LU7K
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 6
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0LV0R
DRUGNAME	Barixibat
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0LV4B
DRUGNAME	Gam-COVID-Vac Lyo vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D0LV7F
DRUGNAME	NCX-1047
INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative
	
TTDDRUID	D0LW0T
DRUGNAME	Savolitinib
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0LW1Y
DRUGNAME	GFT-505
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 3
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0LW4A
DRUGNAME	Anti-DR5 cells
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
	
TTDDRUID	D0LW4O
DRUGNAME	PLEGRIDY
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
	
TTDDRUID	D0LW9U
DRUGNAME	Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co
INDICATI	Varicose veins [ICD-11: BD74-BD75] Approved
	
TTDDRUID	D0LX2Y
DRUGNAME	Aminoazetidine derivative 8
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0LX4K
DRUGNAME	TDI-0066
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0LX8D
DRUGNAME	AZD6918
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0LX8Z
DRUGNAME	OCV-101
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0LX9H
DRUGNAME	Tysuberprost
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3
	
TTDDRUID	D0LY0C
DRUGNAME	Radiolabelled-huA33
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D0LY3A
DRUGNAME	Azithromycin + hydroxychloroquine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0LZ1W
DRUGNAME	PMID26651364-Compound-122
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0LZ1Z
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 7
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0LZ7E
DRUGNAME	TP-434
INDICATI	Intra-abdominal infection [ICD-11: 1A40] Approved
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0LZ7G
DRUGNAME	ACTR707
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0LZ7Z
DRUGNAME	RG6264
INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0M0AA
DRUGNAME	MenHibrix
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved
	
TTDDRUID	D0M0AM
DRUGNAME	Glycopyrrolate
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0M0CO
DRUGNAME	PCAR-019
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2
INDICATI	B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
	
TTDDRUID	D0M0CU
DRUGNAME	ADE-DERM
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Investigative
	
TTDDRUID	D0M0FY
DRUGNAME	Recombinant human hepatocyte growth factor
INDICATI	Renal failure [ICD-11: GB60-GB6Z] Phase 1
	
TTDDRUID	D0M0GJ
DRUGNAME	SPV-30
INDICATI	Chronic fatigue syndrome [ICD-11: 8E49] Terminated
	
TTDDRUID	D0M0HJ
DRUGNAME	S-18986
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
	
TTDDRUID	D0M0JR
DRUGNAME	NsG-33
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0M0KB
DRUGNAME	MK-6592
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0M0KJ
DRUGNAME	X-081-NAB
INDICATI	Hypereosinophilic syndrome [ICD-11: 2A20.3] Investigative
	
TTDDRUID	D0M0MX
DRUGNAME	CIGB-247
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M0NF
DRUGNAME	Tobacco-based vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0M0NT
DRUGNAME	PF-04620110
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D0M0OT
DRUGNAME	Leukemia cancer vaccine
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0M0PY
DRUGNAME	DX-890
INDICATI	Acute lung injury [ICD-11: NB32.3] Phase 2
	
TTDDRUID	D0M0QX
DRUGNAME	MK-591
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0M0RN
DRUGNAME	SCH-42495
INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2
	
TTDDRUID	D0M0SS
DRUGNAME	FARGLITAZAR
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D0M0SV
DRUGNAME	PRS-110
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M0TV
DRUGNAME	BIIB059
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3
INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2
	
TTDDRUID	D0M0UB
DRUGNAME	AZD2184
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0M0UJ
DRUGNAME	GS-9148
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0M0UT
DRUGNAME	Procysteine
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
	
TTDDRUID	D0M0UU
DRUGNAME	ZYGK-1
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0M0UV
DRUGNAME	INXC-ICAM1
INDICATI	Transplant rejection [ICD-11: NE84] Terminated
	
TTDDRUID	D0M0VN
DRUGNAME	BISNAFIDE MESILATE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0M0WM
DRUGNAME	ATI-355
INDICATI	Nerve injury [ICD-11: ND56.4] Phase 1
	
TTDDRUID	D0M0WV
DRUGNAME	Fasiglifam hemihydrate
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0M0WY
DRUGNAME	KSB-307
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Terminated
	
TTDDRUID	D0M0XB
DRUGNAME	Saracatinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 2
INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 2
	
TTDDRUID	D0M0XU
DRUGNAME	Ebola/Marburg vaccine
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D0M0YB
DRUGNAME	BAY 11-42524
INDICATI	Left ventricular dysfunction [ICD-11: BD11] Phase 2
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D0M0YE
DRUGNAME	HCV-specific STAR fusions
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0M1CZ
DRUGNAME	Rh-alphaglucosidase
INDICATI	Pompe disease [ICD-11: 5C51.3] Approved
	
TTDDRUID	D0M1DE
DRUGNAME	PMA-109R
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M1DG
DRUGNAME	RTL-1000
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0M1EP
DRUGNAME	WNV DNA vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0M1II
DRUGNAME	HS-25
INDICATI	Hyperbilirubinemia [ICD-11: 5C58] Phase 2
	
TTDDRUID	D0M1IN
DRUGNAME	acelarin
INDICATI	Biliary tract cancer [ICD-11: 2C17] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0M1IO
DRUGNAME	Bacitracin
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Approved
	
TTDDRUID	D0M1KH
DRUGNAME	PM-181104
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0M1KK
DRUGNAME	PNB-03
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0M1MB
DRUGNAME	NESS-200P
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Investigative
	
TTDDRUID	D0M1MN
DRUGNAME	AFP TCR
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
	
TTDDRUID	D0M1MZ
DRUGNAME	Reviroc
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
	
TTDDRUID	D0M1NS
DRUGNAME	CTT-54
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M1OU
DRUGNAME	XEN-907
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0M1OX
DRUGNAME	COP1-LNP
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative
	
TTDDRUID	D0M1PL
DRUGNAME	Gadoteridol
INDICATI	Brain disease [ICD-11: 8C70-8E61] Approved
	
TTDDRUID	D0M1PQ
DRUGNAME	Mobenakin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0M1PR
DRUGNAME	Prevnar
INDICATI	Otitis media [ICD-11: AA80-AB0Z] Approved
	
TTDDRUID	D0M1RD
DRUGNAME	ICT-107
INDICATI	Brain cancer [ICD-11: 2A00] Phase 3
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0M1UE
DRUGNAME	IDD-5
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Terminated
	
TTDDRUID	D0M1VC
DRUGNAME	Amdinocillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0M1WF
DRUGNAME	SR-13654
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0M1WN
DRUGNAME	L-701324
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0M1WU
DRUGNAME	AJM-300
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
	
TTDDRUID	D0M1WW
DRUGNAME	TDENV
INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 1/2
	
TTDDRUID	D0M1XY
DRUGNAME	DYB-186
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D0M1YN
DRUGNAME	ATI-17000
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Preclinical
	
TTDDRUID	D0M1YS
DRUGNAME	32-P BioSilicon
INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
	
TTDDRUID	D0M1YW
DRUGNAME	ANG-3407
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0M1ZH
DRUGNAME	M4112
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0M2AN
DRUGNAME	AD-412
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0M2BR
DRUGNAME	Factor 8
INDICATI	Hemophilia [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0M2DM
DRUGNAME	BBI-3000
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1
	
TTDDRUID	D0M2DP
DRUGNAME	REACTA
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M2EG
DRUGNAME	Nasal glucagon
INDICATI	Hypoglycemia [ICD-11: 5A41] Phase 3
	
TTDDRUID	D0M2EH
DRUGNAME	Non-PEGylated butyrylcholinesterase
INDICATI	Toxicity [ICD-11: N.A.] Investigative
	
TTDDRUID	D0M2FH
DRUGNAME	Influenza A virus vaccine H1N1
INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0M2GE
DRUGNAME	Ad26-COV2-S vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0M2GI
DRUGNAME	CI-1002
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0M2GQ
DRUGNAME	ISS-1018
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3
	
TTDDRUID	D0M2IS
DRUGNAME	Hebergel
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 3
	
TTDDRUID	D0M2JA
DRUGNAME	ACP-106
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0M2LD
DRUGNAME	BQCA
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0M2LI
DRUGNAME	NNC-0123-0000-0338
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0M2MC
DRUGNAME	Phenmetrazine
INDICATI	Obesity [ICD-11: 5B81] Approved
	
TTDDRUID	D0M2ME
DRUGNAME	INDUSCA-1
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0M2MR
DRUGNAME	Gliclazide
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0M2OW
DRUGNAME	Plasmodium falciparum LSA-NRC vaccine
INDICATI	Malaria [ICD-11: 1F40-1F45] Terminated
	
TTDDRUID	D0M2QH
DRUGNAME	Convallatoxin
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0M2QR
DRUGNAME	TOL-3021
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D0M2RT
DRUGNAME	Pyrazole derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0M2RZ
DRUGNAME	EDP-MRSA-1
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative
	
TTDDRUID	D0M2SR
DRUGNAME	R-803
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2
	
TTDDRUID	D0M2TC
DRUGNAME	SLC-022
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D0M2TG
DRUGNAME	PYM-50028
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 2
	
TTDDRUID	D0M2TS
DRUGNAME	Mivebresib
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0M2UT
DRUGNAME	NANT squamous cell carcinoma vaccine
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2
	
TTDDRUID	D0M2WF
DRUGNAME	Technetium Tc-99m Albumin Microspheres Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0M2WQ
DRUGNAME	CAP-7.1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0M2WZ
DRUGNAME	NS-2710
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0M2XE
DRUGNAME	Insulin-glulisine
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0M2XK
DRUGNAME	CIK-CAR.CD19
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0M2YE
DRUGNAME	Lanreotide acetate
INDICATI	Acromegaly [ICD-11: 5A60.0] Approved
	
TTDDRUID	D0M2YX
DRUGNAME	CIGB-228
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 1
	
TTDDRUID	D0M2ZG
DRUGNAME	PHA-647A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M3AH
DRUGNAME	TachoComb
INDICATI	Wound healing [ICD-11: EL8Y] Approved
	
TTDDRUID	D0M3AR
DRUGNAME	L-168049
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0M3BB
DRUGNAME	Synthetic hypericin
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 3
	
TTDDRUID	D0M3CV
DRUGNAME	Solriamfetol
INDICATI	Excessive daytime sleepiness [ICD-11: MG42] Approved
INDICATI	Narcolepsy [ICD-11: 7A20] Phase 3
	
TTDDRUID	D0M3FJ
DRUGNAME	Oxytocin
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Approved
INDICATI	Lactation failure [ICD-11: JB46.3] Phase 3
	
TTDDRUID	D0M3FZ
DRUGNAME	NOD factors
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M3GK
DRUGNAME	RG7813
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0M3GQ
DRUGNAME	BL-22
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
	
TTDDRUID	D0M3GW
DRUGNAME	E-1210
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D0M3HV
DRUGNAME	Nitric oxide synthase gene therapy
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1/2
	
TTDDRUID	D0M3IE
DRUGNAME	VVZ-140
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0M3IN
DRUGNAME	Xanthine
INDICATI	Apnea [ICD-11: MD11.0] Phase 1
	
TTDDRUID	D0M3JI
DRUGNAME	SM-19712
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0M3KK
DRUGNAME	Perfluorochemical emulsion
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved
	
TTDDRUID	D0M3MN
DRUGNAME	Leucovorin/5-fluorouracil
INDICATI	Colon cancer [ICD-11: 2B90.Z] Approved
	
TTDDRUID	D0M3NF
DRUGNAME	DZ-13
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M3ON
DRUGNAME	Euro-Celtique 4
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0M3OR
DRUGNAME	KW-2450
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1/2
	
TTDDRUID	D0M3QP
DRUGNAME	Digitoxin
INDICATI	Heart failure [ICD-11: BD10-BD13] Approved
INDICATI	Arrhythmia [ICD-11: BC9Z] Approved
INDICATI	Congestive cardiac insufficiency [ICD-11: BD1Z] Approved
	
TTDDRUID	D0M3QT
DRUGNAME	VAL-201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0M3RI
DRUGNAME	CART-138 cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0M3SS
DRUGNAME	GTU-based DNA vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0M3TD
DRUGNAME	Org-43902
INDICATI	Infertility [ICD-11: GB04] Phase 1
	
TTDDRUID	D0M3TM
DRUGNAME	Prussian blue
INDICATI	Thllium and radioactive isotopes of caesium poisoning [ICD-11: NE61] Approved
INDICATI	Metal intoxication [ICD-11: NE60] Approved
	
TTDDRUID	D0M3TZ
DRUGNAME	Mefloquine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0M3VU
DRUGNAME	EQ-318
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0M3XE
DRUGNAME	PF-06826647
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
	
TTDDRUID	D0M3XR
DRUGNAME	MK-3102
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0M3YC
DRUGNAME	FT-201
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0M3YX
DRUGNAME	NPC-09
INDICATI	Myopathy [ICD-11: 8C7Y] Phase 1
	
TTDDRUID	D0M3ZB
DRUGNAME	CanSino COVID-19 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0M4AH
DRUGNAME	GX-19 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D0M4AV
DRUGNAME	CO-1686
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D0M4BB
DRUGNAME	Chi Lob 7/4
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D0M4DE
DRUGNAME	NP-184
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative
	
TTDDRUID	D0M4EQ
DRUGNAME	PMID26815044-Compound-48
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0M4FO
DRUGNAME	PA-1093
INDICATI	Multiple sclerosis [ICD-11: 8A40] Terminated
	
TTDDRUID	D0M4GX
DRUGNAME	Digoxin immune Fab
INDICATI	Eclampsia [ICD-11: JA25] Phase 2/3
	
TTDDRUID	D0M4HC
DRUGNAME	L-757464
INDICATI	Prostate hyperplasia [ICD-11: GA90] Terminated
	
TTDDRUID	D0M4HL
DRUGNAME	P-7435
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0M4HM
DRUGNAME	MEN-10880
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0M4JK
DRUGNAME	UCB-2892
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D0M4LC
DRUGNAME	EPTALOPROST
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0M4LF
DRUGNAME	AZD-1283
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0M4LW
DRUGNAME	BIM-23268
INDICATI	Acromegaly [ICD-11: 5A60.0] Discontinued in Phase 2
	
TTDDRUID	D0M4MG
DRUGNAME	Resten-NG
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0M4MH
DRUGNAME	ATR-107
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
	
TTDDRUID	D0M4MW
DRUGNAME	PPI-1301
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0M4OC
DRUGNAME	Venofer
INDICATI	Fatigue [ICD-11: MG22] Approved
	
TTDDRUID	D0M4OG
DRUGNAME	SCB-2019 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0M4PV
DRUGNAME	AAV5-hFIXco
INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1/2
	
TTDDRUID	D0M4PY
DRUGNAME	GTP-0125
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0M4QA
DRUGNAME	SIM-010603
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M4RX
DRUGNAME	RG7685
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0M4SV
DRUGNAME	BPI-3006
INDICATI	Hypoglycemia [ICD-11: 5A41] Investigative
	
TTDDRUID	D0M4TF
DRUGNAME	Canvaxin
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D0M4TJ
DRUGNAME	Ralinepag
INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 2
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
	
TTDDRUID	D0M4TN
DRUGNAME	BCP-1071
INDICATI	Upper respiratory infection [ICD-11: CA07] Investigative
	
TTDDRUID	D0M4TO
DRUGNAME	MVA-BN RSV vaccine
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D0M4UE
DRUGNAME	Herzyme
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D0M4UR
DRUGNAME	ZyCoV-D vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D0M4UX
DRUGNAME	NT-KO-009
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0M4UY
DRUGNAME	MBI-853NL
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Discontinued in Phase 1
	
TTDDRUID	D0M4UZ
DRUGNAME	JNJ-39758979
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0M4VM
DRUGNAME	Sulfacetamide
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D0M4WA
DRUGNAME	obeticholic acid
INDICATI	Primary biliary cholangitis [ICD-11: DB96.1] Approved
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Clinical trial
	
TTDDRUID	D0M4WU
DRUGNAME	Lisocabtagene maraleucel
INDICATI	Large B-cell lymphoma [ICD-11: 2A81] Approved
INDICATI	Central nervous system lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
INDICATI	Richter syndrome [ICD-11: 2A81.Y] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Precursor B-lymphoblastic neoplasm [ICD-11: 2A70] Phase 1/2
	
TTDDRUID	D0M4WY
DRUGNAME	PMID25666693-Compound-29
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0M4XY
DRUGNAME	Omacetaxine mepesuccinate
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Approved
	
TTDDRUID	D0M4YC
DRUGNAME	Disopyramide
INDICATI	Ventricular arrhythmias [ICD-11: BC71] Approved
INDICATI	Urinary incontinence [ICD-11: MF50.2] Withdrawn from market
	
TTDDRUID	D0M4YK
DRUGNAME	Decorin-like collagen-binding peptidoglycan
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Investigative
	
TTDDRUID	D0M5BI
DRUGNAME	Ampion
INDICATI	Bronchiectasis [ICD-11: CA24] Phase 3
	
TTDDRUID	D0M5BS
DRUGNAME	ONO-6126
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0M5CD
DRUGNAME	Doxorubicin-eluting beads
INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
	
TTDDRUID	D0M5CU
DRUGNAME	YM-337
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Discontinued in Phase 2
	
TTDDRUID	D0M5CW
DRUGNAME	CP-741952
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D0M5DH
DRUGNAME	CRA1000
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical
	
TTDDRUID	D0M5DP
DRUGNAME	KBP-COVID-19 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D0M5EN
DRUGNAME	Trigriluzole
INDICATI	Hereditary spinocerebellar ataxia [ICD-11: 8A03.1] Phase 3
	
TTDDRUID	D0M5FO
DRUGNAME	ML323
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0M5GX
DRUGNAME	Priorix
INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Approved
INDICATI	Measles [ICD-11: 1F03] Approved
	
TTDDRUID	D0M5HV
DRUGNAME	Montelukast/mometasone
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0M5II
DRUGNAME	CART-19 autologous T-cells
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0M5JA
DRUGNAME	Lumiliximab
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D0M5JC
DRUGNAME	BrevaRex
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D0M5JI
DRUGNAME	Luvox
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0M5KQ
DRUGNAME	Edurant LA
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0M5NK
DRUGNAME	SDZ-PGU-693
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D0M5OC
DRUGNAME	Trandolapril
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0M5OG
DRUGNAME	Hydroxyethyl starch
INDICATI	Haemorrhage [ICD-11: MG27] Approved
	
TTDDRUID	D0M5OI
DRUGNAME	CD40L
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Discontinued in Phase 1
	
TTDDRUID	D0M5PD
DRUGNAME	Recombinant new coronavirus vaccine (CHO cell)
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0M5PH
DRUGNAME	PF-04937319
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0M5QD
DRUGNAME	COU-1
INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative
	
TTDDRUID	D0M5QU
DRUGNAME	IkT-014
INDICATI	Polyomavirus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D0M5RF
DRUGNAME	Gestrinone
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0M5UL
DRUGNAME	1,5-Benzodiazepines series
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0M5VS
DRUGNAME	Aerugen
INDICATI	Pseudomonas infection [ICD-11: 1B92] Discontinued in Phase 3
	
TTDDRUID	D0M5VV
DRUGNAME	177Lu-DOTATATE
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0M5WS
DRUGNAME	JNJ-16269110
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0M5XE
DRUGNAME	PP-9706642
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Discontinued in Phase 2
	
TTDDRUID	D0M5XJ
DRUGNAME	DCC-3014
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0M5XN
DRUGNAME	BGB-283
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0M5YS
DRUGNAME	Cupric Chloride
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D0M6AR
DRUGNAME	Mesenchymal stem cell therapy
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
INDICATI	Skin photoaging [ICD-11: EJ20] Phase 1
	
TTDDRUID	D0M6BA
DRUGNAME	AR-67
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0M6BD
DRUGNAME	RO-5126766
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0M6DO
DRUGNAME	Aminoglutethimide
INDICATI	Cushing disease [ICD-11: 5A70] Approved
	
TTDDRUID	D0M6EG
DRUGNAME	Bisplatinum complexes
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M6ER
DRUGNAME	Golodirsen
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Approved
	
TTDDRUID	D0M6GC
DRUGNAME	TRU-015
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
	
TTDDRUID	D0M6GP
DRUGNAME	IMC-HIV
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0M6HE
DRUGNAME	Simplirix
INDICATI	Genital herpes [ICD-11: 1A94] Phase 3
	
TTDDRUID	D0M6IG
DRUGNAME	Prostaganin
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0M6JP
DRUGNAME	S-14080
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0M6LN
DRUGNAME	L-ornithine L-aspartate
INDICATI	Hepatic encephalopathy [ICD-11: DB99.5] Approved
	
TTDDRUID	D0M6OW
DRUGNAME	ANAVEX 1007
INDICATI	Pancreatic cancer [ICD-11: 2C10] Preclinical
INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical
INDICATI	Melanoma [ICD-11: 2C30] Preclinical
	
TTDDRUID	D0M6PA
DRUGNAME	BCT-197
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0M6PB
DRUGNAME	Pyrrole derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0M6QJ
DRUGNAME	Lopinavir + ritonavir + interferon apha + traditional chinese medicines granules
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0M6SB
DRUGNAME	Inactivated SARS-CoV-2 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D0M6TA
DRUGNAME	LK-157
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0M6TX
DRUGNAME	T-109
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0M6VK
DRUGNAME	Methylscopolamine
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D0M6WW
DRUGNAME	PMID30107136-Compound-Example11
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0M6XE
DRUGNAME	ZP-003
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0M6XK
DRUGNAME	ANG1005
INDICATI	Brain metastases [ICD-11: 2D50] Phase 2
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D0M6XY
DRUGNAME	SYM-006
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0M6YE
DRUGNAME	SKF-106760
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0M6YW
DRUGNAME	GYKI-12743
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D0M6ZA
DRUGNAME	Fsn-0306
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M7BL
DRUGNAME	BAY 1067197
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D0M7BT
DRUGNAME	Doxapram
INDICATI	Respiratory disease [ICD-11: CB40] Approved
	
TTDDRUID	D0M7BW
DRUGNAME	GR-89696
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated
	
TTDDRUID	D0M7CB
DRUGNAME	MK-0873
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D0M7DS
DRUGNAME	Valomaciclovir stearate
INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Phase 2
	
TTDDRUID	D0M7DU
DRUGNAME	Radiolabeled onartuzumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M7EP
DRUGNAME	CD79-targeted immunotoxins
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative
	
TTDDRUID	D0M7FX
DRUGNAME	KD-247
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0M7HO
DRUGNAME	SQ-33800
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0M7HZ
DRUGNAME	ISIS-SMNRx
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 3
	
TTDDRUID	D0M7IG
DRUGNAME	RO-4920506
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M7IH
DRUGNAME	Abobotulinum toxin A
INDICATI	Cervical cancer [ICD-11: 2C77.0] Approved
	
TTDDRUID	D0M7IJ
DRUGNAME	DM-PIT-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M7JT
DRUGNAME	Dabigatran
INDICATI	Stroke [ICD-11: 8B20] Approved
	
TTDDRUID	D0M7LQ
DRUGNAME	CBD cannabis derivative
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
	
TTDDRUID	D0M7LV
DRUGNAME	LYSERGIC ACID DIETHYLAMIDE
INDICATI	Addictive disorder [ICD-11: 6C50-6C5Z] Withdrawn from market
	
TTDDRUID	D0M7MB
DRUGNAME	ERC-124
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D0M7MH
DRUGNAME	NAChR alpha 7 APLs
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0M7MR
DRUGNAME	Multivalent carbohydrate-based vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0M7NA
DRUGNAME	A-993610
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0M7OU
DRUGNAME	CP-461
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
	
TTDDRUID	D0M7PS
DRUGNAME	E-4177
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D0M7PU
DRUGNAME	PM-00104
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0M7SG
DRUGNAME	IDP-118
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	D0M7SZ
DRUGNAME	CAT-4000
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0M7TO
DRUGNAME	Tasosartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0M7TT
DRUGNAME	IP-1200
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D0M7TW
DRUGNAME	PF-3900422
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0M7VB
DRUGNAME	AV-1013
INDICATI	Nervous system inflammation [ICD-11: 1D0Y] Investigative
	
TTDDRUID	D0M7VE
DRUGNAME	RO-4905417
INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 2
	
TTDDRUID	D0M7VW
DRUGNAME	GR-65630
INDICATI	Vomiting [ICD-11: MD90] Terminated
	
TTDDRUID	D0M7XB
DRUGNAME	Beta-cyclodextrin conjugate derivative 1
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0M7XS
DRUGNAME	Antithymocyte globulin
INDICATI	Aplastic anemia [ICD-11: 3A70] Approved
	
TTDDRUID	D0M7YU
DRUGNAME	Folate binding protein vaccine
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
	
TTDDRUID	D0M8AB
DRUGNAME	Glycine
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D0M8AI
DRUGNAME	ARRY-380
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0M8CL
DRUGNAME	A-0001
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2
	
TTDDRUID	D0M8EF
DRUGNAME	CD38 CAR-T Cell
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
	
TTDDRUID	D0M8FD
DRUGNAME	SNDX-275
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0M8FF
DRUGNAME	OSL-95II
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0M8HH
DRUGNAME	PUMAPRAZOLE
INDICATI	Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 3
	
TTDDRUID	D0M8HV
DRUGNAME	AZD-4451
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1
	
TTDDRUID	D0M8JF
DRUGNAME	MOR-102
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated
	
TTDDRUID	D0M8KY
DRUGNAME	(S)-DRF-1042
INDICATI	Bladder cancer [ICD-11: 2C94] Clinical trial
	
TTDDRUID	D0M8LN
DRUGNAME	A-690344
INDICATI	Schizophrenia [ICD-11: 6A20] Investigative
	
TTDDRUID	D0M8OC
DRUGNAME	Bavisant
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	D0M8PD
DRUGNAME	Estrogen
INDICATI	Menopause symptom [ICD-11: GA30.0] Approved
	
TTDDRUID	D0M8PL
DRUGNAME	Angiozyme
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0M8PM
DRUGNAME	IRX-4
INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical
	
TTDDRUID	D0M8PW
DRUGNAME	Levocetirizine dihydrochloride
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0M8QG
DRUGNAME	SAN-18
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0M8RC
DRUGNAME	Terbutaline
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0M8RW
DRUGNAME	FluCell
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D0M8UO
DRUGNAME	Imidazo[1,2-b]pyridazine derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D0M8VE
DRUGNAME	Iloperidone
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0M8VL
DRUGNAME	GW-870086-X
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0M8VS
DRUGNAME	PMID28270021-Compound-WO2015042088Example4
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0M8XX
DRUGNAME	ATI-1123
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0M8YM
DRUGNAME	Pyrotinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0M8YQ
DRUGNAME	HIVAX-2
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0M9BW
DRUGNAME	Artemether
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0M9CV
DRUGNAME	TA-993
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0M9DC
DRUGNAME	Oxaprozin
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0M9ER
DRUGNAME	EHT-1864
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0M9EV
DRUGNAME	NBTX-001
INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Phase 2/3
INDICATI	Panic disorder [ICD-11: 6B01] Phase 1
	
TTDDRUID	D0M9FA
DRUGNAME	TCR-transduced T-cell immunotherapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M9FF
DRUGNAME	ReN-1820
INDICATI	Cystitis [ICD-11: GC00] Terminated
	
TTDDRUID	D0M9FQ
DRUGNAME	PF-489791
INDICATI	Raynaud disease [ICD-11: BD42.0] Phase 2
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0M9FT
DRUGNAME	Omniferon
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0M9FZ
DRUGNAME	Pyrazole derivative 6
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0M9GE
DRUGNAME	Rimcazole
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0M9JJ
DRUGNAME	DOV-216419
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D0M9KZ
DRUGNAME	Pyridine derivative 4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D0M9LB
DRUGNAME	NS-2389
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D0M9NI
DRUGNAME	ARCT-021 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D0M9NJ
DRUGNAME	SOM-0005
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0M9OO
DRUGNAME	Galinpepimut-S
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 2
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2
	
TTDDRUID	D0M9PD
DRUGNAME	PP-200
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0M9PI
DRUGNAME	SLP-1003
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Investigative
	
TTDDRUID	D0M9QK
DRUGNAME	Beta-acetyldigoxin
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0M9QZ
DRUGNAME	ABT-869
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0M9RE
DRUGNAME	ARI-809
INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical
	
TTDDRUID	D0M9RI
DRUGNAME	SUVN-D4010
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0M9RM
DRUGNAME	[3H]CGS8216
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0M9RQ
DRUGNAME	MK-0249
INDICATI	Insulin-resistant disorder [ICD-11: 5A44] Clinical trial
	
TTDDRUID	D0M9SD
DRUGNAME	VA-119930
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0M9SL
DRUGNAME	DSP-7238
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D0M9TD
DRUGNAME	MiR-34a mimics
INDICATI	Liver cancer [ICD-11: 2C12] Investigative
	
TTDDRUID	D0M9TO
DRUGNAME	JCAR023
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
	
TTDDRUID	D0M9VE
DRUGNAME	EXISULIND
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
	
TTDDRUID	D0M9VZ
DRUGNAME	Navuridine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0M9WM
DRUGNAME	Chlorothiazide
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0M9WX
DRUGNAME	AMT-030
INDICATI	Hyperoxaluria [ICD-11: 5C51.2] Terminated
	
TTDDRUID	D0M9XH
DRUGNAME	XP-21510
INDICATI	Menorrhagia [ICD-11: GA20.50] Investigative
	
TTDDRUID	D0M9XT
DRUGNAME	NB-003
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 1
	
TTDDRUID	D0M9ZL
DRUGNAME	TPO gene plasmid
INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative
	
TTDDRUID	D0M9ZT
DRUGNAME	TJ-960
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 3
	
TTDDRUID	D0MA0F
DRUGNAME	WF-11605
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0MA2E
DRUGNAME	GLYCAR T cells
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
	
TTDDRUID	D0MA2J
DRUGNAME	POL-443
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0MA4F
DRUGNAME	GD2-CART01
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1/2
	
TTDDRUID	D0MA4O
DRUGNAME	Anti-CD20 CAR-T cells
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
	
TTDDRUID	D0MA7A
DRUGNAME	3-(phenoxymethyl) benzylamine derivative 4
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0MA7C
DRUGNAME	Sodium nitrite
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0MA9N
DRUGNAME	Dapsone
INDICATI	Pneumocystis pneumonia [ICD-11: CA40.20] Approved
	
TTDDRUID	D0MB2Z
DRUGNAME	ATR-101
INDICATI	Malignant adrenal gland cancer [ICD-11: 2D11] Phase 1
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0MB8I
DRUGNAME	Oxacillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0MC0O
DRUGNAME	AZD-1080
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1
	
TTDDRUID	D0MC2E
DRUGNAME	MOR-203
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0MC2S
DRUGNAME	NIC-002
INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Phase 2
	
TTDDRUID	D0MC3K
DRUGNAME	CID755673
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0MC3R
DRUGNAME	Goxalapladib
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D0MC5O
DRUGNAME	CAP-1002
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2
	
TTDDRUID	D0MC6Y
DRUGNAME	LTX-04
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0MD0T
DRUGNAME	Satralizumab
INDICATI	Neuromyelitis optica spectrum disorder [ICD-11: 8E4A.0] Approved
	
TTDDRUID	D0MD2L
DRUGNAME	Rufinamide
INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved
INDICATI	Pediatric lennox-gastaut syndrome [ICD-11: 8A62.1] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved (orphan drug)
	
TTDDRUID	D0MD5M
DRUGNAME	G100
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D0MD6C
DRUGNAME	Sernivo
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
	
TTDDRUID	D0MD7Y
DRUGNAME	Ragweed mix vaccine
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 1
INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 1
	
TTDDRUID	D0MD8D
DRUGNAME	Tecovirimat 
INDICATI	Smallpox [ICD-11: 1E70] Approved
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 3
	
TTDDRUID	D0MD8O
DRUGNAME	Adacel
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D0MD8S
DRUGNAME	CARTmeso/19
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0ME1L
DRUGNAME	Digibind
INDICATI	Eclampsia [ICD-11: JA25] Phase 2b
INDICATI	Pre-eclampsia [ICD-11: JA24] Phase 2
	
TTDDRUID	D0ME2T
DRUGNAME	RTA-901
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 1
	
TTDDRUID	D0ME7Q
DRUGNAME	MP0250
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D0MF3C
DRUGNAME	WAY-123641
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0MF3F
DRUGNAME	AAV8-773
INDICATI	Achromatopsia [ICD-11: 9B70] Investigative
	
TTDDRUID	D0MF7U
DRUGNAME	PF-3052334
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D0MF9G
DRUGNAME	Potassium Perchlorate
INDICATI	Hyperthyroidism [ICD-11: 5A02] Approved
	
TTDDRUID	D0MF9H
DRUGNAME	Delucemine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1
	
TTDDRUID	D0MG0F
DRUGNAME	IW-001
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 1
	
TTDDRUID	D0MG0H
DRUGNAME	NVC-612
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0MG0O
DRUGNAME	BBV152 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	D0MG1Y
DRUGNAME	Belladonna
INDICATI	Colitis [ICD-11: 1A40.Z] Approved
	
TTDDRUID	D0MG2R
DRUGNAME	ALX-0141
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1
	
TTDDRUID	D0MG3Z
DRUGNAME	CAR-T cells targeting PSCA
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0MG4D
DRUGNAME	Heteroaryl-carboxamide derivative 5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0MG6V
DRUGNAME	3-substituted-1,2,4-oxadiazole derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0MH1F
DRUGNAME	MEDI3726
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0MH1R
DRUGNAME	RG7418
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D0MH8K
DRUGNAME	LPO-1010CSR
INDICATI	Retinopathy [ICD-11: 9B71] Investigative
	
TTDDRUID	D0MH8O
DRUGNAME	Angiotensin-(1-7)
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 3
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 2
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 1
	
TTDDRUID	D0MI0Q
DRUGNAME	Amarylline
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0MI0S
DRUGNAME	Antigen-pulsed dendritic cell vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0MI1N
DRUGNAME	CR-5259
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D0MI3E
DRUGNAME	PMID25684022-Compound-WO2008107444
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0MI5G
DRUGNAME	RG2077
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 1/2
	
TTDDRUID	D0MI8F
DRUGNAME	IdeS
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0MI8Z
DRUGNAME	ONS-3010
INDICATI	Crohn disease [ICD-11: DD70] Phase 1
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1
	
TTDDRUID	D0MI9F
DRUGNAME	PTX-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0MJ2H
DRUGNAME	KD-7040
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0MJ5E
DRUGNAME	DMB mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0MJ7W
DRUGNAME	BRX-1002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0MJ9L
DRUGNAME	PB-102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0MK2C
DRUGNAME	SR-31742A
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0MK2F
DRUGNAME	Macrocyclic peptide analog 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0MK2Y
DRUGNAME	Rotavax
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1/2
	
TTDDRUID	D0MK7H
DRUGNAME	Anti-BCMA CAR-T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0ML0L
DRUGNAME	ARRY-614
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Discontinued in Phase 1
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D0ML0R
DRUGNAME	SKF-105685
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D0ML1F
DRUGNAME	Adefovir Dipivoxil
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0ML1G
DRUGNAME	Covax-19 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0ML2V
DRUGNAME	RALURIDINE
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0ML5T
DRUGNAME	EUR-1066
INDICATI	Exocrine pancreatic insufficiency [ICD-11: DC35.1] Phase 1
	
TTDDRUID	D0ML8G
DRUGNAME	Turoctocog alfa
INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 3
	
TTDDRUID	D0ML9K
DRUGNAME	T-506
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0MM0N
DRUGNAME	MPC-300-IV
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0MM1Y
DRUGNAME	Polyhydroxy benzamide derivative 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0MM2K
DRUGNAME	CP-195543
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0MM2L
DRUGNAME	Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0MM3A
DRUGNAME	BIIB104
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2a
	
TTDDRUID	D0MM4H
DRUGNAME	GSK1795091
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0MM4X
DRUGNAME	MIV-710
INDICATI	Bone metastases [ICD-11: 2D50] Investigative
	
TTDDRUID	D0MM5P
DRUGNAME	Subcutaneous furosemide
INDICATI	Acute decompensated heart failure [ICD-11: BD1Z] Phase 2/3
INDICATI	Chronic heart failure [ICD-11: BD1Z] Application submitted
	
TTDDRUID	D0MM6A
DRUGNAME	Coenzyme Q10 analog
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
INDICATI	Leigh syndrome [ICD-11: 5C53.24] Phase 2
INDICATI	Mitochondrial respiratory chain disease [ICD-11: 5C53.2] Phase 2
INDICATI	Rett syndrome [ICD-11: LD90.4] Phase 2
	
TTDDRUID	D0MM6Q
DRUGNAME	MM-POD1
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0MM8M
DRUGNAME	Diazepinone derivative 2
INDICATI	Reflux disease [ICD-11: DA22] Patented
INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented
	
TTDDRUID	D0MM8N
DRUGNAME	Idebenone
INDICATI	Cognitive impairment [ICD-11: 6D71] Approved
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Approved
	
TTDDRUID	D0MN9K
DRUGNAME	Meclofenamate Sodium
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0MO0J
DRUGNAME	MEDI0382
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0MO0Z
DRUGNAME	Alkyl mannoside derivative 5
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0MO7Y
DRUGNAME	MF59 adjuvanted SARS-CoV-2 Sclamp vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0MP0X
DRUGNAME	AZD1480
INDICATI	Myeloproliferative syndrome [ICD-11: 2A22] Phase 2
	
TTDDRUID	D0MP1C
DRUGNAME	Flosequinan
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D0MP1M
DRUGNAME	CERE-110
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0MP2S
DRUGNAME	Centanamycin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0MP2U
DRUGNAME	AN-9
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2
	
TTDDRUID	D0MP5H
DRUGNAME	Debrisoquin
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0MQ6B
DRUGNAME	CVnCoV vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0MR0B
DRUGNAME	TEW-7197
INDICATI	Myeloproliferative neoplasm [ICD-11: 2A20] Phase 2
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0MR2D
DRUGNAME	ARCoV vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0MR4Q
DRUGNAME	CCX-168
INDICATI	Anca-associated vasculitis [ICD-11: 4A44.A] Phase 3
INDICATI	Eosinophilic granulomatosis with polyangiitis [ICD-11: 4A44.A2] Phase 2
INDICATI	Hereditary haemolytic anemia [ICD-11: 3A10.3] Phase 2
	
TTDDRUID	D0MR9V
DRUGNAME	PMID27998201-Compound-15
INDICATI	Pain [ICD-11: MG30-MG3Z] Patented
	
TTDDRUID	D0MS1D
DRUGNAME	FCE-25876
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated
	
TTDDRUID	D0MS1G
DRUGNAME	Fish oil triglycerides
INDICATI	Cholestasis of parenteral nutrition [ICD-11: DB99.60] Approved
	
TTDDRUID	D0MS2T
DRUGNAME	BCMA-specific CAR-expressing T Lymphocytes
INDICATI	Plasma cell myeloma [ICD-11: 2A83.1] Phase 1
	
TTDDRUID	D0MS3Z
DRUGNAME	GSK690693
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0MS6B
DRUGNAME	LOR 253
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1
	
TTDDRUID	D0MT0A
DRUGNAME	CCX915
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1
	
TTDDRUID	D0MT0M
DRUGNAME	Apraclonidine
INDICATI	Intra ocular pressure reduction [ICD-11: 9C40] Approved
	
TTDDRUID	D0MT1Q
DRUGNAME	K-201
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D0MT3A
DRUGNAME	Human retinal progenitor cells
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	D0MT3J
DRUGNAME	Benzimidazole derivative 4
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0MT5C
DRUGNAME	L-742791
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0MT5U
DRUGNAME	DopaFuse
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0MT6W
DRUGNAME	MVC-COV1901 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0MT7W
DRUGNAME	NN8210
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D0MT9G
DRUGNAME	RO-48-8684
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D0MT9X
DRUGNAME	Calcium dobesilate
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Approved
	
TTDDRUID	D0MU0S
DRUGNAME	EM-800
INDICATI	Estrogen deficiency [ICD-11: FB83.0Y] Discontinued in Phase 3
	
TTDDRUID	D0MU1F
DRUGNAME	XTL-6865
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0MU3S
DRUGNAME	PMID25666693-Compound-47
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0MU7N
DRUGNAME	123I-MNI-330
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0MU9L
DRUGNAME	Migalastat
INDICATI	Fabry disease [ICD-11: 5C56.01] Approved
	
TTDDRUID	D0MV3Q
DRUGNAME	Axovan-3
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
INDICATI	Eating disorder [ICD-11: 6B82] Discontinued in Phase 1
	
TTDDRUID	D0MV4T
DRUGNAME	CD19.CAR T Cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
	
TTDDRUID	D0MV4W
DRUGNAME	RUBOXISTAURIN HYDROCHLORIDE
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3
	
TTDDRUID	D0MW0N
DRUGNAME	Masitinib
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3
INDICATI	Metastatic gastric or gastroesophageal junction cancer [ICD-11: 2D8Y] Phase 3
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
	
TTDDRUID	D0MW3H
DRUGNAME	CIPEMASTAT
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0MW7B
DRUGNAME	PF-4494700
INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 3
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0MW7L
DRUGNAME	Heteroaryl-carboxamide derivative 7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0MW7S
DRUGNAME	Lexatumumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0MWS2
DRUGNAME	YTB323
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	D0MX5N
DRUGNAME	ASCT01
INDICATI	Critical limb ischemia [ICD-11: BD4Y] Phase 1/2
	
TTDDRUID	D0MX6K
DRUGNAME	Crysvita
INDICATI	Complex epidermal hamartoma [ICD-11: LC02] Phase 2
	
TTDDRUID	D0MY0F
DRUGNAME	MGD013
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0MY1U
DRUGNAME	Intanza
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0MY3C
DRUGNAME	AR08
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	D0MY3K
DRUGNAME	PMID25666693-Compound-109
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0MY6Q
DRUGNAME	Vibrilase
INDICATI	Burn and burn infection [ICD-11: ND90-NE2Z] Discontinued in Phase 1
	
TTDDRUID	D0MY7F
DRUGNAME	BB3
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 3
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3
	
TTDDRUID	D0MY7X
DRUGNAME	Esonarimod
INDICATI	Arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0MY8N
DRUGNAME	Beta-carotene
INDICATI	Vitamin deficiency [ICD-11: 5B55-5B71] Approved
	
TTDDRUID	D0MZ2B
DRUGNAME	IODOSTEARIC ACID
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0MZ4V
DRUGNAME	1,2,4-oxadiazole derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0MZ7K
DRUGNAME	Triazolo[4,3-b]pyridazine derivative 2
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0MZ8J
DRUGNAME	PMID26651364-Compound-10d
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0MZ9A
DRUGNAME	Suronacrine maleate
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3
	
TTDDRUID	D0N0AJ
DRUGNAME	Double mutant heat-labile toxin
INDICATI	Escherichia coli infection [ICD-11: 1A03] Phase 1
	
TTDDRUID	D0N0AR
DRUGNAME	GPI-1485
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0N0BI
DRUGNAME	SIBRAFIBAN
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3
	
TTDDRUID	D0N0BW
DRUGNAME	ALD-518
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2
	
TTDDRUID	D0N0DP
DRUGNAME	FB-1811
INDICATI	Salmonella infection [ICD-11: 1A09] Investigative
	
TTDDRUID	D0N0DU
DRUGNAME	DS-6051
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0N0EB
DRUGNAME	P-17
INDICATI	Bone metastases [ICD-11: 2D50] Investigative
	
TTDDRUID	D0N0EQ
DRUGNAME	Streptomycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0N0ES
DRUGNAME	Vitamin B3
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Approved
	
TTDDRUID	D0N0HO
DRUGNAME	SX-RDS1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N0IQ
DRUGNAME	Ro-27-3225
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0N0JE
DRUGNAME	UP-275-22
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0N0KG
DRUGNAME	CDRI-85/92
INDICATI	Stomach ulcer [ICD-11: DA60.Z] Investigative
	
TTDDRUID	D0N0KR
DRUGNAME	Emakalim
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 1
	
TTDDRUID	D0N0LB
DRUGNAME	zoxazolamine
INDICATI	Multiple myeloma [ICD-11: 2A83] Terminated
	
TTDDRUID	D0N0MZ
DRUGNAME	ITL-1636
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0N0OG
DRUGNAME	TAK-361S
INDICATI	Diphtheria [ICD-11: 1C17] Discontinued in Phase 2
	
TTDDRUID	D0N0OU
DRUGNAME	Deferiprone
INDICATI	Thalassemia [ICD-11: 3A50] Approved
	
TTDDRUID	D0N0OV
DRUGNAME	Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
	
TTDDRUID	D0N0PU
DRUGNAME	LTB 019
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0N0PW
DRUGNAME	IDP-113
INDICATI	Tinea pedis [ICD-11: 1F28.2] Phase 2
	
TTDDRUID	D0N0QC
DRUGNAME	GV1001
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
	
TTDDRUID	D0N0QN
DRUGNAME	PMID25666693-Compound-146
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0N0RN
DRUGNAME	Marizomib
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0N0RU
DRUGNAME	Bexarotene
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved
	
TTDDRUID	D0N0SB
DRUGNAME	BOF-12013
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0N0SC
DRUGNAME	AIKb2
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0N0SO
DRUGNAME	Autosomal dominant retinitis pigmentosa
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Investigative
	
TTDDRUID	D0N0TF
DRUGNAME	PMID25666693-Compound-156
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0N0TZ
DRUGNAME	Clopidogrel
INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved
	
TTDDRUID	D0N0UY
DRUGNAME	AZD1704
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1
	
TTDDRUID	D0N0VW
DRUGNAME	IDN-5174
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N0XU
DRUGNAME	Pyrazole derivative 29
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0N0YT
DRUGNAME	AP-10295
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N1AS
DRUGNAME	NGD-4715
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D0N1AT
DRUGNAME	BIOO-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N1AY
DRUGNAME	Metallothionein
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D0N1BF
DRUGNAME	LY-2811376
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0N1CF
DRUGNAME	Imidazo[1,2-b]pyridazine derivative 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D0N1CH
DRUGNAME	Arverapamil
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
	
TTDDRUID	D0N1DG
DRUGNAME	F61F12
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N1DQ
DRUGNAME	ANQ-9040
INDICATI	Paralysis [ICD-11: 8B60] Discontinued in Phase 1
	
TTDDRUID	D0N1EC
DRUGNAME	WY-47766
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2
	
TTDDRUID	D0N1EF
DRUGNAME	DARGLITAZONE
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D0N1EW
DRUGNAME	DuP-532
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D0N1EZ
DRUGNAME	SPC-3
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0N1FR
DRUGNAME	BECATECARIN
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D0N1GB
DRUGNAME	APD-916
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 1
	
TTDDRUID	D0N1HL
DRUGNAME	Frakefamide
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0N1HW
DRUGNAME	L-745,870
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2
	
TTDDRUID	D0N1IL
DRUGNAME	HG-1246
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N1KC
DRUGNAME	B-type natriuretic peptide
INDICATI	Heart disease [ICD-11: BA41-BA42] Discontinued in Phase 3
	
TTDDRUID	D0N1MC
DRUGNAME	Cefatrizine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0N1NE
DRUGNAME	Xp-828l
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
	
TTDDRUID	D0N1NL
DRUGNAME	Recombinant Wolinella (rWS) asparaginase
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N1PA
DRUGNAME	CGP-49823
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0N1PZ
DRUGNAME	S-tenatoprazole
INDICATI	Peptic ulcer [ICD-11: DA61] Phase 2
	
TTDDRUID	D0N1QH
DRUGNAME	HuMax-CD38b
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N1QX
DRUGNAME	ImmStat
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0N1RE
DRUGNAME	BIBF100
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0N1RG
DRUGNAME	SoRI-9409
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Preclinical
	
TTDDRUID	D0N1RH
DRUGNAME	AMZ-0026
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0N1RM
DRUGNAME	JR-101
INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Investigative
	
TTDDRUID	D0N1SH
DRUGNAME	VX-15
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0N1SL
DRUGNAME	KI-0801
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0N1ST
DRUGNAME	AFC-5128
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0N1SU
DRUGNAME	Licofelone
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 1
	
TTDDRUID	D0N1TH
DRUGNAME	ATI-2042
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2
	
TTDDRUID	D0N1TP
DRUGNAME	Paricalcitol
INDICATI	Hyperparathyroidism [ICD-11: 5A51] Approved
	
TTDDRUID	D0N1UH
DRUGNAME	VTT-301
INDICATI	Prostate hyperplasia [ICD-11: GA90] Investigative
	
TTDDRUID	D0N1VG
DRUGNAME	DeNVax
INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 2
	
TTDDRUID	D0N1WG
DRUGNAME	GSK-1137585
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0N1WM
DRUGNAME	A-68930
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0N1WU
DRUGNAME	Etodolac
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0N1XJ
DRUGNAME	SCID-X stem cell therapy
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1/2
	
TTDDRUID	D0N1YF
DRUGNAME	Beperminogene perplasmid
INDICATI	Heart disease [ICD-11: BA41-BA42] Phase 3
INDICATI	Critical limb ischemia [ICD-11: BD4Y] Phase 3
	
TTDDRUID	D0N1YG
DRUGNAME	CureXcell
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
	
TTDDRUID	D0N2AI
DRUGNAME	Biphenyl mannoside derivative 19
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0N2AM
DRUGNAME	CAR CD30 T cells
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1
	
TTDDRUID	D0N2AY
DRUGNAME	Stapled peptides
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0N2BX
DRUGNAME	Nadroparin calcium
INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0N2CG
DRUGNAME	Carlecortemcel-L
INDICATI	Lung infection [ICD-11: CA4Z] Phase 2/3
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 2/3
	
TTDDRUID	D0N2CS
DRUGNAME	RP-4000
INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative
	
TTDDRUID	D0N2DD
DRUGNAME	PDL-241
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0N2FI
DRUGNAME	GW-766994
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0N2GC
DRUGNAME	BMS-753493
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0N2GQ
DRUGNAME	ATI-0917
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0N2GS
DRUGNAME	NDC-KM
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N2HF
DRUGNAME	Vanoxerine
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Discontinued in Phase 1
	
TTDDRUID	D0N2HU
DRUGNAME	VRC-EBODNA023-00-VP
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D0N2IE
DRUGNAME	VB-201
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2
	
TTDDRUID	D0N2JI
DRUGNAME	VAS-203
INDICATI	Brain injury [ICD-11: NA07.Z] Phase 2
	
TTDDRUID	D0N2KU
DRUGNAME	PF-3409409
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative
	
TTDDRUID	D0N2LY
DRUGNAME	NN-2501
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0N2QI
DRUGNAME	TA-CD cocaine abuse vaccine
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2
	
TTDDRUID	D0N2QW
DRUGNAME	Patritumab
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0N2RF
DRUGNAME	SMART ABL-364
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D0N2SR
DRUGNAME	Selexipag
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Approved
	
TTDDRUID	D0N2UQ
DRUGNAME	PMID25666693-Compound-24
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0N2YN
DRUGNAME	Spirogermanium hydrochloride
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0N2YY
DRUGNAME	OSPC-rDT vaccine
INDICATI	Shigella infection [ICD-11: 1A02] Phase 1
	
TTDDRUID	D0N3AF
DRUGNAME	Imidazopyridazine derivative 7
INDICATI	Pain [ICD-11: MG30-MG3Z] Patented
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D0N3BB
DRUGNAME	CBX-129801
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0N3EJ
DRUGNAME	RGH-896
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 2
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
	
TTDDRUID	D0N3FJ
DRUGNAME	BL-1889
INDICATI	Pruritus [ICD-11: EC90] Terminated
	
TTDDRUID	D0N3GE
DRUGNAME	CD19 CART
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
	
TTDDRUID	D0N3IA
DRUGNAME	HE3235
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0N3IP
DRUGNAME	Campestanol ascorbyl phosphate
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D0N3IT
DRUGNAME	SNX-1012
INDICATI	Mucositis [ICD-11: CA00] Discontinued in Phase 1
	
TTDDRUID	D0N3JT
DRUGNAME	Cantuzumab mertansine
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0N3NI
DRUGNAME	Deuteroporphyrin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N3NL
DRUGNAME	Acriflavine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0N3NO
DRUGNAME	Limaprost
INDICATI	Spinal stenosis [ICD-11: FA82] Approved
	
TTDDRUID	D0N3NZ
DRUGNAME	Somatomedin-1
INDICATI	Hormone deficiency [ICD-11: 5A61.1] Approved
	
TTDDRUID	D0N3OH
DRUGNAME	A-317920
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative
	
TTDDRUID	D0N3PC
DRUGNAME	MR1-1
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
	
TTDDRUID	D0N3PE
DRUGNAME	Guanethidine
INDICATI	Moderate and severe hypertension [ICD-11: BA00.Z] Approved
	
TTDDRUID	D0N3QF
DRUGNAME	AZD-5122
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0N3RC
DRUGNAME	TZP-301
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Preclinical
	
TTDDRUID	D0N3RK
DRUGNAME	CYSTEMUSTINE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0N3RU
DRUGNAME	Stem cell therapy, heart disease
INDICATI	Heart disease [ICD-11: BA41-BA42] Investigative
	
TTDDRUID	D0N3SA
DRUGNAME	IR-201
INDICATI	Arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0N3SH
DRUGNAME	Pyroxamide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0N3SP
DRUGNAME	Butoconazole
INDICATI	Candidiasis [ICD-11: 1F23] Approved
	
TTDDRUID	D0N3SR
DRUGNAME	Cilnidipine
INDICATI	High blood pressure [ICD-11: BA00] Phase 3
	
TTDDRUID	D0N3TO
DRUGNAME	TRM-115
INDICATI	Gastric ulcer [ICD-11: DA60] Discontinued in Phase 1
	
TTDDRUID	D0N3UG
DRUGNAME	Hylenex
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0N3UL
DRUGNAME	Fosfosal
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0N3UQ
DRUGNAME	123I-MNI-168
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0N3US
DRUGNAME	FA-613
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0N3VR
DRUGNAME	Voriconazole
INDICATI	Invasive aspergillosis [ICD-11: 1F20.0] Approved
	
TTDDRUID	D0N3WN
DRUGNAME	ABT-308
INDICATI	Eosinophilic esophagitis [ICD-11: DA24.1] Phase 2
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0N3XT
DRUGNAME	BREQUINAR
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0N3YL
DRUGNAME	ASC-201
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Investigative
	
TTDDRUID	D0N3YT
DRUGNAME	GLPG-0555
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
	
TTDDRUID	D0N3ZJ
DRUGNAME	LOMERIZINE
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0N3ZN
DRUGNAME	MEDI-8662
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0N3ZY
DRUGNAME	DPC-681
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0N4AB
DRUGNAME	Rx-01
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical
	
TTDDRUID	D0N4DF
DRUGNAME	ALKS-37
INDICATI	Constipation [ICD-11: DD91.1] Phase 2
	
TTDDRUID	D0N4DO
DRUGNAME	Troponin-I
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Terminated
	
TTDDRUID	D0N4EC
DRUGNAME	Taltirelin
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Approved
	
TTDDRUID	D0N4EO
DRUGNAME	GMI-1070
INDICATI	Asthma [ICD-11: CA23] Phase 3
INDICATI	Vaso-occlusive crisis [ICD-11: BE2Y] Phase 3
	
TTDDRUID	D0N4HB
DRUGNAME	Belatacept
INDICATI	Kidney transplant rejection [ICD-11: NE84] Approved
INDICATI	Heart transplant rejection [ICD-11: NE84] NDA filed
	
TTDDRUID	D0N4HQ
DRUGNAME	OXi4503
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1/2
INDICATI	Myelodysplastic malignancy [ICD-11: 2A44] Phase 1/2
	
TTDDRUID	D0N4IU
DRUGNAME	CDNF/MANF
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0N4IV
DRUGNAME	S-3304
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0N4JA
DRUGNAME	CLT-008
INDICATI	Blood transfusion [ICD-11: QB98] Phase 2
	
TTDDRUID	D0N4JG
DRUGNAME	Eladem
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2
	
TTDDRUID	D0N4JI
DRUGNAME	APG-101
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2
	
TTDDRUID	D0N4KK
DRUGNAME	NB-1008
INDICATI	Seasonal influenza infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D0N4LW
DRUGNAME	Human Alpha Antitrypsin
INDICATI	Genetic disease [ICD-11: 8E02] Investigative
	
TTDDRUID	D0N4MK
DRUGNAME	IB-07A037
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0N4MR
DRUGNAME	CDE-5498
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D0N4ND
DRUGNAME	Fontolizumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
	
TTDDRUID	D0N4NH
DRUGNAME	Anti-CD45 mAb 131I-BC8
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0N4NJ
DRUGNAME	YKP-1358
INDICATI	Schizoaffective disorder [ICD-11: 6A21] Phase 1
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0N4OW
DRUGNAME	Vasopressin
INDICATI	Diabetes insipidus [ICD-11: 5A61.5] Approved
INDICATI	Polyuria [ICD-11: MF55] Approved
INDICATI	Enuresis [ICD-11: 6C00] Approved
	
TTDDRUID	D0N4OZ
DRUGNAME	Epothilone D
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D0N4PC
DRUGNAME	RU-46556
INDICATI	Endometrial cancer [ICD-11: 2C76] Terminated
	
TTDDRUID	D0N4PW
DRUGNAME	iOWH032
INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2
	
TTDDRUID	D0N4PZ
DRUGNAME	Incadronate
INDICATI	Hypercalcaemia [ICD-11: 5B91.0] Approved
	
TTDDRUID	D0N4SF
DRUGNAME	GI-4000
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0N4SU
DRUGNAME	Pegorgotein
INDICATI	Head injury [ICD-11: NA00-NA0Z] Terminated
	
TTDDRUID	D0N4TO
DRUGNAME	Biphenyl mannoside derivative 11
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0N4TZ
DRUGNAME	Macrocycle derivative 8
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0N4VB
DRUGNAME	NLG802
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0N4VG
DRUGNAME	CAR-T cells targeting CD123
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical
	
TTDDRUID	D0N4VN
DRUGNAME	INGAP peptide
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2
	
TTDDRUID	D0N4WW
DRUGNAME	PMID26651364-Compound-106
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0N4YU
DRUGNAME	Enterococcus faecalis conjugate vaccine
INDICATI	Enterococcus faecium infection [ICD-11: 1D01.0Y] Terminated
	
TTDDRUID	D0N4YX
DRUGNAME	EAA-090
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2
	
TTDDRUID	D0N4ZS
DRUGNAME	ST-4206
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0N4ZX
DRUGNAME	MK-1029
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0N5AS
DRUGNAME	ITI-014
INDICATI	Hot flushes [ICD-11: GA30] Investigative
	
TTDDRUID	D0N5AY
DRUGNAME	Ranagengliotucel-T
INDICATI	Brain cancer [ICD-11: 2A00] Discontinued in Phase 3
	
TTDDRUID	D0N5BC
DRUGNAME	Autolymphocyte therapy
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 3
	
TTDDRUID	D0N5BL
DRUGNAME	AJA-777
INDICATI	Dyspepsia [ICD-11: MD92] Discontinued in Phase 2
	
TTDDRUID	D0N5CT
DRUGNAME	BIBS-222
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0N5CW
DRUGNAME	Oleoyl-estrone
INDICATI	Obesity [ICD-11: 5B81] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Phase 2
	
TTDDRUID	D0N5DW
DRUGNAME	CG-023132
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0N5DZ
DRUGNAME	CBI-009
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0N5GV
DRUGNAME	Nivolumab + ipilimumab
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 3
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0N5HJ
DRUGNAME	Enalaprilat
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0N5HN
DRUGNAME	M-100240
INDICATI	Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2
	
TTDDRUID	D0N5HO
DRUGNAME	SQ-32709
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2
	
TTDDRUID	D0N5JJ
DRUGNAME	ADROGOLIDE HYDROCHLORIDE
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D0N5JZ
DRUGNAME	PF-04691502
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
	
TTDDRUID	D0N5KF
DRUGNAME	Meropenem + vaborbactam
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
INDICATI	Intra-abdominal infection [ICD-11: 1A40] Approved
	
TTDDRUID	D0N5KS
DRUGNAME	Pumosetrag
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
INDICATI	Gastro-oesophageal reflux [ICD-11: DA22] Phase 1
	
TTDDRUID	D0N5LJ
DRUGNAME	Igmesine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0N5MH
DRUGNAME	Risdiplam
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Approved
	
TTDDRUID	D0N5NC
DRUGNAME	TAS3681
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0N5NI
DRUGNAME	Benlysta + Rituxan
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2
	
TTDDRUID	D0N5NM
DRUGNAME	Org-23366
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0N5NV
DRUGNAME	Biaryl compound 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0N5OL
DRUGNAME	STD-052
INDICATI	Constipation [ICD-11: DD91.1] Investigative
	
TTDDRUID	D0N5OV
DRUGNAME	Cetuximab
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
	
TTDDRUID	D0N5SC
DRUGNAME	UK-369003
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 1/2
	
TTDDRUID	D0N5SS
DRUGNAME	AZD1175
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D0N5SW
DRUGNAME	Sulochrin
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0N5TB
DRUGNAME	ITRI-305
INDICATI	Thyroid cancer [ICD-11: 2D10] Investigative
	
TTDDRUID	D0N5UA
DRUGNAME	Dianicline+rimonabant
INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Terminated
	
TTDDRUID	D0N5UU
DRUGNAME	NRT-100
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0N5VK
DRUGNAME	TSR-042
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1
	
TTDDRUID	D0N5VL
DRUGNAME	Saccharomyces boulardii
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
	
TTDDRUID	D0N5XI
DRUGNAME	DP-001
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D0N5YA
DRUGNAME	Repaglinide
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0N5YD
DRUGNAME	Nepicastat oral
INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Phase 2
	
TTDDRUID	D0N5YX
DRUGNAME	PD-158473
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0N5ZS
DRUGNAME	Vedolizmab
INDICATI	Crohn disease [ICD-11: DD70] Approved
INDICATI	Ulcerative colitis [ICD-11: DD71] Approved
	
TTDDRUID	D0N6AC
DRUGNAME	SHAPE
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0N6CC
DRUGNAME	AFX-300
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0N6CR
DRUGNAME	Propoxycaine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0N6CS
DRUGNAME	FG-2216
INDICATI	Kidney disease [ICD-11: GC2Z] Phase 2
	
TTDDRUID	D0N6DD
DRUGNAME	SF-109
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D0N6EA
DRUGNAME	Odiparcil
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D0N6EL
DRUGNAME	SX-AZD1
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0N6FH
DRUGNAME	Dihydroartemisinin
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0N6FI
DRUGNAME	ChimeriVax-JE
INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Phase 4
	
TTDDRUID	D0N6FZ
DRUGNAME	WS-50030
INDICATI	Schizophrenia [ICD-11: 6A20] Investigative
	
TTDDRUID	D0N6GL
DRUGNAME	Pyrazoline derivative 10
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0N6GW
DRUGNAME	NASPANVAC
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0N6HA
DRUGNAME	COL-2401
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0N6IY
DRUGNAME	TZ101
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D0N6KO
DRUGNAME	THIQ
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D0N6MX
DRUGNAME	Gamunex-C
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 2
	
TTDDRUID	D0N6NA
DRUGNAME	1,3,4-thiadiazole derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0N6NG
DRUGNAME	Bicyclic heteroaryl benzamide derivative 7
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0N6NM
DRUGNAME	CEP-37440
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0N6OE
DRUGNAME	Benafentrine dimaleate
INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated
	
TTDDRUID	D0N6PB
DRUGNAME	VM-106
INDICATI	Chronic granulomatous disease [ICD-11: 4A00.0Y] Discontinued in Phase 1/2
	
TTDDRUID	D0N6PE
DRUGNAME	CART-123 cells
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0N6PV
DRUGNAME	MK-852
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D0N6QB
DRUGNAME	MT-112
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0N6QO
DRUGNAME	RP-1040
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N6RF
DRUGNAME	Telmisartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0N6SO
DRUGNAME	SYR-472
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 3
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0N6TD
DRUGNAME	BIW-8962
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0N6UA
DRUGNAME	Leukemia DNA vaccine
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0N6UJ
DRUGNAME	Diacol
INDICATI	Gastrointestinal infection [ICD-11: 1A40.Z] Approved
	
TTDDRUID	D0N6UP
DRUGNAME	ETHIMIZOL
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3
	
TTDDRUID	D0N6VK
DRUGNAME	Hepapoietin
INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 1
	
TTDDRUID	D0N6VS
DRUGNAME	ADU-S100
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0N6WX
DRUGNAME	AI-128
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0N6YN
DRUGNAME	BN-DF-037
INDICATI	Osteoporosis [ICD-11: FB83.0] Preclinical
	
TTDDRUID	D0N6YV
DRUGNAME	Cenestin
INDICATI	Menopause symptom [ICD-11: GA30.0] Approved
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D0N6ZK
DRUGNAME	CGP-20376
INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Investigative
	
TTDDRUID	D0N6ZP
DRUGNAME	SKF-105494
INDICATI	Diuretic vasodilator [ICD-11: BA00] Phase 1
	
TTDDRUID	D0N7AD
DRUGNAME	Azatadine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0N7AU
DRUGNAME	Nifurzide
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0N7BL
DRUGNAME	UK-240455
INDICATI	Nerve injury [ICD-11: ND56.4] Phase 1
	
TTDDRUID	D0N7BW
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0N7CU
DRUGNAME	HG-1182
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N7CY
DRUGNAME	VLI-27
INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative
	
TTDDRUID	D0N7DQ
DRUGNAME	APC-100
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0N7DW
DRUGNAME	Needle-free influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 2
	
TTDDRUID	D0N7FD
DRUGNAME	Multi-epitope tyrosinase/gp100 vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0N7GN
DRUGNAME	Aerucin
INDICATI	Pneumocystis pneumonia [ICD-11: CA40.20] Phase 2
INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 1
	
TTDDRUID	D0N7HS
DRUGNAME	ASP-3258
INDICATI	Respiratory tract inflammation [ICD-11: CA07] Investigative
	
TTDDRUID	D0N7HT
DRUGNAME	PRO-135
INDICATI	Myotonic dystrophy [ICD-11: 8C71.0] Investigative
	
TTDDRUID	D0N7JP
DRUGNAME	TEM
INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Phase 2
	
TTDDRUID	D0N7JS
DRUGNAME	PG11047
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0N7JZ
DRUGNAME	SAND-26
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D0N7KV
DRUGNAME	Reniale
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved
	
TTDDRUID	D0N7LA
DRUGNAME	BIBH 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0N7ML
DRUGNAME	PV-707
INDICATI	Skin burns [ICD-11: ME65.0] Discontinued in Phase 2
	
TTDDRUID	D0N7SG
DRUGNAME	R-84760
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0N7WB
DRUGNAME	CLR-151
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Investigative
	
TTDDRUID	D0N7WG
DRUGNAME	AM-111
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 3
	
TTDDRUID	D0N7WR
DRUGNAME	Sepimostat mesylate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D0N7WW
DRUGNAME	RVX-208
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D0N7XI
DRUGNAME	Tremetinib
INDICATI	Cutaneous melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D0N7XW
DRUGNAME	Human enterovirus 71 vaccine
INDICATI	Enterovirus infection [ICD-11: 1D91] Phase 2
	
TTDDRUID	D0N7XY
DRUGNAME	111In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide (melanoma), NuView/University of New Mexico
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0N7YK
DRUGNAME	YPEG-EPO
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0N8AB
DRUGNAME	PF-4629991
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
	
TTDDRUID	D0N8CM
DRUGNAME	PAV-616
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0N8CN
DRUGNAME	BVB-808
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N8DP
DRUGNAME	Bentazepam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0N8FQ
DRUGNAME	Reboxetine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0N8GC
DRUGNAME	MRX-4TZT
INDICATI	Spastic paralysis [ICD-11: MB5Y] Phase 1
	
TTDDRUID	D0N8GR
DRUGNAME	CZ-775
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N8IG
DRUGNAME	PdpSC18
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1
	
TTDDRUID	D0N8IL
DRUGNAME	PF-06425090
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 3
	
TTDDRUID	D0N8JA
DRUGNAME	Theradigm-HBV
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2
	
TTDDRUID	D0N8JB
DRUGNAME	JTT-552
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2
	
TTDDRUID	D0N8JG
DRUGNAME	FolateImmune
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0N8JJ
DRUGNAME	MDDR 217769
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0N8JP
DRUGNAME	JTV-803
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D0N8MQ
DRUGNAME	GSK-159797
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D0N8NC
DRUGNAME	SAVOXEPIN MESYLATE
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2
	
TTDDRUID	D0N8NK
DRUGNAME	AZD-6605
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Terminated
	
TTDDRUID	D0N8NN
DRUGNAME	CT-12441
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0N8NT
DRUGNAME	BCMA-UCART
INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial
	
TTDDRUID	D0N8PV
DRUGNAME	Bovine alkaline phosphatase
INDICATI	Renal failure [ICD-11: GB60-GB6Z] Phase 2
	
TTDDRUID	D0N8QK
DRUGNAME	ABT-288
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0N8QQ
DRUGNAME	CARIPORIDE
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D0N8QR
DRUGNAME	GRF6019
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0N8RA
DRUGNAME	GS-5829
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0N8RV
DRUGNAME	OSI-930
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0N8TM
DRUGNAME	XGP-110
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0N8UQ
DRUGNAME	IMD-026259
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0N8UU
DRUGNAME	ADX415
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0N8UY
DRUGNAME	LY-686017
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
	
TTDDRUID	D0N8XL
DRUGNAME	BMS-605339
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated
	
TTDDRUID	D0N8YJ
DRUGNAME	PMID28270010-Compound-Figure21-b
INDICATI	Brain metastases [ICD-11: 2D50] Patented
	
TTDDRUID	D0N9AD
DRUGNAME	RNS-60
INDICATI	Asthma [ICD-11: CA23] Phase 2
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1
	
TTDDRUID	D0N9AS
DRUGNAME	GW-549771
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D0N9BU
DRUGNAME	SSR-97225
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0N9DZ
DRUGNAME	Elmustine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0N9ET
DRUGNAME	MRSAid
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0N9FJ
DRUGNAME	PMID25666693-Compound-7
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0N9GC
DRUGNAME	Neorphine
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0N9IN
DRUGNAME	MTX-25251
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N9JB
DRUGNAME	SAR228810
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0N9KZ
DRUGNAME	TN-871
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D0N9PL
DRUGNAME	ACE-041
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 1
	
TTDDRUID	D0N9PQ
DRUGNAME	Aimspro
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0N9SJ
DRUGNAME	ALTU-237
INDICATI	Hyperoxaluria [ICD-11: 5C51.2] Discontinued in Phase 1
	
TTDDRUID	D0N9TK
DRUGNAME	AR-mTOR-26
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0N9TY
DRUGNAME	AZD-7295
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0N9UP
DRUGNAME	PR-21
INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative
	
TTDDRUID	D0N9VZ
DRUGNAME	ADL-5747
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0N9WB
DRUGNAME	APC-366
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0N9WY
DRUGNAME	NPT-CLN
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0NA4J
DRUGNAME	CAR-T cells targeting MAGE-A1
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
	
TTDDRUID	D0NA5L
DRUGNAME	AAV2-REP1
INDICATI	Choroidal dystrophy [ICD-11: 9B61] Phase 2
	
TTDDRUID	D0NA8B
DRUGNAME	Rubraca rucaparib
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
	
TTDDRUID	D0NA8U
DRUGNAME	Dexamethasone sodium phosphate
INDICATI	Ataxia-telangiectasia [ICD-11: 4A01.31] Approved
	
TTDDRUID	D0NA8W
DRUGNAME	LTA
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0NB2K
DRUGNAME	Pyrrole derivative 4
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0NB5M
DRUGNAME	PMID25666693-Compound-35
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0NB5P
DRUGNAME	Biphenyl mannoside derivative 8
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0NB9T
DRUGNAME	KD018
INDICATI	Liver cancer [ICD-11: 2C12] Phase 2
	
TTDDRUID	D0NC0G
DRUGNAME	RQ-00203066
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0NC1D
DRUGNAME	MX-6120
INDICATI	Heart disease [ICD-11: BA41-BA42] Terminated
	
TTDDRUID	D0NC1Q
DRUGNAME	AMG 172
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
	
TTDDRUID	D0NC8H
DRUGNAME	GMI-1051
INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative
	
TTDDRUID	D0NC9E
DRUGNAME	SGX301
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 3
	
TTDDRUID	D0NC9M
DRUGNAME	CM-CS1 T-cell
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0NC9Y
DRUGNAME	ISIS 2105
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Discontinued in Phase 2
	
TTDDRUID	D0ND2J
DRUGNAME	Flavoxate
INDICATI	Suprapubic pain [ICD-11: MG30-MG3Z] Approved
INDICATI	Nocturia [ICD-11: MF55] Approved
INDICATI	Urgency [ICD-11: N.A.] Approved
INDICATI	Dysuria [ICD-11: MF50.7] Approved
	
TTDDRUID	D0ND3F
DRUGNAME	LM-030
INDICATI	Congenital ichthyosiform erythroderma [ICD-11: EC20.02] Phase 2
	
TTDDRUID	D0ND8N
DRUGNAME	Textilinin
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative
	
TTDDRUID	D0ND9T
DRUGNAME	CRLX101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0NE3C
DRUGNAME	AZD3409
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0NE3W
DRUGNAME	GTx-024
INDICATI	Muscle atrophy [ICD-11: FB32.Y] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0NE5B
DRUGNAME	Rintatolimid
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Chronic fatigue syndrome [ICD-11: 8E49] Application submitted
	
TTDDRUID	D0NE8F
DRUGNAME	EDS-EP
INDICATI	Ataxia-telangiectasia [ICD-11: 4A01.31] Phase 3
	
TTDDRUID	D0NE9T
DRUGNAME	Fondaparinux sodium
INDICATI	Venous thrombosis [ICD-11: BA43] Approved
	
TTDDRUID	D0NE9W
DRUGNAME	CX-1020
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0NF0P
DRUGNAME	ELS-130
INDICATI	Raynaud disease [ICD-11: BD42.0] Investigative
	
TTDDRUID	D0NF0Q
DRUGNAME	ZD-0947
INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2
	
TTDDRUID	D0NF0W
DRUGNAME	Metixene
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0NF1D
DRUGNAME	BAY-1817080
INDICATI	Endometriosis [ICD-11: GA10] Phase 1
	
TTDDRUID	D0NF1U
DRUGNAME	FENOFIBRIC ACID
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0NF1Z
DRUGNAME	UBX0101
INDICATI	Knee osteoarthritis [ICD-11: FA01] Phase 2
	
TTDDRUID	D0NF5J
DRUGNAME	EZN-2968
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0NF6F
DRUGNAME	Trichostatin A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0NF7S
DRUGNAME	R-59494
INDICATI	Ischemia [ICD-11: 8B10-8B11] Terminated
	
TTDDRUID	D0NG1C
DRUGNAME	S. aureus type 336 vaccine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0NG3T
DRUGNAME	BCMA CAR-T Cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0NG7O
DRUGNAME	Zolmitriptan
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0NH0U
DRUGNAME	HYG-440
INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative
	
TTDDRUID	D0NH1E
DRUGNAME	Org-231295
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D0NH1V
DRUGNAME	EDP-08
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0NH2M
DRUGNAME	PMID25666693-Compound-142
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0NH3R
DRUGNAME	ASTX727
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 3
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
	
TTDDRUID	D0NH5E
DRUGNAME	Autologous dendritic cell therapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0NH6F
DRUGNAME	VUF-8929
INDICATI	Heart failure [ICD-11: BD10-BD13] Terminated
	
TTDDRUID	D0NI0C
DRUGNAME	Vidarabine
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Approved
	
TTDDRUID	D0NI0X
DRUGNAME	SCH-721015
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
	
TTDDRUID	D0NI2B
DRUGNAME	Macrocycle derivative 5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0NI9X
DRUGNAME	Autologous stem cell therapy
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 3
INDICATI	Ischemia [ICD-11: 8B10-8B11] Clinical trial
	
TTDDRUID	D0NJ0S
DRUGNAME	Pyrazole derivative 34
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0NJ1A
DRUGNAME	Aloxistatin
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 3
INDICATI	Coronavirus infection [ICD-11: 1D92] Preclinical
	
TTDDRUID	D0NJ2R
DRUGNAME	DFD-05
INDICATI	Common wart [ICD-11: 1E80] Phase 2
	
TTDDRUID	D0NJ3Q
DRUGNAME	WZ-3146
INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
	
TTDDRUID	D0NJ3T
DRUGNAME	CART-19 cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
	
TTDDRUID	D0NJ3V
DRUGNAME	Papaverine
INDICATI	Spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D0NJ5H
DRUGNAME	Alogliptin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D0NJ9W
DRUGNAME	Nfu-PA-D4-RNP
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative
	
TTDDRUID	D0NK2U
DRUGNAME	FK-973
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0NK6K
DRUGNAME	P-BCMA-101 CAR-T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0NK6Z
DRUGNAME	Beta LT
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1/2
	
TTDDRUID	D0NK7X
DRUGNAME	Nordimmun
INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0NK8D
DRUGNAME	SC-53228
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0NK8M
DRUGNAME	Human heterologous liver cells
INDICATI	Urea cycle disorder [ICD-11: 5C50.A] Phase 2
	
TTDDRUID	D0NL5M
DRUGNAME	Mycobacterial cell wall-DNA complex
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0NL9N
DRUGNAME	Anti-CD19/20-CAR vector-transduced T cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial
INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Clinical trial
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Clinical trial
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Clinical trial
INDICATI	Follicular lymphoma [ICD-11: 2A80] Clinical trial
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Clinical trial
INDICATI	Prolymphocytic leukaemia [ICD-11: 2A82.1] Clinical trial
	
TTDDRUID	D0NM3D
DRUGNAME	PMID25666693-Compound-19
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0NN0I
DRUGNAME	APC-8020
INDICATI	Amyloidosis [ICD-11: 5D00] Discontinued in Phase 2
	
TTDDRUID	D0NN5A
DRUGNAME	MK-6096
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 2
	
TTDDRUID	D0NN5B
DRUGNAME	FR-172357
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0NN5H
DRUGNAME	PF-4523655
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2
INDICATI	Diabetic macular degeneration [ICD-11: 9B78] Phase 2
	
TTDDRUID	D0NN7L
DRUGNAME	AC 165198
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0NN7P
DRUGNAME	CART-HER-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0NN7Q
DRUGNAME	HP-802-247
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3
	
TTDDRUID	D0NN7W
DRUGNAME	Cu64-CNND1-L
INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
	
TTDDRUID	D0NN8N
DRUGNAME	TNX-102
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 3
INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Phase 3
	
TTDDRUID	D0NN9I
DRUGNAME	IMU-200
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative
	
TTDDRUID	D0NO0K
DRUGNAME	RBT-101
INDICATI	Respiratory tract infection [ICD-11: CA45] Phase 3
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0NO1A
DRUGNAME	AT001/r84
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0NO1L
DRUGNAME	Pascolizumab
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0NO6E
DRUGNAME	Mteron-F1
INDICATI	Mucositis [ICD-11: CA00] Preclinical
	
TTDDRUID	D0NO7L
DRUGNAME	PRO-289
INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative
	
TTDDRUID	D0NO8S
DRUGNAME	MVA3000
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2
	
TTDDRUID	D0NP1J
DRUGNAME	Bucladesine sodium
INDICATI	Skin ulcer [ICD-11: ME60.Z] Approved
	
TTDDRUID	D0NP8B
DRUGNAME	ERIC-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0NP8M
DRUGNAME	209-342
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0NP8P
DRUGNAME	APG-1387
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D0NQ0V
DRUGNAME	BT-061
INDICATI	Asthma [ICD-11: CA23] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D0NQ0W
DRUGNAME	SB-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0NQ5R
DRUGNAME	AZD-4750
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1
	
TTDDRUID	D0NR2A
DRUGNAME	Resorcinol compound 6
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0NR3V
DRUGNAME	Zatebradine
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D0NR6S
DRUGNAME	Maraviroc
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D0NR6T
DRUGNAME	UB-311
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0NR7H
DRUGNAME	A-837093
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0NR9E
DRUGNAME	Omeprazole + lansoprazole
INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 1
	
TTDDRUID	D0NS0S
DRUGNAME	Vinconate
INDICATI	Amnesia [ICD-11: MB21.1] Discontinued in Preregistration
	
TTDDRUID	D0NS1X
DRUGNAME	SAR-650984
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D0NS2U
DRUGNAME	LLL-12
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0NS3O
DRUGNAME	TT10
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 3
	
TTDDRUID	D0NS6H
DRUGNAME	Donepezil
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D0NS6Z
DRUGNAME	COH29
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0NS7A
DRUGNAME	APN-301
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2
	
TTDDRUID	D0NS8T
DRUGNAME	13-DEOXYADRIAMYCIN HYDROCHLORIDE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0NS9C
DRUGNAME	BIIB-513
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D0NT1S
DRUGNAME	CB-10-01
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0NT4H
DRUGNAME	BEL-0218
INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Phase 1
	
TTDDRUID	D0NT6P
DRUGNAME	MK8242
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0NT8Q
DRUGNAME	DW-514
INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative
	
TTDDRUID	D0NU0U
DRUGNAME	AZD4547
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3
	
TTDDRUID	D0NU2H
DRUGNAME	Propyliodone
INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Approved
	
TTDDRUID	D0NU6Y
DRUGNAME	192C86
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0NU8J
DRUGNAME	PT2977
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
INDICATI	Von hippel-lindau disease [ICD-11: 5A75] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0NU9L
DRUGNAME	CAR-20/19-T Cells
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0NU9N
DRUGNAME	CAR-T cells targeting MUC1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0NV2M
DRUGNAME	PMID25666693-Compound-157
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0NV5O
DRUGNAME	Finerenone
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 3
	
TTDDRUID	D0NV6I
DRUGNAME	Anti-CD19 CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0NV9O
DRUGNAME	BAY 10-00394
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2
	
TTDDRUID	D0NW0T
DRUGNAME	Erdafitinib
INDICATI	Bladder cancer [ICD-11: 2C94] Approved
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0NW2H
DRUGNAME	BG-777
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0NW3X
DRUGNAME	Dofetilide
INDICATI	Sinus rhythm disorder [ICD-11: BC9Y] Approved
	
TTDDRUID	D0NW7Y
DRUGNAME	Ravulizumab
INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Approved
	
TTDDRUID	D0NW8C
DRUGNAME	M3541
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0NW8L
DRUGNAME	Anti-CD19 "armored" CAR-Tcell therapy
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	D0NX0S
DRUGNAME	PTX-100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0NX6F
DRUGNAME	BAY-85-3474
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0NX8G
DRUGNAME	Pre-pandemic Avian influenza vaccine
INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D0NY1R
DRUGNAME	AC-3174
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative
	
TTDDRUID	D0NY1Y
DRUGNAME	CART-34 cells
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0NY2E
DRUGNAME	E-64D
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0NY4H
DRUGNAME	ReN-005
INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative
	
TTDDRUID	D0NY5Y
DRUGNAME	IMA-026
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0NY7A
DRUGNAME	S-19528
INDICATI	Eating disorder [ICD-11: 6B82] Investigative
	
TTDDRUID	D0NZ2D
DRUGNAME	SERCA 2a gene therapy
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D0NZ3C
DRUGNAME	TTC-352
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0O0AF
DRUGNAME	Sodium sulfide sulfur
INDICATI	Ischemia [ICD-11: 8B10-8B11] Approved
	
TTDDRUID	D0O0AH
DRUGNAME	MIRFENTANIL HYDROCHLORIDE
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0O0BM
DRUGNAME	PF-3463275
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0O0BR
DRUGNAME	Poly-ICR
INDICATI	Keratosis [ICD-11: ED56] Investigative
	
TTDDRUID	D0O0DF
DRUGNAME	Lirequinil
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D0O0EX
DRUGNAME	SAR-110894
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0O0FF
DRUGNAME	GW 468816
INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Discontinued in Phase 2
	
TTDDRUID	D0O0GX
DRUGNAME	MedChew-1401
INDICATI	Muscle spasm [ICD-11: MB47.3] Phase 1
	
TTDDRUID	D0O0GZ
DRUGNAME	Bicyclic heteroaryl benzamide derivative 3
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0O0HK
DRUGNAME	CRL-1018
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Terminated
	
TTDDRUID	D0O0HU
DRUGNAME	LAS-41007
INDICATI	Keratosis [ICD-11: ED56] Phase 3
	
TTDDRUID	D0O0II
DRUGNAME	ASC-JMZ1
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D0O0JB
DRUGNAME	PSMA-targeted tubulysin B conjugates
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0O0JH
DRUGNAME	F-12509A
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0O0JP
DRUGNAME	EMA-401
INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Phase 2
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 2
	
TTDDRUID	D0O0LC
DRUGNAME	MER-101
INDICATI	Bone metastases [ICD-11: 2D50] Phase 2
	
TTDDRUID	D0O0LF
DRUGNAME	F-18 exendin-4 derivative PET tracers
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0O0LQ
DRUGNAME	BI 2536
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0O0LS
DRUGNAME	Entrectinib
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Approved
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
INDICATI	Mammary analogue secretory carcinoma [ICD-11: 2C60] Phase 1
	
TTDDRUID	D0O0NY
DRUGNAME	Sutilains
INDICATI	Skin burns [ICD-11: ME65.0] Approved
	
TTDDRUID	D0O0PY
DRUGNAME	Pagoclone
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2/3
	
TTDDRUID	D0O0QB
DRUGNAME	ATG-Fresenius S
INDICATI	Transplant rejection [ICD-11: NE84] Phase 3
	
TTDDRUID	D0O0QG
DRUGNAME	SC-51316
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0O0QM
DRUGNAME	Modified hepatocyte growth factor gene therapy
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D0O0RG
DRUGNAME	MUC-1 dendritic cancer vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0O0RK
DRUGNAME	A-81282
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0O0RY
DRUGNAME	JB-1
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0O0UG
DRUGNAME	PMID25666693-Compound-86
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0O0VE
DRUGNAME	Oncoquest-L
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0O0VW
DRUGNAME	HGP-30W
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D0O0YA
DRUGNAME	SPIO-Stasix nanoparticles
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0O0ZG
DRUGNAME	Micrurus fulvius antivenin
INDICATI	Poison intoxication [ICD-11: NE6Z] Approved
	
TTDDRUID	D0O1AN
DRUGNAME	Hydroxypropyl methylcellulose
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Approved
	
TTDDRUID	D0O1AV
DRUGNAME	Squalestatin 1
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0O1BL
DRUGNAME	BMN053
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D0O1CJ
DRUGNAME	AdVac tuberculosis vaccine
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2
	
TTDDRUID	D0O1DS
DRUGNAME	[123I] iodobenzoyl 12-Ex4
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0O1EH
DRUGNAME	KP415
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
	
TTDDRUID	D0O1EI
DRUGNAME	PMX-500
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0O1GS
DRUGNAME	Fulranumab
INDICATI	Cancer related pain [ICD-11: MG30] Phase 3
INDICATI	Back pain [ICD-11: ME84.Z] Phase 3
INDICATI	Arthralgia [ICD-11: ME82] Phase 3
	
TTDDRUID	D0O1HL
DRUGNAME	SC-49483
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2
	
TTDDRUID	D0O1IM
DRUGNAME	CC-115
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0O1KX
DRUGNAME	Avasimibe
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 3
	
TTDDRUID	D0O1LD
DRUGNAME	ZSTK474
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0O1LU
DRUGNAME	EP-51389
INDICATI	Eating disorder [ICD-11: 6B82] Phase 1
	
TTDDRUID	D0O1MP
DRUGNAME	CARZELESIN
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0O1OL
DRUGNAME	Polymyxins
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0O1OX
DRUGNAME	GA-FSH
INDICATI	Female infertility [ICD-11: GA31.Z] Terminated
	
TTDDRUID	D0O1PH
DRUGNAME	Ethanolamine oleate
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
	
TTDDRUID	D0O1PU
DRUGNAME	BAY-39-9624
INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated
	
TTDDRUID	D0O1RH
DRUGNAME	KYN-54
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0O1TC
DRUGNAME	Gamma-Homolinolenic acid
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D0O1TJ
DRUGNAME	SAR439859
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0O1UC
DRUGNAME	NTC-801
INDICATI	Atrial flutter [ICD-11: BC81.2Z] Discontinued in Phase 1
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Discontinued in Phase 1
	
TTDDRUID	D0O1UT
DRUGNAME	ICX-PRO
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
	
TTDDRUID	D0O1UX
DRUGNAME	Peanut allergy desensitization vaccine
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3
INDICATI	Hypersensitivity [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D0O1UZ
DRUGNAME	Cannabidiol
INDICATI	LennoxGastaut syndrome [ICD-11: 8A62.1] Approved
INDICATI	Dravet syndrome [ICD-11: 8A61.11] Approved
INDICATI	Infantile spasm [ICD-11: 8A62.0] Phase 3
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
	
TTDDRUID	D0O1VU
DRUGNAME	EB-001
INDICATI	Musculoskeletal pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D0O1WJ
DRUGNAME	SR-1001
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Preclinical
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0O1WR
DRUGNAME	GMZ-2
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	D0O1WX
DRUGNAME	Ciprofloxacin XR
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
INDICATI	Biliary cancer [ICD-11: 2E92.7] Phase 1
	
TTDDRUID	D0O1XO
DRUGNAME	SYM-007
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0O1XU
DRUGNAME	XR-3005
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Terminated
	
TTDDRUID	D0O1XV
DRUGNAME	GSK2374697
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D0O1YF
DRUGNAME	RhLT28-171
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0O1ZI
DRUGNAME	AZD8329
INDICATI	Obesity [ICD-11: 5B81] Phase 1
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0O2AC
DRUGNAME	FR-145237
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0O2AG
DRUGNAME	Pirsidomine
INDICATI	Angina pectoris [ICD-11: BA40] Phase 2
	
TTDDRUID	D0O2EB
DRUGNAME	F-11105
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D0O2EM
DRUGNAME	Nevirapine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0O2ET
DRUGNAME	AD-5467
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D0O2FF
DRUGNAME	Epstein-Barr vaccine
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2
	
TTDDRUID	D0O2HQ
DRUGNAME	Iopamidol
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0O2IE
DRUGNAME	Phenacetin
INDICATI	Analgesia [ICD-11: MB40.8] Withdrawn from market
	
TTDDRUID	D0O2JI
DRUGNAME	Ertumaxomab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0O2JT
DRUGNAME	MyVax
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D0O2MO
DRUGNAME	CRX-675
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1
	
TTDDRUID	D0O2MW
DRUGNAME	APN-501
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0O2NQ
DRUGNAME	Eraxis/Vfend
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 3
	
TTDDRUID	D0O2OU
DRUGNAME	HIV vaccines
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0O2PK
DRUGNAME	PV-802
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated
	
TTDDRUID	D0O2PV
DRUGNAME	Carumonam
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0O2QB
DRUGNAME	Zolimomab aritox
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0O2SR
DRUGNAME	Nicorandil
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D0O2TG
DRUGNAME	LCA-AAV7
INDICATI	Visual disturbance [ICD-11: 9D90] Investigative
	
TTDDRUID	D0O2UF
DRUGNAME	Griffithsin
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0O2VZ
DRUGNAME	Otelixizumab
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D0O2WB
DRUGNAME	Pyridostigmine
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Approved
	
TTDDRUID	D0O2WJ
DRUGNAME	Losartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0O2XI
DRUGNAME	Enterotoxigenic E Coli vaccine
INDICATI	Escherichia coli infection [ICD-11: 1A03] Terminated
	
TTDDRUID	D0O2XJ
DRUGNAME	NXN-188
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D0O2XK
DRUGNAME	Mesothelin-targeted T cells
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0O2XQ
DRUGNAME	AMD-070
INDICATI	Whim syndrome [ICD-11: 4A00.Y] Phase 3
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0O2XW
DRUGNAME	VT-111a
INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 2
	
TTDDRUID	D0O2YE
DRUGNAME	HTF 919
INDICATI	Constipation [ICD-11: DD91.1] Approved
	
TTDDRUID	D0O2ZI
DRUGNAME	90Y-labeled humanized anti-Tac mab
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0O3AB
DRUGNAME	Butethal
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0O3CV
DRUGNAME	Ridaforolimus
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 3
	
TTDDRUID	D0O3CX
DRUGNAME	BMS-906024
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	T-cell acute lymphocytic leukaemia [ICD-11: 2B33.4] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0O3DK
DRUGNAME	GTP-010
INDICATI	Dyspepsia [ICD-11: MD92] Phase 2
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
	
TTDDRUID	D0O3DW
DRUGNAME	Meningococcal meningitis polysaccharide serogroups A,C,Y and W-135 vaccine
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 2
	
TTDDRUID	D0O3EP
DRUGNAME	SRT2379
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0O3EX
DRUGNAME	LIQ861
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3
	
TTDDRUID	D0O3FG
DRUGNAME	Desvenlafaxine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
INDICATI	Menopause symptom [ICD-11: GA30.0] Phase 3
	
TTDDRUID	D0O3FS
DRUGNAME	OBR-5-340
INDICATI	Coxsackie virus infection [ICD-11: 1D91] Investigative
	
TTDDRUID	D0O3JR
DRUGNAME	P-coumaric acid derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0O3KA
DRUGNAME	RG7602
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1
	
TTDDRUID	D0O3LC
DRUGNAME	AD-519
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0O3OI
DRUGNAME	AVL-3288
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
INDICATI	Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1
INDICATI	Immune dysregulation [ICD-11: 4A01.2] Phase 1
	
TTDDRUID	D0O3OK
DRUGNAME	Motavizumab
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 3
	
TTDDRUID	D0O3OS
DRUGNAME	SR141716A
INDICATI	Obesity [ICD-11: 5B81] Approved
	
TTDDRUID	D0O3PP
DRUGNAME	ARGENT
INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated
	
TTDDRUID	D0O3QW
DRUGNAME	Trodusquemine
INDICATI	Obesity [ICD-11: 5B81] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0O3SA
DRUGNAME	ATL-801
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0O3TC
DRUGNAME	FK-962
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0O3TE
DRUGNAME	NRG-101
INDICATI	Schizophrenia [ICD-11: 6A20] Investigative
	
TTDDRUID	D0O3TG
DRUGNAME	PMID25666693-Compound-136
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0O3TW
DRUGNAME	PT4.0
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0O3VK
DRUGNAME	CEP-37249
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0O3VP
DRUGNAME	BMS-914392
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2
	
TTDDRUID	D0O3XS
DRUGNAME	GSK311739
INDICATI	Rhinovirus infection [ICD-11: CA07] Phase 1
	
TTDDRUID	D0O3XU
DRUGNAME	HO/03/03
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
	
TTDDRUID	D0O3YA
DRUGNAME	OPRX
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Investigative
	
TTDDRUID	D0O3YF
DRUGNAME	Ciclosporin
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
INDICATI	Brain injury [ICD-11: NA07.Z] Phase 4
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative
	
TTDDRUID	D0O3ZI
DRUGNAME	OpsoVac
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0O4CH
DRUGNAME	CLR1404-I-131
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D0O4EU
DRUGNAME	Acrivastine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0O4EV
DRUGNAME	ADI
INDICATI	Liver cancer [ICD-11: 2C12] Discontinued in Phase 3
	
TTDDRUID	D0O4FF
DRUGNAME	Debrase
INDICATI	Skin burns [ICD-11: ME65.0] Phase 3
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 2
	
TTDDRUID	D0O4GY
DRUGNAME	Aminolevulinic Acid Hydrochloride
INDICATI	Actinic keratosis [ICD-11: EK90.0] Approved
	
TTDDRUID	D0O4IN
DRUGNAME	MOR-202
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0O4JH
DRUGNAME	ACEA-1328
INDICATI	Cancer related pain [ICD-11: MG30] Terminated
	
TTDDRUID	D0O4KT
DRUGNAME	Bioadhesive berry gel therapy
INDICATI	Dysplasia [ICD-11: LB30-LD2F] Phase 1
	
TTDDRUID	D0O4LG
DRUGNAME	HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0O4LU
DRUGNAME	SK-896
INDICATI	Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2
	
TTDDRUID	D0O4MW
DRUGNAME	NV.BC.04
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0O4NJ
DRUGNAME	Z-100
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0O4NR
DRUGNAME	LTB4
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0O4QR
DRUGNAME	Cefodizime sodium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0O4QS
DRUGNAME	WX-554
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0O4RB
DRUGNAME	DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0O4RG
DRUGNAME	ADE-HYPT
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0O4RN
DRUGNAME	Sulfonylated piperazine derivative 5
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0O4RQ
DRUGNAME	Focetria A(H1N1)
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0O4SE
DRUGNAME	Tindamax
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0O4SH
DRUGNAME	SAR-156597
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Phase 2
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2
	
TTDDRUID	D0O4SZ
DRUGNAME	EDP-09
INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative
	
TTDDRUID	D0O4TC
DRUGNAME	PMID26651364-Compound-10b
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0O4UZ
DRUGNAME	Gp41 HIV-1 vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0O4VW
DRUGNAME	TAL-0500018
INDICATI	Peripheral arterial occlusive disorder [ICD-11: BD4Z] Phase 2
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 2
INDICATI	Stroke [ICD-11: 8B20] Phase 1/2
	
TTDDRUID	D0O4WB
DRUGNAME	OBP-601
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0O4XW
DRUGNAME	ONO-4819
INDICATI	Fracture [ICD-11: ND56] Discontinued in Phase 2
	
TTDDRUID	D0O4YE
DRUGNAME	Anti-CD19
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D0O5AG
DRUGNAME	Baloxavir marboxil
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0O5CL
DRUGNAME	ARO 087
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0O5CV
DRUGNAME	MEDI4212
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0O5ER
DRUGNAME	Catumaxomab
INDICATI	Malignant pleural effusion [ICD-11: 2D72] Approved
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D0O5FY
DRUGNAME	Meropenem
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0O5GK
DRUGNAME	R-phenserine
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 1/2
	
TTDDRUID	D0O5HB
DRUGNAME	ATX-MS3
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0O5KH
DRUGNAME	Altrakincept
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0O5KY
DRUGNAME	Recombinant human neuregulin-1 beta
INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 3
	
TTDDRUID	D0O5LA
DRUGNAME	Progabide
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0O5LL
DRUGNAME	GT-2342
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated
	
TTDDRUID	D0O5LU
DRUGNAME	Latamoxef
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0O5NK
DRUGNAME	Oseltamivir
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0O5OF
DRUGNAME	SDZ-281-240
INDICATI	Pruritus [ICD-11: EC90] Phase 2
	
TTDDRUID	D0O5QL
DRUGNAME	HT-1067
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1
	
TTDDRUID	D0O5QT
DRUGNAME	PD-0805
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0O5SZ
DRUGNAME	Homatropine Methylbromide
INDICATI	Uveitis [ICD-11: 9A96.Z] Approved
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D0O5TQ
DRUGNAME	Pentagastrin
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D0O5TR
DRUGNAME	RBP-7000
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Schizophrenia [ICD-11: 6A20] Application submitted
	
TTDDRUID	D0O5UF
DRUGNAME	CNX-011
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0O5VR
DRUGNAME	TP-2758
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0O5WD
DRUGNAME	Lactoferrin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0O5WP
DRUGNAME	Docetaxel
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0O5XF
DRUGNAME	CeaVac
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D0O5XJ
DRUGNAME	XL652/XL014
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D0O5XQ
DRUGNAME	AL-60371
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D0O5YZ
DRUGNAME	Mepindolol
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D0O5ZB
DRUGNAME	Ilodecakin
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 2
	
TTDDRUID	D0O5ZT
DRUGNAME	Organon-2
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0O6AQ
DRUGNAME	Gavestinel
INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 2
	
TTDDRUID	D0O6BJ
DRUGNAME	MP40X
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0O6BW
DRUGNAME	Encepur
INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Flavivirus infection [ICD-11: 1C80] Phase 3
	
TTDDRUID	D0O6DC
DRUGNAME	LY-2463665
INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical
	
TTDDRUID	D0O6DE
DRUGNAME	RG-101
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0O6EQ
DRUGNAME	mRNA-1388
INDICATI	Chikungunya virus infection [ICD-11: 1D40] Phase 1
	
TTDDRUID	D0O6GC
DRUGNAME	Methysergide
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0O6GN
DRUGNAME	Mdl 101,146
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0O6HP
DRUGNAME	KAI-9803
INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 1/2
	
TTDDRUID	D0O6IU
DRUGNAME	Phenylephrine
INDICATI	Fecal incontinence [ICD-11: ME07] Approved
INDICATI	Ophthalmic graves disease [ICD-11: 5A02.0] Approved
	
TTDDRUID	D0O6IZ
DRUGNAME	Naphazoline
INDICATI	Itching [ICD-11: 1F28-1G07] Approved
INDICATI	Hyperaemia [ICD-11: 9A61-9B7Y] Approved
	
TTDDRUID	D0O6JE
DRUGNAME	Multiform PI3K inhibitors
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0O6KE
DRUGNAME	Repirinast
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0O6LR
DRUGNAME	Autologous CD19-targeting CAR T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D0O6LY
DRUGNAME	MAT-304
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0O6NA
DRUGNAME	JNJ-10229570
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0O6OK
DRUGNAME	LY3074828
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
	
TTDDRUID	D0O6OM
DRUGNAME	CGEN-15001
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0O6OZ
DRUGNAME	Sodium iodide I 131
INDICATI	Hyperthyroidism [ICD-11: 5A02] Approved
	
TTDDRUID	D0O6QW
DRUGNAME	Manifaxine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D0O6RK
DRUGNAME	MD-0727
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2
	
TTDDRUID	D0O6RU
DRUGNAME	Cepacidine A
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D0O6SA
DRUGNAME	KA2507
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0O6SQ
DRUGNAME	Ro-25-4835
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0O6SX
DRUGNAME	Hydroxyzine
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0O6TD
DRUGNAME	BBT-021
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0O6UF
DRUGNAME	403U76
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated
	
TTDDRUID	D0O6UY
DRUGNAME	Pemigatinib
INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Approved
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Myeloproliferative syndrome [ICD-11: 2A22] Phase 2
	
TTDDRUID	D0O6UZ
DRUGNAME	Sertaconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D0O6VU
DRUGNAME	PMID25666693-Compound-92
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0O6VZ
DRUGNAME	GDC-0980/RG7422
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0O6WJ
DRUGNAME	Ecalcidene
INDICATI	Acne vulgaris [ICD-11: ED80] Terminated
	
TTDDRUID	D0O6WS
DRUGNAME	APC-004
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0O6WZ
DRUGNAME	OcuNex
INDICATI	Wound healing [ICD-11: EL8Y] Discontinued in Phase 2
	
TTDDRUID	D0O6YE
DRUGNAME	RG7450
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0O6ZO
DRUGNAME	TAK-715
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0O7AK
DRUGNAME	SF-107
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0O7BW
DRUGNAME	SC-102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0O7CO
DRUGNAME	MyoCell
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2/3
INDICATI	Heart injury [ICD-11: NB31] Phase 2/3
	
TTDDRUID	D0O7DB
DRUGNAME	A-204176
INDICATI	Stress urinary incontinence [ICD-11: MF50.20] Terminated
	
TTDDRUID	D0O7DG
DRUGNAME	Histrelin
INDICATI	Polycystic ovarian syndrome [ICD-11: 5A80.1] Approved
INDICATI	Endometriosis [ICD-11: GA10] Approved
INDICATI	Central precocious puberty [ICD-11: 5A60.3] Approved
	
TTDDRUID	D0O7DN
DRUGNAME	CEP-427
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0O7DP
DRUGNAME	CVT-12012
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0O7DU
DRUGNAME	CT-1746
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Terminated
	
TTDDRUID	D0O7DZ
DRUGNAME	R-61837
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2
	
TTDDRUID	D0O7EC
DRUGNAME	ADCON-I
INDICATI	Wound healing [ICD-11: EL8Y] Terminated
	
TTDDRUID	D0O7ES
DRUGNAME	Heberpenta L
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0O7GB
DRUGNAME	SPK-RPE65
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 3
	
TTDDRUID	D0O7GU
DRUGNAME	Palifermin
INDICATI	Oral mucositis [ICD-11: DA01.11] Approved
	
TTDDRUID	D0O7HP
DRUGNAME	example 98 (WO2011020806)
INDICATI	Focal segmental glomerulosclerosis [ICD-11: MF8Y] Clinical trial
	
TTDDRUID	D0O7IQ
DRUGNAME	PMID25666693-Compound-6
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0O7IZ
DRUGNAME	Anti-MIF antibodies
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 4
	
TTDDRUID	D0O7JK
DRUGNAME	ISG15-LNP01
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0O7JW
DRUGNAME	Alcaftadine
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved
	
TTDDRUID	D0O7KV
DRUGNAME	P1201-07
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1
	
TTDDRUID	D0O7NF
DRUGNAME	MCP-205
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative
	
TTDDRUID	D0O7NV
DRUGNAME	DOV-51892
INDICATI	Panic disorder [ICD-11: 6B01] Investigative
	
TTDDRUID	D0O7PS
DRUGNAME	AERAS-402
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2
	
TTDDRUID	D0O7QA
DRUGNAME	PF-05089771
INDICATI	Chronic pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D0O7QQ
DRUGNAME	BIIB 022
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
	
TTDDRUID	D0O7RY
DRUGNAME	IDR-1018
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0O7SC
DRUGNAME	D-11B
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0O7SP
DRUGNAME	Bamifylline
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0O7UU
DRUGNAME	GEM-SP
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0O7VZ
DRUGNAME	AntiCD19 CART
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0O7XA
DRUGNAME	Anti-BCMA CAR-T cell therapy
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0O7XG
DRUGNAME	SEM-606
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0O7XO
DRUGNAME	AOD-9604
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
	
TTDDRUID	D0O7ZR
DRUGNAME	NZ-4
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D0O8AR
DRUGNAME	AZ-23
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0O8AY
DRUGNAME	Combined PR1/WT1 vaccine
INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 2
	
TTDDRUID	D0O8BP
DRUGNAME	ISIS 13920
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0O8BQ
DRUGNAME	NT-KO-012
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0O8BS
DRUGNAME	AZD1656
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0O8DI
DRUGNAME	Nitrous oxide
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0O8EH
DRUGNAME	NKTT-320
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0O8EK
DRUGNAME	A-54145
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical
	
TTDDRUID	D0O8EX
DRUGNAME	PMID26651364-Compound-8c
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0O8FI
DRUGNAME	1,3-dihydroxy phenyl derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0O8FN
DRUGNAME	INDUS-815B
INDICATI	Kidney disease [ICD-11: GC2Z] Investigative
	
TTDDRUID	D0O8GK
DRUGNAME	Osimertinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D0O8GZ
DRUGNAME	KI-0904
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0O8HK
DRUGNAME	BCL-003
INDICATI	Glioma [ICD-11: 2A00.0] Investigative
	
TTDDRUID	D0O8HL
DRUGNAME	EML-16257
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0O8IS
DRUGNAME	Cloperastine
INDICATI	Cough [ICD-11: MD12] Approved
	
TTDDRUID	D0O8JB
DRUGNAME	Secretin
INDICATI	Pancreatic exocrine dysfunction [ICD-11: DC3Z] Approved
INDICATI	Gastrinoma [ICD-11: 2C10.1] Approved
	
TTDDRUID	D0O8JM
DRUGNAME	NX-210
INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative
	
TTDDRUID	D0O8JW
DRUGNAME	Ronomilast
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0O8KI
DRUGNAME	AL-43546
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 2
	
TTDDRUID	D0O8KX
DRUGNAME	Reslizumab
INDICATI	Severe asthma [ICD-11: CA23] Approved
INDICATI	Eosinophilic asthma [ICD-11: CB02.0] Phase 3
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0O8LW
DRUGNAME	CYANIDIN CHLORIDE MONOHYDRATE
INDICATI	Ulcer [ICD-11: CA02-CB40] Discontinued in Phase 2
	
TTDDRUID	D0O8OB
DRUGNAME	Isoxsuprine
INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Withdrawn from market
	
TTDDRUID	D0O8QU
DRUGNAME	B7-2/GM-CSF cancer gene therapy vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0O8RL
DRUGNAME	EQ-1280
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0O8SB
DRUGNAME	OPK-0018
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0O8SJ
DRUGNAME	Umbralisib
INDICATI	Follicular lymphoma [ICD-11: 2A80] Approved
INDICATI	Marginal zone lymphoma [ICD-11: 2A85.0] Approved
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2/3
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D0O8SS
DRUGNAME	SX8
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative
	
TTDDRUID	D0O8SX
DRUGNAME	Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1
INDICATI	Malignant thymoma [ICD-11: 2C27.2] Patented
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0O8SY
DRUGNAME	GI-197111
INDICATI	Alopecia [ICD-11: ED70] Terminated
	
TTDDRUID	D0O8TE
DRUGNAME	LASSBio-1524
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0O8TJ
DRUGNAME	AR101
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3
	
TTDDRUID	D0O8UB
DRUGNAME	RG7129
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0O8UF
DRUGNAME	SRSS-023
INDICATI	Migraine [ICD-11: 8A80] Terminated
	
TTDDRUID	D0O8UM
DRUGNAME	XEL-002BG
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0O8WM
DRUGNAME	SP-003
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0O8YO
DRUGNAME	Technetium Tc-99m Exametazime Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0O9AF
DRUGNAME	TKM-Ebola
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D0O9AZ
DRUGNAME	CCR5Qb
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0O9DK
DRUGNAME	PF-05280586
INDICATI	Cluster headache [ICD-11: 8A81.0] Phase 3
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
	
TTDDRUID	D0O9EM
DRUGNAME	Eptapirone
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D0O9EQ
DRUGNAME	VX-210
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2/3
	
TTDDRUID	D0O9EX
DRUGNAME	NANT merkel cell cancer vaccine
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
	
TTDDRUID	D0O9FH
DRUGNAME	PUMVC3-hIGFBP-2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D0O9GI
DRUGNAME	PMID25666693-Compound-63
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0O9HF
DRUGNAME	TrasGEX
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0O9HG
DRUGNAME	BAY-1006578
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0O9IB
DRUGNAME	CI-933
INDICATI	Cognitive impairment [ICD-11: 6D71] Terminated
	
TTDDRUID	D0O9JI
DRUGNAME	Transferrin CRM-107
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D0O9KY
DRUGNAME	KI-0401
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0O9LN
DRUGNAME	ME-143
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0O9MX
DRUGNAME	Influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0O9OC
DRUGNAME	AZD5658
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D0O9PQ
DRUGNAME	AP26113
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0O9RJ
DRUGNAME	CDX-011
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Approved
	
TTDDRUID	D0O9RV
DRUGNAME	MOD-5023
INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D0O9UC
DRUGNAME	Tak-220
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0O9UG
DRUGNAME	ZD-0490
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1
	
TTDDRUID	D0O9UN
DRUGNAME	SAR231893
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D0O9UZ
DRUGNAME	Alfimeprase
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 3
	
TTDDRUID	D0O9VW
DRUGNAME	Lanperisone
INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Phase 3
	
TTDDRUID	D0O9XN
DRUGNAME	APD-597
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0O9XO
DRUGNAME	KH-902
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 3
	
TTDDRUID	D0O9YG
DRUGNAME	Cycloguanil
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0O9ZT
DRUGNAME	Ebola vaccine
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D0OA0H
DRUGNAME	INO-3112
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
	
TTDDRUID	D0OA1P
DRUGNAME	PMID25666693-Compound-53
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0OA5G
DRUGNAME	SNS-314
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0OA7W
DRUGNAME	HG-1141
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0OB0F
DRUGNAME	Bosutinib
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0OB1J
DRUGNAME	Diltiazem
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0OB2M
DRUGNAME	Mivacurium
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0OB4R
DRUGNAME	EVP-0962
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0OB7J
DRUGNAME	NPC-15669
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D0OB9V
DRUGNAME	Ginkgo biloba extract
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0OC0W
DRUGNAME	AVID100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0OC3J
DRUGNAME	Flupenthixol
INDICATI	Schizophrenia [ICD-11: 6A20] Withdrawn from market
	
TTDDRUID	D0OC4O
DRUGNAME	RG7388
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0OC5C
DRUGNAME	ICAR19 CAR-T cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D0OC5T
DRUGNAME	ANX005
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1
	
TTDDRUID	D0OC6A
DRUGNAME	PMID25666693-Compound-75
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0OC6H
DRUGNAME	S-024
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0OD2I
DRUGNAME	Pralsetinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0OD3T
DRUGNAME	Meningococcal ACYW-135 vaccine
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 3
	
TTDDRUID	D0OD8T
DRUGNAME	CD19 CAR T cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0OE2G
DRUGNAME	Fsn-1006
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0OE2Z
DRUGNAME	ONO-8809
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D0OE4F
DRUGNAME	Imatinib and nilotinib derivative 1
INDICATI	Cas mediated disorder [ICD-11: N.A.] Patented
	
TTDDRUID	D0OE5S
DRUGNAME	UE-2343
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0OF1R
DRUGNAME	Oportuzumab monatox
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
	
TTDDRUID	D0OF2K
DRUGNAME	Rh-thrombomodulin
INDICATI	Stroke [ICD-11: 8B20] Approved
	
TTDDRUID	D0OF4A
DRUGNAME	SART3 peptide cancer vaccine
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D0OF9D
DRUGNAME	Hepatitis delta antigen
INDICATI	Hepatitis D virus infection [ICD-11: 1E51.2] Terminated
	
TTDDRUID	D0OG0X
DRUGNAME	GLS-5300
INDICATI	Coronavirus infection [ICD-11: 1D92] Phase 1
INDICATI	Respiratory syndrome coronavirus infection [ICD-11: 1D92] Phase 1
	
TTDDRUID	D0OG1V
DRUGNAME	MDX-066
INDICATI	Diarrhea [ICD-11: ME05.1] Phase 3
	
TTDDRUID	D0OG3K
DRUGNAME	Lodoxamide
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0OG4A
DRUGNAME	Kirromycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Clinical trial
	
TTDDRUID	D0OG5K
DRUGNAME	Bismuth
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
	
TTDDRUID	D0OG6N
DRUGNAME	LM-1507.NA
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0OG8A
DRUGNAME	Sultamicillin tosilate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0OH1O
DRUGNAME	VULM-1457
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0OH2H
DRUGNAME	BR-4628
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D0OH2W
DRUGNAME	PF-02545920
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
	
TTDDRUID	D0OH4N
DRUGNAME	Oraqix
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0OH5E
DRUGNAME	Cartistem
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0OH5V
DRUGNAME	PIROXANTRONE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0OH8O
DRUGNAME	E coli EPVaccine
INDICATI	Escherichia coli infection [ICD-11: 1A03] Investigative
	
TTDDRUID	D0OH8W
DRUGNAME	Visilizumab
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3
	
TTDDRUID	D0OH9B
DRUGNAME	WS-070117
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Investigative
	
TTDDRUID	D0OI5Y
DRUGNAME	Human serum albumin
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0OI7B
DRUGNAME	AZD-5745
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated
	
TTDDRUID	D0OI8M
DRUGNAME	UISH-001
INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 1/2
	
TTDDRUID	D0OJ4L
DRUGNAME	Hydroxychloroquine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0OJ5M
DRUGNAME	OLPADRONIC ACID SODIUM SALT
INDICATI	Bone resorption [ICD-11: FC0Z] Investigative
	
TTDDRUID	D0OK1N
DRUGNAME	Domagrozumab
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D0OK1S
DRUGNAME	PMID30107136-Compound-Example2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0OK2N
DRUGNAME	AMG 208
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0OK3O
DRUGNAME	Cenderitide
INDICATI	Heart disease [ICD-11: BA41-BA42] Phase 2
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D0OK4O
DRUGNAME	Dalazatide
INDICATI	Inclusion body myositis [ICD-11: 4A41.2] Phase 1b/2a
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1b/2a
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
	
TTDDRUID	D0OK5I
DRUGNAME	Tridihexethyl
INDICATI	Acquired nystagmus [ICD-11: 9C84] Approved
	
TTDDRUID	D0OK5Q
DRUGNAME	Diphemanil Methylsulfate
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D0OK5R
DRUGNAME	OP-R003
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0OK6F
DRUGNAME	TRV734
INDICATI	Chronic pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D0OK8M
DRUGNAME	TEI-6522
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0OK9X
DRUGNAME	AZD6765
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D0OL4S
DRUGNAME	GLY-515n
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0OL6O
DRUGNAME	Methyl aminolevulinate
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D0OL7F
DRUGNAME	Uridine triacetate
INDICATI	Pancreatic cancer [ICD-11: 2C10] Approved
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0OL9V
DRUGNAME	CGS-24565
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0OM0M
DRUGNAME	AVE1625
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2
	
TTDDRUID	D0OM0X
DRUGNAME	IB-201
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative
	
TTDDRUID	D0OM3A
DRUGNAME	Follitropin beta
INDICATI	Female infertility [ICD-11: GA31.Z] Approved
	
TTDDRUID	D0OM5L
DRUGNAME	VC-01
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	D0OM5M
DRUGNAME	Ro-48-1220
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0OMC3
DRUGNAME	2E9IgA1
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Preclinical
	
TTDDRUID	D0ON4J
DRUGNAME	Muscle wasting protein therapeutics
INDICATI	Muscle wasting disease [ICD-11: 8E4A.3] Investigative
	
TTDDRUID	D0ON4M
DRUGNAME	PMID25666693-Compound-8
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0OO1S
DRUGNAME	Anti-CD38 CAR-T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0OO3J
DRUGNAME	FluGEM
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0OO6A
DRUGNAME	Isbogrel
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Preregistration
	
TTDDRUID	D0OO8M
DRUGNAME	MAA868
INDICATI	Stroke [ICD-11: 8B20] Phase 2
	
TTDDRUID	D0OP1L
DRUGNAME	Anti-CEA CAR-T therapy
INDICATI	Liver metastasis [ICD-11: 2D80] Phase 1
INDICATI	Metastatic liver cancer [ICD-11: 2C12] Phase 1
	
TTDDRUID	D0OP2E
DRUGNAME	D-81050
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0OP7B
DRUGNAME	LY-210073
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0OP7I
DRUGNAME	CARCIK-CD19
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2
	
TTDDRUID	D0OP8W
DRUGNAME	Zalospirone
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0OQ1A
DRUGNAME	JNJ-55308942
INDICATI	Anhedonia [ICD-11: MB24.2] Phase 1
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 1
INDICATI	Neuroinflammation [ICD-11: 1D0Y] Phase 1
	
TTDDRUID	D0OQ1I
DRUGNAME	Narciclasine
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0OQ2R
DRUGNAME	Mannoside derivative 1
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0OQ3L
DRUGNAME	SL65.0472
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2
	
TTDDRUID	D0OQ4H
DRUGNAME	A-69024
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D0OQ5H
DRUGNAME	6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D0OQ5R
DRUGNAME	IGN523
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0OQ5W
DRUGNAME	Meninge ACYW
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 2
	
TTDDRUID	D0OQ8Q
DRUGNAME	Vatiquinone
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2
	
TTDDRUID	D0OQ9V
DRUGNAME	BMN-110
INDICATI	Morquio syndrome [ICD-11: 5C56.32] Phase 3
	
TTDDRUID	D0OR2L
DRUGNAME	Cholic Acid
INDICATI	Synthesis disorder [ICD-11: 5C52-5C59] Approved
INDICATI	Peroxisomal disorder [ICD-11: 5C57] Approved
	
TTDDRUID	D0OR2S
DRUGNAME	Broxaterol
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3
	
TTDDRUID	D0OR3G
DRUGNAME	Bexagliflozin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0OR5P
DRUGNAME	TAS-106
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
	
TTDDRUID	D0OR6A
DRUGNAME	Melinamide
INDICATI	Hypocholesterolemia [ICD-11: 5C81] Approved
	
TTDDRUID	D0OR6L
DRUGNAME	CAR-T cells targeting CD20
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D0OR7P
DRUGNAME	DARPins
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0OR8W
DRUGNAME	ETIPREDNOL DICLOACETATE
INDICATI	Rhinitis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0OS3C
DRUGNAME	PF-05230901
INDICATI	Cachexia [ICD-11: MG20] Phase 1
	
TTDDRUID	D0OS6O
DRUGNAME	Sertindole
INDICATI	Schizophrenia [ICD-11: 6A20] Withdrawn from market
	
TTDDRUID	D0OS6P
DRUGNAME	XBIO-101
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
INDICATI	Malignant uterine tumour [ICD-11: 2C76.Z] Phase 2
	
TTDDRUID	D0OS7K
DRUGNAME	EGEN-001
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 2
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 2
	
TTDDRUID	D0OS8C
DRUGNAME	NCX-1015
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0OT0O
DRUGNAME	Foscavir
INDICATI	Cytomegalovirus retinitis [ICD-11: 9B72.00] Approved
	
TTDDRUID	D0OT1Q
DRUGNAME	Axalimogene filolisbac
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 3
INDICATI	Anal cancer [ICD-11: 2C00] Phase 2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
	
TTDDRUID	D0OT1S
DRUGNAME	CP-4200
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0OT3G
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 10
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0OT3L
DRUGNAME	Folate binding protein-E39
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 1/2
	
TTDDRUID	D0OT3Y
DRUGNAME	Sebriplatin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0OT8O
DRUGNAME	STP-601
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D0OT9S
DRUGNAME	Vinflunine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0OU0S
DRUGNAME	FP-0110
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 2
	
TTDDRUID	D0OU1V
DRUGNAME	PD-155392
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0OU3Q
DRUGNAME	TAK-058
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
INDICATI	XY disorder of sex development due to androgen resistance [ICD-11: LD2A.4] Phase 1
	
TTDDRUID	D0OU6W
DRUGNAME	GSK2696275
INDICATI	Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 2
	
TTDDRUID	D0OU7P
DRUGNAME	SKF 38393
INDICATI	Type-2 diabetes [ICD-11: 5A11] Terminated
	
TTDDRUID	D0OV2F
DRUGNAME	212Pb-labelled DOTAMTATE
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1
	
TTDDRUID	D0OV4A
DRUGNAME	Cystic fibrosis therapeutics
INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative
	
TTDDRUID	D0OW1R
DRUGNAME	YM-43611
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D0OW1V
DRUGNAME	Biaryl mannoside derivative 25
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0OW2S
DRUGNAME	AMG 145
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3
	
TTDDRUID	D0OW4A
DRUGNAME	PD-145065
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0OW5Y
DRUGNAME	NW-1772
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0OW6O
DRUGNAME	PMID26651364-Compound-11c
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0OW6V
DRUGNAME	AZM-1
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0OW6Z
DRUGNAME	Sipoglitazar
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D0OW9L
DRUGNAME	MK-3134
INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 1
	
TTDDRUID	D0OX1Y
DRUGNAME	Ad5-ENVA-48
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0OX5H
DRUGNAME	ABT-122
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2
	
TTDDRUID	D0OX6I
DRUGNAME	KB-9520
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0OX9F
DRUGNAME	BIIB074
INDICATI	Lumbosacral radiculopathy [ICD-11: 8B93.Y] Phase 2
INDICATI	Trigeminal neuralgia [ICD-11: 8B82.0] Phase 2
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 2
	
TTDDRUID	D0OX9Q
DRUGNAME	NOX-200
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0OX9W
DRUGNAME	Inolimomab
INDICATI	Heart transplant rejection [ICD-11: NE84] Phase 3
	
TTDDRUID	D0OY0Q
DRUGNAME	Tihotungstate derivative 1
INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Patented
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented
INDICATI	Copper metabolism disorder [ICD-11: 5C64.0] Patented
INDICATI	Aberrant vascularization [ICD-11: BE2Z] Patented
	
TTDDRUID	D0OY1V
DRUGNAME	NS-1608
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0OY4K
DRUGNAME	Vestronidase alfa
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Approved
	
TTDDRUID	D0OY5G
DRUGNAME	Brostallicin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0OY5X
DRUGNAME	DermaGraft
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0OY7A
DRUGNAME	RBx-343E48F0
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0OY9L
DRUGNAME	ALXN6000
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0OY9S
DRUGNAME	Rose Bengal Sodium I-131
INDICATI	Ophthalmic disease [ICD-11: 5A02.0] Approved
	
TTDDRUID	D0OZ0Z
DRUGNAME	Elenagen
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0OZ3S
DRUGNAME	RJM-0035-K002
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0OZ4F
DRUGNAME	Ordopidine
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1
	
TTDDRUID	D0OZ4J
DRUGNAME	RG-7446
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Approved
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3
	
TTDDRUID	D0OZ5H
DRUGNAME	CD19-CAR T cell
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0OZ6W
DRUGNAME	STAGR320
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 3
	
TTDDRUID	D0OZ7P
DRUGNAME	BILN-2061
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2
	
TTDDRUID	D0P0BY
DRUGNAME	Codrituzumab
INDICATI	Hepatic metastasis [ICD-11: 2D80] Phase 2
	
TTDDRUID	D0P0DA
DRUGNAME	BM-162115
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0P0DT
DRUGNAME	TAK-044
INDICATI	Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2
	
TTDDRUID	D0P0EI
DRUGNAME	PRLX93936
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0P0FQ
DRUGNAME	Relenza
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 3
	
TTDDRUID	D0P0HB
DRUGNAME	Ethionamide
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Approved
	
TTDDRUID	D0P0HI
DRUGNAME	AZD8330
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0P0HT
DRUGNAME	Fluorometholone
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0P0HU
DRUGNAME	GSK1070916A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P0KN
DRUGNAME	TG02
INDICATI	Anaplastic astrocytoma [ICD-11: 2A00.0] Phase 1/2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P0LD
DRUGNAME	Efgartigimod
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 2
	
TTDDRUID	D0P0LT
DRUGNAME	GSK3052230
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P0MR
DRUGNAME	PMID25666693-Compound-57
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0P0NH
DRUGNAME	HZ-08
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0P0NS
DRUGNAME	CD22-Targeted CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0P0OE
DRUGNAME	Cefuzonam sodium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0P0OU
DRUGNAME	OPC-34712
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
	
TTDDRUID	D0P0PC
DRUGNAME	S-265744 LAP
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0P0PT
DRUGNAME	Aromatic hydrazine carboxyimidoamide derivative 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0P0QG
DRUGNAME	HuMV833
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0P0QK
DRUGNAME	Cysteine Hydrochloride
INDICATI	Adverse reactions to acetaminophen or acetaminophen overdose [ICD-11: PB24] Approved
	
TTDDRUID	D0P0RP
DRUGNAME	P113D
INDICATI	Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2
	
TTDDRUID	D0P0RX
DRUGNAME	Nemonoxacin
INDICATI	Community-acquired pneumonia [ICD-11: CA40.Z] Approved
INDICATI	infection associated with diabetic foot ulcers [ICD-11: BD54] Phase 3
	
TTDDRUID	D0P0SD
DRUGNAME	Eryaspase
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0P0SM
DRUGNAME	Almogran
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0P0SZ
DRUGNAME	Piperaquine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0P0TA
DRUGNAME	GC-1008
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 1
INDICATI	Pleural disease [ICD-11: CB27] Investigative
	
TTDDRUID	D0P0TR
DRUGNAME	Meluadrine
INDICATI	Premature ejaculation [ICD-11: HA03.0Z] Discontinued in Preregistration
	
TTDDRUID	D0P0VD
DRUGNAME	Co-trimoxazole
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
	
TTDDRUID	D0P0WF
DRUGNAME	PMID25684022-Compound-WO2011137219 35(1-11)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0P0WV
DRUGNAME	Interferon Alfa-2b
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D0P0XX
DRUGNAME	Avermectins
INDICATI	Pest attack [ICD-11: N.A.] Investigative
	
TTDDRUID	D0P0YU
DRUGNAME	human allogeneic NK cell
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P0ZY
DRUGNAME	Pomaglumetad
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0P1AS
DRUGNAME	Rexin-G
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0P1BK
DRUGNAME	NC1153
INDICATI	Renal transplantation [ICD-11: NE84] Investigative
	
TTDDRUID	D0P1BM
DRUGNAME	CAR-GPC3 T cells
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Clinical trial
	
TTDDRUID	D0P1BR
DRUGNAME	VII-87-B
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0P1BZ
DRUGNAME	Daclizumab
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
	
TTDDRUID	D0P1CE
DRUGNAME	CYT 99007
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2
	
TTDDRUID	D0P1CV
DRUGNAME	PHA-793887
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P1DI
DRUGNAME	MCLA-128
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0P1DP
DRUGNAME	NK-2210
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0P1EB
DRUGNAME	NIS215
INDICATI	Type-2 diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0P1FO
DRUGNAME	Marinol
INDICATI	Anorexia nervosa cachexia [ICD-11: 6B80] Approved
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Phase 2/3
	
TTDDRUID	D0P1FZ
DRUGNAME	Osteoblast cell therapy
INDICATI	Osteonecrosis [ICD-11: FB81] Phase 2
	
TTDDRUID	D0P1HZ
DRUGNAME	CHAP1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0P1ID
DRUGNAME	MTRX-1011A
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0P1IJ
DRUGNAME	CytoCor
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D0P1IX
DRUGNAME	OT-551
INDICATI	Ocular inflammation [ICD-11: 9C61.24] Phase 2
	
TTDDRUID	D0P1IZ
DRUGNAME	Gadobutrol
INDICATI	Blood brain barrier [ICD-11: 5C61.5] Approved
	
TTDDRUID	D0P1JA
DRUGNAME	LETRAZURIL
INDICATI	Isosporiasis [ICD-11: 1A33] Phase 1
	
TTDDRUID	D0P1JI
DRUGNAME	Wortmannin
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Terminated
	
TTDDRUID	D0P1JL
DRUGNAME	Avaxim
INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Approved
	
TTDDRUID	D0P1JV
DRUGNAME	Bio-Flow
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0P1KJ
DRUGNAME	SOM1201
INDICATI	Adrenoleukodystrophy [ICD-11: 8A44.1] Phase 1
	
TTDDRUID	D0P1LR
DRUGNAME	Pemedolac
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0P1ME
DRUGNAME	MK-3222
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Phase 3
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
	
TTDDRUID	D0P1MI
DRUGNAME	MDDR 347017
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0P1QN
DRUGNAME	ND-701
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0P1QW
DRUGNAME	Becampanel
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2
	
TTDDRUID	D0P1RC
DRUGNAME	BMP-655
INDICATI	Tendon injuries [ICD-11: NC96.0] Phase 1
	
TTDDRUID	D0P1RL
DRUGNAME	Iodofiltic acid I-123
INDICATI	Myocardial disease [ICD-11: BC43.20] Approved
	
TTDDRUID	D0P1RV
DRUGNAME	ATX-GD
INDICATI	Graves disease [ICD-11: 5A02.0] Investigative
	
TTDDRUID	D0P1SA
DRUGNAME	Autologous endothelial progenitor cell therapy
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 2/3
	
TTDDRUID	D0P1TZ
DRUGNAME	MLN-977
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D0P1UX
DRUGNAME	Venlafaxine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0P1VT
DRUGNAME	Pyrimidinone derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0P1WA
DRUGNAME	Tiotropium
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0P1WB
DRUGNAME	EVT-301
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1
	
TTDDRUID	D0P1WR
DRUGNAME	ZP-004
INDICATI	Cough [ICD-11: MD12] Investigative
	
TTDDRUID	D0P1XQ
DRUGNAME	SEL-73
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Investigative
	
TTDDRUID	D0P1YE
DRUGNAME	Orvepitant
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2
	
TTDDRUID	D0P1YH
DRUGNAME	S-1746
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1
	
TTDDRUID	D0P1YO
DRUGNAME	MOL-218
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0P1ZR
DRUGNAME	Molecule 25
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0P2AC
DRUGNAME	CH-4938056
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0P2AG
DRUGNAME	Formoterol/budesonide
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0P2AL
DRUGNAME	YJP-40101
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0P2BD
DRUGNAME	SAFIRONIL
INDICATI	Transplant rejection [ICD-11: NE84] Phase 1
	
TTDDRUID	D0P2BJ
DRUGNAME	Quinazoline derivative 13
INDICATI	Multiple sclerosis [ICD-11: 8A40] Patented
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Patented
INDICATI	Atopic dermatitis [ICD-11: EA80] Patented
INDICATI	Arteriosclerosis [ICD-11: BD40] Patented
	
TTDDRUID	D0P2BV
DRUGNAME	Human thrombin
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
	
TTDDRUID	D0P2CK
DRUGNAME	Estazolam
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0P2CS
DRUGNAME	EVANS BLUE
INDICATI	Abdominal aortic aneurysm [ICD-11: BD50.4] Approved
	
TTDDRUID	D0P2CZ
DRUGNAME	SPH-260-4
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0P2ED
DRUGNAME	GRC-17536
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0P2EH
DRUGNAME	A-196
INDICATI	Discovery agent [ICD-11: N.A.] Preclinical
	
TTDDRUID	D0P2EX
DRUGNAME	M-enoxaparin
INDICATI	Acute coronary syndrome [ICD-11: BA41] Approved
	
TTDDRUID	D0P2FC
DRUGNAME	ADMDD-15
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0P2GA
DRUGNAME	CART-meso cells
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0P2GK
DRUGNAME	Sodium phenylbutyrate
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Approved
	
TTDDRUID	D0P2GU
DRUGNAME	CSL-362-AML
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D0P2IT
DRUGNAME	Asiaticoside
INDICATI	Vulnerary [ICD-11: ND56.Z] Approved
	
TTDDRUID	D0P2IW
DRUGNAME	Peramivir
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0P2JH
DRUGNAME	Sulfur hexafluoride lipid-type a microspheres
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0P2KG
DRUGNAME	GSK1144814
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 1
	
TTDDRUID	D0P2LR
DRUGNAME	Leprovac
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Approved
	
TTDDRUID	D0P2MD
DRUGNAME	AMB-8LK
INDICATI	Liver cancer [ICD-11: 2C12] Investigative
	
TTDDRUID	D0P2ME
DRUGNAME	INO-5401
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 1/2
	
TTDDRUID	D0P2MF
DRUGNAME	N91115
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D0P2MH
DRUGNAME	BTS-67582
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D0P2OK
DRUGNAME	HPP404
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1
	
TTDDRUID	D0P2OW
DRUGNAME	IR208
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2/3
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0P2QO
DRUGNAME	S-15535
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0P2RO
DRUGNAME	SSR-126517E
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 3
	
TTDDRUID	D0P2SI
DRUGNAME	Galiximab
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
	
TTDDRUID	D0P2TD
DRUGNAME	ElCams
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0P2YD
DRUGNAME	Isosulfan blue
INDICATI	Investigative surgical procedure [ICD-11: QB8Z] Approved
	
TTDDRUID	D0P2YP
DRUGNAME	AGT-181
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2
	
TTDDRUID	D0P2YS
DRUGNAME	A 77636
INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated
	
TTDDRUID	D0P2YU
DRUGNAME	Mitiglinide
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0P2ZM
DRUGNAME	SLX-1016
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0P2ZY
DRUGNAME	INNO-305
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0P3BS
DRUGNAME	TUTI-16
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0P3CF
DRUGNAME	AZD-4407
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D0P3DC
DRUGNAME	LP-10
INDICATI	Cystitis [ICD-11: GC00] Investigative
	
TTDDRUID	D0P3DM
DRUGNAME	Fencamfamine
INDICATI	Depressive fatigue [ICD-11: MG22] Withdrawn from market
	
TTDDRUID	D0P3EG
DRUGNAME	1,3,4-oxadiazole derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0P3IE
DRUGNAME	ZK-93426
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0P3IZ
DRUGNAME	E-2040
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0P3JF
DRUGNAME	SCH-900978
INDICATI	Cough [ICD-11: MD12] Phase 2
	
TTDDRUID	D0P3JU
DRUGNAME	Clorazepate
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0P3KA
DRUGNAME	TEBUFELONE
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0P3KH
DRUGNAME	PMUC5AC
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative
	
TTDDRUID	D0P3LQ
DRUGNAME	SIL-187
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D0P3NZ
DRUGNAME	CMP-1
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1/2
	
TTDDRUID	D0P3PB
DRUGNAME	RX-10045
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Phase 2
	
TTDDRUID	D0P3PF
DRUGNAME	AMX-256
INDICATI	Short bowel syndrome [ICD-11: KB89.1] Investigative
	
TTDDRUID	D0P3QR
DRUGNAME	Carbapenem antibacterials
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0P3SH
DRUGNAME	ReN-1826
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Terminated
	
TTDDRUID	D0P3SJ
DRUGNAME	XP-21279
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0P3SL
DRUGNAME	PMID26651364-Compound-8d
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0P3SY
DRUGNAME	Danaparoid
INDICATI	Deep venous clot [ICD-11: BD71] Approved
	
TTDDRUID	D0P3TF
DRUGNAME	TU-2100
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0P3TT
DRUGNAME	IDR-90104
INDICATI	Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 2
	
TTDDRUID	D0P3TX
DRUGNAME	Abciximab
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D0P3UZ
DRUGNAME	CNJ-H01
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Investigative
	
TTDDRUID	D0P3VP
DRUGNAME	JKB-119
INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative
	
TTDDRUID	D0P3WH
DRUGNAME	Anti-CD27 agonist
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P3ZA
DRUGNAME	AB-3001
INDICATI	Syndrome X [ICD-11: 5C53.4] Investigative
	
TTDDRUID	D0P3ZF
DRUGNAME	IGF-MTX
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P3ZN
DRUGNAME	RDEA3170
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Phase 2
	
TTDDRUID	D0P4BC
DRUGNAME	Disulfiram
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0P4BQ
DRUGNAME	LY-544344
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3
	
TTDDRUID	D0P4DG
DRUGNAME	S-070
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0P4DJ
DRUGNAME	Somatropin recombinant
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved
	
TTDDRUID	D0P4EC
DRUGNAME	Surfactant ta
INDICATI	Respiratory distress syndrome [ICD-11: CB00] Approved
	
TTDDRUID	D0P4FK
DRUGNAME	TB-010
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0P4FT
DRUGNAME	ART-123
INDICATI	Disseminated intravascular coagulation [ICD-11: 3B20] Preclinical
	
TTDDRUID	D0P4IK
DRUGNAME	FK-706
INDICATI	Pulmonary emphysema [ICD-11: CA21.Z] Discontinued in Phase 2
	
TTDDRUID	D0P4IL
DRUGNAME	REGN-728
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D0P4JJ
DRUGNAME	Adoptive T-cell therapy
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0P4KP
DRUGNAME	CART19 cells
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 0
	
TTDDRUID	D0P4KU
DRUGNAME	ABI-011
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0P4KV
DRUGNAME	MesoStem
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0P4MA
DRUGNAME	2-MOE phosphorothioate gapmers
INDICATI	Myotonic dystrophy [ICD-11: 8C71.0] Investigative
	
TTDDRUID	D0P4MN
DRUGNAME	ALO 212
INDICATI	Critical limb ischemia [ICD-11: BD4Y] Phase 1
	
TTDDRUID	D0P4MT
DRUGNAME	Oxamniquine
INDICATI	Schistosomiasis [ICD-11: 1F86] Approved
	
TTDDRUID	D0P4PS
DRUGNAME	Antimalarial peroxides
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0P4PZ
DRUGNAME	Glucarpidase
INDICATI	Delayed methotrexate clearance [ICD-11: N.A.] Approved
	
TTDDRUID	D0P4QX
DRUGNAME	LPG-1030S
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative
	
TTDDRUID	D0P4RA
DRUGNAME	Repifermin
INDICATI	Oral mucositis [ICD-11: DA01.11] Discontinued in Phase 2
	
TTDDRUID	D0P4RC
DRUGNAME	Sitostanol ascorbyl phosphate
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D0P4TH
DRUGNAME	Trastuzumab-DM1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0P4VX
DRUGNAME	Terlipressin
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0P4WI
DRUGNAME	Recombinant human TNF receptor
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0P4WO
DRUGNAME	ADX10059
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0P4XW
DRUGNAME	Tremfya
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 3
	
TTDDRUID	D0P4ZA
DRUGNAME	EM-2198
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0P4ZR
DRUGNAME	Istiratumab
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0P5AA
DRUGNAME	Oratecan
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P5AE
DRUGNAME	Ecallantide
INDICATI	Retina venous occlusion [ICD-11: 9B74.1] Approved
	
TTDDRUID	D0P5AL
DRUGNAME	Profezyme
INDICATI	Wound healing [ICD-11: EL8Y] Approved
	
TTDDRUID	D0P5AP
DRUGNAME	Recombinant factor viii
INDICATI	Hemophilia [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0P5BQ
DRUGNAME	IkT-051
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0P5CD
DRUGNAME	Iocetamic acid
INDICATI	Bladder disease [ICD-11: DC11-DC1Z] Approved
	
TTDDRUID	D0P5CM
DRUGNAME	AZD-3161
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 1
	
TTDDRUID	D0P5DG
DRUGNAME	Temoporfin
INDICATI	Bone metastases [ICD-11: 2D50] Approved
	
TTDDRUID	D0P5DW
DRUGNAME	Ach-02
INDICATI	Analgesia [ICD-11: MB40.8] Approved
	
TTDDRUID	D0P5DZ
DRUGNAME	V920
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 3
	
TTDDRUID	D0P5FA
DRUGNAME	Galnobax
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 1/2
	
TTDDRUID	D0P5GE
DRUGNAME	Dibucaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0P5IZ
DRUGNAME	BI-811283
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0P5JH
DRUGNAME	ABBV-368
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P5LH
DRUGNAME	APL-2
INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 3
	
TTDDRUID	D0P5LX
DRUGNAME	N-6060
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0P5MG
DRUGNAME	BAY 94-9343
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P5NU
DRUGNAME	BN-AA-003-NY
INDICATI	Estrogen deficiency [ICD-11: FB83.0Y] Preclinical
	
TTDDRUID	D0P5NW
DRUGNAME	SB-236049
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0P5NY
DRUGNAME	SPD 535
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D0P5PD
DRUGNAME	IMMU-114
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0P5PJ
DRUGNAME	MK-1972
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0P5QB
DRUGNAME	Cadherin-11
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0P5QR
DRUGNAME	KAC-776
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0P5RD
DRUGNAME	PentaStaph
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1/2
	
TTDDRUID	D0P5RJ
DRUGNAME	BF/PC-18
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0P5SA
DRUGNAME	Fluphenazine
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Approved
	
TTDDRUID	D0P5SB
DRUGNAME	PMID25666693-Compound-49
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0P5SC
DRUGNAME	GTU-TB vaccine
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1/2
	
TTDDRUID	D0P5SU
DRUGNAME	CHS-131
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0P5TC
DRUGNAME	BURKE-103
INDICATI	Verruca vulgaris [ICD-11: 1E80] Investigative
	
TTDDRUID	D0P5TG
DRUGNAME	Multi-epitope peptide melanoma vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D0P5TI
DRUGNAME	CNX-1351
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0P5TR
DRUGNAME	CGP-28014
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0P5UE
DRUGNAME	50-235
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0P5UQ
DRUGNAME	Tissue repair stem cell therapy
INDICATI	Peripheral ischemia [ICD-11: BD30-BD40] Phase 1/2
INDICATI	Dilated cardiomyopathy [ICD-11: BC43.0] Phase 1/2
	
TTDDRUID	D0P5VC
DRUGNAME	Mirimostim
INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Approved
	
TTDDRUID	D0P5VH
DRUGNAME	VennVax
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0P5VX
DRUGNAME	Hormone-independent vaccine
INDICATI	Prostate hyperplasia [ICD-11: GA90] Terminated
	
TTDDRUID	D0P5VZ
DRUGNAME	Tenecrin
INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated
	
TTDDRUID	D0P5XM
DRUGNAME	SM04755
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
	
TTDDRUID	D0P5ZG
DRUGNAME	EradicAide
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0P5ZJ
DRUGNAME	GP-1100
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0P6AL
DRUGNAME	VPX-595
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0P6CF
DRUGNAME	Ozanezumab
INDICATI	Lateral sclerosis [ICD-11: 8B61] Phase 2
	
TTDDRUID	D0P6CN
DRUGNAME	XR-368
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0P6CQ
DRUGNAME	ADS-NPTMZ-1
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0P6DF
DRUGNAME	PD-153103
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0P6DJ
DRUGNAME	VATALANIB
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0P6EL
DRUGNAME	Cordil
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D0P6GT
DRUGNAME	Cipro Inhale
INDICATI	Lung infection [ICD-11: CA4Z] Phase 3
	
TTDDRUID	D0P6GX
DRUGNAME	CZ-2645
INDICATI	Lung inflammation [ICD-11: CA40.Z] Investigative
	
TTDDRUID	D0P6IK
DRUGNAME	Lanatoside b
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0P6JD
DRUGNAME	RGN-259
INDICATI	Vaginal infection [ICD-11: GA02.0] Phase 2
	
TTDDRUID	D0P6LE
DRUGNAME	GSK2696274
INDICATI	Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 2
	
TTDDRUID	D0P6LP
DRUGNAME	CB-01-16
INDICATI	Constipation [ICD-11: DD91.1] Preclinical
	
TTDDRUID	D0P6MB
DRUGNAME	Pexelizumab
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3
	
TTDDRUID	D0P6MW
DRUGNAME	Imprime PGG
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2/3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
	
TTDDRUID	D0P6NL
DRUGNAME	Technetium Tc-99m Pyrophosphate Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0P6NP
DRUGNAME	EDP-239
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0P6OS
DRUGNAME	TT-235
INDICATI	Miscarriage [ICD-11: JA00.0] Discontinued in Phase 1
	
TTDDRUID	D0P6PT
DRUGNAME	Thiazole carboxamide derivative 21
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0P6UB
DRUGNAME	Methamphetamine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
	
TTDDRUID	D0P6UK
DRUGNAME	Citrofen
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0P6VV
DRUGNAME	Dezocine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0P6YD
DRUGNAME	MK-7252
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P6YL
DRUGNAME	MX-35
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D0P6YN
DRUGNAME	CART-33 cells
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0P6YO
DRUGNAME	NSD-721
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0P6ZB
DRUGNAME	Resorcinol compound 14
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0P6ZH
DRUGNAME	Lercanidipine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0P7BA
DRUGNAME	INP102
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 0
	
TTDDRUID	D0P7BQ
DRUGNAME	Atpenin B
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0P7EK
DRUGNAME	Mannitol
INDICATI	Bronchiectasis [ICD-11: CA24] Approved
INDICATI	Renal failure [ICD-11: GB60-GB6Z] Approved
	
TTDDRUID	D0P7FM
DRUGNAME	INCB57643
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0P7GV
DRUGNAME	Annexin A5
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D0P7HI
DRUGNAME	AC-8632
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0P7HM
DRUGNAME	Aom-0821
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0P7HQ
DRUGNAME	Pyrazole derivative 13
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0P7IL
DRUGNAME	GLG-801
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
	
TTDDRUID	D0P7JZ
DRUGNAME	Carbidopa
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0P7KI
DRUGNAME	Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0P7KS
DRUGNAME	N-3601
INDICATI	Heart disease [ICD-11: BA41-BA42] Terminated
	
TTDDRUID	D0P7KU
DRUGNAME	TGF-BR2 mab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P7LP
DRUGNAME	Azetidine derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0P7MF
DRUGNAME	CMLVAX100
INDICATI	leukaemia [ICD-11: 2A60-2B33] Terminated
	
TTDDRUID	D0P7MO
DRUGNAME	SFV IL-12 gene therapy
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0P7PD
DRUGNAME	Empagliflozin/linagliptin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D0P7PY
DRUGNAME	Cirmtuzumab
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
	
TTDDRUID	D0P7QA
DRUGNAME	Pyrazole derivative 14
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0P7QG
DRUGNAME	CNM-Au8
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1
	
TTDDRUID	D0P7RV
DRUGNAME	AVL-181
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0P7SO
DRUGNAME	ADMVA
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0P7TK
DRUGNAME	Ebola virus vaccine + Matrix-M
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D0P7UB
DRUGNAME	Benzothiazine-carboxamide compound 1
INDICATI	Skin inflammation [ICD-11: EF20.Y] Patented
	
TTDDRUID	D0P7VJ
DRUGNAME	Pramiracetam
INDICATI	Brain disease [ICD-11: 8C70-8E61] Approved (orphan drug)
	
TTDDRUID	D0P7VQ
DRUGNAME	BCTC
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0P7WJ
DRUGNAME	PSN357
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0P7WW
DRUGNAME	ET-001
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0P8AY
DRUGNAME	Dibenzepin
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0P8ED
DRUGNAME	Oncoquest-CLL
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D0P8EU
DRUGNAME	Thymocartin
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Discontinued in Phase 3
	
TTDDRUID	D0P8HU
DRUGNAME	CCX-721
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0P8IU
DRUGNAME	AE37/GP2 peptide vaccine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0P8IV
DRUGNAME	Dactinomycin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0P8JC
DRUGNAME	ANG-1007
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0P8JX
DRUGNAME	L-734217
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D0P8LR
DRUGNAME	HC3-1496
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0P8MB
DRUGNAME	AIGIV
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 1/2
	
TTDDRUID	D0P8ME
DRUGNAME	LG-889
INDICATI	Factor VIII deficiency [ICD-11: 3B10] Investigative
	
TTDDRUID	D0P8MG
DRUGNAME	KDS-2000
INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Discontinued in Phase 2
	
TTDDRUID	D0P8MI
DRUGNAME	Suplatast tosilate
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D0P8NR
DRUGNAME	PRB-6014
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative
	
TTDDRUID	D0P8NV
DRUGNAME	BCI-952
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0P8QC
DRUGNAME	CEN-209
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0P8QN
DRUGNAME	Recombinant Factor IX
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Approved
INDICATI	Factor IX deficiency [ICD-11: 3B11] Terminated
	
TTDDRUID	D0P8RS
DRUGNAME	Proguanil
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0P8SR
DRUGNAME	Pyrrolo[2,3-b]pyridine derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0P8TS
DRUGNAME	Eperisone
INDICATI	Muscle spasm [ICD-11: MB47.3] Phase 3
	
TTDDRUID	D0P8UN
DRUGNAME	INV103
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D0P8VT
DRUGNAME	PMID30280939-Compound-US20170128558
INDICATI	Malaria [ICD-11: 1F40-1F45] Patented
	
TTDDRUID	D0P8VZ
DRUGNAME	ACS-14
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0P8YC
DRUGNAME	Batimastat
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Preclinical
	
TTDDRUID	D0P8YJ
DRUGNAME	PTI-80
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0P9AC
DRUGNAME	Phenelzine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
INDICATI	Skin imperfections [ICD-11: EK71] Patented
	
TTDDRUID	D0P9AK
DRUGNAME	CPI-003
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1
	
TTDDRUID	D0P9BT
DRUGNAME	Alicaforsen
INDICATI	Lleum inflammation [ICD-11: 1A40.0] Phase 3
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D0P9CB
DRUGNAME	LG631
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0P9DL
DRUGNAME	HBV vaccine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Terminated
	
TTDDRUID	D0P9EA
DRUGNAME	Paraldehyde
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0P9EL
DRUGNAME	AS-601811
INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1
	
TTDDRUID	D0P9FT
DRUGNAME	REC-15-2739
INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2
	
TTDDRUID	D0P9JE
DRUGNAME	Yuganning
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0P9JW
DRUGNAME	Emeriamine
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D0P9KA
DRUGNAME	YM-16151-4
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D0P9KD
DRUGNAME	PF-3732010
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P9KJ
DRUGNAME	PMID25666693-Compound-43
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0P9KL
DRUGNAME	TAK-683
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D0P9LO
DRUGNAME	BP-2.94
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0P9MW
DRUGNAME	IMP-321
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1/2
	
TTDDRUID	D0P9NT
DRUGNAME	Sodium thiosulfate
INDICATI	Poison intoxication [ICD-11: NE6Z] Approved
	
TTDDRUID	D0P9OU
DRUGNAME	Cat allergy vaccine
INDICATI	Non-cystic fibrosis bronchiectasis [ICD-11: CA24] Approved
	
TTDDRUID	D0P9OW
DRUGNAME	PL-225B
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P9QR
DRUGNAME	JNJ-61187165
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1
	
TTDDRUID	D0P9QW
DRUGNAME	Tipapkinogene sovacivec
INDICATI	Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Phase 2
	
TTDDRUID	D0P9RF
DRUGNAME	Terazosin
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved
	
TTDDRUID	D0P9TS
DRUGNAME	MNX-160
INDICATI	Cachexia [ICD-11: MG20] Terminated
	
TTDDRUID	D0P9UP
DRUGNAME	Civacir
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3
	
TTDDRUID	D0P9UX
DRUGNAME	AMG 211
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0P9WF
DRUGNAME	MTL-003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0P9XE
DRUGNAME	Rx-101005
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0P9XM
DRUGNAME	Cobomarsen
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
	
TTDDRUID	D0P9XW
DRUGNAME	VR465
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D0P9YP
DRUGNAME	AVP-13358
INDICATI	Rhinitis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0P9YQ
DRUGNAME	Avotermin
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Phase 3
	
TTDDRUID	D0PA0S
DRUGNAME	LJP-920
INDICATI	Transplant rejection [ICD-11: NE84] Terminated
	
TTDDRUID	D0PA1B
DRUGNAME	DCDS-4501A
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D0PA2N
DRUGNAME	Azlocillin
INDICATI	Pseudomonas infection [ICD-11: 1B92] Approved
	
TTDDRUID	D0PA2R
DRUGNAME	JD-4000
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0PA5S
DRUGNAME	Risedronate
INDICATI	Paget's disease [ICD-11: FB85] Approved
	
TTDDRUID	D0PB0D
DRUGNAME	SRX-251
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Phase 1
	
TTDDRUID	D0PB0U
DRUGNAME	RG7893
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0PB1C
DRUGNAME	TPM-02/Insulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D0PB3X
DRUGNAME	Vinylsulphones
INDICATI	Infection of P. falciparum [ICD-11: 1F40] Investigative
	
TTDDRUID	D0PB4P
DRUGNAME	XM-323
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0PB6P
DRUGNAME	Org-9935
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0PC1A
DRUGNAME	PAV-617
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative
	
TTDDRUID	D0PC1V
DRUGNAME	T-82
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D0PC5A
DRUGNAME	VER-156084
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0PC7I
DRUGNAME	L-742728
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0PC8Q
DRUGNAME	MCF
INDICATI	Cystic fibrosis [ICD-11: CA25] Investigative
	
TTDDRUID	D0PD0F
DRUGNAME	Paeoniflorin
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0PD2I
DRUGNAME	Thiazole carboxamide derivative 8
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0PD4C
DRUGNAME	CAR-T cells targeting CD22
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0PE0D
DRUGNAME	Nuleusin
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 3
	
TTDDRUID	D0PE1A
DRUGNAME	DBO-11
INDICATI	Cancer related pain [ICD-11: MG30] Terminated
	
TTDDRUID	D0PE2L
DRUGNAME	GSK2402968
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3
	
TTDDRUID	D0PE3J
DRUGNAME	CAR-T Cells targeting CD19
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0PE3Z
DRUGNAME	JNJ-61610588
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0PE8P
DRUGNAME	PD173212
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0PE9T
DRUGNAME	GS-438
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0PF1A
DRUGNAME	CAR-BCMA T cell
INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial
	
TTDDRUID	D0PF3J
DRUGNAME	DOLASTATIN-10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0PF8B
DRUGNAME	PEDF gene therapy
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
	
TTDDRUID	D0PF9G
DRUGNAME	NN-4201
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0PG0F
DRUGNAME	Mitumprotimut-t
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
	
TTDDRUID	D0PG0G
DRUGNAME	Drotrecogin alfa
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved
INDICATI	Severe sepsis [ICD-11: 1G40-1G41] Approved
	
TTDDRUID	D0PG0S
DRUGNAME	CI-999
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0PG2W
DRUGNAME	Biomin Peptide-II
INDICATI	Bone injury [ICD-11: ND56.Y] Investigative
	
TTDDRUID	D0PG5G
DRUGNAME	Infliximab
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
INDICATI	Asthma [ICD-11: CA23] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0PG5J
DRUGNAME	ZD-4927
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D0PG5O
DRUGNAME	MGA012
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Penile squamous cancer [ICD-11: 2C81] Phase 1
	
TTDDRUID	D0PG7V
DRUGNAME	Acocantherin
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0PG8O
DRUGNAME	Naltrexone
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4
	
TTDDRUID	D0PH0G
DRUGNAME	NKTR-171
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0PH0M
DRUGNAME	IDD-3
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 2
	
TTDDRUID	D0PH0U
DRUGNAME	TDI-0042
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0PH4R
DRUGNAME	RG7842
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0PH5J
DRUGNAME	IN0-8000
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0PH5Z
DRUGNAME	Ceftazidime
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0PH6Z
DRUGNAME	CD19+ CAR T Cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0PH9I
DRUGNAME	AZD5153
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0PI1Z
DRUGNAME	Resorcinol compound 13
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0PI2E
DRUGNAME	Sulfoxone
INDICATI	Dermatitis herpetiformis [ICD-11: EB44] Approved
	
TTDDRUID	D0PI3Z
DRUGNAME	Isepamicin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0PI4T
DRUGNAME	BW-42
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0PJ4K
DRUGNAME	Calcium
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D0PJ7M
DRUGNAME	1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0PJ8O
DRUGNAME	PMID25666693-Compound-129
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0PK0R
DRUGNAME	Piperazine derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0PK3W
DRUGNAME	Lotilibcin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0PK5M
DRUGNAME	MLN0002
INDICATI	Crohn disease [ICD-11: DD70] Approved
	
TTDDRUID	D0PK7J
DRUGNAME	bis-triazole derivative 10
INDICATI	Otitis media [ICD-11: AA80-AB0Z] Clinical trial
	
TTDDRUID	D0PL2Q
DRUGNAME	Cytoros
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0PL3N
DRUGNAME	Gefapixant
INDICATI	Cough [ICD-11: MD12] Phase 3
INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 2
	
TTDDRUID	D0PL4F
DRUGNAME	GW-3965
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D0PL5F
DRUGNAME	OT-4003
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0PL7P
DRUGNAME	CYC065
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0PL8D
DRUGNAME	PLX73086
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0PM0Y
DRUGNAME	Lonsurf
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
	
TTDDRUID	D0PM1R
DRUGNAME	TZ-93
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0PM3G
DRUGNAME	BC-RD-03
INDICATI	Raynaud disease [ICD-11: BD42.0] Investigative
	
TTDDRUID	D0PM7Q
DRUGNAME	AZD7762
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0PM9D
DRUGNAME	Porfiromycin
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
	
TTDDRUID	D0PM9P
DRUGNAME	KB-5246
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0PN1F
DRUGNAME	Carbenicillin Indanyl Sodium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0PN3M
DRUGNAME	CD19-directed CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0PN4D
DRUGNAME	CPC-201
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0PN6U
DRUGNAME	PMID26815044-Compound-52
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0PN8H
DRUGNAME	Pacritinib
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 3
	
TTDDRUID	D0PN9E
DRUGNAME	SK-951
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Terminated
	
TTDDRUID	D0PO0B
DRUGNAME	Cilobradine
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 1
	
TTDDRUID	D0PO0L
DRUGNAME	Retroviral vector-transduced autologous T cells to express CD22-specific CARs
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1
	
TTDDRUID	D0PO0T
DRUGNAME	BMS-986036
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0PO5W
DRUGNAME	Tissuegene-Cs
INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Investigative
	
TTDDRUID	D0PO9P
DRUGNAME	EIDD-2801
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0PP0Z
DRUGNAME	CAL-202
INDICATI	Parainfluenza virus infection [ICD-11: 1D9Y] Investigative
	
TTDDRUID	D0PP5M
DRUGNAME	BPH-652
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D0PP6A
DRUGNAME	ABT-165
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0PP8G
DRUGNAME	ONO-5129
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0PQ3G
DRUGNAME	Furosemide
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0PQ3V
DRUGNAME	SYN-1134
INDICATI	Cystic fibrosis [ICD-11: CA25] Terminated
	
TTDDRUID	D0PQ8T
DRUGNAME	SB-436811
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0PR4O
DRUGNAME	Ilixadencel
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D0PR5H
DRUGNAME	BIS-001
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
	
TTDDRUID	D0PR6H
DRUGNAME	PENCLOMEDINE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0PS2W
DRUGNAME	TILNOPROFEN ARBAMEL
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 3
	
TTDDRUID	D0PS2X
DRUGNAME	GEM-ALS
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0PS4C
DRUGNAME	ANGX-1039
INDICATI	Intermittent claudication [ICD-11: BD40.00] Phase 1
	
TTDDRUID	D0PS6X
DRUGNAME	Mega-3-acid ethyl esters
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Approved
	
TTDDRUID	D0PT0U
DRUGNAME	PMID25666693-Compound-112
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0PT1Y
DRUGNAME	SAR-161271
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	D0PT2M
DRUGNAME	EGFRvIII-CARs
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D0PT5D
DRUGNAME	Anti-mesothelin CAR T Cells
INDICATI	Tumour [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0PT6W
DRUGNAME	PIN-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0PT9G
DRUGNAME	INT230-6
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0PU1O
DRUGNAME	GRN-510
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Investigative
	
TTDDRUID	D0PU1W
DRUGNAME	MKC-180
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0PU5L
DRUGNAME	Adaprolol maleate-SME
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2
	
TTDDRUID	D0PU8T
DRUGNAME	E5555
INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 2
	
TTDDRUID	D0PU8Z
DRUGNAME	Dacetuzumab
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Terminated
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Terminated
	
TTDDRUID	D0PU9C
DRUGNAME	TTP-448
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0PV0I
DRUGNAME	AKCEA-APO(a)-LRX
INDICATI	Hyperlipoproteinemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D0PV1U
DRUGNAME	FP-0210
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0PV3Y
DRUGNAME	ME-1036
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0PV4H
DRUGNAME	Legumain-cleavable doxorubicin prodrugs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3
	
TTDDRUID	D0PV9N
DRUGNAME	GC4419
INDICATI	Oral mucositis [ICD-11: DA01.11] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D0PW0G
DRUGNAME	Valategrast
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0PW4C
DRUGNAME	Niravoline
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0PW4N
DRUGNAME	Ispinesib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
	
TTDDRUID	D0PW7C
DRUGNAME	Cefaclor
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0PX0N
DRUGNAME	TF0023
INDICATI	Heart attack [ICD-11: BA41] Phase 2
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0PX5F
DRUGNAME	NU-1001-41
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0PX7X
DRUGNAME	Re-188-P-2045
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
	
TTDDRUID	D0PX8I
DRUGNAME	TTP435
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D0PX8L
DRUGNAME	Clothiapine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0PY0G
DRUGNAME	PMID28270021-Compound-WO2010077680 201
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0PY3L
DRUGNAME	MEDI-565
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1
	
TTDDRUID	D0PY5D
DRUGNAME	Elacytarabine
INDICATI	Late-stage acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	D0PY5I
DRUGNAME	IC9-CAR19 T cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1
INDICATI	Immunoproliferative disorder [ICD-11: 2B32] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0PY5R
DRUGNAME	MDA-106
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0PY7Z
DRUGNAME	Aflunov
INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1/2
	
TTDDRUID	D0PZ4Y
DRUGNAME	PF-3557156
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1
	
TTDDRUID	D0PZ5Q
DRUGNAME	MK-5160
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1
	
TTDDRUID	D0PZ5R
DRUGNAME	BVS-212
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0Q0AJ
DRUGNAME	SM-8849
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0Q0AP
DRUGNAME	BMS-582949
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
INDICATI	Atherosclerosis [ICD-11: BD40] Phase 2
	
TTDDRUID	D0Q0EF
DRUGNAME	ITI-007
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Phase 3
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 3
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0Q0EX
DRUGNAME	Lincomycin
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved
	
TTDDRUID	D0Q0FW
DRUGNAME	N1-methylnicotinamide
INDICATI	Hyperlipidemia [ICD-11: 5C80.Z] Phase 2/3
	
TTDDRUID	D0Q0GY
DRUGNAME	IW-1221
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0Q0HR
DRUGNAME	Y-931
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0Q0HZ
DRUGNAME	Elpamotide
INDICATI	Biliary cancer [ICD-11: 2E92.7] Phase 1/2
	
TTDDRUID	D0Q0IM
DRUGNAME	SNA-125
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
INDICATI	Pruritus [ICD-11: EC90] Phase 1
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0Q0IX
DRUGNAME	BIOD-531
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0Q0JG
DRUGNAME	Ispaghula
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
	
TTDDRUID	D0Q0JI
DRUGNAME	ASP-4058
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0Q0JJ
DRUGNAME	Streptococcal B vaccine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0Q0KX
DRUGNAME	Fluorapacin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Q0LF
DRUGNAME	Vitatropin
INDICATI	Growth failure [ICD-11: LD2F.1Y] Phase 1
	
TTDDRUID	D0Q0LI
DRUGNAME	SER-109
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 3
	
TTDDRUID	D0Q0MH
DRUGNAME	CM-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0Q0MI
DRUGNAME	Zn-DPA-I
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0Q0OD
DRUGNAME	Secukinumab
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Approved
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	Alopecia [ICD-11: ED70] Phase 2
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
INDICATI	Dry eye disease [ICD-11: 9E1Z] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0Q0OP
DRUGNAME	CAB-2
INDICATI	Coronary artery disease [ICD-11: BA80] Discontinued in Phase 1
	
TTDDRUID	D0Q0OY
DRUGNAME	213Bi DOTA-PESIN
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q0PO
DRUGNAME	LY2780301
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Q0PR
DRUGNAME	Novobiocin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0Q0RC
DRUGNAME	Ethopropazine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0Q0RK
DRUGNAME	AZD4721
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0Q0RX
DRUGNAME	CD20-Specific CAR T Cells
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
INDICATI	Large cell lymphoma [ICD-11: 2A80.Z] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0Q0SK
DRUGNAME	MAGE-3-transduced autologous T-cell vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0Q0SZ
DRUGNAME	OLAMUFLOXACIN MESILATE
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3
	
TTDDRUID	D0Q0TI
DRUGNAME	NT-KO-003
INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 2
	
TTDDRUID	D0Q0TK
DRUGNAME	RST100
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	D0Q0UA
DRUGNAME	UFT/leucovorin calcium
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D0Q0XC
DRUGNAME	PMID26651364-Compound-9c
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0Q0XH
DRUGNAME	EP-342
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q0YN
DRUGNAME	SORAPRAZAN
INDICATI	Peptic ulcer [ICD-11: DA61] Discontinued in Phase 2
	
TTDDRUID	D0Q0ZY
DRUGNAME	PRI-724
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0Q1BT
DRUGNAME	Clidinium
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
INDICATI	Abdominal stomach pain [ICD-11: DD91.4] Approved
	
TTDDRUID	D0Q1CD
DRUGNAME	Tanomastat
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 3
INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 3
INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 3
	
TTDDRUID	D0Q1EC
DRUGNAME	STAT-3 DECOY (NSC-741763)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q1ER
DRUGNAME	CGS-12066B
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0Q1GL
DRUGNAME	CT-200
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Q1HD
DRUGNAME	TRV250
INDICATI	Migraine [ICD-11: 8A80] Phase 1
	
TTDDRUID	D0Q1HG
DRUGNAME	PA-1806
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0Q1HU
DRUGNAME	Resorcinol compound 28
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0Q1IH
DRUGNAME	ATX-201
INDICATI	Actinic keratosis [ICD-11: EK90.0] Discontinued in Phase 2
	
TTDDRUID	D0Q1IT
DRUGNAME	Aclidinium/formoterol
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4
	
TTDDRUID	D0Q1JW
DRUGNAME	Hirufaxin
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0Q1JZ
DRUGNAME	Anti-OX40 monoclonal antibody
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0Q1KN
DRUGNAME	SRP 299
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0Q1KP
DRUGNAME	R-18893
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D0Q1LH
DRUGNAME	Micacides
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0Q1LO
DRUGNAME	Sitamaquine
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2
	
TTDDRUID	D0Q1MS
DRUGNAME	Ertapenem
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0Q1MX
DRUGNAME	ImmunoPulse IL-12
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0Q1NF
DRUGNAME	3-(phenoxymethyl) benzylamine derivative 6
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0Q1NI
DRUGNAME	TBC-Thai
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0Q1PR
DRUGNAME	Atracurium
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0Q1PS
DRUGNAME	VR096
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 2
	
TTDDRUID	D0Q1RN
DRUGNAME	IL22-Fc
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
	
TTDDRUID	D0Q1RZ
DRUGNAME	ATA190
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0Q1SA
DRUGNAME	Rosaramicin
INDICATI	Neisseria gonorrhoeae infection [ICD-11: 1A7Z] Approved
	
TTDDRUID	D0Q1SQ
DRUGNAME	EDO-S101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0Q1SX
DRUGNAME	PMID26651364-Compound-7e
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0Q1TX
DRUGNAME	Fusopin
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0Q1UB
DRUGNAME	GZ402666
INDICATI	Pompe disease [ICD-11: 5C51.3] Phase 1
INDICATI	Type 2 glycogen storage disease [ICD-11: 5C51.3] Phase 1
	
TTDDRUID	D0Q1UR
DRUGNAME	TIAPAFANT
INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated
	
TTDDRUID	D0Q1VD
DRUGNAME	SB206
INDICATI	Molluscum contagiosum infection [ICD-11: 1E76] Phase 3
INDICATI	External genital and perianal wart [ICD-11: 1A95] Phase 2
	
TTDDRUID	D0Q1WI
DRUGNAME	RG7745
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2
	
TTDDRUID	D0Q1XV
DRUGNAME	HBV vaccine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D0Q1YX
DRUGNAME	SMNT-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q1YZ
DRUGNAME	Teceleukin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0Q1ZD
DRUGNAME	HO-4038
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D0Q2AS
DRUGNAME	Etozolin
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0Q2AT
DRUGNAME	Flucloxacillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0Q2BB
DRUGNAME	AVE1701
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0Q2BG
DRUGNAME	CU-2010
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Discontinued in Phase 2
	
TTDDRUID	D0Q2BM
DRUGNAME	CB-001
INDICATI	leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1/2
	
TTDDRUID	D0Q2CM
DRUGNAME	CRB-0016
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D0Q2EH
DRUGNAME	Brutieridin
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D0Q2EJ
DRUGNAME	CPH-106
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 1
	
TTDDRUID	D0Q2ES
DRUGNAME	Benzonatate
INDICATI	Cough [ICD-11: MD12] Approved
	
TTDDRUID	D0Q2GX
DRUGNAME	Strada
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0Q2HM
DRUGNAME	EDD7H9
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical
	
TTDDRUID	D0Q2HO
DRUGNAME	Naldemedine Tosylate
INDICATI	Opioid-induced constipation [ICD-11: DB32.1] Approved
	
TTDDRUID	D0Q2IV
DRUGNAME	ALVAC-CEA/hB7.1
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D0Q2JB
DRUGNAME	CP-640922
INDICATI	Dermatomycosis [ICD-11: EA60] Discontinued in Phase 2
	
TTDDRUID	D0Q2JS
DRUGNAME	SB-282241
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0Q2KM
DRUGNAME	MM-111
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0Q2MH
DRUGNAME	Hexafluronium bromide
INDICATI	Spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D0Q2MN
DRUGNAME	Dothiepin
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
	
TTDDRUID	D0Q2PE
DRUGNAME	Norfloxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0Q2PF
DRUGNAME	LY-293284
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0Q2QU
DRUGNAME	Inosine pranobex
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0Q2RF
DRUGNAME	AP-1101
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2
	
TTDDRUID	D0Q2RJ
DRUGNAME	CR-5542
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D0Q2UW
DRUGNAME	DIMS-9054
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0Q2VA
DRUGNAME	EP-37
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0Q2VL
DRUGNAME	PD-157533
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0Q2VU
DRUGNAME	mRNA MRK-1777
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D0Q2WE
DRUGNAME	DFD-04
INDICATI	Rosacea [ICD-11: ED90.0] Phase 2
	
TTDDRUID	D0Q2WS
DRUGNAME	Terbutyline
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0Q2XF
DRUGNAME	Bimatoprost
INDICATI	Alopecia [ICD-11: ED70] Approved
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3
	
TTDDRUID	D0Q2XN
DRUGNAME	Turmeric extracts
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0Q2ZQ
DRUGNAME	PAR-401
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0Q2ZT
DRUGNAME	Kaolin/pectin
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
	
TTDDRUID	D0Q2ZV
DRUGNAME	OLANEXIDINE HYDROCHLORIDE
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Registered
	
TTDDRUID	D0Q3BG
DRUGNAME	Gene therapy, IFN-b
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0Q3BV
DRUGNAME	Colistimethate
INDICATI	Respiratory tract infection [ICD-11: CA45] Approved
	
TTDDRUID	D0Q3ER
DRUGNAME	CVBT-141B
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
	
TTDDRUID	D0Q3ES
DRUGNAME	APD668
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0Q3GV
DRUGNAME	S32504
INDICATI	Parkinson disease [ICD-11: 8A00.0] Preclinical
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated
	
TTDDRUID	D0Q3IS
DRUGNAME	VB4-845
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2/3
	
TTDDRUID	D0Q3OM
DRUGNAME	SKL-19014
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0Q3PB
DRUGNAME	CCX872
INDICATI	Pancreatic tumour [ICD-11: 2C10] Phase 2
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 1
	
TTDDRUID	D0Q3PD
DRUGNAME	S-297995
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2
	
TTDDRUID	D0Q3QS
DRUGNAME	4-aminosalicylate sodium
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1
	
TTDDRUID	D0Q3RC
DRUGNAME	Taxotere-mab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q3SP
DRUGNAME	NPS-1392
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0Q3TF
DRUGNAME	Staphylocide
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0Q3UL
DRUGNAME	PD-160170
INDICATI	Heart disease [ICD-11: BA41-BA42] Preclinical
INDICATI	Obesity [ICD-11: 5B81] Preclinical
INDICATI	Hypertension [ICD-11: BA00-BA04] Preclinical
	
TTDDRUID	D0Q3UQ
DRUGNAME	LC16m8
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D0Q3VE
DRUGNAME	PF-04971729
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D0Q3WB
DRUGNAME	BK-PIFA
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0Q3WN
DRUGNAME	Napsagatran
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2
	
TTDDRUID	D0Q3WP
DRUGNAME	MEDI-553
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0Q3WW
DRUGNAME	BB-15600
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q3XN
DRUGNAME	KR-31360
INDICATI	Nervous system inflammation [ICD-11: 1D0Y] Investigative
	
TTDDRUID	D0Q3YO
DRUGNAME	Cinnarizine
INDICATI	Vertigo meniere disease [ICD-11: AB31.0] Approved
	
TTDDRUID	D0Q3ZN
DRUGNAME	GS-3435
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Terminated
	
TTDDRUID	D0Q4AR
DRUGNAME	Glucagon-like peptide-1 analog
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0Q4BI
DRUGNAME	T-2
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0Q4BQ
DRUGNAME	SA-20896
INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Investigative
	
TTDDRUID	D0Q4BX
DRUGNAME	TA-111
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0Q4CQ
DRUGNAME	Viagenpumatucel-L
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0Q4CS
DRUGNAME	Cevimeline
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Approved
	
TTDDRUID	D0Q4CX
DRUGNAME	MLN-3126
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 1
	
TTDDRUID	D0Q4DS
DRUGNAME	AC vaccine
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
	
TTDDRUID	D0Q4DT
DRUGNAME	HuMax-TAC
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D0Q4EJ
DRUGNAME	Anti-EGFR V III CAR-T cells
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
	
TTDDRUID	D0Q4EQ
DRUGNAME	JNJ-38158471
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative
	
TTDDRUID	D0Q4EW
DRUGNAME	Lithium Citrate
INDICATI	Bipolar disorder [ICD-11: 6A60] Approved
	
TTDDRUID	D0Q4FA
DRUGNAME	PR-P
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Investigative
	
TTDDRUID	D0Q4GL
DRUGNAME	RAVAX
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0Q4GT
DRUGNAME	PM-181108
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0Q4HA
DRUGNAME	EDG-007
INDICATI	Estrogen deficiency [ICD-11: FB83.0Y] Investigative
	
TTDDRUID	D0Q4IE
DRUGNAME	ARX-618
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D0Q4IX
DRUGNAME	GDC-0994
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Q4JM
DRUGNAME	TAK-441
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Q4LG
DRUGNAME	IT-139
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Q4MO
DRUGNAME	ONX-0914
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0Q4NX
DRUGNAME	FANG vaccine
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Melanoma [ICD-11: 2C30] Phase 2/3
INDICATI	Ewing sarcoma [ICD-11: 2B52] Phase 2/3
INDICATI	Adjuvant ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0Q4OV
DRUGNAME	PF530
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0Q4OW
DRUGNAME	Pixantrone
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Q4QV
DRUGNAME	TPIV100
INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0Q4SD
DRUGNAME	Eplerenone
INDICATI	Heart failure [ICD-11: BD10-BD13] Approved
	
TTDDRUID	D0Q4ST
DRUGNAME	Diazepinone derivative 3
INDICATI	Reflux disease [ICD-11: DA22] Patented
INDICATI	Parkinson disease [ICD-11: 8A00.0] Patented
	
TTDDRUID	D0Q4TK
DRUGNAME	Morantel tartrate
INDICATI	Mature gastrointestinal nematode infection [ICD-11: 1F6Y] Approved
	
TTDDRUID	D0Q4TW
DRUGNAME	SCY-644
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0Q4US
DRUGNAME	FR-144420
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D0Q4UY
DRUGNAME	CFC-222
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0Q4WG
DRUGNAME	ACT-1
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
	
TTDDRUID	D0Q4WR
DRUGNAME	Angiotensin therapeutic vaccine
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0Q4XG
DRUGNAME	MOD-3012
INDICATI	Factor IX deficiency [ICD-11: 3B11] Investigative
	
TTDDRUID	D0Q4XQ
DRUGNAME	Ethosuximide
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D0Q4YI
DRUGNAME	Trimetazidine
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D0Q4YK
DRUGNAME	Piracetam
INDICATI	Cognitive impairment [ICD-11: 6D71] Approved
	
TTDDRUID	D0Q4YP
DRUGNAME	TAK-100
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D0Q5AS
DRUGNAME	DUP-860
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 1
	
TTDDRUID	D0Q5AT
DRUGNAME	QVA-149
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D0Q5BK
DRUGNAME	HGT-1410
INDICATI	Sanfilippo syndrome [ICD-11: 5C56.3Y] Phase 2
	
TTDDRUID	D0Q5BU
DRUGNAME	MSH-1001
INDICATI	Ocular hypertension [ICD-11: 9C61.01] Phase 2
	
TTDDRUID	D0Q5CH
DRUGNAME	AP-301-IH
INDICATI	Pneumonia [ICD-11: CA40] Phase 2
	
TTDDRUID	D0Q5DT
DRUGNAME	IM156
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Q5EH
DRUGNAME	Anti-CD19 CAR-T cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0Q5FS
DRUGNAME	Pyrazole derivative 18
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0Q5FT
DRUGNAME	Fibroblast growth factor
INDICATI	Ear disease [ICD-11: AA0Y-AC0Z] Investigative
	
TTDDRUID	D0Q5GK
DRUGNAME	MG7-CART
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0Q5II
DRUGNAME	G009
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0Q5IN
DRUGNAME	Lindane
INDICATI	Infestations of lice and scabies [ICD-11: 1G00.Z] Approved
	
TTDDRUID	D0Q5KL
DRUGNAME	Coagulation Factor IX
INDICATI	Haemophilia B [ICD-11: 3B11.0] Approved
	
TTDDRUID	D0Q5KZ
DRUGNAME	SGI110
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	D0Q5LF
DRUGNAME	BIO-1211
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0Q5MC
DRUGNAME	PCI-34051
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q5MQ
DRUGNAME	Tasimelteon
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0Q5MU
DRUGNAME	R-7025
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Terminated
	
TTDDRUID	D0Q5NX
DRUGNAME	Lenalidomide
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
	
TTDDRUID	D0Q5NZ
DRUGNAME	BP-100-1.02
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative
	
TTDDRUID	D0Q5OC
DRUGNAME	AGS-003
INDICATI	Migraine [ICD-11: 8A80] Phase 2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D0Q5PL
DRUGNAME	INDOPROFEN
INDICATI	Gout [ICD-11: FA25] Withdrawn from market
	
TTDDRUID	D0Q5QC
DRUGNAME	EMD-534085
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0Q5QE
DRUGNAME	AN-10
INDICATI	Alopecia [ICD-11: ED70] Terminated
	
TTDDRUID	D0Q5QF
DRUGNAME	Desferrithiocin
INDICATI	Metal intoxication [ICD-11: NE60] Terminated
	
TTDDRUID	D0Q5QV
DRUGNAME	MVT-5873
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Q5RA
DRUGNAME	CVP S aureus vaccine
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Terminated
	
TTDDRUID	D0Q5SI
DRUGNAME	SHP611
INDICATI	Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 2
	
TTDDRUID	D0Q5SP
DRUGNAME	Sodium phenylacetate/sodium benzoate
INDICATI	Hepatic encephalopathy [ICD-11: DB99.5] Approved
	
TTDDRUID	D0Q5SX
DRUGNAME	HMaxi-K
INDICATI	Overactive bladder [ICD-11: GC50.0] Phase 1
	
TTDDRUID	D0Q5TH
DRUGNAME	XR-5944
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
	
TTDDRUID	D0Q5TP
DRUGNAME	Anti-sortase mab
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0Q5TW
DRUGNAME	TT-112
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative
	
TTDDRUID	D0Q5UQ
DRUGNAME	Exjade
INDICATI	Iron overload disease [ICD-11: 5C64.10] Approved
	
TTDDRUID	D0Q5VC
DRUGNAME	BAN-2203
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0Q5VW
DRUGNAME	L-778123
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0Q5XX
DRUGNAME	Eicosapentaenoic acid/docosa-hexaenoic acid
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Approved
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0Q5YF
DRUGNAME	Cipralisant
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2
	
TTDDRUID	D0Q5YH
DRUGNAME	NGD-94-4
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
	
TTDDRUID	D0Q5YJ
DRUGNAME	PMID25553724-Compound-US2012819831110
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented
	
TTDDRUID	D0Q5ZN
DRUGNAME	Seprilose
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0Q6AE
DRUGNAME	EPI-288
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q6AU
DRUGNAME	NEO-PV-01
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0Q6BH
DRUGNAME	Agriflu
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0Q6DV
DRUGNAME	Metallo-SAHA
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q6DX
DRUGNAME	Triacetin
INDICATI	Onychomycosis [ICD-11: EE12.1] Approved
	
TTDDRUID	D0Q6EA
DRUGNAME	SCH-1450206
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q6ED
DRUGNAME	ASP8497
INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical
	
TTDDRUID	D0Q6EH
DRUGNAME	SBT-20
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 1/2
	
TTDDRUID	D0Q6EN
DRUGNAME	AHR-16303B
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0Q6FV
DRUGNAME	TJN-135
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2
	
TTDDRUID	D0Q6GD
DRUGNAME	WCK-1152
INDICATI	Respiratory tract inflammation [ICD-11: CA07] Phase 1
	
TTDDRUID	D0Q6GK
DRUGNAME	EphB4-131
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q6IF
DRUGNAME	Vmab + Y-90 Emab
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1b
	
TTDDRUID	D0Q6IW
DRUGNAME	Rosiglitazone + simvastatin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0Q6JY
DRUGNAME	A-003
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0Q6KV
DRUGNAME	SG-2274
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q6LA
DRUGNAME	Levoleucovorin
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved
	
TTDDRUID	D0Q6MA
DRUGNAME	Gamma-sarcoglycan gene-containing recombinant AAV1 vector based therapy
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D0Q6MQ
DRUGNAME	CGEN-913
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0Q6MY
DRUGNAME	Nafamostat
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0Q6NN
DRUGNAME	TAK-070
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial
	
TTDDRUID	D0Q6NZ
DRUGNAME	Oxymetholone
INDICATI	Aplastic anemia [ICD-11: 3A70] Approved
	
TTDDRUID	D0Q6OL
DRUGNAME	KM-011
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0Q6OS
DRUGNAME	Macrolides
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0Q6QU
DRUGNAME	MEDI6469
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0Q6RC
DRUGNAME	Thiazole carboxamide derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0Q6RG
DRUGNAME	TD-1792
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 3
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 2
	
TTDDRUID	D0Q6RX
DRUGNAME	Oravax-PX
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0Q6SD
DRUGNAME	Lamectacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3
	
TTDDRUID	D0Q6SF
DRUGNAME	APO-010
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0Q6YT
DRUGNAME	Poloxafuse-I
INDICATI	Injury [ICD-11: NA00-ND5Z] Investigative
	
TTDDRUID	D0Q6ZQ
DRUGNAME	ELND-007
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0Q7AG
DRUGNAME	CGM097
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Q7AH
DRUGNAME	EP-1043
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0Q7AW
DRUGNAME	IMIRESTAT
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 3
	
TTDDRUID	D0Q7AZ
DRUGNAME	Plant-derived antibacterials
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0Q7CR
DRUGNAME	MX-76629
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0Q7FC
DRUGNAME	Lurtotecan
INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2
INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 1
	
TTDDRUID	D0Q7HO
DRUGNAME	PD-153035
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1
	
TTDDRUID	D0Q7IX
DRUGNAME	PF-06342674
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0Q7JC
DRUGNAME	P-552-02
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1/2
	
TTDDRUID	D0Q7JJ
DRUGNAME	NA-808
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Preclinical
	
TTDDRUID	D0Q7MA
DRUGNAME	Cefiderocol
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Approved
INDICATI	Hospital-acquired pneumonia [ICD-11: CA40.Z] Approved
INDICATI	Healthcare-associated pneumonia [ICD-11: CA00-CA40] Phase 3
	
TTDDRUID	D0Q7MI
DRUGNAME	KPE-00001113
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0Q7MQ
DRUGNAME	CP-100263
INDICATI	Vomiting [ICD-11: MD90] Investigative
	
TTDDRUID	D0Q7NB
DRUGNAME	842166X
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0Q7OA
DRUGNAME	HydrocoDex
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0Q7OB
DRUGNAME	RP-656
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q7OE
DRUGNAME	BI-505
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D0Q7OR
DRUGNAME	AdHu5-ZGP
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative
	
TTDDRUID	D0Q7QA
DRUGNAME	PT001 GP
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D0Q7QK
DRUGNAME	Mannoside derivative 13
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0Q7QY
DRUGNAME	SSR-125047
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
INDICATI	Diabetic cataract [ICD-11: 9B10.21] Withdrawn from market
	
TTDDRUID	D0Q7RA
DRUGNAME	Epoietin delta
INDICATI	Constitutional neutropenia [ICD-11: 4B00.0] Approved
	
TTDDRUID	D0Q7RE
DRUGNAME	AZD-1152-HQPA
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Q7RJ
DRUGNAME	SLP-1004
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0Q7SO
DRUGNAME	RS-66252
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0Q7SR
DRUGNAME	Cervarix
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Approved
	
TTDDRUID	D0Q7TH
DRUGNAME	BMS-181885
INDICATI	Migraine [ICD-11: 8A80] Terminated
	
TTDDRUID	D0Q7TI
DRUGNAME	HG-1078
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q7UD
DRUGNAME	ABT-888
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Epithelial ovarian cancer [ICD-11: 2B5D] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0Q7UG
DRUGNAME	Tipelukast
INDICATI	Asthma [ICD-11: CA23] Phase 2
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
	
TTDDRUID	D0Q7VI
DRUGNAME	Siguazodan
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D0Q7WW
DRUGNAME	UR-8328
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0Q7XA
DRUGNAME	LG-888
INDICATI	Factor VIII deficiency [ICD-11: 3B10] Investigative
	
TTDDRUID	D0Q7XS
DRUGNAME	LP-0067
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0Q7YI
DRUGNAME	Alogliptin/pioglitazone
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D0Q7YZ
DRUGNAME	Gantenerumab
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0Q7ZG
DRUGNAME	Proparacaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0Q7ZQ
DRUGNAME	Succinylcholine
INDICATI	Spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D0Q8CA
DRUGNAME	GD2-lm
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D0Q8CS
DRUGNAME	Tiludronic acid
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D0Q8CV
DRUGNAME	CDX-301
INDICATI	Hematopoietic stem cell transplantation [ICD-11: QB63] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0Q8CW
DRUGNAME	PF-738502
INDICATI	Fibromyalgia [ICD-11: MG30.01] Discontinued in Phase 1
	
TTDDRUID	D0Q8DM
DRUGNAME	BIM-26226
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0Q8DZ
DRUGNAME	EX-404
INDICATI	Polycystic ovarian syndrome [ICD-11: 5A80.1] Phase 2/3
	
TTDDRUID	D0Q8FE
DRUGNAME	UR-9660
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Terminated
	
TTDDRUID	D0Q8GV
DRUGNAME	Prostate cancer vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0Q8GX
DRUGNAME	SYM-011
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q8JK
DRUGNAME	Thiazole carboxamide derivative 15
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0Q8LL
DRUGNAME	SYL-040012
INDICATI	Ocular hypertension [ICD-11: 9C61.01] Phase 2
	
TTDDRUID	D0Q8MI
DRUGNAME	Lintopride
INDICATI	Nausea [ICD-11: MD90] Phase 2
	
TTDDRUID	D0Q8ML
DRUGNAME	ROR1 CAR-specific Autologous T-Lymphocytes
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1
	
TTDDRUID	D0Q8MQ
DRUGNAME	Benzothiazine-carboxamide compound 5
INDICATI	Skin inflammation [ICD-11: EF20.Y] Patented
	
TTDDRUID	D0Q8NJ
DRUGNAME	Viomycin sulfate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0Q8OW
DRUGNAME	AnergiX.MS
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2
	
TTDDRUID	D0Q8PF
DRUGNAME	Ad5f35-LMPd1-2-transduced autologous dendritic cells
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D0Q8PJ
DRUGNAME	NLP-91
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D0Q8QR
DRUGNAME	I-387
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q8RX
DRUGNAME	L-368899
INDICATI	Miscarriage [ICD-11: JA00.0] Discontinued in Phase 1
	
TTDDRUID	D0Q8SI
DRUGNAME	SOM-0777
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q8SN
DRUGNAME	ET-003
INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative
	
TTDDRUID	D0Q8TI
DRUGNAME	FX-141L
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0Q8TX
DRUGNAME	Ajinomoto 1
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0Q8UU
DRUGNAME	BM-17.0744
INDICATI	Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 2
	
TTDDRUID	D0Q8VM
DRUGNAME	TT-401
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0Q8WG
DRUGNAME	Tedalinab
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0Q8WX
DRUGNAME	AM-101
INDICATI	Tinnitus [ICD-11: MC41] Phase 3
	
TTDDRUID	D0Q8XH
DRUGNAME	Cefsoludin sodium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0Q8XO
DRUGNAME	CART-19
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0Q8YI
DRUGNAME	VEGF kinoid
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q8YN
DRUGNAME	Sch-40338
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D0Q8YU
DRUGNAME	OX-ESI
INDICATI	Respiratory tract inflammation [ICD-11: CA07] Investigative
	
TTDDRUID	D0Q8YZ
DRUGNAME	DW-286
INDICATI	Respiratory tract infection [ICD-11: CA45] Investigative
	
TTDDRUID	D0Q8ZP
DRUGNAME	TDI-0033
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0Q8ZX
DRUGNAME	Benzocaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0Q9AD
DRUGNAME	Pyrazole derivative 59
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0Q9BV
DRUGNAME	JIN-2019
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Q9CY
DRUGNAME	HKI-272
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0Q9DK
DRUGNAME	Nizatidine
INDICATI	Acid-reflux disorder [ICD-11: DA22] Approved
	
TTDDRUID	D0Q9DL
DRUGNAME	PB-108
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0Q9EH
DRUGNAME	NV-18
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0Q9EV
DRUGNAME	lifitegrast
INDICATI	Dry eye disease [ICD-11: 9E1Z] Approved
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3
	
TTDDRUID	D0Q9GJ
DRUGNAME	BP-C2
INDICATI	Radiation syndrome [ICD-11: NF00] Investigative
	
TTDDRUID	D0Q9HF
DRUGNAME	Acetylcholine
INDICATI	Cataract [ICD-11: 9B10] Approved
	
TTDDRUID	D0Q9HM
DRUGNAME	CM-AT
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 3
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
	
TTDDRUID	D0Q9HT
DRUGNAME	LY-307161
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0Q9IE
DRUGNAME	BMS-707035
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0Q9IK
DRUGNAME	CEP-9722
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1/2
	
TTDDRUID	D0Q9IY
DRUGNAME	PNU-142731A
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0Q9JT
DRUGNAME	Metyrapone
INDICATI	Cushing disease [ICD-11: 5A70] Approved
	
TTDDRUID	D0Q9KR
DRUGNAME	Seviteronel
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0Q9MN
DRUGNAME	COL-204
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Investigative
	
TTDDRUID	D0Q9NJ
DRUGNAME	AC-625
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D0Q9ON
DRUGNAME	Denopamine
INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0Q9PP
DRUGNAME	Recombinant Slit-2-D1-D2-Fc
INDICATI	Acute lung injury [ICD-11: NB32.3] Investigative
	
TTDDRUID	D0Q9PT
DRUGNAME	Synflorix
INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 4
	
TTDDRUID	D0Q9QC
DRUGNAME	DMD-02
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D0Q9RP
DRUGNAME	CBLC137
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Q9RR
DRUGNAME	AZD0328
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
	
TTDDRUID	D0Q9RW
DRUGNAME	HL-135
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0Q9TB
DRUGNAME	White blood cell therapy
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
	
TTDDRUID	D0Q9TC
DRUGNAME	Hexaxim
INDICATI	Haemophilus influenza [ICD-11: 1G40] Approved
	
TTDDRUID	D0Q9UL
DRUGNAME	IATX-FVIII
INDICATI	Factor VIII deficiency [ICD-11: 3B10] Investigative
	
TTDDRUID	D0Q9UX
DRUGNAME	PHA848125
INDICATI	Thymic cancer [ICD-11: 2C27] Phase 2
	
TTDDRUID	D0Q9VA
DRUGNAME	Tritanrix HB
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0Q9VS
DRUGNAME	Phosphatonin
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Investigative
	
TTDDRUID	D0Q9VW
DRUGNAME	Beta-Gly
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0Q9WN
DRUGNAME	FC EPO
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 1
	
TTDDRUID	D0Q9WO
DRUGNAME	Cinolazepam
INDICATI	Muscle spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D0Q9XE
DRUGNAME	MEDI4893
INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2b
INDICATI	Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 1
	
TTDDRUID	D0Q9YT
DRUGNAME	Tetrahydrobiopterin
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D0Q9ZD
DRUGNAME	Camobucol
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0Q9ZU
DRUGNAME	HepTcell
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	D0QA0B
DRUGNAME	RDX-008
INDICATI	Hypernatremia [ICD-11: 5C71] Investigative
	
TTDDRUID	D0QA1M
DRUGNAME	MCP-203
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D0QA3C
DRUGNAME	OMB157
INDICATI	Multiple sclerosis [ICD-11: 8A40] Clinical trial
	
TTDDRUID	D0QA6Q
DRUGNAME	CGP-55847
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0QA7X
DRUGNAME	APG-103
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0QB1O
DRUGNAME	CD19 and CD20 CAR-T Cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D0QB6M
DRUGNAME	ND-901
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0QB7K
DRUGNAME	Yunaoning
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved
	
TTDDRUID	D0QB7N
DRUGNAME	GD2 T cells
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 1
	
TTDDRUID	D0QB8Q
DRUGNAME	EP-2167
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0QC2V
DRUGNAME	AEVI-1
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	D0QC3M
DRUGNAME	Amorolfine
INDICATI	Onychomycosis [ICD-11: EE12.1] Approved
	
TTDDRUID	D0QC5D
DRUGNAME	Gallium Citrate Ga-67
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Approved
	
TTDDRUID	D0QC6Z
DRUGNAME	GALL-200
INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Investigative
	
TTDDRUID	D0QC9I
DRUGNAME	Benzoic acid linked peptide analog 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0QD1G
DRUGNAME	Elvitegravir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0QD4A
DRUGNAME	ABBV-428
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0QD6R
DRUGNAME	Lactobacillus
INDICATI	Diarrhea [ICD-11: ME05.1] Approved
	
TTDDRUID	D0QD9R
DRUGNAME	Thyroglobulin
INDICATI	Hypothyroidism [ICD-11: 5A00] Approved
	
TTDDRUID	D0QE1Y
DRUGNAME	ViperaTAb
INDICATI	Poison intoxication [ICD-11: NE6Z] Approved
	
TTDDRUID	D0QE4F
DRUGNAME	CD19-CAR and CD28-CAR T Cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0QE5B
DRUGNAME	Tagorizine
INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 3
	
TTDDRUID	D0QE5U
DRUGNAME	Insulin-detemir
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved
	
TTDDRUID	D0QE8K
DRUGNAME	PM-72G
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0QE9F
DRUGNAME	P-6915
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0QF0L
DRUGNAME	CD19 CAR-T Cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
	
TTDDRUID	D0QF2W
DRUGNAME	AGTC-0106
INDICATI	Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Phase 2
	
TTDDRUID	D0QF4W
DRUGNAME	Macrocycle derivative 7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0QF4Z
DRUGNAME	MT-500
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 1
	
TTDDRUID	D0QF6E
DRUGNAME	Tridegin
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0QF7Z
DRUGNAME	HER2/neu peptide vaccine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0QF9P
DRUGNAME	GSK-208108
INDICATI	Haemophilus influenza [ICD-11: 1G40] Approved
	
TTDDRUID	D0QG1B
DRUGNAME	Aprocitentan
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0QG2D
DRUGNAME	Amelubant
INDICATI	Pulmonary disease [ICD-11: 1B10-1F85] Phase 2
INDICATI	Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2
	
TTDDRUID	D0QG3E
DRUGNAME	CIGB-598a
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0QG6A
DRUGNAME	NIP-142
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D0QG8F
DRUGNAME	DNCB
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 2
	
TTDDRUID	D0QG9A
DRUGNAME	Apadenoson
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 3
	
TTDDRUID	D0QH0B
DRUGNAME	EPI-2010
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0QH0R
DRUGNAME	SB-206343
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0QH3H
DRUGNAME	DCVax-Prostate cancer vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 3
	
TTDDRUID	D0QH5I
DRUGNAME	N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0QH5K
DRUGNAME	AK-106-001616
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0QH7G
DRUGNAME	RG-7432
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1
	
TTDDRUID	D0QH7H
DRUGNAME	AMP-579
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D0QI0Z
DRUGNAME	IG-MD-009
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0QI1K
DRUGNAME	HuMax-AXL-ADC
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0QI1O
DRUGNAME	SL-601
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D0QI4Z
DRUGNAME	KP484
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
	
TTDDRUID	D0QI6W
DRUGNAME	Non-peptide TPO mimics
INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative
	
TTDDRUID	D0QI9N
DRUGNAME	BN-CB-045
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Preclinical
	
TTDDRUID	D0QJ2K
DRUGNAME	LEO-27989
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0QJ4Y
DRUGNAME	TGF-beta Shield
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0QJ6L
DRUGNAME	Demogastrin
INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 1
	
TTDDRUID	D0QJ8J
DRUGNAME	mRNA-1273 vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0QJ9Z
DRUGNAME	MGN-6114
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Investigative
	
TTDDRUID	D0QK2E
DRUGNAME	SCH-205831
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D0QK5C
DRUGNAME	ALAMIFOVIR
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1/2
	
TTDDRUID	D0QK5X
DRUGNAME	Enzalutamide
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D0QL0D
DRUGNAME	SPIF
INDICATI	Autoimmune hepatitis [ICD-11: DB96.0] Phase 1
	
TTDDRUID	D0QL0X
DRUGNAME	Biaryl mannoside derivative 23
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0QL1U
DRUGNAME	DeOvo
INDICATI	Pediculus capitis infestation [ICD-11: 1G00.0] Phase 2
	
TTDDRUID	D0QL3P
DRUGNAME	Oxcarbazepine
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D0QL3T
DRUGNAME	K-42
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0QL4N
DRUGNAME	Darunavir + ritonavir + favipiravir + hydroxychloroquine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0QL4X
DRUGNAME	SOT-107
INDICATI	Brain cancer [ICD-11: 2A00] Phase 3
	
TTDDRUID	D0QL9W
DRUGNAME	Quadrivalent pediatric combination vaccine
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Registered
	
TTDDRUID	D0QM0D
DRUGNAME	Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1
INDICATI	Pain [ICD-11: MG30-MG3Z] Patented
	
TTDDRUID	D0QM0N
DRUGNAME	BILD-733
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Terminated
	
TTDDRUID	D0QM1T
DRUGNAME	Finazosin
INDICATI	Prostate hyperplasia [ICD-11: GA90] Phase 3
	
TTDDRUID	D0QM2O
DRUGNAME	PMID26651364-Compound-5f
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0QM3Q
DRUGNAME	EP-102
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0QM4O
DRUGNAME	UV1 vaccine
INDICATI	Metastatic melanoma [ICD-11: 2E2Z] Phase 2
	
TTDDRUID	D0QM4U
DRUGNAME	Isoarnebin 4
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0QM6Y
DRUGNAME	IkT-004
INDICATI	Polyomavirus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D0QM9P
DRUGNAME	INfluenza A virus H5N8 vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0QN3Q
DRUGNAME	LNA anti-miR-155
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative
	
TTDDRUID	D0QN5M
DRUGNAME	LAM-001
INDICATI	Lymphangioleiomyomatosis [ICD-11: CB07] Phase 1
	
TTDDRUID	D0QN6U
DRUGNAME	L-790070
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0QN9U
DRUGNAME	GS-156 mab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0QNS3
DRUGNAME	REL-1017
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 3
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D0QO0D
DRUGNAME	H5N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0QO6N
DRUGNAME	MGD010
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
	
TTDDRUID	D0QO7H
DRUGNAME	Dithranol
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Approved
	
TTDDRUID	D0QP1X
DRUGNAME	HIV vaccine Ad4-mGag
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0QP4N
DRUGNAME	PMID25666693-Compound-81
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0QP8X
DRUGNAME	ONO-7579
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0QP9A
DRUGNAME	KI-1001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0QQ0W
DRUGNAME	Selicrelumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0QQ1J
DRUGNAME	BITHIONOL
INDICATI	Trematode infection [ICD-11: 1F8Y] Withdrawn from market
	
TTDDRUID	D0QQ5W
DRUGNAME	Beta-cyclodextrin conjugate derivative 2
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0QQ6Q
DRUGNAME	Enprostil
INDICATI	Ulcer [ICD-11: CA02-CB40] Approved
	
TTDDRUID	D0QQ7D
DRUGNAME	Tazobactam
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0QQ7I
DRUGNAME	BAY1834845
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0QQ7N
DRUGNAME	TH-9229
INDICATI	Reperfusion injury [ICD-11: ND56.Z] Terminated
	
TTDDRUID	D0QR0E
DRUGNAME	Resorcinol compound 27
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0QR2K
DRUGNAME	NKR-2 cells
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0QR3J
DRUGNAME	GC-2107
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D0QR3X
DRUGNAME	Edasalonexent
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3
	
TTDDRUID	D0QR4F
DRUGNAME	Sirolimus
INDICATI	Uveitis [ICD-11: 9A96.Z] Phase 3
	
TTDDRUID	D0QR4H
DRUGNAME	D-21151
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0QR5G
DRUGNAME	5-methoxypsoralen
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
	
TTDDRUID	D0QR8B
DRUGNAME	STP-432
INDICATI	Crohn disease [ICD-11: DD70] Investigative
	
TTDDRUID	D0QS1U
DRUGNAME	Dihydralazine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0QS6G
DRUGNAME	Prevecon
INDICATI	Contraception [ICD-11: QA21] Preclinical
	
TTDDRUID	D0QT8L
DRUGNAME	PMID28270021-Compound-WO2014129431Example8-1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0QT9B
DRUGNAME	LPCN-1002
INDICATI	Testosterone deficiency [ICD-11: 5A81.1] Investigative
	
TTDDRUID	D0QU0H
DRUGNAME	OMS721
INDICATI	Atypical hemolytic uremic syndrome [ICD-11: 3A10.Y] Phase 3
INDICATI	Thrombotic microangiopathy [ICD-11: 3B65] Phase 2
INDICATI	Glomerulonephritis [ICD-11: 5D00.Y] Phase 2
INDICATI	Lupus [ICD-11: 4A40] Phase 2
	
TTDDRUID	D0QU3G
DRUGNAME	Diamine derivative 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0QU6N
DRUGNAME	PMID26651364-Compound-47
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0QU8H
DRUGNAME	(S)-amisulpride
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 4
	
TTDDRUID	D0QU8I
DRUGNAME	PF-06482077
INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 3
	
TTDDRUID	D0QV1E
DRUGNAME	Thiazole carboxamide derivative 28
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0QV3O
DRUGNAME	OCID-4681
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0QV4A
DRUGNAME	NI-0501
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 2
INDICATI	Primary haemophagocytic lymphohistiocytosis [ICD-11: 4A01.23] Phase 2
	
TTDDRUID	D0QV5T
DRUGNAME	Phenprocoumon
INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved
	
TTDDRUID	D0QV9Q
DRUGNAME	CART22 cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0QW0E
DRUGNAME	HBV infection vaccine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D0QW1V
DRUGNAME	MAD-001
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Investigative
	
TTDDRUID	D0QW7D
DRUGNAME	DK-507k
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D0QW9H
DRUGNAME	Imiglucerase
INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Approved
	
TTDDRUID	D0QX0H
DRUGNAME	GTx-134
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0QX0K
DRUGNAME	FT-105
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D0QX8X
DRUGNAME	M2951
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D0QX9K
DRUGNAME	AMG 986
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D0QX9U
DRUGNAME	BN-GU-005-DHP
INDICATI	Arthralgia [ICD-11: ME82] Preclinical
	
TTDDRUID	D0QY1M
DRUGNAME	GS-5806
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D0QY4L
DRUGNAME	Nitroimidazole
INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative
	
TTDDRUID	D0QZ1Z
DRUGNAME	PVS-10200
INDICATI	Artery stenosis [ICD-11: BD52] Phase 1/2
	
TTDDRUID	D0QZ3P
DRUGNAME	QAL964
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0QZ4S
DRUGNAME	LEMINOPRAZOLE
INDICATI	Ulcerative colitis [ICD-11: DD71] Discontinued in Preregistration
	
TTDDRUID	D0QZ7V
DRUGNAME	RXI-SCP
INDICATI	Cutaneous wart [ICD-11: 1E80] Phase 2
	
TTDDRUID	D0QZ9D
DRUGNAME	GRNIC-1
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0R0AO
DRUGNAME	MOR-205
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0R0BI
DRUGNAME	CT-1
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0R0BJ
DRUGNAME	Cirrhosis
INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative
	
TTDDRUID	D0R0BX
DRUGNAME	Nitrofurantoin
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D0R0EF
DRUGNAME	AZD-7268
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0R0EV
DRUGNAME	E-6123
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0R0FE
DRUGNAME	Verapamil
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0R0FO
DRUGNAME	Lenvatinib
INDICATI	Thyroid cancer [ICD-11: 2D10] Approved
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Application submitted
	
TTDDRUID	D0R0FU
DRUGNAME	PXS-4159
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0R0GK
DRUGNAME	NU300
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0R0HY
DRUGNAME	IONIS-DMPK-2.5RX
INDICATI	Myotonic dystrophy [ICD-11: 8C71.0] Phase 2
	
TTDDRUID	D0R0JN
DRUGNAME	PRAX-330
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
	
TTDDRUID	D0R0LB
DRUGNAME	PF-06747775
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0R0MB
DRUGNAME	Ropeginterferon alfa-2b
INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 3
	
TTDDRUID	D0R0ME
DRUGNAME	IDP-204040
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0R0MM
DRUGNAME	Anti-GP88 mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0R0MW
DRUGNAME	Sunitinib
INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Approved
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Approved
	
TTDDRUID	D0R0NX
DRUGNAME	AU-011
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
	
TTDDRUID	D0R0OC
DRUGNAME	U-104067F
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1
	
TTDDRUID	D0R0PC
DRUGNAME	HM 401
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D0R0RW
DRUGNAME	1D05
INDICATI	Coronary artery disease [ICD-11: BA80] Investigative
	
TTDDRUID	D0R0SJ
DRUGNAME	PMID25684022-Compound-WO2012135799 43(1.5)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0R0SP
DRUGNAME	LIPO-5
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0R0TF
DRUGNAME	BN50727
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
	
TTDDRUID	D0R0TS
DRUGNAME	MK-1439
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0R0UJ
DRUGNAME	Pargyline
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
INDICATI	Skin imperfections [ICD-11: EK71] Patented
INDICATI	Muscular dystrophy [ICD-11: 8C70] Patented
	
TTDDRUID	D0R0UW
DRUGNAME	INKP-102
INDICATI	Gastrointestinal infection [ICD-11: 1A40.Z] Investigative
	
TTDDRUID	D0R0WZ
DRUGNAME	KX01 + paclitaxel
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0R0YW
DRUGNAME	HM-5016504
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0R0ZL
DRUGNAME	Clindamycin
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D0R0ZP
DRUGNAME	VXA-RSV-f
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1
	
TTDDRUID	D0R1BA
DRUGNAME	CAR-T cells targeting Muc1
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
	
TTDDRUID	D0R1BD
DRUGNAME	Penicillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0R1CG
DRUGNAME	ASG-22ME
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0R1CR
DRUGNAME	L-Phenylalanine
INDICATI	Malnutrition [ICD-11: 5B50-5B71] Approved
	
TTDDRUID	D0R1DH
DRUGNAME	Oxybutynin hydrochloride
INDICATI	Urinary incontinence [ICD-11: MF50.2] Approved
	
TTDDRUID	D0R1DP
DRUGNAME	A-74283
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0R1DX
DRUGNAME	Adiponectin mimetics
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0R1GD
DRUGNAME	Aryl mannoside derivative 16
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0R1GJ
DRUGNAME	Casimersen
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Approved
	
TTDDRUID	D0R1HK
DRUGNAME	T-9001
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0R1JB
DRUGNAME	Acellular pertussis vaccine
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D0R1JI
DRUGNAME	Rottlerin
INDICATI	Parkinson disease [ICD-11: 8A00.0] Preclinical
	
TTDDRUID	D0R1JO
DRUGNAME	SHP607
INDICATI	Retinopathy [ICD-11: 9B71] Phase 2
	
TTDDRUID	D0R1JV
DRUGNAME	Ziprasidone
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0R1LT
DRUGNAME	E047/1
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2
	
TTDDRUID	D0R1PX
DRUGNAME	Pyrano[2,3-b]pyridine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0R1PZ
DRUGNAME	F-15063
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0R1QE
DRUGNAME	Ibuprofen
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0R1QH
DRUGNAME	99mTc-tropantiol
INDICATI	Brain disease [ICD-11: 8C70-8E61] Phase 2/3
	
TTDDRUID	D0R1QJ
DRUGNAME	D-22888
INDICATI	Allergy [ICD-11: 4A80-4A85] Terminated
	
TTDDRUID	D0R1QX
DRUGNAME	EC-708
INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated
	
TTDDRUID	D0R1RK
DRUGNAME	EpiCept
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0R1RQ
DRUGNAME	BJ-B11
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D0R1RS
DRUGNAME	Indomethacin
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0R1RV
DRUGNAME	ZP-008
INDICATI	Pharyngitis [ICD-11: CA02.Z] Investigative
	
TTDDRUID	D0R1SQ
DRUGNAME	Biaryl mannoside derivative 1
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0R1UE
DRUGNAME	CLR325
INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 2
	
TTDDRUID	D0R1VL
DRUGNAME	BIBN-99
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0R1VR
DRUGNAME	Fluphenazine
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0R1VU
DRUGNAME	Perifosine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0R1WQ
DRUGNAME	Thallous Chloride Tl-201
INDICATI	Diagnostic radiopharmaceutical [ICD-11: N.A.] Approved
	
TTDDRUID	D0R1WR
DRUGNAME	Procyclidine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0R1XF
DRUGNAME	212Pb-TCMC-trastuzumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0R1XI
DRUGNAME	TRK-851
INDICATI	Cough [ICD-11: MD12] Discontinued in Phase 1
	
TTDDRUID	D0R1YJ
DRUGNAME	HCGRP8-37
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0R1YL
DRUGNAME	NGX-267
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0R2CI
DRUGNAME	GI-264879A
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0R2CM
DRUGNAME	TA-383
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0R2CZ
DRUGNAME	Rsv Immune Globulin
INDICATI	Bronchopulmonary dysplasia [ICD-11: KB29.0] Approved
	
TTDDRUID	D0R2EY
DRUGNAME	SKF-97574
INDICATI	Peptic ulcer [ICD-11: DA61] Discontinued in Phase 1
	
TTDDRUID	D0R2GA
DRUGNAME	Biaryl mannoside derivative 29
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0R2GU
DRUGNAME	XRX-001
INDICATI	Yellow fever virus infection [ICD-11: 1D47] Phase 1
	
TTDDRUID	D0R2HZ
DRUGNAME	ETHOXY-IDAZOXAN
INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative
	
TTDDRUID	D0R2JS
DRUGNAME	Droloxifene
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D0R2KF
DRUGNAME	Epervudine
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D0R2KJ
DRUGNAME	Dicloxacillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0R2KO
DRUGNAME	CAF-01
INDICATI	Vaccination [ICD-11: N.A.] Phase 1
	
TTDDRUID	D0R2KR
DRUGNAME	Human Cytomegalovirus vaccine
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated
	
TTDDRUID	D0R2KV
DRUGNAME	CP-316,311
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D0R2KY
DRUGNAME	Ethynodiol Diacetate
INDICATI	Contraception [ICD-11: QA21] Approved
	
TTDDRUID	D0R2LR
DRUGNAME	GR-108359
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D0R2LY
DRUGNAME	Multipeptide vaccine combination
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0R2MG
DRUGNAME	HB-1275
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Investigative
	
TTDDRUID	D0R2MQ
DRUGNAME	BW-858C
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0R2NE
DRUGNAME	Entacapone+levodopa+carbidopa
INDICATI	Restless legs syndrome [ICD-11: 7A80] Phase 3
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D0R2OA
DRUGNAME	Ipriflavone
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D0R2OU
DRUGNAME	Irdabisant
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
	
TTDDRUID	D0R2PR
DRUGNAME	Zn-DPA-P
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0R2QB
DRUGNAME	MT-7716
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Discontinued in Phase 1
	
TTDDRUID	D0R2QG
DRUGNAME	TMI-358
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2
	
TTDDRUID	D0R2QV
DRUGNAME	PMID25666693-Compound-122
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0R2RR
DRUGNAME	Typhoid vaccine
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Approved
	
TTDDRUID	D0R2RV
DRUGNAME	Anti-EGFR humanized mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0R2SK
DRUGNAME	Erteberel
INDICATI	Prostate hyperplasia [ICD-11: GA90] Phase 2
	
TTDDRUID	D0R2SW
DRUGNAME	FSA2
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Preclinical
	
TTDDRUID	D0R2VB
DRUGNAME	PMID25666693-Compound-106
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0R2WK
DRUGNAME	NVP-TAE684
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative
	
TTDDRUID	D0R2YD
DRUGNAME	Lm Melanoma
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0R3BC
DRUGNAME	153Sm-EDTMP
INDICATI	Bone metastases [ICD-11: 2D50] Approved
	
TTDDRUID	D0R3BV
DRUGNAME	Inotersen
INDICATI	Hereditary amyloidosis [ICD-11: 5D00.2] Approved
	
TTDDRUID	D0R3DQ
DRUGNAME	SYL-040003
INDICATI	Ocular hypertension [ICD-11: 9C61.01] Investigative
	
TTDDRUID	D0R3DT
DRUGNAME	AT-006
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0R3EL
DRUGNAME	GSK184072
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Discontinued in Phase 2
INDICATI	Colon cancer [ICD-11: 2B90.Z] Discontinued in Phase 2
	
TTDDRUID	D0R3FP
DRUGNAME	Tenofovir disoproxil fumarate
INDICATI	Discovery agent [ICD-11: N.A.] Approved
	
TTDDRUID	D0R3GE
DRUGNAME	ANG-2010
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0R3HX
DRUGNAME	RB-6145
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0R3IG
DRUGNAME	SJCAR19
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
	
TTDDRUID	D0R3IK
DRUGNAME	EPI-0030
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0R3JB
DRUGNAME	Mitoxantrone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0R3JE
DRUGNAME	GS-2992
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0R3JO
DRUGNAME	PEG-EPO
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0R3KL
DRUGNAME	RRV-TV rotavirus vaccine
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0R3KN
DRUGNAME	MN-462
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D0R3KS
DRUGNAME	DX-2500
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative
	
TTDDRUID	D0R3LH
DRUGNAME	UMN-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0R3LQ
DRUGNAME	EXC 001
INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 2
	
TTDDRUID	D0R3MA
DRUGNAME	Recombinant mab-biocide fusion proteins
INDICATI	Cryptosporidium infection [ICD-11: 1A32] Investigative
	
TTDDRUID	D0R3ML
DRUGNAME	PC-213
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0R3MT
DRUGNAME	Acadesine
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
	
TTDDRUID	D0R3NR
DRUGNAME	GATA-3-specific DNAzyme
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0R3OQ
DRUGNAME	BNV-222
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Investigative
	
TTDDRUID	D0R3OR
DRUGNAME	SR-27950
INDICATI	Eating disorder [ICD-11: 6B82] Terminated
	
TTDDRUID	D0R3PY
DRUGNAME	Tafasitamab
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
	
TTDDRUID	D0R3QY
DRUGNAME	Vigabatrin
INDICATI	Complex partial seizure [ICD-11: 8A68.0] Approved
INDICATI	Infantile spasm [ICD-11: 8A62.0] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D0R3RG
DRUGNAME	GZ402663
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
	
TTDDRUID	D0R3RO
DRUGNAME	AZD-5455
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D0R3SI
DRUGNAME	NNC-09-0026
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0R3VG
DRUGNAME	Thiazole carboxamide derivative 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0R3VK
DRUGNAME	GDC-0623
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0R3VQ
DRUGNAME	BAL-27862
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0R3WG
DRUGNAME	SILPERISONE HYDROCHLORIDE
INDICATI	Spasm [ICD-11: MB47.3] Discontinued in Phase 2
	
TTDDRUID	D0R3XI
DRUGNAME	CDRI-97/78
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	D0R3YO
DRUGNAME	HKT288
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0R3YT
DRUGNAME	LPCN-1090
INDICATI	Cough [ICD-11: MD12] Investigative
	
TTDDRUID	D0R3ZE
DRUGNAME	MEDI-551
INDICATI	Encephalopathy [ICD-11: 8E47] Phase 2
INDICATI	Neuromyelitis optica [ICD-11: 8A43] Phase 2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	D0R4AE
DRUGNAME	MT-7117
INDICATI	Erythropoietic porphyrias [ICD-11: 5C58.12] Phase 2
	
TTDDRUID	D0R4DN
DRUGNAME	NTC-121
INDICATI	Glioma [ICD-11: 2A00.0] Discontinued in Phase 2
	
TTDDRUID	D0R4DP
DRUGNAME	Clotiazepam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0R4EN
DRUGNAME	LXR 623
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1
	
TTDDRUID	D0R4EY
DRUGNAME	Boscalid
INDICATI	Plant grey mould disease [ICD-11: N.A.] Investigative
	
TTDDRUID	D0R4GM
DRUGNAME	MDX-33
INDICATI	Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 2
	
TTDDRUID	D0R4HQ
DRUGNAME	Corticotropin
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Approved
INDICATI	Cushing disease [ICD-11: 5A70] Approved
	
TTDDRUID	D0R4IZ
DRUGNAME	Timothy grass pollen extracts
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1
	
TTDDRUID	D0R4KK
DRUGNAME	verubecestat
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0R4ML
DRUGNAME	P1A
INDICATI	Toxicity [ICD-11: N.A.] Discontinued in Phase 2
	
TTDDRUID	D0R4MT
DRUGNAME	Gemcabene
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2
	
TTDDRUID	D0R4NJ
DRUGNAME	DW-908
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0R4NR
DRUGNAME	Prednisone/ dipyridamole
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0R4NY
DRUGNAME	DTaP-IPV
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D0R4OD
DRUGNAME	Anti-IFN gamma
INDICATI	Alopecia [ICD-11: ED70] Terminated
	
TTDDRUID	D0R4OI
DRUGNAME	K-103-IP
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
	
TTDDRUID	D0R4OM
DRUGNAME	Trifluoperazine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0R4PW
DRUGNAME	Zalutumumab
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
	
TTDDRUID	D0R4RL
DRUGNAME	MYO-102
INDICATI	Limb girdle muscular dystrophy [ICD-11: 8C70.4] Phase 1/2
	
TTDDRUID	D0R4SE
DRUGNAME	FX-87L
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0R4UA
DRUGNAME	Hu3F8 mAb
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2
INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 2
	
TTDDRUID	D0R4UW
DRUGNAME	Roflumilast
INDICATI	Asthma [ICD-11: CA23] Approved
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Withdrawn from market
INDICATI	Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 2
	
TTDDRUID	D0R4WT
DRUGNAME	NB-325
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0R4YQ
DRUGNAME	CB-813
INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 1
	
TTDDRUID	D0R4ZT
DRUGNAME	Gallium nitrate
INDICATI	Hypercalcaemia [ICD-11: 5B91.0] Approved
	
TTDDRUID	D0R5AU
DRUGNAME	LASINAVIR
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0R5ER
DRUGNAME	BPX-01
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0R5GF
DRUGNAME	MRKAd5/ALVAC
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0R5GS
DRUGNAME	Gepirone
INDICATI	Depression [ICD-11: 6A70-6A7Z] Terminated
	
TTDDRUID	D0R5HA
DRUGNAME	Tobacco plant-derived anti-idiotype vaccine
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0R5HH
DRUGNAME	ACE-083
INDICATI	Charcot marie tooth disease [ICD-11: 8C21.Z] Phase 2
INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D0R5IS
DRUGNAME	Flufenoxina
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D0R5JL
DRUGNAME	Polio IPV
INDICATI	Poliovirus infection [ICD-11: 1C8Y] Approved
	
TTDDRUID	D0R5JP
DRUGNAME	Pleuromutilins
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0R5LL
DRUGNAME	Cancer vaccine
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 2
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0R5NB
DRUGNAME	4SC-302
INDICATI	Flavivirus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D0R5NU
DRUGNAME	CART123 cells
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0R5OS
DRUGNAME	Apalcillin sodium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0R5PP
DRUGNAME	PRS-190
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0R5QQ
DRUGNAME	AVE-8134
INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2
	
TTDDRUID	D0R5RR
DRUGNAME	Clofarabine
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Approved
	
TTDDRUID	D0R5TT
DRUGNAME	FR-123826
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0R5TV
DRUGNAME	HD-0801
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2/3
	
TTDDRUID	D0R5TZ
DRUGNAME	SIM-071201
INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Investigative
	
TTDDRUID	D0R5UR
DRUGNAME	ALL-4
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0R5UZ
DRUGNAME	Caracemide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0R5VO
DRUGNAME	Avicin D
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0R5XK
DRUGNAME	ONO-1714
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1
	
TTDDRUID	D0R5XL
DRUGNAME	CAPTAT-414
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative
	
TTDDRUID	D0R5ZJ
DRUGNAME	SU-740
INDICATI	Stomach ulcer [ICD-11: DA60.Z] Terminated
	
TTDDRUID	D0R6AB
DRUGNAME	Droxicam
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market
	
TTDDRUID	D0R6AI
DRUGNAME	TPX-100
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
	
TTDDRUID	D0R6BI
DRUGNAME	Fenoldopam
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0R6BR
DRUGNAME	Amobarbital
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0R6CD
DRUGNAME	Insulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0R6EC
DRUGNAME	BC-7013
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2
	
TTDDRUID	D0R6EL
DRUGNAME	ETC-1001
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1
	
TTDDRUID	D0R6EQ
DRUGNAME	Bivatuzumab mertansine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0R6FO
DRUGNAME	Aryl mannoside derivative 10
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0R6GB
DRUGNAME	AG-SFT103
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0R6HN
DRUGNAME	Strontium Chloride Sr-89
INDICATI	Cancer related pain [ICD-11: MG30] Approved
	
TTDDRUID	D0R6IF
DRUGNAME	EF-4
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Preregistration
	
TTDDRUID	D0R6IM
DRUGNAME	Empagliflozin/metformin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Registered
	
TTDDRUID	D0R6JV
DRUGNAME	CX-1739
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	D0R6MH
DRUGNAME	Cadrofloxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0R6MJ
DRUGNAME	MORAb-009
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
	
TTDDRUID	D0R6OD
DRUGNAME	AnergiX-IDDM
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D0R6OM
DRUGNAME	ACTB-1003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0R6RB
DRUGNAME	PSD-597
INDICATI	Interstitial cystitis [ICD-11: GC00.3] Discontinued in Phase 2
	
TTDDRUID	D0R6RC
DRUGNAME	Chlortetracycline
INDICATI	Pseudomonas infection [ICD-11: 1B92] Approved
	
TTDDRUID	D0R6RE
DRUGNAME	Esterified estrogens
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0R6RM
DRUGNAME	CP-118
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2
	
TTDDRUID	D0R6RO
DRUGNAME	Mianserin
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0R6TI
DRUGNAME	Inamrinone Lactate
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0R6TY
DRUGNAME	Noribogaine
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2
	
TTDDRUID	D0R6UR
DRUGNAME	ACI-24
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D0R6UV
DRUGNAME	BMS-690514
INDICATI	Chronic pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D0R6VH
DRUGNAME	HI-1640V
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0R6VV
DRUGNAME	INO-5150
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0R6WL
DRUGNAME	TAu mAb
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0R6YZ
DRUGNAME	Xultophy
INDICATI	Type-2 diabetes [ICD-11: 5A11] Application submitted
	
TTDDRUID	D0R6ZB
DRUGNAME	EDP-10
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0R7AK
DRUGNAME	CP-601927
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 2
	
TTDDRUID	D0R7BB
DRUGNAME	GSK3359609
INDICATI	Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 2/3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0R7CD
DRUGNAME	INCB59872
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D0R7CP
DRUGNAME	Bromo benzyl ether derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0R7DW
DRUGNAME	Thiomarinols
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0R7EA
DRUGNAME	methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate
INDICATI	Alzheimer disease [ICD-11: 8A20] Clinical trial
	
TTDDRUID	D0R7EQ
DRUGNAME	Crenezumab
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0R7FS
DRUGNAME	BPI-704001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0R7GH
DRUGNAME	CS-526
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1
	
TTDDRUID	D0R7GL
DRUGNAME	BW-A502U
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0R7HL
DRUGNAME	LXS196
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0R7HO
DRUGNAME	Bumetanide
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0R7ID
DRUGNAME	HMN-214
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 1
	
TTDDRUID	D0R7IU
DRUGNAME	NPSP-795
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D0R7JT
DRUGNAME	Fludrocortisone
INDICATI	Cerebral salt-wasting syndrome [ICD-11: 5C72] Approved
	
TTDDRUID	D0R7JW
DRUGNAME	Macrocycle derivative 4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0R7KX
DRUGNAME	Rotarix
INDICATI	Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Approved
	
TTDDRUID	D0R7LD
DRUGNAME	Sotorasib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D0R7LX
DRUGNAME	EU-C-002
INDICATI	Reperfusion injury [ICD-11: ND56.Z] Investigative
	
TTDDRUID	D0R7NI
DRUGNAME	Tagraxofusp
INDICATI	Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Approved
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
	
TTDDRUID	D0R7NP
DRUGNAME	INP-04
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0R7OZ
DRUGNAME	BGC-20-0166
INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Discontinued in Phase 2
	
TTDDRUID	D0R7QW
DRUGNAME	SR-2566
INDICATI	Eczema [ICD-11: EA80-EA89] Terminated
	
TTDDRUID	D0R7UK
DRUGNAME	UR-8308
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0R7UL
DRUGNAME	MD1003
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
	
TTDDRUID	D0R7US
DRUGNAME	Interferon gamma-1a
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0R7WU
DRUGNAME	ACECLIDINE
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D0R7XD
DRUGNAME	GSK1325756
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0R7YH
DRUGNAME	SQZ-PBMC-HPV
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0R7YI
DRUGNAME	PMID30107136-Compound-Example13
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0R7YN
DRUGNAME	Mannoside derivative 3
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0R7YY
DRUGNAME	Darusentan
INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 3
	
TTDDRUID	D0R8AG
DRUGNAME	Prophage cancer vaccine
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0R8CE
DRUGNAME	M-114
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2
	
TTDDRUID	D0R8CN
DRUGNAME	Glycolipids
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0R8ER
DRUGNAME	Enoxacin
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D0R8EW
DRUGNAME	SL-017
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 1
	
TTDDRUID	D0R8FL
DRUGNAME	Egalet-002
INDICATI	Chronic pain [ICD-11: MG30] Phase 3
	
TTDDRUID	D0R8FM
DRUGNAME	Ebrotidine
INDICATI	Duodenal ulcer [ICD-11: DA63] Withdrawn from market
	
TTDDRUID	D0R8GA
DRUGNAME	PMID25666693-Compound-14
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0R8GR
DRUGNAME	OPC-14523
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2
INDICATI	Bulimia nervosa [ICD-11: 6B81] Phase 2
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 1
	
TTDDRUID	D0R8HY
DRUGNAME	DCCCyB
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0R8ID
DRUGNAME	P-7170
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0R8IE
DRUGNAME	Inecalcitol oral
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0R8IU
DRUGNAME	AZD-4017
INDICATI	Ocular hypertension [ICD-11: 9C61.01] Phase 2
	
TTDDRUID	D0R8JN
DRUGNAME	AF-3485
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0R8KF
DRUGNAME	STP-322
INDICATI	Liver cancer [ICD-11: 2C12] Investigative
	
TTDDRUID	D0R8LQ
DRUGNAME	AQST-203
INDICATI	Acute repetitive seizure [ICD-11: 8A67] Phase 3
	
TTDDRUID	D0R8LV
DRUGNAME	NI-0401
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	D0R8LW
DRUGNAME	ORG-34167
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1
	
TTDDRUID	D0R8PE
DRUGNAME	Pivagabine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1
	
TTDDRUID	D0R8PX
DRUGNAME	Vasicine
INDICATI	Postpartum haemorrhage [ICD-11: JA43] Approved
	
TTDDRUID	D0R8QG
DRUGNAME	Tepotinib
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Approved
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0R8QX
DRUGNAME	HMGB-1 protein and its fragments
INDICATI	Bone disease [ICD-11: FC0Z] Phase 3
	
TTDDRUID	D0R8RK
DRUGNAME	Ro-25-0534
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0R8RO
DRUGNAME	SAR-21609
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0R8SY
DRUGNAME	Limtop
INDICATI	Keratosis [ICD-11: ED56] Phase 2
	
TTDDRUID	D0R8TB
DRUGNAME	ERA-923
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D0R8VU
DRUGNAME	MyeloXen
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0R8WT
DRUGNAME	Tocilizumab
INDICATI	Giant cell arteritis [ICD-11: 4A44.2] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0R8YO
DRUGNAME	CEDO-8956
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0R9BG
DRUGNAME	Acetohydroxamic Acid
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D0R9DP
DRUGNAME	CEM-102
INDICATI	Joint infection [ICD-11: FA10] Phase 2/3
	
TTDDRUID	D0R9DX
DRUGNAME	GsMTx4
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative
	
TTDDRUID	D0R9EQ
DRUGNAME	Ropinirole
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0R9FM
DRUGNAME	SentoClone
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0R9GF
DRUGNAME	GALGT2 gene therapy
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2
	
TTDDRUID	D0R9HE
DRUGNAME	BI 113823
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
	
TTDDRUID	D0R9HI
DRUGNAME	SB-742457
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0R9HL
DRUGNAME	Vildagliptin/metformin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0R9IH
DRUGNAME	SAR-339658
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
	
TTDDRUID	D0R9IL
DRUGNAME	CK-2066260
INDICATI	Neuromuscular disease [ICD-11: 8C6Y] Investigative
	
TTDDRUID	D0R9IU
DRUGNAME	PRT-062607
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	D0R9JC
DRUGNAME	H5N1 influenza mab therapy
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0R9KG
DRUGNAME	Temanogrel
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D0R9MN
DRUGNAME	Danoprevir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0R9NB
DRUGNAME	Lprivask
INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved
	
TTDDRUID	D0R9NQ
DRUGNAME	Bi-51013
INDICATI	Transplant rejection [ICD-11: NE84] Terminated
	
TTDDRUID	D0R9OH
DRUGNAME	Sulfamethoxazole
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
INDICATI	Infection of P. falciparum [ICD-11: 1F40] Investigative
	
TTDDRUID	D0R9ON
DRUGNAME	MR-889
INDICATI	Phlegmy cough [ICD-11: SA80-SA8Z] Discontinued in Phase 3
	
TTDDRUID	D0R9PD
DRUGNAME	Hydrazide derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0R9PL
DRUGNAME	RWJ-25730
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D0R9PS
DRUGNAME	Aviscumine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0R9RP
DRUGNAME	PMID25666693-Compound-32
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0R9UO
DRUGNAME	PAN-622
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0R9UQ
DRUGNAME	Long-acting Factor VII conjugate
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative
	
TTDDRUID	D0R9US
DRUGNAME	GSK2140944
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 3
INDICATI	Neisseria gonorrhoeae infection [ICD-11: 1A7Z] Phase 3
INDICATI	Acute bacterial skin infection [ICD-11: 1C41] Phase 2
	
TTDDRUID	D0R9VC
DRUGNAME	GnRH
INDICATI	Female infertility [ICD-11: GA31.Z] Phase 3
	
TTDDRUID	D0R9VR
DRUGNAME	Galantamine
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D0R9VX
DRUGNAME	DS-3078
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0R9WD
DRUGNAME	Egalet-004
INDICATI	Chronic pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D0R9WI
DRUGNAME	F-16242
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Preclinical
	
TTDDRUID	D0R9WP
DRUGNAME	Demeclocycline
INDICATI	Bronchitis [ICD-11: CA20] Approved
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
INDICATI	Lyme disease [ICD-11: 1C1G] Approved
	
TTDDRUID	D0R9XX
DRUGNAME	TG-N
INDICATI	Bone disease [ICD-11: FC0Z] Investigative
	
TTDDRUID	D0R9YR
DRUGNAME	BETULINIC ACID
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0R9ZB
DRUGNAME	Propiomazine
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0RA1R
DRUGNAME	CD19-targeting CAR T cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D0RA5E
DRUGNAME	MK-8835B
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0RA5Q
DRUGNAME	Bestatin
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
	
TTDDRUID	D0RA7L
DRUGNAME	Anti-BCMA CART Cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0RA9C
DRUGNAME	CCT301-38 (targeting ROR2)
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1/2
	
TTDDRUID	D0RA9E
DRUGNAME	Ramosetron
INDICATI	Nausea and vomiting [ICD-11: MD90] Approved
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 4
	
TTDDRUID	D0RB2H
DRUGNAME	PBI-1308
INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative
	
TTDDRUID	D0RB6L
DRUGNAME	rhACE2
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0RC0J
DRUGNAME	ABT-436
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0RC0P
DRUGNAME	EBV-targeted autologous T-cell therapy
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0RC1R
DRUGNAME	Dendritic cell-based exosome vaccine
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
	
TTDDRUID	D0RC2V
DRUGNAME	Albuvirtide
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0RC5I
DRUGNAME	Azetidine derivative 4
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0RC7L
DRUGNAME	PMID25666693-Compound-139
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0RC7R
DRUGNAME	Resorcinol compound 9
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0RD0D
DRUGNAME	BCMA CART
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0RD0Y
DRUGNAME	RetinoStat
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
	
TTDDRUID	D0RD1I
DRUGNAME	XOMA-3AB
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 1
	
TTDDRUID	D0RD1Z
DRUGNAME	Exebryl-1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0RD5W
DRUGNAME	Hyoscyamine
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved
	
TTDDRUID	D0RD6X
DRUGNAME	CLDC
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative
	
TTDDRUID	D0RE0F
DRUGNAME	Biphenyl mannoside derivative 13
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0RE0K
DRUGNAME	PF-05161704
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0RE3R
DRUGNAME	PMID25684022-Compound-US20120277229 44(1.4)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0RE4L
DRUGNAME	KX2-361
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0RE6T
DRUGNAME	Telotristat ethyl
INDICATI	Carcinoid syndrome diarrhea [ICD-11: DA90.0] Approved
INDICATI	Carcinoid syndrome [ICD-11: 5B10] Approved
	
TTDDRUID	D0RE8R
DRUGNAME	SF-101
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0RE9C
DRUGNAME	Lucerastat
INDICATI	Fabry disease [ICD-11: 5C56.01] Phase 3
	
TTDDRUID	D0RE9H
DRUGNAME	NR-LU-13
INDICATI	Colon cancer [ICD-11: 2B90.Z] Terminated
	
TTDDRUID	D0RF3F
DRUGNAME	MGCD-290
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0RF4J
DRUGNAME	CLL1 CAR-T Cell
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2/3
	
TTDDRUID	D0RF9T
DRUGNAME	Lexacalcitol
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0RG1Z
DRUGNAME	Biaryl mannoside derivative 22
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0RG3O
DRUGNAME	Atropine
INDICATI	Organophosphate poisoning [ICD-11: NE6Z] Approved
INDICATI	Poison intoxication [ICD-11: NE6Z] Phase 1
	
TTDDRUID	D0RG8Z
DRUGNAME	FPI-01
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0RG9A
DRUGNAME	Monensin sodium
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0RH0J
DRUGNAME	LAM-111
INDICATI	Muscular dystrophy [ICD-11: 8C70] Investigative
	
TTDDRUID	D0RH3S
DRUGNAME	DC/I540/KLH vaccine
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
	
TTDDRUID	D0RH6G
DRUGNAME	Heterocyclic derivative 16
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0RI4I
DRUGNAME	BioE-743
INDICATI	Leigh syndrome [ICD-11: 5C53.24] Phase 2
INDICATI	Pontocerebellar hypoplasia type 6 [ICD-11: LD20.01] Phase 2
	
TTDDRUID	D0RI6L
DRUGNAME	M-3000
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0RI6Q
DRUGNAME	Monalizumab
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0RI7N
DRUGNAME	Mesenchymal bone marrow-derived stem cell therapy
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1
	
TTDDRUID	D0RI8E
DRUGNAME	GD2-targeted CAR-T cells
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Clinical trial
	
TTDDRUID	D0RI9A
DRUGNAME	LFX453
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2
INDICATI	External genital and perianal wart [ICD-11: 1A95] Phase 2
	
TTDDRUID	D0RJ0J
DRUGNAME	M-5010
INDICATI	Arthritis [ICD-11: FA20] Discontinued in Phase 3
	
TTDDRUID	D0RJ0V
DRUGNAME	GFT14
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D0RJ1W
DRUGNAME	OX-914
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0RJ2P
DRUGNAME	BB-2983
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1
	
TTDDRUID	D0RJ2V
DRUGNAME	LMP1-CAR-T cells
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 1/2
	
TTDDRUID	D0RJ6R
DRUGNAME	Du-123015
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0RK4B
DRUGNAME	IONIS-MAPTRx
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D0RK4I
DRUGNAME	Empagliflozin + linagliptin + metformin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0RK4V
DRUGNAME	Aromatic acetylene derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0RK6W
DRUGNAME	Pyrazolo[4,3-c]pyridine derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0RK8E
DRUGNAME	NI-202
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0RK8U
DRUGNAME	JKB-122
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2
	
TTDDRUID	D0RL4M
DRUGNAME	Pranazepide
INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Discontinued in Phase 2
	
TTDDRUID	D0RL4T
DRUGNAME	Gadolinium based C60 fullerene-paclitaxel-ZME-018 conjugates
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0RL4X
DRUGNAME	AP-761
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0RL5B
DRUGNAME	VLB-01
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3
	
TTDDRUID	D0RM2O
DRUGNAME	S. sonnei-rEPA
INDICATI	Shigella infection [ICD-11: 1A02] Phase 3
	
TTDDRUID	D0RM5W
DRUGNAME	MX2/120
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0RM5Z
DRUGNAME	Sofosbuvir + velpatasvir + voxilaprevir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved
	
TTDDRUID	D0RM6A
DRUGNAME	RST-001
INDICATI	Retinopathy [ICD-11: 9B71] Phase 1/2
	
TTDDRUID	D0RM9Q
DRUGNAME	Budipine
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0RN2W
DRUGNAME	Potassium
INDICATI	Hypokalemia [ICD-11: 5C77] Approved
	
TTDDRUID	D0RN3S
DRUGNAME	GS-4997
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
	
TTDDRUID	D0RN6V
DRUGNAME	BRL-52656
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0RO0T
DRUGNAME	MKC-1313
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0RO2L
DRUGNAME	CAR-T cells targeting PSMA
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1/2
	
TTDDRUID	D0RO7R
DRUGNAME	BhCG vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0RO8H
DRUGNAME	AC-262271
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1
	
TTDDRUID	D0RP2W
DRUGNAME	Mirvetuximab soravtansine
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 1
	
TTDDRUID	D0RP4U
DRUGNAME	PMID25684022-Compound-WO2006015124
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0RP5T
DRUGNAME	RG6206
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2/3
	
TTDDRUID	D0RQ2W
DRUGNAME	Gadopentetate dimeglumine
INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0RQ5Z
DRUGNAME	Shan 6
INDICATI	Pertussis [ICD-11: 1C12] Phase 3
INDICATI	Poliomyelitis [ICD-11: 1C81] Phase 2
INDICATI	Tetanus [ICD-11: 1C13] Phase 2
INDICATI	Diphtheria [ICD-11: 1C17] Phase 2
INDICATI	Haemophilus influenza [ICD-11: 1G40] Phase 2
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
INDICATI	Poliovirus infection [ICD-11: 1C8Y] Phase 2
	
TTDDRUID	D0RR2E
DRUGNAME	IDP-122
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
	
TTDDRUID	D0RR4T
DRUGNAME	GI-270384X
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Terminated
	
TTDDRUID	D0RR8O
DRUGNAME	Pyrido[3,2-d]pyrimidine derivative 2
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0RR9O
DRUGNAME	EDP-24
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0RS0Q
DRUGNAME	Ad-VirRx 007
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0RS1Q
DRUGNAME	E-1413
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D0RS4X
DRUGNAME	PEN-866
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0RT2E
DRUGNAME	RG-83852
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0RT5T
DRUGNAME	ARANOSE
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D0RU0O
DRUGNAME	IPI-145
INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Approved
INDICATI	Follicular lymphoma [ICD-11: 2A80] Approved
INDICATI	Arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0RU5R
DRUGNAME	NEV-801
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0RU6U
DRUGNAME	Dixyrazine
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0RU7T
DRUGNAME	G-619
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0RV0O
DRUGNAME	PMID29334795-Compound-23
INDICATI	Schizophrenia [ICD-11: 6A20] Patented
	
TTDDRUID	D0RV2E
DRUGNAME	Pyrazole derivative 17
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0RV4P
DRUGNAME	Daratumumab
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
	
TTDDRUID	D0RV6F
DRUGNAME	MK-0773
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D0RV6U
DRUGNAME	ADU-623
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0RV7J
DRUGNAME	RG-7256
INDICATI	Melanoma [ICD-11: 2C30] Discontinued in Phase 1
	
TTDDRUID	D0RV8L
DRUGNAME	PAV-667
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative
	
TTDDRUID	D0RV9C
DRUGNAME	GRL-001
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0RW4F
DRUGNAME	CereCRIB
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0RW5O
DRUGNAME	DPX-0907
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0RW9P
DRUGNAME	HiviCides I and II
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0RX3C
DRUGNAME	Piritramide
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0RX6F
DRUGNAME	CLR-131
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0RX7Z
DRUGNAME	DEOXYCYTIDINE
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
	
TTDDRUID	D0RY4N
DRUGNAME	Human and mouse PSMA DNA vaccines
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0RY6M
DRUGNAME	Heterocyclic-carboxamide derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0RZ0N
DRUGNAME	FR-62765
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D0RZ5E
DRUGNAME	Biphenyl mannoside derivative 17
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0RZ9V
DRUGNAME	IDH305
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0S0AF
DRUGNAME	Bunazosin
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D0S0AS
DRUGNAME	Ipratropium
INDICATI	Obstructive lung disease [ICD-11: CA22.Z] Approved
	
TTDDRUID	D0S0BJ
DRUGNAME	IMCgp100
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Cutaneous melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0S0CW
DRUGNAME	AcALY-18
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0S0DU
DRUGNAME	KSB-303
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1/2
	
TTDDRUID	D0S0DY
DRUGNAME	OP-04
INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative
	
TTDDRUID	D0S0EQ
DRUGNAME	AZD-0865
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 2
	
TTDDRUID	D0S0ES
DRUGNAME	Imidapril
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0S0FD
DRUGNAME	E2027
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
INDICATI	Lewy body dementia [ICD-11: 6D82] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0S0FZ
DRUGNAME	Carisbamate
INDICATI	Seizure disorder [ICD-11: 8A6Z] Phase 3
INDICATI	Focal dystonia [ICD-11: 8A02.1] Phase 3
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3
	
TTDDRUID	D0S0GM
DRUGNAME	ADX-10061
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2
	
TTDDRUID	D0S0GO
DRUGNAME	DLYE-5953A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0S0HA
DRUGNAME	O6-Benzylguanine alkylade
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 3
	
TTDDRUID	D0S0II
DRUGNAME	Pyrrolo[2,3-d]pyrimidine derivative 3
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0S0IW
DRUGNAME	PJ-3505
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0S0KP
DRUGNAME	CVX-045
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0S0LD
DRUGNAME	DTwP-HBV vaccine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
	
TTDDRUID	D0S0LZ
DRUGNAME	Doxycycline
INDICATI	Chronic periodontitis [ICD-11: DA0C.Y] Approved
INDICATI	Advanced gum disease [ICD-11: DA0D] Approved
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
	
TTDDRUID	D0S0MP
DRUGNAME	SGN-30
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0S0MR
DRUGNAME	NVB-333
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Preclinical
	
TTDDRUID	D0S0NK
DRUGNAME	Neoandrographolide
INDICATI	Bacillary dysentery [ICD-11: 1A02] Approved
	
TTDDRUID	D0S0NX
DRUGNAME	Peginterferon beta
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0S0OF
DRUGNAME	Macrocyclic peptide analog 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0S0OI
DRUGNAME	ATEVIRDINE
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0S0RE
DRUGNAME	HuMax-CD74
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0S0RS
DRUGNAME	MK-8245
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0S0RX
DRUGNAME	ATGC-OP0359
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0S0SE
DRUGNAME	Rupintrivir
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2
	
TTDDRUID	D0S0ST
DRUGNAME	NPS-31807
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 4
	
TTDDRUID	D0S0TR
DRUGNAME	NeurTriptin
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0S0VR
DRUGNAME	PF-5230894
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2
	
TTDDRUID	D0S0VZ
DRUGNAME	IDRA-21
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0S0WN
DRUGNAME	Biomed 101
INDICATI	Kidney cancer [ICD-11: 2C90.0] Phase 1
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Discontinued in Phase 1
	
TTDDRUID	D0S0WR
DRUGNAME	Luspatercept
INDICATI	Anaemia [ICD-11: 3A90] Approved
INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 3
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
	
TTDDRUID	D0S0XS
DRUGNAME	SR-271425
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0S0ZQ
DRUGNAME	Vesimune
INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
	
TTDDRUID	D0S1AD
DRUGNAME	Tridolgosir
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0S1BF
DRUGNAME	AD02 vaccine
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0S1BN
DRUGNAME	Iptakalim
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 1
	
TTDDRUID	D0S1CR
DRUGNAME	Anti-CD123-CAR-transduced T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D0S1FM
DRUGNAME	G3139 + Paclitaxel
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Investigative
	
TTDDRUID	D0S1HE
DRUGNAME	Rhenium-186 etidronate
INDICATI	Bone metastases [ICD-11: 2D50] Approved
	
TTDDRUID	D0S1HI
DRUGNAME	Azoles
INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Investigative
	
TTDDRUID	D0S1HX
DRUGNAME	TAS-203
INDICATI	Respiratory tract inflammation [ICD-11: CA07] Investigative
	
TTDDRUID	D0S1JV
DRUGNAME	AM-260
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D0S1KP
DRUGNAME	PT003
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D0S1KR
DRUGNAME	RVT-103+RVT-104
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0S1LE
DRUGNAME	Lintuzumab Bi-213
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 1/2
	
TTDDRUID	D0S1NZ
DRUGNAME	Acipimox
INDICATI	Arteriosclerosis [ICD-11: BD40] Approved
	
TTDDRUID	D0S1OE
DRUGNAME	Chlormezanone
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0S1PM
DRUGNAME	RBx-2258
INDICATI	Prostate hyperplasia [ICD-11: GA90] Discontinued in Phase 2
	
TTDDRUID	D0S1QN
DRUGNAME	Anti-CEA-CAR T
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0S1QY
DRUGNAME	SHP620
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 3
	
TTDDRUID	D0S1RT
DRUGNAME	UK-290795
INDICATI	Urinary incontinence [ICD-11: MF50.2] Terminated
	
TTDDRUID	D0S1TI
DRUGNAME	RX-5902
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0S1UW
DRUGNAME	Premarin/Trimegestone
INDICATI	Menopause symptom [ICD-11: GA30.0] Approved
	
TTDDRUID	D0S1UZ
DRUGNAME	PD-360324
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0S1WV
DRUGNAME	Enoblituzumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0S1XO
DRUGNAME	BIBX-79
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0S1XX
DRUGNAME	BMS-986165
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
	
TTDDRUID	D0S1YN
DRUGNAME	MYK-491
INDICATI	Dilated cardiomyopathy [ICD-11: BC43.0] Phase 1
	
TTDDRUID	D0S1YX
DRUGNAME	S-PRAnt
INDICATI	Uterine fibroids [ICD-11: 2E86.0] Phase 2
	
TTDDRUID	D0S1ZB
DRUGNAME	Fotemustine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0S1ZY
DRUGNAME	RSLV-125
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative
	
TTDDRUID	D0S2BL
DRUGNAME	CRTX-074
INDICATI	Cough [ICD-11: MD12] Investigative
	
TTDDRUID	D0S2BT
DRUGNAME	Potassium Aminosalicylate
INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Approved
	
TTDDRUID	D0S2BU
DRUGNAME	BA-058
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 3
	
TTDDRUID	D0S2DU
DRUGNAME	Eligen insulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0S2GT
DRUGNAME	CDP571
INDICATI	Crohn disease [ICD-11: DD70] Discontinued in Phase 3
	
TTDDRUID	D0S2HO
DRUGNAME	Perillyl alcohol
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0S2IQ
DRUGNAME	Sapropterin hydrochloride
INDICATI	Hyperphenylalaninemia [ICD-11: 5C50] Approved
	
TTDDRUID	D0S2JI
DRUGNAME	Clopamide
INDICATI	Edema [ICD-11: MG29] Approved
	
TTDDRUID	D0S2KX
DRUGNAME	PLR-15
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Terminated
	
TTDDRUID	D0S2LQ
DRUGNAME	PYY3-36
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
	
TTDDRUID	D0S2ME
DRUGNAME	Pyrazoline derivative 5
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0S2MG
DRUGNAME	Ambrisentan + tadalafil
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1
	
TTDDRUID	D0S2MQ
DRUGNAME	SD-102
INDICATI	Pneumonia [ICD-11: CA40] Investigative
	
TTDDRUID	D0S2NI
DRUGNAME	Rhpth
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D0S2PD
DRUGNAME	BMS-823778
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2
	
TTDDRUID	D0S2PY
DRUGNAME	MK-866
INDICATI	Discovery agent [ICD-11: N.A.] Phase 2
	
TTDDRUID	D0S2QP
DRUGNAME	COG-248
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0S2RZ
DRUGNAME	XEL-007DO
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0S2UG
DRUGNAME	Selegiline
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
INDICATI	Skin imperfections [ICD-11: EK71] Patented
INDICATI	Chemotherapy-induced nausea [ICD-11: MD90] Discontinued in Phase 3
	
TTDDRUID	D0S2UR
DRUGNAME	PIRODOMAST
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0S2WC
DRUGNAME	Nerisopam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D0S2YX
DRUGNAME	Mofarotene
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0S3AE
DRUGNAME	Anti-MUC1 AR20.5 mab
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0S3AQ
DRUGNAME	CAT-2003
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2
	
TTDDRUID	D0S3BF
DRUGNAME	Pegadricase
INDICATI	Gout [ICD-11: FA25] Phase 1
	
TTDDRUID	D0S3BK
DRUGNAME	GS010
INDICATI	Leber hereditary optic neuropathy [ICD-11: 8C73.Y] Phase 3
	
TTDDRUID	D0S3BR
DRUGNAME	RG7598
INDICATI	Multiple myeloma [ICD-11: 2A83] Discontinued in Phase 1
	
TTDDRUID	D0S3CX
DRUGNAME	Necuparanib
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0S3EF
DRUGNAME	CT-400P
INDICATI	Bone metastases [ICD-11: 2D50] Investigative
	
TTDDRUID	D0S3EK
DRUGNAME	EVT100
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
	
TTDDRUID	D0S3EM
DRUGNAME	CAZ AVI
INDICATI	Serious infection [ICD-11: 1H0Z] Phase 3
	
TTDDRUID	D0S3HR
DRUGNAME	ARA-04
INDICATI	Entamoeba histolytica infection [ICD-11: 1A36.Z] Investigative
	
TTDDRUID	D0S3IG
DRUGNAME	SCH-10363
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0S3LF
DRUGNAME	MFH-244
INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative
	
TTDDRUID	D0S3MY
DRUGNAME	ET-642
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2
	
TTDDRUID	D0S3NU
DRUGNAME	Delamanid
INDICATI	Multi-drug resistant tuberculosis [ICD-11: MG52.00] Approved
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 3
	
TTDDRUID	D0S3PO
DRUGNAME	Pelitinib
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
	
TTDDRUID	D0S3PX
DRUGNAME	Intra-oral lozenge
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Investigative
	
TTDDRUID	D0S3QH
DRUGNAME	AP-CDLD
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D0S3QK
DRUGNAME	CW-343
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Investigative
	
TTDDRUID	D0S3RB
DRUGNAME	ELAROFIBAN
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D0S3RX
DRUGNAME	1,2,3-triazole derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0S3UH
DRUGNAME	SUVN-507
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0S3WH
DRUGNAME	Artemisinin
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0S3WK
DRUGNAME	HRC-302
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Discontinued in Phase 1
	
TTDDRUID	D0S3XA
DRUGNAME	HRG-214
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D0S3XE
DRUGNAME	Turosteride
INDICATI	Prostate disease [ICD-11: GA91] Phase 2
	
TTDDRUID	D0S3YG
DRUGNAME	SNX-9
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0S3YN
DRUGNAME	FE-202158
INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 2
	
TTDDRUID	D0S3YV
DRUGNAME	CD30 CAR T Cells
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1
	
TTDDRUID	D0S3ZP
DRUGNAME	Dorolac
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D0S4AR
DRUGNAME	MX-68
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D0S4BP
DRUGNAME	DP-802
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0S4BR
DRUGNAME	Methimazole
INDICATI	Hyperthyroidism [ICD-11: 5A02] Approved
	
TTDDRUID	D0S4FQ
DRUGNAME	Insulin glargine biosimilar
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0S4GR
DRUGNAME	ETV-004
INDICATI	Toxicity [ICD-11: N.A.] Investigative
	
TTDDRUID	D0S4GT
DRUGNAME	CAR-T cells targeting GD2
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0S4II
DRUGNAME	GSK1292263
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
	
TTDDRUID	D0S4IK
DRUGNAME	PMI-016
INDICATI	Muscle wasting disease [ICD-11: 8E4A.3] Investigative
	
TTDDRUID	D0S4IR
DRUGNAME	PBCAR0191
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0S4JK
DRUGNAME	MLN8237
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0S4JL
DRUGNAME	Simtuzumab
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Primary sclerosing cholangitis [ICD-11: DB96.2] Phase 2
	
TTDDRUID	D0S4JY
DRUGNAME	Ro-24-4736
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2
	
TTDDRUID	D0S4KI
DRUGNAME	Menitorix
INDICATI	Haemophilus influenza [ICD-11: 1G40] Approved
	
TTDDRUID	D0S4KJ
DRUGNAME	KHK-2866
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D0S4LL
DRUGNAME	Sanfetrinem
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3
	
TTDDRUID	D0S4LP
DRUGNAME	VLI-03A
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2
	
TTDDRUID	D0S4LV
DRUGNAME	VB-111
INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0S4MX
DRUGNAME	MGN-1374
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Investigative
	
TTDDRUID	D0S4NZ
DRUGNAME	AVN-458
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D0S4OH
DRUGNAME	Anti-CD20 engineered toxin bodies
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Investigative
	
TTDDRUID	D0S4PN
DRUGNAME	C-1205
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 1
	
TTDDRUID	D0S4PZ
DRUGNAME	SWT-01113
INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative
	
TTDDRUID	D0S4QZ
DRUGNAME	Lobaplatin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0S4RB
DRUGNAME	ITX-7650
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0S4RK
DRUGNAME	Recombinant factor VIII-Fc
INDICATI	Diarrhea [ICD-11: ME05.1] Phase 3
	
TTDDRUID	D0S4RR
DRUGNAME	ProTarg
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0S4SX
DRUGNAME	K-134
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2
	
TTDDRUID	D0S4WA
DRUGNAME	ASP0113
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 3
	
TTDDRUID	D0S4XX
DRUGNAME	INOC-003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0S4XZ
DRUGNAME	GE-1170A
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0S4YT
DRUGNAME	Plasminogen
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3
	
TTDDRUID	D0S4ZZ
DRUGNAME	Anti-HER2 bi-specific mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0S5AL
DRUGNAME	XTL-2125
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1
	
TTDDRUID	D0S5BC
DRUGNAME	CART-19 cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0S5BV
DRUGNAME	ABT-652
INDICATI	Musculoskeletal pain [ICD-11: MG30] Phase 2
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
	
TTDDRUID	D0S5CH
DRUGNAME	Metaxalone
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0S5CU
DRUGNAME	Nisoldipine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0S5CY
DRUGNAME	SGN-CD48A
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0S5EB
DRUGNAME	Adoniside
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0S5EF
DRUGNAME	PF-4418948
INDICATI	Endometriosis [ICD-11: GA10] Phase 1
	
TTDDRUID	D0S5FF
DRUGNAME	BYM338
INDICATI	Inclusion body myositis [ICD-11: 4A41.2] Phase 3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2/3
INDICATI	Muscle atrophy [ICD-11: FB32.Y] Phase 2
	
TTDDRUID	D0S5FQ
DRUGNAME	MCPP
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
	
TTDDRUID	D0S5IR
DRUGNAME	SAGE-217
INDICATI	Postpartum depression [ICD-11: 6E20.0] Phase 3
INDICATI	Essential tremor or related tremors [ICD-11: 8A04.1] Phase 2
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0S5IV
DRUGNAME	Anti-Marburg virus mabs
INDICATI	Marburg virus infection [ICD-11: 1D60.1] Investigative
	
TTDDRUID	D0S5LD
DRUGNAME	BAY 80-6946
INDICATI	Follicular lymphoma [ICD-11: 2A80] Approved
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved
	
TTDDRUID	D0S5LH
DRUGNAME	Edrophonium
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Approved
	
TTDDRUID	D0S5LO
DRUGNAME	PF-04449913
INDICATI	Chronic myelomonocytic leukaemia [ICD-11: 2A40] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0S5LT
DRUGNAME	Deoxynojirimycin
INDICATI	Pompe disease [ICD-11: 5C51.3] Phase 3
	
TTDDRUID	D0S5MJ
DRUGNAME	HDL-based therapeutics
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0S5NG
DRUGNAME	Cetiedil
INDICATI	Sickle-cell anaemia [ICD-11: 3A51] Approved
	
TTDDRUID	D0S5NN
DRUGNAME	ABI-010
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0S5NS
DRUGNAME	Pyrazole derivative 24
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0S5RC
DRUGNAME	SNS-032
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0S5RZ
DRUGNAME	Amtolmetin guacil
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0S5TT
DRUGNAME	ACE-435
INDICATI	Cachexia [ICD-11: MG20] Investigative
	
TTDDRUID	D0S5UB
DRUGNAME	PS522501
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Discontinued in Phase 1
	
TTDDRUID	D0S5UH
DRUGNAME	Clofazimine
INDICATI	Crohn disease [ICD-11: DD70] Approved
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0S5VU
DRUGNAME	Herbicide amitrole
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0S5WG
DRUGNAME	Flucytosine
INDICATI	Endocarditis [ICD-11: BB40-BA42] Approved
	
TTDDRUID	D0S5WP
DRUGNAME	Trametinib + 2141795
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0S5XO
DRUGNAME	NasoVAX
INDICATI	Seasonal influenza infection [ICD-11: 1E30] Phase 2
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative
	
TTDDRUID	D0S5YC
DRUGNAME	MEPTAZINOL
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0S5ZJ
DRUGNAME	SERGOLEXOLE MALEATE
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2
	
TTDDRUID	D0S6AE
DRUGNAME	Diquafosol
INDICATI	Dry eye disease [ICD-11: 9E1Z] Phase 3
	
TTDDRUID	D0S6AH
DRUGNAME	Adiptin
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0S6AQ
DRUGNAME	Ramorelix
INDICATI	Esophageal cancer [ICD-11: 2B70] Discontinued in Phase 1
	
TTDDRUID	D0S6CD
DRUGNAME	NPS-P156
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0S6FE
DRUGNAME	PTX-008
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0S6GJ
DRUGNAME	KC-764
INDICATI	Platelet aggregation disorder [ICD-11: 3B62] Discontinued in Phase 3
	
TTDDRUID	D0S6GY
DRUGNAME	SER-101
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 1
	
TTDDRUID	D0S6HR
DRUGNAME	KI-0802
INDICATI	Gastrointestinal ulcer [ICD-11: DA60.Z] Phase 3
	
TTDDRUID	D0S6IA
DRUGNAME	PMID25623274-Compound-WO2014132220C2
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Patented
	
TTDDRUID	D0S6JG
DRUGNAME	Liothyronine
INDICATI	Hypothyroidism [ICD-11: 5A00] Approved
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 3
	
TTDDRUID	D0S6JV
DRUGNAME	Nepadutant
INDICATI	Postoperative ileus [ICD-11: DA91-DB30] Phase 1/2
INDICATI	Infantile colics [ICD-11: DD93.1] Phase 1/2
	
TTDDRUID	D0S6KA
DRUGNAME	CALANOLIDE A
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1
	
TTDDRUID	D0S6KI
DRUGNAME	AT-101
INDICATI	Hemorrhagic shock [ICD-11: MG40.1] Phase 2
	
TTDDRUID	D0S6KX
DRUGNAME	GSK-677954
INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Discontinued in Phase 2
	
TTDDRUID	D0S6MA
DRUGNAME	OCID-2987
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0S6NH
DRUGNAME	ZAMI-633
INDICATI	Urinary tract disease [ICD-11: GC2Z] Investigative
	
TTDDRUID	D0S6NJ
DRUGNAME	AC-03-636
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0S6OH
DRUGNAME	Relaxin
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Phase 3
	
TTDDRUID	D0S6OY
DRUGNAME	FabOvar
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D0S6QJ
DRUGNAME	C10-1040
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0S6QR
DRUGNAME	BMS-204352
INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 3
	
TTDDRUID	D0S6RY
DRUGNAME	OPC 108459
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 1
	
TTDDRUID	D0S6SJ
DRUGNAME	Piperidine derivative 3
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D0S6SP
DRUGNAME	BPL-002
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0S6SQ
DRUGNAME	Odelepran
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
	
TTDDRUID	D0S6SU
DRUGNAME	KRN-2391
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D0S6TK
DRUGNAME	tamatinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial
	
TTDDRUID	D0S6UH
DRUGNAME	BC-6213
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D0S6VB
DRUGNAME	DG031
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3
	
TTDDRUID	D0S6VX
DRUGNAME	CGP-40215A
INDICATI	Pneumocystis pneumonia [ICD-11: CA40.20] Terminated
	
TTDDRUID	D0S6WW
DRUGNAME	E12/DP3-117
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0S6XJ
DRUGNAME	GS-522
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0S6YO
DRUGNAME	Ajinomoto 3
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0S7AR
DRUGNAME	Papillomavirus vaccine
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Terminated
	
TTDDRUID	D0S7AW
DRUGNAME	KD020
INDICATI	Kidney disease [ICD-11: GC2Z] Phase 1/2
	
TTDDRUID	D0S7BQ
DRUGNAME	GSK1322322
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D0S7CM
DRUGNAME	HDL-100
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1/2
	
TTDDRUID	D0S7CP
DRUGNAME	VK-12
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0S7DS
DRUGNAME	SPD-756
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0S7DV
DRUGNAME	Tiazofurin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0S7EQ
DRUGNAME	PEN-203
INDICATI	Gynecological disease [ICD-11: GA6Z] Discontinued in Phase 2
	
TTDDRUID	D0S7FR
DRUGNAME	Ostabolin-C
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D0S7HM
DRUGNAME	ENMD-2076
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Fibrolamellar liver cancer [ICD-11: 2C12.02] Phase 2
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
	
TTDDRUID	D0S7HW
DRUGNAME	Anti-miR-199a oligonucleotides
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative
	
TTDDRUID	D0S7IQ
DRUGNAME	Anti-VEGF human mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0S7IZ
DRUGNAME	Apricoxib
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2
	
TTDDRUID	D0S7JH
DRUGNAME	Macitentan
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0S7JN
DRUGNAME	GP-2017
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
INDICATI	Psoriatic arthritis [ICD-11: FA21] Application submitted
	
TTDDRUID	D0S7KA
DRUGNAME	(-)-deprenyl
INDICATI	Alopecia [ICD-11: ED70] Patented
	
TTDDRUID	D0S7KQ
DRUGNAME	Hematide
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 3
	
TTDDRUID	D0S7LG
DRUGNAME	ARN-509
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0S7LN
DRUGNAME	GS-9132
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2
	
TTDDRUID	D0S7NS
DRUGNAME	MMI-0100
INDICATI	Airway inflammation [ICD-11: CA05] Phase 1
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D0S7QB
DRUGNAME	JNJ-28165722
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0S7UH
DRUGNAME	ALX-0171
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1
	
TTDDRUID	D0S7UQ
DRUGNAME	RG-7103
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0S7UU
DRUGNAME	PF-06260414
INDICATI	Cachexia [ICD-11: MG20] Discontinued in Phase 1
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0S7VI
DRUGNAME	AXT-914
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 1
	
TTDDRUID	D0S7VN
DRUGNAME	MRL-953
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Terminated
	
TTDDRUID	D0S7VO
DRUGNAME	Tiaprofenic acid
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0S7VZ
DRUGNAME	WAY-100289
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D0S7WX
DRUGNAME	Vitamin A
INDICATI	Night blindness [ICD-11: 9D45] Approved
INDICATI	Kinetoplastids [ICD-11: 1F61-1G2Z] Investigative
	
TTDDRUID	D0S7XR
DRUGNAME	TKP-1002
INDICATI	Schizophrenia [ICD-11: 6A20] Investigative
	
TTDDRUID	D0S7XV
DRUGNAME	Tetanus immune globulin
INDICATI	Clostridium infection [ICD-11: 1A04] Approved
	
TTDDRUID	D0S7YU
DRUGNAME	ALD-601
INDICATI	Lysosomal storage disease [ICD-11: 5C56.Z] Discontinued in Phase 1
	
TTDDRUID	D0S8AF
DRUGNAME	Visceral leishmaniasis vaccine
INDICATI	Visceral leishmaniasis [ICD-11: 1F54.0] Phase 1
	
TTDDRUID	D0S8BG
DRUGNAME	EMD 55900
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D0S8BU
DRUGNAME	SE RNA
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0S8CI
DRUGNAME	ELIPRODIL
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0S8DB
DRUGNAME	Org-9731
INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2
	
TTDDRUID	D0S8DU
DRUGNAME	TGWOOAA
INDICATI	Social phobia [ICD-11: 6B04] Phase 2
INDICATI	Generalized anxiety disorder [ICD-11: 6B00] Phase 2
	
TTDDRUID	D0S8FU
DRUGNAME	Resultz
INDICATI	Head and body lice [ICD-11: 1G00.0] Approved
	
TTDDRUID	D0S8HD
DRUGNAME	PEP-223/CoVaccine HT
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0S8KE
DRUGNAME	NS-2979
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0S8LJ
DRUGNAME	S-1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
	
TTDDRUID	D0S8LV
DRUGNAME	Panipenem
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0S8MG
DRUGNAME	Genz-668764
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0S8MN
DRUGNAME	AAV-miApoB
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D0S8RG
DRUGNAME	Nasalflu Berna
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Terminated
	
TTDDRUID	D0S8RN
DRUGNAME	IPN-100
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Investigative
	
TTDDRUID	D0S8RY
DRUGNAME	GP-531
INDICATI	Myocardial ischemia [ICD-11: BA6Z] Discontinued in Phase 2
	
TTDDRUID	D0S8TD
DRUGNAME	Methohexital
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0S8VG
DRUGNAME	PGL-3001
INDICATI	Female infertility [ICD-11: GA31.Z] Discontinued in Phase 2
	
TTDDRUID	D0S8WA
DRUGNAME	Obinutuzumab
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0S8XP
DRUGNAME	Canagliflozin/metformin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0S8YL
DRUGNAME	Tomelukast
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0S8YV
DRUGNAME	HGP-30
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 2
	
TTDDRUID	D0S9AW
DRUGNAME	Rifamycin b
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0S9BH
DRUGNAME	Ozarelix
INDICATI	Prostate disease [ICD-11: GA91] Phase 2
	
TTDDRUID	D0S9CB
DRUGNAME	Flibanserin
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Approved
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 3
	
TTDDRUID	D0S9EK
DRUGNAME	LIlotomab satetraxetan
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
	
TTDDRUID	D0S9ET
DRUGNAME	Pirprofen
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Approved
	
TTDDRUID	D0S9FI
DRUGNAME	ICasp9M28z T cell
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1
INDICATI	Malignant pleural effusion [ICD-11: 2D72] Phase 1
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Phase 1
	
TTDDRUID	D0S9FU
DRUGNAME	Simotinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0S9GJ
DRUGNAME	AE-443p
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0S9HV
DRUGNAME	MitoAscorbate
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative
	
TTDDRUID	D0S9IE
DRUGNAME	BAY1125976
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0S9KM
DRUGNAME	NGD 91-3
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D0S9LK
DRUGNAME	GSK-2584786A
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0S9LR
DRUGNAME	Beclomethasone dispropionate
INDICATI	Acute radiation syndrome [ICD-11: NF00] Phase 1
	
TTDDRUID	D0S9MC
DRUGNAME	Clobazam - Lundbeck
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D0S9MD
DRUGNAME	DFP-11207
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0S9MO
DRUGNAME	Modified BCG vaccine
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Terminated
	
TTDDRUID	D0S9MU
DRUGNAME	Rizatriptan
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0S9OH
DRUGNAME	L-MDAM
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0S9PV
DRUGNAME	Type VII collagen
INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Investigative
	
TTDDRUID	D0S9QA
DRUGNAME	Ivabradine
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D0S9SD
DRUGNAME	Emtricitabine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Approved
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
	
TTDDRUID	D0S9UO
DRUGNAME	SPI-3608
INDICATI	Spinal disease [ICD-11: FA72] Phase 1
	
TTDDRUID	D0S9VG
DRUGNAME	C4X-101
INDICATI	Endocrine disease [ICD-11: 5B3Z] Investigative
	
TTDDRUID	D0S9WB
DRUGNAME	Lumacaftor + ivacaftor
INDICATI	Cystic fibrosis [ICD-11: CA25] Approved
INDICATI	Acute lung injury [ICD-11: NB32.3] Approved
	
TTDDRUID	D0S9WW
DRUGNAME	GI-6301
INDICATI	Chordoma [ICD-11: 5A61.0] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0S9XR
DRUGNAME	TRx-0037
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1
	
TTDDRUID	D0S9XV
DRUGNAME	A-134974
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D0S9YP
DRUGNAME	ZP-103
INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative
	
TTDDRUID	D0SA3J
DRUGNAME	Ibrolipim
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D0SB0X
DRUGNAME	CX-1040
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0SB1B
DRUGNAME	CPX-351
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D0SB2G
DRUGNAME	EP-1300
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	D0SB2U
DRUGNAME	MVA-BN brachyury vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0SB4A
DRUGNAME	PMID25684022-Compound-US20130053382 35(1-11)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0SB5K
DRUGNAME	SAR164877
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2/3
	
TTDDRUID	D0SB6K
DRUGNAME	DAT-582
INDICATI	Nausea [ICD-11: MD90] Discontinued in Phase 2
	
TTDDRUID	D0SB8E
DRUGNAME	UTL-5g
INDICATI	Toxicity [ICD-11: N.A.] Investigative
	
TTDDRUID	D0SB8X
DRUGNAME	FluNhance
INDICATI	Adenosine deaminase defciency [ICD-11: 4A01.1] Phase 3
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0SC1I
DRUGNAME	S. pneumoniae paediatric next generation
INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 2
	
TTDDRUID	D0SC2J
DRUGNAME	Tanespimycin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Discontinued in Phase 3
	
TTDDRUID	D0SC6I
DRUGNAME	Sodium benzoate
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2/3
	
TTDDRUID	D0SC8F
DRUGNAME	Ethylestrenol
INDICATI	Testosterone deficiency [ICD-11: 5A81.1] Approved
	
TTDDRUID	D0SD1L
DRUGNAME	Mercaptopurine
INDICATI	Acute lymphocytic leukaemia [ICD-11: 2B33.3] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0SD2J
DRUGNAME	INP104
INDICATI	Migraine [ICD-11: 8A80] Phase 1
	
TTDDRUID	D0SD3E
DRUGNAME	PF-05186462
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0SD3Q
DRUGNAME	GIDAZEPAM
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D0SD4G
DRUGNAME	PMID25666693-Compound-16
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0SD4Q
DRUGNAME	Aryl mannoside derivative 11
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0SD6V
DRUGNAME	CFZ533
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Graves disease [ICD-11: 5A02.0] Phase 2
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 2
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2
	
TTDDRUID	D0SD7G
DRUGNAME	LY3002813
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0SD8V
DRUGNAME	TDI-0047
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0SD9L
DRUGNAME	Monoamine derivative 5
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0SD9R
DRUGNAME	ARI-0001 cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0SD9V
DRUGNAME	Flupirtine
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2
INDICATI	Cancer related pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D0SD9Z
DRUGNAME	TRC-253
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0SE4D
DRUGNAME	Org-20599
INDICATI	Anaesthesia [ICD-11: 9A78.6] Terminated
	
TTDDRUID	D0SE7V
DRUGNAME	Alkyl mannoside derivative 3
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0SE9S
DRUGNAME	SCH-221510
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D0SF0U
DRUGNAME	HS-7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0SF2R
DRUGNAME	GVX-3322
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated
	
TTDDRUID	D0SF5F
DRUGNAME	Org-34092
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0SF5Q
DRUGNAME	Pennvax-B
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0SF6C
DRUGNAME	P-coumaric acid derivative 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0SF8V
DRUGNAME	RO7082859
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0SG0J
DRUGNAME	ASC09 + ritonavir + oseltamivir
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0SG0N
DRUGNAME	DB-200
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated
	
TTDDRUID	D0SG4W
DRUGNAME	Oral insulin
INDICATI	Type-1 diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D0SG7B
DRUGNAME	GLPG-0634
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2
	
TTDDRUID	D0SG8X
DRUGNAME	PMID30124346-Compound-LDT66
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Patented
	
TTDDRUID	D0SH2X
DRUGNAME	Amocarzine
INDICATI	Helminth infection [ICD-11: 1F90.0] Phase 3
	
TTDDRUID	D0SH3I
DRUGNAME	Bortezomib
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Approved
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
	
TTDDRUID	D0SH5O
DRUGNAME	FK-317
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0SH7J
DRUGNAME	INO-4212
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D0SI1Z
DRUGNAME	SCLERON
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0SI4C
DRUGNAME	KF-17625
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0SI9L
DRUGNAME	Nicotinamide riboside
INDICATI	Mitochondrial myopathy [ICD-11: 8C73] Phase 1
	
TTDDRUID	D0SJ1U
DRUGNAME	Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 8
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0SJ4S
DRUGNAME	P-coumaric acid derivative 5
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0SJ8Q
DRUGNAME	ERITORAN
INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 3
	
TTDDRUID	D0SK1W
DRUGNAME	AS-602305
INDICATI	Androgen deficiency [ICD-11: 5A81.1] Terminated
	
TTDDRUID	D0SK2J
DRUGNAME	Palux
INDICATI	Intermittent claudication [ICD-11: BD40.00] Discontinued in Phase 2
	
TTDDRUID	D0SK9J
DRUGNAME	AN-3661
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0SL2V
DRUGNAME	Lanatoside c
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0SL4P
DRUGNAME	Sharon-4000
INDICATI	Acne vulgaris [ICD-11: ED80] Investigative
	
TTDDRUID	D0SL8J
DRUGNAME	Ascrolimus
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D0SL8T
DRUGNAME	ISIS-FGFR4
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D0SL8X
DRUGNAME	Edoxaban tosylate
INDICATI	Stroke [ICD-11: 8B20] Approved
INDICATI	Venous thromboembolism [ICD-11: BD72] Approved
INDICATI	Embolism [ICD-11: JB42] Approved
	
TTDDRUID	D0SM4E
DRUGNAME	CD101 IV
INDICATI	Candidiasis [ICD-11: 1F23] Phase 1
	
TTDDRUID	D0SM6N
DRUGNAME	ISIS-PTP1Brx
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0SM6Y
DRUGNAME	MNT-02-07
INDICATI	Clostridium infection [ICD-11: 1A04] Investigative
	
TTDDRUID	D0SM8S
DRUGNAME	Lebrikizumab
INDICATI	Severe asthma [ICD-11: CA23] Phase 3
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
	
TTDDRUID	D0SN0U
DRUGNAME	Alpha-C-galactosyl ceramide
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0SN1T
DRUGNAME	Nikkomycin Z
INDICATI	Candidiasis [ICD-11: 1F23] Phase 1/2
	
TTDDRUID	D0SN2I
DRUGNAME	ABT-555
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0SN2Q
DRUGNAME	AZD-6714
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0SN4Y
DRUGNAME	Trospium
INDICATI	Neurogenic detrusor overactivity [ICD-11: GC01] Phase 1
	
TTDDRUID	D0SN7I
DRUGNAME	SB-656933
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D0SN9T
DRUGNAME	Nilutamide
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D0SO0U
DRUGNAME	AG-122005
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0SO1Z
DRUGNAME	PN-203
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0SO4Z
DRUGNAME	ASP1585
INDICATI	Hypophosphatasia [ICD-11: 5C64.3] Phase 3
	
TTDDRUID	D0SOG8
DRUGNAME	NBM-BMX
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0SP3D
DRUGNAME	Dihydroergotoxine
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D0SP5Q
DRUGNAME	PRT-064445
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative
	
TTDDRUID	D0SP5V
DRUGNAME	Setipiprant
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D0SP6A
DRUGNAME	SL-801
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0SP7S
DRUGNAME	Androgen
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0SQ1O
DRUGNAME	XmAb5981
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
	
TTDDRUID	D0SQ1W
DRUGNAME	Sterile Water
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0SQ2K
DRUGNAME	Miravirsen
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0SQ2Z
DRUGNAME	Ridaforolimus eluting coronary stent
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 3
	
TTDDRUID	D0SQ6A
DRUGNAME	FKW00GA
INDICATI	Social phobia [ICD-11: 6B04] Phase 2
	
TTDDRUID	D0SQ8R
DRUGNAME	V-710
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 2/3
	
TTDDRUID	D0SQ9O
DRUGNAME	Herpes simplex vaccine
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1/2
	
TTDDRUID	D0SR3J
DRUGNAME	Loperamide
INDICATI	Diarrhea [ICD-11: DA90] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0SR3T
DRUGNAME	JN-711
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0SR4G
DRUGNAME	ONT-093
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0SR4T
DRUGNAME	PHENSERINE TARTRATE
INDICATI	Parkinson disease [ICD-11: 8A00.0] Preclinical
	
TTDDRUID	D0SR6S
DRUGNAME	PandyFlu
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Registered
	
TTDDRUID	D0SR8I
DRUGNAME	PMID26651364-Compound-124
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0SS1J
DRUGNAME	SAR399063
INDICATI	Pre-sarcopenia [ICD-11: FB32.Y] Phase 3
	
TTDDRUID	D0SS1Q
DRUGNAME	Influenza vaccine patch
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2
	
TTDDRUID	D0SS2E
DRUGNAME	AZD-8450
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Preclinical
	
TTDDRUID	D0SS4I
DRUGNAME	ASP-2905
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
	
TTDDRUID	D0SS4P
DRUGNAME	Pirbuterol
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0SS6J
DRUGNAME	GR-328713
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D0ST5P
DRUGNAME	TA-5538
INDICATI	Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2
	
TTDDRUID	D0SU0E
DRUGNAME	Biphenyl mannoside derivative 1
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0SU1F
DRUGNAME	CP-122288
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 2
	
TTDDRUID	D0SU1G
DRUGNAME	Zomepirac
INDICATI	Pain [ICD-11: MG30-MG3Z] Withdrawn from market
	
TTDDRUID	D0SU4D
DRUGNAME	Aflibercept + nesvacumab
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	D0SU5N
DRUGNAME	PMID28624700-compound-3-31
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
	
TTDDRUID	D0SV4A
DRUGNAME	CD19 targeted chimeric antigen receptor T cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0SV6D
DRUGNAME	Heterocyclic-substituted 3-alkyl azetidine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0SV6V
DRUGNAME	PP-303
INDICATI	Alopecia [ICD-11: ED70] Investigative
	
TTDDRUID	D0SV7D
DRUGNAME	LOTRAFIBAN
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3
	
TTDDRUID	D0SV8E
DRUGNAME	Methotrexate
INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Proliferative vitreoretinopathy [ICD-11: 9B78.2] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0SW1D
DRUGNAME	Cellspan esophageal implant
INDICATI	Esophageal cancer [ICD-11: 2B70] Clinical trial
	
TTDDRUID	D0SW2H
DRUGNAME	TAK-778
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2
	
TTDDRUID	D0SW2Q
DRUGNAME	Tetra-hydro-1H-1,2,6-triazaazulene derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0SW8L
DRUGNAME	LC-280126
INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative
	
TTDDRUID	D0SX3X
DRUGNAME	TEI-6122
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D0SX4D
DRUGNAME	KD-295
INDICATI	Influenza A virus H5N1 infection [ICD-11: 1E30] Registered
	
TTDDRUID	D0SX4K
DRUGNAME	HR325
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0SX6O
DRUGNAME	Meninvact
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved
	
TTDDRUID	D0SX7F
DRUGNAME	AZALANSTAT
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D0SX9C
DRUGNAME	Alfa-interferon
INDICATI	Endometriosis [ICD-11: GA10] Phase 1
	
TTDDRUID	D0SY0W
DRUGNAME	ASC09 + ritonavir
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1
	
TTDDRUID	D0SY2O
DRUGNAME	ANG-3067
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D0SY7H
DRUGNAME	IDX-184
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2
	
TTDDRUID	D0SY9B
DRUGNAME	SSR149415
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0SZ1G
DRUGNAME	AZD9567
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0SZ2E
DRUGNAME	Acetohydroxamic
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D0SZ2G
DRUGNAME	SC-003
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0SZ3B
DRUGNAME	ER-34122
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0SZ5G
DRUGNAME	ANX-042
INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 1
	
TTDDRUID	D0SZ6E
DRUGNAME	YN-968D1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0SZ8Q
DRUGNAME	CSC-500297
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0SZ9R
DRUGNAME	2X-121
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0SZT3
DRUGNAME	NEXI-001
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
	
TTDDRUID	D0T0BA
DRUGNAME	CX-1010
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative
	
TTDDRUID	D0T0BF
DRUGNAME	EBV CTLs
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0T0BP
DRUGNAME	MenBioVax
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Investigative
	
TTDDRUID	D0T0BS
DRUGNAME	CGS-18102A
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0T0FT
DRUGNAME	AutoSynVax
INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0T0HM
DRUGNAME	PMID28270021-Compound-WO2010077680 109
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0T0IE
DRUGNAME	ISV-215
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D0T0JF
DRUGNAME	PseudIgY
INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 3
	
TTDDRUID	D0T0KA
DRUGNAME	Nicardipine
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D0T0KQ
DRUGNAME	SEL-100130
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0T0KT
DRUGNAME	Briciclib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0T0LE
DRUGNAME	IRX-4310
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 3
	
TTDDRUID	D0T0LM
DRUGNAME	Pirenzepine
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D0T0LO
DRUGNAME	RP-54745
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0T0LR
DRUGNAME	Debio-0929
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T0LU
DRUGNAME	Conjugated Estrogens
INDICATI	Menopause symptom [ICD-11: GA30.0] Approved
INDICATI	Vasomotor symptom [ICD-11: CA08] Approved
	
TTDDRUID	D0T0MY
DRUGNAME	DT-330
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T0NG
DRUGNAME	Arofylline
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D0T0NL
DRUGNAME	ARC031
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0T0OQ
DRUGNAME	Furopyridine derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0T0PN
DRUGNAME	CP-122721
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0T0PU
DRUGNAME	CME-548
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T0QU
DRUGNAME	MEDI-559
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D0T0RU
DRUGNAME	AC-8
INDICATI	Herpetic keratitis [ICD-11: 1F00.10] Investigative
	
TTDDRUID	D0T0SE
DRUGNAME	Anti-EGFR CAR T
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0T0SK
DRUGNAME	ST-2987
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T0SO
DRUGNAME	BI-K0376
INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1
	
TTDDRUID	D0T0TZ
DRUGNAME	Ticrynafen
INDICATI	Congestive heart failure [ICD-11: BD10] Withdrawn from market
	
TTDDRUID	D0T0UC
DRUGNAME	ANAVEX 1-41
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
	
TTDDRUID	D0T0UM
DRUGNAME	EM-6110a
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T0VA
DRUGNAME	B-4474
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0T0VZ
DRUGNAME	XEN-D0104
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D0T0YB
DRUGNAME	Cotrimazine
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D0T0YG
DRUGNAME	Pixuvripixantrone
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
	
TTDDRUID	D0T0ZW
DRUGNAME	ALKS33
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
	
TTDDRUID	D0T1AO
DRUGNAME	MystiTrip
INDICATI	Migraine [ICD-11: 8A80] Investigative
	
TTDDRUID	D0T1DZ
DRUGNAME	EPI-001
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0T1EO
DRUGNAME	Sulfonamides
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0T1EU
DRUGNAME	Ndx-Peptide
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0T1FC
DRUGNAME	PF-4878691
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0T1GF
DRUGNAME	MP470
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0T1GG
DRUGNAME	3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1
INDICATI	Cell proliferative disorder [ICD-11: FB86] Patented
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Patented
INDICATI	Blood vessel proliferative disorder [ICD-11: BE2Z] Patented
	
TTDDRUID	D0T1GT
DRUGNAME	Sulfacytine
INDICATI	Cystitis [ICD-11: GC00] Approved
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	D0T1GV
DRUGNAME	ADD-17014
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 1
	
TTDDRUID	D0T1HE
DRUGNAME	APD-403
INDICATI	Vomiting [ICD-11: MD90] Phase 2
	
TTDDRUID	D0T1IJ
DRUGNAME	Oprelvekin
INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved
	
TTDDRUID	D0T1KL
DRUGNAME	Pankomab-GEX
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0T1LK
DRUGNAME	Primaquine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0T1LX
DRUGNAME	BC-ONY-01
INDICATI	Onychomycosis [ICD-11: EE12.1] Investigative
	
TTDDRUID	D0T1MI
DRUGNAME	INP-01
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0T1MP
DRUGNAME	Lurosetron
INDICATI	Vomiting [ICD-11: MD90] Discontinued in Phase 2
	
TTDDRUID	D0T1MT
DRUGNAME	OTK18 TF mabs
INDICATI	Viral encephalitis [ICD-11: 1C80] Investigative
	
TTDDRUID	D0T1OR
DRUGNAME	BRX-3
INDICATI	Bone disease [ICD-11: FC0Z] Investigative
	
TTDDRUID	D0T1QY
DRUGNAME	Technetium Tc-99m Gluceptate Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0T1RG
DRUGNAME	Sitaxsentan
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Withdrawn from market
	
TTDDRUID	D0T1RJ
DRUGNAME	MDT-012
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0T1SF
DRUGNAME	PNU-109291
INDICATI	Migraine [ICD-11: 8A80] Terminated
	
TTDDRUID	D0T1TC
DRUGNAME	C-5304
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T1UH
DRUGNAME	REC-0467
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Investigative
	
TTDDRUID	D0T1UJ
DRUGNAME	Reteplase
INDICATI	Heart attack [ICD-11: BA41] Approved
	
TTDDRUID	D0T1VK
DRUGNAME	CJ-30002
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0T1WN
DRUGNAME	Zolpidem
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0T1WY
DRUGNAME	Clevudine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
	
TTDDRUID	D0T1XW
DRUGNAME	Meclizine
INDICATI	Dizziness [ICD-11: MB48] Approved
	
TTDDRUID	D0T1YH
DRUGNAME	ALD-806
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T1YN
DRUGNAME	Tiqueside
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D0T1ZJ
DRUGNAME	Naked DNA (B-cell lymphoma)
INDICATI	B-cell lymphoma [ICD-11: 2A86] Discontinued in Phase 2
	
TTDDRUID	D0T2AE
DRUGNAME	V-0251
INDICATI	Labyrinthitis [ICD-11: AB30.1] Phase 2
	
TTDDRUID	D0T2DL
DRUGNAME	GM-7050
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0T2EO
DRUGNAME	MAXY-4
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0T2EP
DRUGNAME	CLOTURIN
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0T2ER
DRUGNAME	TAK-593
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0T2FC
DRUGNAME	NPC-1C
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Pancreatic tumour [ICD-11: 2C10] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0T2FP
DRUGNAME	JNJ-54861911
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3
	
TTDDRUID	D0T2GP
DRUGNAME	DP-5599
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0T2IA
DRUGNAME	Dapiprazole
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D0T2IF
DRUGNAME	DPX-survivac cancer vaccine
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1
	
TTDDRUID	D0T2LP
DRUGNAME	ARM036
INDICATI	Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2
	
TTDDRUID	D0T2LR
DRUGNAME	PMX-30063
INDICATI	Oral mucositis [ICD-11: DA01.11] Phase 2
	
TTDDRUID	D0T2MN
DRUGNAME	Z-300
INDICATI	Gastric ulcer [ICD-11: DA60] Discontinued in Phase 1
	
TTDDRUID	D0T2MS
DRUGNAME	ZX002
INDICATI	Back pain [ICD-11: ME84.Z] Phase 3
	
TTDDRUID	D0T2MV
DRUGNAME	AS-9705
INDICATI	Gastric motility disorder [ICD-11: DA21] Investigative
INDICATI	Vomiting [ICD-11: MD90] Investigative
	
TTDDRUID	D0T2NG
DRUGNAME	SOM-1025
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0T2NV
DRUGNAME	LAMP-Vax + pp65 DC
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
	
TTDDRUID	D0T2OT
DRUGNAME	GW-278884
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Terminated
	
TTDDRUID	D0T2PL
DRUGNAME	Calcitriol
INDICATI	Congenital alopecia [ICD-11: LC30] Approved
	
TTDDRUID	D0T2PT
DRUGNAME	MTbuVax
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0T2QI
DRUGNAME	MPV-1743
INDICATI	Obesity [ICD-11: 5B81] Terminated
	
TTDDRUID	D0T2QN
DRUGNAME	PF-2393296
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1
	
TTDDRUID	D0T2RU
DRUGNAME	PF-277343
INDICATI	Alopecia [ICD-11: ED70] Phase 1
	
TTDDRUID	D0T2RZ
DRUGNAME	Moroctocog alfa
INDICATI	Hemophilia [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0T2SK
DRUGNAME	AmZaar
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0T2ST
DRUGNAME	Azotropin
INDICATI	Growth failure [ICD-11: LD2F.1Y] Investigative
	
TTDDRUID	D0T2TK
DRUGNAME	ZD6416
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0T2UB
DRUGNAME	APCK-110
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T2XU
DRUGNAME	Promethazine
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D0T2YQ
DRUGNAME	N-chlorotaurine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D0T3AD
DRUGNAME	Pentostatin
INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved
	
TTDDRUID	D0T3AW
DRUGNAME	Antroquinonol
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0T3BX
DRUGNAME	IFN-beta
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T3CB
DRUGNAME	Ono 1
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0T3CE
DRUGNAME	SUPER-LEU-DOX
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0T3CH
DRUGNAME	RGI-2001
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 2
	
TTDDRUID	D0T3DG
DRUGNAME	BCI-632
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0T3DO
DRUGNAME	IRX-5183
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0T3EV
DRUGNAME	SR-146131
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D0T3FN
DRUGNAME	RLX030
INDICATI	Acute heart failure [ICD-11: BD10-BD13] Approval submitted
	
TTDDRUID	D0T3HL
DRUGNAME	Cx-611
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1/2
	
TTDDRUID	D0T3HY
DRUGNAME	Levorphanol
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Terminated
	
TTDDRUID	D0T3JF
DRUGNAME	GliAtak
INDICATI	Brain cancer [ICD-11: 2A00] Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0T3JW
DRUGNAME	U-99194A
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0T3JZ
DRUGNAME	ABBV-085
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0T3KI
DRUGNAME	Naratriptan
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0T3KW
DRUGNAME	AS-337
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0T3KZ
DRUGNAME	TENOSAL
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0T3LF
DRUGNAME	Dextroamphetamine
INDICATI	Narcolepsy [ICD-11: 7A20] Approved
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
	
TTDDRUID	D0T3NB
DRUGNAME	Sanguinarine
INDICATI	Dental plaque [ICD-11: DA08.4] Approved
	
TTDDRUID	D0T3NH
DRUGNAME	MBS-105
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0T3NY
DRUGNAME	Crotamiton
INDICATI	Pruritus [ICD-11: EC90] Approved
	
TTDDRUID	D0T3QR
DRUGNAME	GSK679586
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0T3QU
DRUGNAME	MBL-HCV1
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0T3RR
DRUGNAME	ISIS-ANGPTL3
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1
	
TTDDRUID	D0T3TZ
DRUGNAME	Benzimidazole derivative 6
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D0T3VF
DRUGNAME	GSK3050002
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 1
	
TTDDRUID	D0T3VO
DRUGNAME	DX-619
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0T3VY
DRUGNAME	RBT-201
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Investigative
	
TTDDRUID	D0T3ZL
DRUGNAME	RC-552
INDICATI	Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2
	
TTDDRUID	D0T4BL
DRUGNAME	Neovastat
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0T4CD
DRUGNAME	NGN-9077
INDICATI	Multiple system atrophy [ICD-11: 8D87.0] Investigative
	
TTDDRUID	D0T4CF
DRUGNAME	Five membered heterocyclic benzamide derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0T4EA
DRUGNAME	GD2 ganglioside peptide mimics
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T4EL
DRUGNAME	A-80263
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0T4FY
DRUGNAME	CAR-T cells targeting CD30
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D0T4GA
DRUGNAME	INTEGRA Artificial Skin
INDICATI	Skin burns [ICD-11: ME65.0] Approved
	
TTDDRUID	D0T4GG
DRUGNAME	NANT
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D0T4GX
DRUGNAME	Clade C HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0T4GZ
DRUGNAME	MPL-S
INDICATI	Endotoxic shock [ICD-11: 1G41] Phase 3
	
TTDDRUID	D0T4HS
DRUGNAME	GR-95168
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated
	
TTDDRUID	D0T4IQ
DRUGNAME	MEN-11149
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0T4IW
DRUGNAME	8H9 I-131 mab
INDICATI	Leptomeningeal sarcoma [ICD-11: 2A01.0] Phase 2
INDICATI	Small round cell desmoplastic tumour [ICD-11: 2A20.5] Phase 1/2
INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 1
INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 1
	
TTDDRUID	D0T4KG
DRUGNAME	F-8-IL-10 fusion protein
INDICATI	Endometriosis [ICD-11: GA10] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1
	
TTDDRUID	D0T4LT
DRUGNAME	GSK-1842799C
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0T4ME
DRUGNAME	V930
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0T4MK
DRUGNAME	Andexanet alfa
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Application submitted
INDICATI	Harmful effects of drugs, medicaments or biological substances [ICD-11: NE60] Application submitted
	
TTDDRUID	D0T4NV
DRUGNAME	CDX-1135
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
	
TTDDRUID	D0T4OE
DRUGNAME	Palinavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0T4OT
DRUGNAME	Zilascorb (2H)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0T4PA
DRUGNAME	TAK-243
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0T4QA
DRUGNAME	LXH254
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0T4QX
DRUGNAME	CTEP
INDICATI	Fragile X syndrome [ICD-11: LD55] Investigative
	
TTDDRUID	D0T4SG
DRUGNAME	AZD1981
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0T4SJ
DRUGNAME	SCH-546909
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T4SO
DRUGNAME	PRO-367
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0T4TN
DRUGNAME	Vasoactive intestinal peptide
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0T4UL
DRUGNAME	PD-348292
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D0T4WA
DRUGNAME	Trimazosin
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0T4WK
DRUGNAME	AAV2 GDNF
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0T4XQ
DRUGNAME	SEP-227162
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D0T4XV
DRUGNAME	SL-18.1616
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Terminated
	
TTDDRUID	D0T4YH
DRUGNAME	PF-03716539
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0T4YZ
DRUGNAME	CNSB-004
INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical
	
TTDDRUID	D0T4ZW
DRUGNAME	MP-RM-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T5AH
DRUGNAME	PHA-690509
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T5AW
DRUGNAME	Desoxypeganine
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 1
	
TTDDRUID	D0T5BC
DRUGNAME	Lactulose
INDICATI	Constipation [ICD-11: DD91.1] Approved
	
TTDDRUID	D0T5CH
DRUGNAME	HSC835
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	D0T5DC
DRUGNAME	CAR-T cells targeting CEA
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
	
TTDDRUID	D0T5DE
DRUGNAME	Barium sulfate
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved
	
TTDDRUID	D0T5DP
DRUGNAME	Selumetinib
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T5ES
DRUGNAME	MUC-1 cancer vaccine
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D0T5FO
DRUGNAME	CVA-21 DAF
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T5FU
DRUGNAME	DS-3801
INDICATI	Constipation [ICD-11: DD91.1] Phase 1
	
TTDDRUID	D0T5GO
DRUGNAME	Erythropoietin gene therapy
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2
	
TTDDRUID	D0T5GT
DRUGNAME	CE-1037
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D0T5HO
DRUGNAME	Vaxfectin plasmid DNA pandemic influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0T5IN
DRUGNAME	PX-867
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D0T5JG
DRUGNAME	TDI-0114
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0T5JS
DRUGNAME	TT-100
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0T5LQ
DRUGNAME	123-Iodine-labeled MFE-23
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0T5MB
DRUGNAME	Lu-35138
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2
	
TTDDRUID	D0T5NB
DRUGNAME	GS-4774
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0T5NI
DRUGNAME	Saperconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 2
	
TTDDRUID	D0T5OX
DRUGNAME	Remifentanil
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0T5PH
DRUGNAME	Relacatib
INDICATI	Bone metastases [ICD-11: 2D50] Discontinued in Phase 2
INDICATI	Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1
	
TTDDRUID	D0T5QC
DRUGNAME	AAV1-FS344
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1/2
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1/2
INDICATI	Inclusion body myositis [ICD-11: 4A41.2] Phase 1/2
	
TTDDRUID	D0T5QT
DRUGNAME	Becaplermin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0T5SG
DRUGNAME	ME-3221
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0T5SZ
DRUGNAME	PNU-142721
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0T5TN
DRUGNAME	CJM112
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
INDICATI	Chronic plaque psoriasis [ICD-11: EA90.0] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0T5TU
DRUGNAME	TPI-1020
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0T5UL
DRUGNAME	Benzphetamine
INDICATI	Obesity [ICD-11: 5B81] Approved
	
TTDDRUID	D0T5VD
DRUGNAME	EVK-001
INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 3
	
TTDDRUID	D0T5VQ
DRUGNAME	Mearubik
INDICATI	Measles [ICD-11: 1F03] Approved
	
TTDDRUID	D0T5WA
DRUGNAME	Healive
INDICATI	Hepatitis A virus infection [ICD-11: 1E50.0] Approved
	
TTDDRUID	D0T5WK
DRUGNAME	Nitrazepam
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0T5XN
DRUGNAME	LEURUBICIN
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0T5YB
DRUGNAME	MEDI6012
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 1
	
TTDDRUID	D0T5YX
DRUGNAME	DM-71
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0T5ZC
DRUGNAME	BAY-50-9062
INDICATI	Osteoporosis [ICD-11: FB83.0] Terminated
	
TTDDRUID	D0T5ZM
DRUGNAME	NAChR APLs
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0T6AY
DRUGNAME	WX-04554
INDICATI	Bone disease [ICD-11: FC0Z] Investigative
	
TTDDRUID	D0T6BA
DRUGNAME	S-16924
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0T6CN
DRUGNAME	BL-8040
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D0T6EE
DRUGNAME	ACE-031
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D0T6EI
DRUGNAME	Sarecycline 
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
	
TTDDRUID	D0T6ES
DRUGNAME	SSR-125329A
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1
	
TTDDRUID	D0T6FY
DRUGNAME	KD-901
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0T6IM
DRUGNAME	Tetomilast
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0T6IN
DRUGNAME	Peginterferon lambda-1a
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	D0T6IP
DRUGNAME	Cefetamet pivoxil hcl
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0T6KI
DRUGNAME	CAR-T cells targeting CD80/86
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0T6KV
DRUGNAME	GSK933776A
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0T6LF
DRUGNAME	PF-3823863
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T6LU
DRUGNAME	H1N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0T6MM
DRUGNAME	AM-94
INDICATI	Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Discontinued in Phase 2
	
TTDDRUID	D0T6MU
DRUGNAME	FR-113680
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0T6NG
DRUGNAME	CAR-T cells targeting CD138
INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial
	
TTDDRUID	D0T6NS
DRUGNAME	ACPC
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0T6NX
DRUGNAME	Biphenyl mannoside derivative 29
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0T6PF
DRUGNAME	IMX-MEL1
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0T6PV
DRUGNAME	DV-7751A
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D0T6QX
DRUGNAME	ZOTEPINE
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0T6RC
DRUGNAME	Dihydrocodeine
INDICATI	Cancer related pain [ICD-11: MG30] Phase 4
	
TTDDRUID	D0T6RG
DRUGNAME	SAR113244
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D0T6SU
DRUGNAME	Phendimetrazine
INDICATI	Obesity [ICD-11: 5B81] Approved
	
TTDDRUID	D0T6TH
DRUGNAME	EVT-501
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Investigative
	
TTDDRUID	D0T6TQ
DRUGNAME	IS-0402
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0T6TW
DRUGNAME	GSK642444
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D0T6UW
DRUGNAME	Tetraoxane derivatives
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0T6VD
DRUGNAME	Meglumine antimoniate
INDICATI	Leishmania braziliensis infection [ICD-11: 1F54.2] Approved
	
TTDDRUID	D0T6VU
DRUGNAME	ED-110
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0T6WN
DRUGNAME	Rilpivirine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0T6WT
DRUGNAME	Heroin diacetylmorphine
INDICATI	Neurological disorder [ICD-11: 6B60] Approved
	
TTDDRUID	D0T6XU
DRUGNAME	Myelopid
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D0T6XX
DRUGNAME	Pantoprazole
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Approved
	
TTDDRUID	D0T7AE
DRUGNAME	OMS-182410
INDICATI	Schizophrenia [ICD-11: 6A20] Investigative
	
TTDDRUID	D0T7BD
DRUGNAME	PF-06669571
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
	
TTDDRUID	D0T7BH
DRUGNAME	Resorcinol compound 34
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0T7BI
DRUGNAME	V160
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 2
	
TTDDRUID	D0T7BV
DRUGNAME	PMID22911925C2
INDICATI	Diabetic complication [ICD-11: 5A2Y] Clinical trial
	
TTDDRUID	D0T7CM
DRUGNAME	UCL-2000; butabindide
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D0T7CR
DRUGNAME	MOv19-BBz CAR T cells
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0T7EZ
DRUGNAME	CL-387626
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated
	
TTDDRUID	D0T7FO
DRUGNAME	MOD-7023
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Investigative
	
TTDDRUID	D0T7GQ
DRUGNAME	APETX2
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0T7GV
DRUGNAME	Picoplatin
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
	
TTDDRUID	D0T7LV
DRUGNAME	LIPO-4
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0T7MJ
DRUGNAME	PF-06412562
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 1
	
TTDDRUID	D0T7MN
DRUGNAME	ZYH-1
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 3
	
TTDDRUID	D0T7MZ
DRUGNAME	GALE-302
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	D0T7OE
DRUGNAME	NEO100
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2
INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1/2
INDICATI	Recurrent malignant glioma [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D0T7OI
DRUGNAME	Anti-LAG3
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0T7OS
DRUGNAME	AL-6802
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T7OW
DRUGNAME	Dopamine
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 1
	
TTDDRUID	D0T7PZ
DRUGNAME	NAI-107
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0T7QC
DRUGNAME	TRU-016
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
	
TTDDRUID	D0T7QN
DRUGNAME	SPN-811
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1
	
TTDDRUID	D0T7QY
DRUGNAME	Pyrazole derivative 38
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0T7US
DRUGNAME	Eprosartan
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0T7VN
DRUGNAME	Aryl mannoside derivative 20
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0T7WL
DRUGNAME	Pirmenol
INDICATI	Heart arrhythmia [ICD-11: BC65] Approved
	
TTDDRUID	D0T7WQ
DRUGNAME	Datelliptium chloride
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D0T7XI
DRUGNAME	Methaqualone
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Withdrawn from market
	
TTDDRUID	D0T7XN
DRUGNAME	E-2070
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated
	
TTDDRUID	D0T7XO
DRUGNAME	IGEL1.2
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0T7YE
DRUGNAME	LYC-55716
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0T7ZQ
DRUGNAME	Estradiol Acetate
INDICATI	Hormone replacement therapy [ICD-11: 8E01] Approved
	
TTDDRUID	D0T8AI
DRUGNAME	Y-90 Clivatuzumab
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
	
TTDDRUID	D0T8BP
DRUGNAME	AH-9700
INDICATI	Pollakiuria [ICD-11: MF50.1] Terminated
	
TTDDRUID	D0T8CE
DRUGNAME	AMG888/U3-1287
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D0T8CQ
DRUGNAME	CP-70949
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0T8DD
DRUGNAME	EPCAM-targeted CAR-T cells
INDICATI	Liver cancer [ICD-11: 2C12] Clinical trial
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Clinical trial
	
TTDDRUID	D0T8EH
DRUGNAME	Pirarubicin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0T8EL
DRUGNAME	AHL
INDICATI	Hearing disorder [ICD-11: AB50-AB57] Investigative
	
TTDDRUID	D0T8GD
DRUGNAME	Nicotine
INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Approved
INDICATI	Tobacco dependence [ICD-11: 6C4A.2] Clinical trial
	
TTDDRUID	D0T8HR
DRUGNAME	Naptumomab estafenatox
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3
	
TTDDRUID	D0T8HU
DRUGNAME	LU-29252
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0T8HZ
DRUGNAME	Pegvaliase
INDICATI	Phenylketonuria [ICD-11: 5C50.0] Approved
	
TTDDRUID	D0T8IW
DRUGNAME	Ultimab IgG1 antibody
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0T8JY
DRUGNAME	BMS-986277
INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0T8KA
DRUGNAME	JNJ-18038683
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0T8KD
DRUGNAME	Eberconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D0T8KF
DRUGNAME	SUN-8399
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D0T8LF
DRUGNAME	Ragweed pollen extract
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 3
	
TTDDRUID	D0T8MA
DRUGNAME	ATN-224
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0T8NS
DRUGNAME	AZD-8677
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D0T8QB
DRUGNAME	GLYCYRRHIZIN
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0T8QE
DRUGNAME	FMX102
INDICATI	Impetigo [ICD-11: 1B72] Phase 2
	
TTDDRUID	D0T8QM
DRUGNAME	MQX-3016
INDICATI	Keratosis [ICD-11: ED56] Investigative
	
TTDDRUID	D0T8QY
DRUGNAME	PMI-008
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0T8RQ
DRUGNAME	166Ho-phytate
INDICATI	Arthropathy [ICD-11: FA11-FA38] Investigative
	
TTDDRUID	D0T8RV
DRUGNAME	BCMA CART and huCART19
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0T8TC
DRUGNAME	VPC-8
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T8VE
DRUGNAME	Aminoazetidine derivative 5
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0T8VV
DRUGNAME	FLM-5011
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D0T8VY
DRUGNAME	Aceclofenac
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0T8XB
DRUGNAME	Anagliptin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D0T8XD
DRUGNAME	Imidazo[1,2-b]pyridazine derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D0T8XY
DRUGNAME	PMID30280939-Compound-WO2015091734
INDICATI	Malaria [ICD-11: 1F40-1F45] Patented
	
TTDDRUID	D0T8YK
DRUGNAME	EP-01492
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0T8YV
DRUGNAME	LymphoRad-131
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1
	
TTDDRUID	D0T8ZA
DRUGNAME	Zohydro ER
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0T9CD
DRUGNAME	Cobacan
INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Investigative
	
TTDDRUID	D0T9CE
DRUGNAME	BCMA nanobody CAR-T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0T9CO
DRUGNAME	MelCancerVac
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2/3
	
TTDDRUID	D0T9DA
DRUGNAME	NGF-hTNF
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
	
TTDDRUID	D0T9DN
DRUGNAME	Dimiracetam
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D0T9DT
DRUGNAME	Diatrizoate
INDICATI	Urinary tract disease [ICD-11: GC2Z] Approved
	
TTDDRUID	D0T9DV
DRUGNAME	PMID28621580-Compound-WO2013036866C66
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D0T9FD
DRUGNAME	YKP-3089
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3
	
TTDDRUID	D0T9FU
DRUGNAME	BC-3205
INDICATI	Respiratory tract infection [ICD-11: CA45] Phase 1
	
TTDDRUID	D0T9GM
DRUGNAME	Nanoflu
INDICATI	Seasonal influenza infection [ICD-11: 1E30] Phase 3
	
TTDDRUID	D0T9GQ
DRUGNAME	ASB-010
INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative
	
TTDDRUID	D0T9HG
DRUGNAME	GM6001
INDICATI	Corneal ulcer [ICD-11: 9A76] Discontinued in Phase 2
	
TTDDRUID	D0T9JK
DRUGNAME	VER-82160
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T9JW
DRUGNAME	AU101
INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 1/2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
INDICATI	Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1/2
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 1/2
	
TTDDRUID	D0T9KF
DRUGNAME	RDEA-427
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0T9LH
DRUGNAME	MM-131
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0T9LR
DRUGNAME	Liprotamase
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 3
	
TTDDRUID	D0T9MQ
DRUGNAME	KN-203
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1
	
TTDDRUID	D0T9OC
DRUGNAME	TL-118
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0T9PL
DRUGNAME	BLV-0703
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0T9SJ
DRUGNAME	CEP-4186
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Terminated
	
TTDDRUID	D0T9TE
DRUGNAME	Ombitasvir + paritaprevir + ritonavir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved
	
TTDDRUID	D0T9TJ
DRUGNAME	Orlistat
INDICATI	Obesity [ICD-11: 5B81] Approved
	
TTDDRUID	D0T9TR
DRUGNAME	HR2P-M1 peptide
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0T9YF
DRUGNAME	A-74187
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 3
	
TTDDRUID	D0T9YU
DRUGNAME	Imino sugars
INDICATI	Dengue fever [ICD-11: 1D2Z] Investigative
	
TTDDRUID	D0T9YV
DRUGNAME	STD-06
INDICATI	Dermatological disease [ICD-11: DA24.Y] Investigative
	
TTDDRUID	D0T9ZG
DRUGNAME	PLD-180
INDICATI	Motor neurone disease [ICD-11: 8B60] Terminated
	
TTDDRUID	D0TA3V
DRUGNAME	ADC-5510
INDICATI	Movement disorder [ICD-11: 8A07-8A0Z] Investigative
	
TTDDRUID	D0TA4A
DRUGNAME	GLPG0974
INDICATI	Abortion [ICD-11: JA00] Phase 2
	
TTDDRUID	D0TA8O
DRUGNAME	LTT462
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0TB1L
DRUGNAME	Indium In-111 Chloride
INDICATI	Diagnostic radiopharmaceutical [ICD-11: N.A.] Approved
	
TTDDRUID	D0TB1X
DRUGNAME	AL-0671
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0TB2H
DRUGNAME	Heteroaryl-carboxamide derivative 10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0TB8C
DRUGNAME	Nadrolone phenylpropionate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0TC1T
DRUGNAME	Ro-40-1641
INDICATI	Cognitive impairment [ICD-11: 6D71] Terminated
	
TTDDRUID	D0TC4R
DRUGNAME	Desmoteplase
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 3
	
TTDDRUID	D0TC6X
DRUGNAME	Anti-CD30-CAR T cells
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1
INDICATI	Large cell lymphoma [ICD-11: 2A80.Z] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0TC7C
DRUGNAME	Hidrosmin
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0TC7X
DRUGNAME	Isoquinoline derivative 1
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
	
TTDDRUID	D0TD0O
DRUGNAME	Anti-CD19 CAR-T
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1
INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0TD1R
DRUGNAME	Lusutrombopag
INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved
INDICATI	Liver disease [ICD-11: DB90-BD99] Phase 2
	
TTDDRUID	D0TD2F
DRUGNAME	ES-6864
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0TD2G
DRUGNAME	Canakinumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
INDICATI	Cryopyrin-associated periodic syndromes [ICD-11: 4A60.1] Approved
INDICATI	Vasculitis [ICD-11: 4A44] Phase 2
INDICATI	Urticaria [ICD-11: EB00-EB05] Phase 2
	
TTDDRUID	D0TD7J
DRUGNAME	ALKS 8700
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 3
	
TTDDRUID	D0TE0L
DRUGNAME	4SCAR19 cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0TE8W
DRUGNAME	NSD-801
INDICATI	Ataxia [ICD-11: MB45.0] Investigative
	
TTDDRUID	D0TE9G
DRUGNAME	PF-4957325-00
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0TF1E
DRUGNAME	A-366833
INDICATI	Pain [ICD-11: MG30-MG3Z] Preclinical
	
TTDDRUID	D0TF2D
DRUGNAME	CDX-301 + CDX-1401
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0TG1H
DRUGNAME	Diclofenac
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
	
TTDDRUID	D0TG4K
DRUGNAME	Oxycyte
INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Preclinical
	
TTDDRUID	D0TG4S
DRUGNAME	ASN002
INDICATI	Eczema [ICD-11: EA80-EA89] Phase 2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0TG7I
DRUGNAME	Erythromycin/sulfisoxazole
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved
	
TTDDRUID	D0TG9Q
DRUGNAME	MK-0812
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0TH1Z
DRUGNAME	Naxagolide
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2
	
TTDDRUID	D0TH5H
DRUGNAME	Dapansutrile
INDICATI	Acute gout flare [ICD-11: FA25.0] Phase 2
INDICATI	Musculoskeletal pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D0TH6O
DRUGNAME	AR-132
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated
	
TTDDRUID	D0TI3Q
DRUGNAME	1,2,4,5-tetra-substituted imidazole derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0TI3R
DRUGNAME	FLX-787
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
INDICATI	Muscle spasm [ICD-11: MB47.3] Phase 2
	
TTDDRUID	D0TI4C
DRUGNAME	AK002
INDICATI	Urticaria [ICD-11: EB00-EB05] Phase 2
	
TTDDRUID	D0TI4U
DRUGNAME	EGFR/IGFR tandem adnectin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0TJ0R
DRUGNAME	TA-CIN
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2
	
TTDDRUID	D0TJ3M
DRUGNAME	NSC-281612
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0TJ4D
DRUGNAME	PMID30107136-Compound-Example58
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0TJ7S
DRUGNAME	PDC-41
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Phase 1
	
TTDDRUID	D0TJ9I
DRUGNAME	HSB-13
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0TJ9S
DRUGNAME	N-methanocarbathymidine
INDICATI	Zoster [ICD-11: 1E91] Phase 1
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0TK0W
DRUGNAME	Ro-46-5934
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0TK2J
DRUGNAME	BN-AM-206
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0TK7R
DRUGNAME	LGX818
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D0TL1L
DRUGNAME	Fendrix
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0TL2C
DRUGNAME	Resorcinol compound 18
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0TL7L
DRUGNAME	Dexloxiglumide
INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Phase 2
	
TTDDRUID	D0TM0C
DRUGNAME	LIMAZOCIC
INDICATI	Liver disease [ICD-11: DB90-BD99] Discontinued in Phase 2
	
TTDDRUID	D0TM0Y
DRUGNAME	FT-1101
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0TM7Q
DRUGNAME	Ritonavir + oseltamivir
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0TMF3
DRUGNAME	JNJ-64417184
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1
	
TTDDRUID	D0TN0O
DRUGNAME	PRTT-300
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0TN1J
DRUGNAME	MENK 
INDICATI	Pancreatic tumour [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0TN1N
DRUGNAME	NY-ESO-TCR
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
INDICATI	Myxoid round cell liposarcoma [ICD-11: 2B59] Phase 1/2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
INDICATI	Synovial sarcoma [ICD-11: 2B5A] Phase 1/2
	
TTDDRUID	D0TN3D
DRUGNAME	AZD-7140
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D0TN3Q
DRUGNAME	LY3214996
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0TN4M
DRUGNAME	8H9 I-124 mAb
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D0TN5W
DRUGNAME	HER2-CAR T Cells
INDICATI	Malignant neoplasm [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Phase 1
	
TTDDRUID	D0TN6K
DRUGNAME	LSZ102
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0TN7S
DRUGNAME	BAY-1075553
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0TO0C
DRUGNAME	FPA150
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0TO0F
DRUGNAME	VLDM-01
INDICATI	Prostate hyperplasia [ICD-11: GA90] Investigative
	
TTDDRUID	D0TO2R
DRUGNAME	Fludarabine phosphate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0TP1P
DRUGNAME	CPP -15
INDICATI	Infantile spasm [ICD-11: 8A62.0] Phase 1
	
TTDDRUID	D0TP2W
DRUGNAME	Thymopentin
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D0TP5H
DRUGNAME	Esketamine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 3
	
TTDDRUID	D0TP7T
DRUGNAME	SCY-641
INDICATI	Ocular inflammation [ICD-11: 9C61.24] Preclinical
	
TTDDRUID	D0TP8R
DRUGNAME	Iobenguane Sulfate I-131
INDICATI	Pheochromocytoma [ICD-11: 5A75] Approved
	
TTDDRUID	D0TP8T
DRUGNAME	PMID26651364-Compound-113
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0TP9A
DRUGNAME	CB-30865
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0TQ1G
DRUGNAME	Rimantadine
INDICATI	Influenza A virus infection [ICD-11: 1E30] Approved
	
TTDDRUID	D0TQ4Y
DRUGNAME	PF-06648671
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0TR0Z
DRUGNAME	MOGUISTEINE
INDICATI	Cough [ICD-11: MD12] Discontinued in Preregistration
	
TTDDRUID	D0TR3Y
DRUGNAME	Ovapuldencel-T
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 2
	
TTDDRUID	D0TR4Y
DRUGNAME	LN-145
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2
	
TTDDRUID	D0TR4Z
DRUGNAME	Zindoxifene
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D0TR5X
DRUGNAME	Fluoxetine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0TS0R
DRUGNAME	CD19xCD3 DART
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0TS1Z
DRUGNAME	Floxuridine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
	
TTDDRUID	D0TS2B
DRUGNAME	CAR-T cells targeting CD117
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical
	
TTDDRUID	D0TS3S
DRUGNAME	Heterocyclic-substituted 3-alkyl azetidine derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0TS8E
DRUGNAME	ADX71149
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Discontinued in Phase 2
	
TTDDRUID	D0TT0B
DRUGNAME	1,2,4-triazole derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0TT4H
DRUGNAME	E6005
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	D0TT5I
DRUGNAME	FAS-20013
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0TT5K
DRUGNAME	MDL-27531
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
	
TTDDRUID	D0TT6L
DRUGNAME	SF0166
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 1/2
	
TTDDRUID	D0TU0F
DRUGNAME	LAP-001
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative
	
TTDDRUID	D0TU1E
DRUGNAME	EB-101
INDICATI	Dystrophic epidermolysis bullosa [ICD-11: EC32] Phase 1/2
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0TU7B
DRUGNAME	PQR309
INDICATI	Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 2
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0TU7G
DRUGNAME	SUVN-1004028
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0TU7V
DRUGNAME	MB-12066
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D0TU9W
DRUGNAME	BIIB054
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0TV0C
DRUGNAME	Pasireotide
INDICATI	Cushing disease [ICD-11: 5A70] Approved
	
TTDDRUID	D0TV0E
DRUGNAME	JNJ-64457107
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0TV4N
DRUGNAME	T-226296
INDICATI	Obesity [ICD-11: 5B81] Preclinical
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Investigative
	
TTDDRUID	D0TV6H
DRUGNAME	HuM-195-Ac-225
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1/2
	
TTDDRUID	D0TV6I
DRUGNAME	Safinamide
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
INDICATI	Idiopathic parkinson disease [ICD-11: 8A00.0Z] Phase 3
	
TTDDRUID	D0TV9K
DRUGNAME	Propiverine
INDICATI	Urinary incontinence [ICD-11: MF50.2] Approved
	
TTDDRUID	D0TW1Q
DRUGNAME	DP-3005
INDICATI	Angina pectoris [ICD-11: BA40] Investigative
	
TTDDRUID	D0TW2J
DRUGNAME	CMX-020
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D0TW3L
DRUGNAME	CD20Bi aATC
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0TX5P
DRUGNAME	ITX-5061
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0TX7T
DRUGNAME	Sulglycotide
INDICATI	Active duodenal ulcer [ICD-11: DA63] Approved
	
TTDDRUID	D0TX8Z
DRUGNAME	FLOSATIDIL
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 2
	
TTDDRUID	D0TY0G
DRUGNAME	Mumps skin test antigen
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D0TY0P
DRUGNAME	G-573
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0TY1Q
DRUGNAME	Mannoside derivative 9
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0TY1U
DRUGNAME	TDI-0103
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0TY1Y
DRUGNAME	PfSPZ-Cvac
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	D0TY3L
DRUGNAME	KX-01
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 3
	
TTDDRUID	D0TY5K
DRUGNAME	NWP-09
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3
	
TTDDRUID	D0TY5N
DRUGNAME	Cotinine
INDICATI	Insecticide [ICD-11: N.A.] Approved
	
TTDDRUID	D0TY6U
DRUGNAME	BPX-601
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0TY6Y
DRUGNAME	Avicine
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1
	
TTDDRUID	D0TY8B
DRUGNAME	PGGA-PTX
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0TZ1C
DRUGNAME	Curemisinin
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0TZ1G
DRUGNAME	Procaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0TZ2W
DRUGNAME	PMID25666693-Compound-38
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0TZ6M
DRUGNAME	Phenazopyridine
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0TZ8J
DRUGNAME	Clade A HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0U0AM
DRUGNAME	VGV-1
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3
	
TTDDRUID	D0U0AU
DRUGNAME	AZD-9819
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0U0AY
DRUGNAME	AV-101
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0U0BA
DRUGNAME	AERAS-407 rBCG
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1
	
TTDDRUID	D0U0BN
DRUGNAME	JCAR014
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	Mediastinal large B-cell lymphoma [ICD-11: 2A60.32] Phase 1
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0U0BP
DRUGNAME	DFP 13318
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0U0BU
DRUGNAME	TOK-001
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0U0CF
DRUGNAME	CNTX-0290
INDICATI	Chronic pain [ICD-11: MG30] Phase 1
	
TTDDRUID	D0U0DD
DRUGNAME	Phleum pratense-containing vaccine
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2
	
TTDDRUID	D0U0EC
DRUGNAME	TRemelimumab + MEDI0562
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0U0FH
DRUGNAME	Amitivir
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated
	
TTDDRUID	D0U0GC
DRUGNAME	ZP-012
INDICATI	Urinary tract infection [ICD-11: GC08] Investigative
	
TTDDRUID	D0U0GZ
DRUGNAME	Filibuvir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0U0HX
DRUGNAME	Molgramostim
INDICATI	Autoimmune pulmonary alveolar proteinosis [ICD-11: CB04.31] Phase 3
INDICATI	Wound healing [ICD-11: EL8Y] Phase 1
	
TTDDRUID	D0U0IS
DRUGNAME	NP-02
INDICATI	Heart disease [ICD-11: BA41-BA42] Investigative
	
TTDDRUID	D0U0JL
DRUGNAME	Neo-1507
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D0U0KR
DRUGNAME	CF102
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2
	
TTDDRUID	D0U0KW
DRUGNAME	Ramelteon
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
INDICATI	Circadian rhythm sleep disorder [ICD-11: 7A60-7A65] Terminated
	
TTDDRUID	D0U0NS
DRUGNAME	Myeloma cancer vaccine
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D0U0OF
DRUGNAME	TPI-273
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0U0OT
DRUGNAME	Melevodopa
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0U0PV
DRUGNAME	M-40401
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0U0QC
DRUGNAME	ABBV-2737
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1
	
TTDDRUID	D0U0QI
DRUGNAME	GYKI-16084
INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 2
	
TTDDRUID	D0U0RJ
DRUGNAME	Leukocyte interleukin
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
	
TTDDRUID	D0U0RZ
DRUGNAME	Phentermine
INDICATI	Obesity [ICD-11: 5B81] Approved
	
TTDDRUID	D0U0SD
DRUGNAME	RG-125
INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 1
	
TTDDRUID	D0U0SK
DRUGNAME	GZ402668
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0U0TD
DRUGNAME	Gedocarnil
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D0U0VU
DRUGNAME	SILODOSIN
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved
	
TTDDRUID	D0U0VY
DRUGNAME	CNTO-2476
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	D0U0XD
DRUGNAME	Estradiol Cypionate
INDICATI	Hormone replacement therapy [ICD-11: 8E01] Approved
	
TTDDRUID	D0U0XL
DRUGNAME	NN-7415
INDICATI	Factor IX deficiency [ICD-11: 3B11] Phase 1
	
TTDDRUID	D0U0YR
DRUGNAME	SNAP-7941
INDICATI	Depression [ICD-11: 6A70-6A7Z] Preclinical
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0U1BR
DRUGNAME	Herpes simplex DNA vaccine
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1
	
TTDDRUID	D0U1BU
DRUGNAME	HPP-851
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Preclinical
	
TTDDRUID	D0U1BW
DRUGNAME	SIVIG
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0U1CL
DRUGNAME	PGX-200097
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0U1DD
DRUGNAME	KiroVAX-003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0U1DU
DRUGNAME	NVX-207
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U1FR
DRUGNAME	PBI-1393
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0U1FZ
DRUGNAME	EUK-207
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated
	
TTDDRUID	D0U1GM
DRUGNAME	NexVas VI
INDICATI	Vasculitis [ICD-11: 4A44] Investigative
	
TTDDRUID	D0U1GP
DRUGNAME	CD56 CAR T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0U1HE
DRUGNAME	PEGylated PYY-3-36
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D0U1HN
DRUGNAME	AM-211
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0U1HP
DRUGNAME	Org-24461
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0U1HR
DRUGNAME	Donor-derived CD19/22 bispecific CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D0U1HX
DRUGNAME	DIMS-0150
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
	
TTDDRUID	D0U1IR
DRUGNAME	AP-5346
INDICATI	Head and neck cancer [ICD-11: 2D42] Discontinued in Phase 2
	
TTDDRUID	D0U1KE
DRUGNAME	FF-10502-01
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0U1LQ
DRUGNAME	Rotavirus vaccine
INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0U1MO
DRUGNAME	CERE-120
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0U1NA
DRUGNAME	Fadolmidine
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0U1OE
DRUGNAME	Thioridazine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0U1OM
DRUGNAME	Bromfenac
INDICATI	Postoperative inflammation [ICD-11: 1A00-CA43.1] Approved
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market
	
TTDDRUID	D0U1OO
DRUGNAME	ARM210
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1
	
TTDDRUID	D0U1QE
DRUGNAME	VR736
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0U1SA
DRUGNAME	KTP-001
INDICATI	Intervertebral disc displacement [ICD-11: FB1Y] Phase 1/2
	
TTDDRUID	D0U1SI
DRUGNAME	Bimoclomol
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D0U1TA
DRUGNAME	RHuEPO
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0U1TJ
DRUGNAME	NKTR-194
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0U1UN
DRUGNAME	DWP-10292
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1
	
TTDDRUID	D0U1US
DRUGNAME	18F-FEDAA-1106
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0U1VR
DRUGNAME	AFX-9154
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D0U1VZ
DRUGNAME	Flurpiridaz F 18
INDICATI	Myocardial disease [ICD-11: BC43.20] Phase 3
	
TTDDRUID	D0U1WP
DRUGNAME	MV-CEA
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0U1WU
DRUGNAME	ETBX-011 cancer vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1
	
TTDDRUID	D0U1XG
DRUGNAME	Long-acting hGH conjugate
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2
	
TTDDRUID	D0U1ZD
DRUGNAME	Ioversol
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0U1ZV
DRUGNAME	NERATINIB MALEATE
INDICATI	HER2/NEU overexpressing breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0U2BH
DRUGNAME	Epigallocatechin gallate
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Phase 3
	
TTDDRUID	D0U2CB
DRUGNAME	Ibuproxam
INDICATI	Respiratory disease [ICD-11: CB40] Withdrawn from market
	
TTDDRUID	D0U2CE
DRUGNAME	RM-131
INDICATI	Gastroparesis [ICD-11: DA41.00] Phase 3
INDICATI	Cachexia [ICD-11: MG20] Phase 2
INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 2
	
TTDDRUID	D0U2CT
DRUGNAME	EMITEFUR
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Preregistration
	
TTDDRUID	D0U2CV
DRUGNAME	Trapidil
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 4
INDICATI	Acute coronary syndrome [ICD-11: BA41] Phase 4
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0U2DA
DRUGNAME	BNC-210
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0U2DH
DRUGNAME	CC-1088
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D0U2DO
DRUGNAME	FP-1039
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1b
	
TTDDRUID	D0U2DY
DRUGNAME	Recombinant TSH superagonists
INDICATI	Thyroid cancer [ICD-11: 2D10] Investigative
	
TTDDRUID	D0U2EF
DRUGNAME	ACN-1052
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D0U2FD
DRUGNAME	HIV-PV
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0U2FN
DRUGNAME	Romazarit
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Preclinical
	
TTDDRUID	D0U2GT
DRUGNAME	SA3C
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U2JP
DRUGNAME	Sitagliptin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
INDICATI	Peripheral arterial disease [ICD-11: BD4Z] Phase 1/2
	
TTDDRUID	D0U2KX
DRUGNAME	Aloradine
INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
	
TTDDRUID	D0U2MP
DRUGNAME	BP-Inter-014
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D0U2OO
DRUGNAME	Buspirone
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0U2OQ
DRUGNAME	X-071-NAB
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0U2OS
DRUGNAME	GNE-652
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0U2PS
DRUGNAME	HER2p63-71 peptide vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0U2PU
DRUGNAME	Anti-BCMA CAR T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0U2PY
DRUGNAME	UTI vaccine
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 1
	
TTDDRUID	D0U2QI
DRUGNAME	METH-mab
INDICATI	Methamphetamine dependence [ICD-11: 6C46.2] Phase 1
	
TTDDRUID	D0U2QX
DRUGNAME	4-ethynyl-2-fluoro-deoxyadenosine
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0U2RR
DRUGNAME	NLP-83
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U2TQ
DRUGNAME	CGP-60474
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0U2TZ
DRUGNAME	NYX-2925
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 2
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2
	
TTDDRUID	D0U2WO
DRUGNAME	ONO-2231
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1
	
TTDDRUID	D0U2XB
DRUGNAME	PGC GLP-1
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0U2XU
DRUGNAME	XEN-2174
INDICATI	Cancer related pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D0U3AL
DRUGNAME	Interleukin-12 gene therapy
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
	
TTDDRUID	D0U3CR
DRUGNAME	Guanadrel Sulfate
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0U3DE
DRUGNAME	NT-FV-007
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0U3DP
DRUGNAME	VS-5584
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Malignant mesothelioma [ICD-11: 2C26.0] Phase 1
	
TTDDRUID	D0U3DU
DRUGNAME	Dexmedetomidine
INDICATI	Irritability [ICD-11: MB24] Approved
	
TTDDRUID	D0U3DX
DRUGNAME	Mannose phosphate
INDICATI	Lesion [ICD-11: 8A00-8C12] Discontinued in Phase 2
	
TTDDRUID	D0U3EA
DRUGNAME	BVT 933
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0U3EC
DRUGNAME	Benazepril
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0U3ED
DRUGNAME	E-2007
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Approved
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 3
	
TTDDRUID	D0U3EP
DRUGNAME	Resveratrol
INDICATI	Giant cell arteritis [ICD-11: 4A44.2] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 3
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2
	
TTDDRUID	D0U3FP
DRUGNAME	Her-2/neu vaccine
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	D0U3GA
DRUGNAME	SPC5001
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1
	
TTDDRUID	D0U3GB
DRUGNAME	LIQ-001
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0U3GL
DRUGNAME	Oxandrolone
INDICATI	Alcoholic hepatitis [ICD-11: DB94.1] Approved
	
TTDDRUID	D0U3GT
DRUGNAME	MK-8342B
INDICATI	Contraception [ICD-11: QA21] Phase 2
	
TTDDRUID	D0U3GW
DRUGNAME	PXVX0047
INDICATI	Adenovirus infection [ICD-11: 1A20] Phase 1
	
TTDDRUID	D0U3IG
DRUGNAME	Cetrimide
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Approved
	
TTDDRUID	D0U3IS
DRUGNAME	Benzonaphthyridine derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0U3JZ
DRUGNAME	PMX-30024
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0U3KP
DRUGNAME	HT-100
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D0U3LK
DRUGNAME	Metformin glycinate
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2/3
	
TTDDRUID	D0U3LS
DRUGNAME	Triazolam
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0U3MQ
DRUGNAME	UX001 sialic acid
INDICATI	Hereditary inclusion body myositis [ICD-11: 4A41.2] Phase 2
	
TTDDRUID	D0U3OY
DRUGNAME	Rovelizumab
INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Terminated
	
TTDDRUID	D0U3QK
DRUGNAME	OMS824
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
	
TTDDRUID	D0U3RD
DRUGNAME	Pyrido[3,2-d]pyrimidine derivative 3
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0U3RM
DRUGNAME	AL-508
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0U3RU
DRUGNAME	MK-1107
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0U3RV
DRUGNAME	Motexafin lutetium
INDICATI	Artery stenosis [ICD-11: BD52] Phase 3
	
TTDDRUID	D0U3SK
DRUGNAME	Tiapamil
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0U3SY
DRUGNAME	Alectinib
INDICATI	Lung cancer [ICD-11: 2C25.0] Approved
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0U3TE
DRUGNAME	J-555Y
INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative
	
TTDDRUID	D0U3UJ
DRUGNAME	CHT-25
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1
	
TTDDRUID	D0U3VH
DRUGNAME	STEBVax
INDICATI	Endotoxic shock [ICD-11: 1G41] Phase 1
INDICATI	Toxic shock syndrome [ICD-11: 1B52] Phase 1
	
TTDDRUID	D0U3VU
DRUGNAME	Aminoazetidine derivative 9
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0U3XI
DRUGNAME	FT-061
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D0U3XL
DRUGNAME	JNJ-26483327
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0U3YB
DRUGNAME	Masoprocol
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D0U3YU
DRUGNAME	Ademetionine
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Approved
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 4
	
TTDDRUID	D0U3YW
DRUGNAME	ADC-9971
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Investigative
	
TTDDRUID	D0U3YY
DRUGNAME	Pyrano[2,3-b]pyridine derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0U4CE
DRUGNAME	Bosentan
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Approved
	
TTDDRUID	D0U4EU
DRUGNAME	SB-743921
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0U4FF
DRUGNAME	BMS-599626
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0U4FW
DRUGNAME	DU 125530
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
	
TTDDRUID	D0U4GL
DRUGNAME	GLWL-01
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0U4HZ
DRUGNAME	Bilive
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0U4IG
DRUGNAME	AVP-4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U4IV
DRUGNAME	Elfamycin
INDICATI	Enterocolitis [ICD-11: 1A40.Z] Investigative
	
TTDDRUID	D0U4JX
DRUGNAME	Padoporfin photodynamic therapy
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0U4JY
DRUGNAME	Protease activated prodrug
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U4KJ
DRUGNAME	MTV273
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0U4LP
DRUGNAME	Curcumin-ND
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Investigative
	
TTDDRUID	D0U4PG
DRUGNAME	AEOL-11207
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0U4QQ
DRUGNAME	TNFcept
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0U4QZ
DRUGNAME	EU-517
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U4SM
DRUGNAME	NASVAC
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
	
TTDDRUID	D0U4SS
DRUGNAME	CD-160130
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative
	
TTDDRUID	D0U4UQ
DRUGNAME	Hydrochlorothiazide
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0U4VT
DRUGNAME	Trimethadione
INDICATI	Pancreatic cancer [ICD-11: 2C10] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D0U4WB
DRUGNAME	TLC-C-53
INDICATI	Respiratory distress syndrome [ICD-11: CB00] Terminated
	
TTDDRUID	D0U4WF
DRUGNAME	HCG contraceptive vaccine
INDICATI	Contraception [ICD-11: QA21] Terminated
	
TTDDRUID	D0U4WG
DRUGNAME	SLV-307
INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated
	
TTDDRUID	D0U4WY
DRUGNAME	BILD-1357
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Terminated
	
TTDDRUID	D0U4XC
DRUGNAME	Carticel
INDICATI	Articular cartilage disorder [ICD-11: FA34.Y] Approved
	
TTDDRUID	D0U4XJ
DRUGNAME	Luliconazole
INDICATI	Tinea pedis [ICD-11: 1F28.2] Approved
INDICATI	Dry eye disease [ICD-11: 9E1Z] Phase 2/3
	
TTDDRUID	D0U4YD
DRUGNAME	YKP10461
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0U4YG
DRUGNAME	Penicillin G Benzathine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0U5AN
DRUGNAME	ImmuFact IMP321
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
	
TTDDRUID	D0U5AQ
DRUGNAME	ATLCAR.CD30.CCR4 cells
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Phase 1
INDICATI	Immunoproliferative disorder [ICD-11: 2B32] Phase 1
INDICATI	Lymphatic disease [ICD-11: BD9Z] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0U5BF
DRUGNAME	ALPHA-FMH
INDICATI	Pruritus [ICD-11: EC90] Phase 1
	
TTDDRUID	D0U5BV
DRUGNAME	AKT-10082
INDICATI	Vibrio cholerae infection [ICD-11: 1A00] Investigative
	
TTDDRUID	D0U5CE
DRUGNAME	Capsaicin
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Approved
	
TTDDRUID	D0U5CQ
DRUGNAME	PMID25666693-Compound-54
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0U5CS
DRUGNAME	LY354740
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D0U5EU
DRUGNAME	SC-45662
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0U5EY
DRUGNAME	Org-37684
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0U5FF
DRUGNAME	Leuprolide
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D0U5FS
DRUGNAME	Fluspirilene
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0U5GB
DRUGNAME	Lopinavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0U5GI
DRUGNAME	RP-66784
INDICATI	Angina pectoris [ICD-11: BA40] Terminated
	
TTDDRUID	D0U5GU
DRUGNAME	PMID26815044-Compound-125
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0U5GX
DRUGNAME	CXB-724
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative
	
TTDDRUID	D0U5GZ
DRUGNAME	Zadaxin/transarterial chemoembolization(TACE) (cisplatin)
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 3
	
TTDDRUID	D0U5HB
DRUGNAME	Thiazole carboxamide derivative 5
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0U5HU
DRUGNAME	Cisplatin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 2
	
TTDDRUID	D0U5HY
DRUGNAME	Anti-TAG-72 antibody
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U5JJ
DRUGNAME	KT-105
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U5JP
DRUGNAME	MEM-3454
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0U5JR
DRUGNAME	H7N3 avian influenza virus live attenuated vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0U5NO
DRUGNAME	CAR-CD19 T cell
INDICATI	B-cell lymphoma [ICD-11: 2A86] Clinical trial
INDICATI	leukaemia [ICD-11: 2A60-2B33] Clinical trial
	
TTDDRUID	D0U5NU
DRUGNAME	GLENVASTATIN
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D0U5NW
DRUGNAME	BVT-24834
INDICATI	Obesity [ICD-11: 5B81] Terminated
	
TTDDRUID	D0U5NY
DRUGNAME	JTT-553
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D0U5OB
DRUGNAME	Charybdotoxin
INDICATI	Scorpion envenoming syndrome [ICD-11: 8D43] Approved
	
TTDDRUID	D0U5OE
DRUGNAME	Loxapine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0U5ON
DRUGNAME	PMID25666693-Compound-125
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0U5OU
DRUGNAME	Naproxcinod
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 3
	
TTDDRUID	D0U5PR
DRUGNAME	Seridopidine
INDICATI	Neurological disorder [ICD-11: 6B60] Terminated
	
TTDDRUID	D0U5PT
DRUGNAME	GS-9901
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0U5QK
DRUGNAME	Acetaminophen
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0U5RT
DRUGNAME	Primidone
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
	
TTDDRUID	D0U5SC
DRUGNAME	CT-102
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved
	
TTDDRUID	D0U5SI
DRUGNAME	Procainamide
INDICATI	Ventricular arrhythmias [ICD-11: BC71] Approved
	
TTDDRUID	D0U5SU
DRUGNAME	FM-301
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Investigative
	
TTDDRUID	D0U5UC
DRUGNAME	KD025
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 1
INDICATI	Scleroderma [ICD-11: 4A42] Phase 1
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D0U5VM
DRUGNAME	HBN-1
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0U5VX
DRUGNAME	Human AM/AMBP-1
INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative
	
TTDDRUID	D0U5VZ
DRUGNAME	Bepotastine
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0U5WB
DRUGNAME	Alpha-type-1 polarized dendritic cells
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative
	
TTDDRUID	D0U5XI
DRUGNAME	PMID28270021-Compound-WO2015042088Example11
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0U5YJ
DRUGNAME	14F7 humanized mab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U5YM
DRUGNAME	ONO-6950
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0U5YW
DRUGNAME	Travoprost punctal plug
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
	
TTDDRUID	D0U5ZV
DRUGNAME	AT-3375
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0U6AI
DRUGNAME	I-A09
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0U6AL
DRUGNAME	BI-L-357
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0U6BB
DRUGNAME	L-703014
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0U6BJ
DRUGNAME	Desoxyribonuclease
INDICATI	Female genital tract inflammation [ICD-11: GA0Z] Approved
	
TTDDRUID	D0U6BQ
DRUGNAME	Anti-VEGFR2 CD8 cell therapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0U6CL
DRUGNAME	CC-10015
INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 1
	
TTDDRUID	D0U6DC
DRUGNAME	PF-4967544
INDICATI	Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 1
	
TTDDRUID	D0U6DZ
DRUGNAME	L-erythro-3-hydroxyaspartate
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0U6EX
DRUGNAME	Quadracel
INDICATI	leukaemia [ICD-11: 2A60-2B33] Approved
	
TTDDRUID	D0U6FT
DRUGNAME	GSI-136
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0U6KH
DRUGNAME	Figitumumab
INDICATI	Malignant adrenal gland cancer [ICD-11: 2D11] Discontinued in Phase 1
	
TTDDRUID	D0U6LM
DRUGNAME	Midazolam
INDICATI	Irritability [ICD-11: MB24] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 3
	
TTDDRUID	D0U6ML
DRUGNAME	CKD602
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0U6NC
DRUGNAME	PJ-016
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Investigative
	
TTDDRUID	D0U6NV
DRUGNAME	ISIS-1082
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated
	
TTDDRUID	D0U6PA
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 9
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0U6PJ
DRUGNAME	PC-SOD
INDICATI	Interstitial lung disease [ICD-11: CB0Z] Phase 2
	
TTDDRUID	D0U6PK
DRUGNAME	ACY-001
INDICATI	Coronary ischemia [ICD-11: BA50-BA51] Phase 1
	
TTDDRUID	D0U6PZ
DRUGNAME	VS1-011
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U6QN
DRUGNAME	ACH-3102
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0U6RP
DRUGNAME	AL-072
INDICATI	Legionella infection [ICD-11: 1C19] Terminated
	
TTDDRUID	D0U6TV
DRUGNAME	UltraGITRL
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U6UK
DRUGNAME	Tabalumab
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
	
TTDDRUID	D0U6WC
DRUGNAME	RM-4864
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0U6WQ
DRUGNAME	PRALNACASAN
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0U6XE
DRUGNAME	PAN-90806
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 1
	
TTDDRUID	D0U7AH
DRUGNAME	NurOwn
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3
	
TTDDRUID	D0U7BW
DRUGNAME	Carbachol
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Approved
	
TTDDRUID	D0U7CO
DRUGNAME	CRE-319M2
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Discontinued in Phase 1
	
TTDDRUID	D0U7CP
DRUGNAME	KX-03
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0U7DI
DRUGNAME	SM-10661
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2
	
TTDDRUID	D0U7GA
DRUGNAME	Recombinant human fibrinogen
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D0U7GE
DRUGNAME	KUR-116
INDICATI	Spinal disease [ICD-11: FA72] Investigative
	
TTDDRUID	D0U7GK
DRUGNAME	Thalidomide
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
	
TTDDRUID	D0U7GP
DRUGNAME	RAUWOLFIA SERPENTINA ROOT
INDICATI	Discovery agent [ICD-11: N.A.] Approved
	
TTDDRUID	D0U7GW
DRUGNAME	PF-431499
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D0U7HD
DRUGNAME	SQ-33961
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0U7HJ
DRUGNAME	Certoparin sodium
INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved
	
TTDDRUID	D0U7HL
DRUGNAME	N-5984
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D0U7IG
DRUGNAME	SD-281
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0U7IL
DRUGNAME	LX-4211
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D0U7KM
DRUGNAME	Boostrix
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D0U7KR
DRUGNAME	FR-118487
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0U7LW
DRUGNAME	Thiazole carboxamide derivative 26
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0U7NG
DRUGNAME	BAY 86-8050
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	D0U7OS
DRUGNAME	CARD-024
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D0U7PM
DRUGNAME	OPL-CCL2-LPM
INDICATI	Arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0U7PS
DRUGNAME	GSK256066
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0U7SH
DRUGNAME	Desmopressin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0U7SR
DRUGNAME	RO-4998452
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0U7SU
DRUGNAME	Interferon-alpha lozenge
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
INDICATI	Behcet disease [ICD-11: 4A62] Phase 2
	
TTDDRUID	D0U7VO
DRUGNAME	CNS-1307
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0U7VS
DRUGNAME	CAR-T cells targeting CD19
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0U7VU
DRUGNAME	MLN0264
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 2
	
TTDDRUID	D0U7VZ
DRUGNAME	TD-2749
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 1
	
TTDDRUID	D0U7WF
DRUGNAME	16,16-dimethyl-PGE2
INDICATI	Stem cell engraftment [ICD-11: QB63.8] Phase 2
	
TTDDRUID	D0U7WN
DRUGNAME	A-80987
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0U7WY
DRUGNAME	Anti-CD19/BCMA CAR-T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0U7XJ
DRUGNAME	BCA101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0U7ZY
DRUGNAME	SP-MET-1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical
	
TTDDRUID	D0U8AD
DRUGNAME	TLV-1
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D0U8AR
DRUGNAME	DMP-851
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0U8AS
DRUGNAME	Telapristone
INDICATI	Endometriosis [ICD-11: GA10] Phase 2
	
TTDDRUID	D0U8AT
DRUGNAME	Echothiophate Iodide
INDICATI	Chronic glaucoma [ICD-11: 9C61.0Z] Approved
	
TTDDRUID	D0U8CR
DRUGNAME	S-06911
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 3
	
TTDDRUID	D0U8EA
DRUGNAME	S-41744
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D0U8FG
DRUGNAME	APS-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0U8GH
DRUGNAME	LPCN-1056
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0U8IJ
DRUGNAME	SDZ-PCO-400
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D0U8IU
DRUGNAME	PerioPatch
INDICATI	Periodontal disease [ICD-11: DA0C] Phase 2
	
TTDDRUID	D0U8JN
DRUGNAME	Pegaspargase
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0U8KA
DRUGNAME	CGP-43371
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0U8LD
DRUGNAME	MGN-1706
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0U8MF
DRUGNAME	Theradigm-HPV
INDICATI	Carcinoma [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0U8OD
DRUGNAME	CIMICOXIB
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0U8PE
DRUGNAME	CAR19 T cells carrying cytoplasmic activated PD-1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0U8PR
DRUGNAME	HPP-593
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 1
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0U8QB
DRUGNAME	JTT-851
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0U8QC
DRUGNAME	AS-210
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1/2
	
TTDDRUID	D0U8QH
DRUGNAME	GDC-0349
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0U8TW
DRUGNAME	APV-001
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0U8US
DRUGNAME	Interferon gamma-1b
INDICATI	Chronic granulomatous disease [ICD-11: 4A00.0Y] Approved
	
TTDDRUID	D0U8UV
DRUGNAME	Dimenhydrinate
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D0U8VO
DRUGNAME	Lopinavir + ritonavir + interferon beta-1b
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 2/3
	
TTDDRUID	D0U8WW
DRUGNAME	NLCQ-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U8XD
DRUGNAME	KIN-806
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0U8XE
DRUGNAME	Bemcentinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0U8XW
DRUGNAME	APX-3330
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Ocular cancer [ICD-11: 2D00-2D07] Discontinued in Phase 2
	
TTDDRUID	D0U8YK
DRUGNAME	NN5401
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
	
TTDDRUID	D0U8YZ
DRUGNAME	PMID25666693-Compound-45
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0U8ZD
DRUGNAME	OPT-822/OPT-821
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0U9AE
DRUGNAME	AIKa1
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D0U9EN
DRUGNAME	Actimmune
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved
INDICATI	Cystic fibrosis [ICD-11: CA25] Approved
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Approved
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0U9FD
DRUGNAME	Trospium chloride
INDICATI	Discovery agent [ICD-11: N.A.] Approved
	
TTDDRUID	D0U9FJ
DRUGNAME	KA-40X
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0U9GZ
DRUGNAME	Recombinant protein subunit vaccine, Emergent
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Preclinical
	
TTDDRUID	D0U9HM
DRUGNAME	GSK-1322888
INDICATI	Gastroparesis [ICD-11: DA41.00] Phase 1
	
TTDDRUID	D0U9IQ
DRUGNAME	PF-477736
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0U9IZ
DRUGNAME	Alkaline Phosphatase
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
	
TTDDRUID	D0U9JL
DRUGNAME	LY-223982
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0U9LL
DRUGNAME	NKS-01
INDICATI	Bladder cancer [ICD-11: 2C94] Discontinued in Phase 2
	
TTDDRUID	D0U9LT
DRUGNAME	Y-39983
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2
	
TTDDRUID	D0U9LV
DRUGNAME	LY-2428757
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0U9MJ
DRUGNAME	Melanoma vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D0U9MN
DRUGNAME	ACAM-Cdiff
INDICATI	Traveler's diarrhea [ICD-11: ME05.1] Phase 2
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2
	
TTDDRUID	D0U9MR
DRUGNAME	Tilidine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0U9NN
DRUGNAME	OG987SC
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0U9OC
DRUGNAME	ASP8374
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0U9OD
DRUGNAME	CreaVax-RA
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2a
	
TTDDRUID	D0U9OJ
DRUGNAME	GSK-326416
INDICATI	Gastroparesis [ICD-11: DA41.00] Preclinical
	
TTDDRUID	D0U9PV
DRUGNAME	CXB-909
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1/2
	
TTDDRUID	D0U9QT
DRUGNAME	UMN-03
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D0U9QU
DRUGNAME	Ibopamine hci
INDICATI	Cardiac disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0U9RR
DRUGNAME	Quinoxaline
INDICATI	Arteriosclerosis [ICD-11: BD40] Preclinical
	
TTDDRUID	D0U9SM
DRUGNAME	OX-641
INDICATI	Migraine [ICD-11: 8A80] Terminated
	
TTDDRUID	D0U9TM
DRUGNAME	Ponalrestat
INDICATI	Gout [ICD-11: FA25] Discontinued in Phase 3
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0U9UF
DRUGNAME	A-967079
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0U9VO
DRUGNAME	PF-2575799
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D0U9WS
DRUGNAME	LEO-32731
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0U9YV
DRUGNAME	PAT-PM-1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative
	
TTDDRUID	D0UA0I
DRUGNAME	Metergolin
INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Approved
	
TTDDRUID	D0UA0U
DRUGNAME	CAR-T cells targeting CD30
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0UA0Y
DRUGNAME	HKI-46F08
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0UA2Z
DRUGNAME	Epicillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0UA6W
DRUGNAME	Pyrazole derivative 33
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0UA9J
DRUGNAME	VT-1129
INDICATI	Onchocerciasis [ICD-11: 1F6A] Phase 2
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2
INDICATI	Cryptococcal meningitis infection [ICD-11: 1D01.10] Phase 1
	
TTDDRUID	D0UB0T
DRUGNAME	PD176078
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0UB1J
DRUGNAME	BRL-44385
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated
	
TTDDRUID	D0UB5A
DRUGNAME	IC14
INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 2
	
TTDDRUID	D0UB8U
DRUGNAME	Alkyl mannoside derivative 6
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0UC5C
DRUGNAME	DP-1038
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1
	
TTDDRUID	D0UC5G
DRUGNAME	MBN-101
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
	
TTDDRUID	D0UC6H
DRUGNAME	Chlamydocin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0UD1J
DRUGNAME	EDP1066
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0UD1Y
DRUGNAME	Neladenoson bialanate
INDICATI	Chronic heart failure [ICD-11: BD1Z] Phase 2
	
TTDDRUID	D0UD4Y
DRUGNAME	PQ-912
INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 2
	
TTDDRUID	D0UD5P
DRUGNAME	BPR-DC-2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0UD6S
DRUGNAME	NY-ESO-1/LAGE-1-specific T-cells
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Phase 1/2
	
TTDDRUID	D0UD6X
DRUGNAME	Imidazopyridazine derivative 3
INDICATI	Pain [ICD-11: MG30-MG3Z] Patented
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D0UE3F
DRUGNAME	Biphenyl mannoside derivative 28
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0UE8P
DRUGNAME	Recombinant grass pollen allergens
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 3
	
TTDDRUID	D0UE9K
DRUGNAME	PMID25666693-Compound-83
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0UE9X
DRUGNAME	Gamolenic acid
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D0UF0N
DRUGNAME	ACP-319
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
	
TTDDRUID	D0UF1D
DRUGNAME	RG7986
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0UF2N
DRUGNAME	DIADENOSINE TETRAPHOSPHATE
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Phase 2
	
TTDDRUID	D0UF5I
DRUGNAME	MPC-0920
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1
	
TTDDRUID	D0UF6M
DRUGNAME	Thiacetazone
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Approved
	
TTDDRUID	D0UF8E
DRUGNAME	XOMA-629
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0UF8M
DRUGNAME	IMO-9200
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
	
TTDDRUID	D0UF9W
DRUGNAME	Pegaptanib
INDICATI	Neovascular age-related macular degeneration [ICD-11: 9B78.3Z] Approved
	
TTDDRUID	D0UG0K
DRUGNAME	Trastuzumab emtansine
INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0UG3Q
DRUGNAME	VBP-245
INDICATI	Molluscum contagiosum infection [ICD-11: 1E76] Phase 2
	
TTDDRUID	D0UG4P
DRUGNAME	Egaptivon pegol
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D0UG4T
DRUGNAME	CDP840
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D0UG9S
DRUGNAME	Biphenyl mannoside derivative 7
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0UH0S
DRUGNAME	H1N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0UH4P
DRUGNAME	Vasculan
INDICATI	Systemic sclerosis [ICD-11: 4A42] Phase 2
	
TTDDRUID	D0UH4T
DRUGNAME	GW-493838
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2
	
TTDDRUID	D0UH7R
DRUGNAME	Etrolizumab
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
	
TTDDRUID	D0UI0B
DRUGNAME	VTX-763
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0UI0I
DRUGNAME	BL-3010
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1/2
	
TTDDRUID	D0UI3T
DRUGNAME	Elagolix
INDICATI	Uterine fibroids [ICD-11: 2E86.0] Phase 3
	
TTDDRUID	D0UI3Z
DRUGNAME	H1N1 influenza A inactivated split virion vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0UI4K
DRUGNAME	VB4-847
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2
	
TTDDRUID	D0UI4L
DRUGNAME	ND-0801
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1/2
	
TTDDRUID	D0UI4S
DRUGNAME	PF-3475952
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0UI7K
DRUGNAME	Emapalumab
INDICATI	Primary haemophagocytic lymphohistiocytosis [ICD-11: 4A01.23] Approved
	
TTDDRUID	D0UI8K
DRUGNAME	Apogen MS
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1
	
TTDDRUID	D0UI8Y
DRUGNAME	Encapsulated human islet allografts
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	D0UJ3C
DRUGNAME	CD38-specific gene-engineered T cells
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0UJ8E
DRUGNAME	Sch-49209
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0UJ9N
DRUGNAME	Promethazine
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0UK1L
DRUGNAME	EP-217609
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2
	
TTDDRUID	D0UK1Q
DRUGNAME	Prosaptide TX14(A)
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 2
	
TTDDRUID	D0UK1S
DRUGNAME	PMID26651364-Compound-126a
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0UK2N
DRUGNAME	CMT-02
INDICATI	Charcot marie tooth disease [ICD-11: 8C21.Z] Phase 3
	
TTDDRUID	D0UK2Z
DRUGNAME	Vitespen
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D0UK3A
DRUGNAME	Hydroxychloroquine
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0UK7B
DRUGNAME	REGN1400
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0UK7Z
DRUGNAME	Emetine hydrochloride
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0UL0R
DRUGNAME	BK-C-0701
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 3
	
TTDDRUID	D0UL2I
DRUGNAME	PF-06427878
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D0UL2L
DRUGNAME	Lornoxicam
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0UL2X
DRUGNAME	CC-90010
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0UL5X
DRUGNAME	SK-7041
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0UL7L
DRUGNAME	Recombinant human Erbb3 fragment therapeutic tumor vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0UL9R
DRUGNAME	Tesamorelin
INDICATI	HIV-associated lipodystrophy [ICD-11: 1C62.1] Approved
	
TTDDRUID	D0UM1Y
DRUGNAME	SNX-2
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0UM3M
DRUGNAME	AQST-120
INDICATI	LennoxGastaut syndrome [ICD-11: 8A62.1] Application submitted
	
TTDDRUID	D0UM4S
DRUGNAME	ASG-15ME
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 1
	
TTDDRUID	D0UM7H
DRUGNAME	BIA-12
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0UM7O
DRUGNAME	Ketamine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0UM8Q
DRUGNAME	UCART019
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D0UN1S
DRUGNAME	Tigapotide
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0UN4M
DRUGNAME	Six-membered heterocyclic benzamide derivative 5
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0UN8H
DRUGNAME	IC261
INDICATI	Pancreatic cancer [ICD-11: 2C10] Preclinical
	
TTDDRUID	D0UN9X
DRUGNAME	Imidazopyridazine derivative 4
INDICATI	Pain [ICD-11: MG30-MG3Z] Patented
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D0UO0C
DRUGNAME	MAK683
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
	
TTDDRUID	D0UO2H
DRUGNAME	NMS-P715
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0UO2N
DRUGNAME	BUTIXOCORT
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0UO2P
DRUGNAME	Avapritinib
INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Approved
INDICATI	Mast cell leukaemia [ICD-11: 2A21.00] Phase 1
INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Phase 1
	
TTDDRUID	D0UO4B
DRUGNAME	RQ-00000005
INDICATI	Frailty [ICD-11: MG2A] Phase 2
	
TTDDRUID	D0UO6M
DRUGNAME	ReN-004
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0UO7V
DRUGNAME	DW-800
INDICATI	Mucositis [ICD-11: CA00] Investigative
	
TTDDRUID	D0UO9R
DRUGNAME	RGX-202
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1
	
TTDDRUID	D0UO9T
DRUGNAME	VR-147
INDICATI	Migraine [ICD-11: 8A80] Terminated
	
TTDDRUID	D0UP0A
DRUGNAME	CAL-201
INDICATI	Metapneumovirus infection [ICD-11: CA40.13] Investigative
	
TTDDRUID	D0UP1U
DRUGNAME	Recombinant plasmin
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0UP1Z
DRUGNAME	GDC-0032
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3
	
TTDDRUID	D0UP2Y
DRUGNAME	RVEc
INDICATI	Intoxication [ICD-11: 6C40-6C4B] Phase 1
	
TTDDRUID	D0UP5N
DRUGNAME	PN-2107
INDICATI	Gout [ICD-11: FA25] Investigative
	
TTDDRUID	D0UP9M
DRUGNAME	Gusperimus trihydrochloride
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Approved
	
TTDDRUID	D0UQ1R
DRUGNAME	Eloctate
INDICATI	Haemophilia A [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0UQ2G
DRUGNAME	Tri-substituted urea derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0UQ5B
DRUGNAME	GSK-1437173A
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 3
	
TTDDRUID	D0UQ5I
DRUGNAME	Botulinum toxin vaccine
INDICATI	Yersinia infection [ICD-11: 1B93] Phase 2
	
TTDDRUID	D0UR1Z
DRUGNAME	OncoVAX
INDICATI	Melanoma [ICD-11: 2C30] Preregistration
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
	
TTDDRUID	D0UR4K
DRUGNAME	Cenerimod
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D0UR4L
DRUGNAME	SF-110
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0US1X
DRUGNAME	OCT-1547
INDICATI	Osteoporosis [ICD-11: FB83.0] Preclinical
	
TTDDRUID	D0US3C
DRUGNAME	ZK-90695
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0US5I
DRUGNAME	C-linked disaccharide biphenyl mannoside derivative 2
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0US8M
DRUGNAME	OX-CLI
INDICATI	Respiratory tract inflammation [ICD-11: CA07] Investigative
	
TTDDRUID	D0UT0X
DRUGNAME	Aromatic hydrazine carboxyimidoamide derivative 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0UT3F
DRUGNAME	Nolpitantium besilate
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0UT4W
DRUGNAME	Zanubrutinib
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Approved
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 3
INDICATI	Waldenstrom macroglobulinemia [ICD-11: 2A85.4] Phase 3
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D0UT5A
DRUGNAME	SGN-CD19A
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0UT7E
DRUGNAME	Lopinavir + ritonavir + favipiravir
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0UT7F
DRUGNAME	3K3A-APC
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
	
TTDDRUID	D0UT7X
DRUGNAME	Tideglusib
INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 2
	
TTDDRUID	D0UT9H
DRUGNAME	Cyclohexyl carbamate derivative 5
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0UU1E
DRUGNAME	CC-100
INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 1
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1
	
TTDDRUID	D0UU3J
DRUGNAME	RWJ-37868
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D0UU4B
DRUGNAME	CLS006
INDICATI	Verruca vulgaris [ICD-11: 1E80] Phase 3
	
TTDDRUID	D0UU4D
DRUGNAME	Peniel-5000
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0UU9Y
DRUGNAME	Propentofylline propionate
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D0UV2E
DRUGNAME	VOLT02
INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 2
	
TTDDRUID	D0UV4H
DRUGNAME	GSK-706769
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0UV9F
DRUGNAME	GSK-894281
INDICATI	Gastric motility disorder [ICD-11: DA21] Investigative
	
TTDDRUID	D0UW4A
DRUGNAME	Benzimate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0UW7D
DRUGNAME	Varicella zoster virus vaccine live
INDICATI	Zoster [ICD-11: 1E91] Approved
	
TTDDRUID	D0UX0T
DRUGNAME	Milameline
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3
	
TTDDRUID	D0UX2H
DRUGNAME	HG-1109
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0UX2V
DRUGNAME	BMS-817399
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0UX4A
DRUGNAME	HU-433
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D0UX4J
DRUGNAME	Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1
INDICATI	Cerebral ischemia [ICD-11: 8B11] Patented
	
TTDDRUID	D0UX6Z
DRUGNAME	Heparin Sodium
INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved
INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0UXJ2
DRUGNAME	Omidubicel
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 3
	
TTDDRUID	D0UY8U
DRUGNAME	SNX-002
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0UZ0X
DRUGNAME	ACH-2892
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0UZ1I
DRUGNAME	S-33138
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1
	
TTDDRUID	D0UZ2S
DRUGNAME	PMID26651364-Compound-6d
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0UZ4G
DRUGNAME	99mTc-rBitistatin
INDICATI	Embolism [ICD-11: JB42] Phase 1/2
	
TTDDRUID	D0V0AF
DRUGNAME	Seviprotimut-L
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 3
	
TTDDRUID	D0V0AR
DRUGNAME	HLA-A, B7.1-transfected adenocarcinoma vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0V0BD
DRUGNAME	GFT-1229
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0V0BO
DRUGNAME	Anti-FGFR3
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0V0CJ
DRUGNAME	CO-101
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0V0DI
DRUGNAME	CT-2584
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0V0FQ
DRUGNAME	Brain derived neurotrophic factor
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2
	
TTDDRUID	D0V0HU
DRUGNAME	IFN alpha kinoid
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0V0IO
DRUGNAME	NN9223
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0V0IX
DRUGNAME	Epoprostenol
INDICATI	Pulmonary hypertension [ICD-11: BB01] Approved
	
TTDDRUID	D0V0JQ
DRUGNAME	CHF 5407
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1
	
TTDDRUID	D0V0JR
DRUGNAME	Cadi-05
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0V0JV
DRUGNAME	mabionHER2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0V0KJ
DRUGNAME	IDDBCP161883
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0V0LB
DRUGNAME	Cysteamine
INDICATI	Nephropathic cystinosis [ICD-11: 5C60] Approved
	
TTDDRUID	D0V0NL
DRUGNAME	Aminoguanidine
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 1
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
INDICATI	Insulin-resistant disorder [ICD-11: 5A44] Discontinued in Phase 2
	
TTDDRUID	D0V0OP
DRUGNAME	Polyphenon e
INDICATI	Perianal wart [ICD-11: 1A95] Approved
	
TTDDRUID	D0V0RW
DRUGNAME	BB-1433
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0V0RY
DRUGNAME	Factor ix human
INDICATI	Hemophilia [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0V0SE
DRUGNAME	Alpha-Helical lipopeptides FFS
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0V0SL
DRUGNAME	Abexinostat
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Gynecologic cancer [ICD-11: 2F33-2F76] Phase 2
INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0V0TT
DRUGNAME	CS-204
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Terminated
	
TTDDRUID	D0V0UH
DRUGNAME	AMG 557
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2
	
TTDDRUID	D0V0UW
DRUGNAME	Pyridotriazolopyrimidine derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0V0UX
DRUGNAME	RVLYSIN
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V0VI
DRUGNAME	11C-AZD-2184
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0V0VR
DRUGNAME	CMVpp65-A0201
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 2
	
TTDDRUID	D0V0WE
DRUGNAME	NIA-114
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Clinical trial
	
TTDDRUID	D0V0XV
DRUGNAME	FLU-v
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0V0YA
DRUGNAME	Veltuzumab/epratuzumab Y-90
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
	
TTDDRUID	D0V0YH
DRUGNAME	Flu vaccine
INDICATI	Seasonal influenza infection [ICD-11: 1E30] Approved
	
TTDDRUID	D0V0YM
DRUGNAME	MK-5596
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0V1AV
DRUGNAME	JNJ-61186372
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0V1BY
DRUGNAME	EPI-6
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Investigative
	
TTDDRUID	D0V1CG
DRUGNAME	MLI-1018
INDICATI	Otitis media [ICD-11: AA80-AB0Z] Terminated
	
TTDDRUID	D0V1DG
DRUGNAME	EG-Decorin
INDICATI	Ulcer [ICD-11: CA02-CB40] Investigative
	
TTDDRUID	D0V1ES
DRUGNAME	ALM-301
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V1FF
DRUGNAME	Davunetide
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 3
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2
	
TTDDRUID	D0V1FP
DRUGNAME	RHB-104
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
	
TTDDRUID	D0V1GK
DRUGNAME	KB-5359
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated
	
TTDDRUID	D0V1HK
DRUGNAME	Berlafenone
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D0V1KA
DRUGNAME	MTL-104
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V1KD
DRUGNAME	ALT-022
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D0V1KP
DRUGNAME	N-acetylardeemin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V1KS
DRUGNAME	AZD-2836
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2
	
TTDDRUID	D0V1NI
DRUGNAME	AM-66
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0V1NK
DRUGNAME	VER-54505
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V1OC
DRUGNAME	DA-3880
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1
	
TTDDRUID	D0V1OG
DRUGNAME	Glycosaminoglycans
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0V1OY
DRUGNAME	BC-DU-04
INDICATI	Ulcer [ICD-11: CA02-CB40] Investigative
	
TTDDRUID	D0V1QC
DRUGNAME	Ethacrynic
INDICATI	Edema [ICD-11: MG29] Approved
	
TTDDRUID	D0V1QX
DRUGNAME	Axogenesis Factor-1
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0V1RX
DRUGNAME	Mivazerol
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Phase 3
	
TTDDRUID	D0V1SD
DRUGNAME	BP4.879a
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0V1TV
DRUGNAME	CGEN-991
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D0V1UQ
DRUGNAME	FT-101
INDICATI	Heart disease [ICD-11: BA41-BA42] Investigative
	
TTDDRUID	D0V1UV
DRUGNAME	N-885
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V1UW
DRUGNAME	Nitisinone
INDICATI	Hereditary tyrosinemia type 1 [ICD-11: 5C50.11] Approved
	
TTDDRUID	D0V1UZ
DRUGNAME	BF/PC-21
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0V1VG
DRUGNAME	AMRS-001
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D0V1WL
DRUGNAME	Debio-0826
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V1WQ
DRUGNAME	TAK-875
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0V2CN
DRUGNAME	LAS-37779
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0V2CO
DRUGNAME	ML SA1
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical
	
TTDDRUID	D0V2DC
DRUGNAME	ST-0703
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0V2DV
DRUGNAME	Sodium phosphate dibasic/sodium phosphate monobasic
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
	
TTDDRUID	D0V2FZ
DRUGNAME	111In-hEGF
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical
	
TTDDRUID	D0V2GH
DRUGNAME	Nicergoline
INDICATI	Brain ischaemia [ICD-11: 8B1Z] Approved
INDICATI	Senile dementia [ICD-11: 6D8Z] Approved
	
TTDDRUID	D0V2GT
DRUGNAME	BIBP 3226
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0V2GZ
DRUGNAME	BioVant
INDICATI	Vaccination [ICD-11: N.A.] Investigative
	
TTDDRUID	D0V2JK
DRUGNAME	Nomegestrol acetate
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0V2KD
DRUGNAME	CAT-3000
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0V2KE
DRUGNAME	Oralgen
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D0V2KR
DRUGNAME	Yttrium (90Y) clivatuzumab tetraxetan
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
	
TTDDRUID	D0V2LL
DRUGNAME	PF-06873600
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0V2MB
DRUGNAME	GRNCHND-1
INDICATI	Arthropathy [ICD-11: FA11-FA38] Investigative
	
TTDDRUID	D0V2NJ
DRUGNAME	Somatropin biosimilar
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved
	
TTDDRUID	D0V2NK
DRUGNAME	Clade B HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0V2OL
DRUGNAME	NN1841
INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 3
	
TTDDRUID	D0V2OS
DRUGNAME	DX-9065
INDICATI	Coagulation defect [ICD-11: 3B10.0] Discontinued in Phase 2
	
TTDDRUID	D0V2OX
DRUGNAME	Afamelanotide
INDICATI	Erythropoietic porphyrias [ICD-11: 5C58.12] Approved
INDICATI	Vitiligo [ICD-11: ED63.0] Phase 2
	
TTDDRUID	D0V2PG
DRUGNAME	ALD-701
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0V2PK
DRUGNAME	PHY-808
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V2QU
DRUGNAME	Anti-CD22/CD19 mab-toxin conjugate
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Investigative
	
TTDDRUID	D0V2RF
DRUGNAME	Shigella conjugated and outer membrane vaccine
INDICATI	Diarrhea [ICD-11: ME05.1] Phase 2
	
TTDDRUID	D0V2RK
DRUGNAME	NKP-46
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0V2SP
DRUGNAME	INGN-225
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
	
TTDDRUID	D0V2WK
DRUGNAME	A-70826
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0V2WO
DRUGNAME	PC-DAC:Insulin
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0V2YC
DRUGNAME	OC42-92
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0V2YE
DRUGNAME	Vivia-009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V2YJ
DRUGNAME	MK-0731
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0V2ZC
DRUGNAME	SEL24
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D0V2ZH
DRUGNAME	PAV-611
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0V2ZJ
DRUGNAME	BCX-25
INDICATI	Arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0V3BI
DRUGNAME	Aom-0890
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D0V3BS
DRUGNAME	AT-002
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0V3BZ
DRUGNAME	ME-1071
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0V3CK
DRUGNAME	IMD-1041
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0V3CM
DRUGNAME	Opaviraline
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D0V3EQ
DRUGNAME	AD03 vaccine
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0V3FM
DRUGNAME	Delpazolid
INDICATI	Pulmonary tuberculosis [ICD-11: 1B10.Z] Phase 2
	
TTDDRUID	D0V3GA
DRUGNAME	Acetyldigitoxin
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0V3HC
DRUGNAME	Anti-CD40-XTEN
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0V3HP
DRUGNAME	MP-0112
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
	
TTDDRUID	D0V3HZ
DRUGNAME	BSP-C728
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0V3LD
DRUGNAME	DIO-901
INDICATI	Type-1 diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D0V3LF
DRUGNAME	ECCS-50
INDICATI	Scleroderma [ICD-11: 4A42] Phase 3
	
TTDDRUID	D0V3LM
DRUGNAME	P54
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0V3PI
DRUGNAME	PMID25666693-Compound-36
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0V3PN
DRUGNAME	Withaferin A
INDICATI	Melanoma [ICD-11: 2C30] Terminated
	
TTDDRUID	D0V3QE
DRUGNAME	NSL-036
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Terminated
	
TTDDRUID	D0V3RZ
DRUGNAME	Crisnatol
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D0V3SB
DRUGNAME	Prolastin
INDICATI	Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Approved
	
TTDDRUID	D0V3UN
DRUGNAME	CP-80794
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0V3WE
DRUGNAME	Pseudomonas aeruginosa protein vaccine
INDICATI	Pseudomonas infection [ICD-11: 1B92] Phase 3
	
TTDDRUID	D0V3WN
DRUGNAME	BMN-103
INDICATI	Pompe disease [ICD-11: 5C51.3] Investigative
	
TTDDRUID	D0V3WQ
DRUGNAME	Sch-207758
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0V3XK
DRUGNAME	SWT-02.100
INDICATI	Wound healing [ICD-11: EL8Y] Terminated
	
TTDDRUID	D0V3YT
DRUGNAME	BOCEPREVIR
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved
	
TTDDRUID	D0V3YY
DRUGNAME	NN9828
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D0V3ZA
DRUGNAME	Dihydroergotamine
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0V3ZK
DRUGNAME	GX-H9
INDICATI	Dwarfism [ICD-11: 5B11] Investigative
	
TTDDRUID	D0V3ZN
DRUGNAME	AG-SPT201
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
	
TTDDRUID	D0V3ZX
DRUGNAME	DA-3607
INDICATI	Brain cancer [ICD-11: 2A00] Phase 1
	
TTDDRUID	D0V4AS
DRUGNAME	Cellulose Sodium Phosphate
INDICATI	Hypercalciuria [ICD-11: MF98.0] Approved
	
TTDDRUID	D0V4CL
DRUGNAME	GN-1140
INDICATI	Liver cancer [ICD-11: 2C12] Discontinued in Phase 2
	
TTDDRUID	D0V4DH
DRUGNAME	Estriol E3
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0V4DX
DRUGNAME	PF-06700841
INDICATI	Asthma [ICD-11: CA23] Phase 2
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0V4EX
DRUGNAME	AC-710
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0V4FK
DRUGNAME	SM 11044
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0V4FP
DRUGNAME	OX-30
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0V4GT
DRUGNAME	CMI-206
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0V4GY
DRUGNAME	Chlorhexidine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0V4HO
DRUGNAME	Avoralstat
INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Phase 2/3
	
TTDDRUID	D0V4IB
DRUGNAME	Itraconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D0V4IJ
DRUGNAME	AKCEA-APOCIII-LRX
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2
	
TTDDRUID	D0V4IQ
DRUGNAME	RhGDF-5
INDICATI	Periodontal disease [ICD-11: DA0C] Phase 2
	
TTDDRUID	D0V4JO
DRUGNAME	AMPEROZIDE
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Terminated
	
TTDDRUID	D0V4JQ
DRUGNAME	Interferon beta-1a
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
	
TTDDRUID	D0V4JR
DRUGNAME	Fibrinogen
INDICATI	Pulmonary embolism [ICD-11: BB00] Approved
INDICATI	Deep vein thrombosis [ICD-11: BD71] Approved
	
TTDDRUID	D0V4JW
DRUGNAME	SRPIN-340
INDICATI	Choroidal neovascularization [ICD-11: 9B76] Investigative
	
TTDDRUID	D0V4KL
DRUGNAME	VAR-10200
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0V4LG
DRUGNAME	RS-8891
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D0V4MB
DRUGNAME	Remogliflozin etabonate
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0V4PH
DRUGNAME	Tolerimab
INDICATI	Transplant rejection [ICD-11: NE84] Terminated
	
TTDDRUID	D0V4QE
DRUGNAME	BN-58705
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0V4QS
DRUGNAME	Olanzapine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0V4RH
DRUGNAME	Lobucavir
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 3
	
TTDDRUID	D0V4TV
DRUGNAME	CBLB-502
INDICATI	Acute radiation syndrome [ICD-11: NF00] Phase 2
	
TTDDRUID	D0V4TY
DRUGNAME	Oxidized glutathione
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0V4UF
DRUGNAME	Pramoxine
INDICATI	Anal fistula [ICD-11: DB50.1] Approved
	
TTDDRUID	D0V4UO
DRUGNAME	M-16209
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0V4UR
DRUGNAME	NS-1546
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Terminated
	
TTDDRUID	D0V4VQ
DRUGNAME	WASP gene therapy
INDICATI	Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 1/2
	
TTDDRUID	D0V4WD
DRUGNAME	Ulipristal
INDICATI	Contraception [ICD-11: QA21] Approved
	
TTDDRUID	D0V4WG
DRUGNAME	VR-909
INDICATI	Transplant rejection [ICD-11: NE84] Investigative
	
TTDDRUID	D0V4XA
DRUGNAME	ATH-90879
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0V4XG
DRUGNAME	GSK2793660
INDICATI	Bronchiectasis [ICD-11: CA24] Phase 1
	
TTDDRUID	D0V4XL
DRUGNAME	BMEC-1217B
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1
	
TTDDRUID	D0V4XY
DRUGNAME	S-222611
INDICATI	Malignant solid tumour [ICD-11: 2C10-2F32] Phase 1b
	
TTDDRUID	D0V4YA
DRUGNAME	KHK4083
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
	
TTDDRUID	D0V4YE
DRUGNAME	Technetium Tc-99m Pyro/Trimeta Phosphates Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0V4YO
DRUGNAME	ROCICLOVIR
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 1
	
TTDDRUID	D0V4YT
DRUGNAME	CytoRet
INDICATI	Retinopathy [ICD-11: 9B71] Investigative
	
TTDDRUID	D0V4YW
DRUGNAME	Hepcidin mab
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1
	
TTDDRUID	D0V4ZN
DRUGNAME	Cobicistat/darunavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0V4ZQ
DRUGNAME	SAM-531
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0V5AJ
DRUGNAME	Antithrombin iii
INDICATI	Coagulation defect [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0V5AL
DRUGNAME	LC-1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0V5BJ
DRUGNAME	T-2000
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1
	
TTDDRUID	D0V5BV
DRUGNAME	Benzimidazole derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0V5DD
DRUGNAME	CART-meso-19 T cells
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0V5DX
DRUGNAME	GR-79236
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D0V5FQ
DRUGNAME	Axitirome
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 1
	
TTDDRUID	D0V5GO
DRUGNAME	Allox
INDICATI	Wound healing [ICD-11: EL8Y] Discontinued in Phase 2
	
TTDDRUID	D0V5HA
DRUGNAME	VX-128
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0V5IW
DRUGNAME	Secnidazole
INDICATI	Bacterial vaginosis [ICD-11: MF3A] Approved
INDICATI	Amoebiasis [ICD-11: 1A36] Approved
	
TTDDRUID	D0V5JH
DRUGNAME	ALT-801
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 1/2
	
TTDDRUID	D0V5JO
DRUGNAME	T-0128
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0V5JQ
DRUGNAME	COL-172
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0V5KJ
DRUGNAME	Interferon beta 1a
INDICATI	Discovery agent [ICD-11: N.A.] Phase 2
	
TTDDRUID	D0V5LG
DRUGNAME	ChronVac-C hepatitis C DNA vaccine
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2
	
TTDDRUID	D0V5LJ
DRUGNAME	JNJ-10329670
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0V5OG
DRUGNAME	BE-14106
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V5QH
DRUGNAME	ONO-9054
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
	
TTDDRUID	D0V5QY
DRUGNAME	StaphTAME
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2
	
TTDDRUID	D0V5TP
DRUGNAME	Adipose-derived stem cell therapy
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D0V5VA
DRUGNAME	CIGB-814
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0V5VR
DRUGNAME	LEO 90100
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D0V5WL
DRUGNAME	Met-enkephalin
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0V5XJ
DRUGNAME	AG-AFZ709
INDICATI	Genitourinary disease [ICD-11: GA0Z-GC8Z] Approved
	
TTDDRUID	D0V5XL
DRUGNAME	KRI-1314
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0V5YA
DRUGNAME	TA-381
INDICATI	Cerebral infarction [ICD-11: 8B11.5Z] Investigative
	
TTDDRUID	D0V5YQ
DRUGNAME	TS antisense + raltitrexed
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V5ZG
DRUGNAME	TCN-202
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 1
	
TTDDRUID	D0V5ZZ
DRUGNAME	Propantheline
INDICATI	Stomach ulcer [ICD-11: DA60.Z] Approved
INDICATI	Excessive sweating [ICD-11: EE00.Z] Approved
	
TTDDRUID	D0V6AB
DRUGNAME	XR-1500
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0V6AH
DRUGNAME	Endostatin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0V6AN
DRUGNAME	Encapsulated islet cell transplantation therapy
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	D0V6BE
DRUGNAME	ALC-919
INDICATI	Verruca vulgaris [ICD-11: 1E80] Phase 2
	
TTDDRUID	D0V6BS
DRUGNAME	Jemdel
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Application submitted
	
TTDDRUID	D0V6CE
DRUGNAME	GBT-009
INDICATI	Skin fibrosis [ICD-11: EM0Z] Phase 2
INDICATI	Scar conditions [ICD-11: QB83] Phase 2
	
TTDDRUID	D0V6CY
DRUGNAME	ET-005
INDICATI	Acquired haemolytic anemia [ICD-11: 3A4Z] Investigative
	
TTDDRUID	D0V6CZ
DRUGNAME	XG-5XX
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0V6DF
DRUGNAME	LJP-1207
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0V6EC
DRUGNAME	INOmax nitric oxide
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 3
	
TTDDRUID	D0V6EY
DRUGNAME	Pumiliotoxin 251D
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0V6FV
DRUGNAME	OcuXan
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D0V6GN
DRUGNAME	Chlorpromazine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
INDICATI	Schizophrenia [ICD-11: 6A20] Withdrawn from market
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0V6GT
DRUGNAME	IDN-6439
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V6HS
DRUGNAME	R-82913
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0V6IM
DRUGNAME	SBG
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0V6IN
DRUGNAME	PV-267
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0V6JF
DRUGNAME	SAR-104772
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1
	
TTDDRUID	D0V6JJ
DRUGNAME	LP-1810
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D0V6JP
DRUGNAME	Endixaprine
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0V6KF
DRUGNAME	LHRH
INDICATI	Endometriosis [ICD-11: GA10] Investigative
	
TTDDRUID	D0V6KL
DRUGNAME	CLP-635
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative
	
TTDDRUID	D0V6KU
DRUGNAME	CMV glycoprotein B subunit vaccine
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 1
	
TTDDRUID	D0V6KV
DRUGNAME	HL-2353
INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D0V6LF
DRUGNAME	NN9928
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0V6LH
DRUGNAME	PBI-1101
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0V6MX
DRUGNAME	IMA 203
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0V6OA
DRUGNAME	Lurbinectedin
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Approved
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
	
TTDDRUID	D0V6OZ
DRUGNAME	CN-105
INDICATI	Nontraumatic intracerebral hemorrhage [ICD-11: 8B00.4] Phase 2
	
TTDDRUID	D0V6RC
DRUGNAME	Satumomab Pendetide
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0V6RE
DRUGNAME	BCH-371
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0V6RL
DRUGNAME	Stempeucel
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Preregistration
	
TTDDRUID	D0V6SI
DRUGNAME	RESP-4000
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V6SV
DRUGNAME	PG-201
INDICATI	Arthralgia [ICD-11: ME82] Phase 3
	
TTDDRUID	D0V6TP
DRUGNAME	Humanized SMART Anti-IL-12 Antibody
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0V6TY
DRUGNAME	MYO-201
INDICATI	Limb girdle muscular dystrophy [ICD-11: 8C70.4] Phase 1
	
TTDDRUID	D0V6VD
DRUGNAME	Anti-CD20-CAR vector-transduced autologous T cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1/2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1/2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
INDICATI	Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2
	
TTDDRUID	D0V6VL
DRUGNAME	Cilofungin
INDICATI	Candidiasis [ICD-11: 1F23] Terminated
	
TTDDRUID	D0V6VQ
DRUGNAME	PF-956980
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0V6WU
DRUGNAME	CAR-T cells targeting CD38
INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical
	
TTDDRUID	D0V6WW
DRUGNAME	CAR-T cells targeting CD56
INDICATI	Multiple myeloma [ICD-11: 2A83] Clinical trial
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical
	
TTDDRUID	D0V6WZ
DRUGNAME	PN-201
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D0V6XJ
DRUGNAME	Hemsleyadin
INDICATI	Bacillary dysentery [ICD-11: 1A02] Approved
	
TTDDRUID	D0V6XW
DRUGNAME	Teglarinad
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0V6YT
DRUGNAME	SR-33805A
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0V6ZC
DRUGNAME	Aurograb
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 3
	
TTDDRUID	D0V6ZQ
DRUGNAME	VG-LC
INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
	
TTDDRUID	D0V7BD
DRUGNAME	HuCART19
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0V7BH
DRUGNAME	FG-4497
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0V7CF
DRUGNAME	Indinavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0V7DQ
DRUGNAME	CD40LGVAX
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0V7DW
DRUGNAME	Meningococcal groups A, C, Y and W-135 conjugate vaccine
INDICATI	Meningococcal infection [ICD-11: 1C1C] Approved
	
TTDDRUID	D0V7ES
DRUGNAME	DKC-215
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0V7FG
DRUGNAME	SPH-1285
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
	
TTDDRUID	D0V7FX
DRUGNAME	RLP-073
INDICATI	Pseudomonas infection [ICD-11: 1B92] Investigative
	
TTDDRUID	D0V7GC
DRUGNAME	Rolafagrel
INDICATI	Nephritis [ICD-11: GB40] Discontinued in Phase 2
	
TTDDRUID	D0V7GS
DRUGNAME	RG7461
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0V7HB
DRUGNAME	Modified CCR5-transduced autologous hematopoietic stem cells
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0V7HD
DRUGNAME	BN-50726
INDICATI	Nerve injury [ICD-11: ND56.4] Terminated
	
TTDDRUID	D0V7HI
DRUGNAME	PRINOMIDE TROMETHAMINE
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 3
	
TTDDRUID	D0V7HQ
DRUGNAME	ANA-02
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0V7IE
DRUGNAME	Pamiteplase
INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved
	
TTDDRUID	D0V7IS
DRUGNAME	Pumafentrine
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0V7KJ
DRUGNAME	Recombinant Clostridium botulinum A/B vaccine
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2
	
TTDDRUID	D0V7MA
DRUGNAME	AMESERGIDE
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
	
TTDDRUID	D0V7OF
DRUGNAME	Pyrimidine derivative 6
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented
INDICATI	Fibrosis [ICD-11: GA14-GC01] Patented
INDICATI	Blood vessel proliferative disorder [ICD-11: BE2Z] Patented
	
TTDDRUID	D0V7OH
DRUGNAME	Ceftiofur
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0V7PL
DRUGNAME	Lefradafiban
INDICATI	Angina pectoris [ICD-11: BA40] Phase 1
	
TTDDRUID	D0V7PX
DRUGNAME	Apogossypol
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V7PY
DRUGNAME	Giracodazole
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0V7QO
DRUGNAME	BI-836880
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0V7QT
DRUGNAME	AMI-121
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved
	
TTDDRUID	D0V7QW
DRUGNAME	RG7882
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0V7RH
DRUGNAME	Calcium levofolinate
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Approved
	
TTDDRUID	D0V7RN
DRUGNAME	CDR-134D123
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0V7SO
DRUGNAME	PF-06291874
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0V7SU
DRUGNAME	DD-20207
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Investigative
	
TTDDRUID	D0V7SY
DRUGNAME	Neuronal transplant cells
INDICATI	Stroke [ICD-11: 8B20] Phase 2
	
TTDDRUID	D0V7US
DRUGNAME	NKP 608
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2
	
TTDDRUID	D0V7VX
DRUGNAME	ALN-HTT
INDICATI	Huntington disease [ICD-11: 8A01.10] Preclinical
	
TTDDRUID	D0V7WS
DRUGNAME	Zotarolimus
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0V7XC
DRUGNAME	R-1518
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1
	
TTDDRUID	D0V7XF
DRUGNAME	Dopexamine
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Approved
	
TTDDRUID	D0V7YA
DRUGNAME	GMX1777
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0V7YG
DRUGNAME	EHT/AGN-0003
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0V7YK
DRUGNAME	ImBryon
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0V8AG
DRUGNAME	Poly-ICLC
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2
	
TTDDRUID	D0V8AP
DRUGNAME	TRC-4186
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0V8AR
DRUGNAME	Candin
INDICATI	Verruca vulgaris [ICD-11: 1E80] Phase 2
	
TTDDRUID	D0V8BU
DRUGNAME	P-2202
INDICATI	Syndrome X [ICD-11: 5C53.4] Phase 2
	
TTDDRUID	D0V8GT
DRUGNAME	E-0116
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
	
TTDDRUID	D0V8HA
DRUGNAME	Mecamylamine
INDICATI	Essential hypertension [ICD-11: BA00] Approved
	
TTDDRUID	D0V8HB
DRUGNAME	Food allergy epicutaneous immunotherapy
INDICATI	Peanut hypersensitivity [ICD-11: 4A83] Phase 2
	
TTDDRUID	D0V8HF
DRUGNAME	GS-9160
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0V8HJ
DRUGNAME	Fostamatinib
INDICATI	Immune thrombocytopenic purpura [ICD-11: 3B64.13] Approved
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0V8HK
DRUGNAME	H-NOX proteins
INDICATI	Hypoxia [ICD-11: MD11.1] Investigative
	
TTDDRUID	D0V8JZ
DRUGNAME	Pyrrolo[2,3-d]pyrimidine derivative 17
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Patented
	
TTDDRUID	D0V8KB
DRUGNAME	CM-4612
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative
	
TTDDRUID	D0V8KD
DRUGNAME	P-1101
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3
INDICATI	Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 3
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
	
TTDDRUID	D0V8KI
DRUGNAME	Fenspiride hydrochloride
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0V8PA
DRUGNAME	NERIDRONIC ACID
INDICATI	Bone disease [ICD-11: FC0Z] Approved
INDICATI	Complex regional pain syndrome [ICD-11: 8D8A.0] Phase 3
	
TTDDRUID	D0V8PN
DRUGNAME	Droxinavir hydrochloride
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Terminated
	
TTDDRUID	D0V8PQ
DRUGNAME	NGN-9078
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative
	
TTDDRUID	D0V8QT
DRUGNAME	Chlorambucil
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved
	
TTDDRUID	D0V8RV
DRUGNAME	Rotavin
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0V8RY
DRUGNAME	KR-30450
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1
	
TTDDRUID	D0V8TQ
DRUGNAME	Aluminium
INDICATI	Hyperhidrosis [ICD-11: EE00] Approved
	
TTDDRUID	D0V8UJ
DRUGNAME	PEP-6409
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0V9AL
DRUGNAME	MCAF5352A
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0V9BD
DRUGNAME	Bicalutamide
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D0V9BU
DRUGNAME	ABT-492
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
	
TTDDRUID	D0V9BX
DRUGNAME	TD-6989
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D0V9DZ
DRUGNAME	Fluprednisolone
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0V9EN
DRUGNAME	3,4-Dihydroxycinnamic Acid
INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 4
	
TTDDRUID	D0V9EX
DRUGNAME	Mirvetuximab soratansine
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D0V9FU
DRUGNAME	WST11
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0V9HC
DRUGNAME	Darunavir + cobicistat
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0V9HH
DRUGNAME	Taprizosin
INDICATI	Prostate hyperplasia [ICD-11: GA90] Discontinued in Phase 2
	
TTDDRUID	D0V9HI
DRUGNAME	Irindalone
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0V9HL
DRUGNAME	BMS-241027
INDICATI	Tauopathy [ICD-11: 6D85.Y] Phase 1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0V9IE
DRUGNAME	ZD2079
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 2
	
TTDDRUID	D0V9JR
DRUGNAME	Viloxazine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
	
TTDDRUID	D0V9LF
DRUGNAME	Anti-CD28
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0V9LJ
DRUGNAME	Flufirvitide-3
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0V9LY
DRUGNAME	Bertilimumab
INDICATI	Ocular allergy [ICD-11: 4A81] Phase 2
INDICATI	Bullous pemphigoid [ICD-11: EB41.0] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 2
	
TTDDRUID	D0V9ME
DRUGNAME	VT-111
INDICATI	Graft rejection in heart transplantation [ICD-11: NE84] Preclinical
	
TTDDRUID	D0V9MG
DRUGNAME	KY-382
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0V9MO
DRUGNAME	Ono 3
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0V9MR
DRUGNAME	XL888
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Phase 1
	
TTDDRUID	D0V9MT
DRUGNAME	PU-AD
INDICATI	Encephalopathy [ICD-11: 8E47] Phase 1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 0
	
TTDDRUID	D0V9MV
DRUGNAME	IDDBCP226234
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0V9NB
DRUGNAME	Non-Hodgkin lymphoma vaccine
INDICATI	B-cell lymphoma [ICD-11: 2A86] Terminated
	
TTDDRUID	D0V9ND
DRUGNAME	MCP-1
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Preclinical
	
TTDDRUID	D0V9NE
DRUGNAME	Tanaproget
INDICATI	Estrogen deficiency [ICD-11: FB83.0Y] Investigative
	
TTDDRUID	D0V9OL
DRUGNAME	534U87
INDICATI	Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 2
	
TTDDRUID	D0V9PB
DRUGNAME	Gilotrifafatinib
INDICATI	Lung squamous cell carcinoma [ICD-11: 2C25.2] Phase 2
INDICATI	Rhabdomyosarcoma [ICD-11: 2B55] Phase 1/2
	
TTDDRUID	D0V9QR
DRUGNAME	Apricitabine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0V9RM
DRUGNAME	PMID25666693-Compound-89
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0V9RU
DRUGNAME	ENIPORIDE
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2
	
TTDDRUID	D0V9TE
DRUGNAME	GPI-2138
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Terminated
	
TTDDRUID	D0V9UA
DRUGNAME	OligoG CF-5/20
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D0V9UY
DRUGNAME	Technetium Tc-99m Sulfur Colloid Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0V9VG
DRUGNAME	Rimegepant
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0V9WE
DRUGNAME	TS23
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0V9WF
DRUGNAME	Lestaurtinib
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved (orphan drug)
INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 3
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2/3
	
TTDDRUID	D0V9WX
DRUGNAME	KarXT
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D0V9YR
DRUGNAME	Sulfamethazine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0V9YW
DRUGNAME	GYKI-47261
INDICATI	Parkinson disease [ICD-11: 8A00.0] Preclinical
	
TTDDRUID	D0V9ZG
DRUGNAME	Cetraxate
INDICATI	Peptic ulcer [ICD-11: DA61] Approved
	
TTDDRUID	D0V9ZJ
DRUGNAME	Pyrazolo[1,5-a]pyridine derivative 2
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0V9ZL
DRUGNAME	FCE-28161
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0V9ZR
DRUGNAME	GNI-105
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Terminated
	
TTDDRUID	D0VA0I
DRUGNAME	Vorapaxar
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved
	
TTDDRUID	D0VA1D
DRUGNAME	Alkyl mannoside derivative 1
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0VA2I
DRUGNAME	CRx-191
INDICATI	Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0VA4Y
DRUGNAME	Phentermine+topiramate
INDICATI	Obesity [ICD-11: 5B81] Phase 3
	
TTDDRUID	D0VA9Z
DRUGNAME	ND0612
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0VB0U
DRUGNAME	Chlorphenesin
INDICATI	Muscular pain [ICD-11: FB56] Approved
INDICATI	Injury [ICD-11: NA00-ND5Z] Approved
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Withdrawn from market
	
TTDDRUID	D0VB2K
DRUGNAME	SPX-601
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0VB2M
DRUGNAME	1,5-diphenylpyrrolidin-2-one derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0VB3Y
DRUGNAME	Manganese Sulfate
INDICATI	Overactive bladder [ICD-11: GC50.0] Approved
	
TTDDRUID	D0VB4T
DRUGNAME	Aryl mannoside derivative 9
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0VB4X
DRUGNAME	VTP-43742
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
	
TTDDRUID	D0VB9J
DRUGNAME	ISIS 14803
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2
	
TTDDRUID	D0VB9M
DRUGNAME	Peptide analog 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0VC0I
DRUGNAME	Oxindole 94
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0VC3H
DRUGNAME	BT-V003
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0VC4F
DRUGNAME	HG-1226
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0VC8H
DRUGNAME	KI-0003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0VC8T
DRUGNAME	AZ-05
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0VC8Y
DRUGNAME	SAR428926
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0VC8Z
DRUGNAME	Trehalose
INDICATI	Muscular dystrophy [ICD-11: 8C70] Phase 2
INDICATI	Oculopharyngeal muscular dystrophy [ICD-11: 9C82.1] Phase 2
INDICATI	Spinal cerebellar ataxia type 3 [ICD-11: 8A03] Phase 2
	
TTDDRUID	D0VD1R
DRUGNAME	Suramin
INDICATI	African trypanosomiasis [ICD-11: 1F51] Phase 1
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0VD5J
DRUGNAME	PMID28270021-Compound-WO2015042088Example12
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0VD5X
DRUGNAME	KI-0001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0VD6Q
DRUGNAME	RP103
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2/3
	
TTDDRUID	D0VD7H
DRUGNAME	CL-5343
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0VD8S
DRUGNAME	Oral-lyn
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D0VD9X
DRUGNAME	AstroStem
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D0VE1W
DRUGNAME	SB-623
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
INDICATI	Stroke [ICD-11: 8B20] Phase 2
INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 2
	
TTDDRUID	D0VE3U
DRUGNAME	JT02
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
	
TTDDRUID	D0VE4O
DRUGNAME	EVP-4473
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0VE6X
DRUGNAME	R1549
INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 3
	
TTDDRUID	D0VE7B
DRUGNAME	DSP-2230
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D0VE9F
DRUGNAME	SBP-101
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 1
	
TTDDRUID	D0VF3C
DRUGNAME	NPC-01
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Phase 3
	
TTDDRUID	D0VF4H
DRUGNAME	Hydroxocobalamin
INDICATI	Vitamin B12 deficiency [ICD-11: 5B5F] Approved
INDICATI	Lung injury [ICD-11: NB32.3Z] Phase 2
	
TTDDRUID	D0VF5B
DRUGNAME	PMID26651364-Compound-107
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0VF6E
DRUGNAME	PD173074
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D0VF8Z
DRUGNAME	SRD-326
INDICATI	Raynaud disease [ICD-11: BD42.0] Preclinical
	
TTDDRUID	D0VG0D
DRUGNAME	BEZ235
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0VG0F
DRUGNAME	Biphenyl mannoside derivative 23
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0VG0G
DRUGNAME	PeproStat
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Investigative
	
TTDDRUID	D0VG7I
DRUGNAME	MENK
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0VG7Y
DRUGNAME	Elagolix sodium
INDICATI	Endometriosis [ICD-11: GA10] Approved
	
TTDDRUID	D0VH0X
DRUGNAME	Tuberculosis vaccine
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1
	
TTDDRUID	D0VH3D
DRUGNAME	SC-599
INDICATI	Shigella infection [ICD-11: 1A02] Phase 2
	
TTDDRUID	D0VH3H
DRUGNAME	TM38837
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D0VH4T
DRUGNAME	ONO-7475
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0VH4V
DRUGNAME	Teplizumab
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D0VH6V
DRUGNAME	P53 cell pentrating peptide
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Phase 1
	
TTDDRUID	D0VH9C
DRUGNAME	Synuclere
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0VI4N
DRUGNAME	JNJ-54175446
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
	
TTDDRUID	D0VI7R
DRUGNAME	Selinexor oral
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D0VI8H
DRUGNAME	Ribavirin
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0VI8T
DRUGNAME	4SCAR-PSMA
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
	
TTDDRUID	D0VI9P
DRUGNAME	OPN-305
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D0VIG4
DRUGNAME	LY3405105
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0VJ0Q
DRUGNAME	MuStDO 5
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1/2
	
TTDDRUID	D0VJ4N
DRUGNAME	CIGB-230
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0VJ5N
DRUGNAME	SB-705498
INDICATI	Rhinitis [ICD-11: FA20] Phase 2
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 1
	
TTDDRUID	D0VJ7G
DRUGNAME	TECHNETIUM-99M-MRP20
INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 1
	
TTDDRUID	D0VJ9X
DRUGNAME	AXS-06
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0VK9O
DRUGNAME	Sofpironium bromide
INDICATI	Primary axillary hyperhidrosis [ICD-11: EE00.01] Phase 3
	
TTDDRUID	D0VL3L
DRUGNAME	DFD-03
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 3
	
TTDDRUID	D0VL4M
DRUGNAME	AMG0103
INDICATI	Chronic back pain [ICD-11: ME86] Phase 1
	
TTDDRUID	D0VL4V
DRUGNAME	SR-123781A
INDICATI	Venous thrombosis [ICD-11: BA43] Phase 2/3
	
TTDDRUID	D0VL5E
DRUGNAME	Aminoazetidine derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0VL8Q
DRUGNAME	Tiropramide
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0VM2L
DRUGNAME	Zoledronate
INDICATI	Hypercalcaemia [ICD-11: 5B91.0] Approved
	
TTDDRUID	D0VM8B
DRUGNAME	NTP-2014
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Investigative
	
TTDDRUID	D0VM8K
DRUGNAME	Sodium ferric gluconate complex
INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved
	
TTDDRUID	D0VN2N
DRUGNAME	Recombinant opticin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0VN2U
DRUGNAME	Amidine compound 1
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D0VN2Y
DRUGNAME	BL-1825
INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated
	
TTDDRUID	D0VN3O
DRUGNAME	Lmprime P66
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3
	
TTDDRUID	D0VN6O
DRUGNAME	N-65 lacritin
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative
	
TTDDRUID	D0VO0A
DRUGNAME	INV-21
INDICATI	Hand, foot and mouth disease [ICD-11: 1F05.0] Phase 1
	
TTDDRUID	D0VO0T
DRUGNAME	Delanzomib
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D0VO3H
DRUGNAME	CG7060
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2
	
TTDDRUID	D0VO5S
DRUGNAME	LY-2584702
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0VO5V
DRUGNAME	NNZ-4945
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0VO6J
DRUGNAME	FAD-104
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0VO7K
DRUGNAME	Capzola
INDICATI	Bladder cancer [ICD-11: 2C94] Application submitted
	
TTDDRUID	D0VO7R
DRUGNAME	AjvW2
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0VO9O
DRUGNAME	Talizumab
INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2
	
TTDDRUID	D0VP1V
DRUGNAME	Aclidinium
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0VP2T
DRUGNAME	KU-2285
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0VP7D
DRUGNAME	HR-004-1
INDICATI	Bone disease [ICD-11: FC0Z] Investigative
	
TTDDRUID	D0VP9E
DRUGNAME	Cyrtominetin
INDICATI	Phlegmy cough [ICD-11: SA80-SA8Z] Phase 3
	
TTDDRUID	D0VQ7Y
DRUGNAME	SPK-CHM
INDICATI	Choroidal dystrophy [ICD-11: 9B61] Phase 1/2
	
TTDDRUID	D0VQ8Q
DRUGNAME	Ladiratuzumab vedotin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0VR5T
DRUGNAME	BEPH
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0VR7F
DRUGNAME	CNTX-6970
INDICATI	Inflammatory pain [ICD-11: MG30.42] Phase 1
	
TTDDRUID	D0VR7W
DRUGNAME	Gemifloxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0VS1P
DRUGNAME	DRL-21995
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative
	
TTDDRUID	D0VS2M
DRUGNAME	ALS-886
INDICATI	Respiratory distress syndrome [ICD-11: CB00] Terminated
	
TTDDRUID	D0VS2R
DRUGNAME	Tovaxin
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0VS2W
DRUGNAME	YSIL6
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D0VS3J
DRUGNAME	BM-17.0249.2NA
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D0VS3U
DRUGNAME	TAK-020
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0VS3W
DRUGNAME	KAR5585
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1
	
TTDDRUID	D0VS9E
DRUGNAME	GDC-5573
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0VT0T
DRUGNAME	NLX-P101
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2
	
TTDDRUID	D0VT1S
DRUGNAME	TTP889
INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Phase 2
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Terminated
	
TTDDRUID	D0VT2B
DRUGNAME	ALS-8176
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D0VT2C
DRUGNAME	FK-505
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Phase 2
	
TTDDRUID	D0VT6X
DRUGNAME	ABBV-2451
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1
	
TTDDRUID	D0VT8P
DRUGNAME	Famciclovir
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D0VT9O
DRUGNAME	AR28
INDICATI	Skin disease [ICD-11: EA00-EM0Z] Phase 2
	
TTDDRUID	D0VU2M
DRUGNAME	TA-2005
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0VU2X
DRUGNAME	Conivaptan
INDICATI	Euvolemic hyponatremia [ICD-11: 5C72] Approved
	
TTDDRUID	D0VU5M
DRUGNAME	Imiglitazar
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0VU8K
DRUGNAME	REIC gene therapy vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0VU8Q
DRUGNAME	Mebeverine
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Approved
	
TTDDRUID	D0VV2D
DRUGNAME	B-06
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0VV3O
DRUGNAME	GNI-104
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated
	
TTDDRUID	D0VV5X
DRUGNAME	EZN-3920
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0VV6V
DRUGNAME	Reovirus
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
	
TTDDRUID	D0VW0A
DRUGNAME	Dermacyn
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 2
	
TTDDRUID	D0VW0I
DRUGNAME	Cyclopentenylcytosine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0VW1I
DRUGNAME	GLS-5700
INDICATI	Semliki forest virus infection [ICD-11: 1D9Y] Phase 1
	
TTDDRUID	D0VW2Z
DRUGNAME	Nerelimomab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 3
	
TTDDRUID	D0VW4J
DRUGNAME	NT0102
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3
	
TTDDRUID	D0VW7E
DRUGNAME	TPR-100-Rx
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0VX5O
DRUGNAME	Neboglamine
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2
	
TTDDRUID	D0VY5O
DRUGNAME	A-620223
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0VY9O
DRUGNAME	3-(phenoxymethyl) benzylamine derivative 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0VZ0U
DRUGNAME	H5N1 pandemic influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0VZ1C
DRUGNAME	H-103
INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Phase 1
	
TTDDRUID	D0VZ2A
DRUGNAME	SQ-609
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0VZ3D
DRUGNAME	AQ-RA-741
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated
	
TTDDRUID	D0VZ4N
DRUGNAME	Guadecitabine
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
	
TTDDRUID	D0VZ5B
DRUGNAME	Bempedoic acid + ezetimibe
INDICATI	High blood cholesterol level [ICD-11: 5C80.00] Phase 3
	
TTDDRUID	D0VZ5X
DRUGNAME	BI-44370
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D0VZ8S
DRUGNAME	KA-398
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0VZ9S
DRUGNAME	CROMOGLYCATE LISETIL HYDROCHLORIDE
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0W0AM
DRUGNAME	SB 235699
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1
	
TTDDRUID	D0W0BF
DRUGNAME	Anastrozole
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0W0BN
DRUGNAME	NM-2014
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0W0DY
DRUGNAME	Agrippal S1/MF-59 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0W0ED
DRUGNAME	Eflucimibe
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D0W0GE
DRUGNAME	CR-002
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1
	
TTDDRUID	D0W0HZ
DRUGNAME	TZ-101sm
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D0W0IN
DRUGNAME	NN-9925
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0W0JJ
DRUGNAME	AKB-9788
INDICATI	Edema [ICD-11: MG29] Investigative
	
TTDDRUID	D0W0JP
DRUGNAME	OMS405
INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Phase 2
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 2
	
TTDDRUID	D0W0KW
DRUGNAME	Ro-24-8138
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0W0LS
DRUGNAME	TAK-779
INDICATI	Transplant rejection [ICD-11: NE84] Terminated
	
TTDDRUID	D0W0MD
DRUGNAME	MBX2329
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0W0MF
DRUGNAME	Talbutal
INDICATI	Irritability [ICD-11: MB24] Approved
	
TTDDRUID	D0W0MT
DRUGNAME	PMID30107136-Compound-Example51
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0W0NU
DRUGNAME	NIC5-15
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0W0PC
DRUGNAME	1,2,4-oxadiazole derivative 7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0W0RT
DRUGNAME	PTX-008313
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0W0SL
DRUGNAME	LY2940680
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D0W0SM
DRUGNAME	CRL-8131
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D0W0TH
DRUGNAME	R 80122
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1
	
TTDDRUID	D0W0UU
DRUGNAME	CPG23DIAB
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0W0UW
DRUGNAME	CLT-002
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Investigative
	
TTDDRUID	D0W0VD
DRUGNAME	Beta-Lapachone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0W0VR
DRUGNAME	PFK-158
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0W0WP
DRUGNAME	LL-3858
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2
	
TTDDRUID	D0W0WU
DRUGNAME	Diethylnorspermine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0W0XM
DRUGNAME	NPS-2390
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Preclinical
	
TTDDRUID	D0W0XS
DRUGNAME	PolyPEPI1018
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
	
TTDDRUID	D0W0YI
DRUGNAME	BI-54903 + olodaterol
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0W1AR
DRUGNAME	ERC-1671
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D0W1BV
DRUGNAME	Acel-Immune
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D0W1DI
DRUGNAME	AS-1670542
INDICATI	Thrombocytopenia [ICD-11: 3B64] Approved
INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 3
	
TTDDRUID	D0W1GP
DRUGNAME	Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
INDICATI	Plasma cell myeloma [ICD-11: 2A83.1] Phase 1
	
TTDDRUID	D0W1HB
DRUGNAME	BAY-61-2116
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0W1JJ
DRUGNAME	GS-9669
INDICATI	Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0W1JY
DRUGNAME	NAPQI
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Investigative
	
TTDDRUID	D0W1MU
DRUGNAME	TBC-M4
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0W1MX
DRUGNAME	BMS-187745
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D0W1NH
DRUGNAME	Thiophene sulfonamide
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0W1PV
DRUGNAME	Apicidin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W1QA
DRUGNAME	GC-1102
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	D0W1QI
DRUGNAME	Butizide
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0W1RQ
DRUGNAME	PMID30107136-Compound-Example44
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0W1RY
DRUGNAME	Hydroxyamphetamine Hydrobromide
INDICATI	Horner syndrome [ICD-11: 8D8A.1] Approved
	
TTDDRUID	D0W1SD
DRUGNAME	124I-labeled 11-1F4
INDICATI	Amyloidosis [ICD-11: 5D00] Phase 1
	
TTDDRUID	D0W1SE
DRUGNAME	PMID26651364-Compound-5b
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0W1TK
DRUGNAME	NKTR-105
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0W1TL
DRUGNAME	BB-MPI-03
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D0W1US
DRUGNAME	PLECONARIL
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2
	
TTDDRUID	D0W1WF
DRUGNAME	4-iodo-6-phenylpyrimidine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W1YM
DRUGNAME	AS-1406
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0W1YV
DRUGNAME	PLX-5622
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0W1YX
DRUGNAME	BBT-031
INDICATI	Growth failure [ICD-11: LD2F.1Y] Investigative
	
TTDDRUID	D0W1YZ
DRUGNAME	TSERaM
INDICATI	Menopause symptom [ICD-11: GA30.0] Investigative
	
TTDDRUID	D0W2AN
DRUGNAME	Emepronium
INDICATI	Urinary incontinence [ICD-11: MF50.2] Approved
	
TTDDRUID	D0W2BF
DRUGNAME	Vadastuximab talirine
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D0W2BK
DRUGNAME	ICo-007
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 1
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 1
	
TTDDRUID	D0W2CX
DRUGNAME	CG-100649
INDICATI	Arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0W2DV
DRUGNAME	BM-13677
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D0W2EA
DRUGNAME	Theradigm-Melanoma
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0W2ED
DRUGNAME	L-731735
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0W2EG
DRUGNAME	ATL-1222
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Investigative
	
TTDDRUID	D0W2EK
DRUGNAME	Ixabepilone
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0W2FG
DRUGNAME	OPHD-001
INDICATI	Clostridium infection [ICD-11: 1A04] Discontinued in Phase 1
	
TTDDRUID	D0W2FN
DRUGNAME	BBT-018
INDICATI	Neutropenia [ICD-11: 4B00.0] Investigative
	
TTDDRUID	D0W2FZ
DRUGNAME	Solithromycin
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Phase 3
	
TTDDRUID	D0W2HD
DRUGNAME	Mogamulizumab
INDICATI	Sezary syndrome [ICD-11: 2B02] Approved
INDICATI	Mycosis fungoides [ICD-11: 2B01] Approved
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 3
INDICATI	T-cell leukaemia [ICD-11: 2A90] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0W2HG
DRUGNAME	Urocortin 2
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2
	
TTDDRUID	D0W2IU
DRUGNAME	AVE-0847
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2
	
TTDDRUID	D0W2JT
DRUGNAME	LXR-017
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Terminated
	
TTDDRUID	D0W2JY
DRUGNAME	IC-47
INDICATI	Streptococcus infection [ICD-11: 1B53] Discontinued in Phase 1
	
TTDDRUID	D0W2KA
DRUGNAME	ANTI-TWEAK
INDICATI	Lupus [ICD-11: 4A40] Phase 2
	
TTDDRUID	D0W2KG
DRUGNAME	NT-69-L
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Investigative
	
TTDDRUID	D0W2KR
DRUGNAME	CS-0240
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0W2LR
DRUGNAME	Influenza virus vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0W2LW
DRUGNAME	NOX-151
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0W2MI
DRUGNAME	Anti-CD30-CAR-transduced T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0W2NM
DRUGNAME	Flunitrazepam
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0W2NZ
DRUGNAME	VLI-04A
INDICATI	Bacillus anthracis infection [ICD-11: 1G40] Investigative
	
TTDDRUID	D0W2PK
DRUGNAME	Beloxepin
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1
	
TTDDRUID	D0W2PZ
DRUGNAME	Parasin I
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0W2RI
DRUGNAME	JTE-451
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
	
TTDDRUID	D0W2RY
DRUGNAME	G530L
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D0W2SO
DRUGNAME	Orazipone
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1
	
TTDDRUID	D0W2SX
DRUGNAME	NP-0336
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D0W2UY
DRUGNAME	E-5050
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2
	
TTDDRUID	D0W2VS
DRUGNAME	RGI-4100
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0W2ZX
DRUGNAME	UK-387618
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0W3AX
DRUGNAME	SB-281832
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D0W3BA
DRUGNAME	Methanesulfonyl fluoride
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0W3BC
DRUGNAME	ATL1103
INDICATI	Acromegaly [ICD-11: 5A60.0] Phase 1
	
TTDDRUID	D0W3DV
DRUGNAME	Sotatercept
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D0W3GE
DRUGNAME	Plague vaccine
INDICATI	Yersinia infection [ICD-11: 1B93] Phase 2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 2
	
TTDDRUID	D0W3GL
DRUGNAME	SR-147778
INDICATI	Obesity [ICD-11: 5B81] Phase 2
	
TTDDRUID	D0W3GR
DRUGNAME	Prexigebersen
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2
	
TTDDRUID	D0W3JA
DRUGNAME	LA-8045
INDICATI	Acute coronary syndrome [ICD-11: BA41] Investigative
	
TTDDRUID	D0W3JC
DRUGNAME	Heterocyclic derivative 7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0W3JH
DRUGNAME	CM2489
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0W3LI
DRUGNAME	LY333531
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0W3MH
DRUGNAME	BAY-94-9392
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0W3NN
DRUGNAME	Polygeline
INDICATI	Blood transfusion [ICD-11: QB98] Approved
	
TTDDRUID	D0W3NR
DRUGNAME	BetaGRAFT
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0W3OQ
DRUGNAME	BMS-182566
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0W3OS
DRUGNAME	Tibolone
INDICATI	Anabolic metabolism [ICD-11: 5C50-5C8Z] Approved
	
TTDDRUID	D0W3RA
DRUGNAME	Phenylsulfonyl derivative 1
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Patented
	
TTDDRUID	D0W3RW
DRUGNAME	MK-2206
INDICATI	Rectal adenocarcinoma [ICD-11: 2B92] Phase 2
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D0W3SQ
DRUGNAME	H-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0W3SX
DRUGNAME	FSHR NAM
INDICATI	Contraception [ICD-11: QA21] Investigative
	
TTDDRUID	D0W3TC
DRUGNAME	ITV-3
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0W3TZ
DRUGNAME	Tgth-0100
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0W3UH
DRUGNAME	QLT-091568
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2
	
TTDDRUID	D0W3UV
DRUGNAME	ABI-009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Malignant perivascular epithelioid cell tumour [ICD-11: 2B5Y] Phase 2
INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 1/2
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1
	
TTDDRUID	D0W3WB
DRUGNAME	CWF-0808
INDICATI	Transplant rejection [ICD-11: NE84] Investigative
	
TTDDRUID	D0W3WD
DRUGNAME	VRC-HIVADV027-00-VP
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0W3YL
DRUGNAME	Bentoquatam
INDICATI	Contact dermatitis [ICD-11: EK0Z] Approved
	
TTDDRUID	D0W3YW
DRUGNAME	DRF 10945
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1
	
TTDDRUID	D0W4AA
DRUGNAME	PMID25666693-Compound-33
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0W4AR
DRUGNAME	KUR-211
INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 2
	
TTDDRUID	D0W4CC
DRUGNAME	CPI-005
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Investigative
	
TTDDRUID	D0W4EB
DRUGNAME	Endoxifen
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0W4HA
DRUGNAME	MDX-018
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0W4HJ
DRUGNAME	MSX-3
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0W4HO
DRUGNAME	IMT-504
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W4HW
DRUGNAME	SB-9000
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Investigative
	
TTDDRUID	D0W4HZ
DRUGNAME	Lonafarnib
INDICATI	Hutchinson-Gilford progeria syndrome [ICD-11: LD2B] Approved
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
INDICATI	Hepatitis D virus infection [ICD-11: 1E51.2] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 3
	
TTDDRUID	D0W4JI
DRUGNAME	INS-50589
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D0W4JY
DRUGNAME	CPZEN-45
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0W4NM
DRUGNAME	Oltipraz
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0W4OL
DRUGNAME	FK-633
INDICATI	Artery stenosis [ICD-11: BD52] Discontinued in Phase 2
	
TTDDRUID	D0W4OZ
DRUGNAME	GG-8573
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0W4RB
DRUGNAME	BIOO-3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W4SM
DRUGNAME	CD19 and CD22 CAR-T Cells
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0W4SS
DRUGNAME	Interferon beta
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W4TG
DRUGNAME	Recombinant botulinum neurotoxin vaccine
INDICATI	Migraine [ICD-11: 8A80] Phase 3
	
TTDDRUID	D0W4VH
DRUGNAME	Peptide-T
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 2
	
TTDDRUID	D0W4WN
DRUGNAME	BT-101
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D0W4WP
DRUGNAME	CVT-10216
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Investigative
	
TTDDRUID	D0W4XY
DRUGNAME	PRX-08066
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
	
TTDDRUID	D0W4YO
DRUGNAME	NOCICEPTIN
INDICATI	Headache [ICD-11: 8A80-8A84] Phase 1
	
TTDDRUID	D0W5BS
DRUGNAME	FerriSeltz
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Approved
	
TTDDRUID	D0W5CI
DRUGNAME	DWJ-209
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0W5EH
DRUGNAME	Sarizotan
INDICATI	Rett syndrome [ICD-11: LD90.4] Phase 2/3
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2
	
TTDDRUID	D0W5EY
DRUGNAME	LpxCi-4
INDICATI	Multidrug resistant infection [ICD-11: MG51] Investigative
	
TTDDRUID	D0W5GP
DRUGNAME	LN-020
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0W5HA
DRUGNAME	XEP-018
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0W5HK
DRUGNAME	Sorafenib
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D0W5IC
DRUGNAME	SF-103
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D0W5IF
DRUGNAME	CH-4933468
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0W5KA
DRUGNAME	Cefpiroxime
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0W5KO
DRUGNAME	MesoTarg
INDICATI	Pancreatic cancer [ICD-11: 2C10] Investigative
	
TTDDRUID	D0W5LC
DRUGNAME	Forigerimod
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3
	
TTDDRUID	D0W5LS
DRUGNAME	Desoxycorticosterone Pivalate
INDICATI	Addison disease [ICD-11: 5A74.0] Approved
	
TTDDRUID	D0W5MX
DRUGNAME	DTP vaccine
INDICATI	Bordetella pertussis infection [ICD-11: 1C12.0] Approved
	
TTDDRUID	D0W5NP
DRUGNAME	Anatumomab mafenatox
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D0W5NW
DRUGNAME	CMX-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0W5OV
DRUGNAME	DF-1111301
INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1
	
TTDDRUID	D0W5PN
DRUGNAME	Radezolid
INDICATI	Pneumonia [ICD-11: CA40] Phase 2
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0W5QJ
DRUGNAME	Anti-HIV ribozyme therapy
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0W5RE
DRUGNAME	SUN-13837
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2
	
TTDDRUID	D0W5RL
DRUGNAME	Asoprisnil
INDICATI	Endometriosis [ICD-11: GA10] Discontinued in Phase 3
	
TTDDRUID	D0W5UD
DRUGNAME	Adipose stem cell therapy
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 1
	
TTDDRUID	D0W5UV
DRUGNAME	Ethacrynate Sodium
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D0W5VV
DRUGNAME	NVXT
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2
	
TTDDRUID	D0W5WH
DRUGNAME	ET-004
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0W5WZ
DRUGNAME	Tideglusib
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0W5XT
DRUGNAME	ARC-183
INDICATI	Blood forming organ disorder [ICD-11: JB64.1] Discontinued in Phase 1
	
TTDDRUID	D0W5YC
DRUGNAME	Vacc-5q
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0W5YP
DRUGNAME	WVE-120101
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 1/2
	
TTDDRUID	D0W5YY
DRUGNAME	PM-060184
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0W5ZU
DRUGNAME	Antova
INDICATI	Thrombocytopenia [ICD-11: 3B64] Terminated
	
TTDDRUID	D0W6AB
DRUGNAME	NC-100150
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2
	
TTDDRUID	D0W6AF
DRUGNAME	YM-264
INDICATI	Sepsis [ICD-11: 1G40-1G41] Phase 2
	
TTDDRUID	D0W6AQ
DRUGNAME	TZP-201
INDICATI	Diarrhea [ICD-11: ME05.1] Investigative
	
TTDDRUID	D0W6BS
DRUGNAME	PRO-2000
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0W6CA
DRUGNAME	Cefpodoxime
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0W6DG
DRUGNAME	Pentazocine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0W6DY
DRUGNAME	Diphenylpyraline
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0W6EP
DRUGNAME	AMG-889436
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0W6EV
DRUGNAME	ICGD
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W6GR
DRUGNAME	H1N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0W6HO
DRUGNAME	IMO-2055
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D0W6KM
DRUGNAME	Dasotraline
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 3
INDICATI	Eating disorder [ICD-11: 6B82] Phase 3
	
TTDDRUID	D0W6LI
DRUGNAME	Cosyntropin
INDICATI	Adrenocortical insufficiency [ICD-11: 5A74] Approved
	
TTDDRUID	D0W6LW
DRUGNAME	BIT225
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0W6MA
DRUGNAME	E-2050
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0W6NW
DRUGNAME	SD-118
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Phase 1
	
TTDDRUID	D0W6PM
DRUGNAME	CNV-NT
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0W6QN
DRUGNAME	Choroid plexus cell therapy
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1/2
	
TTDDRUID	D0W6SS
DRUGNAME	Choriogonadotropin alfa
INDICATI	Female infertility [ICD-11: GA31.Z] Approved
	
TTDDRUID	D0W6TB
DRUGNAME	MK-7285
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0W6UV
DRUGNAME	FP-289
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0W6WC
DRUGNAME	Apolizumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0W6WD
DRUGNAME	KP106
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 1
	
TTDDRUID	D0W6XL
DRUGNAME	SB-209670
INDICATI	Arrhythmia [ICD-11: BC9Z] Discontinued in Phase 2
	
TTDDRUID	D0W6XV
DRUGNAME	AbGn-7
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0W6YQ
DRUGNAME	SB therapeutics induced gene therapy
INDICATI	Ischemia [ICD-11: 8B10-8B11] Investigative
	
TTDDRUID	D0W6YR
DRUGNAME	PF-06817024
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
	
TTDDRUID	D0W6ZF
DRUGNAME	Sevoflurane
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0W6ZO
DRUGNAME	PMID26815044-Compound-30
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0W6ZV
DRUGNAME	HF-0420
INDICATI	Dementia [ICD-11: 6D80-6D86] Investigative
	
TTDDRUID	D0W7AB
DRUGNAME	Anti-BCMA CAR T cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0W7AE
DRUGNAME	HL-018
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0W7CR
DRUGNAME	EZN-3889
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W7DD
DRUGNAME	BAY-44-3428
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0W7DP
DRUGNAME	TDI-0107
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0W7FC
DRUGNAME	MLN-2704
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D0W7FG
DRUGNAME	ALF-421
INDICATI	Acute liver failure [ICD-11: DB91] Investigative
	
TTDDRUID	D0W7FS
DRUGNAME	PMID29338548-Compound-21
INDICATI	Schizophrenia [ICD-11: 6A20] Patented
	
TTDDRUID	D0W7GH
DRUGNAME	IC-747
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0W7HE
DRUGNAME	Alpelisib
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0W7IR
DRUGNAME	DMP-543
INDICATI	Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2
	
TTDDRUID	D0W7JZ
DRUGNAME	Tivozanib
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Approved
	
TTDDRUID	D0W7KD
DRUGNAME	FANDOFLOXACIN HYDROCHLORIDE
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0W7LO
DRUGNAME	PF9601N
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0W7NL
DRUGNAME	PF-06647263
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0W7NV
DRUGNAME	TDI-0043
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0W7OE
DRUGNAME	Aprindine
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Approved
	
TTDDRUID	D0W7OF
DRUGNAME	PMID20527968-compound-6577871
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
	
TTDDRUID	D0W7OG
DRUGNAME	HPMA-gemcitabine conjugate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W7PP
DRUGNAME	ST-0701
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0W7PQ
DRUGNAME	Glufosfomide
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
	
TTDDRUID	D0W7RJ
DRUGNAME	Hetacillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0W7RZ
DRUGNAME	ST-05
INDICATI	Spinal disease [ICD-11: FA72] Investigative
	
TTDDRUID	D0W7SX
DRUGNAME	CNTO-3649
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0W7TK
DRUGNAME	P-1118
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Investigative
	
TTDDRUID	D0W7TQ
DRUGNAME	IDX-719
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2
	
TTDDRUID	D0W7TU
DRUGNAME	NSC-73306
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W7UC
DRUGNAME	VAL-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W7UD
DRUGNAME	Anti-PD-L1 CSR T cells
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D0W7UN
DRUGNAME	BI-409306
INDICATI	Psychiatric disorder [ICD-11: 6E8Z] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0W7UO
DRUGNAME	CGP71683A
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 3
	
TTDDRUID	D0W7VE
DRUGNAME	Biphenyl mannoside derivative 20
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0W7VG
DRUGNAME	AMG 108
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0W7VQ
DRUGNAME	Imab-468
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W7VX
DRUGNAME	Statin
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D0W7WC
DRUGNAME	Ivacaftor
INDICATI	Cystic fibrosis [ICD-11: CA25] Approved
	
TTDDRUID	D0W7WG
DRUGNAME	Hormone-dependent vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Terminated
	
TTDDRUID	D0W7XH
DRUGNAME	DR2313
INDICATI	Stroke [ICD-11: 8B20] Investigative
	
TTDDRUID	D0W7XX
DRUGNAME	HS-HCV
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0W7YA
DRUGNAME	PP-202
INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative
	
TTDDRUID	D0W7ZN
DRUGNAME	SIM-916
INDICATI	Gynecological disease [ICD-11: GA6Z] Discontinued in Phase 1
	
TTDDRUID	D0W7ZS
DRUGNAME	Del 60 tetramer
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W8AG
DRUGNAME	TPIV 100/110 vaccine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0W8AI
DRUGNAME	Andromustine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0W8BO
DRUGNAME	RA101495
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 3
INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 2
	
TTDDRUID	D0W8CA
DRUGNAME	Genz-667348
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0W8CW
DRUGNAME	D-5519
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	D0W8DA
DRUGNAME	BI-54903
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0W8DG
DRUGNAME	L-19-PDT
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D0W8FE
DRUGNAME	CV-301
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0W8FU
DRUGNAME	Autologous cartilage system
INDICATI	Cartilage lesions [ICD-11: NC93.3Z] Approved
	
TTDDRUID	D0W8GP
DRUGNAME	DP-3590
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W8GT
DRUGNAME	SP160412
INDICATI	Sunburn [ICD-11: EJ40] Phase 2
	
TTDDRUID	D0W8HN
DRUGNAME	Bavencio
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Approved
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 3
INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 3
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2
INDICATI	Testicular cancer [ICD-11: 2C80] Phase 2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D0W8HP
DRUGNAME	MEDI-543
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0W8HW
DRUGNAME	CAL-301
INDICATI	Klebsiella infection [ICD-11: 1C4Y] Investigative
	
TTDDRUID	D0W8IY
DRUGNAME	P-276
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0W8JE
DRUGNAME	Depudecin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0W8JY
DRUGNAME	IL-4
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0W8KT
DRUGNAME	AVI-4065
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1/2
	
TTDDRUID	D0W8MS
DRUGNAME	Injectable MPL allergy vaccine
INDICATI	Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 3
	
TTDDRUID	D0W8NB
DRUGNAME	SC-005
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0W8NP
DRUGNAME	SAR-115740
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0W8NZ
DRUGNAME	SC-112
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Terminated
	
TTDDRUID	D0W8OH
DRUGNAME	SKF-96231
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0W8OJ
DRUGNAME	A-348441
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0W8PU
DRUGNAME	Prohibitin targeting peptide-1
INDICATI	Obesity [ICD-11: 5B81] Phase 1
	
TTDDRUID	D0W8QG
DRUGNAME	FR-229934
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Terminated
	
TTDDRUID	D0W8QH
DRUGNAME	ONO-4817
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1
	
TTDDRUID	D0W8QV
DRUGNAME	FK-613
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0W8RV
DRUGNAME	PMID26815044-Compound-116
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0W8RX
DRUGNAME	Sitimagene ceradenovec
INDICATI	Brain cancer [ICD-11: 2A00] Discontinued in Phase 3
	
TTDDRUID	D0W8SB
DRUGNAME	Penbutolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0W8SJ
DRUGNAME	Minaprine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0W8TQ
DRUGNAME	SL-701
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D0W8UV
DRUGNAME	NP-313
INDICATI	Thrombosis [ICD-11: DB61-GB90] Investigative
	
TTDDRUID	D0W8UW
DRUGNAME	AMG-628
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0W8VC
DRUGNAME	PA-1637
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0W8VI
DRUGNAME	Co-122739
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0W8VY
DRUGNAME	A-86719.1
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0W8WG
DRUGNAME	CD19-targeting CAR T Cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0W8XH
DRUGNAME	PI-103
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Investigative
	
TTDDRUID	D0W8XT
DRUGNAME	Mibefradil
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Withdrawn from market
	
TTDDRUID	D0W8YY
DRUGNAME	HI-con1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0W8YZ
DRUGNAME	IPZ-010
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0W8ZE
DRUGNAME	G3139 + Dexamethasone
INDICATI	Multiple myeloma [ICD-11: 2A83] Investigative
	
TTDDRUID	D0W8ZW
DRUGNAME	PA-342
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Terminated
	
TTDDRUID	D0W9AB
DRUGNAME	Imidazopyridazine derivative 6
INDICATI	Pain [ICD-11: MG30-MG3Z] Patented
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D0W9AI
DRUGNAME	MTC-DOX
INDICATI	Liver cancer [ICD-11: 2C12] Phase 2/3
	
TTDDRUID	D0W9CU
DRUGNAME	HLM-008182
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0W9GA
DRUGNAME	Levormeloxifene
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0W9IH
DRUGNAME	Ad35-GRIN
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0W9IT
DRUGNAME	NXN-462
INDICATI	Headache [ICD-11: 8A80-8A84] Phase 2
	
TTDDRUID	D0W9JH
DRUGNAME	BMY-30123
INDICATI	Acne vulgaris [ICD-11: ED80] Discontinued in Phase 2
	
TTDDRUID	D0W9JM
DRUGNAME	KNI-272
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0W9JP
DRUGNAME	Anti-Clostridium perfringens toxin mabs
INDICATI	Clostridium infection [ICD-11: 1A04] Investigative
	
TTDDRUID	D0W9KE
DRUGNAME	AS-1708727
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Investigative
	
TTDDRUID	D0W9LP
DRUGNAME	LC-9018
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0W9LS
DRUGNAME	ACI-35
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0W9LX
DRUGNAME	Carvedilol
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0W9MJ
DRUGNAME	TPIV 110
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0W9MM
DRUGNAME	Vinblastine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0W9NH
DRUGNAME	Tacedinaline
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0W9NO
DRUGNAME	YT-146
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0W9OR
DRUGNAME	OspA lipoprotein
INDICATI	Lyme disease [ICD-11: 1C1G] Approved
	
TTDDRUID	D0W9OW
DRUGNAME	RAP-310
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0W9PG
DRUGNAME	Pyrazinoylguanidine
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D0W9QG
DRUGNAME	SBI-087
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0W9QI
DRUGNAME	LErafAON
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0W9SL
DRUGNAME	LY2523355
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0W9SN
DRUGNAME	Pertuzumab + trastuzumab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0W9SZ
DRUGNAME	T611
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2
	
TTDDRUID	D0W9TE
DRUGNAME	Pentaerythritol tetranitrate
INDICATI	Angina pectoris [ICD-11: BA40] Approved
	
TTDDRUID	D0W9VB
DRUGNAME	Diphenidol
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D0W9VW
DRUGNAME	TZP-101
INDICATI	Gastrointestinal disease [ICD-11: DE2Z] Phase 2b
INDICATI	Gastroparesis [ICD-11: DA41.00] Phase 2b
INDICATI	Ileus [ICD-11: DA93.0] Phase 2b
	
TTDDRUID	D0W9WF
DRUGNAME	Ketoprofen
INDICATI	Musculoskeletal pain [ICD-11: MG30] Approved
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
INDICATI	Migraine [ICD-11: 8A80] Phase 2
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
	
TTDDRUID	D0W9XF
DRUGNAME	LRN-281
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Investigative
	
TTDDRUID	D0W9YW
DRUGNAME	BI-655130
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Palmoplantar pustulosis [ICD-11: EA90.42] Phase 2
	
TTDDRUID	D0W9ZF
DRUGNAME	Quinagolide
INDICATI	Hyperprolactinaemia [ICD-11: 5A60.1] Approved
	
TTDDRUID	D0W9ZS
DRUGNAME	Zn-DPA-H
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative
	
TTDDRUID	D0W9ZT
DRUGNAME	ADL-5859
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0W9ZY
DRUGNAME	CE-326597
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
	
TTDDRUID	D0WA1R
DRUGNAME	Keratinocyte growth factor
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0WA3T
DRUGNAME	CBNU-06
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0WB0R
DRUGNAME	KPP203
INDICATI	Subacute cutaneous lupus erythematosus [ICD-11: EB50] Phase 2
	
TTDDRUID	D0WB8J
DRUGNAME	PF-06647020 
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0WB9V
DRUGNAME	Barbiturate
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0WC4Y
DRUGNAME	FCX-007
INDICATI	Dystrophic epidermolysis bullosa [ICD-11: EC32] Phase 1/2
	
TTDDRUID	D0WC7S
DRUGNAME	Unsaturated long chain fatty acids
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0WD6K
DRUGNAME	VPM-4-001
INDICATI	Prostate cancer [ICD-11: 2C82.0] Preclinical
	
TTDDRUID	D0WD8M
DRUGNAME	Connexyn
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved
	
TTDDRUID	D0WD8R
DRUGNAME	MDP-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0WE3O
DRUGNAME	Morphine
INDICATI	Chronic pain [ICD-11: MG30] Approved
	
TTDDRUID	D0WF1S
DRUGNAME	Tomeglovir
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2
	
TTDDRUID	D0WF7H
DRUGNAME	ICT-111
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0WF7K
DRUGNAME	Candoxatril
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 3
	
TTDDRUID	D0WF7L
DRUGNAME	Brilinta
INDICATI	Thrombosis [ICD-11: DB61-GB90] Approved
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 3
INDICATI	Arterial thrombosis [ICD-11: DB61-DD30] Phase 3
	
TTDDRUID	D0WG1T
DRUGNAME	IC 1001
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0WG2R
DRUGNAME	Doravirine + lamivudine + tenofovir disoproxil fumarate
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0WG3X
DRUGNAME	HAC-1 vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0WG8A
DRUGNAME	Long-actingloop diuretic
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2
	
TTDDRUID	D0WH1K
DRUGNAME	Amidine compound 2
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Patented
	
TTDDRUID	D0WH4L
DRUGNAME	AVN 211
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2/3
	
TTDDRUID	D0WH4P
DRUGNAME	ENASIDENIB MESYLATE
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Approved
	
TTDDRUID	D0WH9U
DRUGNAME	FK-070
INDICATI	Angina pectoris [ICD-11: BA40] Phase 2
	
TTDDRUID	D0WI1L
DRUGNAME	Arthromir
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0WI3T
DRUGNAME	Saquinavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0WI7N
DRUGNAME	Imidazo pyridine derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0WI9W
DRUGNAME	CPC-250
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0WJ1H
DRUGNAME	Replication-defective HIV vaccine
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0WJ3C
DRUGNAME	Hepatitis B prophylactic vaccine
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	D0WJ3F
DRUGNAME	N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2
INDICATI	Osteoporosis [ICD-11: FB83.0] Patented
	
TTDDRUID	D0WJ5M
DRUGNAME	Bimekizumab
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
INDICATI	Psoriatic arthritis [ICD-11: FA21] Phase 2
	
TTDDRUID	D0WJ7H
DRUGNAME	AGEN2034
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2
	
TTDDRUID	D0WJ8M
DRUGNAME	U3-1402
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0WJ8R
DRUGNAME	PMID25666693-Compound-91
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0WK0P
DRUGNAME	Topiroxostat
INDICATI	Gout [ICD-11: FA25] Phase 2
	
TTDDRUID	D0WK1M
DRUGNAME	Baltaleucel-T
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
INDICATI	Post-transplant lymphoproliferative disorder [ICD-11: 2B32] Phase 2
	
TTDDRUID	D0WK6V
DRUGNAME	PF-05231023
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0WK7B
DRUGNAME	FP-0220
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0WK7Y
DRUGNAME	Men ABCWY vaccine
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 2
	
TTDDRUID	D0WK8I
DRUGNAME	Sulfonylated piperazine derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0WL0G
DRUGNAME	PYN-17
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2
	
TTDDRUID	D0WL0Q
DRUGNAME	GS-5745
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0WL1C
DRUGNAME	Hementin
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0WL1U
DRUGNAME	PMID25656651-Compound-5
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Patented
	
TTDDRUID	D0WL2E
DRUGNAME	PMID30940566-compound-6
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0WL3H
DRUGNAME	LY03005
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 3
	
TTDDRUID	D0WL4D
DRUGNAME	STX-100
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
	
TTDDRUID	D0WL5F
DRUGNAME	Grazax
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0WL5P
DRUGNAME	Antibodie derivative 9
INDICATI	Corneal neovascularization [ICD-11: 9A78] Patented
INDICATI	Carotid artery disease [ICD-11: 8B10] Patented
INDICATI	Macular degeneration [ICD-11: 9B78.3] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D0WL5T
DRUGNAME	BIIB076
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0WL5V
DRUGNAME	LAROPIPRANT
INDICATI	Coronary heart disease [ICD-11: BA80.Z] Phase 4
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 3
	
TTDDRUID	D0WL7V
DRUGNAME	ME-3738
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2
	
TTDDRUID	D0WL8I
DRUGNAME	CJ-30001
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0WM3D
DRUGNAME	TAR-200
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1
	
TTDDRUID	D0WM3E
DRUGNAME	INP-341
INDICATI	Skin burns [ICD-11: ME65.0] Preclinical
	
TTDDRUID	D0WM3Z
DRUGNAME	TI-061
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0WM5H
DRUGNAME	OP-06
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0WM5O
DRUGNAME	G1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0WM6E
DRUGNAME	3,5-diiodothyropropionic acid
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2
	
TTDDRUID	D0WM6I
DRUGNAME	Analatro
INDICATI	Poison intoxication [ICD-11: NE6Z] Phase 3
	
TTDDRUID	D0WM7M
DRUGNAME	Anti-CD19 CAR-T cell therapy
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0WM8D
DRUGNAME	CAD-1833
INDICATI	Essential tremor or related tremors [ICD-11: 8A04.1] Phase 1
INDICATI	Spinocerebellar ataxia [ICD-11: 8A03.16] Phase 1
	
TTDDRUID	D0WN0U
DRUGNAME	Felodipine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0WN1N
DRUGNAME	DM-204
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0WN1T
DRUGNAME	99mTc-labelled adrenomedullin
INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 2
	
TTDDRUID	D0WN2Y
DRUGNAME	CAR-T cells targeting Glypican-3 (GPC3)
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
	
TTDDRUID	D0WN7T
DRUGNAME	MFH-147
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D0WO2I
DRUGNAME	PMID26651364-Compound-111
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0WO4T
DRUGNAME	PMID27998201-Compound-24
INDICATI	Meningioma tumour [ICD-11: 2A01] Patented
INDICATI	Glioma [ICD-11: 2A00.0] Patented
	
TTDDRUID	D0WO6C
DRUGNAME	PMID26651364-Compound-49
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0WO7R
DRUGNAME	ABBV-181
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0WO8I
DRUGNAME	PD-2015
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0WO8W
DRUGNAME	Mepivacaine
INDICATI	Analgesia [ICD-11: MB40.8] Approved
	
TTDDRUID	D0WP0B
DRUGNAME	Acemannan
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
INDICATI	Canine and feline spontaneous neoplasm [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0WP0U
DRUGNAME	CMB305
INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0WP1L
DRUGNAME	NPS-3
INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative
	
TTDDRUID	D0WP2R
DRUGNAME	AC-201
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0WP4E
DRUGNAME	RO-5271983
INDICATI	Asthma [ICD-11: CA23] Phase 1
	
TTDDRUID	D0WP7P
DRUGNAME	NNC-55-0118
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Terminated
	
TTDDRUID	D0WP9A
DRUGNAME	BIIB068
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	D0WQ0R
DRUGNAME	Anti-T-lymphocyte immune globulin
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3
	
TTDDRUID	D0WQ5S
DRUGNAME	U-99363E
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0WQ5U
DRUGNAME	MTR107
INDICATI	Intradialytic hypotension [ICD-11: BA20-BA21] Phase 2
	
TTDDRUID	D0WQ9X
DRUGNAME	PMID30107136-Compound-Example1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0WR3D
DRUGNAME	Abetimus sodium
INDICATI	Lupus [ICD-11: 4A40] Discontinued in Phase 3
	
TTDDRUID	D0WR7C
DRUGNAME	PH-94B
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2
	
TTDDRUID	D0WR7U
DRUGNAME	REN-1053
INDICATI	Ischemic heart disease [ICD-11: BA40-BA6Z] Terminated
	
TTDDRUID	D0WR9U
DRUGNAME	MEDI7352
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 1
	
TTDDRUID	D0WS1V
DRUGNAME	L-751250
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0WS1X
DRUGNAME	Cefdinir
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0WS4E
DRUGNAME	COR-388
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0WS5L
DRUGNAME	BIA-13
INDICATI	Respiratory disease [ICD-11: CB40] Investigative
	
TTDDRUID	D0WS8K
DRUGNAME	Ilatreotide
INDICATI	Duodenal ulcer [ICD-11: DA63] Investigative
	
TTDDRUID	D0WT0E
DRUGNAME	VasoPET
INDICATI	Coronary artery disease [ICD-11: BA80] Investigative
	
TTDDRUID	D0WT1C
DRUGNAME	Benzothiazole analog 2
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0WT1W
DRUGNAME	PMID25666693-Compound-132
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0WT6A
DRUGNAME	Ethylene diamine
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Investigative
	
TTDDRUID	D0WT8Z
DRUGNAME	TDI-0115
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0WT9A
DRUGNAME	Vero-cell H5N1 vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2
	
TTDDRUID	D0WT9J
DRUGNAME	Heteroaryl-carboxamide derivative 8
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0WU0K
DRUGNAME	Sporeamicins
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0WU1O
DRUGNAME	G1T38
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0WU2Y
DRUGNAME	ImmuStem
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Investigative
	
TTDDRUID	D0WU3G
DRUGNAME	99mTc-RP-527
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D0WU7X
DRUGNAME	EMB-001
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 1
	
TTDDRUID	D0WU8Z
DRUGNAME	BB-476
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0WV3U
DRUGNAME	Prazosin
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
INDICATI	Benign prostatic hyperplasia [ICD-11: GA90] Approved
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0WV4H
DRUGNAME	Hemomex I
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0WV4M
DRUGNAME	Propicillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0WV4N
DRUGNAME	AHR-14042
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0WV8Z
DRUGNAME	MEDI4166
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0WV9J
DRUGNAME	Beta-cyclodextrin conjugate derivative 5
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0WW1V
DRUGNAME	MM-310
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0WW3O
DRUGNAME	XEN1101
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 1
	
TTDDRUID	D0WW7U
DRUGNAME	BFPT-12603
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0WW9B
DRUGNAME	Aryl mannoside derivative 18
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0WX1I
DRUGNAME	ProVax
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0WX1N
DRUGNAME	Ensemblin macrocycle
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0WX3N
DRUGNAME	KRP-110
INDICATI	Constipation [ICD-11: DD91.1] Investigative
	
TTDDRUID	D0WX4H
DRUGNAME	Heterocyclic derivative 19
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0WX4W
DRUGNAME	PMID25666693-Compound-120
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0WX5V
DRUGNAME	LP-205A1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0WY0N
DRUGNAME	ALKASAR-18
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2
	
TTDDRUID	D0WY1E
DRUGNAME	MB-106
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0WY2L
DRUGNAME	GSK1018921
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
	
TTDDRUID	D0WY3J
DRUGNAME	Pfizer 4
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 1
	
TTDDRUID	D0WY5Q
DRUGNAME	Rivastigmine
INDICATI	Alzheimer disease [ICD-11: 8A20] Approved
	
TTDDRUID	D0WY9F
DRUGNAME	MenAfriVac
INDICATI	Neisseria meningitis infection [ICD-11: 1C1C.0] Approved
	
TTDDRUID	D0WY9H
DRUGNAME	ZD-0892
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D0WY9N
DRUGNAME	Agrimophol
INDICATI	Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved
	
TTDDRUID	D0WZ0E
DRUGNAME	TV-Kidney-1
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D0WZ0X
DRUGNAME	ABP 980
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
	
TTDDRUID	D0WZ3G
DRUGNAME	Entolimod
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Radiation syndrome [ICD-11: NF00] Phase 1
	
TTDDRUID	D0WZ4J
DRUGNAME	CYC-800
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0WZ9R
DRUGNAME	PRS-343
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0WZ9T
DRUGNAME	CGP-44532
INDICATI	Drug abuse [ICD-11: 6C4G.1Z] Investigative
	
TTDDRUID	D0WZC1
DRUGNAME	JNJ-61393215
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0WZX4
DRUGNAME	AB-205
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0X0CB
DRUGNAME	Lumacaftor
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D0X0CH
DRUGNAME	Ganaxolone
INDICATI	Complex partial seizure [ICD-11: 8A68.0] Phase 3
INDICATI	Postpartum depression [ICD-11: 6E20.0] Phase 2
	
TTDDRUID	D0X0EF
DRUGNAME	XGP-210
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X0EU
DRUGNAME	E-5531
INDICATI	Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2
	
TTDDRUID	D0X0FU
DRUGNAME	KP-1461
INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0X0FW
DRUGNAME	B1-655075
INDICATI	Coagulation defect [ICD-11: 3B10.0] Phase 1
	
TTDDRUID	D0X0GB
DRUGNAME	LetibotulinumtoxinA
INDICATI	Glabellar frown line [ICD-11: NA0Z] Phase 3
	
TTDDRUID	D0X0GI
DRUGNAME	Gadoversetamide
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Approved
	
TTDDRUID	D0X0IQ
DRUGNAME	Modified GDNF
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	D0X0IU
DRUGNAME	LMB-2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
	
TTDDRUID	D0X0IY
DRUGNAME	Rolofylline
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3
	
TTDDRUID	D0X0KJ
DRUGNAME	Chlorotrianisene
INDICATI	Menopause symptom [ICD-11: GA30.0] Withdrawn from market
	
TTDDRUID	D0X0KM
DRUGNAME	Tasisulam
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	D0X0NA
DRUGNAME	R-524
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Investigative
	
TTDDRUID	D0X0OF
DRUGNAME	Pennvax-G
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0X0OT
DRUGNAME	Needle-free ETEC vaccine
INDICATI	Diarrhea [ICD-11: ME05.1] Discontinued in Phase 3
	
TTDDRUID	D0X0PP
DRUGNAME	AMG 579
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0X0PQ
DRUGNAME	NHS-IL2-LT
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0X0PW
DRUGNAME	Revamilast
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0X0QC
DRUGNAME	DES-6
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Terminated
	
TTDDRUID	D0X0RI
DRUGNAME	Mexiletine
INDICATI	Ventricular tachycardia [ICD-11: BC71] Approved
	
TTDDRUID	D0X0RV
DRUGNAME	PMID26815044-Compound-47
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0X0SK
DRUGNAME	GSK-2302025A
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0X0TM
DRUGNAME	Trichuris suis ova
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D0X0WQ
DRUGNAME	SHP680
INDICATI	Neurologic conditions associated with aminoacylase 1 deficiency [ICD-11: 5C50.E1] Phase 1
	
TTDDRUID	D0X0WU
DRUGNAME	Tolperisone
INDICATI	Muscle spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D0X0ZD
DRUGNAME	EXRD-4605
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0X0ZK
DRUGNAME	HG-1343
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X1BJ
DRUGNAME	Denibulin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0X1BR
DRUGNAME	MEDI-550
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0X1BX
DRUGNAME	hESC-derived pancreatic endoderm (VC-01)
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	D0X1EV
DRUGNAME	TNT009
INDICATI	Bullous pemphigoid [ICD-11: EB41.0] Phase 1
INDICATI	Cold type autoimmune haemolytic anemia [ICD-11: 3A20.1] Phase 1
	
TTDDRUID	D0X1EX
DRUGNAME	TIBENELAST
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0X1EZ
DRUGNAME	Cyclofenil
INDICATI	Infertility [ICD-11: GB04] Approved
	
TTDDRUID	D0X1HE
DRUGNAME	Ozenoxacin
INDICATI	Impetigo [ICD-11: 1B72] Approved
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
	
TTDDRUID	D0X1IB
DRUGNAME	111In-labeled LFA-1 targeted imaging agent (lymphoma/leukemia), NuView/University of New Mexico
INDICATI	leukaemia [ICD-11: 2A60-2B33] Investigative
	
TTDDRUID	D0X1IL
DRUGNAME	SPC4955
INDICATI	High blood cholesterol level [ICD-11: 5C80.00] Phase 1
	
TTDDRUID	D0X1LE
DRUGNAME	ST-383
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Investigative
	
TTDDRUID	D0X1LO
DRUGNAME	EMR-62203
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2
	
TTDDRUID	D0X1LP
DRUGNAME	N-acylpiperidine ether derivative 3
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0X1LW
DRUGNAME	Ragweed pollen allergen sublingual immunotherapy
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1
	
TTDDRUID	D0X1NX
DRUGNAME	ACE-920
INDICATI	Escherichia coli infection [ICD-11: 1A03] Investigative
	
TTDDRUID	D0X1OO
DRUGNAME	PMID25666693-Compound-39
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0X1OV
DRUGNAME	HO/07/09
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D0X1OW
DRUGNAME	AZD9496
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0X1QM
DRUGNAME	AT-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0X1QN
DRUGNAME	Neurotrophic factor-producing stem cells
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0X1RQ
DRUGNAME	MTR105
INDICATI	Hypotension [ICD-11: BA20-BA21] Phase 2
	
TTDDRUID	D0X1RR
DRUGNAME	Coccidioidin
INDICATI	Dermatomycosis [ICD-11: EA60] Approved
	
TTDDRUID	D0X1ST
DRUGNAME	ESR0114
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1/2
	
TTDDRUID	D0X1SV
DRUGNAME	Epratuzumab Y-90
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0X1TD
DRUGNAME	RemeStim-CEA
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0X1VJ
DRUGNAME	AGI-1067
INDICATI	Artery stenosis [ICD-11: BD52] Phase 3
	
TTDDRUID	D0X1WJ
DRUGNAME	Josamycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0X1XA
DRUGNAME	62Cu-ETS
INDICATI	Kidney disease [ICD-11: GC2Z] Phase 2
	
TTDDRUID	D0X1XK
DRUGNAME	CPC-212
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0X1YF
DRUGNAME	T-1095
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2
	
TTDDRUID	D0X1YZ
DRUGNAME	KM-4056
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X1ZV
DRUGNAME	Trimidox
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0X2DK
DRUGNAME	Phenoxybenzamine
INDICATI	Malignant essential hypertension [ICD-11: BA00] Approved
	
TTDDRUID	D0X2EM
DRUGNAME	UNI-PH (1-34)
INDICATI	Osteoporosis [ICD-11: FB83.0] Phase 2
	
TTDDRUID	D0X2FT
DRUGNAME	Gadoxetate disodium
INDICATI	Imaging [ICD-11: QA0B] Approved
	
TTDDRUID	D0X2GM
DRUGNAME	PRX-12256
INDICATI	Neurological disorder [ICD-11: 6B60] Investigative
	
TTDDRUID	D0X2HD
DRUGNAME	ELS-120
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D0X2HE
DRUGNAME	GlycoPEG-GCSF
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0X2HJ
DRUGNAME	PTI-125
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0X2IE
DRUGNAME	Dimercaprol
INDICATI	Poison intoxication [ICD-11: NE6Z] Approved
	
TTDDRUID	D0X2JM
DRUGNAME	XL418
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0X2JY
DRUGNAME	Multiclade DNA recombinant adenovirus-5 (rAd5) vaccine
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0X2KY
DRUGNAME	99mTc-Hynic-Annexin V
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0X2LB
DRUGNAME	IDP-120
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0X2LQ
DRUGNAME	LY03004
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D0X2LV
DRUGNAME	Betamethasone butyrate propion
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0X2LW
DRUGNAME	DPT/Hib vaccine
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 3
	
TTDDRUID	D0X2MB
DRUGNAME	Oxprenolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0X2MZ
DRUGNAME	Syn-1020
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0X2NB
DRUGNAME	AZD-6319
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0X2NE
DRUGNAME	PAT-SM3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X2NN
DRUGNAME	BIBT986
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0X2OV
DRUGNAME	ONO-8711
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0X2PQ
DRUGNAME	IX207-887
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0X2PR
DRUGNAME	MEDI-541
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0X2QH
DRUGNAME	PBI-1402
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1/2
	
TTDDRUID	D0X2RJ
DRUGNAME	Technetium TC 99M votumumab
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
	
TTDDRUID	D0X2RL
DRUGNAME	LY3012212
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 2
	
TTDDRUID	D0X2SY
DRUGNAME	CR-3663
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Investigative
	
TTDDRUID	D0X2TO
DRUGNAME	Adatanserin
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
	
TTDDRUID	D0X2TZ
DRUGNAME	Streptococcus pneumoniae vaccine
INDICATI	Pneumonia [ICD-11: CA40] Phase 1
INDICATI	Meningitis [ICD-11: 1D01] Phase 1
INDICATI	Streptococcus infection [ICD-11: 1B53] Phase 1
	
TTDDRUID	D0X2UE
DRUGNAME	Sulprostone
INDICATI	Medical abortion [ICD-11: JA00.1Z] Approved
	
TTDDRUID	D0X2UI
DRUGNAME	LIK-066
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D0X2UK
DRUGNAME	Affitope AD-01
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0X2XF
DRUGNAME	Piboserod
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 2
	
TTDDRUID	D0X2XZ
DRUGNAME	CFI-400945
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0X2YI
DRUGNAME	IPLl576092
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D0X3AK
DRUGNAME	GL-438
INDICATI	Hepatitis E virus infection [ICD-11: 1E50.4] Phase 4
	
TTDDRUID	D0X3BG
DRUGNAME	Acid sphingomyelinase
INDICATI	Niemann-pick disease [ICD-11: 5C56.0Y] Phase 1
	
TTDDRUID	D0X3CD
DRUGNAME	Thiarabine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0X3ER
DRUGNAME	OP-145
INDICATI	Otitis media [ICD-11: AA80-AB0Z] Phase 2
INDICATI	Chronic suppurative otitis media [ICD-11: AA91] Phase 2
INDICATI	Bronchitis [ICD-11: CA20] Discontinued in Phase 2
	
TTDDRUID	D0X3FX
DRUGNAME	Naloxone
INDICATI	Narcotic depression [ICD-11: 6A7Z] Approved
INDICATI	Respiratory depression [ICD-11: MD11.5] Phase 3
INDICATI	Pruritus [ICD-11: EC90] Phase 3
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 1
	
TTDDRUID	D0X3GA
DRUGNAME	NN8717
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3
	
TTDDRUID	D0X3GD
DRUGNAME	LPCVD
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative
	
TTDDRUID	D0X3HV
DRUGNAME	BI-695500
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Application submitted
	
TTDDRUID	D0X3JK
DRUGNAME	V120083
INDICATI	Chronic pain [ICD-11: MG30] Phase 2
	
TTDDRUID	D0X3JV
DRUGNAME	MalariVax
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	D0X3JY
DRUGNAME	NTX-010
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0X3KX
DRUGNAME	U-80816
INDICATI	Amnesia [ICD-11: MB21.1] Terminated
	
TTDDRUID	D0X3LD
DRUGNAME	Valtorcitabine
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2
	
TTDDRUID	D0X3NK
DRUGNAME	MP-PN-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X3OF
DRUGNAME	NPT-1162
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0X3OI
DRUGNAME	TAK-700
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	D0X3PN
DRUGNAME	DR-5/DR-4 cross reactive mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X3QL
DRUGNAME	PD-3766
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0X3QR
DRUGNAME	AVA-101
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2
	
TTDDRUID	D0X3RK
DRUGNAME	LLY-507
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0X3TI
DRUGNAME	SRT3025
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0X3UW
DRUGNAME	Saurestat
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative
	
TTDDRUID	D0X3XV
DRUGNAME	AdCMV-PR8.ha
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0X3YY
DRUGNAME	OMP-52M51
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0X4AN
DRUGNAME	CGEN-791
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0X4AV
DRUGNAME	GV-150013
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D0X4BZ
DRUGNAME	Virulizin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0X4CE
DRUGNAME	NMK-36
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0X4CS
DRUGNAME	Cefroxadine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0X4DB
DRUGNAME	Drisapersen
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 3
	
TTDDRUID	D0X4DJ
DRUGNAME	Tumor-associated macrophage immunotherapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X4EC
DRUGNAME	Benzoic acid linked peptide analog 5
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0X4FM
DRUGNAME	Docusate
INDICATI	Constipation [ICD-11: DD91.1] Approved
	
TTDDRUID	D0X4FW
DRUGNAME	AT9183
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	D0X4FY
DRUGNAME	Cis-tetracosenoyl sulfatide
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0X4IA
DRUGNAME	FK778
INDICATI	Kidney/heart transplant rejection [ICD-11: NE84] Discontinued in Phase 2
	
TTDDRUID	D0X4IH
DRUGNAME	Fluciclatide F-18
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0X4IO
DRUGNAME	Sulforaphane
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
INDICATI	Skin disease [ICD-11: EA00-EM0Z] Investigative
	
TTDDRUID	D0X4IV
DRUGNAME	PSD-508
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Discontinued in Phase 2
	
TTDDRUID	D0X4JN
DRUGNAME	Pelubiprofen
INDICATI	Back pain [ICD-11: ME84.Z] Approved
	
TTDDRUID	D0X4JO
DRUGNAME	EncorStat
INDICATI	Corneal abrasion [ICD-11: NA06.4] Investigative
	
TTDDRUID	D0X4KN
DRUGNAME	BI-836845
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0X4LA
DRUGNAME	N-acylpyrrolidine ether derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0X4MC
DRUGNAME	AMG 076
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 1
	
TTDDRUID	D0X4MN
DRUGNAME	CC-930
INDICATI	Discoid lupus erythematosus [ICD-11: EB51.0] Phase 2
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
	
TTDDRUID	D0X4MO
DRUGNAME	SPVF-2801-30
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X4NF
DRUGNAME	Radiosensitizer gene therapy
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 3
	
TTDDRUID	D0X4OJ
DRUGNAME	AdipoCell
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1/2
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 1/2
	
TTDDRUID	D0X4OM
DRUGNAME	SPD-701
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 1
	
TTDDRUID	D0X4RN
DRUGNAME	Lidocaine
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Phase 2
	
TTDDRUID	D0X4RS
DRUGNAME	Cortisone Acetate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0X4RT
DRUGNAME	DS-7423
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0X4SI
DRUGNAME	RS-504393
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Preclinical
	
TTDDRUID	D0X4TK
DRUGNAME	Nadofaragene firadenovec
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3
	
TTDDRUID	D0X4TV
DRUGNAME	PMID26651364-Compound-118
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0X4UA
DRUGNAME	DISC GM-CSF
INDICATI	Melanoma [ICD-11: 2C30] Terminated
	
TTDDRUID	D0X4UH
DRUGNAME	S-8184
INDICATI	Ovarian cancer [ICD-11: 2C73] Preclinical
	
TTDDRUID	D0X4UP
DRUGNAME	Liposomal amikacin
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 3
INDICATI	Bronchiectasis [ICD-11: CA24] Phase 2
	
TTDDRUID	D0X4VA
DRUGNAME	Imlygictalimogene laherparepvec
INDICATI	Peripheral nervous system tumour [ICD-11: 2B5E] Phase 1
	
TTDDRUID	D0X4VG
DRUGNAME	Anti-Notch-1 receptor mabs
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X4WV
DRUGNAME	IDV-007
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative
	
TTDDRUID	D0X4YJ
DRUGNAME	ImCOOH
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0X4ZL
DRUGNAME	AN-1792
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0X4ZR
DRUGNAME	Bupropion
INDICATI	Smoking dependence [ICD-11: 6C4A.2] Approved
	
TTDDRUID	D0X4ZV
DRUGNAME	BAX-499
INDICATI	Factor IX deficiency [ICD-11: 3B11] Phase 1
	
TTDDRUID	D0X5AN
DRUGNAME	U300
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0X5BC
DRUGNAME	DT-320
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X5CU
DRUGNAME	AM-491
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Terminated
	
TTDDRUID	D0X5ES
DRUGNAME	NCX 950
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1/2
	
TTDDRUID	D0X5GF
DRUGNAME	K22
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0X5IV
DRUGNAME	1,2,4-oxadiazole derivative 6
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0X5JF
DRUGNAME	AR-H050642
INDICATI	Heart arrhythmia [ICD-11: BC65] Terminated
	
TTDDRUID	D0X5KF
DRUGNAME	Hydrocodone
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0X5LG
DRUGNAME	ABJ-879
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0X5LL
DRUGNAME	WBI-2000
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X5NX
DRUGNAME	Clenbuterol
INDICATI	Chronic breathing disorder [ICD-11: 7A4Z] Approved
	
TTDDRUID	D0X5OV
DRUGNAME	TTA-A8
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Preclinical
	
TTDDRUID	D0X5SD
DRUGNAME	Disulfiram
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Approved
	
TTDDRUID	D0X5SI
DRUGNAME	Carbocisteine
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Approved
	
TTDDRUID	D0X5SJ
DRUGNAME	Alacepril
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0X5UH
DRUGNAME	ADOZELESIN
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2
	
TTDDRUID	D0X5UL
DRUGNAME	Salmonella typhi vaccine
INDICATI	Salmonella infection [ICD-11: 1A09] Approved
	
TTDDRUID	D0X5UN
DRUGNAME	Mirabegron
INDICATI	Overactive bladder [ICD-11: GC50.0] Approved
	
TTDDRUID	D0X5UY
DRUGNAME	HL-146
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X5VH
DRUGNAME	Monoamine derivative 4
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0X5WJ
DRUGNAME	Levodropropizine
INDICATI	Cough [ICD-11: MD12] Approved
	
TTDDRUID	D0X5XU
DRUGNAME	Decitabine
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Approved
	
TTDDRUID	D0X5YN
DRUGNAME	CHS-1420
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 3
	
TTDDRUID	D0X5YU
DRUGNAME	KOS-2484
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0X5ZH
DRUGNAME	LC-445
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X5ZI
DRUGNAME	Ambrisentan
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Approved
	
TTDDRUID	D0X5ZO
DRUGNAME	SSR-162369
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0X5ZU
DRUGNAME	ET-01
INDICATI	Facial wrinkles [ICD-11: EJ9Y] Phase 2
	
TTDDRUID	D0X6AU
DRUGNAME	FAS-031
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X6BV
DRUGNAME	Vilazodone
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
	
TTDDRUID	D0X6BX
DRUGNAME	ABC294640
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0X6DC
DRUGNAME	STM 434
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D0X6DE
DRUGNAME	FemiVac
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
	
TTDDRUID	D0X6DK
DRUGNAME	TDI-0098
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0X6EM
DRUGNAME	T2c-001
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2
	
TTDDRUID	D0X6EX
DRUGNAME	OX-MPI
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0X6FB
DRUGNAME	KI-0903
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0X6FF
DRUGNAME	SPPI-339
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Terminated
	
TTDDRUID	D0X6FU
DRUGNAME	C-CAR011
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D0X6GN
DRUGNAME	Loteprednol Etabonate
INDICATI	Eye inflammation [ICD-11: 9A02] Approved
	
TTDDRUID	D0X6GP
DRUGNAME	PF-04577806
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Investigative
	
TTDDRUID	D0X6HD
DRUGNAME	Anileridine
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0X6IU
DRUGNAME	Chloramphenicol
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0X6LC
DRUGNAME	Monteplase
INDICATI	Thrombin deficiency [ICD-11: 3B14.Z] Approved
	
TTDDRUID	D0X6LG
DRUGNAME	MC-1002
INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical
	
TTDDRUID	D0X6MO
DRUGNAME	Ralitoline
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Terminated
	
TTDDRUID	D0X6NU
DRUGNAME	Debio-1142
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X6NZ
DRUGNAME	AFN-1720
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D0X6OW
DRUGNAME	Cefminox sodium
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0X6OX
DRUGNAME	CAB-051
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X6PG
DRUGNAME	LY-274614
INDICATI	Dementia [ICD-11: 6D80-6D86] Terminated
	
TTDDRUID	D0X6QL
DRUGNAME	KGP94
INDICATI	Coagulation defect [ICD-11: 3B10.0] Clinical trial
	
TTDDRUID	D0X6SZ
DRUGNAME	GNTI
INDICATI	Obesity [ICD-11: 5B81] Preclinical
	
TTDDRUID	D0X6TZ
DRUGNAME	RCD-1
INDICATI	Stress urinary incontinence [ICD-11: MF50.20] Preclinical
	
TTDDRUID	D0X6VC
DRUGNAME	HIV vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0X6XC
DRUGNAME	Lm Ft
INDICATI	Tularemia [ICD-11: 1B94] Investigative
	
TTDDRUID	D0X6XF
DRUGNAME	VTP-201227
INDICATI	Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0X6XH
DRUGNAME	CM-2395
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D0X6XP
DRUGNAME	JIN-2011
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X6ZG
DRUGNAME	XEN-D0101
INDICATI	Atrial fibrillation [ICD-11: BC81.3] Phase 1
	
TTDDRUID	D0X7BN
DRUGNAME	AP32788
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0X7CV
DRUGNAME	PTX-200
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D0X7DE
DRUGNAME	Nefazodone
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Approved
INDICATI	Depression [ICD-11: 6A70-6A7Z] Withdrawn from market
	
TTDDRUID	D0X7DZ
DRUGNAME	Pyrazolo[1,5-a]pyrimidine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0X7EG
DRUGNAME	OC-000459
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D0X7EQ
DRUGNAME	Resorcinol compound 19
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0X7GA
DRUGNAME	RO-6036
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0X7GL
DRUGNAME	Retigabine
INDICATI	Behcet disease [ICD-11: 4A62] Approved
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Withdrawn from market
	
TTDDRUID	D0X7GU
DRUGNAME	Rizaport
INDICATI	Migraine [ICD-11: 8A80] Application submitted
	
TTDDRUID	D0X7GX
DRUGNAME	Dendritic cancer vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0X7HM
DRUGNAME	Carboplatin
INDICATI	Ovarian cancer [ICD-11: 2C73] Approved
	
TTDDRUID	D0X7HN
DRUGNAME	PMID26651364-Compound-50
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0X7HQ
DRUGNAME	NitroSense PA6
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
	
TTDDRUID	D0X7HV
DRUGNAME	ZD-6169
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2
	
TTDDRUID	D0X7IN
DRUGNAME	BGT226
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0X7IT
DRUGNAME	Ioxaglate
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0X7IW
DRUGNAME	Tolerizing peptide
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2
	
TTDDRUID	D0X7JC
DRUGNAME	BAY-86-4367
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0X7JN
DRUGNAME	Clavulanate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0X7JR
DRUGNAME	Eflornithine
INDICATI	African trypanosomiasis [ICD-11: 1F51] Approved
INDICATI	Trypanosomiasis [ICD-11: 1D51-1F53] Phase 2
	
TTDDRUID	D0X7KB
DRUGNAME	Lisuride
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 3
	
TTDDRUID	D0X7KZ
DRUGNAME	Strontium ranelate
INDICATI	Osteoporosis [ICD-11: FB83.0] Approved
	
TTDDRUID	D0X7LY
DRUGNAME	CT-100
INDICATI	Kidney disease [ICD-11: GC2Z] Investigative
	
TTDDRUID	D0X7MY
DRUGNAME	AGS-16 mab
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
	
TTDDRUID	D0X7NT
DRUGNAME	SAF-312
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0X7NU
DRUGNAME	Pralidoxime Chloride
INDICATI	Poisoning due to pesticides and chemicals [ICD-11: NE6Z] Approved
	
TTDDRUID	D0X7OE
DRUGNAME	PMID32321856-compound-11a
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0X7OH
DRUGNAME	EPZ028862
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0X7QQ
DRUGNAME	Benperidol
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0X7VB
DRUGNAME	MBX-102
INDICATI	Gout [ICD-11: FA25] Phase 2/3
	
TTDDRUID	D0X7WK
DRUGNAME	AZD-6553
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D0X7XG
DRUGNAME	Fusidic Acid
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Phase 3
	
TTDDRUID	D0X7YC
DRUGNAME	IGE-026
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Terminated
	
TTDDRUID	D0X7YR
DRUGNAME	PGCvax
INDICATI	Pneumonia [ICD-11: CA40] Terminated
	
TTDDRUID	D0X7ZE
DRUGNAME	AdVac Malaria Vaccine
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	D0X7ZG
DRUGNAME	Ledgins
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0X7ZH
DRUGNAME	PAT-CM-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X7ZL
DRUGNAME	Sodium salicylate
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0X7ZS
DRUGNAME	MAT-303
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0X8AB
DRUGNAME	Mannoside derivative 4
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0X8AU
DRUGNAME	KNI-764
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1
	
TTDDRUID	D0X8CH
DRUGNAME	GSK2330672
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Pruritus [ICD-11: EC90] Phase 2
	
TTDDRUID	D0X8DU
DRUGNAME	Clinprost
INDICATI	Asthma [ICD-11: CA23] Discontinued in Preregistration
	
TTDDRUID	D0X8EE
DRUGNAME	VitiGam
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0X8GJ
DRUGNAME	TMA-230
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2
	
TTDDRUID	D0X8HB
DRUGNAME	NAV5001
INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 3
	
TTDDRUID	D0X8HP
DRUGNAME	TRIDMAC
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Phase 2
	
TTDDRUID	D0X8ID
DRUGNAME	SEL-24
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X8JN
DRUGNAME	GFC-003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X8KY
DRUGNAME	Fosinopril
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0X8MI
DRUGNAME	Berupipam
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1
	
TTDDRUID	D0X8MZ
DRUGNAME	Alvameline
INDICATI	Alzheimer disease [ICD-11: 8A20] Terminated
	
TTDDRUID	D0X8NK
DRUGNAME	Tripropeptin C
INDICATI	Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative
	
TTDDRUID	D0X8OW
DRUGNAME	QBX258
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0X8PD
DRUGNAME	XGP-510
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0X8PU
DRUGNAME	Leukozene
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative
	
TTDDRUID	D0X8QI
DRUGNAME	UP-116-77
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0X8QO
DRUGNAME	PL-3994
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
INDICATI	Congestive heart failure [ICD-11: BD10] Phase 2
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0X8QP
DRUGNAME	FOSOPAMINE
INDICATI	Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2
	
TTDDRUID	D0X8RA
DRUGNAME	Anti-BCR mabs
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative
	
TTDDRUID	D0X8RS
DRUGNAME	RG6125
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0X8SM
DRUGNAME	Anti-TNF human mabs
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0X8SY
DRUGNAME	Oxazyme
INDICATI	Hyperoxaluria [ICD-11: 5C51.2] Phase 1/2
	
TTDDRUID	D0X8TK
DRUGNAME	IMC-F106C
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0X8TS
DRUGNAME	RRx-001
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
INDICATI	Ovarian epithelial cancer [ICD-11: 2C73] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Anaplastic glioma [ICD-11: 2A00.0] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0X8UW
DRUGNAME	TRN-101
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0X8VV
DRUGNAME	Flobufen
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0X8VX
DRUGNAME	DV281
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0X8XA
DRUGNAME	Sulconazole
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D0X8XT
DRUGNAME	CS-0777
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D0X8ZY
DRUGNAME	BIA-10
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0X9CH
DRUGNAME	Telaprevir
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Approved
	
TTDDRUID	D0X9FO
DRUGNAME	KC-399
INDICATI	Alopecia [ICD-11: ED70] Terminated
	
TTDDRUID	D0X9GE
DRUGNAME	CIGB-500
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1
	
TTDDRUID	D0X9GV
DRUGNAME	ANA-012
INDICATI	Muscle wasting disease [ICD-11: 8E4A.3] Investigative
	
TTDDRUID	D0X9HB
DRUGNAME	MKT-077
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0X9HF
DRUGNAME	ABT-354
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0X9IQ
DRUGNAME	BND-002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0X9IS
DRUGNAME	FGI-102
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0X9JR
DRUGNAME	QR-313
INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Phase 1/2
	
TTDDRUID	D0X9KB
DRUGNAME	ACER-002
INDICATI	Ehlers-Danlos syndrome [ICD-11: LD28.1] Phase 3
	
TTDDRUID	D0X9KE
DRUGNAME	A-78773
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0X9KI
DRUGNAME	Technetium Tc-99m Disofenin Kit
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0X9LC
DRUGNAME	IC-41
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2
	
TTDDRUID	D0X9LK
DRUGNAME	Iralukast
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0X9MP
DRUGNAME	Zipeprol
INDICATI	Cough [ICD-11: MD12] Approved
	
TTDDRUID	D0X9NG
DRUGNAME	M2del11 H1N1
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0X9PB
DRUGNAME	HO/04/09
INDICATI	Acne vulgaris [ICD-11: ED80] Investigative
	
TTDDRUID	D0X9PF
DRUGNAME	Bremelanotide
INDICATI	Hypoactive sexual desire dysfunction [ICD-11: HA00] Approved
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Phase 3
	
TTDDRUID	D0X9PW
DRUGNAME	Tesmilifene
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D0X9RG
DRUGNAME	Butorphanol
INDICATI	Pain [ICD-11: MG30-MG3Z] Approved
	
TTDDRUID	D0X9RN
DRUGNAME	Robatumumab
INDICATI	Sarcoma [ICD-11: 2A60-2C35] Discontinued in Phase 2
INDICATI	Osteosarcoma [ICD-11: 2B51] Discontinued in Phase 2
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2
	
TTDDRUID	D0X9RY
DRUGNAME	Benzoic Acid
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Approved
	
TTDDRUID	D0X9TM
DRUGNAME	LPMD
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D0X9UA
DRUGNAME	Vatelizumab
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0X9VP
DRUGNAME	Furnidipine
INDICATI	Nerve injury [ICD-11: ND56.4] Discontinued in Phase 3
	
TTDDRUID	D0X9VR
DRUGNAME	BGB-324
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative
	
TTDDRUID	D0X9WC
DRUGNAME	ISIS-DMPK
INDICATI	Myotonic dystrophy [ICD-11: 8C71.0] Phase 1/2
	
TTDDRUID	D0X9XP
DRUGNAME	Diosmin
INDICATI	Hemorrhoids [ICD-11: DB60] Approved
	
TTDDRUID	D0X9YB
DRUGNAME	OCV-105
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0X9YP
DRUGNAME	AZD7594
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2
	
TTDDRUID	D0X9ZC
DRUGNAME	Cefadroxil
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0XA1B
DRUGNAME	RTA-301
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0XA2G
DRUGNAME	INDUS-860
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D0XA4U
DRUGNAME	Ebola recombinant viral vector vaccine
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 2
	
TTDDRUID	D0XA5N
DRUGNAME	NVP-LDE276
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0XB0T
DRUGNAME	Acolbifene
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	D0XB1M
DRUGNAME	MSH-372
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0XB4D
DRUGNAME	NTC-100
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Preclinical
	
TTDDRUID	D0XB8P
DRUGNAME	Betaine
INDICATI	Inborn error of metabolism [ICD-11: 5C50-5C59] Approved
	
TTDDRUID	D0XB8Y
DRUGNAME	COL-195
INDICATI	Chronic pain [ICD-11: MG30] Phase 1/2
	
TTDDRUID	D0XC1F
DRUGNAME	CX-9051
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0XD0N
DRUGNAME	REL-1028
INDICATI	Chronic pain [ICD-11: MG30] Phase 1
INDICATI	Opioid dependence [ICD-11: 6C43.2Z] Phase 1
	
TTDDRUID	D0XD4I
DRUGNAME	AZD0156
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0XD4N
DRUGNAME	ERB-002
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0XD5A
DRUGNAME	E-101
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 3
	
TTDDRUID	D0XD5N
DRUGNAME	LY3202626
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0XD7V
DRUGNAME	FLX475
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0XE0U
DRUGNAME	14C-urea
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
INDICATI	Helicobacter infection [ICD-11: DA42-DA63] Approved
	
TTDDRUID	D0XE0X
DRUGNAME	Aplindore fumarate
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0XE1C
DRUGNAME	Regadenoson
INDICATI	Radionuclide imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D0XE2O
DRUGNAME	BIIB063
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 1
	
TTDDRUID	D0XE4G
DRUGNAME	Mesenchymal stromal cells secreting neurotrophic factors
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
	
TTDDRUID	D0XE4W
DRUGNAME	Actimab-M
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0XE5L
DRUGNAME	Rispenzepine
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2
	
TTDDRUID	D0XE5M
DRUGNAME	SAR247799
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1
	
TTDDRUID	D0XE8H
DRUGNAME	Von willebrand factor
INDICATI	Hemophilia [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0XF4B
DRUGNAME	RIGS CC49
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
	
TTDDRUID	D0XF8W
DRUGNAME	Pyrazinamide
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Approved
	
TTDDRUID	D0XG0L
DRUGNAME	Anti-CD19 CAR T cells
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0XG0Z
DRUGNAME	A-82186
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0XG3Y
DRUGNAME	TZP-102
INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 2
	
TTDDRUID	D0XG4K
DRUGNAME	KI-0804
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0XG7H
DRUGNAME	IB-09A149
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0XG8I
DRUGNAME	PSI-879
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0XH0K
DRUGNAME	Mitemcinal fumarate
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0XH1H
DRUGNAME	DBO-17
INDICATI	Cancer related pain [ICD-11: MG30] Terminated
	
TTDDRUID	D0XH1P
DRUGNAME	CRx-102
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2
	
TTDDRUID	D0XH2N
DRUGNAME	RS-1748
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0XH3V
DRUGNAME	Inebilizumab
INDICATI	Neuromyelitis optica spectrum disorder [ICD-11: 8E4A.0] Approved
	
TTDDRUID	D0XH4K
DRUGNAME	C-linked disaccharide biphenyl mannoside derivative 3
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0XH8X
DRUGNAME	APC-8015F
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0XH9B
DRUGNAME	Tabimorelin
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 2
	
TTDDRUID	D0XI1B
DRUGNAME	NBI-18
INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Investigative
	
TTDDRUID	D0XI3E
DRUGNAME	INCB01158
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0XI4P
DRUGNAME	BMS-932481
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0XI9O
DRUGNAME	RWJ-46458
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0XJ0P
DRUGNAME	BCX-140
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Terminated
	
TTDDRUID	D0XJ0S
DRUGNAME	PD-134308
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D0XJ4G
DRUGNAME	PF-3049423
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Discontinued in Phase 2
	
TTDDRUID	D0XJ5I
DRUGNAME	DNA-C
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0XJ6C
DRUGNAME	DIAPLASININ
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	D0XJ8K
DRUGNAME	Recombinant soluble human CD5
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D0XJ9U
DRUGNAME	BMS-986242
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0XK1F
DRUGNAME	S-16961
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1
	
TTDDRUID	D0XK2N
DRUGNAME	Sinbaro
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 3
	
TTDDRUID	D0XK4R
DRUGNAME	EFLETIRIZINE
INDICATI	Rhinitis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0XK6O
DRUGNAME	SMaRT FVIII
INDICATI	Hemophilia [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D0XK6P
DRUGNAME	HS-210
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D0XL0E
DRUGNAME	NVX-272
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0XL1T
DRUGNAME	PDT with Photofrin
INDICATI	Brain cancer [ICD-11: 2A00] Phase 2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0XL4I
DRUGNAME	ER-319711-15
INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical
	
TTDDRUID	D0XL6C
DRUGNAME	SB-M00026
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
	
TTDDRUID	D0XL8W
DRUGNAME	ASN003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0XM1A
DRUGNAME	Safinamide mesylate
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0XM3S
DRUGNAME	CX-1501
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
	
TTDDRUID	D0XM3W
DRUGNAME	HRA-072033
INDICATI	Endocrine disease [ICD-11: 5B3Z] Investigative
	
TTDDRUID	D0XM4G
DRUGNAME	Bindarit
INDICATI	Nephritis [ICD-11: GB40] Phase 3
	
TTDDRUID	D0XM6L
DRUGNAME	OT-010
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0XM9E
DRUGNAME	Human plasminogen
INDICATI	Ligneous conjunctivitis [ICD-11: 9A02.2] Phase 2/3
	
TTDDRUID	D0XM9M
DRUGNAME	Methyl-piperidine compound 1
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Patented
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Patented
	
TTDDRUID	D0XM9Y
DRUGNAME	Pinazepam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0XN1F
DRUGNAME	Nimodipine
INDICATI	Cerebral vasospasm [ICD-11: BA85.Z] Approved
	
TTDDRUID	D0XN5L
DRUGNAME	Albutropin
INDICATI	Growth failure [ICD-11: LD2F.1Y] Phase 3
	
TTDDRUID	D0XN8C
DRUGNAME	Rosaprostol
INDICATI	Ulcer [ICD-11: CA02-CB40] Approved
	
TTDDRUID	D0XN8W
DRUGNAME	LB-101
INDICATI	Memory loss [ICD-11: MB21.1Z] Investigative
	
TTDDRUID	D0XO1O
DRUGNAME	CC8464
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Phase 1
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0XO3E
DRUGNAME	Gene therapy, neurodegenerative diseases
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0XO4I
DRUGNAME	3-(phenoxymethyl) benzylamine derivative 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0XO4K
DRUGNAME	TA-HPV
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1
	
TTDDRUID	D0XO7I
DRUGNAME	PF-06753512
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0XO7Q
DRUGNAME	Alequel
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 1/2
	
TTDDRUID	D0XO8D
DRUGNAME	PJJ-34
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0XO9F
DRUGNAME	FS118
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0XP0Q
DRUGNAME	FCE-24265
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0XP3A
DRUGNAME	BFPT-16864
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0XP3W
DRUGNAME	Ro-24-7429
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0XP4A
DRUGNAME	Labetuzumab I-131
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 2
	
TTDDRUID	D0XP5X
DRUGNAME	Mannoside derivative 5
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0XP7T
DRUGNAME	NEOD001
INDICATI	Amyloidosis [ICD-11: 5D00] Phase 3
	
TTDDRUID	D0XP7V
DRUGNAME	TWIN
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0XQ0Q
DRUGNAME	Cefsulodin
INDICATI	Pseudomonas infection [ICD-11: 1B92] Approved
	
TTDDRUID	D0XQ0V
DRUGNAME	DC-9703
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0XQ1W
DRUGNAME	SDZ-62-434
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0XQ2X
DRUGNAME	Calcium Chloride
INDICATI	Magnesium intoxication [ICD-11: 5C64.4] Approved
	
TTDDRUID	D0XQ5X
DRUGNAME	Halaven
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 1/2
	
TTDDRUID	D0XQ6J
DRUGNAME	99mTc-NC-100668
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2
	
TTDDRUID	D0XQ6V
DRUGNAME	APD-515
INDICATI	Xerostomia [ICD-11: DA02.1] Phase 2
	
TTDDRUID	D0XQ8A
DRUGNAME	TPN-729
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D0XR0B
DRUGNAME	SPI-205
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0XR0V
DRUGNAME	DWP-451
INDICATI	Lung cancer [ICD-11: 2C25.0] Investigative
	
TTDDRUID	D0XR1B
DRUGNAME	Vyndaqel
INDICATI	Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3
INDICATI	Familial amyloid polyneuropathy [ICD-11: 5D00.20] Application submitted
	
TTDDRUID	D0XR1C
DRUGNAME	Biaryl mannoside derivative 28
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0XR6B
DRUGNAME	ACH-2881
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0XR6I
DRUGNAME	TDI-0113
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0XR7C
DRUGNAME	YM-598
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0XR7R
DRUGNAME	RG7386
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0XR7V
DRUGNAME	TG-B
INDICATI	Osteoporosis [ICD-11: FB83.0] Investigative
	
TTDDRUID	D0XS1W
DRUGNAME	Lisinopril
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0XS3T
DRUGNAME	Vagonixen
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	D0XS4X
DRUGNAME	Ibodutant
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 3
	
TTDDRUID	D0XS7I
DRUGNAME	PF-06939926
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 1
	
TTDDRUID	D0XT0I
DRUGNAME	BIA
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0XT0W
DRUGNAME	Debio 1347
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D0XT1M
DRUGNAME	Valrocemide
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2
	
TTDDRUID	D0XT3G
DRUGNAME	ET-009
INDICATI	Bladder cancer [ICD-11: 2C94] Investigative
	
TTDDRUID	D0XT5F
DRUGNAME	Onyvax-O
INDICATI	Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 1
	
TTDDRUID	D0XT5Q
DRUGNAME	AGS-16C3F
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
	
TTDDRUID	D0XT5Y
DRUGNAME	Sargramostim
INDICATI	Bone marrow transplantation [ICD-11: QB63.6] Approved
	
TTDDRUID	D0XT6W
DRUGNAME	PDX-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 1
	
TTDDRUID	D0XT8V
DRUGNAME	Calcium nanoparticles
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0XT8W
DRUGNAME	SOM3355
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
INDICATI	Tardive dyskinesia [ICD-11: 8A02.10] Phase 1
	
TTDDRUID	D0XU1I
DRUGNAME	G3139 + Dacarbazine
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0XU3D
DRUGNAME	IDP-124
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3
	
TTDDRUID	D0XU4O
DRUGNAME	NVX-412
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0XU5Y
DRUGNAME	HL-025
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0XU9F
DRUGNAME	G3139 + cytarabine (ARA-C)
INDICATI	Acute leukaemia [ICD-11: 2A60] Investigative
	
TTDDRUID	D0XV0Y
DRUGNAME	CT-P6
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0XV2U
DRUGNAME	BIIB093
INDICATI	Cerebral edema [ICD-11: 8D60.1] Phase 3
	
TTDDRUID	D0XV3Z
DRUGNAME	Allervax Ragweed
INDICATI	Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 3
	
TTDDRUID	D0XV5B
DRUGNAME	Human insulin zinc suspension
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0XV6L
DRUGNAME	Kanglaite
INDICATI	Cachexia [ICD-11: MG20] Phase 1
	
TTDDRUID	D0XV7Y
DRUGNAME	1,3-dihydroxy phenyl derivative 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0XV8M
DRUGNAME	CVT-012000
INDICATI	Coronary artery disease [ICD-11: BA80] Investigative
	
TTDDRUID	D0XW2H
DRUGNAME	Mometasone furoate/ formoterol fumarate
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0XW4W
DRUGNAME	SEP-227900
INDICATI	Cognitive impairment [ICD-11: 6D71] Terminated
	
TTDDRUID	D0XW6B
DRUGNAME	Autologous dendritic cell vaccine
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0XW6Y
DRUGNAME	S-38093
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0XW8R
DRUGNAME	11C-R-129144
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Investigative
	
TTDDRUID	D0XW8Y
DRUGNAME	CNTX-4975
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 3
INDICATI	Knee osteoarthritis [ICD-11: FA01] Phase 3
INDICATI	Morton neuroma [ICD-11: 8C11.6] Phase 2
	
TTDDRUID	D0XW9L
DRUGNAME	Rifalazil
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
	
TTDDRUID	D0XX2I
DRUGNAME	NPH-30907
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2
	
TTDDRUID	D0XX6Y
DRUGNAME	Pipecuronium
INDICATI	Spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D0XX7E
DRUGNAME	RNA-144101
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D0XX8R
DRUGNAME	PMID25666693-Compound-161
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0XY4A
DRUGNAME	BPS-804
INDICATI	Metabolic bone disease [ICD-11: FB8Y] Phase 2
	
TTDDRUID	D0XY4Q
DRUGNAME	Cholazol
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0XY6T
DRUGNAME	Humanized CD19 CAR-T cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
	
TTDDRUID	D0XY8C
DRUGNAME	Encapsulated cell therapy
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 1/2
	
TTDDRUID	D0XY8K
DRUGNAME	ZP-007
INDICATI	Pharyngitis [ICD-11: CA02.Z] Investigative
	
TTDDRUID	D0XZ1D
DRUGNAME	BLU-554
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
	
TTDDRUID	D0XZ2S
DRUGNAME	CAR-T cells targeting MAGE-A4
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
	
TTDDRUID	D0XZ3W
DRUGNAME	SEL-120
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0XZ9H
DRUGNAME	LY2951742
INDICATI	Migraine [ICD-11: 8A80] Phase 4
	
TTDDRUID	D0Y0AP
DRUGNAME	GR-144053
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0Y0BC
DRUGNAME	XL-541
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0Y0BZ
DRUGNAME	PUP-1
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative
	
TTDDRUID	D0Y0EP
DRUGNAME	Lanabecestat
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0Y0ER
DRUGNAME	Thiethylperazine
INDICATI	Nausea [ICD-11: MD90] Approved
	
TTDDRUID	D0Y0FE
DRUGNAME	PWT-33597
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Y0FZ
DRUGNAME	PF-05230905
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0Y0GG
DRUGNAME	Epanolol
INDICATI	Angina pectoris [ICD-11: BA40] Discontinued in Preregistration
	
TTDDRUID	D0Y0GH
DRUGNAME	Mitomycin
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
INDICATI	Gastrointestinal cancer [ICD-11: 2C11] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0Y0GS
DRUGNAME	PMA-406
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y0HC
DRUGNAME	PF-06671008
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Y0HR
DRUGNAME	XOMA 358
INDICATI	Congenital hyperinsulinism [ICD-11: 5A4Y] Phase 2
	
TTDDRUID	D0Y0ID
DRUGNAME	6-azacytidine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y0JH
DRUGNAME	Salsalate
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0Y0KV
DRUGNAME	RS-118641
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0Y0KY
DRUGNAME	ISIS-APO(a)
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 2
	
TTDDRUID	D0Y0LA
DRUGNAME	PG2-2000
INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative
	
TTDDRUID	D0Y0PY
DRUGNAME	PI-2301
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0Y0QB
DRUGNAME	PF-4522625
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 1
	
TTDDRUID	D0Y0RF
DRUGNAME	Dendritic cancer cell vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0Y0RG
DRUGNAME	PMID25684022-Compound-US20130053382 37(4-6)
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0Y0RW
DRUGNAME	Alniditan
INDICATI	Migraine [ICD-11: 8A80] Discontinued in Phase 3
	
TTDDRUID	D0Y0SI
DRUGNAME	Aryl mannoside derivative 7
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0Y0SW
DRUGNAME	Flutamide
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D0Y0SY
DRUGNAME	E-3620
INDICATI	Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2
	
TTDDRUID	D0Y0TQ
DRUGNAME	AGX-1053
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y0UK
DRUGNAME	MX-6
INDICATI	Cervical cancer [ICD-11: 2C77.0] Discontinued in Phase 3
	
TTDDRUID	D0Y0VC
DRUGNAME	NLS-1
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	D0Y0WW
DRUGNAME	FM-303
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0Y0XJ
DRUGNAME	PMID28270021-Compound-WO2013009582Example76
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0Y0ZB
DRUGNAME	SB-219825
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0Y0ZQ
DRUGNAME	Ecabapide
INDICATI	Peptic ulcer [ICD-11: DA61] Discontinued in Preregistration
	
TTDDRUID	D0Y1AA
DRUGNAME	Chymopapain
INDICATI	Musculoskeletal disorder [ICD-11: FA00-FC0Z] Approved
	
TTDDRUID	D0Y1BF
DRUGNAME	APG-201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y1BI
DRUGNAME	TT-124
INDICATI	Coagulation defect [ICD-11: 3B10.0] Investigative
	
TTDDRUID	D0Y1BS
DRUGNAME	TGFTX-3
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0Y1FG
DRUGNAME	HSV-Tk
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 3
	
TTDDRUID	D0Y1FI
DRUGNAME	SP-03
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0Y1FO
DRUGNAME	Rubitecan
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D0Y1FP
DRUGNAME	RO-5310074
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0Y1FU
DRUGNAME	GDC0134
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1
	
TTDDRUID	D0Y1GJ
DRUGNAME	MLN-576
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0Y1HZ
DRUGNAME	IMD-026260
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y1IO
DRUGNAME	Galectin-3C
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y1IT
DRUGNAME	Sodium thiosalicylate
INDICATI	Gout [ICD-11: FA25] Approved
	
TTDDRUID	D0Y1KF
DRUGNAME	Feraheme/Rienso
INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved
	
TTDDRUID	D0Y1LD
DRUGNAME	RX-1792
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y1MK
DRUGNAME	99mTc-nitrocade
INDICATI	Diagnostic imaging [ICD-11: N.A.] Discontinued in Phase 3
	
TTDDRUID	D0Y1NC
DRUGNAME	CHS-828
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0Y1NH
DRUGNAME	Azaindazole amide derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0Y1OF
DRUGNAME	VA-045
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0Y1RN
DRUGNAME	AC-1204
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2/3
	
TTDDRUID	D0Y1RU
DRUGNAME	CAL-102-R
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D0Y1SI
DRUGNAME	PMID25666693-Compound-100
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0Y1UC
DRUGNAME	Trofosfamide
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved
	
TTDDRUID	D0Y1UO
DRUGNAME	VS-6063
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0Y1VI
DRUGNAME	SJ-3249
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y1VZ
DRUGNAME	GT-389255
INDICATI	Obesity [ICD-11: 5B81] Discontinued in Phase 2
	
TTDDRUID	D0Y1XD
DRUGNAME	ProCord
INDICATI	Spinal cord injury [ICD-11: ND51.2] Phase 2
	
TTDDRUID	D0Y1XR
DRUGNAME	CY-403
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Investigative
	
TTDDRUID	D0Y1YA
DRUGNAME	Human embryonic stem cell-derived hepatocytes
INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative
	
TTDDRUID	D0Y1YP
DRUGNAME	Doqualast
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2
	
TTDDRUID	D0Y1YX
DRUGNAME	AZD-9935
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0Y1ZU
DRUGNAME	SA-237
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
INDICATI	Encephalopathy [ICD-11: 8E47] Phase 3
INDICATI	Neuromyelitis optica [ICD-11: 8A43] Phase 3
	
TTDDRUID	D0Y2CJ
DRUGNAME	Minoxidil
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0Y2DI
DRUGNAME	Chlorproguanil
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0Y2DW
DRUGNAME	CHAP31
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y2EN
DRUGNAME	IB-09A133
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Investigative
	
TTDDRUID	D0Y2ES
DRUGNAME	Bepafant
INDICATI	Sepsis [ICD-11: 1G40-1G41] Terminated
	
TTDDRUID	D0Y2FY
DRUGNAME	Pediarix Vaccine
INDICATI	Diphtheria [ICD-11: 1C17] Approved
	
TTDDRUID	D0Y2GJ
DRUGNAME	DSP-1053
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
	
TTDDRUID	D0Y2HA
DRUGNAME	Pramiconazole
INDICATI	Dermatological disease [ICD-11: DA24.Y] Phase 2
	
TTDDRUID	D0Y2HH
DRUGNAME	KC706
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
	
TTDDRUID	D0Y2HR
DRUGNAME	Astemizole
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Withdrawn from market
	
TTDDRUID	D0Y2IE
DRUGNAME	Cefuroxime
INDICATI	Acute bronchitis [ICD-11: CA42] Approved
	
TTDDRUID	D0Y2IF
DRUGNAME	AZD-6357
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Terminated
	
TTDDRUID	D0Y2IH
DRUGNAME	LY-255283
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0Y2IN
DRUGNAME	Doranidazole
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0Y2IP
DRUGNAME	HLA-B7.75-84
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2
	
TTDDRUID	D0Y2IZ
DRUGNAME	Trichlormethiazide
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0Y2JM
DRUGNAME	Soluble ferric pyrophosphate
INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Phase 3
	
TTDDRUID	D0Y2KX
DRUGNAME	COL-1777
INDICATI	Uterine fibroids [ICD-11: 2E86.0] Investigative
	
TTDDRUID	D0Y2LR
DRUGNAME	Doxylamine
INDICATI	Morning sickness [ICD-11: SC00] Approved
	
TTDDRUID	D0Y2MC
DRUGNAME	Alkavervir
INDICATI	High blood pressure [ICD-11: BA00] Approved
	
TTDDRUID	D0Y2MP
DRUGNAME	E-5110
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0Y2NE
DRUGNAME	Diethylstilbestrol
INDICATI	Gonorrheal vaginitis [ICD-11: GA02] Approved
	
TTDDRUID	D0Y2NN
DRUGNAME	Replication-defective HIV-1 vaccine
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0Y2NS
DRUGNAME	MLN1117
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0Y2NU
DRUGNAME	ALX-40-4C
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0Y2OG
DRUGNAME	YM-511
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D0Y2RF
DRUGNAME	Lnfluvac TC
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0Y2RN
DRUGNAME	PMID25553724-Compound-US2011788838110
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Patented
	
TTDDRUID	D0Y2SE
DRUGNAME	Alpha-glucosidase
INDICATI	Muscle disease [ICD-11: FB3Z] Phase 3
	
TTDDRUID	D0Y2SW
DRUGNAME	Ixazomib
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
	
TTDDRUID	D0Y2TI
DRUGNAME	Glionitrin A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y2TK
DRUGNAME	Tetanus toxoid
INDICATI	Clostridium infection [ICD-11: 1A04] Approved
	
TTDDRUID	D0Y2VA
DRUGNAME	Nefecon
INDICATI	IgA nephropathy [ICD-11: MF8Y] Phase 2
	
TTDDRUID	D0Y2XQ
DRUGNAME	PF-3526299
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	D0Y2XZ
DRUGNAME	MK-4166
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Y2YP
DRUGNAME	Flurandrenolide
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0Y2YV
DRUGNAME	BECIPARCIL
INDICATI	Coagulation defect [ICD-11: 3B10.0] Discontinued in Phase 1
	
TTDDRUID	D0Y3AG
DRUGNAME	VIR-576
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2
	
TTDDRUID	D0Y3AR
DRUGNAME	RhASM enzyme replacement therapy (acid sphingomyelinase deficiency)
INDICATI	Niemann-pick disease [ICD-11: 5C56.0Y] Phase 1
	
TTDDRUID	D0Y3AZ
DRUGNAME	MK-2637
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	D0Y3BU
DRUGNAME	VAK-694
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2
	
TTDDRUID	D0Y3HP
DRUGNAME	CD20 CAR T cells
INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D0Y3JI
DRUGNAME	DG-17
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0Y3JR
DRUGNAME	ISIS 16507
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y3KG
DRUGNAME	Valproate
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Approved
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
	
TTDDRUID	D0Y3KR
DRUGNAME	GSK-2302024A
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0Y3LJ
DRUGNAME	AZD5904
INDICATI	Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1
	
TTDDRUID	D0Y3LL
DRUGNAME	Taprenepag
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
	
TTDDRUID	D0Y3ME
DRUGNAME	Oxaliplatin
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Approved
	
TTDDRUID	D0Y3MO
DRUGNAME	Amikacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Investigative
	
TTDDRUID	D0Y3MW
DRUGNAME	Tolecine
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D0Y3OQ
DRUGNAME	AZM-145
INDICATI	Diabetic complication [ICD-11: 5A2Y] Terminated
	
TTDDRUID	D0Y3OR
DRUGNAME	SQ-33600
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Terminated
	
TTDDRUID	D0Y3OX
DRUGNAME	TN-14003
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Investigative
	
TTDDRUID	D0Y3QR
DRUGNAME	BQS-481
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y3RN
DRUGNAME	BAY-Y-1015
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1
	
TTDDRUID	D0Y3RY
DRUGNAME	R-1578
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2
	
TTDDRUID	D0Y3TB
DRUGNAME	ALGRX 2872
INDICATI	Cluster headache [ICD-11: 8A81.0] Investigative
INDICATI	Migraine [ICD-11: 8A80] Investigative
	
TTDDRUID	D0Y3TM
DRUGNAME	Iron
INDICATI	Iron-deficiency anemia [ICD-11: 3A00] Approved
	
TTDDRUID	D0Y3TX
DRUGNAME	Apovasc
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0Y3TY
DRUGNAME	NAB-001
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 3
	
TTDDRUID	D0Y3UB
DRUGNAME	PMID26651364-Compound-7d
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0Y3VN
DRUGNAME	Ii-key/MHC class II epitope hybrid peptides
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0Y3VQ
DRUGNAME	Ryzodeq
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D0Y3VT
DRUGNAME	ORB-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Y3WY
DRUGNAME	RG7841
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Y3XA
DRUGNAME	Ge2270a
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0Y3XF
DRUGNAME	Stem cell-derived astrocytes
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0Y3ZC
DRUGNAME	CBT-501
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Y3ZP
DRUGNAME	Terodiline
INDICATI	Urinary incontinence [ICD-11: MF50.2] Phase 3
	
TTDDRUID	D0Y3ZX
DRUGNAME	D-21775
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0Y4AW
DRUGNAME	Meprobamate
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
INDICATI	Ischemic reperfusion injury [ICD-11: DB98.B] Discontinued in Phase 1
	
TTDDRUID	D0Y4AZ
DRUGNAME	Galocitabine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3
	
TTDDRUID	D0Y4BF
DRUGNAME	Pentraxin 2/analog
INDICATI	Fibrosis [ICD-11: GA14-GC01] Investigative
	
TTDDRUID	D0Y4BO
DRUGNAME	ABI-013
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0Y4CN
DRUGNAME	IMC-TR1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Y4DY
DRUGNAME	Xylometazoline
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 4
	
TTDDRUID	D0Y4EM
DRUGNAME	Thrombomodulin
INDICATI	Disseminated intravascular coagulation [ICD-11: 3B20] Discontinued in Phase 3
	
TTDDRUID	D0Y4EU
DRUGNAME	PMID25656651-Compound-11a
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Patented
	
TTDDRUID	D0Y4FL
DRUGNAME	Roxithromycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market
	
TTDDRUID	D0Y4GJ
DRUGNAME	AVE-5883
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1/2
	
TTDDRUID	D0Y4GO
DRUGNAME	Pemetrexed
INDICATI	Malignant pleural mesothelioma [ICD-11: 2C26.0] Approved
	
TTDDRUID	D0Y4HO
DRUGNAME	LMV-601
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1
	
TTDDRUID	D0Y4IR
DRUGNAME	UBC1967
INDICATI	Ophthalmic graves disease [ICD-11: 5A02.0] Phase 1
	
TTDDRUID	D0Y4IX
DRUGNAME	XEL-002BI
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0Y4JJ
DRUGNAME	Bepridil
INDICATI	Chronic/stable angina [ICD-11: BA40.1] Approved
	
TTDDRUID	D0Y4KE
DRUGNAME	Collagenase
INDICATI	Skin burns [ICD-11: ME65.0] Approved
INDICATI	Dermal ulcers [ICD-11: 1A36] Approved
	
TTDDRUID	D0Y4LI
DRUGNAME	PF-4708671
INDICATI	Ulcerative colitis [ICD-11: DD71] Clinical trial
	
TTDDRUID	D0Y4LX
DRUGNAME	Favipiravir
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Registered
	
TTDDRUID	D0Y4MA
DRUGNAME	CART-138 cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0Y4MJ
DRUGNAME	KQ-791
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0Y4OI
DRUGNAME	SKF-105809
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0Y4PL
DRUGNAME	QAP-642
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Terminated
	
TTDDRUID	D0Y4QG
DRUGNAME	Bedaquiline
INDICATI	Multi-drug resistant tuberculosis [ICD-11: MG52.00] Approved
	
TTDDRUID	D0Y4QY
DRUGNAME	Long-acting IL-11 analog
INDICATI	Thrombocytopenia [ICD-11: 3B64] Investigative
	
TTDDRUID	D0Y4SI
DRUGNAME	Ponesimod
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D0Y4TQ
DRUGNAME	VK-11
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0Y4WR
DRUGNAME	R-1
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Investigative
	
TTDDRUID	D0Y4XN
DRUGNAME	AGX-1009
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0Y4YG
DRUGNAME	Iodixanol
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0Y4ZE
DRUGNAME	BGC-20-0582
INDICATI	Pediculus capitis infestation [ICD-11: 1G00.0] Phase 2
	
TTDDRUID	D0Y4ZI
DRUGNAME	Silicon-modified indomethacin
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0Y4ZS
DRUGNAME	Endovion
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0Y5AM
DRUGNAME	Darifenacin
INDICATI	Overactive bladder [ICD-11: GC50.0] Approved
	
TTDDRUID	D0Y5BR
DRUGNAME	Phylomers
INDICATI	Brain injury [ICD-11: NA07.Z] Investigative
	
TTDDRUID	D0Y5BV
DRUGNAME	AXImab
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D0Y5DC
DRUGNAME	ZJM-289
INDICATI	Reperfusion injury [ICD-11: ND56.Z] Investigative
	
TTDDRUID	D0Y5DO
DRUGNAME	Citalopram
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0Y5ED
DRUGNAME	AV-203
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Y5EX
DRUGNAME	DuP 714
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0Y5GK
DRUGNAME	Bromodiphenhydramine
INDICATI	Hay fever [ICD-11: CA08.00] Approved
	
TTDDRUID	D0Y5IH
DRUGNAME	MPDL-3280A
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D0Y5JC
DRUGNAME	Avanafil
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved
	
TTDDRUID	D0Y5JZ
DRUGNAME	JB991
INDICATI	Skin infection [ICD-11: 1F28-1G0Z] Phase 2
INDICATI	Sarcoidosis [ICD-11: 4B20.5] Discontinued in Phase 2
	
TTDDRUID	D0Y5KL
DRUGNAME	RI-001
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D0Y5LR
DRUGNAME	AEN-100
INDICATI	Motor neurone disease [ICD-11: 8B60] Phase 4
	
TTDDRUID	D0Y5MF
DRUGNAME	BND-001
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0Y5MY
DRUGNAME	GRN1005
INDICATI	Brain metastases [ICD-11: 2D50] Phase 2
	
TTDDRUID	D0Y5NA
DRUGNAME	PF-06751979
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0Y5NT
DRUGNAME	VT-224
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0Y5OP
DRUGNAME	18F-fluoromethylallylcholine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y5OY
DRUGNAME	MK-3641
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D0Y5QA
DRUGNAME	AVB-S6-500
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Y5QD
DRUGNAME	ENMD-1198
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Y5QO
DRUGNAME	GK-128
INDICATI	Vomiting [ICD-11: MD90] Terminated
	
TTDDRUID	D0Y5RZ
DRUGNAME	Brovincamine fumarate
INDICATI	Cerebral vasodilator [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0Y5UC
DRUGNAME	PC-24
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y5UG
DRUGNAME	Amitriptyline
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0Y5VR
DRUGNAME	H5N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0Y5WL
DRUGNAME	TTL-1177
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y5WX
DRUGNAME	GBR 310
INDICATI	Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 1
	
TTDDRUID	D0Y5ZA
DRUGNAME	Arteether
INDICATI	Malaria [ICD-11: 1F40-1F45] Approved
	
TTDDRUID	D0Y5ZG
DRUGNAME	Theradigm-HIV
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Terminated
	
TTDDRUID	D0Y5ZT
DRUGNAME	KRP-203
INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2
	
TTDDRUID	D0Y6BO
DRUGNAME	Milatuzumab-doxorubicin conjugate
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D0Y6CE
DRUGNAME	Metocurine Iodide
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0Y6DO
DRUGNAME	Streptokinase rectal suppository
INDICATI	Hemorrhoids [ICD-11: DB60] Phase 3
	
TTDDRUID	D0Y6HA
DRUGNAME	CYC-103
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0Y6HV
DRUGNAME	EMD-53998
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1
	
TTDDRUID	D0Y6HW
DRUGNAME	Ecopipam
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 3
INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 2
	
TTDDRUID	D0Y6HY
DRUGNAME	A-364
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0Y6IJ
DRUGNAME	Ro-48-5545
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0Y6KO
DRUGNAME	Methyldopate Hydrochloride
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0Y6KY
DRUGNAME	Optiquel
INDICATI	Uveitis [ICD-11: 9A96.Z] Phase 1
	
TTDDRUID	D0Y6LO
DRUGNAME	NNC-13-8119
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0Y6MD
DRUGNAME	NRC-2694
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y6MH
DRUGNAME	Tebipenem
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 3
INDICATI	Obesity [ICD-11: 5B81] Phase 2
INDICATI	Nicotine dependence [ICD-11: 6C4A.2] Phase 2
	
TTDDRUID	D0Y6NL
DRUGNAME	Arepanrix
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0Y6NO
DRUGNAME	Anti-CD326 humanized mab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y6OA
DRUGNAME	Coumate
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0Y6OC
DRUGNAME	REC-1819
INDICATI	Overactive bladder [ICD-11: GC50.0] Investigative
	
TTDDRUID	D0Y6QC
DRUGNAME	Dapagliflozin Propanediol; Saxagliptin Hydrochloride
INDICATI	Type-2 diabetes [ICD-11: 5A11] Approved
	
TTDDRUID	D0Y6QO
DRUGNAME	Antipruritic agents
INDICATI	Pruritus [ICD-11: EC90] Investigative
	
TTDDRUID	D0Y6QX
DRUGNAME	FOLIGO 002
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D0Y6SN
DRUGNAME	SB-277011
INDICATI	Schizophrenia [ICD-11: 6A20] Terminated
	
TTDDRUID	D0Y6SQ
DRUGNAME	Camostat
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D0Y6TI
DRUGNAME	YM-355179
INDICATI	Asthma [ICD-11: CA23] Preclinical
	
TTDDRUID	D0Y6UU
DRUGNAME	Atrasentan
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Withdrawn from market
	
TTDDRUID	D0Y6VW
DRUGNAME	Fingolimod
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0Y6XD
DRUGNAME	B-247
INDICATI	Wound healing [ICD-11: EL8Y] Investigative
	
TTDDRUID	D0Y6XG
DRUGNAME	Atu-195
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y6ZK
DRUGNAME	IB-MECA
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 3
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2/3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0Y6ZS
DRUGNAME	Esterom
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0Y7BD
DRUGNAME	Ceftizoxime
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0Y7BV
DRUGNAME	Florifenine
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0Y7CO
DRUGNAME	ABT-072
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0Y7DP
DRUGNAME	Uridine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0Y7EM
DRUGNAME	Felbinac
INDICATI	Arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0Y7HW
DRUGNAME	Clomet
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0Y7IC
DRUGNAME	Baricitinib
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0Y7IU
DRUGNAME	Budesonide
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0Y7JU
DRUGNAME	GW685698X
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0Y7KH
DRUGNAME	Degarelix
INDICATI	Prostate cancer [ICD-11: 2C82.0] Approved
	
TTDDRUID	D0Y7LD
DRUGNAME	Sitosterol
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Approved
	
TTDDRUID	D0Y7LV
DRUGNAME	Anti-CD38 CAR-T cell therapy
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0Y7NA
DRUGNAME	INCB9471
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2a
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0Y7OI
DRUGNAME	vialinin A
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical
	
TTDDRUID	D0Y7OJ
DRUGNAME	LU302146
INDICATI	Pulmonary hypertension [ICD-11: BB01] Approved
	
TTDDRUID	D0Y7PG
DRUGNAME	Tolcapone
INDICATI	Parkinson disease [ICD-11: 8A00.0] Approved
	
TTDDRUID	D0Y7PJ
DRUGNAME	ELS-110
INDICATI	Migraine [ICD-11: 8A80] Investigative
	
TTDDRUID	D0Y7RR
DRUGNAME	XGP-515
INDICATI	Allergy [ICD-11: 4A80-4A85] Investigative
	
TTDDRUID	D0Y7RW
DRUGNAME	Phenobarbital
INDICATI	Seizure disorder [ICD-11: 8A6Z] Approved
	
TTDDRUID	D0Y7SN
DRUGNAME	PTI-188
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0Y7TC
DRUGNAME	Cancer vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0Y7TO
DRUGNAME	Doxacurium
INDICATI	Spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D0Y7TS
DRUGNAME	Trimetrexate
INDICATI	Toxoplasmosis [ICD-11: 1F57] Approved
	
TTDDRUID	D0Y7VM
DRUGNAME	Forskolin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y7VP
DRUGNAME	VRS-317
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 3
	
TTDDRUID	D0Y7WA
DRUGNAME	SYN-1003
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0Y7WL
DRUGNAME	Lorglumide
INDICATI	Pancreatic malfunction [ICD-11: DC30-DC3Z] Terminated
	
TTDDRUID	D0Y7XG
DRUGNAME	Ocriplasmin
INDICATI	Symptomatic vitreomacular adhesion [ICD-11: 9B8Z] Approved
	
TTDDRUID	D0Y7YB
DRUGNAME	HIV recombinant vaccine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0Y7YD
DRUGNAME	SMT-C1100
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D0Y7YH
DRUGNAME	TK-54
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 1/2
	
TTDDRUID	D0Y7YR
DRUGNAME	CAT-1920
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0Y7ZD
DRUGNAME	Aminolevulinic acid hci
INDICATI	Acne vulgaris [ICD-11: ED80] Approved
INDICATI	Actinic keratosis [ICD-11: EK90.0] Approved
	
TTDDRUID	D0Y7ZU
DRUGNAME	Dacarbazine
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D0Y8AW
DRUGNAME	CB3304
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0Y8BJ
DRUGNAME	CT-112
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0Y8BW
DRUGNAME	TMC-647055
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0Y8DP
DRUGNAME	Rorifone
INDICATI	Cough [ICD-11: MD12] Approved
	
TTDDRUID	D0Y8GL
DRUGNAME	APF-580
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0Y8IE
DRUGNAME	AR-13165
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3
	
TTDDRUID	D0Y8IF
DRUGNAME	MX-781
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Terminated
	
TTDDRUID	D0Y8IS
DRUGNAME	VP-025
INDICATI	Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1
	
TTDDRUID	D0Y8KM
DRUGNAME	STP-900
INDICATI	Organ transplant rejection [ICD-11: NE84] Investigative
	
TTDDRUID	D0Y8KN
DRUGNAME	Ilaris canakinumab
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Approved
	
TTDDRUID	D0Y8KZ
DRUGNAME	AIM-501
INDICATI	Artery stenosis [ICD-11: BD52] Investigative
	
TTDDRUID	D0Y8LT
DRUGNAME	AstaFactor
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0Y8ND
DRUGNAME	VERED
INDICATI	Rosacea [ICD-11: ED90.0] Phase 3
	
TTDDRUID	D0Y8NZ
DRUGNAME	Efatutazone
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
	
TTDDRUID	D0Y8OK
DRUGNAME	Peginterferon alfa-2a
INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Approved
	
TTDDRUID	D0Y8PH
DRUGNAME	CI-996
INDICATI	Hypertension [ICD-11: BA00-BA04] Terminated
	
TTDDRUID	D0Y8PM
DRUGNAME	LJP-1082
INDICATI	Hughes syndrome [ICD-11: 4A45.Z] Discontinued in Phase 1
	
TTDDRUID	D0Y8PT
DRUGNAME	UFT
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0Y8RS
DRUGNAME	DSP-6745
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D0Y8SS
DRUGNAME	MufroSyn
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0Y8TZ
DRUGNAME	PF-06410293
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0Y8UB
DRUGNAME	Agomelatine
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Withdrawn from market
	
TTDDRUID	D0Y8UV
DRUGNAME	EMD-1204831
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Y8VC
DRUGNAME	M-5200
INDICATI	Skin allergy [ICD-11: 4A82] Investigative
	
TTDDRUID	D0Y8ZN
DRUGNAME	Ofatumumab
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0Y8ZZ
DRUGNAME	GI-10001
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Investigative
	
TTDDRUID	D0Y9BX
DRUGNAME	Peptide p277
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
INDICATI	Grass pollen hypersensitivity [ICD-11: 4B07] Phase 3
	
TTDDRUID	D0Y9CC
DRUGNAME	TM-31
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0Y9CV
DRUGNAME	Ketolides
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0Y9ES
DRUGNAME	AD-0802
INDICATI	Alzheimer disease [ICD-11: 8A20] Investigative
	
TTDDRUID	D0Y9EW
DRUGNAME	Vemurafenib
INDICATI	Melanoma [ICD-11: 2C30] Approved
	
TTDDRUID	D0Y9FF
DRUGNAME	Human factor viii
INDICATI	Hemophilia [ICD-11: 3B10.0] Approved
	
TTDDRUID	D0Y9FX
DRUGNAME	example 7 [US8664233]
INDICATI	Bladder cancer [ICD-11: 2C94] Clinical trial
	
TTDDRUID	D0Y9GA
DRUGNAME	Dehydroxymethylepoxyquinomicin
INDICATI	Cachexia [ICD-11: MG20] Investigative
	
TTDDRUID	D0Y9GF
DRUGNAME	Entyvio
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 3
	
TTDDRUID	D0Y9GM
DRUGNAME	Pexiganan
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Approved
	
TTDDRUID	D0Y9HH
DRUGNAME	SIB-1508Y
INDICATI	Parkinson disease [ICD-11: 8A00.0] Terminated
	
TTDDRUID	D0Y9HW
DRUGNAME	ISIS-TTR
INDICATI	Amyloidosis [ICD-11: 5D00] Phase 3
	
TTDDRUID	D0Y9JY
DRUGNAME	XGP-410
INDICATI	Acne vulgaris [ICD-11: ED80] Investigative
	
TTDDRUID	D0Y9KR
DRUGNAME	SSR-103800
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D0Y9LL
DRUGNAME	Lorcainide
INDICATI	Heart arrhythmia [ICD-11: BC65] Approved
	
TTDDRUID	D0Y9NA
DRUGNAME	MN-2011
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Investigative
	
TTDDRUID	D0Y9NE
DRUGNAME	NWP-08
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Discontinued in Phase 2
	
TTDDRUID	D0Y9OS
DRUGNAME	Euro-Celtique 1
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0Y9PQ
DRUGNAME	AM-1101
INDICATI	Arteriosclerosis [ICD-11: BD40] Investigative
	
TTDDRUID	D0Y9PZ
DRUGNAME	Efungumab
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	D0Y9RN
DRUGNAME	Salinosporamide B
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Y9RO
DRUGNAME	Dexanabinol
INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 3
	
TTDDRUID	D0Y9SB
DRUGNAME	RG7444
INDICATI	Refractory metastatic multiple myeloma [ICD-11: 2A83.1] Phase 1
	
TTDDRUID	D0Y9ST
DRUGNAME	PMID25666693-Compound-64
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0Y9TQ
DRUGNAME	Cytotect CP
INDICATI	Cytomegalovirus infection [ICD-11: 1D82] Phase 3
	
TTDDRUID	D0Y9TS
DRUGNAME	Ceruletide
INDICATI	Caerulein stimulated gastric and pancreatic secretion [ICD-11: 5A4Y] Approved
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0Y9VC
DRUGNAME	IMT-1012 immunotherapeutic vaccine
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D0Y9XD
DRUGNAME	Dalvastatin
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 3
	
TTDDRUID	D0Y9XO
DRUGNAME	SDZ-FOX-988
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 1
	
TTDDRUID	D0Y9XU
DRUGNAME	Turgenpumatucel-L
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3
	
TTDDRUID	D0Y9YG
DRUGNAME	SLV-342
INDICATI	Arteriosclerosis [ICD-11: BD40] Phase 1
	
TTDDRUID	D0Y9YN
DRUGNAME	Velimogene aliplasmid
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D0Y9ZE
DRUGNAME	Milrinone
INDICATI	Congestive heart failure [ICD-11: BD10] Approved
	
TTDDRUID	D0YA0N
DRUGNAME	BR3-Fc
INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Discontinued in Phase 2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2
	
TTDDRUID	D0YA1B
DRUGNAME	Flotetuzumab
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Acute biphenotypic leukaemia [ICD-11: 2B33.4] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D0YA2L
DRUGNAME	Teriparatide
INDICATI	Osteogenesis imperfecta [ICD-11: LD24.K0] Approved
INDICATI	Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2
	
TTDDRUID	D0YA6U
DRUGNAME	ELN-864709
INDICATI	Central nervous system injury [ICD-11: KA40] Investigative
	
TTDDRUID	D0YA9Z
DRUGNAME	Ampicillin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0YB1G
DRUGNAME	Fentiazac
INDICATI	Dysmenorrhea [ICD-11: GA34.3] Approved
	
TTDDRUID	D0YB2Y
DRUGNAME	AMG 853
INDICATI	Asthma [ICD-11: CA23] Phase 2
	
TTDDRUID	D0YB3D
DRUGNAME	CytoregUNO
INDICATI	Skin cancer [ICD-11: 2C30-2C37] Investigative
	
TTDDRUID	D0YB3N
DRUGNAME	HTNV + PUUV DNA vaccine
INDICATI	Hemorrhagic fever [ICD-11: 1D61] Phase 2
	
TTDDRUID	D0YB3W
DRUGNAME	CI-1033
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
	
TTDDRUID	D0YB4D
DRUGNAME	Eldacimibe
INDICATI	Hyperlipidaemia [ICD-11: 5C80] Phase 2
	
TTDDRUID	D0YB5G
DRUGNAME	Sodium cellulose po4
INDICATI	Hypercalciuria [ICD-11: MF98.0] Approved
	
TTDDRUID	D0YB5Z
DRUGNAME	ARX-Trail
INDICATI	Colon cancer [ICD-11: 2B90.Z] Investigative
	
TTDDRUID	D0YB6P
DRUGNAME	YP-004
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0YB7F
DRUGNAME	MT-II
INDICATI	Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative
	
TTDDRUID	D0YB7P
DRUGNAME	IFN-Kinoid
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D0YC1R
DRUGNAME	BMS-520
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0YC1Z
DRUGNAME	Doxorubicin-hemoglobin conjugate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical
	
TTDDRUID	D0YC4F
DRUGNAME	K-828-AB
INDICATI	Dementia [ICD-11: 6D80-6D86] Phase 2
	
TTDDRUID	D0YC7U
DRUGNAME	Eptaplatin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0YC8W
DRUGNAME	Folotynpralatrexate
INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2
	
TTDDRUID	D0YC9M
DRUGNAME	AllerT
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D0YD1Q
DRUGNAME	PMID25684022-Compound-EP20041486488
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0YD6K
DRUGNAME	APC-200
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0YD9E
DRUGNAME	PF-00212062
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0YE2N
DRUGNAME	Eperezolid
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3
	
TTDDRUID	D0YE6C
DRUGNAME	BN-brachyury cancer vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0YF2T
DRUGNAME	HepaVaxx C
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Investigative
	
TTDDRUID	D0YF3X
DRUGNAME	Ethamsylate
INDICATI	Menorrhagia [ICD-11: GA20.50] Approved
	
TTDDRUID	D0YF4I
DRUGNAME	MN-221
INDICATI	Exacerbation of acute asthma [ICD-11: CA23.30] Phase 2
INDICATI	Aging skin [ICD-11: EE40] Phase 2
	
TTDDRUID	D0YF6K
DRUGNAME	HER2-specific CAR T cell
INDICATI	Atypical teratoid/rhabdoid tumour [ICD-11: 2A00.1Y] Phase 1
INDICATI	Choroid plexus carcinoma [ICD-11: 2A02.12] Phase 1
INDICATI	Ependymoma [ICD-11: 2A00.0Y] Phase 1
INDICATI	Germ cell tumour [ICD-11: 2C80.2] Phase 1
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 1
INDICATI	Pineoblastoma [ICD-11: 2A00.20] Phase 1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
	
TTDDRUID	D0YF6L
DRUGNAME	KST-5468
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0YF9W
DRUGNAME	FST-200
INDICATI	Otitis externa [ICD-11: AA00-AA13] Investigative
	
TTDDRUID	D0YG3K
DRUGNAME	Soluble insulin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0YG4I
DRUGNAME	Bevasiranib
INDICATI	Exudative age-related macular degeneration [ICD-11: 9B78.3Z] Discontinued in Phase 3
	
TTDDRUID	D0YG4P
DRUGNAME	Anti-OX40 mab
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0YG4Q
DRUGNAME	OG-9
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0YG7H
DRUGNAME	CM-2359
INDICATI	Nervous system disease [ICD-11: 8A00-8E7Z] Terminated
	
TTDDRUID	D0YG7M
DRUGNAME	Ketotifen
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Approved
	
TTDDRUID	D0YH0I
DRUGNAME	EP HIV-1090 vaccine
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D0YH0N
DRUGNAME	Metadoxine
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
	
TTDDRUID	D0YH5F
DRUGNAME	Ridostin
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D0YH5L
DRUGNAME	CART-56 cells
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0YH5V
DRUGNAME	MK-8189
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	D0YH8F
DRUGNAME	RG7347
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0YH8T
DRUGNAME	MI-09018
INDICATI	Schizophrenia [ICD-11: 6A20] Investigative
	
TTDDRUID	D0YH9A
DRUGNAME	TPT-43
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
	
TTDDRUID	D0YI4F
DRUGNAME	Vecabrutinib
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	D0YI6W
DRUGNAME	SPN-805
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1
	
TTDDRUID	D0YJ2G
DRUGNAME	ADXS11-001
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2
	
TTDDRUID	D0YJ5F
DRUGNAME	PT-112
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0YJ5H
DRUGNAME	EX-1311
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative
	
TTDDRUID	D0YJ9T
DRUGNAME	DU-6681
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D0YK4L
DRUGNAME	PAC-10649
INDICATI	Arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D0YK7C
DRUGNAME	XR-5118
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0YK7J
DRUGNAME	CDP-492
INDICATI	Vomiting [ICD-11: MD90] Terminated
	
TTDDRUID	D0YK8M
DRUGNAME	1,3,4-oxadiazole derivative 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0YK9D
DRUGNAME	CHIR-99021
INDICATI	Graft rejection [ICD-11: NE84] Patented
INDICATI	Allergic inflammation [ICD-11: 4A80-4A85] Patented
	
TTDDRUID	D0YL0L
DRUGNAME	G-256
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Investigative
	
TTDDRUID	D0YL3E
DRUGNAME	GSK159802
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0YL8U
DRUGNAME	Omecamtiv mecarbil
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3
	
TTDDRUID	D0YL9G
DRUGNAME	TS-091
INDICATI	Hypersomnia [ICD-11: 7A21] Phase 2
	
TTDDRUID	D0YM1M
DRUGNAME	PMID25666693-Compound-67
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0YM2K
DRUGNAME	Atezolizumab
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Approved
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 3
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 3
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Bronchioalveolar carcinoma [ICD-11: 2C25.0] Phase 0
INDICATI	Ulcer [ICD-11: CA02-CB40] Phase 0
	
TTDDRUID	D0YM4F
DRUGNAME	ACC-002
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 0
	
TTDDRUID	D0YM7U
DRUGNAME	Rituximab
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved
INDICATI	Pemphigus vulgaris [ICD-11: EB40] Phase 3
	
TTDDRUID	D0YM8K
DRUGNAME	[99mTc]Met
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0YN0I
DRUGNAME	PMID28270021-Compound-WO2014078408Example26
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0YN2F
DRUGNAME	HG-1209
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0YN2I
DRUGNAME	Pyrazole derivative 54
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0YN3T
DRUGNAME	Tamiphosphor
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Investigative
	
TTDDRUID	D0YN4S
DRUGNAME	BI 754111
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0YN4Y
DRUGNAME	PTI-202
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0YN5T
DRUGNAME	Selumetinib
INDICATI	Neurofibromatosis type 1 [ICD-11: LD2D.10] Approved
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0YN9H
DRUGNAME	VVP-100X
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0YN9Y
DRUGNAME	MB-101
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	D0YO0Z
DRUGNAME	IB-08A099
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Investigative
	
TTDDRUID	D0YO2N
DRUGNAME	MP-0260
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Investigative
	
TTDDRUID	D0YO4B
DRUGNAME	Cabiralizumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D0YO4C
DRUGNAME	Xilonix
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0YO4D
DRUGNAME	LG100268
INDICATI	Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 1
	
TTDDRUID	D0YO5Z
DRUGNAME	UshStat
INDICATI	Deafness [ICD-11: AB52] Phase 1/2
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1
	
TTDDRUID	D0YO6R
DRUGNAME	ADXS-DUAL
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 3
	
TTDDRUID	D0YO7Y
DRUGNAME	DAS-181
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0YP0C
DRUGNAME	DT-TX-30
INDICATI	Angina pectoris [ICD-11: BA40] Phase 1
	
TTDDRUID	D0YP2R
DRUGNAME	99mTc-teboroxime
INDICATI	Myocardial disease [ICD-11: BC43.20] Approved
	
TTDDRUID	D0YP5Z
DRUGNAME	Streptococcus pneumoniae vaccine, Cytovax
INDICATI	Streptococcus infection [ICD-11: 1B53] Terminated
	
TTDDRUID	D0YP6F
DRUGNAME	AZD-4121
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1
	
TTDDRUID	D0YP7B
DRUGNAME	Setmelanotide
INDICATI	Obesity [ICD-11: 5B81] Approved
INDICATI	Bardet biedl syndrome [ICD-11: 5A61.0] Phase 3
INDICATI	Prader-Willi syndrome [ICD-11: LD90.3] Phase 2
INDICATI	Diabetic complication [ICD-11: 5A2Y] Preclinical
	
TTDDRUID	D0YP7L
DRUGNAME	SB-269970
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated
	
TTDDRUID	D0YP8F
DRUGNAME	Glypican3-ADC
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0YQ0V
DRUGNAME	Cefpirome sulfate
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0YQ2K
DRUGNAME	YS110 mAb clone
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
	
TTDDRUID	D0YQ3M
DRUGNAME	EP-2104R
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2
	
TTDDRUID	D0YQ7U
DRUGNAME	Cenicriviroc
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	D0YQ9G
DRUGNAME	GT-16-239
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0YQ9I
DRUGNAME	FF-10101-01
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0YQ9P
DRUGNAME	Amodiaquine
INDICATI	Malaria [ICD-11: 1F40-1F45] Withdrawn from market
INDICATI	Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical
	
TTDDRUID	D0YR4E
DRUGNAME	PMID25666693-Compound-21
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0YS0B
DRUGNAME	DF-1012
INDICATI	Cough [ICD-11: MD12] Discontinued in Phase 2
	
TTDDRUID	D0YS1U
DRUGNAME	sparsentan
INDICATI	Focal segmental glomerulosclerosis [ICD-11: MF8Y] Phase 3
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
INDICATI	Hypertension [ICD-11: BA00-BA04] Phase 2
	
TTDDRUID	D0YS2W
DRUGNAME	PT005
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D0YS3H
DRUGNAME	Debio-0617
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0YS7D
DRUGNAME	Isosorbide Mononitrate
INDICATI	Hydrocephalus [ICD-11: 8D64] Approved
	
TTDDRUID	D0YS8C
DRUGNAME	BTA-188
INDICATI	Rhinovirus infection [ICD-11: CA07] Terminated
	
TTDDRUID	D0YT3Z
DRUGNAME	AR-7947
INDICATI	Non-insulin dependent diabetes [ICD-11: 5A11] Investigative
	
TTDDRUID	D0YT6Z
DRUGNAME	Mirisetron maleate
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D0YT8P
DRUGNAME	JNJ-38877605
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0YU0L
DRUGNAME	GPA-TriMAR-T cells
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0YU1L
DRUGNAME	MP-124
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 1
INDICATI	Stroke [ICD-11: 8B20] Phase 1
	
TTDDRUID	D0YU1M
DRUGNAME	G-207 virus construct
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1/2
	
TTDDRUID	D0YU9B
DRUGNAME	PMID25666693-Compound-151
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0YV0N
DRUGNAME	GSK2857916
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D0YV1Q
DRUGNAME	Kanamycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0YV4F
DRUGNAME	Ocrelizumab
INDICATI	Multiple sclerosis [ICD-11: 8A40] Approved
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved
	
TTDDRUID	D0YW3K
DRUGNAME	Pyrazole derivative 16
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0YW4R
DRUGNAME	IDM-2
INDICATI	Bladder cancer [ICD-11: 2C94] Discontinued in Phase 2/3
	
TTDDRUID	D0YW6B
DRUGNAME	AM-679
INDICATI	Ocular inflammation [ICD-11: 9C61.24] Investigative
	
TTDDRUID	D0YW6P
DRUGNAME	RU-101
INDICATI	Xerophthalmia [ICD-11: 5B55.Y] Phase 1/2
	
TTDDRUID	D0YX1C
DRUGNAME	Thiazole derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0YX3D
DRUGNAME	Olipudase alfa
INDICATI	Sphingolipidosis [ICD-11: 5C56.0] Phase 2
	
TTDDRUID	D0YX4L
DRUGNAME	PMID26651364-Compound-126b
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0YX4S
DRUGNAME	Cefprozil
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0YX4Z
DRUGNAME	IC-43
INDICATI	Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Phase 2/3
	
TTDDRUID	D0YX7E
DRUGNAME	Ortataxel
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Heart transplant rejection [ICD-11: NE84] Preclinical
	
TTDDRUID	D0YX8X
DRUGNAME	MG-1104
INDICATI	Factor IX deficiency [ICD-11: 3B11] Investigative
	
TTDDRUID	D0YY6O
DRUGNAME	CLIC-1901
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D0YY8N
DRUGNAME	PMID25470667-Compound-GO-CoA-Tat
INDICATI	Type-2 diabetes [ICD-11: 5A11] Patented
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0YZ0B
DRUGNAME	HT-2678
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D0YZ1J
DRUGNAME	APG-2305
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0YZ1Q
DRUGNAME	RGX-104
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0YZ4T
DRUGNAME	SFLT-01
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
	
TTDDRUID	D0YZ5T
DRUGNAME	NT-345
INDICATI	Sarcopenia [ICD-11: FB32.Y] Investigative
	
TTDDRUID	D0YZ8I
DRUGNAME	JWH-015
INDICATI	Organ transplant rejection [ICD-11: NE84] Patented
	
TTDDRUID	D0Z0AM
DRUGNAME	PSI-697
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
INDICATI	Atherosclerosis [ICD-11: BD40] Phase 1
	
TTDDRUID	D0Z0AS
DRUGNAME	CDRI-93/478
INDICATI	Hypertension [ICD-11: BA00-BA04] Investigative
	
TTDDRUID	D0Z0CH
DRUGNAME	Almokalant
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 3
	
TTDDRUID	D0Z0CU
DRUGNAME	Cx-621
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	D0Z0DW
DRUGNAME	Folic Acid
INDICATI	Vitamin deficiency [ICD-11: 5B55-5B71] Approved
INDICATI	Folate-deficiency anemia [ICD-11: 3A02.Y] Approved
	
TTDDRUID	D0Z0DX
DRUGNAME	Benzothiazole analog 5
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0Z0EH
DRUGNAME	PheTQS
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0Z0EP
DRUGNAME	CIGB-M3
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D0Z0FA
DRUGNAME	MLN7243
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Z0GH
DRUGNAME	AZD-2563
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	D0Z0GX
DRUGNAME	SUVN-502
INDICATI	Neurological disorder [ICD-11: 6B60] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D0Z0HH
DRUGNAME	Gossypol
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0Z0HL
DRUGNAME	Lixisenatide + Lantus
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0Z0HS
DRUGNAME	Hu Dreg 55
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Terminated
	
TTDDRUID	D0Z0JA
DRUGNAME	TDI-0046
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0Z0JC
DRUGNAME	NS-640
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative
	
TTDDRUID	D0Z0KD
DRUGNAME	PD-0183812
INDICATI	Retinoblastoma [ICD-11: 2D02.2] Terminated
	
TTDDRUID	D0Z0KE
DRUGNAME	BX-044
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0Z0KH
DRUGNAME	Azole
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
INDICATI	Candidiasis [ICD-11: 1F23] Investigative
	
TTDDRUID	D0Z0KL
DRUGNAME	1,3,4-oxadiazole derivative 6
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0Z0LJ
DRUGNAME	ABT-107
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 1
	
TTDDRUID	D0Z0LZ
DRUGNAME	IT-121
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Investigative
	
TTDDRUID	D0Z0MG
DRUGNAME	Carglumic acid
INDICATI	Acute hyperammonaemia [ICD-11: 5C50.A] Approved
	
TTDDRUID	D0Z0MI
DRUGNAME	Iomab-B CD45
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	D0Z0NX
DRUGNAME	AR-06
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3
	
TTDDRUID	D0Z0OT
DRUGNAME	ONO-4057
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
	
TTDDRUID	D0Z0PB
DRUGNAME	NGD-8243
INDICATI	Acute or chronic pain [ICD-11: MG30-MG31] Discontinued in Phase 2
	
TTDDRUID	D0Z0PR
DRUGNAME	L-006235-1
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Preclinical
	
TTDDRUID	D0Z0QO
DRUGNAME	SX-PCK9
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D0Z0RR
DRUGNAME	VGV-X
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0Z0RU
DRUGNAME	APC-6336
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Terminated
	
TTDDRUID	D0Z0SI
DRUGNAME	TBD-2
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0Z0TU
DRUGNAME	ITCA-638
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0Z0XM
DRUGNAME	CBL0137
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Z0ZJ
DRUGNAME	M-108101
INDICATI	Acne vulgaris [ICD-11: ED80] Investigative
	
TTDDRUID	D0Z0ZT
DRUGNAME	CTX-4430
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	D0Z1AB
DRUGNAME	ABBV-927
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Z1BQ
DRUGNAME	Cefluprenam
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3
	
TTDDRUID	D0Z1CQ
DRUGNAME	HumaRAD-OV
INDICATI	Ovarian cancer [ICD-11: 2C73] Investigative
	
TTDDRUID	D0Z1CS
DRUGNAME	Recombinant glucocerebrosidase enzyme
INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Investigative
	
TTDDRUID	D0Z1CZ
DRUGNAME	IR502
INDICATI	Psoriatic disorder [ICD-11: EA90] Phase 2
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
	
TTDDRUID	D0Z1DH
DRUGNAME	LY2090314
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	D0Z1EN
DRUGNAME	CIGB-166
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z1FX
DRUGNAME	Estriol
INDICATI	Hormone deficiency [ICD-11: 5A61.1] Approved
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D0Z1GP
DRUGNAME	FT-1050-treated umbilical cord stem cell therapy
INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 1
	
TTDDRUID	D0Z1HA
DRUGNAME	TDI-0020
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0Z1HQ
DRUGNAME	PNU156804
INDICATI	Renal transplantation [ICD-11: NE84] Terminated
	
TTDDRUID	D0Z1KC
DRUGNAME	Interferon gamma
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Approved
	
TTDDRUID	D0Z1LJ
DRUGNAME	3-(phenoxymethyl) benzylamine derivative 1
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0Z1MM
DRUGNAME	KP-9928
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D0Z1NF
DRUGNAME	BFPET
INDICATI	Coronary artery disease [ICD-11: BA80] Phase 1
	
TTDDRUID	D0Z1NY
DRUGNAME	BMS214662
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D0Z1OR
DRUGNAME	IPP-204106
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0Z1OS
DRUGNAME	ARI-2243
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0Z1OT
DRUGNAME	ALD-403
INDICATI	Migraine [ICD-11: 8A80] Phase 2
	
TTDDRUID	D0Z1PA
DRUGNAME	GG-818
INDICATI	Prostate disease [ICD-11: GA91] Investigative
	
TTDDRUID	D0Z1QC
DRUGNAME	Monoctanoin
INDICATI	Gallstone [ICD-11: DC11.3] Approved
	
TTDDRUID	D0Z1QR
DRUGNAME	TD-1473
INDICATI	Ulcerative colitis [ICD-11: DD71] Phase 1
	
TTDDRUID	D0Z1RJ
DRUGNAME	Adaphostin
INDICATI	Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1
	
TTDDRUID	D0Z1RQ
DRUGNAME	L-365260
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2
	
TTDDRUID	D0Z1RV
DRUGNAME	Clozapine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0Z1SL
DRUGNAME	Bazedoxifene/ conjugated estrogens
INDICATI	Postmenopausal osteoporosis [ICD-11: FB83.11] Phase 3
	
TTDDRUID	D0Z1TF
DRUGNAME	Ro-25-4094
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Terminated
	
TTDDRUID	D0Z1UA
DRUGNAME	Nebivolol
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
	
TTDDRUID	D0Z1UB
DRUGNAME	NAI-acne
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0Z1UW
DRUGNAME	TTPABC
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 1
	
TTDDRUID	D0Z1VE
DRUGNAME	SER-203
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z1VS
DRUGNAME	RN6G
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Discontinued in Phase 2
	
TTDDRUID	D0Z1VU
DRUGNAME	Second generation therapeutics
INDICATI	Obesity [ICD-11: 5B81] Phase 3
	
TTDDRUID	D0Z1WA
DRUGNAME	Procaterol
INDICATI	Asthma [ICD-11: CA23] Approved
	
TTDDRUID	D0Z1WH
DRUGNAME	CRAM 1-2
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0Z1XD
DRUGNAME	Methyltestosterone
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0Z1YF
DRUGNAME	Biphenyl mannoside derivative 16
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0Z1YK
DRUGNAME	EM-703
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	D0Z1ZA
DRUGNAME	Mannoside derivative 2
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0Z1ZM
DRUGNAME	Clarithromycin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0Z2AY
DRUGNAME	RLIP76 protein
INDICATI	Sunburn [ICD-11: EJ40] Investigative
	
TTDDRUID	D0Z2BI
DRUGNAME	mRNA-1851
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D0Z2BO
DRUGNAME	CX-072
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0Z2BT
DRUGNAME	DP-266
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z2CM
DRUGNAME	Lutropin alfa
INDICATI	Female infertility [ICD-11: GA31.Z] Approved
	
TTDDRUID	D0Z2FB
DRUGNAME	Piclamilast
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0Z2FD
DRUGNAME	BMS-908662
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Z2FX
DRUGNAME	AL-209
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Investigative
	
TTDDRUID	D0Z2GF
DRUGNAME	NI-101
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D0Z2GH
DRUGNAME	AS-1387392
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0Z2GQ
DRUGNAME	DV-601
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	D0Z2HG
DRUGNAME	V950 vaccine
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0Z2IY
DRUGNAME	TMX-201
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0Z2JF
DRUGNAME	Nivocasan
INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 2
	
TTDDRUID	D0Z2JP
DRUGNAME	Vi-CRM197
INDICATI	Salmonella infection [ICD-11: 1A09] Phase 2
	
TTDDRUID	D0Z2JR
DRUGNAME	LG-911
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z2KU
DRUGNAME	S-288310
INDICATI	Bladder cancer [ICD-11: 2C94] Discontinued in Phase 1/2
	
TTDDRUID	D0Z2LG
DRUGNAME	Sennoside a
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Approved
	
TTDDRUID	D0Z2MB
DRUGNAME	Cilansetron
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 3
	
TTDDRUID	D0Z2NA
DRUGNAME	AT-005
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Preclinical
	
TTDDRUID	D0Z2NJ
DRUGNAME	ASN100
INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2
INDICATI	Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 2
	
TTDDRUID	D0Z2NY
DRUGNAME	Aom-0763
INDICATI	Gout [ICD-11: FA25] Investigative
	
TTDDRUID	D0Z2QR
DRUGNAME	DS-7250
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D0Z2RA
DRUGNAME	Cantharidin
INDICATI	Molluscum contagiosum infection [ICD-11: 1E76] Approved
	
TTDDRUID	D0Z2TH
DRUGNAME	IMD-015213
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z2UD
DRUGNAME	RS-100975
INDICATI	Prostate disease [ICD-11: GA91] Discontinued in Phase 1
	
TTDDRUID	D0Z2UQ
DRUGNAME	AZD2014
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0Z2UT
DRUGNAME	BNP-FIX
INDICATI	Factor IX deficiency [ICD-11: 3B11] Investigative
	
TTDDRUID	D0Z2UW
DRUGNAME	Nicaraven
INDICATI	Cerebrovascular disease [ICD-11: 8B2Z] Phase 3
	
TTDDRUID	D0Z2UY
DRUGNAME	Antigen-specific melanoma vaccine
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
	
TTDDRUID	D0Z2WQ
DRUGNAME	Quinelorane
INDICATI	Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 3
	
TTDDRUID	D0Z2WV
DRUGNAME	ASP6981
INDICATI	Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1
INDICATI	Immune dysregulation [ICD-11: 4A01.2] Phase 1
	
TTDDRUID	D0Z2YQ
DRUGNAME	Patiromer calcium
INDICATI	Hyperkalemia [ICD-11: 5C76] Approved
	
TTDDRUID	D0Z2ZY
DRUGNAME	SL-401
INDICATI	Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Phase 1/2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
INDICATI	Myeloproliferative neoplasm [ICD-11: 2A20] Phase 1/2
	
TTDDRUID	D0Z3AB
DRUGNAME	Anti-PSA mabs
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0Z3AK
DRUGNAME	NPC-17923
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Terminated
	
TTDDRUID	D0Z3BU
DRUGNAME	Drug 2878175
INDICATI	Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1
	
TTDDRUID	D0Z3DY
DRUGNAME	Benzbromarone
INDICATI	Gout [ICD-11: FA25] Approved
	
TTDDRUID	D0Z3EI
DRUGNAME	Quinolones
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
INDICATI	Tuberculosis [ICD-11: 1B10-1B1Z] Approved
	
TTDDRUID	D0Z3ES
DRUGNAME	Melanoma vaccine, University of Virginia
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D0Z3FV
DRUGNAME	MPL-containing Pollinex allergy desensitization vaccine
INDICATI	Allergy [ICD-11: 4A80-4A85] Approved
	
TTDDRUID	D0Z3HF
DRUGNAME	AE-IG
INDICATI	Genetic disease [ICD-11: 8E02] Phase 1
	
TTDDRUID	D0Z3HW
DRUGNAME	Thiazole carboxamide derivative 30
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0Z3KK
DRUGNAME	PMID32321856-compound-11b
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0Z3LC
DRUGNAME	SR-4554
INDICATI	Diagnostic imaging [ICD-11: N.A.] Phase 1
	
TTDDRUID	D0Z3LN
DRUGNAME	LT-1945
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Investigative
	
TTDDRUID	D0Z3LY
DRUGNAME	SOM-0010
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0Z3OO
DRUGNAME	PneuGEM
INDICATI	Streptococcus infection [ICD-11: 1B53] Investigative
	
TTDDRUID	D0Z3PD
DRUGNAME	Purified secretory immunoglobulin
INDICATI	Enterocolitis [ICD-11: 1A40.Z] Investigative
	
TTDDRUID	D0Z3PO
DRUGNAME	BIIB014
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0Z3RF
DRUGNAME	UCB-11056
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	D0Z3RZ
DRUGNAME	EISO
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2
	
TTDDRUID	D0Z3UP
DRUGNAME	Dabuzalgron
INDICATI	Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2
	
TTDDRUID	D0Z3XO
DRUGNAME	MP-136
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1
	
TTDDRUID	D0Z3YP
DRUGNAME	ALGRX-1207
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1
	
TTDDRUID	D0Z3ZF
DRUGNAME	TOCA-621
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0Z4BH
DRUGNAME	Celtura
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	D0Z4BP
DRUGNAME	Human liver-engrafting cells
INDICATI	Liver disease [ICD-11: DB90-BD99] Investigative
	
TTDDRUID	D0Z4BV
DRUGNAME	Oxiracetam
INDICATI	Dementia [ICD-11: 6D80-6D86] Approved
	
TTDDRUID	D0Z4CY
DRUGNAME	PEN-221
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1/2
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D0Z4EI
DRUGNAME	Mifepristone
INDICATI	Cushing disease [ICD-11: 5A70] Approved
	
TTDDRUID	D0Z4FE
DRUGNAME	MIN-117
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0Z4KX
DRUGNAME	Farampator
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1
	
TTDDRUID	D0Z4NA
DRUGNAME	EG-P119
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Preclinical
	
TTDDRUID	D0Z4NI
DRUGNAME	Zinc Acetate
INDICATI	Wilson disease [ICD-11: 5C64.00] Approved
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0Z4NX
DRUGNAME	FR-171113
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0Z4OQ
DRUGNAME	TAK-783
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0Z4PE
DRUGNAME	Zinostatin stimalamer
INDICATI	Brain cancer [ICD-11: 2A00] Approved
	
TTDDRUID	D0Z4QC
DRUGNAME	SDZ-SER-082
INDICATI	Neurological disorder [ICD-11: 6B60] Terminated
	
TTDDRUID	D0Z4QJ
DRUGNAME	PMID25623274-Compound-WO2014132220C1
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Patented
	
TTDDRUID	D0Z4QQ
DRUGNAME	PMID25666693-Compound-160
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0Z4QT
DRUGNAME	3-substituted-1,2,4-oxadiazole derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0Z4QV
DRUGNAME	DUP-734
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1
	
TTDDRUID	D0Z4RC
DRUGNAME	CUDC-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Z4RX
DRUGNAME	HuMax-cMet
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z4SB
DRUGNAME	Glipizide
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0Z4SP
DRUGNAME	RG7426
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D0Z4UN
DRUGNAME	Pimecrolimus
INDICATI	Atopic dermatitis [ICD-11: EA80] Approved
	
TTDDRUID	D0Z4UY
DRUGNAME	Sodium Acetate Anhydrous
INDICATI	Hyponatraemia [ICD-11: 5C72] Approved
	
TTDDRUID	D0Z4VA
DRUGNAME	UD-CG-212
INDICATI	Heart failure [ICD-11: BD10-BD13] Terminated
	
TTDDRUID	D0Z4VG
DRUGNAME	HG-1092
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0Z4VX
DRUGNAME	BI 695501
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 3
	
TTDDRUID	D0Z4XW
DRUGNAME	Topetecan
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Approved
	
TTDDRUID	D0Z4YF
DRUGNAME	Ad5-nCoV vaccine
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D0Z4YK
DRUGNAME	SMT-C2100
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0Z4ZT
DRUGNAME	Drospirenone
INDICATI	Contraception [ICD-11: QA21] Approved
	
TTDDRUID	D0Z5AC
DRUGNAME	Gonadimmune
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2
	
TTDDRUID	D0Z5BC
DRUGNAME	Undecylenic acid
INDICATI	Dermatitis [ICD-11: EA80-EA89] Approved
	
TTDDRUID	D0Z5BD
DRUGNAME	CER-627
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 1
	
TTDDRUID	D0Z5DJ
DRUGNAME	Long-acting oxyntomodulin
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0Z5DM
DRUGNAME	IMD-0354
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 1
	
TTDDRUID	D0Z5EJ
DRUGNAME	PSMA-617
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D0Z5EM
DRUGNAME	Cephalexin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0Z5FC
DRUGNAME	Allogeneic cytotoxic T-cell therapy
INDICATI	Epstein barr virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D0Z5HA
DRUGNAME	VLTS-934
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D0Z5HB
DRUGNAME	FH-510
INDICATI	Psychotic disorder [ICD-11: 6A20-6A25] Terminated
	
TTDDRUID	D0Z5HH
DRUGNAME	PMID25666693-Compound-144
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0Z5HL
DRUGNAME	Thiazole carboxamide derivative 6
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0Z5HR
DRUGNAME	VX-661
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 3
	
TTDDRUID	D0Z5IP
DRUGNAME	Ixiaro
INDICATI	Japanese encephalitis virus infection [ICD-11: 1C85] Approved
	
TTDDRUID	D0Z5IU
DRUGNAME	Sulindac
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0Z5LB
DRUGNAME	AT1022
INDICATI	Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2
	
TTDDRUID	D0Z5LI
DRUGNAME	MEDI9447
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Z5LZ
DRUGNAME	Tilmacoxib
INDICATI	Colon polyp [ICD-11: DB35] Discontinued in Phase 2
	
TTDDRUID	D0Z5OE
DRUGNAME	Mitotane
INDICATI	Adrenocortical carcinoma [ICD-11: 2D11.Z] Approved
	
TTDDRUID	D0Z5OJ
DRUGNAME	NMI-150
INDICATI	Pain [ICD-11: MG30-MG3Z] Terminated
	
TTDDRUID	D0Z5OV
DRUGNAME	Delorazepam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0Z5QI
DRUGNAME	Fentanyl/droperidol
INDICATI	Anaesthesia [ICD-11: 9A78.6] Approved
	
TTDDRUID	D0Z5SC
DRUGNAME	Dengue fever vaccine
INDICATI	Dengue fever [ICD-11: 1D2Z] Phase 3
	
TTDDRUID	D0Z5SM
DRUGNAME	Sodium Tetradecyl Sulfate
INDICATI	Hemangioma [ICD-11: 2E81-2F2Y] Approved
INDICATI	Varicose and spider veins of leg [ICD-11: BD74.1] Approved
	
TTDDRUID	D0Z5SR
DRUGNAME	Fosfructose
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 3
	
TTDDRUID	D0Z5TS
DRUGNAME	KI-0503
INDICATI	Arthropathy [ICD-11: FA11-FA38] Phase 2
	
TTDDRUID	D0Z5TW
DRUGNAME	Parietaria Judaica-containing vaccine
INDICATI	Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3
	
TTDDRUID	D0Z5UB
DRUGNAME	CX-2076
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative
	
TTDDRUID	D0Z5UD
DRUGNAME	MIP-1375
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0Z5UT
DRUGNAME	INOpulse
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3
	
TTDDRUID	D0Z5VG
DRUGNAME	CZ-48
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0Z5VL
DRUGNAME	PPMX-2017
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z5VQ
DRUGNAME	Terutroban sodium
INDICATI	Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3
	
TTDDRUID	D0Z5VW
DRUGNAME	H3B-6545
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D0Z5XT
DRUGNAME	Imexon
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D0Z5YI
DRUGNAME	AVI-5038
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Investigative
	
TTDDRUID	D0Z6AM
DRUGNAME	Ipafricept
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D0Z6AR
DRUGNAME	Descartes-08
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D0Z6AX
DRUGNAME	BAY-27-9955
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1
	
TTDDRUID	D0Z6BF
DRUGNAME	Grastek
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0Z6DE
DRUGNAME	RPSGL-Ig
INDICATI	Delayed graft function [ICD-11: 4B24.0] Phase 2
	
TTDDRUID	D0Z6EQ
DRUGNAME	ZP-009
INDICATI	Pharyngitis [ICD-11: CA02.Z] Investigative
	
TTDDRUID	D0Z6GW
DRUGNAME	TMC649128
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	D0Z6IB
DRUGNAME	AVP-786
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
INDICATI	Neurobehavioral disorder [ICD-11: 8A00-8A0Z] Phase 2
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 1
	
TTDDRUID	D0Z6KF
DRUGNAME	TAS-114
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Z6KK
DRUGNAME	AZD-5847
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2
	
TTDDRUID	D0Z6MT
DRUGNAME	Famitinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0Z6MW
DRUGNAME	ODS-656
INDICATI	Osteopetrosis [ICD-11: LD24.10] Investigative
	
TTDDRUID	D0Z6NK
DRUGNAME	CHB-111
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 1
	
TTDDRUID	D0Z6OI
DRUGNAME	DS-6930
INDICATI	Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1
	
TTDDRUID	D0Z6OW
DRUGNAME	Staphylococcus aureus vaccine
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2/3
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1
	
TTDDRUID	D0Z6PF
DRUGNAME	Alkyl mannoside derivative 2
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0Z6QG
DRUGNAME	Pipotiazine
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D0Z6RW
DRUGNAME	LMP-1/LMP-2 CTLs
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	D0Z6SP
DRUGNAME	Andecaliximab
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Z6ST
DRUGNAME	Buflomedil
INDICATI	Peripheral vascular disease [ICD-11: BD4Z] Approved
	
TTDDRUID	D0Z6UC
DRUGNAME	Sumatriptan
INDICATI	Migraine [ICD-11: 8A80] Approved
	
TTDDRUID	D0Z6VR
DRUGNAME	Buthionine sulfoximine
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z6WI
DRUGNAME	EP-51216
INDICATI	Eating disorder [ICD-11: 6B82] Phase 1
	
TTDDRUID	D0Z6WN
DRUGNAME	NDM-10107
INDICATI	Obesity [ICD-11: 5B81] Investigative
	
TTDDRUID	D0Z6XQ
DRUGNAME	Recombinant human zinc alpha-2 glycoprotein (ZAG)
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0Z7AB
DRUGNAME	Olodaterol/tiotropium bromide
INDICATI	Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3
	
TTDDRUID	D0Z7AM
DRUGNAME	Ether lipid
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0Z7AN
DRUGNAME	Ro-19-8022
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated
	
TTDDRUID	D0Z7BE
DRUGNAME	H-100
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	D0Z7BX
DRUGNAME	GSK3145095
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	D0Z7EV
DRUGNAME	Carboxamide derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0Z7FK
DRUGNAME	XMT-1001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Z7FU
DRUGNAME	INS 316
INDICATI	Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 3
	
TTDDRUID	D0Z7FY
DRUGNAME	CEM-301
INDICATI	Gastric motility disorder [ICD-11: DA21] Investigative
	
TTDDRUID	D0Z7FZ
DRUGNAME	VN-180
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Investigative
	
TTDDRUID	D0Z7GJ
DRUGNAME	EUK-418
INDICATI	Radiation syndrome [ICD-11: NF00] Terminated
	
TTDDRUID	D0Z7GX
DRUGNAME	BBT-032
INDICATI	Multiple sclerosis [ICD-11: 8A40] Investigative
	
TTDDRUID	D0Z7IW
DRUGNAME	JI-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D0Z7KB
DRUGNAME	HPMA-docetaxel conjugate
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z7KE
DRUGNAME	Isradipine
INDICATI	Hypertension [ICD-11: BA00-BA04] Approved
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 3
	
TTDDRUID	D0Z7LK
DRUGNAME	GSC-1
INDICATI	Hyperglycemia [ICD-11: MA18.0] Investigative
	
TTDDRUID	D0Z7MJ
DRUGNAME	Prednisolone sodium metazoate
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2
	
TTDDRUID	D0Z7PI
DRUGNAME	GR-233548
INDICATI	Thrombosis [ICD-11: DB61-GB90] Terminated
	
TTDDRUID	D0Z7QK
DRUGNAME	UCART123
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Phase 1
	
TTDDRUID	D0Z7RA
DRUGNAME	GLY-220
INDICATI	Diabetic angiopathy [ICD-11: BD53.Y] Investigative
	
TTDDRUID	D0Z7RR
DRUGNAME	ARRY-770
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z7TR
DRUGNAME	ACP-01
INDICATI	Critical limb ischemia [ICD-11: BD4Y] Phase 2
	
TTDDRUID	D0Z7UN
DRUGNAME	H5N1 influenza vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 3
	
TTDDRUID	D0Z7ZM
DRUGNAME	Rhucin
INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Approved
INDICATI	Erectile dysfunction [ICD-11: HA01.1] Approved
	
TTDDRUID	D0Z8AA
DRUGNAME	Propiolactone
INDICATI	Sterilant [ICD-11: N.A.] Approved
	
TTDDRUID	D0Z8AE
DRUGNAME	Chromic Chloride
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Approved
	
TTDDRUID	D0Z8BI
DRUGNAME	IMGN-007
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z8CQ
DRUGNAME	Sarilumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Approved
	
TTDDRUID	D0Z8DO
DRUGNAME	SPD-556
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 2
	
TTDDRUID	D0Z8EA
DRUGNAME	FMX104
INDICATI	Chronic post cancer treatment pain [ICD-11: 8E43] Phase 2
	
TTDDRUID	D0Z8EJ
DRUGNAME	KOS-1815
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D0Z8EV
DRUGNAME	Mycophenolic acid
INDICATI	Crohn disease [ICD-11: DD70] Approved
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative
	
TTDDRUID	D0Z8EX
DRUGNAME	Stavudine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0Z8GD
DRUGNAME	CD19 CAR T Cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
INDICATI	Large cell lymphoma [ICD-11: 2A80.Z] Phase 1/2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
	
TTDDRUID	D0Z8HG
DRUGNAME	Vecuronium
INDICATI	Spasm [ICD-11: MB47.3] Approved
	
TTDDRUID	D0Z8JR
DRUGNAME	BMS-936564
INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0Z8KS
DRUGNAME	Zanolimumab
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 3
	
TTDDRUID	D0Z8KU
DRUGNAME	SGN-2FF
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0Z8LA
DRUGNAME	Cyclocreatine
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1
	
TTDDRUID	D0Z8LN
DRUGNAME	Ebola virus vaccine
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 3
	
TTDDRUID	D0Z8MC
DRUGNAME	Botulinum toxin type A gel
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
	
TTDDRUID	D0Z8PO
DRUGNAME	KPE-06001
INDICATI	Arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	D0Z8SF
DRUGNAME	Sarkomycin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved
	
TTDDRUID	D0Z8UJ
DRUGNAME	TDI-0111
INDICATI	Motor neurone disease [ICD-11: 8B60] Investigative
	
TTDDRUID	D0Z8UQ
DRUGNAME	DM-83
INDICATI	Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2
	
TTDDRUID	D0Z8WF
DRUGNAME	Pyridotriazolopyrimidine derivative 3
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0Z8XI
DRUGNAME	HG-1077
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z8ZW
DRUGNAME	EGF-SLiP fusion protein
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D0Z9AV
DRUGNAME	H5N1 vaccine
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D0Z9BN
DRUGNAME	NBRI-16716a
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z9BU
DRUGNAME	99mTc-EC-0652
INDICATI	Prostate cancer [ICD-11: 2C82.0] Investigative
	
TTDDRUID	D0Z9EO
DRUGNAME	Metreleptin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Approved
	
TTDDRUID	D0Z9GM
DRUGNAME	LY-2940094
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D0Z9HW
DRUGNAME	AZD6280
INDICATI	Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1
	
TTDDRUID	D0Z9LD
DRUGNAME	SC-49992
INDICATI	Arterial thrombosis [ICD-11: DB61-DD30] Terminated
	
TTDDRUID	D0Z9LP
DRUGNAME	RP101
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2/3
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2/3
	
TTDDRUID	D0Z9MR
DRUGNAME	TG-1042
INDICATI	B-cell lymphoma [ICD-11: 2A86] Discontinued in Phase 2
	
TTDDRUID	D0Z9NY
DRUGNAME	API-023
INDICATI	Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 1
	
TTDDRUID	D0Z9NZ
DRUGNAME	Glutethimide
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0Z9OS
DRUGNAME	BT-VACC
INDICATI	Yersinia infection [ICD-11: 1B93] Discontinued in Phase 2
	
TTDDRUID	D0Z9PX
DRUGNAME	Isopropamide iodide
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Approved
	
TTDDRUID	D0Z9QR
DRUGNAME	Zalcitabine
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0Z9QX
DRUGNAME	CTX-1301
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1
	
TTDDRUID	D0Z9RJ
DRUGNAME	GS 9667
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 1
	
TTDDRUID	D0Z9UJ
DRUGNAME	Peptide analog 4
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Patented
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Patented
INDICATI	Hepatitis [ICD-11: DB97.Z] Patented
	
TTDDRUID	D0Z9VB
DRUGNAME	Halazepam
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Approved
	
TTDDRUID	D0Z9VY
DRUGNAME	UCN-01
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D0Z9WP
DRUGNAME	ZP-3022
INDICATI	Diabetic complication [ICD-11: 5A2Y] Investigative
	
TTDDRUID	D0Z9WV
DRUGNAME	Sharon-1000
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Investigative
	
TTDDRUID	D0Z9YF
DRUGNAME	Recombinant Bet v 1 immunotherapy
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 2/3
	
TTDDRUID	D0Z9YV
DRUGNAME	BT-D005
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0Z9YW
DRUGNAME	FK-3311
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
	
TTDDRUID	D0Z9ZT
DRUGNAME	MDNA55
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D0ZA0W
DRUGNAME	PSA/IL-2/GM-CSF vaccine
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D0ZA1K
DRUGNAME	BPX-701
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D0ZA2L
DRUGNAME	ER-35786
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1
	
TTDDRUID	D0ZA4G
DRUGNAME	Varicella-zoster immune globulin
INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Approved
	
TTDDRUID	D0ZA6P
DRUGNAME	CBT-501 + CBT-502
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0ZA6V
DRUGNAME	MNPR-201
INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2
	
TTDDRUID	D0ZB2E
DRUGNAME	NV-07a
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Investigative
	
TTDDRUID	D0ZB7K
DRUGNAME	Zopiclone
INDICATI	Insomnia [ICD-11: 7A00-7A0Z] Approved
	
TTDDRUID	D0ZB9D
DRUGNAME	ER-21036
INDICATI	Hypercholesterolaemia [ICD-11: 5C80.0] Investigative
	
TTDDRUID	D0ZB9U
DRUGNAME	Lopinavir + ritonavir + oseltamivir
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	D0ZC0M
DRUGNAME	GSK561679
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
INDICATI	Alcohol dependence [ICD-11: 6C40.2] Phase 2
	
TTDDRUID	D0ZC3C
DRUGNAME	GTS-21
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0ZC3K
DRUGNAME	Anti-ricin mabs
INDICATI	Poison intoxication [ICD-11: NE6Z] Investigative
	
TTDDRUID	D0ZC6X
DRUGNAME	PRTX-100
INDICATI	Arthritis [ICD-11: FA20] Phase 1/2
INDICATI	Behcet disease [ICD-11: 4A62] Phase 1/2
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1/2
INDICATI	Thrombocytopenia [ICD-11: 3B64] Phase 1/2
	
TTDDRUID	D0ZC7P
DRUGNAME	Bamaquimast
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 2
	
TTDDRUID	D0ZC7W
DRUGNAME	Phenylsulfonyl derivative 4
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Patented
	
TTDDRUID	D0ZD2M
DRUGNAME	MLN4924
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 2
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative
	
TTDDRUID	D0ZD3C
DRUGNAME	Gemigliptin
INDICATI	Diabetic complication [ICD-11: 5A2Y] Phase 3
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0ZD6N
DRUGNAME	Biaryl mannoside derivative 3
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0ZD6Y
DRUGNAME	RUS 3108
INDICATI	Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1
	
TTDDRUID	D0ZDP2
DRUGNAME	TAK-573
INDICATI	Refractory multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D0ZE0S
DRUGNAME	BMS-986183
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
INDICATI	Angiogenesis disorder [ICD-11: BE2Z] Patented
	
TTDDRUID	D0ZE1M
DRUGNAME	PMID25666693-Compound-107
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0ZE1O
DRUGNAME	Plinabulin
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D0ZE2J
DRUGNAME	Oxetane 3,3-dicarboxamide compound 2
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Patented
	
TTDDRUID	D0ZE3S
DRUGNAME	RESP-6000
INDICATI	Atopic dermatitis [ICD-11: EA80] Investigative
	
TTDDRUID	D0ZE5U
DRUGNAME	Indolinone derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0ZE5V
DRUGNAME	FPL-55712
INDICATI	Asthma [ICD-11: CA23] Terminated
	
TTDDRUID	D0ZE6H
DRUGNAME	Six-membered heterocyclic benzamide derivative 1
INDICATI	Pruritus [ICD-11: EC90] Patented
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Chronic pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Thymic cancer [ICD-11: 2C27] Patented
	
TTDDRUID	D0ZE7B
DRUGNAME	VLD-631
INDICATI	Melanoma [ICD-11: 2C30] Investigative
	
TTDDRUID	D0ZE8B
DRUGNAME	Azetidine-1-carboxamide derivative 2
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0ZE9C
DRUGNAME	Pazinaclone
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3
	
TTDDRUID	D0ZE9T
DRUGNAME	DA-3811
INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Investigative
	
TTDDRUID	D0ZF1D
DRUGNAME	Ambasilide
INDICATI	Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2
	
TTDDRUID	D0ZF8F
DRUGNAME	HIP-2B
INDICATI	Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D0ZF9J
DRUGNAME	HuCART-meso cells
INDICATI	Lymphatic disease [ICD-11: BD9Z] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
INDICATI	Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0ZG0K
DRUGNAME	Thiazole carboxamide derivative 13
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0ZG1Y
DRUGNAME	RG-7167
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1
	
TTDDRUID	D0ZG3S
DRUGNAME	Reproxalap
INDICATI	Sjogren-Larsson syndrome [ICD-11: 5C52.03] Phase 3
	
TTDDRUID	D0ZG5K
DRUGNAME	Kiacta
INDICATI	Amyloidosis [ICD-11: 5D00] Phase 3
	
TTDDRUID	D0ZG7S
DRUGNAME	BXL-01-0029
INDICATI	Heart transplant rejection [ICD-11: NE84] Investigative
	
TTDDRUID	D0ZG9N
DRUGNAME	SC-53116
INDICATI	Gastric motility disorder [ICD-11: DA21] Terminated
	
TTDDRUID	D0ZH0X
DRUGNAME	IPH-24
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0ZH2L
DRUGNAME	Autologous fat-derived stem cell therapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0ZH4J
DRUGNAME	MOB015B
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 3
	
TTDDRUID	D0ZI0C
DRUGNAME	Dersalazine
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Phase 2
	
TTDDRUID	D0ZI0K
DRUGNAME	NMI-870
INDICATI	Sexual dysfunction [ICD-11: HA00-HA01] Discontinued in Phase 2
	
TTDDRUID	D0ZI1F
DRUGNAME	Tivantinib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
	
TTDDRUID	D0ZI4H
DRUGNAME	Ornoprostil
INDICATI	Ulcer [ICD-11: CA02-CB40] Approved
INDICATI	Gastritis [ICD-11: DA42] Approved
	
TTDDRUID	D0ZI4L
DRUGNAME	CX-01
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D0ZI5A
DRUGNAME	PF-00337210
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0ZI5U
DRUGNAME	XeriJect
INDICATI	Acute repetitive seizure [ICD-11: 8A67] Phase 1
	
TTDDRUID	D0ZI7Q
DRUGNAME	Miboplatin
INDICATI	Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 3
	
TTDDRUID	D0ZJ0A
DRUGNAME	2164U90
INDICATI	Arteriosclerosis [ICD-11: BD40] Terminated
	
TTDDRUID	D0ZJ0R
DRUGNAME	PDC-APB
INDICATI	Contact dermatitis [ICD-11: EK0Z] Phase 1
	
TTDDRUID	D0ZJ1C
DRUGNAME	(S)-(+)-Dimethindene maleate
INDICATI	Pruritus [ICD-11: EC90] Approved
	
TTDDRUID	D0ZJ4M
DRUGNAME	Resorcinol compound 3
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0ZJ6W
DRUGNAME	Ragweed peptide allergy desensitization
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 2
	
TTDDRUID	D0ZJ8G
DRUGNAME	FM-501
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Investigative
	
TTDDRUID	D0ZK0N
DRUGNAME	BMS-931699
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D0ZK3X
DRUGNAME	BBI-2000
INDICATI	Allergic contact dermatitis [ICD-11: EK00] Phase 2
	
TTDDRUID	D0ZK5H
DRUGNAME	PW-4156
INDICATI	Muscle hypertonia [ICD-11: MB47.8] Investigative
	
TTDDRUID	D0ZK7B
DRUGNAME	Tesofensine
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D0ZK8H
DRUGNAME	Gardasil
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Approved
	
TTDDRUID	D0ZL1T
DRUGNAME	SK-NBP601
INDICATI	Hemophilia [ICD-11: 3B10.0] Preregistration
	
TTDDRUID	D0ZL3U
DRUGNAME	Allogeneic CART-33
INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Phase 1
	
TTDDRUID	D0ZL5J
DRUGNAME	XCUR17
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 1
	
TTDDRUID	D0ZL9B
DRUGNAME	Diaspirin crosslinked hemoglobin
INDICATI	Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated
	
TTDDRUID	D0ZM1H
DRUGNAME	Isoquinoline derivative 3
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
	
TTDDRUID	D0ZM2S
DRUGNAME	R1204
INDICATI	Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1
	
TTDDRUID	D0ZM5B
DRUGNAME	AG-021541
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1
	
TTDDRUID	D0ZM5E
DRUGNAME	VCL-1M01
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D0ZM5O
DRUGNAME	Pexacerfont
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2/3
	
TTDDRUID	D0ZM5W
DRUGNAME	Esuprone
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D0ZM8B
DRUGNAME	FK-409
INDICATI	Angina pectoris [ICD-11: BA40] Phase 2
	
TTDDRUID	D0ZM8F
DRUGNAME	ASP7374
INDICATI	Seasonal influenza infection [ICD-11: 1E30] Phase 3
	
TTDDRUID	D0ZM8H
DRUGNAME	PMID25666693-Compound-18
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0ZN1R
DRUGNAME	Delphinidin
INDICATI	Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2
	
TTDDRUID	D0ZN3M
DRUGNAME	PMID27998201-Compound-19
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
	
TTDDRUID	D0ZO2Z
DRUGNAME	Lingliptin + pioglitazone
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	D0ZO5K
DRUGNAME	MEDI0562
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0ZO7A
DRUGNAME	Dorgenmeltucel-L
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	D0ZP2C
DRUGNAME	PMID25666693-Compound-105
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0ZP2E
DRUGNAME	HinsBet
INDICATI	Insulin-dependent diabetes [ICD-11: 5A10] Phase 2
	
TTDDRUID	D0ZP3Q
DRUGNAME	Multikine
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
	
TTDDRUID	D0ZP4B
DRUGNAME	RP-3035
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative
	
TTDDRUID	D0ZP7D
DRUGNAME	GenePro
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Investigative
	
TTDDRUID	D0ZP8Z
DRUGNAME	CART22-65s cells
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	D0ZQ2W
DRUGNAME	PMID25666693-Compound-96
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0ZQ3K
DRUGNAME	Anti-CD22 CAR-T cells
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	D0ZQ6N
DRUGNAME	CAR-T Cells targeting EGFRvIII
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D0ZQ7P
DRUGNAME	Sch-49210
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated
	
TTDDRUID	D0ZR1Z
DRUGNAME	IMGN779
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D0ZR2O
DRUGNAME	Biaryl mannoside derivative 6
INDICATI	Crohn disease [ICD-11: DD70] Patented
INDICATI	Ulcerative colitis [ICD-11: DD71] Patented
INDICATI	Urinary tract infection [ICD-11: GC08] Patented
	
TTDDRUID	D0ZR2W
DRUGNAME	S-47445
INDICATI	Cognitive impairment [ICD-11: 6D71] Investigative
	
TTDDRUID	D0ZR3N
DRUGNAME	Pro 542
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2
	
TTDDRUID	D0ZR4Q
DRUGNAME	SSS-08
INDICATI	Cervical cancer [ICD-11: 2C77.0] Investigative
	
TTDDRUID	D0ZR4W
DRUGNAME	Nuedexta
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D0ZR6E
DRUGNAME	TVI-Brain-1 cancer vaccine
INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2
INDICATI	Glioma [ICD-11: 2A00.0] Phase 2
INDICATI	Astrocytoma [ICD-11: 2A00.0Y] Phase 2
INDICATI	Brain cancer [ICD-11: 2A00] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D0ZR8T
DRUGNAME	MSB 11022
INDICATI	Chronic plaque psoriasis [ICD-11: EA90.0] Phase 3
	
TTDDRUID	D0ZS3E
DRUGNAME	PMID25666693-Compound-152
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D0ZS5X
DRUGNAME	SHP610
INDICATI	Sanfilippo syndrome [ICD-11: 5C56.3Y] Phase 2
	
TTDDRUID	D0ZS6R
DRUGNAME	Technetium Tc-99m Apcitide
INDICATI	Radioactive tracer [ICD-11: N.A.] Approved
	
TTDDRUID	D0ZS8P
DRUGNAME	Clomipramine
INDICATI	Depression [ICD-11: 6A70-6A7Z] Approved
	
TTDDRUID	D0ZS8S
DRUGNAME	CT-750
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0ZT0G
DRUGNAME	Cinaciguat
INDICATI	Acute decompensated heart failure [ICD-11: BD1Z] Phase 2
	
TTDDRUID	D0ZT1L
DRUGNAME	AP33
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D0ZT3U
DRUGNAME	Resorcinol compound 29
INDICATI	Albinism [ICD-11: EC23.2] Patented
INDICATI	Ephelides [ICD-11: ED61.0] Patented
INDICATI	Menkes disease [ICD-11: 5C64.0] Patented
INDICATI	Senile lentigines [ICD-11: ED61.0] Patented
INDICATI	Melasma [ICD-11: ED60.1] Patented
	
TTDDRUID	D0ZT4J
DRUGNAME	JSM 6427
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
	
TTDDRUID	D0ZT5T
DRUGNAME	NTHi-Pneumo vaccine
INDICATI	Haemophilus influenza [ICD-11: 1G40] Phase 2
	
TTDDRUID	D0ZT8A
DRUGNAME	T3D-959
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D0ZU2X
DRUGNAME	K-510
INDICATI	Malaria [ICD-11: 1F40-1F45] Investigative
	
TTDDRUID	D0ZU4U
DRUGNAME	MLR-1023
INDICATI	Obesity [ICD-11: 5B81] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0ZU5F
DRUGNAME	SGX523
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0ZU6O
DRUGNAME	T-1106
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Investigative
	
TTDDRUID	D0ZU9P
DRUGNAME	Napirimus
INDICATI	Immune System disease [ICD-11: 4A01-4B41] Investigative
	
TTDDRUID	D0ZU9R
DRUGNAME	Ritonavir
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Approved
	
TTDDRUID	D0ZU9T
DRUGNAME	NSC-134754
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0ZV0R
DRUGNAME	F-200
INDICATI	Ocular disease [ICD-11: 1F00.1Z] Terminated
	
TTDDRUID	D0ZV0Z
DRUGNAME	Moxifloxacin
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0ZV1F
DRUGNAME	Ro-09-1227
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Terminated
	
TTDDRUID	D0ZV4I
DRUGNAME	HL-020
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D0ZV6W
DRUGNAME	Albupoietin
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Terminated
	
TTDDRUID	D0ZV7Y
DRUGNAME	MorphPlus
INDICATI	Pain [ICD-11: MG30-MG3Z] Investigative
	
TTDDRUID	D0ZV9P
DRUGNAME	Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Patented
	
TTDDRUID	D0ZVM5
DRUGNAME	177-Lu-NeoB
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D0ZW1W
DRUGNAME	SoluMatrix naproxen
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
INDICATI	Osteoarthritis [ICD-11: FA00-FA05] Phase 2
	
TTDDRUID	D0ZW2F
DRUGNAME	NSC-119910
INDICATI	Cardiac failure [ICD-11: BD10-BD13] Investigative
	
TTDDRUID	D0ZW2I
DRUGNAME	RVT-104
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
INDICATI	Lewy body dementia [ICD-11: 6D82] Phase 1
	
TTDDRUID	D0ZW3R
DRUGNAME	TG-4010
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 2/3
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3
	
TTDDRUID	D0ZW4W
DRUGNAME	(+)-JQ1
INDICATI	Testicular cancer [ICD-11: 2C80] Phase 1
	
TTDDRUID	D0ZW5D
DRUGNAME	LY-2409021
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D0ZW5Y
DRUGNAME	Recombinant pox virus vaccine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2
	
TTDDRUID	D0ZW6X
DRUGNAME	Anti-GITR antibody
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D0ZW8B
DRUGNAME	Human anti-rabies mab
INDICATI	Rabies [ICD-11: 1C82] Phase 2
	
TTDDRUID	D0ZX0C
DRUGNAME	Tetanus vaccine
INDICATI	Clostridium infection [ICD-11: 1A04] Terminated
	
TTDDRUID	D0ZX1E
DRUGNAME	CNT0-5825
INDICATI	Allergic asthma [ICD-11: CA23.0] Phase 1
	
TTDDRUID	D0ZX1P
DRUGNAME	FADROZOLE
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Approved
	
TTDDRUID	D0ZX2D
DRUGNAME	11C-6-Me-BTA-1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D0ZX2G
DRUGNAME	Hexachlorophene
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Approved
	
TTDDRUID	D0ZX2L
DRUGNAME	GSK2831781
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Phase 1
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1
	
TTDDRUID	D0ZX7I
DRUGNAME	SR-57227
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2
	
TTDDRUID	D0ZY0Z
DRUGNAME	ABT-560
INDICATI	Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1
	
TTDDRUID	D0ZY3E
DRUGNAME	INO-1001
INDICATI	Brain cancer [ICD-11: 2A00] Phase 3
	
TTDDRUID	D0ZY3R
DRUGNAME	MEDI8111
INDICATI	Bleeding disorder [ICD-11: GA20-GA21] Phase 1
	
TTDDRUID	D0ZY6C
DRUGNAME	Diaryl piperazine derivative 1
INDICATI	Obesity [ICD-11: 5B81] Patented
	
TTDDRUID	D0ZY9U
DRUGNAME	SLV-305
INDICATI	Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2
	
TTDDRUID	D0ZZ3Q
DRUGNAME	AOB101
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D0ZZ6C
DRUGNAME	EB-001A
INDICATI	Glabellar frown line [ICD-11: NA0Z] Phase 2
INDICATI	Keloidal surgical scar [ICD-11: EL50.0] Phase 2
	
TTDDRUID	D0ZZ8F
DRUGNAME	PMID25666693-Compound-68
INDICATI	Osteoarthritis pain [ICD-11: MG30.31] Patented
INDICATI	Cancer related pain [ICD-11: MG30] Patented
INDICATI	Neuropathic pain [ICD-11: 8E43.0] Patented
INDICATI	Inflammatory pain [ICD-11: MG30.42] Patented
	
TTDDRUID	D10GPJ
DRUGNAME	STRO-002
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D10LNV
DRUGNAME	MRX-2843
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D12AIV
DRUGNAME	PRGN-3005
INDICATI	Refractory hematologic malignancy [ICD-11: 2A85.5] Phase 1
	
TTDDRUID	D12DYT
DRUGNAME	HPN217
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D12EFM
DRUGNAME	RG7854
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	D12QYO
DRUGNAME	JNJ-64300535
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	D12THW
DRUGNAME	AGN-241751
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	D14NDZ
DRUGNAME	Deguelin
INDICATI	Esophageal squamous cell carcinoma [ICD-11: 2E60.1] Investigative
	
TTDDRUID	D14SKB
DRUGNAME	MGTA-456
INDICATI	Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2
	
TTDDRUID	D15ZUR
DRUGNAME	RO6870810
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D16JNF
DRUGNAME	3-Oxo-C12-(2-amino-cyclohexanone)
INDICATI	Pseudomonas infection [ICD-11: 1B92] Preclinical
	
TTDDRUID	D17TRG
DRUGNAME	2-Amino-4-[3-hydroxyphenyl]-4-hydroxybutanoic acid
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical
	
TTDDRUID	D17URP
DRUGNAME	Cosibelimab
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1
	
TTDDRUID	D18QIB
DRUGNAME	MSC110
INDICATI	Pigmented villonodular synovitis [ICD-11: FA27.1] Phase 1
	
TTDDRUID	D18SHN
DRUGNAME	Tecartus
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Approved
	
TTDDRUID	D19OMU
DRUGNAME	PF-06741086
INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 3
	
TTDDRUID	D1A5GK
DRUGNAME	DSTA-4637S
INDICATI	Bacteremia [ICD-11: 1A73] Phase 1
	
TTDDRUID	D1A8NU
DRUGNAME	NG-641
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D1AD6L
DRUGNAME	NPS-1034
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D1AVT5
DRUGNAME	SEA-TGT
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D1B2US
DRUGNAME	BTI-410
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D1BCW8
DRUGNAME	APY29
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D1BG7C
DRUGNAME	BOS172738
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D1BT2M
DRUGNAME	NJA-730
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 1
	
TTDDRUID	D1C0WB
DRUGNAME	DZD1516
INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D1CG5M
DRUGNAME	VLS-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D1CWL0
DRUGNAME	lumateperone tosylate
INDICATI	Schizophrenia [ICD-11: 6A20] Approved
	
TTDDRUID	D1CZ8K
DRUGNAME	177-Lu-PSMA-R2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D1EW3O
DRUGNAME	IN10018
INDICATI	Metastatic melanoma [ICD-11: 2E2Z] Phase 1
	
TTDDRUID	D1FO9C
DRUGNAME	GNX102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D1FR3T
DRUGNAME	Mitoquinone
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2
	
TTDDRUID	D1FUQ2
DRUGNAME	ASP9801
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D1G7XU
DRUGNAME	SPYK04
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D1GWL7
DRUGNAME	PLG-0206
INDICATI	Joint infection [ICD-11: FA10] Phase 2
	
TTDDRUID	D1HEN2
DRUGNAME	Ga-68-DOTATOC
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D1J4GS
DRUGNAME	BT595
INDICATI	Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 3
	
TTDDRUID	D1JS9X
DRUGNAME	ABTAA
INDICATI	Sepsis [ICD-11: 1G40-1G41] Investigative
	
TTDDRUID	D1KC8H
DRUGNAME	AB-4166
INDICATI	Parkinson disease [ICD-11: 8A00.0] Clinical Trial
	
TTDDRUID	D1KIY9
DRUGNAME	HH2710
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D1KO3P
DRUGNAME	SXC-2023
INDICATI	Trichotillomania [ICD-11: 6B25.0] Phase 2
	
TTDDRUID	D1L7DE
DRUGNAME	GEM3PSCA
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1
	
TTDDRUID	D1LEU5
DRUGNAME	JAB-3312
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D1LU7W
DRUGNAME	NP001
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D1M5NW
DRUGNAME	Exebacase
INDICATI	Bacteremia [ICD-11: 1A73] Phase 3
	
TTDDRUID	D1M8GC
DRUGNAME	PRO 140
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2/3
	
TTDDRUID	D1MEH5
DRUGNAME	Enmetazobactam
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 3
	
TTDDRUID	D1MK7G
DRUGNAME	AR-501
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 1/2
	
TTDDRUID	D1N2BO
DRUGNAME	GSK'963
INDICATI	Myeloid leukaemia [ICD-11: 2B33.1] Investigative
	
TTDDRUID	D1NC2O
DRUGNAME	Ifx-Hu2.0
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1
INDICATI	Cutaneous squamous cell carcinoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D1O9XQ
DRUGNAME	SKY59
INDICATI	Haemolytic uraemic syndrome [ICD-11: 3A21.2] Phase 3
	
TTDDRUID	D1ONZ8
DRUGNAME	AVID200
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D1PC9J
DRUGNAME	CX2009
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D1PYC8
DRUGNAME	MGD019
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D1RIW2
DRUGNAME	APN401
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D1RMS5
DRUGNAME	OTL-300
INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 1/2
	
TTDDRUID	D1S7EP
DRUGNAME	SI-B003
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D1SL2W
DRUGNAME	PRT811
INDICATI	Glioma [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D1SWN3
DRUGNAME	Afegostat
INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Discontinued in Phase 2
	
TTDDRUID	D1TED8
DRUGNAME	Reloxaliase
INDICATI	Hyperoxaluria [ICD-11: 5C51.2] Phase 3
	
TTDDRUID	D1TNJ2
DRUGNAME	XL092
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D1U3EG
DRUGNAME	MAb114
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 2/3
	
TTDDRUID	D1U4BC
DRUGNAME	BIIB-087
INDICATI	X-linked retinoschisis [ICD-11: 9B73.11] Phase 1/2
	
TTDDRUID	D1U5BA
DRUGNAME	Remestemcel-L
INDICATI	Crohn disease [ICD-11: DD70] Phase 3
INDICATI	Graft-versus-host disease [ICD-11: 4B24] Phase 3
	
TTDDRUID	D1UA2E
DRUGNAME	AM001
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2
	
TTDDRUID	D1W2DS
DRUGNAME	GEN3009
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
	
TTDDRUID	D1WB6Z
DRUGNAME	DSP-107
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D1WOX4
DRUGNAME	CT053
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D1X2VT
DRUGNAME	JNJ-56136379
INDICATI	Hepatitis B [ICD-11: 1E51] Phase 2
	
TTDDRUID	D1XI9E
DRUGNAME	BDC-1001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D1Y6RQ
DRUGNAME	NTU281
INDICATI	Renal fibrosis [ICD-11: GC01] Preclinical
	
TTDDRUID	D1YZ5O
DRUGNAME	CPI-818
INDICATI	T-cell lymphoma [ICD-11: 2A90] Phase 1
	
TTDDRUID	D1Z0IM
DRUGNAME	IMR-687
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 2
	
TTDDRUID	D1Z6TS
DRUGNAME	ONCR-177
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D1ZD0N
DRUGNAME	VMD-928
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D1ZG5E
DRUGNAME	OTSA-101-DTPA-90Y
INDICATI	Synovial sarcoma [ICD-11: 2B5A] Phase 1
	
TTDDRUID	D20IMG
DRUGNAME	LAM-003
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D20OCB
DRUGNAME	VAC52416
INDICATI	Escherichia coli infection [ICD-11: 1A03] Phase 1/2
	
TTDDRUID	D21OLD
DRUGNAME	BW-1010
INDICATI	Anthrax [ICD-11: 1B97] Phase 1
	
TTDDRUID	D23FRK
DRUGNAME	F26G3
INDICATI	Anthrax [ICD-11: 1B97] Preclinical
	
TTDDRUID	D24EPJ
DRUGNAME	CAT4001
INDICATI	Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Preclinical
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Preclinical
	
TTDDRUID	D24GYL
DRUGNAME	GS-6207
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2/3
	
TTDDRUID	D26DCA
DRUGNAME	RP2-001-18
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D27SXO
DRUGNAME	FMX-8
INDICATI	Anaemia [ICD-11: 3A90] Phase 2
	
TTDDRUID	D28EMJ
DRUGNAME	IW001
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 1
	
TTDDRUID	D28HJI
DRUGNAME	FF-10101
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	D28JEC
DRUGNAME	ATA3219
INDICATI	B-cell lymphoma [ICD-11: 2A86] Preclinical
	
TTDDRUID	D28MNU
DRUGNAME	CDX-527
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D28VIO
DRUGNAME	DNX-2440
INDICATI	Liver metastasis [ICD-11: 2D80] Phase 1
	
TTDDRUID	D2AYS0
DRUGNAME	PF-06473871
INDICATI	Hypertrophic scars [ICD-11: EE60] Phase 2
	
TTDDRUID	D2B7WM
DRUGNAME	Torin2
INDICATI	T-cell leukaemia [ICD-11: 2A90] Investigative
	
TTDDRUID	D2C0DY
DRUGNAME	SPL-108
INDICATI	Ovarian epithelial cancer [ICD-11: 2C73] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	D2CZR3
DRUGNAME	YE-NEO-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D2D9CN
DRUGNAME	Z-VAD-fmk
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Preclinical
	
TTDDRUID	D2DB5T
DRUGNAME	TBX-3400
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D2DLN9
DRUGNAME	5N,6S-(N'-butyliminomethylidene)-6-thio-1-deoxygalactonojirimycin
INDICATI	GM1 gangliosidosis [ICD-11: 5C56.00] Preclinical
	
TTDDRUID	D2F7JC
DRUGNAME	PZ-128
INDICATI	Peripheral arterial occlusive disorder [ICD-11: BD4Z] Phase 2
	
TTDDRUID	D2FCM4
DRUGNAME	VB 1953
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	D2G4HB
DRUGNAME	Bulevirtide
INDICATI	Hepatitis D virus infection [ICD-11: 1E51.2] Approved
	
TTDDRUID	D2GJ4P
DRUGNAME	TP-1287
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D2GV9Q
DRUGNAME	Salvianolic acid B
INDICATI	Vascular dementia [ICD-11: 6D81] Phase 2
	
TTDDRUID	D2GY5C
DRUGNAME	APVO436
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D2H4RZ
DRUGNAME	BMS-986263
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Phase 2
	
TTDDRUID	D2H5CI
DRUGNAME	RBX7455
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 1
	
TTDDRUID	D2H6NI
DRUGNAME	OBI-999
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D2HDB8
DRUGNAME	Mosunetuzumab
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
	
TTDDRUID	D2HE9I
DRUGNAME	TAK-169
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D2ITJ1
DRUGNAME	FPT155
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D2J4YT
DRUGNAME	211At-labelled aLAT-1
INDICATI	Multiple myeloma [ICD-11: 2A83] Preclinical
	
TTDDRUID	D2K6DU
DRUGNAME	P22077
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical
	
TTDDRUID	D2KA0W
DRUGNAME	GS-2872
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D2KB3W
DRUGNAME	ALLO-501
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D2KOX5
DRUGNAME	BMS-986301
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D2KV8B
DRUGNAME	AB-106
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 2
	
TTDDRUID	D2L8NT
DRUGNAME	TBR-760
INDICATI	Pituitary adenoma [ICD-11: 2F37.0] Phase 2
	
TTDDRUID	D2LUK7
DRUGNAME	PF-06936308
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1
	
TTDDRUID	D2MA0E
DRUGNAME	IONIS-TMPRSS6-LRx
INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 2
	
TTDDRUID	D2MZF8
DRUGNAME	TAK-102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D2NU0H
DRUGNAME	MAb173
INDICATI	Kaposi sarcoma [ICD-11: 2B57] Preclinical
	
TTDDRUID	D2OZ9D
DRUGNAME	CodaVax-H1N1
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	D2P8LR
DRUGNAME	AGEN1181
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D2PFY3
DRUGNAME	AMG 562
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1
	
TTDDRUID	D2Q0OI
DRUGNAME	CLBS14
INDICATI	Myocardial ischemia [ICD-11: BA6Z] Phase 2
	
TTDDRUID	D2Q3VY
DRUGNAME	Tepoditamab
INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1
	
TTDDRUID	D2QO5J
DRUGNAME	BMS-986012
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D2QY0Z
DRUGNAME	MCLA-145
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D2R0UM
DRUGNAME	Naratuximab emtansine
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	D2RTQ0
DRUGNAME	SB12
INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 3
	
TTDDRUID	D2SJZ9
DRUGNAME	EAPB0203
INDICATI	T-cell leukaemia [ICD-11: 2A90] Investigative
	
TTDDRUID	D2SPH4
DRUGNAME	IW-1701
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 2
	
TTDDRUID	D2TH1E
DRUGNAME	NasoShield
INDICATI	Anthrax [ICD-11: 1B97] Phase 1
	
TTDDRUID	D2U4RX
DRUGNAME	S109
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D2U5CW
DRUGNAME	GSK3228836
INDICATI	Hepatitis B [ICD-11: 1E51] Phase 2
	
TTDDRUID	D2V4YI
DRUGNAME	BI 891065
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D2V6BI
DRUGNAME	AV-1 mAb
INDICATI	Dengue [ICD-11: 1D20-1D2Z] Phase 1
	
TTDDRUID	D2V6MO
DRUGNAME	VXA-G1.1-NN
INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1
	
TTDDRUID	D2VRE1
DRUGNAME	NGM120
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D2WT8Y
DRUGNAME	V212
INDICATI	Herpes zoster [ICD-11: 1E91] Phase 3
	
TTDDRUID	D2Y7ZG
DRUGNAME	APG-2575
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1/2
	
TTDDRUID	D2Y9IG
DRUGNAME	JNJ-63898081
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D2YN1W
DRUGNAME	NKTR-255
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2
	
TTDDRUID	D2YT5I
DRUGNAME	ADP-A2M4
INDICATI	Synovial sarcoma [ICD-11: 2B5A] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D2Z6WF
DRUGNAME	CA-170
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D2Z7EL
DRUGNAME	CYAD-02
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D2ZI3H
DRUGNAME	BNC-102
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D30EUC
DRUGNAME	GSK3844766A
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D31NIC
DRUGNAME	PDS0101
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
	
TTDDRUID	D31ZLD
DRUGNAME	pbi-shRNA EWS-FLI-Type 1
INDICATI	Ewing sarcoma [ICD-11: 2B52] Phase 1
	
TTDDRUID	D32PZT
DRUGNAME	LY2382770
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
INDICATI	Diabetic kidney disease [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D32XRQ
DRUGNAME	BAY 853934
INDICATI	Anaemia [ICD-11: 3A90] Phase 3
	
TTDDRUID	D34CWV
DRUGNAME	EP-301
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D34SXJ
DRUGNAME	Avalglucosidase alfa
INDICATI	Pompe disease [ICD-11: 5C51.3] Phase 3
	
TTDDRUID	D35SKV
DRUGNAME	EPZ032597
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D37JBX
DRUGNAME	MK-0482
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D39VXL
DRUGNAME	JNJ-32729463
INDICATI	Community-acquired pneumonia [ICD-11: CA40.Z] Phase 2
	
TTDDRUID	D3AIE0
DRUGNAME	BMS-986141
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2
	
TTDDRUID	D3B1MS
DRUGNAME	ONC-392
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D3C9MX
DRUGNAME	JNJ-63682918
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 1/2
	
TTDDRUID	D3CG6E
DRUGNAME	MB-66
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 1
	
TTDDRUID	D3DPR8
DRUGNAME	Sleeping Beauty CAR-TCR
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	D3FYE1
DRUGNAME	M802
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D3G2BO
DRUGNAME	VIR-2482
INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 1
	
TTDDRUID	D3GD1L
DRUGNAME	Octahydrocurcumin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D3GIQ9
DRUGNAME	JNJ-67856633
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	D3HBJ1
DRUGNAME	GEN1046
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D3HBL2
DRUGNAME	MEDI7219
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D3HL1R
DRUGNAME	NT-I7
INDICATI	Progressive multifocal leukoencephalopathy [ICD-11: 8A45.02] Phase 1
	
TTDDRUID	D3IK7O
DRUGNAME	NYX-783
INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Phase 2
	
TTDDRUID	D3J9XC
DRUGNAME	Cemdisiran
INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 2
INDICATI	Haemolytic uraemic syndrome [ICD-11: 3A21.2] Phase 2
	
TTDDRUID	D3JN6C
DRUGNAME	GRN 1201
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D3JP7R
DRUGNAME	VE416
INDICATI	Food allergy [ICD-11: 4A85.2] Phase 1/2
	
TTDDRUID	D3KMC9
DRUGNAME	Elipovimab
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D3KZ4Y
DRUGNAME	OG2023SC
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D3KZ6M
DRUGNAME	LY2624587
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1
	
TTDDRUID	D3LT5W
DRUGNAME	ASP3772
INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2
	
TTDDRUID	D3LW8A
DRUGNAME	HXP124
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2
	
TTDDRUID	D3M6SN
DRUGNAME	ACHM-CNGA3
INDICATI	Achromatopsia [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	D3M7FK
DRUGNAME	CNSA-001
INDICATI	Gastroparesis [ICD-11: DA41.00] Phase 2
INDICATI	Hyperphenylalaninemia [ICD-11: 5C50] Phase 1/2
	
TTDDRUID	D3MG8L
DRUGNAME	PLX-R18
INDICATI	Acute radiation syndrome [ICD-11: NF00] Phase 3
	
TTDDRUID	D3MP1S
DRUGNAME	CS1001
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 3
	
TTDDRUID	D3N5TB
DRUGNAME	Apraglutide
INDICATI	Short bowel syndrome [ICD-11: KB89.1] Phase 3
	
TTDDRUID	D3NLJ9
DRUGNAME	Dusquetide
INDICATI	Oral cavity squamous cell carcinoma [ICD-11: 2B6E.0] Phase 3
INDICATI	Oral mucositis [ICD-11: DA01.11] Phase 3
	
TTDDRUID	D3NTA9
DRUGNAME	MK-8504
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D3OUH0
DRUGNAME	RX108
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D3OWG9
DRUGNAME	M1774
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D3P8JK
DRUGNAME	GC4711
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D3PD8C
DRUGNAME	AXS-05
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 3
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3
	
TTDDRUID	D3Q1OL
DRUGNAME	Debio1453
INDICATI	Neisseria gonorrhoeae infection [ICD-11: 1A7Z] Preclinical
	
TTDDRUID	D3Q4SZ
DRUGNAME	DTRMWXHS-12
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	D3QEZ2
DRUGNAME	LY3295668
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D3RT4A
DRUGNAME	SRP-9003
INDICATI	Limb girdle muscular dystrophy [ICD-11: 8C70.4] Phase 1/2
	
TTDDRUID	D3S2UY
DRUGNAME	GS-1156
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D3SPE5
DRUGNAME	BAY 1905254
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D3T7NY
DRUGNAME	CART-ddBCMA
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D3TW6X
DRUGNAME	ZEN003694
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D3U1LH
DRUGNAME	V158411
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D3U2QM
DRUGNAME	AST-VAC2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D3U8YR
DRUGNAME	WP1220
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1
	
TTDDRUID	D3UG0T
DRUGNAME	90Y-loaded glass microspheres
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Approved
	
TTDDRUID	D3W5TL
DRUGNAME	ABO-102
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2
	
TTDDRUID	D3X1TS
DRUGNAME	BAY 1902607
INDICATI	Cough [ICD-11: MD12] Phase 1/2
	
TTDDRUID	D3X2TH
DRUGNAME	TPI-287
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D3XYK2
DRUGNAME	VAC52150
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 3
	
TTDDRUID	D3ZN5U
DRUGNAME	Axatilamab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D3ZY1K
DRUGNAME	ARV-110
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D40DVS
DRUGNAME	SR9009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D41OJE
DRUGNAME	BTL-TML
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D42TUS
DRUGNAME	Telisotuzumab vedotin
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	D43ADF
DRUGNAME	P-007
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Preclinical
INDICATI	Renal fibrosis [ICD-11: GC01] Preclinical
	
TTDDRUID	D43GZX
DRUGNAME	SAR566658
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	D46EBX
DRUGNAME	VCB101
INDICATI	Multiple sclerosis [ICD-11: 8A40] Preclinical
	
TTDDRUID	D46RKC
DRUGNAME	Fitusiran
INDICATI	Hemophilia [ICD-11: 3B10.0] Phase 3
	
TTDDRUID	D47MOS
DRUGNAME	Alofanib
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
	
TTDDRUID	D47RIS
DRUGNAME	OTL-101
INDICATI	Severe combined immunodeficiency [ICD-11: 4A01.10] Phase 3
	
TTDDRUID	D48MDS
DRUGNAME	HPN424
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D48UEV
DRUGNAME	IGM-8444
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D48ZBO
DRUGNAME	FOR46
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D49AGF
DRUGNAME	CB7993113
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D49YEO
DRUGNAME	ABI-H3733
INDICATI	Hepatitis B [ICD-11: 1E51] Phase 1
	
TTDDRUID	D4A2DQ
DRUGNAME	SAGE-324
INDICATI	Essential tremor or related tremors [ICD-11: 8A04.1] Phase 2
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D4AGB6
DRUGNAME	Voyager-V1
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 2
	
TTDDRUID	D4AY6B
DRUGNAME	SUVN 911
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
	
TTDDRUID	D4BC6I
DRUGNAME	RG7827
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D4CGN3
DRUGNAME	RG6139
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D4D0XY
DRUGNAME	M2SR
INDICATI	Influenza A virus H3N2 infection [ICD-11: 1E30] Phase 2
	
TTDDRUID	D4DK2R
DRUGNAME	DBI-001
INDICATI	Tinea pedis [ICD-11: 1F28.2] Phase 2
	
TTDDRUID	D4H2CP
DRUGNAME	Ceftobiprole medocaril
INDICATI	Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Phase 3
	
TTDDRUID	D4HDR2
DRUGNAME	LVGN6051
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D4HQ1F
DRUGNAME	Zolbetuximab
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
INDICATI	Esophagogastric junction neoplasm [ICD-11: 2B71] Phase 3
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D4IS0G
DRUGNAME	GLR2007
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 1/2
	
TTDDRUID	D4IWF1
DRUGNAME	AAV-AQP1
INDICATI	Xerostomia [ICD-11: DA02.1] Phase 1/2
	
TTDDRUID	D4J9HV
DRUGNAME	ABBV-011
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D4JPV8
DRUGNAME	MER5101
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	D4JS3A
DRUGNAME	Cu-anti-hAXL
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical
	
TTDDRUID	D4JU8H
DRUGNAME	MK-2118
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D4JV0H
DRUGNAME	ASP1948
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D4JYH3
DRUGNAME	FPI-1434
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D4K2CQ
DRUGNAME	DP-3975
INDICATI	Mesothelioma [ICD-11: 2C51.2] Preclinical
	
TTDDRUID	D4K7BI
DRUGNAME	DPK 060
INDICATI	Otitis externa [ICD-11: AA00-AA13] Phase 2
	
TTDDRUID	D4KTA9
DRUGNAME	INCAGN2385
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D4L3IZ
DRUGNAME	Sym022
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D4LJO1
DRUGNAME	RGN-137
INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Phase 2
	
TTDDRUID	D4LJO9
DRUGNAME	CLG561
INDICATI	Geographic retinal atrophy [ICD-11: 9B78.9] Phase 2
	
TTDDRUID	D4LOR2
DRUGNAME	Tebipenem pivoxil
INDICATI	Respiratory tract infection [ICD-11: CA45] Approved
	
TTDDRUID	D4M0GR
DRUGNAME	CNX-011-67
INDICATI	Type 2 diabetes [ICD-11: 5A11] Preclinical
	
TTDDRUID	D4M8RS
DRUGNAME	TNP-2092
INDICATI	Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Phase 2
INDICATI	Joint infection [ICD-11: FA10] Phase 1
	
TTDDRUID	D4MO2K
DRUGNAME	Granexin
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
	
TTDDRUID	D4MW3O
DRUGNAME	MK-8776
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 1
	
TTDDRUID	D4N2JV
DRUGNAME	PRX002
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D4N7TE
DRUGNAME	mRNA-1944
INDICATI	Chikungunya virus infection [ICD-11: 1D40] Phase 1
	
TTDDRUID	D4ON2Y
DRUGNAME	mRNA-1893
INDICATI	Zika virus infection [ICD-11: 1D48] Phase 1
	
TTDDRUID	D4OU6H
DRUGNAME	Rivo-cel
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2/3
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2/3
	
TTDDRUID	D4OZC7
DRUGNAME	Suvodirsen
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2/3
	
TTDDRUID	D4P8YO
DRUGNAME	AB023
INDICATI	End-stage renal disease [ICD-11: GB61.5] Phase 1
	
TTDDRUID	D4PG6A
DRUGNAME	Nobiletin
INDICATI	Atherosclerosis [ICD-11: BD40] Preclinical
	
TTDDRUID	D4PL6G
DRUGNAME	BNV-222
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2/3
	
TTDDRUID	D4PV0B
DRUGNAME	AGN-242266
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1
	
TTDDRUID	D4Q5AW
DRUGNAME	Beraprost
INDICATI	Pulmonary hypertension [ICD-11: BB01] Phase 4
	
TTDDRUID	D4RD0C
DRUGNAME	Bamosiran
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
	
TTDDRUID	D4RGV9
DRUGNAME	2-Ethoxypropanoic acid
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical
	
TTDDRUID	D4RMB0
DRUGNAME	3PO
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Investigative
	
TTDDRUID	D4TI9A
DRUGNAME	JNJ-69086420
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	D4UFT5
DRUGNAME	2-D08
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical
	
TTDDRUID	D4USX5
DRUGNAME	9-ING-41
INDICATI	Myelofibrosis [ICD-11: 2A20.2] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D4V0SI
DRUGNAME	MS2177
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D4VBY6
DRUGNAME	Bafilomycin A1
INDICATI	B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Investigative
	
TTDDRUID	D4VZ2A
DRUGNAME	TT-00420
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D4WN2M
DRUGNAME	APG-1252
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D4X9MD
DRUGNAME	9-(Ethoxyimino)-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D4XBR9
DRUGNAME	Pozelimab
INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 2
	
TTDDRUID	D4Y0IM
DRUGNAME	INCB054329
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Refractory hematologic malignancy [ICD-11: 2A85.5] Phase 1/2
	
TTDDRUID	D4Y0SB
DRUGNAME	Vonvendi
INDICATI	Von willebrand disease [ICD-11: 3B12] Approved
	
TTDDRUID	D4Z5CU
DRUGNAME	M710
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 3
	
TTDDRUID	D4ZLC2
DRUGNAME	RXI-109
INDICATI	Fibrosis [ICD-11: GA14-GC01] Phase 2
INDICATI	Hypertrophic scars [ICD-11: EE60] Phase 2
	
TTDDRUID	D50CXM
DRUGNAME	PRT1419
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D50ESV
DRUGNAME	Polivy
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2
	
TTDDRUID	D50NHR
DRUGNAME	YW327.6S2
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Preclinical
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Preclinical
	
TTDDRUID	D50OLM
DRUGNAME	INCB00928
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 2
	
TTDDRUID	D51HBQ
DRUGNAME	CD20-CD19 cCAR
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D51VYQ
DRUGNAME	514G3
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 1/2
	
TTDDRUID	D52NOH
DRUGNAME	BNT411
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	D52NZX
DRUGNAME	Belantamab mafodotin
INDICATI	Multiple myeloma [ICD-11: 2A83] Approved
	
TTDDRUID	D53CGK
DRUGNAME	PC14586
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D53CMU
DRUGNAME	Methylselenocysteine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Clinical Trial
INDICATI	Prostate cancer [ICD-11: 2C82.0] Clinical Trial
	
TTDDRUID	D53QMP
DRUGNAME	Beta-caryophyllene
INDICATI	Pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	D54FYW
DRUGNAME	TPST-1495
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D56ERU
DRUGNAME	INBRX-109
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D56WJV
DRUGNAME	AAV-CNGB3
INDICATI	Achromatopsia [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	D58AMF
DRUGNAME	ABBV-CX-2029
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D59BZJ
DRUGNAME	177Lu-labelled RM2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D59OTG
DRUGNAME	OBI-888
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D5AV3Q
DRUGNAME	AT-527
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	D5BMY9
DRUGNAME	TMX-049
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D5CP3S
DRUGNAME	SV-BR-1-GM cancer vaccine
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D5D6ZM
DRUGNAME	IK-175
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 1
	
TTDDRUID	D5DAR1
DRUGNAME	LYS-SAF302
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 2/3
	
TTDDRUID	D5DBU7
DRUGNAME	CarVAC
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D5DO9L
DRUGNAME	Brolucizumab
INDICATI	Wet age-related macular degeneration [ICD-11: 9B78.3Z] Approved
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 3
	
TTDDRUID	D5EOV9
DRUGNAME	ABBV-CLS-579
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D5FCP1
DRUGNAME	TTI-622
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D5FSV8
DRUGNAME	TRx0237
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 3
	
TTDDRUID	D5GI0O
DRUGNAME	VIMO-001
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D5I3MF
DRUGNAME	GRL0617
INDICATI	Coronavirus infection [ICD-11: 1D92] Preclinical
	
TTDDRUID	D5IS6V
DRUGNAME	Abametapir
INDICATI	Head and body lice [ICD-11: 1G00.0] Approved
	
TTDDRUID	D5ISZ1
DRUGNAME	NKTR-214
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D5IZ1S
DRUGNAME	BI 685509
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	D5J3BL
DRUGNAME	Bintrafusp alfa
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 2
	
TTDDRUID	D5JVD6
DRUGNAME	ALLO-ASC-DFU
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
	
TTDDRUID	D5KIL8
DRUGNAME	RG6290
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D5LB7Y
DRUGNAME	RG6346
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	D5MF8Y
DRUGNAME	Lithium
INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 2
	
TTDDRUID	D5OEL4
DRUGNAME	212Pb-labelled aTEM1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D5ON9Z
DRUGNAME	ASP9831
INDICATI	Steatohepatitis [ICD-11: DB92] Phase 2
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2
	
TTDDRUID	D5P3SI
DRUGNAME	STP1002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D5Q6FS
DRUGNAME	MPC-25-IC
INDICATI	Acute cardiac ischemia [ICD-11: BA4Z] Phase 2
	
TTDDRUID	D5R6AG
DRUGNAME	ATI-2173
INDICATI	Hepatitis B [ICD-11: 1E51] Phase 2
	
TTDDRUID	D5R7AE
DRUGNAME	Piperlongumine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D5S7JL
DRUGNAME	ODN-1411
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	D5T1RN
DRUGNAME	BAY 1834942
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D5T3OY
DRUGNAME	DPX Survivac
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
	
TTDDRUID	D5T6DY
DRUGNAME	AMG 404
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D5T7QW
DRUGNAME	LX2761
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D5T9GZ
DRUGNAME	CLL1-CD33 cCART cell therapy
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D5TH2B
DRUGNAME	PF-07104091
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1
	
TTDDRUID	D5V2HR
DRUGNAME	IBI188
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D5VE7C
DRUGNAME	SAR442085
INDICATI	Plasma cell myeloma [ICD-11: 2A83.1] Phase 1
	
TTDDRUID	D5VMP4
DRUGNAME	BTX-A51
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D5VRX2
DRUGNAME	Dociparstat sodium
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	D5W7BG
DRUGNAME	M012
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 1
INDICATI	Thalassemia [ICD-11: 3A50] Phase 1
	
TTDDRUID	D5WAG1
DRUGNAME	DTX401
INDICATI	Pompe disease [ICD-11: 5C51.3] Phase 1
	
TTDDRUID	D5WB0F
DRUGNAME	RG6279
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D5WU7B
DRUGNAME	CEND-1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D5XV9K
DRUGNAME	PF-06882961
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	D5Y3NP
DRUGNAME	Donislecel
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 3
	
TTDDRUID	D5YN8U
DRUGNAME	ALLO-715
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D60SWR
DRUGNAME	VAC89220
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3
	
TTDDRUID	D61LJZ
DRUGNAME	RiMO-301
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D62FLA
DRUGNAME	BHQ880
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	D62LKT
DRUGNAME	BI 836880
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1
	
TTDDRUID	D63QIY
DRUGNAME	ABBV-467
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D63WMQ
DRUGNAME	Ingrezza
INDICATI	Tardive dyskinesia [ICD-11: 8A02.10] Phase 4
INDICATI	Tourette syndrome [ICD-11: 8A05.00] Phase 2
	
TTDDRUID	D64FNH
DRUGNAME	SAR441236
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	D65IMT
DRUGNAME	MS1943
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	D67AKN
DRUGNAME	PXL-770
INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 2
	
TTDDRUID	D67IRW
DRUGNAME	DF6002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D67ZDJ
DRUGNAME	PHE885
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D68DPH
DRUGNAME	IOV-2001
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1/2
	
TTDDRUID	D68PVB
DRUGNAME	PD01A
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	D68RMI
DRUGNAME	CLN-081
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D69KBS
DRUGNAME	ASP7317
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 1
	
TTDDRUID	D6AHO2
DRUGNAME	LY3410738
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D6CV1Q
DRUGNAME	TG4050
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D6CZ0T
DRUGNAME	CPL207-280CA
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	D6DPI4
DRUGNAME	ABI-H2158
INDICATI	Hepatitis B [ICD-11: 1E51] Phase 2
	
TTDDRUID	D6DR8F
DRUGNAME	INO-4201
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Phase 1
	
TTDDRUID	D6DT3X
DRUGNAME	Sitafloxacin
INDICATI	Escherichia coli infection [ICD-11: 1A03] Phase 2
	
TTDDRUID	D6EI9F
DRUGNAME	NEXI-002
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D6EQ3X
DRUGNAME	MV-CHIK
INDICATI	Chikungunya virus infection [ICD-11: 1D40] Phase 2
	
TTDDRUID	D6ETD2
DRUGNAME	PTI-125
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	D6EU7R
DRUGNAME	HH2853
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D6FNV9
DRUGNAME	IXT-m200
INDICATI	Methamphetamine use disorder [ICD-11: 6C46] Phase 2
	
TTDDRUID	D6FTN1
DRUGNAME	ABSK021
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D6FX2G
DRUGNAME	VIC-1911
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D6H9TE
DRUGNAME	SEA-CD70
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D6INZ9
DRUGNAME	ATI-501
INDICATI	Alopecia [ICD-11: ED70] Phase 2
	
TTDDRUID	D6IOB5
DRUGNAME	BAY 2701439
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D6JM8Z
DRUGNAME	SI-B001
INDICATI	Metastatic epithelial tumour [ICD-11: 2D60] Phase 1
	
TTDDRUID	D6MEX0
DRUGNAME	ALN-TMP
INDICATI	Beta thalassemia [ICD-11: 3A50.2] Preclinical
	
TTDDRUID	D6N5UC
DRUGNAME	ATI-502
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	Alopecia [ICD-11: ED70] Phase 2
	
TTDDRUID	D6N8UJ
DRUGNAME	NAM-NK cells
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	D6O2PN
DRUGNAME	ATIR101
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3
	
TTDDRUID	D6ONY2
DRUGNAME	KUR-502
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D6P9OU
DRUGNAME	ONC206
INDICATI	Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 1
	
TTDDRUID	D6PRE7
DRUGNAME	GRL001
INDICATI	Coronavirus infection [ICD-11: 1D92] Preclinical
	
TTDDRUID	D6Q4TS
DRUGNAME	JNJ-66684657
INDICATI	Zika virus infection [ICD-11: 1D48] Phase 1
	
TTDDRUID	D6Q5MG
DRUGNAME	JNJ-74494550
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D6QA4N
DRUGNAME	S-(2-Aminophenyl)-L-cysteine S,S-dioxide
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical
	
TTDDRUID	D6QO5V
DRUGNAME	CPI-100
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D6QRJ2
DRUGNAME	RG6115
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
	
TTDDRUID	D6SL3N
DRUGNAME	Zenocutuzomab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D6VLX2
DRUGNAME	JNJ-42905343
INDICATI	Anaemia [ICD-11: 3A90] Preclinical
INDICATI	Iron deficiency [ICD-11: 5B5K.0] Preclinical
	
TTDDRUID	D6W2MF
DRUGNAME	ST-400
INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 1/2
	
TTDDRUID	D6X7KR
DRUGNAME	SR-T100
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 3
	
TTDDRUID	D6XMS1
DRUGNAME	DTX301
INDICATI	Ornithine transcarbamylase deficiency [ICD-11: 5C50.AY] Phase 1/2
	
TTDDRUID	D6XS7L
DRUGNAME	BMS-986315
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D6YB1E
DRUGNAME	CDK-002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D6YD0X
DRUGNAME	Tilsotolimod
INDICATI	Melanoma [ICD-11: 2C30] Phase 3
	
TTDDRUID	D6Z3HR
DRUGNAME	MV-012-968
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D70HIN
DRUGNAME	CCT251545
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Preclinical
	
TTDDRUID	D70SHJ
DRUGNAME	mRNA-2416
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D72HXF
DRUGNAME	EB8018
INDICATI	Crohn disease [ICD-11: DD70] Phase 2
	
TTDDRUID	D72UDH
DRUGNAME	OXB-102
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1/2
	
TTDDRUID	D73ZML
DRUGNAME	T3011
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D74BRK
DRUGNAME	BGB-11417
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D74ZUI
DRUGNAME	GSK3903133A
INDICATI	Rabies [ICD-11: 1C82] Phase 1
	
TTDDRUID	D75LNO
DRUGNAME	BMS-986299
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D76INB
DRUGNAME	Tesidolumab
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2
	
TTDDRUID	D76PDV
DRUGNAME	BI 425809
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 3
	
TTDDRUID	D79HBK
DRUGNAME	NBE-002
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D79JZU
DRUGNAME	FT538
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D7AFK9
DRUGNAME	KUR-501
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 1
	
TTDDRUID	D7AOL8
DRUGNAME	BNT321
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	D7BF8Y
DRUGNAME	BMS-986288
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D7C3JA
DRUGNAME	UCART-22
INDICATI	B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 1
	
TTDDRUID	D7CE6N
DRUGNAME	AB680
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D7CI5F
DRUGNAME	C-178
INDICATI	Aicardi-Goutieres syndrome [ICD-11: 5C55.2] Investigative
	
TTDDRUID	D7CWQ0
DRUGNAME	RG6286
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	D7EZ0H
DRUGNAME	CG0070
INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 3
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
	
TTDDRUID	D7FJQ3
DRUGNAME	INCB057643
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D7FPZ4
DRUGNAME	A-337
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D7GQR3
DRUGNAME	CPK850
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	D7HLI1
DRUGNAME	Valoctocogene roxaparvovec
INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 3
	
TTDDRUID	D7HZ3T
DRUGNAME	RXDX-106
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D7I9JH
DRUGNAME	Dichloroacetate
INDICATI	Insulin-resistant disorder [ICD-11: 5A44] Phase 4
INDICATI	Pyruvate dehydrogenase complex deficiency [ICD-11: 5C53.02] Phase 3
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Phase 1
	
TTDDRUID	D7IA0N
DRUGNAME	AMG 757
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1
	
TTDDRUID	D7J2NK
DRUGNAME	TTX-080
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D7K0GP
DRUGNAME	PT630
INDICATI	Lung cancer [ICD-11: 2C25.0] Preclinical
INDICATI	Colon cancer [ICD-11: 2B90.Z] Preclinical
	
TTDDRUID	D7K3FB
DRUGNAME	CPX-POM
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D7K5XP
DRUGNAME	NEO-201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D7L1MP
DRUGNAME	MEDI5752
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1
	
TTDDRUID	D7L8JC
DRUGNAME	DpC
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D7LC8N
DRUGNAME	MIK665
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D7LN0E
DRUGNAME	TNB-486
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D7LQJ8
DRUGNAME	PX-102
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Phase 1
	
TTDDRUID	D7LU8R
DRUGNAME	PBCAR269A
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	D7M3JN
DRUGNAME	Disufenton
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D7M8LI
DRUGNAME	TPX-0022
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D7NEV4
DRUGNAME	PXL01
INDICATI	Scar tissue [ICD-11: QB83] Phase 2
	
TTDDRUID	D7PVH4
DRUGNAME	LPN023
INDICATI	IgA nephropathy [ICD-11: MF8Y] Phase 2
	
TTDDRUID	D7QHV6
DRUGNAME	ABBV-184
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D7RK2M
DRUGNAME	THZ531
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	D7S9LP
DRUGNAME	Somapacitan
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Approved
	
TTDDRUID	D7SJE2
DRUGNAME	MVA-BN WEV vaccine
INDICATI	Encephalitis virus infection [ICD-11: 1C83-1C84] Phase 1
	
TTDDRUID	D7T5AN
DRUGNAME	CMP-001
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D7TA4P
DRUGNAME	PF-06826647
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	D7TB6I
DRUGNAME	ZIKV-IG
INDICATI	Zika virus infection [ICD-11: 1D48] Phase 1
	
TTDDRUID	D7TIB0
DRUGNAME	RS2-1G9
INDICATI	Pseudomonas infection [ICD-11: 1B92] Preclinical
	
TTDDRUID	D7TV5I
DRUGNAME	MK-4280
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D7UIZ1
DRUGNAME	BGB-A425
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2
	
TTDDRUID	D7W6SO
DRUGNAME	IMT1012
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	D7WOL5
DRUGNAME	COM701
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D7X8AQ
DRUGNAME	M3258
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D7XB0Q
DRUGNAME	SEP-378614
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 1
	
TTDDRUID	D7XE8J
DRUGNAME	VLA84
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2
	
TTDDRUID	D7XNQ1
DRUGNAME	Exeporfinium chloride
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 2
	
TTDDRUID	D7Z1CR
DRUGNAME	TP-3654
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D7ZXE5
DRUGNAME	Beta-aminopropionitrile
INDICATI	Cardiac arrest [ICD-11: MC82] Preclinical
	
TTDDRUID	D80OLH
DRUGNAME	CPI-200
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D81AQG
DRUGNAME	AMG 890
INDICATI	Cardiac fibrosis [ICD-11: DB98.8] Phase 2
	
TTDDRUID	D81KMY
DRUGNAME	Neupro
INDICATI	Restless legs syndrome [ICD-11: 7A80] Phase 4
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	D81YIK
DRUGNAME	WVT078
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	D81YNE
DRUGNAME	CFI-402257
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D82COK
DRUGNAME	FLU-IGIV
INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2
	
TTDDRUID	D82DGN
DRUGNAME	JT08
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D82DMK
DRUGNAME	LM11A-31
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1/2
	
TTDDRUID	D82GST
DRUGNAME	JNJ-65195208
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 1/2
	
TTDDRUID	D82UVG
DRUGNAME	ALPN-202
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D83YSR
DRUGNAME	680C91
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D84EGX
DRUGNAME	AT-342
INDICATI	Crigler-Najjar syndrome [ICD-11: 5C58.00] Phase 1/2
	
TTDDRUID	D85NEG
DRUGNAME	BAY 2253651
INDICATI	Obstructive sleep apnea [ICD-11: 7A41] Phase 2
	
TTDDRUID	D86ALC
DRUGNAME	SBX-101
INDICATI	Intestinal toxicities from therapy [ICD-11: DA94.1 ] Preclinical
	
TTDDRUID	D86ILE
DRUGNAME	SPHINX31
INDICATI	Wet age-related macular degeneration [ICD-11: 9B78.3Z] Preclinical
	
TTDDRUID	D87KMZ
DRUGNAME	ISA101
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2
	
TTDDRUID	D87PWZ
DRUGNAME	IPH5201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D87TMY
DRUGNAME	OT-58
INDICATI	Homocystinuria [ICD-11: 5C50.B] Phase 1/2
	
TTDDRUID	D89XBL
DRUGNAME	STMC-103H
INDICATI	Allergic rhinitis [ICD-11: CA08.0] Phase 1
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 1
	
TTDDRUID	D8AF1M
DRUGNAME	OPC-167832
INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 1/2
	
TTDDRUID	D8AG3S
DRUGNAME	Vorolanib
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 2
	
TTDDRUID	D8AI0N
DRUGNAME	ATA3271
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
INDICATI	Mesothelioma [ICD-11: 2C51.2] Preclinical
	
TTDDRUID	D8AOC1
DRUGNAME	AMG 330
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D8B9KJ
DRUGNAME	Jivi
INDICATI	Haemophilia A [ICD-11: 3B10.0] Approved
	
TTDDRUID	D8BJX5
DRUGNAME	TAEK-VAC-HerBy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D8CFX3
DRUGNAME	REGN6569
INDICATI	Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 1
	
TTDDRUID	D8CJE9
DRUGNAME	Norketotifen
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	D8D1MI
DRUGNAME	MDR-101
INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 3
	
TTDDRUID	D8DJX0
DRUGNAME	OBT076
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	D8EB7G
DRUGNAME	eFT226
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D8EIB7
DRUGNAME	MCY-M11
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
INDICATI	Peritoneal cancer [ICD-11: 2C51.Z] Phase 1
INDICATI	Fallopian tube cancer [ICD-11: 2C74] Phase 1
INDICATI	Peritoneal mesothelioma [ICD-11: 2C51.2] Phase 1
	
TTDDRUID	D8F6PB
DRUGNAME	FKB238
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	D8FJ9K
DRUGNAME	XmAb23104
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D8GN2C
DRUGNAME	TRN-148
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Clinical Trial
	
TTDDRUID	D8IQ0D
DRUGNAME	ME-401
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
	
TTDDRUID	D8JN5H
DRUGNAME	NKTR-262
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	D8L5PA
DRUGNAME	Loncastuximab tesirine
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
	
TTDDRUID	D8MS6C
DRUGNAME	BGB-15025
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D8OJX6
DRUGNAME	SO-C101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D8PE7D
DRUGNAME	AVB-500
INDICATI	IgA nephropathy [ICD-11: MF8Y] Phase 2
	
TTDDRUID	D8RN3B
DRUGNAME	JNJ-63682931
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 1/2
	
TTDDRUID	D8SO5T
DRUGNAME	RNS60
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 2
	
TTDDRUID	D8SV9R
DRUGNAME	DNX-2401
INDICATI	Brain cancer [ICD-11: 2A00] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D8TE4F
DRUGNAME	AMXI 5001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D8U2EM
DRUGNAME	PVX-2
INDICATI	Human papillomavirus infection [ICD-11: 1A9Y] Phase 2
	
TTDDRUID	D8UNG2
DRUGNAME	TG-1801
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	D8UZ5R
DRUGNAME	NBF-006
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	D8UZM7
DRUGNAME	REGN5678
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	D8VH5Q
DRUGNAME	ML209
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Preclinical
	
TTDDRUID	D8VJT5
DRUGNAME	ZEN-3694
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D8W1DJ
DRUGNAME	[153Sm]CycloSam
INDICATI	Osteosarcoma [ICD-11: 2B51] Phase 1
	
TTDDRUID	D8WBZ2
DRUGNAME	PMID25197057-Compound6e
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Preclinical
	
TTDDRUID	D8XHT1
DRUGNAME	RGX-111
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1
	
TTDDRUID	D8XK7F
DRUGNAME	RGLS4326
INDICATI	Autosomal dominant polycystic kidney disease [ICD-11: GB81] Phase 1
	
TTDDRUID	D8ZNW0
DRUGNAME	MDR-102
INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 2
	
TTDDRUID	D8ZV2Q
DRUGNAME	FCN-437
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	D90GKY
DRUGNAME	PrabotulinumtoxinA
INDICATI	Glabellar frown line [ICD-11: NA0Z] Approved
	
TTDDRUID	D90UZW
DRUGNAME	Ad-RTS-hIL-12
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 2
INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D91CMX
DRUGNAME	AMG 427
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D92KBX
DRUGNAME	RG6217
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	D92KUQ
DRUGNAME	ARN-6039
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	D93JXG
DRUGNAME	Somatrogon
INDICATI	Growth hormone deficiency [ICD-11: 5A61.3] Phase 3
	
TTDDRUID	D93TWL
DRUGNAME	GSK3389245A
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	D94NTP
DRUGNAME	GSK3277511A
INDICATI	Respiratory tract disease [ICD-11: CB7Z] Phase 2
	
TTDDRUID	D95GKC
DRUGNAME	BCL11a shRNA
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 1
	
TTDDRUID	D95KWS
DRUGNAME	KL001
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Preclinical
	
TTDDRUID	D95YSW
DRUGNAME	BPI-9016 M
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D96DPA
DRUGNAME	ECT-001
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 2
	
TTDDRUID	D96XNU
DRUGNAME	3VM1001
INDICATI	Postherpetic neuralgia [ICD-11: 1E91.5] Phase 1/2
INDICATI	Knee osteoarthritis [ICD-11: FA01] Phase 1/2
	
TTDDRUID	D97YGW
DRUGNAME	SNDX-5613
INDICATI	T lymphoblastic leukaemia [ICD-11: 2B33.4] Phase 1/2
	
TTDDRUID	D98FBH
DRUGNAME	DN1508052
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D98UXE
DRUGNAME	NNZ-2256
INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 2
	
TTDDRUID	D98VPM
DRUGNAME	MS-553
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	D9CI7V
DRUGNAME	Donaperminogene seltoplasmid
INDICATI	Diabetic foot ulcer [ICD-11: BD54] Phase 3
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 3
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1/2
	
TTDDRUID	D9D6QN
DRUGNAME	SR1078
INDICATI	Liver cancer [ICD-11: 2C12] Preclinical
	
TTDDRUID	D9DN5J
DRUGNAME	RG6076
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	D9DQ1I
DRUGNAME	BI 905681
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D9DS8O
DRUGNAME	NDV-3A
INDICATI	Vulvovaginal Candidiasis [ICD-11: 1F23.10] Phase 2
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Phase 2
INDICATI	Candidiasis [ICD-11: 1F23] Phase 1/2
	
TTDDRUID	D9E6KQ
DRUGNAME	Copper dotatate Cu-64
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	D9EC0G
DRUGNAME	Zemaira
INDICATI	Emphysema [ICD-11: CA21] Approved
	
TTDDRUID	D9EGS5
DRUGNAME	ITI-1000
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	D9FGB3
DRUGNAME	AMG 119
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	D9FJ5V
DRUGNAME	BDTX-189
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D9FT0A
DRUGNAME	R552
INDICATI	Nervous system paraneoplastic or autoimmune disorders [ICD-11: 8E4A.1] Phase 1
	
TTDDRUID	D9FZN0
DRUGNAME	SG-2-0776
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Preclinical
	
TTDDRUID	D9HY7D
DRUGNAME	SVV-001
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 2
	
TTDDRUID	D9HYU8
DRUGNAME	Reltecimod
INDICATI	Necrotizing soft tissue infection [ICD-11: 1B71] Phase 3
	
TTDDRUID	D9I3WE
DRUGNAME	SYN120
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	D9ILC1
DRUGNAME	PD98059
INDICATI	Cardiac arrest [ICD-11: MC82] Investigative
	
TTDDRUID	D9IQ6N
DRUGNAME	TJ4309
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D9J4ZI
DRUGNAME	JNJ-64213175
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1/2
	
TTDDRUID	D9J6XV
DRUGNAME	Vobarilizumab
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 2
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	D9JHN4
DRUGNAME	INV-1120
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D9L2WN
DRUGNAME	PEP-CMV
INDICATI	Medulloblastoma [ICD-11: 2A00.10] Phase 1
INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	D9LA6Q
DRUGNAME	COM902
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D9LT5G
DRUGNAME	CV301
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
	
TTDDRUID	D9M0KJ
DRUGNAME	SRF617
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D9M8FK
DRUGNAME	SRP-9001
INDICATI	Duchenne dystrophy [ICD-11: 8C70] Phase 2
	
TTDDRUID	D9MT4S
DRUGNAME	CA-074Me
INDICATI	Cardiac arrest [ICD-11: MC82] Preclinical
INDICATI	Pulmonary fibrosis [ICD-11: CB03.4] Preclinical
INDICATI	Cystic fibrosis [ICD-11: CA25] Preclinical
	
TTDDRUID	D9MWL4
DRUGNAME	Faricimab
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 3
	
TTDDRUID	D9NJS5
DRUGNAME	INO-5151
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	D9NL3R
DRUGNAME	Trebananib
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D9O7GC
DRUGNAME	GTB-3550
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
INDICATI	Systemic mastocytosis [ICD-11: 2A21.0] Phase 1/2
INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1/2
INDICATI	Mast cell leukaemia [ICD-11: 2A21.00] Phase 1/2
	
TTDDRUID	D9OMQ3
DRUGNAME	GEN3013
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1/2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
	
TTDDRUID	D9OQ6R
DRUGNAME	VAX014
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 1
	
TTDDRUID	D9OS5I
DRUGNAME	SB623
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 2
	
TTDDRUID	D9OZ3B
DRUGNAME	JNJ-67571244
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	D9P8LE
DRUGNAME	RG70099
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D9PBQ8
DRUGNAME	PF-04859989
INDICATI	Cognitive impairment [ICD-11: 6D71] Preclinical
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	D9Q5UP
DRUGNAME	TBA-354
INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 1
	
TTDDRUID	D9RH0V
DRUGNAME	DCC-3014
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	D9S1KL
DRUGNAME	TS-161
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2
	
TTDDRUID	D9S7XO
DRUGNAME	DN1406131
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D9SL1N
DRUGNAME	TAK-252
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D9SMC5
DRUGNAME	C30
INDICATI	Pseudomonas infection [ICD-11: 1B92] Preclinical
	
TTDDRUID	D9SMF2
DRUGNAME	KVD824
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	D9TG4H
DRUGNAME	JNJ-63709178
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	D9U5LY
DRUGNAME	REGN3051
INDICATI	Coronavirus infection [ICD-11: 1D92] Phase 1
	
TTDDRUID	D9UDT8
DRUGNAME	ASP2397
INDICATI	Invasive pulmonary aspergillosis [ICD-11: 1F20.0] Phase 2
	
TTDDRUID	D9UGX7
DRUGNAME	Encequidar
INDICATI	Metastatic breast cancer [ICD-11: 2C6Y] Phase 2
	
TTDDRUID	D9UZ5Q
DRUGNAME	NC318
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 2
	
TTDDRUID	D9WQD2
DRUGNAME	V114
INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 3
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	D9Y2KA
DRUGNAME	4-(4-fluoropyrazol-1-yl)-1,2-oxazol-5-amine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	D9Y8OG
DRUGNAME	CEVA101
INDICATI	Traumatic brain injury [ICD-11: NA07.Z] Phase 2
	
TTDDRUID	D9Y8ZU
DRUGNAME	BI 905711
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D9YG4P
DRUGNAME	APX3330
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	D9ZEM7
DRUGNAME	HPP971
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1
	
TTDDRUID	D9ZQ7T
DRUGNAME	VYR 006
INDICATI	Toxoplasmosis [ICD-11: 1F57] Phase 1
	
TTDDRUID	DA01IB
DRUGNAME	MTL-CEPBA
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
	
TTDDRUID	DA02DE
DRUGNAME	BGB-10188
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	DA08WU
DRUGNAME	EDP-938
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	DA0OZ2
DRUGNAME	HBX19818
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DA1L7V
DRUGNAME	AADvac-1
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	DA1MG8
DRUGNAME	ONO-7475
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
INDICATI	Acute leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	DA1X5W
DRUGNAME	INBRX-105
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DA37BQ
DRUGNAME	Jynneos
INDICATI	Monkeypox virus infection [ICD-11: 1E71] Phase 3
	
TTDDRUID	DA3F2X
DRUGNAME	TP-6076
INDICATI	Enterobacteriaceae infection [ICD-11: MG50.C] Phase 1
INDICATI	Multidrug resistant infection [ICD-11: MG51] Phase 1
	
TTDDRUID	DA3GL5
DRUGNAME	ZGN-1061
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	DA4O8C
DRUGNAME	IMGC936
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DA4W1I
DRUGNAME	AO-176
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DA5RC6
DRUGNAME	BC-1215
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical
	
TTDDRUID	DA69JF
DRUGNAME	Tirzepatide
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 3
	
TTDDRUID	DA6C8N
DRUGNAME	LXE408
INDICATI	Visceral leishmaniasis [ICD-11: 1F54.0] Phase 2
	
TTDDRUID	DA6F1D
DRUGNAME	MERS-4
INDICATI	Coronavirus infection [ICD-11: 1D92] Preclinical
	
TTDDRUID	DA6NG5
DRUGNAME	Nimacimab
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	DA6OU0
DRUGNAME	GL-ONC1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Peritoneal carcinomatosis [ICD-11: 2D91] Phase 1/2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
INDICATI	Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1
	
TTDDRUID	DA6T3R
DRUGNAME	VLA1553
INDICATI	Chikungunya virus infection [ICD-11: 1D40] Phase 3
	
TTDDRUID	DA74SC
DRUGNAME	P1101
INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 3
	
TTDDRUID	DA78ZH
DRUGNAME	MEDI5395
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DA79HM
DRUGNAME	SB 11285
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Head-neck squamous cell carcinoma [ICD-11: 2D60.0] Phase 1
	
TTDDRUID	DA85KQ
DRUGNAME	M102
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Preclinical
	
TTDDRUID	DA85NC
DRUGNAME	60P002
INDICATI	Dengue [ICD-11: 1D20-1D2Z] Phase 2
	
TTDDRUID	DA8MK6
DRUGNAME	M6223
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DA8W3Q
DRUGNAME	THR-149
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	DA91HS
DRUGNAME	ODM-207
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DA9N4O
DRUGNAME	BJ-001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DAD65R
DRUGNAME	RP-3500
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DAD95G
DRUGNAME	VX-371
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
INDICATI	Primary ciliary dyskinesia [ICD-11: LA75.Y] Phase 2
	
TTDDRUID	DAD9V4
DRUGNAME	GSK2643943A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DAJ3D2
DRUGNAME	SMI-4a
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Investigative
	
TTDDRUID	DAL5C7
DRUGNAME	Eftilagimod alpha
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 2
	
TTDDRUID	DALG29
DRUGNAME	KY1044
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DAOT46
DRUGNAME	LY2787106
INDICATI	Anemia [ICD-11: 3A00-3A9Z] Phase 1
	
TTDDRUID	DAPZ09
DRUGNAME	PSMA VRP
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	DAQ31P
DRUGNAME	2-aminophenoxazine-3-one
INDICATI	T-cell leukaemia [ICD-11: 2A90] Investigative
	
TTDDRUID	DAQ4G0
DRUGNAME	NC043
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical
	
TTDDRUID	DARV32
DRUGNAME	GP-2250
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	DAS4D6
DRUGNAME	PSMA CAR-T cell therapy
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	DAT0U5
DRUGNAME	NV-5138
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 1
	
TTDDRUID	DATO92
DRUGNAME	AZD9833
INDICATI	ER-positive breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	DAW86K
DRUGNAME	AV7909
INDICATI	Anthrax [ICD-11: 1B97] Phase 3
	
TTDDRUID	DAX06Q
DRUGNAME	AMG 509
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	DAY4L1
DRUGNAME	SX-682
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	DB0V3R
DRUGNAME	Spautin 1
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical
	
TTDDRUID	DB18SE
DRUGNAME	SAGE-718
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	DB1P9T
DRUGNAME	LpxC-1
INDICATI	Acinetobacter baumannii infection [ICD-11: CA40.0Y] Preclinical
	
TTDDRUID	DB1U9N
DRUGNAME	S-Phenyl-L-cysteine sulfoxide
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical
	
TTDDRUID	DB26FH
DRUGNAME	EO2401
INDICATI	Adrenocortical carcinoma [ICD-11: 2D11.Z] Phase 1/2
INDICATI	Pheochromocytoma [ICD-11: 5A75] Phase 1/2
INDICATI	Paraganglioma [ICD-11: 2E92.2] Phase 1/2
	
TTDDRUID	DB29TN
DRUGNAME	MER4101
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Phase 1
INDICATI	Influenza [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	DB2U3O
DRUGNAME	GSK3640254
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	DB35WK
DRUGNAME	Fresolimumab
INDICATI	Brain cancer [ICD-11: 2A00] Phase 2
	
TTDDRUID	DB4C5H
DRUGNAME	CD123-CD33 Ccar
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	DB4D2N
DRUGNAME	UNC0379
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Preclinical
	
TTDDRUID	DB4M9J
DRUGNAME	Epcoritamab
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3
	
TTDDRUID	DB53NH
DRUGNAME	HTI-1090
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DB58KR
DRUGNAME	RT001
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 3
INDICATI	Iron overload disease [ICD-11: 5C64.10] Phase 2/3
	
TTDDRUID	DB5O1U
DRUGNAME	H3B-8800
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Chronic myelomonocytic leukaemia [ICD-11: 2A40] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	DB5UA2
DRUGNAME	CC-90011
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
	
TTDDRUID	DB5UO0
DRUGNAME	CAN04
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	DB5YU0
DRUGNAME	DMT210
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
INDICATI	Rosacea [ICD-11: ED90.0] Phase 2
	
TTDDRUID	DB6GK4
DRUGNAME	DS-1055
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DB6XD8
DRUGNAME	BMS-986177
INDICATI	Cerebral ischemia [ICD-11: 8B11] Phase 2
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	DB82TO
DRUGNAME	Tofisopam
INDICATI	Irritable bowel syndrome [ICD-11: DD91.0] Phase 2
INDICATI	Hyperuricaemia [ICD-11: 5C55.Y] Phase 2
	
TTDDRUID	DB8J2U
DRUGNAME	KPG-818
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1
	
TTDDRUID	DB8MR6
DRUGNAME	OS2966
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	DB91HQ
DRUGNAME	ADG106
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DBA40S
DRUGNAME	Recifercept
INDICATI	Achondroplasia [ICD-11: LD24.00] Phase 2
	
TTDDRUID	DBA5M7
DRUGNAME	PMX205
INDICATI	Central nervous system disease [ICD-11: 8A04-8D87] Preclinical
	
TTDDRUID	DBDW09
DRUGNAME	GMI-1359
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	DBE26P
DRUGNAME	ADXS-NEO
INDICATI	Colon cancer [ICD-11: 2B90.Z] Phase 1
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	DBE87X
DRUGNAME	MRG-110
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	DBG46D
DRUGNAME	PSMA-11 Ga-68
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	DBGD91
DRUGNAME	PTX-35
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DBHO19
DRUGNAME	AMT-061
INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 3
	
TTDDRUID	DBI81F
DRUGNAME	AMG 397
INDICATI	Refractory hematologic malignancy [ICD-11: 2A85.5] Phase 1
	
TTDDRUID	DBJ36R
DRUGNAME	JT07
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DBJ5Z0
DRUGNAME	N-Octyl-4-epi-beta-valienamine
INDICATI	GM1 gangliosidosis [ICD-11: 5C56.00] Preclinical
	
TTDDRUID	DBL5H8
DRUGNAME	MK-8527
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	DBND71
DRUGNAME	GS-9674
INDICATI	Primary sclerosing cholangitis [ICD-11: DB96.2] Phase 3
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2
	
TTDDRUID	DBO39X
DRUGNAME	JNJ-64264681
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	DBP9Q5
DRUGNAME	SAR442257
INDICATI	Malignant neoplasm [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DBPV74
DRUGNAME	BP1002
INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	DBT1H4
DRUGNAME	CC100
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1
	
TTDDRUID	DBU13L
DRUGNAME	Cavrotolimod
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DBU16T
DRUGNAME	JSI-1187
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DBU2W3
DRUGNAME	EYP001
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2
	
TTDDRUID	DBY42T
DRUGNAME	LP-108
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Chronic myelomonocytic leukaemia [ICD-11: 2A40] Phase 1
	
TTDDRUID	DBZ87Q
DRUGNAME	BGB-A445
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DC0P6U
DRUGNAME	AT-752
INDICATI	Dengue [ICD-11: 1D20-1D2Z] Phase 1
	
TTDDRUID	DC19UI
DRUGNAME	SQX770
INDICATI	Herpes simplex virus infection [ICD-11: 1F00] Phase 2
	
TTDDRUID	DC1AV3
DRUGNAME	DNL758
INDICATI	Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2
	
TTDDRUID	DC29HL
DRUGNAME	Lu AF11167
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	DC2DO5
DRUGNAME	PDC-1421
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	DC37YW
DRUGNAME	IMSA101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DC3Y7O
DRUGNAME	RG6296
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DC3ZD5
DRUGNAME	DRP-104
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DC4AT7
DRUGNAME	MERS-27
INDICATI	Coronavirus infection [ICD-11: 1D92] Preclinical
	
TTDDRUID	DC4U0L
DRUGNAME	ADPS
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	DC52UD
DRUGNAME	CTP-692
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	DC57TE
DRUGNAME	BT8009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DC5A9Q
DRUGNAME	mRNA-2752
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DC5VW9
DRUGNAME	BGB-A333
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DC6IR4
DRUGNAME	INO-4700
INDICATI	Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 2
	
TTDDRUID	DC6LS1
DRUGNAME	AB-110
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	DC6UG5
DRUGNAME	PRT543
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	DC72LG
DRUGNAME	RMJH-111b
INDICATI	Essential hypertension [ICD-11: BA00] Phase 1/2
	
TTDDRUID	DC7UF3
DRUGNAME	Remlarsen
INDICATI	Keloid [ICD-11: EE60] Phase 2
	
TTDDRUID	DC8EN0
DRUGNAME	131I-labelled aCD45
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
	
TTDDRUID	DC8HR6
DRUGNAME	LY3415244
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DC9FD4
DRUGNAME	RC-01
INDICATI	Gram-negative bacterial infection [ICD-11: 1B74-1G40] Terminated
	
TTDDRUID	DC9J1Y
DRUGNAME	RO5461111
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Preclinical
	
TTDDRUID	DCA5M2
DRUGNAME	Padsevonil
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2/3
	
TTDDRUID	DCD1M8
DRUGNAME	ABBV-621
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	DCE09U
DRUGNAME	GSK3437949A
INDICATI	Malaria [ICD-11: 1F40-1F45] Phase 2
	
TTDDRUID	DCI8V2
DRUGNAME	GEN-009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DCIP24
DRUGNAME	LDN-57444
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DCIX20
DRUGNAME	ADU- S100
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 2
	
TTDDRUID	DCJ75Y
DRUGNAME	CUTX-101
INDICATI	Menkes disease [ICD-11: 5C64.0] Phase 3
	
TTDDRUID	DCJX65
DRUGNAME	UNC2025
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Investigative
	
TTDDRUID	DCL84J
DRUGNAME	VLA1601
INDICATI	Zika virus infection [ICD-11: 1D48] Phase 1
	
TTDDRUID	DCL8J5
DRUGNAME	WZB-117
INDICATI	Skin fibrosis [ICD-11: EM0Z] Preclinical
	
TTDDRUID	DCMG03
DRUGNAME	TTX-030
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DCN2U9
DRUGNAME	BC-7013
INDICATI	Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Phase 1
	
TTDDRUID	DCT2Q3
DRUGNAME	Annamycin
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	DCU94X
DRUGNAME	NmVac-4 A/C/Y/W-135 DT
INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 2
	
TTDDRUID	DCVO04
DRUGNAME	OSU-53
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	DCWS23
DRUGNAME	166Ho microspheres
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
	
TTDDRUID	DCWT40
DRUGNAME	Seclidemstat
INDICATI	Ewing sarcoma [ICD-11: 2B52] Phase 1
	
TTDDRUID	DCXB47
DRUGNAME	QBS10072S
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DCYV91
DRUGNAME	TBA-7371
INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2
	
TTDDRUID	DCZ16N
DRUGNAME	SD1002
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
	
TTDDRUID	DCZ28G
DRUGNAME	Ibezapolstat
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2
	
TTDDRUID	DD1GK8
DRUGNAME	Lumasiran
INDICATI	Hyperoxaluria [ICD-11: 5C51.2] Approved
	
TTDDRUID	DD1TJ8
DRUGNAME	XmAb20717
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	DD1ZV6
DRUGNAME	BI 1358894
INDICATI	Depression [ICD-11: 6A70-6A7Z] Phase 2
	
TTDDRUID	DD25UM
DRUGNAME	177Lu-labelled NeoBOMB1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	DD2C5E
DRUGNAME	IONIS-416858
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2
	
TTDDRUID	DD36YG
DRUGNAME	OP-0595
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	DD39ET
DRUGNAME	NVX-CoV2373
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	DD3IE7
DRUGNAME	ENERGI-F701
INDICATI	Alopecia [ICD-11: ED70] Phase 2
	
TTDDRUID	DD3MB0
DRUGNAME	IDR-1002
INDICATI	Asthma [ICD-11: CA23] Investigative
	
TTDDRUID	DD3XO8
DRUGNAME	SSYA10-001
INDICATI	Coronavirus infection [ICD-11: 1D92] Preclinical
	
TTDDRUID	DD4H6V
DRUGNAME	BI 1206
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	DD4XR3
DRUGNAME	MB-105
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	DD5NX2
DRUGNAME	AT-777
INDICATI	Hepatitis C [ICD-11: 1E51] Phase 1/2
	
TTDDRUID	DD5VO3
DRUGNAME	TAK-906
INDICATI	Diabetic gastroparesis [ICD-11: DA41.00] Phase 2
	
TTDDRUID	DD6AZ5
DRUGNAME	BNC-101
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 1
	
TTDDRUID	DD76ER
DRUGNAME	RV001V
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 2
	
TTDDRUID	DD76HZ
DRUGNAME	SNF472
INDICATI	Calciphylaxis [ICD-11: EB90.42] Phase 3
INDICATI	Calcific uremic arteriolopathy [ICD-11: EB90.42 ] Phase 3
	
TTDDRUID	DD8QK9
DRUGNAME	Bexsero
INDICATI	Meningococcal infection [ICD-11: 1C1C] Approved
	
TTDDRUID	DD94ZN
DRUGNAME	A166
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DD9J4X
DRUGNAME	SNS-301
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	DD9NG5
DRUGNAME	SHP-627
INDICATI	Cardiac arrest [ICD-11: MC82] Preclinical
	
TTDDRUID	DD9VR3
DRUGNAME	MIJ821
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	DDC63W
DRUGNAME	EPZ033294
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DDE3Z4
DRUGNAME	HMPL-689
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	DDE82F
DRUGNAME	ABBV-155
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DDG8W9
DRUGNAME	SGN-CD30C
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	DDH8L6
DRUGNAME	Almonertinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	DDI6B0
DRUGNAME	Nuplazid
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	DDK1I4
DRUGNAME	AT-GAA
INDICATI	Pompe disease [ICD-11: 5C51.3] Phase 3
	
TTDDRUID	DDK53C
DRUGNAME	BTRX-335140
INDICATI	Major depressive disorder [ICD-11: 6A70.3] Phase 2
	
TTDDRUID	DDKF39
DRUGNAME	Evenamide
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 2
	
TTDDRUID	DDKY53
DRUGNAME	BI 754091
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DDL79K
DRUGNAME	XMT-1592
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
	
TTDDRUID	DDL86V
DRUGNAME	MGTA-145
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 2
	
TTDDRUID	DDN3B1
DRUGNAME	BIVV-003
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 1/2
	
TTDDRUID	DDNL40
DRUGNAME	KB174
INDICATI	Cirrhosis [ICD-11: DB93] Clinical Trial
	
TTDDRUID	DDP27A
DRUGNAME	JNJ-64152348
INDICATI	Poliomyelitis [ICD-11: 1C81] Phase 2
	
TTDDRUID	DDP74J
DRUGNAME	MGC018
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DDU2Y0
DRUGNAME	Vupanorsen
INDICATI	Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2
INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 2
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	DDV09U
DRUGNAME	DS-1558
INDICATI	Type 2 diabetes [ICD-11: 5A11] Preclinical
	
TTDDRUID	DDV8H5
DRUGNAME	AlphaMedix
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1
	
TTDDRUID	DDV9M0
DRUGNAME	SB209762
INDICATI	Measles [ICD-11: 1F03] Phase 3
INDICATI	Mumps virus infection [ICD-11: 1D80] Phase 3
INDICATI	Rubella prophylaxis [ICD-11: 1F02] Phase 3
	
TTDDRUID	DDX95P
DRUGNAME	AAV-RPE65
INDICATI	Leber congenital amaurosis [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	DDXH71
DRUGNAME	LMP744
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DDY51F
DRUGNAME	EDP-514
INDICATI	Chronic HBV infection [ICD-11: 1E51.0Z] Phase 1
	
TTDDRUID	DDZ6B0
DRUGNAME	RG6330
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DE09IO
DRUGNAME	BNZ-1
INDICATI	Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2
INDICATI	T-cell leukaemia [ICD-11: 2A90] Phase 2
INDICATI	Large granular lymphocytic leukemia [ICD-11: 2A90.1] Phase 1/2
	
TTDDRUID	DE0L6O
DRUGNAME	ISB 1342
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	DE0TD1
DRUGNAME	CP-870,893
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DE2U5N
DRUGNAME	TVB-2640
INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 2
	
TTDDRUID	DE2V3Y
DRUGNAME	Inodiftagene vixteplasmid
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
	
TTDDRUID	DE2Z7V
DRUGNAME	BT1718
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2a
	
TTDDRUID	DE49RW
DRUGNAME	CTX120
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DE4AO8
DRUGNAME	HC-1119
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	DE53JQ
DRUGNAME	Camsirubicin
INDICATI	Soft tissue sarcoma [ICD-11: 2B57] Phase 2
	
TTDDRUID	DE58RZ
DRUGNAME	CUE-101
INDICATI	Oropharyngeal squamous cell carcinoma [ICD-11: 2B6A.0] Phase 2
	
TTDDRUID	DE5L6B
DRUGNAME	DSP-7888
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 3
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DE5N3K
DRUGNAME	Dasiglucagon
INDICATI	Hypoglycemia [ICD-11: 5A41] Approved
INDICATI	Hyperinsulinemia [ICD-11: 5A4Y] Phase 2
	
TTDDRUID	DE6GF4
DRUGNAME	ZYH7
INDICATI	Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2
INDICATI	Dyslipidemia [ICD-11: 5C80-5C81] Phase 2
	
TTDDRUID	DE7BZ4
DRUGNAME	SR2211
INDICATI	Autoimmune disease [ICD-11: 4A40-4A45] Preclinical
	
TTDDRUID	DE7N6F
DRUGNAME	ASTX295
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DE8H1W
DRUGNAME	Aglatimagene besadenovec
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3
INDICATI	Pediatric glioma [ICD-11: 2A00.0] Phase 2
INDICATI	Malignant glioma [ICD-11: 2A00.0] Phase 2
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
INDICATI	Malignant pleural effusion [ICD-11: 2D72] Phase 1
	
TTDDRUID	DE8OJ0
DRUGNAME	ZYAN1
INDICATI	Anaemia [ICD-11: 3A90] Phase 1
	
TTDDRUID	DE8S2F
DRUGNAME	DFP-14927
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DE8V1R
DRUGNAME	ARO-HIF2
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
	
TTDDRUID	DEC8O3
DRUGNAME	CT 868
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	DEDP81
DRUGNAME	AMG 910
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
INDICATI	Esophagogastric junction neoplasm [ICD-11: 2B71] Phase 1
	
TTDDRUID	DEI07S
DRUGNAME	AIP-303
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	DEI4U0
DRUGNAME	HMR59
INDICATI	Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 2
INDICATI	Dry age-related macular degeneration [ICD-11: 9B75] Phase 2
INDICATI	Geographic retinal atrophy [ICD-11: 9B78.9] Phase 2
	
TTDDRUID	DEKM09
DRUGNAME	GWP42006
INDICATI	Epilepsy [ICD-11: 8A60-8A68] Phase 2
	
TTDDRUID	DELC48
DRUGNAME	A-893
INDICATI	Lung cancer [ICD-11: 2C25.0] Preclinical
	
TTDDRUID	DENA17
DRUGNAME	CD24Fc
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	DENO49
DRUGNAME	RV521
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	DEP3Z8
DRUGNAME	AMG 199
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 1
INDICATI	Esophagogastric junction neoplasm [ICD-11: 2B71] Phase 1
	
TTDDRUID	DES36M
DRUGNAME	Q301
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 2
	
TTDDRUID	DEU08Q
DRUGNAME	GS-5423
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	DEU8O6
DRUGNAME	Sym023
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DEUC70
DRUGNAME	TJC4
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DEV97R
DRUGNAME	PK68
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Investigative
	
TTDDRUID	DEWC27
DRUGNAME	Odevixibat
INDICATI	Alagille syndrome [ICD-11: LB20.0Y] Phase 3
	
TTDDRUID	DEX8D5
DRUGNAME	NJH395
INDICATI	HER2-positive metastatic breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	DEXM29
DRUGNAME	LY3499446
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DEZ3D7
DRUGNAME	Fucoxanthin
INDICATI	Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 2
	
TTDDRUID	DEZV54
DRUGNAME	SPR206
INDICATI	Multidrug resistant infection [ICD-11: MG51] Phase 1
	
TTDDRUID	DF04YM
DRUGNAME	AIC499
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	DF0DN4
DRUGNAME	EDP-788
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	DF0L3G
DRUGNAME	INCB99280
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DF0PI8
DRUGNAME	BAY 1817080
INDICATI	Endometriosis [ICD-11: GA10] Phase 1
INDICATI	Cough [ICD-11: MD12] Phase 1
	
TTDDRUID	DF0PR6
DRUGNAME	ZN-e4
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	DF0R5I
DRUGNAME	ASP0819
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2
	
TTDDRUID	DF14RB
DRUGNAME	CRV-101
INDICATI	Varicella zoster virus infection [ICD-11: 1E91] Phase 1
INDICATI	Herpes zoster [ICD-11: 1E91] Phase 1
	
TTDDRUID	DF1JO7
DRUGNAME	CXA10
INDICATI	Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2
INDICATI	Focal segmental glomerulosclerosis [ICD-11: MF8Y] Phase 2
	
TTDDRUID	DF1S3A
DRUGNAME	GSK180
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical
INDICATI	Pancreatitis [ICD-11: DC31-DC34] Preclinical
	
TTDDRUID	DF2E5G
DRUGNAME	VXA-G2.4-NS
INDICATI	Norovirus infection [ICD-11: 1A23] Phase 1
	
TTDDRUID	DF36DY
DRUGNAME	Givosiran
INDICATI	Acute intermittent hepatic porphyria [ICD-11: 5C58.11] Approved
	
TTDDRUID	DF37QR
DRUGNAME	VE800
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DF3QH8
DRUGNAME	IMM-529
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 1/2
	
TTDDRUID	DF3UN2
DRUGNAME	CAD106
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2/3
	
TTDDRUID	DF43EH
DRUGNAME	AMG 701
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DF5C2I
DRUGNAME	RIPA-56
INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Investigative
	
TTDDRUID	DF5LB8
DRUGNAME	NSC 19630
INDICATI	T-cell leukaemia [ICD-11: 2A90] Investigative
	
TTDDRUID	DF5R7E
DRUGNAME	Romilkimab
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
	
TTDDRUID	DF6UP7
DRUGNAME	Tadekinig alfa
INDICATI	XIAP deficiency [ICD-11: 4A01.22] Phase 3
	
TTDDRUID	DF6Y1J
DRUGNAME	MK-8583
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	DF8M1T
DRUGNAME	TPST-1120
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DF8M3V
DRUGNAME	KB109
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Clinical Trial
	
TTDDRUID	DF90DS
DRUGNAME	SIS-3
INDICATI	Renal fibrosis [ICD-11: GC01] Preclinical
	
TTDDRUID	DF9S1L
DRUGNAME	ATA2271
INDICATI	Mesothelioma [ICD-11: 2C51.2] Phase 1
	
TTDDRUID	DFBJ28
DRUGNAME	6-Formylindolo[3,2-b]carbazole
INDICATI	Dermatitis [ICD-11: EA80-EA89] Investigative
	
TTDDRUID	DFC0V4
DRUGNAME	CB-5339
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	DFDT39
DRUGNAME	Anti-RAS-G12V mTCR-transduced PBL
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DFHC16
DRUGNAME	ARNAX
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	DFLK16
DRUGNAME	Sintilimab
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Approved
	
TTDDRUID	DFO5W3
DRUGNAME	MK-4621
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DFPS93
DRUGNAME	Pravibismane
INDICATI	Respiratory tract infection [ICD-11: CA45] Phase 2
	
TTDDRUID	DFQ17Y
DRUGNAME	TMB-365
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	DFU4B0
DRUGNAME	RO7040547
INDICATI	Asthma [ICD-11: CA23] Discontinued in Phase 1
	
TTDDRUID	DFV71O
DRUGNAME	AAV2/8-LSPhGAA
INDICATI	Pompe disease [ICD-11: 5C51.3] Phase 1
	
TTDDRUID	DFW5P7
DRUGNAME	DermaVir
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	DFX7K1
DRUGNAME	BPZE1
INDICATI	Pertussis [ICD-11: 1C12] Phase 2
	
TTDDRUID	DFY58O
DRUGNAME	RTB101
INDICATI	Respiratory tract infection [ICD-11: CA45] Phase 3
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	DFYL51
DRUGNAME	Ociperlimab
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2
	
TTDDRUID	DFZ0V3
DRUGNAME	JNJ-64619178
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DFZJ79
DRUGNAME	SRK-181
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DG07UD
DRUGNAME	VCB102
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Preclinical
	
TTDDRUID	DG07WN
DRUGNAME	RGX-314
INDICATI	Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 2
	
TTDDRUID	DG0NA1
DRUGNAME	MEDI1191
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DG17UJ
DRUGNAME	AMG 228
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DG1CX7
DRUGNAME	ABO-101
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2
	
TTDDRUID	DG1ED2
DRUGNAME	Pepinemab
INDICATI	Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 1/2
	
TTDDRUID	DG38QS
DRUGNAME	G1T-48
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	DG4A0Y
DRUGNAME	Cefilavancin
INDICATI	Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Phase 3
	
TTDDRUID	DG4YF6
DRUGNAME	SYN125
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Uterine serous carcinoma [ICD-11: 2C72.1] Phase 1
	
TTDDRUID	DG5K6D
DRUGNAME	APN301
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2
	
TTDDRUID	DG5T9Q
DRUGNAME	RTL1000
INDICATI	Multiple sclerosis [ICD-11: 8A40] Phase 1
	
TTDDRUID	DG61OC
DRUGNAME	MGCD290
INDICATI	Vulvovaginal Candidiasis [ICD-11: 1F23.10] Phase 2
	
TTDDRUID	DG68CL
DRUGNAME	TTP399
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	DG6V7E
DRUGNAME	GS-1423
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DG80IS
DRUGNAME	MEDI2228
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DG90VQ
DRUGNAME	SHP656
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Preclinical
	
TTDDRUID	DG9LF8
DRUGNAME	DKY709
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DG9QY7
DRUGNAME	Brivoligide
INDICATI	Postoperative pain [ICD-11: MG30-MG3Z] Phase 2
	
TTDDRUID	DGCQ13
DRUGNAME	MK-7162
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DGD72N
DRUGNAME	BAY 1142524
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
	
TTDDRUID	DGH83L
DRUGNAME	DNL747
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1
	
TTDDRUID	DGJD82
DRUGNAME	Ravidasvir
INDICATI	Hepatitis C [ICD-11: 1E51] Phase 2/3
	
TTDDRUID	DGN26L
DRUGNAME	BST-236
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	DGO2C1
DRUGNAME	Leniolisib
INDICATI	Sjogren syndrome [ICD-11: 4A43.20] Phase 2
	
TTDDRUID	DGP6V3
DRUGNAME	BAP-15
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DGQU43
DRUGNAME	Dostarlimab
INDICATI	Endometrial cancer [ICD-11: 2C76] Approved
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 3
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	DGQW52
DRUGNAME	177Lu-labelled PSMA-617
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	DGU51Y
DRUGNAME	Benapenem
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 2/3
INDICATI	Acute pyelonephritis [ICD-11: GB51] Phase 2/3
	
TTDDRUID	DGV5Z3
DRUGNAME	MK-1092
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1
	
TTDDRUID	DGV8K5
DRUGNAME	GSK065
INDICATI	Pancreatitis [ICD-11: DC31-DC34] Phase 1
	
TTDDRUID	DGWE36
DRUGNAME	90Y-loaded resin microspheres
INDICATI	Liver cancer [ICD-11: 2C12] Approved
	
TTDDRUID	DGZ38L
DRUGNAME	NK314
INDICATI	T-cell leukaemia [ICD-11: 2A90] Investigative
	
TTDDRUID	DH09QZ
DRUGNAME	ZW49
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DH0M2P
DRUGNAME	131I-labelled CLR 131
INDICATI	Waldenstrom macroglobulinemia [ICD-11: 2A85.4] Phase 2
	
TTDDRUID	DH17JI
DRUGNAME	DS-8273
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1
	
TTDDRUID	DH19QJ
DRUGNAME	CTX-101
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	DH1D5R
DRUGNAME	Nerofe
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
INDICATI	Acute myelogenous leukaemia [ICD-11: 2A41] Phase 2
	
TTDDRUID	DH1OY4
DRUGNAME	OMS527
INDICATI	Substance use disorder [ICD-11: 6C4Z] Phase 1
	
TTDDRUID	DH1W0G
DRUGNAME	VY-AADC
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 2
	
TTDDRUID	DH2S8X
DRUGNAME	GT103
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	DH3YK4
DRUGNAME	Zimura
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 3
	
TTDDRUID	DH40QT
DRUGNAME	SB-FIX
INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 1/2
	
TTDDRUID	DH42RF
DRUGNAME	PD-L1 t-haNK
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DH4Y3O
DRUGNAME	LY3484356
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	DH5BX2
DRUGNAME	CC-99712
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DH5RN1
DRUGNAME	HQP1351
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 2
	
TTDDRUID	DH5S6Z
DRUGNAME	CTT1403
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	DH67XF
DRUGNAME	LJ001
INDICATI	Coronavirus infection [ICD-11: 1D92] Preclinical
	
TTDDRUID	DH6GK7
DRUGNAME	ADG116
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DH7F9S
DRUGNAME	Fevipiprant
INDICATI	Asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	DH82BG
DRUGNAME	ARQ-154
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 2
	
TTDDRUID	DH8FY6
DRUGNAME	ARC1779
INDICATI	Intracranial embolism [ICD-11: 8B22.1] Phase 2
	
TTDDRUID	DHB2K8
DRUGNAME	OLX10010
INDICATI	Hypertrophic scars [ICD-11: EE60] Phase 2
	
TTDDRUID	DHD2S9
DRUGNAME	DNL104
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	DHD79B
DRUGNAME	SMER3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DHG2O3
DRUGNAME	OT551
INDICATI	Age-related macular degeneration [ICD-11: 9B75.0] Phase 2
	
TTDDRUID	DHG36S
DRUGNAME	ETP-45658
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	DHLU46
DRUGNAME	GSK2904545A
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 1
	
TTDDRUID	DHMO41
DRUGNAME	KITE-439
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DHQ9S3
DRUGNAME	AMG 256
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DHS3X7
DRUGNAME	GSK3901961
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DHTN76
DRUGNAME	ALN-CC5
INDICATI	Haemolytic uraemic syndrome [ICD-11: 3A21.2] Phase 2
	
TTDDRUID	DHV2L8
DRUGNAME	Rexlemestrocel-L
INDICATI	Intervertebral disc degeneration [ICD-11: FA80] Phase 3
	
TTDDRUID	DHY3Q9
DRUGNAME	ABI-H0731
INDICATI	Hepatitis B [ICD-11: 1E51] Phase 2
	
TTDDRUID	DHY6S0
DRUGNAME	Arfolitixorin
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 3
	
TTDDRUID	DHYZ53
DRUGNAME	GSK3368715
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DI0ZA3
DRUGNAME	Enapotamab vedotin
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DI10NU
DRUGNAME	AMG 650
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DI17KH
DRUGNAME	TAS-1440
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	DI1L7M
DRUGNAME	PF-06821497
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
	
TTDDRUID	DI1S4K
DRUGNAME	GSK3888550A
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	DI1VM3
DRUGNAME	HM43239
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	DI29VD
DRUGNAME	mRNA-1653
INDICATI	Metapneumovirus infection [ICD-11: CA40.13] Phase 1
INDICATI	Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1
	
TTDDRUID	DI2X8V
DRUGNAME	ATA2321
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Preclinical
	
TTDDRUID	DI37UY
DRUGNAME	Viralym-M
INDICATI	Virus infection [ICD-11: 1A24-1D9Z] Phase 2
	
TTDDRUID	DI4HA7
DRUGNAME	Mobocertinib
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 3
	
TTDDRUID	DI4SM3
DRUGNAME	MT-1621
INDICATI	Thymidine kinase 2 deficiency [ICD-11: 5C55.1 ] Phase 3
	
TTDDRUID	DI57MF
DRUGNAME	Nivatrotamab
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DI6G5U
DRUGNAME	KB001A
INDICATI	Infectious disease [ICD-11: 1A00-CA43.1] Phase 2
INDICATI	Cystic fibrosis [ICD-11: CA25] Phase 2
	
TTDDRUID	DI7SP5
DRUGNAME	L1-79
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 2
	
TTDDRUID	DI81LW
DRUGNAME	UNC569
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Investigative
	
TTDDRUID	DI8WC4
DRUGNAME	CC-90002
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	DI8ZG7
DRUGNAME	VIS513
INDICATI	Dengue [ICD-11: 1D20-1D2Z] Preclinical
	
TTDDRUID	DI9ZQ6
DRUGNAME	212Pb-labelled aCD37
INDICATI	leukaemia [ICD-11: 2A60-2B33] Preclinical
	
TTDDRUID	DIA08F
DRUGNAME	SKI-G-801
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	DIAM05
DRUGNAME	Aerosurf
INDICATI	Respiratory distress syndrome [ICD-11: CB00] Phase 2
	
TTDDRUID	DIB8G5
DRUGNAME	KBP-V001
INDICATI	Influenza [ICD-11: 1E30-1E32] Phase 1
	
TTDDRUID	DIC20P
DRUGNAME	HB-AdMSC
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	DIE75V
DRUGNAME	AR201
INDICATI	Food allergy [ICD-11: 4A85.2] Phase 2
	
TTDDRUID	DIK8W5
DRUGNAME	MGB-BP-3
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2
	
TTDDRUID	DILV59
DRUGNAME	HB-101
INDICATI	Cytomegalovirus Disease [ICD-11: 1D82] Phase 2
	
TTDDRUID	DILZ67
DRUGNAME	HB-202
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2
	
TTDDRUID	DIPY14
DRUGNAME	NOV1501
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DIQ9G6
DRUGNAME	VBI-2601
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	DIQE54
DRUGNAME	XmAB24306
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DIS4N5
DRUGNAME	ABM-1310
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DIW37N
DRUGNAME	NPT200-11
INDICATI	Multiple system atrophy [ICD-11: 8D87.0] Phase 1
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	DIW58H
DRUGNAME	UCART-CLL1
INDICATI	Multiple myeloma [ICD-11: 2A83] Preclinical
	
TTDDRUID	DIWL76
DRUGNAME	PVSRIPO
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	DIX61C
DRUGNAME	CC-90010
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 1
INDICATI	Astrocytoma [ICD-11: 2A00.0Y] Phase 1
	
TTDDRUID	DIY4C2
DRUGNAME	CCS1477
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DJ0E7P
DRUGNAME	ALN-TTR01
INDICATI	Amyloidosis [ICD-11: 5D00] Phase 1
INDICATI	Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 1
	
TTDDRUID	DJ0L4K
DRUGNAME	Sutimlimab
INDICATI	Cold type autoimmune haemolytic anemia [ICD-11: 3A20.1] Phase 3
	
TTDDRUID	DJ0P6A
DRUGNAME	PBF-999
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 1
	
TTDDRUID	DJ1Q9B
DRUGNAME	MS012
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical
	
TTDDRUID	DJ1W5R
DRUGNAME	ZN-c5
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	DJ25DI
DRUGNAME	227Th-labelled MSLN-TTC
INDICATI	Epithelioid mesothelioma [ICD-11: 2F10 ] Phase 1
	
TTDDRUID	DJ29KW
DRUGNAME	FSI-189
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	DJ2N3L
DRUGNAME	BMS-986253
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	DJ48HT
DRUGNAME	LNP023
INDICATI	IgA nephropathy [ICD-11: MF8Y] Phase 3
INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 3
	
TTDDRUID	DJ4GE9
DRUGNAME	INO-4500
INDICATI	Lassa fever [ICD-11: 1D61.2] Phase 1
	
TTDDRUID	DJ4X7D
DRUGNAME	DS-6157
INDICATI	Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1
	
TTDDRUID	DJ51FH
DRUGNAME	REGN3048
INDICATI	Coronavirus infection [ICD-11: 1D92] Phase 1
	
TTDDRUID	DJ5D4G
DRUGNAME	NA-831
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	DJ5E7O
DRUGNAME	SAIT101
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 3
	
TTDDRUID	DJ5I6L
DRUGNAME	SPK-8016
INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 1/2
	
TTDDRUID	DJ5XY8
DRUGNAME	SLN124
INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 1
	
TTDDRUID	DJ6NE2
DRUGNAME	TRX518
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DJ7K9G
DRUGNAME	RBN-2397
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DJ7Z5W
DRUGNAME	Ro 61-8048
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical
	
TTDDRUID	DJ81QF
DRUGNAME	VE303
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2
	
TTDDRUID	DJ8CY4
DRUGNAME	F901318
INDICATI	Fungal infection [ICD-11: 1F29-1F2F] Phase 2
	
TTDDRUID	DJ8TN2
DRUGNAME	HL-085
INDICATI	Melanoma [ICD-11: 2C30] Phase 1/2
	
TTDDRUID	DJ9WC4
DRUGNAME	SY-5609
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DJCN38
DRUGNAME	REGN1193
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	DJH9P4
DRUGNAME	BI 695502
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	DJK0W9
DRUGNAME	NCGC607
INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Preclinical
	
TTDDRUID	DJN3E2
DRUGNAME	mRNA-3704
INDICATI	Methylmalonic acidemia [ICD-11: 5C50.E0] Phase 1/2
	
TTDDRUID	DJNY65
DRUGNAME	GSK3528869A
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	DJR94F
DRUGNAME	PMD-026
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1
INDICATI	Metastatic breast cancer [ICD-11: 2C6Y] Phase 1
	
TTDDRUID	DJVH04
DRUGNAME	CC-97540
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	DJVR06
DRUGNAME	KD033
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DJX7K9
DRUGNAME	RG6084
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	DJYD13
DRUGNAME	SGN-B6A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DK1CU4
DRUGNAME	SGT-94
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DK1MX0
DRUGNAME	GMA102
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
INDICATI	Obesity [ICD-11: 5B81] Phase 3
	
TTDDRUID	DK1PA2
DRUGNAME	225Ac-labelled aCD38
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DK26FL
DRUGNAME	CYC140
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	DK28GS
DRUGNAME	NOUS-209
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DK28NV
DRUGNAME	ION 224
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1
	
TTDDRUID	DK3QD9
DRUGNAME	ORIN1001
INDICATI	Metastatic breast cancer [ICD-11: 2C6Y] Phase 1/2
	
TTDDRUID	DK4I9R
DRUGNAME	MK-4830
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DK52QX
DRUGNAME	RG6292
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DK5JP3
DRUGNAME	GZ17-6.02
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DK65RJ
DRUGNAME	IDCT
INDICATI	Intervertebral disc degeneration [ICD-11: FA80] Phase 1/2
	
TTDDRUID	DK6J7M
DRUGNAME	NC410
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DK6P5A
DRUGNAME	VDA-1102
INDICATI	Actinic keratosis [ICD-11: EK90.0] Phase 2
	
TTDDRUID	DK6S3G
DRUGNAME	CTX-471
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DK87UQ
DRUGNAME	PF-07062119
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DK8QG3
DRUGNAME	AFM24
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DKB8X2
DRUGNAME	MDR-103
INDICATI	Kidney transplant rejection [ICD-11: NE84] Phase 2
	
TTDDRUID	DKCI94
DRUGNAME	ABBV-151
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DKCU40
DRUGNAME	FN-1501
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DKF7G0
DRUGNAME	RG6062
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 1
	
TTDDRUID	DKF9I3
DRUGNAME	GRANITE
INDICATI	Gastric adenocarcinoma [ICD-11: 2B72] Phase 3
	
TTDDRUID	DKGB36
DRUGNAME	TnMUC-1 CAR-T cell therapy
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DKH94Z
DRUGNAME	BIIB-088
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 2/3
	
TTDDRUID	DKJ93L
DRUGNAME	131 I-omburtamab
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2/3
INDICATI	Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 2/3
	
TTDDRUID	DKL13E
DRUGNAME	CPI-006
INDICATI	Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DKL3Z7
DRUGNAME	CC-95251
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DKM79E
DRUGNAME	INCB86550
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	DKM7S3
DRUGNAME	CDX-1140
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	DKM90C
DRUGNAME	SP0173
INDICATI	Diphtheria [ICD-11: 1C17] Phase 1/2
INDICATI	Tetanus [ICD-11: 1C13] Phase 1/2
INDICATI	Pertussis [ICD-11: 1C12] Phase 1/2
	
TTDDRUID	DKS3G5
DRUGNAME	Neuprex
INDICATI	Burn and burn infection [ICD-11: ND90-NE2Z] Phase 2
	
TTDDRUID	DKUF26
DRUGNAME	SL-172154
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	DL07ZP
DRUGNAME	GSK4074386
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DL0C5E
DRUGNAME	VLPM01
INDICATI	Falciparum malaria [ICD-11: 1F40-1F45] Phase 1
	
TTDDRUID	DL1E6F
DRUGNAME	212Pb-labelled PLEa
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DL1FG3
DRUGNAME	SAR440234
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1/2
	
TTDDRUID	DL1XC2
DRUGNAME	609A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DL2AD7
DRUGNAME	ERC1671
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	DL30JC
DRUGNAME	FF-10502
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DL36FJ
DRUGNAME	CH-223191
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	DL4WG9
DRUGNAME	ALVAC-HIV
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2/3
	
TTDDRUID	DL51QK
DRUGNAME	EA-230
INDICATI	Acute kidney injury [ICD-11: GB60] Phase 2
	
TTDDRUID	DL5C1W
DRUGNAME	Lifileucel
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	DL5UR0
DRUGNAME	BI 3011441
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DL6EZ5
DRUGNAME	AG019
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 1/2
	
TTDDRUID	DL74RO
DRUGNAME	Virstatin
INDICATI	Acinetobacter baumannii infection [ICD-11: CA40.0Y] Preclinical
	
TTDDRUID	DL76CW
DRUGNAME	EP-100
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DL7HD5
DRUGNAME	RP-L102
INDICATI	Fanconi's anemia [ICD-11: 3A70.0] Phase 2
	
TTDDRUID	DL7J8B
DRUGNAME	RAPA-201
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	DL8T4I
DRUGNAME	SCO-088
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 1
	
TTDDRUID	DL9F3C
DRUGNAME	O-304
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	DL9ZT4
DRUGNAME	Utomilumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DLCB65
DRUGNAME	IONIS-DNM2-2.5Rx
INDICATI	Centronuclear myopathy [ICD-11: 8C72.01] Phase 2
	
TTDDRUID	DLG95A
DRUGNAME	NYX-2925
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 2
INDICATI	Fibromyalgia [ICD-11: MG30.01] Phase 2
	
TTDDRUID	DLJN17
DRUGNAME	DSP-0337
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DLJQ42
DRUGNAME	MB-107
INDICATI	Severe combined immunodeficiency [ICD-11: 4A01.10] Phase 1/2
	
TTDDRUID	DLKQ59
DRUGNAME	LH846
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Preclinical
	
TTDDRUID	DLN0P8
DRUGNAME	TP-1454
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DLO18H
DRUGNAME	CB-103
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	DLOQ25
DRUGNAME	KN046
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	DLPD74
DRUGNAME	NT-501 ECT
INDICATI	Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2
	
TTDDRUID	DLQ4N0
DRUGNAME	REGN-COV2
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	DLV0Z8
DRUGNAME	REMD 477
INDICATI	Type-1 diabetes [ICD-11: 5A10] Phase 2
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 1/2
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 1/2
	
TTDDRUID	DLW69V
DRUGNAME	1,2,3,4,5,6-hexabromocyclohexane
INDICATI	Liver cancer [ICD-11: 2C12] Investigative
	
TTDDRUID	DLXO91
DRUGNAME	MB-108
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	DLY65X
DRUGNAME	AMG 424
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DLY89F
DRUGNAME	SRF388
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Liver cancer [ICD-11: 2C12] Phase 1
	
TTDDRUID	DM04QU
DRUGNAME	AVN-101
INDICATI	Cognitive impairment [ICD-11: 6D71] Phase 2
	
TTDDRUID	DM14CQ
DRUGNAME	HPN328
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	DM16HS
DRUGNAME	JAB-3068
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DM16YT
DRUGNAME	VX-166
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Preclinical
	
TTDDRUID	DM1FD5
DRUGNAME	ASTX029
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DM1VE5
DRUGNAME	PF-06939999
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DM2Y8T
DRUGNAME	GSK2820151
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DM3J5I
DRUGNAME	BI 1467335
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Discontinued in Phase 2
	
TTDDRUID	DM4K9V
DRUGNAME	EDP-305
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2
INDICATI	Primary biliary cholangitis [ICD-11: DB96.1] Phase 2
	
TTDDRUID	DM5T2B
DRUGNAME	Mical
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	DM5X0L
DRUGNAME	SHR2554
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
INDICATI	Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	DM69TL
DRUGNAME	Z-Phe-Ala-diazomethylketone
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
	
TTDDRUID	DM6CE2
DRUGNAME	177Lu-labelled CTT-1403
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	DM6KV2
DRUGNAME	TEV-48125
INDICATI	Migraine [ICD-11: 8A80] Phase 3
	
TTDDRUID	DM7WY2
DRUGNAME	MRG002
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 2
	
TTDDRUID	DM7Z6Y
DRUGNAME	Lampalizumab
INDICATI	Geographic retinal atrophy [ICD-11: 9B78.9] Phase 3
	
TTDDRUID	DM8BN1
DRUGNAME	Otesaconazole
INDICATI	Vulvovaginal Candidiasis [ICD-11: 1F23.10] Phase 3
INDICATI	Onychomycosis [ICD-11: EE12.1] Phase 2
	
TTDDRUID	DM8Y2N
DRUGNAME	DZD9008
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2
	
TTDDRUID	DM90BJ
DRUGNAME	AAV-CNGA3
INDICATI	Achromatopsia [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	DM9GO4
DRUGNAME	IO-202
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Chronic myelomonocytic leukaemia [ICD-11: 2A40] Phase 1
	
TTDDRUID	DMAU56
DRUGNAME	mRNA-5671
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	DMBG04
DRUGNAME	ATP128
INDICATI	Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2
	
TTDDRUID	DMD26W
DRUGNAME	CRV431
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2
	
TTDDRUID	DMD9W8
DRUGNAME	AB-2004
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 1
	
TTDDRUID	DMDS20
DRUGNAME	LY2922470
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	DMEQ73
DRUGNAME	ADPT01
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	DMEV15
DRUGNAME	Dilpacimab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	DMF73Z
DRUGNAME	DKN-01
INDICATI	Endometrial cancer [ICD-11: 2C76] Phase 2
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
INDICATI	Esophageal cancer [ICD-11: 2B70] Phase 2
INDICATI	Biliary tract cancer [ICD-11: 2C17] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 1/2
INDICATI	Oesophagogastric junction cancer [ICD-11: 2B71.Z] Phase 1/2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	DMF82G
DRUGNAME	Glepaglutide
INDICATI	Short bowel syndrome [ICD-11: KB89.1] Phase 3
	
TTDDRUID	DMK65T
DRUGNAME	Longeveron Mesenchymal Stem Cells
INDICATI	Frailty [ICD-11: MG2A] Phase 1/2
INDICATI	Hypoplastic left heart syndrome [ICD-11: LA89.3] Phase 1/2
	
TTDDRUID	DMK6W0
DRUGNAME	Emodepside
INDICATI	Filarial disease [ICD-11: 1F66] Phase 1
	
TTDDRUID	DMN03O
DRUGNAME	IMM-124E
INDICATI	Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 2
	
TTDDRUID	DMOF95
DRUGNAME	Tezepelumab
INDICATI	Severe asthma [ICD-11: CA23] Phase 3
	
TTDDRUID	DMP6A9
DRUGNAME	INXN 2001
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	DMR72A
DRUGNAME	JNJ-70218902
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DMS5N4
DRUGNAME	Adagloxad simolenin
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 3
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2/3
	
TTDDRUID	DMV0H7
DRUGNAME	GSK3536819A
INDICATI	Meningococcal infection [ICD-11: 1C1C] Phase 3
	
TTDDRUID	DMVR61
DRUGNAME	BAY 2416964
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DMXD02
DRUGNAME	mRNA-1172
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1
	
TTDDRUID	DMYS25
DRUGNAME	BGB-3245
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	DN18SP
DRUGNAME	MB-110
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	DN28KM
DRUGNAME	GEN1042
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DN28SH
DRUGNAME	Descartes-11
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 2
	
TTDDRUID	DN2F9A
DRUGNAME	AMG 506
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DN2MC5
DRUGNAME	AUTO1
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
	
TTDDRUID	DN3B5E
DRUGNAME	KPG-121
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	DN3U0I
DRUGNAME	Polyvalent pneumococcal conjugate vaccine
INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 3
	
TTDDRUID	DN3Z5D
DRUGNAME	L-DOS47
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Lung cancer [ICD-11: 2C25.0] Phase 1/2
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2
	
TTDDRUID	DN46RL
DRUGNAME	KITE-718
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DN5CM6
DRUGNAME	Magrolimab
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 3
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 3
	
TTDDRUID	DN5F7C
DRUGNAME	BNT131
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DN5J9R
DRUGNAME	SRK-015
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Phase 2
	
TTDDRUID	DN62DG
DRUGNAME	I3C
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 3
	
TTDDRUID	DN62IU
DRUGNAME	AG-270
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DN65GW
DRUGNAME	LY3475070
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DN68MW
DRUGNAME	P-PSMA-101
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	DN6MT7
DRUGNAME	OT-82
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
	
TTDDRUID	DN6YE0
DRUGNAME	PRGN-2009
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DN71VY
DRUGNAME	TAK-007
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	DN7M4T
DRUGNAME	BBP-398
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DN81JB
DRUGNAME	OPB-111077
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1
INDICATI	Haematological malignancy [ICD-11: 2B33.Y] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DN87BL
DRUGNAME	Fidanacogene elaparvovec
INDICATI	Haemophilia B [ICD-11: 3B11.0] Phase 3
	
TTDDRUID	DN8F1Z
DRUGNAME	AR-301
INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 3
INDICATI	Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 2
INDICATI	Pneumonia [ICD-11: CA40] Phase 1/2
	
TTDDRUID	DN8VS3
DRUGNAME	AEF0117
INDICATI	Marijuana use disorder [ICD-11: 6C41] Phase 2
	
TTDDRUID	DN91RC
DRUGNAME	IGM-2323
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	DN9IC4
DRUGNAME	GSK3186899
INDICATI	Leishmaniasis [ICD-11: 1F54] Phase 1
	
TTDDRUID	DNA7I1
DRUGNAME	OPT-302
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	DNC79U
DRUGNAME	ISB 1302
INDICATI	HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	DNC97Y
DRUGNAME	BI 690517
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 1
	
TTDDRUID	DNCA54
DRUGNAME	CLR 131
INDICATI	Waldenstrom macroglobulinemia [ICD-11: 2A85.4] Phase 2
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1
	
TTDDRUID	DNE4B9
DRUGNAME	ZBzl-YAA5911
INDICATI	Enterococcus faecium infection [ICD-11: 1D01.0Y] Preclinical
	
TTDDRUID	DNE73Q
DRUGNAME	F26G4
INDICATI	Anthrax [ICD-11: 1B97] Preclinical
	
TTDDRUID	DNET17
DRUGNAME	GSK3810109
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	DNF95E
DRUGNAME	Nirsevimab
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	DNF9L1
DRUGNAME	Fluorodopa F 18
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	DNH67V
DRUGNAME	SiG12D-LODER
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2
	
TTDDRUID	DNI28K
DRUGNAME	TP-0184
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DNI61P
DRUGNAME	CP101
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 2
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 2
	
TTDDRUID	DNL2F1
DRUGNAME	MK6-83
INDICATI	Discovery agent [ICD-11: N.A.] Preclinical
	
TTDDRUID	DNM79H
DRUGNAME	DS-3201b
INDICATI	T-cell leukaemia [ICD-11: 2A90] Phase 2
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Phase 1
INDICATI	Renal cell carcinoma [ICD-11: 2C90] Phase 1
	
TTDDRUID	DNM9C4
DRUGNAME	ALN-RSV01
INDICATI	Respiratory infection [ICD-11: CA07-CA4Z] Phase 2
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	DNML54
DRUGNAME	Lumoxiti
INDICATI	Hairy cell leukaemia [ICD-11: 2A82.2] Phase 1
	
TTDDRUID	DNS2P1
DRUGNAME	AMG 673
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	DNS4D6
DRUGNAME	KB195
INDICATI	Urea cycle disorder [ICD-11: 5C50.A] Phase 2
	
TTDDRUID	DNS58L
DRUGNAME	SRX246
INDICATI	Huntington disease [ICD-11: 8A01.10] Phase 2
INDICATI	Post-traumatic stress disorder [ICD-11: 6B40] Phase 2
INDICATI	Intermittent explosive disorder [ICD-11: 6C73] Phase 1/2
INDICATI	Fear-related disorder [ICD-11: 6B0Z] Phase 1
INDICATI	Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1
	
TTDDRUID	DNTW18
DRUGNAME	SCO-120
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	DNV17I
DRUGNAME	LY3113593
INDICATI	Anaemia [ICD-11: 3A90] Phase 2
	
TTDDRUID	DNXH76
DRUGNAME	Eptacog beta
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2
	
TTDDRUID	DNY16U
DRUGNAME	MI-219
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	DNY63Z
DRUGNAME	CC-94676
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
INDICATI	Invasive prostate cancer [ICD-11: 2C82] Phase 1
	
TTDDRUID	DNYC95
DRUGNAME	LBP-EC01
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 1
	
TTDDRUID	DNZ96J
DRUGNAME	INT-767
INDICATI	Hepatic fibrosis [ICD-11: DB93.0] Preclinical
	
TTDDRUID	DO0GJ1
DRUGNAME	LKA651
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	DO0LP3
DRUGNAME	NMS-03305293
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DO20LT
DRUGNAME	ATRC-101
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DO2LE6
DRUGNAME	CC-31244
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	DO2P5G
DRUGNAME	CVN058
INDICATI	Schizophrenia [ICD-11: 6A20] Phase 1
	
TTDDRUID	DO3E7R
DRUGNAME	PF-06940434
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DO3XB8
DRUGNAME	KAZ954
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DO5H6K
DRUGNAME	OT-101
INDICATI	Melanoma [ICD-11: 2C30] Phase 2/3
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 2/3
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 2/3
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2/3
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	DO61WZ
DRUGNAME	Combinectin
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	DO6UE8
DRUGNAME	227Th-labelled HER2-TTC
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DO75VX
DRUGNAME	LYS228
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 2
	
TTDDRUID	DO76YM
DRUGNAME	AGTC-501
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	DO78YZ
DRUGNAME	GMA105
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 3
INDICATI	Obesity [ICD-11: 5B81] Phase 3
	
TTDDRUID	DO7D1L
DRUGNAME	E7766
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DO7HS1
DRUGNAME	FAP5-DM1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DO7MC9
DRUGNAME	CD4CAR
INDICATI	T-cell leukaemia [ICD-11: 2A90] Phase 1
	
TTDDRUID	DO7PX4
DRUGNAME	VerorabVax
INDICATI	Rabies [ICD-11: 1C82] Phase 3
	
TTDDRUID	DO7QK1
DRUGNAME	KSI-301
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 3
	
TTDDRUID	DO8W9E
DRUGNAME	M9241
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1
	
TTDDRUID	DO9B3Y
DRUGNAME	AB-729
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	DOA3J0
DRUGNAME	AGEN2373
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DOBZ63
DRUGNAME	NKX101
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	DOD24G
DRUGNAME	Isunakinra
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DODG42
DRUGNAME	HMPL-523
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	DOE7C4
DRUGNAME	GSK3389404
INDICATI	Hepatitis B [ICD-11: 1E51] Phase 2
	
TTDDRUID	DOHM41
DRUGNAME	7HP349
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DOI7H2
DRUGNAME	INCAGN01876
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	DOJ6D9
DRUGNAME	COR-D
INDICATI	T-cell leukaemia [ICD-11: 2A90] Preclinical
	
TTDDRUID	DOJ6E8
DRUGNAME	AMG 596
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	DOJG79
DRUGNAME	SEL120
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1
	
TTDDRUID	DOL04T
DRUGNAME	CPCB-RPE1
INDICATI	Dry age-related macular degeneration [ICD-11: 9B75] Phase 1/2
	
TTDDRUID	DOMC56
DRUGNAME	SYMB-104
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Preclinical
	
TTDDRUID	DONA19
DRUGNAME	CKI-7
INDICATI	Mood disorder [ICD-11: 6A60-6E23] Preclinical
	
TTDDRUID	DOQ13X
DRUGNAME	CC-93269
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DOR1I0
DRUGNAME	ETP-46321
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Investigative
	
TTDDRUID	DORB45
DRUGNAME	Enfortumab
INDICATI	Urothelial carcinoma [ICD-11: 2C92.0] Approved
	
TTDDRUID	DOS62C
DRUGNAME	SKB264
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DOST52
DRUGNAME	MK-1654
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2/3
	
TTDDRUID	DOV7J4
DRUGNAME	Selgantolimod
INDICATI	Hepatitis B [ICD-11: 1E51] Phase 2
	
TTDDRUID	DOY1D6
DRUGNAME	HTI-2088
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	DOY4E6
DRUGNAME	AMG 160
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1
	
TTDDRUID	DOYP92
DRUGNAME	V937
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	DOZQ70
DRUGNAME	TH301
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Preclinical
	
TTDDRUID	DP07NC
DRUGNAME	Zolgensma
INDICATI	Spinal muscular atrophy [ICD-11: 8B61] Approved
	
TTDDRUID	DP0G9N
DRUGNAME	Anti-CD19 EBV CTL therapy
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1
	
TTDDRUID	DP0NU9
DRUGNAME	AIC100
INDICATI	Thyroid cancer [ICD-11: 2D10] Phase 1
	
TTDDRUID	DP17AI
DRUGNAME	Palomid-529
INDICATI	Macular degeneration [ICD-11: 9B78.3] Phase 1
	
TTDDRUID	DP1SE6
DRUGNAME	Parsaclisib
INDICATI	Follicular lymphoma [ICD-11: 2A80] Phase 2
	
TTDDRUID	DP2F6W
DRUGNAME	C-176
INDICATI	Aicardi-Goutieres syndrome [ICD-11: 5C55.2] Investigative
	
TTDDRUID	DP2Z0X
DRUGNAME	Sasanlimab
INDICATI	Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 3
	
TTDDRUID	DP3J2W
DRUGNAME	UPF-648
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical
	
TTDDRUID	DP3Q0C
DRUGNAME	Flucelvax Quadrivalent
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Approved
INDICATI	Influenza virus infection [ICD-11: 1E30-1E32] Approved
	
TTDDRUID	DP3S1J
DRUGNAME	IMU-201
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	DP48WE
DRUGNAME	Stenoparib
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	DP4J2K
DRUGNAME	MRx0518
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2
	
TTDDRUID	DP4KH3
DRUGNAME	PF-07265807
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DP63FS
DRUGNAME	VOB560
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	DP6GC3
DRUGNAME	NZV930
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DP6J5K
DRUGNAME	177Lu-labelled PSMA-R2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
	
TTDDRUID	DP6Y5N
DRUGNAME	MK-8719
INDICATI	Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1
	
TTDDRUID	DP7GK8
DRUGNAME	ABBV-951
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 3
	
TTDDRUID	DP7J0Z
DRUGNAME	MEDI3617
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1
	
TTDDRUID	DP7Z9Q
DRUGNAME	Nesvacumab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DP85ES
DRUGNAME	177Lu-labelled DOTA-JR11
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1/2
	
TTDDRUID	DP8T7K
DRUGNAME	KP3
INDICATI	Pneumonia due to Klebsiella pneumoniae [ICD-11: CA40.03] Preclinical
	
TTDDRUID	DP9SF6
DRUGNAME	THR-184
INDICATI	Renal fibrosis [ICD-11: GC01] Phase 2
	
TTDDRUID	DPAS02
DRUGNAME	AGEN1223
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DPB04G
DRUGNAME	GLS-1200
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2
	
TTDDRUID	DPBE75
DRUGNAME	NSC-207895
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DPG5T9
DRUGNAME	ACT017
INDICATI	Cerebral ischemia [ICD-11: 8B11] Phase 1/2
	
TTDDRUID	DPIR35
DRUGNAME	OMP-131R10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DPJ01T
DRUGNAME	ABV3
INDICATI	Bacterial vaginosis [ICD-11: MF3A] Phase 2
	
TTDDRUID	DPJ05C
DRUGNAME	TFM735
INDICATI	Multiple sclerosis [ICD-11: 8A40] Preclinical
	
TTDDRUID	DPJ70I
DRUGNAME	SAR444245
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DPJM92
DRUGNAME	225Ac-labelled FPX-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DPN1F0
DRUGNAME	ADXS-503
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	DPN2R7
DRUGNAME	YM-201636
INDICATI	Discovery agent [ICD-11: N.A.] Preclinical
	
TTDDRUID	DPNT63
DRUGNAME	AZD7648
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DPQ4U3
DRUGNAME	BFF-122
INDICATI	Cognitive impairment [ICD-11: 6D71] Preclinical
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	DPQ6Y9
DRUGNAME	PF-06928316
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1
	
TTDDRUID	DPS6V0
DRUGNAME	SPK-7001
INDICATI	Choroidal dystrophy [ICD-11: 9B61] Phase 1/2
	
TTDDRUID	DPTM94
DRUGNAME	MAU868
INDICATI	Epstein barr virus infection [ICD-11: 1C80] Phase 1
	
TTDDRUID	DPUF69
DRUGNAME	N-Octyl-beta-valienamine
INDICATI	Gaucher disease [ICD-11: 5C56.0Y] Preclinical
	
TTDDRUID	DQ04FJ
DRUGNAME	MBS301
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DQ0I4N
DRUGNAME	RP-L201
INDICATI	Leukocyte adhesion deficiency type 1 [ICD-11: 4A00.0Y ] Phase 1/2
	
TTDDRUID	DQ12XP
DRUGNAME	BXQ-350
INDICATI	Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DQ15HJ
DRUGNAME	GEN1044
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DQ18VG
DRUGNAME	BOS-228
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2
	
TTDDRUID	DQ1OJ4
DRUGNAME	VIR-2218
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2
	
TTDDRUID	DQ1P6X
DRUGNAME	AZD0466
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1/2
	
TTDDRUID	DQ1S0B
DRUGNAME	Berotralstat
INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Approved
	
TTDDRUID	DQ21NM
DRUGNAME	TG-1701
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	DQ2T3S
DRUGNAME	HB-201
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2
	
TTDDRUID	DQ2XP5
DRUGNAME	Viralym-C
INDICATI	Cytomegalovirus Disease [ICD-11: 1D82] Phase 1
	
TTDDRUID	DQ2Y7L
DRUGNAME	IONIS-FB-LRx
INDICATI	IgA nephropathy [ICD-11: MF8Y] Phase 2
	
TTDDRUID	DQ3AM0
DRUGNAME	PTG-300
INDICATI	Hemochromatosis [ICD-11: 5C64.1Y] Phase 2
INDICATI	Polycythemia vera [ICD-11: 2A20.4] Phase 2
	
TTDDRUID	DQ3NC4
DRUGNAME	2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester
INDICATI	Glioma [ICD-11: 2A00.0] Preclinical
	
TTDDRUID	DQ43PA
DRUGNAME	Cetrelimab
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DQ45GY
DRUGNAME	VIS410
INDICATI	Influenza A virus infection [ICD-11: 1E30] Phase 2
	
TTDDRUID	DQ4OU8
DRUGNAME	MK-1454
INDICATI	Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DQ4TO3
DRUGNAME	OTL-200
INDICATI	Metachromatic leukodystrophy [ICD-11: 5C56.02] Approved
	
TTDDRUID	DQ5V7F
DRUGNAME	MEDI0457
INDICATI	Oropharyngeal squamous cell carcinoma [ICD-11: 2B6A.0] Phase 1/2
	
TTDDRUID	DQ5X1Z
DRUGNAME	Amivantamab
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	DQ5Y6Z
DRUGNAME	PF-06952229
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DQ62VF
DRUGNAME	SOBI003
INDICATI	Sanfilippo syndrome [ICD-11: 5C56.3Y] Phase 1/2
	
TTDDRUID	DQ6J0W
DRUGNAME	GSK3745417
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DQ7PB1
DRUGNAME	IONIS-C9Rx
INDICATI	Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2
	
TTDDRUID	DQ83JW
DRUGNAME	INVAC-1
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
	
TTDDRUID	DQ9B8C
DRUGNAME	NUC-3373
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DQ9OL5
DRUGNAME	OBI-3424
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1/2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DQ9T7I
DRUGNAME	Viralym-A
INDICATI	Adenovirus infection [ICD-11: 1A20] Phase 1
	
TTDDRUID	DQC80I
DRUGNAME	TRPH-222
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	DQD1T2
DRUGNAME	GEM333
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	DQGF20
DRUGNAME	ALKS 4230
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
	
TTDDRUID	DQJX34
DRUGNAME	JS016
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2
	
TTDDRUID	DQM0X1
DRUGNAME	BIO-11006
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	DQM48O
DRUGNAME	RO7121661
INDICATI	Esophageal squamous cell carcinoma [ICD-11: 2E60.1] Phase 2
	
TTDDRUID	DQN76R
DRUGNAME	CardiAMP
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 3
	
TTDDRUID	DQP87H
DRUGNAME	177-Lu-oxodotreotide
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3
	
TTDDRUID	DQVR30
DRUGNAME	JBH492
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	DQX83Z
DRUGNAME	INCB81776
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DQY14Z
DRUGNAME	CSL 112
INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 2
	
TTDDRUID	DR03FL
DRUGNAME	INO-4600
INDICATI	Zika virus infection [ICD-11: 1D48] Phase 1
	
TTDDRUID	DR0M3F
DRUGNAME	CEA CAR-T
INDICATI	Ascites [ICD-11: ME04] Phase 1
INDICATI	Peritoneal metastasis [ICD-11: 2D91] Phase 1
	
TTDDRUID	DR15DO
DRUGNAME	FT-819
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1
	
TTDDRUID	DR1YQ7
DRUGNAME	GEN-011
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1
INDICATI	Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 1
	
TTDDRUID	DR36YB
DRUGNAME	Prulifloxacin
INDICATI	Urinary tract infection [ICD-11: GC08] Approved
	
TTDDRUID	DR3FA8
DRUGNAME	JNJ-73841937
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	DR49KB
DRUGNAME	CSL312
INDICATI	Hereditary angioedema [ICD-11: 4A00.14] Phase 3
	
TTDDRUID	DR4K0V
DRUGNAME	BI 1701963
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DR4ND6
DRUGNAME	D2C7
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	DR5LW8
DRUGNAME	INB03
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DR5VQ1
DRUGNAME	CYT-0851
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1/2
	
TTDDRUID	DR6BU1
DRUGNAME	Vaborbactam
INDICATI	Urinary tract infection [ICD-11: GC08] Phase 3
	
TTDDRUID	DR7EV6
DRUGNAME	ARO-AAT
INDICATI	Alopecia [ICD-11: ED70] Phase 2
INDICATI	Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Phase 1
	
TTDDRUID	DR7Q5N
DRUGNAME	REGN5458
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	DR7ZU0
DRUGNAME	GBT-101
INDICATI	Epidermolysis bullosa [ICD-11: EC3Z] Phase 2
INDICATI	Pressure ulcers [ICD-11: EH90] Phase 2
	
TTDDRUID	DRA84P
DRUGNAME	Tivanisiran
INDICATI	Dry eye disease [ICD-11: 9E1Z] Phase 3
	
TTDDRUID	DRD0M5
DRUGNAME	SYMB-202
INDICATI	Inflammatory bowel disease [ICD-11: DD72] Preclinical
	
TTDDRUID	DRF94Z
DRUGNAME	AIV001
INDICATI	Basal cell carcinoma [ICD-11: 2C32] Phase 1/2
	
TTDDRUID	DRFT15
DRUGNAME	CLBS12
INDICATI	Critical limb ischemia [ICD-11: BD4Y] Phase 2
	
TTDDRUID	DRG3B4
DRUGNAME	TAK-648
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	DRGC82
DRUGNAME	VRC07-523LS
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	DRGZ61
DRUGNAME	S-648414
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	DRH80V
DRUGNAME	JNJ-53718678
INDICATI	Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2
	
TTDDRUID	DRI23U
DRUGNAME	ARQ-751
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DRI97M
DRUGNAME	MGD014
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	DRJU35
DRUGNAME	ADC-01
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DRK7Q1
DRUGNAME	BAY 1238097
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DRL5Y7
DRUGNAME	SPN-812
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 4
	
TTDDRUID	DRL76S
DRUGNAME	AMXT1501
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DRM1X5
DRUGNAME	Ansuvimab
INDICATI	Ebola virus infection [ICD-11: 1D60.0] Approved
	
TTDDRUID	DRN30U
DRUGNAME	BMS-986118
INDICATI	Type 2 diabetes [ICD-11: 5A11] Preclinical
	
TTDDRUID	DRO7H6
DRUGNAME	FOXO4-DRI
INDICATI	Hypogonadism [ICD-11: 5A61.0] Preclinical
	
TTDDRUID	DRP4Q9
DRUGNAME	Vicineum
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 3
	
TTDDRUID	DRQ18X
DRUGNAME	ABP959
INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 3
	
TTDDRUID	DRQN21
DRUGNAME	ZN-c3
INDICATI	Uterine serous carcinoma [ICD-11: 2C72.1] Phase 2
	
TTDDRUID	DRT2P7
DRUGNAME	GEN-1
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 2
	
TTDDRUID	DRT90B
DRUGNAME	NSC632839
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DRU0M6
DRUGNAME	MB-104
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DRV14M
DRUGNAME	GSK3902986A
INDICATI	Bacillary dysentery [ICD-11: 1A02] Phase 2
	
TTDDRUID	DRZ1J4
DRUGNAME	HuMNC2-CAR44 T cells
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	DS01GZ
DRUGNAME	Dilanubicel
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
	
TTDDRUID	DS14FO
DRUGNAME	Sepofarsen
INDICATI	Leber congenital amaurosis [ICD-11: 9B70] Phase 2/3
	
TTDDRUID	DS15QG
DRUGNAME	Romyelocel-L
INDICATI	Neutropenia [ICD-11: 4B00.0] Phase 2
	
TTDDRUID	DS19UZ
DRUGNAME	Savirin
INDICATI	Staphylococcus infection [ICD-11: 1B5Y] Preclinical
	
TTDDRUID	DS1BJ7
DRUGNAME	RPTR-147
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DS2J7Q
DRUGNAME	EOS100850
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DS31JZ
DRUGNAME	SEP--4199
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 2
	
TTDDRUID	DS39MT
DRUGNAME	GSK3845097
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DS40LF
DRUGNAME	GD2-GD3 vaccine
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2
	
TTDDRUID	DS41PJ
DRUGNAME	ARV-471
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	DS4JE8
DRUGNAME	KO-539
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	DS4M1A
DRUGNAME	SM09419
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	DS4U1W
DRUGNAME	Ligelizumab
INDICATI	Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 3
	
TTDDRUID	DS53MJ
DRUGNAME	TC-110
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
INDICATI	Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2
	
TTDDRUID	DS58AE
DRUGNAME	M64
INDICATI	Pseudomonas infection [ICD-11: 1B92] Preclinical
	
TTDDRUID	DS5C0K
DRUGNAME	BT5528
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DS5LI8
DRUGNAME	LL-37
INDICATI	Venous leg ulcer [ICD-11: BD74.3] Phase 2
	
TTDDRUID	DS5UH0
DRUGNAME	VBI-1501
INDICATI	Cytomegalovirus Disease [ICD-11: 1D82] Phase 1
	
TTDDRUID	DS60CK
DRUGNAME	MT-5111
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DS68GD
DRUGNAME	REGN910-3
INDICATI	Neovascular age-related macular degeneration [ICD-11: 9B78.3Z] Phase 2
	
TTDDRUID	DS6B1L
DRUGNAME	SGN-LIV1A
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 2
	
TTDDRUID	DS6BE2
DRUGNAME	SGN-CD228A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DS6C1Y
DRUGNAME	CybroCell
INDICATI	Intervertebral disc degeneration [ICD-11: FA80] Phase 1/2
	
TTDDRUID	DS6OV9
DRUGNAME	THR-687
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 1
INDICATI	Diabetic retinopathy [ICD-11: 9B71.0] Phase 1
	
TTDDRUID	DS6VD0
DRUGNAME	GS-4224
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DS6W8Z
DRUGNAME	UCARTCS1
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DS70MP
DRUGNAME	DM199
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
INDICATI	Cerebral ischemia [ICD-11: 8B11] Phase 2
INDICATI	Autoimmune diabetes [ICD-11: 5A10] Phase 1/2
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 1/2
	
TTDDRUID	DS79KP
DRUGNAME	TNX-1300
INDICATI	Cocaine addiction [ICD-11: 6C45.2] Phase 2
	
TTDDRUID	DS7CY4
DRUGNAME	TPX-0046
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DS9R3G
DRUGNAME	SAR442720
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DSC90Z
DRUGNAME	AZD-1222
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	DSE59Z
DRUGNAME	pbi-shRNA STMN1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	DSEF47
DRUGNAME	KBP-7072
INDICATI	Community-acquired pneumonia [ICD-11: CA40.Z] Phase 1
INDICATI	Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 1
INDICATI	Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 1
	
TTDDRUID	DSHE52
DRUGNAME	EPZ031686
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DSHT18
DRUGNAME	ABL001
INDICATI	Chronic myeloid leukaemia [ICD-11: 2A20] Phase 3
	
TTDDRUID	DSI31T
DRUGNAME	AMY-101
INDICATI	Gingivitis [ICD-11: DA0B] Phase 2
	
TTDDRUID	DSI4G9
DRUGNAME	225Ac-labelled aCD33
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	DSIW85
DRUGNAME	OPC-64005
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2
	
TTDDRUID	DSK7I5
DRUGNAME	MP-101
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 2
	
TTDDRUID	DSK96I
DRUGNAME	IBP-9414
INDICATI	Necrotizing enterocolitis of newborn [ICD-11: KB88] Phase 3
	
TTDDRUID	DSM03D
DRUGNAME	SD1003
INDICATI	Alzheimer disease [ICD-11: 8A20] Preclinical
	
TTDDRUID	DSM5X9
DRUGNAME	177-Lu-PSMA-617
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 3
	
TTDDRUID	DSOE74
DRUGNAME	GQ1001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DST04F
DRUGNAME	ARQ-151
INDICATI	Atopic dermatitis [ICD-11: EA80] Phase 3
INDICATI	Psoriasis vulgaris [ICD-11: EA90] Phase 2
INDICATI	Plaque psoriasis [ICD-11: EA90.0] Phase 1/2
	
TTDDRUID	DSU7K2
DRUGNAME	Tosyl-l-arginine methyl ester
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DSWZ60
DRUGNAME	CD38 CAR-T
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DSYM73
DRUGNAME	FT500
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
	
TTDDRUID	DT1FS0
DRUGNAME	AB154
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DT1Z9I
DRUGNAME	HS-130
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DT28NV
DRUGNAME	AVR-RD-01
INDICATI	Fabry disease [ICD-11: 5C56.01] Phase 1/2
	
TTDDRUID	DT29OQ
DRUGNAME	SMITB14
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Preclinical
	
TTDDRUID	DT2B6G
DRUGNAME	SER-401
INDICATI	Metastatic melanoma [ICD-11: 2E2Z] Phase 1
	
TTDDRUID	DT30FV
DRUGNAME	VNRX-5133
INDICATI	Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1
	
TTDDRUID	DT3BA1
DRUGNAME	CG-806
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
	
TTDDRUID	DT3OE6
DRUGNAME	AL102
INDICATI	Desmoid tumour [ICD-11: 2F7C] Phase 2
	
TTDDRUID	DT41EO
DRUGNAME	CB-06-01
INDICATI	Acne vulgaris [ICD-11: ED80] Phase 2
	
TTDDRUID	DT45OV
DRUGNAME	TAK-831
INDICATI	Friedreich's ataxia [ICD-11: 8A03.10] Phase 2
	
TTDDRUID	DT4WU3
DRUGNAME	TTC-352
INDICATI	Metastatic melanoma [ICD-11: 2E2Z] Phase 1
	
TTDDRUID	DT52FI
DRUGNAME	MYK-491
INDICATI	Dilated cardiomyopathy [ICD-11: BC43.0] Phase 2
	
TTDDRUID	DT56YX
DRUGNAME	PBI-4050
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
	
TTDDRUID	DT6EN8
DRUGNAME	PBCAR20A
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2
INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1/2
	
TTDDRUID	DT6N0O
DRUGNAME	ODN-2088
INDICATI	Spinal cord injury [ICD-11: ND51.2] Investigative
	
TTDDRUID	DT6P8M
DRUGNAME	BAY 598
INDICATI	Discovery agent [ICD-11: N.A.] Preclinical
	
TTDDRUID	DT6ZE3
DRUGNAME	ASP0892
INDICATI	Allergy [ICD-11: 4A80-4A85] Phase 1
INDICATI	Food allergy [ICD-11: 4A85.2] Phase 1
	
TTDDRUID	DT7I5A
DRUGNAME	N-803
INDICATI	Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	DT7O8R
DRUGNAME	Tavokinogene telseplasmid
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	DT7SN5
DRUGNAME	Air polymer-type A
INDICATI	Diagnostic imaging [ICD-11: N.A.] Approved
	
TTDDRUID	DT8IL6
DRUGNAME	FT-7051
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	DT8R1L
DRUGNAME	DS-7300
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DTB43H
DRUGNAME	BI 905677
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DTF20P
DRUGNAME	HM71224
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Phase 1
	
TTDDRUID	DTHR46
DRUGNAME	IMC-002
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DTJ5W8
DRUGNAME	HeV-sG-V
INDICATI	Henipavirus Encephalitis [ICD-11: 1D63] Phase 1
	
TTDDRUID	DTM8B0
DRUGNAME	NG-350A
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DTO06Y
DRUGNAME	Macozinone
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1
	
TTDDRUID	DTP85B
DRUGNAME	Hippuristanol
INDICATI	T-cell leukaemia [ICD-11: 2A90] Investigative
	
TTDDRUID	DTQ3Z8
DRUGNAME	Dectrekumab
INDICATI	Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2
	
TTDDRUID	DTR05Z
DRUGNAME	BCMA-CD19 cCAR
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DTU7W2
DRUGNAME	K-NK002
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 2
	
TTDDRUID	DTV6Q7
DRUGNAME	Tonogenchoncel-L
INDICATI	Knee osteoarthritis [ICD-11: FA01] Phase 3
	
TTDDRUID	DTY5W0
DRUGNAME	mRNA-4157
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DTYP21
DRUGNAME	CA102N
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DTYQ45
DRUGNAME	TAK-676
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DU04SO
DRUGNAME	RGN-352
INDICATI	Acute myocardial infarction [ICD-11: BA41] Phase 2
INDICATI	Myocardial infarction [ICD-11: BA41-BA43] Phase 2
INDICATI	Peripheral neuropathy [ICD-11: 8C0Z] Phase 1
INDICATI	Stroke [ICD-11: 8B20] Phase 1
	
TTDDRUID	DU0K2R
DRUGNAME	Livoletide
INDICATI	Prader-Willi syndrome [ICD-11: LD90.3] Phase 2/3
INDICATI	Hyperphagia [ICD-11: MG43.9] Phase 2/3
	
TTDDRUID	DU10JI
DRUGNAME	CTP-543
INDICATI	Alopecia [ICD-11: ED70] Phase 2
	
TTDDRUID	DU1DL0
DRUGNAME	RLY-4008
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DU2G0C
DRUGNAME	LHC165
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DU3GQ9
DRUGNAME	TP-271
INDICATI	Respiratory tract infection [ICD-11: CA45] Phase 1
INDICATI	Pneumonia [ICD-11: CA40] Phase 1
	
TTDDRUID	DU47SF
DRUGNAME	Crizanlizumab
INDICATI	Vaso-occlusive crisis [ICD-11: BE2Y] Approved
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 4
	
TTDDRUID	DU54BA
DRUGNAME	MB-103
INDICATI	Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1
	
TTDDRUID	DU60ND
DRUGNAME	Ofranergene obadenovec
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 3
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 2
	
TTDDRUID	DU6H8Z
DRUGNAME	TR1801-ADC
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DU8CF6
DRUGNAME	Cenobamate
INDICATI	Complex partial seizure [ICD-11: 8A68.0] Approved
	
TTDDRUID	DU98JH
DRUGNAME	Belvarafenib
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DU9RB1
DRUGNAME	GL21.T
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Preclinical
	
TTDDRUID	DUA7N4
DRUGNAME	SNX281
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DUA7P2
DRUGNAME	SBT6050
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DUAO82
DRUGNAME	Evt201
INDICATI	Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2
	
TTDDRUID	DUBW95
DRUGNAME	Omburtamab
INDICATI	Neuroblastoma [ICD-11: 2D11.2] Phase 2/3
	
TTDDRUID	DUCA08
DRUGNAME	Caplacizumab
INDICATI	Thrombotic thrombocytopenic purpura [ICD-11: 3B64.14] Approved
	
TTDDRUID	DUDT78
DRUGNAME	RVT-1801
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 1/2
	
TTDDRUID	DUF26L
DRUGNAME	SEP-378608
INDICATI	Bipolar disorder [ICD-11: 6A60] Phase 1
	
TTDDRUID	DUI1N7
DRUGNAME	TP 6076
INDICATI	Multidrug resistant infection [ICD-11: MG51] Phase 1
	
TTDDRUID	DUI59O
DRUGNAME	NT219
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DUIA46
DRUGNAME	SRP-9004
INDICATI	Limb girdle muscular dystrophy [ICD-11: 8C70.4] Phase 1/2
	
TTDDRUID	DUK2V4
DRUGNAME	LP-300
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1
	
TTDDRUID	DUM25X
DRUGNAME	BMS-986120
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 1
	
TTDDRUID	DUO7Y0
DRUGNAME	V938
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DUP48T
DRUGNAME	SPR741
INDICATI	Acinetobacter baumannii infection [ICD-11: CA40.0Y] Phase 1
	
TTDDRUID	DUQV41
DRUGNAME	MRTX849
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3
	
TTDDRUID	DUR0F6
DRUGNAME	SYNB1891
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DURD59
DRUGNAME	SPR720
INDICATI	Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1/2
	
TTDDRUID	DUSB35
DRUGNAME	GSK3036656
INDICATI	Tuberculosis [ICD-11: 1B10-1B14] Phase 2
	
TTDDRUID	DUTJ12
DRUGNAME	ICP-022
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 3
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
	
TTDDRUID	DUVH60
DRUGNAME	NM21-1480
INDICATI	Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2
	
TTDDRUID	DUW81M
DRUGNAME	Tarloxotinib
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	DUZ0F7
DRUGNAME	AMG 420
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DUZ35W
DRUGNAME	PF-06842433
INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2
	
TTDDRUID	DV19IS
DRUGNAME	mAb926
INDICATI	Urinary tract infection [ICD-11: GC08] Preclinical
	
TTDDRUID	DV1R0X
DRUGNAME	CC-95775
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	DV25QN
DRUGNAME	Cadazolid
INDICATI	Clostridium difficile associated diarrhea [ICD-11: 1A04] Phase 3
	
TTDDRUID	DV2CR7
DRUGNAME	AMG 570
INDICATI	Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2
	
TTDDRUID	DV2N5P
DRUGNAME	KN026
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 2
	
TTDDRUID	DV3H6T
DRUGNAME	Arabaclofen
INDICATI	Fragile X syndrome [ICD-11: LD55] Phase 3
	
TTDDRUID	DV3KC5
DRUGNAME	P5091
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DV3WF1
DRUGNAME	LMP400
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DV3Y7F
DRUGNAME	APL-101
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 2
	
TTDDRUID	DV3ZI0
DRUGNAME	CD19t-haNK
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
	
TTDDRUID	DV59ZT
DRUGNAME	PR-619
INDICATI	Esophageal squamous cell carcinoma [ICD-11: 2E60.1] Preclinical
	
TTDDRUID	DV74TF
DRUGNAME	EPZ0330456
INDICATI	Colon cancer [ICD-11: 2B90.Z] Preclinical
	
TTDDRUID	DV7O1M
DRUGNAME	ProTmune
INDICATI	Refractory hematologic malignancy [ICD-11: 2A85.5] Phase 1/2
	
TTDDRUID	DV8A1L
DRUGNAME	CHDI-340246
INDICATI	Huntington disease [ICD-11: 8A01.10] Preclinical
	
TTDDRUID	DV8I4Q
DRUGNAME	MCLA-158
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DV9M0Y
DRUGNAME	GPRC5D CAR-T cell therapy
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DVA36E
DRUGNAME	INCAGN2390
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DVA7X9
DRUGNAME	DARE-BV1
INDICATI	Bacterial vaginosis [ICD-11: MF3A] Phase 3
	
TTDDRUID	DVCN93
DRUGNAME	INCAGN01949
INDICATI	Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Phase 2
	
TTDDRUID	DVD0E9
DRUGNAME	Quaratusugene ozeplasmid
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2
	
TTDDRUID	DVI8T3
DRUGNAME	SEP-380135
INDICATI	Agitation [ICD-11: 6A70.3] Phase 1
	
TTDDRUID	DVIY25
DRUGNAME	CTX130
INDICATI	T-cell lymphoma [ICD-11: 2A90] Phase 1
	
TTDDRUID	DVO4H2
DRUGNAME	APL-501
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DVOB28
DRUGNAME	AFM11
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	DVQ37G
DRUGNAME	(S)-4-(Ethylsulfonyl)benzoylalanine
INDICATI	Cognitive impairment [ICD-11: 6D71] Preclinical
INDICATI	Schizophrenia [ICD-11: 6A20] Preclinical
	
TTDDRUID	DVR84A
DRUGNAME	131I-labelled CLR1404
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DVS81T
DRUGNAME	DTRM-555
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2
	
TTDDRUID	DVS91L
DRUGNAME	MCC1 TCR
INDICATI	Merkel cell carcinoma [ICD-11: 2C34] Phase 1
	
TTDDRUID	DVT3F8
DRUGNAME	BBI-5000
INDICATI	Alopecia [ICD-11: ED70] Phase 2
	
TTDDRUID	DVU2H8
DRUGNAME	CV8102
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
INDICATI	Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1
	
TTDDRUID	DVU2Y5
DRUGNAME	CTX001
INDICATI	Sickle-cell disorder [ICD-11: 3A51] Phase 1/2
INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 1/2
	
TTDDRUID	DVX3H0
DRUGNAME	Sibrotuzumab
INDICATI	Metastatic colorectal cancer [ICD-11: 2B91] Phase 2
	
TTDDRUID	DVX4P3
DRUGNAME	GEN1029
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DVY5D9
DRUGNAME	TXA709
INDICATI	MRSA infection [ICD-11: 1D01.0Y] Phase 1
	
TTDDRUID	DVZ6M1
DRUGNAME	BI 7273
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Investigative
	
TTDDRUID	DVZN13
DRUGNAME	INB-200
INDICATI	Glioblastoma of brain [ICD-11: 2A00.00] Phase 1
	
TTDDRUID	DW01LJ
DRUGNAME	CLT030
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1
	
TTDDRUID	DW08BG
DRUGNAME	mRNA-1647
INDICATI	Cytomegalovirus Disease [ICD-11: 1D82] Phase 2
	
TTDDRUID	DW0D7G
DRUGNAME	GNE684
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical
	
TTDDRUID	DW0Z1Y
DRUGNAME	IU1
INDICATI	Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical
	
TTDDRUID	DW18LK
DRUGNAME	SR9011
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DW1H9O
DRUGNAME	TNB-383B
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DW24LQ
DRUGNAME	CLIK-148
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Preclinical
	
TTDDRUID	DW3AX4
DRUGNAME	BI 907828
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DW3J9N
DRUGNAME	DACRA 089
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	DW43DG
DRUGNAME	Bimagrumab
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	DW4J6M
DRUGNAME	GM602
INDICATI	Ischemic stroke [ICD-11: 8B11.5Z] Phase 2
	
TTDDRUID	DW56QV
DRUGNAME	Calmidazolium
INDICATI	Huntington disease [ICD-11: 8A01.10] Investigative
	
TTDDRUID	DW5R6Y
DRUGNAME	SR1555
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Preclinical
	
TTDDRUID	DW5Z1R
DRUGNAME	RG7907
INDICATI	Hepatitis B [ICD-11: 1E51] Phase 1
	
TTDDRUID	DW68KF
DRUGNAME	5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one
INDICATI	Pompe disease [ICD-11: 5C51.3] Preclinical
	
TTDDRUID	DW7PT6
DRUGNAME	SPK-8011
INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 1/2
	
TTDDRUID	DW7XC5
DRUGNAME	IONIS-GCGR-Rx
INDICATI	Type-2 diabetes [ICD-11: 5A11] Phase 2
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	DW9ML8
DRUGNAME	LMB763
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2
INDICATI	Diabetic nephropathy [ICD-11: GB61.Z] Phase 2
	
TTDDRUID	DWB8C5
DRUGNAME	VLA15
INDICATI	Lyme disease [ICD-11: 1C1G] Phase 2
	
TTDDRUID	DWD06K
DRUGNAME	AVN-322
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	DWF98V
DRUGNAME	GSK2807
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DWH79Q
DRUGNAME	LY-CoV555
INDICATI	Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3
	
TTDDRUID	DWJ3A7
DRUGNAME	DS-2969
INDICATI	Clostridium infection [ICD-11: 1A04] Phase 1
	
TTDDRUID	DWK5H3
DRUGNAME	C16G2
INDICATI	Dental caries [ICD-11: DA08.0] Phase 2
	
TTDDRUID	DWK96T
DRUGNAME	ASP1929
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 3
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DWOY01
DRUGNAME	RTA 901
INDICATI	Diabetic neuropathy [ICD-11: 8C0Z] Phase 1
	
TTDDRUID	DWQ6J1
DRUGNAME	EMB-01
INDICATI	Neoplasm [ICD-11: 2A00-2F9Z] Phase 1/2
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2
	
TTDDRUID	DWR6A9
DRUGNAME	ML364
INDICATI	Inflammation [ICD-11: 1A00-CA43.1] Preclinical
	
TTDDRUID	DWS08I
DRUGNAME	BPL-HRIG
INDICATI	Rabies [ICD-11: 1C82] Phase 2/3
	
TTDDRUID	DWS5G1
DRUGNAME	ARO-HBV
INDICATI	Hepatitis B [ICD-11: 1E51] Phase 1/2
	
TTDDRUID	DWSO57
DRUGNAME	SAB-176
INDICATI	Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 2
	
TTDDRUID	DWX4A0
DRUGNAME	ZM-H1505R
INDICATI	Hepatitis B [ICD-11: 1E51] Phase 1
	
TTDDRUID	DX06ZU
DRUGNAME	AV-MEL-1
INDICATI	Melanoma [ICD-11: 2C30] Phase 1
	
TTDDRUID	DX1LD3
DRUGNAME	BCMA-CS1 cCAR
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DX1U3C
DRUGNAME	BI 456906
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 2
	
TTDDRUID	DX1U8I
DRUGNAME	F24F2
INDICATI	Anthrax [ICD-11: 1B97] Preclinical
	
TTDDRUID	DX2B8E
DRUGNAME	TG4010
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3
	
TTDDRUID	DX2J9R
DRUGNAME	Ad/PNP
INDICATI	Head and neck cancer [ICD-11: 2D42] Phase 1/2
	
TTDDRUID	DX30BA
DRUGNAME	IBI318
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1
	
TTDDRUID	DX36OY
DRUGNAME	RP-A501
INDICATI	Type 2 glycogen storage disease [ICD-11: 5C51.3] Phase 1
	
TTDDRUID	DX45IW
DRUGNAME	COV08-0064
INDICATI	Parkinson disease [ICD-11: 8A00.0] Investigative
	
TTDDRUID	DX4A3Q
DRUGNAME	DA-1241
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	DX56JK
DRUGNAME	MET409
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2
	
TTDDRUID	DX5T9B
DRUGNAME	MSC-1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DX6J8M
DRUGNAME	CC-98633
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1
	
TTDDRUID	DX6O9V
DRUGNAME	TC-210
INDICATI	Ovarian cancer [ICD-11: 2C73] Phase 1/2
INDICATI	Cholangiocarcinoma [ICD-11: 2C12.10] Phase 1/2
INDICATI	Peritoneal mesothelioma [ICD-11: 2C51.2] Phase 1/2
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2
	
TTDDRUID	DX6RV3
DRUGNAME	IVA337
INDICATI	Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2
	
TTDDRUID	DX7M4S
DRUGNAME	Perchlozone
INDICATI	Multi-drug resistant tuberculosis [ICD-11: MG52.00] Approved
	
TTDDRUID	DX8QZ3
DRUGNAME	CK0801
INDICATI	Hematologic disease [ICD-11: 3C0Z] Phase 1
	
TTDDRUID	DX9KC2
DRUGNAME	GT-AADC
INDICATI	Aromatic L-amino acid decarboxylase deficiency [ICD-11: 5C59.00] Phase 2
	
TTDDRUID	DX9T0N
DRUGNAME	AZD8701
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DXC94O
DRUGNAME	HCVax
INDICATI	Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1
	
TTDDRUID	DXCR87
DRUGNAME	OKG-0301
INDICATI	Acute adenoviral conjunctivitis [ICD-11: 1D84.0] Phase 2
	
TTDDRUID	DXD69J
DRUGNAME	AZD2811
INDICATI	Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	DXF93J
DRUGNAME	CI-8993
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DXJ4B7
DRUGNAME	LY2880070
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DXJH93
DRUGNAME	AK104
INDICATI	Cervical cancer [ICD-11: 2C77.0] Phase 2
INDICATI	Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2
	
TTDDRUID	DXK49H
DRUGNAME	CFI-402411
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DXL38G
DRUGNAME	CPI-0209
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DXM30Y
DRUGNAME	LJPC-401
INDICATI	Hemochromatosis [ICD-11: 5C64.1Y] Phase 2
INDICATI	Beta thalassemia [ICD-11: 3A50.2] Phase 2
	
TTDDRUID	DXNT71
DRUGNAME	DecRVKRCMK
INDICATI	Coronavirus infection [ICD-11: 1D92] Preclinical
	
TTDDRUID	DXO1V4
DRUGNAME	AT-787
INDICATI	Hepatitis C [ICD-11: 1E51] Phase 1
	
TTDDRUID	DXP04H
DRUGNAME	Pirtobrutinib
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3
INDICATI	Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 3
	
TTDDRUID	DXR7G0
DRUGNAME	Next Gen PCV
INDICATI	Pneumococcal infection [ICD-11: CA00-CA40] Phase 2
	
TTDDRUID	DXRP68
DRUGNAME	Vutrisiran
INDICATI	Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3
	
TTDDRUID	DXV06E
DRUGNAME	Ciltacabtagene autoleucel
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 3
	
TTDDRUID	DXV67Q
DRUGNAME	227Th-labelled PSMA-TTC
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	DXWP72
DRUGNAME	SEphB4-HSA
INDICATI	Kaposi sarcoma [ICD-11: 2B57] Phase 2
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DY03KH
DRUGNAME	LHF-535
INDICATI	Lassa fever [ICD-11: 1D61.2] Phase 1
	
TTDDRUID	DY0HV9
DRUGNAME	GSK366
INDICATI	Pancreatitis [ICD-11: DC31-DC34] Preclinical
	
TTDDRUID	DY13WU
DRUGNAME	TAS-0728
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DY1H2Z
DRUGNAME	NCO-48
INDICATI	Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1
	
TTDDRUID	DY21QW
DRUGNAME	RGX-121
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2
	
TTDDRUID	DY2EJ1
DRUGNAME	ATA2431
INDICATI	B-cell lymphoma [ICD-11: 2A86] Preclinical
	
TTDDRUID	DY2UG0
DRUGNAME	DF1001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DY2WH5
DRUGNAME	OTL-103
INDICATI	Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 3
	
TTDDRUID	DY36LD
DRUGNAME	GSK6097608
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DY38JR
DRUGNAME	Astodrimer
INDICATI	Bacterial vaginosis [ICD-11: MF3A] Approved
	
TTDDRUID	DY46GM
DRUGNAME	Lefitolimod
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2
	
TTDDRUID	DY4OZ6
DRUGNAME	Thymoquinone
INDICATI	Polycystic ovarian syndrome [ICD-11: 5A80.1] Phase 2/3
	
TTDDRUID	DY4Q6M
DRUGNAME	Tabelecleucel
INDICATI	Post-transplant lymphoproliferative disorder [ICD-11: 2B32] Phase 3
INDICATI	Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 2
	
TTDDRUID	DY4X5W
DRUGNAME	CCW702
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	DY5KS2
DRUGNAME	m337
INDICATI	Coronavirus infection [ICD-11: 1D92] Preclinical
	
TTDDRUID	DY7D9A
DRUGNAME	ZL-1201
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DY7IP9
DRUGNAME	12B9m
INDICATI	Anaemia [ICD-11: 3A90] Preclinical
	
TTDDRUID	DY7MH5
DRUGNAME	Balovaptan
INDICATI	Autism spectrum disorder [ICD-11: 6A02] Phase 3
	
TTDDRUID	DY7Q1O
DRUGNAME	EPI-7386
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
	
TTDDRUID	DY9CM8
DRUGNAME	BRD1240
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative
	
TTDDRUID	DY9CP0
DRUGNAME	TAK-426
INDICATI	Zika virus infection [ICD-11: 1D48] Phase 1
	
TTDDRUID	DY9DX8
DRUGNAME	SB-913
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2
	
TTDDRUID	DY9G1D
DRUGNAME	REGN5459
INDICATI	Multiple myeloma [ICD-11: 2A83] Phase 1/2
	
TTDDRUID	DYCI37
DRUGNAME	TST001
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DYF2N4
DRUGNAME	HHCYH33
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1
	
TTDDRUID	DYG0W5
DRUGNAME	Coversin
INDICATI	Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 3
	
TTDDRUID	DYH42L
DRUGNAME	INXN 4001
INDICATI	Heart failure [ICD-11: BD10-BD13] Phase 1
	
TTDDRUID	DYIA63
DRUGNAME	CVM-1118
INDICATI	Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2
	
TTDDRUID	DYJ0V9
DRUGNAME	Anti-RAS-G12D mTCR-transduced PBL
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DYJ0Z1
DRUGNAME	NeoTCR-P1
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DYK5U6
DRUGNAME	EI1071
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DYM1J4
DRUGNAME	ASP7517
INDICATI	Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2
INDICATI	Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2
	
TTDDRUID	DYNT08
DRUGNAME	KM-819
INDICATI	Parkinson disease [ICD-11: 8A00.0] Phase 1
	
TTDDRUID	DYP56K
DRUGNAME	VXA-A1.1-H1
INDICATI	Influenza [ICD-11: 1E30-1E32] Phase 2
	
TTDDRUID	DYQZ38
DRUGNAME	RLY-1971
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DYRC18
DRUGNAME	ACHM-CNGB3
INDICATI	Achromatopsia [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	DYS56C
DRUGNAME	SB218078
INDICATI	Triple negative breast cancer [ICD-11: 2C60-2C65] Investigative
	
TTDDRUID	DYSA16
DRUGNAME	RT-400
INDICATI	Acute decompensated heart failure [ICD-11: BD1Z] Phase 2
	
TTDDRUID	DYSI03
DRUGNAME	ASP1951
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DYU37E
DRUGNAME	EDP-1503
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	DYU3I8
DRUGNAME	CLIK-181
INDICATI	Rheumatoid arthritis [ICD-11: FA20] Preclinical
	
TTDDRUID	DYWK46
DRUGNAME	SB-318
INDICATI	Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2
	
TTDDRUID	DZ0DT2
DRUGNAME	Generx
INDICATI	Angina pectoris [ICD-11: BA40] Phase 3
	
TTDDRUID	DZ0LJ5
DRUGNAME	ABBV-4083
INDICATI	Filarial disease [ICD-11: 1F66] Phase 1
	
TTDDRUID	DZ1IL2
DRUGNAME	MK-1308
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DZ27CY
DRUGNAME	INB-100
INDICATI	leukaemia [ICD-11: 2A60-2B33] Phase 1
	
TTDDRUID	DZ28EB
DRUGNAME	SR3335
INDICATI	Type-2 diabetes [ICD-11: 5A11] Preclinical
	
TTDDRUID	DZ38PI
DRUGNAME	INP1855
INDICATI	Pseudomonas infection [ICD-11: 1B92] Preclinical
	
TTDDRUID	DZ4A1W
DRUGNAME	HF10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2
INDICATI	Melanoma [ICD-11: 2C30] Phase 2
	
TTDDRUID	DZ5K6F
DRUGNAME	GB1275
INDICATI	Pancreatic cancer [ICD-11: 2C10] Phase 1/2
	
TTDDRUID	DZ68IC
DRUGNAME	MK-8558
INDICATI	Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1
	
TTDDRUID	DZ76PB
DRUGNAME	PF-06648671
INDICATI	Alzheimer disease [ICD-11: 8A20] Phase 1
	
TTDDRUID	DZ7OC3
DRUGNAME	Iomab-ACT
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1
INDICATI	B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 1
	
TTDDRUID	DZ8DF0
DRUGNAME	DCR-PHXC
INDICATI	Hyperoxaluria [ICD-11: 5C51.2] Phase 2
	
TTDDRUID	DZ8FV2
DRUGNAME	AAV-RPGR
INDICATI	Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2
	
TTDDRUID	DZ8UP4
DRUGNAME	LM10
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DZ91HE
DRUGNAME	OP-1250
INDICATI	Breast cancer [ICD-11: 2C60-2C65] Phase 1/2
	
TTDDRUID	DZ9AJ3
DRUGNAME	PF-07055480
INDICATI	Haemophilia A [ICD-11: 3B10.0] Phase 3
	
TTDDRUID	DZ9BD3
DRUGNAME	CHIKV VLP
INDICATI	Chikungunya virus infection [ICD-11: 1D40] Phase 2
	
TTDDRUID	DZA98D
DRUGNAME	ARGX-113
INDICATI	Myasthenia gravis [ICD-11: 8C6Y] Phase 3
	
TTDDRUID	DZB84T
DRUGNAME	Maralixibat
INDICATI	Progressive familial intrahepatic cholestasis [ICD-11: 5C58.03] Phase 3
INDICATI	Alagille syndrome [ICD-11: LB20.0Y] Phase 2
	
TTDDRUID	DZBV67
DRUGNAME	BI 765063
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DZEF27
DRUGNAME	HCB1019
INDICATI	Diabetic macular edema [ICD-11: 9B71.02] Phase 2
	
TTDDRUID	DZJ3D5
DRUGNAME	PF-07220060
INDICATI	Prostate cancer [ICD-11: 2C82.0] Phase 1
INDICATI	Liposarcoma [ICD-11: 2B59] Phase 1
	
TTDDRUID	DZK24C
DRUGNAME	EPL-1410
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical
	
TTDDRUID	DZK7E0
DRUGNAME	PF-670462
INDICATI	Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Preclinical
	
TTDDRUID	DZL3F8
DRUGNAME	VTR-297
INDICATI	Hematologic tumour [ICD-11: 2B33.Y] Phase 1
	
TTDDRUID	DZL8S6
DRUGNAME	DSP-0509
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DZLM72
DRUGNAME	SHR0534
INDICATI	Type 2 diabetes [ICD-11: 5A11] Phase 1
	
TTDDRUID	DZM2L1
DRUGNAME	AFM13
INDICATI	Hodgkin lymphoma [ICD-11: 2B30] Phase 2
INDICATI	Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2
INDICATI	Mycosis fungoides [ICD-11: 2B01] Phase 2
INDICATI	Lymphoma [ICD-11: 2A80-2A86] Phase 1/2
	
TTDDRUID	DZM65T
DRUGNAME	ICP-192
INDICATI	Bladder cancer [ICD-11: 2C94] Phase 2
	
TTDDRUID	DZMO76
DRUGNAME	JTX-4014
INDICATI	Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2
	
TTDDRUID	DZNH43
DRUGNAME	MT-3724
INDICATI	Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2
INDICATI	Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2
INDICATI	B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1
INDICATI	B-cell lymphoma [ICD-11: 2A86] Phase 1
INDICATI	B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1
	
TTDDRUID	DZQ32M
DRUGNAME	TAPA-pulsed dendritic cell vaccine
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2
	
TTDDRUID	DZTL59
DRUGNAME	INO-A002
INDICATI	Zika virus infection [ICD-11: 1D48] Phase 1
	
TTDDRUID	DZTX12
DRUGNAME	ASC-J9
INDICATI	Thrombosis [ICD-11: DB61-GB90] Phase 2
INDICATI	End-stage renal disease [ICD-11: GB61.5] Phase 2
	
TTDDRUID	DZU72C
DRUGNAME	OKI 179
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1
	
TTDDRUID	DZVF15
DRUGNAME	TRN-110
INDICATI	Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Clinical Trial
	
TTDDRUID	DZW53X
DRUGNAME	GSK4069889
INDICATI	Non-small cell lung cancer [ICD-11: 2C25] Phase 2
	
TTDDRUID	DZY4R2
DRUGNAME	JNJ-74699157
INDICATI	Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1